PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Luchini, C; Cros, J; Pea, A; Pilati, C; Veronese, N; Rusev, B; Capelli, P; Mafficini, A; Nottegar, A; Brosens, LAA; Noe, M; Offerhaus, GJA; Chianchiano, P; Riva, G; Piccoli, P; Parolini, C; Malleo, G; Lawlor, RT; Corbo, V; Sperandio, N; Barbareschi, M; Fassan, M; Cheng, L; Wood, LD; Scarpa, A				Luchini, Claudio; Cros, Jerome; Pea, Antonio; Pilati, Camilla; Veronese, Nicola; Rusev, Borislav; Capelli, Paola; Mafficini, Andrea; Nottegar, Alessia; Brosens, Lodewijk A. A.; Noe, Michael; Offerhaus, G. Johan A.; Chianchiano, Peter; Riva, Giulio; Piccoli, Paola; Parolini, Claudia; Malleo, Giuseppe; Lawlor, Rita T.; Corbo, Vincenzo; Sperandio, Nicola; Barbareschi, Mattia; Fassan, Matteo; Cheng, Liang; Wood, Laura D.; Scarpa, Aldo			PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications	HUMAN PATHOLOGY			English	Article						UCOGC; PDAC; Osteoclast; Pancreatic cancer; Tumor-associated macrophages	TUMOR-ASSOCIATED MACROPHAGES; CLASS-I; PD-1/PD-L1; CANCERS; IMPACT; STROMA; P53	Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) of 27 cases, more often in cases with an associated PDAC (P = .04). Expression of PD-L1 was associated with poor prognosis, confirmed by multivariate analysis: patients with PD-L1-positive UCOGCs had a risk of all-cause mortality that was 3 times higher than did patients with PD-L1-negative UCOGCs (hazard ratio, 3.397; 95% confidence interval, 1.023-18.375; P = .034). PD-L1 expression on tumor cells was also associated with aberrant P53 expression (P = .035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs (44.4%), mainly located at the tumor periphery. CD163 was expressed on histiocytes, with a diffuse and strong staining pattern in all UCOGCs. Extrapancreatic tumors with osteoclast-like giant cells showed very similar staining patterns for the same proteins. Anaplastic carcinomas have some similarities to UCOGCs, but PD-L1 has no prognostic roles. Our results may have important implications for immunotherapeutic strategies in UCOGCs; these tumors may also represent a model for future therapeutic approaches against PDAC. (C) 2018 Elsevier Inc. All rights reserved.	[Luchini, Claudio; Capelli, Paola; Riva, Giulio; Piccoli, Paola; Parolini, Claudia; Corbo, Vincenzo; Sperandio, Nicola; Scarpa, Aldo] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, I-37134 Verona, Italy; [Cros, Jerome] Beaujon Hosp, Dept Pathol, F-92110 Clichy, France; [Cros, Jerome] Paris Diderot Sch Med, Inflammat Res Ctr, F-75013 Paris, France; [Pea, Antonio] Univ Verona, Dept Surg, I-37134 Verona, Italy; [Pea, Antonio] Hosp Trust Verona, I-37134 Verona, Italy; [Pilati, Camilla] Paris Descartes Univ, Personalized Med, Pharmacogen, Therapeut Optimizat, F-75006 Paris, France; [Veronese, Nicola] Natl Inst Gastroenterol Res Hosp, IRCCS S de Bellis, I-70013 Bari, Italy; [Rusev, Borislav; Mafficini, Andrea; Fassan, Matteo; Wood, Laura D.] Univ Verona, ARC Net Res Ctr, I-37134 Verona, Italy; [Brosens, Lodewijk A. A.; Offerhaus, G. Johan A.] San Bortolo Hosp, Sect Pathol, Dept Surg, I-36100 Vicenza, Italy; [Nottegar, Alessia] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 Utrecht, Netherlands; [Brosens, Lodewijk A. A.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Noe, Michael; Chianchiano, Peter] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21211 USA; [Barbareschi, Mattia] Santa Chiara Hosp, Surg Pathol Unit, I-38122 Trento, Italy; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Wood, Laura D.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21211 USA	Wood, LD (reprint author), CRB2 Room 345,1550 Orleans St, Baltimore, MD 21231 USA.; Scarpa, A (reprint author), Piazzale Scuro 10, I-37134 Verona, VR, Italy.	ldwood@jhmi.edu; aldo.scarpa@univr.it	Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016; Malleo, Giuseppe/H-8507-2019; Cros, Jerome/X-7677-2019	Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; Malleo, Giuseppe/0000-0001-5467-2628; Cros, Jerome/0000-0002-4935-3865	Associazione Italiana Ricerca CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [12182]; FP7 European Community Grant Cam-Pac [602783]; Italian Ministry of HealthMinistry of Health, Italy [FIMP-CUP_J33G13000210001]; Sol Goldman Pancreatic Cancer Research Center; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bemard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-1ncyte Corporation Career Development Award for Pancreatic Cancer Research; Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees); Sigma Beta Sorority; Fondazione Caritro; Cassini Project 2017; NII-I/NCI [P50 CA62924]; NIFINIDDK [K08 DK107781]; Buffone Family Gastrointestinal Cancer Research Fund; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; Progetto Trebionet	The authors acknowledge the following sources of funding: Cassini Project 2017, Associazione Italiana Ricerca Cancro (12182), FP7 European Community Grant Cam-Pac (602783), Italian Ministry of Health (FIMP-CUP_J33G13000210001), NII-I/NCI P50 CA62924, NIFINIDDK K08 DK107781, Sol Goldman Pancreatic Cancer Research Center, Buffone Family Gastrointestinal Cancer Research Fund, Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention, AGA-Bemard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer, Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award, AACR-1ncyte Corporation Career Development Award for Pancreatic Cancer Research, Rolfe Pancreatic Cancer Foundation, Joseph C Monastra Foundation, The Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees), Sigma Beta Sorority, Progetto Trebionet, and Fondazione Caritro.	Amaya CN, 2017, PATHOLOGY, V49, P292, DOI 10.1016/j.pathol.2016.10.015; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bosman FT, 2010, WHO CLASSIFICATION T; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Braun MW, 2016, TRANSL CANCER RES, V5, P692, DOI 10.21037/tcr.2016.11.76; Cha YJ, 2016, LUNG CANCER, V97, P73, DOI 10.1016/j.lungcan.2016.05.001; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Helm O, 2014, INT J CANCER, V135, P843, DOI 10.1002/ijc.28736; Hu H, 2016, TUMOR BIOL, V37, P8657, DOI 10.1007/s13277-015-4741-z; Imai D, 2017, CANCER MED-US, V6, P1614, DOI 10.1002/cam4.1087; Jiang LY, 2017, ONCOTARGET, V8, P26845, DOI 10.18632/oncotarget.15839; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lehrke HD, 2017, AM J CLIN PATHOL, V148, P441, DOI [10.1093/ajcp/aqx092, 10.1093/AJCP/AQX092]; Luchini C, 2018, APPL IMMUNOHISTO M M, V26, P383; Luchini C, 2017, J PATHOL, V243, P148, DOI 10.1002/path.4941; Luchini Claudio, 2016, Surg Pathol Clin, V9, P547, DOI 10.1016/j.path.2016.05.003; Luchini C, 2015, PLACENTA, V36, P1318, DOI 10.1016/j.placenta.2015.09.012; Manson G, 2016, ANN ONCOL, V27, P1199, DOI 10.1093/annonc/mdw181; Muraki T, 2016, AM J SURG PATHOL, V40, P1203, DOI 10.1097/PAS.0000000000000689; Nottegar A, 2018, APPL IMMUNOHISTO M M, V26, P383, DOI 10.1097/PAI.0000000000000440; Peng HG, 2017, NANO LETT, V17, P7684, DOI 10.1021/acs.nanolett.7b03756; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Sabbatino F, 2016, CLIN CANCER RES, V22, P470, DOI 10.1158/1078-0432.CCR-15-0715; Saraggi D, 2017, HISTOPATHOLOGY, V71, P470, DOI 10.1111/his.13254; Tessier-Cloutier B, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3634-5; Wang Y, 2017, ONCOTARGET, V8, P9354, DOI 10.18632/oncotarget.14069; Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031230	34	1	1	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						157	165		10.1016/j.humpath.2018.07.006			9	Pathology	Pathology	HB5LM	WOS:000451102300019	30031096				2019-10-28	
J	Jiang, YN; Xie, J; Wang, B; Mu, YD; Liu, PJ				Jiang, Yina; Xie, Juan; Wang, Bo; Mu, Yudong; Liu, Peijun			TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas	HUMAN PATHOLOGY			English	Article						TFE3; Solid pseudopapillary neoplasms of the pancreas; Diagnostic marker; PDACs; PanNETs; PanNECs; ACCs	ENDOLYSOSOMAL BIOGENESIS; TUMOR; CARCINOMA; PAPILLARY; CELL	Aberrant Wnt signaling is a hallmark of solid pseudopapillary neoplasms (SPNs) of the pancreas. Transcription factor E3 (TFE3) plays a critical role in activation and regulation of the Wnt pathway and is predicted to be a candidate gene implicated in SPN by gene regulatory network analysis. The aim of this study was to evaluate TFE3 as a marker for SPN. Paraffin-embedded tissues of SPN (n = 75) and other primary pancreatic tumors were analyzed, including pancreatic neuroendocrine tumors (n = 17), pancreatic ductal adenocarcinomas (n = 14), pancreatic neuroendocrine carcinomas (n = 4), and acinar cell carcinomas (n = 3). The clinicopathological features were summarized as well. Differentiation of specific pancreatic duct or acinus was not found in any SPN tissue. Morphologic and immunohistochemical results indicated that SPN displays certain characteristics of neuroendocrine cells. Overall, 71 (94.67%) cases of SPN showed nuclear accumulation for TFE3, most of which displayed moderate to intense expression. The TFE3 positive rates in pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma, and pancreatic neuroendocrine carcinoma were 23.53%, 14.29%, and 25%, respectively. All 3 cases of acinar cell carcinoma were negative for TFE3. We conclude that SPN may originate from primordial pancreatic cells and is accompanied by some characteristics of neuroendocrine tumors. TFE3, besides beta-catenin, can be an additional diagnostic marker of SPN in differential diagnosis. (C) 2018 The Authors. Published by Elsevier Inc.	[Jiang, Yina; Wang, Bo; Liu, Peijun] Xi An Jiao Tong Univ, Ctr Translat Med, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China; [Jiang, Yina; Wang, Bo; Liu, Peijun] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China; [Jiang, Yina] Xi An Jiao Tong Univ, Dept Pathol, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China; [Xie, Juan] Shaanxi Prov Peoples Hosp, Dept Clin Lab, Xian 710068, Shaanxi, Peoples R China; [Mu, Yudong] Tumor Hosp Shaanxi Prov, Dept Clin Lab, Xian 710061, Shaanxi, Peoples R China	Liu, PJ (reprint author), Xi An Jiao Tong Univ, Ctr Translat Med, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China.; Liu, PJ (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.	liupeijun@xjtu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502413, 81502620]	This work was supported by 2 grants from the National Natural Science Foundation of China (Nos. 81502413 and 81502620).	Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Bergmann F, 2011, HUM PATHOL, V42, P817, DOI 10.1016/j.humpath.2010.10.005; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Cao DF, 2005, MODERN PATHOL, V18, P752, DOI 10.1038/modpathol.3800363; Frantz VK, 1959, ATLAS TUMOR PATHOL, V7, P32; Geers C, 2006, AM J SURG PATHOL, V30, P1243, DOI 10.1097/01.pas.0000213311.28682.b2; Hodge JC, 2014, MODERN PATHOL, V27, P113, DOI 10.1038/modpathol.2013.83; Ismael O, 2012, PEDIATR BLOOD CANCER, V58, P827, DOI 10.1002/pbc.23337; Kallichanda N, 2006, EXP MOL PATHOL, V81, P101, DOI 10.1016/j.yexmp.2006.05.005; Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018; Klimstra DS, 2000, SEMIN DIAGN PATHOL, V17, P66; Kosmahl M, 2000, VIRCHOWS ARCH, V436, P473, DOI 10.1007/s004280050475; Li PP, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0718-3; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Mills SE, 2015, STERNBERGS DIAGNOSTI, P1637; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; PETTINATO G, 1992, AM J CLIN PATHOL, V98, P478, DOI 10.1093/ajcp/98.5.478; Ploper D, 2015, PHARMACOL RES, V99, P36, DOI 10.1016/j.phrs.2015.04.006; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Raben N, 2016, ANNU REV CELL DEV BI, V32, P255, DOI 10.1146/annurev-cellbio-111315-125407; SCHLOSNAGLE DC, 1981, CANCER, V47, P2603, DOI 10.1002/1097-0142(19810601)47:11<2603::AID-CNCR2820471115>3.0.CO;2-Z; Singhi AD, 2014, MODERN PATHOL, V27, P1355, DOI 10.1038/modpathol.2014.40; STOMMER P, 1991, CANCER, V67, P1635, DOI 10.1002/1097-0142(19910315)67:6<1635::AID-CNCR2820670627>3.0.CO;2-M; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tanaka Y, 2001, CANCER RES, V61, P8401; Weiss V, 2016, WORLD J GASTRO ONCOL, V8, P615, DOI 10.4251/wjgo.v8.i8.615; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	29	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						166	175		10.1016/j.humpath.2018.07.005			10	Pathology	Pathology	HB5LM	WOS:000451102300020	30030118	Other Gold			2019-10-28	
J	Kang, J; Han, K; Kim, HJ; Park, JH; Kong, JS; Park, S; Myung, JK				Kang, JiHoon; Han, Kanghee; Kim, Hyeon Jin; Park, Ju Hui; Kong, Jun Suk; Park, Sunhoo; Myung, Jae Kyung			The clinical significance of PINX1 expression in papillary thyroid carcinoma	HUMAN PATHOLOGY			English	Article						PINX1; Papillary thyroid carcinoma; Prognostic marker; Metastasis; Recurrence	HISTONE DEACETYLASE SIRT6; BINDING-FACTOR PINX1; MOLECULAR-GENETICS; TUMOR-SUPPRESSOR; NOTCH PATHWAY; CANCER; TELOMERASE; PROTEIN; POOR; PACLITAXEL	PIN2/TERF1 interacting telomerase inhibitor 1 (PINX1) is a telomerase inhibitor located on human chromosome 8p23 and also acts as a tumor suppressor in several types of cancers, including breast, gastric, ovarian, and bladder cancer. However, the role of PINX1 expression in papillary thyroid carcinoma (PTC) has not been defined. Therefore, we investigated the role of PINX1 expression in PTC by analyzing the correlation between PINX1 expression and various clinicopathological factors. Immunohistochemistry for PINX1 was performed using a tissue microarray of samples taken from the 160 patients with PTC. We also assessed mRNA and protein expression for PINX1 via quantitative real-time polymerase chain reaction and immunohistochemical analysis. Positive staining for PINX1 was found in 16.3% of PTC cases. PINX1 expression was significantly associated with tumor size, lymph node metastasis, telomerase reverse transcriptase, promoter mutation and recurrence. PINX1 mRNA expression was more pronounced in the recurrent group than in the nonrecurrent group. In addition, results of the binary logistic regression model showed that PINX1 protein expression had a significant influence on recurrence. We concluded that PINX1 expression was associated with several clinicopathological factors and had a significant influence on recurrence in patients with PTC. Therefore, PINX1 expression could be a useful prognostic marker in PTC patients. (C) 2018 Elsevier Inc. All rights reserved.	[Kang, JiHoon; Kim, Hyeon Jin; Park, Ju Hui; Park, Sunhoo; Myung, Jae Kyung] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul 01812, South Korea; [Han, Kanghee; Kong, Jun Suk; Park, Sunhoo; Myung, Jae Kyung] Korea Canc Ctr Hosp, Dept Pathol, Seoul 01812, South Korea	Myung, JK (reprint author), Korea Canc Ctr Hosp, Dept Pathol, 75 Nowon Ro, Seoul 139706, South Korea.	tontos016@naver.com			Korea Institute of Radiological and Medical Sciences - Ministry of Science and ICT, Gwacheon-si, Gyeonggi-do, Republic of Korea	This study was supported by a grant from the Korea Institute of Radiological and Medical Sciences funded by the Ministry of Science and ICT, Gwacheon-si, Gyeonggi-do, Republic of Korea (50476-2018).	Ahn HS, 2015, NEW ENGL J MED, V373, P2389, DOI 10.1056/NEJMc1507622; Bai J, 2015, INT J CLIN EXP PATHO, V8, P6952; Bauer I, 2012, J BIOL CHEM, V287, P40924, DOI 10.1074/jbc.M112.405837; Cai MY, 2010, CANCER SCI, V101, P1543, DOI 10.1111/j.1349-7006.2010.01560.x; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Kondo T, 2005, ONCOGENE, V24, P157, DOI 10.1038/sj.onc.1207832; Lee SE, 2016, THYROID, V26, P901, DOI 10.1089/thy.2015.0488; Li HL, 2016, ONCOTARGET, V7, P66267, DOI [10.18632/oncotarget.11728, 10.18632/oncotarget.11411]; Li HL, 2015, ONCOTARGET, V6, P21406, DOI 10.18632/oncotarget.4011; Liu CP, 2016, SCI REP-UK, V6, DOI 10.1038/srep36990; Liu JY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-148; Liu YW, 2013, PROTEIN CELL, V4, P702, DOI 10.1007/s13238-013-3054-5; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Myung JK, 2016, CANCER RES TREAT, V48, P942, DOI 10.4143/crt.2015.362; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/mpath.2008.10; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Nikiforova MN, 2008, EXPERT REV MOL DIAGN, V8, P83, DOI 10.1586/14737159.8.1.83; Qian D, 2013, J PATHOL, V229, P765, DOI 10.1002/path.4163; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Shi ML, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0332-2; Shi R, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-46; Tian XP, 2014, CANCER LETT, V353, P104, DOI 10.1016/j.canlet.2014.07.012; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987; Zhou XZ, 2011, J CLIN INVEST, V121, P1266, DOI 10.1172/JCI43452; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	35	0	0	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						176	183		10.1016/j.humpath.2018.07.004			8	Pathology	Pathology	HB5LM	WOS:000451102300021	30026037				2019-10-28	
J	Davick, JJ; Frierson, HF; Smolkin, M; Gru, AA				Davick, Jonathan J.; Frierson, Henry F.; Smolkin, Mark; Gru, Alejandro A.			PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases	HUMAN PATHOLOGY			English	Article						Bladder cancer; Urothelial carcinoma; Transitional cell carcinoma; PD-L1; PD-1; Immune checkpoint inhibitors; lmmunohistochemistry	UROTHELIAL CARCINOMA; B7-H1 EXPRESSION; PROTEIN EXPRESSION; LUNG-CANCER; ASSOCIATION; THERAPY	Programmed death ligand 1 (PD-L1) is a transmembrane protein that plays a major role in immune suppression. Its interaction with the receptor PD-1 results in downregulation of antitumoral immunity. Humanized monoclonal antibodies that interrupt the PD-L1/PD-1 interaction have shown therapeutic efficacy in patients with advanced urothelial cancer. However, immunohistochemical staining of PD-L1 in bladder tumors and its relationship to tumor histologic type, grade, and overall survival has been incompletely analyzed. Slides from 165 cystectomy specimens were reviewed for tumor type, grade of urothelial carcinoma, pathologic stage, and overall survival. A tissue microarray (TMA) using four 0.6 mm cores from each case was constructed. Immunohistochemistry was performed on the TMA using a variety of new PD-L1 antibodies and platforms now widely available. For each case, the percent of tumor cells positive for PD-L1 and the percent of positive immune cells were scored. The overall number of bladder cancers positive for PD-L1 depended on the antibody/platform combination used and the threshold for considering a tumor "PD-L1 positive." Squamous cell carcinomas (SCCs) of the bladder demonstrated PD-L1 positivity more frequently than urothelial cell carcinomas (UCCs). High-grade UCCs were positive for PD-L1 on tumor cells more frequently than low-grade UCCs. There was no difference in survival between PD-L1 positive and PD-L1 negative bladder cancers in our study. Further studies should consider examining the predictive significance of PD-Ll IHC in bladder cancers. (C) 2018 Elsevier Inc. All rights reserved.	[Davick, Jonathan J.; Frierson, Henry F.; Gru, Alejandro A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Smolkin, Mark] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA	Davick, JJ (reprint author), Univ Virginia Hlth Syst, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	JJD7Y@virginia.edu					Aggen DH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0299-1; Apolo AB, 2017, J CLIN ONCOL, V35, P2117, DOI 10.1200/JCO.2016.71.6795; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Boorjian SA, 2008, CLIN CANCER RES, V14, P4800, DOI 10.1158/1078-0432.CCR-08-0731; Faraj SF, 2015, UROLOGY, V85, DOI 10.1016/j.urology.2014.10.020; Huang YD, 2015, ONCOL REP, V33, P3075, DOI 10.3892/or.2015.3933; Inman BA, 2007, CANCER, V109, P1499, DOI 10.1002/cncr.22588; Karim R, 2009, CLIN CANCER RES, V15, P6341, DOI 10.1158/1078-0432.CCR-09-1652; Konishi J, 2004, CLIN CANCER RES, V10, P5094, DOI 10.1158/1078-0432.CCR-04-0428; Le Goux C, 2017, UROL ONCOL-SEMIN ORI, V35, P257, DOI 10.1016/j.urolonc.2017.01.014; Lipson EJ, 2013, CANCER IMMUNOL RES, V1, P54, DOI 10.1158/2326-6066.CIR-13-0034; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Nakanishi J, 2007, CANCER IMMUNOL IMMUN, V56, P1173, DOI 10.1007/s00262-006-0266-z; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Pichler R, 2017, ONCOTARGET, V8, P66849, DOI 10.18632/oncotarget.19913; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sznurkowski JJ, 2017, ONCOTARGET, V8, P89903, DOI 10.18632/oncotarget.20911; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Ukpo OC, 2013, HEAD NECK PATHOL, V7, P113, DOI 10.1007/s12105-012-0406-z; Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403; Xylinas E, 2014, EJSO-EUR J SURG ONC, V40, P121, DOI 10.1016/j.ejso.2013.08.023	23	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						184	191		10.1016/j.humpath.2018.06.028			8	Pathology	Pathology	HB5LM	WOS:000451102300022	29969606				2019-10-28	
J	Yang, YC; Yang, LF; Li, YX				Yang, Yongchao; Yang, Linfei; Li, Yixiong			Neuropilin-1 (NRP-1) upregulated by IL-6/STAT3 signaling contributes to invasion in pancreatic neuroendocrine neoplasms	HUMAN PATHOLOGY			English	Article						NRP-1; Pancreatic neuroendocrine neoplasms; pNEN; IL-6; Signal transducer and activator of transcription 3; Invasion	ENDOTHELIAL GROWTH-FACTOR; CELL CARCINOMA; CANCER; EXPRESSION; INFLAMMATION; ACTIVATION; STAT3; INTERLEUKIN-6; TUMORS; VEGF	Although the upregulation of Neuropilin-1 (NRP-1) is associated with many solid tumors, its role in pancreatic neuroendocrine neoplasms (pNEN) has not been well elucidated. The aim of this study was to investigate the role of NRP-1 in improving treatment and determining the prognosis of pNEN. In this study, the expression of NRP-1 in pNEN tissue samples and pNEN cell line BON1 was analyzed by Western blot, polymerase chain reaction (PCR) and immunocytochemistry upon exposure to interleukin-6 (IL-6). Additionally, pNEN cell line BON1 was transfected with small interfering RNAs against NRP-1 or signal transducer and activator of transcription 3 (STAT3) and assessed by in vitro invasion assays. The expression of NRP-1 in pNEN tissues was markedly increased compared with adjacent normal pancreatic tissues. High NRP-1 expression was strongly correlated with tumor grades (P = .026), lymph node metastasis (P = .025), and tumor-node-metastasis stages (P = .012). Furthermore, NRP-1 downregulation notably inhibited the metastatic capacity of pNEN cells, and STAT3 knockdown was found to downregulate the expression of NRP-1. BONI cells upregulated NRP-1 expression upon stimulation with IL-6. This was accompanied by activation/phosphorylation of the AKT and STAT3 signaling pathways. Western blot of extracts of human pNENs confirmed increased NRP-1 expression, as well as AKT/STAT3 phosphorylation in tissue of pNENs with elevated expression levels of 1L-6. In conclusion, our findings suggest that NRP-1 is upregulated in pNEN and is correlated with the metastatic capacity of pNEN cells, potentially via interaction with the IL-6/STAT3 signaling pathway. (C) 2018 Published by Elsevier Inc.	[Yang, Yongchao; Li, Yixiong] Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China; [Yang, Linfei] Cent S Univ, Ctr Med Expt, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Li, YX (reprint author), Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China.	liyixiong2011@hotmail.com	Yang, Yongchao/W-2065-2019		China Scholarship Council (CSC)China Scholarship Council [201506370096]	Yongchao Yang has been sponsored by the China Scholarship Council (CSC, 201506370096).	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Alattar M, 2014, EUR J CARDIO-THORAC, V45, P514, DOI 10.1093/ejcts/ezt380; Bosman F. T., 2010, CLASSIFICATION TUMOU; Chatterjee M, 2007, BLOOD, V109, P720, DOI 10.1182/blood-2006-05-024372; Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0; Chen MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061901; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Geretti E, 2008, ANGIOGENESIS, V11, P31, DOI 10.1007/s10456-008-9097-1; Groblewska M, 2008, CLIN CHEM LAB MED, V46, P1423, DOI 10.1515/CCLM.2008.278; Hambek M, 2004, ANTICANCER RES, V24, P3881; Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007; Hartmann N, 2014, CLIN CANCER RES, V20, P3422, DOI 10.1158/1078-0432.CCR-13-2972; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jubb AM, 2012, J PATHOL, V226, P50, DOI 10.1002/path.2989; Kim DK, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-155; Landskron G, 2014, J IMMUNOL RES, DOI 10.1155/2014/149185; Lawrence B, 2011, ENDOCRIN METAB CLIN, V40, P1, DOI 10.1016/j.ecl.2010.12.005; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; Metz DC, 2008, GASTROENTEROLOGY, V135, P1469, DOI 10.1053/j.gastro.2008.05.047; Negrier S, 2004, J CLIN ONCOL, V22, P2371, DOI 10.1200/JCO.2004.06.121; Ohmoto A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010143; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Ptaszynska MM, 2008, MOL CANCER RES, V6, P352, DOI 10.1158/1541-7786.MCR-07-0143; Ravishankaran P, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-18; Ro C, 2013, CHIN J CANCER, V32, P312, DOI 10.5732/cjc.012.10295; Ruffini F, 2013, INT J ONCOL, V43, P297, DOI 10.3892/ijo.2013.1948; Schimmack S, 2012, CANCER-AM CANCER SOC, V118, P2763, DOI 10.1002/cncr.26592; Siddique ZL, 2009, NEUROENDOCRINOLOGY, V89, P458, DOI 10.1159/000209330; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yun UJ, 2012, CANCER LETT, V323, P155, DOI 10.1016/j.canlet.2012.04.003; Zhou M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15433	35	1	1	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						192	200		10.1016/j.humpath.2018.06.030			9	Pathology	Pathology	HB5LM	WOS:000451102300023	30420046				2019-10-28	
J	de Vilhena, AF; Pereira, JCD; Parra, ER; Balancin, ML; Ab'Saber, A; Martins, V; Farhat, C; Abrantes, MM; de Campos, JRM; Tedde, ML; Takagaki, T; Capelozzi, VL				de Vilhena, Alyne Fonseca; das Neves Pereira, Joao Carlos; Parra, Edwin Roger; Balancin, Marcelo Luiz; Ab'Saber, Alexandre; Martins, Vanessa; Farhat, Cecilia; Abrantes, Marcelo Militao; Milanez de Campos, Jose Ribas; Tedde, Miguel Lia; Takagaki, Teresa; Capelozzi, Vera Luiza			Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome	HUMAN PATHOLOGY			English	Article						Carcinoid tumors; Morphometry; Ki-67 index; CD34; D2-40; Survival	LYMPHATIC MICROVESSEL DENSITY; HEALTH-ORGANIZATION CLASSIFICATION; NEUROENDOCRINE TUMORS; HIGH-GRADE; INTRATUMORAL LYMPHATICS; PROGNOSTIC-SIGNIFICANCE; BREAST-CANCER; INDEX; LUNG; DIAGNOSIS	Ki-67 has shown promise as a prognostic factor in pulmonary carcinoids. In this study, we sought to validate the importance of Ki-67 and study the relationships between Ki-67 and other stromal biomarkers of vascular density. We examined Ki-67, CD34, and D2-40 in tumor tissues from 128 patients with surgically excised typical carcinoid of the lung. We used immunohistochemistry and morphometry to evaluate the amount of tumor staining for cellular proliferation (Ki-67), microvascular density (CD34-MVD), and D2-40 lymphovascular density. The main outcome was overall survival, considered as life expectancy until death from metastasis. Specimens from patients with central tumors showed high CD34-MVD (P = .01), which was also significantly associated with a compromised surgical margin, lymph node metastasis, and clinical stage Ib. Equally significant was high D2-40 lymphovascular density in central specimens with a compromised surgical margin and lymph node metastasis. A high Ki-67 proliferation rate was significantly associated with tumors from patients with clinical stage IIb, IIIa, and IV disease. Multivariate Cox model analysis demonstrated that tumor location and stage, surgical margin, tumor size, and N stage were significantly related to survival time (P < .05). Quantitative staining of the tumor for Ki-67 and CD34-MVD served as prognostic factors (P < .05), which were more relevant than the surgical and pathological stage. Ki-67 greater than 5% and CD34-MVD greater than 7% staining comprise a subset of patients with higher death hazard; this outcome may harbor evidence for further prospective studies of target therapy after surgical resection. (C) 2018 Elsevier Inc. All rights reserved.	[de Vilhena, Alyne Fonseca; das Neves Pereira, Joao Carlos; Abrantes, Marcelo Militao; Milanez de Campos, Jose Ribas; Tedde, Miguel Lia] Heart Inst Incor, Dept Thorac Surg, BR-05403000 Sao Paulo, Brazil; [Parra, Edwin Roger] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Balancin, Marcelo Luiz; Ab'Saber, Alexandre; Martins, Vanessa; Farhat, Cecilia; Capelozzi, Vera Luiza] Univ Sao Paulo, Dept Pathol, Lab Genom & Histomorphometry, Sch Med, BR-01246903 Sao Paulo, Brazil; [Takagaki, Teresa] Univ Sao Paulo, Div Pneumol, Heart Inst Incor, Fac Med, BR-05403000 Sao Paulo, Brazil	Capelozzi, VL (reprint author), Univ Sao Paulo, Dept Pathol, Fac Med, Ave Dr Arnaldo 455,Rm 1143, BR-01246903 Sao Paulo, SP, Brazil.	vera.capelozzi@fin.usp.br	AB'SABER, ALEXANDRE/O-9090-2019; Tedde, Miguel L./V-1173-2019; CAPELOZZI, VERA LUIZA/N-1737-2019	Tedde, Miguel L./0000-0002-8178-4243; CAPELOZZI, VERA LUIZA/0000-0001-9732-5853; Balancin, Marcelo/0000-0003-3798-8414	National Counsel of Technological and Scientific Development of the Ministry of Science-CNPq, Technology and Innovation of Brazil [P246042/2012-5]; Foundation for the Support of Research of the State of Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2013/14277-4]	The authors are grateful for financial support provided by the National Counsel of Technological and Scientific Development of the Ministry of Science-CNPq, Technology and Innovation of Brazil (P246042/2012-5), and the Foundation for the Support of Research of the State of Sao Paulo (FAPESP 2013/14277-4).	Abdalla SA, 1999, ONCOL REP, V6, P839; Al-Khafaji B, 1998, HUM PATHOL, V29, P992, DOI 10.1016/S0046-8177(98)90206-4; Anthony LB, 2010, PANCREAS, V39, P767, DOI 10.1097/MPA.0b013e3181ec1261; Basavanhally AN, 2010, IEEE T BIO-MED ENG, V57, P642, DOI 10.1109/TBME.2009.2035305; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Beasley NJP, 2002, CANCER RES, V62, P1315; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Brown LM, 2018, ANN THORAC SURG, V105, P207, DOI 10.1016/j.athoracsur.2017.07.049; Clay V, 2017, CLIN TRANSL ONCOL, V19, P579, DOI 10.1007/s12094-016-1568-z; COSTES V, 1995, HUM PATHOL, V26, P740, DOI 10.1016/0046-8177(95)90221-X; Daddi N, 2014, EUR J CARDIO-THORAC, V45, P677, DOI 10.1093/ejcts/ezt470; El-Gohary YM, 2008, AM J CLIN PATHOL, V129, P578, DOI 10.1309/2HGNJ1GU57JMBJAQ; Erovic BM, 2005, WIEN KLIN WOCHENSCHR, V117, P53, DOI 10.1007/s00508-004-0298-3; Faggiano A, 2008, J ENDOCRINOL INVEST, V31, P216, DOI 10.1007/BF03345593; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Folkman J, 2003, EXS, V79, P1; Grimaldi Franco, 2011, Front Endocrinol (Lausanne), V2, P20, DOI 10.3389/fendo.2011.00020; Guldhammer B, 2010, J THORAC ONCOL, V5, P453, DOI 10.1097/JTO.0b013e3181ca063b; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hall FT, 2003, ARCH OTOLARYNGOL, V129, P716, DOI 10.1001/archotol.129.7.716; Karpanen T, 2001, J EXP MED, V194, pF37, DOI 10.1084/jem.194.6.F37; Klimstra DS, 2010, AM J SURG PATHOL, V34, P300, DOI 10.1097/PAS.0b013e3181ce1447; Liang L, 2018, ONCOTARGET, V9, P5406, DOI 10.18632/oncotarget.23526; Lin HT, 2013, MOL VIS, V19, P166; Ling SQ, 2012, ARCH OPHTHALMOL-CHIC, V130, P735, DOI 10.1001/archophthalmol.2012.293; Liu SZ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0174-z; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marion-Audibert AM, 2003, GASTROENTEROLOGY, V125, P1094, DOI 10.1016/S0016-5085(03)01198-3; Marks A, 1999, BRIT J CANCER, V80, P569, DOI 10.1038/sj.bjc.6690393; Matsumoto K, 2007, DIS COLON RECTUM, V50, P308, DOI 10.1007/s10350-006-0792-y; Maula SM, 2003, CANCER RES, V63, P1920; Meijer-Jorna LB, 2007, J CLIN PATHOL, V60, P798, DOI 10.1136/jcp.2006.038885; Nassif Aissar Eduardo, 2010, Rev. Col. Bras. Cir., V37, P338, DOI 10.1590/S0100-69912010000500006; Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464; Neder L, 2004, CLIN NEUROPATHOL, V23, P262; Pathmanathan N, 2013, J CLIN PATHOL, V66, P512, DOI 10.1136/jclinpath-2012-201085; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Reid MD, 2015, MODERN PATHOL, V28, P686, DOI 10.1038/modpathol.2014.156; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Rindi G, 2014, ENDOCR-RELAT CANCER, V21, P1, DOI 10.1530/ERC-13-0246; Ruben I, 2010, DIAGN CYTOPATHOL, V38, P217, DOI 10.1002/dc.21180; Rugge M, 2008, CLIN CANCER RES, V14, P149, DOI 10.1158/1078-0432.CCR-07-1631; Swarts DRA, 2017, HISTOPATHOLOGY, V70, P412, DOI 10.1111/his.13096; Tang LH, 2016, CLIN CANCER RES, V22, P1011, DOI 10.1158/1078-0432.CCR-15-0548; Thunnissen E, 2017, J THORAC ONCOL, V12, P334, DOI 10.1016/j.jtho.2016.12.004; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152; Walts AE, 2012, MODERN PATHOL, V25, P1258, DOI 10.1038/modpathol.2012.81; Yildiz E, 2008, BJU INT, V101, P758, DOI 10.1111/j.1464-410X.2007.07318.x; Zhang S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3338-x; Zheng G, 2013, ACTA CYTOL, V57, P281, DOI 10.1159/000346394	54	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						201	210		10.1016/j.humpath.2018.07.007			10	Pathology	Pathology	HB5LM	WOS:000451102300024	30031097				2019-10-28	
J	Atmangush, A; Ruuskanen, M; Hagstrom, J; Hirvikoski, P; Tommola, S; Kosma, VM; Nieminen, P; Makitie, A; Leivo, L				Atmangush, Athadi; Ruuskanen, Miia; Hagstrom, Jaana; Hirvikoski, Pasi; Tommola, Satu; Kosma, Veli-Matti; Nieminen, Pentti; Makitie, Antti; Leivo, Limo			Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study	HUMAN PATHOLOGY			English	Article						Nasopharyngeal carcinoma (NPC); Tumor-infiltrating lymphocytes (TILs); Prognosis; Marker; Survival	PROGNOSTIC-SIGNIFICANCE; BREAST-CANCER; INTEROBSERVER AGREEMENT; TILS; PATHOLOGISTS	The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been studied recently in many cancers. For the first time in a nonendemic region, we have evaluated the prognostic value of TILs in a whole population based nationwide cohort of nasopharyngeal carcinoma (NPC) in Finland. A total of 115 cases from Finnish hospitals were included. TILs were analyzed using hematoxylin and eosin stained slides according to the criteria of the International Immuno-Oncology Biomarker Working Group. TILs were evaluated separately in stromal and tumor compartments. The log-rank test and univariable and multivariable analyses were used to compare survival in patients with tumors with low and high TILs. A significant positive correlation was observed between the occurrence of intratumoral and stromal TILs (P < .001). In multivariable analysis, NPC cases with low intratumoral TILs had poor overall survival with a hazard ratio (HR) of 2.55 and 95% confidence interval (95% CI) of 1.60 to 4.05 (P < .001). Cases with low intratumoral TILs also had poor disease-specific survival (HR, 2.02; 95% CI, 1.16-3.52; P = .015). Keratinized tumors with low intratumoral TILs were associated with an even poorer overall survival (HR, 3.94; 95% CI, 2.17-7.15; P < .001) and a poor disease-specific survival (HR, 2.97; 95% CI, 1.46-6.05; P = .009). Our study demonstrates that the evaluation of TILs is simple and can be assessed routinely in NPC. (C) 2018 Elsevier Inc. All rights reserved.	[Atmangush, Athadi; Hagstrom, Jaana] Univ Helsinki, Dept Pathol, POB 21, Helsinki, Finland; [Atmangush, Athadi; Leivo, Limo] Univ Turku, Inst Biomed, Pathol, POB 20520, Turku, Finland; [Atmangush, Athadi] Univ Misurata, Inst Dent, POB 2478, Misurata, Libya; [Ruuskanen, Miia] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, POB 52, Turku 20521, Finland; [Ruuskanen, Miia] Univ Turku, POB 52, Turku 20521, Finland; [Hagstrom, Jaana] Helsinki Univ Hosp, HusLab, POB 100, FI-00029 Helsinki, Finland; [Hagstrom, Jaana] Univ Helsinki, Res Programs Unit, Translat Canc Biol, FI-00290 Helsinki, Finland; [Hirvikoski, Pasi] Oulu Univ Hosp, Dept Pathol, POB 10, Oulu 90029, Finland; [Tommola, Satu] Fimlab Labs, Dept Pathol, POB 66, FI-33101 Tampere, Finland; [Kosma, Veli-Matti] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Sch Med, POB 1627, Kuopio, Finland; [Kosma, Veli-Matti] Univ Eastern Finland, Canc Ctr Eastern Finland, POB 1627, Kuopio, Finland; [Kosma, Veli-Matti] Kuopio Univ Hosp, Imaging Ctr, Clin Pathol, POB 100, Kuopio, Finland; [Nieminen, Pentti] Univ Oulu, Med Informat & Stat Res Grp, POB 5000, FI-90014 Oulu, Finland; [Makitie, Antti] Helsinki Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, POB 263, FI-00029 Helsinki, Finland; [Makitie, Antti] Univ Helsinki, POB 263, FI-00029 Helsinki, Finland; [Makitie, Antti] Karolinska Inst, Div Ear Nose & Throat Dis, Dept Clin Sci Intervent & Technol, Karolinska Univ Hosp, SE-17176 Stockholm, Sweden	Atmangush, A (reprint author), Univ Helsinki, Dept Pathol, POB 21, Helsinki, Finland.	alhadi.almangush@helsinki.fi	Nieminen, Pentti/A-7571-2012; Hagstrom, Jaana/G-1468-2018	Nieminen, Pentti/0000-0003-0591-586X; Hagstrom, Jaana/0000-0001-6079-7881	Helsinki University Hospital Research Fund; Finnish Cancer Society; Finska Lakaresallskapet; Maritza and Reino Salonen Foundation	The authors acknowledge the funders of this study: Helsinki University Hospital Research Fund, The Finnish Cancer Society, Finska Lakaresallskapet, and Maritza and Reino Salonen Foundation.	APPLEBAUM EL, 1982, LARYNGOSCOPE, V92, P510; Azimi F, 2012, J CLIN ONCOL, V30, P2678, DOI 10.1200/JCO.2011.37.8539; Badalamenti G, 2018, CELL IMMUNOL; Buisseret L, 2017, MODERN PATHOL, V30, P1204, DOI 10.1038/modpathol.2017.43; de Ruiter EJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356148; El-Naggar AK, 2017, HUM PATHOL, V66, P10, DOI 10.1016/j.humpath.2017.05.014; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161; Huang WB, 2018, CANCER-AM CANCER SOC, V124, P530, DOI 10.1002/cncr.31031; Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35; Ilie M, 2017, CURR MOL MED, V17, P527, DOI 10.2174/1566524018666180222114038; James FR, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3585-x; Kashiwagi S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170634; Kirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021; Kleinbaum DGKM, 2005, SURVIVAL ANAL SELF L; Kojima YA, 2018, ANN DIAGN PATHOL, V35, P77, DOI 10.1016/j.anndiagpath.2018.05.007; Lang-Schwarz C, 2018, HUM PATHOL, V79, P160, DOI 10.1016/j.humpath.2018.05.010; Larbcharoensub N, 2018, AM J CLIN ONCOL; Lee AWM, 2012, RADIOTHER ONCOL, V104, P272, DOI 10.1016/j.radonc.2012.08.001; Ooft ML, 2017, ORAL ONCOL, V71, P16, DOI 10.1016/j.oraloncology.2017.05.015; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Rakaee M, 2018, HUM PATHOL, V79, P188, DOI 10.1016/j.humpath.2018.05.017; Ruuskanen M, 2018, ACTA ONCOL, V57, P251, DOI 10.1080/0284186X.2017.1346378; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Sobin LH, 2009, TNM CLASSIFICATION M; Stein AV, 2017, PATHOLOGY, V49, P30, DOI 10.1016/j.pathol.2016.10.005; Sung NS, 1998, INT J CANCER, V76, P207, DOI 10.1002/(SICI)1097-0215(19980413)76:2<207::AID-IJC7>3.0.CO;2-0; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Toh JWT, 2016, CLIN COLORECTAL CANC, V15, P285, DOI 10.1016/j.clcc.2016.07.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tramm T, 2018, ACTA ONCOL, V57, P90, DOI 10.1080/0284186X.2017.1403040; Wang YQ, 2018, INT J CANCER, V142, P2558, DOI 10.1002/ijc.31279; Wei KR, 2011, ASIAN PAC J CANCER P, V12, P1141; Zhang XK, 2015, TUMOR BIOL, V36, P5201, DOI 10.1007/s13277-015-3176-x	37	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						211	219		10.1016/j.humpath.2018.07.009			9	Pathology	Pathology	HB5LM	WOS:000451102300025	30030117	Green Accepted, Green Published			2019-10-28	
J	Wang, R; He, DF; Zhao, LL; Liang, SS; Liang, DD; Xu, F; Zhang, MC; Zhu, XD; Chen, HP; Xie, HT; Zeng, CH; Tang, Z; Liu, ZH				Wang, Rong; He, Dafeng; Zhao, Lili; Liang, Shaoshan; Liang, Dandan; Xu, Feng; Zhang, Mingchao; Zhu, Xiaodong; Chen, Huiping; Xie, Hongtang; Zeng, Caihong; Tang, Zheng; Liu, Zhihong			Role of complement system in patients with biopsy-proven immunoglobulin G4 related kidney disease	HUMAN PATHOLOGY			English	Article						IgG4-related kidney disease; Complement; Tubulointerstitial nephritis; Membranous glomerulone-phritis; Storiform fibrosis	IGG4-RELATED DISEASE; DIAGNOSTIC-CRITERIA; ACTIVATION	Hypocomplementemia has been frequently reported in immunoglobulin G4-related kidney disease (IgG4-RKD). However, studies on the role of complement system in IgG4-RKD are lacking. A total of 40 429 renal biopsies from January 2010 to January 2018 were reexamined in the present study, and 17 patients were confirmed to meet the criteria of IgG4-RKD. According to the serum C3 levels, they were divided into 2 groups: the low-C3 group (C3 <0.8 g/L, n = 7) and the normal-C3 group (C3 >= 0.8 g/L, n = 10). Compared with the normal-C3-level group, the patients in the low-C3-level group had lower serum C4 concentrations (P = .025), higher serum IgG4 concentrations (P = .003), higher positive rates in rheumatoid factor (P = .033), more severe storiform fibrosis (P = .007) at diagnosis, and higher blood urea nitrogen levels at the latest test (P = .04). The serum levels of C3 were in negative correlation with the serum levels of IgG4 (P = .003), the levels of rheumatoid factor (P = .002), renal deposition of Clq (P = .028), storiform fibrosis (P < .001), scores of interstitial fibrosis (P = .015), the amount of renal IgG4 positive (IgG4(+)) plasma cells (P = .020), the ratios of IgG4(+) plasma cells/CD138(+) cells (P = .018), and the blood urea nitrogen concentrations at the last test (P = .023). Our study shows that IgG4-RKD is a relatively rare entity. Complement system may participate in the development of IgG4-RKD. (C) 2018 Elsevier Inc. All rights reserved.	[Wang, Rong; He, Dafeng; Zhao, Lili; Liang, Shaoshan; Liang, Dandan; Xu, Feng; Zhang, Mingchao; Zhu, Xiaodong; Chen, Huiping; Xie, Hongtang; Zeng, Caihong; Tang, Zheng; Liu, Zhihong] Nanjing Med Univ, Natl Clin Res Ctr Kidney Dis, Jinling Clin Med Coll, Nanjing 210002, Jiangsu, Peoples R China; [Wang, Rong; He, Dafeng] Yangzhou Univ, Nephrol Dept, Northern Jiangsu Peoples Hosp, Yangzhou 225001, Jiangsu, Peoples R China	Tang, Z (reprint author), Nanjing Med Univ, Natl Clin Res Ctr Kidney Dis, Jinling Clin Med Coll, Nanjing 210002, Jiangsu, Peoples R China.	tang_dr@163.com					Alexander MP, 2013, KIDNEY INT, V83, P455, DOI 10.1038/ki.2012.382; Cook HT, 2018, J AM SOC NEPHROL, V29, P9, DOI 10.1681/ASN.2017111183; Cornell LD, 2012, SEMIN DIAGN PATHOL, V29, P245, DOI 10.1053/j.semdp.2012.07.004; Cortazar FB, 2015, NAT REV NEPHROL, V11, P599, DOI 10.1038/nrneph.2015.95; Huber-Lang M, 2018, SEMIN IMMUNOPATHOL, V40, P87, DOI 10.1007/s00281-017-0646-9; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Kawano M, 2016, SEMIN LIVER DIS, V36, P283, DOI 10.1055/s-0036-1584316; Kawano M, 2015, CURR OPIN NEPHROL HY, V24, P193, DOI 10.1097/MNH.0000000000000102; Kawano M, 2011, CLIN EXP NEPHROL, V15, P615, DOI 10.1007/s10157-011-0521-2; Kim TY, 2011, CLIN NEPHROL, V76, P440, DOI 10.5414/CN107117; Koscielska-Kasprzak K, 2014, ARCH IMMUNOL THER EX, V62, P47, DOI 10.1007/s00005-013-0254-x; Kuroda N, 2014, INT J CLIN EXP PATHO, V7, P6379; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Mac K, 2017, J CLIN PATHOL, V70, P483, DOI 10.1136/jclinpath-2016-203905; Mann Shawna, 2016, Can J Kidney Health Dis, V3, P34, DOI 10.1186/s40697-016-0126-5; Muraki T, 2006, PANCREAS, V32, P16, DOI 10.1097/01.mpa.0000188308.75043.e4; Nada R, 2016, INT J RHEUM DIS, V19, P721, DOI 10.1111/1756-185X.12675; Nakashima H, 2017, CLIN EXP NEPHROL, V21, P97, DOI 10.1007/s10157-016-1260-1; Pradhan D, 2015, PATHOL RES PRACT, V211, P707, DOI 10.1016/j.prp.2015.03.004; Quattrocchio G, 2016, J NEPHROL, V29, P487, DOI 10.1007/s40620-016-0279-4; Raissian Y, 2011, J AM SOC NEPHROL, V22, P1343, DOI 10.1681/ASN.2011010062; Saeki T, 2013, KIDNEY INT, V84, P826, DOI 10.1038/ki.2013.191; Saeki T, 2010, KIDNEY INT, V78, P1016, DOI 10.1038/ki.2010.271; Saeki T, 2009, RHEUMATOL INT, V30, P99, DOI 10.1007/s00296-009-0925-4; Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x; Song D, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4142; Sugimoto M, 2016, MOD RHEUMATOL, V26, P251, DOI 10.3109/14397595.2015.1076924; Tang XL, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0311-3; Yamaguchi Y, 2012, HUM PATHOL, V43, P536, DOI 10.1016/j.humpath.2011.06.002; Yoshita K, 2012, NEPHROL DIAL TRANSPL, V27, P2755, DOI 10.1093/ndt/gfr761	30	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						220	228		10.1016/j.humpath.2018.07.008			9	Pathology	Pathology	HB5LM	WOS:000451102300026	30031099				2019-10-28	
J	Vischini, G; Kapp, ME; Wheeler, FC; Hopp, L; Fogo, AB				Vischini, Gisella; Kapp, Meghan E.; Wheeler, Ferrin C.; Hopp, Laszlo; Fogo, Agnes B.			A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome	HUMAN PATHOLOGY			English	Article						Alpha 3 type IV collagen; Alport; Glomerular basement membrane; IgAN; Hematuria	NEPHROPATHY; MUTATIONS; FEATURES	Alport syndrome is due to mutations in one of the genes encoding (alpha 3,4,5) type IV collagen resulting in defective type IV collagen, a key component of the glomerular basement membrane (GBM). The GBM is initially thin and, with ongoing remodeling, develops a thickened basket-woven appearance. We report a unique case of a 9-year-old boy who underwent biopsy for hematuria and proteinuria, diagnosed as IgA nephropathy, with normal GBM appearance and thickness. Because of a family history of hematuria and chronic kidney disease, he subsequently underwent genetic evaluation, and a mutation of alpha 3 type IV collagen (COL4A3) was detected. Additional studies of the initial biopsy demonstrated abnormal type IV collagen immunostaining. A repeat biopsy 4 years later showed characteristic glomerular basement membrane morphology of Alport syndrome and scarring consistent with sequelae of IgA nephropathy. This is the first description of this unusual transition from an initial normal appearance of the glomerular basement membrane to the classic Alport phenotype. (C) 2018 Elsevier Inc. All rights reserved.	[Vischini, Gisella] Catholic Univ, Dept Internal Med & Med Special, Columbus Gemelli Univ Hosp, Div Nephrol, Via Moscati 31-33, I-00176 Rome, Italy; [Vischini, Gisella; Kapp, Meghan E.; Wheeler, Ferrin C.; Fogo, Agnes B.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Hopp, Laszlo] East Tennessee Childrens Hosp, Dept Pediat, Div Nephrol, Knoxville, TN 37916 USA	Vischini, G (reprint author), Catholic Univ, Dept Internal Med & Med Special, Columbus Gemelli Univ Hosp, Div Nephrol, Via Moscati 31-33, I-00176 Rome, Italy.	vischini.gisella@gmail.com; meghan.e.kapp@vanderbilt.edu; ferrin.c.wheeler@vanderbilt.edu; lhopp@etch.com; agnes.fogo@vanderbilt.edu	Vischini, Gisella/N-9980-2019	Vischini, Gisella/0000-0001-5829-4396			Fallerini C, 2014, CLIN GENET, V86, P252, DOI 10.1111/cge.12258; GUBLER M, 1981, AM J MED, V70, P493, DOI 10.1016/0002-9343(81)90571-4; Haas M, 2017, J AM SOC NEPHROL, V28, P691, DOI 10.1681/ASN.2016040433; Hotta O, 1985, AM J KIDNEY DIS, V5, P157; Hwang YJ, 2013, KIDNEY RES CLIN PRAC, V32, P111, DOI 10.1016/j.krcp.2013.07.001; Jais JP, 2000, J AM SOC NEPHROL, V11, P649; Lanteri M, 1996, NEPHROL DIAL TRANSPL, V11, P791, DOI 10.1093/oxfordjournals.ndt.a027400; Leiden University Medical Center, LEID OP VAR DAT V3 0; Miner JH, 2014, KIDNEY INT, V86, P679, DOI 10.1038/ki.2014.229; Roberts ISD, 2009, KIDNEY INT, V76, P546, DOI 10.1038/ki.2009.168; Rosado C, 2015, KIDNEY BLOOD PRESS R, V40, P435, DOI 10.1159/000368519; Storey H, 2013, J AM SOC NEPHROL, V24, P1945, DOI 10.1681/ASN.2012100985; Xie JY, 2014, J MOL CELL BIOL, V6, P498, DOI 10.1093/jmcb/mju040	13	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						229	234		10.1016/j.humpath.2018.02.024			6	Pathology	Pathology	HB5LM	WOS:000451102300027	29530752				2019-10-28	
J	Libera, L; Craparotta, I; Sahnane, N; Chiaravalli, AM; Mannarino, L; Cerutti, R; Riva, C; Marchini, S; Furlan, D				Libera, Laura; Craparotta, Ilaria; Sahnane, Nora; Chiaravalli, Anna Maria; Mannarino, Laura; Cerutti, Roberta; Riva, Cristina; Marchini, Sergio; Furlan, Daniela			Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas	HUMAN PATHOLOGY			English	Article						Endometrial cancer; MMR defect; Lynch syndrome; Targeted sequencing; ARID 1A; MLH 1 silencing	CANCER; EXPRESSION; MUTATIONS; DEFICIENCY	About one-third of endometrial carcinomas (ECs), mainly of endometrioid histology, harbor the mismatch repair (MMR) defects and microsatellite instability (MSI). Among these, ECs arising in women with Lynch syndrome (LS) account for a large proportion. To date, no somatic genetic analyses have been published comparing LS-ECs with sporadic ECs. In this work, we examined the mutational profiles of a well-characterized series of sporadic and LS-related ECs, performing exonic targeted sequencing of 16 genes mainly involved in MSI ECs. Next-generation sequencing analysis was performed in 35 ECs on the MiSeq platform (Illumina, San Diego, CA), and the mutational profile was analyzed integrating molecular and immunohistochemical data. PTEN, ARID1A, and ARID2 were the most frequently mutated genes regardless of MSI status or family history. MSI ECs showed a higher mutational load than MMR-proficient cases, exhibiting an MMR-deficient mutational signature. Among MSI tumors, LS-related and sporadic ECs exhibited similar mutational profiles, with MSH2 as the most commonly mutated gene. KRAS mutations seemed to be more common in sporadic MSI ECs than in LS-related ECs even if further studies are needed to confirm this finding. MMR-deficient ECs carried a higher mutational load and an excess of C>T transitions compared with MMR-proficient ECs, suggesting that the use of a small gene panel may be adequate to highlight significant differences between these 2 groups. An integrated analysis of genetic and epigenetic features of LS-related and sporadic ECs provides useful insights into disease biology and diagnostic classification of these tumors. (C) 2018 Elsevier Inc. All rights reserved.	[Libera, Laura; Sahnane, Nora; Cerutti, Roberta; Riva, Cristina; Furlan, Daniela] Univ Insubria, Dept Med & Surg, Unit Pathol, I-21100 Varese, Italy; [Craparotta, Ilaria; Mannarino, Laura; Marchini, Sergio] IRCCS Inst Pharmacol Res Mario Negri, Dept Oncol, I-20156 Milan, Italy; [Sahnane, Nora; Chiaravalli, Anna Maria; Cerutti, Roberta; Riva, Cristina; Furlan, Daniela] Univ Insubria, Dept Med & Surg, Res Ctr Study Hereditary & Familial Tumors, I-21100 Varese, Italy; [Chiaravalli, Anna Maria] ASST Sette Laghi, Unit Pathol, I-21100 Varese, Italy	Sahnane, N (reprint author), Univ Insubria, Dept Med & Surg, Via O Rossi 9, IT-21100 Varese, Italy.	n.salmane@gmail.com	Mannarino, Laura/AAB-3766-2019	Mannarino, Laura/0000-0002-0290-4228; Cerutti, Roberta/0000-0002-3570-4070	Epigenomics Flagship Project-Epigen CNR-IT (Roma, Italy) [08934412]; University of Insubria (Varese, Italy)	This study was supported by the Epigenomics Flagship Project-Epigen CNR-IT (Roma, Italy) (to D. Furlan, project number 08934412) and by the University of Insubria (Varese, Italy).	Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Banno K, 2014, J OBSTET GYNAECOL RE, V40, P1957, DOI 10.1111/jog.12442; Bosse T, 2013, MODERN PATHOL, V26, P1525, DOI 10.1038/modpathol.2013.96; Carnevali I, 2017, INT J GYNECOL CANCER, V27, P1543, DOI 10.1097/IGC.0000000000001010; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Fang MG, 2016, P NATL ACAD SCI USA, V113, P1250, DOI 10.1073/pnas.1525619113; Fang MG, 2014, MOL CELL, V55, P904, DOI 10.1016/j.molcel.2014.08.010; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hong B, 2015, CURR OPIN GENET DEV, V30, P25, DOI 10.1016/j.gde.2014.12.004; Huang M, 2013, CANCER-AM CANCER SOC, V119, P3027, DOI 10.1002/cncr.28152; Joensuu EI, 2015, GENE CHROMOSOME CANC, V54, P776, DOI 10.1002/gcc.22289; Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liang H, 2012, GENOME RES, V22, P2120, DOI 10.1101/gr.137596.112; Libera L, 2017, J CLIN PATHOL, V70, P792, DOI 10.1136/jclinpath-2017-204348; Loeb LA, 2016, CANCER RES, V76, P2057, DOI 10.1158/0008-5472.CAN-16-0794; McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyer LA, 2009, CANCER CONTROL, V16, P14, DOI 10.1177/107327480901600103; O'Hara Andrea J, 2012, Adv Genomics Genet, V2012, P33; Peltomaki P, 2016, FAM CANCER, V15, P385, DOI 10.1007/s10689-016-9882-8; Risinger JI, 1997, CANCER RES, V57, P4736; Sahnane N, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0165-2; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Shia J, 2013, FAM CANCER, V12, P241, DOI 10.1007/s10689-013-9612-4; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Takeda T, 2016, ONCOL REP, V35, P607, DOI [10.3892/or.20154421, 10.3892/or.2015.4421]; Vaughn CP, 2010, HUM MUTAT, V31, P588, DOI 10.1002/humu.21230	30	0	0	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						235	244		10.1016/j.humpath.2018.06.029			10	Pathology	Pathology	HB5LM	WOS:000451102300028	30420047				2019-10-28	
J	Lodewijk, L; Willems, SM; Dreijerink, KMA; de Keizer, B; van Diest, PJ; Schepers, A; Morreau, H; Bonenkamp, HJ; Van Engen-van Grunsven, IACH; Kruijff, S; van Hemel, BM; Links, TP; van Dijkum, EN; van Eeden, S; Valk, GD; Rinkes, IHMB; Vriens, MR				Lodewijk, Lutske; Willems, Stefan M.; Dreijerink, Koen M. A.; de Keizer, Bart; van Diest, Paul J.; Schepers, Abbey; Morreau, Hans; Bonenkamp, Han J.; Van Engen-van Grunsven, Ilse A. C. H.; Kruijff, Schelto; van Hemel, Bettien M.; Links, Thera P.; van Dijkum, Els Nieveen; van Eeden, Susanne; Valk, Gerlof D.; Rinkes, Inne H. M. Borel; Vriens, Menno R.			The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer	HUMAN PATHOLOGY			English	Article						Medullary thyroid cancer; Prostate-specific membrane antigen; Theranostics; Tissue microarray; Immunohistochemistry; Imaging	MONOCLONAL-ANTIBODY J591; PSMA; THERAPY; CARCINOMA; NEOVASCULATURE; PET	Medullary thyroid cancer (MTC) accounts for 4% of all thyroid cancers and originates from the parafollicular C-cells. Prostate-specific membrane antigen (PSMA) is known for its expression in the epithelium of prostate cancer and has been demonstrated to be useful both for therapeutic and diagnostic purposes as a so-called theranostic target. As PSMA is also expressed in the neovasculature of other solid tumor types, our aim was to assess PSMA expression and its prognostic role in MTC. Tissues from patients that underwent surgery for MTC between 1988 and 2014 in five tertiary referral centers in The Netherlands were included in a tissue microarray. Using immunohistochemistry, total numbers of PSMA and CD31-positive microvessels were evaluated. Results showed that 92% of MTC expressed PSMA in the neovasculature, whereas the tumor cells were consistently negative. The average number of PSMA-positive microvessels did not differ significantly between the primary tumor and initial lymph node metastases (P = .09), nor between initial and recurrent lymph node metastases (P = 1.00). The PSMA score was found to be correlated with progression-free survival and overall survival. In multivariate analysis, a higher number of PSMA-positive microvessels was associated with favorable prognosis (odds ratio 3.6; 95% confidence interval 1.0-12.8; P = .05). In conclusion, over 90% of MTC appears to express PSMA in the neovasculature. A higher number of PSMA-positive microvessels is prognostically favorable. Since it is highly expressed in MTC, PSMA is an interesting novel target for imaging and potentially also as a target for peptide radioligand therapy in MTC. (C) 2018 Elsevier Inc. All rights reserved.	[Lodewijk, Lutske; Rinkes, Inne H. M. Borel; Vriens, Menno R.] Univ Med Ctr Utrecht, Dept Surg, NL-3584 CX Utrecht, Netherlands; [Willems, Stefan M.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands; [Dreijerink, Koen M. A.; Valk, Gerlof D.] Univ Med Ctr Utrecht, Dept Endocrine Oncol, NL-3584 CX Utrecht, Netherlands; [de Keizer, Bart] Univ Med Ctr Utrecht, Dept Radiol, NL-3584 CX Utrecht, Netherlands; [Schepers, Abbey] Leiden Univ, Med Ctr, Dept Surg, NL-2333 ZA Leiden, Netherlands; [Morreau, Hans] Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands; [Bonenkamp, Han J.] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6525 GA Nijmegen, Netherlands; [Van Engen-van Grunsven, Ilse A. C. H.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 GA Nijmegen, Netherlands; [Kruijff, Schelto] Univ Med Ctr Groningen, Dept Surg, NL-9700 RB Groningen, Netherlands; [van Hemel, Bettien M.] Univ Med Ctr Groningen, Dept Pathol, NL-9700 RB Groningen, Netherlands; [Links, Thera P.] Univ Med Ctr Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands; [van Dijkum, Els Nieveen] Acad Med Ctr Amsterdam, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [van Eeden, Susanne] Acad Med Ctr Amsterdam, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Vriens, MR (reprint author), Univ Med Ctr Utrecht, Dept Surg G 04 228, POB 85500, NL-3508 GA Utrecht, Netherlands.	mvriens@umcutrecht.nl		de Keizer, Bart/0000-0002-6270-9483			Arora S, 2018, CLIN NUCL MED, V43, P359, DOI 10.1097/RLU.0000000000002010; Bander NH, 2005, J CLIN ONCOL, V23, P4591, DOI 10.1200/JCO.2005.05.160; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Bouchelouche K, 2016, SEMIN NUCL MED, V46, P522, DOI 10.1053/j.semnuclmed.2016.07.006; Bradbury R, 2015, BIOMARK MED, V9, P1353, DOI 10.2217/bmm.15.94; Cakir M, 2009, NEUROENDOCRINOLOGY, V90, P323, DOI 10.1159/000220827; Crowley MJP, 2016, J CLIN ENDOCR METAB, V101, P981, DOI 10.1210/jc.2015-4021; Gordon IO, 2008, MODERN PATHOL, V21, P1421, DOI 10.1038/modpathol.2008.143; Haffner MC, 2012, MODERN PATHOL, V25, P1079, DOI 10.1038/modpathol.2012.66; Haffner MC, 2009, HUM PATHOL, V40, P1754, DOI 10.1016/j.humpath.2009.06.003; ISRAELI RS, 1994, CANCER RES, V54, P1807; Koperek O, 2011, J PATHOL, V225, P63, DOI 10.1002/path.2926; Kratochwil C, 2016, J NUCL MED, V57, P1941, DOI 10.2967/jnumed.116.178673; Lodewijk L, 2017, ONCOTARGET, V8, P28650, DOI 10.18632/oncotarget.15622; Lutje S, 2017, CLIN NUCL MED, V42, P20, DOI 10.1097/RLU.0000000000001454; Maurer T, 2016, NAT REV UROL, V13, P226, DOI 10.1038/nrurol.2016.26; Milowsky MI, 2007, J CLIN ONCOL, V25, P540, DOI 10.1200/JCO.2006.07.8097; Modigliani E, 1998, CLIN ENDOCRINOL, V48, P265, DOI 10.1046/j.1365-2265.1998.00392.x; Moore M, 2017, ENDOCR PATHOL, V28, P339, DOI 10.1007/s12022-017-9500-9; Morris MJ, 2007, CLIN CANCER RES, V13, P2707, DOI 10.1158/1078-0432.CCR-06-2935; Pandit-Taskar N, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0104-4; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Pellegriti G, 2003, BRIT J CANCER, V88, P1537, DOI 10.1038/sj.bjc.6600930; Perner S, 2007, HUM PATHOL, V38, P696, DOI 10.1016/j.humpath.2006.11.012; Rahbar K, 2017, J NUCL MED, V58, P85, DOI 10.2967/jnumed.116.183194; Ristau BT, 2014, UROL ONCOL-SEMIN ORI, V32, P272, DOI 10.1016/j.urolonc.2013.09.003; Sweat SD, 1998, UROLOGY, V52, P637, DOI 10.1016/S0090-4295(98)00278-7; Tagawa ST, 2013, CLIN CANCER RES, V19, P5182, DOI 10.1158/1078-0432.CCR-13-0231; Tagawa ST, 2010, CANCER-AM CANCER SOC, V116, P1075, DOI 10.1002/cncr.24795; van der Groep P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056055; van Diest PJ, 2002, BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Wang HL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125924; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335; Wernicke AG, 2017, APPL IMMUNOHISTO M M, V25, P271, DOI 10.1097/PAI.0000000000000297; Wernicke AG, 2014, APMIS, V122, P482, DOI 10.1111/apm.12195	35	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						245	254		10.1016/j.humpath.2018.06.035			10	Pathology	Pathology	HB5LM	WOS:000451102300029	30055186				2019-10-28	
J	Toki, S; Motoi, T; Miyake, M; Kobayashi, E; Kawai, A; Yoshida, A				Toki, Shunichi; Motoi, Toru; Miyake, Mototaka; Kobayashi, Eisuke; Kawai, Akira; Yoshida, Akihiko			Minute mesenchymal chondrosarcoma within osteochondroma: an unexpected diagnosis confirmed by HEY1-NCOA2 fusion	HUMAN PATHOLOGY			English	Article						mesenchymal chondrosarcoma; osteochondroma; HEY1-NCOA2; gene fusion; bone; molecular diagnostics	SOFT-TISSUE; BONE; TRANSFORMATION; OSTEOSARCOMA; MARKER	Mesenchymal chondrosarcoma is rare and can be challenging to diagnose. Herein, we report a minute mesenchymal chondrosarcoma within an osteochondroma. A 12-year-old girl presented with an asymptomatic exophytic lesion of the rib. The tumor was clinically diagnosed as osteochondroma and was excised after observation for 3 years. The resected specimen revealed an unexpected minute (0.9 cm) "monophasic" mesenchymal chondrosarcoma in the apex of the lesion. The sarcoma consisted of monomorphic spindle cells without hyaline cartilage. Fluorescence in situ hybridization detected NCOA2 rearrangement, and reverse-transcription polymerase chain reaction and sequencing detected a HEY1 (exon 4)-NCOA2 (exon 13) fusion transcript. The patient did not receive adjuvant therapy and is alive with no recurrence 6 years after surgery. The present case highlights the value of careful pathological examination of specimens submitted as osteochondroma and emphasizes the usefulness of molecular assays in the diagnosis of mesenchymal chondrosarcoma in an atypical setting. (C) 2018 Elsevier Inc. All rights reserved.	[Toki, Shunichi; Yoshida, Akihiko] Natl Canc Ctr, Dept Pathol, Tokyo 1040045, Japan; [Toki, Shunichi; Yoshida, Akihiko] Natl Canc Ctr, Clin Labs, Tokyo 1040045, Japan; [Toki, Shunichi; Kobayashi, Eisuke; Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo 1040045, Japan; [Motoi, Toru] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Pathol, Tokyo 1138677, Japan; [Miyake, Mototaka] Natl Canc Ctr, Dept Diagnost Radiol, Tokyo 1040045, Japan; [Kobayashi, Eisuke; Kawai, Akira; Yoshida, Akihiko] Natl Canc Ctr, Rare Canc Ctr, Tokyo 1040045, Japan	Yoshida, A (reprint author), Natl Canc Ctr, Dept Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.; Yoshida, A (reprint author), Natl Canc Ctr, Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	akyoshid@ncc.go.jp			JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15 K19065]	The study was supported in part by the JSPS Grant-in-Aid for Young Scientists (15 K19065).	Barrera PAM, 2014, ORTHOPEDICS, V37, pE403, DOI 10.3928/01477447-20140401-65; CABALLES RL, 1982, HUM PATHOL, V13, P734, DOI 10.1016/S0046-8177(82)80296-7; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Czerniak B, 2016, DORFMAN CZEMIAKS BON; Dantonello TM, 2008, CANCER, V112, P2424, DOI 10.1002/cncr.23457; de Andrea CE, 2012, ONCOGENE, V31, P1095, DOI 10.1038/onc.2011.311; DORFMAN HD, 1994, HUM PATHOL, V25, P1234, DOI 10.1016/0046-8177(94)90041-8; Engel EE, 2012, GENET MOL RES, V11, P448, DOI 10.4238/2012.March.1.1; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Mandal S, 2013, CYTOPATHOLOGY, V24, P399, DOI 10.1111/cyt.12025; NAKASHIMA Y, 1986, CANCER-AM CANCER SOC, V57, P2444, DOI 10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K; Purandare NC, 2009, CLIN NUCL MED, V34, P350, DOI 10.1097/RLU.0b013e3181a34525; Unni KK, 2010, DAHLINS BONE TUMORS; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124	15	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						255	260		10.1016/j.humpath.2018.03.014			6	Pathology	Pathology	HB5LM	WOS:000451102300030	29596896				2019-10-28	
J	Sun, W; Feng, L; Yang, X; Li, L; Liu, Y; Lv, N; Lin, DM				Sun, Wei; Feng, Lin; Yang, Xin; Li, Lin; Liu, Yu; Lv, Ning; Lin, Dongmei			Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis	HUMAN PATHOLOGY			English	Article						Copy number variation; Epidermal growth factor receptor; Lepidic lesion; Multifocal lung adenocarcinoma; Pulmonary metastases	COMPARATIVE GENOMIC HYBRIDIZATION; LEPIDIC PULMONARY METASTASIS; KINASE DOMAIN MUTATIONS; CANCER; EGFR; LESIONS; CLASSIFICATION; HETEROGENEITY; PATTERNS; FEATURES	The aim of this study was to explore morphologic and molecular features distinguishing between multifocal lung adenocarcinoma (MLA) and intrapulmonary metastases (IMs). Sixteen patients with MLAs, a total of 34 tumors, were reviewed. Four approaches were used: (1) array comparative genomic hybridization (CGH) as a standard clonality assessment; (2) EGFR and KRAS mutational profiles as a supplementary method; (3) comprehensive histologic assessment (CHA) was method I in pathology evaluation; and (4) CHA combined with lepidic component analysis was method II. The lepidic component was divided into low grade and high grade according to extent of atypia; tumors with low-grade lepidic component were defined as primary. Eight patients were found to have IMs and 8 to have multiple primaries (MPs) by array-CGH; 7 had MPs and 9 had IMs by method I; 5 had MPs and 11 had IMs by method II. Compared with array-CGH, method I had a lower coincidence rate (65%) than method II (85%). Univariate analysis revealed that patients with MP had a better clinical outcome than those with IM only if the MPs were diagnosed by array-CGH (P = .034) or method 11 (P = .027) but not EGFR/KRAS mutation (P = .843) or method I (P = .493). Our results suggest that a low-grade lepidic component is a sign of a primary tumor. CHA combined with a low-grade lepidic component (method II) is more accurate clinically and more cost-effective in distinguishing MLAs from IMs. Also, EGFR mutation is not an appropriate molecular marker for clonality assessment. (C) 2018 Elsevier Inc. All rights reserved.	[Sun, Wei; Yang, Xin; Lin, Dongmei] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Pathol,Canc Hosp & Inst, 52 Fu Chong Rd, Beijing 100142, Peoples R China; [Sun, Wei; Li, Lin; Lv, Ning] Chinese Acad Med Sci, Dept Pathol, Canc Inst & Hosp, Peking Union Med Coll, 17 Pan Jia Yuan Nan Li, Beijing 100021, Peoples R China; [Feng, Lin; Liu, Yu] Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Peking Union Med Coll, Beijing 100021, Peoples R China	Lin, DM (reprint author), Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Pathol,Canc Hosp & Inst, 52 Fu Chong Rd, Beijing 100142, Peoples R China.; Lv, N (reprint author), Chinese Acad Med Sci, Dept Pathol, Canc Inst & Hosp, Peking Union Med Coll, 17 Pan Jia Yuan Nan Li, Beijing 100021, Peoples R China.	nlu03@126.com; Lindm3@163.com	Lv, Ning/V-5706-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472743]; Capital Health Research and Development Special Fund [2011-4002-01]; Beijing, China	This work was supported by the National Natural Science Foundation of China (81472743) and the Capital Health Research and Development Special Fund (2011-4002-01), Beijing, China.	Aguilo R, 2008, EUR J CARDIO-THORAC, V34, P1075, DOI 10.1016/j.ejcts.2008.08.004; Aokage K, 2010, PATHOL INT, V60, P765, DOI 10.1111/j.1440-1827.2010.02596.x; Arai J, 2012, LUNG CANCER, V77, P281, DOI 10.1016/j.lungcan.2012.04.003; Bollet MA, 2008, JNCI-J NATL CANCER I, V100, P48, DOI 10.1093/jnci/djm266; Chang YL, 2007, CLIN CANCER RES, V13, P52, DOI 10.1158/1078-0432.CCR-06-1743; Chung JH, 2009, J THORAC ONCOL, V4, P1490, DOI 10.1097/JTO.0b013e3181bc9731; Edge SB, 2010, AJCC CANC STAGING MA; Gaeta M, 1996, J COMPUT ASSIST TOMO, V20, P300, DOI 10.1097/00004728-199603000-00025; Ruiz MIG, 2007, J THORAC ONCOL, V2, P12; Girard N, 2009, AM J SURG PATHOL, V33, P1752, DOI 10.1097/PAS.0b013e3181b8cf03; Girard N, 2009, CLIN CANCER RES, V15, P5184, DOI 10.1158/1078-0432.CCR-09-0594; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Gu B, 2013, ANN THORAC SURG, V96, P411, DOI 10.1016/j.athoracsur.2013.04.048; Han HS, 2011, CLIN LUNG CANCER, V12, P380, DOI 10.1016/j.cllc.2011.02.006; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Liu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13200; Munfus-McCray D, 2011, HUM PATHOL, V42, P1447, DOI 10.1016/j.humpath.2010.12.011; Nagayoshi Y, 2016, INTERNAL MED, V55, P2849, DOI 10.2169/internalmedicine.55.5972; Nind NR, 2003, HISTOPATHOLOGY, V42, P150, DOI 10.1046/j.1365-2559.2003.01555.x; Ostrovnaya I, 2010, CLIN CANCER RES, V16, P1358, DOI 10.1158/1078-0432.CCR-09-2398; Park SC, 2007, CLIN EXP MED, V7, P1, DOI 10.1007/s10238-007-0123-1; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Sun W, 2014, INT J CLIN EXP PATHO, V7, P7583; Takamochi K, 2012, LUNG CANCER, V75, P313, DOI 10.1016/j.lungcan.2011.08.007; Tang XN, 2005, CANCER RES, V65, P7568, DOI 10.1158/0008-5472.CAN-05-1705; Tokunaga T, 2005, CLIN RADIOL, V60, P1213, DOI 10.1016/j.crad.2005.05.013; Travis WD, 2015, WHO CLASSIFICATION T, P34; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Vazquez M, 2009, LUNG CANCER, V64, P148, DOI 10.1016/j.lungcan.2008.08.009; Wa CV, 2005, MODERN PATHOL, V18, P591, DOI 10.1038/modpathol.3800332; Warth A, 2012, EUR RESPIR J, V39, P1437, DOI 10.1183/09031936.00105911; Weiss MM, 2003, J CLIN PATHOL, V56, P522, DOI 10.1136/jcp.56.7.522; Wong QWL, 2005, HUM PATHOL, V36, P893, DOI 10.1016/j.humpath.2005.06.007; Wu CY, 2015, J THORAC ONCOL, V10, P778, DOI 10.1097/JTO.0000000000000487; Xu LR, 2012, INT J SURG PATHOL, V20, P577, DOI 10.1177/1066896912449039	36	0	0	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						261	271		10.1016/j.humpath.2018.01.030			11	Pathology	Pathology	HB5LM	WOS:000451102300031	30420048				2019-10-28	
J	Andeen, NK; Jefferson, JA; Akilesh, S; Alpers, CE; Bissonnette, ML; Finn, LS; Higgins, J; Houghton, DC; Kambham, N; Magil, A; Najafian, B; Nicosia, RF; Troxell, ML; Smith, KD				Andeen, Nicole K.; Jefferson, J. Ashley; Akilesh, Shreeram; Alpers, Charles E.; Bissonnette, Mei Lin; Finn, Laura S.; Higgins, John; Houghton, Donald C.; Kambham, Neeraja; Magil, Alex; Najafian, Behzad; Nicosia, Roberto F.; Troxell, Megan L.; Smith, Kelly D.			IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury	HUMAN PATHOLOGY			English	Article						Membranoproliferative glomerulonephritis; IgA; Kidney biopsy; Hepatitis; Liver failure; Infection	IMMUNOGLOBULIN-A NEPHROPATHY; INFECTION-ASSOCIATED GLOMERULONEPHRITIS; OXFORD CLASSIFICATION; CIRRHOSIS	Immunoglobulin A (IgA)-dominant membranoproliferative glomerulonephritis (MPGN) is a descriptive term for renal biopsies in which differential diagnoses of unusual IgA nephropathy (IgAN), infection-related GN, or other etiologies are considered. We sought to understand clinical and pathologic features of this finding. Native kidney biopsies with IgA-dominant immune deposits and diffuse MPGN features without significant exudative features or subepithelial deposits were retrospectively reviewed. Two groups (n = 27, 33 biopsies) were identified: patients with chronic liver disease and those without. Patients without chronic liver disease (n = 15) were men (73%, age 40) who presented with nephrotic-range proteinuria, hematuria, renal insufficiency, negative serologic studies, and no history of infection. At a median interval of 3 years, 11 had available follow-up information. Three (27%) progressed to end-stage renal disease. One had recurrent IgA-dominant GN in the renal allograft less than 1 year posttransplant. Four of 5 patients with repeat biopsies had persistent IgA-dominant MPGN. Patients with chronic liver disease (n = 12) had similar biopsy findings, but 42% had concurrent infections, some occult. At a median interval of 7 weeks, 8 patients (80% of those with follow-up) had died and 2 were dialysis dependent. In conclusion, IgA-dominant MPGN was seen in 2 clinical cohorts in this study. In patients without chronic liver disease, this appears to represent either a unique clinicopathologic entity with a poorer prognosis than IgAN or an aggressive variant of IgAN. Patients with chronic liver disease often have underlying infection, and regardless of treatment, die within 1 year because of complex medical conditions. (C) 2018 Elsevier Inc. All rights reserved.	[Andeen, Nicole K.; Houghton, Donald C.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA; [Jefferson, J. Ashley] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA; [Akilesh, Shreeram; Alpers, Charles E.; Finn, Laura S.; Najafian, Behzad; Nicosia, Roberto F.; Smith, Kelly D.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Bissonnette, Mei Lin; Magil, Alex] Univ British Columbia, St Paul Hosp, Dept Pathol, Vancouver, BC V6Z 1Y6, Canada; [Finn, Laura S.] Seattle Childrens Hosp, Dept Pathol, Seattle, WA 98105 USA; [Higgins, John; Kambham, Neeraja; Troxell, Megan L.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Nicosia, Roberto F.] Seattle Vet Affairs Med Ctr, Seattle, WA 98108 USA	Andeen, NK (reprint author), 3181 SW Sam Jackson Pk Rd,Mail Code L113, Portland, OR 97239 USA.	andeen@ohsu.edu	Jefferson, Jonathan/AAA-9679-2019				Agrawal V, 2015, Indian J Nephrol, V25, P168, DOI 10.4103/0971-4065.145425; Alghamdi SA, 2012, SAUDI J GASTROENTERO, V18, P214, DOI 10.4103/1319-3767.96463; Arvaniti V, 2010, GASTROENTEROLOGY, V139, P1246, DOI 10.1053/j.gastro.2010.06.019; Bunchorntavakul C, 2016, WORLD J HEPATOL, V8, P307, DOI 10.4254/wjh.v8.i6.307; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; Chakera A, 2016, J NEPHROL, V29, P367, DOI 10.1007/s40620-015-0227-8; Cracolici VM, 2017, SPECTRUM IGA ASS GLO; ENDO Y, 1983, ACTA PATHOL JAPON, V33, P333; FERRARIO G, 1986, Pathologica (Genoa), V78, P469; Haas M, 1997, AM J KIDNEY DIS, V29, P829, DOI 10.1016/S0272-6386(97)90456-X; Haas M, 2008, HUM PATHOL, V39, P1309, DOI 10.1016/j.humpath.2008.02.015; Haas M, 2017, J AM SOC NEPHROL, V28, P691, DOI 10.1681/ASN.2016040433; Iitaka Kikuo, 2003, Clin Exp Nephrol, V7, P284, DOI 10.1007/s10157-003-0253-z; Jennette JC, 2007, HEPTINSTALLS PATHOLO; Kurosu A, 2012, TOHOKU J EXP MED, V228, P253, DOI 10.1620/tjem.228.253; Moriyama T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091756; Roberts ISD, 2013, CURR OPIN NEPHROL HY, V22, P281, DOI 10.1097/MNH.0b013e32835fe65c; Satoskar AA, 2006, CLIN J AM SOC NEPHRO, V1, P1179, DOI 10.2215/CJN.01030306; Satoskar AA, 2017, CLIN J AM SOC NEPHRO, V12, P39, DOI 10.2215/CJN.05070516; Satoskar AA, 2013, CLIN NEPHROL, V79, P302, DOI 10.5414/CN107756; Soares MF, 2017, CURR OPIN NEPHROL HY, V26, P165, DOI 10.1097/MNH.0000000000000312; Takada D, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0769-1; Wen YK, 2010, RENAL FAILURE, V32, P572, DOI 10.3109/08860221003753331; Worawichawong S, 2011, HUM PATHOL, V42, P279, DOI 10.1016/j.humpath.2010.07.009; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793	25	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						272	280		10.1016/j.humpath.2018.06.031			9	Pathology	Pathology	HB5LM	WOS:000451102300032	30420049				2019-10-28	
J	Cohen, JN; Sabnis, AJ; Krings, G; Cho, SJ; Horvai, AE; Davis, JL				Cohen, Jarish N.; Sabnis, Amit J.; Krings, Gregor; Cho, Soo-Jin; Horvai, Andrew E.; Davis, Jessica L.			EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature	HUMAN PATHOLOGY			English	Article						EWSR1; NFATC2; Ewing sarcoma; Myoepithelial; Soft tissue; Bone	EWING SARCOMA; MYOEPITHELIAL TUMORS; EWSR1 REARRANGEMENT; READ ALIGNMENT; PAIRED-END; TRANSLOCATION; BONE; VARIANT; CHROMOSOME; GENERATION	Mesenchymal round cell tumors are a diverse group of neoplasms defined by primitive, often high-grade cytomorphology. The most common molecular alterations detected in these tumors are gene re-arrangements involving EWSRI to one of many fusion partners. Rare EWSR1-NFATC2 gene rearrangements, corresponding to a t(20;22) gene translocation, have been described in mesenchymal tumors with clear round cell morphology and a predilection for the skeleton. We present a case of a tumor harboring the EWSR1-NFATC2 gene fusion arising in the subcutaneous tissue of a young woman. The tumor exhibited corded and trabecular architecture of epithelioid cells within abundant myxoid and fibrous stroma. The cells showed strong immunoreactivity for NKX2.2, variable CD99, keratin, and epithelial membrane antigen, but were negative for S100 and myoepithelial markers. Importantly, similar to previously reported cases, the clinical course was more indolent than that of Ewing sarcoma. This case highlights the distinctive clinicopathological characteristics of EWSR1-NFATC2 gene fusion-associated neoplasms that distinguish them from Ewing sarcoma. (C) 2018 Elsevier Inc. All rights reserved.	[Cohen, Jarish N.; Krings, Gregor; Cho, Soo-Jin; Horvai, Andrew E.; Davis, Jessica L.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA; [Sabnis, Amit J.] Univ Calif San Francisco, Dept Pediat, Div Hematol Oncol, San Francisco, CA 94158 USA; [Krings, Gregor] Univ Calif San Francisco, Clin Canc Genom Lab, San Francisco, CA 94158 USA; [Davis, Jessica L.] Oregon Hlth & Sci Univ, Dept Pathol, 3181 SW Sam Jackson Pk Rd,L-471, Portland, OR 97239 USA	Davis, JL (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, 3181 SW Sam Jackson Pk Rd,L-471, Portland, OR 97239 USA.	davisjes@ohsu.edu					Agaram NP, 2015, GENE CHROMOSOME CANC, V54, P63, DOI 10.1002/gcc.22216; Antonescu C, 2014, HISTOPATHOLOGY, V64, P26, DOI 10.1111/his.12281; Antonescu CR, 2014, PATHOLOGY, V46, P105, DOI 10.1097/PAT.0000000000000049; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; AURIAS A, 1983, NEW ENGL J MED, V309, P496; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Berg T, 2009, CANCER GENET CYTOGEN, V194, P53, DOI 10.1016/j.cancergencyto.2009.06.002; Brandal P, 2008, GENE CHROMOSOME CANC, V47, P558, DOI 10.1002/gcc.20559; Brandal P, 2009, GENE CHROMOSOME CANC, V48, P1051, DOI 10.1002/gcc.20706; Chen S, 2016, GENE CHROMOSOME CANC, V55, P340, DOI 10.1002/gcc.22336; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fisher C, 2014, HISTOPATHOLOGY, V64, P134, DOI 10.1111/his.12269; Flucke U, 2012, HUM PATHOL, V43, P764, DOI 10.1016/j.humpath.2011.08.004; Flucke U, 2011, MODERN PATHOL, V24, P1444, DOI 10.1038/modpathol.2011.108; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hornick JL, 2003, AM J SURG PATHOL, V27, P1183, DOI 10.1097/00000478-200309000-00001; Huang SC, 2015, GENE CHROMOSOME CANC, V54, P267, DOI 10.1002/gcc.22240; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Jo VY, 2015, HEAD NECK PATHOL, V9, P32, DOI 10.1007/s12105-015-0618-0; Kinkor Zdenek, 2014, Cesk Patol, V50, P87; Kurzawa P, 2013, AM J SURG PATHOL, V37, P960, DOI 10.1097/PAS.0b013e3182858a0e; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Ng TL, 2007, J MOL DIAGN, V9, P459, DOI 10.2353/jmoldx.2007.070009; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Rekhi B, 2016, APMIS, V124, P278, DOI 10.1111/apm.12506; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Romeo S, 2012, VIRCHOWS ARCH, V461, P561, DOI 10.1007/s00428-012-1306-z; Sadri N, 2014, VIRCHOWS ARCH, V465, P233, DOI 10.1007/s00428-014-1613-7; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Shing DC, 2003, CANCER RES, V63, P4568; Sumegi J, 2011, MODERN PATHOL, V24, P333, DOI 10.1038/modpathol.2010.201; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Verma A, 2017, HISTOL HISTOPATHOL, V32, P861, DOI 10.14670/HH-11-879; Wang L, 2007, J MOL DIAGN, V9, P498, DOI 10.2353/jmoldx.2007.070053; Yamaguchi S, 2005, GENE CHROMOSOME CANC, V43, P217, DOI 10.1002/gcc.20171; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	48	4	5	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						281	290		10.1016/j.humpath.2018.03.020			10	Pathology	Pathology	HB5LM	WOS:000451102300033	29626598				2019-10-28	
J	Zhang, SL; Xiao, HD; Cai, ZJ; Covinsky, M; Saluja, K; Patino, MO; Liu, XM; Zhu, H				Zhang, Songlin; Xiao, Hong D.; Cai, Zhenjian; Covinsky, Michael; Saluja, Karan; Patino, Maria O.; Liu, Xinmin; Zhu, Hui			P16-positive cystic squamous cell carcinoma in midline neck: metastasis from oropharynx or primary carcinoma arising from thyroglossal duct cyst?	HUMAN PATHOLOGY			English	Article						Cystic squamous cell carcinoma; Thyroglossal duct cyst; HPV-related squamous cell carcinoma; p16 immunohistochemistry; Carcinoma arising from thyroglossal duct cyst	HUMAN-PAPILLOMAVIRUS; HEAD; HPV; CANCER; DIVERSITY; EPIDEMIC; SMOKING	Cystic squamous cell carcinoma (SCC) of the lateral neck is considered metastatic human papilloma-virus (HPV) related oropharyngeal SCC (HPV-OPSCC) until proven otherwise. P16 immunohistochemistry is diffusely positive in those carcinomas and is used as a surrogate marker of active human papillomavirus (HPV) infection. Thyroglossal duct cysts (TDC) are one of the differential diagnoses for cystic neck lesions. SCC arising from TDC is extremely rare. In this study, we report a p16-positive cystic SCC located in the midline neck. Radiologic features and the presence of thyroid tissue in the cyst wall indicated that it was a TDC. The morphologic features of the lesion raised the question: is the carcinoma metastatic HPV-OPSCC? The HPV confirmative test, high-risk HPV RNA in situ hybridization, was negative. We then studied p16 immunohistochemistry in the squamous epithelium of benign TDC and found that rare benign TDC can show diffuse and strong p16 positivity. Published by Elsevier Inc.	[Zhang, Songlin; Cai, Zhenjian; Covinsky, Michael; Saluja, Karan; Liu, Xinmin; Zhu, Hui] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Xiao, Hong D.] Providence Portland Med Ctr, Dept Pathol, Portland, OR 97213 USA; [Patino, Maria O.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Liu, Xinmin] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Gynecol, Beijing 100053, Peoples R China	Zhu, H (reprint author), 6431 Fannin St,MSB 2-290, Houston, TX 77030 USA.	hui.zhu@uth.tmc.edu					Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bishop JA, 2015, AM J SURG PATHOL, V39, P1591, DOI 10.1097/PAS.0000000000000521; Cao DF, 2010, HUM PATHOL, V41, P535, DOI 10.1016/j.humpath.2009.09.006; El-Naggar AK, 2017, WHO CLASSIFICATION H, P133; Goldenberg D, 2008, HEAD NECK-J SCI SPEC, V30, P898, DOI 10.1002/hed.20796; Gondim DD, 2016, AM J SURG PATHOL, V40, P1117, DOI 10.1097/PAS.0000000000000650; Herrero R, 2013, PLOS ONE, V8; Iakovou I, 2011, HELL J NUCL MED, V14, P62; Karni RJ, 2011, LARYNGOSCOPE, V121, P1194, DOI 10.1002/lary.21743; Lewis JS, 2017, MODERN PATHOL, V30, pS44, DOI 10.1038/modpathol.2016.152; Lewis JS Jr, ARCH PATHOL LAB MED; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Motamed Mehdi, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P106, DOI 10.1097/00020840-200404000-00009; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; PERRY ME, 1994, J ANAT, V185, P111; Radkay-Gonzalez L, 2016, HEAD NECK PATHOL, V10, P167, DOI 10.1007/s12105-015-0653-x; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Shah S, 2015, AM J OTOLARYNG, V36, P460, DOI 10.1016/j.amjoto.2015.01.012; Smeets SJ, 2007, INT J CANCER, V121, P2465, DOI 10.1002/ijc.22980; Sturgis EM, 2007, CANCER, V110, P1429, DOI 10.1002/cncr.22963; Thompson LDR, 2016, HEAD NECK PATHOL, V10, P465, DOI 10.1007/s12105-016-0724-7; Tribius S, 2012, ORAL ONCOL, V48, P1178, DOI 10.1016/j.oraloncology.2012.05.022; Wei SZ, 2015, ENDOCR PATHOL, V26, P75, DOI 10.1007/s12022-015-9354-y; Westra WH, 2017, HEAD NECK PATHOL, V11, P41, DOI 10.1007/s12105-017-0793-2; Westra WH, 2012, HEAD NECK PATHOL, V6, pS48, DOI 10.1007/s12105-012-0371-6; Zengel P, 2012, VIRCHOWS ARCH, V461, P283, DOI 10.1007/s00428-012-1290-3	27	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						291	297		10.1016/j.humpath.2018.03.002			7	Pathology	Pathology	HB5LM	WOS:000451102300034	29555577				2019-10-28	
J	McClure, RF; Ewalt, MD; Crow, J; Temple-Smolkin, RL; Pullambhatla, M; Sargent, R; Kim, AS				McClure, Rebecca F.; Ewalt, Mark D.; Crow, Jennifer; Temple-Smolkin, Robyn L.; Pullambhatla, Mrudula; Sargent, Rachel; Kim, Annette S.			Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms A Report of the Association for Molecular Pathology	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; METHYLTRANSFERASE GENE EZH2; PROGNOSTIC SCORING SYSTEM; V617F MUTATION STATUS; AGE-RELATED MUTATIONS; MYELODYSPLASTIC SYNDROMES; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; CLONAL HEMATOPOIESIS	To address the clinical relevance of small DNA variants in chronic myeloid neoplasms (CMNs), an Association for Molecular Pathology Working Group comprehensively reviewed published literature, summarized key findings that support clinical utility, and defined critical gene inclusions for high throughput sequencing testing panels. This review highlights the biological complexity of CMNs [including myelodysplastic syndromes, myeloproliferative neoplasms, entities with overlapping features (myelodysplastic syndromes/myeloproliferative neoplasms), and systemic mastocytosis], the genetic heterogeneity within diagnostic categories, and similarities between apparently disparate diagnostic entities. The founding variant's hematopoietic differentiation compartment, specific genes and variants present, order of variant appearance, individual subclone dynamics, and therapeutic intervention all contribute to the clinicopathologic features of CMNs. Selection and efficacy of targeted therapies are increasingly based on DNA variant profiles present at various time points; therefore, high -throughput sequencing remains critical for patient management. The following genes are a minimum recommended list to provide relevant clinical information for the management of most CMNs: ASXL1, BCOR, BCORL1, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF361, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, and ZRSR2. This list is not comprehensive for all myeloid neoplasms and will evolve as insights into effects of combinations of relevant biomarkers on specific clinicopathologic characteristics of CMNs accumulate.	[McClure, Rebecca F.; Ewalt, Mark D.; Crow, Jennifer; Sargent, Rachel; Kim, Annette S.] Clin Practice Comm, Chron Myeloid Neoplasms Working Grp, Bethesda, MD USA; [Temple-Smolkin, Robyn L.; Pullambhatla, Mrudula] Assoc Mol Pathol, Bethesda, MD USA; [McClure, Rebecca F.] Hlth Sci North Horizon Sante Nord, Dept Lab Med & Pathol, Sudbury, ON, Canada; [Ewalt, Mark D.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Crow, Jennifer] Huguley Pathol Consultants, Huguley Mem Med Ctr, Dept Pathol, Burleson, TX USA; [Sargent, Rachel] Janssen Diagnost, Res & Dev, Oncol Diagnost, Spring House, PA USA; [Kim, Annette S.] Harvard Med Sch, Dept Pathol, Brigham & Womens Hosp, Boston, MA USA	Kim, AS (reprint author), 75 Francis St,Thorn 613A, Boston, MA 02115 USA.	askim@bwh.harvard.edu	Ewalt, Mark D/Y-4878-2019	Ewalt, Mark D/0000-0003-4245-752X	Association for Molecular Pathology	Supported by the Association for Molecular Pathology.	Abdel-Wahab O, 2011, LEUKEMIA, V25, P1200, DOI 10.1038/leu.2011.58; Al Assaf C, 2015, HAEMATOLOGICA, V100, P893, DOI 10.3324/haematol.2014.118299; Alfonso A, 2017, CURR OPIN ONCOL, V29, P79, DOI 10.1097/CCO.0000000000000337; Andrikovics H, 2014, HAEMATOLOGICA, V99, P1184, DOI 10.3324/haematol.2014.107482; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bains A, 2011, AM J CLIN PATHOL, V135, P62, DOI 10.1309/AJCPEI9XU8PYBCIO; Barosi G, 2007, BLOOD, V110, P4030, DOI 10.1182/blood-2007-07-099184; Beer PA, 2008, BLOOD, V112, P141, DOI 10.1182/blood-2008-01-131664; Bejar R, 2014, BLOOD, V124, P2705, DOI 10.1182/blood-2014-06-582809; Bejar R, 2014, HAEMATOLOGICA, V99, P956, DOI 10.3324/haematol.2013.085217; Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Bejar R, 2011, J CLIN ONCOL, V29, P504, DOI 10.1200/JCO.2010.31.1175; Brecqueville M, 2012, GENE CHROMOSOME CANC, V51, P743, DOI 10.1002/gcc.21960; Broseus J, 2013, LEUKEMIA, V27, P1826, DOI 10.1038/leu.2013.120; Broseus J, 2012, HAEMATOL-HEMATOL J, V97, P1036, DOI 10.3324/haematol.2011.053918; Campbell PJ, 2006, BLOOD, V107, P2098, DOI 10.1182/blood-2005-08-3395; Campbell PJ, 2005, LANCET, V366, P1945, DOI 10.1016/S0140-6736(05)67785-9; Carbuccia N, 2009, LEUKEMIA, V23, P2183, DOI 10.1038/leu.2009.141; Carobbio A, 2011, BLOOD, V117, P5857, DOI 10.1182/blood-2011-02-339002; Caudill JSC, 2006, BRIT J HAEMATOL, V133, P638, DOI 10.1111/j.1365-2141.2006.06081.x; Cazzola M, 2014, BLOOD, V123, P3714, DOI 10.1182/blood-2014-03-530865; Chen E, 2010, CANCER CELL, V18, P524, DOI 10.1016/j.ccr.2010.10.013; Chesnais V, 2016, BLOOD, V127, P749, DOI 10.1182/blood-2015-04-640128; Damm F, 2013, LEUKEMIA, V27, P1401, DOI 10.1038/leu.2013.35; Damm F, 2012, LEUKEMIA, V26, P1137, DOI 10.1038/leu.2011.321; Damm F, 2013, BLOOD, V122, P3169, DOI 10.1182/blood-2012-11-469619; Damm F, 2012, BLOOD, V119, P3211, DOI 10.1182/blood-2011-12-400994; Daver N, 2013, AM J HEMATOL, V88, P56, DOI 10.1002/ajh.23345; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dicker F, 2010, LEUKEMIA, V24, P1528, DOI 10.1038/leu.2010.124; DiNardo CD, 2016, LEUKEMIA, V30, P980, DOI 10.1038/leu.2015.211; Ernst T, 2010, HAEMATOL-HEMATOL J, V95, P1473, DOI 10.3324/haematol.2010.021808; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Fernandez-Mercado M, 2013, BRIT J HAEMATOL, V163, P235, DOI 10.1111/bjh.12491; Flach J, 2010, HAEMATOL-HEMATOL J, V95, P518, DOI 10.3324/haematol.2009.013631; Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381; Gambacorti-Passerini CB, 2015, BLOOD, V125, P499, DOI 10.1182/blood-2014-06-579466; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Gelsi-Boyer V, 2010, BRIT J HAEMATOL, V151, P365, DOI 10.1111/j.1365-2141.2010.08381.x; Gelsi-Boyer V, 2009, BRIT J HAEMATOL, V145, P788, DOI 10.1111/j.1365-2141.2009.07697.x; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Geyer HL, 2014, HEMATOL-AM SOC HEMAT, P277, DOI 10.1182/asheducation-2014.1.277; Gotlib J, 2013, BLOOD, V122, P1707, DOI 10.1182/blood-2013-05-500959; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Greenberg PL, 2013, J NATL COMPR CANC NE, V11, P877, DOI 10.6004/jnccn.2013.0105; Grossmann V, 2011, LEUKEMIA, V25, P877, DOI 10.1038/leu.2011.10; Grossmann V, 2011, BLOOD, V118, P6153, DOI 10.1182/blood-2011-07-365320; Gu J, 2017, CANCER BIOL THER, V18, P843, DOI 10.1080/15384047.2017.1281491; Guglielmelli P, 2007, BRIT J HAEMATOL, V137, P244, DOI 10.1111/j.1365-2141.2007.06565.x; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Guglielmelli P, 2009, BLOOD, V114, P1477, DOI 10.1182/blood-2009-04-216044; Guglielmelli P, 2009, HAEMATOL-HEMATOL J, V94, P144, DOI 10.3324/haematol.13721; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Hong JY, 2015, ANTICANCER RES, V35, P3081; Hou HA, 2014, AM J HEMATOL, V89, P181, DOI 10.1002/ajh.23611; Hultcrantz M, 2012, J CLIN ONCOL, V30, P2995, DOI 10.1200/JCO.2012.42.1925; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Itzykson R, 2013, BLOOD, V121, P2186, DOI 10.1182/blood-2012-06-440347; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jawhar M, 2016, LEUKEMIA, V30, P136, DOI 10.1038/leu.2015.284; Jawhar M, 2015, LEUKEMIA, V29, P1115, DOI 10.1038/leu.2015.4; Jeromin S, 2013, HAEMATOLOGICA, V98, pE15, DOI 10.3324/haematol.2012.072538; Jin J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100206; Kita-Sasai Y, 2001, BRIT J HAEMATOL, V115, P309, DOI 10.1046/j.1365-2141.2001.03073.x; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kon A, 2013, NAT GENET, V45, P1232, DOI 10.1038/ng.2731; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; Kosmider O, 2018, CLIN LYMPHOMA MYELOM, V13, P347; Kosmider O, 2009, HAEMATOL-HEMATOL J, V94, P1676, DOI 10.3324/haematol.2009.011205; Kosmider O, 2009, BLOOD, V114, P3285, DOI 10.1182/blood-2009-04-215814; KUENDGEN A, 2013, BLOOD, V122; Kuo MC, 2009, LEUKEMIA, V23, P1426, DOI 10.1038/leu.2009.48; Laborde RR, 2013, LEUKEMIA, V27, P2100, DOI 10.1038/leu.2013.97; Lasho TL, 2012, LEUKEMIA, V26, P1135, DOI 10.1038/leu.2011.320; Lasho TL, 2012, BLOOD, V120, P4168, DOI 10.1182/blood-2012-05-429696; Lehmann U, 2013, BLOOD, V121, P4011, DOI 10.1182/blood-2012-11-467662; Lindsley RC, 2017, NEW ENGL J MED, V376, P536, DOI 10.1056/NEJMoa1611604; Lindsley RC, 2015, BLOOD, V125, P1367, DOI 10.1182/blood-2014-11-610543; Lippert E, 2006, BLOOD, V108, P1865, DOI 10.1182/blood-2006-01-013540; Loh ML, 2005, LEUKEMIA RES, V29, P459, DOI 10.1016/j.leukres.2004.10.001; Losada A, 2014, NAT REV CANCER, V14, P389, DOI 10.1038/nrc3743; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Makishima H, 2013, NAT GENET, V45, P942, DOI 10.1038/ng.2696; Makishima H, 2012, BLOOD, V119, P3203, DOI 10.1182/blood-2011-12-399774; Malcovati L, 2017, BLOOD, V129, P3371, DOI 10.1182/blood-2017-01-763425; Malcovati L, 2015, BLOOD, V126, P233, DOI 10.1182/blood-2015-03-633537; Malcovati L, 2009, BLOOD, V114, P3538, DOI 10.1182/blood-2009-05-222331; Mason CC, 2016, LEUKEMIA, V30, P906, DOI 10.1038/leu.2015.337; Matsunawa M, 2014, LEUKEMIA, V28, P1844, DOI 10.1038/leu.2014.73; Maxson JE, 2017, BLOOD, V129, P715, DOI [10.1182/Blood-2016-10-695981, 10.1182/blood-2016-10-695981]; Maxson JE, 2013, NEW ENGL J MED, V368, P1781, DOI 10.1056/NEJMoa1214514; McKerrell T, 2015, CELL REP, V10, P1239, DOI 10.1016/j.celrep.2015.02.005; Meggendorfer M, 2013, LEUKEMIA, V27, P1852, DOI 10.1038/leu.2013.133; Meggendorfer M, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.113159; Meggendorfer M, 2012, BLOOD, V120, P3080, DOI 10.1182/blood-2012-01-404863; Merlevede J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10767; Morreale FE, 2016, CELL, V165, P248, DOI 10.1016/j.cell.2016.03.003; Mossner M, 2016, BLOOD, V128, P1246, DOI 10.1182/blood-2015-11-679167; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Nazha A, 2016, LEUKEMIA, V30, P2214, DOI 10.1038/leu.2016.138; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ortmann CA, 2015, NEW ENGL J MED, V372, P601, DOI 10.1056/NEJMoa1412098; Panagiota V, 2014, LEUKEMIA, V28, P1552, DOI 10.1038/leu.2014.66; Pandey R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0388-z; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Papaemmanuil E, 2011, EUR J CANCER, V26, P377; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Pardanani A, 2013, LEUKEMIA, V27, P1870, DOI 10.1038/leu.2013.122; Pardanani A, 2011, LEUKEMIA, V25, P1834, DOI 10.1038/leu.2011.161; Pardanani A, 2010, LEUKEMIA, V24, P1713, DOI 10.1038/leu.2010.163; Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Passamonti F, 2006, BLOOD, V107, P3676, DOI 10.1182/blood-2005-09-3826; Passamonti F, 2010, LEUKEMIA, V24, P1574, DOI 10.1038/leu.2010.148; Patnaik MM, 2014, LEUKEMIA, V28, P2206, DOI 10.1038/leu.2014.125; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Patnaik MM, 2012, BLOOD, V119, P569, DOI 10.1182/blood-2011-09-377994; Piazza R, 2013, NAT GENET, V45, P18, DOI 10.1038/ng.2495; Ricci C, 2012, BRIT J HAEMATOL, V156, P404, DOI 10.1111/j.1365-2141.2011.08865.x; Rotunno G, 2014, BLOOD, V123, P1552, DOI 10.1182/blood-2013-11-538983; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Rumi E, 2013, BLOOD, V121, P4388, DOI 10.1182/blood-2013-02-486050; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Scott LM, 2006, BLOOD, V108, P2435, DOI 10.1182/blood-2006-04-018259; Shah NP, 2006, BLOOD, V108, P286, DOI 10.1182/blood-2005-10-3969; Shih LY, 2005, CLIN CANCER RES, V11, P1821, DOI 10.1158/1078-0432.CCR-04-1932; Singh VP, 2015, CURR OPIN CELL BIOL, V37, P9, DOI 10.1016/j.ceb.2015.08.003; Smith AE, 2010, BLOOD, V116, P3923, DOI 10.1182/blood-2010-03-274704; Soucie E, 2012, BLOOD, V120, P4846, DOI 10.1182/blood-2011-12-397588; Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747; Stegelmann F, 2011, LEUKEMIA, V25, P1217, DOI 10.1038/leu.2011.77; Swerdlow SH, 2017, CLASSIFICATION TUMOU, V2; Tefferi A, 2008, LEUKEMIA, V22, P756, DOI 10.1038/sj.leu.2405097; Tefferi A, 2006, CANCER, V106, P631, DOI 10.1002/cncr.21645; Tefferi A, 2014, LEUKEMIA, V28, P1494, DOI 10.1038/leu.2014.57; Tefferi A, 2014, LEUKEMIA, V28, P1472, DOI 10.1038/leu.2014.3; Tefferi A, 2012, LEUKEMIA, V26, P475, DOI 10.1038/leu.2011.253; Tefferi A, 2010, LEUKEMIA, V24, P1302, DOI 10.1038/leu.2010.113; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Tefferi A, 2009, LEUKEMIA, V23, P900, DOI 10.1038/leu.2009.37; Tenedini E, 2014, LEUKEMIA, V28, P1052, DOI 10.1038/leu.2013.302; Thol F, 2012, BLOOD, V119, P3578, DOI 10.1182/blood-2011-12-399337; Thol F, 2011, J CLIN ONCOL, V29, P2499, DOI 10.1200/JCO.2010.33.4938; Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494; Thota S, 2014, BLOOD, V124, P1790, DOI 10.1182/blood-2014-04-567057; Traina F, 2014, LEUKEMIA, V28, P78, DOI 10.1038/leu.2013.269; Traina F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043090; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Vannucchi AM, 2007, BLOOD, V110, P840, DOI 10.1182/blood-2006-12-064287; Verstovsek S, 2013, EUR J HAEMATOL, V90, P89, DOI 10.1111/ejh.12043; Visconte V, 2012, LEUKEMIA, V26, P542, DOI 10.1038/leu.2011.232; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Walter MJ, 2013, LEUKEMIA, V27, P1275, DOI 10.1038/leu.2013.58; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Wang SA, 2016, MODERN PATHOL, V29, P854, DOI 10.1038/modpathol.2016.75; Wu SJ, 2013, AM J HEMATOL, V88, pE277, DOI 10.1002/ajh.23541; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Yonal-Hindilerden Ipek, 2016, J Clin Med Res, V8, P29, DOI 10.14740/jocmr2405w; Young AL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12484; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120; Zoi K, 2015, INT J HEMATOL, V101, P229, DOI 10.1007/s12185-014-1670-3	167	3	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					717	737		10.1016/j.jmoldx.2018.07.002			21	Pathology	Pathology	GY5RC	WOS:000448637200001	30138727				2019-10-28	
J	Wei, F; Strom, CM; Cheng, J; Lin, CC; Hsu, CY; Hoo, GWS; Chia, D; Kim, Y; Li, F; Elashoff, D; Grognan, T; Tu, M; Liao, W; Xian, RN; Grody, WW; Su, WC; Wong, DTW				Wei, Fang; Strom, Charles M.; Cheng, Jordan; Lin, Chien -Chung; Hsu, Ching-Yun; Hoo, Guy W. Soo; Chia, David; Kim, Yong; Li, Feng; Elashoff, David; Grognan, Tristan; Tu, Michael; Liao, Wei; Xian, Rena; Grody, Wayne W.; Su, Wu-Chou; Wong, David T. W.			Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MUTATION DETECTION	Previously, we detected circulating tumor DNA that contained two EGFR mutations (p.L858R and exon19 del) in plasma of patients with late-stage non small-cell lung carcinoma (NSCLC) using the electric field induced release and measurement (EFIRM) platform. Our aim was to determine whether EFIRM technology can detect these mutations in patients with early-stage NSCLC. Prospectively, 248 patients with radiographically determined pulmonary nodules were recruited. Plasma was collected before biopsy and histologic examination of the nodule. Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or exon19 del EGFR mutations. Plasma samples were available from 44 patients: 23 with biopsy-proven benign pulmonary nodules and 21 with stage I or II adenocarcinoma (12 p.L858R and 9 exon19 del EGFR variants). Samples were analyzed for the EGFR mutations using the EFIRM platform. Assay sensitivity was 92% for p.L858R (11 of 12 samples positive) and 77% for exon19 del (7 of 9 samples positive). Specificity was 91% with two false-positive results in 23 patients with EGFR-positive nodules and 95% for the entire 44-patient series. Concordance was 100% with identical mutations discovered in plasma and nodule biopsy. The EFIRM platform is able to noninvasively detect two EGFR mutations in individuals with early-stage NSCLC.	[Wei, Fang; Strom, Charles M.; Cheng, Jordan; Hsu, Ching-Yun; Chia, David; Kim, Yong; Li, Feng; Elashoff, David; Grognan, Tristan; Tu, Michael; Liao, Wei; Wong, David T. W.] Univ Calif Los Angeles, Sch Dent, 10833 La Conte Ave, Los Angeles, CA USA; [Xian, Rena; Grody, Wayne W.] Univ Calif Los Angeles, Dept Pathol & Mol Med, Los Angeles, CA USA; [Lin, Chien -Chung; Hoo, Guy W. Soo; Su, Wu-Chou] Natl Cheng Kung Univ, Dept Internal Med, Natl Cheng Kung Univ Hosp, Coll Med, 35 Xiaodong Rd, Tainan 704, Taiwan	Strom, CM (reprint author), Univ Calif Los Angeles, Sch Dent, 10833 La Conte Ave, Los Angeles, CA USA.; Su, WC (reprint author), Natl Cheng Kung Univ, Dept Internal Med, Natl Cheng Kung Univ Hosp, Coll Med, 35 Xiaodong Rd, Tainan 704, Taiwan.	cstrom@mednet.ucla.edu; sunnysu@mail.ncku.edu.tw	Lin, Chien-Chung/T-1496-2019	Lin, Chien-Chung/0000-0002-4739-5631; Soo Hoo, Guy/0000-0002-0793-5031; Li, Feng/0000-0002-5819-734X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UH2 CA206126, UH3 TR000923]; Center of Applied Nanomedicine, National Cheng Kung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	Supported by NIH grants UH2 CA206126 (D.T.W.W.) and UH3 TR000923 (D.T.W.W.) and by the Center of Applied Nanomedicine, National Cheng Kung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.	Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; Aravanis AM, 2017, CELL, V168, P571, DOI 10.1016/j.cell.2017.01.030; Brock G, 2015, TRANSL CANCER RES, V4, P280, DOI 10.3978/j.issn.2218-676X.2015.06.05; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Phallen J, 2017, SCI TRANSL MED, P9; Pu D, 2016, THORAC CANCER, V7, P428, DOI 10.1111/1759-7714.12350; Stewart CM, 2018, CANC GENET, DOI [10.1016/j.cancer-gen.2018.02.005, DOI 10.1016/J.CANCER-GEN.2018.02.005]; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Wei F, 2014, AM J RESP CRIT CARE, V190, P1117, DOI 10.1164/rccm.201406-1003OC; WONG MCS, 2017, SCI REP UK, V7	15	2	2	3	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					738	742		10.1016/j.jmoldx.2018.06.008			5	Pathology	Pathology	GY5RC	WOS:000448637200002	30309763				2019-10-28	
J	Hiemenz, MC; Ostrow, DG; Busse, TM; Buckley, J; Maglinte, DT; Bootwalla, M; Done, J; Ji, JL; Raca, G; Ryutov, A; Xu, XJ; Zhen, CJ; Conroy, JM; Hazard, FK; Deignan, JL; Rogers, BB; Treece, AL; Parham, DM; Gai, XW; Judkins, AR; Triche, TJ; Biegel, JA				Hiemenz, Matthew C.; Ostrow, Dejerianne G.; Busse, Tracy M.; Buckley, Jonathan; Maglinte, Dennis T.; Bootwalla, Moiz; Done, James; Ji, Jianling; Raca, Gordan; Ryutov, Alex; Xu, Xinjie; Zhen, Chao Jie; Conroy, Jeffrey M.; Hazard, Florette K.; Deignan, Joshua L.; Rogers, Beverly B.; Treece, Amanda L.; Parham, David M.; Gai, Xiaowu; Judkins, Alexander R.; Triche, Timothy J.; Biegel, Jaclyn A.			OncoKids A Comprehensive Next-Generation Sequencing Panel for Pediatric Malignancies	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CANCER; CHILDHOOD; THERAPY; TUMOR	The OncoKids panel is an amplification-based next-generation sequencing assay designed to detect diagnostic, prognostic, and therapeutic markers across the spectrum of pediatric malignancies, including leukemias, sarcomas, brain tumors, and embryonal tumors. This panel uses low input amounts of DNA (20 ng) and RNA (20 ng) and is compatible with formalin-fixed, paraffin-embedded and frozen tissue, bone marrow, and peripheral blood. The DNA content of this panel covers the full coding regions of 44 cancer predisposition loci, tumor suppressor genes, and oncogenes; hotspots for mutations in 82 genes; and amplification events in 24 genes. The RNA content includes 1421 targeted gene fusions. We describe the validation of this panel by using a large cohort of 192 unique clinical samples that included a wide range of tumor types and alterations. Robust performance was observed for analytical sensitivity, reproducibility, and limit of detection studies. The results from this study support the use of OncoKids for routine clinical testing of a wide variety of pediatric malignancies.	[Hiemenz, Matthew C.; Ostrow, Dejerianne G.; Busse, Tracy M.; Buckley, Jonathan; Maglinte, Dennis T.; Bootwalla, Moiz; Done, James; Ji, Jianling; Raca, Gordan; Ryutov, Alex; Parham, David M.; Gai, Xiaowu; Judkins, Alexander R.; Triche, Timothy J.; Biegel, Jaclyn A.] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA; [Hiemenz, Matthew C.; Buckley, Jonathan; Ji, Jianling; Raca, Gordan; Parham, David M.; Gai, Xiaowu; Judkins, Alexander R.; Triche, Timothy J.; Biegel, Jaclyn A.] USC, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; [Xu, Xinjie] ARUP Labs, Cytogenet & Genom Microarray, Salt Lake City, UT USA; [Xu, Xinjie] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; [Zhen, Chao Jie] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Conroy, Jeffrey M.] OmniSeq Inc, Buffalo, NY USA; [Conroy, Jeffrey M.] Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Hazard, Florette K.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Deignan, Joshua L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Rogers, Beverly B.] Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA USA; [Treece, Amanda L.] Childrens Hosp Colorado, Dept Pathol & Lab Med, Denver, CO USA	Hiemenz, MC (reprint author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,MS 173, Los Angeles, CA 90027 USA.	mhiemenz@chla.usc.edu	Ji, Jianling/W-5854-2019		Thermo Fisher Scientific, Inc.; Children's Hospital Los Angeles	Supported by institutional funding from the Children's Hospital Los Angeles and Thermo Fisher Scientific, Inc.	Abdel-Wahab O, 2010, LEUKEMIA, V24, P1656, DOI 10.1038/leu.2010.144; Abel HJ, 2014, J MOL DIAGN, V16, P405, DOI 10.1016/j.jmoldx.2014.03.006; Arva NC, 2016, DIAGN PATHOL OPEN, V1, P110; Babiceanu M, 2016, NUCLEIC ACIDS RES, V44, P2859, DOI 10.1093/nar/gkw032; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cheng YF, 2012, AM J CLIN PATHOL, V137, P142, DOI 10.1309/AJCP34ZVFLAUTMGL; Chung C, 2017, PHARMACOTHERAPY, V37, P1052, DOI 10.1002/phar.1977; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Gelsi-Boyer V, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-12; Harris MH, 2016, JAMA ONCOL, V2, P608, DOI 10.1001/jamaoncol.2015.5689; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jin YL, 2016, CANCER MED-US, V5, P337, DOI 10.1002/cam4.579; Khotskaya YB, 2017, PHARMACOL THERAPEUT, V173, P58, DOI 10.1016/j.pharmthera.2017.02.006; Laehnemann D, 2016, BRIEF BIOINFORM, V17, P154, DOI 10.1093/bib/bbv029; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Nikiforova M. N., 2015, CLIN GENOMICS GUIDE, P57, DOI [10.1016/B978-0-12-404748-8.00004-6, DOI 10.1016/B978-0-12-404748-8.00004-6]; Oberg JA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0389-6; Quail MA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-341; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Ryall S, 2017, BRAIN TUMOR PATHOL, V34, P51, DOI 10.1007/s10014-017-0282-z; Samorodnitsky E, 2015, HUM MUTAT, V36, P903, DOI 10.1002/humu.22825; Sangkhathat Surasak, 2015, World J Clin Pediatr, V4, P94, DOI 10.5409/wjcp.v4.i4.94; Santiago R, 2017, EXPERT OPIN PHARMACO, V18, P1081, DOI 10.1080/14656566.2017.1340938; Schiffman JD, 2010, CANCER RES, V70, P512, DOI 10.1158/0008-5472.CAN-09-1851; Steppan DA, 2017, ADOLESC HEALTH MED T, V8, P41, DOI 10.2147/AHMT.S70377; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vohra H. A., 2004, EUR J INTERN MED, V15, P465, DOI [10.1016/j.ejim.2004.08.004, DOI 10.1016/J.EJIM.2004.08.004]; Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219; Yokota T, 2016, CANCER SCI, V107, P721, DOI 10.1111/cas.12927	30	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					765	776		10.1016/j.jmoldx.2018.06.009			12	Pathology	Pathology	GY5RC	WOS:000448637200005	30138724				2019-10-28	
J	Kosztolanyi, S; Kiss, R; Atanesyan, L; Gango, A; de Groot, K; Steenkamer, M; Jakso, P; Matolcsy, A; Kajtar, B; Pajor, L; Szuhai, K; Savola, S; Bodor, C; Alpar, D				Kosztolanyi, Szabolcs; Kiss, Richard; Atanesyan, Lilit; Gango, Ambrus; de Groot, Karel; Steenkamer, Maryvonne; Jakso, Pal; Matolcsy, Andras; Kajtar, Bela; Pajor, Laszlo; Szuhai, Karoly; Savola, Suvi; Bodor, Csaba; Alpar, Donat			High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							IN-SITU HYBRIDIZATION; CHROMOSOMAL-ABNORMALITIES; MLPA; CLASSIFICATION; IMPACT; DETECT; FISH; TRISOMIES; LEUKEMIA; DELETION	Multiple myeloma (MM) is a genetically heterogeneous disease with a diverse clinical outcome. Copy number alterations (CNAs), including whole chromosome and subchromosomal gains and losses, are common contributors of the pathogenesis and have demonstrated prognostic impact in MM. We tested the performance of digital multiplex ligation-dependent probe amplification (digitalMLPA), a novel technique combining MLPA and next-generation sequencing, to detect disease-related CNAs. Copy number status at 371 genomic loci was simultaneously analyzed in 56 diagnostic bone marrow samples, which were also examined by conventional MLPA and interphase fluorescence in situ hybridization (iFISH). On average, digitalMLPA identified 4.4 subchromosomal CNAs per patient. The increased number of probes compared with conventional MLPA allowed a detailed mapping of CNAs, especially on chromosome 1, where 24 different patterns were observed in 38 patients harboring loss(1p) and/or gain(1q). iFISH, MLPA, and digitalMLPA results at loci investigated by multiple methods showed a congruency of 95%. Besides precise characterization of hyperdiploid karyotypes not efficiently achievable by iFISH or MLPA, digitalMLPA unraveled 156 CNAs not detected by the other two methods in 45 patients (80%). In addition, we provide proof of principle that digitalMLPA can detect known point mutations, in this case the BRAF(V600E). Our study demonstrates the robustness of digitalMLPA to profile CNAs and to screen point mutations in MM, which could efficiently be used in myeloma diagnostics.	[Kosztolanyi, Szabolcs] Univ Pecs, Ctr Clin, Dept Internal Med 1, Pecs, Hungary; [Kiss, Richard; Gango, Ambrus; Matolcsy, Andras; Bodor, Csaba; Alpar, Donat] Semmelweis Univ, MTA SE Lendulet Mol Oncohematol Res Grp, Dept Pathol & Expt Canc Res 1, 26 Ulloi Str, H-1085 Budapest, Hungary; [Atanesyan, Lilit; de Groot, Karel; Steenkamer, Maryvonne; Savola, Suvi] MRC Holland, Amsterdam, Netherlands; [Jakso, Pal; Kajtar, Bela; Pajor, Laszlo; Alpar, Donat] Univ Pecs, Sch Med, Dept Pathol, Pecs, Hungary; [Szuhai, Karoly] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	Alpar, D (reprint author), Semmelweis Univ, MTA SE Lendulet Mol Oncohematol Res Grp, Dept Pathol & Expt Canc Res 1, 26 Ulloi Str, H-1085 Budapest, Hungary.	donat@med.semmelweis-univ.hu	Szuhai, Karoly/A-1100-2008; Bodor, Csaba/O-4524-2017	Szuhai, Karoly/0000-0002-1228-4245; Bodor, Csaba/0000-0002-0729-692X; Alpar, Donat/0000-0002-2638-5418; Savola, Suvi/0000-0002-6221-8617	Hungarian National Research, Development and Innovation Office - NKFIH [K_16 119950, NVKP_16-1-2016-0004]; New National Excellence Program of the Ministry of Human Capacities, Hungary [UNKP-17-4-III-SE-9]; Hungarian Academy of Sciences Lendulet Research [LP95021]	Supported by the Hungarian National Research, Development and Innovation Office - NKFIH grants K_16 #119950 and NVKP_16-1-2016-0004, the New National Excellence Program of the Ministry of Human Capacities, Hungary grant UNKP-17-4-III-SE-9, and the Hungarian Academy of Sciences Lendulet Research grant LP95021. MRC-Holland provided the digital multiplex ligation-dependent probe amplification probemix and reagents.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alpar D, 2013, GENE CHROMOSOME CANC, V52, P785, DOI 10.1002/gcc.22074; Alpar D, 2012, CANCER GENET-NY, V205, P465, DOI 10.1016/j.cancergen.2012.05.007; Andrulis M, 2013, CANCER DISCOV, V3, P862, DOI 10.1158/2159-8290.CD-13-0014; Atanesyan L, 2017, AM J CLIN PATHOL, V147, P60, DOI [10.1093/ajcp/aqw205, 10.1093/AJCP/AQW205]; Avet-Loiseau H, 2009, J CLIN ONCOL, V27, P4585, DOI 10.1200/JCO.2008.20.6136; Benard-Slagter A, 2017, J MOL DIAGN, V19, P659, DOI 10.1016/j.jmoldx.2017.05.004; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Boyd KD, 2012, LEUKEMIA, V26, P349, DOI 10.1038/leu.2011.204; Boyle EM, 2015, GENE CHROMOSOME CANC, V54, P91, DOI 10.1002/gcc.22222; Buijs A, 2006, HAEMATOL-HEMATOL J, V91, P1434; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chavan SS, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.12; Chng WJ, 2014, LEUKEMIA, V28, P269, DOI 10.1038/leu.2013.247; Chretien ML, 2015, BLOOD, V126, P2713, DOI 10.1182/blood-2015-06-650242; Coll-Mulet L, 2008, BRIT J HAEMATOL, V142, P793, DOI 10.1111/j.1365-2141.2008.07268.x; Donahue AC, 2011, LEUKEMIA RES, V35, P1477, DOI 10.1016/j.leukres.2011.06.019; du Pont SR, 2017, J CLIN ONCOL, V35, P963, DOI 10.1200/JCO.2016.70.6705; Fabris S, 2011, GENE CHROMOSOME CANC, V50, P726, DOI 10.1002/gcc.20894; Fonseca R, 2009, LEUKEMIA, V23, P2210, DOI 10.1038/leu.2009.174; Hebraud B, 2014, LEUKEMIA, V28, P675, DOI 10.1038/leu.2013.225; Homig-Holzel C, 2012, DIAGN MOL PATHOL, V21, P189, DOI 10.1097/PDM.0b013e3182595516; Jacobus SJ, 2011, BRIT J HAEMATOL, V155, P340, DOI 10.1111/j.1365-2141.2011.08849.x; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kumar S, 2012, BLOOD, V119, P2100, DOI 10.1182/blood-2011-11-390658; Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Ross FM, 2012, HAEMATOL-HEMATOL J, V97, P1272, DOI 10.3324/haematol.2011.056176; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Schwab CJ, 2010, GENE CHROMOSOME CANC, V49, P1104, DOI 10.1002/gcc.20818; Shah V, 2018, LEUKEMIA, V32, P102, DOI 10.1038/leu.2017.179; Smetana J, 2014, BIOMED RES INT, DOI 10.1155/2014/209670; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thanendrarajan S, 2017, HAEMATOLOGICA, V102, pE364, DOI 10.3324/haematol.2017.168872; Walker BA, 2015, J CLIN ONCOL, V33, P3911, DOI 10.1200/JCO.2014.59.1503; Walker BA, 2010, BLOOD, V116, pE56, DOI 10.1182/blood-2010-04-279596; Zang MR, 2015, ONCOTARGET, V6, P34276, DOI 10.18632/oncotarget.5371; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	41	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					777	788		10.1016/j.jmoldx.2018.06.004			12	Pathology	Pathology	GY5RC	WOS:000448637200006	30096382				2019-10-28	
J	Suh, E; Grando, K; Van Deerlin, VM				Suh, EunRan; Grando, Kaitlyn; Van Deerlin, Vivianna M.			Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; DISEASE; SIZE; ALS; REGION; FTD	A hexanucleotide GGGGCC repeat expansion in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal degeneration. Accurate determination and quantitation of the repeat length is critical in both clinical and research settings. However, because of the complexity of the C9orf72 expansion with high GC content, large size of repeats, and high rate of insertions/deletions (indels) and sequence variations in the flanking regions, molecular genetic analysis of the locus is challenging. To improve the performance characteristics for clinical testing, we evaluated a commercially available long-read C9orf72 PCR assay for research use only, AmplideX PCR/CE C9orf72 assay (AmplideX-C9), and compared its performance with our existing laboratory-developed C9orf72 expansion procedure. Overall, in comparison to the laboratory-developed C9orf72 expansion procedure, AmplideX-C9 demonstrated a more efficient workflow, greater PCR efficiency for sizing of repeat expansions, and improved peak amplitude with lower DNA input and higher analytic sensitivity. This, in turn, permitted detection of indels in the 3' downstream of the repeat expansion region in expanded alleles, showed a higher success rate with formalin-fixed, paraffin-embedded tissue specimens, and facilitated the assessment of repeat mosaicism. In summary, AmplideX-C9 will not only help to improve clinical testing for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal degeneration but will also be a valuable research tool to better characterize the complexity of expansions and study the effects of indels/sequence variations in the flanking region.	[Suh, EunRan; Grando, Kaitlyn; Van Deerlin, Vivianna M.] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Perelman Sch Med, 3400 Spruce St,7-103 Founders Pavil, Philadelphia, PA 19104 USA	Van Deerlin, VM (reprint author), Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Perelman Sch Med, 3400 Spruce St,7-103 Founders Pavil, Philadelphia, PA 19104 USA.	vivianna@upenn.edu		Van Deerlin, Vivianna/0000-0002-7400-9097	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-AG-017586, R44-NS089423]; ALS Association [16-LGCA-285]	Supported by NIH grants P01-AG-017586 (V.M.V.D.) and R44-NS089423 (V.M.V.D.) and ALS Association grant 16-LGCA-285 (V.M.V.D.). Eran Bram and Kristen Culp (Asuragen Inc.) provided reagents and technical consultation.	Akimoto C, 2014, J MED GENET, V51, P419, DOI 10.1136/jmedgenet-2014-102360; Beck J, 2013, AM J HUM GENET, V92, P345, DOI 10.1016/j.ajhg.2013.01.011; Belzil VV, 2016, ACTA NEUROPATHOL, V132, P487, DOI 10.1007/s00401-016-1587-4; Chen YP, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.11.016; Cooper-Knock J, 2014, ACTA NEUROPATHOL, V127, P333, DOI 10.1007/s00401-014-1251-9; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Dols-Icardo O, 2014, HUM MOL GENET, V23, P749, DOI 10.1093/hmg/ddt460; Filipovic-Sadic S, 2010, CLIN CHEM, V56, P399, DOI 10.1373/clinchem.2009.136101; Fratta P, 2013, ACTA NEUROPATHOL, V126, P401, DOI 10.1007/s00401-013-1147-0; Galimberti D, 2014, J ALZHEIMERS DIS, V39, P19, DOI 10.3233/JAD-131172; Garcia-Redondo A, 2013, HUM MUTAT, V34, P79, DOI 10.1002/humu.22211; Gomez-Tortosa E, 2013, NEUROLOGY, V80, P366, DOI 10.1212/WNL.0b013e31827f08ea; Goncalves TF, 2016, EXPERT REV MOL DIAGN, V16, P501, DOI 10.1586/14737159.2016.1135739; Hubers A, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.11.034; Irwin DJ, 2015, ACTA NEUROPATHOL, V129, P469, DOI 10.1007/s00401-014-1380-1; Jiao B, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00164; Kraus-Perrotta Cara, 2016, Cerebellum Ataxias, V3, P20; Nordin A, 2017, AMYOTROPH LAT SCL FR, V18, P256, DOI 10.1080/21678421.2016.1262423; Nuytemans K, 2013, ANN HUM GENET, V77, P351, DOI 10.1111/ahg.12033; Ratti A, 2012, NEUROBIOL AGING, V33; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Rollinson S, 2015, NEUROBIOL AGING, V36; Suh E, 2015, ACTA NEUROPATHOL, V130, P363, DOI 10.1007/s00401-015-1445-9; Taylor JP, 2016, NATURE, V539, P197, DOI 10.1038/nature20413; van Blitterswijk M, 2013, LANCET NEUROL, V12, P978, DOI 10.1016/S1474-4422(13)70210-2; van der Zee J, 2013, HUM MUTAT, V34, P363, DOI 10.1002/humu.22244; Van Mossevelde S, 2017, JAMA NEUROL, V74, P445, DOI 10.1001/jamaneurol.2016.4847; Van Mossevelde S, 2017, CURR OPIN GENET DEV, V44, P117, DOI 10.1016/j.gde.2017.02.008; Xi ZR, 2012, ARCH NEUROL-CHICAGO, V69, P1583, DOI 10.1001/archneurol.2012.2016	29	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					871	882		10.1016/j.jmoldx.2018.07.001			12	Pathology	Pathology	GY5RC	WOS:000448637200014	30138726				2019-10-28	
J	Shin, SA; Na, HY; Choe, JY; Chung, D; Park, M; Oh, S; Kim, JE				Shin, Sun Ah; Na, Hee Young; Choe, Ji Young; Chung, Doohyun; Park, Mira; Oh, Sohee; Kim, Ji Eun			The Expression of Adipophilin Is Frequently Found in Solid Subtype Adenocarcinoma and Is Associated with Adverse Outcomes in Lung Adenocarcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Adipophilin; Lung adenocarcinoma; Hypoxia; Prognosis	ACID SYNTHASE FAS; LIPID-ACCUMULATION; MARKER; CELLS; CARCINOMA	Background: The up-regulation of the lipogenic pathway has been reported in many types of malignant tumors. However, its pathogenic role or clinical significance is not fully understood. The objective of this study was to examine the expression levels of adipophilin and related hypoxic signaling proteins and to determine their prognostic impacts and associations with the pathologic characteristics of lung adenocarcinoma. Methods: Expression levels of adipophilin, heat shock protein 27 (HSP27), carbonic anhydrase IX, and hypoxia-inducible factor la were examined by immunohistochemical staining using tissue microarray blocks. Correlations between protein expression levels and various clinicopathologic features were analyzed. Results: A total of 230 cases of primary adenocarcinoma of the lung were enrolled in this study. Adipophilin expression was more frequent in males and with the solid histologic type. It was correlated with HSP27 expression. Patients with adipophilin-positive adenocarcinoma showed a shorter progression-free survival (PFS) (median PFS, 17.2 months vs 18.4 months) in a univariable survival analysis, whereas HSP27 positivity correlated with favorable overall survival (OS) and PFS. In a multivariable analysis, adipophilin and HSP27 were independent prognostic markers of both OS and PFS. Conclusions: Activated lipid metabolism and the hypoxic signaling pathway might play a major role in the progression of lung adenocarcinoma, especially in the solid histologic type.	[Shin, Sun Ah; Chung, Doohyun] Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea; [Na, Hee Young] Seoul Natl Univ, Dept Pathol, Bundang Hosp, Seongnam, South Korea; [Choe, Ji Young] Hallym Univ, Dept Pathol, Sacred Heart Hosp, Anyang, South Korea; [Park, Mira; Kim, Ji Eun] Seoul Natl Univ, Boramae Hosp, Dept Pathol, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea; [Oh, Sohee] Seoul Natl Univ, Boramae Hosp, Dept Biostat, Seoul, South Korea	Kim, JE (reprint author), Seoul Natl Univ, Boramae Hosp, Dept Pathol, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.	npol181@snu.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2017R1A2B4005052]	This study was supported by the Grant of National Research Foundation of Korea (2017R1A2B4005052).	Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Brierley JD, 2017, TNM CLASSFICATION MA; Camassei FD, 2003, INVEST OPHTH VIS SCI, V44, P2399, DOI 10.1167/iovs.02-0934; Fujimoto M, 2017, HISTOPATHOLOGY, V70, P232, DOI 10.1111/his.13048; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Kaigorodova EV, 2014, CURR CANCER DRUG TAR, V14, P713, DOI 10.2174/1568009614666140926122846; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kohe S, 2017, J HISTOL HISTOPATHOL, V4, P4, DOI DOI 10.7243/2055-091X-4-4; Luque-Garcia JL, 2010, PROTEOMICS, V10, P940, DOI 10.1002/pmic.200900441; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Moritani S, 2011, AM J SURG PATHOL, V35, P861, DOI 10.1097/PAS.0b013e31821a7f3e; Straub BK, 2013, HISTOPATHOLOGY, V62, P617, DOI 10.1111/his.12038; Tolkach Y, 2017, ONCOTARGET, V8, P28672, DOI 10.18632/oncotarget.15639; Zhang XD, 2014, INT J CLIN EXP MED, V7, P1190; Zheng XW, 2006, MOL CELL BIOL, V26, P4628, DOI 10.1128/MCB.02236-05	17	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					357	362		10.4132/jptm.2018.09.13			6	Pathology	Pathology	HA3IV	WOS:000450144200002	30286563	DOAJ Gold, Green Published			2019-10-28	
J	Abdou, AG; Maraee, A; Yassien, H; Sarin, M				Abdou, Asmaa Gaber; Maraee, Alaa; Yassien, Hossam; Sarin, Mona			Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Vitiligo; Janus kinase 1; HMB45; Immunohistochemistry	NARROW-BAND UVB; MELANOCYTES; AUTOIMMUNE; THERAPY; CELLS	Background: Vitiligo is a chronic autoimmune disease in which the destruction of melanocytes causes white spots on the affected skin. Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-signal transducer and activator of transcription pathway. The aim of the present study is to explore the possible role of JAK1 in the pathogenesis of vitiligo using immunohistochemical methods. Methods: The current study was conducted in a sample of 39 patients who presented with vitiligo and 22 healthy individuals who were age and sex matched as a control group. We used immunohistochemistry to evaluate JAK1 status (intensity and distribution) and assess the percentage of residual melanocytes using human melanoma black 45 (HMB45). Results: Intense and diffuse JAK1 expression was significantly more likely to indicate vitiliginous skin compared to normal skin (p<.001). Strong and diffuse JAK1 expression was associated with short disease duration, female sex, and lower percentage of melanocytes (detected by HMB45) (p<.05). Conclusions: JAK1 may be involved in the pathogenesis of vitiligo, as indicated by intense and diffuse expression compared to control and association with lower percentage of melanocytes detected by HMB45 immunostaining.	[Abdou, Asmaa Gaber] Menoufia Univ, Fac Med, Dept Pathol, Shebein Elkom 32511, Egypt; [Maraee, Alaa; Yassien, Hossam; Sarin, Mona] Menoufia Univ, Fac Med, Dept Dermatol, Shebein Elkom, Egypt	Abdou, AG (reprint author), Menoufia Univ, Fac Med, Dept Pathol, Shebein Elkom 32511, Egypt.	Asmaa_elsaidy@yahoo.com					Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; Attwa E, 2012, ARCH DERMATOL RES, V304, P823, DOI 10.1007/s00403-012-1269-6; Basak PY, 2008, J EUR ACAD DERMATOL, V22, P970, DOI 10.1111/j.1468-3083.2008.02681.x; Bassiouny DA, 2011, CLIN EXP DERMATOL, V36, P292, DOI 10.1111/j.1365-2230.2010.03972.x; Bhise SB, 2004, INDIAN J BIOCHEM BIO, V41, P273; Bhor Urmila, 2006, Indian J Dermatol Venereol Leprol, V72, P315; Bonotis K, 2016, J DTSCH DERMATOL GES, V14, P45, DOI 10.1111/ddg.12729; Craiglow BG, 2015, JAMA DERMATOL, V151, P1110, DOI 10.1001/jamadermatol.2015.1520; Klarquist J, 2010, PIGM CELL MELANOMA R, V23, P276, DOI 10.1111/j.1755-148X.2010.00688.x; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Landry DA, 2017, MOL CELL BIOCHEM, V433, P79, DOI 10.1007/s11010-017-3017-x; Nada HR, 2018, ARCH DERMATOL RES, V310, P39, DOI 10.1007/s00403-017-1792-6; Nakagawa R, 2011, J IMMUNOL, V187, P4611, DOI 10.4049/jimmunol.1100649; Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32	16	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					363	368		10.4132/jptm.2018.09.18			6	Pathology	Pathology	HA3IV	WOS:000450144200003	30347972	DOAJ Gold, Green Published			2019-10-28	
J	Shim, B; Jie, MS; Moon, JH; Park, IA; Ryu, HS				Shim, Bobae; Jie, Min-Sun; Moon, Ji Hye; Park, In Ae; Ryu, Han Suk			High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						CXCR4; CXCL12; Triple negative breast neoplasms; Prognostic marker	CHEMOKINE RECEPTOR CXCR4; TUMOR-GROWTH; PROGNOSIS; METAANALYSIS; METASTASIS; LEVEL; CELLS; AXIS	Background: Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy. Methods: Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalinfixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome. Results: High cytoplasmic CXCR4 expression was associated with younger age (p= .008), higher histologic grade (p = .007) and lower pathologic stage (p= .045), while high CXCL12 expression was related to larger tumor size (p=.045), positive lymph node metastasis (p=.005), and higher pathologic stage (p=.017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p=.006) and better recurrence-free survival (RFS) (log-rank p= .020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p=.019) and RFS (p=.038) after multivariate analysis. Conclusions: High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TN BC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.	[Shim, Bobae; Moon, Ji Hye; Park, In Ae; Ryu, Han Suk] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Pathol, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea; [Jie, Min-Sun] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Pathol, Bucheon, South Korea	Ryu, HS (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Pathol, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea.	karlnash@naver.com					Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187; Chen HW, 2013, CURR MOL MED, V13, P410; Chu QYD, 2010, J SURG RES, V159, P689, DOI 10.1016/j.jss.2008.09.020; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Guembarovski AL, 2018, MOL BIOL REP, V45, P741, DOI 10.1007/s11033-018-4215-7; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hassan S, 2009, AM J PATHOL, V175, P66, DOI 10.2353/ajpath.2009.080948; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kobayashi T, 2010, BREAST CANCER RES TR, V123, P733, DOI 10.1007/s10549-009-0672-y; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Lefort S, 2017, ONCOGENE, V36, P1211, DOI 10.1038/onc.2016.284; Liu YX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-16; Mirisola V, 2009, EUR J CANCER, V45, P2579, DOI 10.1016/j.ejca.2009.06.026; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Samarendra H, 2017, BRIT J CANCER, V117, P124, DOI 10.1038/bjc.2017.134; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yan M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2869; Yu SN, 2013, ACTA MED OKAYAMA, V67, P369; Zhang ZG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-49; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	32	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					369	377		10.4132/jptm.2018.09.19			9	Pathology	Pathology	HA3IV	WOS:000450144200004	30269472	DOAJ Gold, Green Published			2019-10-28	
J	Wi, YC; Moon, A; Jung, MJ; Kim, Y; Bang, SS; Fang, K; Paik, SS; Shin, SJ				Wi, Young Chan; Moon, Ahrim; Jung, Min Jung; Kim, Yeseul; Bang, Seong Sik; Fang, Kiseok; Paik, Seung Sam; Shin, Su-Jin			Loss of Nuclear BAP1 Expression s Associated with High WHO/ISUP Grade in Clear Cell Renal Cell Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; renal cell; Clear cell; BAP1; Immunostaining	FREQUENT MUTATION; IMMUNOHISTOCHEMISTRY; OUTCOMES	Background: BRCA1-associated protein 1 (BAP1) mutations are frequently reported in clear cell renal cell carcinoma (ccRCC); however, very few studies have evaluated the role of these mutations in other renal cell carcinoma (RCC) subtypes. Therefore, we analyzed BAP1 protein expression using immunohistochemistry in several RCC subtypes and assessed its relationship with clinicopathological characteristics of patients. Methods: BAP1 expression was immunohisto-chemically evaluated in tissue microarray blocks constructed from 371 samples of RCC collected from two medical institutions. BAP1 expression was evaluated based on the extent of nuclear staining in tumor cells, and no expression or expression in < 10% of tumor cells was defined as negative. Results: Loss of BAP1 expression was observed in ccRCC (56/300, 18.7%), chromophobe RCC (6/26, 23.1%), and clear cell papillary RCC (1/4, 25%), while we failed to detect BAP1 expression loss in papillary RCC, acquired cystic disease-associated RCC, or collecting duct carcinoma. In ccRCC, loss of BAP1 expression was significantly associated with high World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grade (p =.002); however, no significant correlation was observed between loss of BAP1 expression and survival in ccRCC. Loss of BAP1 expression showed no association with prognostic factors in chromophobe RCC. Conclusions: Loss of BAP1 nuclear expression was observed in both ccRCC and chromophobe RCC. In addition, BAP1 expression loss was associated with poor prognostic factors such as high WHO/ISUP grade in ccRCC.	[Wi, Young Chan; Kim, Yeseul; Bang, Seong Sik; Fang, Kiseok; Paik, Seung Sam; Shin, Su-Jin] Hanyang Univ, Dept Pathol, Coll Med, 222-1 Wangsimni Ro, Seoul 04763, South Korea; [Moon, Ahrim; Jung, Min Jung] Soonchunhyang Univ, Bucheon Hosp, Dept Pathol, Coll Med, Bucheon, South Korea	Shin, SJ (reprint author), Hanyang Univ, Dept Pathol, Coll Med, 222-1 Wangsimni Ro, Seoul 04763, South Korea.	cham@hanyang.ac.kr	Shin, Su-Jin/K-3248-2017	Shin, Su-Jin/0000-0001-9114-8438	research fund of Hanyang University (HY-2016)	This work was supported by the research fund of Hanyang University (HY-2016).	Andrici J, 2015, MODERN PATHOL, V28, P1360, DOI 10.1038/modpathol.2015.87; Bhattacharya S, 2015, SCI REP-UK, V5, DOI 10.1038/srep18462; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; da Costa WH, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.01.002; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Eble JN, 2016, WHO CLASSIFICATION T; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Joseph RW, 2014, CANCER-AM CANCER SOC, V120, P1059, DOI 10.1002/cncr.28521; Kapur P, 2014, J UROLOGY, V191, P603, DOI 10.1016/j.juro.2013.09.041; Kim SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179610; Koopmans AE, 2014, MODERN PATHOL, V27, P1321, DOI 10.1038/modpathol.2014.43; Minardi D, 2017, VIRCHOWS ARCH, V471, P99, DOI 10.1007/s00428-017-2143-x; Murali R, 2013, PATHOLOGY, V45, P116, DOI 10.1097/PAT.0b013e32835d0efb; Oka S, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.04.015; Paner GP, 2010, AM J SURG PATHOL, V34, P1233, DOI 10.1097/PAS.0b013e3181e96f2a; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Rai K, 2016, CLIN GENET, V89, P285, DOI 10.1111/cge.12630; Ricketts CJ, 2018, CELL REP, V23, P3698, DOI 10.1016/j.celrep.2018.06.032; Ricketts CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140257; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; White AE, 2012, SCIENCE, V337, P1463, DOI 10.1126/science.1228463	25	1	1	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					378	385		10.4132/jptm.2018.09.21			8	Pathology	Pathology	HA3IV	WOS:000450144200005	30269473	DOAJ Gold, Green Published			2019-10-28	
J	Park, HE; Yoo, S; Bae, JM; Jeong, S; Cho, NY; Kang, GH				Park, Hye Eun; Yoo, Seungyeon; Bae, Jeong Mo; Jeong, Seorin; Cho, Nam-Yun; Kang, Gyeong Hoon			Multiplicity of Advanced T Category-Tumors Is a Risk Factor for Survival in Patients with Colorectal Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Synchronous colorectal carcinoma; Multiple colorectal carcinoma; Clinical outcome; T category	CLINICOPATHOLOGICAL FEATURES; CLINICAL-FEATURES; CURRENT TRENDS; CANCER; PROGNOSIS; COLON; RECTUM; EPIDEMIOLOGY; DIAGNOSIS; LOCATION	Background: Previous studies on synchronous colorectal carcinoma (SCRC) have reported inconsistent results about its clinicopathologic and molecular features and prognostic significance. Methods: Forty-six patients with multiple advanced tumors (T2 or higher category) who did not receive neoadjuvant chemotherapy and/or radiotherapy and who are not associated with familial adenomatous polyposis were selected and 99 tumors from them were subjected to clinicopathologic and molecular analysis. Ninety-two cases of solitary colorectal carcinoma (CRC) were selected as a control considering the distributions of types of surgeries performed on patients with SCRC and T categories of individual tumors from SCRC. Results: SCRC with multiple advanced tumors was significantly associated with more frequent nodal metastasis (p=.003) and distant metastasis (p=.001) than solitary CRC. KRAS mutation, miaosatellite instability, and CpG island methylator phenotype statuses were not different between SCRC and solitary CRC groups. In univariate survival analysis, overall and recurrence-free survival were significantly lower in patients with SCRC than in patients with solitary CRC, even after adjusting for the extensiveness of surgical procedure, adjuvant chemotherapy, or staging. Multivariate Cox regression analysis revealed that tumor multiplicity was an independent prognostic factor for overall survival (hazard ratio, 4.618; 95% confidence interval, 2.126 to 10.030; p < .001), but not for recurrence-free survival (p=.151). Conclusions: Findings suggested that multiplicity of advanced T category-tumors might be associated with an increased risk of nodal metastasis and a risk factor for poor survival, which raises a concern about the guideline of American Joint Committee on Cancer's tumor-node-metastasis staging that T staging of an index tumor determines T staging of SCRC.	[Park, Hye Eun; Yoo, Seungyeon; Bae, Jeong Mo; Cho, Nam-Yun; Kang, Gyeong Hoon] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Pathol, Coll Med, Seoul, South Korea; [Jeong, Seorin; Kang, Gyeong Hoon] Seoul Natl Univ, Canc Res Inst, Lab Epigenet, Coll Med, Seoul, South Korea	Kang, GH (reprint author), Seoul Natl Univ, Dept Pathol, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea.	ghkang@snu.ac.kr	Kang, Gyeong Hoon/F-1051-2010	Kang, Gyeong Hoon/0000-0003-2380-6675	National Research Foundation (NRF) - Korean Ministry of Science, ICT and Future Planning [2016M3A9B6026921]; Korea Health Industry Development Institute - Korean Ministry of Health and Welfare [HI14C1277]	This work was supported by a grant from the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT and Future Planning (2016M3A9B6026921) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Korean Ministry of Health and Welfare (HI14C1277).	Bae JM, 2013, BRIT J CANCER, V109, P1004, DOI 10.1038/bjc.2013.430; Bae JM, 2016, ARCH PATHOL LAB MED, V140, P406, DOI 10.5858/arpa.2015-0310-RA; Brueckl WM, 2000, ANTICANCER RES, V20, P4727; Chen HS, 2000, DIS COLON RECTUM, V43, P1093, DOI 10.1007/BF02236556; CUNLIFFE WJ, 1984, BRIT J SURG, V71, P941, DOI 10.1002/bjs.1800711210; Dykes SL, 2003, CANCER-AM CANCER SOC, V98, P48, DOI 10.1002/cncr.11445; Eguchi K, 2000, MODERN PATHOL, V13, P131, DOI 10.1038/modpathol.3880024; ENKER WE, 1978, ANN SURG, V187, P8, DOI 10.1097/00000658-197801000-00002; EVERS BM, 1988, DIS COLON RECTUM, V31, P518; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FINAN PJ, 1987, BRIT J SURG, V74, P945, DOI 10.1002/bjs.1800741021; Fukatsu H, 2007, DIGEST LIVER DIS, V39, P40, DOI 10.1016/j.dld.2006.07.015; Ghiringhelli F, 2014, DIGEST LIVER DIS, V46, P854, DOI 10.1016/j.dld.2014.05.011; Giannini R, 2014, ONCOL LETT, V7, P1532, DOI 10.3892/ol.2014.1905; Gonzalo V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091033; Hu HK, 2013, AM J SURG PATHOL, V37, P1660, DOI 10.1097/PAS.0b013e31829623b8; KAIBARA N, 1984, CANCER, V54, P1870, DOI 10.1002/1097-0142(19841101)54:9<1870::AID-CNCR2820540917>3.0.CO;2-5; Kamiyama H, 2012, ONCOGENE, V31, P5029, DOI 10.1038/onc.2011.652; Kato T, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1027-x; KIMURA T, 1994, HEPATO-GASTROENTEROL, V41, P409; Lam AKY, 2014, WORLD J GASTROENTERO, V20, P6815, DOI 10.3748/wjg.v20.i22.6815; Lam AKY, 2011, AM J SURG, V202, P39, DOI 10.1016/j.amjsurg.2010.05.012; Latournerie M, 2008, BRIT J SURG, V95, P1528, DOI 10.1002/bjs.6382; Mulder SA, 2011, CANCER EPIDEMIOL, V35, P442, DOI 10.1016/j.canep.2010.12.007; Norrie MWA, 2002, DIS COLON RECTUM, V45, P674, DOI 10.1007/s10350-004-6266-1; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; Oh HJ, 2017, J PATHOL TRANSL MED, V51, P306, DOI 10.4132/jptm.2017.01.19; Oya M, 2003, JPN J CLIN ONCOL, V33, P38, DOI 10.1093/jjco/hyg010; Pedroni M, 1999, INT J CANCER, V81, P1; Ronnekleiv-Kelly SM, 2017, HEPATOL SURG NUTR, V6, P35, DOI 10.21037/hbsn.2016.10.02; Ueno Masashi, 2003, Int J Clin Oncol, V8, P162, DOI 10.1007/s10147-003-0322-z; Wang HZ, 2004, WORLD J GASTROENTERO, V10, P2136, DOI 10.3748/wjg.v10.i14.2136; WELCH JP, 1981, AM J SURG, V142, P274, DOI 10.1016/0002-9610(81)90292-0; Yang J, 2011, DIGEST SURG, V28, P379, DOI 10.1159/000334073; 강중구, 2006, Annals of Coloproctolgy, V22, P418; 김용진, 2002, Annals of Coloproctolgy, V18, P343	36	0	0	1	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					386	395		10.4132/jptm.2018.10.02			10	Pathology	Pathology	HA3IV	WOS:000450144200006	30458607	DOAJ Gold, Green Published			2019-10-28	
J	Chu, J; Bae, H; Seo, Y; Cho, SY; Kim, SH; Cho, EY				Chu, Jinah; Bae, Hyunsik; Seo, Youjeong; Cho, Soo Youn; Kim, Seok-Hyung; Cho, Eun Yoon			The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Breast neoplasms; Multiplicity; Disease-free survival; Prognosis; Molecular subtype	LYMPH-NODE STATUS; TUMOR SIZE; MULTIFOCALITY; CARCINOMA; DISEASE; MULTICENTRICITY; SOCIETY	Background: In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer. Methods: We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012. Results: Patients were divided into two groups according to multiplicity (single, n= 4,744; multiple, n= 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p<.001). Patients with multiple masses tended to have luminal A molecular subtype (p< .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p=.019 and p = .032, respectively). When targeting patients with T1-2 NO MO, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p= .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 123; 95% confidence interval, 1.03 to 1.47; p= .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS. Conclusions: Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1-2 N0 M0, hormone-receptor-positive, and HER2-negative cancer.	[Chu, Jinah; Bae, Hyunsik; Seo, Youjeong; Cho, Soo Youn; Kim, Seok-Hyung; Cho, Eun Yoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 06351, South Korea	Kim, SH; Cho, EY (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 06351, South Korea.	pannenides.kim@samsung.com; eunyoon.cho@samsung.com					Andea AA, 2004, CANCER, V100, P20, DOI 10.1002/cncr.11880; Bendifallah S, 2010, SURG ONCOL, V19, pE115, DOI 10.1016/j.suronc.2010.06.001; Boyages J, 2010, EUR J CANCER, V46, P1990, DOI 10.1016/j.ejca.2010.03.003; Cabioglu N, 2009, J AM COLL SURGEONS, V208, P67, DOI 10.1016/j.jamcollsurg.2008.09.001; Coombs NJ, 2005, J CLIN ONCOL, V23, P7497, DOI 10.1200/JCO.2005.02.1147; Duraker N, 2014, BREAST J, V20, P61, DOI 10.1111/tbj.12205; EGAN RL, 1982, CANCER, V49, P1123, DOI 10.1002/1097-0142(19820315)49:6<1123::AID-CNCR2820490610>3.0.CO;2-R; Fish EB, 1998, ANN SURG ONCOL, V5, P442, DOI 10.1007/BF02303863; Giuliano AE, 2018, ANN SURG ONCOL, V25, P1783, DOI 10.1245/s10434-018-6486-6; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Joergensen LE, 2008, BREAST, V17, P587, DOI 10.1016/j.breast.2008.06.004; Litton JK, 2007, CANCER, V110, P1445, DOI 10.1002/cncr.22928; Lynch SP, 2012, ANN ONCOL, V23, P3063, DOI 10.1093/annonc/mds136; Moon HG, 2013, ANN ONCOL, V24, P2298, DOI 10.1093/annonc/mdt187; Neri A, 2015, BMC SURG, V15, DOI 10.1186/1471-2482-15-1; O'Daly BJ, 2007, J AM COLL SURGEONS, V204, P282, DOI 10.1016/j.jamcollsurg.2006.11.005; Pedersen L, 2004, BREAST, V13, P188, DOI 10.1016/j.breast.2003.11.004; QUALHEIM RE, 1957, CANCER, V10, P460, DOI 10.1002/1097-0142(195705/06)10:3<460::AID-CNCR2820100307>3.0.CO;2-E; Rezo A, 2011, BREAST, V20, P259, DOI 10.1016/j.breast.2011.01.005; Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764; Tot T, 2012, ANN SURG ONCOL, V19, P3395, DOI 10.1245/s10434-012-2346-y; Tot T, 2011, HUM PATHOL, V42, P1761, DOI 10.1016/j.humpath.2011.02.002; Ustaalioglu BO, 2012, AM J CLIN ONCOL-CANC, V35, P580, DOI 10.1097/COC.0b013e31822d9cd6; Vlastos G, 2000, ANN SURG ONCOL, V7, P581, DOI 10.1007/BF02725337; Weissenbacher TM, 2010, BREAST CANCER RES TR, V122, P27, DOI 10.1007/s10549-010-0917-9; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Yerushalmi R, 2009, BREAST CANCER RES TR, V117, P365, DOI 10.1007/s10549-008-0265-1	28	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					396	403		10.4132/jptm.2018.10.03			8	Pathology	Pathology	HA3IV	WOS:000450144200007	30347971	DOAJ Gold, Green Published			2019-10-28	
J	Cha, H; Pyo, JY; Hong, SW				Cha, Hyunseo; Pyo, Ju Yeon; Hong, Soon Won			The Usefulness of Immunocytochemistry of CD56 in Determining Malignancy from Indeterminate Thyroid Fine-Needle Aspiration Cytology	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Biopsy; fine-needle; Thyroid fine-needle aspiration; Immunohistochemical staining; CD56; HBME-1	UNDETERMINED SIGNIFICANCE; DIAGNOSTIC-VALUE; BETHESDA SYSTEM; CELL-TRANSFER; DIFFERENTIAL-DIAGNOSIS; PAPILLARY CARCINOMA; FOLLICULAR LESION; E-CADHERIN; EXPRESSION; NODULES	Background: Fine-needle aspiration cytology serves as a safe, economical tool in evaluating thyroid nodules. However, about 30% of the samples are categorized as indeterminate. Hence, many immunocytochemistry markers have been studied, but there has not been a single outstanding marker. We studied the efficacy of CD56 with human bone marrow endothelial cell marker-1 (HBME-1) in diagnosis in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category III. Methods: We reviewed ThinPrep liquid-based cytology (LBC) samples with Papanicolaou stain from July 1 to December 31, 2016 (2,195 cases) and selected TBSRTC category III cases (n=363). Twenty-six cases were histologically confirmed as benign (six cases, 23%) or malignant (20 cases, 77%); we stained 26 LBC slides with HBME-1 and CD56 through the cell transfer method. For evaluation of reactivity of immunocytochemistry, we chose atypical follicular cell clusters. Results: CD56 was not reactive in 18 of 20 cases (90%) of malignant nodules and showed cytoplasmic positivity in five of six cases (83%) of benign nodules. CD56 showed high sensitivity (90.0%) and relatively low specificity (83.3%) in detecting malignancy (p= .004). HBME-1 was reactive in 17 of 20 cases (85%) of malignant nodules and was not reactive in five of six cases (83%) of benign nodules. HBME-1 showed slightly lower sensitivity (85.0%) than CD56. The specificity in detecting malignancy by HBME-1 was similar to that of CD56 (83.3%, p=.008). CD56 and HBME-1 tests combined showed lower sensitivity (75.0% vs 90%) and higher specificity (93.8% vs 83.3%) in detecting malignancy compared to using CD56 alone. Conclusions: Using CD56 alone showed relatively low specificity despite high sensitivity for detecting malignancy. Combining CD56 with HBME-1 could increase the specificity. Thus, we suggest that CD56 could be a useful preoperative marker for differential diagnosis of TBSRTC category III samples.	[Cha, Hyunseo; Pyo, Ju Yeon; Hong, Soon Won] Gangnam Severance Hosp, Dept Pathol, 211 Eonju Ro, Seoul 06273, South Korea	Hong, SW (reprint author), Gangnam Severance Hosp, Dept Pathol, 211 Eonju Ro, Seoul 06273, South Korea.	SOONWONH@yuhs.ac					Abd El Atti RM, 2012, J EGYPT NATL CANCER, V24, P175, DOI 10.1016/j.jnci.2012.10.002; Abouhashem NS, 2017, PATHOL RES PRACT, V213, P509, DOI 10.1016/j.prp.2017.01.017; Ahn HS, 2016, THYROID, V26, P1535, DOI 10.1089/thy.2016.0075; Ceyran AB, 2015, INT J CLIN EXP PATHO, V8, P3670; Choi SE, 2017, J PATHOL TRANSL MED, V51, P505, DOI [10.4132/jptm.2017.01.04, 10.4132/jptm.2017.09.26]; Cibas ES, 2017, THYROID, V27, P1341, DOI 10.1089/thy.2017.0500; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Cochand-Priollet B, 2011, THYROID, V21, P1067, DOI 10.1089/thy.2011.0014; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; El Demellawy D, 2009, PATHOL RES PRACT, V205, P303, DOI 10.1016/j.prp.2008.11.011; Erdogan-Durmus S, 2016, J RES MED SCI, V21; Fadda G, 2011, EUR J ENDOCRINOL, V165, P447, DOI 10.1530/EJE-11-0181; Garg S, 2017, J CYTOL, V34, P5, DOI 10.4103/0970-9371.197590; Golu I, 2017, INDIAN J PATHOL MICR, V60, P161, DOI 10.4103/0377-4929.208378; Huang LH, 2018, ONCOL LETT, V15, P4269, DOI 10.3892/ol.2018.7873; Jung CK, 2017, J PATHOL TRANSL MED, V51, P571, DOI 10.4132/jptm.2017.10.19; Kang Y, 2016, J PATHOL TRANSL MED, V50, P287, DOI 10.4132/jptm.2016.04.04; Kholova I, 2014, ACTA CYTOL, V58, P319, DOI 10.1159/000366498; Kim SJ, 2017, CYTOPATHOLOGY, V28, P65, DOI 10.1111/cyt.12352; Misiakos EP, 2016, WORLD J CLIN CASES, V4, P38, DOI 10.12998/wjcc.v4.i2.38; Mokhtari M, 2013, J RES MED SCI, V18, P1046; Muzafar A, 2017, PAK J MED SCI, V33, P726, DOI 10.12669/pjms.333.12251; Nechifor-Boila A, 2014, ROM J MORPHOL EMBRYO, V55, P49; Nechifor-Boila A, 2013, PATHOL RES PRACT, V209, P585, DOI 10.1016/j.prp.2013.06.012; Oh EJ, 2014, DIAGN CYTOPATHOL, V42, P671, DOI 10.1002/dc.23110; Ohori NP, 2010, CANCER CYTOPATHOL, V118, P17, DOI 10.1002/cncy.20063; Oosthuizen JL, 2018, AM J SURG, V215, P819, DOI 10.1016/j.amjsurg.2017.12.018; Ozolins A, 2012, MED LITH, V48, P507; Powsner SM, 2000, ARCH PATHOL LAB MED, V124, P1040; Rossi ED, 2013, EUR J ENDOCRINOL, V168, P853, DOI 10.1530/EJE-13-0023; Rossi M, 2017, ENDOCRINE, V57, P98, DOI 10.1007/s12020-016-1105-4; Satoh S, 2017, J PATHOL TRANSL MED, V51, P548, DOI 10.4132/jptm.2017.09.29; Scarpino S, 2007, J PATHOL, V212, P411, DOI 10.1002/path.2183; Shahebrahimi K, 2013, INDIAN J PATHOL MICR, V56, P2, DOI 10.4103/0377-4929.116139; SHERMAN ME, 1994, ACTA CYTOL, V38, P18; Shi Y, 2009, CANCER CYTOPATHOL, V117, P298, DOI 10.1002/cncy.20039; Solmaz OA, 2018, CYTOJOURNAL, V15, DOI 10.4103/cytojournal.cytojournal_42_17; Vivero M, 2017, CANCER CYTOPATHOL, V125, P534, DOI 10.1002/cncy.21858; Yashaswini R, 2017, J CYTOL, V34, P197, DOI 10.4103/JOC.JOC_87_16; Yoo C, 2013, KOREAN J PATHOL, V47, P61, DOI 10.4132/KoreanJPathol.2013.47.1.61; ZEROMSKI J, 1992, CLIN EXP IMMUNOL, V89, P474; Zu Y, 2002, DIAGN CYTOPATHOL, V27, P308, DOI 10.1002/dc.10180	42	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					404	410		10.4132/jptm.2018.09.20			7	Pathology	Pathology	HA3IV	WOS:000450144200008	30317844	DOAJ Gold, Green Published			2019-10-28	
J	Sharma, S; Mehendiratta, M; Chaudhary, N; Gupta, V; Kohli, M; Arora, A				Sharma, Swati; Mehendiratta, Monica; Chaudhary, Nivedita; Gupta, Vineet; Kohli, Maulshree; Arora, Anjana			Squamous Metaplasia in Pleomorphic Adenoma: A Diagnostic and Prognostic Enigma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Squamous metaplasia; Pleomorphic adenoma; Pathology	SALIVARY-GLAND	Pleomorphic adenoma (PA) is the most common benign salivary gland tumor. Histologically, squamous metaplasia has been reported in PA, but has rarely been documented as being extensive enough to cause significant misdiagnosis. Here, we present an unusual case of PA in a 50-year-old female patient presenting with swelling on the postero-lateral aspect of the palate for a week. Histopathologically, the tumor exhibited the features of conventional PA with extensive squamous metaplasia and giant keratotic lamellae in cyst-like areas. Such exuberant squamous metaplasia and keratin can be a diagnostic and prognostic pitfall and lead to ovettreatment of the patient.	[Sharma, Swati; Mehendiratta, Monica; Chaudhary, Nivedita; Gupta, Vineet; Kohli, Maulshree] Hosp & Res Ctr, ITS Dent Coll, Dept Oral & Maxillofacial Pathol & Microbiol, Greater Noida 201308, Uttar Pradesh, India; [Arora, Anjana] Hosp & Res Ctr, ITS Dent Coll, Dept Oral Med & Radiol, Greater Noida, India	Sharma, S (reprint author), Hosp & Res Ctr, ITS Dent Coll, Dept Oral & Maxillofacial Pathol & Microbiol, Greater Noida 201308, Uttar Pradesh, India.	sharmaswatisharma86@gmail.com	Mehendiratta, Monica/Y-5420-2019				COMPAGNO J, 1977, AM J CLIN PATHOL, V68, P213, DOI 10.1093/ajcp/68.2.213; DARDICK I, 1985, AM J PATHOL, V119, P33; Jaishankar HP, 2016, INT J HLTH SCI RES, V6, P516; Kaveri H, 2014, ASIAN J MED SC, V5, P108; Lam KY, 1998, J ORAL PATHOL MED, V27, P407; Lim S, 2013, OPEN J PATHOLOGY, V3, P113; Neville B, 2009, ORAL MAXILLOFACIAL P, P473; Rajendran R, 2012, SHAFERS TXB ORAL PAT, P223; Takegawa K, 1998, JPN J CANCER RES, V89, P105, DOI 10.1111/j.1349-7006.1998.tb00536.x; Goulart MCV, 2011, J APPL ORAL SCI, V19, P182, DOI 10.1590/S1678-77572011000200016	10	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					411	415		10.4132/jptm.2018.07.15			5	Pathology	Pathology	HA3IV	WOS:000450144200009	30269471	DOAJ Gold, Green Published			2019-10-28	
J	Lee, JH; Choi, YD; Cho, NH				Lee, Ji Hee; Choi, Young Deuk; Cho, Nam Hoon			An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Adrenocortical carcinoma; Adrenal rest tumor; Carcinoma; Renal cell		We describe a case of a 61-year-old Korean man who was diagnosed with renal cell carcinoma that was discovered on abdominopelvic computed tomography obtained after the patient complained of back pain. A radical nephrectomy was performed, and the surgical specimen showed a relatively well-circumscribed and yellowish lobulated hard mass. Microscopically, the tumor showed sheets and nests of hypercellular pleomorphic cells with thick fibrous septation, frequent mitoses, and areas of adrenal cortical-like tissue. Immunohistochemical staining revealed that the tumor cells were positive for inhibin-alpha, vimentin, synaptophysin, and melan A. It also revealed that the tumor cells were negative for pan-cytokeratin, epithelial membrane antigen, paired box 8, alpha-methylacyl-coenzyme A racemase, CD10, cytokeratin 7, carbonic anhydrase 9, c-kit, renal cell carcinoma, transcription factor E3, human melanoma black 45, desmin, smooth muscle actin, S-100, chromogranin A, CD34, anaplastic lymphoma kinase, and integrase interactor 1. Based on these histopathological and immunohistochemical findings, we diagnosed the tumor as intrarenal adrenocortical carcinoma arising in an adrenal rest. Several cases of intrarenal adrenocortical carcinoma have been reported, although they are very rare. Due to its poor prognosis and common recurrence or metastasis, clinicians and pathologists must be aware of this entity.	[Lee, Ji Hee; Cho, Nam Hoon] Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Choi, Young Deuk] Yonsei Univ, Coll Med, Dept Urol, Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea	Cho, NH (reprint author), Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea.	CH01988@yuhs.ac		Choi, Young Deuk/0000-0002-8545-5797; Lee, Ji Hee/0000-0003-0054-7033; jo, namhun/0000-0002-0045-6441			Allolio B, 2006, J CLIN ENDOCR METAB, V91, P2027, DOI 10.1210/jc.2005-2639; Barwick TD, 2005, CLIN RADIOL, V60, P953, DOI 10.1016/j.crad.2005.04.006; Berruti A, 2017, J CLIN ENDOCR METAB, V102, P1358, DOI 10.1210/jc.2016-2894; Cornejo KM, 2017, ENDOCR PATHOL, V28, P165, DOI 10.1007/s12022-017-9472-9; ENGEL FL, 1964, J CLIN ENDOCR METAB, V24, P528, DOI 10.1210/jcem-24-6-528; GOREN E, 1991, UROLOGY, V38, P187, DOI 10.1016/S0090-4295(05)80085-8; Jain SH, 2008, NAT CLIN PRACT ENDOC, V4, P695, DOI 10.1038/ncpendmet0985; Langer P, 2000, LANGENBECK ARCH SURG, V385, P393, DOI 10.1007/s004230000151; MORIMOTO Y, 1971, J CLIN ENDOCR METAB, V32, P201, DOI 10.1210/jcem-32-2-201; Terzolo M, 2007, NEW ENGL J MED, V356, P2372, DOI 10.1056/NEJMoa063360; Ye HH, 2009, MODERN PATHOL, V22, P175, DOI 10.1038/modpathol.2008.162	11	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					416	419		10.4132/jptm.2018.07.20			4	Pathology	Pathology	HA3IV	WOS:000450144200010	30269470	DOAJ Gold, Green Published			2019-10-28	
J	Kim, GE; Kim, NI; Lee, JS; Park, MH				Kim, Ga-Eon; Kim, Nah Ihm; Lee, Ji Shin; Park, Min Ho			Collagenous Spherulosis Associated with Lobular Carcinoma In Situ of the Breast: Two Case Reports	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							ADENOID-CYSTIC CARCINOMA; LESIONS; SPECTRUM		[Kim, Ga-Eon; Kim, Nah Ihm; Lee, Ji Shin] Chonnam Natl Univ, Med Sch, Dept Pathol, Gwangju, South Korea; [Park, Min Ho] Chonnam Natl Univ, Med Sch, Dept Surg, Gwangju, South Korea	Lee, JS (reprint author), Chonnam Natl Univ, Dept Pathol, Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, South Korea.	jshinlee@hanmail.net		Kim, Ga-Eon/0000-0001-8539-6654			Cabibi D, 2012, PATHOL RES PRACT, V208, P405, DOI 10.1016/j.prp.2012.05.002; CLEMENT PB, 1987, AM J SURG PATHOL, V11, P411, DOI 10.1097/00000478-198706000-00001; Eisenberg REK, 2014, BREAST J, V20, P440, DOI 10.1111/tbj.12292; Hoda SA, 2014, ROSENS BREAST PATHOL, P143; Mooney EE, 1999, ARCH PATHOL LAB MED, V123, P626; Rabban JT, 2006, MODERN PATHOL, V19, P1351, DOI 10.1038/modpathol.3800658; Resetkova E, 2006, AM J SURG PATHOL, V30, P20, DOI 10.1097/01.pas.0000179237.91515.81; SGROI D, 1995, AM J SURG PATHOL, V19, P1366, DOI 10.1097/00000478-199512000-00004; Toll A, 2016, ARCH PATHOL LAB MED, V140, P644, DOI 10.5858/arpa.2015-0250-RA; Torous VF, 2017, PATHOLOGY, V49, P181, DOI 10.1016/j.pathol.2016.12.002	10	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					420	424		10.4132/jptm.2018.03.29			5	Pathology	Pathology	HA3IV	WOS:000450144200011	29590747	DOAJ Gold, Green Published			2019-10-28	
J	Dadone-Montaudie, B; Alberti, L; Duc, A; Delespaul, L; Lesluyes, T; Perot, G; Lancon, A; Paindavoine, S; Di Mauro, I; Blay, JY; de la Fouchardiere, A; Chibon, F; Karanian, M; MacGrogan, G; Kubiniek, V; Keslair, F; Cardot-Leccia, N; Michot, A; Perrin, V; Zekri, Y; Coindre, JM; Tirode, F; Pedeutour, F; Ranchere-Vince, D; Le Loarer, F; Pissaloux, D				Dadone-Montaudie, Berengere; Alberti, Laurent; Duc, Adeline; Delespaul, Lucile; Lesluyes, Tom; Perot, Gaelle; Lancon, Agnes; Paindavoine, Sandrine; Di Mauro, Ilaria; Blay, Jean-Yves; de la Fouchardiere, Arnaud; Chibon, Frederic; Karanian, Marie; MacGrogan, Gaetan; Kubiniek, Valerie; Keslair, Frederique; Cardot-Leccia, Nathalie; Michot, Audrey; Perrin, Virginie; Zekri, Yanis; Coindre, Jean-Michel; Tirode, Franck; Pedeutour, Florence; Ranchere-Vince, Dominique; Le Loarer, Francois; Pissaloux, Daniel			Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions	MODERN PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; MONOPHASIC SYNOVIAL SARCOMA; POLYMERASE CHAIN-REACTION; COLLAGEN GENE COL1A1; GROWTH-FACTOR-D; EXPRESSION; CANCER; TUMOR; CARCINOMA; DIAGNOSIS	Dermatofibrosarcoma protuberans is underlined by recurrent collagen type I alpha 1 chain-platelet-derived growth factor B chain (COL1A1-PDGFB) fusions but similar to 4% of typical dermatofibrosarcoma protuberans remain negative for this translocation in routine molecular screening. We investigated a series of 21 cases not associated with the pathognomonic COL1A1-PDGFB fusion on routine fluorescence in situ hybridization (FISH) testing. All cases displayed morphological and clinical features consistent with the diagnosis of dermatofibrosarcoma protuberans. RNA-sequencing analysis was successful in 20 cases. The classical COL1A1-PDGFB fusion was present in 40% of cases (n = 8/20), and subsequently confirmed with a COL1A1 break-apart FISH probe in all but one case (n = 7/8). 55% of cases (n = 11/20) displayed novel PDGFD rearrangements; PDGFD being fused either to the 5' part of COL6A3 (2q37.3) (n = 9/11) or EMILIN2 (18p11) (n = 2/11). All rearrangements led to in-frame fusion transcripts and were confirmed at genomic level by FISH and/or array-comparative genomic hybridization. PDGFD-rearranged dermatofibrosarcoma protuberans presented clinical outcomes similar to typical dermatofibrosarcoma protuberans. Notably, the two EMILIN2-PDGFD cases displayed fibrosarcomatous transformation and homozygous deletions of CDKN2A at genomic level. We report the first recurrent molecular variant of dermatofibrosarcoma protuberans involving PDGFD, which functionally mimic bona fide COL1A1-PDGFB fusions, leading presumably to a similar autocrine loop-stimulating PDGFRB. This study also emphasizes that COL1A1-PDGFB fusions can be cytogenetically cryptic on FISH testing in a subset of cases, thereby representing a diagnostic pitfall that pathologists should be aware of.	[Dadone-Montaudie, Berengere; Di Mauro, Ilaria; Kubiniek, Valerie; Keslair, Frederique; Pedeutour, Florence] Univ Cote Azur, CHU Nice, Lab Solid Tumors Genet, IRCAN,CNRS,UMR 7284,INSERM,U1081, Nice, France; [Alberti, Laurent; Blay, Jean-Yves; Tirode, Franck; Pissaloux, Daniel] Univ Claude Bernard Lyon 1, Canc Res Ctr Lyon, CNRS 5286, INSERM,U1052, Lyon, France; [Alberti, Laurent; Duc, Adeline; Lancon, Agnes; Paindavoine, Sandrine; de la Fouchardiere, Arnaud; Karanian, Marie; Ranchere-Vince, Dominique; Pissaloux, Daniel] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Delespaul, Lucile; Lesluyes, Tom; Chibon, Frederic] INSERM, ACT U1218, Bordeaux, France; [Delespaul, Lucile; Lesluyes, Tom; Coindre, Jean-Michel; Le Loarer, Francois] Univ Bordeaux, Bordeaux, France; [Perot, Gaelle; Chibon, Frederic; MacGrogan, Gaetan; Coindre, Jean-Michel; Le Loarer, Francois] Inst Bergonie, Dept Pathol, Bordeaux, France; [Blay, Jean-Yves] Ctr Leon Berard, Dept Oncol, Lyon, France; [Cardot-Leccia, Nathalie] CHU Nice, Cent Lab Pathol, Nice, France; [Michot, Audrey] Inst Bergonie, Dept Surg, Bordeaux, France; [Perrin, Virginie; Zekri, Yanis; Tirode, Franck] Ctr Leon Berard, Dept Translat Res & Innovat, Lyon, France; [Delespaul, Lucile; Lesluyes, Tom; Chibon, Frederic] IUCT Oncopole, Inst Claudius Regaud, CRCT, INSERM,U1037, Toulouse, France	Pissaloux, D (reprint author), Univ Claude Bernard Lyon 1, Canc Res Ctr Lyon, CNRS 5286, INSERM,U1052, Lyon, France.; Pissaloux, D (reprint author), Ctr Leon Berard, Dept Biopathol, Lyon, France.	daniel.pissaloux@lyon.unicancer.fr	Delespaul, Philippe/L-1396-2019; Tirode, Franck/O-3820-2019; chibon, frederic/A-2651-2013; Tirode, Franck/B-4586-2009; Perot, Gaelle/W-8038-2019; Lesluyes, Tom/AAB-6229-2019	Delespaul, Philippe/0000-0001-7420-0898; Tirode, Franck/0000-0003-4731-7817; Tirode, Franck/0000-0003-4731-7817; Lesluyes, Tom/0000-0003-2251-5884; Duc Gallet, Adeline/0000-0003-4581-7949; PISSALOUX, Daniel/0000-0003-1118-950X	La Ligue contre le Cancer de l'Ain et de Savoie, Institut National du Cancer (NETSARC, RREPS, RESOS)	We wish to thank pathologists and clinicians who provided samples and clinical follow-up: M Chargeboeuf (Lons le Saunier), C Charon-Barra (Dijon), C Delfour (Montpellier), S Depardieu (Metz), A Leroux (Vandoeuvre les Nancy), A Lipandy (Nimes), E Maubec (Paris), C de Mauroy (Rouen), YM Robin (Lille), JF Titton (Besancon), M Battistella (Paris), and MP Wissler (Villeurbanne). We are grateful to A Bazin, AC Peyron, and A Ribeiro for their insights and participation in this study. This work was supported by grants from La Ligue contre le Cancer de l'Ain et de Savoie, Institut National du Cancer (NETSARC, RREPS, RESOS).	Arafat H, 2011, SURGERY, V150, P306, DOI 10.1016/j.surg.2011.05.011; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bianchini L, 2008, VIRCHOWS ARCH, V452, P689, DOI 10.1007/s00428-008-0580-2; Brassesco MS, 2010, CANCER GENET CYTOGEN, V196, P189, DOI 10.1016/j.cancergencyto.2009.10.001; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Chen S, 2016, GENE CHROMOSOME CANC, V55, P340, DOI 10.1002/gcc.22336; Colombatti A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00093; Ge HY, 2011, BIOINFORMATICS, V27, P1922, DOI 10.1093/bioinformatics/btr310; Greco A, 1998, ONCOGENE, V17, P1313, DOI 10.1038/sj.onc.1202051; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Karanian M, 2015, MODERN PATHOL, V28, P230, DOI 10.1038/modpathol.2014.97; Kovar H, 1999, GENOMICS, V60, P371, DOI 10.1006/geno.1999.5919; Lagstad S, 2017, BIOINFORMATICS, V33, P2954, DOI 10.1093/bioinformatics/btx329; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Lestou VS, 2002, CANCER GENET CYTOGEN, V138, P153, DOI 10.1016/S0165-4608(02)00583-6; Li ZY, 2016, J PATHOL, V240, P224, DOI 10.1002/path.4770; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Mentzel T, 2013, WHO CLASSIFICATION T, P77; Moller E, 2008, GENE CHROMOSOME CANC, V47, P21, DOI 10.1002/gcc.20501; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Nakamura I, 2015, JAMA DERMATOL, V151, P1330, DOI 10.1001/jamadermatol.2015.2389; Park J, 2013, EMBO MOL MED, V5, P935, DOI 10.1002/emmm.201202006; Patel KU, 2008, HUM PATHOL, V39, P184, DOI 10.1016/j.humpath.2007.06.009; Qiao J, 2015, ONCOTARGET, V6, P29929, DOI 10.18632/oncotarget.4966; Rebouissou S, 2012, J PATHOL, V227, P315, DOI 10.1002/path.4017; Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Saab J, 2017, AM J DERMATOPATH, V39, P304, DOI 10.1097/DAD.0000000000000746; Saiag P, 2015, EUR J CANCER, V51, P2604, DOI 10.1016/j.ejca.2015.06.108; Salgado R, 2011, GENE CHROMOSOME CANC, V50, P510, DOI 10.1002/gcc.20874; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shimizu A, 1999, CANCER RES, V59, P3719; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SINOVIC J, 1994, CANCER GENET CYTOGEN, V75, P156, DOI 10.1016/0165-4608(94)90171-6; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Sjoblom T, 2001, CANCER RES, V61, P5778; Stacchiotti S, 2016, CLIN CANCER RES, V22, P837, DOI 10.1158/1078-0432.CCR-15-1243; Torres L, 2008, CANCER GENET CYTOGEN, V187, P45, DOI 10.1016/j.cancergencyto.2008.07.008; Torres-Martin M, 2014, ONCOL REP, V32, P2327, DOI 10.3892/or.2014.3526; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; Wang ZW, 2007, CANCER RES, V67, P11377, DOI 10.1158/0008-5472.CAN-07-2803; Wang ZW, 2009, CURR DRUG TARGETS, V10, P38, DOI 10.2174/138945009787122914; West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103; Xie XJ, 2014, ONCOL LETT, V7, P1537, DOI 10.3892/ol.2014.1910; Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008-5472.CAN-04-4313; Yu J, 2015, GUT, V64, P636, DOI 10.1136/gutjnl-2013-306620	49	6	6	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1683	1693		10.1038/s41379-018-0089-4			11	Pathology	Pathology	GY9FA	WOS:000448943600006	29955147				2019-10-28	
J	Renaudin, K; Smati, S; Wargny, M; Al Ghuzlan, A; Aubert, S; Leteurtre, E; Patey, M; Sibony, M; Sturm, N; Tissier, F; Amar, L; Bertherat, J; Berthozat, C; Chabre, O; Do Cao, C; Haissaguerre, M; Pierre, P; Briet, C; Vezzosi, D; Lifante, JC; Pattou, F; Mirallie, E; Baudin, E; Cariou, B; Libe, R; Drui, D				Renaudin, Karine; Smati, Sarra; Wargny, Matthieu; Al Ghuzlan, Abir; Aubert, Sebastien; Leteurtre, Emmanuelle; Patey, Martine; Sibony, Mathilde; Sturm, Nathalie; Tissier, Frederique; Amar, Laurence; Bertherat, Jerome; Berthozat, Claudine; Chabre, Olivier; Do Cao, Christine; Haissaguerre, Magalie; Pierre, Peggy; Briet, Claire; Vezzosi, Delphine; Lifante, Jean Christophe; Pattou, Francois; Mirallie, Eric; Baudin, Eric; Cariou, Bertrand; Libe, Rossella; Drui, Delphine		Comete-Canc Network	Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation	MODERN PATHOLOGY			English	Article							OF-THE-LITERATURE; DIAGNOSTIC ALGORITHM; PROGNOSTIC ROLE; HELSINKI SCORE; CARCINOMA; NEOPLASMS	Oncocytic adrenocortical tumors are a rare subtype of adrenal tumors with challenging diagnosis and histoprognostic assessment. It is usually believed that oncocytic adrenocortical tumors have a more indolent clinical behavior than conventional adrenocortical tumors. As the Weiss score overestimates the malignancy of oncocytic adrenocortical tumors owing to intrinsic parameters, alternative scores have been proposed. The Lin-Weiss-Bisceglia score is currently recommended. We performed a large nationwide multicenter retrospective clinicopathologic study of oncocytic adrenocortical tumors. Among the 43 patients in our cohort, 40 patients were alive without disease, 2 patients died of their disease and 1 patient was alive with relapse after a median follow-up of 38 months (20-59). Our data revealed that over 50% of the oncocytic adrenocortical tumor cases were diagnosed as carcinoma whatever the classification systems used, including the Lin-Weiss-Bisceglia score. The exception is the Helsinki score, which incorporates the Ki-67 proliferation index and was the most specific prognostic score for oncocytic adrenocortical tumor malignancy without showing a loss in sensitivity. A comparison of malignant oncocytic adrenocortical tumors with conventional adrenocortical carcinomas matched for age, sex, ENS@T stage and surgical resection status showed significant better overall survival of malignant oncocytic adrenocortical tumors.	[Renaudin, Karine] CHU Nantes, Dept Pathol, F-44093 Nantes, France; [Smati, Sarra; Wargny, Matthieu; Cariou, Bertrand; Drui, Delphine] CHU Nantes, Inst Thorax, Dept Endocrinol Diabet & Nutr, F-44093 Nantes, France; [Al Ghuzlan, Abir] Gustave Roussy Canc Ctr, Dept Pathol, F-94805 Villejuif, France; [Aubert, Sebastien; Leteurtre, Emmanuelle] CHRU Lille, Inst Pathol, F-59037 Lille, France; [Patey, Martine] CHU Reims, Dept Pathol, F-51092 Reims, France; [Sibony, Mathilde] Hop Cochin, Dept Pathol, F-75014 Paris, France; [Sturm, Nathalie] CHU Grenoble Alpes, Dept Pathol, F-38043 Grenoble, France; [Tissier, Frederique] Univ Paris 06, Hop Pitie Salpetriere, Dept Pathol, F-75013 Paris, France; [Amar, Laurence] Hop Europeen Georges Pompidou, Hypertens Unit, F-75015 Paris, France; [Bertherat, Jerome; Libe, Rossella] Hop Cochin, Dept Endocrinol & Metab Dis, F-75014 Paris, France; [Berthozat, Claudine; Chabre, Olivier] CHU Grenoble Alpes, Dept Endocrinol Diabet & Nutr, F-38043 Grenoble, France; [Do Cao, Christine] CHRU Lille, Dept Endocrinol, F-59037 Lille, France; [Haissaguerre, Magalie] CHU Bordeaux, Dept Endocrinol Diabet & Nutr, F-33604 Pessac, France; [Pierre, Peggy] CHRU Tours, Dept Endocrinol, F-37044 Tours, France; [Briet, Claire] CHU Angers, Dept Endocrinol Diabet & Nutr, F-49933 Angers, France; [Vezzosi, Delphine] CHU Toulouse, Dept Endocrinol Metab Dis & Nutr, Pole Cardiovasc & Metabol, F-31059 Toulouse, France; [Lifante, Jean Christophe] Univ Lyon, Hosp Civils Lyon, CHU Lyon Sud, Dept Digest & Endocrine Surg, F-69495 Pierre Benite, France; [Pattou, Francois] CHRU Lille, Dept Gen & Endocrine Surg, F-59037 Lille, France; [Mirallie, Eric] CHU Nantes, Dept Endocrine Surg, F-44093 Nantes, France; [Baudin, Eric; Libe, Rossella] Gustave Roussy Canc Ctr, Dept Nucl Med & Endocrine Oncol, F-94805 Villejuif, France; [Libe, Rossella] Natl Canc Inst, French Adrenal Canc Network, F-75000 Paris, France	Renaudin, K (reprint author), CHU Nantes, Dept Pathol, F-44093 Nantes, France.	karine.renaudin@chu-nantes.fr	Pattou, Francois/Y-8448-2019; CAO, CHRISTINE DO/M-7950-2018	CAO, CHRISTINE DO/0000-0002-1617-0149; BERTHERAT, Jerome/0000-0003-2551-3008			Allolio B, 2006, J CLIN ENDOCR METAB, V91, P2027, DOI 10.1210/jc.2005-2639; Assie G, 2007, J CLIN ENDOCR METAB, V92, P148, DOI 10.1210/jc.2006-0706; Beuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182; Bilimoria KY, 2008, CANCER, V113, P3130, DOI 10.1002/cncr.23886; Bisceglia M, 2004, INT J SURG PATHOL, V12, P231, DOI 10.1177/106689690401200304; Duregon E, 2017, HUM PATHOL, V62, P1, DOI 10.1016/j.humpath.2016.09.035; Duregon E, 2015, HUM PATHOL, V46, P1799, DOI 10.1016/j.humpath.2015.08.012; Duregon E, 2011, AM J SURG PATHOL, V35, P1882, DOI 10.1097/PAS.0b013e31822da401; Giordano TJ, 2017, WHO CLASSIFICATION T, P163; Lin BTY, 1998, AM J SURG PATHOL, V22, P603, DOI 10.1097/00000478-199805000-00012; Ohtake H, 2010, ANN DIAGN PATHOL, V14, P204, DOI 10.1016/j.anndiagpath.2009.06.006; Pennanen M, 2015, HUM PATHOL, V46, P404, DOI 10.1016/j.humpath.2014.11.015; Tissier F, 2012, AM J SURG PATHOL, V36, P1194, DOI 10.1097/PAS.0b013e31825a6308; Volante M, 2009, HISTOPATHOLOGY, V55, P535, DOI 10.1111/j.1365-2559.2009.03423.x; WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004; Wong DD, 2011, HUM PATHOL, V42, P489, DOI 10.1016/j.humpath.2010.08.010	16	1	1	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1708	1716		10.1038/s41379-018-0077-8			9	Pathology	Pathology	GY9FA	WOS:000448943600008	29921900				2019-10-28	
J	Reimann, JDR; Salim, S; Velazquez, EF; Wang, L; Williams, KM; Flejter, WL; Brooke, L; Sunder, S; Busam, KJ				Reimann, Julie D. R.; Salim, Sadia; Velazquez, Elsa F.; Wang, Lu; Williams, Kelly Morrissey; Flejter, Wendy L.; Brooke, Linda; Sunder, Sujatha; Busam, Klaus J.			Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms	MODERN PATHOLOGY			English	Article							MALIGNANT-MELANOMA; GENOMIC HYBRIDIZATION; CUTANEOUS MELANOMA; BENIGN NEVI; FISH; DIAGNOSIS; SIGNATURE; TUMORS; LESIONS; DISTINCTION	While most melanomas can be distinguished from nevi by histopathology, the histology is ambiguous for some melanocytic tumors, contributing to diagnostic uncertainty. Therefore molecular assays, including FISH or SNP array, and more recently a gene expression test (myPath, Myriad Genetics) have been proposed to aid in the work-up of ambiguous tumors. Two hundred and sixty-eight prospectively submitted cases were gathered, with the goal of comparing the myPath assay to morphologic diagnosis in (1) morphologically unequivocal cases (198), and to morphologic diagnosis and FISH in (2) morphologically ambiguous cases (70). Melanoma FISH was performed using probes for 6p25, 6q23, 11q13, Cep6, 9p21, and Cep9 and scored according to established criteria. The myPath assay was scored by the manufacturer as benign, indeterminate, or malignant. In the unequivocal group, myPath assay showed 75% agreement with morphologic diagnosis, with 67% sensitivity and 81% specificity. In the ambiguous group, FISH and myPath showed 69% inter-test agreement. For these cases agreement with histopathologic interpretation was 84% for FISH and 74% for myPath. Sensitivity and specificity of FISH was 61 and 100%, 50 and 93% for myPath, respectively. Cases from both groups in which myPath was discordant with either morphologic diagnosis and/or FISH (81/268 cases), were submitted for evaluation by two experienced dermatopathologist and also by SNP-array. SNP-array results correlated better than FISH, which correlated better than myPath, with the morphologic interpretation. Our findings document that molecular diagnostics show good correlation with consensus diagnoses, but discordant results occur, and vary in level of correlation with consensus interpretations. Studies with long-term outcomes data within specific ambiguous lesion subsets are required to establish the accuracy of this test, as each molecular diagnostic technique has limitations based on both lack of clinical outcomes data in ambiguous melanocytic tumors and in terms of their sensitivity and specificity in melanocytic lesion subtypes.	[Reimann, Julie D. R.; Salim, Sadia; Velazquez, Elsa F.; Williams, Kelly Morrissey] Inform Diagnost, Needham, MA 02494 USA; [Reimann, Julie D. R.; Velazquez, Elsa F.; Williams, Kelly Morrissey] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA; [Salim, Sadia] Inform Diagnost, Irving, TX USA; [Wang, Lu; Busam, Klaus J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Flejter, Wendy L.; Brooke, Linda; Sunder, Sujatha] Inform Diagnost, Phoenix, AZ USA	Reimann, JDR (reprint author), Inform Diagnost, Needham, MA 02494 USA.; Reimann, JDR (reprint author), Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA.	Julie.reimann@informdx.com			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]		Ali L, 2010, INT J CLIN EXP PATHO, V3, P593; Blokx WAM, 2010, HISTOPATHOLOGY, V56, P121, DOI 10.1111/j.1365-2559.2009.03452.x; Brunner G, 2013, J CANCER RES CLIN, V139, P249, DOI 10.1007/s00432-012-1322-z; Busam KJ, 2010, J CUTAN PATHOL, V37, P196, DOI 10.1111/j.1600-0560.2009.01488.x; Cerroni L, 2010, AM J SURG PATHOL, V34, P314, DOI 10.1097/PAS.0b013e3181cf7fa0; Clarke LE, 2017, HUM PATHOL, V70, P113, DOI 10.1016/j.humpath.2017.10.005; Clarke LE, 2017, CANCER-AM CANCER SOC, V123, P617, DOI 10.1002/cncr.30385; Clarke LE, 2015, J CUTAN PATHOL, V42, P244, DOI 10.1111/cup.12475; Cockerell C, 2017, PERS MED, V14, P123, DOI 10.2217/pme-2016-0097; Cockerell CJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004887; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dalton MAJSR, 2010, AM J SURG PATHOL, V34, P231, DOI 10.1097/PAS.0b013e3181c805c4; Gaiser T, 2010, MODERN PATHOL, V23, P413, DOI 10.1038/modpathol.2009.177; Gammon B, 2012, AM J SURG PATHOL, V36, P81, DOI 10.1097/PAS.0b013e31822d5ff8; Gammon B, 2011, J CUTAN PATHOL, V38, P335, DOI 10.1111/j.1600-0560.2010.01667.x; Gerami P, 2013, AM J SURG PATHOL, V37, P676, DOI 10.1097/PAS.0b013e3182753de6; Gerami P, 2012, AM J SURG PATHOL, V36, P808, DOI 10.1097/PAS.0b013e31824b1efd; Gerami P, 2011, ARCH PATHOL LAB MED, V135, P830, DOI 10.1043/2011-0048-RAIR.1; Gerami P, 2010, ARCH DERMATOL, V146, P273, DOI 10.1001/archdermatol.2009.386; Gerami P, 2009, AM J SURG PATHOL, V33, P1146, DOI 10.1097/PAS.0b013e3181a1ef36; Jewell R, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12315; Ko JS, 2017, CANCER EPIDEM BIOMAR, V26, P1107, DOI 10.1158/1055-9965.EPI-16-0958; Lang UE, 2017, CLIN LAB MED, V37, P473, DOI 10.1016/j.cll.2017.06.002; Massi D, 2011, J AM ACAD DERMATOL, V64, P919, DOI 10.1016/j.jaad.2010.05.043; Minca EC, 2016, MODERN PATHOL, V29, P832, DOI 10.1038/modpathol.2016.84; Morey AL, 2009, PATHOLOGY, V41, P383, DOI 10.1080/00313020902915875; Nsengimana J, 2015, ONCOTARGET, V6, P11683, DOI 10.18632/oncotarget.3549; Pouryazdanparast P, 2011, AM J SURG PATHOL, V35, P1405, DOI 10.1097/PAS.0b013e31822678d2; Requena C, 2012, HISTOPATHOLOGY, V61, P899, DOI 10.1111/j.1365-2559.2012.04293.x; Scolyer RA, 2003, AM J SURG PATHOL, V27, P1571, DOI 10.1097/00000478-200312000-00011; Shinkins B, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2778; Tetzlaff MT, 2013, AM J SURG PATHOL, V37, P1783, DOI 10.1097/PAS.0b013e31829d20f5; Troxel DB, 2006, ARCH PATHOL LAB MED, V130, P617; U. S. Food and Drug Administration (FDA), 2007, STAT GUID REP RES ST; Vergier B, 2011, MODERN PATHOL, V24, P613, DOI 10.1038/modpathol.2010.228; Wang L, 2013, J MOL DIAGN, V15, P581, DOI 10.1016/j.jmoldx.2013.04.001; Wiesner T, 2016, PATHOLOGY, V48, P113, DOI 10.1016/j.pathol.2015.12.007; Winnepenninckx VR, 2006, J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103	38	2	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1733	1743		10.1038/s41379-018-0087-6			11	Pathology	Pathology	GY9FA	WOS:000448943600010	29955141	Green Accepted			2019-10-28	
J	Straub, BK; Ridder, DA; Schad, A; Loquai, C; Schattenberg, JM				Straub, B. K.; Ridder, D. A.; Schad, A.; Loquai, C.; Schattenberg, J. M.			Liver injury induced by immune checkpoint inhibitor-therapy. Example of an immune-mediated drug side effect	PATHOLOGE			German	Article						Acute liver failure; Drug induced or toxic liver injury; Drug-related side effects and adverse reactions; Polymedication; Transaminases	ADVERSE EVENTS; PATHOLOGY	BackgroundDrug-induced liver injury is increasing, especially in elderly patients with polymedication and multimorbidity.ObjectivesClinicopathologic correlation of immune-mediated liver injury, specifically liver injury following therapy with immune checkpoint inhibitors against PD-1, PDL-1, and CTLA4.MethodsHistologic assessment of liver biopsies of ninepatients after therapy with immune checkpoint inhibitors and correlation with clinical parameters.ResultsIn all ninepatients, liver injury was apparent after variable administration of immune checkpoint inhibitors. Transaminase levels were increased up to a maximum of 3818U/l. Liver histology showed liver injury resembling autoimmune hepatitis respective cholangitis. In twopatients, veno-occlusive disease was seen. Corticosteroid therapy was initiated in eightpatients, subsequently fourpatients showed decreasing transaminases and fivepatients died of tumor progress. In threepatients, it remains unclear whether liver injury by immune checkpoint inhibitors may have ultimately contributed to the fatal course, especially in one patient with liver cirrhosis and hepatocellular carcinoma.ConclusionsTherapy with immune checkpoint inhibitors may lead to potentially fatal immune phenomena in susceptible patients, which may affect liver and/or other organs independently. Other causes of hepatopathy need to be ruled out clinically and/or histologically.	[Straub, B. K.; Ridder, D. A.; Schad, A.] Johannes Gutenberg Univ Mainz, Univ Med Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany; [Loquai, C.] Johannes Gutenberg Univ Mainz, Univ Med Mainz, Hautklin & Poliklin, Mainz, Germany; [Schattenberg, J. M.] Johannes Gutenberg Univ Mainz, Univ Med Mainz, Med Klin 1, Mainz, Germany	Straub, BK (reprint author), Johannes Gutenberg Univ Mainz, Univ Med Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	beate.straub@unimedizin-mainz.de	Schattenberg, Jorn M./C-1301-2013	Schattenberg, Jorn M./0000-0002-4224-4703			Bleibel W, 2007, DIGEST DIS SCI, V52, P2463, DOI 10.1007/s10620-006-9472-y; Burt AD, 2018, MACSWEENS PATHOLOGY, P673; De Martin E, 2018, J HEPATOL, V68, P1181, DOI 10.1016/j.jhep.2018.01.033; Dienes HP, 2010, DIGEST DIS, V28, P57, DOI 10.1159/000282065; Doherty GJ, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000268; Gelsomino F, 2017, ANN ONCOL, V28, P671, DOI 10.1093/annonc/mdw649; Guo YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051723; Hofmann L, 2016, EUR J CANCER, V60, P190, DOI 10.1016/j.ejca.2016.02.025; Karamchandani DM, 2018, J CLIN PATHOL, V71, P665, DOI 10.1136/jclinpath-2018-205143; Kleiner DE, 2017, GASTROENTEROL CLIN N, V46, P273, DOI 10.1016/j.gtc.2017.01.004; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Koelzer VH, 2017, PATHOLOGE, V38, P197, DOI 10.1007/s00292-017-0281-1; Neilan TG, 2018, ONCOLOGIST, V23, P874, DOI 10.1634/theoncologist.2018-0157; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481; Reuben A, 2010, HEPATOLOGY, V52, P2065, DOI 10.1002/hep.23937; Rosner S, 2014, Z GASTROENTEROL, V52, P58, DOI 10.1055/s-0033-1356224; Simmons D, 2017, CUREUS, V9, DOI 10.7759/cureus.1774; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Wang WJ, 2017, INT J CANCER, V141, P1018, DOI 10.1002/ijc.30678; Weber J, 2010, SEMIN ONCOL, V37, P430, DOI 10.1053/j.seminoncol.2010.09.005; Williams KJ, 2019, J ONCOL PHARM PRACT, V25, P544, DOI 10.1177/1078155217744872; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zarrabi K, 2018, ONCOLOGY-BASEL, V94, P259, DOI 10.1159/000486679; Zen Y, 2018, MODERN PATHOL, V31, P965, DOI 10.1038/s41379-018-0013-y	24	0	0	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					556	562		10.1007/s00292-018-0519-6			7	Pathology	Pathology	HB0NX	WOS:000450713000008	30310977				2019-10-28	
J	Pfister, F; Buttner-Herold, M; Amann, K				Pfister, F.; Buettner-Herold, M.; Amann, K.			(Immuno-)Pathology of drug side effects in the kidney	PATHOLOGE			German	Article						Immunopathology; Interstitial nephritis; Tubular damage; acute; Drug-related side effects and adverse reactions; Thrombotic microangiopathies	THERAPY; NEPHRITIS	Nephrotoxicity or renal side effects of drugs are frequent and may vary in their clinical presentation. Various types of acute and chronic kidney disease are known to develop as a consequence or side effect of along list of drugs with nephrotoxicity most commonly being associated with injury in the tubulointerstitial compartment. In addition, drug-induced glomerular and vascular disease have also been reported, either as the result of direct cellular injury or immune-mediated injury to glomerular or endothelial cells. From aclinical point of view it is important to recognize such drug-induced nephropathies early in order to prevent or adequately treat them to favour kidney recovery and to avoid long-lasting negative consequences for kidney function.This article will focus on the typical morphology and pathogenesis of some frequent drug-induced renal diseases.	[Pfister, F.; Buettner-Herold, M.; Amann, K.] Univ Erlangen Nurnberg, Pathol Inst, Abt Nephropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Amann, K (reprint author), Univ Erlangen Nurnberg, Pathol Inst, Abt Nephropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	kerstin.amann@uk-erlangen.de					Bailey WJ, 2018, INT J TOXICOL, V37, P116, DOI 10.1177/1091581817752405; Bottlaender L, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0261-2; Dobre M, 2009, RENAL FAILURE, V31, P745, DOI 10.3109/08860220903118590; Dvanajscak Z, 2018, KIDNEY INT REP, V3, P492, DOI 10.1016/j.ekir.2017.10.011; Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330; Eremina V, 2010, SEMIN NEPHROL, V30, P582, DOI 10.1016/j.semnephrol.2010.09.006; Haake H, 2007, MED KLIN, V102, P852, DOI 10.1007/s00063-007-1104-6; Hogan JJ, 2015, CLIN J AM SOC NEPHRO, V10, P1300, DOI 10.2215/CJN.01910215; Izzedine H, 2017, KIDNEY INT REP, V2, P504, DOI 10.1016/j.ekir.2017.02.008; Izzedine H, 2017, NEPHROL DIAL TRANSPL, V32, P1089, DOI 10.1093/ndt/gfw467; Jaworska K, 2015, J IMMUNOL, V194, P325, DOI 10.4049/jimmunol.1400497; Krishnan N, 2015, IRAN J KIDNEY DIS, V9, P3; Lameire N, 2011, ACTA CLIN BELG, V66, P337, DOI 10.2143/ACB.66.5.2062585; Manohar S, 2019, NEPHROL DIAL TRANSPL, V34, P108, DOI 10.1093/ndt/gfy105; Markowitz GS, 2015, CLIN J AM SOC NEPHRO, V10, P1291, DOI 10.2215/CJN.00860115; Mehta RL, 2015, KIDNEY INT, V88, P226, DOI 10.1038/ki.2015.115; Paueksakon P, 2017, HISTOPATHOLOGY, V70, P94, DOI 10.1111/his.13064; Perazella MA, 2018, J AM SOC NEPHROL, V29, P2039, DOI 10.1681/ASN.2018050488; Perazella MA, 2012, CLIN J AM SOC NEPHRO, V7, P1713, DOI 10.2215/CJN.02780312; Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509; Radhakrishnan J, 2015, CLIN J AM SOC NEPHRO, V10, P1287, DOI 10.2215/CJN.01010115; Roncone D, 2007, NAT CLIN PRACT NEPHR, V3, P287, DOI 10.1038/ncpneph0476; Schmaderer C, 2015, NEPHROLOGE, V10, P145, DOI 10.1007/s11560-014-0976-8; Soo JYC, 2018, NAT REV NEPHROL, V14, P378, DOI 10.1038/s41581-018-0003-9; Starke A, 2010, KIDNEY INT, V78, P38, DOI 10.1038/ki.2010.97; Suneja M, 2014, JCR-J CLIN RHEUMATOL, V20, P99, DOI 10.1097/RHU.0000000000000049; Waeckerle-Men Y, 2007, NEPHROL DIAL TRANSPL, V22, P1527, DOI 10.1093/ndt/gfl818; Yahata Mayumi, 2013, BMC Res Notes, V6, P450, DOI 10.1186/1756-0500-6-450	28	1	1	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					576	582		10.1007/s00292-018-0475-1			7	Pathology	Pathology	HB0NX	WOS:000450713000011	30167781				2019-10-28	
J	French, CA				French, Christopher A.			NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment	PATHOLOGY INTERNATIONAL			English	Review						BET inhibitor; BRD3; BRD4-NUT; differentiation therapy; histone acetyl-transferase; histone deacetylase inhibitor; NSD3; ZNF532; NUT carcinoma; NUT midline carcinoma; www.NMCRegistry.org	BROMODOMAIN PROTEIN BRD4; HISTONE DEACETYLASE INHIBITOR; MIDLINE CARCINOMA; P-TEFB; SELECTIVE-INHIBITION; THYMIC CARCINOMA; NUCLEAR-PROTEIN; FUSION ONCOGENE; TARGETING MYCN; TUMOR	NUT carcinoma (NC) is a rare, aggressive subtype of squamous cell carcinoma defined by rearrangement of the NUTM1 (aka NUT) gene. NC is driven by NUT-fusion oncoproteins resulting from chromosomal translocation, most commonly BRD4-NUT. This is a nearly uniformly lethal cancer affecting patients of all ages, but predominantly teens and young adults. The cell of origin is unknown, but NC most commonly arises within the thorax and head and neck. NC typically consists of sheets of monomorphic primitive round cells that can exhibit focal abrupt squamous differentiation. Diagnosis of NC is easy, and can be established by positive NUT nuclear immunohistochemical staining. Though characterization of the NUTM1-fusion gene is desirable by molecular analysis, it is not required for the diagnosis. The increasingly widespread availability of the NUT diagnostic test is leading to increasing diagnoses of this vastly underdiagnosed disease. The NUT midline carcinoma registry () serves as a central repository that has provided the main source of clinical and outcomes data for NC. Currently there is no effective therapy for NC, however small molecules directly targeting the BRD4 portion of BRD4-NUT, termed BET bromodomain inhibitors, have shown activity.	[French, Christopher A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA	French, CA (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.	cfrench@bwh.harvard.edu					Alekseyenko AA, 2017, P NATL ACAD SCI USA, V114, pE4184, DOI 10.1073/pnas.1702086114; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Beesley AH, 2014, BRIT J CANCER, V110, P1189, DOI 10.1038/bjc.2014.54; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bisgrovet DA, 2007, P NATL ACAD SCI USA, V104, P13690, DOI 10.1073/pnas.0705053104; Bishop JA, 2016, CANCER CYTOPATHOL, V124, P901, DOI 10.1002/cncy.21761; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bragelmann J, 2017, CELL REP, V20, P2833, DOI 10.1016/j.celrep.2017.08.082; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; Chirieac LR, 2015, CLASSIFICATION TUMOU, P2; Chute DJ, 2010, DIAGN CYTOPATHOL, V38, P65, DOI 10.1002/dc.21134; Salles PGD, 2014, APPL IMMUNOHISTO M M, V22, P262, DOI 10.1097/PAI.0b013e3182a4ef2e; den Bakker MA, 2009, AM J SURG PATHOL, V33, P1253, DOI 10.1097/PAS.0b013e3181abe120; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dickson BC, 2018, AM J SURG PATHOL, V42, P636, DOI 10.1097/PAS.0000000000001021; El-Mofty SK, 2012, HEAD NECK PATHOL, V6, pS55, DOI 10.1007/s12105-012-0363-6; Elomaa I, 2000, EUR J CANCER, V36, P875, DOI 10.1016/S0959-8049(00)00028-9; Engleson J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-69; Evans AG, 2012, AM J SURG PATHOL, V36, P1222, DOI 10.1097/PAS.0b013e318258f03b; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2015, NUT CARCINOMA, P412; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Gatalica Z, 2018, LAB INVEST, V98, P698; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Gu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13331; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LEE ACW, 1993, CANCER, V72, P2273, DOI 10.1002/1097-0142(19931001)72:7<2273::AID-CNCR2820720735>3.0.CO;2-U; Lee JK, 2017, ANN ONCOL, V28, P890, DOI 10.1093/annonc/mdw686; Lewin J, 2018, J CLIN ONCOL; Lilljebjorn H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11790; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Maher OM, 2015, PEDIATR BLOOD CANCER, V62, P715, DOI 10.1002/pbc.25350; Mertens F, 2007, PEDIATR BLOOD CANCER, V49, P1015, DOI 10.1002/pbc.20755; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; O'Dwyer PJ, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-CT014; Petrini I, 2012, J THORAC ONCOL, V7, P744, DOI 10.1097/JTO.0b013e3182460f8f; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10; Raza A, 2015, EXPERT REV ANTICANC, V15, P1199, DOI 10.1586/14737140.2015.1082909; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Schaefer IM, 2018, GENE CHROMOSOME CANC, V57, P446, DOI 10.1002/gcc.3; Schroder S, 2012, J BIOL CHEM, V287, P1090, DOI 10.1074/jbc.M111.282855; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Shehata BM, 2010, PEDIATR DEVEL PATHOL, V13, P481, DOI 10.2350/09-10-0727-CR.1; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Shiota H, 2018, MOL CANC RES; Sholl LM, 2015, J THORAC ONCOL, V10, P951, DOI 10.1097/JTO.0000000000000545; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Stelow EB, 2009, ADV ANAT PATHOL, V16, P92, DOI 10.1097/PAP.0b013e31819923e4; Stirnweiss A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.33; Stirnweiss A, 2017, ONCOTARGET, V8, P112313, DOI 10.18632/oncotarget.22862; Storck S, 2017, PEDIATR HEMAT ONCOL, V34, P231, DOI 10.1080/08880018.2017.1363839; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Su C, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e18614; Sun KM, 2017, MOL CANCER THER, V16, P285, DOI 10.1158/1535-7163.MCT-16-0390; Tanaka M, 2012, AM J SURG PATHOL, V36, P381, DOI 10.1097/PAS.0b013e31824230a8; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson LDR, 2003, CURR DIAGN PATHOL, V9, P384, DOI DOI 10.1016/S0968-6053(03)00069-3; Thompson-Wicking K, 2013, ONCOGENE, V32, P4664, DOI 10.1038/onc.2012.487; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Vargas SO, 2001, CANCER, V92, P1195, DOI 10.1002/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3; Wang RR, 2015, J BIOL CHEM, V290, P2744, DOI 10.1074/jbc.M114.600759; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Ziai J, 2010, HEAD NECK PATHOL, V4, P163, DOI 10.1007/s12105-010-0174-6; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	98	6	6	3	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					583	595		10.1111/pin.12727			13	Pathology	Pathology	HC4OG	WOS:000451782400001	30362654				2019-10-28	
J	Sakashita, M; Sakashita, S; Murata, Y; Shiba-Ishii, A; Kim, Y; Matsuoka, R; Nakano, N; Sato, Y; Noguchi, M				Sakashita, Mai; Sakashita, Shingo; Murata, Yoshihiko; Shiba-Ishii, Aya; Kim, Yunjung; Matsuoka, Ryota; Nakano, Noriyuki; Sato, Yukio; Noguchi, Masayuki			High expression of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) is associated with poor prognosis in lung adenocarcinoma	PATHOLOGY INTERNATIONAL			English	Article						AIS; lung adenocarcinoma; MIA; OCIAD2; prognosis	SURVIVAL; STAT3; MODEL	The clinicopathological implications of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) in lung adenocarcinoma were investigated. The expression of OCIAD2 in 191 surgically resected lung adenocarcinomas was examined using immunohistochemistry. OCIAD2 expression was quantified using the H-score and dichotomized as high or low. High OCIAD2 protein expression was significantly correlated with vascular invasion (P = 0.0018), lymphatic permeation (P = 0.049), T factor (P = 0.0024), and pathological stage (P = 0.0003). High OCIAD2 expression was significantly associated with poorer overall survival (OS) (n = 191, P = 0.0325). In peripheral-type lung adenocarcinomas (n = 161), high OCIAD2 expression was significantly associated with both poorer OS (P = 0.0214) and poorer disease-free survival (P = 0.0496). Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) showed weaker OCIAD2 expression than invasive adenocarcinoma. Among small adenocarcinomas measuring 2 cm or less in greatest dimension classified according to the Noguchi's classification (n = 79), invasive adenocarcinomas showed significantly higher OCIAD2 expression than non-invasive adenocarcinomas (P = 0.0007). Interestingly, OCIAD2 was expressed heterogeneously even within a tumor, and its expression was higher in areas of invasion than in areas of in situ spread. Our results suggest that OCIAD2 could be a useful prognostic biomarker of lung adenocarcinoma.	[Sakashita, Mai] Univ Tsukuba, Grad Sch Comprehens Human Sci, Doctoral Program Biomed Sci, Ibaraki, Japan; [Sakashita, Shingo; Murata, Yoshihiko; Shiba-Ishii, Aya; Kim, Yunjung; Matsuoka, Ryota; Nakano, Noriyuki; Noguchi, Masayuki] Univ Tsukuba, Dept Pathol, Fac Med, Ibaraki, Japan; [Sato, Yukio] Univ Tsukuba, Dept Thorac Surg, Fac Med, Ibaraki, Japan	Sakashita, S (reprint author), Univ Tsukuba, Dept Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	s_sakashita@md.tsukuba.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP 17K08715]	This work was supported by JSPS KAKENHI Grant Number JP 17K08715.	Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012; Brierley JD, 2017, TNM CLASSIFICATION M; BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419; Cheng TYD, 2016, J THORAC ONCOL, V11, P1653, DOI 10.1016/j.jtho.2016.05.021; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Han J, 2014, CELL MOL LIFE SCI, V71, P2561, DOI 10.1007/s00018-013-1515-x; Harada D, 2014, CANCERS, V6, P708, DOI 10.3390/cancers6020708; Honda S, 2016, CANCER SCI, V107, P812, DOI 10.1111/cas.12928; Ishiyama T, 2007, CANCER SCI, V98, P50, DOI 10.1111/j.1349-7006.2006.00346.x; Kadota K, 2014, AM J SURG PATHOL, V38, P448, DOI 10.1097/PAS.0000000000000134; Lau SK, 2002, MODERN PATHOL, V15, P538, DOI 10.1038/modpathol.3880560; Luo LY, 2001, BIOCHEM BIOPH RES CO, V280, P401, DOI 10.1006/bbrc.2000.4126; Maeshima AM, 2010, J THORAC ONCOL, V5, P333, DOI 10.1097/JTO.0b013e3181c8cb95; Minami Y, 2005, LUNG CANCER, V48, P339, DOI 10.1016/j.lungcan.2004.11.016; Nagata C, 2012, PATHOL INT, V62, P471, DOI 10.1111/j.1440-1827.2012.02825.x; Nikas JB, 2016, AM J CANCER RES, V6, P1408; Nikas JB, 2014, AM J CANCER RES, V4, P862; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Noguchi M, 2010, CANCER METAST REV, V29, P15, DOI 10.1007/s10555-010-9210-y; Sengupta S, 2008, GYNECOL ONCOL, V109, P226, DOI 10.1016/j.ygyno.2007.12.024; Sinha S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25667-3; Stenhouse G, 2004, J CLIN PATHOL, V57, P383, DOI 10.1136/jcp.2003.007138; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Travis WD, 2015, WHO CLASSIFICATION T, V7, P26; Wang CY, 2010, MOL CANCER THER, V9, P1709, DOI 10.1158/1535-7163.MCT-09-1024; Zhang RJ, 2014, BIOMED RES INT, DOI 10.1155/2014/351095; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	27	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					596	604		10.1111/pin.12724			9	Pathology	Pathology	HC4OG	WOS:000451782400002	30320419				2019-10-28	
J	Cho, H; Kim, JY; Oh, YL				Cho, Haeyon; Kim, Ji-Ye; Oh, Young Lyun			Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma	PATHOLOGY INTERNATIONAL			English	Article						CD56; CK19; follicular variant; Gal-3; HBME-1; NIFTP; papillary carcinoma; thyroid	FINE-NEEDLE-ASPIRATION; NUCLEAR FEATURES; NEOPLASM; CYTOLOGY; DISTINCT; TUMOR; NIFTP; OVERTREATMENT; CRITERIA; BRAF	Our aim is to explore differences in Hector Battifora mesothelial-1 (HBME-1), cytokeratin-19 (CK19), Galectin-3 (Gal-3), and CD56 expression in infiltrative follicular variants of papillary carcinoma (IFVPTC) and encapsulated follicular variants of papillary carcinoma (EFVPTC) and to provide clues for distinguishing the two subtypes preoperatively. Tissue microarrays from 100 EFVPTC (45 non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) and 55 invasive EFVPTCs), 43 IFVPTCs, and 64 follicular neoplasms (FN) were immunostained with HBME-1, CK19, Gal-3, and CD56. Each case was scored 1 point for every positive result. Immunohistochemical expression was not significantly different in invasive EFVPTC and NIFTP, except for that of HBME-1. HBME-1, CK19, Gal-3, and CD56 expression were significantly higher in IFVPTC than in EFVPTC. At the cutoff of 3 points, the score method had special diagnostic value for differentiating IFVPTC from EFVPTC and FN and for predicting lymph node metastasis. Scoring of immunohistochemistry results may be applied to core biopsy or cell blocks to assist ultrasonographic, cytologic and molecular tests in differentiating IFVPTC and EFVPTC preoperatively, possibly appropriately guiding EFVPTC preoperatively for limited operation or active surveillance.	[Cho, Haeyon; Oh, Young Lyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea; [Kim, Ji-Ye] Natl Canc Ctr, Dept Pathol, Goyang, South Korea	Oh, YL (reprint author), Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Ilwon Ro, Seoul 06351, South Korea.	bijou@skku.edu					Agrawal N, 2017, ENDOCR PRACT, V23, P451, DOI 10.4158/EP161632.OR; Alves VAF, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e576; Brandler TC, 2018, DIAGN CYTOPATHOL, V46, P139, DOI 10.1002/dc.23863; Bychkov A, 2018, ENDOCR PATHOL, V29, P276, DOI 10.1007/s12022-018-9519-6; Chandler JB, 2017, CANCER CYTOPATHOL, V125, P865, DOI 10.1002/cncy.21910; CHEN KTK, 1977, AM J SURG PATHOL, V1, P123, DOI 10.1097/00000478-197706000-00003; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; du Jour KP, 2018, ENDOCR PATHOL, V29, P35, DOI 10.1007/s12022-017-9509-0; Dunderovic D, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0428-4; Finnerty BM, 2015, ANN SURG ONCOL, V22, P1200, DOI 10.1245/s10434-014-4126-3; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Hahn SY, 2017, CLIN ENDOCRINOL, V86, P444, DOI 10.1111/cen.13263; Hahn SY, 2017, CLIN ENDOCRINOL, V86, P113, DOI 10.1111/cen.13144; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jeon MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167756; Jiang XY, 2016, CANCER CYTOPATHOL, V124, P893, DOI 10.1002/cncy.21802; Kakudo K, 2017, CYTOPATHOLOGY, V28, P455, DOI 10.1111/cyt.12491; Kakudo K, 2018, PATHOL INT, V68, P327, DOI 10.1111/pin.12673; Kakudo K, 2012, PATHOL INT, V62, P155, DOI 10.1111/j.1440-1827.2011.02773.x; Kim MJ, 2018, THYROID, V28, P311, DOI 10.1089/thy.2016.0671; Kim TH, 2018, HISTOPATHOLOGY, V72, P648, DOI 10.1111/his.13401; Kwon MR, 2018, CLIN RADIOL, V73, DOI 10.1016/j.crad.2017.12.008; Laderach DJ, 2010, IUBMB LIFE, V62, P1, DOI 10.1002/iub.281; Lagana A, 2006, MOL CELL BIOL, V26, P3181, DOI 10.1128/MCB.26.8.3181-3193.2006; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Lloyd RV, 2018, HUM PATHOL, V74, P1, DOI 10.1016/j.humpath.2017.12.027; Mahajan S, 2018, CYTOPATHOLOGY, V29, P233, DOI 10.1111/cyt.12537; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Min HS, 2013, J KOREAN MED SCI, V28, P534, DOI 10.3346/jkms.2013.28.4.534; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohta M, 2015, PATHOL INT, V65, P119, DOI 10.1111/pin.12252; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; ROSAI J, 1983, AM J SURG PATHOL, V7, P809, DOI 10.1097/00000478-198307080-00010; Satoh S, 2017, J PATHOL TRANSL MED, V51, P548, DOI 10.4132/jptm.2017.09.29; Song SJ, 2017, CYTOPATHOLOGY, V28, P488, DOI 10.1111/cyt.12501; Sowder AM, 2018, HEAD NECK PATHOL, V12, P105, DOI 10.1007/s12105-017-0835-9; Strickland KC, 2016, THYROID, V26, P1466, DOI 10.1089/thy.2016.0280; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Torregrossa L, 2007, HUM PATHOL, V38, P1482, DOI 10.1016/j.humpath.2007.02.013; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Yang GCH, 2017, DIAGN CYTOPATHOL, V45, P533, DOI 10.1002/dc.23709	42	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					605	613		10.1111/pin.12729			9	Pathology	Pathology	HC4OG	WOS:000451782400003	30350394				2019-10-28	
J	Shimono, J; Miyoshi, H; Arakawa, F; Abe, H; Miyagishima, T; Akiba, J; Teshima, T; Ohshima, K				Shimono, Joji; Miyoshi, Hiroaki; Arakawa, Fumiko; Abe, Hideyuki; Miyagishima, Takuto; Akiba, Jun; Teshima, Takanori; Ohshima, Koichi			Synchronous case of follicular lymphoma and Langerhans cell sarcoma in the same lymph node	PATHOLOGY INTERNATIONAL			English	Article						clonality; follicular lymphoma; Langerhans cell sarcoma	RECEPTOR GENE REARRANGEMENTS; HISTIOCYTIC SARCOMA; TRANSDIFFERENTIATION; FEATURES	Langerhans cell sarcoma (LCS) is a very rare histiocytic and dendritic cell neoplasm originating from Langerhans cells. There are case reports of histiocytic and dendritic cell neoplasms synchronously or sequentially observed in patients with malignant lymphoma. We present a case in which LCS and follicular lymphoma (FL) grade 3a were observed within the same lymph node. A 66-year-old male visited our hospital with a general malaise. Pleural effusion and systemic lymph adenopathy were detected. Biopsy of an inguinal lymph node was performed. The lymph node had regions with follicular structure and regions with acidophilic cytoplasm and large proliferating atypical cells. The tumor cells in the regions with follicular structure showed positivity for CD20 and BCL2 consistent with an FL grade 3a diagnosis. The tumor cells in the regions without follicular structure showed positivity for CD1a and S-100 and were consistent with an LCS diagnosis. Both tumor cells showed the positivity of BCL6 split by FISH. PCR detected IgH clonality in DNA collected from each region, and direct sequence analysis of cells from both tumors detected almost identical amino acid sequences. This finding is important for future research on the development of very rare histiocytic and dendritic cell neoplasms.	[Shimono, Joji; Miyoshi, Hiroaki; Arakawa, Fumiko; Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Asahimachi 67, Kurume, Fukuoka 8300011, Japan; [Shimono, Joji; Teshima, Takanori] Hokkaido Univ, Fac Med, Dept Hematol, Sapporo, Hokkaido, Japan; [Abe, Hideyuki; Akiba, Jun] Kurume Univ, Sch Med, Dept Diagnost Pathol, Kurume, Fukuoka, Japan; [Miyagishima, Takuto] Kushiro Rosai Hosp, Dept Hematol, Kushiro, Hokkaido, Japan	Miyoshi, H (reprint author), Kurume Univ, Sch Med, Dept Pathol, Asahimachi 67, Kurume, Fukuoka 8300011, Japan.	miyoshi_hiroaki@med.kurume-u.ac.jp					Ambrosio MR, 2015, VIRCHOWS ARCH, V467, P471, DOI 10.1007/s00428-015-1814-8; Ansari J, 2016, EUR J HAEMATOL, V97, P9, DOI 10.1111/ejh.12755; Brunner P, 2014, LEUKEMIA, V28, P1937, DOI 10.1038/leu.2014.167; Chen W, 2010, AM J SURG PATHOL, V34, P1049, DOI 10.1097/PAS.0b013e3181e5341a; Chen W, 2009, AM J SURG PATHOL, V33, P863, DOI 10.1097/PAS.0b013e31819287b8; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Howard JEF, 2015, CANCER TREAT REV, V41, P320, DOI 10.1016/j.ctrv.2015.02.011; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Shimono J, 2017, ONCOTARGET, V8, P98723, DOI 10.18632/oncotarget.21920; Shimono J, 2017, ANN HEMATOL, V96, P2063, DOI 10.1007/s00277-017-3139-y; Shimono J, 2017, PATHOL INT, V67, P17, DOI 10.1111/pin.12478; Swerdlow SH, 2017, WHO CLASSIFICATION T; Wang ED, 2010, LEUKEMIA LYMPHOMA, V51, P802, DOI 10.3109/10428191003699845; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; Xie HF, 2007, NATURE, V449, P410, DOI 10.1038/449410a	16	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					614	617		10.1111/pin.12722			4	Pathology	Pathology	HC4OG	WOS:000451782400004	30255584				2019-10-28	
J	Asahina, M; Fukumura, Y; Mamat, O; Saito, T; Hayashi, T; Uekusa, T; Suzuki, K; Yao, T				Asahina, Miki; Fukumura, Yuki; Mamat, Osman; Saito, Tsuyoshi; Hayashi, Takuo; Uekusa, Toshimasa; Suzuki, Kenji; Yao, Takashi			A case of combined small cell lung carcinoma with unique morphology: Investigation of tumorigenesis	PATHOLOGY INTERNATIONAL			English	Article						combined small cell lung carcinoma; loss of heterozygosity; monoclonality; pure small cell lung carcinoma; tumorigenesis	EARLY-STAGE; FEATURES	Small cell lung carcinoma (SCLC) usually grows in a pure form with no other associated histological components. However, combined small cell lung carcinoma (cSCLC), which is accompanied by other histological components (cSCLCs) may sometimes occur. Herein, we analyzed the tumorigenesis of cSCLC containing a demarcated area of pure SCLC. A 76-year-old man had a 25-mm mass in the perihilar portion of his right upper lung. Histologically, the cSCLC contained two relatively demarcated areas: one area composed of pure SCLC cells and another area of SCLC, squamous-like component (SLC), and spindle cell carcinoma (SpCC) cells. Loss of heterozygosity (LOH) was observed at allele 3p in all tumor components and at 22q in the pure SCLC component. Histological and immunohistochemical analysis and LOH study suggested that all components were likely to be monoclonal in origin and revealed that the pure SCLC component was not the precursor of the cSCLC. In the tumorigenesis of this case, the pure SCLC and the cSCLC may have originated from a common pluripotent tumor cell and then diverged, although we cannot state this conclusively. Further studies with more cases are necessary to test this theory.	[Asahina, Miki; Fukumura, Yuki; Mamat, Osman; Saito, Tsuyoshi; Hayashi, Takuo; Yao, Takashi] Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Uekusa, Toshimasa] Kanto Rosai Hosp, Dept Diagnost Pathol, Nakahara Ku, 1-1 Kizukisumiyoshi Cho, Kawasaki, Kanagawa 2118510, Japan; [Suzuki, Kenji] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan	Fukumura, Y (reprint author), Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yfuku@juntendo.ac.jp					Anami Y, 2000, INT J CANCER, V89, P19, DOI 10.1002/(SICI)1097-0215(20000120)89:1<19::AID-IJC4>3.0.CO;2-3; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Fukui T, 2007, CANCER SCI, V98, P1714, DOI 10.1111/j.1349-7006.2007.00600.x; HIBI K, 1992, ONCOGENE, V7, P445; Hiroshima K, 2004, CANCER-AM CANCER SOC, V100, P1190, DOI 10.1002/cncr.20108; HIRSCH FR, 1983, VIRCHOWS ARCH A, V402, P147, DOI 10.1007/BF00695056; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Murase T, 2003, HUM PATHOL, V34, P1178, DOI 10.1053/S0046-8177(03)00466-0; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/01.PAS.0000022995.91977.CD; Pelosi G, 2011, VIRCHOWS ARCH, V458, P497, DOI 10.1007/s00428-010-1011-8; Ruffini E, 2002, EUR J CARDIO-THORAC, V22, P701, DOI 10.1016/S1010-7940(02)00481-5; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Takeuchi T, 2006, PATHOL INT, V56, P434, DOI 10.1111/j.1440-1827.2006.01985.x; Travis WD, 2015, WHO CLASSIFICATION T; Yamada K, 2014, PATHOL INT, V64, P28, DOI 10.1111/pin.12127; Zhao XL, 2018, J THORAC ONCOL, V13, P237, DOI 10.1016/j.jtho.2017.10.010	17	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					618	623		10.1111/pin.12726			6	Pathology	Pathology	HC4OG	WOS:000451782400005	30311995				2019-10-28	
J	Ichihara, S; Kawamura, M; Hirasawa, K; Yagi, K				Ichihara, Shin; Kawamura, Masashi; Hirasawa, Kingo; Yagi, Kazuyoshi			MUC6-positive cell proliferation in the glandular neck zone of low-grade well-differentiated carcinoma	PATHOLOGY INTERNATIONAL			English	Letter							ADENOCARCINOMA; STOMACH		[Ichihara, Shin] Sapporo Kosei Gen Hosp, Dept Surg Pathol, Sapporo, Hokkaido, Japan; [Kawamura, Masashi] Sendai City Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan; [Hirasawa, Kingo] Yokohama City Univ, Med Ctr, Div Endoscopy, Yokohama, Kanagawa, Japan; [Yagi, Kazuyoshi] Niigata Univ Med & Dent Hosp, Uonuma Inst Community Med, Dept Gastroenterol & Hepatol, Niigata, Japan	Ichihara, S (reprint author), Sapporo Kosei Gen Hosp, Dept Surg Pathol, Sapporo, Hokkaido, Japan.						Kanesaka T, 2017, CLIN J GASTROENTEROL, V10, P224, DOI 10.1007/s12328-017-0727-2; Kawamura M, 2016, STOMACH INTEST, V51, P820; MATSUYAMA M, 1970, SCIENCE, V169, P385, DOI 10.1126/science.169.3943.385; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0; Yao T, 2006, WORLD J GASTROENTERO, V12, P2510, DOI 10.3748/wjg.v12.i16.2510	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					624	626		10.1111/pin.12713			3	Pathology	Pathology	HC4OG	WOS:000451782400006	30136360				2019-10-28	
J	Tabei, T; Tsuura, Y; Kobayashi, K				Tabei, Tadashi; Tsuura, Yukio; Kobayashi, Kazuki			Pseudoprogression: A case of metastatic renal clear cell carcinoma treated with nivolumab	PATHOLOGY INTERNATIONAL			English	Letter							ANTIBODY		[Tabei, Tadashi; Kobayashi, Kazuki] Yokosuka Kyosai Hosp, Dept Urol, Yokosuka, Kanagawa, Japan; [Tsuura, Yukio] Yokosuka Kyosai Hosp, Dept Pathol, Yokosuka, Kanagawa, Japan	Tabei, T (reprint author), Yokosuka Kyosai Hosp, Dept Urol, Yokosuka, Kanagawa, Japan.						Di Giacomo AM, 2009, CANCER IMMUNOL IMMUN, V58, P1297, DOI 10.1007/s00262-008-0642-y; Gettinger SN, 2015, J CLIN ONCOL, V33, P2004, DOI 10.1200/JCO.2014.58.3708; Tanizaki J, 2016, LUNG CANCER, V102, P44, DOI 10.1016/j.lungcan.2016.10.014; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	4	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					627	629		10.1111/pin.12714			3	Pathology	Pathology	HC4OG	WOS:000451782400007	30151940				2019-10-28	
J	Shintaku, M; Kamada, Y; Sumitomo, M				Shintaku, Masayuki; Kamada, Yasuyuki; Sumitomo, Masahiro			Mullerian carcinosarcoma with neuroendocrine differentiation arising in hydrocele of the canal of Nuck	PATHOLOGY INTERNATIONAL			English	Letter							TUMOR		[Shintaku, Masayuki] Shiga Gen Hosp, Dept Pathol, Moriyama Ku, Otsu, Shiga, Japan; [Kamada, Yasuyuki] Shiga Gen Hosp, Dept Surg, Moriyama Ku, Otsu, Shiga, Japan; [Sumitomo, Masahiro] Shiga Gen Hosp, Dept Gynecol, Moriyama Ku, Otsu, Shiga, Japan	Shintaku, M (reprint author), Shiga Gen Hosp, Dept Pathol, Moriyama Ku, Otsu, Shiga, Japan.			Sumitomo, Masahiro/0000-0003-1141-5618			BLOCK RE, 1975, OBSTET GYNECOL, V45, P464; CHUMAS JC, 1986, GYNECOL ONCOL, V23, P227, DOI 10.1016/0090-8258(86)90228-3; GEORGE E, 1991, HUM PATHOL, V22, P215, DOI 10.1016/0046-8177(91)90153-G; GERSELL DJ, 1989, INT J GYNECOL PATHOL, V8, P169, DOI 10.1097/00004347-198906000-00011; Ito M., 2010, J JPN SURG, V71, P2145	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					630	632		10.1111/pin.12717			3	Pathology	Pathology	HC4OG	WOS:000451782400008	30198090				2019-10-28	
J	Ohara, K; Arai, E; Takahashi, Y; Fukamachi, Y; Ito, N; Maeshima, AM; Fujimoto, H; Yoshida, T; Kanai, Y				Ohara, Kentaro; Arai, Eri; Takahashi, Yoriko; Fukamachi, Yukihiro; Ito, Nanako; Maeshima, Akiko Miyagi; Fujimoto, Hiroyuki; Yoshida, Teruhiko; Kanai, Yae			Feasibility of methylome analysis using small amounts of genomic DNA from formalin-fixed paraffin-embedded tissue	PATHOLOGY INTERNATIONAL			English	Letter									[Ohara, Kentaro; Arai, Eri; Ito, Nanako; Kanai, Yae] Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan; [Takahashi, Yoriko; Fukamachi, Yukihiro] Mitsui Knowledge Ind Co Ltd, Biomed Dept, Tokyo 1056215, Japan; [Maeshima, Akiko Miyagi] Natl Canc Ctr, Pathol Div, Dept Pathol, Tokyo 1040045, Japan; [Maeshima, Akiko Miyagi] Natl Canc Ctr, Pathol Div, Clin Labs, Tokyo 1040045, Japan; [Fujimoto, Hiroyuki] Natl Canc Ctr, Dept Urol, Tokyo 1040045, Japan; [Yoshida, Teruhiko] Natl Canc Ctr, Res Inst, Fundamental Innovat Oncol Core Ctr, Tokyo 1040045, Japan	Arai, E (reprint author), Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan.				Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [JP17ak0101043]	This study was supported by funding for Research to Expedite Effective Drug Discovery by Government, Academia and Private Partnership (JP17ak0101043) from the Japan Agency for Medical Research and Development (AMED).	Gilbert MT, 2007, PLOS ONE, V2, pe33; Hovestadt V, 2013, ACTA NEUROPATHOL, V125, P913, DOI 10.1007/s00401-013-1126-5; Kanai Y, 2018, PATHOL INT, V68, P63, DOI 10.1111/pin.12631; Kanai Y, 2010, CANCER SCI, V101, P36, DOI 10.1111/j.1349-7006.2009.01383.x; Kling T, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0333-7	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					633	635		10.1111/pin.12716			3	Pathology	Pathology	HC4OG	WOS:000451782400009	30239063	Other Gold			2019-10-28	
J	[Anonymous]				[Anonymous]			107th Annual Meeting of the Japanese Society of Pathology, Sapporo, Japan, June 21-23, 2018	PATHOLOGY INTERNATIONAL			English	Article																	0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2018	68	11					636	639		10.1111/pin.12725			4	Pathology	Pathology	HC4OG	WOS:000451782400010	30390379				2019-10-28	
J	Wang, Z; Guo, LM; Wang, SC; Chen, D; Yan, J; Liu, FX; Huang, JF; Xiong, K				Wang, Zhen; Guo, Li-min; Wang, Shu-chao; Chen, Dan; Yan, Jie; Liu, Feng-xia; Huang, Ju-fang; Xiong, Kun			Progress in studies of necroptosis and its relationship to disease processes	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Necroptosis; Necroptotic proteins; RIPs; MLKL; Disease processes	MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; ACUTE KIDNEY INJURY; CELL-DEATH; PROGRAMMED NECROSIS; STAPHYLOCOCCUS-AUREUS; RIP1 KINASE; TUMOR NECROSIS; UP-REGULATION; MLKL	This review briefly introduces the mechanism and detection methods of necroptosis in recent years. The most significant points of this review focus on the involvement of necroptotic proteins in disease progression. The following aspects are summarized: 1) RIPs, MLKL, and the upstream and downstream molecules that mediate necroptosis; 2) The development of detection methods for necroptosis; 3) The involvement of related necroptotic proteins in diverse diseases etiology; and 4) The application of necroptotic proteins in disease diagnosis.	[Wang, Zhen] Jiangnan Univ, Wuxi Sch Med, Wuxi 214122, Jiangsu, Peoples R China; [Guo, Li-min; Wang, Shu-chao; Chen, Dan; Huang, Ju-fang; Xiong, Kun] Cent S Univ, Sch Basic Med Sci, Dept Neurobiol & Human Anat, Changsha 410013, Hunan, Peoples R China; [Yan, Jie] Cent S Univ, Sch Basic Med Sci, Dept Forens Sci, Changsha 410013, Hunan, Peoples R China; [Liu, Feng-xia] Xinjiang Med Univ, Sch Basic Med Sci, Dept Human Anat, Urumqi 830011, Xinjiang, Peoples R China	Huang, JF; Xiong, K (reprint author), Cent S Univ, Dept Anat & Neurobiol, Morphol Sci Bldg,172 Tongzi Po Rd, Changsha 410013, Hunan, Peoples R China.	huangjufang@csu.edu.cn; xiongkun2001@163.com		Xiong, Kun/0000-0002-3103-6028	National Key Research and Development Program of China [2016YFC1201800]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81571939, 81772134, 81671225, 81871089]; Key Research and Development Program of Hunan Province [2018SK2090, 2018SK2091]; Wu Jie-Ping Medical Foundation of the Minister of Health of China [320.6750.14118]; Teacher Research Foundation of Central South University [2014JSJJ026]	This study was supported by the National Key Research and Development Program of China (No. 2016YFC1201800), the National Natural Science Foundation of China (Nos. 81571939, 81772134, 81671225, and 81871089), the Key Research and Development Program of Hunan Province (Nos. 2018SK2090 and 2018SK2091), Wu Jie-Ping Medical Foundation of the Minister of Health of China (No. 320.6750.14118), Teacher Research Foundation of Central South University (No. 2014JSJJ026). We would like to thank Dr. Jim Vaught, Editor-in-Chief of Biopreservation and Biobanking, Bethesda, Maryland, USA, who edited the manuscript for us, and Dr. Ya Cao, Professor of Cancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, Hunan, China, who reviewed our manuscript.	Annibaldi A, 2018, MOL CELL, V69, P566, DOI 10.1016/j.molcel.2018.01.027; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Bian PY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00303; Cabal-Hierro L, 2017, MOL CANCER RES, V15, P395, DOI 10.1158/1541-7786.MCR-16-0329; Caccamo A, 2017, NAT NEUROSCI, V20, P1236, DOI 10.1038/nn.4608; Callow MG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0301-y; Chan FKM, 2012, CELL, V148, P17, DOI 10.1016/j.cell.2011.12.020; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Chen S, 2016, J HUAZHONG U SCI-MED, V36, P639, DOI 10.1007/s11596-016-1639-y; Chen WZ, 2015, NAT CELL BIOL, V17, P434, DOI 10.1038/ncb3120; Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Daniels BP, 2017, CELL, V169, P301, DOI 10.1016/j.cell.2017.03.011; Davies K. A., 2018, CELL DEATH DIFFERENT; de Almagro MC, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.158; de Almagro MC, 2017, CELL DEATH DIFFER, V24, P26, DOI 10.1038/cdd.2016.78; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Ding W, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0187-x; Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026; Dovey CM, 2018, MOL CELL, V70, P936, DOI 10.1016/j.molcel.2018.05.010; Feng N, 2017, J MOL CELL CARDIOL, V103, P102, DOI 10.1016/j.yjmcc.2016.12.007; Feoktistova M., 2016, COLD SPRING HARB PRO; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Geng JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00406-w; Gonzalez-Juarbe N, 2017, CELL DEATH DIFFER, V24, P917, DOI 10.1038/cdd.2017.49; Greenlee-Wacker MC, 2014, J IMMUNOL, V192, P4709, DOI 10.4049/jimmunol.1302692; Grootjans S, 2017, CELL DEATH DIFFER, V24, P1184, DOI 10.1038/cdd.2017.65; Guo XY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.294; Haga S, 2018, ONCOL RES, V26, P503, DOI 10.3727/096504017X15005102445191; He SD, 2016, CELL MOL LIFE SCI, V73, P2177, DOI 10.1007/s00018-016-2192-3; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hockendorf U, 2016, CANCER CELL, V30, P75, DOI 10.1016/j.ccell.2016.06.002; Huang DL, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00497-16; Huang JF, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-16; Huang ZJ, 2018, CELL DEATH DIFFER, V25, P180, DOI 10.1038/cdd.2017.141; Iannielli A, 2018, CELL REP, V22, P2066, DOI 10.1016/j.celrep.2018.01.089; Ito Y, 2016, SCIENCE, V353, P603, DOI 10.1126/science.aaf6803; Jacobsen AV, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.386; Jacobsen AV, 2016, CELL CHEM BIOL, V23, P205, DOI 10.1016/j.chembiol.2016.02.003; Jiao DL, 2018, CELL RES, V28, P868, DOI 10.1038/s41422-018-0058-y; Kim CR, 2017, CURR EYE RES, V42, P771, DOI 10.1080/02713683.2016.1227449; Kitur K, 2016, CELL REP, V16, P2219, DOI 10.1016/j.celrep.2016.07.039; Kitur K, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004820; Koo GB, 2015, CELL RES, V25, P707, DOI 10.1038/cr.2015.56; Lawlor KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7282; Lee H. L., 2017, METHODS, P56; Lee H. L., 2017, METHODS, P134; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Li DR, 2016, CELL CHEM BIOL, V23, P257, DOI 10.1016/j.chembiol.2015.08.018; Li DR, 2015, P NATL ACAD SCI USA, V112, P5017, DOI 10.1073/pnas.1505244112; Li N, 2016, NEUROTOX RES, V30, P392, DOI 10.1007/s12640-016-9624-6; Li X, 2017, TECHNOL CANCER RES T, V16, P428, DOI 10.1177/1533034616655909; Li X, 2018, J SURG RES, V225, P108, DOI 10.1016/j.jss.2018.01.007; Li Y, 2017, CURR OPIN CHEM BIOL, V39, P74, DOI 10.1016/j.cbpa.2017.05.007; Liao LS, 2017, ACTA BIOCH BIOPH SIN, V49, P879, DOI 10.1093/abbs/gmx088; Limb M, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2155; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Liu P, 2012, LEUKEMIA, V26, P1293, DOI 10.1038/leu.2011.357; Liu WJ, 2018, P NATL ACAD SCI USA, V115, pE1475, DOI 10.1073/pnas.1716959115; Liu X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.197; Liu XY, 2015, CANCER RES, V75, P1736, DOI 10.1158/0008-5472.CAN-14-2199; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mahul-Mellier AL, 2012, CELL DEATH DIFFER, V19, P891, DOI 10.1038/cdd.2011.185; Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021; Mandelkow R, 2017, ANTICANCER RES, V37, P2239, DOI 10.21873/anticanres.11560; Marshall KD, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00323; Martin-Sanchez D, 2018, P NATL ACAD SCI USA, V115, P4182, DOI 10.1073/pnas.1716578115; McQuade T, 2013, BIOCHEM J, V456, P409, DOI 10.1042/BJ20130860; Menon MB, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2017.1396389; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Negroni A, 2017, DIGEST LIVER DIS, V49, P1201, DOI 10.1016/j.dld.2017.08.017; Newton K, 2016, CELL DEATH DIFFER, V23, P1565, DOI 10.1038/cdd.2016.46; Newton K, 2016, ANNU REV BIOCHEM, V85, P743, DOI 10.1146/annurev-biochem-060815-014830; Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361; Nugues AL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.347; O'Donnell JA, 2018, J IMMUNOL, V200, P737, DOI 10.4049/jimmunol.1701229; Papatriantafyllou Maria, 2012, Nat Rev Mol Cell Biol, V13, P135, DOI 10.1038/nrm3292; Park YH, 2014, BIOCHEM BIOPH RES CO, V443, P1155, DOI 10.1016/j.bbrc.2013.12.068; Perry SW, 1997, BIOTECHNIQUES, V22, P1102, DOI 10.2144/97226st01; Pierdomenico M, 2014, AM J GASTROENTEROL, V109, P279, DOI 10.1038/ajg.2013.403; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Qian YY, 2018, CELL PHYSIOL BIOCHEM, V45, P2268, DOI 10.1159/000488172; Qin DZ, 2016, J BIOL CHEM, V291, P20247, DOI 10.1074/jbc.M116.732735; Qiu X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.229; Qiu XF, 2018, CELL DEATH DIFFER, V25, P821, DOI 10.1038/s41418-018-0075-x; Qu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.54; Rebsamen M, 2009, EMBO REP, V10, P916, DOI 10.1038/embor.2009.109; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Ruan JY, 2015, INT J CLIN EXP PATHO, V8, P15035; Sawai H, 2011, BIOCHEM BIOPH RES CO, V411, P569, DOI 10.1016/j.bbrc.2011.06.186; Schneider AT, 2017, CANCER CELL, V31, P94, DOI 10.1016/j.ccell.2016.11.009; Seifert L, 2017, CLIN CANCER RES, V23, P1132, DOI 10.1158/1078-0432.CCR-16-0968; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Seldon CS, 2016, WORLD J GASTRO ONCOL, V8, P358, DOI 10.4251/wjgo.v8.i4.358; Shan B, 2018, GENE DEV, V32, P327, DOI 10.1101/gad.312561.118; Shang L, 2017, ACTA BIOCH BIOPH SIN, V49, P128, DOI 10.1093/abbs/gmw130; Shang L, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-63; Shashaty MGS, 2016, SHOCK, V46, P139, DOI 10.1097/SHK.0000000000000596; Shutinoski B, 2016, CELL DEATH DIFFER, V23, P1628, DOI 10.1038/cdd.2016.51; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Tokunaga F, 2012, ENDOCR J, V59, P641, DOI 10.1507/endocrj.EJ12-0148; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Vieira M, 2014, NEUROBIOL DIS, V68, P26, DOI 10.1016/j.nbd.2014.04.002; Vitner EB, 2014, NAT MED, V20, P204, DOI 10.1038/nm.3449; Wang C, 2016, TUMOR BIOL, V37, P15305, DOI 10.1007/s13277-016-5342-1; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang HB, 2017, P NATL ACAD SCI USA, V114, P11944, DOI 10.1073/pnas.1715742114; Wang SC, 2018, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00425; Wang TZ, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317711539; Wang Y, 2018, BIOCHEM BIOPH RES CO, V497, P80, DOI 10.1016/j.bbrc.2018.02.024; Wang Z., 2018, HISTOL HISTOPATHOL, P11968; Wang Z, 2018, J CELL PHYSIOL, V233, P4864, DOI 10.1002/jcp.26294; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wei R, 2017, GENE DEV, V31, P1162, DOI 10.1101/gad.299776.117; Wen SH, 2017, J CELL MOL MED, V21, P432, DOI 10.1111/jcmm.12987; Wen SH, 2014, INT IMMUNOPHARMACOL, V23, P709, DOI 10.1016/j.intimp.2014.10.027; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Wu JF, 2013, CELL RES, V23, P994, DOI 10.1038/cr.2013.91; Xia BQ, 2016, CELL RES, V26, P517, DOI 10.1038/cr.2016.26; Xin J, 2017, LEUKEMIA, V31, P1154, DOI 10.1038/leu.2016.287; Xiong K, 2016, TOXICOL IN VITRO, V35, P163, DOI 10.1016/j.tiv.2016.06.002; Xu GF, 2010, J BIOL CHEM, V285, P969, DOI 10.1074/jbc.M109.042689; Yang CK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.483; Yang H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0202-z; Yang ZT, 2018, NAT CELL BIOL, V20, P186, DOI 10.1038/s41556-017-0022-y; Zeng FX, 2018, CANCER RES, V78, P2876, DOI 10.1158/0008-5472.CAN-17-3082; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang T, 2016, NAT MED, V22, P175, DOI 10.1038/nm.4017; Zhang Y., 2017, NANO RES, V3, P1, DOI DOI 10.1016/J.GENE.2017.03.001; Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133; Zhang YY, 2016, CELL RES, V26, P643, DOI 10.1038/cr.2016.64; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109; Zhao XM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.390; Zhu H, 2018, J MOL CELL CARDIOL, V116, P125, DOI 10.1016/j.yjmcc.2018.01.018	139	4	4	2	19	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1749	1757		10.1016/j.prp.2018.09.002			9	Pathology	Pathology	HA0MP	WOS:000449902400001	30244947				2019-10-28	
J	Da, LS; Zhang, Y; Zhang, CJ; Bu, LJ; Zhu, YZ; Ma, T; Gu, KS				Da, Liang-Shan; Zhang, Ying; Zhang, Cong-Jun; Bu, Li-Jia; Zhu, Yan-Zhe; Ma, Tai; Gu, Kang-sheng			The PD-1 rs36084323 A > G polymorphism decrease cancer risk in Asian: A meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Review						PD-1; Polymorphism; Cancer; Meta	CO-INHIBITORY MOLECULES; LUNG-CANCER; CHINESE; LIGANDS; GENE; SUSCEPTIBILITY; POPULATION; STATISTICS; ACTIVATION; TOLERANCE	The rs36084323 A > G polymorphism in programmed cell death-1(PD-1) gene has been reported to be associated with cancer risk. However, the results of previous studies were inconsistent. Therefore, we performed a meta-analysis to identify the potential association, by searching the PubMed, EMBASE, Cochrane Library, and the Chinese CNKI, WANFANG and CBM databases. Data were extracted and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the strength of the association. A total of 10 relevant studies involving 4445 cancer cases and 5126 controls were recruited. Overall, the results indicated that the PD-1 rs36084323 A > G polymorphism was not statistically associated with cancer risk. However, stratified analysis revealed that there was a statistically reduced cancer risk in Asians(G vs. A, OR = 0.89, 95%CI:0.81-0.97, P = 0.008, I-2 = 48.8%; GG vs. AA, OR = 0.79, 95% CI:0.66-0.94, P = 0.008, I-2 = 48.7%; GG/AG vs. AA, OR = 0.87, 95%CI:0.76-0.98, P = 0.017, I-2 = 34.9%; GG vs. AG/AA, OR = 0.85, 95%CI:0.75-0.97, P = 0.027, I-2 = 40%) and in the patients with EOC(AG vs. AA, OR = 0.69, 95%CI:0.54-0.90, P = 0.005, I-2 = 0%; GG/AG vs. AA, OR = 0.67, 95%C1:0.52-0.85, P = 0.001, I-2 = 0). Meta-regression showed that ethnicity (P = 0.029) but not cancer types (P = 0.792), source of controls (P = 0.207) or ample size (P = 0.585) were the sources of heterogeneity. This meta-analysis demonstrates the PD-1 rs36084323 A > G polymorphism is associated with decreased cancer risk in Asian, and suggests it could potentially serve as a biomarker to screen high-risk individuals. Large-scale and well-designed case-control studies are needed to enrich the evidence of this result.	[Da, Liang-Shan; Zhang, Cong-Jun; Bu, Li-Jia; Zhu, Yan-Zhe; Ma, Tai; Gu, Kang-sheng] Anhui Med Univ, Dept Med Oncol, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China; [Zhang, Ying] Anhui Med Univ, Dept Ultrasound, Affiliated Prov Hosp, Hefei 230001, Anhui, Peoples R China	Ma, T; Gu, KS (reprint author), Anhui Med Univ, Dept Med Oncol, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China.	matayd@yeah.net; 13805692145@163.com			Anhui Natural Science FoundationNatural Science Foundation of Anhui Province [1408085QH151]; Projects of Foreign Science and Technology Cooperation of Anhui Province [1604b0602027]	This work was supported by Anhui Natural Science Foundation (1408085QH151) and Projects of Foreign Science and Technology Cooperation of Anhui Province (1604b0602027).	Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; de Vooght KMK, 2009, CLIN CHEM, V55, P698, DOI 10.1373/clinchem.2008.120931; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dinesh RK, 2010, AUTOIMMUN REV, V9, P583, DOI 10.1016/j.autrev.2010.04.003; Dong WJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152448; Fidler M. M., 2017, SCAND J PUBLIC HEALT; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gomez GVB, 2018, PIGM CELL MELANOMA R, V31, DOI 10.1111/pcmr.12665; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hua Z, 2011, BREAST CANCER RES TR, V129, P195, DOI 10.1007/s10549-011-1440-3; Huang CH, 2011, RHEUMATOLOGY, V50, P1809, DOI 10.1093/rheumatology/ker211; Inman BA, 2007, CURR CANCER DRUG TAR, V7, P15, DOI 10.2174/156800907780006878; Ishizaki Y, 2010, HUM GENET, V127, P411, DOI 10.1007/s00439-009-0781-z; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kong EKP, 2005, ARTHRITIS RHEUM-US, V52, P1058, DOI 10.1002/art.20966; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Li T., 2016, ASS PD 1 GENE POLYMO; Li Y, 2017, GYNECOL ONCOL, V144, P140, DOI 10.1016/j.ygyno.2016.11.010; Liu Y, 2018, PATHOL RES PRACT, V214, P507, DOI 10.1016/j.prp.2018.03.001; Ma Y, 2015, INT J CLIN EXP MED, V8, P16585; MANTEL N, 1959, J NATL CANCER I, V22, P719; Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Salmaninejad A, 2018, IMMUNOGENETICS, V70, P73, DOI 10.1007/s00251-017-1015-5; Sasaki H, 2014, MOL CLIN ONCOL, V2, P1035, DOI 10.3892/mco.2014.358; Shamsdin Seyedeh Azra, 2018, Asian Pac J Cancer Prev, V19, P693; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tang WF, 2017, ONCOTARGET, V8, P39198, DOI 10.18632/oncotarget.17338; Tang WF, 2015, INT J CLIN EXP MED, V8, P22278; Tang WF, 2015, INT J CLIN EXP MED, V8, P8086; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wei L, 2017, CHIN J WOMAN CHILD H, V28, P1608; Wells G, 2015, NEWCASTLE OTTAWA SCA; Xiao FF, 2017, ONCOTARGET, V8, P48488, DOI 10.18632/oncotarget.17290; Xu YL, 2017, PATHOL RES PRACT, V213, P1152, DOI 10.1016/j.prp.2017.07.003; Zhang J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004423; Zhao YP, 2018, GOV INFORM Q, V35, P1, DOI 10.1016/j.giq.2018.01.002; Zhou RM, 2016, CANCER GENET-NY, V209, P365, DOI 10.1016/j.cancergen.2016.06.006	38	1	1	1	11	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1758	1764		10.1016/j.prp.2018.09.015			7	Pathology	Pathology	HA0MP	WOS:000449902400002	30249505				2019-10-28	
J	Li, YH; Yang, ZW				Li, Yehong; Yang, Zhongwen			Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Prostate adenocarcinoma; Long non-coding RNA; MicroRNA; Regulatory network; Enrichment analysis	GENE-EXPRESSION; CANCER; UCA1; IDENTIFICATION; METASTASIS; CARCINOMA; DIAGNOSIS; DATABASE; CELLS; RISK	Objectives: Prostate adenocarcinoma (PRAD) is the most common cancer in men. The aim of this study was to reveal the critical long non-coding RNA (lncRNAs), microRNA (miRNAs) and mRNAs involved in the pathogenesis of PRAD. Methods: The level 3 mRNA and miRNA sequencing data of PRAD were downloaded from The Cancer Genome Atlas database. Using the edgeR package of R, the differentially expressed mRNAs (DEGs), lncRNAs (DElncRNAs) and miRNAs (DE-miRNAs) between PRAD and normal tissues were screened. The Cox proportional hazards regression method in the survival package was used to select the lncRNAs significantly related to clinical characteristics. After the miRNA-lncRNA and miRNA-mRNA pairs were predicted, a regulatory network was constructed by the Cytoscape software. For the DEGs involved in the network, enrichment analysis was conducted by the Fisher algorithm. Results: Compared to the normal samples, 25 DE-lncRNAs, 1421 DEGs and 68 DE-miRNAs were identified in the PRAD samples. The down-regulated MESTIT1 had a significantly negative correlation with overall survival. A total of 44 DE-miRNA-DE-lncRNA pairs were predicted, including the PCA3-miR-96 and UCAI-miR-96. Meanwhile, 33 DEGs targeted by miRNAs (for example, miR-96-CYP19A1) were found to correlate with cancers. Conclusion: Functional enrichment analysis showed that the reproductive development process (which involved TDRD1) was enriched for the DEGs implicated in the lncRNA-miRNA-mRNA regulatory network. The lncRNAs MESTIT1, PCA3, and UCAI; mRNAs CYP19A1 and TDRDJ; as well as miR-96 might affect the pathogenesis of PRAD.	[Li, Yehong] Jining 1 Peoples Hosp, Dept Spinal Surg, Jining 272011, Shandong, Peoples R China; [Yang, Zhongwen] Jining 1 Peoples Hosp, Dept Urol Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China	Yang, ZW (reprint author), Jining 1 Peoples Hosp, Dept Urol Surg, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.	yangzhongwenzw@163.com					Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Baade PD, 2009, MOL NUTR FOOD RES, V53, P171, DOI 10.1002/mnfr.200700511; Bernard W, 2014, WORLD CANC REPORT 20; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Boormans JL, 2013, INT J CANCER, V133, P335, DOI 10.1002/ijc.28025; Carpenter S, 2014, NAT REV IMMUNOL, V14, P361, DOI 10.1038/nri3682; Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258; Chun FK, 2009, EUR UROL, V56, P659, DOI 10.1016/j.eururo.2009.03.029; Damar IH, 2016, ANATOL J CARDIOL, V16, P616, DOI 10.5152/AnatolJCardiol.2015.6454; Deras IL, 2008, J UROLOGY, V179, P1587, DOI 10.1016/j.juro.2007.11.038; Dobosy J. R., 2005, CANCER RES, V65, P655; Eyre TA, 2006, NUCLEIC ACIDS RES, V34, pD319, DOI 10.1093/nar/gkj147; Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Ge YC, 2003, TEST, V12, P1, DOI 10.1007/BF02595811; Groskopf J, 2006, CLIN CHEM, V52, P1089, DOI 10.1373/clinchem.2005.063289; Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400; Hessels D, 2003, EUR UROL, V44, P8, DOI 10.1016/S0302-2838(03)00201-X; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Huret JL, 2000, NUCLEIC ACIDS RES, V28, P349, DOI 10.1093/nar/28.1.349; Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344; Kacprzyk LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059976; Kanda S, 2015, INT J CANCER, V136, P74, DOI 10.1002/ijc.28952; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Kleinbaum D.G., 2006, SURVIVAL ANAL SELF L; Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Li YF, 2016, MOL MED REP, V13, P3326, DOI 10.3892/mmr.2016.4894; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lumley T., 2004, NEWSLETTER R PROJECT, V4/1, P26; Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396; Na XY, 2015, INT J CLIN EXP MED, V8, P12609; Nam RK, 2003, CANCER EPIDEM BIOMAR, V12, P1429; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sen R, 2014, SCI WORLD J, DOI 10.1155/2014/896206; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Srivastava AK, 2014, TUMOR BIOL, V35, P11435, DOI 10.1007/s13277-014-2474-z; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Yu JJ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0910-y; Zeegers MPA, 2003, CANCER-AM CANCER SOC, V97, P1894, DOI 10.1002/cncr.11262; Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902	44	0	0	1	6	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1811	1817		10.1016/j.prp.2018.08.029			7	Pathology	Pathology	HA0MP	WOS:000449902400009	30195637				2019-10-28	
J	Moghaddam, PA; Singh, R; Mahmoodi, M; Mehrotra, M; Benaim, G; Luthra, R; Paniz-Mondolfi, A				Moghaddam, Parnian Ahmadi; Singh, Rajesh; Mahmoodi, Mandana; Mehrotra, Meenakshi; Benaim, Gustavo; Luthra, Rajyalakshmi; Paniz-Mondolfi, Alberto			Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma: Uncovering its mutational landscape through massive parallel sequencing	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Squamous cell carcinoma; Osteoclast-like giant cells; KRAS; Mutation	ATYPICAL FIBROXANTHOMA; STROMAL CHANGES; RAS ONCOGENE; CARCINOSARCOMA; TUMORS; CANCER; PANCREAS; INSIGHTS; ORIGIN		[Moghaddam, Parnian Ahmadi] Univ Massachusetts, Mem Med Ctr, Dept Pathol, Worcester, MA 01605 USA; [Singh, Rajesh; Mehrotra, Meenakshi; Luthra, Rajyalakshmi] Univ Texas MD Anderson Canc Ctr, Mol Diagnost Lab, Houston, TX 77030 USA; [Mahmoodi, Mandana] Miraca Life Sci Res Inst, Dept Dermatopathol, Boston, MA USA; [Mahmoodi, Mandana] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Benaim, Gustavo; Paniz-Mondolfi, Alberto] Inst Estudios Avanzados IDEA, Lab Senalizac Celular & Bioquim Parasitos, Caracas, Venezuela; [Paniz-Mondolfi, Alberto] Inst Invest Biomed IDB, Cabudare, Venezuela; [Paniz-Mondolfi, Alberto] IVSS, Direcc Salud Docencia & Invest, Merida, Venezuela	Paniz-Mondolfi, A (reprint author), Inst Invest Biomed IDB, Lab Cutaneous Biol, Av Intercomunal Barquisimetocabudare, Cabudare 03023, Venezuela.	apaniz@clinicaidb.com.ve					Al-Brahim N, 2005, AM J DERMATOPATH, V27, P126, DOI 10.1097/00000372-200504000-00007; Aljerian K, 2006, J CLIN PATHOL, V59, P1309, DOI 10.1136/jcp.2005.034991; Aru A, 2001, ACTA OBSTET GYN SCAN, V80, P371, DOI 10.1034/j.1600-0412.2001.080004371.x; Atreya CE, 2015, J CLIN ONCOL, V33, P682, DOI 10.1200/JCO.2014.58.9325; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Beer TW, 2010, AM J DERMATOPATH, V32, P414, DOI 10.1097/DAD.0b013e3181b6bdcb; BOS JL, 1989, CANCER RES, V49, P4682; Boyd AS, 2010, DERMATOPATHOLOGY, P556; Calonje JE, 2012, MCKEES PATHOLOGY SKI, P1076; Chan E., 2014, MY CANC GENOME; Chung HJ, 2016, J CUTAN PATHOL, V43, P148, DOI 10.1111/cup.12607; Emanuel PO, 2007, J CUTAN PATHOL, V34, P930, DOI 10.1111/j.1600-0560.2007.00748.x; Gamsizkan M, 2015, AM J DERMATOPATH, V37, P26, DOI 10.1097/DAD.0000000000000131; Geraud C, 2015, J EUR ACAD DERMATOL, V29, P2056, DOI 10.1111/jdv.12592; Harwood CA, 2016, ACTA DERM-VENEREOL, V96, P3, DOI 10.2340/00015555-2181; Hatano Y, 2014, BIOCHEM BIOPH RES CO, V446, P149, DOI 10.1016/j.bbrc.2014.02.113; Khan ZM, 1997, AM J DERMATOPATH, V19, P174, DOI 10.1097/00000372-199704000-00012; Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005; Mondolfi AEP, 2013, HUM PATHOL, V44, P2853, DOI 10.1016/j.humpath.2013.07.014; Neumann TE, 2009, EUR J HUM GENET, V17, P420, DOI 10.1038/ejhg.2008.188; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Paniz-Mondolfi A, 2015, VIRCHOWS ARCH, V466, P359, DOI 10.1007/s00428-015-1718-7; Paniz-Mondolfi A, 2014, VIRCHOWS ARCH, V465, P339, DOI 10.1007/s00428-014-1628-0; Przygodzki RM, 2001, MOL DIAGN, V6, P109, DOI 10.2165/00066982-200106020-00005; Shishido-Hara Y, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-55; Siiskonen SJ, 2016, CANCER EPIDEM BIOMAR, V25, P714, DOI 10.1158/1055-9965.EPI-15-1070; Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003; To MD, 2013, ONCOGENE, V32, P4028, DOI 10.1038/onc.2012.404; To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211; Wang W, 2018, CANCER IMMUNOL IMMUN, V67, P1123, DOI 10.1007/s00262-018-2168-2; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Weedon D, 2010, WEEDONS SKIN PATHOLO, P667; Westra WH, 1998, AM J SURG PATHOL, V22, P1247, DOI 10.1097/00000478-199810000-00010; Wooff J, 2009, AM J DERMATOPATH, V31, P282, DOI 10.1097/DAD.0b013e31819cf6f4	34	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1898	1903		10.1016/j.prp.2018.08.017			6	Pathology	Pathology	HA0MP	WOS:000449902400020	30146254				2019-10-28	
J	Kim, MS; Jeon, EH; Mo, HY; Yoo, NJ; Lee, SH				Kim, Min Sung; Jeon, Eun Ha; Mo, Ha Yoon; Yoo, Nam Jin; Lee, Sug Hyung			Promoter mutation in long non-coding RNA NEAT1 is not common in common solid cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Letter									[Kim, Min Sung; Jeon, Eun Ha; Mo, Ha Yoon; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea.	suhulee@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2017R1D1A1B03027840]	This study was supported by grants from National Research Foundation of Korea (2017R1D1A1B03027840).	Fang J, 2017, ONCOTARGET, V8, P45918, DOI 10.18632/oncotarget.17439; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Mello SS, 2017, GENE DEV, V31, P1095, DOI 10.1101/gad.284661.116; Rheinbay E, 2017, NATURE, V547, P55, DOI 10.1038/nature22992; Wang ZM, 2017, BIOMED PHARMACOTHER, V94, P612, DOI 10.1016/j.biopha.2017.07.111; Yoo NJ, 2012, HISTOPATHOLOGY, V60, P943, DOI 10.1111/j.1365-2559.2012.04178.x	6	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1912	1913		10.1016/j.prp.2018.07.013			2	Pathology	Pathology	HA0MP	WOS:000449902400023	30097212				2019-10-28	
J	Caswell, JL; Bassel, LL; Rothenburger, JL; Grone, A; Sargeant, JM; Beck, AP; Ekman, S; Gibson-Corley, KN; Kuiken, T; LaDouceur, EEB; Meyerholz, DK; Origgi, FC; Posthaus, H; Priestnall, SL; Ressel, L; Sharkey, L; Teixeira, LBC; Uchida, K; Ward, JM; Webster, JD; Yamate, J				Caswell, Jeff L.; Bassel, Laura L.; Rothenburger, Jamie L.; Grone, Andrea; Sargeant, Jan M.; Beck, Amanda P.; Ekman, Stina; Gibson-Corley, Katherine N.; Kuiken, Thijs; LaDouceur, Elise E. B.; Meyerholz, David K.; Origgi, Francesco C.; Posthaus, Horst; Priestnall, Simon L.; Ressel, Lorenzo; Sharkey, Leslie; Teixeira, Leandro B. C.; Uchida, Kazuyuki; Ward, Jerrold M.; Webster, Joshua D.; Yamate, Jyoji			Observational Study Design in Veterinary Pathology, Part 2: Methodology	VETERINARY PATHOLOGY			English	Editorial Material						histologic grading; immunohistochemistry; epidemiology; method validation; pathology; observational studies; quantitative PCR; reproducibility of results; research design; robustness	MAST-CELL TUMOR; POLYMERASE-CHAIN-REACTION; STROBE-VET STATEMENT; EXPRESSION; DOGS; IMMUNOHISTOCHEMISTRY; IDENTIFICATION; EPIDEMIOLOGY; ANTIBODIES; TISSUE	Observational studies are a basis for much of our knowledge of veterinary pathology, yet considerations for conducting pathology-based observational studies are not readily available. In part 1 of this series, we offered advice on planning and carrying out an observational study. Part 2 of the series focuses on methodology. Our general recommendations are to consider using already-validated methods, published guidelines, data from primary sources, and quantitative analyses. We discuss 3 common methods in pathology research-histopathologic scoring, immunohistochemistry, and polymerase chain reaction-to illustrate principles of method validation. Some aspects of quality control include use of clear objective grading criteria, validation of key reagents, assessing sample quality, determining specificity and sensitivity, use of technical and biologic negative and positive controls, blinding of investigators, approaches to minimizing operator-dependent variation, measuring technical variation, and consistency in analysis of the different study groups. We close by discussing approaches to increasing the rigor of observational studies by corroborating results with complementary methods, using sufficiently large numbers of study subjects, consideration of the data in light of similar published studies, replicating the results in a second study population, and critical analysis of the study findings.	[Caswell, Jeff L.; Bassel, Laura L.] Univ Guelph, Dept Pathobiol, Guelph, ON, Canada; [Rothenburger, Jamie L.] Univ Calgary, Fac Vet Med, Canadian Wildlife Hlth Cooperat Alberta, Dept Ecosyst & Publ Hlth, Calgary, AB, Canada; [Grone, Andrea] Univ Utrecht, Dept Pathobiol, Fac Vet Med, Utrecht, Netherlands; [Sargeant, Jan M.] Univ Guelph, Dept Populat Med, Guelph, ON, Canada; [Sargeant, Jan M.] Univ Guelph, Ctr Publ Hlth & Zoonoses, Guelph, ON, Canada; [Beck, Amanda P.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Ekman, Stina] Swedish Univ Agr Sci, Dept Biomed & Vet Publ Hlth, Uppsala, Sweden; [Gibson-Corley, Katherine N.] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Kuiken, Thijs] Erasmus Univ, Med Ctr, Dept Virosci, Rotterdam, Netherlands; [LaDouceur, Elise E. B.] Joint Pathol Ctr, Silver Spring, MD USA; [Meyerholz, David K.] Univ Iowa, Carver Coll Med, Med Labs 1165, Iowa City, IA USA; [Origgi, Francesco C.] Univ Bern, Vetsuisse Fac, Ctr Fish & Wildlife Hlth, Bern, Switzerland; [Posthaus, Horst] Univ Bern, Vetsuisse Fac, Inst Anim Pathol, Bern, Switzerland; [Priestnall, Simon L.] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England; [Ressel, Lorenzo] Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Liverpool, Merseyside, England; [Sharkey, Leslie] Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA USA; [Teixeira, Leandro B. C.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; [Uchida, Kazuyuki] Univ Tokyo, Dept Vet Pathol, Tokyo, Japan; [Ward, Jerrold M.] GlobalVetPathol, Montgomery Village, AL USA; [Webster, Joshua D.] Genentech Inc, San Francisco, CA 94080 USA; [Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, Izumisano City, Osaka, Japan	Caswell, JL (reprint author), Univ Guelph, Dept Pathobiol, Guelph, ON, Canada.	jcaswell@uoguelph.ca	Meyerholz, David/J-8131-2019; Caswell, Jeff/B-9279-2018	Meyerholz, David/0000-0003-1552-3253; Bassel, Laura/0000-0003-1684-6839; Rothenburger, Jamie/0000-0003-1634-9154; Gibson-Corley, Katherine/0000-0002-1846-1580; Caswell, Jeff/0000-0002-1991-3219	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada [RGPIN-2017-03872]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Some aspects of this work were supported by a grant from the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-03872, J. Caswell).	Avallone G, 2016, VET PATHOL, V53, P773, DOI 10.1177/0300985815626573; Bland SK, 2017, VET PATHOL, V54, P490, DOI 10.1177/0300985817690213; Burrai GP, 2015, TUMOR BIOL, V36, P9083, DOI 10.1007/s13277-015-3661-2; Camus MS, 2016, VET PATHOL, V53, P1117, DOI 10.1177/0300985816638721; Casadevall A, 2016, MBIO, V7, DOI 10.1128/mBio.01902-16; Caswell JL, 2018, VET PATHOL, V55, P607, DOI 10.1177/0300985818785705; Charney VA, 2017, VET PATHOL, V54, P380, DOI 10.1177/0300985816677152; Cianciolo RE, 2016, VET PATHOL, V53, P113, DOI 10.1177/0300985815579996; Cohen JF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012799; Diaz-Delgado J, 2016, VET PATHOL, V53, P1233, DOI 10.1177/0300985816642228; DiVincenzo MJ, 2017, VET PATHOL, V54, P828, DOI 10.1177/0300985817716261; Epperson ED, 2017, VET PATHOL, V54, P44, DOI 10.1177/0300985816653169; Fitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P1432, DOI 10.5858/arpa.2013-0610-CP; Flatland B, 2014, VET CLIN PATH, V43, P475, DOI 10.1111/vcp.12199; Gardner IA, 2011, PREV VET MED, V101, P18, DOI 10.1016/j.prevetmed.2011.04.002; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Goodwin PC, 2018, COMP ANATOMY HISTOLO, P53, DOI [10. 1016/B978-0-12-802900-8. 00004-X ., DOI 10.1016/B978-0-12-802900-8.00004-X]; Guenther S, 2008, J MICROBIOL METH, V75, P75, DOI 10.1016/j.mimet.2008.05.008; Halsey CHC, 2017, VET PATHOL, V54, P387, DOI 10.1177/0300985816688943; Hewitt SM, 2014, J HISTOCHEM CYTOCHEM, V62, P693, DOI 10.1369/0022155414545224; Horta RS, 2018, VET PATHOL, V55, P212, DOI 10.1177/0300985817747325; Janke LJ, 2019, VET PATHOL, V56; Klopfleisch R, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-123; Knoblaugh SE, 2019, VET PATHOL, V56; La Perle KMD, 2019, VET PATHOL, V56; Luff J, 2016, VET PATHOL, V53, P1160, DOI 10.1177/0300985816630795; Maeda S, 2017, VET PATHOL, V54, P595, DOI 10.1177/0300985817705175; Meason-Smith C, 2017, VET PATHOL, V54, P640, DOI 10.1177/0300985817698207; Meuten D, 2018, VET PATHOL, V55, P195, DOI 10.1177/0300985817753869; Meyerholz DK, 2018, LAB INVEST, V98, P844, DOI 10.1038/s41374-018-0057-0; Meyerholz DK, 2018, VET PATHOL, V55, P42, DOI 10.1177/0300985817726117; Meyerholz DK, 2019, VET PATHOL, V56; Mitchell EP, 2017, VET PATHOL, V54, P977, DOI 10.1177/0300985817728556; Munafo MR, 2018, NATURE, V553, P399, DOI 10.1038/d41586-018-01023-3; Nagamine E, 2015, VET PATHOL, V52, P977, DOI 10.1177/0300985815574006; O'Connor AM, 2016, J VET INTERN MED, V30, P1896, DOI 10.1111/jvim.14592; Pesavento P, 2019, VET PATHOL, V56; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Rasotto R, 2017, VET PATHOL, V54, P571, DOI 10.1177/0300985817698208; Ressel L, 2013, RES VET SCI, V94, P299, DOI 10.1016/j.rvsc.2012.09.016; Rijks JM, 2008, VET PATHOL, V45, P516, DOI 10.1354/vp.45-4-516; Rousselet MC, 2005, HEPATOLOGY, V41, P257, DOI 10.1002/hep.20535; Sabattini S, 2015, VET PATHOL, V52, P70, DOI 10.1177/0300985814521638; Sargeant JM, 2016, PREV VET MED, V134, P188, DOI 10.1016/j.prevetmed.2016.09.005; Schafer KA, 2018, TOXICOL PATHOL, V46, P256, DOI 10.1177/0192623318761348; Schjaerff M, 2016, IMMUNOGENETICS, V68, P191, DOI 10.1007/s00251-015-0889-3; Schott CR, 2018, VET PATHOL, V55, P202, DOI 10.1177/0300985817747329; Senthilkumaran C, 2015, VET RES, V46, DOI 10.1186/s13567-014-0134-3; Sierra E, 2017, VET PATHOL, V54, P298, DOI 10.1177/0300985816660747; Stahl M, 2011, VET MICROBIOL, V151, P307, DOI 10.1016/j.vetmic.2011.03.013; Timsit E, 2010, J VET DIAGN INVEST, V22, P238, DOI 10.1177/104063871002200211; Treuting P, 2019, VET PATHOL, V56; Uhlen M, 2016, NAT METHODS, V13, P823, DOI [10.1038/NMETH.3995, 10.1038/nmeth.3995]; Ward JM, 2014, VET PATHOL, V51, P88, DOI 10.1177/0300985813503571; Webster JD, 2011, VET PATHOL, V48, P7, DOI 10.1177/0300985810377187; Weller MG, 2016, ANAL CHEM INSIGHTS, V11, P21, DOI [10.4137/ACI.S31614, 10.4137/ACICI.S31614]	56	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					774	785		10.1177/0300985818798121			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600003	30227783	Green Accepted			2019-10-28	
J	Bolfa, P; Kelly, SJ; Wells, HC; Sizeland, KH; Scott, EM; Kirby, N; Mudie, S; Armien, AG; Haverkamp, RG; Kelly, PJ				Bolfa, Pompei; Kelly, Susyn J.; Wells, Hannah C.; Sizeland, Katie H.; Scott, Erin M.; Kirby, Nigel; Mudie, Stephen; Armien, Anibal G.; Haverkamp, Richard G.; Kelly, Patrick J.			Tropical Keratopathy (Florida Spots) in Cats	VETERINARY PATHOLOGY			English	Article						feline; cornea; corneal opacity; eyes; punctate keratopathy; collagen disorder; Florida spots; ophthalmology	INDIAN PUNCTATE KERATOPATHY; CORNEAL DISEASE; WEST-INDIANS; TRANSPARENCY; SPECIMENS; MEMBRANE	The authors used microscopy and synchrotron-based small-angle X-ray scattering analysis (SAXS) to describe lesions macroscopically typical of tropical keratopathy ("Florida spots") from 6 cats on St Kitts. Microscopically, there were varying degrees of epithelial hyperplasia and thinning of the cornea (by 4% to 18%) due to loss of corneal stroma associated with dense accumulations of collagen in the superficial stroma. The collagen fibrils in lesions were wider and had more variable diameters (39.5 +/- 5.0 nm, mean +/- SD) than in normal corneas (25.9 +/- 3.6 nm; P < .01). There were occasional vacuoles (<1 mu m) in the corneal epithelial basement membrane but no evidence of inflammation, edema, stromal neovascularization, fibrosis, acid-fast organisms, or structures suggestive of a fungal organism. SAXS analysis showed collagen fibril diameters and variation in size were greater in stroma containing the lesions compared to normal corneas (48.8 +/- 4.5 nm vs 35.5 +/- 2.6; P < .05). The d-spacing of collagen in the stroma of lesions and normal corneas was the same, but the average orientation index of collagen in lesions was greater (0.428 +/- 0.08 vs 0.285 +/- 0.03; P < .05). A survey revealed Florida spots lesions were static over time and became less obvious in only 1 of 6 affected cats adopted on St Kitts and taken to areas in the US where lesions are not reported. An anterior stromal collagen disorder with various degrees of epithelial hyperplasia is the pathologic hallmark of lesions clinically identical to Florida spots in cats from St Kitts.	[Bolfa, Pompei] Ross Univ, Dept Biomed Sci, Sch Vet Med, POB 334, Basseterre, St Kitts & Nevi; [Kelly, Susyn J.; Wells, Hannah C.; Haverkamp, Richard G.] Massey Univ, Sch Engn & Adv Technol, Palmerston North, New Zealand; [Sizeland, Katie H.; Kirby, Nigel; Mudie, Stephen] Australian Synchrotron, Clayton, Vic, Australia; [Sizeland, Katie H.] AgResearch, Prot & Biomat, Lincoln, New Zealand; [Scott, Erin M.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, College Stn, TX USA; [Armien, Anibal G.] Univ Minnesota, Ultrastruct Pathol Unit, Vet Diagnost Lab, St Paul, MN 55108 USA; [Kelly, Patrick J.] Ross Univ, Dept Clin Sci, Sch Vet Med, Basseterre, St Kitts & Nevi	Bolfa, P (reprint author), Ross Univ, Dept Biomed Sci, Sch Vet Med, POB 334, Basseterre, St Kitts & Nevi.	pompeibolfa@gmail.com	Haverkamp, Richard/H-1149-2012; Bolfa, Pompei/C-1322-2011; Sizeland, Katie/F-6347-2015	Haverkamp, Richard/0000-0002-3890-7105; Bolfa, Pompei/0000-0002-2903-1535; Scott, Erin/0000-0002-9702-7298; Kelly, Susyn/0000-0002-6151-545X; Sizeland, Katie/0000-0001-8075-1901			[Anonymous], 2009, VET OPHTHALMOL, V12, P61, DOI 10.1111/j.1463-5224.2009.00682.x; Barros PSD, 1977, BRAZ J VET RES ANIM, V34, P276; Cookson D, 2006, J SYNCHROTRON RADIAT, V13, P440, DOI 10.1107/S0909049506030184; Cullen CL, 2005, VET OPHTHALMOL, V8, P295, DOI 10.1111/j.1463-5224.2005.00402.x; DILLON EC, 1992, OPHTHALMIC SURG LAS, V23, P729; Doutch JJ, 2012, BIOPHYS J, V102, P1258, DOI 10.1016/j.bpj.2012.02.023; Dubielzig RR, 2010, VET OCULAR PATHOLOGY; Farrell RA, 2000, PRINCIPLES PRACTICE, P629; Fischer CS, 1987, T 18 ANN SCI PROGR A, P241; Galvis V, 2015, OPEN OPHTHALMOL J, V9, P12, DOI 10.2174/1874364101509010012; Gilger BC, 2007, VET OPHTHALMOLOGY, V2, P690; Ilavsky J, 2009, J APPL CRYSTALLOGR, V42, P347, DOI 10.1107/S0021889809002222; Jester JV, 2008, SEMIN CELL DEV BIOL, V19, P82, DOI 10.1016/j.semcdb.2007.09.015; LEMP M A, 1991, CLAO Journal, V17, P258; MCLENDON BF, 1993, CORNEA, V12, P406, DOI 10.1097/00003226-199309000-00007; Meek KM, 2015, PROG RETIN EYE RES, V49, P1, DOI 10.1016/j.preteyeres.2015.07.001; Michaud B., 2010, Point Veterinaire, V41, P59; Moore PA, 2005, CLIN TECH SMALL AN P, V20, P83, DOI 10.1053/j.ctsap.2004.12.012; Njaa LB, 2012, PATHOLOGIC BASIS VET, P1206; Obata H, 2007, CORNEA, V26, pS82, DOI 10.1097/ICO.0b013e31812f6f1b; PEIFFER RL, 1979, J AM ANIM HOSP ASSOC, V15, P93; RICE NSC, 1968, BRIT J OPHTHALMOL, V52, P865, DOI 10.1136/bjo.52.12.865; Roze M, 2004, REV MED VET-TOULOUSE, V155, P598; Sacks MS, 1997, ANN BIOMED ENG, V25, P678, DOI 10.1007/BF02684845; Theron L., 2007, HYPOTHESE KERATOPATH; Tietze B, 2011, CORNEA, V30, P1270, DOI 10.1097/ICO.0b013e31821b721c; Torricelli AAM, 2013, INVEST OPHTH VIS SCI, V54, P6390, DOI 10.1167/iovs.13-12547; Treuting PM, 2011, COMP ANATOMY HISTOLO; TUCKER G S, 1979, Journal of Cell Biology, V83, p479A; WALLER SG, 1994, CORNEA, V13, P377, DOI 10.1097/00003226-199407000-00019; WEISS JS, 1988, CORNEA, V7, P127	31	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					861	870		10.1177/0300985818789483			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600011	30071782				2019-10-28	
J	Baumgart, JV; Stuhlmann-Laeisz, C; Hegenbart, U; Nattenmuller, J; Schonland, S; Kruger, S; Behrens, HM; Rocken, C				Baumgart, Julius-Valentin; Stuhlmann-Laeisz, Christiane; Hegenbart, Ute; Nattenmueller, Johanna; Schoenland, Stefan; Krueger, Sandra; Behrens, Hans-Michael; Roecken, Christoph			Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management	VIRCHOWS ARCHIV			English	Article						Amyloid; Light chain; Immunoglobulin; Transthyretin	LIGHT-CHAIN AMYLOIDOSIS; IMMUNOHISTOCHEMICAL CLASSIFICATION; NATURAL-HISTORY; EXPERIENCE	Immunoglobulin-derived light-chain (AL) amyloidosis of lungs and bronchi can appear as a systemic and a local form. While systemic AL amyloidosis may need haemato-oncological care, the localised form can be treated restrained. We re-evaluated 207 specimens of lungs and bronchi sent in for amyloid diagnostics. Amyloid was diagnosed by polarization microscopy using Congo red-stained tissue specimens and classified immunohistochemically. Histoanatomical amyloid distribution patterns were documented as well as additional histological findings. For 118 patients with AL amyloidosis, we retrieved clinical data. CT scan results were available from 59 patients. AL amyloidosis was the most common type (183 cases). AL was found in 141 and of AL in 27 cases. Fifteen cases were AL amyloid not otherwise specified. Twenty cases harboured transthyretin and three serum amyloid A derived amyloid. By correlation of histoanatomy, radiological and clinical data, amyloid was rarely in the initial differential diagnosis. Local AL amyloidosis often presented with a nodular pattern on CT scan and showed a significantly better disease-specific 10-year survival compared with systemic AL amyloidosis (96.0 vs. 51.9%). Localised and systemic pulmonary and bronchial AL amyloidosis are having a completely different prognosis. While CT scan might be indicative, histological and clinical assessment are mandatory to reach a proper diagnosis and guide patient care.	[Baumgart, Julius-Valentin; Stuhlmann-Laeisz, Christiane; Krueger, Sandra; Behrens, Hans-Michael; Roecken, Christoph] Univ Kiel, Dept Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany; [Hegenbart, Ute; Nattenmueller, Johanna; Schoenland, Stefan] Heidelberg Univ, Med Dept 5, Amyloidosis Ctr, Heidelberg, Germany; [Nattenmueller, Johanna] Heidelberg Univ, Dept Diagnost & Intervent Radiol, Heidelberg, Germany	Rocken, C (reprint author), Univ Kiel, Dept Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany.	christoph.roecken@uksh.de	Rocken, Christoph/A-9239-2010	Rocken, Christoph/0000-0002-6989-8002			Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289; Chung MJ, 2005, EUR J RADIOL, V54, P233, DOI 10.1016/j.ejrad.2004.07.003; de Almeida RR, 2015, LUNG, V193, P875, DOI 10.1007/s00408-015-9791-x; Dubrey S, 2015, POSTGRAD MED J, V91, P439, DOI 10.1136/postgradmedj-2014-133224; Freudenthaler S, 2016, VIRCHOWS ARCH, V468, P569, DOI 10.1007/s00428-016-1916-y; Gertz MA, 2011, ONCOLOGY-NY, V25, P620; Gillmore JD, 1999, THORAX, V54, P444, DOI 10.1136/thx.54.5.444; Gioeva Z, 2013, AMYLOID, V20, P1, DOI 10.3109/13506129.2012.750604; Hagmeyer Lars, 2012, Pneumologie, V66, P483, DOI 10.1055/s-0032-1309811; Howie AJ, 2009, MICRON, V40, P285, DOI 10.1016/j.micron.2008.10.002; Kebbel A, 2006, AM J SURG PATHOL, V30, P673, DOI 10.1097/00000478-200606000-00002; Kourelis TV, 2017, MAYO CLIN PROC, V92, P908, DOI 10.1016/j.mayocp.2017.02.016; Kristen AV, 2016, J AM COLL CARDIOL, V68, P13, DOI 10.1016/j.jacc.2016.04.035; Kuci H, 2007, HISTOL HISTOPATHOL, V22, P379, DOI 10.14670/HH-22.379; KYLE RA, 1992, BLOOD, V79, P1817; Lang SM, 2015, RESPIR MED CASE REP, V15, P115, DOI 10.1016/j.rmcr.2015.05.004; Magy-Bertrand N, 2008, CLIN EXP RHEUMATOL, V26, P1074; Mahmood S, 2015, LANCET HAEMATOL, V2, pE241, DOI 10.1016/S2352-3026(15)00068-X; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Merlini G, 2011, J CLIN ONCOL, V29, P1924, DOI 10.1200/JCO.2010.32.2271; Milani P, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0046-2017; Ohdama S, 1996, EUR RESPIR J, V9, P1569, DOI 10.1183/09031936.96.09071569; Palladini G, 2016, BLOOD, V128, P159, DOI 10.1182/blood-2016-01-629790; Plante-Bordeneuve V, 2014, J NEUROL, V261, P1227, DOI 10.1007/s00415-014-7373-0; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Renapurkar RD, 2013, INSIGHTS IMAGING, V4, P773, DOI 10.1007/s13244-013-0289-x; Rocken C, 1996, HISTOPATHOLOGY, V29, P325, DOI 10.1111/j.1365-2559.1996.tb01416.x; Rocken C, 2003, VIRCHOWS ARCH, V443, P3, DOI 10.1007/s00428-003-0834-y; Rocken C, 2009, PATHOLOGE, V30, P182, DOI 10.1007/s00292-009-1128-1; Rocken C, 2015, LANCET HAEMATOL, V2, pE225, DOI 10.1016/S2352-3026(15)00071-X; Scala R, 2015, ANN THORAC MED, V10, P212, DOI 10.4103/1817-1737.157290; Schonland SO, 2012, BLOOD, V119, P488, DOI 10.1182/blood-2011-06-358507; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; THOMPSON PJ, 1983, THORAX, V38, P84, DOI 10.1136/thx.38.2.84; Ussavarungsi K, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02313-2016; Utz JP, 1996, ANN INTERN MED, V124, P407, DOI 10.7326/0003-4819-124-4-199602150-00004; Xiang H, 2015, INT J CLIN EXP PATHO, V8, P7482	38	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					627	637		10.1007/s00428-018-2442-x			11	Pathology	Pathology	GY8GR	WOS:000448861800011	30136180	Other Gold			2019-10-28	
J	El Jabbour, T; Durie, N; Lee, H				El Jabbour, Tony; Durie, Nicole; Lee, Hwajeong			Co-expression of CDX2 and CK20 in hepatocellular carcinoma, an exceedingly rare co-incidence with potential diagnostic pitfall	HUMAN PATHOLOGY			English	Letter									[El Jabbour, Tony; Lee, Hwajeong] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA; [Durie, Nicole] Saratoga Hosp Lab, Saratoga Springs, NY 12866 USA	Lee, H (reprint author), Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA.	LeeH5@amc.edu					Bayrak R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-9; Mourra N, 2013, APPL IMMUNOHISTO M M, V21, P94, DOI 10.1097/PAI.0b013e31824c4c4a; Shah SS, 2017, HUM PATHOL, V64, P13, DOI 10.1016/j.humpath.2016.12.029	3	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						298	299		10.1016/j.humpath.2018.04.031			2	Pathology	Pathology	HB5LM	WOS:000451102300035	29953895				2019-10-28	
J	Babaoglu, B; Ercin, ME; Kosemehmetoglu, K				Babaoglu, Berrin; Ercin, Mustafa Emre; Kosemehmetoglu, Kemal			Atypical mitoses are present in otherwise classical pleomorphic lipomas	HUMAN PATHOLOGY			English	Letter							SPINDLE-CELL		[Babaoglu, Berrin; Kosemehmetoglu, Kemal] Hacettepe Univ, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey; [Ercin, Mustafa Emre] Karadeniz Tech Univ, Fac Med, Dept Pathol, Trabzon, Turkey	Kosemehmetoglu, K (reprint author), Hacettepe Univ, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey.	dokemal@hotmail.com					Creytens D, 2018, HUM PATHOL, V74, P188, DOI 10.1016/j.humpath.2017.11.023; Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Michal M, 2018, HUM PATHOL, V74, P189, DOI 10.1016/j.humpath.2017.11.024; Michal M, 2017, HUM PATHOL, V70, P143, DOI 10.1016/j.humpath.2017.06.024; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006	5	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						299	300		10.1016/j.humpath.2018.04.033			2	Pathology	Pathology	HB5LM	WOS:000451102300037	30420050				2019-10-28	
J	Chandan, VS; Shah, SS; Torbenson, MS; Wu, TT				Chandan, Vishal S.; Shah, Sejal S.; Torbenson, Michael S.; Wu, Tsung-Teh			Co-expression of CDX2 and CK20 in hepatocellular carcinoma, an exceedingly rare co-incidence with potential diagnostic pitfall-reply	HUMAN PATHOLOGY			English	Letter									[Chandan, Vishal S.; Shah, Sejal S.; Torbenson, Michael S.; Wu, Tsung-Teh] Mayo Clin, Anat Pathol, Rochester, MN 55905 USA	Chandan, VS (reprint author), Mayo Clin, Anat Pathol, Rochester, MN 55905 USA.	chandan.vishal@mayo.edu					Shah SS, 2017, HUM PATHOL, V64, P13, DOI 10.1016/j.humpath.2016.12.029	1	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						299	299		10.1016/j.humpath.2018.04.030			1	Pathology	Pathology	HB5LM	WOS:000451102300036	29981308				2019-10-28	
J	Creytens, D; Mentzel, T; Ferdinande, L; van Gorp, J; Van Dorpe, J; Flucke, U				Creytens, David; Mentzel, Thomas; Ferdinande, Liesbeth; van Gorp, Joost; Van Dorpe, Jo; Flucke, Uta			Atypical mitoses are present in otherwise classical pleomorphic lipomas-reply	HUMAN PATHOLOGY			English	Letter									[Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Dept Pathol, Ghent Univ Hosp, Ghent, Belgium; [Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, CRIG, Ghent, Belgium; [Mentzel, Thomas] Dermatopathol Bodensee, Friedrichshafen, Germany; [van Gorp, Joost] Diakonessenhuis Utrecht, Dept Pathol, Utrecht, Netherlands; [Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands	Creytens, D (reprint author), Univ Ghent, Dept Pathol, Ghent Univ Hosp, Ghent, Belgium.; Creytens, D (reprint author), Univ Ghent, CRIG, Ghent, Belgium.	creytensdavid@hotmail.com					Creytens D, 2018, HUM PATHOL, V74, P188, DOI 10.1016/j.humpath.2017.11.023; Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Fletcher C, 2013, WHO CLASSIFICATION T; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Michal M, 2017, HUM PATHOL, V70, P143, DOI 10.1016/j.humpath.2017.06.024	5	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2018	81						300	302		10.1016/j.humpath.2018.04.032			3	Pathology	Pathology	HB5LM	WOS:000451102300038	30084357				2019-10-28	
J	Sobczynska-Malefora, A; Harrington, DJ				Sobczynska-Malefora, Agata; Harrington, Dominic J.			Laboratory assessment of folate (vitamin B-9) status	JOURNAL OF CLINICAL PATHOLOGY			English	Article						folate; vitaminB(9); homocysteine; folic acid; diagnosis	NEURAL-TUBE DEFECTS; PLASMA TOTAL HOMOCYSTEINE; UNMETABOLIZED FOLIC-ACID; TANDEM MASS-SPECTROMETRY; SERUM FOLATE; RISK-FACTOR; VASCULAR-DISEASE; DNA METHYLATION; MICROBIOLOGICAL ASSAY; COGNITIVE IMPAIRMENT	Folate (vitamin B-9) plays a crucial role in fundamental cellular processes, including nucleic acid biosynthesis, methyl group biogenesis and amino acid metabolism. The detection and correction of folate deficiency prevents megaloblastic anaemia and reduces the risk of neural tube defects. Coexisting deficiencies of folate and vitamin B-12 are associated with cognitive decline, depression and neuropathy. Folate deficiency and excess has also been implicated in some cancers. Excessive exposure to folic acid, a synthetic compound used in supplements and fortified foods, has also been linked to adverse health effects. Of at least three distinct laboratory markers of folate status, it is the total abundance of folate in serum/plasma that is used by the majority of laboratories. The analysis of folate in red cells is also commonly performed. Since the folate content of red cells is fixed during erythropoiesis, this marker is indicative of folate status over the preceding 4 months. Poor stability, variation in polyglutamate chain length and unreliable extraction from red cells are factors that make the analysis of folate challenging. The clinical use of measuring specific folate species has also been explored. 5-Methyltetrahydrofolate, the main form of folate found in blood, is essential for the vitamin B-12-dependent methionine synthase mediated remethylation of homocysteine to methionine. As such, homocysteine measurement reflects cellular folate and vitamin B-12 use. When interpreting homocysteine results, age, sex and pregnancy, specific reference ranges should be applied. The evaluation of folate status using combined markers of abundance and cellular use has been adopted by some laboratories. In the presence of discordance between laboratory results and strong clinical features of deficiency, treatment should not be delayed. High folate status should be followed up with the assessment of vitamin B-12 status, a review of previous results and reassessment of folic acid supplementation regime.	[Sobczynska-Malefora, Agata; Harrington, Dominic J.] St Thomas Hosp, Nutristasis Unit, Viapath, London, England; [Sobczynska-Malefora, Agata] Kings Coll London, Fac Life Sci & Med, London, England; [Harrington, Dominic J.] Kings Coll London, Sch Med, Div Womens Hlth, London, England	Harrington, DJ (reprint author), St Thomas Hosp NHS Fdn Trust, London SE1 7EH, England.	Dominic.Harrington@viapath.co.uk					Administration UDoHaHSFaD, 1996, FED REGISTER, V61, P8781; [Anonymous], 1968, World Health Organ Tech Rep Ser, V405, P5; [Anonymous], 1972, World Health Organ Tech Rep Ser, V503, P1; Antoniades C, 2006, CIRCULATION, V114, P1193, DOI 10.1161/CIRCULATIONAHA.106.612325; APPLING DR, 1991, FASEB J, V5, P2645; Bailey LB, 2015, J NUTR, V145, P1636, DOI 10.3945/jn.114.206599; Bailey RL, 2012, FOOD NUTR RES, V56, DOI 10.3402/fnr.v56i0.5616; Bednarska-Makaruk M, 2016, EXP GERONTOL, V81, P83, DOI 10.1016/j.exger.2016.05.002; Blackmore S, 2011, CLIN CHEM, V57, P986, DOI 10.1373/clinchem.2010.160135; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Brito A, 2016, AM J CLIN NUTR, V103, P250, DOI 10.3945/ajcn.115.116509; Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5; Chanarin I, 1980, VITAMINS MED, P247; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; Clement NF, 2009, LABMEDICINE, V40, P657, DOI 10.1309/LMWD82YZ7QZPSNQP; Control of nutritional anaemia with special reference to iron deficiency, 1975, WHO TECH REP SER, P5; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Da Silva L, 2016, BIOANALYSIS, V8, P1937, DOI 10.4155/bio-2016-0112; DAVIS RE, 1970, J CLIN PATHOL, V23, P47, DOI 10.1136/jcp.23.1.47; De Wals P, 2007, NEW ENGL J MED, V357, P135, DOI 10.1056/NEJMoa067103; Dwarkanath P, 2013, AM J CLIN NUTR, V98, P1450, DOI 10.3945/ajcn.112.056382; European Food Safety Authority Scientific Committee on Food, 2000, TOL UPP INT LEV VIT; Farrell CJL, 2013, CLIN CHEM LAB MED, V51, P555, DOI 10.1515/cclm-2012-0639; Fazili Z, 2004, CLIN CHEM, V50, P2378, DOI 10.1373/clinchem.2004.036541; Fazili Z, 2013, ANAL BIOANAL CHEM, V405, P4549, DOI 10.1007/s00216-013-6854-9; Finglas PM, 2003, P NUTR SOC, V62, P591, DOI 10.1079/PNS2003271; Food and Nutrition Board Institute of Medicine, 1998, DIET REF INT THIAM R; Fu XW, 2013, JIMD REP, V10, P69, DOI 10.1007/8904_2012_205; Gordon N, 2009, DEV MED CHILD NEUROL, V51, P180, DOI 10.1111/j.1469-8749.2008.03185.x; GROSSOWICZ N, 1981, CLIN CHEM, V27, P745; Hannisdal R, 2009, J NUTR, V139, P1415, DOI 10.3945/jn.109.105635; Hansen FJ, 2005, MOL GENET METAB, V84, P371, DOI 10.1016/j.ymgme.2004.12.001; Harrington DJ, 2016, DACIE LEWIS PRACTICA, P187; Harrington DJ, 2017, J CLIN PATHOL, V70, P168, DOI 10.1136/jclinpath-2015-203502; HORNE DW, 1988, CLIN CHEM, V34, P2357; Hvas AM, 2001, CLIN CHEM, V47, P1396; Jacob RA, 1998, J NUTR, V128, P1204; Kelly P, 1997, AM J CLIN NUTR, V65, P1790; La'ulu SL, 2008, AM J CLIN PATHOL, V130, P969, DOI 10.1309/AJCP64BJIPNPSQDJ; LAMBIE DG, 1985, DRUGS, V30, P145, DOI 10.2165/00003495-198530020-00003; LEEMING RJ, 1990, METABOLISM, V39, P902, DOI 10.1016/0026-0495(90)90298-Q; Lewerin C, 2003, EUR J CLIN NUTR, V57, P1426, DOI 10.1038/sj.ejcn.1601707; Mason JB, 2003, J NUTR, V133, p941S, DOI 10.1093/jn/133.3.941S; McCully KS, 2007, AM J CLIN NUTR, V86, p1563S; McNulty H, 2008, P NUTR SOC, V67, P232, DOI 10.1017/S0029665108007076; McNulty H, 2008, BRIT J NUTR, V99, pS48, DOI 10.1017/S0007114508006855; Miller JW, 2009, AM J CLIN NUTR, V90, P1586, DOI 10.3945/ajcn.2009.27514; Mills JL, 2011, AM J CLIN NUTR, V94, P495, DOI 10.3945/ajcn.111.014621; Morris MS, 2010, AM J CLIN NUTR, V91, P1733, DOI 10.3945/ajcn.2009.28671; National Academy of Sciences, 1998, DIET REF INT FOL OTH; NEWMAN EM, 1986, ANAL BIOCHEM, V154, P509, DOI 10.1016/0003-2697(86)90023-0; Nexo E, 2000, CLIN CHEM, V46, P1150; Nurk E, 2001, J NUTR, V131, P1214; Obeid R, 2017, ADV NUTR, V8, P971, DOI 10.3945/an.117.015628; Paniz C, 2017, J NUTR, V147, P1684, DOI 10.3945/jn.117.247445; Patel KR, 2017, EUR J CLIN NUTR, V71, P159, DOI 10.1038/ejcn.2016.194; Perez-Duenas B, 2011, ARCH NEUROL-CHICAGO, V68, P615, DOI 10.1001/archneurol.2011.80; Pfeiffer CM, 2007, AM J CLIN NUTR, V86, P718; Pfeiffer CM, 2015, BRIT J NUTR, V113, P1965, DOI 10.1017/S0007114515001142; Pfeiffer CM, 2004, CLIN CHEM, V50, P423, DOI 10.1373/clinchem.2003.026955; Quadri P, 2004, AM J CLIN NUTR, V80, P114; Quere I, 2002, LANCET, V359, P747, DOI 10.1016/S0140-6736(02)07876-5; Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998; Rasmussen K, 1996, CLIN CHEM, V42, P630; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; Refsum H, 2006, J NUTR, V136, p1731S, DOI 10.1093/jn/136.6.1731S; Reynolds EH, 2016, EUR J CLIN NUTR, V70, P537, DOI 10.1038/ejcn.2015.231; Rossi E, 1999, ANN CLIN BIOCHEM, V36, P56, DOI 10.1177/000456329903600107; Sauer J, 2009, CURR OPIN CLIN NUTR, V12, P30, DOI 10.1097/MCO.0b013e32831cec62; Sawaengsri H, 2016, AM J CLIN NUTR, V104, P1665, DOI 10.3945/ajcn.116.139030; SCOTT JM, 1994, CIBA F SYMP, V181, P180; Scott J, 1994, ESSAYS BIOCHEM, V28, P63; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Selhub J, 2008, FOOD NUTR BULL, V29, pS67, DOI 10.1177/15648265080292S110; Selhub J, 2016, BIOCHIMIE, V126, P71, DOI 10.1016/j.biochi.2016.04.010; Selhub J, 2009, AM J CLIN NUTR, V89, p702S, DOI 10.3945/ajcn.2008.26947C; Shane B, 2011, AM J CLIN NUTR, V94, DOI 10.3945/ajcn.111.013367; Shmeleva VM, 2003, THROMB RES, V111, P351, DOI 10.1016/j.thromres.2003.10.004; Smith AD, 2016, ANNU REV NUTR, V36, P211, DOI 10.1146/annurev-nutr-071715-050947; Smulders YM, 2007, J NUTR BIOCHEM, V18, P693, DOI 10.1016/j.jnutbio.2006.11.010; Sobczyn'ska-Malefora A, 2015, J HEMATOL THROMB, V1, P8; Sobczynska-Malefora A, 2015, 10 INT C CARB MET VI, V68, P29; Sobczynska-Malefora A, 2018, FOLIC ACID VITAMIN B; Sobczynska-Malefora A, 2016, ANN CLIN BIOCHEM, V531, P94; Sobczynska-Malefora Agata, 2014, Adv Hematol, V2014, P465623, DOI 10.1155/2014/465623; Sweeney MR, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-295; UELAND PM, 1993, CLIN CHEM, V39, P1764; UK NEQAS Haematinics, 2008, REP REF RANG DAT COL; Verhaar MC, 2002, ARTERIOSCL THROM VAS, V22, P6, DOI 10.1161/hq0102.102190; WALD N, 1991, LANCET, V338, P131; WHO, 2015, WHONMHNHDEPG1501; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Yetley EA, 2011, BIOFACTORS, V37, P285, DOI 10.1002/biof.176; Yetley EA, 2011, AM J CLIN NUTR, V94, p313S, DOI 10.3945/ajcn.111.013243	96	3	3	4	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					949	956		10.1136/jclinpath-2018-205048			8	Pathology	Pathology	HB4BT	WOS:000450998000001	30228213				2019-10-28	
J	Lui, GYL; Grandori, C; Kemp, CJ				Lui, Goldie Y. L.; Grandori, Carla; Kemp, Christopher J.			CDK12: an emerging therapeutic target for cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						cancer genetics; cell biology; C-MYC oncogene; breast cancer; ovarian cancer	RNA-POLYMERASE-II; DNA-DAMAGE RESPONSE; C-TERMINAL DOMAIN; SYNTHETIC LETHALITY; MESSENGER-RNA; KINASE; EXPRESSION; PHOSPHORYLATION; MUTATIONS; COMPLEX	Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases that regulate transcriptional and post-transcriptional processes, thereby modulating multiple cellular functions. Early studies characterised CDK12 as a transcriptional CDK that complexes with cyclin K to mediate gene transcription by phosphorylating RNA polymerase II. CDK12 has been demonstrated to specifically upregulate the expression of genes involved in response to DNA damage, stress and heat shock. More recent studies have implicated CDK12 in regulating mRNA splicing, 3' end processing, pre-replication complex assembly and genomic stability during embryonic development. Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal and pancreatic cancers, ranging from 5% to 15% of sequenced cases. An increasing number of studies point to CDK12 inhibition as an effective strategy to inhibit tumour growth, and synthetic lethal interactions have been described with MYC, EWS/FLI and PARP/CHK1 inhibition. Herein, we discuss the present literature on CDK12 in cell function and human cancer, highlighting important roles for CDK12 as a clinical biomarker for treatment response and potential as an effective therapeutic target.	[Lui, Goldie Y. L.; Kemp, Christopher J.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Grandori, Carla] SEngine Precis Med, Seattle, WA USA	Lui, GYL (reprint author), Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.	glui@fredhutch.org	Lui, Goldie/J-7874-2019	Lui, Goldie/0000-0003-2741-6025	NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA217883, U54 CA132381]; Ovarian Cancer Research Fund Alliance	GYLL is funded by the Ovarian Cancer Research Fund Alliance. CJK is funded by grants from the NIH/NCI (U01 CA217883, U54 CA132381).	Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bajrami I, 2014, CANCER RES, V74, P287, DOI 10.1158/0008-5472.CAN-13-2541; Bartkowiak B, 2015, J BIOL CHEM, V290, P1786, DOI 10.1074/jbc.M114.612226; Bartkowiak B, 2010, GENE DEV, V24, P2303, DOI 10.1101/gad.1968210; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Biswas R, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a001263; Blazek D, 2011, GENE DEV, V25, P2158, DOI 10.1101/gad.16962311; Bosken CA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4505; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Cermelli S, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014209; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Chen HR, 2017, CEREB CORTEX, V27, P2289, DOI 10.1093/cercor/bhw081; Chen HR, 2014, EXP NEUROL, V261, P10, DOI 10.1016/j.expneurol.2014.06.024; Chen HH, 2007, BIOCHEM BIOPH RES CO, V354, P735, DOI 10.1016/j.bbrc.2007.01.049; Cheng SWG, 2012, MOL CELL BIOL, V32, P4691, DOI 10.1128/MCB.06267-11; Dai Q, 2012, J BIOL CHEM, V287, P25344, DOI 10.1074/jbc.M111.321760; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Davidson L, 2014, GENE DEV, V28, P342, DOI 10.1101/gad.231274.113; Delehouze C, 2014, ONCOGENE, V33, P5675, DOI 10.1038/onc.2013.513; Dixon-Clarke SE, 2015, SCI REP-UK, V5, DOI 10.1038/srep17122; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Ekumi KM, 2015, NUCLEIC ACIDS RES, V43, P2575, DOI 10.1093/nar/gkv101; Even Y, 2006, J CELL BIOCHEM, V99, P890, DOI 10.1002/jcb.20986; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Galganski L, 2017, NUCLEIC ACIDS RES, V45, P10350, DOI 10.1093/nar/gkx759; Geyer JT, 2015, HUM PATHOL, V46, P260, DOI 10.1016/j.humpath.2014.10.021; Greifenberg AK, 2016, CELL REP, V14, P320, DOI 10.1016/j.celrep.2015.12.025; Iniguez AB, 2018, CANCER CELL, V33, P202, DOI 10.1016/j.ccell.2017.12.009; Johannes JW, 2018, CHEMMEDCHEM, V13, P231, DOI 10.1002/cmdc.201700695; Johnson SF, 2016, CELL REP, V17, P2367, DOI 10.1016/j.celrep.2016.10.077; Joshi PM, 2014, J BIOL CHEM, V289, P9247, DOI 10.1074/jbc.M114.551143; Juan HC, 2016, CELL DEATH DIFFER, V23, P1038, DOI 10.1038/cdd.2015.157; Kauraniemi P, 2006, ENDOCR-RELAT CANCER, V13, P39, DOI 10.1677/erc.1.01147; Ko TK, 2001, J CELL SCI, V114, P2591; Lei TJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04258-w; Li X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21455; Liang K, 2015, MOL CELL BIOL, V35, P928, DOI 10.1128/MCB.01426-14; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Marques F, 2000, BIOCHEM BIOPH RES CO, V279, P832, DOI 10.1006/bbrc.2000.4042; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayer BJ, 2001, J CELL SCI, V114, P1253; Naidoo K, 2018, MOL CANCER THER, V17, P306, DOI 10.1158/1535-7163.MCT-17-0760; Natrajan R, 2014, J PATHOL, V232, P553, DOI 10.1002/path.4325; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Paculova H, 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317727479; Popova T, 2016, CANCER RES, V76, P1882, DOI 10.1158/0008-5472.CAN-15-2128; Riches JC, 2015, J CLIN ONCOL S, V33; Robinson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005951; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shepard PJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-242; Subbiah Ishwaria M, 2017, Oncoscience, V4, P47, DOI 10.18632/oncoscience.352; Tien JF, 2017, NUCLEIC ACIDS RES, V45, P6698, DOI 10.1093/nar/gkx187; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749; Zhang K, 2016, J CANCER RES THER, V12, pC186, DOI 10.4103/0973-1482.200597; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166	61	3	4	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					957	962		10.1136/jclinpath-2018-205356			6	Pathology	Pathology	HB4BT	WOS:000450998000002	30104286	Bronze			2019-10-28	
J	Rajkovic, MG; Popovic-Grle, S; Dugac, AV; Rogic, D; Rako, I; Antolic, MR; Berisa, M; Rumora, L				Rajkovic, Marija Grdic; Popovic-Grle, Sanja; Dugac, Andrea Vukic; Rogic, Dunja; Rako, Ivana; Antolic, Margareta Radic; Berisa, Mirela; Rumora, Lada			PON1 gene polymorphisms in patients with chronic obstructive pulmonary disease	JOURNAL OF CLINICAL PATHOLOGY			English	Article						chronic obstructive pulmonary disease; paraoxonase 1; polymorphisms; Q192R; L55M; -108C > T	PARAOXONASE 1 ACTIVITY; OXIDATIVE STRESS; SERUM CONCENTRATIONS; Q192R POLYMORPHISM; MOLECULAR-BASIS; LUNG-FUNCTION; ASSOCIATION; COPD; L55M; ARYLESTERASE	Aims Chronic obstructive pulmonary disease (COPD) is characterised with oxidative stress. Paraoxonase 1 (PON1) is an enzyme, coded by PON1 gene, with distinctive antiatherogenic and antioxidative roles. We aimed to investigate the frequencies of Q192R, L55M and -108C>T polymorphisms and association of those polymorphisms with paraoxonase and arylesterase activities in patients with COPD. MethodsPON1 genotype was determined by PCR-restriction fragment length polymorphism method. PON1 activity was measured by paraoxon and phenylacetate. Results Only -108C>T polymorphism resulted in significantly different distribution of genotypes and alleles, with higher frequency of TT genotype and T allele in patients compared with control subjects. Moreover, T allele (OR 2.29 (95% CI 1.54 to 3.41); p<0.001) as well as TT genotype (OR 5.00 (95% CI 2.19 to 11.43); p<0.001) showed an association with the disease. -108C>T polymorphism was suggested as a significant diagnostic predictor for the disease (OR (95%CI) 2.65 (1.53 to 4.59), p=0.001), with an area under the receiver operating characteristic curve of 0.90 (95% CI 0.84 to 0.93) and with 83.90% of correctly classified cases. Conclusions Higher frequency of TT genotype and T allele could contribute to the observed reduction of PON1 activity in patients with COPD. T allele and TT genotype are associated with COPD, and the PON1-108C>T polymorphism could be a potential predictor of the disease.	[Rajkovic, Marija Grdic; Rogic, Dunja; Berisa, Mirela; Rumora, Lada] Univ Zagreb, Fac Pharm & Biochem, Dept Med Biochem & Hematol, HR-10000 Zagreb, Croatia; [Popovic-Grle, Sanja; Dugac, Andrea Vukic] Univ Hosp Ctr Zagreb, Clin Dept Lung Dis Jordanovac, Zagreb, Croatia; [Popovic-Grle, Sanja; Dugac, Andrea Vukic] Univ Zagreb, Sch Med, Zagreb, Croatia; [Rako, Ivana; Antolic, Margareta Radic; Berisa, Mirela] Univ Hosp Ctr Zagreb, Clin Inst Lab Diagnost, Zagreb, Croatia	Rumora, L (reprint author), Univ Zagreb, Fac Pharm & Biochem, Dept Med Biochem & Hematol, HR-10000 Zagreb, Croatia.	lrumora@pharma.hr			Croatian Science Foundation [IP-2014-09-1247]	This work has been fully supported by the Croatian Science Foundation under the project number IP-2014-09-1247.	ADKINS S, 1993, AM J HUM GENET, V52, P598; [Anonymous], 2008, PARAOXONASE THEIR RO, P3; Bacchetti T, 2019, SEMIN CANCER BIOL, V56, P72, DOI 10.1016/j.semcancer.2017.11.013; Brophy VH, 2000, PHARMACOGENETICS, V10, P453, DOI 10.1097/00008571-200007000-00008; Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600; Brophy VH, 2001, PHARMACOGENETICS, V11, P77, DOI 10.1097/00008571-200102000-00009; Browne RO, 2006, FASEB J, V20, P1733, DOI 10.1096/fj.05-5576fje; Campo S, 2004, EXP GERONTOL, V39, P1089, DOI 10.1016/j.exger.2004.03.017; Chen H, 2018, HERZ, V43, P642, DOI 10.1007/s00059-017-4611-0; Cheraghi M, 2017, REP BIOCHEM MOL BIOL, V6, P1; Costa LG, 2005, BIOCHEM PHARMACOL, V69, P541, DOI 10.1016/j.bcp.2004.08.027; Crow JA, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2967; Deakin SP, 2004, CLIN SCI, V107, P435, DOI 10.1042/CS20040187; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Durrington PN, 2002, ARTERIOSCL THROM VAS, V22, P1248, DOI 10.1161/01.ATV.0000027414.34728.1F; ECKERSON HW, 1983, AM J HUM GENET, V35, P1126; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2018, GLOBAL STRATEGY DIAG; Gungoren F, 2018, ACTA CARDIOL, V73, P85, DOI 10.1080/00015385.2017.1351237; Gurbuz S, 2015, WORLD J EMERG MED, V6, P201, DOI 10.5847/wjem.j.1920-8642.2015.03.007; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; Isik B, 2005, SAUDI MED J, V26, P1882; Isik B, 2005, TURK RESP J, V6, P19; Isik B, 2007, INHAL TOXICOL, V19, P767, DOI 10.1080/08958370701401418; Jarvik GP, 2003, PHARMACOGENETICS, V13, P291, DOI 10.1097/00008571-200305000-00009; Lamprecht B, 2011, CHEST, V139, P752, DOI 10.1378/chest.10-1253; Landers JE, 2008, AMYOTROPH LATERAL SC, V9, P306, DOI 10.1080/17482960802233177; Leviev I, 2000, ARTERIOSCL THROM VAS, V20, P516, DOI 10.1161/01.ATV.20.2.516; Leviev I, 1997, ARTERIOSCL THROM VAS, V17, P2935, DOI 10.1161/01.ATV.17.11.2935; Lioudaki S., 2017, CURRENT VASCULAR PHA, V20, P323; Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582; Marciniak SJ, 2009, THORAX, V64, P359, DOI 10.1136/thx.2008.099408; Matokanovic M, 2012, CLIN BIOCHEM, V45, P770, DOI 10.1016/j.clinbiochem.2012.04.003; Mouhamed Dhouha Haj, 2012, Environmental Health and Preventive Medicine, V17, P316, DOI 10.1007/s12199-011-0256-4; Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeraddbiomed; Rajkovic MG, 2011, CLIN BIOCHEM, V44, P964, DOI 10.1016/j.clinbiochem.2011.05.012; Rajkovic MG, 2011, BIOCHEM MEDICA, V21, P122; Rajkovic MG, 2010, CLIN BIOCHEM, V43, P1375, DOI 10.1016/j.clinbiochem.2010.08.024; Rodrigo L, 2001, CHEM-BIOL INTERACT, V137, P123, DOI 10.1016/S0009-2797(01)00225-3; Rumora L, 2014, COPD, V11, P539, DOI 10.3109/15412555.2014.898028; Sarioglu N, 2015, IRAN J ALLERGY ASTHM, V14, P60; Seo T, 2008, ANN EPIDEMIOL, V18, P330, DOI 10.1016/j.annepidem.2007.10.002; Sozmen EY, 2008, PROTEINS CELL REGUL, V6, P61, DOI 10.1007/978-1-4020-6561-3_4; Stanojkovic I, 2011, RESP MED, V105, pS31, DOI 10.1016/S0954-6111(11)70008-7; Suehiro T, 2000, ATHEROSCLEROSIS, V150, P295, DOI 10.1016/S0021-9150(99)00379-2; Takayuki S, 2007, PHARMACOGENOMICS, V8, P901, DOI 10.2217/14622416.8.8.901; Tekes S, 2010, BIOTECHNOL BIOTEC EQ, V24, P1644, DOI 10.2478/V10133-010-0019-1; Wang MS, 2011, ATHEROSCLEROSIS, V214, P377, DOI 10.1016/j.atherosclerosis.2010.11.028; Wheeler JG, 2004, LANCET, V363, P689, DOI 10.1016/S0140-6736(04)15642-0	49	0	0	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					963	970		10.1136/jclinpath-2018-205194			8	Pathology	Pathology	HB4BT	WOS:000450998000003	29858231				2019-10-28	
J	Butnor, KJ; Rueckert, J; Pavlisko, EN; Sporn, TA; Roggli, VL				Butnor, Kelly J.; Rueckert, Justin; Pavlisko, Elizabeth N.; Sporn, Thomas A.; Roggli, Victor L.			Malignant peritoneal mesothelioma in patients with endometriosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						malignant tumours; pelvic inflammatory; cancer	DIFFERENTIATED PAPILLARY MESOTHELIOMA; MULTICYSTIC MESOTHELIOMA; ASBESTOS; PATHOGENESIS; MANAGEMENT; EXPOSURE	Aims Florid mesothelial hyperplasia is known to result from endometriosis. Well-differentiated papillary mesothelioma and multiloculated peritoneal inclusion cysts have also been described in women with endometriosis. To our knowledge, peritoneal diffuse malignant mesothelioma (MM) arising in the setting of endometriosis has not been reported. The purpose of this study is to report the clinicopathological characteristics of women with MM and endometriosis. Methods The surgical pathology files of a tertiary academic medical centre and the consultation files of one of the study authors were reviewed for cases of MM in females with and without endometriosis. Results Six women with MM and endometriosis ranging in age from 29 to 55 years (median=45 years) were identified. All had peritoneal MM and endometriosis involving the peritoneum and/or adnexa. Five had epithelioid MM and one had biphasic MM. Two had paraoccupational exposure to asbestos. The median age of women with MM and endometriosis (44.5 years) was significantly less than the median age of cases without endometriosis (58.0 years) (p value=0.01). Conclusions To our knowledge, this is the first report of MM in women with endometriosis. Interestingly, MM in the setting of endometriosis has only been observed in the peritoneum and not in other serosal cavities. The findings in the present study suggest that chronic serosal inflammation secondary to endometriosis may be an inducing factor in rare cases of MM of the peritoneum.	[Butnor, Kelly J.; Rueckert, Justin] Univ Vermont, Med Ctr, Dept Pathol & Lab Med, Burlington, VT 05401 USA; [Pavlisko, Elizabeth N.; Sporn, Thomas A.; Roggli, Victor L.] Duke Univ Hlth Syst, Dept Pathol, Durham, NC USA	Butnor, KJ (reprint author), Univ Vermont, Med Ctr, Dept Pathol & Lab Med, Burlington, VT 05401 USA.	kelly.butnor@vtmednet.org					BARIS I, 1979, REV FR MAL RESPIR, V7, P687; Baris Y I, 1979, Ann N Y Acad Sci, V330, P423, DOI 10.1111/j.1749-6632.1979.tb18744.x; BRENNER J, 1982, CANCER, V49, P2431, DOI 10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W; Butnor KJ, 2017, J CLIN PATHOL, V70, P228, DOI 10.1136/jclinpath-2016-203945; CHAHINIAN AP, 1982, ANN INTERN MED, V96, P746, DOI 10.7326/0003-4819-96-6-746; de Ridder GG, 2016, ULTRASTRUCT PATHOL, V40, P134, DOI 10.3109/01913123.2016.1170085; Gentiloni N, 1997, J CLIN GASTROENTEROL, V24, P276, DOI 10.1097/00004836-199706000-00023; GROISMAN GM, 1992, ACTA OBSTET GYN SCAN, V71, P642, DOI 10.3109/00016349209006236; Han SJ, 2015, CELL, V163, P960, DOI 10.1016/j.cell.2015.10.034; HILLERDAL G, 1985, CANCER, V55, P1968, DOI 10.1002/1097-0142(19850501)55:9<1968::AID-CNCR2820550923>3.0.CO;2-9; HUTER O, 1991, GEBURTSH FRAUENHEILK, V51, P856, DOI 10.1055/s-2008-1026225; KERNER H, 1981, HISTOPATHOLOGY, V5, P277, DOI 10.1111/j.1365-2559.1981.tb01786.x; Kodama Y, 2008, BIOSCI TRENDS, V2, P250; Kraynie A, 2016, ULTRASTRUCT PATHOL, V40, P142, DOI 10.3109/01913123.2016.1154633; Kurisu Y, 2011, INT J GYNECOL PATHOL, V30, P163, DOI 10.1097/PGP.0b013e3181f99def; Malpica A, 2012, AM J SURG PATHOL, V36, P117, DOI 10.1097/PAS.0b013e3182354a79; MANGAL R, 1995, FERTIL STERIL, V63, P196, DOI 10.1016/S0015-0282(16)57319-1; Moen MH, 1997, ACTA OBSTET GYN SCAN, V76, P559, DOI 10.3109/00016349709024584; Morassutto C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154227; Mossman BT, 2013, AM J PATHOL, V182, P1065, DOI 10.1016/j.ajpath.2012.12.028; Nezhat FR, 2010, J MINIM INVAS GYN, V17, P646, DOI 10.1016/j.jmig.2010.03.025; Oparka R, 2011, J CLIN PATHOL, V64, P313, DOI 10.1136/jcp.2010.086074; RIDDELL RH, 1981, CANCER, V48, P134, DOI 10.1002/1097-0142(19810701)48:1<134::AID-CNCR2820480124>3.0.CO;2-4; Roggli V L, 1997, Anat Pathol, V2, P147; Roggli VL, 2002, ULTRASTRUCT PATHOL, V26, P55, DOI 10.1080/01913120252959227; ROGGLI VL, 1982, CANCER, V50, P2423, DOI 10.1002/1097-0142(19821201)50:11<2423::AID-CNCR2820501130>3.0.CO;2-I; Roggli VL, 1989, MICROPROBE ANAL MED, P97; SPIRTAS R, 1994, OCCUP ENVIRON MED, V51, P804, DOI 10.1136/oem.51.12.804; Travis WD, 2015, WHO CLASSIFICATION O; Wang YH, 2004, INT J ONCOL, V25, P173; Zotalis G, 1998, INT J GYNECOL PATHOL, V17, P178, DOI 10.1097/00004347-199804000-00015	31	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					971	974		10.1136/jclinpath-2018-205099			4	Pathology	Pathology	HB4BT	WOS:000450998000004	29794065				2019-10-28	
J	Alvarez-Larran, A; Martinez, D; Arenillas, L; Rubio, A; Arellano-Rodrigo, E; Boluda, JCH; Papaleo, N; Caballero, G; Martinez, C; Ferrer-Marin, F; Mata, MI; Perez-Encinas, M; Duran, MA; Alonso, JM; Carreno-Tarragona, G; Alonso, JM; Noya, S; Magro, E; Perez, R; Lopez-Guerra, M; Pastor-Galan, I; Cervantes, F; Besses, C; Colomo, L; Rozman, M				Alvarez-Larran, Alberto; Martinez, Daniel; Arenillas, Leonor; Rubio, Ariadna; Arellano-Rodrigo, Eduardo; Hernandez Boluda, Juan Carlos; Papaleo, Natalia; Caballero, Gonzalo; Martinez, Clara; Ferrer-Marin, Francisca; Isabel Mata, Maria; Perez-Encinas, Manuel; Antonia Duran, Maria; Maria Alonso, Jose; Carreno-Tarragona, Gonzalo; Manuel Alonso, Juan; Noya, Soledad; Magro, Elena; Perez, Raul; Lopez-Guerra, Monica; Pastor-Galan, Irene; Cervantes, Francisco; Besses, Carlos; Colomo, Luis; Rozman, Maria			Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes	JOURNAL OF CLINICAL PATHOLOGY			English	Article						essential thrombocythemia; diagnostic hematology; histopathology; genetics; myeloproliferative neoplasms	MYELOPROLIFERATIVE NEOPLASMS; MARROW FIBROSIS; JAK2; CALRETICULIN; MYELOFIBROSIS; PROGRESSION; DISORDERS; PHENOTYPE	Aim To characterise the clinical and histological features of MPL-mutated essential thrombocythaemia (ET). Patients and methods Bone marrow biopsies of 175 patients with ET were centrally reviewed according to the 2016 WHO classification, including 42 cases with MPL mutation, 98 JAK2V617F-mutated and 35 CALR-mutated. Clinical and histological features were compared among the three genotypes included in the current 2016 WHO classification and among the different types of MPL mutations. Results Patients with MPL-mutated ET were significantly older than those with the other genotypes. Haematological values at diagnosis were similar among MPL-mutated and CALR-mutated ET, with both genotypes showing higher platelet counts and lower haemoglobin values than ET with JAK2V617F genotype. In the bone marrow, the median number of megakaryocytes was higher in MPL and CALR than in JAK2V617F genotype (16, 19 and 14 megakaryocytes per x20 power field, respectively, p=0.004). Histological features of prefibrotic myelofibrosis were rarely observed in MPL genotype, whereas sinusoidal hyperplasia, dense clusters of megakaryocytes and reticulin fibrosis were more frequent in CALR-mutated ET, with 11% of such cases fulfilling WHO 2016 histological criteria of prefibrotic myelofibrosis. With a median follow-up of 3.5 years, no significant differences were seen among genotypes regarding survival, vascular complications or myelofibrotic transformation. There were no significant differences in the clinical data or in the histological characteristics depending on the type of MPL mutation. ConclusionMPL and CALR ET genotypes share clinical and histological characteristics. In contrast to CALR genotype, features of prefibrotic myelofibrosis are uncommon in MPL-mutated ET.	[Alvarez-Larran, Alberto; Cervantes, Francisco] Hosp Clin Barcelona, IDIBAPS, Hematol Dept, Barcelona, Spain; [Martinez, Daniel; Lopez-Guerra, Monica; Rozman, Maria] Hosp Clin Barcelona, IDIBAPS, Pathol Dept, Barcelona, Spain; [Arenillas, Leonor; Papaleo, Natalia; Colomo, Luis] Univ Autonoma Barcelona, Hosp Mar, Pathol Dept, IMIM, Barcelona, Spain; [Rubio, Ariadna; Besses, Carlos] Univ Autonoma Barcelona, Hosp Mar, IMIM, Hematol Dept, Barcelona, Spain; [Arellano-Rodrigo, Eduardo] Hosp Clin Barcelona, IDIBAPS, Hemotherapy & Hemostasis Dept, Barcelona, Spain; [Hernandez Boluda, Juan Carlos; Pastor-Galan, Irene] Hosp Clin, INCLIVA, Hematol Dept, Valencia, Spain; [Caballero, Gonzalo] Hosp Miguel Servet, Dept Hematol, Zaragoza, Spain; [Martinez, Clara] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain; [Ferrer-Marin, Francisca] UCAM, Hosp Morales Messeguer, Hematol & Med Oncol, CIBERER, Murcia, Spain; [Isabel Mata, Maria] Hosp Costa del Sol, Dept Hematol, Marbella, Spain; [Perez-Encinas, Manuel] Hosp Clin, Dept Hematol, Santiago De Compostela, Spain; [Antonia Duran, Maria] Hosp Son Espases, Dept Hematol, Palma De Mallorca, Spain; [Maria Alonso, Jose] Hosp Palencia, Dept Hematol, Palencia, Spain; [Carreno-Tarragona, Gonzalo] Hosp 12 Octubre, Dept Hematol, Madrid, Spain; [Manuel Alonso, Juan] Fdn Jimenez Diaz, Dept Hematol, Madrid, Spain; [Noya, Soledad] Complexo Hosp, Dept Hematol, La Coruna, Spain; [Magro, Elena] Hosp Principe de Asturias, Dept Hematol, Alcala De Henares, Spain; [Perez, Raul] Hosp Virgen Arrixaca, Dept Hematol, Murcia, Spain	Alvarez-Larran, A (reprint author), Hosp Clin Barcelona, Dept Hematol, Barcelona 08034, Spain.	aalvar@clinic.ub.es	Colomo, Luis/B-1057-2019; Arellano-Rodrigo, Eduardo/R-7079-2019	Colomo, Luis/0000-0001-5236-5085; Arellano-Rodrigo, Eduardo/0000-0001-6236-7826; Carreno-Tarragona, Gonzalo/0000-0002-9570-5542	Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI13/00557, PI13/0636, PI1300393, RD12/0036/0010]	This work was supported by grants from the Instituto de Salud Carlos III (PI13/00557, PI13/0636, PI1300393 and RD12/0036/0010).	Al Assaf C, 2015, HAEMATOLOGICA, V100, P893, DOI 10.3324/haematol.2014.118299; Alvarez-Larran A, 2017, BRIT J HAEMATOL, V178, P764, DOI 10.1111/bjh.14762; Alvarez-Larran A, 2014, BRIT J HAEMATOL, V166, P911, DOI 10.1111/bjh.12990; Angona A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.75; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beer PA, 2008, BLOOD, V112, P141, DOI 10.1182/blood-2008-01-131664; Cabagnols X, 2016, BLOOD, V127, P333, DOI 10.1182/blood-2015-07-661983; Feenstra JDM, 2016, BLOOD, V127, P325, DOI 10.1182/blood-2015-07-661835; Gianelli U, 2012, MODERN PATHOL, V25, P1193, DOI 10.1038/modpathol.2012.87; Guglielmelli P, 2007, BRIT J HAEMATOL, V137, P244, DOI 10.1111/j.1365-2141.2007.06565.x; Haider M, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.98; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Li J, 2018, BLOOD, V131, P649, DOI 10.1182/blood-2017-09-806356; Ma WL, 2011, DIAGN MOL PATHOL, V20, P34, DOI 10.1097/PDM.0b013e3181ecd261; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Rotunno G, 2014, BLOOD, V123, P1552, DOI 10.1182/blood-2013-11-538983; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Rumi E, 2013, BLOOD, V121, P4388, DOI 10.1182/blood-2013-02-486050; Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136; Vannucchi AM, 2008, BLOOD, V112, P844, DOI 10.1182/blood-2008-01-135897	23	2	2	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					975	980		10.1136/jclinpath-2018-205227			6	Pathology	Pathology	HB4BT	WOS:000450998000005	29934356				2019-10-28	
J	van Zummeren, M; Leeman, A; Kremer, WW; Bleeker, MCG; Jenkins, D; van de Sandt, M; Heideman, DAM; Steenbergen, R; Snijders, PJF; Quint, WGV; Berkhof, J; Meijer, CJLM				van Zummeren, Marjolein; Leeman, Annemiek; Kremer, Wieke W.; Bleeker, Maaike C. G.; Jenkins, David; van de Sandt, Miekel; Heideman, Danielle A. M.; Steenbergen, Renske; Snijders, Peter J. F.; Quint, Wim G. V.; Berkhof, Johannes; Meijer, Chris J. L. M.			Three-tiered score for Ki-67 and p16(ink4a) improves accuracy and reproducibility of grading CIN lesions	JOURNAL OF CLINICAL PATHOLOGY			English	Article						cervical cancer; immunohistochemistry; HPV; Ki 67; diagnosis	CERVICAL INTRAEPITHELIAL NEOPLASIA; LOCAL IMMUNE-RESPONSE; EPITHELIAL BIOMARKERS; NATURAL-HISTORY; HPV; MARKER; REGRESSION; STRATIFICATION; TERMINOLOGY; HISTOLOGY	Aims To investigate the accuracy and reproducibility of a scoring system for cervical intraepithelial neoplasia (CIN1-3) based on immunohistochemical (IHC) biomarkers Ki-67 and p16(ink4a). Methods 115 cervical tissue specimens were reviewed by three expert gynaecopathologists and graded according to three strategies: (1) CIN grade based on H&E staining only; (2) immunoscore based on the cumulative score of Ki-67 and p16(ink4a) only (0-6); and (3) CIN grade based on H&E supported by non-objectified IHC 2weeks after scoring 1 and 2. The majority consensus diagnosis of the CIN grade based on H&E supported by IHC was used as the Reference Standard. The proportion of test positives (accuracy) and the absolute agreements across pathologists (reproducibility) of the three grading strategies within each Reference Standard category were calculated. Results We found that immunoscoring with positivity definition 6 yielded the highest proportion of test positives for Reference Standard CIN3 (95.5%), in combination with the lowest proportion of test positives in samples with CIN1 (1.8%). The proportion of test positives for CIN3 was significantly lower for sole H&E staining (81.8%) or combined H&E and IHC grading (84.8%) with positivity definition CIN3. Immunoscore 6 also yielded high absolute agreements for CIN3 and CIN1, but the absolute agreement was low for CIN2. Conclusions The higher accuracy and reproducibility of the immunoscore opens the possibility of a more standardised and reproducible definition of CIN grade than conventional pathology practice, allowing a more accurate comparison of CIN-based management strategies and evaluation of new biomarkers to improve the understanding of progression of precancer from human papillomavirus infection to cancer.	[van Zummeren, Marjolein; Kremer, Wieke W.; Bleeker, Maaike C. G.; Heideman, Danielle A. M.; Steenbergen, Renske; Snijders, Peter J. F.; Meijer, Chris J. L. M.] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Pathol, Amsterdam, Netherlands; [Leeman, Annemiek; Jenkins, David; van de Sandt, Miekel; Quint, Wim G. V.] DDL Diagnost Lab, Rijswijk, Netherlands; [Berkhof, Johannes] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Meijer, CJLM (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands.	cjlm.meijer@vumc.nl		Steenbergen, Renske/0000-0002-2327-9839			[Anonymous], 2013, WHO GUIDELINES FOR S; Baak JPA, 2006, J CLIN PATHOL, V59, P1017, DOI 10.1136/jcp.2005.027839; Bergeron C, 2015, INT J CANCER, V136, P2741, DOI 10.1002/ijc.28900; Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Bierkens M, 2013, INT J CANCER, V133, P1293, DOI 10.1002/ijc.28138; Bulten J, 1996, J PATHOL, V178, P268; Castle PE, 2007, AM J CLIN PATHOL, V127, P805, DOI 10.1309/PT3PNC1QL2F4D2VL; Castle PE, 2009, OBSTET GYNECOL, V113, P18, DOI 10.1097/AOG.0b013e31818f5008; Conesa-Zamora P, 2009, J CLIN PATHOL, V62, P159, DOI 10.1136/jcp.2008.061408; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634; Doorbar J, 2007, DIS MARKERS, V23, P297, DOI 10.1155/2007/613150; Dray M, 2005, PATHOLOGY, V37, P112, DOI 10.1080/00313020500058607; Federation of biomedical scientific societies, 2011, HUM TISS MED RES COD; Griffin H, 2015, MODERN PATHOL, V28, P977, DOI 10.1038/modpathol.2015.52; Heatley MK, 2002, HISTOPATHOLOGY, V40, P377, DOI 10.1046/j.1365-2559.2002.01365.x; Herrington CS, 2015, CYTOPATHOLOGY, V26, P346, DOI 10.1111/cyt.12307; Horn LC, 2008, AM J SURG PATHOL, V32, P502, DOI 10.1097/PAS.0b013e31815ac420; Koeneman MM, 2015, EXPERT REV MOL DIAGN, V15, P527, DOI 10.1586/14737159.2015.1012068; Korzeniewski N, 2011, CANCER LETT, V305, P113, DOI 10.1016/j.canlet.2010.10.013; Kruse AJ, 2001, J PATHOL, V193, P48; Kurman RJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P1, DOI 10.1007/978-1-4419-0489-8; Kyrgiou M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6192; Martin CM, 2011, BEST PRACT RES CL OB, V25, P605, DOI 10.1016/j.bpobgyn.2011.04.005; Mills AM, 2015, AM J SURG PATHOL, V39, P611, DOI 10.1097/PAS.0000000000000374; Munk AC, 2012, GYNECOL ONCOL, V127, P489, DOI 10.1016/j.ygyno.2012.09.010; Natl Guidel, 2004, CERVICAL INTRAEPITHE; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Ovestad IT, 2011, J CLIN PATHOL, V64, P303, DOI 10.1136/jcp.2010.083626; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Trimble CL, 2005, CLIN CANCER RES, V11, P4717, DOI 10.1158/1078-0432.CCR-04-2599; van Baars R, 2015, AM J SURG PATHOL, V39, P1518, DOI 10.1097/PAS.0000000000000498; van Zummeren M, 2018, MODERN PATHOL, V31, P1842, DOI 10.1038/s41379-018-0101-z; von Karsa L, 2015, PAPILLOMAVIRUS RES, V1, P22, DOI 10.1016/j.pvr.2015.06.006	34	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					981	988		10.1136/jclinpath-2018-205271			8	Pathology	Pathology	HB4BT	WOS:000450998000006	30012698	Other Gold, Green Published			2019-10-28	
J	Richman, SD; Fairley, J; Hall, JA; Nataraj, N; Bhide, M; Lau, A; Norman, KL; Deans, ZC				Richman, Susan D.; Fairley, Jennifer; Hall, Jacqueline A.; Nataraj, Nakul; Bhide, Mrudul; Lau, Aron; Norman, Kara L.; Deans, Zandra C.			Results of the UK NEQAS for Molecular Genetics reference sample analysis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						EQA; colorectal cancer; lung cancer; melanoma	CELL LUNG-CANCER; GASTROINTESTINAL STROMAL TUMORS; METASTATIC COLORECTAL-CANCER; EXTERNAL QUALITY ASSESSMENT; PHASE-III; 1ST-LINE TREATMENT; MUTATIONS; PANITUMUMAB; GEFITINIB; FLUOROURACIL	Aims In addition to providing external quality assessment (EQA) schemes, United Kingdom National External Quality Assessment service (UK NEQAS) for Molecular Genetics also supports the education of laboratories. As an enhancement to the Molecular Pathology EQA scheme, a human cell-line reference sample, manufactured by Thermo Fisher Scientific (AcroMetrix), was provided for analysis. This contained many variants, present at frequencies between 1% and 17.9%. Methods One hundred and one laboratories submitted results, with a total of 2889 test results on 53 genes being reported. Known polymorphisms, 46/2889 (1.59%) results, were excluded. Variants detected in the seven most commonly reported (and clinically relevant) genes, KRAS, NRAS, BRAF, EGFR, PIK3CA, KIT and PDGFRA, are reported here, as these genes fall within the scope of UK NEQAS EQA schemes. Results Next generation sequencing (NGS) was the most commonly performed testing platform. There were between 5 and 27 validated variants in the seven genes reported here. Eight laboratories correctly reported all five NRAS variants, and two correctly reported all eight BRAF variants. The validated mean variant frequency was lower than that determined by participating laboratories, with single-gene testing methodologies showing less variation in estimated frequencies than NGS platforms. Laboratories were more likely to correctly identify clinically relevant variants. Conclusions Over 100 laboratories took the opportunity to test the educational reference sample', showing a willingness to further validate their testing platforms. While it was encouraging to see that the most widely reported variants were those which should be included in routine testing panels, reporting of variants was potentially open to interpretation, thus clarity is still required on whether laboratories selectively reported variants, by either clinical relevance or variant frequency.	[Richman, Susan D.] St James Univ Hosp, Leeds Inst Canc & Pathol, Dept Pathol & Tumour Biol, Leeds, W Yorkshire, England; [Fairley, Jennifer; Hall, Jacqueline A.; Deans, Zandra C.] Royal Infirm, Dept Lab Med, UK NEQAS Mol Genet, Edinburgh EH16 4SA, Midlothian, Scotland; [Nataraj, Nakul; Bhide, Mrudul; Lau, Aron; Norman, Kara L.] Thermo Fisher Sci, Fremont, CA USA	Deans, ZC (reprint author), Royal Infirm, Dept Lab Med, UK NEQAS Mol Genet, Edinburgh EH16 4SA, Midlothian, Scotland.	Sandi.Deans@ed.ac.uk		Richman, Susan/0000-0003-3993-5041; Nataraj, Nakul/0000-0002-6772-8288	Medical Research Council (MRC)Medical Research Council UK (MRC); Yorkshire Cancer Research (YCR); UK NEQAS for Molecular Genetics	SDR was funded by Medical Research Council (MRC) and Yorkshire Cancer Research (YCR). ZCD and JF were funded by UK NEQAS for Molecular Genetics.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Deans ZC, 2014, J CLIN PATHOL, V67, P120, DOI 10.1136/jclinpath-2013-201848; Deans ZC, 2013, J CLIN PATHOL, V66, P319, DOI 10.1136/jclinpath-2012-201227; Deans ZC, 2011, GENET TEST MOL BIOMA, V15, P777, DOI 10.1089/gtmb.2010.0239; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Haller F, 2007, AM J SURG PATHOL, V31, P933, DOI 10.1097/01.pas.0000213440.78407.27; Lasota J, 2008, HISTOPATHOLOGY, V53, P245, DOI 10.1111/j.1365-2559.2008.02977.x; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Richman SD, 2017, VIRCHOWS ARCH, V471, P721, DOI 10.1007/s00428-017-2162-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wong NACS, 2012, J CLIN PATHOL, V65, P786, DOI 10.1136/jclinpath-2012-200851; Wong NACS, 2011, HISTOPATHOLOGY, V59, P807, DOI 10.1111/j.1365-2559.2011.03812.x	19	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					989	994		10.1136/jclinpath-2018-205277			6	Pathology	Pathology	HB4BT	WOS:000450998000007	30030291	Green Published, Other Gold			2019-10-28	
J	Peck, M; Moffat, D; Latham, B; Badrick, T				Peck, Martyn; Moffat, David; Latham, Bruce; Badrick, Tony			Review of diagnostic error in anatomical pathology and the role and value of second opinions in error prevention	JOURNAL OF CLINICAL PATHOLOGY			English	Review						diagnostic error; diagnostic imprecision; interpretative error; diagnostic accuracy; quality assurance; second opinion; anatomical pathology; case review	SURGICAL PATHOLOGY; IMPACT; HEAD; QUALITY	Aims Diagnostic/interpretative accuracy can be challenging in anatomical pathology due to the subjective element of the diagnostic process. This can lead to false-negative or false-positive diagnoses of malignancy, variations in grading and diagnostic misclassification of a condition. It is imperative that an accurate diagnosis is achieved so that an appropriate and timely treatment is administered to the patient, for example, the success of targeted molecular therapeutic options for treatment of cancer is dependent on accurate anatomical pathology diagnoses being issued. Methods A literature review of diagnostic accuracy in selected specimen categories was undertaken and was compared with data on metropolitan and regional pathologist diagnostic proficiency performance in an external quality assurance programme from surveys provided 2015-2017. For each specimen category, cases having attracted a diagnostic inaccuracy (ie, major discordance) of 20%and cases attracting a combined error rate (ie, major and minor discordance) of 30% are reviewed and discussed. Results The rate of inaccurate diagnoses (assessed as a major discordance) ranged from 3% to 9% among the different specimen groups, with highest mean percentage of inaccurate diagnoses in gynaecology, dermatopathology and gastrointestinal specimens. Conclusions It was possible to ascertain that gynaecology, dermatopathology and gastrointestinal specimens had presented the greatest diagnostic challenge to the participant pathologists, determined as highest rate of diagnostic inaccuracy, that is, major discordance with respective case target diagnoses. Through a combination of routine second opinions, directed retrospective peer review and participation in appropriate external quality assurance schemes, the risk associated with these diagnoses can be minimised.	[Peck, Martyn; Badrick, Tony] RCPA Qual Assurance Programs, Sydney, NSW, Australia; [Moffat, David] Flinders Med Ctr, Adelaide, SA, Australia; [Latham, Bruce] Fiona Stanley Hosp, Perth, WA 6150, Australia	Badrick, T (reprint author), Fiona Stanley Hosp, Perth, WA 6150, Australia.	Tony.Badrick@rcpaqap.com.au	Badrick, Tony/AAC-1610-2019				ABT AB, 1995, ARCH PATHOL LAB MED, V119, P514; Allen TC, 2013, ARCH PATHOL LAB MED, V137, P310, DOI 10.5858/arpa.2012-0512-ED; Bozzo P, 1991, IMPLEMENTING QUALITY; Epstein JI, 1996, AM J SURG PATHOL, V20, P851, DOI 10.1097/00000478-199607000-00008; Frable WJ, 2006, ARCH PATHOL LAB MED, V130, P620; Kang HP, 2009, AM J CLIN PATHOL, V132, P521, DOI 10.1309/AJCPQZXR1NMF2VDX; Kronz Joseph D, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P81, DOI 10.1097/01.moo.0000156162.20789.66; Mullin MH, 2015, OR SURG OR MED OR PA, V119, P656, DOI 10.1016/j.oooo.2014.12.020; Nakhleh RE, 2016, ARCH PATHOL LAB MED, V140, P29, DOI 10.5858/arpa.2014-0511-SA; Nakhleh RE, 2010, ARCH PATHOL LAB MED, V134, P740, DOI 10.1043/1543-2165-134.5.740; Priebe MT M, 2016, J MOL BIOMARK DIAGN, V7, DOI DOI 10.4172/2155-9929.1000297; Raab SS, 2005, CANCER, V104, P2205, DOI 10.1002/cncr.21431; Raab SS, 2008, CLIN LAB MED, V28, P245, DOI 10.1016/j.cll.2007.12.004; Reason J, 2000, BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Smith ML, 2012, ADV ANAT PATHOL, V19, P331, DOI 10.1097/PAP.0b013e31826661b7; The Royal College of Pathologists of Australasia, PROV 2 OP PART REF M; Troxel DB, 2006, ARCH PATHOL LAB MED, V130, P617; Tsung JSH, 2004, AM J SURG PATHOL, V28, P399, DOI 10.1097/00000478-200403000-00015; Valenstein P, 2005, QUALITY MANAGEMENT C; Westra WH, 2002, HEAD NECK-J SCI SPEC, V24, P684, DOI 10.1002/hed.10105; Woolgar J, 2014, EUR ARCH OTO-RHINO-L, V271, P847, DOI 10.1007/s00405-014-2879-8; Zarbo RJ, 2005, ARCH PATHOL LAB MED, V129, P1237	22	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					995	1000		10.1136/jclinpath-2018-205226			6	Pathology	Pathology	HB4BT	WOS:000450998000008	30068638				2019-10-28	
J	Moore, DA; Balbi, K; Ingham, A; Arkenau, HT; Bennett, P				Moore, David Allan; Balbi, Kevin; Ingham, Alexander; Arkenau, Hendrik-Tobias; Bennett, Philip			Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice	JOURNAL OF CLINICAL PATHOLOGY			English	Article						diagnostics; cancer genetics; lung cancer; molecular pathology	TYROSINE KINASE INHIBITORS; MUTATION ANALYSIS; EGFR; ADENOCARCINOMA; VALIDATION; GEFITINIB	Aims Targeted next-generation sequencing (tNGS) is increasingly being adopted as an alternative to single gene testing in some centres. Our aim was to assess the overall fitness and utility of tNGS as a routine clinical test in non-small cell lung cancer (NSCLC). Methods All NSCLC cases submitted to a single laboratory for tNGS analysis over a 3-year period were included. Rejection/failure rates and turnaround times were calculated. For reportable cases, data relating to observed genetic changes likely to be driving tumour growth and/or contributing to therapeutic resistance were extracted. The impact of varied referral site practices (tissue processing and sample format submitted) on analytical outcomes was also considered. Results A total of 2796 cases were submitted, of which 217 (7.8%) were rejected and 131 (5.1%) failed. The median turnaround time was seven working days. Of 2448 reported cases, KRAS, EGFR or other recognised driver mutations were observed in 35%, 17% and 5.4%, respectively. Of the remaining cases, 3.5% demonstrated significant incidental evidence of gene amplification. In 15% of EGFR-driven cases, evidence of an EGFR tyrosine kinase inhibitor resistance mechanism was observed. Potential concerns around the provision of slides or precut rolls' only (cf, formalin fixed paraffin embedded (FFPE) tissue blocks) as standard practice by certain referral sites were identified. Conclusions A tNGS panel approach is practically achievable, with acceptable success rates and turnaround times, in the context of a routine clinical service. Furthermore, it provides additional clinically and analytically relevant information, which is not available from single gene testing alone.	[Moore, David Allan; Balbi, Kevin; Ingham, Alexander; Bennett, Philip] Sarah Cannon Mol Diagnost, London WC1E 6JSA, England; [Moore, David Allan] UCL, Dept Pathol, Canc Inst, London, England; [Arkenau, Hendrik-Tobias] Sarah Cannon Res Inst UK, London, England	Moore, DA (reprint author), Sarah Cannon Mol Diagnost, London WC1E 6JSA, England.	d.moore@ucl.ac.uk					Chabon JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11815; De Pas T, 2011, J THORAC ONCOL, V6, P1895, DOI 10.1097/JTO.0b013e318227e8c6; Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Hiley CT, 2016, LANCET, V388, P1002, DOI 10.1016/S0140-6736(16)31340-X; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lindeman NI, 2018, J THORAC ONCOL, V13, P323, DOI 10.1016/j.jtho.2017.12.001; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; National Institute for Clinical Excellence, 2013, EGFR TK MUT TEST AD; National Institute for Clinical Excellence, 2017, CET PAN PREV UNTR ME; National Institute for Clinical Excellence, 2015, VEM TREAT LOC ADV ME; Ohashi K, 2017, CLIN LUNG CANCER, V18, P92, DOI 10.1016/j.cllc.2016.06.014; Pirker Robert, 2010, J Thorac Oncol, V5, P1706, DOI 10.1097/JTO.0b013e3181f1c8de; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Querings S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019601; Sholl LM, 2015, J THORAC ONCOL, V10, P768, DOI 10.1097/JTO.0000000000000516; Siu LL, 2015, CLIN CANCER RES, V21, P4536, DOI 10.1158/1078-0432.CCR-14-3215; Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352; Takano T, 2008, J CLIN ONCOL, V26, P5589, DOI 10.1200/JCO.2008.16.7254; Tuononen K, 2013, GENE CHROMOSOME CANC, V52, P503, DOI 10.1002/gcc.22047; Walsh K, 2014, J CLIN PATHOL, V67, P734, DOI 10.1136/jclinpath-2014-202313; Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	25	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1001	1006		10.1136/jclinpath-2018-205319			6	Pathology	Pathology	HB4BT	WOS:000450998000009	30054375				2019-10-28	
J	Liu, M; Tsang, JYS; Lee, M; Ni, YB; Chan, SK; Cheung, SY; Hu, JT; Hu, H; Tse, GMK				Liu, Ming; Tsang, Julia Y. S.; Lee, Michelle; Ni, Yun-Bi; Chan, Siu-Ki; Cheung, Sai-Yin; Hu, Jintao; Hu, Hong; Tse, Gary M. K.			CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast cancer; immunohistochemistry; histopathology	SIGNALING PATHWAY; RNA INTERFERENCE; GROWTH-FACTOR; EMMPRIN; HYALURONAN; BASAL; CHEMORESISTANCE; INDUCER; CELLS; CD44	Aims In breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes. Methods In this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets. Its relationship with patients' survival was also analysed. Results CD147 was expressed in 11.9%(140/1174) of all cases and in 23.8% (40/168) of TNBC. The expression was associated with tumour histological subtypes (p=0.01) and most commonly seen in carcinoma with medullary features (26.0%). CD147 expression correlated with high tumour grade, presence of necrosis and basal-like breast cancer (BLBC) subtype, high Ki67 and expression of some other basal markers and stem-like markers. CD147 expression was also associated with poor overall survival in chemotherapy treated patients with TNBC. Conclusions CD147 is a putative marker in identifying TNBC or BLBC, and may be useful as a prognosis indicator for patients with TNBC or BLBC post chemotherapy.	[Liu, Ming] Xin Jiang Med Univ, Affiliated Hosp 1, Dept Pathol, Urumqi, Peoples R China; [Tsang, Julia Y. S.; Lee, Michelle; Ni, Yun-Bi; Tse, Gary M. K.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Chan, Siu-Ki] Kwong Wah Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Cheung, Sai-Yin] Tuen Mun Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Hu, Jintao] Shenzhen Peoples Hosp, Dept Pathol, Shenzhen, Peoples R China; [Hu, Hong] Shenzhen Peoples Hosp, Dept Breast Surg, Shenzhen, Peoples R China	Tse, GMK (reprint author), Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	garytse@cuhk.edu.hk					Dai L, 2013, AM J PATHOL, V182, P577, DOI 10.1016/j.ajpath.2012.10.011; Grass GD, 2014, ADV CANCER RES, V123, P351, DOI 10.1016/B978-0-12-800092-2.00013-7; Grass GD, 2013, J BIOL CHEM, V288, P26089, DOI 10.1074/jbc.M113.497685; Kang MJ, 2013, PROTEOMICS, V13, P1714, DOI 10.1002/pmic.201200511; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145; Kuang YH, 2009, CANCER LETT, V276, P189, DOI 10.1016/j.canlet.2008.11.010; Lakhani SREI, 2012, WHO CLASSIFICATION T; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liu FF, 2010, BREAST CANCER RES TR, V124, P677, DOI 10.1007/s10549-010-0790-6; Liu Y, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0366-x; Liu YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep28329; Marieb EA, 2004, CANCER RES, V64, P1229, DOI 10.1158/0008-5472.CAN-03-2832; Ni YB, 2014, ANN SURG ONCOL, V21, P2928, DOI 10.1245/s10434-014-3691-9; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Pinheiro C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1842-4; Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x; Qin Z, 2011, LEUKEMIA, V25, P1598, DOI 10.1038/leu.2011.144; Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916; Reimers N, 2004, CLIN CANCER RES, V10, P3422, DOI 10.1158/1078-0432.CCR-03-0610; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Slomiany MG, 2009, CLIN CANCER RES, V15, P7593, DOI 10.1158/1078-0432.CCR-09-2317; Slomiany MG, 2009, CANCER RES, V69, P1293, DOI 10.1158/0008-5472.CAN-08-2491; Sun JX, 2001, CANCER RES, V61, P2276; Suzuki S, 2004, EXP CELL RES, V293, P259, DOI 10.1016/j.yexcr.2003.10.010; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Toole BP, 2008, DRUG RESIST UPDATE, V11, P110, DOI 10.1016/j.drup.2008.04.002; Tsang JYS, 2013, HUM PATHOL, V44, P2782, DOI 10.1016/j.humpath.2013.07.029; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Xiong LJ, 2016, ONCOTARGET, V7, P57737, DOI 10.18632/oncotarget.10252; Yang J, 2016, CANCER BIOMARK, V17, P237, DOI 10.3233/CBM-160636; Zeng HZ, 2011, NEOPLASMA, V58, P449, DOI 10.4149/neo_2011_05_449; Zhao S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0335-4; Zhou SY, 2013, CANCER LETT, V337, P285, DOI 10.1016/j.canlet.2013.04.025	34	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1007	1014		10.1136/jclinpath-2018-205342			8	Pathology	Pathology	HB4BT	WOS:000450998000010	30099407				2019-10-28	
J	Riva, N; Vella, K; Hickey, K; Bertu, L; Zammit, D; Spiteri, S; Kitchen, S; Makris, M; Ageno, W; Gatt, A				Riva, Nicoletta; Vella, Kevin; Hickey, Kieron; Bertu, Lorenza; Zammit, Daniel; Spiteri, Silvana; Kitchen, Steve; Makris, Michael; Ageno, Walter; Gatt, Alex			Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin	JOURNAL OF CLINICAL PATHOLOGY			English	Article						biomarkers; diagnosis; venous thromboembolism	PULMONARY-EMBOLISM; MICROPARTICLES; UTILITY; COHORT	Background The diagnostic algorithm for venous thromboembolism (VTE) currently involves a composite of pre-test probability, D-dimer and imaging. Other laboratory tests, however, may assist in the identification of patients with VTE. Aim To assess the accuracy of different coagulation tests (D-dimer, thrombin generation, phospholipid-dependent (PPL) clotting time, soluble P-selectin (sP-selectin)) as biomarkers of acute VTE. Methods Random samples arriving at the Coagulation Laboratory at Mater Dei Hospital (Msida, Malta) from the Accident and Emergency Department with a request for D-dimer measurement were collected between August 2015 and February 2016. The following tests were performed: Innovance D-dimer (Siemens Healthcare Diagnostics), HemosIL D-dimer HS (Instrumentation Laboratory), thrombin generation (using the calibrated automated thrombogram), STA Procoag PPL (Diagnostica Stago) and sP-selectin (Affymetrix; eBioscience). VTE was objectively confirmed by compression ultrasonography, CT pulmonary angiography or ventilation/perfusion lung scan. Results 100 samples were collected (33 with VTE). A strong positive linear correlation was found between the two D-dimer tests (r=0.97, p<0.001). Patients with VTE showed significantly higher sP-selectin concentrations compared with patients without VTE (75.7 ng/mL vs 53.0 ng/mL, p<0.001). In the random forest plot, the two D-dimer assays showed the highest variable importance, followed by sP-selectin. A sP-selectin cut-off of 74.8 ng/mL was associated with 72.7% sensitivity and 78.2% specificity for acute VTE in our cohort. Conclusion Our results confirmed D-dimer as the main biomarker of VTE and speculated a role for sP-selectin. The impact of thrombin generation was limited and no role emerged for the PPL clotting time. These observations need to be confirmed in large management studies.	[Riva, Nicoletta; Gatt, Alex] Univ Malta, Fac Med & Surg, Dept Pathol, MSD-2080 Msida, Malta; [Vella, Kevin; Zammit, Daniel; Spiteri, Silvana; Gatt, Alex] Mater Dei Hosp, Dept Pathol, Coagulat Med Lab, Msida, Malta; [Hickey, Kieron; Kitchen, Steve; Makris, Michael] Univ Sheffield, Sheffield Haemophilia & Thrombosis Ctr, Sheffield, S Yorkshire, England; [Bertu, Lorenza; Ageno, Walter] Univ Insubria, Dept Med & Surg, Varese, Italy	Gatt, A (reprint author), Univ Malta, Fac Med & Surg, Dept Pathol, MSD-2080 Msida, Malta.	alexander.gatt@um.edu.mt	Riva, Nicoletta/H-6874-2019	Riva, Nicoletta/0000-0002-8922-8823; Vella, Kevin/0000-0002-0826-1921	University of Malta	This study was supported by a research grant from the University of Malta.	Ay C, 2008, BLOOD, V112, P2703, DOI 10.1182/blood-2008-02-142422; Bates SM, 2012, SEMIN THROMB HEMOST, V38, P673, DOI 10.1055/s-0032-1326782; Cambien B, 2004, TRENDS MOL MED, V10, P179, DOI 10.1016/j.molmed.2004.02.007; Chaireti R, 2009, THROMB RES, V124, P178, DOI 10.1016/j.thromres.2008.12.033; Di Nisio M, 2007, J THROMB HAEMOST, V5, P296, DOI 10.1111/j.1538-7836.2007.02328.x; Exner T, 2003, BLOOD COAGUL FIBRIN, V14, P773, DOI 10.1097/01.mbc.0000061366.73802.df; Haas FJLM, 2011, SCAND J CLIN LAB INV, V71, P12, DOI 10.3109/00365513.2010.534173; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Hunt BJ, 2018, BRIT J HAEMATOL, V180, P694, DOI 10.1111/bjh.15102; Kemkes-Matthes B, 2011, BLOOD COAGUL FIBRIN, V22, P215, DOI 10.1097/MBC.0b013e328343f8bf; Lacroix R, 2013, J THROMB HAEMOST, V11, P24, DOI 10.1111/jth.12268; Le Gal G, 2006, ANN INTERN MED, V144, P165, DOI 10.7326/0003-4819-144-3-200602070-00004; Liaw A, 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Pabinger I, 2009, ARTERIOSCL THROM VAS, V29, P332, DOI 10.1161/ATVBAHA.108.182188; Patil R, 2016, CLIN CHEM LAB MED, V54, P799, DOI 10.1515/cclm-2015-0508; R Core Team, 2015, R LANG ENV STAT COMP; Ramacciotti E, 2011, CLIN APPL THROMB-HEM, V17, P425, DOI 10.1177/1076029611405032; Rectenwald JE, 2005, THROMB HAEMOSTASIS, V94, P1312, DOI 10.1160/TH05-06-0426; Torres C, 2017, BLOOD COAGUL FIBRIN, V28, P589, DOI 10.1097/MBC.0000000000000650; Tripodi A, 2016, CLIN CHEM, V62, P699, DOI 10.1373/clinchem.2015.248625; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416; Wexels F, 2017, CLIN APPL THROMB-HEM, V23, P416, DOI 10.1177/1076029617700999; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Zhao Y, 2013, INT J LAB HEMATOL, V35, P566, DOI 10.1111/ijlh.12113	26	1	1	2	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1015	1022		10.1136/jclinpath-2018-205293			8	Pathology	Pathology	HB4BT	WOS:000450998000011	30093507	Green Accepted			2019-10-28	
J	Hahn, E; Liu, SK; Vesprini, D; Xu, B; Downes, MR				Hahn, Elan; Liu, Stanley K.; Vesprini, Danny; Xu, Bin; Downes, Michelle R.			Immune infiltrates and PD-L1 expression in treatment-naive acinar prostatic adenocarcinoma: an exploratory analysis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						prostate; PD-L1; immune checkpoint blockade		Tumour-induced immunosuppression plays a role in the development and progression of cancer. Of interest is the interaction between programmed death-1 and programmed death ligand-1 (PD-L1) which can be targeted through immune checkpoint blockade; however, there are limited data surrounding the composition of the immune milieu in prostate cancer. We preliminarily assessed 21 radical prostatectomies in therapy-naive patients for immune markers and PD-L1 expression. The immune infiltrates were higher in adenocarcinoma than benign prostate (lymphocytes p<0.001, macrophages p=0.010) with 5% of cases being PD-L1 high (5% expression). Increased peritumoural CD68 and CD163 expression correlated with lower grade group (GG) (p=0.024 and p=0.014, respectively) with a trend towards increased CD68 expression in lower stage cases (p=0.086). There was also increased CD45 expression in lower GGs (p=0.063). We found the immune infiltrate in acinar prostate cancer to be extremely heterogeneous with an overall immunophenotype unlikely to respond to immune checkpoint blockade.	[Hahn, Elan; Xu, Bin; Downes, Michelle R.] Sunnybrook Hlth Sci Ctr, Anat Pathol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Hahn, Elan; Xu, Bin; Downes, Michelle R.] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; [Liu, Stanley K.; Vesprini, Danny] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Radiat Oncol, Toronto, ON, Canada; [Liu, Stanley K.; Vesprini, Danny] Univ Toronto, Toronto, ON, Canada	Downes, MR (reprint author), Sunnybrook Hlth Sci Ctr, Anat Pathol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	michelle.downes@sunnybrook.ca		Liu, Stanley/0000-0001-6851-0857; Xu, Bin/0000-0003-4638-9835			Baas W, 2017, CLIN GENITOURIN CANC, V15, P577, DOI 10.1016/j.clgc.2017.04.002; Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Fankhauser Christian D, 2018, Oncotarget, V9, P10284, DOI 10.18632/oncotarget.22888; Haffner MC, 2018, AM J PATHOL, V188, P1478, DOI 10.1016/j.ajpath.2018.02.014; Huang CY, 2017, J IMMUNOTHER, V40, P323, DOI 10.1097/CJI.0000000000000187; Hussein MRA, 2009, EXP MOL PATHOL, V86, P108, DOI 10.1016/j.yexmp.2008.11.010; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Martin AM, 2015, PROSTATE CANCER P D, V18, P325, DOI 10.1038/pcan.2015.39; Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806; Morse MD, 2012, PROSTATE, V72, P1239, DOI 10.1002/pros.22476; Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053; Sanda MG, 2018, J UROLOGY, V199, P683, DOI 10.1016/j.juro.2017.11.095; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965	21	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1023	1027		10.1136/jclinpath-2018-205404			5	Pathology	Pathology	HB4BT	WOS:000450998000012	30257853				2019-10-28	
J	Quinn, C; Rakha, EA				Quinn, Cecily; Rakha, Emad A.			Eighth Edition Cancer Staging Manual of Breast Cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool?	JOURNAL OF CLINICAL PATHOLOGY			English	Article						breast cancer; staging TNM; AJCC; treatment			[Quinn, Cecily] Univ Coll, St Vincents Univ Hosp, Dept Histopathol, Dublin, Ireland; [Rakha, Emad A.] Univ Nottingham, Nottingham Univ Hosp NHS Trust, City Hosp Nottingham, Dept Pathol, Nottingham, England	Rakha, EA (reprint author), Univ Nottingham, Nottingham Univ Hosp NHS Trust, Dept Histopathol, Nottingham NG5 1PB, England.	emadrakha@yahoo.com	Rakha, Emad/Q-5554-2019	Rakha, Emad/0000-0002-5009-5525			Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Chae YK, 2017, MOL CANCER THER, V16, P1412, DOI 10.1158/1535-7163.MCT-17-0061; Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986; Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607; Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764; Stein RC, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20100	9	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1028	1029		10.1136/jclinpath-2018-205255			2	Pathology	Pathology	HB4BT	WOS:000450998000013	30049817				2019-10-28	
J	Ling, C; Shen, YM				Ling, Chen; Shen, Yangmei			Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material						carcinoid; cervical cancer; gynaecological pathology		Clinical question A 45-year-old woman presented with painless vaginal bleeding for 2 months. A biopsy was taken from the uterine cervix, andpoorly differentiated adenocarcinoma was suspected. After three cycles of neoadjuvant chemotherapy treatment, the patient underwent radical hysterectomy with bilateral salpingo-oophorectomy, andpelvic and para-aortic lymphadenectomy. Review the highquality, interactive digital Aperio slide athttp://virtualacp.com/JCPCases/jclinpath-2018-205081-1/ and consider your diagnosis. What is your diagnosis? Typical carcinoid. Poorly differentiated adenocarcinoma. Atypical carcinoid. Small cell neuroendocrine carcinoma. Sex cord-stromal tumours of theuterine cervix. The correct answer is after the discussion. Discussion Neuroendocrine tumours of the uterine cervix are arare cancer of the female reproductive system, accounting for approximately 1% of all female cervical malignancies.1 2 In 1997, a consensus workshop suggested four types of neuroendocrine tumours of the uterine cervix: typical and atypical carcinoid tumours, small cell neuroendocrine carcinomas, and large cell carcinomas.1 Among all the categories, small cell neuroendocrine carcinomas are of the highest incidence. A PubMed search revealed thatonly 15 cases of atypical carcinoid tumours of the uterine cervix have been reported.3 4 Because of infrequency, the clinical and pathological features of atypical carcinoid tumours of the uterine cervix remain unknown. Atypical carcinoids are characterised by great cytological atypia, which means abundant or scanty cytoplasm and visible nucleoli with granular chromatin. Tumour cells lined up in insular, trabecular, columnar and nested organoid patterns; they are epithelioid in appearance, but can be spindled(figure 1A). Necrosis could be observed in some areas and mitotic activity is up to 10 mitotic figures/10high-power field (figure 1B). On immunohistochemistry, atypical carcinoids are diffuse andpositive for Syn, CgA and CD56(figure 2). Anelectron microscopic test was done, and severalneuroendocrine granules were distributed in thetumour cell plasma(figure 3). (fig id="F1") <caption> (A)Insular, trabecular and columnar patterns of tumour cells were focally observed in the deep stroma of thecervix (H&E x200). (B) Tumour cells showed small-sized, scanty cytoplasm, enlarged and deeply stained nuclei with condensed chromatin, obvious atypia, and increased mitotic activity(H&E x400). (C) The cervical gland hasshown atypical hyperplasia and adenocarcinoma in situ (H&E x200). </caption> "http://www.w3.org/1999/xlink" (fig id="F2") <caption> Immunohistochemical study findings: (A-C) The neuroendocrine markers Syn, CgA and CD56 were diffuse withstrong expression in the tumour cellplasma. (D-E)P63 and CK5/6 for the squamous cell carcinomas showed no expression. (F-G) P16 for atypical carcinoid and adenocarcinoma in situ, respectively, hadstrong diffuse expression. (H-I)Ki67 hadlow expression in both atypical carcinoid and adenocarcinoma in situ (x200). </caption> "http://www.w3.org/1999/xlink" (fig id="F3") <caption> Severalneuroendocrine granules were distributed in thetumour cell plasma. </caption> "http://www.w3.org/1999/xlink" Neuroendocrine tumours of the uterine cervix are sometimes combined with adenocarcinoma(figure 1C); their cytological and immunohistochemical features showed the neuroendocrine and adenomatous components shared the same origin.	[Ling, Chen] Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet, Chengdu, Sichuan, Peoples R China; [Ling, Chen] Sichuan Univ, West China Sch Med, Chengdu, Sichuan, Peoples R China; [Ling, Chen; Shen, Yangmei] Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Peoples R China; [Shen, Yangmei] Sichuan Univ, West China Univ Hosp 2, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China	Shen, YM (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China.	sym.julia@163.com					AlboresSaavedra J, 1997, ARCH PATHOL LAB MED, V121, P34; Hara H, 2012, DIAGN CYTOPATHOL, V40, P724, DOI 10.1002/dc.21657; Margolis B, 2016, GYNECOL ONCOL, V141, P247, DOI 10.1016/j.ygyno.2016.02.008; Yoshida Y, 2011, J OBSTET GYNAECOL RE, V37, P636, DOI 10.1111/j.1447-0756.2010.01402.x	4	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1030	+		10.1136/jclinpath-2018-205081			2	Pathology	Pathology	HB4BT	WOS:000450998000014	30154130				2019-10-28	
J	Gai, L; Done, SJ; Cook, D; Denic, N; Erivwo, P; Voisey, K; Kao, K				Gai, Luis; Done, Susan J.; Cook, Donald; Denic, Nash; Erivwo, Polycarp; Voisey, Kim; Kao, Kenneth			Breast tumour resembling tall cell variant of papillary thyroid carcinoma: case presentation (in a patient with Lynch syndrome)	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						BTPTC; breast cancer; case report; tall cell variant			[Gai, Luis; Cook, Donald; Denic, Nash; Erivwo, Polycarp; Voisey, Kim; Kao, Kenneth] Eastern Hlth, Div Anat Pathol, Lab Med Program, St John, NF A1B 3V6, Canada; [Done, Susan J.] Univ Hlth Network, Lab Med Program, Toronto, ON, Canada; [Kao, Kenneth] Mem Univ, Div Biomed Sci, Fac Med, St John, NF, Canada	Gai, L (reprint author), Eastern Hlth, Div Anat Pathol, Lab Med Program, St John, NF A1B 3V6, Canada.	luis.gai@easternhealth.ca		Done, Susan/0000-0002-1770-988X			Bhargava R, 2017, AM J CLIN PATHOL, V147, P399, DOI [10.1093/AJCP/AQX016, 10.1093/ajcp/aqx016]; Chang SY, 2009, BREAST J, V15, P531, DOI 10.1111/j.1524-4741.2009.00773.x; Colella R, 2015, INT J SURG PATHOL, V23, P217, DOI 10.1177/1066896914536222; Eusebi V, 2003, AM J SURG PATHOL, V27, P1114, DOI 10.1097/00000478-200308000-00008; Fazekas-Lavu M, 2017, THER CLIN RISK MANAG, V13, P915, DOI 10.2147/TCRM.S121812; Foschini MP, 2017, AM J SURG PATHOL, V41, P887, DOI 10.1097/PAS.0000000000000853; Masood S, 2012, ADV ANAT PATHOL, V19, P108, DOI 10.1097/PAP.0b013e318249d090; Pelizzo MR, 2015, BIOMED PHARMACOTHER, V74, P9, DOI 10.1016/j.biopha.2015.06.008	8	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	NOV	2018	71	11					1032	1033		10.1136/jclinpath-2018-205337			2	Pathology	Pathology	HB4BT	WOS:000450998000015	29982234				2019-10-28	
J	Roth, W				Roth, W.			Immunopathology	PATHOLOGE			German	Editorial Material									[Roth, W.] Johannes Gutenberg Univ Mainz, Univ Med, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany	Roth, W (reprint author), Johannes Gutenberg Univ Mainz, Univ Med, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	wilfried.roth@unimedizin-mainz.de						0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					491	491		10.1007/s00292-018-0533-8			1	Pathology	Pathology	HB0NX	WOS:000450713000001	30255282				2019-10-28	
J	Bopp, T; Schild, H				Bopp, T.; Schild, H.			Immunological foundations of modern (tumor) immunotherapy	PATHOLOGE			German	Article						Active immunotherapy; Immune evasion; Immune checkpoint inhibitors; Neoplasms; Tumor escape	T-CELL EXHAUSTION; LACTATE-DEHYDROGENASE; CANCER; MACROPHAGES; ANTIBODY; THERAPY; VACCINATION; RECEPTORS; IMMUNITY; TARGETS	Understanding the fundamental principles underlying the development, activation, regulation, plasticity, diversification, and even death of immune cells is aprerequisite for the development of targeted strategies to modulate the immune system in the fight against cancer. As our understanding of these processes evolves, their translation has led to the development of pioneering therapeutic approaches in the treatment of malignant diseases.	[Bopp, T.] Johannes Gutenberg Univ Mainz, Univ Med, Inst Immunol, Gebaude 308A,Langenbeckstr 1, D-55131 Mainz, Germany	Schild, H (reprint author), Johannes Gutenberg Univ Mainz, Univ Med, Inst Immunol, Gebaude 308A,Langenbeckstr 1, D-55131 Mainz, Germany.	schild@uni-mainz.de					Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Ochoa MC, 2017, IMMUNOL CELL BIOL, V95, P347, DOI 10.1038/icb.2017.6; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Diem S, 2016, BRIT J CANCER, V114, P256, DOI 10.1038/bjc.2015.467; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; EVANS R, 1970, NATURE, V228, P620, DOI 10.1038/228620a0; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kalos M, 2013, IMMUNITY, V39, P49, DOI 10.1016/j.immuni.2013.07.002; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Kochenderfer JN, 2013, NAT REV CLIN ONCOL, V10, P267, DOI 10.1038/nrclinonc.2013.46; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; MANTOVANI A, 1978, INT J CANCER, V22, P741, DOI 10.1002/ijc.2910220617; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marin-Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0582-8; Mittendorf EA, 2012, CANCER-AM CANCER SOC, V118, P2594, DOI 10.1002/cncr.26574; Noguchi M, 2012, PROSTATE, V72, P834, DOI 10.1002/pros.21485; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Petrelli F, 2015, ACTA ONCOL, V54, P961, DOI 10.3109/0284186X.2015.1043026; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883; Wargo JA, 2014, CANCER DISCOV, V4, P1377, DOI 10.1158/2159-8290.CD-14-0477; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620	42	0	0	2	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					492	497		10.1007/s00292-018-0517-8			6	Pathology	Pathology	HB0NX	WOS:000450713000002	30327859				2019-10-28	
J	Schildhaus, HU				Schildhaus, H. -U.			Predictive value of PD-L1 diagnostics	PATHOLOGE			German	Article						Biomarkers; Immuno-oncology; Immune checkpoint inhibitor; NSCLC; Urothelial carcinoma	COMBINED NIVOLUMAB; CELL; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; EXPRESSION; IPILIMUMAB; LANDSCAPE	Immuno-oncology related treatments have become standard of care for many tumor entities. Numerous additional indications are currently under investigation in ongoing clinical trials. Predictive biomarkers include microsatellite instability as well as tumor mutational burden. However, PD-L1testing by immunohistochemistry (IHC) is already widely established as abiomarker in clinical routine for certain treatment decisions in non-small cell lung cancer, head and neck cancer and in urothelial carcinomas. More applications of that kind are expected to follow. Moreover, PD-L1testing can provide clinicians with valuable information even if the test is not mandatory (i.e., complementary diagnostics). PD-L1staining requires ahighly specific staining over abroad dynamic range. Sensitive and specific primary antibodies and suitable staining protocols are prerequisite. Selection of appropriate patients' materials, validation and contiguous quality assurance need to meet the highest standards. There are different scoring algorithms for PD-L1stainings which are specific to tumor entities and certain clinical decisions. The tumor proportion score (TPS) is aPD-L1measurement which is applied, for example, to lung cancer, head and neck cancer and melanomas. Within this approach, only membranous staining of tumor cells is regarded as asignificant staining. In contrast, the combined positivity score (CPS) and inflammatory cell (IC) scoring include or are restricted to PD-L1expression in certain inflammatory cells, respectively. CPS and IC scoring are standard measurements of PD-L1 in urothelial carcinoma.	[Schildhaus, H. -U.] Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany	Schildhaus, HU (reprint author), Univ Med Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	Hans-Ulrich.Schildhaus@med.uni-goettingen.de					Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Daud A, 2015, P AM SOC CLIN ONCO S, V33, P9005, DOI DOI 10.1200/JC0.2014.57.5027; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Fuchs CS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4003; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gettinger SN, 2015, J CLIN ONCOL, V33, P2004, DOI 10.1200/JCO.2014.58.3708; Griesinger F, 2017, FORUM FAM PLAN W HEM, V32, P157; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Koppel C, 2018, MODERN PATHOL, V31, P1630, DOI 10.1038/s41379-018-0071-1; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Munari Enrico, 2018, Oncotarget, V9, P30465, DOI 10.18632/oncotarget.25770; O'Donnell PH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4502; Peters S, 2017, COMMUNICATION; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Scheel AH, 2016, PATHOLOGE, V37, P557, DOI 10.1007/s00292-016-0189-1; Scheel AH, 2018, HISTOPATHOLOGY, V72, P449, DOI 10.1111/his.13375; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Skov BG, 2017, APPL IMMUNOHISTO M M, V25, P453, DOI 10.1097/PAI.0000000000000540; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Sweis RF, 2016, CANCER IMMUNOL RES, V4, P563, DOI 10.1158/2326-6066.CIR-15-0274; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Zhang P, 2008, MOL IMMUNOL, V45, P1470, DOI 10.1016/j.molimm.2007.08.013	28	6	6	1	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					498	519		10.1007/s00292-018-0507-x			22	Pathology	Pathology	HB0NX	WOS:000450713000003	30367225				2019-10-28	
J	Denkert, C; Loibl, S; Budczies, J; Wienert, S; Klauschen, F				Denkert, C.; Loibl, S.; Budczies, J.; Wienert, S.; Klauschen, F.			Standardized determination of tumor-infiltrating lymphocytes in breast cancer. A prognostic marker for histological diagnosis	PATHOLOGE			German	Article						Biomarkers; Breast neoplasms; Neoadjuvant therapy; Prognosis; Immune infiltrate	INTEROBSERVER AGREEMENT; INTERNATIONAL KI67; FREE SURVIVAL; SOLID TUMORS; CELL-DEATH; PATHOLOGISTS; CHEMOTHERAPY; TRASTUZUMAB; CARCINOMA; IMMUNE	BackgroundTumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer.ObjectivesThe aim of this review article is to provide an overview on the clinical and analytical validation of TILs in breast cancer.Materials and methodsSummary of international guidelines of the TIL working group as well as clinical and translational studies.Results, ConclusionsBreast carcinomas with ahigh TIL level have an improved response to neoadjuvant chemotherapy. Triple-negative and HER2-positive carcinomas with increased TIL levels have improved survival. TILs are anew prognostic biomarker for routine histopathological diagnosis.	[Denkert, C.; Budczies, J.; Wienert, S.; Klauschen, F.] Univ Med Berlin, Inst Pathol Charite, Charitepl 1, D-10117 Berlin, Germany; [Denkert, C.] Standort Berlin, DKTK, Berlin, Germany; [Loibl, S.] German Breast Grp, Neu Isenburg, Germany; [Wienert, S.] VMscope GmbH, Berlin, Germany; [Budczies, J.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany	Denkert, C (reprint author), Univ Med Berlin, Inst Pathol Charite, Charitepl 1, D-10117 Berlin, Germany.	carsten.denkert@charite.de					Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Budczies J, 2015, J PATHOL CLIN RES, V1, P225, DOI 10.1002/cjp2.25; Cabuk FK, 2018, INDIAN J PATHOL MICR, V61, P181, DOI 10.4103/IJPM.IJPM_131_17; Curigliano G, 2017, ANN ONCOL, V28, P1700, DOI 10.1093/annonc/mdx308; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Denkert C, 2016, MODERN PATHOL, V29, P1155, DOI 10.1038/modpathol.2016.109; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Dieci MV, 2015, ANN ONCOL, V26, P1518, DOI 10.1093/annonc/mdv241; Dieci MV, 2018, SEMIN CANCER BIOL, V52, P16, DOI 10.1016/j.semcancer.2017.10.003; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Dunbier AK, 2013, CLIN CANCER RES, V19, P2775, DOI 10.1158/1078-0432.CCR-12-1000; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI [10.1038/nn.2016.107, 10.1038/nri.2016.107]; Heindl A, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx137; Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161; Hendry S, 2017, ADV ANAT PATHOL, V24, P235, DOI 10.1097/PAP.0000000000000162; Ignatiadis M, 2018, EUR J CANCER, V92, pS15, DOI 10.1016/S0959-8049(18)30283-1; Klauschen F, 2015, CLIN CANCER RES, V21, P3651, DOI 10.1158/1078-0432.CCR-14-1283; Kojima YA, 2018, ANN DIAGN PATHOL, V35, P77, DOI 10.1016/j.anndiagpath.2018.05.007; Lakhani SR, 2012, IARC CLASSIFICATIONS; Leung SCY, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.14; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Luen SJ, 2017, LANCET ONCOL, V18, P52, DOI [10.1016/S1470-2045(16)30631-3, 10.1016/s1470-2045(16)30631-3]; MOORE OS, 1949, CANCER, V2, P635, DOI 10.1002/1097-0142(194907)2:4<635::AID-CNCR2820020411>3.0.CO;2-Q; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Perez EA, 2016, JAMA ONCOL, V2, P56, DOI 10.1001/jamaoncol.2015.3239; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; RIGAUD C, 1993, ARCH PATHOL LAB MED, V117, P1005; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Salgado R, 2015, JAMA ONCOL, V1, P448, DOI 10.1001/jamaoncol.2015.0830; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Tramm T, 2018, ACTA ONCOL, V57, P90, DOI 10.1080/0284186X.2017.1403040	37	0	0	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					520	531		10.1007/s00292-018-0530-y			12	Pathology	Pathology	HB0NX	WOS:000450713000004	30327858				2019-10-28	
J	Wagner, DC; Roth, W				Wagner, D. -C.; Roth, W.			Prognostic significance of immune cell infiltrates in tumor pathology	PATHOLOGE			German	Article						Cancer; Immune system; Leukocytes; Prognostic factors; Immunohistochemistry	CANCER	BackgroundThe quantity, distribution, activation status, cytokine profile, and spatial distribution of tumor-infiltrating immune cells have prognostic value and may be predictive of response to immunotherapies.ObjectivesA survey of relevant immune cell populations including their prognostic significance in the most common types of tumors.MethodsNonsystematic assessment and a discussion of studies that were conducted to estimate the prognostic significance of certain immune cell subsets and the methodical approaches used.ResultsFor many tumor entities, prognostically favorable and unfavorable immune cell populations can be differentiated. However, nonspecific cell markers that may partly summarize antithetic immune cell subsets can be employed. Differences in sampling procedures and the determination of cut-off levels further limit the comparability of the studies carried out so far.ConclusionThe phenotypic and functional heterogeneity of tumor-infiltrating immune cells requires the use of cell subset-specific antibodies and antibody combinations. Furthermore, harmonized assessment routines, validation studies, and meta-analyses are important prerequisites for potential diagnostic implementation.	[Wagner, D. -C.; Roth, W.] Johannes Gutenberg Univ Mainz, Univ Med, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany	Wagner, DC (reprint author), Johannes Gutenberg Univ Mainz, Univ Med, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	daniel-christoph.wagner@unimedizin-mainz.de					Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Cao J, 2017, ONCOTARGET, V8, P83261, DOI 10.18632/oncotarget.18743; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; de Ruiter EJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356148; Dieu-Nosjean MC, 2016, IMMUNOL REV, V271, P260, DOI 10.1111/imr.12405; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Geng YT, 2015, CELL PHYSIOL BIOCHEM, V37, P1560, DOI 10.1159/000438523; Green JA, 2017, J EXP MED, V214, P3565, DOI 10.1084/jem.20170356; Hu GM, 2017, ONCOTARGET, V8, P75361, DOI 10.18632/oncotarget.17722; Hu GM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11122-2; Huang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094376; Jiang W, 2017, ONCOTARGET, V8, P62312, DOI 10.18632/oncotarget.17602; Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Soo Ross A, 2018, Oncotarget, V9, P24801, DOI 10.18632/oncotarget.24835; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wu Shui-Qing, 2018, Oncotarget, V9, P25294, DOI 10.18632/oncotarget.25334; Yuen GJ, 2016, TRENDS CANCER, V2, P747, DOI 10.1016/j.trecan.2016.10.010; Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031230; Zheng X, 2017, ONCOTARGET, V8, P57386, DOI 10.18632/oncotarget.18065	23	2	2	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					532	538		10.1007/s00292-018-0541-8			7	Pathology	Pathology	HB0NX	WOS:000450713000005	30350175				2019-10-28	
J	Grabe, N; Roth, W; Foersch, S				Grabe, N.; Roth, W.; Foersch, S.			Digital pathology in immuno-oncology-current opportunities and challenges. Overview of the analysis of immune cell infiltrates using whole slide imaging	PATHOLOGE			German	Article						Pathology; Biomarker; Computer-assisted image analysis; Tumor microenvironment; Machine learning	CANCER; LYMPHOCYTES; DENSITY	BackgroundImmuno-oncology requires objective and standardized methods for measuring immune cell infiltrates for therapy selection and clinical trials.MethodsCurrent approaches in applying digital pathology in immuno-oncology and developments in computational image analysis were analyzed.ResultsSince 2008, digital pathology has had an ever increasing importance in immuno-oncology. It is currently the only technology allowing the systematic and cost-effective quantitative spatial immune-profiling of patients. The analysis of immunological biomarkers requires integrated staining and image analysis strategies from single- to multistain on slide stacks. Statistical limits of the hypothesis to be tested have to be taken into account. Digital image analysis opens anew technological role for pathology in immuno-oncology and thereby serves as akey technological driver.ConclusionDigital pathology delivers objective and quantitative data on the tumor microenvironment. But currently, afully automatic, high-throughput analytics capability is still missing. Deep learning is the remedy for this, as it improves image analysis with increasing data availability. This requires the creation of systematic data collections but will in the end deliver standardized and automatic immunological analyses.	[Grabe, N.] Univ Klinikam Heidelberg, Natl Ctr Tumorerkrankungen & Med Onkol, Heidelberg, Germany; [Roth, W.; Foersch, S.] Univ Med Mainz, Inst Pathol, Mainz, Germany; [Grabe, N.] Heidelberg Univ, Tissue Imaging & Anal Ctr, Neuenheimer Feld 267, D-69120 Heidelberg, Germany	Grabe, N (reprint author), Heidelberg Univ, Tissue Imaging & Anal Ctr, Neuenheimer Feld 267, D-69120 Heidelberg, Germany.	niels.grabe@gmail.com					Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; CLARK WH, 1969, CANCER RES, V29, P705; COLEY WB, 1991, CLIN ORTHOP RELAT R, P3; DAVID H, 1988, PATHOL RES PRACT, V183, P356, DOI 10.1016/S0344-0338(88)80138-9; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Halama N, 2010, ANAL QUANT CYTOL, V32, P333; Hufnagl P, 2018, LEITFADEN DIGITALE P, P1; HUSBY G, 1976, J CLIN INVEST, V57, P1471, DOI 10.1172/JCI108417; Klintrup K, 2005, EUR J CANCER, V41, P2645, DOI 10.1016/j.ejca.2005.07.017; Michel S, 2008, BRIT J CANCER, V99, P1867, DOI 10.1038/sj.bjc.6604756; Mihm MC, 2015, CANCER IMMUNOL RES, V3, P827, DOI 10.1158/2326-6066.CIR-15-0143; Nagar Y, 2011, MAKING BUSINESS PRED; Remark R, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf6925; Royal College of Pathologists, 2018, M PATH DEM HIST WORK; Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594; Zlobec I, 2009, CANCER-AM CANCER SOC, V115, P4021, DOI 10.1002/cncr.24450	18	1	1	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					539	545		10.1007/s00292-018-0540-9			7	Pathology	Pathology	HB0NX	WOS:000450713000006	30350177				2019-10-28	
J	Weichert, W				Weichert, W.			Molecular predictors in immune oncology	PATHOLOGE			German	Article						PD-L1; PD-1; Molecular diagnostics; DNA damage response; Microbiome	SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; ACQUIRED-RESISTANCE; CHECKPOINT INHIBITORS; PD-1 BLOCKADE; MULTICENTER; TUMORS; ATEZOLIZUMAB; EXPRESSION; DOCETAXEL	The current rapid development of novel therapeutic approaches in immune oncology (IO) and specifically in the field of immune checkpoint inhibition is accompanied by an equally dynamic development of novel biomarker approaches for the identification of responding/non-responding patients under IO treatment. In addition to the measurement of the expression of checkpoint ligands/receptors, complex molecular predictors are gaining increasing attention in certain IO treatment constellations. This includes the entity informed identification of molecularly defined biological tumor subtypes (e.g., microsatellite instable neoplasms), the measurement of tumor mutational load and immune cell effector signatures as relatively routine diagnostic compatible novel biomarker strategies. In addition, amultitude of even more complex molecular IO biomarker approaches is emerging. This development is accompanied by new patient selection strategies which are based on the simultaneous combinatorial evaluation of more than one parameter. This article provides acomprehensive overview on currently relevant aspects in the field of IO biomarkers.	[Weichert, W.] Tech Univ Munich, Inst Pathol, Trogerstra 18, D-81675 Munich, Germany; [Weichert, W.] DKTK, Partner Site Munich, Munich, Germany	Weichert, W (reprint author), Tech Univ Munich, Inst Pathol, Trogerstra 18, D-81675 Munich, Germany.	wilko.weichert@tum.de					Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bellmunt J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw373.10; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Borghaei H, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9001; Boxberg M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1389366; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Delaunay M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.145; Fabrizio D, 2017, ANN ONCOL, V28, pv22, DOI [10.1093/annonc/mdx363, DOI 10.1093/ANNONC/MDX363]; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grasso CS, 2018, CANCER DISCOV, V8, P730, DOI 10.1158/2159-8290.CD-17-1327; Haddad RI, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6009; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hopkins AM, 2017, BRIT J CANCER, V117, P913, DOI 10.1038/bjc.2017.274; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133; Kowanetz M, 2016, ANN ONCOL, V27, P77; Lanitis E, 2017, ANN ONCOL, V28, P18, DOI 10.1093/annonc/mdx238; Lauss M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01460-0; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Legrand FA, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.12000; Leung DK, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.139; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Nebot-Bral L, 2017, EUR J CANCER, V84, P290, DOI 10.1016/j.ejca.2017.07.026; Nicolazzo C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31726; Oh DY, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3029; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Peters S, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-CT082; Powles T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.409; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Ramalingam SS, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT078; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rosenberg JE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.104; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schmid P, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.11506; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Teo MY, 2018, J CLIN ONCOL, V36, P1685, DOI 10.1200/JCO.2017.75.7740; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Velcheti V, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.12001; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	61	1	1	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					546	555		10.1007/s00292-018-0508-9			10	Pathology	Pathology	HB0NX	WOS:000450713000007	30215118				2019-10-28	
J	Niebel, D; Wenzel, J				Niebel, D.; Wenzel, J.			Immunopathology of cutaneous drug eruptions	PATHOLOGE			German	Article						Adverse drug reaction; Drug hypersensitivity; Checkpoint inhibitor; Dermatitis; Drug reactions	PANNICULITIS; PATHOGENESIS; INHIBITORS; VITILIGO; DISTINCT	BackgroundAdverse drug reactions (ADR) are common and may present clinically and histologically in avery heterogeneous manner. The pathophysiological understanding about causal immunological and non-immunological events has developed significantly over the past years. Skin and mucosa are commonly affected and are prone for histopathological examination. Certain groups of drugs such as immune checkpoint inhibitors may cause specific adverse reactions.ObjectivesTo provide acomprehensive overview of the complex immunological events and the most common dermatohistopathological findings of cutaneous adverse drug reactions.Material and methodsReview of the literature (PubMed), own study data and pictures obtained via routine diagnostics at the University of Bonn.Results and discussionDrugs may induce awide range of skin reactions displaying adiversity of cutaneous inflammatory patterns. Histopathological clues for drug eruptions may be: eosinophils, lichenoid infiltrate and isolated keratinocytic apoptosis; athorough medical history and correlation of clinical findings and dermatohistopathology are most important. Knowledge of typical adverse reactions to checkpoint inhibitors and their management is of great clinical interest as their use is rising steadily.	[Niebel, D.; Wenzel, J.] Univ Klinikum Bonn, Klin & Poliklin Dermatol & Allergol, Sigmund Freud Str 25, D-53127 Bonn, Germany	Niebel, D; Wenzel, J (reprint author), Univ Klinikum Bonn, Klin & Poliklin Dermatol & Allergol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	Dennis.Niebel@ukbonn.de; Joerg.Wenzel@ukbonn.de	Niebel, Dennis/L-1203-2019	Niebel, Dennis/0000-0003-2069-0486			Adam J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095339; [Anonymous], 1969, World Health Organ Tech Rep Ser, V425, P5; Baha A, 2015, J INVESTIG MED HIGH, V3; Baldo BA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26333; Below J, 2017, HAUTARZT, V68, P12, DOI 10.1007/s00105-016-3902-3; Braegelmann C, 2017, DEUT MED WOCHENSCHR, V142, P1855, DOI 10.1055/s-0043-120060; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Cerroni L, 2016, HISTOPATHOLOGIE HAUT; Choy B, 2014, AM J DERMATOPATH, V36, P493, DOI 10.1097/DAD.0000000000000023; Collins LK, 2017, CURR PROB CANCER, V41, P125, DOI 10.1016/j.currproblcancer.2016.12.001; COOMBS RRA, 1969, BRIT J DERMATOL, VS 81, P2, DOI 10.1111/j.1365-2133.1969.tb12847.x; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; Ferreira J, 2017, J CUTAN PATHOL, V44, P307, DOI 10.1111/cup.12857; Ferreli C, 2017, CLIN REV ALLERG IMMU, V53, P306, DOI 10.1007/s12016-017-8625-4; Hausmann O, 2012, CHEM IMMUNOL ALLERGY, V97, P32, DOI 10.1159/000335614; Hua C, 2016, JAMA DERMATOL, V152, P45, DOI 10.1001/jamadermatol.2015.2707; Kerl K, 2012, CHEM IMMUNOL ALLERGY, V97, P61, DOI 10.1159/000335616; Larsabal M, 2017, J AM ACAD DERMATOL, V76, P863, DOI 10.1016/j.jaad.2016.10.044; Mizukawa Y, 2002, AM J PATHOL, V161, P1337, DOI 10.1016/S0002-9440(10)64410-0; Perret RE, 2017, INT J DERMATOL, V56, P527, DOI 10.1111/ijd.13540; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Seitz CS, 2013, J AM ACAD DERMATOL, V69, P721, DOI 10.1016/j.jaad.2013.06.022; Sibaud V, 2017, J EUR ACAD DERMATOL, V31, pE464, DOI 10.1111/jdv.14284; Sibaud V, 2018, AM J CLIN DERMATOL, V19, P345, DOI 10.1007/s40257-017-0336-3; Werninghaus I, 2018, CLIN EXP DERMATOL, V43, P458, DOI 10.1111/ced.13366; Weyers Wolfgang, 2011, Dermatol Pract Concept, V1, P33, DOI 10.5826/dpc.0101a09; Yip VLM, 2017, PHARMACOGEN PERS MED, V10, P29, DOI 10.2147/PGPM.S108598; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zarbo A, 2017, BRIT J DERMATOL, V176, P1649, DOI 10.1111/bjd.15237; Ziemer M, 2014, HAUTARZT, V65, P397, DOI 10.1007/s00105-013-2696-9	30	1	1	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					563	570		10.1007/s00292-018-0487-x			8	Pathology	Pathology	HB0NX	WOS:000450713000009	30215117				2019-10-28	
J	Blaker, H				Blaeker, H.			Gastrointestinal tract diseases induced by medications	PATHOLOGE			German	Article						Drug-induced diseases; Enteritis; Apoptotic colopathy; Immunosuppression; Corticosteroids	TNF-ALPHA; MYCOPHENOLATE; INFECTION; COLITIS; PATIENT; ULCERS	Gastrointestinal symptoms are common side effects of medical drugs. They are usually mild but sometimes require diagnostic endoscopy and histologic evaluation. Due to the rapidly increasing number of drugs developed especially for cancer treatment, pathologists are faced with aspectrum of different drug-associated histologies in all segments of the gastrointestinal tract. Some medication-induced mucosal damage features may mimic classical pathologies of nondrug-associated diseases, while others result in novel phenotypes. The present article focusses on the histologic presentations of gastrointestinal diseases induced by medications that either compromise or induce immune response.	[Blaeker, H.] Charite, Pathol Inst, Charitepl 1, D-10117 Berlin, Germany	Blaker, H (reprint author), Charite, Pathol Inst, Charitepl 1, D-10117 Berlin, Germany.	hendrik.blaeker@charite.de					Ben-Horin S, 2012, GUT, V61, P327, DOI 10.1136/gutjnl-2011-300398; Detweiler CJ, 2018, J PEDIAT HEMATOL ONC, V40, pE364, DOI 10.1097/MPH.0000000000001227; Goetz M, 2007, INFLAMM BOWEL DIS, V13, P1365, DOI 10.1002/ibd.20215; Hammami MB, 2017, CLIN J GASTROENTEROL, V10, P142, DOI 10.1007/s12328-016-0707-y; HASHIMOTO S, 1995, INTERNAL MED, V34, P212, DOI 10.2169/internalmedicine.34.212; Khalil PN, 2009, EUR J MED RES, V14, P231, DOI 10.1186/2047-783X-14-6-231; Kokkinidis DG, 2017, SCAND J GASTROENTERO, V52, P923, DOI 10.1080/00365521.2017.1326163; Lee J, 2008, CYTOKINE, V44, P49, DOI 10.1016/j.cyto.2008.06.006; Logan C, 2016, CURR OPIN INFECT DIS, V29, P486, DOI 10.1097/QCO.0000000000000305; Machado ER, 2011, AM J TROP MED HYG, V84, P957, DOI 10.4269/ajtmh.2011.10-0490; Makino Y, 2015, INTERNAL MED, V54, P2851, DOI 10.2169/internalmedicine.54.4735; McDonald HH, 2017, NEW ENGL J MED, V376, P2376, DOI 10.1056/NEJMicm1612018; Pecoraro A, 2018, J CLIN IMMUNOL, V38, P67, DOI 10.1007/s10875-017-0461-z; Rubio-Tapia A, 2012, MAYO CLIN PROC, V87, P732, DOI 10.1016/j.mayocp.2012.06.003; Saraei M, 2014, INFECTION, V42, P1039, DOI 10.1007/s15010-014-0637-x; Segarra-Newnham M, 2007, ANN PHARMACOTHER, V41, P1992, DOI 10.1345/aph.1K302; Soldini D, 2014, J CLIN PATHOL, V67, P582, DOI 10.1136/jclinpath-2014-202199; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; Tashiro Y, 2006, PATHOL INT, V56, P530, DOI 10.1111/j.1440-1827.2006.02001.x; Umetsu SE, 2018, VIRCHOWS ARCH, V472, P55, DOI 10.1007/s00428-017-2243-7; Varma P, 2017, SCAND J GASTROENTERO, V52, P606, DOI 10.1080/00365521.2017.1280530; Vieth M, 2017, VIRCHOWS ARCH, V470, P245, DOI 10.1007/s00428-017-2077-3; Weber A, 2013, PATHOBIOLOGY, V80, P282, DOI 10.1159/000350758; Wei JP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002436; Wright Naomi Jane, 2011, BMJ Case Rep, V2011, DOI 10.1136/bcr.07.2011.4518	25	0	0	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					571	575		10.1007/s00292-018-0478-y			5	Pathology	Pathology	HB0NX	WOS:000450713000010	30171343				2019-10-28	
J	Schirmacher, P; Stenzinger, A; Kirchner, T				Schirmacher, P.; Stenzinger, A.; Kirchner, T.			Centralized Molecular Tumor Diagnosis by commercial Providers Consequences for Patients, Patient Care and Research	PATHOLOGE			German	Editorial Material									[Schirmacher, P.; Stenzinger, A.] Univ Kiln Heidelberg, Pathol Inst, Neuenheimer Feld 224, D-69120 Heidelberg, Germany; [Kirchner, T.] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany	Schirmacher, P (reprint author), Univ Kiln Heidelberg, Pathol Inst, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	Peter.Schirmacher@med.uni-heidelberg.de					Guerrini CJ, 2017, SCIENCE, V356, P586, DOI 10.1126/science.aal3224; Kuderer NM, 2017, JAMA ONCOL, V3, P996, DOI 10.1001/jamaoncol.2016.4983	2	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					583	586		10.1007/s00292-018-0523-x			4	Pathology	Pathology	HB0NX	WOS:000450713000012	30338351				2019-10-28	
J	Stenzel, P				Stenzel, P.			Prognostic Relevance of TIM-3 in Renal Cell Carcinoma	PATHOLOGE			German	Editorial Material									[Stenzel, P.] Univ Med Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany	Stenzel, P (reprint author), Univ Med Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	philipp.stenzel@unimedizin-mainz.de					Escudier B, 2016, J CLIN ONCOL, V34, P1, DOI [10.1200/JCO.2016.34.15_suppl.LBA1, DOI 10.1200/JCO.2016.34.15_SUPPL.LBA1]; Kim KS, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1413519; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Sun T, 2017, INT J MOL SCI, V18, DOI [10.3390/ijms18040745, 10.3390/ijms18030645]; Yuan J, 2014, NEOPLASMA, V61, P35, DOI 10.4149/neo_2014_006	5	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					587	588		10.1007/s00292-018-0462-6			2	Pathology	Pathology	HB0NX	WOS:000450713000013	30022225				2019-10-28	
J	Junker, K; Buttner, R; Langer, T; Ukena, D				Junker, K.; Buettner, R.; Langer, T.; Ukena, D.			Pathological-anatomical diagnosis according to the German lung cancer guideline 2018	PATHOLOGE			German	Article						Non-small-cell lung cancer; Resection margins; WHO-classification; TNM-classification; Molecular diagnostics	MICROSCOPIC RESIDUAL DISEASE; TNM CLASSIFICATION; STAGING PROJECT; PD-L1 IMMUNOHISTOCHEMISTRY; TUMOR-REGRESSION; 7TH EDITION; CELL; IMPACT; RESECTION	The German S3-guideline on prevention, diagnosis, therapy and follow-up of lung cancer, published in February 2018, expands on the 2010 guideline to include atotal of 19recommendations and statements regarding the processing of lung resection specimens (tumor resection specimens), processing of lymph nodes, histo-pathological typing and immunophenotype, extent of tumor growth in resection specimens, resection margins or R-classification, grade of malignancy (grading), regression grading as well as the examination of molecular targets. The statements regarding the analysis of molecular targets result from the diagnostic requirements of the current targeted therapy of advanced lung cancer. At the same time, apathological-anatomical diagnosis according to the current S3-guideline fulfills all corresponding requirements in certified lung cancer centers.	[Junker, K.] Klinkum Bremen Mitte, Zentrum Pathol, St Jurgen Str 1, D-28177 Bremen, Germany; [Buettner, R.] Univ Klin Koln, Inst Pathol, Cologne, Germany; [Langer, T.] Deutsch Krebsgesellschaft, Berlin, Germany; [Ukena, D.] Klinikum Bremen Ost, Klin Pneumol & Beatmungsmed, Bremen, Germany	Junker, K (reprint author), Klinkum Bremen Mitte, Zentrum Pathol, St Jurgen Str 1, D-28177 Bremen, Germany.	klaus.junker@klinikum-bremen-mitte.de					Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; Dienemann H, 1997, CHIRURG, V68, P1014, DOI 10.1007/s001040050313; Fassunke J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07078-0; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Hancock JG, 2015, ANN THORAC SURG, V99, P406, DOI 10.1016/j.athoracsur.2014.09.033; Hattori A, 2017, THORAC CARDIOV SURG, V65, P142, DOI 10.1055/s-0036-1572437; Heydt C, 2016, ANN ONCOL, V27, P25, DOI 10.1093/annonc/mdw303; Heydt Carina, 2018, Oncotarget, V9, P15418, DOI 10.18632/oncotarget.24624; Junker K, 2014, PATHOLOGE, V35, P574, DOI 10.1007/s00292-014-1919-x; Kawaguchi T, 2008, J THORAC ONCOL, V3, P599, DOI 10.1097/JTO.0b013e3181753b70; Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF): Pravention Diagnostik, 2018, THERAPIE NACHSORGE L; Moskalev EA, 2013, VIRCHOWS ARCH, V462, P409, DOI 10.1007/s00428-013-1376-6; Passlick B, 2001, ANN THORAC SURG, V72, P1160, DOI 10.1016/S0003-4975(01)03067-3; Querings S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019601; Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334; Riquet M, 2010, ANN THORAC SURG, V89, P870, DOI 10.1016/j.athoracsur.2009.11.052; Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e; Scheel AH, 2016, PATHOLOGE, V37, P557, DOI 10.1007/s00292-016-0189-1; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Thomas M, 1999, J CLIN ONCOL, V17, P1185, DOI 10.1200/JCO.1999.17.4.1185; Travis WD, 2015, CLASSIFICATION TUMOU; Travis WD, 2009, HISTOPATHOLOGY, V54, P3, DOI 10.1111/j.1365-2559.2008.03179.x; Warth A, 2012, HISTOPATHOLOGY, V61, P1017, DOI 10.1111/j.1365-2559.2012.04308.x; Wittekind C, 2017, TNM KLASSIFIKATION M	24	2	2	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					589	603		10.1007/s00292-018-0531-x			15	Pathology	Pathology	HB0NX	WOS:000450713000014	30357460				2019-10-28	
J	[Anonymous]				[Anonymous]			84th annual congress of the Swiss Society of Pathology: November 8-10, 2018, Palazzo dei Congressi, Lugano Abstracts	PATHOLOGE			English	Article																	0	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	NOV	2018	39	6					616	630		10.1007/s00292-018-0544-5			15	Pathology	Pathology	HB0NX	WOS:000450713000015	30338350				2019-10-28	
J	Handra-Luca, A				Handra-Luca, Adriana			Alveolar Squamous Cell Metaplasia: Preneoplastic Lesion?	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Letter							LUNG		[Handra-Luca, Adriana] GHU Avicenne, APHP, Serv Anat Pathol, Bobigny, France; [Handra-Luca, Adriana] Univ Paris Nord Sorbonne Cite, Bobigny, France	Handra-Luca, A (reprint author), Univ Paris Nord Sorbonne Cite, GHU Avicenne, APHP, Serv Anat Pathol, 125 Rue Stalingrad, F-93009 Bobigny, France.	adriana.handra-luca@aphp.fr					Chilosi M, 2002, LAB INVEST, V82, P1335, DOI 10.1097/01.LAB.0000032380.82232.67; Kato E, 2018, ERJ OPEN RES, V4, DOI [10.1183/23120541.00111-2016, DOI 10.1183/23120541.00111-2016]; Krimsky W, 2016, J COMMUNITY HOSP INT, V6, DOI 10.3402/jchimp.v6.33299; MEYER EC, 1965, CANCER-AM CANCER SOC, V18, P322, DOI 10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J; Rosai J., 2011, ROSAI ACKERMANS SURG; Song Dae Hyun, 2014, Korean J Pathol, V48, P10, DOI 10.4132/KoreanJPathol.2014.48.1.10; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	7	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					355	356		10.4132/jptm.2018.09.07			2	Pathology	Pathology	HA3IV	WOS:000450144200001	30269474	DOAJ Gold, Green Published			2019-10-28	
J	Choi, S; Go, JH				Choi, Seungkyu; Go, Jai-Hyang			Follicular T-Cell Lymphoma with Concomitant Lennert Lymphoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article									[Choi, Seungkyu; Go, Jai-Hyang] Dankook Univ, Dept Pathol, Coll Med, 119 Dandae Ro, Cheonan 31116, South Korea	Go, JH (reprint author), Dankook Univ, Dept Pathol, Coll Med, 119 Dandae Ro, Cheonan 31116, South Korea.	cyjy555@hanmail.net					Dogan A, 2017, WHO CLASSIFICATION T, P407; Hartmann S, 2011, HISTOPATHOLOGY, V59, P1173, DOI 10.1111/j.1365-2559.2011.04069.x; Hu SM, 2012, HUM PATHOL, V43, P1789, DOI 10.1016/j.humpath.2012.05.002; Huang YL, 2009, AM J SURG PATHOL, V33, P682, DOI 10.1097/PAS.0b013e3181971591; Jaffe E, 2017, HEMATOPATHOLOGY, P64405; Kurita D, 2016, AM J SURG PATHOL, V40, P1249, DOI 10.1097/PAS.0000000000000694; Pileri SA, 2017, WHO CLASSIFICATION T, P403	7	0	0	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	NOV	2018	52	6					425	427		10.4132/jptm.2018.04.16			3	Pathology	Pathology	HA3IV	WOS:000450144200012	30008198	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, CX; Qin, H; Zheng, R; Wang, YB; Yan, T; Huan, F; Han, Y; Zhu, WC; Zhang, LL				Zhang, Chengxiang; Qin, Heng; Zheng, Rui; Wang, Yubang; Yan, Ting; Huan, Fei; Han, Yang; Zhu, Weicheng; Zhang, Lulu			A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Alzheimer's disease; P-glycoprotein; Ibuprofen; Inflammatory reaction	BLOOD-BRAIN-BARRIER; NF-KAPPA-B; CEREBRAL AMYLOID ANGIOPATHY; IN-VITRO MODEL; MOUSE MODEL; MULTIDRUG-RESISTANCE; TRANSGENIC MICE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GLYCOPROTEIN	This study was aimed to investigate whether ibuprofen could alter the P-glycoprotein expression and function under Alzheimer's Disease condition and whether this alteration was induced by the inhibition of inflammatory reaction. APP/PS1 mice were used as AD model mice and ibuprofen-treated AD mice were given ibuprofen for 5 months. Then, Abcb1a/lbmRNA levels and P-gp expression were evaluated by qRT-PCR and western blot. Abcbl mRNA levels were significantly reduced in AD mice compared to control mice, and it could be restored by ibuprofen treatment. Meanwhile, P-gp expression result showed a similar trend. A beta plaques in cerebral cortices and hippocampus were investigated via immunohistochemical, and the results revealed that All plaques were reduced in ibuprofen-treated AD mice compared with the AD mice, indicated that P-gp function may be recovered by ibuprofen treatment. qRT-PCR and ELISA were used to determined TNF-alpha, IL-1 beta, IL-6 and NF-x.13 levels. The results demonstrated that TNF-, IL-1 beta mRNA levels and NF-kappa B expression were all significantly upregulated in AD mice in comparison with the control mice, and ibuprofen treatment could suppress the increase of inflammatory factors. In conclusion, the P-gp expression and function were suppressed in AD condition by activating inflammatory reaction, and then causing the All efflux decreased. However, upregulating P-gp could increase the Ali efflux in further to treat A beta via inhibiting the inflammatory factors expression.	[Zhang, Chengxiang; Qin, Heng; Zheng, Rui; Wang, Yubang; Yan, Ting; Huan, Fei; Zhang, Lulu] Nanjing Med Univ, Key Lab Modern Toxicol, Minist Educ, Dept Toxicol,Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Zhang, Chengxiang; Qin, Heng; Wang, Yubang; Yan, Ting; Huan, Fei; Han, Yang; Zhu, Weicheng; Zhang, Lulu] Nanjing Med Univ, Safety Assessment & Res Ctr Drugs, Nanjing 211166, Jiangsu, Peoples R China	Zhang, LL (reprint author), Nanjing Med Univ, Key Lab Modern Toxicol, Minist Educ, Dept Toxicol,Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China.	zcx@njmu.edu.cn; qh@njmu.edu.cn; 1142277464@qq.com; wyb@njmu.edu.cn; yanting@njmu.edu.cn; huanfei@njmu.edu.cn; 604971292@qq.com; zhuzhunjmu@163.com; lulu_0219@njmu.edu.cn			National Natural Sciences Foundation of ChinaNational Natural Science Foundation of China [81202581]	The work was supported by the National Natural Sciences Foundation of China (No. 81202581).	Abuznait AH, 2013, ACS CHEM NEUROSCI, V4, P973, DOI 10.1021/cn400024q; Abuznait AH, 2011, J PHARM PHARMACOL, V63, P1111, DOI 10.1111/j.2042-7158.2011.01309.x; Ando H, 2001, ANTIMICROB AGENTS CH, V45, P3462, DOI 10.1128/AAC.45.12.3462-3467.2001; Brenn Anja, 2011, Int J Alzheimers Dis, V2011, P690121, DOI 10.4061/2011/690121; Bruckmann S, 2017, CURR ALZHEIMER RES, V14, P656, DOI 10.2174/1567205013666161201201227; Cao W, 2017, IMMUNITY, V47, P1182, DOI 10.1016/j.immuni.2017.11.012; Carrano A, 2014, NEUROBIOL AGING, V35, P565, DOI 10.1016/j.neurobiolaging.2013.09.015; Chen HQ, 2016, CURR MED CHEM, V23, P701, DOI 10.2174/0929867323666160112122724; Fan X, 2015, INT J MOL SCI, V16, P27576, DOI 10.3390/ijms161126051; Feher A, 2014, J MOL NEUROSCI, V54, P826, DOI 10.1007/s12031-014-0427-z; Gibson CJ, 2012, J PHARMACOL EXP THER, V343, P650, DOI 10.1124/jpet.112.196543; Hartmann G, 2001, INT IMMUNOPHARMACOL, V1, P189, DOI 10.1016/S0162-3109(00)00271-X; Hartz AMS, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00186; Hartz AMS, 2010, MOL PHARMACOL, V77, P715, DOI 10.1124/mol.109.061754; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; HOLMES JA, 1994, BRIT J CANCER, V69, P382, DOI 10.1038/bjc.1994.70; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Kania KD, 2011, BRAIN RES, V1418, P1, DOI 10.1016/j.brainres.2011.08.044; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kloster-Jensen K, 2015, TRANSPL INT, V28, P1152, DOI 10.1111/tri.12617; Kuntz M, 2015, J ALZHEIMERS DIS, V48, P849, DOI 10.3233/JAD-150469; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Li YH, 2014, CHEM-BIOL INTERACT, V213, P44, DOI 10.1016/j.cbi.2014.02.004; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709; Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3; Manda S, 2016, EUR J MED CHEM, V107, P1, DOI 10.1016/j.ejmech.2015.10.049; Mohamed LA, 2016, BBA-MOL BASIS DIS, V1862, P778, DOI 10.1016/j.bbadis.2016.01.013; Nwaozuzu OM, 2003, J NEUROCHEM, V87, P1043, DOI 10.1046/j.1471-4159.2003.02061.x; Park R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.258; Percy C, 2017, TRANSPL P, V49, P2065, DOI 10.1016/j.transproceed.2017.09.019; Shinde Pravin, 2016, Central Nervous System Agents in Medicinal Chemistry, V16, P50, DOI 10.2174/1871524915666150826092152; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Torres-Vergara P., 2018, J PHARM PHARM; Do TM, 2016, J ALZHEIMERS DIS, V49, P287, DOI 10.3233/JAD-150350; Wang W, 2016, CURR ALZHEIMER RES, V13, P615, DOI 10.2174/1567205013666160314151012; Wang X, 2017, J ETHNOPHARMACOL, V209, P175, DOI 10.1016/j.jep.2017.07.039; Wu W, 2016, WORLD J HEPATOL, V8, P985, DOI 10.4254/wjh.v8.i23.985; Yang XF, 2017, CHEM-BIOL INTERACT, V278, P22, DOI 10.1016/j.cbi.2017.10.008; Zhang LL, 2011, ACTA PHARMACOL SIN, V32, P956, DOI 10.1038/aps.2011.33	40	0	0	3	11	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1765	1771		10.1016/j.prp.2018.08.011			7	Pathology	Pathology	HA0MP	WOS:000449902400003	30139557				2019-10-28	
J	Bu, QT; He, HR; Fan, D; Lyu, J; Pan, ZY; You, HS				Bu, Qingting; He, Hairong; Fan, Di; Lyu, Jun; Pan, Zhenyu; You, Haisheng			Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Wilms' tumor; LOH of 16q; Survival; Meta-analysis	ALLELE LOSS; CANCER; PROGNOSIS; GENE; 1P	Background: Wilms' tumor (WT) is the most common pediatric renal tumor. Despite its high survival rate, the potential prognostic factors should further be studied to reduce the intensity of the treatment. A few studies have found LOH of 16q is associated with worse survival in patients with WT, but it is still contradictory. This study aimed to performed a meta-analysis to clarify this. Methods: Databases including the Wanfang, PubMed, Chinese National Knowledge Infrastructure, Embase, and Cochrane Library databases were searched July 2018. The meta-analysis was done using Stata (version 14.0). Publication bias was evaluated by funnel plots, Begg's test, and Egger's test. The trim-and-fill method was applied if significant publication bias existed. Sensitivity analysis was performed to evaluate the stability of the results. Results: This meta-analysis identified 9 cohort studies encompassing 3266 cases. The pooled relative risk when comparing LOH of 16q groups with control groups was 2.22 195% confidence interval (CI) = 1.64-3.00, P < 0.001], and the pooled hazard ratio was 1.92 (95%CI = 1.32-2.80, P = 0.001). The results were stable after correcting for publication bias and performing a leave-one-out sensitivity analysis. Conclusions: This meta-analysis indicated that LOH of 16q was significantly associated with worse survival in WT. Further studies need to identify this conclusion because the overall quality of the included studies is not high, investigate the impact of LOH of 16q on the survival of WT patients in different subgroups and identify better treatments for WT patients with LOH of 16q in order to lengthen their survival.	[Bu, Qingting; He, Hairong; Lyu, Jun; Pan, Zhenyu] Xi An Jiao Tong Univ, Clin Res Ctr, Affiliated Hosp 1, Xian 710061, Peoples R China; [Bu, Qingting] Northwest Womens & Childrens Hosp, Dept Genet, Xian 710061, Peoples R China; [Fan, Di; You, Haisheng] Xi An Jiao Tong Univ, Dept Pharm, Affiliated Hosp 1, Xian 710061, Peoples R China; [Lyu, Jun; Pan, Zhenyu] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Peoples R China; [Pan, Zhenyu] Xi An Jiao Tong Univ, Dept Pharm, Affiliated Children Hosp, Xian 710003, Shaanxi, Peoples R China	You, HS (reprint author), Xi An Jiao Tong Univ, Dept Pharm, Affiliated Hosp 1, Xian 710061, Peoples R China.; Pan, ZY (reprint author), Xi An Jiao Tong Univ, Dept Pharm, Affiliated Children Hosp, Xian 710003, Shaanxi, Peoples R China.	pzyxch@126.com; haishengyou77@163.com		Lyu, Jun/0000-0002-2237-8771	National Social Science Foundation of China [16BGL183]; Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2015JM8415]; Fundamental Research Funds for the Central Universities of ChinaFundamental Research Funds for the Central Universities [2011jdhz55]; Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China [XJTU1AF-CRF-2016-021]	This study was funded by the National Social Science Foundation of China (No. 16BGL183), the Natural Science Foundation of Shaanxi Province (No. 2015JM8415), the Fundamental Research Funds for the Central Universities of China (No. 2011jdhz55), and the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China (No. XJTU1AF-CRF-2016-021).	BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BIRCH JM, 1995, HEMATOL ONCOL CLIN N, V9, P1157; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Chagtai T, 2016, J CLIN ONCOL, V34, P3195, DOI 10.1200/JCO.2015.66.0001; Cheung PFY, 2014, CANCER CELL INT, V14, DOI [10.1186/s12935-014-0103, 10.1186/s12935-014-0103-y]; Davidoff Andrew M, 2012, Adv Pediatr, V59, P247, DOI 10.1016/j.yapd.2012.04.001; Dome Jeffrey S, 2014, Am Soc Clin Oncol Educ Book, P215, DOI 10.14694/EdBook_AM.2014.34.215; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy PE, 2005, J CLIN ONCOL, V23, P7312, DOI 10.1200/JCO.2005.01.2799; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Joseph CG, 2014, SCIENCE, V343, P152, DOI 10.1126/science.1246886; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; Kluth M, 2015, INT J CANCER, V137, P2354, DOI 10.1002/ijc.29613; Kong XY, 2017, ONCOTARGETS THER, V10, P1335, DOI 10.2147/OTT.S120341; Margulis AV, 2014, CLIN EPIDEMIOL, V6, P359, DOI 10.2147/CLEP.S66677; Mengelbier LH, 2010, AM J PATHOL, V177, P2609, DOI 10.2353/ajpath.2010.100130; Messahel B, 2009, EUR J CANCER, V45, P819, DOI 10.1016/j.ejca.2009.01.005; Metzger ML, 2005, ONCOLOGIST, V10, P815, DOI 10.1634/theoncologist.10-10-815; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Mummert SK, 2005, GENE CHROMOSOME CANC, V43, P155, DOI 10.1002/gcc.20176; Pan Z., 2017, ONCOTARGET, V8; Ryland GL, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0123-z; Safford SD, 2003, ANN SURG ONCOL, V10, P136, DOI 10.1245/ASO.2003.03.038; Sana M, 2015, J CANCER RES THER, V11, P508, DOI 10.4103/0973-1482.163698; Schulz S, 2000, J PATHOL, V191, P162; Skotnicka-Klonowicz G, 2000, EUR J SURG ONCOL, V26, P61, DOI 10.1053/ejso.1999.0742; Spreafico F, 2013, J UROLOGY, V189, P260, DOI 10.1016/j.juro.2012.09.009; Sui QQ, 2017, J CANCER, V8, P3969, DOI 10.7150/jca.21476; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wiener JS, 1998, J UROLOGY, V159, P1316, DOI 10.1016/S0022-5347(01)63608-5; Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141; Zhang Lei, 2014, J Evid Based Med, V7, P263, DOI 10.1111/jebm.12126; [张亮 Zhang Liang], 2002, [中华小儿外科杂志, Chinese Journal of Pediatric Surgery], V23, P202	35	1	1	0	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1772	1777		10.1016/j.prp.2018.08.010			6	Pathology	Pathology	HA0MP	WOS:000449902400004	30143352				2019-10-28	
J	Xue, L; Lu, XL; He, JT; Zhang, T; Wu, XK; Zhang, YP; Wang, NN; An, Z; Xu, JR; Geng, Y				Xue, Li; Lu, Xiaolan; He, Juntao; Zhang, Ting; Wu, Xiaokang; Zhang, Yanping; Wang, Ningning; An, Zhe; Xu, Jiru; Geng, Yan			Serum CK 18-M30 reflect liver pathological severity during NAFLD progression in a rat model	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cytokeratin 18; Nonalcoholic fatty liver; Liver pathological severity; Routine clinico-biological indices	NONALCOHOLIC FATTY LIVER; DISEASE SEVERITY; FRAGMENT LEVELS; SCORING SYSTEM; CYTOKERATIN 18; KERATIN 8; STEATOHEPATITIS; APOPTOSIS; BIOMARKER; BIOPSY	Background: CK 18-M30 was increased in patients with NAFLD. However, little is known about the relationship between CK 18-M30 and NAFLD progression. We aimed to analyze the variety of CK 18-M30 and other metabolism indices during NAFLD progression. Meanwhile, we aimed to investigate the correlation between CK 18-M30 and liver pathology during NAFLD progression. Materials and methods: Rats were fed with high sucrose and high fat diet for building NAFLD models. We detected liver pathology by hematoxylin-eosin (HE) staining. We also detected serum CK 18-M30 and metabolism indices including liver enzymes, serum lipids and glycometabolism indices. Results: The aggravating degree of liver pathology appeared with prolonged feeding period. The relevance of CK 18-M30 to the severity of liver pathology were higher relative to other indices. Conclusion: Our results suggested the significance of CK 18-M30 in the progression of NAFLD and provided new evidence for the early diagnosis and prognostic estimation of NAFLD.	[Xue, Li; He, Juntao; Wu, Xiaokang; Zhang, Yanping; An, Zhe; Geng, Yan] Xi An Jiao Tong Univ, Dept Lab, Affiliated Hosp 2, Coll Med, Xian 710004, Shaanxi, Peoples R China; [Lu, Xiaolan] Xi An Jiao Tong Univ, Dept Gastroenterol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China; [Zhang, Ting] Nanjing Med Univ, Dept Lab, Wuxi Matern & Child Hlth Care Hosp, Wuxi 214002, Jiangsu, Peoples R China; [Wang, Ningning] Xi An Jiao Tong Univ, Dept Infect Control, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China; [Xu, Jiru] Xi An Jiao Tong Univ, Dept Immunol & Pathogen Biol, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China	Geng, Y (reprint author), Xi An Jiao Tong Univ, Dept Lab, Affiliated Hosp 2, Coll Med, Xian 710004, Shaanxi, Peoples R China.	zhangting040715@163.com; ninglian2000@163.com; xujiru@mail.xjtu.edu.cn; gengyanjyk@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81070328, 81200583]; Fundamental Research Funds for the Central Universities of ChinaFundamental Research Funds for the Central Universities [xjj2016109]	This research was supported by the National Natural Science Foundation of China (81070328 and 81200583) and the Fundamental Research Funds for the Central Universities of China (No. xjj2016109).	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Ashraf NU, 2015, FREE RADICAL RES, V49, P1405, DOI 10.3109/10715762.2015.1078461; Bantel H, 2009, HEPATOLOGY, V50, P991, DOI 10.1002/hep.23092; Bettermann K, 2016, ONCOTARGET, V7, P73309, DOI 10.18632/oncotarget.12325; Campos GM, 2008, HEPATOLOGY, V47, P1916, DOI 10.1002/hep.22241; Canbay A, 2014, Z GASTROENTEROL, V52, P290, DOI 10.1055/s-0033-1356138; Diab DL, 2008, CLIN GASTROENTEROL H, V6, P1249, DOI 10.1016/j.cgh.2008.07.016; Ebbert JO, 2013, NUTRIENTS, V5, P498, DOI 10.3390/nu5020498; Feldstein AE, 2005, FRONT BIOSCI-LANDMRK, V10, P3093, DOI 10.2741/1765; Feldstein AE, 2013, AM J GASTROENTEROL, V108, P1526, DOI 10.1038/ajg.2013.168; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Fitzpatrick E., 2010, J PEDIAT GASTROENTER, V51; Harwood J, 2010, J CLIN GASTROENTEROL, V44, pE253, DOI 10.1097/MCG.0b013e3181cf8358; Haybaeck J, 2012, LAB INVEST, V92, P857, DOI 10.1038/labinvest.2012.49; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455; Kucukoglu O, 2014, HEPATOLOGY, V60, P169, DOI 10.1002/hep.27068; Mahajan V, 2011, GASTROENTEROLOGY, V141, P1080, DOI 10.1053/j.gastro.2011.05.039; Maximos M, 2015, HEPATOLOGY, V61, P153, DOI 10.1002/hep.27395; Milic S, 2014, WORLD J GASTROENTERO, V20, P9330, DOI 10.3748/wjg.v20.i28.9330; Molnar A, 2011, EXPERT REV GASTROENT, V5, P167, DOI [10.1586/egh.11.5, 10.1586/EGH.11.5]; Musso G, 2010, HEPATOLOGY, V51, P715, DOI 10.1002/hep.23255; Palekar NA, 2006, LIVER INT, V26, P151, DOI 10.1111/j.1478-3231.2005.01209.x; Poynard T, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-34; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Rosenstengel S, 2011, J INVEST SURG, V24, P273, DOI 10.3109/08941939.2011.586094; Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354; Schattenberg JM, 2010, DIGEST DIS, V28, P247, DOI 10.1159/000282097; Seeff LB, 2010, CLIN GASTROENTEROL H, V8, P877, DOI 10.1016/j.cgh.2010.03.025; Singh S, 2015, CLIN GASTROENTEROL H, V13, P643, DOI 10.1016/j.cgh.2014.04.014; Stojsavljevic S, 2014, WORLD J GASTROENTERO, V20, P18070, DOI 10.3748/wjg.v20.i48.18070; Szabo S, 2015, J HEPATOL, V62, P1357, DOI 10.1016/j.jhep.2015.01.007; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Wieckowska A, 2006, HEPATOLOGY, V44, P27, DOI 10.1002/hep.21223; Zatloukal B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096690	35	0	0	1	10	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1778	1786		10.1016/j.prp.2018.08.016			9	Pathology	Pathology	HA0MP	WOS:000449902400005	30149902				2019-10-28	
J	Wang, XY; Qi, M				Wang, Xiuyan; Qi, Ming			miR-718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Akt-mTOR pathway; miR-718; Papillary thyroid cancer; PDPK1; Malignancy	MICRORNA; PATHWAY; CARCINOMAS; REGULATOR; PREDICTS; SURVIVAL; MUTATION; STRESS; PDK1	Background: MicroRNAs bind the 3' untranslated regions (3'-UTRs) of mRNAs and thereby regulate gene expression post-transcriptionally and play an important role in cancer delvelopment. In the present study, we have explored the role of miR-718 in papillary thyroid cancer cell malignancy. Materials/methods: Here we examined the miRNA expression in human papillary thyroid cancer by RT-PCR. Luciferase activity, RT-PCR and western blot assays were used to confirmed the target of miRNA. MU, colony formation, transwell, glucose consumption and lactate production assays were performed to analyze papillary thyroid cancer cell function. Western blot for signaling proteins was used to reveal the mechanism. Results: We first determined that miR-718 mRNA expression levels in PTC samples were reduced. The 3'-UTR of 3-Phosphoinositide Dependent Protein Kinase 1 (PDPK1) was then identified as a target of miR-718. Luciferase assays showed that miR-718 does in fact bind the wild-type PDPK1 3'-UTR. We assessed the effects of miR-718 on p-Akt, Akt, p-mTOR and mTOR expression. We determined that miR-718 negatively regulates their levels, respectively, of Akt-mTOR pathway components. We then assessed the effects of miR-718 on PTC cell behavior. The results revealed that miR-718 negatively regulates PTC cell proliferation, migration, and invasion. In addition, miR-718 was found to inhibit cell glucose metabolism, likely through the Akt-mTOR pathway. Finally, PDPK1 could rescue PTC cell inhibition induced by miR-718. Conclusions: The present study strongly suggests that miR-718 inhibits PTC cell proliferation, metastasis, and glucose metabolism by negatively regulating the Akt-mTOR signaling pathway.	[Wang, Xiuyan; Qi, Ming] First Hosp Harbin, Dept Gen Surg, 151 Diduan St, Harbin 150010, Heilongjiang, Peoples R China	Qi, M (reprint author), First Hosp Harbin, Dept Gen Surg, 151 Diduan St, Harbin 150010, Heilongjiang, Peoples R China.	sige004@163.com					Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Emmanouilidi A., 2017, CANCERS BASEL; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Kazaure HS, 2012, ANN SURG ONCOL, V19, P1874, DOI 10.1245/s10434-011-2129-x; Kim HI, 2018, ORAL ONCOL, V78, P80, DOI 10.1016/j.oraloncology.2018.01.021; Lee JH, 2007, CANCER-AM CANCER SOC, V110, P38, DOI 10.1002/cncr.22754; Leng RB, 2014, FEBS LETT, V588, P2078, DOI 10.1016/j.febslet.2014.04.040; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lien EC, 2016, RECENT RESULTS CANC, V207, P39, DOI 10.1007/978-3-319-42118-6_3; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Perdas E., 2018, CURR DRUG TARGETS; Pontius LN, 2017, THYROID, V27, P1408, DOI 10.1089/thy.2017.0306; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Randolph G. W., 2012, PROGNOSTIC SIGNIFICA; Rusinek D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081817; Saito T, 2010, NEW BIOTECHNOL, V27, P243, DOI 10.1016/j.nbt.2010.02.016; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sipos JA, 2010, CLIN ONCOL-UK, V22, P395, DOI 10.1016/j.clon.2010.05.004; Song JY, 2017, BIOCHEM BIOPH RES CO, V490, P217, DOI 10.1016/j.bbrc.2017.06.024; Sugimachi K, 2015, BRIT J CANCER, V112, P532, DOI 10.1038/bjc.2014.621; Sun L, 2016, CANCER BIOMARK, V16, P265, DOI 10.3233/CBM-150564; Wang TT, 2018, ONCOTARGET, V9, P5473, DOI 10.18632/oncotarget.16681; Wang ZD, 2017, J ZHEJIANG UNIV-SC B, V18, P27, DOI 10.1631/jzus.B1600205; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987	36	4	4	0	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1787	1793		10.1016/j.prp.2018.08.022			7	Pathology	Pathology	HA0MP	WOS:000449902400006	30166214				2019-10-28	
J	Zhang, YT; Liu, J; Ma, YY; Wang, JJ; Zhu, J; Liu, J; Zhang, J				Zhang, Yitong; Liu, Jing; Ma, Yanyun; Wang, Jingjie; Zhu, Jie; Liu, Jie; Zhang, Jun			Integrated profiling of long non-coding RNAs and mRNAs identifies novel regulators associated with liver fibrosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Liver fibrosis; Long noncoding RNA; mRNA	LARGE GENE LISTS; HEPATIC LIPOCYTES; X-CHROMOSOME; CHROMATIN; COLLAGEN; CELLS; DIFFERENTIATION; DISEASE; TARGETS	Liver fibrosis is the underlying cause of cirrhosis and liver failure in any type of chronic liver injury. However, the function of lncRNAs in liver fibrosis is largely unknown. In this study, we performed transcriptome sequencing of CC14 induced mouse fibrotic liver tissues and normal liver tissues, and found 118 lncRNAs and 1921 mRNAs were significantly up-regulated, whereas 59 lncRNAs and 1504 mRNAs were down-regulated in fibrotic livers. Gene ontology analysis revealed that the differentially expressed lncRNAs are implicated in cell junction, cell differentiation and cell proliferation, pathways closely associated with EMT. The co-expression network of highly conserved lncRNAs and highly co-expressed mRNAs were constructed, whose differential expression were further confirmed by quantitative real-time PCR. Two highly conserved lncRNAs, Gm11149 and Gm20471, were identified to be significantly up-regulated in liver fibrosis. Their target genes, Ncam1 and Prix1 respectively, are important modulators of EMT. Thus, the relative dynamic levels of Gm11149 and Ncam1, Gm20471 and Prrx1 were further monitored during the progress of liver fibrosis and their co-expression pattern was proved. Collectively, our results uncovered a crucial role of lncRNAs in the regulation of liver fibrosis and the lncRNA -mRNA network might provide new therapeutic strategies.	[Zhang, Yitong; Wang, Jingjie; Zhu, Jie; Liu, Jie; Zhang, Jun] Fudan Univ, Dept Digest Dis, Huashan Hosp, Shanghai, Peoples R China; [Liu, Jing; Ma, Yanyun] Fudan Univ, Minist Educ, Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai, Peoples R China; [Liu, Jing; Ma, Yanyun] Fudan Univ, State Key Lab Genet Engn, Sch Life Sci, Shanghai, Peoples R China	Zhang, J (reprint author), Fudan Univ, Dept Digest Dis, Huashan Hosp, Shanghai, Peoples R China.	archsteed@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81420108005]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [16JC1420104]	This work was supported by grants from the National Natural Science Foundation of China (No. 81420108005) and the Science and Technology Commission of Shanghai Municipality (No. 16JC1420104). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bartke T, 2011, CELL CYCLE, V10, P182, DOI 10.4161/cc.10.2.14477; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CLEMENT B, 1986, HEPATOLOGY, V6, P225, DOI 10.1002/hep.1840060212; Frame MC, 2008, DEV CELL, V15, P494, DOI 10.1016/j.devcel.2008.09.016; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; Gressner AM, 2006, J CELL MOL MED, V10, P76, DOI 10.1111/j.1582-4934.2006.tb00292.x; Hannon GJ, 2006, COLD SPRING HARB SYM, V71, P551, DOI 10.1101/sqb.2006.71.064; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Moran-Salvador E, 2017, CELL MOL GASTROENTER, V4, P125, DOI 10.1016/j.jcmgh.2017.04.007; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; ROJKIND M, 1976, P NATL ACAD SCI USA, V73, P539, DOI 10.1073/pnas.73.2.539; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Song YF, 2017, HEPATOLOGY, V66, P1183, DOI 10.1002/hep.29209; Turner R, 2011, HEPATOLOGY, V53, P1035, DOI 10.1002/hep.24157; van Dongen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11115; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wu N, 2017, FASEB J, V31, P4305, DOI 10.1096/fj.201700097R; Xie CY, 2014, NUCLEIC ACIDS RES, V42, pD98, DOI 10.1093/nar/gkt1222; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Zeybel M, 2013, J HEPATOL, V59, P1349, DOI 10.1016/j.jhep.2013.05.039; Zhang K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00204-4; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; Zheng JJ, 2016, ONCOTARGET, V7, P62886, DOI 10.18632/oncotarget.11709	32	2	2	0	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1794	1803		10.1016/j.prp.2018.08.021			10	Pathology	Pathology	HA0MP	WOS:000449902400007	30193772				2019-10-28	
J	Hong, J; Zhou, WZ; Wang, XW				Hong, Jiang; Zhou, Weizheng; Wang, Xiaowei			Involvement of miR-455 in the protective effect of H2S against chemical hypoxia-induced injury in BEAS-2B cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						BEAS-2B cells; Hydrogen sulfide; microRNA-455; Hypoxia-induced injury; Endoplasmic reticulum stress; Calreticulin	ACUTE LUNG INJURY; ENDOPLASMIC-RETICULUM STRESS; OBSTRUCTIVE PULMONARY-DISEASE; EPITHELIAL-CELLS; MICRORNA REGULATION; HYDROGEN-SULFIDE; EXPRESSION; ACTIVATION; MECHANISM; APOPTOSIS	The protective effect of hydrogen sulfide (H2S) against hypoxia-induced injury via anti-apoptosis is well established, but the underlying mechanism remains unclear. The present study aimed to investigate whether miR455 participated in the H2S protection of lung epithelial cells against CoCl2-induced apoptosis by regulating endoplasmic reticulum stress (ERS)-related genes. Human lung epithelial cells BEAS-28 were subjected to hypoxia injury with or without H2S preconditioning. It was found that hypoxia injury increased apoptosis of BEAS2B cells, down-regulated the expression of miR-455, and upregulated the expression of calreticulin (Calr). H2S preconditioning attenuated lung epithelial cells apoptosis, enhanced cell viability, up-regulated the expression of miR-455, as well as down-regulated the expression of Calr following hypoxia injury. In addition, Calr, GRP78, C/EBP homologous protein (CHOP) and Caspase-12 protein was down-regulated by the miR-455 mimic and upregulated by the miR-455 inhibitor. These results implicate miR-455 regulated H2S protection of lung epithelial cells against hypoxia-induced apoptosis by stimulating Calr.	[Hong, Jiang; Zhou, Weizheng; Wang, Xiaowei] Changhai Hosp, Dept Thorac Surg, 168 Changhai Rd, Shanghai 200435, Peoples R China	Wang, XW (reprint author), Changhai Hosp, Dept Thorac Surg, 168 Changhai Rd, Shanghai 200435, Peoples R China.	Jacques83@163.com					Adyshev DM, 2013, AM J RESP CELL MOL, V49, P58, DOI 10.1165/rcmb.2012-0397OC; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Bernard O., 2017, J PHYSL LUNG CEL S59, V46; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Filipovic MR, 2012, BIOCHEM J, V441, P609, DOI 10.1042/BJ20111389; Frank JA, 2007, AM J PHYSIOL-LUNG C, V293, pL52, DOI 10.1152/ajplung.00256.2006; Gold LI, 2010, FASEB J, V24, P665, DOI 10.1096/fj.09-145482; Hippenstiel S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-97; Hu R, 2015, J IMMUNOL, V195, P4802, DOI 10.4049/jimmunol.1500073; Kang B., 2014, J MED POSTGRADUATES; Kang B, 2014, MOL BIOL REP, V41, P1927, DOI 10.1007/s11033-014-3039-3; Ke XS, 2003, CURR OPIN CHEM BIOL, V7, P516, DOI 10.1016/S1367-5931(03)00075-9; Lee SM, 2014, MOL MED REP, V10, P292, DOI 10.3892/mmr.2014.2155; Li PC, 2018, INT J MOL MED, V41, P2505, DOI 10.3892/ijmm.2018.3486; Lim SK, 2013, BIOCHEM BIOPH RES CO, V440, P707, DOI 10.1016/j.bbrc.2013.09.136; Lin F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00675; Liu ZW, 2015, WORLD J EMERG MED, V6, P67, DOI 10.5847/wjem.j.1920-8642.2015.01.012; Lowicka E, 2007, PHARMACOL REP, V59, P4; Paul BD, 2015, TRENDS BIOCHEM SCI, V40, P687, DOI 10.1016/j.tibs.2015.08.007; Rajasekaran S, 2016, J CELL PHYSIOL, V231, P2097, DOI 10.1002/jcp.25316; Rao R, 2015, TOXICOL SCI, V144, P284, DOI 10.1093/toxsci/kfu315; Roff AN, 2014, AM J CLIN EXP IMMUNO, V3, P68; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Tian M, 2012, MOL MED REP, V6, P335, DOI 10.3892/mmr.2012.904; Tuder RM, 2012, J CLIN INVEST, V122, P2749, DOI 10.1172/JCI60324; Varga ZV, 2014, AM J PHYSIOL-HEART C, V307, pH216, DOI 10.1152/ajpheart.00812.2013; Vergadi E, 2014, J IMMUNOL, V192, P394, DOI 10.4049/jimmunol.1300959; Wagner F, 2009, CRIT CARE, V13, DOI 10.1186/cc7700; Wu CT, 2015, INT J MOL MED, V35, P893, DOI 10.3892/ijmm.2015.2105; Wu DD, 2015, OXID MED CELL LONGEV, DOI 10.1155/2015/186908; Xu FF, 2015, CHINESE MED J-PEKING, V128, P353, DOI 10.4103/0366-6999.150103; Xu ZJ, 2014, BIOCHEM BIOPH RES CO, V445, P48, DOI 10.1016/j.bbrc.2014.01.108; Yang K, 2015, INT J CLIN EXP PATHO, V8, P1104; Zhang HX, 2016, CELL PHYSIOL BIOCHEM, V40, P1603, DOI 10.1159/000453210; Zhong Q, 2011, AM J RESP CELL MOL, V45, P498, DOI 10.1165/rcmb.2010-0347OC; Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010	37	0	1	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1804	1810		10.1016/j.prp.2018.08.008			7	Pathology	Pathology	HA0MP	WOS:000449902400008	30193773				2019-10-28	
J	Yan, TF; Wu, MJ; Xiao, B; Hu, Q; Fan, YH; Zhu, XG				Yan, Teng-feng; Wu, Miao-jing; Xiao, Bing; Hu, Qing; Fan, Yang-hua; Zhu, Xin-gen			Knockdown of HOXC6 inhibits glioma cell proliferation and induces cell cycle arrest by targeting WIF-1 in vitro and vivo	PATHOLOGY RESEARCH AND PRACTICE			English	Article						HOXC6; WIF-1; Glioblastoma; Proliferation; Cell cycle	ESTROGEN-RECEPTOR; EXPRESSION; CARCINOMA; MIGRATION	Background: Homeobox C6 (HOXC6) is one of several HOXC genes and is frequently overexpressed in multiple cancers. However, the function and mechanism of HOXC6 in glioma remain unclear. Methods: The expression level of HOXC6 and its relationship with prognosis in glioma were determined through the TCGA database. The expressions of HOXC6 mRNA in glioblastoma tissues and normal brain tissues were detected by qRT-PCR and Western blot. To explore the role of HOXC6 in glioma, a lentiviral vector that expressed HOXC6-shRNA was constructed and transfected into glioma U87 cells. The expression levels of HOXC6 and WNT inhibitory factor 1 (WIF-1) in the glioma U87 cells after transfection with HOXC6-shRNA were measured by real-time PCR and Western blot . CCK-8, colony formation and EdU assays were used to measure the effects of HOXC6 on U87 cell proliferation, and flow cytometry was used to monitor the changes in the cell cycle and cell apoptosis after transfection with HOXC6-shRNA. Xenograft tumors were examined in vivo for the carcinogenic effects and prognostic value of HOXC6 in glioma tissues. Results: In this study, HOXC6 was highly expressed in human glioma tissues, and a high expression of HOXC6 was associated with poor prognosis in GBM patients. We demonstrated that HOXC6 was highly expressed in human GBM tissues and three glioma cell lines. The knockdown of HOXC6 expression significantly inhibited the proliferation and colony formation ability of U87 cells by blocking cell cycle progression in the GO/G1 phase and induced apoptosis. In addition, we found that the mRNA and protein levels of WIF-1 were substantially increased after transfection with HOXC6-shRNA compared with Ctrl-shRNA in vitro. Consistent with the results of the in vitro assays, the xenograft assay and immunohistochemistry also demonstrated that in response to HOXC6 inhibition, the tumor growth and Ki-67 expression level were inhibited and the WIF-1 expression was increased in vivo. Conclusions: In conclusion, the results of the current study indicate that HOXC6 promotes glioma U87 cell growth through the WIF-1/Wnt signaling pathway and HOXC6 might be a novel target in clinical treatment for gliomas.	[Yan, Teng-feng; Wu, Miao-jing; Xiao, Bing; Hu, Qing; Fan, Yang-hua; Zhu, Xin-gen] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China	Fan, YH; Zhu, XG (reprint author), Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.	fanyanghua1992@163.com; xingenzhu_2015@sina.com			Science and Youth Technology Research Project of the Jiangxi Province Education Department [GJJ160253]	This article was supported by the Science and Youth Technology Research Project of the Jiangxi Province Education Department (NO. GJJ160253).	Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Asslaber M, 2017, J NEUROPATH EXP NEUR, V76, P16, DOI 10.1093/jnen/nlw098; Chariot A., 1966, BIOCH J 1, V319, P91; Chen SW, 2016, MOL MED REP, V14, P3261, DOI 10.3892/mmr.2016.5640; Fan YH, 2017, ONCOL REP, V38, P1149, DOI 10.3892/or.2017.5731; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Guo YB, 2016, ONCOL LETT, V11, P75, DOI 10.3892/ol.2015.3893; Ji CX, 2018, ONCOL REP, V39, P1825, DOI 10.3892/or.2018.6261; Ji ML, 2016, ONCOTARGET, V7, P29216, DOI 10.18632/oncotarget.8703; Li PD, 2018, AGING-US, V10, P115, DOI 10.18632/aging.101363; Malinauskas T, 2011, NAT STRUCT MOL BIOL, V18, P886, DOI 10.1038/nsmb.2081; Shen LY, 2017, ONCOL LETT, V14, P4835, DOI 10.3892/ol.2017.6772; Singleton DW, 2006, ENVIRON RES, V100, P86, DOI 10.1016/j.envres.2005.05.004; Sui CJ, 2016, AM J CANCER RES, V6, P2787; Vinarskaja Anna, 2011, Cancers (Basel), V3, P3714, DOI 10.3390/cancers3043714; Wu J, 2012, J CLIN NEUROSCI, V19, P1428, DOI 10.1016/j.jocn.2011.12.023; Zhang Q, 2013, NEOPLASMA, V60, P439, DOI 10.4149/neo_2013_057	17	0	0	2	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1818	1824		10.1016/j.prp.2018.09.001			7	Pathology	Pathology	HA0MP	WOS:000449902400010	30228024				2019-10-28	
J	Luo, LF; Chi, HB; Ling, J				Luo, Lifei; Chi, Hongbo; Ling, Jie			MiR-124-3p suppresses glioma aggressiveness via targeting of Fra-2	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; Fra-2; miR-124-3p; EMT	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; TRANSCRIPTION FACTORS; FOS FAMILY; GLIOBLASTOMA; INVASION; EXPRESSION; MICRORNA; CELLS; TRANSFORMATION	Malignant glioma is the most common and deadly primary brain tumor in adults. However, the mechanisms underlying the malignancy of glioma remain unclear. In the present study, we found that Fos-related antigen-2 (Fra-2) was overexpressed in most glioma cells, and knockdown of Fra-2 prevented cell proliferation, migration, and invasion. Mechanistically, Fra-2 silencing led to a significant reduction in cell-cycle drivers (Cyclin D1 and Cyclin E1), one invasion-associated gene (MMP9), the mesenchymal marker (Vimentin), and induction of the epithelial marker (E-cadherin). Further study confirmed that miR-124-3p decreased the expression of Fra-2 via directly targeting the 3'-UTR, and transfection with miR-124-3p in glioma cells inhibited expression of the above cell-cycle and EMT promoters. Phenotypic experiments also showed that overexpression of Fra-2 weakened the inhibitory effects of miR-124-3p on the proliferation, migration, and invasion of glioma cells. In addition, Fra-2 knockdown impaired the malignant phenotypes enhanced by miR-124-3p inhibition, which suggested a crucial role for the miR-124-3p/Fra-2 pathway in glioma development. Consistently, high expression of Fra-2 was closely associated with low miR-124-3p level and indicated a poor prognosis in patients with glioma. In conclusion, this study indicates the existence of an aberrant miR-124-3p/Fra-2 pathway that results in glioma aggressiveness, which suggests novel therapeutic opportunities for this fatal disease.	[Luo, Lifei; Chi, Hongbo] Enze Hosp, Taizhou Enze Med Ctr, Clin Lab, Luqiao 318050, Peoples R China; [Ling, Jie] Wenzhou Med Univ, Taizhou Peoples Hosp 1, Clin Lab, Huangyan Hosp, Huangyan 318020, Zhejiang, Peoples R China	Ling, J (reprint author), Wenzhou Med Univ, Taizhou Peoples Hosp 1, Clin Lab, Huangyan Hosp, Huangyan 318020, Zhejiang, Peoples R China.	lingjie2001@yeah.net			Zhejiang Traditional Chinese Medicine Science and Technology Plan [2015ZA217]	This work was supported by Zhejiang Traditional Chinese Medicine Science and Technology Plan (2015ZA217).	An LW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069478; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Eto I, 2000, CELL PROLIFERAT, V33, P167, DOI 10.1046/j.1365-2184.2000.00176.x; Fowler A, 2011, EUR J CANCER, V47, P953, DOI 10.1016/j.ejca.2010.11.026; Gupta S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16811; Iser IC, 2017, MED RES REV, V37, P271, DOI 10.1002/med.21408; Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383; Liu LP, 2010, CANCER RES, V70, P3750, DOI 10.1158/0008-5472.CAN-09-3838; Liu ZG, 2016, ONCOTARGET, V7, P65946, DOI 10.18632/oncotarget.11779; Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289; Mangiola A, 2010, EXPERT REV NEUROTHER, V10, P507, DOI [10.1586/ern.09.158, 10.1586/ERN.09.158]; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Moller HG, 2013, MOL NEUROBIOL, V47, P131, DOI 10.1007/s12035-012-8349-7; Ozanne B. W., 1990, EUR J CANCER, V36, P1640; Poznic M, 2009, J BIOSCIENCES, V34, P305, DOI 10.1007/s12038-009-0034-2; Qiao YC, 2015, ONCOTARGET, V6, P7804, DOI 10.18632/oncotarget.3158; Qin W, 2014, INT J ONCOL, V45, P1225, DOI 10.3892/ijo.2014.2506; Qu DW, 2014, EUR REV MED PHARMACO, V18, P516; Reardon DA, 2011, NEURO-ONCOLOGY, V13, P353, DOI 10.1093/neuonc/noq203; Schroder C, 2010, EUR J CANCER, V46, P1650, DOI 10.1016/j.ejca.2010.02.008; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Sonntag KC, 2012, EXP NEUROL, V235, P427, DOI 10.1016/j.expneurol.2011.11.035; Tan Ping-Guo, 2004, Ai Zheng, V23, P63; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-276; Xue Q, 2017, ONCOL LETT, V13, P1325, DOI 10.3892/ol.2017.5567; Zhang L, 2017, BIOSCI REP, V37	35	2	2	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1825	1834		10.1016/j.prp.2018.09.017			10	Pathology	Pathology	HA0MP	WOS:000449902400011	30243808				2019-10-28	
J	Cen, WN; Pang, JS; Huang, JC; Hou, JY; Bao, WG; He, RQ; Ma, J; Peng, ZG; Hu, XH; Ma, FC				Cen, Wei-ning; Pang, Jin-shu; Huang, Jia-cheng; Hou, Jia-yin; Bao, Wen-guang; He, Rong-quan; Ma, Jie; Peng, Zhi-gang; Hu, Xiao-hua; Ma, Fu-chao			The expression and biological information analysis of miR-375-3p in head and neck squamous cell carcinoma based on 1825 samples from GEO, TCGA, and peer-reviewed publications	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-375-3p; HNSCC; Clinical significance; Prognosis; Biological pathway	PREDICTS POOR-PROGNOSIS; CLINICAL-OUTCOMES; GASTRIC-CANCER; TUMOR-GROWTH; MICRORNA-375; INVASION; SURVIVAL; PROLIFERATION; BIOMARKERS; EDIL3	Background: The specific expression level and clinical significance of miR-375-3p in HNSCC had not been fully stated, as well as the overall biological function and molecular mechanisms. Therefore, we purpose to carry out a comprehensive meta-analysis to further explore the clinical significance and potential function mechanism of miR-375-3p in HNSCC. Methods: HNSCC-related data was gained from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and peer-reviewed journals. A meta-analysis was carried out to comprehensively explore the relationship between miR-375-3p expression level and clinicopathological features of HNSCC. And summary receiver operating characteristic (SROC) curve analysis was applied for evaluating disease diagnosis value of miR375-3p. In addition, a biological pathway analysis was also performed to assess the possible molecular mechanism of miR-375-3p in HNSCC. Results: A total of 24 available records and references were added into analysis. The overall pooled meta-analysis outcome revealed a relatively lower expression level of miR-375-3p in HNSCC specimens than that in noncancerous controls (P < 0.001). And SROC curve analysis showed that the pooled area under the SROC curve (AUC) was 0.90 (95%CI: 0.88-0.93). In addition, biological pathway analysis indicated that LAMC1, EDIL3, FN1, VEGFA, IGF2BP2, and IGF2BP3 maybe the latent target genes of miR-375-3p, which were greatly enriched in the pathways of beta3 integrin cell surface interactions and the binding of RNA via the insulin-like growth factor-2 mRNA-binding protein (IGF2BPs/IMPs/VICKZs). Conclusion: MiR-375-3p expression clearly decreased in HNSCC samples compared with non-cancerous controls. Meanwhile, miR-375-3p may serve as a tumor suppressor via regulating tumor-related genes LAMC1, EDIL3, FN1, VEGFA, IGF2BP2, and IGF2BP3 in HNSCC.	[Cen, Wei-ning; Pang, Jin-shu; Huang, Jia-cheng; Bao, Wen-guang; He, Rong-quan; Ma, Jie; Peng, Zhi-gang; Hu, Xiao-hua; Ma, Fu-chao] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning 530021, Peoples R China; [Hou, Jia-yin] Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, Nanning 530021, Peoples R China	Ma, FC (reprint author), Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning 530021, Peoples R China.	mafuchao@live.cn		Hou, Jiayin/0000-0002-7441-3540	Guangxi Zhuang Autonomous Region University Student Innovative Plan [201710598068]	The study was supported by the funds of the Guangxi Zhuang Autonomous Region University Student Innovative Plan (201710598068). And all data used for the analysis were acquired from TCGA, GEO, and publications.	Abedini Fatemeh, 2018, Microrna, V7, P74, DOI 10.2174/2211536607666180129153307; Alajez NM, 2012, ONCOTARGET, V3, P1641; Amundson SA, 2010, CANCER BIOL THER, V10, P1252, DOI 10.4161/cbt.10.12.13731; Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Beckham CJ, 2014, J UROLOGY, V192, P583, DOI 10.1016/j.juro.2014.02.035; Chen Dan, 2013, J Oral Maxillofac Res, V4, pe2, DOI 10.5037/jomr.2013.4102; Chen WJ, 2017, PATHOL RES PRACT, V213, P364, DOI 10.1016/j.prp.2017.01.007; Chen ZL, 2017, ONCOTARGETS THER, V10, P3353, DOI 10.2147/OTT.S137726; Chung JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20086-w; Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116; Deiuliis JA, 2016, INT J OBESITY, V40, P88, DOI 10.1038/ijo.2015.170; Fawzy IO, 2016, GROWTH FACTORS, V34, P42, DOI 10.3109/08977194.2016.1169532; Gan TQ, 2017, MED SCI MONITOR, V23, P2453, DOI 10.12659/MSM.901460; Gao YP, 2016, CELL PHYSIOL BIOCHEM, V39, P2186, DOI 10.1159/000447913; Gao YP, 2016, CELL PHYSIOL BIOCHEM, V38, P427, DOI 10.1159/000438641; Giricz O, 2012, J PATHOL, V226, P108, DOI 10.1002/path.2978; Guo Y, 2016, ONCOL REP, V36, P952, DOI 10.3892/or.2016.4852; Guo Z, 2016, MOL MED REP, V13, P1943, DOI 10.3892/mmr.2016.4782; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Hu A, 2014, AM J TRANSL RES, V6, P604; Hu CM, 2017, ONCOL LETT, V13, P4769, DOI 10.3892/ol.2017.6098; Hua YJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026521; Hudcova K, 2016, TUMOR BIOL, V37, P12627, DOI 10.1007/s13277-016-5147-2; Izzotti A, 2016, AM J CANCER RES, V6, P1461; Jia Ling-fei, 2016, Beijing Da Xue Xue Bao Yi Xue Ban, V48, P5; Jia LF, 2015, ONCOL REP, V33, P2061, DOI 10.3892/or.2015.3759; Jiang SH, 2016, ONCOTARGET, V7, P4226, DOI 10.18632/oncotarget.6772; Jimenez L, 2017, AM J PATHOL, V187, P1523, DOI 10.1016/j.ajpath.2017.02.019; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kanzaki A, 2016, INT J ONCOL, V48, P1007, DOI 10.3892/ijo.2016.3323; Kashima H, 2015, GYNECOL ONCOL, V139, P338, DOI 10.1016/j.ygyno.2015.08.025; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Kuang J, 2016, ONCOL LETT, V11, P3009, DOI 10.3892/ol.2016.4358; Laengsri V, 2018, LAB MED, V49, P97, DOI 10.1093/labmed/lmx080; Lee JE, 2016, J PROTEOMICS, V131, P17, DOI 10.1016/j.jprot.2015.10.005; Li XL, 2017, ONCOL RES, V25, P579, DOI 10.3727/97818823455816X14760504645779; Li XL, 2014, GENE, V533, P1, DOI 10.1016/j.gene.2013.09.105; Lian L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101633; Liu XJ, 2016, EUR REV MED PHARMACO, V20, P3319; Lopez YON, 2018, REP PRACT ONCOL RADI, V23, P6, DOI [10.1016/j.rpot.2017.10.003, 10.1016/j.rpor.2017.10.003]; Luo J, 2014, BIOMED RES INT, DOI 10.1155/2014/374598; Pasqualini L, 2015, MOL ENDOCRINOL, V29, P1037, DOI 10.1210/me.2014-1358; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Perdomo S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191701; Pickl JMA, 2016, ONCOTARGET, V7, P59589, DOI 10.18632/oncotarget.10729; Selth LA, 2017, ONCOGENE, V36, P24, DOI 10.1038/onc.2016.185; Serocki M, 2018, ANGIOGENESIS, V21, P183, DOI 10.1007/s10456-018-9600-2; Shao YJ, 2014, DIS MARKERS, DOI 10.1155/2014/626185; Sheldrake HM, 2009, CURR CANCER DRUG TAR, V9, P519, DOI 10.2174/156800909788486713; Siow MY, 2014, ORAL DIS, V20, P345, DOI 10.1111/odi.12118; Strauss L, 2005, MED SCI MONITOR, V11, pBR280; Tsai SC, 2017, ONCOL REP, V38, P1613, DOI 10.3892/or.2017.5811; Verduci L, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1368-y; Virgilio E, 2018, ANTICANCER RES, V38, P613, DOI 10.21873/anticanres.12265; Wang CQ, 2017, EUR REV MED PHARMACO, V21, P5101, DOI 10.26355/eurrev_201711_13826; Wang J, 2013, INT J ORAL MAX SURG, V42, P949, DOI 10.1016/j.ijom.2013.04.016; Wang W, 2016, ONCOTARGETS THER, V9, P1371, DOI 10.2147/OTT.S97969; Wise-Draper T, 2018, TRANSL ONCOL, V11, P168, DOI 10.1016/j.tranon.2017.12.001; Wu QW, 2018, ONCOL REP, V39, P1461, DOI 10.3892/or.2018.6177; Wu Y., 2017, CANC MED, V6, P1666; Wu Y, 2016, ONCOL LETT, V12, P871, DOI 10.3892/ol.2016.4707; Xia HP, 2015, J HEPATOL, V63, P863, DOI 10.1016/j.jhep.2015.05.005; Xie DF, 2017, ONCOL LETT, V14, P2305, DOI 10.3892/ol.2017.6423; Xue HY, 2016, ONCOTARGET, V7, P86675, DOI 10.18632/oncotarget.13431; Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563; Yan Y, 2017, ONCOTARGET, V8, P8206, DOI 10.18632/oncotarget.14143; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Ye S, 2016, FEBS LETT, V590, P1641, DOI 10.1002/1873-3468.12205; Ye Y, 2017, ONCOL LETT, V14, P7799, DOI 10.3892/ol.2017.7201; Zhang B, 2017, CELL PHYSIOL BIOCHEM, V42, P2105, DOI 10.1159/000479913; Zhang YJ, 2017, J CANCER, V8, P2992, DOI 10.7150/jca.21038; Zhao W, 2017, ONCOTARGET, V8, P93672, DOI 10.18632/oncotarget.21280; Zhou X., 2018, BIOSCI REP, V38; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2; Zu CH, 2016, ANN CLIN LAB SCI, V46, P666	75	1	1	5	11	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1835	1847		10.1016/j.prp.2018.09.010			13	Pathology	Pathology	HA0MP	WOS:000449902400012	30243807				2019-10-28	
J	Pyo, JS; Son, BK; Oh, IH				Pyo, Jung-Soo; Son, Byoung Kwan; Oh, Il Hwan			Cytoplasmic Pin1 expression is correlated with poor prognosis in colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; Pin1; Subcellular localization; Immunohistochemistry; Prognosis	PROLYL-ISOMERASE PIN1; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; CYCLIN D1; OVEREXPRESSION; TARGET; CELLS; CARCINOMA; SURVIVAL	Objective: The aim of this study was to determine the clinicopathological significance and prognostic role of Pin1 expression and subcellular localization in colorectal cancer (CRC). Methods: The Pin1 expression, as well as cytoplasmic and nuclear localization, was investigated using immunohistochemistry in 265 human CRC tissues. The impact of subcellular localization of Pin1 on clinicopathological significance and prognosis in CRC was evaluated. Results: Pin1 was expressed in 164 of 265 CRCs (61.9%). Pin1 expression was not significantly correlated with any clinicopathological parameters. However, Pin1 expression was significantly correlated with worse overall and recurrence-free survivals (P = 0.002 and P = 0.001, respectively). CRCs with only nuclear Pin1 expression showed no difference in survival compared to CRCs with no Pini expression. Over half (51.7%, 137/265) of the CRCs had any cytoplasmic Pin1 expression, and 26.8% (71/265) had both cytoplasmic and nuclear expression. Cytoplasmic Pin1 expression was more frequent than only nuclear or no Pin1 expression in cases with vascular invasion and distant metastasis. Cytoplasmic Pin1 expression was significantly correlated with worse overall and recurrence-free survivals (P < 0.001 and P < 0.001, respectively). Conclusion: Taken together, our results indicated different prognostic roles of subcellular Pin1 expression in CRC. Cytoplasmic expression of Pin1, with or without nuclear expression, is an important factor in predicting aggressive tumor behavior and worse prognosis.	[Pyo, Jung-Soo] Eulji Univ, Eulji Univ Hosp, Sch Med, Dept Pathol, Daejeon, South Korea; [Son, Byoung Kwan; Oh, Il Hwan] Eulji Univ, Eulji Hosp, Sch Med, Dept Internal Med, 68 Hangeulbiseok Ro, Seoul 01830, South Korea	Son, BK (reprint author), Eulji Univ, Eulji Hosp, Sch Med, Dept Internal Med, 68 Hangeulbiseok Ro, Seoul 01830, South Korea.	sbk1026@eulji.ac.kr			SAMJIN PHARM [ITT-17-09]	This study was supported by SAMJIN PHARM (ITT-17-09) in 2018.	Amin MB, 2016, AJCC CANC STAGING MA; Atkinson GP, 2009, ONCOGENE, V28, P3735, DOI 10.1038/onc.2009.232; Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Cheng CW, 2016, WORLD J GASTROENTERO, V22, P9921, DOI 10.3748/wjg.v22.i45.9921; Fedchenko N, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0221-9; Han HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147038; He J, 2007, LUNG CANCER, V56, P51, DOI 10.1016/j.lungcan.2006.11.024; Jin HW, 2011, ONCOL LETT, V2, P1191, DOI 10.3892/ol.2011.392; Kim CJ, 2005, WORLD J GASTROENTERO, V11, P5006, DOI 10.3748/wjg.v11.i32.5006; Kim MR, 2009, CANCER SCI, V100, P1834, DOI 10.1111/j.1349-7006.2009.01260.x; Kuramochi J, 2006, J SURG ONCOL, V94, P155, DOI 10.1002/jso.20510; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Magli A, 2010, J BIOL CHEM, V285, P34518, DOI 10.1074/jbc.M110.104133; Miyashita H, 2003, ONCOL REP, V10, P455; Peng JH, 2016, ONCOTARGET, V7, P22939, DOI 10.18632/oncotarget.8217; Pyo JS, 2015, J CANCER RES CLIN, V141, P1181, DOI 10.1007/s00432-014-1890-1; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; REMMELE W, 1987, PATHOLOGE, V8, P138; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Sakuma Y, 2016, LAB INVEST, V96, P391, DOI 10.1038/labinvest.2015.155; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	27	0	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1848	1853		10.1016/j.prp.2018.09.018			6	Pathology	Pathology	HA0MP	WOS:000449902400013	30244946				2019-10-28	
J	Luo, B; Gu, YY; Wang, XD; Chen, G; Peng, ZG				Luo, Bin; Gu, Yong-yao; Wang, Xiao-dong; Chen, Gang; Peng, Zhi-gang			Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Diffuse large B-cell lymphoma; Connectivity map database; KEGG pathway; Small molecule drugs; Drug-Pathway network	CENTRAL-NERVOUS-SYSTEM; CANCER CELLS; PACLITAXEL; APOPTOSIS; RISK; CHOP; LENALIDOMIDE; METHOTREXATE; MECHANISM; RITUXIMAB	Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs were analyzed using the Database for Annotation, Visualization, and Integrated Discovery. The R software package (SubpathwayMiner) was used to perform pathway analysis on DEGs affected by drugs found in the Connectivity Map (CMap) database. Protein-protein interaction (PPI) networks of DEGs were constructed using the Search Tool for the Retrieval of Interacting Genes online database and Cytoscape software. In order to identify potential novel drugs for DLBCL, the DLBCL-related pathways and drug-affected pathways were integrated. The results showed that 1927 DEGs were identified from TCGA and GEO. We found 54 significant pathways of DLBCL using KEGG pathway analysis. By integrating pathways, we identified five overlapping pathways and 47 drugs that affected these pathways. The PPI network analysis results showed that the CDK2 is closely associated with three overlapping pathways (cell cycle, p53 signaling pathway, and small cell lung cancer). The further literature verification results showed that etoposide, rinotecan, methotrexate, resveratrol, and irinotecan have been used as classic clinical drugs for DLBCL. Anisomycin, naproxen, gossypol, vorinostat, emetine, mycophenolic acid and daunorubicin also act on DLBCL. It was found through bioinformatics analysis that paclitaxel in the drug-pathway network can be used as a potential novel drug for DLBCL.	[Luo, Bin; Peng, Zhi-gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Gu, Yong-yao; Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Wang, Xiao-dong] Guangxi Med Univ, Affiliated Hosp 1, Radiol Dept, Ultrason Div, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China	Peng, ZG (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.	drpzg001@163.com		luo, bin/0000-0002-3530-9433	Natural Science Foundation of Guangxi, ChinaNational Natural Science Foundation of Guangxi Province [2017GXNSFAA198107, 2015GXNSFDA139028]; Guangxi Zhuang Autonomous Region Education Department University [ZD2014033]; Open Fund of Guangxi Colleges and Universities Key Laboratory of Biological Molecular Medicine Research [GXBMR201601]; Guangxi Zhuang Autonomous Region Health and Family Planning Commission Self-Financed Scientific Research Project [Z20170556]	Natural Science Foundation of Guangxi, China (2015GXNSFDA139028), 2 Guangxi Zhuang Autonomous Region Education Department University Research Funding Project (ZD2014033), 3 Open Fund of Guangxi Colleges and Universities Key Laboratory of Biological Molecular Medicine Research (GXBMR201601), 4 Fund of Natural Science Foundation of Guangxi, China (2017GXNSFAA198107), 5 Guangxi Zhuang Autonomous Region Health and Family Planning Commission Self-Financed Scientific Research Project (Z20170556).	Abramson JS, 2010, CANCER-AM CANCER SOC, V116, P4283, DOI 10.1002/cncr.25278; Aoki T, 2017, ONCOTARGET, V8, P13085, DOI 10.18632/oncotarget.14393; Araf S, 2016, EXPERT REV MOL DIAGN, V16, P1093, DOI 10.1080/14737159.2016.1235974; Bassig BA, 2018, INT J CANCER, V143, P570, DOI 10.1002/ijc.31385; Beck A, 2016, CANCER BIOL THER, V17, P1168, DOI 10.1080/15384047.2016.1235664; Belizario JE, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00312; Burness CB, 2016, DRUGS, V76, P1393, DOI 10.1007/s40265-016-0633-9; Chen J, 2018, BIOCHEM BIOPH RES CO, V501, P212, DOI 10.1016/j.bbrc.2018.04.218; Chen L, 2016, MOL GENET GENOMICS, V291, P2065, DOI 10.1007/s00438-016-1240-x; Chowdhury MR, 2018, MOL PHARMACEUT, V15, P2484, DOI 10.1021/acs.molpharmaceut.8b00305; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; Dada R, 2017, ACTA HAEMATOL-BASEL, V138, P216, DOI 10.1159/000484515; Dang YW, 2018, PATHOL RES PRACT, V214, P631, DOI 10.1016/j.prp.2018.03.029; Diaz-Montana JJ, 2018, BIOSYSTEMS, V166, P61, DOI 10.1016/j.biosystems.2018.01.007; Ding J, 2017, COMB CHEM HIGH T SCR, V20, P861, DOI 10.2174/1386207321666171218120133; Dobashi A, 2016, J CLIN EXP HEMATOP, V56, P71; Dou AX, 2017, ONCOL REP, V37, P3572, DOI 10.3892/or.2017.5626; Feldman T, 2014, BRIT J HAEMATOL, V166, P77, DOI 10.1111/bjh.12846; Fernandez-Rodriguez C, 2016, LEUKEMIA LYMPHOMA, V57, P692, DOI 10.3109/10428194.2015.1063143; Gao L, 2018, PATHOL RES PRACT, V214, P732, DOI 10.1016/j.prp.2018.03.002; Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043; Go S. I., 2017, TUMORI, DOI DOI 10.5301/TJ.5000694; Griffa A, 2017, NEUROIMAGE, V155, P490, DOI 10.1016/j.neuroimage.2017.04.015; Gupta NK, 2009, LEUKEMIA LYMPHOMA, V50, P2075, DOI 10.3109/10428190903144642; Han Y, 2018, Zhonghua Yi Xue Za Zhi, V98, P1250, DOI 10.3760/cma.j.issn.0376-2491.2018.16.013; Hori T, 2008, CHEM-BIOL INTERACT, V172, P125, DOI 10.1016/j.cbi.2007.12.003; Hua Z, 2007, CLIN CANCER RES, V13, P5455; Hussain AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024703; Ji HF, 2018, CELL PHYSIOL BIOCHEM, V45, P951, DOI 10.1159/000487288; Kim HI, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030353; Klonowska K, 2016, ONCOTARGET, V7, P176, DOI 10.18632/oncotarget.6128; Kong YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37417; Koudijs KKM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23195-8; Lee H, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12496; Li CC, 2018, MED SCI MONITOR, V24, P2750, DOI 10.12659/MSM.907336; Li L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24631-5; Li SY, 2013, ADV ANAT PATHOL, V20, P315, DOI 10.1097/PAP.0b013e3182a289f2; Li T, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1409-3; Liu XH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179037; Lockhart AC, 2019, INVEST NEW DRUG, V37, P87, DOI 10.1007/s10637-018-0610-0; Martellotta F, 2015, EUR REV MED PHARMACO, V19, P4681; Masaki Y., 2005, J CLIN HEMATOL, V46, P1074; Mazan-Mamczarz K, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0091-0; Modvig L, 2017, BRIT J HAEMATOL, V179, P75, DOI 10.1111/bjh.14822; Mohammad RM, 2005, MOL CANCER THER, V4, P13; Nandagopal L, 2017, EXPERT REV HEMATOL, V10, P259, DOI 10.1080/17474086.2017.1283214; Pasqualucci L, 2016, SEMIN CANCER BIOL, V39, P26, DOI 10.1016/j.semcancer.2016.08.001; Peng ZG, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15013904; Persky DO, 2018, AM J HEMATOL, V93, P486, DOI 10.1002/ajh.25010; Petre Adeline, 2018, Oncotarget, V9, P22038, DOI 10.18632/oncotarget.25157; Petrusevska Marija, 2017, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V38, P97, DOI 10.2478/prilozi-2018-0010; Raghavan R, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3149-5; Richardson DS, 1997, INVEST NEW DRUG, V15, P247, DOI 10.1023/A:1005879219554; Risnayanti C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25930-7; Shi YK, 2018, INT J HEMATOL, V107, P405, DOI 10.1007/s12185-018-2404-8; Sun X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.472; Sze-To AS, 2016, METHODS, V110, P26, DOI 10.1016/j.ymeth.2016.07.018; Tampaki EC, 2018, CLIN DRUG INVEST, V38, P639, DOI 10.1007/s40261-018-0655-z; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vanderstocken G, 2018, AM J RESP CELL MOL, V58, P727, DOI 10.1165/rcmb.2017-0202OC; Varatharajan S, 2012, EUR J CLIN PHARMACOL, V68, P1577, DOI 10.1007/s00228-012-1291-9; Wang JY, 2016, ONCOTARGETS THER, V9, P1221, DOI 10.2147/OTT.S97211; Wang JR, 2018, BIOCHEM BIOPH RES CO, V501, P1034, DOI 10.1016/j.bbrc.2018.05.104; Wei XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13254-x; Witte Hanno, 2018, Oncotarget, V9, P19613, DOI 10.18632/oncotarget.24701; Wu FF, 2016, INT J ONCOL, V48, P1561, DOI 10.3892/ijo.2016.3393; Xiang JJ, 2018, SCI CHINA LIFE SCI, V61, P436, DOI 10.1007/s11427-017-9274-9; Yang HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06897-3; Yoo KH, 2015, ACTA HAEMATOL-BASEL, V133, P179, DOI 10.1159/000362149; Yoo M., 2018, COMPUT METH PROG BIO, p[30851, S0169]; Yu JY, 2018, METHODS MOL BIOL, V1783, P361, DOI 10.1007/978-1-4939-7834-2_18; Zhu XH, 2017, ONCOL REP, V37, P622, DOI 10.3892/or.2016.5233; Zhu ZR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0539-4; Zou HX, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010707	74	1	1	3	8	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1854	1867		10.1016/j.prp.2018.09.013			14	Pathology	Pathology	HA0MP	WOS:000449902400014	30244948				2019-10-28	
J	Aydin, HA; Pestereli, E; Ozcan, M; Bayramoglu, Z; Erdogan, G; Simsek, T				Aydin, Hulya Ayik; Pestereli, Elif; Ozcan, Mualla; Bayramoglu, Zeynep; Erdogan, Gulgun; Simsek, Tayup			A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						FISH; Immunohistochemistry; ROS1; Ovarian serous tumors	LUNG-CANCER; ABRIDGED-REPUBLICATION; STAGING CLASSIFICATION; TYROSINE KINASE; FALLOPIAN-TUBE; PERITONEUM	Objective: ROS1 is an orphan receptor protein tyrosine kinase which is supposed to undergo genetic rearrangement in carcinogenesis. In the current study, we aimed to investigate the frequency and clinicopathologic features associated with ROS1 gene fusion and ROS1 protein expression in patients with ovarian serous carcinoma or serous borderline tumors. Materials and methods: Tissue samples of 102 patients with high or low grade serous carcinoma and borderline serous tumors were selected randomly from the archives of Department of Gyneco-pathology, and analyzed for ROS1 gene expression. (Fluorescence in situ hybridization (FISH) method was used to assess ROS1 gene rearrangement, while ROS1 protein expression was analyzed using immunohistochemistry. Results: The study consisted of 94 cases of high-grade serous carcinoma (92.1%), 2 cases of low-grade serous carcinoma (%2) and 6 cases of serous borderline tumor (5.9%). ROS1 gene rearrangement analysis revealed that 4 patients (3.9%) were FISH-positive; whereas the immunohistochemical analysis yielded only 1 patient (0.9%) exhibiting faint positive expression of ROS1 protein. Given the low incidences of ROS1 gene rearrangement and protein expression, their relationships with clinicopathologic parameters could not be statistically analyzed. Conclusion: Although rare, patients with ovarian serous carcinoma or serous borderline tumor may exhibit ROS1 gene rearrangement and ROS1 protein expression. Further large-scale studies are necessary to explore the clinicopathologic significance of ROS1 gene expression in ovarian serous carcinoma.	[Aydin, Hulya Ayik; Simsek, Tayup] Akdeniz Univ, Sch Med, Dept Gynecol Oncol, Antalya, Turkey; [Pestereli, Elif; Ozcan, Mualla; Bayramoglu, Zeynep; Erdogan, Gulgun] Akdeniz Univ, Sch Med, Dept Gynecopathol, Antalya, Turkey	Aydin, HA (reprint author), Akdeniz Univ, Sch Med, TR-07059 Antalya, Turkey.	hulya_ayik@hotmail.com; epestereli63@gmail.com; muallao@yahoo.com; drzeynepbayramoglu@hotmail.com; gerdogan@akdeniz.edu.tr; tsimsek@akdeniz.edu.tr					Acquaviva J, 2009, BBA-REV CANCER, V1795, P37, DOI 10.1016/j.bbcan.2008.07.006; Birch AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028250; Bubendorf L, 2016, VIRCHOWS ARCH, V469, P489, DOI 10.1007/s00428-016-2000-3; Charest A, 2003, P NATL ACAD SCI USA, V100, P916, DOI 10.1073/pnas.242741799; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Davies KD, 2013, CLIN CANCER RES, V19, P4040, DOI 10.1158/1078-0432.CCR-12-2851; Deng X., 2017, N A J MED SCI, V10, P53; Ferlay J, 2010, GLOBOCAN 2008 CANC I; Gu TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015640; Jun HJ, 2012, CANCER RES, V72, P3764, DOI 10.1158/0008-5472.CAN-11-3990; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee J, 2013, CANCER-AM CANCER SOC, V119, P1627, DOI 10.1002/cncr.27967; Prat J, 2015, CANCER-AM CANCER SOC, V121, P3452, DOI 10.1002/cncr.29524; Prat J, 2015, OBSTET GYNECOL, V126, P171, DOI 10.1097/AOG.0000000000000917; Rogers TM, 2015, J THORAC ONCOL, V10, P611, DOI 10.1097/JTO.0000000000000465; Shih M, 2002, TUMOR MARKERS PHYS, P239; Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7; Zhang K, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0388-x	18	0	0	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1868	1872		10.1016/j.prp.2018.09.016			5	Pathology	Pathology	HA0MP	WOS:000449902400015	30249502				2019-10-28	
J	Liu, LJ; Cheng, ZP; Yang, J				Liu, Lijun; Cheng, Ziping; Yang, Jie			miR-23 regulates cell proliferation and apoptosis of vascular smooth muscle cells in coronary heart disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Coronary heart disease; miR-23; VSMCs; BCL2L11; Proliferation; Apoptosis	DOWN-REGULATION; ARTERY-DISEASE; MICRORNA; RECEPTOR; MIRNAS; ACTIVATION; EXPRESSION; MIGRATION; BCL2L11; GROWTH	Background: Aberrant proliferation and migration of vascular smooth muscle cells (VSMCs) play an important role in the pathogenesis of cardiovascular diseases including coronary heart disease (CHD). MicroRNAs has reported play critical roles in VSMCs function. The present study was to investigate the effects of microRNA-23 (miR-23) on VSMCs and uncover its potential mechanism. Methods: Cell viability was detected by CCK-8 assay. Cell apoptosis was measured by flow cytometry. Dual luciferase reporter assay was conducted to verify whether BCL2L11 is a target gene of miR-23. The protein levels of BCL2L11 and caspase-3 were detect by quantitative real time PCR and western blot. Results: Our results showed that the expression of miR-23 was upregulated in peripheral blood of CHD patients compared with controls. Overexpression of miR-23 promoted VSMCs proliferation and inhibited VSMCs apoptosis. Downregulation of miR-23 suppressed VSMCs proliferation and promoted VSMCs apoptosis. In addition, we identified BCL2L11 was a direct gene of miR-23. Overexpression of miR-23 decreased the levels of BCL2L11 and caspase-3, and downregulate of miR-23 increased the levels of BCL2L11and caspase-3 in VSMCs. Conclusion. Our findings suggest that miR-23 plays a crucial role in controlling VSMCs proliferation and apoptosis by targeting BCL2L11.	[Liu, Lijun] Huainan First Peoples Hosp, Dept Cardiovasc Med, 203 Huaibin Rd, Huainan 232007, Anhui, Peoples R China; [Cheng, Ziping; Yang, Jie] Anui Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Hefei 230022, Anhui, Peoples R China	Liu, LJ (reprint author), Huainan First Peoples Hosp, Dept Cardiovasc Med, 203 Huaibin Rd, Huainan 232007, Anhui, Peoples R China.	lijun_liu23@163.com					Anderson JL, 2011, J AM COLL CARDIOL, V57, pE215, DOI 10.1016/j.jacc.2011.02.011; Bang C, 2012, MICROCIRCULATION, V19, P208, DOI 10.1111/j.1549-8719.2011.00153.x; Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166; Di YF, 2015, INT J CLIN EXP MED, V8, P11759; Hu TX, 2018, CANCER RES, V78, P3522, DOI 10.1158/0008-5472.CAN-17-4049; Huang F, 2013, CARDIOLOGY, V125, P18, DOI 10.1159/000347081; Karnuth B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093067; Katz MG, 2014, FUTUR CARDIOL, V10, P789, DOI [10.2217/FCA.14.64, 10.2217/fca.14.64]; Li P, 2013, CARDIOVASC RES, V99, P185, DOI 10.1093/cvr/cvt082; Li Z, 2015, CELL PROLIFERAT, V48, P278, DOI 10.1111/cpr.12180; Li Z, 2015, ONCOTARGET, V6, P4562, DOI 10.18632/oncotarget.2923; Liu HJ, 2018, CARDIOVASC TOXICOL, V18, P450, DOI 10.1007/s12012-018-9455-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu HQ, 2013, J GERIATR CARDIOL, V10, P34, DOI [10.3724/SP.J.1263.2013.01011, 10.3969/j.issn.1671-5411.2013.01.007]; Ooi JYY, 2014, FUTURE MED CHEM, V6, P205, DOI 10.4155/fmc.13.196; Puymirat Etienne, 2015, Rev Prat, V65, P317; Qi H, 2018, PHYS CHEM CHEM PHYS, V20, P1964, DOI 10.1039/c7cp06726g; Larrubia JR, 2013, WORLD J GASTROENTERO, V19, P1877, DOI 10.3748/wjg.v19.i12.1877; Song L, 2012, ARCH BIOCHEM BIOPHYS, V528, P204, DOI 10.1016/j.abb.2012.08.015; Sruthi TV, 2018, J CELL PHYSIOL, V233, P3498, DOI 10.1002/jcp.26202; Tang WC, 2017, AM J TRANSL RES, V9, P4984; Varga ZV, 2014, AM J PHYSIOL-HEART C, V307, pH216, DOI 10.1152/ajpheart.00812.2013; Yu X, 2015, ONCOTARGET, V6, P23297, DOI 10.18632/oncotarget.4195; Yu X, 2015, CELL PROLIFERAT, V48, P271, DOI 10.1111/cpr.12179; Yu X, 2014, INT J MOL MED, V34, P923, DOI 10.3892/ijmm.2014.1853; Yuan HR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053887; Zhao J, 2013, ARTERIOSCL THROM VAS, V33, P257, DOI 10.1161/ATVBAHA.112.300200	27	1	1	3	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1873	1878		10.1016/j.prp.2018.09.004			6	Pathology	Pathology	HA0MP	WOS:000449902400016	30249504	Other Gold			2019-10-28	
J	Zhu, R; Ma, XC				Zhu, Ran; Ma, Xiao-chun			Role of metabolic changes of mucosal layer in the intestinal barrier dysfunction following trauma/hemorrhagic shock	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Trauma-hemorrhagic shock; THS; Mucosal layer; Intestinal barrier dysfunction; Trauma/hemorrhagic shock; Multiorgan dysfunction syndrome	HEMORRHAGIC-SHOCK; MUCUS LAYER; GUT BARRIER; COMPONENT; OCCLUDIN; FAILURE; MUCIN; CELLS; MODEL; COLON	Background: The mucosal layer plays an important role in regulating the intestinal barrier function. However, the underlying mechanisms of intestinal barrier dysfunction caused by trauma-hemorrhagic shock (THS) are still unknown. Methods: In this study, we examined the barrier damages, inflammatory responses as well as the metabolic changes of the mucosal layer of the colon in a THS rat model. Results: The results showed that compared to the rats treated with trauma only, THS induced marked failure of intestinal barrier characterized by increased intestinal permeability, inflammatory cell infiltration and decreased expression of genes involved in epithelial integrity. Moreover, decreased colonic mucus content and goblet cell numbers indicated that the mucosal layer was also impaired in response to THS. This was companied by the anomalous inflammatory responses in the tissue. Finally, microdialysis catheter examination showed that metabolites including glycerol, glucose, lactate and pyruvate, glutamate and glutamine were also altered by THS. Conclusion: Our results provide evidence that mucus layer-associated metabolic changes may contribute to the THS-induced intestinal barrier dysfunction.	[Zhu, Ran; Ma, Xiao-chun] China Med Univ, Hosp 1, Dept Crit Care Med, 155 Nanjingbei St, Shenyang 110001, Liaoning, Peoples R China	Ma, XC (reprint author), China Med Univ, Hosp 1, Dept Crit Care Med, 155 Nanjingbei St, Shenyang 110001, Liaoning, Peoples R China.	xcma2972@sina.com					Beeman N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.14; Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546; Boutry C, 2012, AMINO ACIDS, V43, P1485, DOI 10.1007/s00726-012-1221-2; Cannon JW, 2018, NEW ENGL J MED, V378, P370, DOI 10.1056/NEJMra1705649; Caron TJ, 2015, WORLD J GASTROENTERO, V21, P11411, DOI 10.3748/wjg.v21.i40.11411; D'Alessandro A, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0612-z; Deitch EA, 2006, FRONT BIOSCI, V11, P520, DOI 10.2741/1816; Dicksved J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046399; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fink Mitchell P, 2003, Curr Opin Crit Care, V9, P143, DOI 10.1097/00075198-200304000-00011; Fishman JE, 2014, SHOCK, V42, P264, DOI 10.1097/SHK.0000000000000209; Fishman JE, 2013, AM J PHYSIOL-GASTR L, V304, pG57, DOI 10.1152/ajpgi.00170.2012; George ME, 2010, J TRAUMA, V68, P662, DOI 10.1097/TA.0b013e3181d3cbc0; Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105; Kleber C, 2015, J ORTHOP RES, V33, P965, DOI 10.1002/jor.22857; Kuhn KA, 2018, MUCOSAL IMMUNOL, V11, P357, DOI 10.1038/mi.2017.55; Lu Q, 2011, J TRAUMA, V70, P630, DOI 10.1097/TA.0b013e3181e1221b; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Moore FA, 1996, J TRAUMA, V40, P510; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Ohno M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185999; Park HY, 2015, BIOSCI BIOTECH BIOCH, V79, P130, DOI 10.1080/09168451.2014.951027; Qin XF, 2011, SHOCK, V35, P275, DOI 10.1097/SHK.0b013e3181f6aaf1; Rixen D, 2002, SHOCK, V18, P355, DOI 10.1097/00024382-200210000-00011; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; TYTGAT KMAJ, 1994, GASTROENTEROLOGY, V107, P1352, DOI 10.1016/0016-5085(94)90537-1; Zhang Y, 2017, SURGERY, V161, P546, DOI 10.1016/j.surg.2016.08.029	27	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1879	1884		10.1016/j.prp.2018.08.023			6	Pathology	Pathology	HA0MP	WOS:000449902400017	30262430				2019-10-28	
J	Zhao, JK; Shao, JC; Zhu, L; Yu, KK; Zhao, RY; Ding, WJ; Zhang, J; Han, YC				Zhao, Jikai; Shao, Jinchen; Zhu, Lei; Yu, Keke; Zhao, Ruiying; Ding, Wenjie; Zhang, Jie; Han, Yuchen			Solitary pulmonary capillary hemangioma: Clinicopathologic and radiologic characteristics of nine surgically resected cases	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Solitary pulmonary capillary hemangioma; SPCH; Ground-glass opacity; Imaging; Treatment	LUNG; CT	Background: Solitary pulmonary capillary hemangioma (SPCH) is an extraordinarily rare capillary derived mesenchymal neoplasm. Although routine morphology and immunohistochemistry are adequate for the diagnosis of classical SPCH in surgical specimens, true gross appearance identification of most tumor themselves and diagnosis for some exceptional cases are still very difficult. Furthermore, preoperative imaging and frozen diagnosis remain a challenge. Methods: We reported nine original cases of solitary pulmonary capillary hemangioma and summarized the clinical characteristics of twenty-one reported lesions. Imaging materials were reviewed by the image experts of our hospital. Quick hematoxylin-eosin stained intraoperative frozen sections and routine histological diagnosis were re-confirmed by 3 specialist pathologists with at least 10 years of diagnostic experience in our department. Immunohistochemistry analysis was performed on formalin fixed archival tissue. The surgical methods, following up information and prognosis were retrospectively analyzed. Results: In imaging, three tumors showed solid nodules, three cases displayed mix ground glass nodules, two nodules were pure ground glass density, and one case was a cystic-solid mass. Macroscopically, solitary pulmonary capillary hemangiomas were ill-defined soft hemorrhagic lesion with pale yellow or dark brownish cut surface. Two cases had a clear boundary and seven lesions were poorly demarcated. Typical morphological features were densely proliferating thin-walled capillaries composing of single layer of flatten or cuboidal endothelial cells within the thickened alveolar septa. One case was mistaken for a histiocytogenic lesion during freezing. The cystic-solid lesion showed a hyperplasia capillary network along the submucosal interstitium of bronchioles. Immunohistochemically, tumor endothelial cells were positive for ERG, Fli-1, CD31, CD34 and Vimentin and negative for CK, alpha-SMA, TTF-1, HMB45, S-100 and CD68. Lobectomy was performed on seven cases, wedge resection and segmentectomy were proceeded in two patients respectively. Follow up information showed no evidence of complication or recurrence. Conclusions: Solitary pulmonary capillary hemangioma has special imaging and various histological features and must be distinguished from small benign lung lesions and preinvasive cancer. Although the prognosis of this tumor is good after surgical resection, the correct interpretation of the gross appearance and radiographic findings are still important. Choosing appropriate resection mode depends on accurate evaluation preoperative and intraoperative.	[Zhao, Jikai; Shao, Jinchen; Zhu, Lei; Zhao, Ruiying; Ding, Wenjie; Zhang, Jie; Han, Yuchen] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, 241 West Huaihai Rd, Shanghai 200030, Peoples R China; [Yu, Keke] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Biobank, Shanghai 200030, Peoples R China	Han, YC (reprint author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.	ychan@cmu.edu.cn					Almagro P, 2002, MEDICINE, V81, P417, DOI 10.1097/00005792-200211000-00002; Ferretti GR, 2004, AM J ROENTGENOL, V183, P99, DOI 10.2214/ajr.183.1.1830099; Frazier AA, 2007, RADIOGRAPHICS, V27, P867, DOI 10.1148/rg.273065194; Fugo K, 2006, AM J SURG PATHOL, V30, P750, DOI 10.1097/00000478-200606000-00012; Hakiri S, 2010, HAIGAN, V50, P841; Hashimoto H, 2016, AM J SURG PATHOL, V40, P1380, DOI 10.1097/PAS.0000000000000708; Hochhegger B, 2015, LUNG, V193, P855, DOI 10.1007/s00408-015-9772-0; Isaka T, 2013, PATHOL INT, V63, P615, DOI 10.1111/pin.12120; Kato H, 2009, J JAPANESE ASS CHEST, V23, P932; Lau EMT, 2015, CAN J CARDIOL, V31, P367, DOI 10.1016/j.cjca.2014.09.033; Lee HW, 2012, J LUNG CANC, V11, P102; Matsushita M, 2012, JPN J RADIOL, V30, P772, DOI 10.1007/s11604-012-0113-4; Ogawa A, 2012, CIRC J, V76, P1729, DOI 10.1253/circj.CJ-11-0973; Ryan John J, 2012, Pulm Circ, V2, P107, DOI 10.4103/2045-8932.94843; Sakaguchi Y, 2014, ANN THORAC CARDIOVAS, V20, P578, DOI 10.5761/atcs.cr.12.02222; Taniguchi D, 2010, Kyobu Geka, V63, P423; Uegami S, 2008, J JAPANESE ASS CHEST, V22, P641; WAGENVOORT CA, 1978, HISTOPATHOLOGY, V2, P401, DOI 10.1111/j.1365-2559.1978.tb01734.x; Yanagawa N, 2007, JAPANESE J DIAGNOSTI, V24, P426; Zhu YM, 2017, BIOMED REP, V7, P515, DOI 10.3892/br.2017.997	20	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1885	1891		10.1016/j.prp.2018.09.014			7	Pathology	Pathology	HA0MP	WOS:000449902400018	30268596				2019-10-28	
J	Li, JM; Liu, JB; Yu, XM; Bao, XL; Qian, LX				Li, Jianming; Liu, Jibin; Yu, Xiaomeng; Bao, Xiaoli; Qian, Linxue			BRAF(v600e) mutation combined with thyroglobulin and fine-needle aspiration in diagnosis of lymph node metastasis of papillary thyroid carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lymph node metastasis; Papillary thyroid carcinoma; BRAFv600e test; FNAC; FNA-Tg	CANCER; ASSOCIATION; MANAGEMENT; ULTRASOUND	Background Papillary thyroid carcinoma (PTC) is often associated with cervical lymph node metastasis (LNM), which may cause poor prognosis. Both fine-needle aspiration cytology (FNAC) and thyroglobulin measurement with fine-needle aspiration (Tg-FNA) have high diagnostic efficacy, but the diagnostic values and relationships among BRAF(v600e) mutation (BRAF(MUT)) testing, FNAC and FNA-Tg are unclear. Methods: We enrolled 145 patients with confirmed PTC and lymph nodes (LNs) that were suspected to be metastatic based on ultrasound findings, who were treated from May 2017 to April 2018, and underwent FNAC, Tg-FNA and BRAF(MUT) tests. Diagnostic efficacy was calculated by diagnostic and chi-square tests. Results: Diagnostic values were FNAC-sensitivity: 67%, specificity: 100%, PPV: 100%, NPV: 66%, accuracy: 80%; and FNA-Tg (at a cut-off of 2.23 ng/mL)-sensitivity: 97.3%, specificity: 87.8%, PPV: 87.8%, NPV: 97.3%, accuracy: 92.3%. In the BRAF(MUT+) group, sensitivities and specificities were FNAC: 68.6% and 100%, Tg-FNA: 94.4% and 85.7%; compared with FNAC: 75% and 90.9%, Tg-FNA: 80% and 100% in the BRAF(MUT-) group. Conclusion: The combination of Tg-FNA + FNAC is useful in diagnosing metastatic PTC. BRAF mutational status does not affect the diagnostic performance of FNAC or Tg-FNA.	[Li, Jianming; Qian, Linxue] Capital Med Univ, Beijing Friendship Hosp, Ultrasound Dept, Beijing, Peoples R China; [Liu, Jibin] Thomas Jefferson Univ, Ultrasound Dept, Philadelphia, PA 19107 USA; [Yu, Xiaomeng] Capital Med Univ, Beijing Friendship Hosp, Pathol Dept, Beijing, Peoples R China; [Bao, Xiaoli] Capital Med Univ, Beijing Friendship Hosp, Lab Dept, Beijing, Peoples R China	Qian, LX (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Ultrasound, 95 Yongan Rd, Beijing, Peoples R China.	Qianlinxue2002@163.com		jianming, li/0000-0002-0615-8816	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [041320015]	This work wasfunded by the National Natural Science Foundation of China (041320015)	Al-Hilli Z, 2017, ANN SURG ONCOL, V24, P739, DOI 10.1245/s10434-016-5625-1; Chen D, 2018, PATHOL RES PRACT, V214, P303, DOI 10.1016/j.prp.2017.09.001; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong SY, 2017, ONCOL LETT, V14, P4122, DOI 10.3892/ol.2017.6694; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hong YR, 2017, ULTRASOUND MED BIOL, V43, P2567, DOI 10.1016/j.ultrasmedbio.2017.07.010; Jung JY, 2013, AM J NEURORADIOL, V34, P2349, DOI 10.3174/ajnr.A3687; Kim Wan Wook, 2016, [The Koreran journal of Endocrine Surgery, 대한내분비외과학회지], V16, P36; Leonardi GC, 2012, MOL MED REP, V6, P687, DOI 10.3892/mmr.2012.1016; Liu S, 2018, CHINESE J CANCER RES, V30, P13, DOI 10.21147/j.issn.1000-9604.2018.01.02; Lu JL, 2015, INT J CLIN EXP PATHO, V8, P793; Mitra Sumit, 2013, J Indian Med Assoc, V111, P599; PACINI F, 1992, J CLIN ENDOCR METAB, V74, P1401, DOI 10.1210/jc.74.6.1401; Park VY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004292; Reitzel Lorraine R., 2013, THYROID, V23, P1980; Salmaslioglu A, 2011, LANGENBECK ARCH SURG, V396, P77, DOI 10.1007/s00423-010-0723-1; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stack BC, 2012, THYROID, V22, P501, DOI 10.1089/thy.2011.0312; Stulak JM, 2006, ARCH SURG-CHICAGO, V141, P489, DOI 10.1001/archsurg.141.5.489; Zhao H, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3296-3; Zhao L, 2016, CLIN ENDOCRINOL, V84, P748, DOI 10.1111/cen.12878	21	0	0	2	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1892	1897		10.1016/j.prp.2018.09.003			6	Pathology	Pathology	HA0MP	WOS:000449902400019	30270103				2019-10-28	
J	Liu, XY; Liu, XD; Wang, XQ; Wu, R; Zhang, KG; Liu, BY; Liu, QC; Shao, YK; Tang, R; You, JF; Pei, F				Liu, Xinying; Liu, Xiaodan; Wang, Xiaoqiang; Wu, Rui; Zhang, Kuangen; Liu, Beiying; Liu, Qichen; Shao, Yakun; Tang, Ran; You, Jiangfeng; Pei, Fei			A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Endometrial dedifferentiated carcinoma; Microsatellite instability; MLH1; PD-1; PD-L1	CANCER; CARCINOMA; EXPRESSION; TUMORS	Endometrial dedifferentiated carcinoma is a rare, malignant tumor whose molecular alterations have not been clarified yet. We report a novel case of a 61-year old woman who presented with irregular vaginal bleeding after menopause and a 3 cm uterus mass. Histology revealed endometrial dedifferentiated adenocarcinoma, a rare subtype comprised of undifferentiated adenocarcinoma. The patient still survived 1 year after surgery without chemotherapy and radiotherapy. Immunohistochemistry revealed loss of MLH1/PMS2 expression and retained MSH2/MSH6 expression. Consistently, microsatellite instability was detected indicative of high microsatellite instability (MSI-H). No BRAF V600E, KRAS and POLE mutations were identified. Remarkably, the promoter regions of mutL homolog 1(MLH1) were methylated. Furthermore, several tumor cells were PD-L1 positive in this case with a concentration at the infiltrating tumor edge indicating MSI-H in endometrial dedifferentiated adenocarcinoma is a potential predictive factor for response to immunotherapy targeting the PD-1 or its ligand PD-L1.	[Liu, Xinying; Liu, Xiaodan; Zhang, Kuangen; Shao, Yakun; Tang, Ran; You, Jiangfeng; Pei, Fei] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing 100191, Peoples R China; [Wang, Xiaoqiang; Wu, Rui; Pei, Fei] Peking Univ, Hosp 3, Dept Pathol, Beijing 100191, Peoples R China; [Liu, Beiying] Univ Sci & Technol Beijing, Sch Mech Engn, Beijing 100083, PR, Peoples R China; [Liu, Qichen] Georgia Inst Technol, Coll Sci, North Ave, Atlanta, GA 30332 USA	Pei, F (reprint author), 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	lxy920429@126.com; liuxiaodan@bjmu.edu.cn; xiaoerqd@126.com; raynwu98@163.com; 1158982958@qq.com; byliu@me.ustb.edu.cn; iamliuqichen@gatech.edu; 793118871@qq.com; tangran.hi@163.com; yjf107@126.com; peifei@bjmu.edu.cn			National Sciences Foundation of ChinaNational Natural Science Foundation of China [81572533]	The article was supportedby the National Sciences Foundation of China (81572533). Thanks to Beiying Liu and Qichen Liu for data analysis.	Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Kim TM, 2013, CELL, V155, P858, DOI 10.1016/j.cell.2013.10.015; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Min BH, 2016, GASTRIC CANCER, V19, P852, DOI 10.1007/s10120-015-0524-x; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sloan EA, 2017, AM J SURG PATHOL, V41, P326, DOI 10.1097/PAS.0000000000000783; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	14	1	1	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1904	1908		10.1016/j.prp.2018.08.015			5	Pathology	Pathology	HA0MP	WOS:000449902400021	30173944				2019-10-28	
J	Tambuwala, MM; Kesharwani, P; Shukla, R; Thompson, PD; McCarron, PA				Tambuwala, Murtaza M.; Kesharwani, Prashant; Shukla, Rahul; Thompson, Paul D.; McCarron, Paul A.			Caffeic acid phenethyl ester (CAPE) reverses fibrosis caused by chronic colon inflammation in murine model of colitis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Inflammation; Fibrosis; Colitis; Natural compounds; Caffeic acid phenethyl ester	ULCERATIVE-COLITIS; DISEASE	Fibrosis is known to be the hallmarks of chronic inflammation of the bowel. Epithelial damage due to inflammation compromises the barrier function of the gastrointestinal tract. This barrier dysfunction leads to further spread of inflammation resulting in a chronic state of inflammation. This chronic inflammation leads to development of fibrosis, which has very limited therapeutic options and usually requires surgical removal of the affected tissue. Our previous work has shown that Caffeic acid phenethyl ester (CAPE) is a naturally occurring anti-inflammatory agent, found in propolis, has been found to be protective in experimental colitis via enhancement of epithelial barrier function. However, the impact of CAPE on resolution of fibrosis in the long-term is unknown. The aim of this follow up study was to investigate the effect of CAPE on colon fibrosis in a chronic model of Dextran sulphate sodium induced colitis in mice. Dextran sulphate sodium (DSS) 2.5% w/v was administered in drinking water to induce colitis in C57/BL6 mice for 5 days on the 6th day DSS was stopped and test group mice were treated with intraperitoneal administration of CAPE (30 mg kg(-1 )day(-1)) for a further 7 days. Disease activity index (DAI) score, colon length and tissue histology and level of tissue fibrosis was observed. CAPE-treated mice had significantly lower levels of DAI, tissue inflammation scores and fibrosis as compared with control group. Our results show that CAPE is effective in resolving colon fibrosis in chronic inflammation. Thus, we can conclude CAPE could be a potential therapeutic agent for further clinical investigations for treatment of fibrosis in inflammatory bowel diseases in humans.	[Tambuwala, Murtaza M.; McCarron, Paul A.] Ulster Univ, Sch Pharm & Pharmaceut Sci, SAAD Ctr Pharm & Diabet, Coleraine BT52 1SA, Londonderry, North Ireland; [Kesharwani, Prashant] Int Med Univ, Sch Pharm, Dept Pharmaceut Technol, Kuala Lumpur 57000, Malaysia; [Shukla, Rahul] Natl Inst Pharmaceut Sci & Educ, Shree Bhawani Paper Mill Rd, Raebareli 229010, UP, India; [Tambuwala, Murtaza M.; Thompson, Paul D.; McCarron, Paul A.] Ulster Univ, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland; [Kesharwani, Prashant] CSIR, Cent Drug Res Inst, Pharmaceut & Pharmacokinet Div, Lucknow, Uttar Pradesh, India	Tambuwala, MM (reprint author), Ulster Univ, Sch Pharm & Pharmaceut Sci, SAAD Ctr Pharm & Diabet, Coleraine BT52 1SA, Londonderry, North Ireland.	m.tambuwala@ulster.ac.uk	Tambuwala, Murtaza/O-7156-2019	Tambuwala, Murtaza/0000-0001-8499-9891; Shukla, Rahul/0000-0002-4864-0133	Ulster University	We wish to thank Ulster University for providing financial support this work in form of Research Challenge Fund (RCF-2014) strategic award.	Fichtner-Feigl S, 2007, J IMMUNOL, V178, P5859, DOI 10.4049/jimmunol.178.9.5859; Fiocchi C, 2011, AM J PHYSIOL-GASTR L, V300, pG677, DOI 10.1152/ajpgi.00104.2011; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Khan MN, 2018, INFLAMMOPHARMACOLOGY, V26, P561, DOI 10.1007/s10787-017-0364-x; Manresa MC, 2016, AM J PHYSIOL-GASTR L, V311, pG1076, DOI 10.1152/ajpgi.00229.2016; Rieder F, 2007, GUT, V56, P130, DOI 10.1136/gut.2006.090456; SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4; Suzuki K, 2011, PATHOL INT, V61, P228, DOI 10.1111/j.1440-1827.2011.02647.x	8	1	1	3	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	NOV	2018	214	11					1909	1911		10.1016/j.prp.2018.08.020			3	Pathology	Pathology	HA0MP	WOS:000449902400022	30170869				2019-10-28	
J	[Anonymous]				[Anonymous]			Image Challenge in Veterinary Pathology, Answers: Viral Skin Disease	VETERINARY PATHOLOGY			English	Editorial Material																	0	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					769	+		10.1177/0300985818800332			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600019					2019-10-28	
J	Roccabianca, P				Roccabianca, Paola			Canine Skin Cancer and the Art of Classifications	VETERINARY PATHOLOGY			English	Editorial Material									[Roccabianca, Paola] Univ Milan, Dept Vet Med, Milan, Italy	Roccabianca, P (reprint author), Univ Milan, Dept Vet Med DIMEVET, Via Celoria 10, I-20133 Milan, Italy.	paola.roccabianca@unimi.it	ROCCABIANCA, PAOLA/I-6110-2017	ROCCABIANCA, PAOLA/0000-0002-3672-4612			Baioni E, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1126-0; Cross SS, 1998, HISTOPATHOLOGY, V33, P99, DOI 10.1046/j.1365-2559.1998.00495.x; Graf R, 2018, VET PATHOL, V55, P809, DOI 10.1177/0300985818789466; Gruntzig K, 2016, J COMP PATHOL, V155, P156, DOI 10.1016/j.jcpa.2016.05.011; Kok MK, 2018, VET PATHOL, V55, P821, DOI 10.1177/0300985818785680	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					770	771		10.1177/0300985818790783			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600001	30381036	Bronze			2019-10-28	
J	Caswell, JL				Caswell, Jeff L.			Ensuring Observational Studies Have Validity and Impact	VETERINARY PATHOLOGY			English	Editorial Material						research design; pathology; epidemiology; observational studies; laboratory medicine; hypothesis testing			[Caswell, Jeff L.] Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada	Caswell, JL (reprint author), Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada.	jcaswell@uoguelph.ca	Caswell, Jeff/B-9279-2018	Caswell, Jeff/0000-0002-1991-3219			Caswell JL, 2018, VET PATHOL, V55, P607, DOI 10.1177/0300985818785705	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					772	773		10.1177/0300985818798104			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600002	30381033	Bronze			2019-10-28	
J	Becker, K; Cana, A; Baumgartner, W; Spitzbarth, I				Becker, Kathrin; Cana, Armend; Baumgaertner, Wolfgang; Spitzbarth, Ingo			p75 Neurotrophin Receptor: A Double-Edged Sword in Pathology and Regeneration of the Central Nervous System	VETERINARY PATHOLOGY			English	Review						aldynoglia; apoptosis; central nervous system; dog; demyelinating disease; p75(NTR); remyelination; Schwann cells	GROWTH-FACTOR RECEPTOR; OLFACTORY ENSHEATHING CELLS; SPINAL-CORD-INJURY; CANINE-DISTEMPER VIRUS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FOREBRAIN CHOLINERGIC NEURONS; MULTIPLE-SCLEROSIS LESIONS; ADULT-RAT BRAIN; REMYELINATION FOLLOWING TRANSPLANTATION; OLIGODENDROCYTE PRECURSOR CELLS	The low-affinity nerve growth factor receptor p75(NTR) is a major neurotrophin receptor involved in manifold and pleiotropic functions in the developing and adult central nervous system (CNS). Although known for decades, its entire functions are far from being fully elucidated. Depending on the complex interactions with other receptors and on the cellular context, p75(NTR) is capable of performing contradictory tasks such as mediating cell death as well as cell survival. In parallel, as a prototype marker for certain differentiation stages of Schwann cells and related CNS aldynoglial cells, p75(NTR) has recently gained increasing notice as a marker for cells with proposed regenerative potential in CNS diseases, such as demyelinating disease and traumatic CNS injury. Besides its pivotal role as a marker for transplantation candidate cells, recent studies in canine neuroinflammatory CNS conditions also highlight a spontaneous endogenous occurrence of p75(NTR)-positive glia, which potentially play a role in Schwann cell-mediated CNS remyelination. The aim of the present communication is to review the pleiotropic functions of p75(NTR) in the CNS with a special emphasis on its role as an immunohistochemical marker in neuropathology. Following a brief illustration of the expression of p75(NTR) in neurogenesis and in developed neuronal populations, the implications of p75(NTR) expression in astrocytes, oligodendrocytes, and microglia are addressed. A special focus is put on the role of p75(NTR) as a cell marker for specific differentiation stages of Schwann cells and a regeneration-promoting CNS population, collectively referred to as aldynoglia.	[Becker, Kathrin; Cana, Armend; Baumgaertner, Wolfgang; Spitzbarth, Ingo] Univ Vet Med Hannover, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany; [Cana, Armend; Baumgaertner, Wolfgang; Spitzbarth, Ingo] Ctr Syst Neurosci, Hannover, Germany	Baumgartner, W (reprint author), Univ Vet Med Hannover, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.baumgaertner@tiho-hannover.de		Cana, Armend/0000-0001-6034-4903	European UnionEuropean Union (EU); Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: A. Cana was supported by a scholarship from the European Union. This study was supported in part by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany.	Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Araque A, 2010, PHILOS T R SOC B, V365, P2375, DOI 10.1098/rstb.2009.0313; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Armati PJ, 2013, J NEUROL SCI, V333, P68, DOI 10.1016/j.jns.2013.01.018; Bai Y, 2008, NEUROSCI RES, V62, P9, DOI 10.1016/j.neures.2008.05.004; Bajo VM, 2014, EUR J NEUROSCI, V40, P2922, DOI 10.1111/ejn.12653; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; Barrette B, 2007, MOL CELL NEUROSCI, V34, P519, DOI 10.1016/j.mcn.2006.12.004; Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bechade C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00032; Bentley CA, 2000, J NEUROSCI, V20, P7706; Benzel I, 2001, GENE, V281, P19, DOI 10.1016/S0378-1119(01)00730-2; Bernabeu RO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-136; BLAKEMORE WF, 1975, J NEUROCYTOL, V4, P745, DOI 10.1007/BF01181634; BLAKEMORE WF, 1976, NEUROPATH APPL NEURO, V2, P21, DOI 10.1111/j.1365-2990.1976.tb00559.x; Blakemore WF, 2005, NEUROPATH APPL NEURO, V31, P1, DOI 10.1111/j.1365-2990.2005.00637.x; Bock P, 2007, J COMP NEUROL, V505, P572, DOI 10.1002/cne.21519; Bothwell Mark, 2016, F1000Res, V5, DOI 10.12688/f1000research.8434.1; Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Brandes G, 2011, HISTOCHEM CELL BIOL, V135, P397, DOI 10.1007/s00418-011-0796-0; Bronfman FC, 2007, J NEUROCHEM, V103, P91, DOI 10.1111/j.1471-4159.2007.04781.x; Bruce JH, 2000, J NEUROTRAUM, V17, P781, DOI 10.1089/neu.2000.17.781; BUNGE MB, 1980, J CELL BIOL, V84, P184, DOI 10.1083/jcb.84.1.184; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; CAREY DJ, 1983, J CELL BIOL, V97, P473, DOI 10.1083/jcb.97.2.473; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chijiwa K, 2004, VET PATHOL, V41, P307, DOI 10.1354/vp.41-4-307; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Cohen RI, 1996, J NEUROSCI, V16, P6433; Copray JCVM, 2005, NEUROPATH APPL NEURO, V31, P600, DOI 10.1111/j.1365-2990.2005.00656.x; Copray JCVM, 2003, NEUROSCIENCE, V116, P685, DOI 10.1016/S0306-4522(02)00755-8; Cragnolini AB, 2008, TRENDS NEUROSCI, V31, P99, DOI 10.1016/j.tins.2007.11.005; Cragnolini AB, 2009, GLIA, V57, P1386, DOI 10.1002/glia.20857; Crang AJ, 2004, EUR J NEUROSCI, V20, P1445, DOI 10.1111/j.1460-9568.2004.03606.x; Crawford AH, 2013, J COMP PATHOL, V149, P242, DOI 10.1016/j.jcpa.2013.05.004; de Castro GM, 2015, AM J PATHOL, V185, P2431, DOI 10.1016/j.ajpath.2015.05.011; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Dowling P, 1999, NEUROLOGY, V53, P1676, DOI 10.1212/WNL.53.8.1676; Du YZ, 2006, MOL CELL NEUROSCI, V31, P366, DOI 10.1016/j.mcn.2005.11.001; Elkabes S, 1996, J NEUROSCI, V16, P2508; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; Ferreira G, 2001, NEUROSCIENCE, V104, P419, DOI 10.1016/S0306-4522(01)00075-6; Fields RD, 2008, SCI AM, V298, P54; Fombonne J, 2009, ANN NEUROL, V65, P294, DOI 10.1002/ana.21578; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; FRANKLIN RJM, 1993, INT J DEV NEUROSCI, V11, P641, DOI 10.1016/0736-5748(93)90052-F; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franklin RJM, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020594; FRIEDMAN WJ, 1991, DEV BRAIN RES, V63, P43, DOI 10.1016/0165-3806(91)90065-Q; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; Galvan V, 2007, CLIN INTERV AGING, V2, P605; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Gerhauser I, 2012, VET REC, V170, DOI 10.1136/vr.100255; GHATAK NR, 1973, ARCH NEUROL-CHICAGO, V29, P262, DOI 10.1001/archneur.1973.00490280074011; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Gilson JM, 2002, NEUROREPORT, V13, P1205, DOI 10.1097/00001756-200207020-00027; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Giuliani A, 2004, J MOL HISTOL, V35, P749, DOI 10.1007/s10735-004-9609-2; Gluska S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004348; GONG QZ, 1994, J COMP NEUROL, V344, P336, DOI 10.1002/cne.903440303; Gonzalez-Perez Oscar, 2012, Biol Biomed Rep, V2, P59; Goodman T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00387; Granger N, 2012, BRAIN, V135, P3227, DOI 10.1093/brain/aws268; Gudino-Cabrera G, 2000, GLIA, V30, P49, DOI 10.1002/(SICI)1098-1136(200003)30:1<49::AID-GLIA6>3.0.CO;2-M; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; Hanbury R, 2002, J COMP NEUROL, V444, P291, DOI 10.1002/cne.10104; Heese K, 1998, J NEUROCHEM, V70, P699; HEFTI F, 1986, NEUROSCI LETT, V69, P37, DOI 10.1016/0304-3940(86)90410-6; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Hu B, 1998, GLIA, V24, P187, DOI 10.1002/(SICI)1098-1136(199810)24:2<187::AID-GLIA4>3.0.CO;2-1; Hu B, 1999, NEUROREPORT, V10, P1293, DOI 10.1097/00001756-199904260-00026; HUTTON LA, 1992, J NEUROSCI RES, V32, P375, DOI 10.1002/jnr.490320309; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Imbschweiler I, 2012, GLIA, V60, P358, DOI 10.1002/glia.22270; Insua D, 2012, J ALZHEIMERS DIS, V28, P291, DOI 10.3233/JAD-2011-110905; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; ITOYAMA Y, 1985, ACTA NEUROPATHOL, V65, P217, DOI 10.1007/BF00687001; ITOYAMA Y, 1983, ANN NEUROL, V14, P339, DOI 10.1002/ana.410140313; Jasmin L, 2002, NEUROSCIENTIST, V8, P198; Jeffery ND, 2005, J NEUROTRAUM, V22, P1282, DOI 10.1089/neu.2005.22.1282; Jeffery ND, 1997, BRAIN, V120, P27, DOI 10.1093/brain/120.1.27; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Jessen KR, 1998, MICROSC RES TECHNIQ, V41, P393, DOI 10.1002/(SICI)1097-0029(19980601)41:5<393::AID-JEMT6>3.0.CO;2-R; Ji K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056293; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kahn MA, 1999, GLIA, V26, P153, DOI 10.1002/(SICI)1098-1136(199904)26:2<153::AID-GLIA6>3.0.CO;2-Z; Kanning KC, 2003, J NEUROSCI, V23, P5425; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kegler K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133916; Kegler K, 2014, J NEURAL TRANSM, V121, P569, DOI 10.1007/s00702-014-1163-9; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khankan RR, 2016, J NEUROSCI, V36, P6269, DOI 10.1523/JNEUROSCI.0085-16.2016; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOH S, 1989, EXP NEUROL, V106, P209, DOI 10.1016/0014-4886(89)90154-4; Kohman RA, 2013, BRAIN BEHAV IMMUN, V27, P22, DOI 10.1016/j.bbi.2012.09.003; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kumar S, 1998, J NEUROSCI RES, V54, P754, DOI 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K; Ladiwala U, 1998, J NEUROSCI, V18, P1297; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Lankford KL, 2002, J COMP NEUROL, V443, P259, DOI 10.1002/cne.10117; Lebrun-Julien F, 2010, P NATL ACAD SCI USA, V107, P3817, DOI 10.1073/pnas.0909276107; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Lempp C, 2014, VIRUSES-BASEL, V6, P2571, DOI 10.3390/v6072571; LEVIMONTALCINI R, 1951, J EXP ZOOL, V116, P321, DOI 10.1002/jez.1401160206; LEVIMONTALCINI R, 1953, J EXP ZOOL, V123, P233, DOI 10.1002/jez.1401230203; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LUDWIN SK, 1984, J NEUROL SCI, V64, P193, DOI 10.1016/0022-510X(84)90037-6; MacLean CJ, 1997, BRAIN RES BULL, V43, P197, DOI 10.1016/S0361-9230(96)00441-8; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Mandara MT, 2013, RES VET SCI, V95, P548, DOI 10.1016/j.rvsc.2013.04.009; Marco-Salazar P, 2014, J COMP PATHOL, V150, P449, DOI 10.1016/j.jcpa.2013.11.209; MARTINEZMURILLO R, 1993, NEUROSCIENCE, V52, P587, DOI 10.1016/0306-4522(93)90408-8; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Micera A, 1998, EXP NEUROL, V154, P41, DOI 10.1006/exnr.1998.6864; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mirsky R, 2008, J PERIPHER NERV SYST, V13, P122, DOI 10.1111/j.1529-8027.2008.00168.x; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; MUFSON EJ, 1992, P NATL ACAD SCI USA, V89, P569, DOI 10.1073/pnas.89.2.569; Mujtaba T, 1998, DEV BIOL, V200, P1, DOI 10.1006/dbio.1998.8913; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; Nataf S, 1998, J NEUROSCI RES, V52, P83; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oderfeld-Nowak B, 2003, NEUROSCIENCE, V120, P31, DOI 10.1016/S0306-4522(03)00289-6; Oh JD, 2000, BRAIN RES, V853, P174, DOI 10.1016/S0006-8993(99)02054-5; Omar M, 2011, CELL TISSUE RES, V344, P391, DOI 10.1007/s00441-011-1168-8; Orlando EA, 2008, NEUROPATH APPL NEURO, V34, P621, DOI 10.1111/j.1365-2990.2008.00958.x; Petratos S, 2004, GLIA, V48, P64, DOI 10.1002/glia.20056; Petratos S, 2003, J NEUROPATH EXP NEUR, V62, P398, DOI 10.1093/jnen/62.4.398; PIORO EP, 1988, BRAIN RES, V455, P182, DOI 10.1016/0006-8993(88)90131-X; Prinz M, 2017, NAT IMMUNOL, V18, P385, DOI 10.1038/ni.3703; Raddatz BB, 2016, BRAIN PATHOL, V26, P102, DOI 10.1111/bpa.12266; Radtke C, 2014, BIOMED TECH, V59, ps1053; RAINE CS, 1978, J NEUROCYTOL, V7, P541, DOI 10.1007/BF01260888; Ramos A, 2007, J NEUROSCI, V27, P1498, DOI 10.1523/JNEUROSCI.4806-06.2007; RENDE M, 1993, J COMP NEUROL, V338, P560, DOI 10.1002/cne.903380406; Robins SC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3049; Rossner S, 2000, METAB BRAIN DIS, V15, P17; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SAIKA T, 1991, MOL BRAIN RES, V9, P157, DOI 10.1016/0169-328X(91)90142-K; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; SCHATTEMAN GC, 1988, J NEUROSCI, V8, P860; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Shields SA, 2000, J NEUROSCI RES, V60, P571, DOI 10.1002/(SICI)1097-4547(20000601)60:5<571::AID-JNR1>3.0.CO;2-Q; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Smith PM, 2002, EXP NEUROL, V176, P402, DOI 10.1006/exnr.2002.7936; SNYDER DH, 1975, J NEUROPATH EXP NEUR, V34, P209, DOI 10.1097/00005072-197505000-00001; Song XY, 2006, J NEUROCHEM, V96, P833, DOI 10.1111/j.1471-4159.2005.03564.x; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; Spitzbarth I, 2017, VET PATHOL, V54, P369, DOI 10.1177/0300985816688745; Spitzbarth I, 2015, BRAIN RES, V1595, P29, DOI 10.1016/j.brainres.2014.11.027; Spitzbarth I, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.472; Steffensen N, 2018, J TISSUE ENG REGEN M, V12, pE422, DOI 10.1002/term.2478; Su ZD, 2010, PROG NEUROBIOL, V92, P517, DOI 10.1016/j.pneurobio.2010.08.008; Sugiura Y, 2011, BIOSCIENCE REP, V31, P295, DOI 10.1042/BSR20100107; Sulaiman W, 2013, OCHSNER J, V13, P100; Suzuki S, 2014, VET PATHOL, V51, P722, DOI 10.1177/0300985813501336; Syroid DE, 2000, J NEUROSCI, V20, P5741; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; Techangamsuwan S, 2009, J NEUROSCI METH, V176, P112, DOI 10.1016/j.jneumeth.2008.08.030; Techangamsuwan S, 2011, THAI J VET MED, V41, P213; Techangamsuwan S, 2009, VIRUS RES, V144, P195, DOI 10.1016/j.virusres.2009.04.027; Techangamsuwan S, 2008, BRAIN RES, V1240, P31, DOI 10.1016/j.brainres.2008.08.092; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Tomita K, 2007, GLIA, V55, P1199, DOI 10.1002/glia.20533; Toyomoto M, 2005, NEUROSCI LETT, V379, P185, DOI 10.1016/j.neulet.2004.12.063; Tuffereau C, 2007, J VIROL, V81, P13622, DOI 10.1128/JVI.02368-06; Ulrich R, 2014, GLIA, V62, P1559, DOI 10.1002/glia.22700; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Walton RM, 2013, HISTOCHEM CELL BIOL, V139, P415, DOI 10.1007/s00418-012-1053-x; WANAKA A, 1990, DEV BRAIN RES, V55, P288, DOI 10.1016/0165-3806(90)90211-G; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Watzlawick R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002468; Wewetzer K, 2005, GLIA, V49, P577, DOI 10.1002/glia.20149; Wewetzer K, 2002, CELL TISSUE RES, V309, P337, DOI 10.1007/s00441-002-0607-y; Wewetzer K, 2011, EXP NEUROL, V229, P80, DOI 10.1016/j.expneurol.2010.08.029; Wohlsein P, 2013, VET PATHOL, V50, P122, DOI 10.1177/0300985812450719; WYATT S, 1990, NEURON, V4, P421, DOI 10.1016/0896-6273(90)90054-J; Xiao JH, 2010, NEUROSIGNALS, V18, P186, DOI 10.1159/000323170; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1; Young KM, 2007, J NEUROSCI, V27, P5146, DOI 10.1523/JNEUROSCI.0654-07.2007; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002; Zhang JY, 2017, MOL NEUROBIOL, V54, P943, DOI 10.1007/s12035-016-9709-5; Zhang JZ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00121; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X; Zhang SX, 2013, NEURAL REGEN RES, V8, P177, DOI 10.3969/j.issn.1673-5374.2013.02.011; Zhou XF, 2005, NEUROSCIENCE, V132, P591, DOI 10.1016/j.neuroscience.2004.12.034; Zhou XF, 1996, J NEUROSCI, V16, P2901; Zhou XF, 2011, PRION, V5, P161, DOI 10.4161/pri.5.3.16896; Ziege S, 2013, CELL TRANSPLANT, V22, P355, DOI 10.3727/096368912X656108	224	2	2	3	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					786	801		10.1177/0300985818781930			16	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600004	29940812				2019-10-28	
J	Noland, EL; Keller, SM; Kiupel, M				Noland, Erica L.; Keller, Stefan M.; Kiupel, Matti			Subcutaneous Panniculitis-Like T-cell Lymphoma in Dogs: Morphologic and Immunohistochemical Classification	VETERINARY PATHOLOGY			English	Article						dog; skin; lymphoma; nonepitheliotropic; subcutaneous; panniculitis-like; NECTCL; immunohistochemistry	CUTANEOUS LYMPHOMAS; ORGANIZATION; CLONALITY; NEOPLASIA; DIAGNOSIS; CRITERIA; DISEASE	Canine nonepitheliotropic cutaneous T-cell lymphomas (NECTCL) are poorly characterized. In humans, a number of distinct subtypes of NECTCL have been recognized, including subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Five dogs with subcutaneous T-cell lymphomas histologically similar to SPTCL in humans are herein described. The mean age was 8.5 years (5.5 to 12 years). No breed or sex predilection was identified in this small cohort. Two dogs presented with an acute onset of multiple skin masses and 3 dogs had solitary masses with subsequent development of multiple smaller masses within 0.5 to 2 months post-diagnosis without treatment. Locations, when specified, included shoulder, neck, and ventral abdomen. Two dogs were euthanized following diagnosis and one dog treated with chemotherapy (CCNU) survived 7 months post-diagnosis. Histologically, all cases were characterized by proliferations of either small to intermediate or large sized, CD3-positive T cells that infiltrated the subcutis in a lace-like pattern and frequently rimmed adipocytes. No epitheliotropism was observed, neoplastic cells were often karyorrhectic, and there were regions of extensive necrosis. Heavy infiltrates of histiocytes with prominent phagocytosis masked the lymphoid neoplastic cell population in some sections. A clonal T-cell receptor gamma gene rearrangement was found in 4 of the 5 cases. While SPTCLs typically have a less aggressive clinical course in humans, their biological behavior in dogs remains to be determined. In summary, SPTCL may represent a distinct entity in dogs and needs to be accurately diagnosed to better determine clinical behavior.	[Noland, Erica L.; Kiupel, Matti] Michigan State Univ, Vet Diagnost Lab, 4125 Beaumont Rd, Lansing, MI 48910 USA; [Noland, Erica L.; Kiupel, Matti] Michigan State Univ, Dept Pathobiol & Diagnost Invest, 4125 Beaumont Rd, Lansing, MI 48910 USA; [Keller, Stefan M.] Univ Guelph, Ontario Vet Coll, Guelph, ON, Canada	Kiupel, M (reprint author), Michigan State Univ, Vet Diagnost Lab, 4125 Beaumont Rd, Lansing, MI 48910 USA.; Kiupel, M (reprint author), Michigan State Univ, Dept Pathobiol & Diagnost Invest, 4125 Beaumont Rd, Lansing, MI 48910 USA.	kiupel@dcpah.msu.edu					Ali L, 2015, J CUTAN PATHOL, V42, P987, DOI 10.1111/cup.12591; Biswas P, 2000, EUR J IMMUNOL, V30, P2172, DOI 10.1002/1521-4141(2000)30:18<2172::AID-IMMU2172>3.0.CO;2-5; Burnett RC, 2003, VET PATHOL, V40, P32, DOI 10.1354/vp.40-1-32; Carrasco V, 2015, VET PATHOL, V52, P668, DOI 10.1177/0300985814559398; Chan JKC, 2000, DIAGNOSTIC HISTOPATH, P1182; Gibson JF, 2015, J AM ACAD DERMATOL, V72, P1010, DOI 10.1016/j.jaad.2015.01.003; GONZALEZ CL, 1991, AM J SURG PATHOL, V15, P17, DOI 10.1097/00000478-199101000-00002; Hosler GA, 2008, J CUTAN PATHOL, V35, P1063, DOI 10.1111/j.1600-0560.2007.00931.x; Jaffe Elaine S, 2009, Hematology Am Soc Hematol Educ Program, P523, DOI 10.1182/asheducation-2009.1.523; Keller SM, 2012, VET IMMUNOL IMMUNOP, V145, P410, DOI 10.1016/j.vetimm.2011.12.019; KNOWLES DM, 1989, AM J PATHOL, V134, P761; Lozzi GP, 2006, AM J DERMATOPATH, V28, P9, DOI 10.1097/01.dad.0000187933.87103.03; Magro CM, 2012, AM J CLIN PATHOL, V138, P50, DOI 10.1309/AJCPQGVLTZQ77VFF; Michonneau D, 2017, ACTA DERM-VENEREOL, V97, P358, DOI 10.2340/00015555-2543; Moore PF, 2013, VET DERMATOL, V24, P204, DOI 10.1111/j.1365-3164.2012.01106.x; Moore PF, 2009, VET DERMATOL, V20, P569, DOI 10.1111/j.1365-3164.2009.00814.x; MOORE PF, 1994, CLIN DERMATOL, V12, P499, DOI 10.1016/0738-081X(94)90216-X; Nel S, 2015, ARCH ORAL BIOL, V60, P1577, DOI 10.1016/j.archoralbio.2015.08.002; Park HM, 2007, VET PATHOL, V44, P921, DOI 10.1354/vp.44-6-921; Parveen Z, 2009, ARCH PATHOL LAB MED, V133, P303, DOI 10.1043/1543-2165-133.2.303; Pitch M, 2017, DERMATOL ONLINE J, V23; RALFKIAER E, 1991, SEMIN DIAGN PATHOL, V8, P62; Rutgen BC, 2015, VET CLIN PATH, V44, P58, DOI 10.1111/vcp.12221; Salhany KE, 1998, AM J SURG PATHOL, V22, P881, DOI 10.1097/00000478-199807000-00010; Swerdlow SH, 2008, WHO CLASSIFICATION T; Thakur A, 2015, INTERNAL MED, V5, P198; Valli VE, 2011, VET PATHOL, V48, P198, DOI 10.1177/0300985810379428; Valli VE, 2006, VET PATHOL, V43, P241, DOI 10.1354/vp.43-3-241; Valli VE, 2016, JUBB KENNEDY PALMERS, P232; Valli VE, 2007, VET COMP HEMATOPATHO, P327; Willemze R, 2008, BLOOD, V111, P838, DOI 10.1182/blood-2007-04-087288	31	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					802	808		10.1177/0300985818789474			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600005	30071780				2019-10-28	
J	Graf, R; Pospischil, A; Guscetti, F; Meier, D; Welle, M; Dettwiler, M				Graf, Ramona; Pospischil, Andreas; Guscetti, Franco; Meier, Daniela; Welle, Monika; Dettwiler, Martina			Cutaneous Tumors in Swiss Dogs: Retrospective Data From the Swiss Canine Cancer Registry, 2008-2013	VETERINARY PATHOLOGY			English	Article						dog; skin; cutaneous; soft tissue; neoplasms; cancer registry; epidemiology; incidence rate; breeds; anatomic location; sex; age	NEOPLASMS; BREED; AGE	Data collected in animal cancer registries comprise extensive and valuable information, even more so when evaluated in context with precise population data. The authors evaluated 11 740 canine skin tumors collected in the Swiss Canine Cancer Registry from 2008-2013, considering data on breed, sex, age, and anatomic locations. Their incidence rate (IR) per 100 000 dogs/year in the Swiss dog population was calculated based on data from the official and mandatory Swiss dog registration database ANIS. The most common tumor types were mast cell tumors (16.35%; IR, 60.3), lipomas (12.47%; IR, 46.0), hair follicle tumors (12.34%; IR, 45.5), histiocytomas (12.10%; IR, 44.6), soft tissue sarcomas (10.86%; IR, 40.1), and melanocytic tumors (8.63%; IR, 31.8) with >1000 tumors per type. The average IR of all tumor types across the 227 registered breeds was 372.2. The highest tumor incidence was found in the Giant Schnauzer (IR, 1616.3), the Standard Schnauzer (IR, 1545.4), the Magyar Vizsla (IR, 1534.6), the Rhodesian Ridgeback (IR, 1445.0), the Nova Scotia Duck Tolling Retriever (IR, 1351.7), and the Boxer (IR, 1350.0). Mixed-breed dogs (IR, 979.4) had an increased IR compared to the average of all breeds. Previously reported breed predispositions for most tumor types were confirmed. Nevertheless, the data also showed an increased IR for mast cell tumors and melanocytic tumors in the Nova Scotia Duck Tolling Retriever and for histiocytomas in the Flat Coated Retriever. The results from this study can be taken into consideration when selecting purebred dogs for breeding to improve a breed's health.	[Graf, Ramona; Pospischil, Andreas] Univ Zurich, Semper Sternwarte, Coll Helveticum, Zurich, Switzerland; [Graf, Ramona; Pospischil, Andreas] ETHZ, Semper Sternwarte, Coll Helveticum, Zurich, Switzerland; [Pospischil, Andreas; Guscetti, Franco] Univ Zurich, Inst Vet Pathol, Vetsuisse Fac, Zurich, Switzerland; [Meier, Daniela] Zyto Histo Diagnost, Rorbas Freienstein, Switzerland; [Welle, Monika; Dettwiler, Martina] Univ Bern, Inst Anim Pathol, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Langgassstr 122, Bern, Switzerland	Dettwiler, M (reprint author), Univ Bern, Inst Anim Pathol, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Langgassstr 122, Bern, Switzerland.	martina.dettwiler@vetsuisse.unibe.ch		Dettwiler, Martina/0000-0001-9404-7122			Abramo F, 1999, J SMALL ANIM PRACT, V40, P479, DOI 10.1111/j.1748-5827.1999.tb02999.x; Baioni E, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1126-0; Belluco S, 2013, VET PATHOL, V50, P1078, DOI 10.1177/0300985813490757; Bronden LB, 2010, VET REC, V166, P586, DOI 10.1136/vr.b4808; Bronden LB, 2010, ACTA VET SCAND, V52, DOI 10.1186/1751-0147-52-6; Chikweto A, 2011, INT SCH RES NETW ISR, V2011; Dobson J. M., 2013, ISRN VET SCI, V2013, DOI DOI 10.1155/2013/941275); Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x; DORN CR, 1967, CALIF MED, V107, P481; Gamlem H, 2008, APMIS, V116, P5, DOI 10.1111/j.1600-0463.2008.125m2.x; Goldschmidt M. H., 2017, Tumors in domestic animals, P88; Goldschmidt MH, 2007, WHO HISTOLOGICAL CLA, P3; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P1, DOI 10.1002/9780470752487; Gruntzig K, 2015, J COMP PATHOL, V152, P161, DOI 10.1016/j.jcpa.2015.02.005; Gruntzig K, 2016, J COMP PATHOL, V155, P156, DOI 10.1016/j.jcpa.2016.05.011; Hendrick M, 2007, WHO HISTOLOGICAL CLA, P2; Merlo DF, 2008, J VET INTERN MED, V22, P976, DOI 10.1111/j.1939-1676.2008.0133.x; MILLER W. H., 2013, MULLER KIRKS SMALL A, P774; Pakhrin B, 2007, J VET SCI, V8, P229, DOI 10.4142/jvs.2007.8.3.229; The Swiss Federal Assembly, 2017, SCHWEIZ TIERS SR 916; Vascellari M, 2009, BMC VET RES, V5, DOI 10.1186/1746-6148-5-39; Villamil JA, 2011, JAVMA-J AM VET MED A, V239, P960, DOI 10.2460/javma.239.7.960	22	1	1	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					809	820		10.1177/0300985818789466			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600006	30131007				2019-10-28	
J	Kok, MK; Chambers, JK; Ong, SM; Nakayama, H; Uchida, K				Kok, Mun Keong; Chambers, James K.; Ong, Siew Mei; Nakayama, Hiroyuki; Uchida, Kazuyuki			Hierarchical Cluster Analysis of Cytokeratins and Stem Cell Expression Profiles of Canine Cutaneous Epithelial Tumors	VETERINARY PATHOLOGY			English	Article						cutaneous epithelial tumors; diagnostic criteria; dogs; hierarchical cluster analysis; immunohistochemistry	INTERMEDIATE FILAMENT PROTEINS; MYOEPITHELIAL CELLS; SKIN; ADIPOPHILIN; CARCINOMA; DIFFERENTIATION; NEOPLASMS; VIMENTIN; KERATINS; LESIONS	The diagnosis of cutaneous epithelial tumors (CETs) in dogs is based on predominant histological differentiation patterns. However, the expression of a broad panel of antigens has not been comprehensively examined with immunohistochemistry. The present study aims to establish a comprehensive expression profile and identify useful diagnostic markers for each CET type. Cytokeratin (CK), stem cell, and other associated markers were immunohistochemically examined in 110 canine CETs. Among these, CK16 was useful for differentiating between basal and squamous cell carcinomas. Acantholytic squamous cell carcinomas were positive for CK8, CK18, and CK19, suggesting their close association with the apocrine duct. Unlike their benign counterparts, sebaceous carcinomas coexpressed CK5/6 and adipophilin. Smooth muscle actin (SMA) and p63 immunostaining were useful for accurately distinguishing between glandular and ductal differentiation in apocrine tumors. A case of apocrine carcinoma and malignant myoepithelioma was identified using anti-SMA antibodies. Stem cell expression profiles (CK8, CK15, CK19, and CD34) of hair follicle tumors were discrete and indicative of their anatomic origins. The effectiveness of immunohistochemistry for tumor diagnosis was further confirmed by hierarchical cluster analysis, through which selected markers were able to sort CETs into specific groups: CK5/6, CK8, CK14, CK16, CK18, CK19, p63, adipophilin, and SMA sorted tumors of epidermal, apocrine, or sebaceous origin; while CK8, CK14, CK15, CK16, CK19, CD34, and p63 sorted hair follicle tumors in agreement with their histological differentiation. In conclusion, the present study provides comprehensive immunohistochemical information, which could complement histomorphological features for the future classification of canine CETs.	[Kok, Mun Keong; Chambers, James K.; Nakayama, Hiroyuki; Uchida, Kazuyuki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Tokyo, Japan; [Ong, Siew Mei] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Surg, Tokyo, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp		Kok, Mun Keong/0000-0001-9337-3209			Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Ansai S, 2011, AM J DERMATOPATH, V33, P579, DOI 10.1097/DAD.0b013e31820a2027; Balachander N, 2015, J PHARM BIOALLIED SC, V7, pS190, DOI 10.4103/0975-7406.155898; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Brachelente C, 2013, VET DERMATOL, V24, P188, DOI 10.1111/j.1365-3164.2012.01101.x; Bragulla HH, 2009, J ANAT, V214, P516, DOI 10.1111/j.1469-7580.2009.01066.x; Demirkesen C, 1995, J CUTAN PATHOL, V22, P518, DOI 10.1111/j.1600-0560.1995.tb01147.x; FERRER L, 1990, J VET MED A, V37, P569, DOI 10.1111/j.1439-0442.1990.tb00946.x; Gerhards NM, 2016, J HISTOCHEM CYTOCHEM, V64, P190, DOI 10.1369/0022155415627679; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Goldschmidt M. H., 2017, Tumors in domestic animals, P88; Goldschmidt MH, 1998, HISTOLOGICAL CLASSIF; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jasik A, 2009, B VET I PULAWY, V53, P277; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Kato K, 2007, J VET MED SCI, V69, P233, DOI 10.1292/jvms.69.233; Mercati F, 2008, HISTOL HISTOPATHOL, V23, P1035, DOI 10.14670/HH-23.1035; Misago N, 2006, J DERMATOL, V33, P2, DOI 10.1111/j.1346-8138.2006.00001.x; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; MORRIS RJ, 1986, CANCER RES, V46, P3061; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Muthusamy K, 2006, J CLIN PATHOL, V59, P1166, DOI 10.1136/jcp.2005.033381; Ohnishi T, 1999, AM J DERMATOPATH, V21, P337, DOI 10.1097/00000372-199908000-00005; Ostler DA, 2010, MODERN PATHOL, V23, P567, DOI 10.1038/modpathol.2010.1; Pascucci L, 2006, VET DERMATOL, V17, P244, DOI 10.1111/j.1365-3164.2006.00527.x; Pieper JB, 2015, J VET DIAGN INVEST, V27, P497, DOI 10.1177/1040638715594115; RABANAL RM, 1994, RES VET SCI, V56, P225, DOI 10.1016/0034-5288(94)90108-2; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Reis JS, 2002, J CUTAN PATHOL, V29, P517, DOI 10.1034/j.1600-0560.2002.290902.x; Saraiva AL, 2008, VET J, V177, P136, DOI 10.1016/j.tvjl.2007.03.027; Sharif M, 2006, J VET MED A, V53, P352, DOI 10.1111/j.1439-0442.2006.00834.x; Shiraki A, 2012, J VET MED SCI, V74, P801, DOI 10.1292/jvms.11-0532; Solanas G, 2013, NAT REV MOL CELL BIO, V14, P737, DOI 10.1038/nrm3675; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Walter J, 2000, J COMP PATHOL, V122, P278, DOI 10.1053/jcpa.1999.0372; Watanabe K, 2017, J VET MED SCI, V79, P670, DOI 10.1292/jvms.16-0610; Yao Jeng-Yuan, 2012, Biomed J, V35, P457, DOI 10.4103/2319-4170.104410	38	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					821	837		10.1177/0300985818785680			17	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600007	30071783				2019-10-28	
J	Degner, S; Schoon, HA; Laik-Schandelmaier, C; Aupperle-Lellbach, H; Schoniger, S				Degner, Sophie; Schoon, Heinz-Adolf; Laik-Schandelmaier, Claudia; Aupperle-Lellbach, Heike; Schoeniger, Sandra			Estrogen Receptor-alpha and Progesterone Receptor Expression in Mammary Proliferative Lesions of Female Pet Rabbits	VETERINARY PATHOLOGY			English	Article						estrogen receptor; histopathology; immunohistochemistry; mammary carcinoma; rabbits; progesterone receptor; mammary hyperplasia/dysplasia	TUMORS; CANINE; GLAND; IMMUNOHISTOCHEMISTRY; TISSUE; DOG	In breast cancer of women, the estrogen receptor-alpha (ER alpha) and progesterone receptor (PR) status has prognostic and therapeutic significance. The aim of this study was (1) to characterize by immunohistochemistry the expression of ER alpha and PR in nonneoplastic and neoplastic mammary gland tissue of pet rabbits and (2) to correlate the ER alpha/PR status and histological features. All 124 rabbits included in this study had a mammary tumor; in addition, 2 rabbits had lobular hyperplasia and 25 had multiple cysts. Of the 124 neoplasms, 119 (96%) were carcinoma, 2 (2%) were carcinoma in situ, and 3 (2%) were adenoma. ER alpha or PR or both were detected in 2 of 2 carcinomas in situ, 3 of 3 adenomas, 19 of 25 cysts, and 2 of 2 lesions of lobular hyperplasia. Most carcinomas (75/119, 63%) were negative for both ER alpha and PR; 22 of 119 carcinomas (18%) were double-immunopositive. The ER alpha and PR expression was not influenced by histotype or histological tumor grade. In carcinomas, there was a statistically significant correlation between increased mitotic count and reduced expression of ER alpha and PR, and the mitotic count was higher in double-immunonegative carcinomas (75/119). The findings suggest that in rabbit mammary carcinomas, proliferative activity is mainly influenced by factors other than estrogen and progesterone and provides the basis for future investigations into the prognostic significance of the ER alpha and PR status of mammary tumors.	[Degner, Sophie; Schoon, Heinz-Adolf; Schoeniger, Sandra] Univ Leipzig, Inst Vet Pathol, Fac Vet Med, Tierkliniken 33, D-04103 Leipzig, Germany; [Laik-Schandelmaier, Claudia; Aupperle-Lellbach, Heike] Laboklin GmbH Co KG, Bad Kissingen, Germany	Schoniger, S (reprint author), Univ Leipzig, Inst Vet Pathol, Fac Vet Med, Tierkliniken 33, D-04103 Leipzig, Germany.	sandra.schoeniger@vetmed.uni-leipzig.de					Asakawa MG, 2008, VET PATHOL, V45, P217, DOI 10.1354/vp.45-2-217; Aupperle H, 2000, EQUINE VET J, V32, P228, DOI 10.2746/042516400776563554; Bacci B, 2010, J COMP PATHOL, V143, P350, DOI 10.1016/j.jcpa.2010.09.117; Baum B, 2015, J COMP PATHOL, V152, P291, DOI 10.1016/j.jcpa.2015.01.009; BENAVENTE M. A., 2016, J VET ADV, V6, P1291, DOI DOI 10.5455/jva.20160916045115; Bhargava S., 1993, Indian Journal of Experimental Biology, V31, P673; Brewer NR, 2006, J AM ASSOC LAB ANIM, V45, P8; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Chang CC, 2009, JAVMA-J AM VET MED A, V235, P391, DOI 10.2460/javma.235.4.391; de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200; Ellis IO, 2007, DIAGNOSTIC HISTOPATH, V1, P903; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Goldschmidt M. H., 2017, Tumors in domestic animals, P723; Greene HSN, 1939, J EXP MED, V70, P147, DOI 10.1084/jem.70.2.147; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; KELLY PA, 1983, J STEROID BIOCHEM, V18, P215, DOI 10.1016/0022-4731(83)90093-6; LaMarca HL, 2008, ENDOCRINOLOGY, V149, P4317, DOI 10.1210/en.2008-0450; Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35; Majka J, 1994, PATHOLOGY NEOPLASIA, P1; Meuten DJ, 2016, VET PATHOL, V53, P7, DOI 10.1177/0300985815593349; Millanta F, 2005, RES VET SCI, V79, P225, DOI 10.1016/j.rvsc.2005.02.002; Misdorp W, 1999, HISTOLOGICAL CLASSIF; Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; RUTTEMAN GR, 1988, BRIT J CANCER, V58, P594, DOI 10.1038/bjc.1988.266; Schoniger S, 2014, VET PATHOL, V51, P569, DOI 10.1177/0300985813497486; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Vinci A, 2010, J COMP PATHOL, V142, P323, DOI 10.1016/j.jcpa.2009.12.005; Walter B, 2010, VET REC, V166, P230, DOI 10.1136/vr.b4749	31	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					838	848		10.1177/0300985818788611			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600008	30114981				2019-10-28	
J	Joselevitch, JA; Barra, CN; Vargas, THM; Pulz, LH; Nishiya, AT; Kleeb, SR; Xavier, JG; Catao-Dias, JL; Strefezzi, RF				Joselevitch, Julia A.; Barra, Camila N.; Vargas, Thiago Henrique M.; Pulz, Lidia H.; Nishiya, Adriana T.; Kleeb, Silvia Regina; Xavier, Jose Guilherme; Catao-Dias, Jose Luiz; Strefezzi, Ricardo F.			Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors	VETERINARY PATHOLOGY			English	Article						dogs; mitotic index; Ki-67; NANOG homeobox protein; mast cells; mastocytoma; skin; neoplasm; grading; prognosis; western blot; immunohistochemistry	CANCER CELLS; STEM-CELLS; SURVIVAL; OCT4; GENE; DOGS	Mast cell tumors are one of the most frequent skin tumors in dogs. Treatment decisions often depend on a wide range of clinical information and the main criteria for prognostic formulation are histological grade, mitotic count, Ki67 index, and KIT immunostaining pattern. NANOG is a pluripotency factor expressed by normal and cancer stem cells, which is a prognostic marker and a potential therapeutic target for several human tumors. In the present study, mast cell tumor samples from 41 dogs were evaluated for NANOG and Ki67 by immunohistochemistry. All samples were positive for NANOG but its expression was not correlated with Ki67 index and no significant differences were found with respect to histopathological grades, disease-related mortality, or survival. Our results suggest that, although related to pluripotency, NANOG expression does not correlate with proliferative activity, and is not a reliable prognostic factor for canine cutaneous mast cell tumors.	[Joselevitch, Julia A.; Barra, Camila N.; Vargas, Thiago Henrique M.; Pulz, Lidia H.; Strefezzi, Ricardo F.] Univ Sao Paulo, Dept Med Vet, LOCT, Fac Zootecnia & Engn Alimentos, Av Duque de Caxias Norte 225, BR-13635 Pirassununga, SP, Brazil; [Barra, Camila N.; Pulz, Lidia H.; Catao-Dias, Jose Luiz] Univ Sao Paulo, Dept Patol, Fac Med Vet & Zootecnia, Sao Paulo, Brazil; [Nishiya, Adriana T.] Univ Anhembi Morumbi, Sao Paulo, SP, Brazil; [Kleeb, Silvia Regina] Univ Metodista Sao Paulo, Sao Bernardo Do Campo, SP, Brazil; [Xavier, Jose Guilherme] Univ Paulista, Sao Paulo, SP, Brazil	Joselevitch, JA (reprint author), Univ Sao Paulo, Dept Med Vet, LOCT, Fac Zootecnia & Engn Alimentos, Av Duque de Caxias Norte 225, BR-13635 Pirassununga, SP, Brazil.	julia.joselevitch@usp.br	CATAO-DIAS, JOSE LUIZ/C-4897-2012; Strefezzi, Ricardo F/B-8754-2010	CATAO-DIAS, JOSE LUIZ/0000-0003-2999-3395; Strefezzi, Ricardo F/0000-0002-8810-2815; Antongiovanni Joselevitch, Julia/0000-0002-0900-3529	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/13252-8, 2014/20872-5, 2016/03862-1]	This research was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, grants 2013/13252-8, 2014/20872-5, and 2016/03862-1).	Barra CN, 2018, VET COMP ONCOL, V16, pE38, DOI 10.1111/vco.12330; Blackwood L, 2012, VET COMP ONCOL, V10, pe1, DOI 10.1111/j.1476-5829.2012.00341.x; Ji W, 2013, ONCOL LETT, V6, P367, DOI 10.3892/ol.2013.1394; Kiupel M, 2004, VET PATHOL, V41, P371, DOI 10.1354/vp.41-4-371; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Lu YH, 2013, CANCER LETT, V340, P113, DOI 10.1016/j.canlet.2013.07.009; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Pang Lisa Y, 2011, Cancers (Basel), V3, P1744, DOI 10.3390/cancers3021744; Pang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095635; PATNAIK AK, 1984, VET PATHOL, V21, P469, DOI 10.1177/030098588402100503; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Strefezzi R. F., 2009, Brazilian Journal of Veterinary Pathology, V2, P110; Strefezzi RD, 2003, VET PATHOL, V40, P268, DOI 10.1354/vp.40-3-268; Vargas THM, 2015, J COMP PATHOL, V153, P251, DOI 10.1016/j.jcpa.2015.08.010; Wang ML, 2013, ONCOTARGETS THER, V6, P1207, DOI 10.2147/OTT.S38114; Wilson-Robles HM, 2015, VET COMP ONCOL, V13, P60, DOI 10.1111/vco.12019; Yin X, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0119-3; Zhang W, 2016, INT J BIOL SCI, V12, P1372, DOI 10.7150/ijbs.16349; Zhao XZ, 2016, ONCOL LETT, V11, P442, DOI 10.3892/ol.2015.3884	19	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					849	852		10.1177/0300985818789470			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600009	30025495				2019-10-28	
J	Gal, A; Burchell, RK; Worth, AJ; Lopez-Villallobos, N; Marshall, JC; MacNeill, AL				Gal, Arnon; Burchell, Richard K.; Worth, Andrew J.; Lopez-Villallobos, Nicolas; Marshall, Jonathan C.; MacNeill, Amy L.			The Site of Bone Marrow Acquisition Affects the Myeloid to Erythroid Ratio in Apparently Healthy Dogs	VETERINARY PATHOLOGY			English	Article						bone marrow; biopsy; canine; cytology; quality assurance; anatomy; hematology	BIOPSY; MRI; OSTEOARTHRITIS; CATS	Bone marrow (BM) cytology and histopathology are complementary tools used to investigate hematological diseases. The purpose of this study was to determine if there are site-dependent differences in the diagnostic quality, myeloid to erythroid ratio (MER), and discordant findings in samples from different sites in the same dog. Eighteen apparently healthy dogs were used in the study. The sequence of sample acquisition was randomized according to a Latin square, and samples for BM cytology and histology were collected from both humeri and both ilial crests immediately after death. Board-certified clinical and anatomical pathologists read the cytology and histology, respectively. The data were analyzed using a mixed-effect model. The site of BM acquisition did not affect BM sample quality. The rate of discordant clinical findings between sites was 0.05 (95% confidence interval, 0.01-0.13). In general, by cytology, the MERs were slightly but significantly greater in samples from the ilial crests than from the humeri (P = .01). The measured MER for histology was nearly twice that for cytology for all sites (P < .001). In conclusion, there was a low-rate, site-dependent discordance in diagnostic findings in BM samples and differences in MER between the ilial crest and the humerus. A similar study is justified in sick dogs with hematological disease to determine the effect of sampling site on discordant findings between sites.	[Gal, Arnon; Burchell, Richard K.; Worth, Andrew J.; Lopez-Villallobos, Nicolas] Massey Univ, Sch Vet Sci, Tennent Dr, Palmerston North 4410, New Zealand; [Marshall, Jonathan C.] Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand; [MacNeill, Amy L.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Gal, A (reprint author), Massey Univ, Sch Vet Sci, Tennent Dr, Palmerston North 4410, New Zealand.	a.gal@massey.ac.nz	Burchell, Richard/Q-9453-2019	Burchell, Richard/0000-0002-8527-9308; Gal`, Arnon/0000-0002-6449-2812; Worth, Andrew/0000-0003-3800-4886	New Zealand Companion Animal Health Foundation Project Grant of the New Zealand Veterinary Association	This work was supported by the New Zealand Companion Animal Health Foundation Project Grant of the New Zealand Veterinary Association. Preliminary results were presented at the European College of Veterinary Medicine Annual Meeting in Malta 2017.	Abrams-Ogg ACG, 2012, VET CLIN PATH, V41, P235, DOI 10.1111/j.1939-165X.2012.00422.x; Bates D, 2015, J STAT SOFTW, V67, P1; Baum T, 2015, J MAGN RESON IMAGING, V42, P1018, DOI 10.1002/jmri.24854; Bland JM, 1996, BRIT MED J, V312, P1079; Bugatti S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4115; Corbee RJ, 2014, VET J, V202, P116, DOI 10.1016/j.tvjl.2014.07.001; GOLDSTEIN SA, 1987, J BIOMECH, V20, P1055, DOI 10.1016/0021-9290(87)90023-6; Grindem CB, 2002, VET CLIN N AM-SMALL, V32, P1313, DOI 10.1016/S0195-5616(02)00052-9; GRINDEM CB, 1989, VET CLIN N AM-SMALL, V19, P669, DOI 10.1016/S0195-5616(89)50078-0; GROSS PM, 1979, AM J PHYSIOL, V237, pH440; HARVEY JW, 1984, COMP CONT EDUC PRACT, V6, P909; Harvey JW, 2012, VET HEMATOLOGY DIAGN, P254; Harvey JW, 2001, ATLAS VET HEMATOLOGY, P114; Jain NC, 1993, ESSENTIALS VET HEMAT, P12; Link TM, 2011, SEMIN MUSCULOSKEL R, V15, P238, DOI 10.1055/s-0031-1278423; Marenzana M, 2013, BONE RES, V1, P203, DOI 10.4248/BR201303001; Martig S, 2007, VET RADIOL ULTRASOUN, V48, P105, DOI 10.1111/j.1740-8261.2007.00213.x; Mortiz A, 2010, SCHALMS VET HEMATOLO, P1039; PENNY RHC, 1970, J SMALL ANIM PRACT, V11, P727, DOI 10.1111/j.1748-5827.1970.tb05577.x; Pichardo JC, 2011, J NUCL MED, V52, P1482, DOI 10.2967/jnumed.111.087957; R Core Team, 2017, R LANG ENV STAT COMP; Raskin RE, 2012, VET CLIN N AM-SMALL, V42, P23, DOI 10.1016/j.cvsm.2011.10.001; RUMPH PF, 1994, AM J VET RES, V55, P756; Savvopoulou V, 2008, EUR RADIOL, V18, P1876, DOI 10.1007/s00330-008-0943-8; Stasney J, 1937, AM J MED SCI, V193, P462, DOI 10.1097/00000441-193704000-00002; STERN A, 1983, MOD VET PRACT, V64, P877; Weiss DJ, 2006, J VET INTERN MED, V20, P955, DOI 10.1892/0891-6640(2006)20[955:ARSOTI]2.0.CO;2	27	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					853	860		10.1177/0300985818780469			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600010	29940832				2019-10-28	
J	Miller, MA; Bruyette, DS; Scott-Moncrieff, JC; Owen, TJ; Ramos-Vara, JA; Weng, HY; Vanderpool, AL; Chen, AV; Martin, LG; DuSold, DM; Jahan, S				Miller, Margaret A.; Bruyette, David S.; Scott-Moncrieff, J. Catharine; Owen, Tina Jo; Ramos-Vara, Jose A.; Weng, Hsin-Yi; Vanderpool, Andrea L.; Chen, Annie V.; Martin, Linda G.; DuSold, Deidre M.; Jahan, Sina			Histopathologic Findings in Canine Pituitary Glands	VETERINARY PATHOLOGY			English	Article						adenohypophyseal hyperplasia; dogs; hyperadrenocorticism; pituitary adenoma; pituitary-dependent hypercortisolism; transsphenoidal hypophysectomy	DEPENDENT HYPERADRENOCORTICISM; TRANSSPHENOIDAL HYPOPHYSECTOMY; DOGS; ADENOMAS; CLASSIFICATION; PATHOLOGY; HYPOPHYSITIS; DIAGNOSIS; PROGRESS; DISEASE	To optimize the histologic evaluation of hypophysectomy specimens, sections of 207 canine pituitary glands (196 postmortem, 11 hypophysectomy specimens) were reviewed. Adenohypophyseal proliferation was the most common (n = 79) lesion. Proliferative lesions were sparsely to densely granulated; the granules were usually basophilic to chromophobic and periodic acid-Schiff-positive. Adenohypophyseal proliferation was classified as hyperplasia (n = 40) if <= 2 mm diameter with intact reticulin network, as microadenoma (n = 22) for 1-5 mm homogeneous nodules with lost reticulin network, or as macroadenoma (n = 17) for larger tumors. Craniopharyngeal duct cysts were common incidental lesions and the only lesion in 15 dogs. Uncommon diagnoses included lymphoma (n = 4), hemorrhagic necrosis (n = 4), metastatic carcinoma (n = 3), hypophysitis (n = 3), ependymoma (n = 2), craniopharyngioma (n = 2), and 1 case each of metastatic melanoma, pituicytoma, gliomatosis, germ cell tumor, meningioma, and atrophy. The pituitary histologic diagnosis was associated with hyperadrenocorticism (HAC; P < .001) and adrenocortical histologic diagnosis (P = .025). Both HAC and adrenocortical hyperplasia showed a positive trend with the degree of adenohypophyseal proliferation. The association of adrenocortical hyperplasia with HAC was not significant (P = .077). Dogs with adenohypophyseal proliferations were older than dogs with normal pituitary glands (P < .05). Brachycephalic breeds were overrepresented among dogs with pituitary macroadenoma or craniopharyngeal duct cysts, but the association was not statistically significant (P = .076). Adenohypophyseal hyperplasia was more common than adenoma among postmortem specimens, but was unexpected in >80% of cases. Pituitary macroadenoma was the most common diagnosis in hypophysectomy specimens.	[Miller, Margaret A.; Ramos-Vara, Jose A.; Vanderpool, Andrea L.; DuSold, Deidre M.] Purdue Univ, Indiana Anim Dis Diagnost Lab, W Lafayette, IN 47907 USA; [Miller, Margaret A.; Ramos-Vara, Jose A.; Weng, Hsin-Yi; Vanderpool, Andrea L.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Bruyette, David S.] Aniv Life Sci, Long Beach, CA USA; [Scott-Moncrieff, J. Catharine] Purdue Univ, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; [Scott-Moncrieff, J. Catharine] Purdue Univ, Vet Teaching Hosp, W Lafayette, IN 47907 USA; [Owen, Tina Jo; Chen, Annie V.; Martin, Linda G.] Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA; [Owen, Tina Jo; Chen, Annie V.; Martin, Linda G.] Washington State Univ, Vet Teaching Hosp, Pullman, WA 99164 USA; [Jahan, Sina] Univ Tehran, Small Anim Hosp, Dept Internal Med, Vet Fac, Tehran, Iran	Miller, MA (reprint author), Purdue Univ, Anim Dis Diagnost Lab, 406 S Univ St, W Lafayette, IN 47907 USA.	pegmiller@purdue.edu		Owen, Tina/0000-0002-6652-5315			Adissu HA, 2010, VET PATHOL, V47, P1082, DOI 10.1177/0300985810382520; Al-Brahim NYY, 2006, J CLIN PATHOL, V59, P1245, DOI 10.1136/jcp.2005.031187; Alenza DP, 2006, J AM ANIM HOSP ASSOC, V42, P269, DOI 10.5326/0420269; Asa SL, 2007, ENDOTEXT; Asa SL, 2008, ARCH PATHOL LAB MED, V132, P1231, DOI 10.1043/1543-2165(2008)132[1231:PPPWDT]2.0.CO;2; Behrend EN, 2013, J VET INTERN MED, V27, P1292, DOI 10.1111/jvim.12192; Berry M, 1994, J VET INTERN MED, V8, P163; Bruyette D., 2016, Today's Veterinary Practice, V6, P30; Bruyette D., 2016, Today's Veterinary Practice, V6, P36; CAPEN CC, 1967, PATHOL VET, V4, P301, DOI 10.1177/030098586700400401; den Hertog E, 1999, VET REC, V144, P12, DOI 10.1136/vr.144.1.12; Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412; Gestier S, 2012, J COMP PATHOL, V146, P327, DOI 10.1016/j.jcpa.2011.08.002; Kiupel M, 2008, WHO INT HISTOLOGICAL, V12, P17; Lien YH, 2008, JAVMA-J AM VET MED A, V233, P1896, DOI 10.2460/javma.233.12.1896; Mamelak AN, 2014, VET SURG, V43, P369, DOI 10.1111/j.1532-950X.2014.12146.x; Martin LG, 2016, J VET INTERN MED, V30, P1941; Meij B, 2002, MOL CELL ENDOCRINOL, V197, P89, DOI 10.1016/S0303-7207(02)00283-6; Meij BP, 2012, J COMP PATHOL, V147, P503, DOI 10.1016/j.jcpa.2012.04.006; Meij BP, 1998, VET SURG, V27, P246, DOI 10.1111/j.1532-950X.1998.tb00123.x; Meij BP, 1997, VET SURG, V26, P295, DOI 10.1111/j.1532-950X.1997.tb01502.x; Mete O, 2012, J MOL ENDOCRINOL, V49, pR69, DOI 10.1530/JME-12-0113; Neiger R, 2002, VET REC, V150, P799, DOI 10.1136/vr.150.26.799; Osamura RY, 2008, HISTOCHEM CELL BIOL, V130, P495, DOI 10.1007/s00418-008-0472-1; Owen TJ, 2016, J VET INTERN MED, V30, P1939; Perez-Alenza MD, 2017, TXB VET INTERNAL MED, V2, P1796; Raverot G, 2014, EUR J ENDOCRINOL, V170, pR121, DOI 10.1530/EJE-13-1031; Rosol T, 2016, JUBB KENNEDY PALMERS, P269, DOI DOI 10.1016/B978-0-7020-5319-1.00014-1; Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326; Syro LV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00097; Syro LV, 2015, PITUITARY, V18, P217, DOI 10.1007/s11102-014-0619-0; Wolfesberger B, 2011, J COMP PATHOL, V145, P231, DOI 10.1016/j.jcpa.2011.01.004	32	2	2	3	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					871	879		10.1177/0300985818766211			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600012	29665752				2019-10-28	
J	Polledo, L; Grinwis, GCM; Graham, P; Dunning, M; Baiker, K				Polledo, Laura; Grinwis, Guy C. M.; Graham, Peter; Dunning, Mark; Baiker, Kerstin			Pathological Findings in the Pituitary Glands of Dogs and Cats	VETERINARY PATHOLOGY			English	Article						dogs; cats; adenohypophysis; hyperadrenocorticism; Crooke's change; incidentaloma; hyperplasia; pituitary gland; neoplasms; cysts; inflammation	TRANSSPHENOIDAL HYPOPHYSECTOMY; DEPENDENT HYPERADRENOCORTICISM; CARCINOMA; ADENOHYPOPHYSITIS; ADENOMAS; TUMORS	With the exception of classic functional adenomas in dogs and horses, pituitary lesions are infrequently described in the veterinary literature. Approximately 10% of pituitary glands from asymptomatic humans contain abnormalities, but the equivalent proportion in small animals is unknown. Pituitary glands from 136 dogs and 65 cats collected during routine necropsies were examined to determine the prevalence of pituitary lesions and their histopathological diagnosis. Lesions were characterized in sections stained with hematoxylin and eosin, periodic acid-Schiff (PAS), Gordon and Sweet's and reticulin stains, and immunohistochemistry for adrenocorticotropic hormone (ACTH), growth hormone, melanocyte stimulating hormone-alpha, and prolactin. Pituitary abnormalities were identified in 36 of 136 (26.4%) dogs and 10 of 65 (15.3%) cats. Cystic changes were the most common lesion, occurring in 18 (13.2%) dogs and 8 (12.3%) cats. Pituitary neoplasia was detected in 14.1% (12/85) of middle-aged and old dogs; 1 (1.5%) cat had pituitary nodular hyperplasia. PAS and reticulin stains helped differentiate ACTH-immunoreactive adenomas from hyperplastic nodules: adenomas contained PAS-positive intracytoplasmic granules and loss of the normal reticulin network. One dog had a pituitary carcinoma with infiltration into the thalamus. Other pituitary abnormalities included secondary metastases (2 dogs) and hypophysitis (4 dogs, 1 cat). In most cases, the lesion appeared to be subclinical and could be considered incidental, whereas clinical manifestations were apparent in only 4 dogs (2.9%) and none of the cats with pituitary lesions. Pituitary abnormalities are common in dogs and cats, and their clinical relevance requires further investigation.	[Polledo, Laura; Graham, Peter; Dunning, Mark; Baiker, Kerstin] Univ Nottingham, Sch Vet Med & Sci, Bonington Campus, Loughborough LE12 5RD, England; [Grinwis, Guy C. M.] Fac Vet Med Utrecht, Dept Pathobiol, Utrecht, Netherlands	Baiker, K (reprint author), Univ Nottingham, Sch Vet Med & Sci, Bonington Campus, Loughborough LE12 5RD, England.	Kerstin.Baiker@nottingham.ac.uk		Baiker, Kerstin/0000-0003-4855-6879; Graham, Peter/0000-0001-7133-1358; Polledo, Laura/0000-0002-6781-3300			Adissu HA, 2010, VET PATHOL, V47, P1082, DOI 10.1177/0300985810382520; Al-Brahim NYY, 2006, J CLIN PATHOL, V59, P1245, DOI 10.1136/jcp.2005.031187; Cosio C, 2017, VET PATHOL, V54, P972, DOI [10.1177/0300985817726118, 10.1177/030]; Dawson AB, 1937, ANAT REC, V69, P471, DOI 10.1002/ar.1090690407; DIETRICH RB, 1995, AM J NEURORADIOL, V16, P1413; Ellison D, 2013, NEUROPATHOLOGY, P819; Fassett DR, 2004, NEUROSURG FOCUS, V16, P8; Freda PU, 2011, J CLIN ENDOCR METAB, V96, P894, DOI 10.1210/jc.2010-1048; Gestier S, 2012, J COMP PATHOL, V146, P327, DOI 10.1016/j.jcpa.2011.08.002; GOOSSENS MMC, 1995, J VET INTERN MED, V9, P361, DOI 10.1111/j.1939-1676.1995.tb01099.x; Hashizume M, 2011, PATHOL INT, V61, P13, DOI 10.1111/j.1440-1827.2010.02610.x; Kimitsuki K, 2014, J VET MED SCI, V76, P133, DOI 10.1292/jvms.13-0373; Kiupel M, 2008, HISTOLOGICAL CLASSIF; Kraft SL, 1997, J VET INTERN MED, V11, P218, DOI 10.1111/j.1939-1676.1997.tb00094.x; Kumar V., 2015, ROBBINS COTRAN PATHO, P265; Lamb CR, 2014, J FELINE MED SURG, V16, P99, DOI 10.1177/1098612X13497212; Lloyd RV, 2004, WHO CLASSIFICATION T, P10; Longo M, 2016, OPEN VET J, V6, P158, DOI 10.4314/ovj.v6i3.2; Maitra A, 2015, ROBBINS COTRAN PATHO, P1074; MCALLISTER MM, 1991, VET PATHOL, V28, P340, DOI 10.1177/030098589102800413; Meij B, 2002, MOL CELL ENDOCRINOL, V197, P89, DOI 10.1016/S0303-7207(02)00283-6; Meij BP, 2005, VET PATHOL, V42, P92, DOI 10.1354/vp.42-1-92; Mete O, 2012, BRAIN PATHOL, V22, P443, DOI 10.1111/j.1750-3639.2012.00599.x; Miller MA, 2017, PATHOLOGIC BASIS VET, P682; Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699; Molitch ME, 2014, HAND CLINIC, V124, P167, DOI 10.1016/B978-0-444-59602-4.00012-5; Moore SA, 2008, COMPENDIUM, V30, P33; Myers NC, 1997, VET CLIN N AM-SMALL, V27, P381, DOI 10.1016/S0195-5616(97)50038-6; Newkirk KM, 2017, PATHOLOGIC BASIS VET, P286; Oldfield EH, 2015, J CLIN ENDOCR METAB, V100, P3165, DOI 10.1210/JC.2015-2493; Plant TM, 2015, KNOBIL NEILLS PHYSL; Pollard RE, 2010, J VET INTERN MED, V24, P160, DOI 10.1111/j.1939-1676.2009.0414.x; Polledo L, 2017, J VET INTERN MED, V31, P1527, DOI 10.1111/jvim.14790; Rosol T, 2016, JUBB KENNEDY PALMERS, P269, DOI DOI 10.1016/B978-0-7020-5319-1.00014-1; Rosol T. J., 2017, Tumors in domestic animals, P766; Rzechorzek NM, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-0983-x; SANO T, 1993, MAYO CLIN PROC, V68, P971, DOI 10.1016/S0025-6196(12)62269-1; SARFATY D, 1988, J AM VET MED ASSOC, V193, P854; Sato A, 2016, J SMALL ANIM PRACT, V57, P240, DOI 10.1111/jsap.12474; SCHIEFER B, 1967, ACTA NEUROPATHOL, V7, P232, DOI 10.1007/BF00686374; Snyder JM, 2008, J VET INTERN MED, V22, P172, DOI 10.1111/j.1939-1676.2007.0002.x; Troxel MT, 2010, CONSULTATIONS FELINE, V6, P884; van Rijn SJ, 2016, J VET INTERN MED, V30, P989, DOI 10.1111/jvim.14367; van Rijn SJ, 2010, DOMEST ANIM ENDOCRIN, V38, P244, DOI 10.1016/j.domaniend.2009.11.003; Wolfesberger B, 2011, J COMP PATHOL, V145, P231, DOI 10.1016/j.jcpa.2011.01.004; Wood FD, 2007, JAVMA-J AM VET MED A, V231, P1081, DOI 10.2460/javma.231.7.1081; Zielinski G, 2013, ENDOCR PATHOL, V24, P92, DOI 10.1007/s12022-013-9237-z	47	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					880	888		10.1177/0300985818784162			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600013	29929454	Green Accepted			2019-10-28	
J	Miller, MA; Owen, TJ; Bruyette, DS; Scott-Moncrieff, JC; Ramos-Vara, JA; Weng, HY; Chen, AV; Martin, LG; DuSold, DM				Miller, Margaret A.; Owen, Tina Jo; Bruyette, David S.; Scott-Moncrieff, J. Catharine; Ramos-Vara, Jose A.; Weng, Hsin-Yi; Chen, Annie V.; Martin, Linda G.; DuSold, Deidre M.			Immunohistochemical Evaluation of Canine Pituitary Adenomas Obtained by Transsphenoidal Hypophysectomy	VETERINARY PATHOLOGY			English	Article						corticotroph adenoma; dog; immunohistochemistry; melanotroph adenoma; pituitary adenoma; pituitary-dependent hypercortisolism; transsphenoidal hypophysectomy	DEPENDENT HYPERADRENOCORTICISM; DOGS; HYPERCORTISOLISM; CLASSIFICATION; EXPERIENCE; SURGERY; DISEASE; SIZE	Hypophysectomy specimens from 16 dogs with pituitary adenoma were evaluated with periodic acid-Schiff (PAS), reticulin, and immunohistochemistry for adrenocorticotrophic hormone (ACTH), melanocyte stimulating hormone (MSH), growth hormone (GH), and Ki-67. The reticulin network was obliterated in all adenomas. One adenoma expressed ACTH and GH. Eight corticotroph adenomas were basophilic to chromophobic, and PAS- and ACTH-positive. Seven melanotroph adenomas were distinguished from corticotroph adenomas by expression of MSH. Pituitary-dependent hypercortisolism was diagnosed in 5 of 8 dogs with corticotroph and 4 of 7 with melanotroph adenoma. Pituitary height/brain area (P/B) ratio was elevated in all dogs. Previous canine hypophysectomy studies suggested that melanotroph adenomas were larger and carried a worse prognosis than corticotroph adenomas; however, in this study, corticotroph adenomas in comparison to melanotroph adenomas were larger (median P/B ratio: 1.06 versus 0.76), more proliferative (median Ki-67 index: 9.47% versus 1.99%), and associated with shorter survival (median: 300 versus 793 days). Recommended immunohistochemistry for PAS-positive pituitary adenomas includes ACTH and MSH to distinguish corticotrophs from melanotrophs and Ki-67 for proliferation index.	[Miller, Margaret A.; Ramos-Vara, Jose A.; DuSold, Deidre M.] Purdue Univ, Indiana Anim Dis Diagnost Lab, W Lafayette, IN 47907 USA; [Miller, Margaret A.; Ramos-Vara, Jose A.; Weng, Hsin-Yi] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Owen, Tina Jo; Chen, Annie V.; Martin, Linda G.] Washington State Univ, Dept Vet Clin Sci, Pullman, WA 99164 USA; [Owen, Tina Jo; Chen, Annie V.; Martin, Linda G.] Washington State Univ, Vet Teaching Hosp, Pullman, WA 99164 USA; [Bruyette, David S.] Anivive Life Sci, Long Beach, CA USA; [Scott-Moncrieff, J. Catharine] Purdue Univ, Dept Vet Clin Sci, W Lafayette, IN 47907 USA; [Scott-Moncrieff, J. Catharine] Purdue Univ, Vet Teaching Hosp, W Lafayette, IN 47907 USA	Miller, MA (reprint author), Purdue Univ, Anim Dis Diagnost Lab, 406 South Univ St, W Lafayette, IN 47907 USA.	pegmiller@purdue.edu		Owen, Tina/0000-0002-6652-5315			Asa SL, 2007, ENDOTEXT; CAPEN CC, 1967, PATHOL VET, V4, P301, DOI 10.1177/030098586700400401; Ciric I, 2012, NEUROSURGERY, V70, P70, DOI 10.1227/NEU.0b013e31822dda2c; Hanson JM, 2007, J NEUROSURG, V107, P830, DOI 10.3171/JNS-07/10/0830; Hanson JM, 2005, J VET INTERN MED, V19, P687, DOI 10.1892/0891-6640(2005)19[687:EOTHIT]2.0.CO;2; Ishino H, 2011, DOMEST ANIM ENDOCRIN, V41, P207, DOI 10.1016/j.domaniend.2011.07.002; Kiupel M, 2008, WHO INT HISTOLOGICAL, V12, P17; Kooistra HS, 1997, J ENDOCRINOL, V152, P387, DOI 10.1677/joe.0.1520387; LANTZ GC, 1988, AM J VET RES, V49, P1134; Mamelak AN, 2014, VET SURG, V43, P369, DOI 10.1111/j.1532-950X.2014.12146.x; Mamelak AN, 2011, PITUITARY, V14, P92, DOI 10.1007/s11102-008-0151-1; Mayson SE, 2014, J NEURO-ONCOL, V117, P429, DOI 10.1007/s11060-014-1425-2; Meij B, 2002, MOL CELL ENDOCRINOL, V197, P89, DOI 10.1016/S0303-7207(02)00283-6; Meij BP, 1998, VET SURG, V27, P246, DOI 10.1111/j.1532-950X.1998.tb00123.x; Mete O, 2012, J MOL ENDOCRINOL, V49, pR69, DOI 10.1530/JME-12-0113; Miller MA, 2018, VET PATHOL, V55, P871, DOI 10.1177/0300985818766211; RIJNBERK A, 1968, J ENDOCRINOL, V41, P397, DOI 10.1677/joe.0.0410397; Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326; Syro LV, 2015, PITUITARY, V18, P217, DOI 10.1007/s11102-014-0619-0; van Rijn SJ, 2016, J VET INTERN MED, V30, P989, DOI 10.1111/jvim.14367; van Rijn SJ, 2010, DOMEST ANIM ENDOCRIN, V38, P244, DOI 10.1016/j.domaniend.2009.11.003	21	0	0	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					889	895		10.1177/0300985818784160			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600014	29925292				2019-10-28	
J	Pischon, H; Petrick, A; Muller, M; Koster, N; Pietsch, J; Mundhenk, L				Pischon, Hannah; Petrick, Anne; Mueller, Matthias; Koester, Nils; Pietsch, Joerg; Mundhenk, Lars			Grayanotoxin I Intoxication in Pet Pigs	VETERINARY PATHOLOGY			English	Article						andromedotoxin; ericaceae; pieris japonica; Japanese andromeda; lily-of-the-valley shrub; HPLC-MS/MS; toxicology; swine	GATED SODIUM-CHANNELS; MAD HONEY; GENUS RHODODENDRON; POISONOUS PLANTS; GOATS	Contaminated honey is a common cause of grayanotoxin intoxication in humans. Intoxication of animals, especially cattle, is usually due to ingestion of plants of the Ericaceae family, such as Rhododendron. Here, we report the ingestion of Pieris japonica as the cause of grayanotoxin I intoxication in 2 miniature pigs that were kept as pets. The pigs showed sudden onset of pale oral mucosa, tachycardia, tachypnea, hypersalivation, tremor, and ataxia that progressed to lateral recumbency. The pathological examination of one pig revealed no specific indications for intoxication except for the finding of plant material of Pieris japonica in the intestine. Grayanotoxin I was identified in the ingested plant, gastric content, blood, liver, bile, kidney, urine, lung, and skeletal muscle via HPLC-MS/MS. Grayanotoxin I should be considered as a differential etiological diagnosis in pigs with unspecific signs and discovery of ingested plant material as the only indication in the pathologic examination.	[Pischon, Hannah; Petrick, Anne; Mundhenk, Lars] Free Univ Berlin, Inst Vet Pathol, Berlin, Germany; [Mueller, Matthias] Tierarztpraxis Matthias Muller, Berlin, Germany; [Koester, Nils] Free Univ Berlin, Bot Garden & Bot Museum, Berlin, Germany; [Pietsch, Joerg] Tech Univ Dresden, Inst Legal Med, Dresden, Germany	Mundhenk, L (reprint author), Robert von Ostertag Str 15, D-14163 Berlin, Germany.	lars.mundhenk@fu-berlin.de					Aygun A, 2015, ANN SAUDI MED, V35, P161, DOI 10.5144/0256-4947.2015.161; Bagchi D, 2017, FOOD TOXICOLOGY; Bajcsik N, 2017, J CHROMATOGR B, V1052, P128, DOI 10.1016/j.jchromb.2017.03.030; BIBEROGLU S, 1988, JAMA-J AM MED ASSOC, V259, P1943, DOI 10.1001/jama.1988.03720130021010; CASTEEL S, 1989, VET HUM TOXICOL, V31, P176; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Constable P, 2017, VET MED, P2002; Gunduz A, 2008, CLIN TOXICOL, V46, P437, DOI 10.1080/15563650701666306; Jansen SA, 2012, CARDIOVASC TOXICOL, V12, P208, DOI 10.1007/s12012-012-9162-2; Kim SE, 2010, NEUROTOXICOLOGY, V31, P230, DOI 10.1016/j.neuro.2009.12.006; KNIGHT AP, 1987, COMP CONT EDUC PRACT, V9, pF26; Koca I, 2007, FOOD CHEM TOXICOL, V45, P1315, DOI 10.1016/j.fct.2007.04.006; Kucuk M, 2007, FOOD CHEM, V100, P526, DOI 10.1016/j.foodchem.2005.10.010; Lechtenberg M, 2014, PLANTA MED, V80, P1321, DOI 10.1055/s-0034-1383039; MEERDINK GL, 1989, VET CLIN N AM-FOOD A, V5, P375; Milewski LM, 2006, J VET EMERG CRIT CAR, V16, P25, DOI 10.1111/j.1476-4431.2005.00151.x; ONAT F Y, 1991, Reviews on Environmental Health, V9, P3; PLUMLEE KH, 1992, J VET DIAGN INVEST, V4, P363, DOI 10.1177/104063879200400330; Poppenga RH, 2010, EXPERIENTIA SUPPL, V100, P123; Puschner B, 2001, J AM VET MED ASSOC, V218, P573, DOI 10.2460/javma.2001.218.573; Qiang Y, 2011, CHEM BIODIVERS, V8, P792, DOI 10.1002/cbdv.201000046; Rhododendron sp / Kalmia sp / Leucothoe sp / Pieris sp, RHOD SP KALM SP LEUC; Wang JuiJen, 2017, THESIS; Wang SY, 2003, CELL SIGNAL, V15, P151, DOI 10.1016/S0898-6568(02)00085-2; YAVUZ H, 1991, LANCET, V337, P789, DOI 10.1016/0140-6736(91)91405-J; Yilmaz O, 2006, RESUSCITATION, V68, P405, DOI 10.1016/j.resuscitation.2005.07.014	26	0	0	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					896	899		10.1177/0300985818789482			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600015	30071802				2019-10-28	
J	Crossland, NA; DiGeronimo, PM; Sokolova, Y; Childress, AL; Wellehan, JFX; Nevarez, J; Paulsen, D				Crossland, Nicholas A.; DiGeronimo, Peter M.; Sokolova, Yulia; Childress, April L.; Wellehan, James F. X., Jr.; Nevarez, Javier; Paulsen, Daniel			Pneumonia in a Captive Central Bearded Dragon With Concurrent Detection of Helodermatid Adenovirus 2 and a Novel Mycoplasma Species	VETERINARY PATHOLOGY			English	Article						adenovirus; bearded dragon; electron microscopy; helodermatid adenovirus 2; Mycoplasma pogonae; Mycoplasma iguanae; polymerase chain reaction; squamata	CONSENSUS PRIMER PCR; POGONA-VITTICEPS; INFECTION; AMPLIFICATION; PATHOGENESIS; SP.	A 4-year-old captive male central bearded dragon (Pogona vitticeps) was presented for recurrent episodic dyspnea and anorexia with occasional expulsion of oral mucoid discharge. Despite empirical antimicrobial therapy and supportive care, the animal died and was submitted for autopsy. Defining histologic features included heterophilic and lymphocytic interstitial pneumonia, with occasional amphophilic intranuclear inclusions and prominent type II pneumocyte hyperplasia. Transmission electron microscopy revealed intranuclear 80-nm, nonenveloped, hexagonal viral particles within pneumocytes. Helodermatid adenovirus 2 (HeAdV2) was determined as the etiologic agent through pan-adenoviral consensus polymerase (PCR) chain reaction and sequencing. Nucleic acid from a novel Mycoplasma sp. (provisionally called Mycoplasma pogonae) was identified by pan-generic PCR targeting the mycoplasma 16S ribosomal RNA gene with sequencing and phylogenetic analysis. As bacteria morphologically consistent with Mycoplasma sp. were not observed by special stains and transmission electron microscopy, the detection of M. pogonae nucleic acid is of indeterminate significance; however, M. pogonae and HeAdV2 coinfection may have exacerbated disease.	[Crossland, Nicholas A.; Paulsen, Daniel] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA; [DiGeronimo, Peter M.; Nevarez, Javier] Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA; [Sokolova, Yulia] Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA; [Childress, April L.; Wellehan, James F. X., Jr.] Univ Florida, Coll Vet Med, Gainesville, FL USA; [Paulsen, Daniel] Louisiana State Univ, Louisiana Anim Dis Diagnost Lab, Baton Rouge, LA 70803 USA	Crossland, NA (reprint author), Boston Univ, NEIDL, 620 Albany St, Boston, MA 02118 USA.	ncrossla@bu.edu		Crossland, Nicholas/0000-0003-3873-9188			BOYCE JT, 1978, AM J PATHOL, V91, P259; Brown DR, 2007, J ZOO WILDLIFE MED, V38, P348, DOI 10.1638/1042-7260(2007)038[0348:MIGIII]2.0.CO;2; Chen EC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002155; Doneley RJT, 2014, AUST VET J, V92, P41, DOI 10.1111/avj.12136; Hyndman T, 2011, AUST VET J, V89, P232, DOI 10.1111/j.1751-0813.2011.00712.x; Jacobson ER., 2007, INFECT DIS PATHOLOGY, P401; JULIAN AF, 1982, NEW ZEAL VET J, V30, P59, DOI 10.1080/00480169.1982.34880; Kim DY, 2002, J VET DIAGN INVEST, V14, P332, DOI 10.1177/104063870201400411; Kosulin K, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.12.013; Lehmkuhl HD, 1997, AM J VET RES, V58, P608; Mao JH, 1997, VIROLOGY, V229, P212, DOI 10.1006/viro.1996.8435; MITTAL SK, 1995, VIROLOGY, V213, P131, DOI 10.1006/viro.1995.1553; Moormann S, 2009, J COMP PATHOL, V141, P78, DOI 10.1016/j.jcpa.2009.03.002; Papp T, 2009, VET MICROBIOL, V134, P233, DOI 10.1016/j.vetmic.2008.08.003; Penner JD, 1997, J COMP PATHOL, V117, P283, DOI 10.1016/S0021-9975(97)80024-2; Schuurman T, 2004, J CLIN MICROBIOL, V42, P734, DOI 10.1128/JCM.42.2.734-740.2004; Shahhosseiny MH, 2010, J BASIC MICROB, V50, P171, DOI 10.1002/jobm.200800174; Tong S, 2008, J CLIN MICROBIOL, V46, P2652, DOI 10.1128/JCM.00192-08; VanDevanter DR, 1996, J CLIN MICROBIOL, V34, P1666; Wellehan JFX, 2009, VET MICROBIOL, V133, P34, DOI 10.1016/j.vetmic.2008.06.011; Wellehan JFX, 2004, J VIROL, V78, P13366, DOI 10.1128/JVI.78.23.13366-13369.2004	21	1	1	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					900	904		10.1177/0300985818780451			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600016	29940815				2019-10-28	
J	Koistinen, K; Mullaney, L; Bell, T; Zaki, S; Nalca, A; Frick, O; Livingston, V; Robinson, CG; Estep, JS; Batey, KL; Dick, EJ; Owston, MA				Koistinen, Keith; Mullaney, Lisa; Bell, Todd; Zaki, Sherif; Nalca, Aysegul; Frick, Ondraya; Livingston, Virginia; Robinson, Camenzind G.; Estep, J. Scot; Batey, K. Lance; Dick, Edward J., Jr.; Owston, Michael A.			Coccidioidomycosis in Nonhuman Primates: Pathologic and Clinical Findings	VETERINARY PATHOLOGY			English	Article						animals; coccidioidomycosis; Coccidioides; emerging infectious diseases; primates; review	CHIMPANZEE PAN-TROGLODYTES; PULMONARY COCCIDIOIDOMYCOSIS; RHESUS-MONKEY; IMMITIS; BABOON; CALIFORNIA; DOGS; FLUCONAZOLE; DIAGNOSIS; THERAPY	Coccidioidomycosis in nonhuman primates has been sporadically reported in the literature. This study describes 22 cases of coccidioidomycosis in nonhuman primates within an endemic region, and 79 cases of coccidioidomycosis from the veterinary literature are also reviewed. The 22 cases included baboons (n = 10), macaques (n = 9), and chimpanzees (n = 3). The majority died or were euthanized following episodes of dyspnea, lethargy, or neurologic and locomotion abnormalities. The lungs were most frequently involved followed by the vertebral column and abdominal organs. Microscopic examination revealed granulomatous inflammation accompanied by fungal spherules variably undergoing endosporulation. Baboons represented a large number of cases presented here and had a unique presentation with lesions in bone or thoracic organs, but none had both intrathoracic and extrathoracic lesions. Although noted in 3 cases in the literature, cutaneous infections were not observed among the 22 contemporaneous cases. Similarly, subclinical infections were only rarely observed (2 cases). This case series and review of the literature illustrates that coccidioidomycosis in nonhuman primates reflects human disease with a varied spectrum of presentations from localized lesions to disseminated disease.	[Koistinen, Keith; Bell, Todd; Nalca, Aysegul; Frick, Ondraya; Livingston, Virginia; Robinson, Camenzind G.] US Army Med Res Inst Infect Dis, Frederick, MD USA; [Mullaney, Lisa; Dick, Edward J., Jr.; Owston, Michael A.] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA; [Zaki, Sherif] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA; [Estep, J. Scot; Batey, K. Lance] Texas Vet Pathol Associates LLC, Spring Branch, TX USA	Koistinen, K (reprint author), US Army Publ Hlth Ctr, 5158 Blackhawk Rd, Gunpowder, MD 21010 USA.	keith.a.koistinen.mil@mail.mil	Robinson, Camenzind G/S-3432-2019; Robinson, Camenzind/O-5097-2018; Nalca, Aysegul/L-8149-2019	Robinson, Camenzind G/0000-0002-7277-692X; Robinson, Camenzind/0000-0002-7277-692X; Nalca, Aysegul/0000-0001-8581-7535	Southwest National Primate Research Center from the National Center for Research Resources, National Institutes of Health - Office of Research Infrastructure Programs [P51 OD011133, P51 RR013986]; Office of Biodefense Research Affairs (OBRA)/National Institute of Allergy and Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [A120-B.11]; USAMRIID; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID); Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health [C06 RR014578, C06 RR015456, C06 RR016228]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This investigation used resources that were supported by the Southwest National Primate Research Center (grant P51 RR013986) from the National Center for Research Resources, National Institutes of Health, which are currently supported by the Office of Research Infrastructure Programs through P51 OD011133 as well as the Office of Biodefense Research Affairs (OBRA)/National Institute of Allergy and Infectious Diseases (NIAID) with interagency agreement (A120-B.11) between USAMRIID and NIAID. This investigation was conducted in facilities constructed with support from the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health through grants C06 RR014578, C06 RR015456, and C06 RR016228.	Adam RD, 2009, AM J MED, V122, P770, DOI 10.1016/j.amjmed.2008.12.024; Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P105; BEAMAN L, 1980, J MED PRIMATOL, V9, P254; BELLINI S, 1991, LAB ANIM SCI, V41, P509; Benirschke K, 1981, ERKRANKUNGEN ZOOTIER, V23, P119; Biddle M, 1953, A 6 CIM, V5, P80; Black R, 2009, ASS PRIM VET WORKSH, P79; BLUNDELL GP, 1961, AM J PATHOL, V39, P613; BREZNOCK AW, 1975, J AM VET MED ASSOC, V167, P657; BURTON M, 1986, J AM VET MED ASSOC, V189, P1209; CASTLEMAN WL, 1980, J AM VET MED ASSOC, V177, P933; Caswell JL, 2007, JUBB KENNEDY PALMERS, P644; Centers for Disease Control and Prevention, 2012, FUNG PNEUM SIL EP CO; Clemons KV, 2007, ANN NY ACAD SCI, V1111, P208, DOI 10.1196/annals.1406.029; CONVERSE JL, 1963, J BACTERIOL, V86, P1041; CONVERSE JL, 1962, J BACTERIOL, V83, P871; CONVERSE JL, 1966, BACTERIOL REV, V30, P678; Cox RA, 2004, CLIN MICROBIOL REV, V17, P804, DOI 10.1128/CMR.17.4.804-839.2004; Fiennes R, 1967, FUNGI ZOONOSES PRIMA, P77; Finquelievich JL, 2000, MYCOSES, V43, P333, DOI 10.1046/j.1439-0507.2000.00561.x; Fisher MC, 2002, MYCOLOGIA, V94, P73, DOI 10.2307/3761847; Gautam R, 2013, ZOONOSES PUBLIC HLTH, V60, P174, DOI 10.1111/j.1863-2378.2012.01526.x; Goff AJ, 2011, J VIROL, V85, P4898, DOI 10.1128/JVI.02525-10; Graupmann-Kuzma A, 2008, J AM ANIM HOSP ASSOC, V44, P226, DOI 10.5326/0440226; GRAYBILL JR, 1990, REV INFECT DIS, V12, pS286; Hamerton AE, 1937, P ZOOL SOC LOND B-SY, V107, P443; Hector RF, 2005, PLOS MED, V2, P15, DOI 10.1371/journal.pmed.0020002; Herrin KV, 2005, MYCOSES, V48, P447, DOI 10.1111/j.1439-0507.2005.01155.x; Hoffman K, 2007, ANN NY ACAD SCI, V1111, P404, DOI 10.1196/annals.1406.018; Hood HB, 1984, 4 INT C COCC SAN DIE; Ingram K.A., 1975, Annual Proc Am Ass Zoo Vet, V1975, P127; Johnson JH, 1998, J ZOO WILDLIFE MED, V29, P208; Kaufman L, 1998, J CLIN MICROBIOL, V36, P3721; Kirkland TN, 1996, EMERG INFECT DIS, V2, P192, DOI 10.3201/eid0203.960305; KRUSE RICHARD H., 1967, P387; Long JC, 1981, PREHISTORIC TUBERCUL, P69; MADDY KT, 1960, AM J VET RES, V21, P748; MARZKE MW, 1984, J MED PRIMATOL, V13, P135; McKenney F. D., 1944, Journal of the American Veterinary Medical Association, V104, P136; Mense MG, 2013, J PRIMATOL, V2, P111; Montone KT, 2010, DIAGN MOL PATHOL, V19, P99, DOI 10.1097/PDM.0b013e3181b3aa55; Munoz-Cadavid C, 2010, J CLIN MICROBIOL, V48, P2147, DOI 10.1128/JCM.00459-10; PAPPAGIANIS D, 1973, SABOURAUDIA, V11, P52; RAPLEY WA, 1974, CAN VET J, V15, P39; Reed RE, 1984, COCCIDIOIDOMYCOSIS; ROSENBERG DP, 1984, J AM VET MED ASSOC, V185, P1379; Shubitz LF, 2005, JAVMA-J AM VET MED A, V226, P1846, DOI 10.2460/javma.2005.226.1846; Shubitz LE, 2007, ANN NY ACAD SCI, V1111, P395, DOI 10.1196/annals.1406.007; SMITH CE, 1946, AM J PUBLIC HEALTH, V36, P1394; Sorensen KN, 2000, ANTIMICROB AGENTS CH, V44, P3087, DOI 10.1128/AAC.44.11.3087-3091.2000; Strutton WH, 1964, CASE REPORT COCCIDIO; Sutton DA, 2007, ANN NY ACAD SCI, V1111, P315, DOI 10.1196/annals.1406.005; Thompson GR, 2011, SEMIN RESP CRIT CARE, V32, P754, DOI 10.1055/s-0031-1295723; Tsang CA, 2013, MMWR-MORBID MORTAL W, V62, P217; WELSHMAN MD, 1981, VET REC, V108, P62, DOI 10.1136/vr.108.3.62-a; Wright E T, 1971, Int J Dermatol, V10, P17, DOI 10.1111/j.1365-4362.1971.tb04456.x	56	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					905	915		10.1177/0300985818787306			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600017	30071801				2019-10-28	
J	Ressel, L				Ressel, Lorenzo			The Biopsy "Undead"	VETERINARY PATHOLOGY			English	Letter									[Ressel, Lorenzo] Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Neston, England	Ressel, L (reprint author), Univ Liverpool, Sch Vet Sci, Vet Pathol, Leahurst Campus,Chester High Rd, Neston CH64 7TE, England.	l.ressel@liverpool.ac.uk					Cullen J. M., 2017, Tumors in domestic animals, P602; Guo YJ, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43035	2	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2018	55	6					916	917		10.1177/0300985818789478			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	HA3IZ	WOS:000450144600018	30381035				2019-10-28	
J	Jessee, J; Kopp, JB				Jessee, Joseph; Kopp, Jeffrey B.			APOL1-miR-193 Axis as a Bifunctional Regulator of the Glomerular Parietal Epithelium Maintaining Parietal Cell Phenotype versus Promoting Podocyte Differentiation	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							VARIANTS; HYPERTENSION; NEPHROPATHY; DISEASE		[Jessee, Joseph; Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, Kidney Dis Branch, NIH, Bethesda, MD 20892 USA	Kopp, JB (reprint author), NIDDK, Branch Kidney Dis, NIH, 10 Clin Ctr Dr,Room 3N102, Bethesda, MD 20892 USA.	jbkopp@nih.gov			NIH Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Supported by NIH Intramural Research Program and the National Institute of Diabetes and Digestive and Kidney Diseases.	Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Heymann J, 2017, NEPHROL DIAL TRANSPL, V32, P65, DOI 10.1093/ndt/gfw402; Johnstone DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051546; Kasembeli AN, 2015, J AM SOC NEPHROL, V26, P2882, DOI 10.1681/ASN.2014050469; Kietzmann L, 2015, J AM SOC NEPHROL, V26, P1389, DOI 10.1681/ASN.2014020190; Kopp JB, 2011, J AM SOC NEPHROL, V22, P2129, DOI 10.1681/ASN.2011040388; Kumar V, 2018, AM J PATHOL, V188, P2508, DOI 10.1016/j.ajpath.2018.07.025; Lasagni L, 2015, STEM CELL REP, V5, P248, DOI 10.1016/j.stemcr.2015.07.003; Li YC, 2011, CURR DIABETES REV, V7, P35, DOI 10.2174/157339911794273964; Lipkowitz MS, 2013, KIDNEY INT, V83, P114, DOI 10.1038/ki.2012.263; Mishra A, 2018, AM J PHYSIOL-RENAL, V314, pF832, DOI 10.1152/ajprenal.00541.2017; Shankland SJ, 2017, CURR OPIN NEPHROL HY, V26, P154, DOI 10.1097/MNH.0000000000000311; Sharma S, 2014, CIRCULATION, V130, P776, DOI 10.1161/CIRCULATIONAHA.114.007405; Smith EE, 2009, GENOME RES, V19, P850, DOI 10.1101/gr.085647.108; Tzur S, 2010, HUM GENET, V128, P345, DOI 10.1007/s00439-010-0861-0	15	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2461	2463		10.1016/j.ajpath.2018.08.002			3	Pathology	Pathology	GZ0FK	WOS:000449036900003	30201493				2019-10-28	
J	Loder, SJ; Agarwal, S; Chung, MT; Cholok, D; Hwang, C; Visser, N; Vasquez, K; Sorkin, M; Habbouche, J; Sung, HH; Peterson, J; Fireman, D; Ranganathan, K; Breuler, C; Priest, C; Li, J; Bai, X; Li, SL; Cederna, PS; Levi, B				Loder, Shawn J.; Agarwal, Shailesh; Chung, Michael T.; Cholok, David; Hwang, Charles; Visser, Noelle; Vasquez, Kaetlin; Sorkin, Michael; Habbouche, Joe; Sung, Hsiao H.; Peterson, Joshua; Fireman, David; Ranganathan, Kavitha; Breuler, Christopher; Priest, Caitlin; Li, John; Bai, Xue; Li, Shuli; Cederna, Paul S.; Levi, Benjamin			Characterizing the Circulating Cell Populations in Traumatic Heterotopic Ossification	AMERICAN JOURNAL OF PATHOLOGY			English	Article							OSTEOBLAST PROGENITOR CELLS; ECTOPIC BONE-FORMATION; PRECURSOR CELLS; PARABIOTIC MICE; CONTRIBUTE; MUSCLE; SKELETOGENESIS; PROGRESSIVA; PREVENTS; RESIDENT	Heterotopic ossification (HO) occurs secondary to trauma, causing pain and functional limitations. Identification of the cells that contribute to HO is critical to the development of therapies. Given that innate immune cells and mesenchymal stem cells are known contributors to HO, we sought to define the contribution of these populations to HO and to identify what, if any, contribution circulating populations have to HO. A shared circulation was obtained using a parabiosis model, established between an enhanced green fluorescent protein-positive/Luciferase(+) donor and a same-strain nonreporter recipient mouse. The nonreporter mouse received Achilles tendon transection and dorsal burn injury to induce HO formation. Bioluminescence imaging and immunostaining were performed to define the circulatory contribution of immune and mesenchymal cell populations. Histologic analysis showed circulating cells present throughout each stage of the developing HO anlagen. Circulating cells were present at the injury site during the inflammatory phase and proliferative period, with diminished contribution in mature HO. Immunostaining demonstrated that most early circulatory cells were from the innate immune system; only a small population of mesenchymal cells were present in the HO. We demonstrate the time course of the participation of circulatory cells in trauma-induced HO and identify populations of circulating cells present in different stages of HO. These findings further elucidate the relative contribution of Local and systemic cell populations to HO.	[Loder, Shawn J.; Agarwal, Shailesh; Chung, Michael T.; Cholok, David; Hwang, Charles; Visser, Noelle; Vasquez, Kaetlin; Sorkin, Michael; Habbouche, Joe; Sung, Hsiao H.; Peterson, Joshua; Fireman, David; Ranganathan, Kavitha; Breuler, Christopher; Priest, Caitlin; Li, John; Bai, Xue; Li, Shuli; Cederna, Paul S.; Levi, Benjamin] Univ Michigan, Dept Surg, Sect Plast Surg, Burn Wound & Regenerat Med Lab, Ann Arbor, MI 48109 USA	Levi, B (reprint author), Taubman Ctr, SPC 5340,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	blevi@umich.edu		Sung-Hsieh, Hsiao Hsin/0000-0001-6016-3838	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32 AR066499, R01GM123069, 1R01AR071379, F32 AR068902]; NIH Loan Repayment ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Howard Hughes Medical Institute Medical Fellows Program; NIH/National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM109105]; American Association of Plastic Surgery Academic Scholarship; American College of Surgeons Clowes Award; International FOP Association	Supported by NIH grants F32 AR066499, R01GM123069, 1R01AR071379, and F32 AR068902 (K.R.), the NIH Loan Repayment Program (S.A.), the Howard Hughes Medical Institute Medical Fellows Program (S.J.L.), NIH/National Institute of General Medical Sciences grant K08GM109105, an American Association of Plastic Surgery Academic Scholarship, the American College of Surgeons Clowes Award, and the International FOP Association (B.L.).	Agarwal S, 2017, MOL THER, V25, P1974, DOI 10.1016/j.ymthe.2017.01.008; Agarwal S, 2017, STEM CELLS, V35, P705, DOI 10.1002/stem.2515; Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113; Asakura A, 2012, J STEM CELL RES S11, V11; Beckmann JT, 2015, J BONE JOINT SURG AM, V97A, P2032, DOI 10.2106/JBJS.N.01156; Chakkalakal SA, 2012, J BONE MINER RES, V27, P1746, DOI 10.1002/jbmr.1637; Costopoulos CL, 2017, J SHOULDER ELB SURG, V26, P295, DOI 10.1016/j.jse.2016.11.011; Dey D, 2017, TRANSL RES, V186, P95, DOI 10.1016/j.trsl.2017.06.004; Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090; Egan KP, 2018, BONE, V109, P61, DOI 10.1016/j.bone.2017.12.028; Farahani RM, 2015, STEM CELLS INT, DOI 10.1155/2015/362753; Genet F, 2015, J PATHOL, V236, P229, DOI 10.1002/path.4519; Gibney BC, 2012, J CELL PHYSIOL, V227, P821, DOI 10.1002/jcp.22796; Januszyk M, 2014, DIABETES, V63, P3047, DOI 10.2337/db13-1366; Kaback LA, 2008, J CELL PHYSIOL, V214, P173, DOI 10.1002/jcp.21176; Kan LX, 2014, ORTHOPEDICS, V37, P329, DOI 10.3928/01477447-20140430-07; Kan LX, 2013, BONE, V53, P194, DOI 10.1016/j.bone.2012.12.008; Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008-0576; Kan SL, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000828; Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472; Kumagai K, 2008, J ORTHOP RES, V26, P165, DOI 10.1002/jor.20477; Lemos DR, 2015, BONE, V80, P19, DOI 10.1016/j.bone.2015.06.013; Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177; Otsuru S, 2008, STEM CELLS, V26, P223, DOI 10.1634/stemcells.2007-0515; Otsuru S, 2007, BIOCHEM BIOPH RES CO, V354, P453, DOI 10.1016/j.bbrc.2006.12.226; Peterson JR, 2015, JOVE-J VIS EXP, DOI 10.3791/52880; Pignolo RJ, 2011, J BONE MINER RES, V26, P1685, DOI 10.1002/jbmr.370; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Rath E, 2016, AM J SPORT MED, V44, P677, DOI 10.1177/0363546515618623; Shehab D, 2002, J NUCL MED, V43, P346; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Song GD, 2010, WOUND REPAIR REGEN, V18, P426, DOI 10.1111/j.1524-475X.2010.00595.x; Suda RK, 2009, STEM CELLS, V27, P2209, DOI 10.1002/stem.150; Sun YB, 2015, J SHOULDER ELB SURG, V24, P1735, DOI 10.1016/j.jse.2015.07.006; Torossian F, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96034; Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Yeung M, 2016, ARTHROSCOPY, V32, P519, DOI 10.1016/j.arthro.2015.08.007	38	0	0	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2464	2473		10.1016/j.ajpath.2018.07.014			10	Pathology	Pathology	GZ0FK	WOS:000449036900004	30142335				2019-10-28	
J	Zhang, JH; Ye, YQ; Chang, DW; Lin, SH; Huang, MS; Tannir, NM; Matin, S; Karam, JA; Wood, CG; Chen, ZN; Wu, XF				Zhang, Jinhua; Ye, Yuanqing; Chang, David W.; Lin, Shu-Hong; Huang, Maosheng; Tannir, Nizar M.; Matin, Surena; Karam, Jose A.; Wood, Christopher G.; Chen, Zhi-Nan; Wu, Xifeng			Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SERUM MIR-210; IDENTIFICATION; MICRORNAS; BIOMARKER; PROLIFERATION; INFLAMMATION; BIOGENESIS; HYPOXIA; CANCER; PCR	About 30% of patients undergoing nephrectomy for renal cell carcinoma (RCC) experience disease recurrence. We profiled miRNAs dysregulated in clear-cell (cc) RCC tumor tissues and predictive of recurrence. The expression levels of 800 miRNAs were assessed in paired tumor and normal tissues from a discovery cohort of 18 ccRCC patients. miRNAs found to be differentially expressed were examined in a validation set of 205 patients, using real-time quantitative PCR. Tumor-normal data from 64 patients in The Cancer Genome Atlas were used for external validation. Twenty-eight miRNAs were consistently dysregulated in tumor tissues. On dichotomized analysis, patients with high levels of miR-155-5p and miR-210-3p displayed an increased risk for ccRCC recurrence (hazard ratio, 2.64; 95% CI, 1.49 to 4.70; P = 0.0009; and hazard ratio, 1.80; 95% CI, 1.04 to 3.12; P = 0.036, respectively) and a shorter median recurrence-free survival time than did patients with low levels [P < 0.01 (log rank test)]. A risk score was generated based on the expression levels of miR-155-5p and miR-210-3p, and the trend test was significant (P = 0.005). On pathway analysis, target genes regulated by miR-155-5p and miR-210-3p were mainly enriched in inflammation-related pathways. We identified and validated multiple miRNAs dysregulated in ccRCC tissues; miR-155-5p and miR-210-3p were predictive of ccRCC recurrence, pointing to potential utility as biomarkers and underlying biological mechanisms.	[Zhang, Jinhua; Ye, Yuanqing; Chang, David W.; Lin, Shu-Hong; Huang, Maosheng; Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340,1515 Holcombe Blvd, Houston, TX 77030 USA; [Tannir, Nizar M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Matin, Surena; Karam, Jose A.; Wood, Christopher G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Zhang, Jinhua; Chen, Zhi-Nan] Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Sch Sci, Beijing, Peoples R China; [Chen, Zhi-Nan] Fourth Mil Med Univ, State Key Lab Canc, Cell Engn Res Ctr, Xian, Shaanxi, Peoples R China; [Chen, Zhi-Nan] Fourth Mil Med Univ, State Key Lab Canc, Dept Cell Biol, Xian, Shaanxi, Peoples R China	Wu, XF (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340,1515 Holcombe Blvd, Houston, TX 77030 USA.	xwu@mdanderson.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA170298]; Center for Translational and Public Health Genomics, Duncan Family Institute for Cancer Prevention; University of Texas MD Anderson Cancer Center	Supported in part by NIH grant R01 CA170298 (X.W.) and the Center for Translational and Public Health Genomics, Duncan Family Institute for Cancer Prevention, The University of Texas MD Anderson Cancer Center (institutional funding; X.W.).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Clague J, 2009, CANCER EPIDEM BIOMAR, V18, P801, DOI 10.1158/1055-9965.EPI-08-0601; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Fedorko M, 2015, INT J MOL SCI, V16, P23382, DOI 10.3390/ijms161023382; Gao Y, 2016, ONCOTARGET, V7, P20324, DOI 10.18632/oncotarget.7951; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu LY, 2015, ONCOTARGET, V6, P32545, DOI 10.18632/oncotarget.5324; Gupta K, 2008, CANCER TREAT REV, V34, P193, DOI 10.1016/j.ctrv.2007.12.001; Ha SC, 2015, J ONCOL, DOI 10.1155/2015/364807; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125672; He XH, 2016, ONCOGENE, V35, P6015, DOI 10.1038/onc.2016.132; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.9, 10.1038/nrdp.2017.10]; Iwamoto H, 2014, INT J ONCOL, V44, P53, DOI 10.3892/ijo.2013.2169; Ji JF, 2015, HEPATOLOGY, V62, P829, DOI 10.1002/hep.27886; Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033; Jung M, 2009, J CELL MOL MED, V13, P3918, DOI 10.1111/j.1582-4934.2009.00705.x; Kolbert CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052517; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Li SC, 2012, MOL MED REP, V5, P949, DOI 10.3892/mmr.2012.779; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390; Nakada C, 2008, J PATHOL, V216, P418, DOI 10.1002/path.2437; Nakata W, 2015, ONCOTARGET, V6, P21645, DOI 10.18632/oncotarget.4064; Neal CS, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-64; Nerich V, 2014, ONCOTARGETS THER, V7, P365, DOI 10.2147/OTT.S56370; Osanto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038298; Pichler M, 2011, J UROLOGY, V186, P1773, DOI 10.1016/j.juro.2011.07.034; Redova M, 2013, TUMOR BIOL, V34, P481, DOI 10.1007/s13277-012-0573-2; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Samaan S, 2015, J MOL DIAGN, V17, P136, DOI 10.1016/j.jmoldx.2014.10.005; Shu X, 2017, BRIT J CANCER, V116, P77, DOI 10.1038/bjc.2016.392; Slaby O, 2012, GENE CHROMOSOME CANC, V51, P707, DOI 10.1002/gcc.21957; Slaby O, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-90; White NMA, 2011, J UROLOGY, V186, P1077, DOI 10.1016/j.juro.2011.04.110; Yi ZJ, 2010, J CANCER RES CLIN, V136, P855, DOI 10.1007/s00432-009-0726-x; Zhao A, 2013, EXP MOL PATHOL, V94, P115, DOI 10.1016/j.yexmp.2012.10.005; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	44	2	2	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2487	2496		10.1016/j.ajpath.2018.07.026			10	Pathology	Pathology	GZ0FK	WOS:000449036900006	30201497				2019-10-28	
J	Mattu, S; Satiba, C; Sulas, P; Zavattari, P; Perra, A; Kowatik, MA; Monga, SP; Columbano, A				Mattu, Sandra; Satiba, Christian; Sulas, Pia; Zavattari, Patrizia; Perra, Andrea; Kowatik, Marta A.; Monga, Satdarshan P.; Columbano, Amedeo			High Frequency of beta-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CADHERIN-MEDIATED ADHESION; LIVER-TUMORS; NUCLEAR RECEPTOR; GENE; PATHWAY; HEPATOCARCINOGENESIS; GROWTH; MICE; CAR; OVEREXPRESSION	Activation of Wnt/beta-catenin signaling is frequent in human and rodent hepatocarcinogenesis. Although in mice the tumor-promoting activity of agonists of constitutive androstane receptor (CAR) occurs by selection of carcinogen-initiated cells harboring beta-catenin mutations, the molecular alterations leading to hepatocellular carcinoma (HCC) development by the CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCP) in the absence of genotoxic injury are unknown. Here, we show that CAR activation per se induced HCC in mice and that 91% of them carried beta-catenin point mutations or large in-frame deletions/exon skipping targeting Ctnnb1 exon 3. Point mutations in HCCs induced by TCP alone displayed different nucleotide substitutions compared with those found in HCCs from mice pretreated with diethylnitrosamine. Moreover, unlike those occurring in HCCs from diethylnitrosamine TCP mice, they did not result in increased expression of beta-catenin target genes, such as Glul, Lgr5, Rgn, Lect2, Tbx3, Axing, and Ccnd1, or nuclear translocation of beta-catenin compared with the control liver. Remarkably, in the nontumoral Liver tissue, chronic CAR activation led to down-regulation of these genes and to a partial loss of glutamine synthetase-positive hepatocytes. These results show that, although chronic CAR activation per se induces HCCs carrying beta-catenin mutations, it concurrently down-regulates the Wnt/beta-catenin pathway in nontumoral liver. They also indicate that the relationship between CAR and beta-catenin may be profoundly different between normal and neoplastic hepatocytes.	[Mattu, Sandra; Sulas, Pia; Zavattari, Patrizia; Perra, Andrea; Kowatik, Marta A.; Columbano, Amedeo] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy; [Satiba, Christian] Univ Malta, Ctr Mol Med & Biobanking, Msida, Malta; [Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Dept Pathol, Med Ctr, Pittsburgh, PA USA	Columbano, A (reprint author), Univ Cagliari, Dept Biomed Sci, Unit Oncol & Mol Pathol, Via Porcell 4, I-09124 Cagliari, Italy.	columbano@unica.it		Columbano, Amedeo/0000-0002-6956-9030; Monga, Satdarshan/0000-0002-8437-3378	Associazione Italiana Ricerca sul Cancro (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-15279]; Fondazione di SardegnaFondazione Banco di Sardegna; AIRCAssociazione Italiana per la Ricerca sul Cancro (AIRC); Fondazione Umberto Veronesi fellowshipsFondazione Umberto Veronesi	Supported by Associazione Italiana Ricerca sul Cancro (AIRC) grant IG-15279 and Fondazione di Sardegna (A.C.). S.M. and M.A.K. are recipients of AIRC and Fondazione Umberto Veronesi fellowships, respectively.	ABERLE H, 1994, J CELL SCI, V107, P3655; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Aydinlik H, 2001, ONCOGENE, V20, P7812, DOI 10.1038/sj.onc.1204982; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Columbano A, 2005, HEPATOLOGY, V42, P1118, DOI 10.1002/hep.20883; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; Committee for the Update of the Guide for the Care and Use of Laboratory Animals;, 2011, NAT RES COUNC GUID C; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; DIWAN BA, 1992, CARCINOGENESIS, V13, P1893, DOI 10.1093/carcin/13.10.1893; Dong BN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6944; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1985, CARCINOGENESIS, V6, P225, DOI 10.1093/carcin/6.2.225; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Huang WD, 2005, MOL ENDOCRINOL, V19, P1646, DOI 10.1210/me.2004-0520; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Kowalik MA, 2011, HEPATOLOGY, V53, P2086, DOI 10.1002/hep.24289; LASKIN DL, 1988, HEPATOLOGY, V8, P1051, DOI 10.1002/hep.1840080512; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Loeppen S, 2002, CANCER RES, V62, P5685; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu JA, 2010, BBA-REV CANCER, V1806, P268, DOI 10.1016/j.bbcan.2010.07.001; Mattu S, 2016, J HEPATOL, V64, P891, DOI 10.1016/j.jhep.2015.11.029; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Monga SS, 2014, GENE EXPRESSION, V16, P51, DOI 10.3727/105221614X13919976902138; Nejak-Bowen KN, 2009, J BIOL CHEM, V284, P28115, DOI 10.1074/jbc.M109.047258; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Okabe H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152695; Orsulic S, 1999, J CELL SCI, V112, P1237; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Petrelli A, 2014, HEPATOLOGY, V59, P228, DOI 10.1002/hep.26616; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; RAO MS, 1987, CARCINOGENESIS, V8, P19, DOI 10.1093/carcin/8.1.19; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Rignall B, 2011, CARCINOGENESIS, V32, P52, DOI 10.1093/carcin/bgq226; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zucman-Rossi J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824	52	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2497	2507		10.1016/j.ajpath.2018.07.022			11	Pathology	Pathology	GZ0FK	WOS:000449036900007	30201494				2019-10-28	
J	Kumar, V; Vashistha, H; Lan, XQ; Chandel, N; Ayasolla, K; Shoshtari, SSM; Aslam, R; Paliwal, N; Abbruscato, F; Mikulak, J; Popik, W; Atta, MG; Chander, PN; Malhotra, A; Meyer-Schwesinger, C; Skorecki, K; Singhal, PC				Kumar, Vinod; Vashistha, Himanshu; Lan, Xiqian; Chandel, Nirupama; Ayasolla, Kamesh; Shoshtari, Seyedeh Shadafarin Marashi; Aslam, Rukhsana; Paliwal, Nitpriya; Abbruscato, Frank; Mikulak, Joanna; Popik, Waldemar; Atta, Mohamed G.; Chander, Praveen N.; Malhotra, Ashwani; Meyer-Schwesinger, Catherine; Skorecki, Karl; Singhal, Pravin C.			Role of Apolipoprotein L1 in Human Parietal Epithelial Cell Transition	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-ASSOCIATED NEPHROPATHY; RISK VARIANTS; PODOCYTE PHENOTYPE; DOWN-REGULATION; KIDNEY-DISEASE; APOL1 RISK; POPULATION; MICRORNA-193A; LOCALIZATION	Human parietal epithelial cells (PECs) are progenitor cells that sustain podocyte homeostasis. We hypothesized that the lack of apolipoprotein (APO) L1 ensures the PEC phenotype, but its induction initiates PEC transition (expression of podocyte markers). APOL1 expression and down-regulation of miR193a coincided with the expression of podocyte markers during the transition. The induction of APOL1 also stimulated transition markers in human embryonic kidney cells (cells with undetectable APOL1 protein expression). APOL1 silencing in PECs up-regulated miR193a expression, suggesting the possibility of a reciprocal feedback relationship between APOL1 and miR193a. HIV, interferon-gamma, and vitamin D receptor agonist down-regulated miR193a expression and induced APOL1 expression along with transition markers in PECs. Luciferase assay suggested a putative interaction between miR193a and APOL1. Since silencing of APOL1 attenuated HIV-, vitamin D receptor agonist-, miR193a inhibitor-, and interferon-gamma-induced expression of transition markers, APOL1 appears to be a critical functional constituent of the miR193a-APOL1 axis in PECs. This notion was confirmed by further enhanced expression of PEC markers in APOL1 mRNA-silenced PECs. In vivo studies, glomeruli in patients with HIV, and HIV/APOL1 transgenic mice had foci of PECs expressing synaptopodin, a transition marker. APOL1 Likely regulates PEC molecular phenotype through modulation of miR193a expression, and APOL1 and miR193a share a reciprocal feedback relationship.	[Kumar, Vinod; Lan, Xiqian; Chandel, Nirupama; Ayasolla, Kamesh; Shoshtari, Seyedeh Shadafarin Marashi; Aslam, Rukhsana; Paliwal, Nitpriya; Malhotra, Ashwani; Singhal, Pravin C.] Feinstein Inst Med Res, Immunol & Inflammat Ctr, 350 Community Dr, Manhasset, NY 11030 USA; [Kumar, Vinod; Lan, Xiqian; Chandel, Nirupama; Ayasolla, Kamesh; Shoshtari, Seyedeh Shadafarin Marashi; Aslam, Rukhsana; Paliwal, Nitpriya; Malhotra, Ashwani; Singhal, Pravin C.] Zucker Sch Med Hofstra Northwell, 350 Community Dr, Manhasset, NY 11030 USA; [Vashistha, Himanshu; Abbruscato, Frank] Ochsner Clin & Alton Ochsner Med Fdn, Inst Translat Res, New Orleans, LA USA; [Mikulak, Joanna] Humanitas Clin & Res Ctr, Milan, Italy; [Popik, Waldemar] Meharry Med Coll, Hlth Dispar & HIV, Nashville, TN 37208 USA; [Atta, Mohamed G.] Johns Hopkins Univ Hosp, Nephr Div, Baltimore, MD 21287 USA; [Chander, Praveen N.] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; [Meyer-Schwesinger, Catherine] Univ Hamburg, Nephrol Div, Hamburg, Germany; [Skorecki, Karl] Technion Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel	Singhal, PC (reprint author), Feinstein Inst Med Res, Immunol & Inflammat Ctr, 350 Community Dr, Manhasset, NY 11030 USA.; Singhal, PC (reprint author), Zucker Sch Med Hofstra Northwell, 350 Community Dr, Manhasset, NY 11030 USA.	psinghal@northwell.edu		Singhal, Pravin/0000-0002-6898-358X	ME [RO1DK098074, RO1DK118017]; Rambam Medical Center; Beutler Foundation For Genomic Medicine Research; Israel Science FoundationIsrael Science Foundation; Kaylie Kidney Health Center of Excellence	Supported by ME grants RO1DK098074 and RO1DK118017 (P.C.S.), the Israel Science Foundation and Rambam Medical Center, Kaylie Kidney Health Center of Excellence, and the Beutler Foundation For Genomic Medicine Research (K.S.).	Appel D, 2009, J AM SOC NEPHROL, V20, P333, DOI 10.1681/ASN.2008070795; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Berger K, 2014, J AM SOC NEPHROL, V25, P693, DOI 10.1681/ASN.2013050481; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chandel N, 2013, AM J PHYSIOL-RENAL, V304, pF1347, DOI 10.1152/ajprenal.00717.2012; Dijkman HBPM, 2006, KIDNEY INT, V70, P338, DOI 10.1038/sj.ki.5001574; Dummer PD, 2015, SEMIN NEPHROL, V35, P222, DOI 10.1016/j.semnephrol.2015.04.008; Eng DG, 2015, KIDNEY INT, V88, P999, DOI 10.1038/ki.2015.152; Freedman BI, 2010, J AM SOC NEPHROL, V21, P1422, DOI 10.1681/ASN.2010070730; Friedman DJ, 2011, J AM SOC NEPHROL, V22, P2098, DOI 10.1681/ASN.2011050519; Gebeshuber CA, 2013, NAT MED, V19, P481, DOI 10.1038/nm.3142; Grams ME, 2016, J AM SOC NEPHROL, V27, P2842, DOI 10.1681/ASN.2015070763; Hague S, 2017, BIOSCIENCE REP, V37; Husain M, 2009, J BIOL CHEM, V284, P16648, DOI 10.1074/jbc.M109.008482; Johnstone DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051546; Kietzmann L, 2015, J AM SOC NEPHROL, V26, P1389, DOI 10.1681/ASN.2014020190; KLOTMAN PE, 1995, AIDS, V9, P313; KOPP JB, 1994, CONTRIB NEPHROL, V107, P194; Kopp JB, 2011, J AM SOC NEPHROL, V22, P2129, DOI 10.1681/ASN.2011040388; Kumar D, 2010, AM J PATHOL, V177, P813, DOI 10.2353/ajpath.2010.100131; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Lan XQ, 2015, EXP MOL PATHOL, V99, P139, DOI 10.1016/j.yexmp.2015.06.003; Lan XQ, 2014, AM J PHYSIOL-RENAL, V307, pF326, DOI 10.1152/ajprenal.00647.2013; Larsen CP, 2015, J AM SOC NEPHROL, V26, P1232, DOI 10.1681/ASN.2014101052; Lazzeri E, 2015, NAT REV NEPHROL, V11, P7, DOI 10.1038/nrneph.2014.218; Lee H, 2018, AM J PHYSIOL-RENAL, V315, pF140, DOI 10.1152/ajprenal.00254.2017; Limou S, 2014, ADV CHRONIC KIDNEY D, V21, P426, DOI 10.1053/j.ackd.2014.06.005; Ma LJ, 2015, J AM SOC NEPHROL, V26, P339, DOI 10.1681/ASN.2013091017; Madhavan SM, 2011, J AM SOC NEPHROL, V22, P2119, DOI 10.1681/ASN.2011010069; Miesen L, 2017, CELL TISSUE RES, V369, P237, DOI 10.1007/s00441-017-2600-5; Mikulak J, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0296-3; Mishra A, 2018, AM J PHYSIOL-RENAL, V314, pF832, DOI 10.1152/ajprenal.00541.2017; Roeder SS, 2015, AM J PHYSIOL-RENAL, V309, pF164, DOI 10.1152/ajprenal.00144.2015; Shankland SJ, 2017, CURR OPIN NEPHROL HY, V26, P154, DOI 10.1097/MNH.0000000000000311; Shankland SJ, 2014, NAT REV NEPHROL, V10, P158, DOI 10.1038/nrneph.2014.1; Tzur S, 2010, HUM GENET, V128, P345, DOI 10.1007/s00439-010-0861-0; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Yang Y, 2002, NEPHRON, V91, P416, DOI 10.1159/000064281	38	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2508	2528		10.1016/j.ajpath.2018.07.025			21	Pathology	Pathology	GZ0FK	WOS:000449036900008	30201495				2019-10-28	
J	Prochnicki, A; Amann, K; Wegner, M; Sock, E; Pfister, E; Shankland, S; Pippin, J; Daniel, C				Prochnicki, Ania; Amann, Kerstin; Wegner, Michael; Sock, Elisabeth; Pfister, Eva; Shankland, Stuart; Pippin, Jeffrey; Daniel, Christoph			Characterization of Glomerular Sox9(+) Cells in Anti-Glomerular Basement Membrane Nephritis in the Rat	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PARIETAL EPITHELIAL-CELLS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; PODOCYTE REGENERATION; PROGENITOR CELLS; CELLULAR CRESCENTS; RENAL PROGENITORS; URINARY-EXCRETION; BOWMANS CAPSULE; GLOMERULONEPHRITIS; KIDNEY	Mechanisms of glomerular crescent formation and podocyte repair processes are still unclear. Therefore, we investigated the expression of the transcription factor Sox9 as a potential marker of a subpopulation of parietal epithelial cells (PECs) with potential regenerative properties. Glomerular Sox9 expression was characterized in detail in a rat anti-glomerular basement membrane (GBM) nephritis model using immunofluorescence and confocal laser scanning microscopy. In healthy kidneys Sox9 is expressed in a subpopulation of PECs restricted to approximately 20% to 50% of PEC nuclei and was highly conserved in all investigated species. During rat anti-GBM nephritis the number of glomerular Sox9(+) cells increased and was associated with proliferation activity. In nephritic glomeruli Sox9 expression was not restricted to Bowman's capsule lining but was also found on cells of the glomerular tuft. Nearly all Sox9(+) cells also expressed the PEC marker Pax8, whereas endothelial cells, mesangial cells, macrophages, and T lymphocytes Lacked Sox9 expression. At the margins of crescents Sox9(+)/Pax8(+) cells additionally expressed podocyte markers. In contrast, in sclerotic lesions a minority of Sox9(+)/Pax8(+) cells expressed the myofibroblast marker alpha-smooth muscle actin. In glomerular Sox9(+) cells Jagged 1 was up-regulated. During anti-GBM nephritis Sox9(+) PECs proliferate and migrate onto the glomerular tuft. Future studies are needed to confirm the origin of Sox9(+) cells from PECs and differentiation in both podocytes and/or myofibroblasts.	[Prochnicki, Ania; Amann, Kerstin; Pfister, Eva; Daniel, Christoph] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Erlangen, Germany; [Wegner, Michael; Sock, Elisabeth] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany; [Shankland, Stuart; Pippin, Jeffrey] Univ Washington, Dept Nephrol, Seattle, WA USA	Daniel, C (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, Dept Nephropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	christoph.daniel@uk-erlangen.de		Sock, Elisabeth/0000-0001-9925-3136; Daniel, Christoph/0000-0002-6803-4755	EFI initiative CYDER Erlangen TP3; Interdisciplinary Center for Clinical Research of the Friedrich-Alexander-University Erlangen-Nurnberg, Germany	Supported by the EFI initiative CYDER Erlangen TP3 (K.A. and C.D.). A.P. was supported by a scholarship from the Interdisciplinary Center for Clinical Research of the Friedrich-Alexander-University Erlangen-Nurnberg, Germany.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Appel D, 2009, J AM SOC NEPHROL, V20, P333, DOI 10.1681/ASN.2008070795; Asanuma K, 2017, CLIN EXP NEPHROL, V21, P1, DOI 10.1007/s10157-016-1247-y; Bariety J, 2006, J AM SOC NEPHROL, V17, P2770, DOI 10.1681/ASN.2006040325; BOUCHER A, 1987, LAB INVEST, V56, P526; Chatzeli L, 2017, DEVELOPMENT, V144, P2294, DOI 10.1242/dev.146019; Chen LH, 2005, AM J PHYSIOL-RENAL, V288, pF939, DOI 10.1152/ajprenal.00369.2004; Dijkman H, 2005, KIDNEY INT, V68, P1562, DOI 10.1111/j.1523-1755.2005.00568.x; Eng DG, 2015, KIDNEY INT, V88, P999, DOI 10.1038/ki.2015.152; Formeister EJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1108, DOI 10.1152/ajpgi.00004.2009; FRIES JWU, 1989, LAB INVEST, V60, P205; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Grahammer F, 2013, AM J PATHOL, V183, P333, DOI 10.1016/j.ajpath.2013.04.009; HARA M, 1995, NEPHRON, V69, P397, DOI 10.1159/000188509; Huang J, 2017, ONCOL RES, V25, P167, DOI 10.3727/096504016X14732772150307; JENNETTE JC, 1986, AM J CLIN PATHOL, V86, P274, DOI 10.1093/ajcp/86.3.274; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Kang HM, 2016, CELL REP, V14, P861, DOI 10.1016/j.celrep.2015.12.071; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kumar S, 2015, CELL REP, V12, P1325, DOI 10.1016/j.celrep.2015.07.034; Lasagni L, 2015, STEM CELL REP, V5, P248, DOI 10.1016/j.stemcr.2015.07.003; Lasagni L, 2010, STEM CELLS, V28, P1673, DOI 10.1002/stem.492; Ma QW, 2018, LIFE SCI, V193, P104, DOI 10.1016/j.lfs.2017.11.041; Marshall CB, 2006, NEPHRON EXP NEPHROL, V102, P39, DOI 10.1159/000088400; MIN KW, 1974, KIDNEY INT, V5, P47, DOI 10.1038/ki.1974.6; Moeller MJ, 2014, NEPHRON EXP NEPHROL, V126, P97, DOI 10.1159/000360677; Moeller MJ, 2004, J AM SOC NEPHROL, V15, P61, DOI 10.1097/01.ASN.0000102468.37809.C6; MORITA T, 1973, AM J PATHOL, V72, P349; PABST R, 1983, KIDNEY INT, V24, P626, DOI 10.1038/ki.1983.203; Paganelli M, 2014, STEM CELLS DEV, V23, P1377, DOI 10.1089/scd.2013.0169; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Reginensi A, 2011, HUM MOL GENET, V20, P1143, DOI 10.1093/hmg/ddq558; Romagnani P, 2009, STEM CELLS, V27, P2247, DOI 10.1002/stem.140; Ronconi E, 2009, J AM SOC NEPHROL, V20, P322, DOI 10.1681/ASN.2008070709; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shankland SJ, 2014, SEMIN NEPHROL, V34, P418, DOI 10.1016/j.semnephrol.2014.06.008; Shankland SJ, 2014, NAT REV NEPHROL, V10, P158, DOI 10.1038/nrneph.2014.1; Smeets B, 2009, J AM SOC NEPHROL, V20, P2604, DOI 10.1681/ASN.2009010122; Swetha G, 2011, J CELL MOL MED, V15, P396, DOI 10.1111/j.1582-4934.2009.00937.x; Turcatel G, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-117; Ueno T, 2013, KIDNEY INT, V83, P1065, DOI 10.1038/ki.2013.48; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Vogelmann SU, 2003, AM J PHYSIOL-RENAL, V285, pF40, DOI 10.1152/ajprenal.00404.2002; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Yu DH, 2005, J AM SOC NEPHROL, V16, P1733, DOI 10.1681/ASN.2005020159	49	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2529	2541		10.1016/j.ajpath.2018.07.023			13	Pathology	Pathology	GZ0FK	WOS:000449036900009	30201496	Bronze			2019-10-28	
J	Antognelli, C; Mancuso, F; Frosini, R; Arato, I; Calvitti, M; Calafiore, R; Talesa, VN; Luca, G				Antognelli, Cinzia; Mancuso, Francesca; Frosini, Roberta; Arato, Iva; Calvitti, Mario; Calafiore, Riccardo; Talesa, Vincenzo N.; Luca, Giovanni			Testosterone and Follicle Stimulating Hormone-Dependent Glyoxalase 1 Up-Regulation Sustains the Viability of Porcine Sertoli Cells through the Control of Hydroimidazolone- and Argpyrimidine-Mediated NF-kappa B Pathway	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GLYCATION END-PRODUCTS; IN-VITRO; PROTEIN MODIFICATION; CRYSTALLINE SILICA; MECHANISM DRIVEN; EPITHELIAL-CELLS; GENE-EXPRESSION; MODIFIED HSP70; TNF-ALPHA; METHYLGLYOXAL	Because Sertoli cells (SCs) play a central role in germ cell survival, their death may result in marked germ cell loss and infertility. SCs are the only somatic cells within the seminiferous tubules and are essential for regulating spermatogenesis. Factors that enhance or diminish the viability of SCs may have profound effects on spermatogenesis. Yet the mechanisms underlying the maintenance of SC viability remain largely unknown. Glyoxalase 1 (Glo1) detoxifies methylglyoxal (MG), a highly reactive carbonyl species mainly formed during glycolysis, which is a potent precursor of cytotoxic advanced glycation end products (AGEs). Hydroimidazolone (MG-H1) and argpyrimidine (ArgPyr) are AGEs resulting from MG-mediated post-translational modification of arginine residues in various proteins. The role of Glo1 and MG-derived AGEs in regulating the fate of SCs has never been investigated. By using gene silencing and the specific MG scavenger, aminoguanidine, the authors demonstrate that Glo1, under testosterone and follicle-stimulating hormone control, sustains viability of porcine neonatal SCs through a mechanism involving the NF-kappa B pathway. Glo1 knockdown induces a mitochondrial apoptotic pathway driven by the intracellular accumulation of MG-H1 and ArgPyr that desensitizes NF-kappa B signaling by modifying the inhibitor of NF-kappa B kinase, IKK beta. This is the first report describing a role for Glo1 and MG-derived AGEs in SC biology, providing valuable new insights into the potential involvement of this metabolic axis into spermatogenesis.	[Antognelli, Cinzia; Mancuso, Francesca; Frosini, Roberta; Arato, Iva; Calvitti, Mario; Talesa, Vincenzo N.; Luca, Giovanni] Univ Perugia, Dept Expt Med, L Severi Sq, I-06129 Perugia, Italy; [Calafiore, Riccardo] Univ Perugia, Dept Med, Perugia, Italy	Antognelli, C (reprint author), Univ Perugia, Dept Expt Med, L Severi Sq, I-06129 Perugia, Italy.	antognelli@unipg.it			University of Perugia local research grant [cantRB14]	Supported by the University of Perugia local research grant cantRB14 (C.A.).	Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Alves Marco G, 2014, Curr Mol Pharmacol, V7, P83; Antognelli C, 2014, BRIT J CANCER, V111, P395, DOI 10.1038/bjc.2014.280; Antognelli C, 2007, CANCER BIOL THER, V6, P1880, DOI 10.4161/cbt.6.12.4961; Antognelli C, 2018, J CELL MOL MED, V22, P2865, DOI 10.1111/jcmm.13581; Antognelli C, 2018, DATA BRIEF, V16, P929, DOI 10.1016/j.dib.2017.12.026; Antognelli C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020415; Antognelli C, 2018, FREE RADICAL BIO MED, V115, P292, DOI 10.1016/j.freeradbiomed.2017.11.014; Antognelli C, 2016, FREE RADICAL BIO MED, V92, P110, DOI 10.1016/j.freeradbiomed.2016.01.009; Antognelli C, 2015, FREE RADICAL BIO MED, V84, P128, DOI 10.1016/j.freeradbiomed.2015.03.026; Antognelli C, 2014, APOPTOSIS, V19, P102, DOI 10.1007/s10495-013-0902-y; Antognelli C, 2013, INT J BIOCHEM CELL B, V45, P836, DOI 10.1016/j.biocel.2013.01.003; Antognelli C, 2013, PROSTATE, V73, P121, DOI 10.1002/pros.22547; Arato I, 2018, ASIAN J ANDROL, V20, P160, DOI 10.4103/aja.ja_47_17; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bansode SB, 2013, MOL CELL PROTEOMICS, V12, P228, DOI 10.1074/mcp.M112.020651; Basu S, 2018, CELL TISSUE RES, V371, P351, DOI 10.1007/s00441-017-2698-5; Brouwers O, 2011, J BIOL CHEM, V286, P1374, DOI 10.1074/jbc.M110.144097; Cardoso AM, 2018, ARCH TOXICOL, V92, P601, DOI 10.1007/s00204-017-2091-x; Carlsson L, 2004, J ANDROL, V25, P699; Choi EM, 2014, FREE RADICAL RES, V48, P729, DOI 10.3109/10715762.2014.903562; Delfino F, 1999, MOL CELL ENDOCRINOL, V157, P1, DOI 10.1016/S0303-7207(99)00127-6; Dias TR, 2015, J STEROID BIOCHEM, V154, P1, DOI 10.1016/j.jsbmb.2015.06.004; Dimitriadis F, 2015, HORM-INT J ENDOCRINO, V14, P479, DOI 10.14310/horm.2002.1633; Franca LR, 2016, ANDROLOGY-US, V4, P189, DOI 10.1111/andr.12165; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Hunter SJ, 2003, DIABETES, V52, P492, DOI 10.2337/diabetes.52.2.492; Kaur G, 2014, SEMIN CELL DEV BIOL, V30, P36, DOI 10.1016/j.semcdb.2014.02.011; Kim J, 2012, EXP MOL MED, V44, P167, DOI 10.3858/emm.2012.44.2.012; Kim J, 2010, BIOCHEM BIOPH RES CO, V391, P346, DOI 10.1016/j.bbrc.2009.11.061; Laga M, 2007, BIOCHEM PHARMACOL, V74, P579, DOI 10.1016/j.bcp.2007.05.026; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luca G, 2018, PROTEIN PEPTIDE LETT, V25, P440, DOI 10.2174/0929866525666180412163151; Luca G, 2015, XENOTRANSPLANTATION, V22, P273, DOI 10.1111/xen.12175; Mancuso F, 2018, TOXICOL IN VITRO, V48, P45, DOI 10.1016/j.tiv.2017.12.013; Mannervik B, 1981, Methods Enzymol, V77, P297; Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017; Menegazzo M, 2011, HUM REPROD, V26, P2598, DOI 10.1093/humrep/der248; Morcos M, 2008, AGING CELL, V7, P260, DOI 10.1111/j.1474-9726.2008.00371.x; Nass N, 2010, INT J BIOCHEM CELL B, V42, P749, DOI 10.1016/j.biocel.2010.01.012; Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194; Oliveira PF, 2015, MED RES REV, V35, P126, DOI 10.1002/med.21325; Pentikainen V, 2002, AM J PATHOL, V160, P205, DOI 10.1016/S0002-9440(10)64364-7; Rabbani N, 2012, AMINO ACIDS, V42, P1133, DOI 10.1007/s00726-010-0783-0; Rabbani N, 2011, SEMIN CELL DEV BIOL, V22, P309, DOI 10.1016/j.semcdb.2011.02.015; Rato L, 2016, HISTOL HISTOPATHOL, V31, P499, DOI 10.14670/HH-11-717; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Riera MF, 2001, GEN COMP ENDOCR, V122, P88, DOI 10.1006/gcen.2001.7619; ROBINSON R, 1981, BIOL REPROD, V24, P1032, DOI 10.1095/biolreprod24.5.1032; Roy A, 2017, MOL CARCINOGEN, V56, P2086, DOI 10.1002/mc.22665; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Silva MS, 2013, BIOCHEM J, V453, P1, DOI 10.1042/BJ20121743; Syed V, 2002, MOL CELL ENDOCRINOL, V186, P155, DOI 10.1016/S0303-7207(01)00656-6; Talesa VN, 2017, PROSTATE, V77, P196, DOI 10.1002/pros.23261; Tatone C, 2010, J BIOL REG HOMEOS AG, V24, P63; Tatone C, 2014, BIOCHEM SOC T, V42, P433, DOI 10.1042/BST20140023; Tatone C, 2011, HUM REPROD, V26, P1843, DOI 10.1093/humrep/der140; Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113; Wang H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45298; Yao D, 2007, J BIOL CHEM, V282, P31038, DOI 10.1074/jbc.M704703200; Zhou JL, 2015, J BIOL CHEM, V290, P27215, DOI 10.1074/jbc.M115.680363	64	2	2	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2553	2563		10.1016/j.ajpath.2018.07.013			11	Pathology	Pathology	GZ0FK	WOS:000449036900011	30125541				2019-10-28	
J	Sano, T; Kobayashi, T; Ogawa, O; Matsuda, M				Sano, Takeshi; Kobayashi, Takashi; Ogawa, Osamu; Matsuda, Michiyuki			Gliding Basal Cell Migration of the Urothelium during Wound Healing	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BLADDER UROTHELIUM; ACTIVATION; PROTEIN; DYNAMICS; KINASE; REPAIR; MICE; REGENERATION; PROGRESSION; MORPHOLOGY	Collective cell migration during wound healing has been extensively studied in the epidermis. However, it remains unknown whether the urothelium repairs wounds in a manner similar to the epidermis. By in vivo two-photon excitation microscopy of transgenic mice that express fluorescent biosensors, we studied the collective cell migration of the urothelium in comparison with that of the epidermis. In vivo time-lapse imaging revealed that, even in the absence of a wound, urothelial cells continuously moved and sometimes glided as a sheet over the underlying lamina propria. On abrasion of the epithelium, the migration speed of each epidermal cell was inversely correlated with the distance to the wound edge. Repetitive activation waves of extracellular signal-regulated kinase (ERK) were generated at and propagated away from the wound edge. In contrast, urothelial cells glided as a sheet over the lamina propria without any ERK activation waves. Accordingly, the mitogen-activated protein kinase/ERK kinase inhibitor PD0325901 decreased the migration velocity of the epidermis but not the urothelium. Interestingly, the tyrosine kinase inhibitor dasatinib inhibited migration of the urothelium as well as the epidermis, suggesting that the gliding migration of the urothelium is an active, not a passive, migration. In conclusion, the urothelium glides over the lamina propria to fill wounds in an ERK-independent manner, whereas the epidermis crawls to cover wounds in an ERK-dependent manner.	[Sano, Takeshi; Matsuda, Michiyuki] Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Yoshidakonoe Cho, Kyoto 6068501, Japan; [Sano, Takeshi; Kobayashi, Takashi; Ogawa, Osamu] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan	Matsuda, M (reprint author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Yoshidakonoe Cho, Kyoto 6068501, Japan.	matsuda.michiyuki.2c@kyoto-u.ac.jp		Kobayashi, Takashi/0000-0003-1069-2816; Matsuda, Michiyuki/0000-0002-5876-9969	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H02397, 15H05949, 16H06280]; JST CRESTJapan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST) [JPMJCR1654]; Nakatani Foundation; JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25713055]	Supported by JSPS KAKENHI grants 15H02397, 15H05949, and 16H06280, JST CREST grant JPMJCR1654, the Nakatani Foundation (M.M.), and JSPS grant-in-aid for young scientists (A) 25713055 (T.K.).	ALROY J, 1980, ULTRASTRUCT PATHOL, V1, P201, DOI 10.3109/01913128009141417; Andreoni CR, 2004, J UROLOGY, V171, P859, DOI 10.1097/01.ju.0000108383.18165.f5; Aoki K, 2017, DEV CELL, V43, P305, DOI 10.1016/j.devcel.2017.10.016; Aoki K, 2013, DEV GROWTH DIFFER, V55, P515, DOI 10.1111/dgd.12039; Apodaca G, 2003, AM J PHYSIOL-RENAL, V284, pF966, DOI 10.1152/ajprenal.00359.2002; Applegate KT, 2011, J STRUCT BIOL, V176, P168, DOI 10.1016/j.jsb.2011.07.009; Cordeiro JV, 2013, NAT REV MOL CELL BIO, V14, P249, DOI 10.1038/nrm3541; DALAL E, 1994, INFECT IMMUN, V62, P5505; Enterina JR, 2015, CURR OPIN CHEM BIOL, V27, P10, DOI 10.1016/j.cbpa.2015.05.001; Escuin-Ordinas H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12348; Farooqui R, 2005, J CELL SCI, V118, P51, DOI 10.1242/jcs.01577; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Haeger A, 2015, TRENDS CELL BIOL, V25, P556, DOI 10.1016/j.tcb.2015.06.003; Hiratsuka T, 2015, ELIFE, V4, DOI 10.7554/eLife.05178; Huang JH, 2007, J IMMUNOL, V178, P7747, DOI 10.4049/jimmunol.178.12.7747; Jaqaman K, 2008, NAT METHODS, V5, P695, DOI 10.1038/nmeth.1237; JOST SP, 1989, VIRCHOWS ARCH B, V57, P27, DOI 10.1007/BF02899062; JOST SP, 1989, J ANAT, V167, P103; Kamioka Y, 2012, CELL STRUCT FUNCT, V37, P65, DOI 10.1247/csf.11045; Kleinschmidt EG, 2017, CURR OPIN CELL BIOL, V45, P24, DOI 10.1016/j.ceb.2017.01.003; Kreft ME, 2005, HISTOCHEM CELL BIOL, V123, P529, DOI 10.1007/s00418-005-0770-9; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Ladoux B, 2016, TRENDS CELL BIOL, V26, P420, DOI 10.1016/j.tcb.2016.02.002; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Mizuno R, 2014, J EXP MED, V211, P1123, DOI 10.1084/jem.20132112; Nikolic DL, 2006, AM J PHYSIOL-CELL PH, V291, pC68, DOI 10.1152/ajpcell.00411.2005; Oldach L, 2014, CHEM BIOL, V21, P186, DOI 10.1016/j.chembiol.2013.12.012; OWARIBE K, 1990, DIFFERENTIATION, V45, P207, DOI 10.1111/j.1432-0436.1990.tb00475.x; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Reffay M, 2014, NAT CELL BIOL, V16, P217, DOI 10.1038/ncb2917; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sano T., 2016, PHYSL REP, V4, DOI 10.14814/phy2.13033; Schueth A, 2014, J UROLOGY, V192, P973, DOI 10.1016/j.juro.2014.03.103; Shaw TJ, 2016, CURR OPIN CELL BIOL, V42, P29, DOI 10.1016/j.ceb.2016.04.001; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sonnemann KJ, 2011, ANNU REV CELL DEV BI, V27, P237, DOI 10.1146/annurev-cellbio-092910-154251; TANAKA K, 1962, Arch Histol Jpn, V22, P229; Veranic P, 2000, BIOL CELL, V92, P105, DOI 10.1016/S0248-4900(00)89018-8; Weijer CJ, 2009, J CELL SCI, V122, P3215, DOI 10.1242/jcs.036517; Woldemeskel M, 1998, ANAT HISTOL EMBRYOL, V27, P51, DOI 10.1111/j.1439-0264.1998.tb00155.x; Xie H, 1998, J CELL SCI, V111, P615; Xu J, 2013, SCANNING, V35, P387, DOI 10.1002/sca.21079; Zhuo SM, 2009, LASER PHYS LETT, V6, P80, DOI 10.1002/lapl.200810097	48	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2564	2573		10.1016/j.ajpath.2018.07.010			10	Pathology	Pathology	GZ0FK	WOS:000449036900012	30121259				2019-10-28	
J	Wang, Y; Chen, WN; Han, C; Zhang, JQ; Song, K; Kwon, H; Dash, S; Yao, L; Wu, T				Wang, Ying; Chen, Weina; Han, Chang; Zhang, Jinqiang; Song, Kyoungsub; Kwon, Hyunjoo; Dash, Srikanta; Yao, Lu; Wu, Tong			Adult Hepatocytes Are Hedgehog-Responsive Cells in the Setting of Liver Injury Evidence for Smoothened-Mediated Activation of NF-kappa B/Epidermal Growth Factor Receptor/Akt in Hepatocytes that Counteract Fas-Induced Apoptosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; PRIMARY BILIARY-CIRRHOSIS; PATHWAY ACTIVATION; SIGNALING PATHWAY; MOUSE HEPATOCYTES; PLASMID DNA; NONALCOHOLIC STEATOHEPATITIS; VIRAL-HEPATITIS; B ACTIVATION; FAS	Although hedgehog (Hh) signaling pathway is inactive in adult healthy liver, it becomes activated during acute and chronic liver injury and, thus, modulates the reparative process and disease progression. We developed a novel mouse model with liver-specific knockout of Smoothened (Smo LKO), and animals were subjected to Fas-induced liver injury in vivo. Results showed that Smo deletion in hepatocytes enhances Fas-induced liver injury. Activation of Hh signaling in hepatocytes in the setting of Fas-induced injury was indicated by the fact that Jo2 treatment enhanced hepatic expression of Ptch1, Smo, and its downstream target Gli1 in control but not Smo LKO mice. Primary hepatocytes from control mice showed increased Hh signaling activation in response to Jo2 treatment in vitro. On the other hand, the Smo KO hepatocytes were devoid of Hh activation and were more susceptible to Jo2-induced apoptosis. The levels of NF-kappa B and related signaling molecules, including epidermal growth factor receptor and Akt, were Lower in Smo KO livers/hepatocytes than in control livers/hepatocytes. Accordingly, hydrodynamic gene delivery of active NK-kappa B prevented Jo2-induced liver injury in the Smo LKO mice. Our findings provide important evidence that adult hepatocytes become responsive to Hh signaling through up-regulation of Smo in the setting of Fas-induced liver injury and that such alteration leads to activation of NF-kappa B/epidermal growth factor receptor/Akt, which counteracts Fas-induced hepatocyte apoptosis.	[Wang, Ying; Chen, Weina; Han, Chang; Zhang, Jinqiang; Song, Kyoungsub; Kwon, Hyunjoo; Dash, Srikanta; Yao, Lu; Wu, Tong] Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA; [Wang, Ying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol & Internal Med, Wuhan, Hubei, Peoples R China	Wu, T (reprint author), Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA.	twu@tulane.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA106280, CA102325]	Supported by NIH grants CA106280 and CA102325 (T.W.).	Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bohinc BN, 2012, CLIN LIVER DIS, V16, P549, DOI 10.1016/j.cld.2012.05.002; Chen WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137979; Chen YP, 2012, GASTROENTEROLOGY, V143, P1319, DOI 10.1053/j.gastro.2012.07.115; Choi SS, 2010, J BIOL CHEM, V285, P36551, DOI 10.1074/jbc.M110.168542; Choi SS, 2009, AM J PHYSIOL-GASTR L, V297, pG1093, DOI 10.1152/ajpgi.00292.2009; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Fleig SV, 2007, LAB INVEST, V87, P1227, DOI 10.1038/labinvest.3700689; Fox CK, 2001, LIVER, V21, P272, DOI 10.1034/j.1600-0676.2001.021004272.x; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRISHAM JW, 1975, AM J ANAT, V144, P295, DOI 10.1002/aja.1001440304; Grzelak CA, 2014, J HEPATOL, V60, P143, DOI 10.1016/j.jhep.2013.08.012; Guy CD, 2012, HEPATOLOGY, V55, P1711, DOI 10.1002/hep.25559; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; Jung Y, 2008, GASTROENTEROLOGY, V134, P1532, DOI 10.1053/j.gastro.2008.02.022; Jung YM, 2007, HEPATOLOGY, V45, P1091, DOI 10.1002/hep.21660; Jung YM, 2010, GUT, V59, P655, DOI 10.1136/gut.2009.204354; Kornberg TB, 2014, DEV BIOL, V394, P1, DOI 10.1016/j.ydbio.2014.07.015; Lapinski TW, 2004, WORLD J GASTROENTERO, V10, P3650, DOI 10.3748/wjg.v10.i24.3650; Li GY, 2011, J HEPATOL, V55, P1281, DOI 10.1016/j.jhep.2011.03.017; Li PF, 2010, J BIOL CHEM, V285, P22713, DOI 10.1074/jbc.M110.105692; Li WC, 2010, METHODS MOL BIOL, V633, P185, DOI 10.1007/978-1-59745-019-5_13; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Matz-Soja M, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-11; Matz-Soja M, 2013, MED HYPOTHESES, V80, P589, DOI 10.1016/j.mehy.2013.01.032; Ochoa B, 2010, HEPATOLOGY, V51, P1712, DOI 10.1002/hep.23525; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Omenetti A, 2008, GUT, V57, P1275, DOI 10.1136/gut.2008.148619; Omenetti A, 2007, LAB INVEST, V87, P499, DOI 10.1038/labinvest.3700537; Omenetti A, 2011, J HEPATOL, V54, P366, DOI 10.1016/j.jhep.2010.10.003; Patil MA, 2006, CANCER BIOL THER, V5, P111, DOI 10.4161/cbt.5.1.2379; Pereira TD, 2010, LAB INVEST, V90, P1690, DOI 10.1038/labinvest.2010.147; Philips GM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023943; Qu CJ, 2013, BLOOD, V121, P4718, DOI 10.1182/blood-2012-12-470153; Rajurkar M, 2012, P NATL ACAD SCI USA, V109, pE1038, DOI 10.1073/pnas.1114168109; Rangwala F, 2011, J PATHOL, V224, P401, DOI 10.1002/path.2888; Rivero M, 2002, J VIRAL HEPATITIS, V9, P107, DOI 10.1046/j.1365-2893.2002.00338.x; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Rutherford AE, 2007, CLIN GASTROENTEROL H, V5, P1477, DOI 10.1016/j.cgh.2007.08.007; Ryo K, 2000, AM J GASTROENTEROL, V95, P2047; Shevde LA, 2014, INT J CANCER, V135, P1, DOI 10.1002/ijc.28424; Sicklick JK, 2006, AM J PHYSIOL-GASTR L, V290, pG859, DOI 10.1152/ajpgi.00456.2005; Sicklick JK, 2006, CARCINOGENESIS, V27, P748, DOI 10.1093/carcin/bgi292; Syn WK, 2012, GUT, V61, P1323, DOI 10.1136/gutjnl-2011-301857; Syn WK, 2011, HEPATOLOGY, V53, P106, DOI 10.1002/hep.23998; Syn WK, 2010, HEPATOLOGY, V51, P1998, DOI 10.1002/hep.23599; Taieb J, 1998, LANCET, V351, P1930, DOI 10.1016/S0140-6736(05)78614-1; Tsoulfas G, 2006, J SURG RES, V135, P242, DOI 10.1016/j.jss.2006.04.020; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Wang Y, 2013, HEPATOLOGY, V58, P995, DOI 10.1002/hep.26394; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	55	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2605	2616		10.1016/j.ajpath.2018.07.018			12	Pathology	Pathology	GZ0FK	WOS:000449036900015	30366594				2019-10-28	
J	Zhang, RZ; Lin, ZF; Fu, M; Guan, XS; Yu, JK; Zhong, W; Zeng, JX; Lui, VCH; Tam, PKH; Lamb, JR; Xia, HM; Chen, Y				Zhang, Ruizhong; Lin, Zefeng; Fu, Ming; Guan, Xisi; Yu, Jiakang; Zhong, Wei; Zeng, Jixiao; Lui, Vincent C. H.; Tam, Paul K. H.; Lamb, Jonathan R.; Xia, Huimin; Chen, Yan			The Role of Neonatal Gr-1(+) Myeloid Cells in a Murine Model of Rhesus-Rotavirus-Induced Biliary Atresia	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BILE-DUCT INJURY; SUPPRESSOR-CELLS; MICE; NEUTROPHILS; FIBROSIS; INFILTRATION; INFECTION; DIFFERENTIATION; MACROPHAGES; ACTIVATION	Activation of innate immunity together with cholangiocyte damage occurs in biliary atresia (BA). However, detailed information on the inflammatory cells involved is lacking. This study investigates both the pathophysiology of CD11b(+)Gr-1(+) cells in a mouse model of BA and their presence in BA patients. CD11b(+)Gr-1(+) cells were targeted by an anti-Ly6G antibody in murine BA induced by inoculation with rhesus rotavirus. Expression of the Ly6G homolog CD177(+) was examined in biopsies from BA patients. The symptoms of BA were ameliorated, and survival was prolonged in those mice receiving 5 to 10 mu g of antibody per mouse every 3 days for four times compared with the mice treated with virus alone. However, the mice later developed chronic BA with persistent low body weight and jaundice. Hepatic inflammatory cells were reduced compared with acute BA. Blockade of extrahepatic bile ducts occurred, whereas intrahepatic ductules were partially preserved, and a progressive increase in liver fibrosis was observed. High levels of CD11b(+)Gr-1(+) cells were present in these mice. The administration of an anti-Ly6G antibody again in those chronic BA mice reduced jaundice and restored body weight. In BA patients CD177(+) cells were highly expressed in the liver. Our data suggest that the chronic mouse BA model shares key characteristics with clinical BA and indicates the importance of CD11b(+)Gr-1(+) cells in the initiation and progression of BA.	[Zhang, Ruizhong; Lin, Zefeng; Fu, Ming; Guan, Xisi; Yu, Jiakang; Zhong, Wei; Zeng, Jixiao; Xia, Huimin; Chen, Yan] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Pediat Surg, Guangzhou, Guangdong, Peoples R China; [Lui, Vincent C. H.; Tam, Paul K. H.; Chen, Yan] Univ Hong Kong, Dept Surg, L9-43,Fac Med Bldg,21,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China; [Lamb, Jonathan R.] Imperial Coll London, Fac Nat Sci, Dept Life Sci, London, England	Chen, Y (reprint author), Univ Hong Kong, Dept Surg, L9-43,Fac Med Bldg,21,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.; Xia, HM; Chen, Y (reprint author), Guangzhou Women & Childrens Med Ctr, 9 Jinsui Rd, Guangzhou 510623, Guangdong, Peoples R China.	xia-huimin@foxmail.com; ychenc@hku.hk	/C-4359-2009	/0000-0002-1758-8854	Science and Technology Project of Guangzhou [201707010014]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81600399, 81770510, 81671498]	Supported by the Science and Technology Project of Guangzhou grant 201707010014 (R.Z.) and the National Natural Science Foundation of China grants 81600399 (R.Z.), 81770510 (R.Z.), and grant 81671498 (Y.C.).	Arnold Michelle, 2009, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/9780471729259.mc15c03s15; Bowen JL, 2009, J IMMUNOL, V183, P6971, DOI 10.4049/jimmunol.0902193; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bruhl H, 2007, ARTHRITIS RHEUM, V56, P2975, DOI 10.1002/art.22854; Chen YC, 2014, HEPATOLOGY, V59, P1435, DOI 10.1002/hep.26790; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Egan CE, 2008, IMMUNOL RES, V40, P35, DOI 10.1007/s12026-007-0061-8; Emoto M, 2010, EUR J IMMUNOL, V40, P1328, DOI 10.1002/eji.200939594; Engel DR, 2015, J IMMUNOL, V194, P1628, DOI 10.4049/jimmunol.1402149; Gallo A, 2013, PEDIATR TRANSPLANT, V17, P95, DOI 10.1111/petr.12040; Gregory AD, 2015, J LEUKOCYTE BIOL, V98, P143, DOI 10.1189/jlb.3HI1014-493R; Guo CB, 2012, PEDIATR RES, V71, P638, DOI 10.1038/pr.2012.17; Kristensen MB, 2015, IMMUN INFLAMM DIS, V3, P309, DOI 10.1002/iid3.70; Lee SC, 2009, INFECT IMMUN, V77, P2168, DOI 10.1128/IAI.01350-08; Liang MR, 2015, LAB INVEST, V95, P342, DOI 10.1038/labinvest.2014.145; Ma C, 2012, J LEUKOCYTE BIOL, V92, P1199, DOI 10.1189/jlb.0212059; Mack CL, 2007, GASTROENTEROLOGY, V133, P278, DOI 10.1053/j.gastro.2007.04.032; Mack CL, 2005, CLIN IMMUNOL, V115, P200, DOI 10.1016/j.clim.2005.01.012; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; McDermott AJ, 2015, IMMUNOLOGY, V144, P704, DOI 10.1111/imm.12425; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Panas MW, 2014, CLIN VACCINE IMMUNOL, V21, P1120, DOI 10.1128/CVI.00363-14; Petersen C, 2012, SEMIN PEDIATR SURG, V21, P185, DOI 10.1053/j.sempedsurg.2012.05.002; Rich Lillian, 2005, Brazilian Journal of Morphological Sciences, V22, P97; Shivakumar P, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88747; Shivakumar P, 2009, J CLIN INVEST, V119, P2281, DOI 10.1172/JCI38879; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Wang JX, 2012, BLOOD, V120, P1489, DOI 10.1182/blood-2012-01-404046; Wojtasiak M, 2010, VIROLOGY, V407, P143, DOI 10.1016/j.virol.2010.08.001; Zhou GX, 2018, GUT, V67, P1052, DOI 10.1136/gutjnl-2016-313535	31	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2617	2628		10.1016/j.ajpath.2018.07.024			12	Pathology	Pathology	GZ0FK	WOS:000449036900016	30201498	Other Gold			2019-10-28	
J	de Sousa, JR; Azevedo, RSS; Martins, AJ; Araujo, MTF; Moutinho, ERC; Vasconcelos, BCB; Cruz, ACR; Oliveira, CS; Martins, LC; Vasconcelos, BHB; Casseb, LMN; Chiang, JO; Quaresma, JAS; Vasconcelos, PFC				de Sousa, Jorge R.; Azevedo, Raimunda S. S.; Martins Filho, Arnaldo J.; Araujo, Marialva T. F.; Moutinho, Ermelinda R. C.; Baldez Vasconcelos, Barbara C.; Cruz, Ana C. R.; Oliveira, Consuelo S.; Martins, Livia C.; Baldez Vasconcelos, Beatriz H.; Casseb, Livia M. N.; Chiang, Jannifer O.; Quaresma, Juarez A. S.; Vasconcelos, Pedro F. C.			Correlation between Apoptosis and in Situ Immune Response in Fatal Cases of Microcephaly Caused by Zika Virus	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INDUCED ENCEPHALITIS; INFECTION; OUTBREAK; DENGUE; CELLS; MECHANISMS; EPIDEMIC; FEVER; LIVER	Zika virus (ZIKV) is a single-stranded positive-sense RNA flavivirus that possesses a genome approximately 10.7 Kb in length. Although pro-inflammatory and anti-inflammatory cytokines and apoptotic markers belonging to the extrinsic and intrinsic pathways are suggested to be involved in fatal cases of ZIKV-induced microcephaly, their exact roles and associations are unclear. To address this, brain tissue samples were collected from 10 individuals, five of whom were diagnosed as ZIKV positive with microcephaly and a further five were flavivirus-negative controls that died because of other causes. Examination of material from the fatal cases of microcephaly revealed lesions in the cerebral cortex, edema, vascular proliferation, neuronal necrosis, gliosis, neuronophagy, calcifications, apoptosis, and neuron loss. The expression of various apoptosis markers in the neural parenchyma, including FasL, FAS, BAX, BCL2, and caspase 3 differed between ZIKV-positive cases and controls. Further investigation of type 1 and 2 helper T-cell cytokines confirmed a greater anti-inflammatory response in fatal ZIKV-associated microcephaly cases. Finally, an analysis of the linear correlation between tumor necrosis factor-alpha, IL-1 beta, IL-4, IL-10, transforming growth factor-beta, and IL-33 expression and various apoptotic markers suggested that the immune response may be associated with the apoptotic phenomenon observed in ZIKV-induced microcephaly.	[de Sousa, Jorge R.; Azevedo, Raimunda S. S.; Cruz, Ana C. R.; Oliveira, Consuelo S.; Martins, Livia C.; Casseb, Livia M. N.; Chiang, Jannifer O.; Vasconcelos, Pedro F. C.] Minist Hlth, Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Rodovia BR-316,Km 07 S-N, BR-67030000 Ananindeua, Brazil; [Martins Filho, Arnaldo J.; Araujo, Marialva T. F.; Moutinho, Ermelinda R. C.; Quaresma, Juarez A. S.] Minist Hlth, Evandro Chagas Inst, Dept Pathol, Rodovia BR-316,Km 07 S-N, BR-67030000 Ananindeua, Brazil; [Baldez Vasconcelos, Barbara C.; Cruz, Ana C. R.; Quaresma, Juarez A. S.; Vasconcelos, Pedro F. C.] State Univ Para, Ctr Biol & Hlth Sci, Belem, Para, Brazil; [Baldez Vasconcelos, Beatriz H.; Quaresma, Juarez A. S.] Fed Univ Para, Trop Med Ctr, Belem, Para, Brazil	Vasconcelos, PFC (reprint author), Minist Hlth, Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Rodovia BR-316,Km 07 S-N, BR-67030000 Ananindeua, Brazil.; Quaresma, JAS (reprint author), Minist Hlth, Evandro Chagas Inst, Dept Pathol, Rodovia BR-316,Km 07 S-N, BR-67030000 Ananindeua, Brazil.	juarez@ufpa.br; pedrovasconcelos@iec.gov.br	Quaresma, Juarez AS/M-4190-2014; Cruz, Ana Cecilia Ribeiro/V-9276-2019; Azevedo, Raimunda/T-4656-2019; QUARESMA, JUAREZ ANTONIO SIMOES/F-8390-2012; Martins Filho, Arnaldo Jorge/B-9329-2019	Quaresma, Juarez AS/0000-0002-6267-9966; Azevedo, Raimunda/0000-0003-1932-9976; QUARESMA, JUAREZ ANTONIO SIMOES/0000-0002-6267-9966; Martins Filho, Arnaldo Jorge/0000-0001-9153-1234	Ministry of Science, Technology and Innovation/National Council for Scientific and Technological Development CNPQ, Brazil [303999/2016-0, 439971/2016-0, 440405/2016-5]; Coordination for the Improvement of Higher Level Personnel (CAPES), BrazilCAPES	Supported by the Ministry of Science, Technology and Innovation/National Council for Scientific and Technological Development CNPQ, Brazil grants 303999/2016-0, 439971/2016-0, and 440405/2016-5 and Coordination for the Improvement of Higher Level Personnel (CAPES), Brazil (Zika Fast-Track) (P.F.C.V.).	Ali A, 2017, ASIAN PAC J TROP MED, V10, P301, DOI 10.1016/j.apjtm.2017.03.020; Araujo LM, 2016, ARQ NEURO-PSIQUIAT, V74, P253, DOI 10.1590/0004-282X20160035; Arjona A, 2007, J IMMUNOL, V179, P8403, DOI 10.4049/jimmunol.179.12.8403; Ashhurst TM, 2013, INDIAN J MED RES, V138, P632; Azevedo RSS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17765-5; Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024; Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138; Chen J, 2018, NAT MICROBIOL, V3, P302, DOI 10.1038/s41564-017-0092-4; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; Culshaw A, 2017, CURR OPIN IMMUNOL, V48, P1, DOI 10.1016/j.coi.2017.07.001; Desclaux A, 2018, NEW ENGL J MED, V378, P1458, DOI 10.1056/NEJMc1710453; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Faizan MI, 2016, INTERVIROLOGY, V59, P152, DOI 10.1159/000452950; Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005; Franca RFO, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0628-1; Ghosh Roy Sounak, 2014, World J Biol Chem, V5, P93, DOI 10.4331/wjbc.v5.i2.93; Hennessey M., 2015, CTR DIS CONTROL PREV, V65, P55, DOI DOI 10.15585/MMWR.MM6503E1; Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217; Ho CY, 2017, ANN NEUROL, V82, P121, DOI 10.1002/ana.24968; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P1349, DOI 10.1177/29.11.6172466; Jouannic JM, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00625-5; Kam YW, 2017, J INFECT DIS, V216, P172, DOI 10.1093/infdis/jix261; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Limonta D, 2014, J MED VIROL, V86, P1437, DOI 10.1002/jmv.23832; Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004; Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045; Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004; Mocarski ES, 2012, NAT REV IMMUNOL, V12, P79, DOI 10.1038/nri3131; Murray CL, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-50; Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Okamoto T, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090243; Olmos G, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/861231; Pagliari C, 2014, J MED VIROL, V86, P1193, DOI 10.1002/jmv.23758; Quaresma JAS, 2006, VIROLOGY, V345, P22, DOI 10.1016/j.virol.2005.09.058; Ritter JM, 2017, ARCH PATHOL LAB MED, V141, P49, DOI 10.5858/arpa.2016-0397-SA; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Shrestha B, 2007, J VIROL, V81, P11749, DOI 10.1128/JVI.01136-07; Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296; Spender LC, 2009, CELL DEATH DIFFER, V16, P593, DOI 10.1038/cdd.2008.183; Sun PF, 2013, SCI WORLD J, DOI 10.1155/2013/843469; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Teng Y, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00327; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Tricarico PM, 2017, BIOCHEM BIOPH RES CO, V492, P597, DOI 10.1016/j.bbrc.2017.01.158; Tsao CH, 2008, J GEN VIROL, V89, P1930, DOI 10.1099/vir.0.2008/000182-0; Wang Y, 2004, IMMUNOL CELL BIOL, V82, P170, DOI 10.1046/j.0818-9641.2004.01227.x; Winkler CW, 2017, J IMMUNOL, V198, P3526, DOI 10.4049/jimmunol.1601949; Zorrilla CD, 2017, J INFECT DIS, V216, pS891, DOI 10.1093/infdis/jix448	52	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2644	2652		10.1016/j.ajpath.2018.07.009			9	Pathology	Pathology	GZ0FK	WOS:000449036900018	30121258				2019-10-28	
J	Nikitski, AV; Rominski, SL; Wankhede, M; Kelly, LM; Panebianco, F; Barila, G; Altschuler, DL; Nikiforov, YE				Nikitski, Alyaksandr, V; Rominski, Susan L.; Wankhede, Mamta; Kelly, Lindsey M.; Panebianco, Federica; Barila, Guillermo; Altschuler, Daniel L.; Nikiforov, Yuri E.			Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ANAPLASTIC LYMPHOMA KINASE; TURIN PROPOSAL; LUNG-CANCER; GENE; BRAF; EXPRESSION; MICE; THYROGLOBULIN; PATTERNS; TUMORS	Chromosomal rearrangements of the ALK gene, which lead to constitutive activation of ALK tyrosine kinase, are found in various cancers. In thyroid cancers, ALK fusions, most commonly the STRN-ALK fusion, are detected in papillary thyroid cancer and with higher frequency in poorly differentiated and anaplastic thyroid cancers. Our aim was to establish a mouse model of thyroid-specific expression of STRN-ALK and to test whether this fusion drives the development of thyroid cancer with a propensity for dedifferentiation. Transgenic Tg-STRN-ALK mice with thyroglobulin-controlled expression of STRN-ALK were generated and aged with or without goitrogen treatment. Thyroids from these mice were subjected to histologic and immunohistochemical analysis. Transgenic mice with thyroid-specific expression of STRN-ALK developed poorly differentiated thyroid tumors by the age of 12 months in 22% of mice without goitrogen treatment and in 36% of mice with goitrogen treatment. Histologically and immunohistochemically, the tumors resembled poorly differentiated thyroid cancers in humans, demonstrating a solid growth pattern with sheets of round or spindle-shaped cells, decreased expression of thyroglobulin, and a tendency to lose E-cadherin. In this study, we report a novel mouse model of poorly differentiated thyroid cancer driven by the STRN-ALK oncogene with phenotypic features closely recapitulating human tumor, and with a more pronounced phenotype after additional thyroid stimulating hormone stimulation.	[Nikitski, Alyaksandr, V; Rominski, Susan L.; Kelly, Lindsey M.; Panebianco, Federica; Nikiforov, Yuri E.] Univ Pittsburgh, Dept Pathol, 3477 Euler Way,CLB Room 8031, Pittsburgh, PA 15213 USA; [Wankhede, Mamta; Barila, Guillermo; Altschuler, Daniel L.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Nikiforov, YE (reprint author), Univ Pittsburgh, Dept Pathol, 3477 Euler Way,CLB Room 8031, Pittsburgh, PA 15213 USA.	nikiforovye@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA181150]	Supported by NIH grant R01CA181150.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Arciuch VGA, 2011, ONCOTARGET, V2, P1109; Asioli S, 2010, MODERN PATHOL, V23, P1269, DOI 10.1038/modpathol.2010.117; Baquero P, 2013, CANCER LETT, V335, P232, DOI 10.1016/j.canlet.2013.02.033; Barreca A, 2011, J MOL ENDOCRINOL, V47, pR11, DOI 10.1530/JME-11-0004; Basolo F, 2000, THYROID, V10, P19, DOI 10.1089/thy.2000.10.19; Bejarano PA, 2000, APPL IMMUNOHISTO M M, V8, P189, DOI 10.1097/00022744-200009000-00004; Bongiovanni M, 2009, ADV ANAT PATHOL, V16, P283, DOI 10.1097/PAP.0b013e3181b50640; Chakravarty D, 2011, J CLIN INVEST, V121, P4700, DOI 10.1172/JCI46382; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chou A, 2015, AM J SURG PATHOL, V39, P652, DOI 10.1097/PAS.0000000000000368; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Efanov AA, 2018, JNCI-J NATL CANCER I, V110, P371, DOI 10.1093/jnci/djx209; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Godbert Y, 2015, J CLIN ONCOL, V33, pE84, DOI 10.1200/JCO.2013.49.6596; Hamatani K, 2012, THYROID, V22, P1153, DOI 10.1089/thy.2011.0511; Haymart MR, 2008, J CLIN ENDOCR METAB, V93, P809, DOI 10.1210/jc.2007-2215; Holla VR, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001115; Howlader N, 2016, SEER CANC STAT REV 1; Ito Y, 2008, WORLD J SURG, V32, P1535, DOI 10.1007/s00268-007-9406-7; Ji JH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005467; Kazaure HS, 2012, CANCER-AM CANCER SOC, V118, P3260, DOI 10.1002/cncr.26638; Kelly LM, 2014, P NATL ACAD SCI USA, V111, P4233, DOI 10.1073/pnas.1321937111; Kilfoy BA, 2009, CANCER CAUSE CONTROL, V20, P525, DOI 10.1007/s10552-008-9260-4; Kim SS, 2011, ENDOCRINE, V39, P259, DOI 10.1007/s12020-010-9430-5; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Knauf JA, 2011, ONCOGENE, V30, P3153, DOI 10.1038/onc.2011.44; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; La Perle KMD, 2000, AM J PATHOL, V157, P671, DOI 10.1016/S0002-9440(10)64577-4; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lamant L, 1999, BLOOD, V93, P3088; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Lin E, 2009, MOL CANCER RES, V7, P1466, DOI 10.1158/1541-7786.MCR-08-0522; Lloyd RV, 2017, WORLD HLTH ORG CLASS; Maddalo D, 2014, NATURE, V516, P423, DOI 10.1038/nature13902; McFadden DG, 2014, P NATL ACAD SCI USA, V111, pE1600, DOI 10.1073/pnas.1404357111; McLeod DSA, 2014, THYROID, V24, P35, DOI 10.1089/thy.2013.0062; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nikiforov YE, 2004, ENDOCR PATHOL, V15, P319, DOI 10.1385/EP:15:4:319; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; PAPOTTI M, 1993, AM J SURG PATHOL, V17, P291, DOI 10.1097/00000478-199303000-00010; Penna GC, 2016, CYTOGENET GENOME RES, V150, P194, DOI 10.1159/000456576; Perot G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087170; PIETRIBIASI F, 1990, AM J CLIN PATHOL, V94, P687, DOI 10.1093/ajcp/94.6.687; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Rocha AS, 2003, HISTOPATHOLOGY, V42, P580, DOI 10.1046/j.1365-2559.2003.01642.x; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smallridge RC, 2010, CLIN ONCOL-UK, V22, P486, DOI 10.1016/j.clon.2010.03.013; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Tallini G, 1999, AM J SURG PATHOL, V23, P678, DOI 10.1097/00000478-199906000-00007; Turner SD, 2005, LEUKEMIA, V19, P1128, DOI 10.1038/sj.leu.2403797; Vitagliano D, 2006, ONCOGENE, V25, P5467, DOI 10.1038/sj.onc.1209527; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xu B, 2016, ENDOCR PATHOL, V27, P205, DOI 10.1007/s12022-016-9445-4; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239; Zhu XG, 2014, NEOPLASIA, V16, P757, DOI 10.1016/j.neo.2014.08.003	60	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2653	2661		10.1016/j.ajpath.2018.07.012			9	Pathology	Pathology	GZ0FK	WOS:000449036900019	30125543				2019-10-28	
J	Estato, V; Stipursky, J; Gomes, F; Mergener, TC; Frazao-Teixeira, E; Allodi, S; Tibirica, E; Barbosa, HS; Adesse, D				Estato, Vanessa; Stipursky, Joice; Gomes, Fabiana; Mergener, Tally C.; Frazao-Teixeira, Edwards; Allodi, Silvana; Tibirica, Eduardo; Barbosa, Helene S.; Adesse, Daniel			The Neurotropic Parasite Toxoplasma gondii Induces Sustained Neuroinflammation with Microvascular Dysfunction in Infected Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MATRIX METALLOPROTEINASES; COGNITIVE IMPAIRMENT; NEUROVASCULAR UNIT; OXIDATIVE STRESS; T-CELLS; BRAIN; ENCEPHALITIS; EXPRESSION; SEPSIS; VCAM-1	Toxoplasmosis is one of the leading parasitic diseases worldwide. Some data suggest that chronic acquired toxoplasmosis could be Linked to behavioral alterations in humans. The parasite infects neurons, forming immunologically silent cysts. Cerebral microcirculation homeostasis is determinant to brain functions, and pathologic states can alter capillarity or blood perfusion, leading to neurodegeneration and cognitive deficits. Albino mice were infected with Toxoplasma gondii (ME49 strain) and analyzed after 10, 40, and 180 days. Infected mice presented decreased cerebral blood flow at 10 and 40 days post infection (dpi), which were restored at 180 dpi, as shown by laser speckle contrast imaging. Intravital microscopy demonstrated that infection led to significant capillary rarefaction, accompanied by neuroinflammation, with microglial activation and increased numbers of rolling and adherent leukocytes to the wall of cerebral capillaries. Acetylcholine-induced vasodilation was altered at all time points, and blood brain barrier permeability was evident in infected animals at 40 dpi. Infection reduced angiogenesis, with a decreased number of isolectin B4-stained blood vessels and a decrease in length and branching of laminin-stained capillaries. Sulfadiazine reduced parasite load and partially repaired microvascular damages. We conclude that T. gondii latent infection causes a harmful insult in the brain, promoting neuroinflammation and microcirculatory dysfunction in the brain, with decreased angiogenesis and can contribute to a neurodegenerative process.	[Estato, Vanessa; Gomes, Fabiana; Tibirica, Eduardo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Invest Cardiovasc, Rio De Janeiro, RJ, Brazil; [Mergener, Tally C.; Frazao-Teixeira, Edwards; Barbosa, Helene S.; Adesse, Daniel] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Estrut, Ave Brasil,4365 Pavilhao Carlos Chagas,Room 307, BR-21040360 Rio De Janeiro, RJ, Brazil; [Estato, Vanessa] Fundacao Oswaldo Cruz, Farmanguinhos, Dept Prod Nat, Lab Prod Nat, Rio De Janeiro, Brazil; [Stipursky, Joice] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Neurobiol Celular, Rio De Janeiro, Brazil; [Allodi, Silvana] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Neurobiol Comparat & Desenvolvimento, Rio De Janeiro, RJ, Brazil	Adesse, D (reprint author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Estrut, Ave Brasil,4365 Pavilhao Carlos Chagas,Room 307, BR-21040360 Rio De Janeiro, RJ, Brazil.	adesse@ioc.fiocruz.br	Stipursky, Joice/Y-1961-2019	Barbosa, Helene/0000-0002-5672-5444; Adesse, Daniel/0000-0002-7421-9510	Fundacao Oswaldo Cruz; Conselho Nacional de Pesquisa e Desenvolvimento TecnologicoNational Council for Scientific and Technological Development (CNPq) [401772/2015-2, 444478/2014-0, 304917/2016-8, 407490/2012-4]	Supported by Fundacao Oswaldo Cruz and Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico grants 401772/2015-2 (D.A.), 444478/2014-0 (D.A.), 304917/2016-8 (H.S.B.), and 407490/2012-4 (H.S.B).	Afonso C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032489; Amalinei C, 2010, ROM J MORPHOL EMBRYO, V51, P215; Babi MA, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/643216; Berenreiterova M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028925; Berrett AN, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060564; Brooks JM, 2015, MBIO, V6, DOI 10.1128/mBio.01428-15; Buoli M, 2017, PSYCHIAT DANUB, V29, P24, DOI 10.24869/psyd.2017.24; Cabral CM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005447; Cai W, 2017, AGEING RES REV, V34, P77, DOI 10.1016/j.arr.2016.09.006; Clark RT, 2011, ASN NEURO, V3, P1, DOI 10.1042/AN20100027; D'haeseleer M, 2015, J CEREBR BLOOD F MET, V35, P1406, DOI 10.1038/jcbfm.2015.131; David CN, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005643; Deckert-Schluter M, 1999, AM J PATHOL, V154, P1549, DOI 10.1016/S0002-9440(10)65408-9; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; Del Grande C, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6010003; DESMONTS G, 1974, B NEW YORK ACAD MED, V50, P146; Dincel GC, 2016, NEUROPATHOLOGY, V36, P211, DOI 10.1111/neup.12263; Dincel GC, 2015, EXP PARASITOL, V156, P104, DOI 10.1016/j.exppara.2015.06.009; Dubey JP, 2010, VET PARASITOL, V172, P195, DOI 10.1016/j.vetpar.2010.05.013; DUBEY JP, 1987, EQUINE VET J, V19, P337, DOI 10.1111/j.2042-3306.1987.tb01426.x; Eisenhut M, 2014, INT J INFLAMM, DOI 10.1155/2014/509707; Elsheikha HM, 2016, CURR OPIN INFECT DIS, V29, P311, DOI 10.1097/QCO.0000000000000265; FERGUSON DJP, 1991, INT J EXP PATHOL, V72, P463; FERGUSON DJP, 1989, PARASITOL RES, V75, P599, DOI 10.1007/BF00930955; Flegr J, 2017, EUR PSYCHIAT, V40, P82, DOI 10.1016/j.eurpsy.2016.09.001; Flegr J, 2013, TRENDS PARASITOL, V29, P156, DOI 10.1016/j.pt.2013.01.007; Gaskell EA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004801; Gulinello M, 2010, MICROBES INFECT, V12, P528, DOI 10.1016/j.micinf.2010.03.009; Harker KS, 2013, J LEUKOCYTE BIOL, V93, P789, DOI 10.1189/jlb.1012517; Haroon F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035516; Hermes G, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-48; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Hunter CA, 2001, J IMMUNOL, V166, P5878, DOI 10.4049/jimmunol.166.10.5878; Konradt C, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.1, 10.1038/nmicrobiol.2016.1]; Lambert H, 2006, CELL MICROBIOL, V8, P1611, DOI 10.1111/j.1462-5822.2006.00735.x; Leardini-Tristao M, 2017, BRAIN RES, V1657, P43, DOI 10.1016/j.brainres.2016.11.030; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Lucchese G, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00037; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; Machado VS, 2016, EXP PARASITOL, V169, P51, DOI 10.1016/j.exppara.2016.07.006; Mahmoudvand H, 2015, PATHOG GLOB HEALTH, V109, P369, DOI 10.1080/20477724.2015.1117742; Martin HL, 2015, NEUROSCIENCE, V306, P50, DOI 10.1016/j.neuroscience.2015.08.005; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Melzer T. C., 2010, Journal of Neuroparasitology, V1, pN100505, DOI 10.4303/jnp/N100505; Mina F, 2014, MOL NEUROBIOL, V49, P1069, DOI 10.1007/s12035-013-8581-9; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-142; Nisimura LM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002998; Okusaga O, 2011, SCHIZOPHR RES, V133, P150, DOI 10.1016/j.schres.2011.08.006; Palomo J, 2013, EUR J IMMUNOL, V43, P2683, DOI 10.1002/eji.201343327; Parlog A, 2015, PARASITE IMMUNOL, V37, P159, DOI 10.1111/pim.12157; Parlog A, 2014, DIS MODEL MECH, V7, P459, DOI 10.1242/dmm.014183; Poirotte C, 2016, CURR BIOL, V26, pR98, DOI 10.1016/j.cub.2015.12.020; Poulet R, 2006, J CEREBR BLOOD F MET, V26, P253, DOI 10.1038/sj.jcbfm.9600188; Prandovszky E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023866; Pyo KH, 2014, KOREAN J PARASITOL, V52, P605, DOI 10.3347/kjp.2014.52.6.605; Reis PA, 2017, BRAIN BEHAV IMMUN, V60, P293, DOI 10.1016/j.bbi.2016.11.006; Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099; Roberts F, 1999, PARASITOL TODAY, V15, P51, DOI 10.1016/S0169-4758(98)01377-5; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Roustit M, 2013, TRENDS PHARMACOL SCI, V34, P373, DOI 10.1016/j.tips.2013.05.007; Sa QL, 2014, INFECT IMMUN, V82, P2826, DOI 10.1128/IAI.01494-13; Silva NM, 2010, EXP PARASITOL, V126, P167, DOI 10.1016/j.exppara.2010.04.019; Siqueira M, 2018, MOL NEUROBIOL, V55, P3660, DOI 10.1007/s12035-017-0557-8; Stock AK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10926-6; Suzuki Y, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002018; Taccone FS, 2014, CRIT CARE MED, V42, pE114, DOI 10.1097/CCM.0b013e3182a641b8; Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Ueno N, 2014, CELL MICROBIOL, V16, P580, DOI 10.1111/cmi.12239; Uhl E, 2000, J CEREBR BLOOD F MET, V20, P979, DOI 10.1097/00004647-200006000-00010; Wang XS, 2007, J INTERF CYTOK RES, V27, P329, DOI 10.1089/jir.2006.0154; Watts E, 2015, MBIO, V6, DOI 10.1128/mBio.01155-15; Wohlfert EA, 2017, TRENDS PARASITOL, V33, P519, DOI 10.1016/j.pt.2017.04.001; Worth AR, 2014, ADV PARASIT, V85, P109, DOI 10.1016/B978-0-12-800182-0.00003-9; Yang CH, 2015, J SURG RES, V194, P591, DOI 10.1016/j.jss.2014.11.030; Zhang HS, 2013, EXP PARASITOL, V134, P275, DOI 10.1016/j.exppara.2013.03.015; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	79	4	4	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2674	2687		10.1016/j.ajpath.2018.07.007			14	Pathology	Pathology	GZ0FK	WOS:000449036900021	30121257				2019-10-28	
J	Tu, WL; You, LR; Tsou, AP; Chen, CM				Tu, Wei-Ling; You, Li-Ru; Tsou, Ann-Ping; Chen, Chun-Ming			Pten Haplodeficiency Accelerates Liver Tumor Growth in miR-122a-Null Mice via Expansion of Periportal Hepatocyte-Like Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CANCER STEM-CELLS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR GENE; CRE RECOMBINASE; IN-VIVO; DUCTULAR REACTIONS; PROSTATE-CANCER; DOWN-REGULATION; UNITED-STATES; PHOSPHATASE	This study aimed to shed tight on the molecular and cellular mechanisms responsible for initiation and progression of liver malignancies by examining the role of phosphatase and tensin homolog on chromosome 10 (Pten) in liver tumor progression in miR-122a (Mir122a)-null mice. We generated and monitored liver tumor initiation in Mir122a-null Pten heterozygous (Mir122a(-/-);Pten(+/-) and Mir122a(-/-);Alb-Cre;Pten(fx/+)) mice and compared the results with those in Mir122a(-/-) mice. Both Mir122a(-/-);Pten(+/-) and Mir122a(-/-);Alb-Cre;Pten(fx/+) mice developed visible liver tumor nodules at 6 months of age. In premalignant livers of Mir122a(-/-);Pten(+/-) mice, decreased PTEN and increased phosphorylated AKT were specifically observed in periportal cells, associated with inflammatory and fibrotic microenvironments. Furthermore, IL-1 beta and tumor necrosis factor-alpha levels significantly increased in Mir122a(-/-);Pten(+/-) premalignant livers at 6 months of age. Oval cells expressing A6, epithelial cell adhesion molecule, keratin (K) 8, K19, and SRY (sex determining region Y)-box 9 (SOX9) were present in both Mir122a(-/-) and Mir122a(-/-); Pten(+/-) livers. Interestingly, a hybrid hepatocyte-like population with intermediate levels of K8, HNF4 alpha, and SOX9 was located proximally to the oval cells in Mir122a(-/-);Pten(+/-) livers. Lineage-tracing experiments revealed that these intermediate levels of K8 hepatocyte-like cells may be the cells of origin for Mir122a(-/-);Pten(+/-) liver tumors. These findings suggest that inflammatory microenvironments in the periportal area of Mir122a-null mice may locally cause Pten down-regulation and expand tumor-initiating cells, causing hepatocellular carcinoma.	[Tu, Wei-Ling; Chen, Chun-Ming] Natl Yang Ming Univ, Dept Life Sci, 155,Li Nong St,Sect 2, Taipei 112, Taiwan; [Tu, Wei-Ling; Chen, Chun-Ming] Natl Yang Ming Univ, Inst Genome Sci, 155,Li Nong St,Sect 2, Taipei 112, Taiwan; [You, Li-Ru] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [You, Li-Ru; Chen, Chun-Ming] Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan; [Tsou, Ann-Ping] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei, Taiwan	Chen, CM (reprint author), Natl Yang Ming Univ, Dept Life Sci, 155,Li Nong St,Sect 2, Taipei 112, Taiwan.; Chen, CM (reprint author), Natl Yang Ming Univ, Inst Genome Sci, 155,Li Nong St,Sect 2, Taipei 112, Taiwan.	cmchen@ym.edu.tw		You, Li-Ru/0000-0003-1775-0097; Chen, Chun-Ming/0000-0001-8873-7602	National Health Research InstitutesNational Health Research Institutes, JapanNational Health Research Institutes - Taiwan [NHRI-EX106-10515BI, NHRI-EX107-10515BI]; Ministry of Education Aim for the Top University PlanMinistry of Education, Taiwan; Featured Areas Research Center Program within the framework of the Higher Education Sprout Project; Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST 104-2320-B-010-025, MOST 105-2320-B-010-003, MOST 105-2320-B-010-028-MY3]	Supported by the National Health Research Institutes grants NHRI-EX106-10515BI and NHRI-EX107-10515BI (C.-M.C.); the Ministry of Education Aim for the Top University Plan and the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project; and the Ministry of Science and Technology grants MOST 104-2320-B-010-025, MOST 105-2320-B-010-003, and MOST 105-2320-B-010-028-MY3 (C-M.C.).	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; BUHLER R, 1992, EUR J BIOCHEM, V204, P407, DOI 10.1111/j.1432-1033.1992.tb16650.x; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Chen C-M, 2012, TUMOR SUPPRESSOR GEN, P35; Chen JS, 2009, HEPATOL RES, V39, P177, DOI 10.1111/j.1872-034X.2008.00449.x; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Golding M, 1996, HUM PATHOL, V27, P872, DOI 10.1016/S0046-8177(96)90212-9; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hsu SH, 2013, AM J PATHOL, V183, P1719, DOI 10.1016/j.ajpath.2013.08.004; Hsu SH, 2012, J CLIN INVEST, V122, P2871, DOI 10.1172/JCI63539; Hu TH, 2003, CANCER, V97, P1929, DOI 10.1002/cncr.11266; Jors S, 2015, J CLIN INVEST, V125, P2445, DOI 10.1172/JCI78585; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang CC, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-2; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Lu TL, 2013, AM J PATHOL, V182, P975, DOI 10.1016/j.ajpath.2012.11.025; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Mu X, 2015, J CLIN INVEST, V125, P3891, DOI 10.1172/JCI77995; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Ping PH, 2016, ARCH BIOCHEM BIOPHYS, V604, P20, DOI 10.1016/j.abb.2016.06.001; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Sell S, 2008, J CLIN ONCOL, V26, P2800, DOI 10.1200/JCO.2007.15.5945; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Tsai WC, 2012, J CLIN INVEST, V122, P2884, DOI 10.1172/JCI63455; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tummala KS, 2017, CELL REP, V19, P584, DOI 10.1016/j.celrep.2017.03.059; Tummala KS, 2014, CANCER CELL, V26, P826, DOI 10.1016/j.ccell.2014.10.002; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Villanueva A, 2008, GASTROENTEROLOGY, V135, DOI DOI 10.1053/J.GASTR0.2008.08.008]; Xu H, 2010, HEPATOLOGY, V52, P1431, DOI 10.1002/hep.23818; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhou LD, 2010, MED ONCOL, V27, P255, DOI 10.1007/s12032-009-9201-4	57	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2018	188	11					2688	2702		10.1016/j.ajpath.2018.07.019			15	Pathology	Pathology	GZ0FK	WOS:000449036900022	30165041				2019-10-28	
J	Tack, V; Spans, L; Schuuring, E; Keppens, C; Zwaenepoel, K; Pauwels, P; Van Houdt, J; Dequeker, EMC				Tack, Veronique; Spans, Lien; Schuuring, Ed; Keppens, Cleo; Zwaenepoel, Karen; Pauwels, Patrick; Van Houdt, Jeroen; Dequeker, Elisabeth M. C.			Describing the Reportable Range Is Important for Reliable Treatment Decisions A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							LUNG-CANCER; GUIDELINES; PATHOLOGY; MUTATIONS; GEFITINIB; STANDARDS; ONCOLOGY; THERAPY; QUALITY	Because interpretation of next-generation sequencing (NGS) data remains challenging, optimization of the NGS process is needed to obtain correct sequencing results. Therefore, extensive validation and continuous monitoring of the quality is essential. NGS performance was compared with traditional detection methods and technical quality of nine NGS technologies was assessed. First, nine formalin-fixed, paraffin-embedded patient samples were analyzed by 114 laboratories by using different detection methods. No significant differences in performance were observed between analyses with NGS and traditional techniques. Second, two DNA control samples were analyzed for a selected number of variants by 26 participants with the use of nine different NGS technologies. Quality control metrics were analyzed from raw data files and a survey about routine procedures. Results showed large differences in coverages, but observed variant allele frequencies in raw data files were in line with predefined variant allele frequencies. Many false negative results were found because of low-quality regions, which were not reported as such. It is recommended to disclose the reportable range, the fraction of targeted genomic regions for which calls of acceptable quality can be generated, to avoid any errors in therapy decisions. NGS can be a reliable technique, only if essential quality control during analysis is applied and reported.	[Tack, Veronique; Keppens, Cleo; Dequeker, Elisabeth M. C.] Univ Leuven, Biomed Qual Assurance Res Unit, Leuven, Belgium; [Spans, Lien] Univ Leuven, Dept Publ Hlth & Primary Care, Ctr Human Genet, Leuven, Belgium; [Schuuring, Ed] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands; [Zwaenepoel, Karen] Univ Hosp Antwerp, Dept Pathol, Edegem, Belgium; [Pauwels, Patrick] Univ Antwerp, Ctr Oncol Res CORE, Antwerp, Belgium; [Van Houdt, Jeroen] Univ Hosp Leuven, Genom Core, Leuven, Belgium; [Dequeker, Elisabeth M. C.] Univ Hosp Leuven, Dept Med Diagnost, Leuven, Belgium	Dequeker, EMC (reprint author), Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Biomed Qual Assurance Res Unit, Kapucijnenvoer 35 Blok D, B-3000 Leuven, Belgium.	els.dequeker@kuleuven.be		Keppens, Cleo/0000-0002-4498-8386	RocheRoche Holding; Biocartis; PfizerPfizer; BMSBristol-Myers Squibb	V.T. has received speaker fees from Qiagen. E.S. performed lectures for Illumina, Novartis, Pfizer, BioCartis; is consultant on advisory boards for Astra ineca, Pfizer, Novartis, BioCartis; and received financial support from Roche, Biocartis, BMS, and Pfizer (all fees to the Institution). Horizon Discovery and Thermo Fisher Scientific provided DNA control material to the participating laboratories. Illumina, Multiplicom, Roche, Thermo Fisher Scientific, and Qiagen provided reagents to the participating laboratories.	Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Betge J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127146; Cagle PT, 2016, ADV EXP MED BIOL, V890, P25, DOI 10.1007/978-3-319-24932-2_2; Chang FQ, 2013, CANCER GENET-NY, V206, P413, DOI 10.1016/j.cancergen.2013.10.003; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Froyen G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154038; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Gonzalez-Garay ML, 2014, PERS MED, V11, P523, DOI 10.2217/PME.14.34; Hagemann IS, 2013, CANCER GENET-NY, V206, P420, DOI 10.1016/j.cancergen.2013.11.003; Hardwick SA, 2017, NAT REV GENET, V18, P473, DOI 10.1038/nrg.2017.44; Hinrichs JWJ, 2015, AM J CLIN PATHOL, V143, P573, DOI 10.1309/AJCP40XETVYAMJPY; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Keppens Cleo, 2018, Oncotarget, V9, P20524, DOI 10.18632/oncotarget.24980; Liu J, 2016, ONCOTARGETS THER, V9, P557, DOI 10.2147/OTT.S86966; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malde K, 2011, BIOINFORMATICS, V27, P1041, DOI 10.1093/bioinformatics/btr063; Martinez DA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000906; Matthijs G, 2016, EUR J HUM GENET, V24, P2, DOI 10.1038/ejhg.2015.226; McCourt CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069604; Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006; OECD, 2007, GUID QUAL ASS MOL GE; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Quinlan AR, 2014, CURR PROTOC BIOINFOR, V47; Renfro LA, 2017, CANCER LETT, V387, P121, DOI 10.1016/j.canlet.2016.03.015; Ross JS, 2011, AM J CLIN PATHOL, V136, P527, DOI 10.1309/AJCPR1SVT1VHUGXW; Shao D, 2016, SCI REP-UK, V6, DOI 10.1038/srep22338; Strom SP, 2014, GENET MED, V16, P510, DOI 10.1038/gim.2013.183; van Krieken JH, 2013, VIRCHOWS ARCH, V462, P27, DOI 10.1007/s00428-012-1354-4; Weiss MM, 2013, HUM MUTAT, V34, P1313, DOI 10.1002/humu.22368	30	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					743	753		10.1016/j.jmoldx.2018.06.006			11	Pathology	Pathology	GY5RC	WOS:000448637200003	30055348				2019-10-28	
J	Vendrell, JA; Vilquin, P; Larrieux, M; Van Goethem, C; Solassol, J				Vendrell, Julie A.; Vilquin, Paul; Larrieux, Marion; Van Goethem, Charles; Solassol, Jerome			Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							OVARIAN-CANCER; BREAST-CANCER; HEREDITARY BREAST; DIAGNOSIS; OLAPARIB; WORKFLOW; GENES; MUTATIONS; CANDIDATE; VARIANTS	The recent deployment of next-generation sequencing approaches in routine laboratory analysis has considerably modified the landscape of BRCA1 and BRCA2 germline alteration detection in patients with a high risk of developing breast and/or ovarian cancer. Several commercial multiplex amplicon-based panels and bioinformatics solutions are currently available. In this study, we evaluated the combinations of several BRCA testing assays and bioinformatics solutions for the identification of single-nucleotide variants, insertion/deletion variants, and copy number variations (CNVs). Four assays (BRCA Tumor, BRCA HC, Ion AmpliSeq BRCA, and Access Array BRCA) and two commercial bioinformatics solutions (SeqNext software version 4.3.1 and Sophia DDM version 5.0.13) were tested on a set of 28 previously genotyped samples. All solutions exhibited accurate detection of single-nucleotide variants and insertion/deletion variants, except for Ion AmpliSeq BRCA, which exhibited a decrease in coverage. Of interest, for CNV analysis, the best accuracy was observed with the Sophia DDM platform regardless of the BRCA kit used. Finally, the performance of the most relevant combination (BRCA Tumor and Sophia DDM) was blindly validated on an independent set of 152 samples. Altogether, our results emphasize the need to accurately compare and control both molecular next-generation sequencing approaches and bioinformatics pipelines to limit the number of discrepant alterations and to provide a powerful tool for reliable detection of genetic alterations in BRCA1 and BRCA2, notably CNVs.	[Vendrell, Julie A.; Vilquin, Paul; Larrieux, Marion; Van Goethem, Charles; Solassol, Jerome] CHU Montpellier, Solid Tumor Lab, Dept Pathol & Oncobiol, Montpellier, France; [Solassol, Jerome] Univ Montpellier, INSERM, U1194, Montpellier, France	Solassol, J (reprint author), CHU Montpellier, Solid Tumor Lab, Arnaud de Villeneuve Hosp, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier, France.	j-solassol@chu-montpellier.fr	Vendrell, Julie/I-5867-2012	Vendrell, Julie/0000-0002-2071-6634	Simone and Gustave Prevot Foundation	Supported by the Simone and Gustave Prevot Foundation.	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Badoer C, 2016, ONCOTARGET, V7, P81357, DOI 10.18632/oncotarget.12877; Balmana J, 2011, ANN ONCOL, V22, pvi31, DOI 10.1093/annonc/mdr373; Bosdet IE, 2013, J MOL DIAGN, V15, P796, DOI 10.1016/j.jmoldx.2013.07.004; Buzolin AL, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0110-x; Capone GL, 2018, J MOL DIAGN, V20, P87, DOI 10.1016/j.jmoldx.2017.09.005; Caputo S, 2012, NUCLEIC ACIDS RES, V40, pD992, DOI 10.1093/nar/gkr1160; Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Chong HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097408; D'Argenio V, 2015, CLIN CHIM ACTA, V446, P221, DOI 10.1016/j.cca.2015.03.045; Daly MB, 2014, J NATL COMPR CANC NE, V12, P1326, DOI 10.6004/jnccn.2014.0127; Ellison G, 2015, BMC CLIN PATHOL, V15, DOI 10.1186/s12907-015-0004-6; Enyedi MZ, 2016, ONCOTARGET, V7, P61845, DOI 10.18632/oncotarget.11259; Feliubadalo L, 2013, EUR J HUM GENET, V21, P864, DOI 10.1038/ejhg.2012.270; Fraile-Bethencourt E, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006691; Houdayer C, 2012, HUM MUTAT, V33, P1228, DOI 10.1002/humu.22101; Koczkowska M, 2016, CANCER MED-US, V5, P1640, DOI 10.1002/cam4.748; Kwong A, 2015, CANCER GENET-NY, V208, P448, DOI 10.1016/j.cancergen.2015.05.031; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470-2045(16)30376-X; Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198; MathieuDaude F, 1996, NUCLEIC ACIDS RES, V24, P2080, DOI 10.1093/nar/24.11.2080; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Park HS, 2017, ANN SURG TREAT RES, V92, P331, DOI 10.4174/astr.2017.92.5.331; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Ruiz A, 2014, BIOMED RES INT, DOI 10.1155/2014/542541; Sanz DJ, 2010, CLIN CANCER RES, V16, P1957, DOI 10.1158/1078-0432.CCR-09-2564; Shin S, 2016, BREAST CANCER RES TR, V158, P433, DOI 10.1007/s10549-016-3891-z; Spurdle AB, 2008, HUM MUTAT, V29, P1304, DOI 10.1002/humu.20901; Strom CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136419; Tarabeux J, 2014, EUR J HUM GENET, V22, P535, DOI 10.1038/ejhg.2013.181; Vallee MP, 2012, HUM MUTAT, V33, P22, DOI 10.1002/humu.21629; Wallace AJ, 2016, EUR J HUM GENET, V24, pS10, DOI 10.1038/ejhg.2016.94; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zanella I, 2017, EXP MOL PATHOL, V102, P314, DOI 10.1016/j.yexmp.2017.03.001	37	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					754	764		10.1016/j.jmoldx.2018.06.003			11	Pathology	Pathology	GY5RC	WOS:000448637200004	30055349				2019-10-28	
J	DiStefano, MT; Hemphill, SE; Cushman, BJ; Bowser, MJ; Hynes, E; Grant, AR; Siegert, RK; Oza, AM; Gonzalez, MA; Amr, SS; Rehm, HL; Abou Tayoun, AN				DiStefano, Marina T.; Hemphill, Sarah E.; Cushman, Brandon J.; Bowser, Mark J.; Hynes, Elizabeth; Grant, Andrew R.; Siegert, Rebecca K.; Oza, Andrea M.; Gonzalez, Michael A.; Amr, Sami S.; Rehm, Heidi L.; Abou Tayoun, Ahmad N.			Curating Clinically Relevant Transcripts for the Interpretation of Sequence Variants	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							NONSYNDROMIC HEARING IMPAIRMENT; AUTOSOMAL RECESSIVE DEAFNESS; WAARDENBURG SYNDROME TYPE-2; HAIR CELL STEREOCILIA; INNER-EAR; GENOMIC STRUCTURE; HIRSCHSPRUNG DISEASE; MOLECULAR-PATHOLOGY; ENDOTHELIN-3 GENE; AMERICAN-COLLEGE	Variant interpretation depends on accurate annotations using biologically relevant transcripts. We have developed a systematic strategy for designating primary transcripts and have applied it to 109 hearing loss associated genes that were divided into three categories. Category 1 genes (n = 38) had a single transcript; category 2 genes (n = 33) had multiple transcripts, but a single transcript was sufficient to represent all exons; and category 3 genes (n = 38) had multiple transcripts with unique exons. Transcripts were curated with respect to gene expression reported in the literature and the Genotype-Tissue Expression Project. In addition, high-frequency loss-of-function variants in the Genome Aggregation Database and disease-causing variants in ClinVar and the Human Gene Mutation Database across the 109 genes were queried. These data were used to classify exons as clinically significant, insignificant, or of uncertain significance. Interestingly, 6% of all exons, containing 124 reportedly disease-causing variants, were of uncertain significance. Finally, we used exon-level next-generation sequencing quality metrics generated at two clinical laboratories and identified a total of 43 technically challenging exons in 20 different genes that had inadequate coverage and/or homology issues that might lead to false-variant calls. We have demonstrated that transcript analysis plays a critical role in accurate clinical variant interpretation.	[DiStefano, Marina T.; Hemphill, Sarah E.; Cushman, Brandon J.; Bowser, Mark J.; Hynes, Elizabeth; Grant, Andrew R.; Siegert, Rebecca K.; Oza, Andrea M.; Amr, Sami S.; Rehm, Heidi L.] Partners Healthcare Personalized Med, Mol Med Lab, Cambridge, MA USA; [Gonzalez, Michael A.; Abou Tayoun, Ahmad N.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Genom Diagnost, Philadelphia, PA 19104 USA; [Amr, Sami S.] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Rehm, Heidi L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Rehm, Heidi L.] Broad Inst MIT & Harvard, Dept Med & Populat Genet, Cambridge, MA 02142 USA; [Abou Tayoun, Ahmad N.] Al Jalila Childrens Specialty Hosp, Dept Genet, Dubai, U Arab Emirates	Abou Tayoun, AN (reprint author), Al Jalila Childrens Hosp, POB 7662, Al Jaddaf, Dubai, U Arab Emirates.	ahmad.tayoun@ajch.ae		Duffy Hynes, Elizabeth/0000-0002-3817-2145	National Human Genome Research InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI); Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U41HG006834]	Supported in part by the National Human Genome Research Institute, in conjunction with additional funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award U41HG006834 (H.L.R.).	Abou Tayoun AN, 2016, GENET MED, V18, P545, DOI 10.1038/gim.2015.141; Adato A, 2005, HUM MOL GENET, V14, P3921, DOI 10.1093/hmg/ddi416; Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831; Ahituv N, 2000, GENE, V261, P269, DOI 10.1016/S0378-1119(00)00535-7; Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Ahmed ZM, 2008, NAT GENET, V40, P1335, DOI 10.1038/ng.245; Ahmed ZM, 2011, AM J HUM GENET, V88, P19, DOI 10.1016/j.ajhg.2010.11.010; Aken BL, 2017, NUCLEIC ACIDS RES, V45, pD635, DOI 10.1093/nar/gkw1104; Alagramam KN, 2001, HUM MOL GENET, V10, P1709, DOI 10.1093/hmg/10.16.1709; Alagramam KN, 2007, GENOMICS, V90, P482, DOI 10.1016/j.ygeno.2007.06.007; Alford RL, 2014, GENET MED, V16, P347, DOI 10.1038/gim.2014.2; Azaiez H, 2014, HUM MUTAT, V35, P819, DOI 10.1002/humu.22557; Bahloul A, 2010, HUM MOL GENET, V19, P3557, DOI 10.1093/hmg/ddq271; Baig SM, 2011, NAT NEUROSCI, V14, P77, DOI 10.1038/nn.2694; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Beisel KW, 2005, J NEUROSCI, V25, P9285, DOI 10.1523/JNEUROSCI.2110-05.2005; Blake JA, 2005, DEV GROWTH DIFFER, V47, P627; Borck G, 2011, AM J HUM GENET, V88, P127, DOI 10.1016/j.ajhg.2010.12.011; Campeau PM, 2014, LANCET NEUROL, V13, P44, DOI 10.1016/S1474-4422(13)70265-5; Casper J, 2018, NUCLEIC ACIDS RES, V46, pD762, DOI 10.1093/nar/gkx1020; Chen L, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0273-2; Cheng J, 2011, AM J HUM GENET, V89, P56, DOI 10.1016/j.ajhg.2011.05.027; Choi BY, 2009, CLIN GENET, V75, P237, DOI 10.1111/j.1399-0004.2008.01128.x; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; Cui L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066631; Delmaghani S, 2006, NAT GENET, V38, P770, DOI 10.1038/ng1829; den Dunnen JT, 2016, HUM MUTAT, V37, P564, DOI 10.1002/humu.22981; Diaz-Horta O, 2014, P NATL ACAD SCI USA, V111, P9864, DOI 10.1073/pnas.1401950111; Duzkale H, 2013, CLIN GENET, V84, P453, DOI 10.1111/cge.12257; Ebrahim S, 2016, CELL REP, V15, P935, DOI 10.1016/j.celrep.2016.03.081; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; Falace A, 2010, AM J HUM GENET, V87, P365, DOI 10.1016/j.ajhg.2010.07.020; Gagnon LH, 2006, J NEUROSCI, V26, P10188, DOI 10.1523/JNEUROSCI.2166-06.2006; Grati M, 2012, J NEUROSCI, V32, P14288, DOI 10.1523/JNEUROSCI.3071-12.2012; Grifa A, 1999, NAT GENET, V23, P16; Grillet N, 2009, AM J HUM GENET, V85, P328, DOI 10.1016/j.ajhg.2009.07.017; Guven A, 2013, J MED GENET, V50, P199, DOI 10.1136/jmedgenet-2012-101313; Haraksingh RR, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1155; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hershey CL, 2005, GENE, V347, P73, DOI 10.1016/j.gene.2004.12.002; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; Housley GD, 1999, J NEUROSCI, V19, P8377; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kelley PM, 1997, GENOMICS, V40, P73, DOI 10.1006/geno.1996.4545; Khan SY, 2007, HUM MUTAT, V28, P417, DOI 10.1002/humu.20469; Khateb S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051566; Lagziel A, 2009, MOL VIS, V15, P1843; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Lynch KJ, 1999, MOL PHARMACOL, V56, P1171; Mathur PD, 2015, HUM MOL GENET, V24, P6213, DOI 10.1093/hmg/ddv339; Modamio-Hoybjor S, 2007, AM J HUM GENET, V80, P1076, DOI 10.1086/518311; Monsoro-Burq AH, 2015, SEMIN CELL DEV BIOL, V44, P87, DOI 10.1016/j.semcdb.2015.09.015; Nakane T, 2000, BIOCHEM BIOPH RES CO, V273, P759, DOI 10.1006/bbrc.2000.3004; Namburi P, 2016, AM J HUM GENET, V99, P777, DOI 10.1016/j.ajhg.2016.07.010; Niazi R, 2018, BIORXIV, DOI [10.1101/248906, DOI 10.1101/248906]; Nyegaard M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005386; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Pruitt KD, 2009, GENOME RES, V19, P1316, DOI 10.1101/gr.080531.108; Rehman AU, 2014, AM J HUM GENET, V94, P144, DOI 10.1016/j.ajhg.2013.12.004; Riazuddin S, 2006, AM J HUM GENET, V79, P1040, DOI 10.1086/510022; Riazuddin S, 2012, NAT GENET, V44, P1265, DOI 10.1038/ng.2426; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Robertson NG, 1997, GENOMICS, V46, P345, DOI 10.1006/geno.1997.5067; Robertson NG, 2001, HUM MOL GENET, V10, P2493, DOI 10.1093/hmg/10.22.2493; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Sanchez-Mejias A, 2010, GENET MED, V12, P39, DOI 10.1097/GIM.0b013e3181c371b0; Santos-Cortez RLP, 2014, HUM MOL GENET, V23, P3289, DOI 10.1093/hmg/ddu042; Santos-Cortez RLP, 2013, AM J HUM GENET, V93, P132, DOI 10.1016/j.ajhg.2013.05.018; Schneider E, 2009, HUM MOL GENET, V18, P655, DOI 10.1093/hmg/ddn395; Schraders M, 2012, AM J HUM GENET, V91, P883, DOI 10.1016/j.ajhg.2012.09.012; Schultz JM, 2009, AM J HUM GENET, V85, P25, DOI 10.1016/j.ajhg.2009.06.003; Scott HS, 2001, NAT GENET, V27, P59; Seco CZ, 2015, AM J HUM GENET, V97, P647, DOI 10.1016/j.ajhg.2015.09.011; Shi YF, 2016, EXP THER MED, V11, P1516, DOI 10.3892/etm.2016.3042; Song J, 2016, CLIN GENET, V89, P416, DOI 10.1111/cge.12631; Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12; Thoenes M, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0238-5; TSUKAMOTO K, 1994, HUM GENET, V93, P270, DOI 10.1007/BF00212021; Van Laer L, 1998, NAT GENET, V20, P194; Vastinsalo H, 2011, EUR J HUM GENET, V19, P30, DOI 10.1038/ejhg.2010.140; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Wang YF, 2016, FRONT MED-PRC, V10, P250, DOI 10.1007/s11684-016-0454-y; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8; Xu TH, 2007, J BIOL CHEM, V282, P23899, DOI 10.1074/jbc.M702108200; Yang J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000955; Zhang LP, 2014, HUM MUTAT, V35, P814, DOI 10.1002/humu.22558; Zhao B, 2016, ELIFE, V5, DOI 10.7554/eLife.14222; Zwaenepoel I, 2002, P NATL ACAD SCI USA, V99, P6240, DOI 10.1073/pnas.082515999	95	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					789	801		10.1016/j.jmoldx.2018.06.005			13	Pathology	Pathology	GY5RC	WOS:000448637200007	30096381				2019-10-28	
J	Chun, SM; Sung, CO; Jeon, H; Kim, TI; Lee, JY; Park, H; Kim, Y; Kim, D; Jang, SJ				Chun, Sung-Min; Sung, Chang Ohk; Jeon, Hyejoon; Kim, Tae-Im; Lee, Ji-Young; Park, Hwan; Kim, Yujin; Kim, Deokhoon; Jang, Se Jin			Next-Generation Sequencing Using S1 Nuclease for Poor-Quality Formalin-Fixed, Paraffin-Embedded Tumor Specimens	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							DNA-DAMAGE; MUTATIONS; FRAMEWORK	Next-generation sequencing (NGS) testing of formalin-fixed, paraffin-embedded (FFPE) tissues is widely used in clinical diagnosis. However, the failure of high-quality DNA library construction, a critical step for NGS, often limits NGS application for FFPE tissues, particularly for old FFPE tissues. The aim was to develop a high-quality DNA library construction method optimized for NGS of FFPE specimens. DNA library construction was developed for FFPE specimens by using S1 nuclease and compared with the Covaris method-the widely accepted DNA library construction protocol. The Covaris method includes a DNA shearing step with sonication to generate shortened DNA fragments. DNA shearing was found to be unnecessary, and S1 nuclease treatment only during genomic DNA extraction significantly improved the success rate of library construction from FFPE tissues. Moreover, poor-quality FFPE tissues that failed the Covaris method were rescued with the S1 method. Higher complexity was observed in DNA libraries constructed by the S1 method. Among 223 FFPE specimens, DNA libraries were successfully constructed for 134 cases with the Covaris method (60.0% success rate), whereas the success rate was 86.5% (193 of 223) with the S1 method (P = 5.255e(-10)). Furthermore, we were able to rescue 59 samples, including 25 primary lung cancers, from the 89 failed Covaris method cases. In conclusion, the S1 method is optimal for NGS testing of poor-quality FFPE specimens.	[Chun, Sung-Min; Sung, Chang Ohk; Kim, Deokhoon; Jang, Se Jin] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 05505, South Korea; [Sung, Chang Ohk; Jeon, Hyejoon; Kim, Tae-Im; Lee, Ji-Young; Park, Hwan; Kim, Yujin; Kim, Deokhoon; Jang, Se Jin] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Canc Genome Discovery,Asan Inst Life Sci, Seoul, South Korea	Chun, SM; Jang, SJ (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 05505, South Korea.	smchun@amc.seoul.kr; jangsejin@amc.seoul.kr		Sung, Chang Ohk/0000-0002-8567-456X	Leading Foreign Research Institute Recruitment Program of the National Research Foundation of Korea (NRFK) - Ministry of Education, Science, and Technology (MEST) [NRF-2011-0030105]; Basic Science Research Program of the NRFK - Ministry of Education [NRF-2015R1D1A1A01056895]; Post-Genome Technology Development Program - Ministry of Trade, Industry and Energy (MOTIE) [10053582]; Bio & Medical Technology Development Program of the NRFK - Korean government [NRF-2017M3A9G5061671, NRF-2017M3A9G5061673]	Supported by the Leading Foreign Research Institute Recruitment Program of the National Research Foundation of Korea (NRFK) funded by the Ministry of Education, Science, and Technology (MEST) grant NRF-2011-0030105 (S.J.J.), the Basic Science Research Program of the NRFK funded by the Ministry of Education grant NRF-2015R1D1A1A01056895 (S.-M.C.), the Post-Genome Technology Development Program grant 10053582 funded by the Ministry of Trade, Industry and Energy (MOTIE), and the Bio & Medical Technology Development Program of the NRFK funded by the Korean government grants NRF-2017M3A9G5061671 (S.-M.C.) and NRF-2017M3A9G5061673 (C.O.S.).	Arcila M, 2011, J MOL DIAGN, V13, P64, DOI 10.1016/j.jmoldx.2010.11.005; Chen LX, 2017, SCIENCE, V355, P752, DOI 10.1126/science.aai8690; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Douglas MP, 1998, MUTAT RES-FUND MOL M, V401, P77, DOI 10.1016/S0027-5107(97)00314-X; Head SR, 2014, BIOTECHNIQUES, V56, P61, DOI 10.2144/000114133; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MacConaill LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007887; MacMillan AM, 2001, J CHEM SOC PERK T 2, P1263, DOI 10.1039/b103013m; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Patel PG, 2016, JOVE-J VIS EXP, DOI 10.3791/54299; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Strom SP, 2016, CANCER BIOL MED, V13, P3, DOI 10.28092/j.issn.2095-3941.2016.0004; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43	17	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					802	811		10.1016/j.jmoldx.2018.06.002			10	Pathology	Pathology	GY5RC	WOS:000448637200008	30055350	Bronze			2019-10-28	
J	Balla, A; Hampel, KJ; Sharma, MK; Cottrell, CE; Sidiropoulos, N				Balla, Agnes; Hampel, Ken J.; Sharma, Mukesh K.; Cottrell, Catherine E.; Sidiropoulos, Nikoletta			Comprehensive Validation of Cytology Specimens for Next-Generation Sequencing and Clinical Practice Experience	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CELL LUNG-CANCER; NEEDLE-ASPIRATION BIOPSY; OF-AMERICAN-PATHOLOGISTS; GROWTH-FACTOR RECEPTOR; KINASE INHIBITORS GUIDELINE; MOLECULAR TESTING GUIDELINE; INTERNATIONAL-ASSOCIATION; MUTATION STATUS; SAMPLES; EGFR	Biopsy specimens are subjected to an expanding portfolio of assays that regularly include mutation profiling via next-generation sequencing (NGS). Specimens derived via fine-needle aspiration, a common biopsy technique, are subjected to a variety of cytopreparatory methods compared with surgical biopsies that are almost uniformly processed as formalin-fixed, paraffin-embedded tissue. Therefore, the fine-needle aspiration-derived specimens most commonly accepted for molecular analysis are cell blocks (CBs), because they are processed most similarly to surgical biopsy tissue. However, CB preparations are fraught with challenges that risk unsuccessful sequencing and repeat biopsies, with the potential to further increase health care costs and delay clinical care. The diversity of cytopreparations and the resource-intensive clinical validation of NGS pose significant challenges to more consistent use of non-CB (NCB) cytology specimens. As part of clinical validation of a targeted NGS assay, DNA subjected to nine cytopreparatory methods was evaluated for sequencing performance and was shown to be uniformly acceptable for clinical NGS. Of the 379 clinical cases analyzed after validation, the majority (56%) were derived from NCB cytology specimens. This specimen class had the lowest DNA insufficiency rate (1.5%) and showed equivalent sequencing performance to surgical and CB formalin-fixed, paraffin-embedded tissue. NCB cytology specimens are valuable sources of tumor nucleic acid and are the preferred specimen type for clinical NGS at our institution.	[Balla, Agnes; Hampel, Ken J.; Sidiropoulos, Nikoletta] Univ Vermont, Med Ctr, Dept Pathol & Lab Med, Burlington, VT USA; [Sharma, Mukesh K.; Cottrell, Catherine E.] Washington Univ, Sch Med, Dept Pathol & Immunol, Genom Serv, St Louis, MO USA; [Sharma, Mukesh K.; Cottrell, Catherine E.] Washington Univ, Sch Med, Dept Pathol & Immunol, Pathol Serv, St Louis, MO USA; [Sidiropoulos, Nikoletta] Univ Vermont, Larner Coll Med, Dept Pathol & Lab Med, Burlington, VT USA	Sidiropoulos, N (reprint author), 111 Colchester Ave,Mailstop 233MP1, Burlington, VT 05401 USA.	nikoletta.sidiropoulos@uvmhealth.org			Department of Pathology and Laboratory Medicine, University of Vermont Health Network	Supported by the Department of Pathology and Laboratory Medicine, University of Vermont Health Network.	Abedi-Ardekani B, 2014, ACTA CYTOL, V58, P574, DOI 10.1159/000366260; Betz BL, 2011, AM J CLIN PATHOL, V136, P564, DOI 10.1309/AJCP84TUTQOSUONG; Billah S, 2011, CANCER CYTOPATHOL, V119, P111, DOI 10.1002/cncy.20151; Boldrini L, 2007, J THORAC ONCOL, V2, P1086, DOI 10.1097/JTO.0b013e31815ba1fa; BRUTLAG D, 1969, BIOCHEMISTRY-US, V8, P3214, DOI 10.1021/bi00836a013; Buttitta F, 2013, CLIN CANCER RES, V19, P691, DOI 10.1158/1078-0432.CCR-12-1958; Carter JH, 2017, J MOL DIAGN, V19, P328, DOI 10.1016/j.jmoldx.2016.10.010; Centeno BA, 2005, CANCER CYTOPATHOL, V105, P101, DOI 10.1002/cncr.20737; Clark DP, 2009, CANCER CYTOPATHOL, V117, P289, DOI 10.1002/cncy.20045; Crapanzano JP, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.129187; Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; de Biase D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087651; Dejmek A, 2013, CANCER CYTOPATHOL, V121, P344, DOI 10.1002/cncy.21276; Fairley JA, 2012, CURR DRUG TARGETS, V13, P1475; Feldman M Y, 1973, Prog Nucleic Acid Res Mol Biol, V13, P1, DOI 10.1016/S0079-6603(08)60099-9; Gailey MP, 2015, CANCER CYTOPATHOL, V123, P30, DOI 10.1002/cncy.21476; Greenhalgh J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010383.pub2; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Jain D, 2014, CYTOPATHOLOGY, V25, P356, DOI 10.1111/cyt.12174; Kanagal-Shamanna R, 2014, MODERN PATHOL, V27, P314, DOI 10.1038/modpathol.2013.122; Karmakar S, 2015, NAT CHEM, V7, P752, DOI [10.1038/nchem.2307, 10.1038/NCHEM.2307]; Karnes HE, 2014, CANCER CYTOPATHOL, V122, P104, DOI 10.1002/cncy.21361; Killian JK, 2010, J MOL DIAGN, V12, P739, DOI 10.2353/jmoldx.2010.090238; Knoepp SM, 2013, CANCER CYTOPATHOL, V121, P120, DOI 10.1002/cncy.21214; Ko HM, 2017, CYTOPATHOLOGY, V28, P221, DOI 10.1111/cyt.12419; Krishnamurthy S, 2007, CANCER CYTOPATHOL, V111, P106, DOI 10.1002/cncr.22489; Levy BP, 2015, ONCOLOGIST, V20, P1175, DOI 10.1634/theoncologist.2015-0114; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Lindeman NI, 2013, J THORAC ONCOL, V8, P823, DOI 10.1097/JTO.0b013e318290868f; Lozano MD, 2018, ARCH PATHOL LAB MED, V142, P291, DOI 10.5858/arpa.2017-0208-RA; Lozano MD, 2011, ONCOLOGIST, V16, P877, DOI 10.1634/theoncologist.2010-0155; Mattu R, 2004, MODERN PATHOL, V17, P1295, DOI 10.1038/modpathol.3800185; Nagel H, 2002, MODERN PATHOL, V15, P818, DOI 10.1097/01.MP.0000024521.67720.0F; Petriella D, 2013, MOL BIOTECHNOL, V54, P913, DOI 10.1007/s12033-012-9640-6; Rekhtman N, 2016, ARCH PATHOL LAB MED, V140, P1189, DOI 10.5858/arpa.2016-0379-ED; Roh MH, 2015, J PATHOL TRANSL MED, V49, P300, DOI 10.4132/jptm.2015.06.16; Roy-Chowdhuri S, 2017, MODERN PATHOL, V30, P499, DOI 10.1038/modpathol.2016.228; Roy-Chowdhuri S, 2015, CANCER CYTOPATHOL, V123, P659, DOI 10.1002/cncy.21597; Santos GD, 2015, CANCER CYTOPATHOL, V123, P633, DOI 10.1002/cncy.21595; Santos GD, 2011, CANCER CYTOPATHOL, V119, P80, DOI 10.1002/cncy.20150; Savic S, 2008, BRIT J CANCER, V98, P154, DOI 10.1038/sj.bjc.6604142; Scarpa A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080478; Smouse JH, 2009, CANCER CYTOPATHOL, V117, P67, DOI 10.1002/cncy.20011; Treece AL, 2016, CANCER CYTOPATHOL, V124, P406, DOI 10.1002/cncy.21699; Volmar KE, 2015, ARCH PATHOL LAB MED, V139, P1115, DOI 10.5858/arpa.2014-0513-CP; Young G, 2013, CANCER CYTOPATHOL, V121, P688, DOI 10.1002/cncy.21338	46	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					812	821		10.1016/j.jmoldx.2018.06.001			10	Pathology	Pathology	GY5RC	WOS:000448637200009	29981866				2019-10-28	
J	Wrzeszczynski, KO; Felice, V; Abhyankar, A; Kozon, L; Geiger, H; Manaa, D; London, F; Robinson, D; Fang, X; Lin, D; Lanzendola-Essel, MF; Khaira, D; Dikoglu, E; Emde, AK; Robine, N; Shah, M; Arora, K; Basturk, O; Bhanot, U; Kentsis, A; Mansukhani, MM; Bhagat, G; Jobanputra, V				Wrzeszczynski, Kazimierz O.; Felice, Vanessa; Abhyankar, Avinash; Kozon, Lukasz; Geiger, Heather; Manaa, Dina; London, Farrah; Robinson, Dino; Fang, Xiaolan; Lin, David; Lanzendola-Essel, Michelle F.; Khaira, Depinder; Dikoglu, Esra; Emde, Anne-Katrin; Robine, Nicolas; Shah, Minita; Arora, Kanika; Basturk, Olca; Bhanot, Umesh; Kentsis, Alex; Mansukhani, Mahesh M.; Bhagat, Govind; Jobanputra, Vaidehi			Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							FOR-MOLECULAR-PATHOLOGY; COPY NUMBER ANALYSIS; PAIRED-END; STRUCTURAL VARIATION; PRECISION MEDICINE; METASTATIC CANCER; NCI-MPACT; TRIAL; MUTATIONS; ONCOLOGY	We developed and validated a clinical whole-genome and transcriptome sequencing (WGTS) assay that provides a comprehensive genomic profile of a patient's tumor. The ability to fully capture the mappable genome with sufficient sequencing coverage to precisely call DNA somatic single nucleotide variants, insertions/deletions, copy number variants, structural variants, and RNA gene fusions was analyzed. New York State's Department of Health next-generation DNA sequencing guidelines were expanded for establishing performance validation applicable to whole-genome and transcriptome sequencing. Whole-genome sequencing laboratory protocols were validated for the Illumina HiSeq X Ten platform and RNA sequencing for Illumina HiSeq2500 platform for fresh or frozen and formalin-fixed, paraffin-embedded tumor samples. Various bioinformatics tools were also tested, and CIs for sensitivity and specificity thresholds in calling clinically significant somatic aberrations were determined. The validation was performed on a set of 125 tumor normal pairs. RNA sequencing was performed to call fusions and to confirm the DNA variants or exonic alterations. Here, we present our results and WGTS standards for variant allele frequency, reproducibility, analytical sensitivity, and present limit of detection analysis for single nucleotide variant calling, copy number identification, and structural variants. We show that The New York Genome Center WGTS clinical assay can provide a comprehensive patient variant discovery approach suitable for directed oncologic therapeutic applications.	[Wrzeszczynski, Kazimierz O.; Felice, Vanessa; Abhyankar, Avinash; Kozon, Lukasz; Geiger, Heather; Manaa, Dina; London, Farrah; Robinson, Dino; Fang, Xiaolan; Lin, David; Lanzendola-Essel, Michelle F.; Khaira, Depinder; Dikoglu, Esra; Emde, Anne-Katrin; Robine, Nicolas; Shah, Minita; Arora, Kanika; Jobanputra, Vaidehi] New York Genome Ctr, 101 Ave Amer, New York, NY 10013 USA; [Basturk, Olca; Bhanot, Umesh; Kentsis, Alex] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA; [Kentsis, Alex] Cornell Univ, Dept Pediat, Weill Cornell Med Coll, New York, NY 10021 USA; [Kentsis, Alex] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Mansukhani, Mahesh M.; Bhagat, Govind; Jobanputra, Vaidehi] Columbia Univ, Med Ctr, New York, NY USA	Wrzeszczynski, KO; Jobanputra, V (reprint author), New York Genome Ctr, 101 Ave Amer, New York, NY 10013 USA.	kwrzeszczynski@nygenome.org; vjobanputra@nygenome.org	Basturk, Olca/N-7214-2017	Basturk, Olca/0000-0003-2747-1366; Bhagat, Govind/0000-0001-6250-048X; Felice, Vanessa/0000-0002-0576-4101	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 CA008748]; Damon Runyon-Richard Lumsden Foundation	Supported in part by NIH grant P30 CA008748 (A.K.) and the Damon Runyon-Richard Lumsden Foundation (A.K.).	Aken BL, 2017, NUCLEIC ACIDS RES, V45, pD635, DOI 10.1093/nar/gkw1104; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Belkadi A, 2015, P NATL ACAD SCI USA, V112, P5473, DOI 10.1073/pnas.1418631112; Berardini TZ, 2010, NUCLEIC ACIDS RES, V38, pD331, DOI 10.1093/nar/gkp1018; Bergmann Ewa A, 2016, Bioinformatics, V32, P3196, DOI 10.1093/bioinformatics/btw389; Borad MJ, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0021-4; Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Cottrell CE, 2014, J MOL DIAGN, V16, P89, DOI 10.1016/j.jmoldx.2013.10.002; Coyne GO, 2017, CURR PROB CANCER, V41, P182, DOI 10.1016/j.currproblcancer.2017.02.001; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Emde AK, 2012, BIOINFORMATICS, V28, P619, DOI 10.1093/bioinformatics/bts019; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Griffith M, 2016, EXP HEMATOL, V44, P603, DOI 10.1016/j.exphem.2016.04.011; Ha G, 2014, GENOME RES, V24, P1881, DOI 10.1101/gr.180281.114; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kim S., 2017, BIORXIV, DOI [10.1101/192872, DOI 10.1101/192872]; Kroigard AB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151664; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Lih CJ, 2016, J MOL DIAGN, V18, P51, DOI 10.1016/j.jmoldx.2015.07.006; Linderman MD, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-20; Lopez-Chavez A, 2015, J CLIN ONCOL, V33, P1000, DOI 10.1200/JCO.2014.58.2007; Magi A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r120; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Narzisi G, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0023-9; Nicorici D., 2014, BIORXIV, DOI [10.1101/011650, DOI 10.1101/011650]; Petersen BS, 2017, BMC GENET, V18, DOI 10.1186/s12863-017-0479-5; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Rennert H, 2016, NPJ GENOM MED, V1, DOI 10.1038/npjgenmed.2016.19; Robbe P, 2018, GENET MED, V20, P1196, DOI 10.1038/gim.2017.241; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Samorodnitsky E, 2015, J MOL DIAGN, V17, P64, DOI 10.1016/j.jmoldx.2014.09.009; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Secrier M, 2016, NAT GENET, V48, P1131, DOI 10.1038/ng.3659; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Simon R, 2013, NAT REV DRUG DISCOV, V12, P359, DOI 10.1038/nrd3979; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wala JA, 2018, GENOME RES, V28, P581, DOI 10.1101/gr.221028.117; Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/NMETH.1628, 10.1038/nmeth.1628]; Wrzeszczynski KO, 2018, METHODS MOL BIOL, V1741, P1, DOI 10.1007/978-1-4939-7659-1_1; Wrzeszczynski KO, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000164; Xi RB, 2016, NUCLEIC ACIDS RES, V44, P6274, DOI 10.1093/nar/gkw491; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yohe SL, 2015, ARCH PATHOL LAB MED, V139, P1400, DOI 10.5858/arpa.2014-0568-CP; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang W, 2018, NAT GENET, V50, P613, DOI 10.1038/s41588-018-0091-2	59	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					822	835		10.1016/j.jmoldx.2018.06.007			14	Pathology	Pathology	GY5RC	WOS:000448637200010	30138725	Other Gold			2019-10-28	
J	Paradiso, V; Garofoli, A; Tosti, N; Lanzafame, M; Perrina, V; Quagliata, L; Matter, MS; Wieland, S; Heim, MH; Piscuoglio, S; Ng, CKY; Terracciano, LM				Paradiso, Viola; Garofoli, Andrea; Tosti, Nadia; Lanzafame, Manuela; Perrina, Valeria; Quagliata, Luca; Matter, Matthias S.; Wieland, Stefan; Heim, Markus H.; Piscuoglio, Salvatore; Ng, Charlotte K. Y.; Terracciano, Luigi M.			Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MUTATIONAL LANDSCAPE; MOLECULAR CLASSIFICATION; MALIGNANT-TRANSFORMATION; RECURRENT MUTATIONS; SOMATIC MUTATIONS; CANCER; VALIDATION; DISCOVERY	Commercially available targeted panels miss genomic regions frequently altered in hepatocellular carcinoma (HCC). We sought to design and benchmark a sequencing assay for genomic screening of HCC. We designed an AmpliSeq custom panel targeting all exons of 33 protein-coding and two long non coding RNA genes frequently mutated in HCC, TERT promoter, and nine genes with frequent copy number alterations. By using this panel, the profiling of DNA from fresh-frozen (n = 10, 1495x) and/or formalin-fixed, paraffin-embedded (FFPE) tumors with low-input DNA (n = 36, 530x) from 39 HCCs identified at least one somatic mutation in 900/0 of the cases. Median of 2.5 (range, 0 to 74) and 3 (range, 0 to 76) mutations were identified in fresh-frozen and FFPE tumors, respectively. Benchmarked against the mutations identified from Illumina whole-exome sequencing (WES) of the corresponding fresh-frozen tumors (105x), 98% (61 of 62) and 100% (104 of 104) of the mutations from WES were detected in the 10 fresh-frozen tumors and the 36 FFPE tumors, respectively, using the HCC panel. In addition, 18 and 70 somatic mutations in coding and noncoding genes, respectively, not found by WES were identified by using our HCC panel. Copy number alterations between WES and our HCC panel showed an overall concordance of 86%. In conclusion, we established a cost-effective assay for the detection of genomic alterations in HCC.	[Paradiso, Viola; Garofoli, Andrea; Tosti, Nadia; Lanzafame, Manuela; Perrina, Valeria; Quagliata, Luca; Matter, Matthias S.; Piscuoglio, Salvatore; Ng, Charlotte K. Y.; Terracciano, Luigi M.] Univ Hosp Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland; [Wieland, Stefan; Heim, Markus H.; Ng, Charlotte K. Y.] Univ Basel, Dept Biomed, Basel, Switzerland; [Heim, Markus H.] Univ Hosp Basel, Dept Gastroenterol & Hepatol, Basel, Switzerland	Terracciano, LM (reprint author), Univ Hosp Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland.	luigi.terracciano@usb.ch	Lanzafame, Manuela/Q-2353-2018; Piscuoglio, Salvatore/F-9248-2014	Lanzafame, Manuela/0000-0002-0456-1134; Matter, Matthias/0000-0002-2005-5266; Heim, Markus/0000-0002-7523-4894; Piscuoglio, Salvatore/0000-0003-2686-2939	Swiss Cancer League (Oncosuisse) [KLS-3639-02-2015, KFS-3995-08-2016]; Krebsliga beider Basel project [KLbB-4183-03-2017]; Swiss National Science Foundation Ambizione grant [PZ00P3_168165]; Swiss Centre for Applied Human Toxicology (SCAHT); European Research Council ERC Synergy grant [609883]	Supported in part by the Swiss Cancer League (Oncosuisse) grants KLS-3639-02-2015 (L.M.T.) and KFS-3995-08-2016 (S.P.), Krebsliga beider Basel project KLbB-4183-03-2017 (C.K.Y.N.), Swiss National Science Foundation Ambizione grant PZ00P3_168165 (S.P.), the Swiss Centre for Applied Human Toxicology (SCAHT; V.Pa.), and the European Research Council ERC Synergy grant 609883 (C.K.Y.N. and M.H.H.). V.Pa. and A.G. contributed equally to this work.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Chakravarty D, 2017, JCO PRECIS ONCOL 201; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Desert R, 2017, HEPATOLOGY, V66, P1502, DOI 10.1002/hep.29254; Farshidfar F, 2017, CELL REP, V19, P2878, DOI 10.1016/j.celrep.2017.06.008; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Fujimoto A, 2016, NAT GENET, V48, P500, DOI 10.1038/ng.3547; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Gao JJ, 2017, GENOME MED, V9, DOI 10.1186/s13073-016-0393-x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386; Goossens N, 2015, HEPAT ONCOL, V2, P371, DOI 10.2217/hep.15.26; Grasso C, 2015, J MOL DIAGN, V17, P53, DOI 10.1016/j.jmoldx.2014.09.008; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Jhunjhunwala S, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0436-9; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kancherla V, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00002; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Nault JC, 2017, GASTROENTEROLOGY, V152, P880, DOI 10.1053/j.gastro.2016.11.042; Ng CKY, 2018, ANN ONCOL, V29, P1286, DOI 10.1093/annonc/mdy083; Ng CKY, 2017, CLIN CANCER RES, V23, P3859, DOI 10.1158/1078-0432.CCR-16-2857; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pilati C, 2014, CANCER CELL, V25, P428, DOI 10.1016/j.ccr.2014.03.005; Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Seed G, 2017, CLIN CANCER RES, V23, P6070, DOI 10.1158/1078-0432.CCR-17-0972; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shiraishi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114263; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	45	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					836	848		10.1016/j.jmoldx.2018.07.003			13	Pathology	Pathology	GY5RC	WOS:000448637200011	30142445	Green Accepted			2019-10-28	
J	Jaworek, H; Koudelakova, V; Drabek, J; Vrbkova, J; Zborilova, B; Oborna, I; Brezinova, J; Marek, R; Huml, K; Vanek, P; Hajduch, M				Jaworek, Hana; Koudelakova, Vladimira; Drabek, Jiri; Vrbkova, Jana; Zborilova, Blazena; Oborna, Ivana; Brezinova, Jana; Marek, Radim; Huml, Karel; Vanek, Peter; Hajduch, Marian			A Head-to-Head Analytical Comparison of Cobas 4800 HPV, PapilloCheck HPV Screening, and LMNX Genotyping Kit HPV GP for Detection of Human Papillomavirus DNA in Cervical and Cervicovaginal Swabs	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							HYBRID CAPTURE 2; CLINICAL VALIDATION; COLLECTED SAMPLES; CANCER; WOMEN; RISK; METAANALYSIS; ASSAYS; PERFORMANCE; POPULATION	High-risk human papillomavirus (hrHPV) infection is a cause of cervical cancer development. The addition of hrHPV testing to cervical cancer screening and monitoring of cervical intraepithelial neoplasia treatment improves the efficacy of screening and treatment, respectively. Self-sampling for hrHPV testing seems a promising tool for increasing patient participation in cervical cancer screening. In this project, 1198 cervical swabs obtained by physicians and 176 cervicovaginal swabs obtained by self-sampling (not collected in parallel) were analyzed for the presence of 14 hrHPV genotypes using three commercially available assays in comparison. HPV DNA was detected in 21.2% of all samples (21% of cervical swabs and 22.7% of cervicovaginal swabs). The cobas 4800 HPV Test was the most sensitive (0.983) and specific (0.992) for hrHPV detection overall. The PapilloCheck HPV-Screening and LMNX Genotyping Kit HPV GP had comparable specificity with that of the cobas (0.989 and 0.955, respectively), but lesser sensitivity (0.897 and 0.909, respectively). In physician-obtained cervical swabs, the cobas showed the highest sensitivity and specificity (0.980 and 0.994, respectively) for hrHPV detection, whereas in cervicovaginal swabs, the cobas had the highest sensitivity (1.00), but the PapilloCheck had the highest specificity (0.993). In conclusion, all of the detection methods evaluated were highly sensitive and specific for hrHPV detection from both clinician-collected cervical swabs and self-sampled cervicovaginal swabs.	[Jaworek, Hana; Koudelakova, Vladimira; Drabek, Jiri; Vrbkova, Jana; Vanek, Peter; Hajduch, Marian] Palacky Univ Olomouc, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic; [Zborilova, Blazena] Palacky Univ Olomouc, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic; [Oborna, Ivana; Marek, Radim; Huml, Karel] Palacky Univ Olomouc, Fac Med & Dent, Dept Obstet & Gynecol, Olomouc, Czech Republic; [Jaworek, Hana; Koudelakova, Vladimira; Drabek, Jiri; Vrbkova, Jana; Vanek, Peter; Hajduch, Marian] Canc Res Czech Republ, Olomouc, Czech Republic; [Zborilova, Blazena; Oborna, Ivana] Fertimed Ltd, Olomouc, Czech Republic; [Brezinova, Jana] Arleta IVF Ltd, Kostelec Nad Orlici, Czech Republic	Hajduch, M (reprint author), Palacky Univ Olomouc, Inst Mol & Translat Med, Fac Med & Dent, Canc Res Czech Republ, Hnevotinska 5, Olomouc 77515, Czech Republic.	marian.hajduch@upol.cz	Hajduch, Marian/J-4015-2014; Drabek, Jiri/A-6135-2008	Hajduch, Marian/0000-0002-4834-908X; Koudelakova, Vladimira/0000-0001-5842-7478; Drabek, Jiri/0000-0002-5747-6478; Jaworek, Hana/0000-0001-6263-0049	Palacky University [LF_2018_005]; Ministry of School, Education and Youth [L01304, CZ.02.1.01/0.0/0.0/16_013/0001818, LM2015064]; Technological Agency of the Czech Republic [TE02000058]; Cancer Research Czech Republic	Supported by Palacky University grant LF_2018_005 (H.J.); Ministry of School, Education and Youth grants L01304, CZ.02.1.01/0.0/0.0/16_013/0001818, and LM2015064 (M.H.); Technological Agency of the Czech Republic grant TE02000058 (M.H.); and Cancer Research Czech Republic.	Arbyn M, 2015, CLIN MICROBIOL INFEC, V21, P817, DOI 10.1016/j.cmi.2015.04.015; Arbyn M, 2016, J CLIN VIROL, V76, pS14, DOI 10.1016/j.jcv.2015.09.014; Arbyn M, 2015, CANCER EPIDEM BIOMAR, V24, P769, DOI 10.1158/1055-9965.EPI-14-1417; Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9; Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Bulkmans NWJ, 2007, LANCET, V370, P1764, DOI 10.1016/S0140-6736(07)61450-0; Cuzick J, 2013, BRIT J CANCER, V108, P908, DOI 10.1038/bjc.2013.22; Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Duskova J, 2014, Klin Onkol, V27 Suppl 2, P79; Eklund C, 2014, J CLIN MICROBIOL, V52, P449, DOI 10.1128/JCM.02453-13; Geraets DT, 2014, J CLIN MICROBIOL, V52, P3996, DOI 10.1128/JCM.01962-14; Gok M, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1040; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Heideman DAM, 2011, J CLIN MICROBIOL, V49, P3983, DOI 10.1128/JCM.05552-11; Hesselink AT, 2010, J CLIN MICROBIOL, V48, P797, DOI 10.1128/JCM.01743-09; Khan MJ, 2005, JNCI-J NATL CANCER I, V97, P1072, DOI 10.1093/jnci/dji187; Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016/S1470-2045(09)70156-1; Lloveras B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058153; Lindemann MLM, 2012, J MOL DIAGN, V14, P65, DOI 10.1016/j.jmoldx.2011.09.005; Meijer CJ, 2006, GYNECOL ONCOL, V103, P12, DOI 10.1016/j.ygyno.2006.07.031; Meijer CJLM, 2009, INT J CANCER, V124, P516, DOI 10.1002/ijc.24010; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204; Park Y, 2012, J CLIN MICROBIOL, V50, P2359, DOI 10.1128/JCM.00337-12; Petignat P, 2007, GYNECOL ONCOL, V105, P530, DOI 10.1016/j.ygyno.2007.01.023; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2; Soderlund-Strand A, 2014, J MED VIROL, V86, P634, DOI 10.1002/jmv.23806; Tachezy R, 1999, J MED VIROL, V58, P378, DOI 10.1002/(SICI)1096-9071(199908)58:4<378::AID-JMV10>3.0.CO;2-P; Tachezy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079156	33	1	1	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					849	858		10.1016/j.jmoldx.2018.07.004			10	Pathology	Pathology	GY5RC	WOS:000448637200012	30165205				2019-10-28	
J	Biancon, G; Gimondi, S; Vendramin, A; Carniti, C; Corradini, P				Biancon, Giulia; Gimondi, Silvia; Vendramin, Antonio; Carniti, Cristiana; Corradini, Paolo			Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW-CYTOMETRY; IMMUNOGLOBULIN; CRITERIA; TRANSPLANTATION; REARRANGEMENTS; DIAGNOSIS; SURVIVAL; SYSTEM; IMPACT	Novel treatments for multiple myeloma (MM) have increased rates of complete response, raising interest in more accurate methods to evaluate residual disease. Cell-free tumor DNA (cfDNA) analysis may represent a minimally invasive approach complementary to multiparameter flow cytometry (MFC) and molecular methods on bone marrow aspirates. A sequencing approach using the Ion Torrent Personal Genome Machine was applied to identify clonal IGH gene rearrangements in tumor plasma cells (PCs) and in serial plasma samples of 25 patients with MM receiving second-line therapy. The same clonal. IGH rearrangement identified in tumor PCs was detected in paired plasma samples, and levels of IGH cfDNA correlated with outcome and mirrored tumor dynamics evaluated using conventional laboratory parameters. In addition, IGH cfDNA levels reflected the number of PCs enumerated by MFC immuno-phenotyping even in the complete response context. Patients determined by MFC to be free of minimal residual disease were characterized by low frequencies of tumor clonotypes in cfDNA and longer survival. This pilot study supports the clinical applicability of the noninvasive monitoring of tumor levels in plasma samples of patients with MM by IGH sequencing.	[Biancon, Giulia; Gimondi, Silvia; Carniti, Cristiana; Corradini, Paolo] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Via Venezian 1, I-20133 Milan, Italy; [Biancon, Giulia; Gimondi, Silvia; Vendramin, Antonio; Corradini, Paolo] Univ Milan, Dept Hematol, Milan, Italy	Carniti, C (reprint author), Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Via Venezian 1, I-20133 Milan, Italy.	cristiana.carniti@istitutotumori.mi.it		Biancon, Giulia/0000-0003-0182-7766	Associazione Italiana contro le Leucemie-linfomi e mieloma; Fondazione Adiuvare; Associazione Italiana Ricerca CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC)	Supported by Associazione Italiana contro le Leucemie-linfomi e mieloma, Associazione Italiana Ricerca Cancro, and Fondazione Adiuvare.	Alamyar E, 2012, IMMUNOME RES, V8, P1; Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919; Bashford-Rogers RJM, 2013, GENOME RES, V23, P1874, DOI 10.1101/gr.154815.113; Bohers E, 2015, HAEMATOLOGICA, V100, pE280, DOI 10.3324/haematol.2015.123612; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Corradini P, 2003, BLOOD, V102, P1927, DOI 10.1182/blood-2003-01-0189; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022; Farina L, 2009, HAEMATOL-HEMATOL J, V94, P654, DOI 10.3324/haematol.2008.000273; Ferrero S, 2012, HAEMATOL-HEMATOL J, V97, P849, DOI 10.3324/haematol.2011.052852; Flanders A, 2013, BLOOD, V122, P1088, DOI 10.1182/blood-2013-05-506170; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Gonzalez D, 2005, HAEMATOL-HEMATOL J, V90, P906; Herrera AF, 2016, BRIT J HAEMATOL, V175, P841, DOI 10.1111/bjh.14311; Hocking J, 2016, CANCER BIOL MED, V13, P215, DOI 10.20892/j.issn.2095-3941.2016.0025; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Lee N, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.14; Mailankody S, 2015, NAT REV CLIN ONCOL, V12, P286, DOI 10.1038/nrclinonc.2014.239; Martinez-Lopez J, 2014, BLOOD, V123, P3073, DOI 10.1182/blood-2014-01-550020; McClure R, 2015, J MOL DIAGN, V17, P145, DOI 10.1016/j.jmoldx.2014.11.006; Moreau P, 2017, BLOOD CANC J, V7, P7; Nishihori T, 2016, CURR HEMATOL MALIG R, V11, P118, DOI 10.1007/s11899-016-0308-3; Oberle A, 2017, HAEMATOLOGICA, V102, P1105, DOI 10.3324/haematol.2016.161414; Paiva B, 2015, BLOOD, V125, P3059, DOI 10.1182/blood-2014-11-568907; Paiva B, 2009, HAEMATOL-HEMATOL J, V94, P1599, DOI 10.3324/haematol.2009.009100; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; R Core Team, 2018, R LANG ENV STAT COMP, DOI [10.1007/978-3-540-74686-7, DOI 10.1007/978-3-540-74686-7]; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rawstron AC, 2013, J CLIN ONCOL, V31, P2540, DOI 10.1200/JCO.2012.46.2119; Roschewski M, 2016, BLOOD, V127, P3127, DOI 10.1182/blood-2016-03-635219; Roschewski M, 2015, LANCET ONCOL, V16, P541, DOI 10.1016/S1470-2045(15)70106-3; Scherer F, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8545; Shin S, 2017, ANN LAB MED, V37, P331, DOI 10.3343/alm.2017.37.4.331; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; Sonneveld P, 2016, BLOOD, V127, P2955, DOI 10.1182/blood-2016-01-631200; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Voena C, 1997, LEUKEMIA, V11, P1793, DOI 10.1038/sj.leu.2400801	38	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					859	870		10.1016/j.jmoldx.2018.07.006			12	Pathology	Pathology	GY5RC	WOS:000448637200013	30165206	Other Gold, Green Published			2019-10-28	
J	Risberg, B; Tsui, DWY; Biggs, H; de Almagro, ARVM; Dawson, SJ; Hodgkin, C; Jones, L; Parkinson, C; Piskorz, A; Marass, F; Chandrananda, D; Moore, E; Morris, J; Plagnol, V; Rosenfeld, N; Caldas, C; Brenton, JD; Gale, D				Risberg, Bente; Tsui, Dana W. Y.; Biggs, Heather; de Almagro, Andrea Ruiz-Valdepenas Martin; Dawson, Sarah-Jane; Hodgkin, Charlotte; Jones, Linda; Parkinson, Christine; Piskorz, Anna; Marass, Francesco; Chandrananda, Dineika; Moore, Elizabeth; Morris, James; Plagnol, Vincent; Rosenfeld, Nitzan; Caldas, Carlos; Brenton, James D.; Gale, Davina			Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							TUMOR DNA; BLOOD COLLECTION; MATERNAL PLASMA; LIQUID BIOPSIES; DIGITAL PCR; STORAGE; SAMPLE; GENOME; FETAL	Circulating tumor DNA (ctDNA) offers new opportunities for noninvasive cancer management. Detecting ctDNA in plasma is challenging because it constitutes only a minor fraction of the total cell-free DNA (cfDNA). Pre-analytical factors affect cfDNA levels contributed from leukocyte lysis, hence the ability to detect low frequency mutant alleles. This study investigates the effects of the delay in processing, storage temperatures, different blood collection tubes, centrifugation protocols, and sample shipment on cfDNA levels. Peripheral blood (n = 231) from cancer patients (n = 62) were collected into K(3)EDTA or Cell-free DNA BCT tubes and analyzed by digital PCR, targeted amplicon, or shallow whole-genome sequencing. To assess pre-analytic effects, plasma was processed under different conditions after 0, 6, 24, 48, 96 hours, and 1 week at room temperature or 4 degrees C, or using different centrifugation protocols. Digital PCR showed that cfDNA levels increased gradually with time in K3EDTA tubes, but were stable in BCT tubes. K(3)EDTA samples stored at 4 degrees C showed less variation than room temperature storage, but levels were elevated compared with BCT. A second centrifugation at 3000 x g gave similar cfDNA yields compared with higher-speed centrifugation. Next-generation sequencing showed negligible differences in background error or copy number changes between K(3)EDTA and BCT, or following shipment in BCT. This study provides insights into the effects of sample processing on ctDNA analysis.	[Risberg, Bente; Tsui, Dana W. Y.; de Almagro, Andrea Ruiz-Valdepenas Martin; Dawson, Sarah-Jane; Piskorz, Anna; Marass, Francesco; Chandrananda, Dineika; Moore, Elizabeth; Morris, James; Rosenfeld, Nitzan; Caldas, Carlos; Brenton, James D.; Gale, Davina] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Robinson Way, Cambridge, England; [Risberg, Bente] Inst Canc Res, Dept Canc Genet, Oslo, Norway; [Risberg, Bente] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Tsui, Dana W. Y.; de Almagro, Andrea Ruiz-Valdepenas Martin; Piskorz, Anna; Marass, Francesco; Chandrananda, Dineika; Moore, Elizabeth; Morris, James; Rosenfeld, Nitzan; Caldas, Carlos; Brenton, James D.; Gale, Davina] Canc Res UK Major Ctr, Cambridge, England; [Biggs, Heather; Dawson, Sarah-Jane; Jones, Linda; Caldas, Carlos] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge Breast Unit, Cambridge, England; [Hodgkin, Charlotte; Parkinson, Christine; Caldas, Carlos; Brenton, James D.] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Oncol, Cambridge, England; [Plagnol, Vincent] UCL, UCL Genet Inst, London, England	Tsui, DWY; Gale, D (reprint author), Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England.	tsuiw@mskcc.org; davina.gale@cruk.cam.ac.uk	Caldas, Carlos/U-7250-2019; Brenton, James D/B-3174-2008	Caldas, Carlos/0000-0003-3547-1489; Brenton, James D/0000-0002-5738-6683; Chandrananda, Dineika/0000-0002-8834-9500; Dawson, Sarah-Jane/0000-0002-8276-0374; Marass, Francesco/0000-0002-8993-7320	NIHR Cambridge Biomedical Research Center	We thank the patients for consenting to participate, the Human Research Tissue Bank at Addenbrooke's Hospital, which is supported by the NIHR Cambridge Biomedical Research Center, Frank Diehl for discussions about method standardization, Irena Hudecova for help preparing figures, and the Genomics Core of the Cancer Research UK Cambridge Institute for providing sequencing support.	[Anonymous], 2008, AFFYMETRIX MEDIAN AB; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Chiu RWK, 2001, CLIN CHEM, V47, P1607; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Diaz EH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168153; Diaz IM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166354; El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022; Fernando MR, 2010, PRENATAL DIAG, V30, P418, DOI 10.1002/pd.2484; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021; Gusnanto A, 2012, BIOINFORMATICS, V28, P40, DOI 10.1093/bioinformatics/btr593; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Katsanis SH, 2013, NAT REV GENET, V14, P415, DOI 10.1038/nrg3493; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lui YNYN, 2002, CLIN CHEM, V48, P421; Norton SE, 2013, CLIN BIOCHEM, V46, P1561, DOI 10.1016/j.clinbiochem.2013.06.002; Page K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077963; Parpart-Li S, 2017, CLIN CANCER RES, V23, P2471, DOI 10.1158/1078-0432.CCR-16-1691; R Core Team, 2015, R LANG ENV STAT COMP; Rothwell DG, 2016, MOL ONCOL, V10, P566, DOI 10.1016/j.molonc.2015.11.006; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Wang J, 2010, CLIN CHEM, V56, P623, DOI 10.1373/clinchem.2009.134973; Warton K, 2017, MOL DIAGN THER, V21, P563, DOI 10.1007/s40291-017-0284-x; Wong D, 2013, CLIN BIOCHEM, V46, P1099, DOI 10.1016/j.clinbiochem.2013.04.023	28	7	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	NOV	2018	20	6					883	892		10.1016/j.jmoldx.2018.07.005			10	Pathology	Pathology	GY5RC	WOS:000448637200015	30165204	Green Published, Other Gold			2019-10-28	
J	Koppel, C; Schwellenbach, H; Zielinski, D; Eckstein, S; Martin-Ortega, M; D'Arrigo, C; Schildhaus, HU; Ruschoff, J; Jasani, B				Koppel, Christina; Schwellenbach, Helena; Zielinski, Dirk; Eckstein, Sina; Martin-Ortega, Mercedes; D'Arrigo, Corrado; Schildhaus, Hans-Ulrich; Rueschoff, Josef; Jasani, Bharat			Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms	MODERN PATHOLOGY			English	Article							DEATH-LIGAND 1; PULMONARY SQUAMOUS-CELL; LUNG-CANCER; MOLECULAR PATHWAYS; IHC ASSAY; EXPRESSION; NIVOLUMAB; B7-H1; DOCETAXEL; CARCINOMA	Several immunohistochemistry (IHC) assays have been developed to assess tumor programmed death-ligand 1 (PD-L1) expression levels in patients who are candidates for programmed death-1 (PD-1)/PD-L1 inhibitor therapy. The PD-L1 IHC 28-8 pharmDx kit is FDA-approved as a complementary diagnostic and CE-marked as an in vitro diagnostic device for nivolumab therapy in melanoma and specific lung cancer subtypes (and for squamous cell carcinoma of the head and neck/urothelial carcinoma in Europe only). Kit availability is limited outside the United States, and its use requires the Dako Autostainer Link 48 platform, which is unavailable in many laboratories. Validated laboratory-developed tests based on 28-8 concentrated antibody outside the kit are needed. This study compared the results from PD-L1 expression level analysis across four immunohistochemistry platforms (Dako Autostainer Link 48, Dako Omnis, Leica Bond-III, and Ventana BenchMark ULTRA) with the 28-8 pharmDx kit in lung cancer (multiple histologies), melanoma, and head and neck cancer (multiple histologies). Samples were prepared per protocol for each platform and stained using PD-L1 IHC 28-8 pharmDx kit on Dako Autostainer Link 48, and per protocol for each platform. The control samples (tonsil and placenta tissue; cell lines with prespecified PD-L1 expression levels) were tested to evaluate the specificity and the sensitivity of test assays. An agreement level of 0.90 with the pharmDx kit was set for each platform. Inter-and intra-assay reliability were assessed. Evaluable samples were lung cancer = 29; melanoma = 31; head and neck cancer = 30. Mean agreement was calculated for PD-L1 expression levels of >= 1%, >= 5%, >= 10%, and >= 50%. Mean overall agreement for all indications was 0.87-0.99. Interand intra-assay of scoring/classification repeatability was 100%. Analysis of PD-L1 expression levels using laboratorydeveloped immunohistochemistry assays with 28-8 antibody may be permissible if the platform is validated using reference samples with defined expression levels.	[Koppel, Christina; Schwellenbach, Helena; Zielinski, Dirk; Rueschoff, Josef; Jasani, Bharat] Targos Mol Pathol GmbH, Kassel, Germany; [Eckstein, Sina; Martin-Ortega, Mercedes; Schildhaus, Hans-Ulrich] Univ Med Gottingen, Inst Pathol, Gottingen, Germany; [D'Arrigo, Corrado] Poundbury Canc Inst, Dorchester, England; [Rueschoff, Josef] Inst Pathol Nordhessen, Kassel, Germany	Zielinski, D (reprint author), Targos Mol Pathol GmbH, Kassel, Germany.	Dirk.Zielinski@targos-gmbh.de			Bristol-Myers SquibbBristol-Myers Squibb	The authors would like to thank the patients who donated samples, as well as the contribution of Alexander Pieper (Bristol-Myers Squibb). Medical writing and editorial support was provided by Eloise Aston, MSc, and Jay Rathi, MA, of Spark Medica Inc (USA), funded by Bristol-Myers Squibb.	Abcam, 2017, ANTI PD L1 ANT 28 8; Adam J, 2018, ANN ONCOL, V29, P953, DOI 10.1093/annonc/mdy014; Alvarez S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14588; [Anonymous], 2016, KEYTR; [Anonymous], 2016, VENTANA PD L1 SP142; AstraZeneca Pharmaceuticals LP, 2017, IMFINZI PRESCR INF; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Batenchuk C, 2017, COMP STUDY PD L1 IHC; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Bristol-Myers Squibb, 2016, OPD SUMM PROD CHAR; Bristol-Myers-Squibb, 2014, OPD; Brunnstrom H, 2017, MODERN PATHOL, V30, P1411, DOI 10.1038/modpathol.2017.59; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; Chen YB, 2012, TUMORI, V98, P751, DOI 10.1700/1217.13499; Cogswell J, 2017, MOL DIAGN THER, V21, P85, DOI 10.1007/s40291-016-0237-9; Cree IA, 2016, HISTOPATHOLOGY, V69, P177, DOI 10.1111/his.12996; Dako, 2017, PD L1 IHC 28 8 PHARM; Dako, 2016, PD L1 IHC 28 8 PHARM; Dako, AUT LINK 48 IMM STAI; Dako Omnis, 2015, PD L1 STAIN PROT ANT; Dong HD, 1999, NAT MED, V5, P1365; Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875; Edwards R, 2017, 29 EUR C PATH AMST N; F Hoffmann-La Roche AG, TEC SUMM PROD CHAR; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Genentech Inc, 2016, TECENTRIQ; Gniadek TJ, 2017, MODERN PATHOL, V30, P530, DOI 10.1038/modpathol.2016.213; Gowrishankar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123410; Hato SV, 2014, CLIN CANCER RES, V20, P2831, DOI 10.1158/1078-0432.CCR-13-3141; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Horizon Discovery Group, 2017, CD274 PD L1 EXPR IHC; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Ilie M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183023; Janzic U, 2017, RADIOL ONCOL, V51, P357, DOI 10.1515/raon-2017-0037; Pinto GDJ, 2016, J IMMUNOL RES, DOI 10.1155/2016/9839685; Konishi J, 2004, CLIN CANCER RES, V10, P5094, DOI 10.1158/1078-0432.CCR-04-0428; Kwong FNK, 2018, HISTOPATHOLOGY, V72, P1024, DOI 10.1111/his.13466; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Leica Biosystems, 2012, FULL AUT IHC ISH; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; Marchetti A, 2017, J THORAC ONCOL, V12, P1654, DOI 10.1016/j.jtho.2017.07.031; Merck & Co. Inc, 2017, KEYTR SUMM PROD CHAR; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; Neuman T, 2016, J THORAC ONCOL, V11, P1863, DOI 10.1016/j.jtho.2016.08.146; Novotny JF, 2016, ANN ONCOL, V27, P1966, DOI 10.1093/annonc/mdw288; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Pai SI, 2016, ORAL ONCOL, V61, P152, DOI 10.1016/j.oraloncology.2016.08.001; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Pedoeem A, 2014, CLIN IMMUNOL, V153, P145, DOI 10.1016/j.clim.2014.04.010; Pharmaceuticals and medical devices agency, 2014, OPD; Phillips T, 2018, APPL IMMUNOHISTO M M, V26, P6, DOI [10.1097/PAI.0000000000000605, 10.1097/PAI.0000000000000380]; Phillips T, 2015, APPL IMMUNOHISTO M M, V23, P541, DOI 10.1097/PAI.0000000000000256; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Santos RADL, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14585; Schats K, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3028; Scheel AH, 2018, HISTOPATHOLOGY, V72, P449, DOI 10.1111/his.13375; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Skov BG, 2017, APPL IMMUNOHISTO M M, V25, P453, DOI 10.1097/PAI.0000000000000540; Smith J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0494-2; Sun J, 2007, TISSUE ANTIGENS, V69, P19, DOI 10.1111/j.1399-0039.2006.00701.x; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; van Essen HF, 2010, J CLIN PATHOL, V63, P1090, DOI 10.1136/jcp.2010.079905; Ventana Medical Systems Inc, 2013, BENCHM ULTR SLID STA	71	3	3	4	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1630	1644		10.1038/s41379-018-0071-1			15	Pathology	Pathology	GY9FA	WOS:000448943600001	29946185				2019-10-28	
J	Augustin, J; Mandavit, M; Outh-Gauer, S; Grard, O; Gasne, C; Lepine, C; Mirghani, H; Hans, S; Bonfils, P; Denize, T; Bruneval, P; Bishop, JA; Fontugne, J; Pere, H; Tartour, E; Badoual, C				Augustin, Jeremy; Mandavit, Marion; Outh-Gauer, Sophie; Grard, Ophelie; Gasne, Cassandre; Lepine, Charles; Mirghani, Haitham; Hans, Stephane; Bonfils, Pierre; Denize, Thomas; Bruneval, Patrick; Bishop, Justin A.; Fontugne, Jacqueline; Pere, Helene; Tartour, Eric; Badoual, Cecile			HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population	MODERN PATHOLOGY			English	Article							E6/E7 MESSENGER-RNA; HUMAN-PAPILLOMAVIRUS; NECK CANCERS; VIRAL LOAD; HEAD; RISK; DNA; INFECTION; SURVIVAL; TUMOR	HPV-related and HPV-unrelated oropharyngeal squamous cell carcinomas are two distinct entities according to the Union for International Cancer Control, with a better prognosis conferred to HPV-related oropharyngeal squamous cell carcinomas. However, variable clinical outcomes are observed among patients with p16 positive oropharyngeal squamous cell carcinoma, which is a surrogate marker of HPV infection. We aimed to investigate the prognostic value of RNA CISH against E6 and E7 transcripts (HPV RNA CISH) to predict such variability. We retrospectively included 50 histologically confirmed p16 positive oropharyngeal squamous cell carcinomas (p16 positive immunostaining was defined by a strong staining in 70% or more of tumor cells). HPV RNA CISH staining was assessed semi-quantitatively to define two scores: RNA CISH " low" and RNA CISH " high". Negative HPV RNA CISH cases were scored as RNA CISH "low". This series contained 29 RNA CISH low cases (58%) and 21 RNA CISH high cases (42%). Clinical and pathologic baseline characteristics were similar between the two groups. RNA CISH high staining was associated with a better overall survival in both univariate and multivariate analyses (p = 0.033 and p = 0.042, respectively). Other recorded parameters had no prognostic value. In conclusion, HPV RNA CISH might be an independent prognostic marker in p16 positive oropharyngeal squamous cell carcinomas and might help guide therapeutics.	[Augustin, Jeremy; Outh-Gauer, Sophie; Lepine, Charles; Denize, Thomas; Bruneval, Patrick; Badoual, Cecile] Hop Europeen Georges Pompidou, APHP, Dept Pathol, Paris, France; [Mandavit, Marion; Grard, Ophelie; Gasne, Cassandre; Bruneval, Patrick; Pere, Helene; Tartour, Eric; Badoual, Cecile] Univ Paris 05, Sorbonne Paris Cite, INSERM, U970, F-75015 Paris, France; [Augustin, Jeremy; Grard, Ophelie; Badoual, Cecile] Equipe Labellisee Ligue Canc, Paris, France; [Gasne, Cassandre; Hans, Stephane; Bonfils, Pierre] Hop Europeen Georges Pompidou, Dept ENT Surg, Paris, France; [Mirghani, Haitham] Inst Gustave Roussy, Dept ENT Surg, Paris, France; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Fontugne, Jacqueline] Inst Curie, Res Ctr, F-75005 Paris, France; [Pere, Helene] Hop Europeen Georges Pompidou, Dept Microbiol, Paris, France; [Tartour, Eric] Hop Europeen Georges Pompidou, Dept Immunol, Paris, France	Badoual, C (reprint author), Hop Europeen Georges Pompidou, APHP, Dept Pathol, Paris, France.; Badoual, C (reprint author), Univ Paris 05, Sorbonne Paris Cite, INSERM, U970, F-75015 Paris, France.; Badoual, C (reprint author), Equipe Labellisee Ligue Canc, Paris, France.	cecile.badoual@aphp.fr					Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bingham V, 2017, ONCOTARGET, V8, P93392, DOI 10.18632/oncotarget.21851; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Boscolo-Rizzo P, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0424-5; Cheraghlou S, 2018, CANCER-AM CANCER SOC, V124, P717, DOI 10.1002/cncr.31104; CULLEN AP, 1991, J VIROL, V65, P606; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Dong L, 2018, GYNECOL ONCOL, V148, P103, DOI 10.1016/j.ygyno.2017.11.016; Dreyer JH, 2013, VIRCHOWS ARCH, V462, P381, DOI 10.1007/s00428-013-1393-5; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Holzinger D, 2012, CANCER RES, V72, P4993, DOI 10.1158/0008-5472.CAN-11-3934; Huang SH, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0484-y; Jung AC, 2010, INT J CANCER, V126, P1882, DOI 10.1002/ijc.24911; Jung HM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-80; Kelly JR, 2016, EUR J CANCER, V68, P125, DOI 10.1016/j.ejca.2016.09.006; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Kumar B, 2008, J CLIN ONCOL, V26, P3128, DOI 10.1200/JCO.2007.12.7662; Kuo KT, 2008, MODERN PATHOL, V21, P376, DOI 10.1038/modpathol.3800979; Lajer CB, 2011, BRIT J CANCER, V104, P830, DOI 10.1038/bjc.2011.29; Lassen P, 2018, RADIOTHER ONCOL, V126, P107, DOI 10.1016/j.radonc.2017.10.018; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lim MY, 2016, HEAD NECK-J SCI SPEC, V38, P1139, DOI 10.1002/hed.24429; Lohaus F, 2014, RADIOTHER ONCOL, V113, P317, DOI 10.1016/j.radonc.2014.11.011; Marur S, 2017, J CLIN ONCOL, V35, P490, DOI 10.1200/JCO.2016.68.3300; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Maxwell JH, 2010, CLIN CANCER RES, V16, P1226, DOI 10.1158/1078-0432.CCR-09-2350; Mirghani H, 2016, ORAL ONCOL, V62, P101, DOI 10.1016/j.oraloncology.2016.10.009; Mirghani H, 2015, MODERN PATHOL, V28, P1518, DOI 10.1038/modpathol.2015.113; National Collaborating Centre for Cancer (UK), 2016, CANC UPP AER TRACT A; Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Papillon-Cavanagh S, 2017, NAT GENET, V49, P180, DOI 10.1038/ng.3757; Park IS, 2011, CANCER PREV RES, V4, P207, DOI 10.1158/1940-6207.CAPR-10-0147; Rietbergen MM, 2013, ANN ONCOL, V24, P2740, DOI 10.1093/annonc/mdt319; Rietbergen MM, 2014, INT J CANCER, V134, P2366, DOI 10.1002/ijc.28580; Shi W, 2009, J CLIN ONCOL, V27, P6213, DOI 10.1200/JCO.2009.23.1670; Taberna M, 2017, ANN ONCOL, V28, P2386, DOI 10.1093/annonc/mdx304; Vainshtein J, 2015, HEAD NECK-J SCI SPEC, V37, P8, DOI 10.1002/hed.23548; Wald AI, 2011, HEAD NECK-J SCI SPEC, V33, P504, DOI 10.1002/hed.21475; Ward MJ, 2014, BRIT J CANCER, V110, P489, DOI 10.1038/bjc.2013.639; Wiest T, 2002, ONCOGENE, V21, P1510, DOI 10.1038/sj.onc.1205214	41	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1645	1652		10.1038/s41379-018-0090-y			8	Pathology	Pathology	GY9FA	WOS:000448943600002	29925856				2019-10-28	
J	Martin, IW; Atkinson, AE; Liu, XY; Suriawinata, AA; Lefferts, JA; Lisovsky, M				Martin, Isabella W.; Atkinson, Aaron E.; Liu, Xiaoying; Suriawinata, Arief A.; Lefferts, Joel A.; Lisovsky, Mikhail			Mucosal inflammation in Candida esophagitis has distinctive features that may be helpful diagnostically	MODERN PATHOLOGY			English	Article							LYMPHOCYTIC ESOPHAGITIS; INTRAEPITHELIAL LYMPHOCYTES; RISK-FACTORS; BIOPSIES; CELLS	The diagnosis of Candida esophagitis can be challenging when the epithelium containing Candida filamentous forms is not readily seen or is entirely sloughed away. Mucosal inflammation could be helpful diagnostically, if distinctive. However it is thought to be nonspecific in Candida esophagitis. The goal of this retrospective study was to identify features of mucosal inflammation helpful in alerting a pathologist to the possibility of Candida esophagitis when Candida mycelia are not readily observed. The study group consisted of 99 consecutive cases of Candida esophagitis and a control group of 64 consecutive cases of reflux esophagitis diagnosed at our institution from 2008-2016. Band-like superficial intraepithelial neutrophils and increased intraepithelial lymphocytes were observed in 75 and 67% of Candida esophagitis cases, respectively and only in 14 and 19% of reflux esophagitis cases, respectively (p <.0001). Intraepithelial lymphocytes were peripapillary or CD4-predominant in 75% of Candida esophagitis cases with increased lymphocytes, in contrast to 17% of reflux esophagitis cases (p =.0011). Concurrent presence of intraepithelial neutrophils and increased lymphocytes showed increased specificity for Candida esophagitis and was observed in 61% of patients with Candida esophagitis and only in 2% of patients with reflux esophagitis (p <.0001). In addition, superficial band-like neutrophils were observed concurrently with increased peripapillary lymphocytes or CD4-predominant lymphocytes in 35 and 50% of Candida esophagitis cases, respectively, in contrast to no reflux esophagitis cases. Basal cell hyperplasia and elongation of stromal papillae were frequent in both groups. The data suggest that when Candida microorganisms are not readily observed, concurrent presence of superficial band-like neutrophils and increased lymphocytes may be indicative of Candida etiology of active esophagitis.	[Martin, Isabella W.; Atkinson, Aaron E.; Liu, Xiaoying; Suriawinata, Arief A.; Lefferts, Joel A.; Lisovsky, Mikhail] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA; [Martin, Isabella W.; Atkinson, Aaron E.; Liu, Xiaoying; Suriawinata, Arief A.; Lefferts, Joel A.; Lisovsky, Mikhail] Geisel Sch Med Dartmouth, Lebanon, NH USA	Lisovsky, M (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA.; Lisovsky, M (reprint author), Geisel Sch Med Dartmouth, Lebanon, NH USA.	Mikhail.lisovsky@hitchcock.org					Alsomali MI, 2017, AM J CLIN PATHOL, V147, P33, DOI [10.1093/AJCP/AQW210, 10.1093/ajcp/aqw210]; Conti HR, 2016, JAMA-J AM MED ASSOC, V315, P2104; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; Demir D, 2014, TURK J GASTROENTEROL, V25, P481, DOI 10.5152/tjg.2014.4967; Dunbar KB, 2016, JAMA-J AM MED ASSOC, V315, P2104, DOI 10.1001/jama.2016.5657; GEBOES K, 1983, VIRCHOWS ARCH A, V401, P45, DOI 10.1007/BF00644788; Haulk A A, 1991, Adv Intern Med, V36, P307; Hernandez-Santos N, 2012, CELL HOST MICROBE, V11, P425, DOI 10.1016/j.chom.2012.04.008; ISMAIL-BEIGI F, 1970, Gastroenterology, V58, P163; Kakati B, 2015, J CLIN DIAGN RES, V9, pDC16, DOI 10.7860/JCDR/2015/15171.6975; Kliemann DA, 2008, REV I MED TROP, V50, P261, DOI 10.1590/S0036-46652008000500002; KODSI BE, 1976, GASTROENTEROLOGY, V71, P715; Lauwers GY, 2010, DIAGNOSTIC PATHOLOGY, P215; Lucendo AJ, 2007, AM J SURG PATHOL, V31, P598, DOI 10.1097/01.pas.0000213392.49698.8c; Martin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018394; MATHIESON R, 1983, DIGEST DIS SCI, V28, P365, DOI 10.1007/BF01324956; MOULINIER B, 1972, NOUV PRESSE MED, V1, P2629; Muller KE, 2014, MODERN PATHOL, V27, p194A; Munoz-Cadavid C, 2010, J CLIN MICROBIOL, V48, P2147, DOI 10.1128/JCM.00459-10; Putra J, 2016, AM J SURG PATHOL, V40, P1679, DOI 10.1097/PAS.0000000000000712; Resnick MB, 1999, HUM PATHOL, V30, P397, DOI 10.1016/S0046-8177(99)90114-4; Rubio CA, 2006, AM J CLIN PATHOL, V125, P432, DOI 10.1309/7LABLGY08UEM3H26; Sutton LM, 2014, INFLAMM BOWEL DIS, V20, P1324, DOI 10.1097/MIB.0000000000000100; Underwood JA, 2003, DIS ESOPHAGUS, V16, P66, DOI 10.1046/j.1442-2050.2003.00305.x; WALSH TJ, 1986, AM J CLIN PATHOL, V85, P498, DOI 10.1093/ajcp/85.4.498; Xue Y, 2015, AM J SURG PATHOL, V39, P1558, DOI 10.1097/PAS.0000000000000493	26	3	3	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1653	1660		10.1038/s41379-018-0060-4			8	Pathology	Pathology	GY9FA	WOS:000448943600003	29921901				2019-10-28	
J	Krings, G; Chen, YY				Krings, Gregor; Chen, Yunn-Yi			Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma	MODERN PATHOLOGY			English	Article							TERT PROMOTER MUTATIONS; IN-SITU; PHYLLODES TUMORS; WORSE PROGNOSIS; READ ALIGNMENT; PAIRED-END; CANCER; AMPLIFICATION; PROGRESSION; ASSOCIATION	Metaplastic breast carcinomas comprise a histologically heterogenous group of tumors. Although most are triple (estrogen/ progesterone receptor, HER2) negative, these rare tumors are clinicopathologically distinct from other triple negative carcinomas and may be aggressive with worse chemotherapy responses. On the other hand, metaplastic carcinomas are histologically diverse, which is reflected in gene expression differences among subtypes. Whether metaplastic carcinomas are genetically distinct from other triple negative cancers and whether genetic differences underlie histologic subtypes remains poorly understood. We sequenced 408 cancer-related genes in 28 metaplastic carcinomas, including chondroid matrix-producing carcinomas (n = 10), spindle cell carcinomas (n = 5), and carcinomas with squamous (n = 5), mixed spindle/squamous (n = 5), and mixed metaplastic (n = 3) differentiation. Metaplastic carcinomas were highly enriched for PIK3CA/PIK3R1 (61%) and Ras-Map kinase (25%) pathway aberrations compared to other triple negative carcinomas (TCGA dataset 14%, p < 0.001 and 7%, p = 0.005, respectively) and harbored a high frequency of TP53 (64%) and TERT promoter (25%) mutations, but this varied among subtypes. Chondroid-matrix producing carcinomas lacked PI-3 kinase and Ras-Map kinase aberrations and TERT promoter mutations, compared to 100%, 39%, and 39% of non-matrix-producing tumors, respectively. TERT promoter mutations were enriched (47%) in spindle cell carcinomas and tumors with squamous or spindle/squamous differentiation. Spindle cell carcinomas lacked TP53 mutations, in contrast to other subtypes (78%, p = 0.003). Separate analysis of paired ductal carcinoma in situ and metaplastic carcinoma revealed shared clonality in all cases (n = 8). Activating PI-3 kinase and Ras pathway mutations were early events, and inactivating mutations in tumor suppressors including RB1, CDKN2A, and TP53 were associated with invasion in individual cases. Metaplastic components of two tumors showed genetic progression from separately sequenced paired invasive ductal carcinoma. The findings suggest that metaplastic carcinomas are genetically distinct from other triple negative breast cancers and highlight genetic heterogeneity that broadly correlates with histologic subtype. Heterologous elements progress from associated ductal carcinoma.	[Krings, Gregor; Chen, Yunn-Yi] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA	Krings, G (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.	gregor.krings@ucsf.edu			Department of Pathology of the University of California San Francisco	This study was funded by the Department of Pathology of the University of California San Francisco.	Abba MC, 2015, CANCER RES, V75, P3980, DOI 10.1158/0008-5472.CAN-15-0506; [Anonymous], SET TOOLS JAV WORK N; Avigdor BE, 2017, CLIN CANCER RES, V23, P4875, DOI 10.1158/1078-0432.CCR-17-0108; Basho RK, 2017, JAMA ONCOL, V3, P509, DOI 10.1001/jamaoncol.2016.5281; Bell RJA, 2016, MOL CANCER RES, V14, P315, DOI 10.1158/1541-7786.MCR-16-0003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chhieng C, 1998, AM J SURG PATHOL, V22, P188, DOI 10.1097/00000478-199802000-00006; Cimino-Mathews A, 2016, AM J CLIN PATHOL, V145, P365, DOI [10.1093/AJCP/AQV097, 10.1093/ajcp/aqv097]; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; El Zein D, 2017, CLIN BREAST CANCER, V17, P382, DOI 10.1016/j.clbc.2017.04.009; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Gay-Bellile M, 2017, ONCOTARGET, V8, P77540, DOI 10.18632/oncotarget.20560; Gay-Bellile M, 2016, J PATHOL CLIN RES, V2, P234, DOI 10.1002/cjp2.52; George JR, 2015, J CLIN ENDOCR METAB, V100, pE1550, DOI 10.1210/jc.2015-2690; Geyer FC, 2010, J PATHOL, V220, P562, DOI 10.1002/path.2675; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990; Jang MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3239; Joneja U, 2017, J CLIN PATHOL, V70, P255, DOI 10.1136/jclinpath-2016-203874; Jung SY, 2010, BREAST CANCER RES TR, V120, P627, DOI 10.1007/s10549-010-0780-8; Kang JH, 2001, J MOL MED-JMM, V79, P648, DOI 10.1007/s001090100269; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim SY, 2015, ONCOTARGET, V6, P7597, DOI 10.18632/oncotarget.3162; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Krings G, 2017, MODERN PATHOL, V30, P1086, DOI 10.1038/modpathol.2017.32; Lakhani SR, 2012, WHO CLASSIFICATION T, P48; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624; Liu SY, 2016, MODERN PATHOL, V29, P1012, DOI 10.1038/modpathol.2016.97; Lu LG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2893; Luini A, 2007, BREAST CANCER RES TR, V101, P349, DOI 10.1007/s10549-006-9301-1; Martelotto LG, 2017, NAT MED, V23, P376, DOI 10.1038/nm.4279; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miron A, 2010, CANCER RES, V70, P5674, DOI 10.1158/0008-5472.CAN-08-2660; Moulder S, 2015, ANN ONCOL, V26, P1346, DOI 10.1093/annonc/mdv163; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Ng CKY, 2017, CLIN CANCER RES, V23, P3859, DOI 10.1158/1078-0432.CCR-16-2857; Pang JMB, 2017, MODERN PATHOL, V30, P952, DOI 10.1038/modpathol.2017.21; Pang JMB, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0586-z; Pareja F, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.36; Piscuoglio S, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0048-0; Piscuoglio S, 2016, J PATHOL, V238, P508, DOI 10.1002/path.4672; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rakha EA, 2015, BRIT J CANCER, V112, P283, DOI 10.1038/bjc.2014.592; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Reis JS, 2006, J PATHOL, V209, P445, DOI 10.1002/path.2004; Robanus-Maandag EC, 2003, J PATHOL, V201, P75, DOI 10.1002/path.1385; Ross JS, 2015, ARCH PATHOL LAB MED, V139, P642, DOI 10.5858/arpa.2014-0200-OA; Schwartz TL, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-31; Shimoi T, 2018, BREAST CANCER-TOKYO, V25, P292, DOI 10.1007/s12282-017-0825-5; Song YN, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-129; Subhawong AP, 2009, AM J SURG PATHOL, V33, P163, DOI 10.1097/PAS.0b013e31817f9790; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Teixeira MR, 1998, GENE CHROMOSOME CANC, V22, P145, DOI 10.1002/(SICI)1098-2264(199806)22:2<145::AID-GCC9>3.3.CO;2-V; Tzanninis IG, 2016, CLIN BREAST CANCER, V16, P437, DOI 10.1016/j.clbc.2016.06.002; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; van Deurzen CHM, 2011, J PATHOL, V224, P434, DOI 10.1002/path.2872; Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465; Wang XJ, 2001, MODERN PATHOL, V14, P1183, DOI 10.1038/modpathol.3880456; WARGOTZ ES, 1989, CANCER, V64, P1490, DOI 10.1002/1097-0142(19891001)64:7<1490::AID-CNCR2820640722>3.0.CO;2-L; WARGOTZ ES, 1989, HUM PATHOL, V20, P628, DOI 10.1016/0046-8177(89)90149-4; WARGOTZ ES, 1989, HUM PATHOL, V20, P732, DOI 10.1016/0046-8177(89)90065-8; Weigelt B, 2015, MODERN PATHOL, V28, P340, DOI 10.1038/modpathol.2014.142; Weigelt B, 2014, NAT REV CANCER, V14, P147, DOI 10.1038/nrc3637; Weigelt B, 2009, BREAST CANCER RES TR, V117, P273, DOI 10.1007/s10549-008-0197-9; Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131409; Zhou WJ, 2009, MOL ONCOL, V3, P214, DOI 10.1016/j.molonc.2009.03.001; Zhuang ZP, 1997, MODERN PATHOL, V10, P354	76	9	9	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1661	1674		10.1038/s41379-018-0081-z			14	Pathology	Pathology	GY9FA	WOS:000448943600004	29946183				2019-10-28	
J	Sonbul, SN; Aleskandarany, MA; Kurozumi, S; Joseph, C; Toss, MS; Diez-Rodriguez, M; Nolan, CC; Mukherjee, A; Martin, S; Caldas, C; Ellis, IO; Green, AR; Rakha, EA				Sonbul, Sultan N.; Aleskandarany, Mohammed A.; Kurozumi, Sasagu; Joseph, Chitra; Toss, Michael S.; Diez-Rodriguez, Maria; Nolan, Christopher C.; Mukherjee, Abhik; Martin, Stewart; Caldas, Carlos; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.			Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion	MODERN PATHOLOGY			English	Article							PROSTATE-CANCER; NEOADJUVANT CHEMOTHERAPY; VASCULAR INVASION; GENE; PROGRESSION; ESTROGEN; RECEPTOR; PTEN; RECOMMENDATIONS; MECHANISMS	Lymphovascular invasion is strongly related to breast cancer metastasis. However, the underlying mechanisms of lymphovascular invasion and its driver molecules in breast cancer remain to be defined. In this study, we explore differential expression of genes in large molecularly characterized and clinically annotated datasets of invasive breast cancer patients (n = 8056) coupled with histological review and strict definition for lymphovascular invasion status. The METABRIC series was used to identify genes associated with lymphovascular invasion, as defined using hematoxylin and eosin staining supplemented by immunohistochemistry, at the genomic/transcriptomic levels. Saccharomyces cerevisiae-like 1 (SEC14L1) was identified as one of the most significant genes associated with lymphovascular invasion. The prognostic significance of SEC14L1 gene copy number and mRNA expression was further investigated in the METABRIC series and externally validated using the Breast Cancer Gene-Expression Miner v4.0. Protein expression of SEC14L1 was also assessed using immunohistochemistry in series of early stage breast cancer using tissue microarrays. SEC14L1 gene copy number gain was significantly associated with high histological grade and poor outcome. SEC14L1 mRNA expression showed positive association with higher grade, lymph node metastasis, and poor outcome. SEC14L1 protein overexpression was significantly associated with lymphovascular invasion (p < 0.0001), higher grade (p = 0.011), HER2 positivity (p = 0.036), and shorter survival (p = 0.00075). Our findings specify SEC14L1 as an independent prognostic factor in breast cancer. Its association, at both transcriptome and protein expression levels, with lymphovascular invasion and outcome could imply an important role in tumor progression. A further mechanistic insight into its molecular roles including potential therapeutic utility is warranted.	[Sonbul, Sultan N.; Aleskandarany, Mohammed A.; Kurozumi, Sasagu; Joseph, Chitra; Toss, Michael S.; Diez-Rodriguez, Maria; Nolan, Christopher C.; Mukherjee, Abhik; Martin, Stewart; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Nottingham, England; [Sonbul, Sultan N.; Aleskandarany, Mohammed A.; Kurozumi, Sasagu; Joseph, Chitra; Toss, Michael S.; Diez-Rodriguez, Maria; Nolan, Christopher C.; Mukherjee, Abhik; Martin, Stewart; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.] Nottingham City Hosp, Nottingham Univ Hosp NHS Trust, Nottingham, England; [Sonbul, Sultan N.] King Abdulaziz Univ, Dept Biochem, Fac Sci, Jeddah, Saudi Arabia; [Aleskandarany, Mohammed A.; Rakha, Emad A.] Menoufia Univ, Fac Med, Shibin Al Kawm, Egypt; [Caldas, Carlos] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge Breast Unit, Cambridge, England	Rakha, EA (reprint author), Univ Nottingham, Sch Med, Div Canc & Stem Cells, Nottingham, England.; Rakha, EA (reprint author), Nottingham City Hosp, Nottingham Univ Hosp NHS Trust, Nottingham, England.; Rakha, EA (reprint author), Menoufia Univ, Fac Med, Shibin Al Kawm, Egypt.	Emad.Rakha@nottingham.ac.uk	Caldas, Carlos/U-7250-2019; Rakha, Emad/Q-5554-2019; Aleskandarany, Mohammed/X-8585-2019; Martin, Stewart/F-5999-2012	Caldas, Carlos/0000-0003-3547-1489; Ellis, Ian/0000-0001-5292-8474; Green, Andrew/0000-0002-0488-5913; Rakha, Emad/0000-0002-5009-5525; Martin, Stewart/0000-0002-2810-2338	Breast Cancer Research Trust; University of Nottingham	We show our gratitude to Dr. Oscar Rueda (CRUK Cambridge Research Institute, University of Cambridge, Cambridge, UK) for providing the clinical, genomic, and transcriptomic profiles of the METABRIC patients in this study. We thank the Breast Cancer Research Trust and the University of Nottingham for funding this project, and the Nottingham Health Science Biobank (NHSB) and Breast Cancer Now Tissue Bank for the provision of tissue samples.	Agell L, 2012, AM J PATHOL, V181, P1585, DOI 10.1016/j.ajpath.2012.08.005; Aleskandarany MA, 2017, BRIT J CANCER, V117, P1176, DOI 10.1038/bjc.2017.261; Aleskandarany MA, 2015, PATHOBIOLOGY, V82, P113, DOI 10.1159/000433583; Banin-Hirata BK, 2018, INT REV IMMUNOL, V37, P144, DOI 10.1080/08830185.2017.1401620; Burdelski C, 2015, HUM PATHOL, V46, P514, DOI 10.1016/j.humpath.2014.06.006; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Kalikin LM, 2001, MAMM GENOME, V12, P925, DOI 10.1007/s00335-001-2073-3; Khwaja SS, 2016, CANCER MED-US, V5, P230, DOI 10.1002/cam4.586; Li MT, 2013, J VIROL, V87, P10037, DOI 10.1128/JVI.01073-13; Liu YL, 2016, BREAST CANCER RES TR, V157, P555, DOI 10.1007/s10549-016-3837-5; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mohammed RAA, 2009, HISTOPATHOLOGY, V55, P1, DOI 10.1111/j.1365-2559.2008.03169.x; Mohammed RAA, 2011, J PATHOL, V223, P358, DOI 10.1002/path.2810; Mousley CJ, 2007, BBA-MOL CELL BIOL L, V1771, P727, DOI 10.1016/j.bbalip.2007.04.002; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Polson ES, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2627; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Rakha EA, 2017, HISTOPATHOLOGY, V70, P622, DOI 10.1111/his.13108; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Rakha EA, 2012, CANCER-AM CANCER SOC, V118, P3670, DOI 10.1002/cncr.26711; Ribeiro FM, 2007, NEUROCHEM INT, V50, P356, DOI 10.1016/j.neuint.2006.09.010; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Shah AV, 2016, VASC PHARMACOL, V86, P3, DOI 10.1016/j.vph.2016.05.003; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Stern HM, 2015, CLIN CANCER RES, V21, P2065, DOI 10.1158/1078-0432.CCR-14-2993; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang S, 2017, ONCOTARGET, V8, P2863, DOI 10.18632/oncotarget.13752; Zhao S, 2008, DNA CELL BIOL, V27, P159, DOI 10.1089/dna.2007.0634	31	0	0	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1675	1682		10.1038/s41379-018-0092-9			8	Pathology	Pathology	GY9FA	WOS:000448943600005	29955149	Green Accepted			2019-10-28	
J	Holand, M; Kolberg, M; Danielsen, SA; Bjerkehagen, B; Eilertsen, IA; Hektoen, M; Mandahl, N; van den Berg, E; Smeland, S; Mertens, F; Hall, KS; Picci, P; Sveen, A; Lothe, RA				Holand, Maren; Kolberg, Matthias; Danielsen, Stine Aske; Bjerkehagen, Bodil; Eilertsen, Ina A.; Hektoen, Merete; Mandahl, Nils; van den Berg, Eva; Smeland, Sigbjorn; Mertens, Fredrik; Hall, Kirsten Sundby; Picci, Piero; Sveen, Anita; Lothe, Ragnhild A.			Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53	MODERN PATHOLOGY			English	Article							COPY NUMBER VARIATION; NEUROFIBROMATOSIS TYPE-1; GENE OCCUR; P53; CANCER; METHYLATION; EXPRESSION; MUTATIONS; TRANSFORMATION; INACTIVATION	Malignant peripheral nerve sheath tumor is a rare and aggressive disease with poor treatment response, mainly affecting adolescents and young adults. Few molecular biomarkers are used in the management of this cancer type, and although TP53 is one of few recurrently mutated genes in malignant peripheral nerve sheath tumor, the mutation prevalence and the corresponding clinical value of the TP53 network remains unsettled. We present a multi-level molecular study focused on aberrations in the TP53 network in relation to patient outcome in a series of malignant peripheral nerve sheath tumors from 100 patients and 38 neurofibromas, including TP53 sequencing, high-resolution copy number analyses of TP53 and MDM2, and gene expression profiling. Point mutations in TP53 were accompanied by loss of heterozygosity, resulting in complete loss of protein function in 8.2% of the malignant peripheral nerve sheath tumors. Another 5.5% had MDM2 amplification. TP53 mutation and MDM2 amplification were mutually exclusive and patients with either type of aberration in their tumor had a worse prognosis, compared to those without (hazard ratio for 5-year disease-specific survival 3.5, 95% confidence interval 1.78-6.98). Both aberrations had similar consequences on the gene expression level, as analyzed by a TP53-associated gene signature, a property also shared with the copy number aberrations and/or loss of heterozygosity at the TP53 locus, suggestin g a common "P53-mutated phenotype" in as many as 60% of the tumors. This was a poor prognostic phenotype (hazard ratio = 4.1, confidence interval: 1.7-9.8), thus revealing a TP53-non-aberrant patient subgroup with a favorable outcome. The frequency of the " TP53-mutated phenotype" warrants explorative studies of stratified treatment strategies in malignant peripheral nerve sheath tumor.	[Holand, Maren; Kolberg, Matthias; Danielsen, Stine Aske; Eilertsen, Ina A.; Hektoen, Merete; Sveen, Anita; Lothe, Ragnhild A.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway; [Holand, Maren; Smeland, Sigbjorn; Lothe, Ragnhild A.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Bjerkehagen, Bodil] Univ Oslo, Dept Oral Biol, Oslo, Norway; [Bjerkehagen, Bodil] Oslo Univ Hosp, Dept Pathol, Div Lab Med, Oslo, Norway; [Mandahl, Nils; Mertens, Fredrik] Lund Univ, Univ & Reg Labs, Dept Clin Genet, Lund, Sweden; [van den Berg, Eva] Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Smeland, Sigbjorn; Hall, Kirsten Sundby] Oslo Univ Hosp, Div Canc Med, Dept Oncol, Oslo, Norway; [Picci, Piero] Ist Ortoped Rizzoli, Expt Oncol Lab, Bologna, Italy	Lothe, RA (reprint author), Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway.; Lothe, RA (reprint author), Univ Oslo, Inst Clin Med, Oslo, Norway.	rlothe@rr-research.no	Kolberg, Matthias/G-2784-2011	Kolberg, Matthias/0000-0001-8288-5364; Mertens, Fredrik/0000-0002-6278-5232	Norwegian Cancer SocietyNorwegian Cancer Society [6824048-2016, 72190-PR-2006-0442]; Southern and Eastern Norway Regional Health Authority (RAL); Stiftelsen Kristian Gerhard Jebsen; Research Council of NorwayResearch Council of Norway	This study was supported by the Norwegian Cancer Society (project number 6824048-2016 to AS and project number 72190-PR-2006-0442 to RAL), the Southern and Eastern Norway Regional Health Authority (RAL), the foundation "Stiftelsen Kristian Gerhard Jebsen", and the Research Council of Norway.	Almeida LO, 2009, GENET MOL RES, V8, P8, DOI 10.4238/vol8-1gmr518; Amatya VJ, 2005, ACTA NEUROPATHOL, V110, P178, DOI 10.1007/s00401-005-1041-5; Berner JM, 1999, GENE CHROMOSOME CANC, V26, P151, DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.3.CO;2-1; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bottillo I, 2009, J PATHOL, V217, P693, DOI 10.1002/path.2494; Bradford D, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0328-6; Brekke HR, 2010, J CLIN ONCOL, V28, P1573, DOI 10.1200/JCO.2009.24.8989; Brosius SN, 2014, ACTA NEUROPATHOL, V127, P573, DOI 10.1007/s00401-013-1209-3; Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Dubbink HJ, 2014, J NEURO-ONCOL, V120, P267, DOI 10.1007/s11060-014-1553-8; Evans DGR, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-17; ExAC Browser, VAR 17 7579472 G C; Feber A, 2011, GENOME RES, V21, P515, DOI 10.1101/gr.109678.110; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hirbe AC, 2015, CLIN CANCER RES, V21, P4201, DOI 10.1158/1078-0432.CCR-14-3049; Holtkamp N, 2007, NEOPLASIA, V9, P671, DOI 10.1593/neo.07304; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Kolberg M, 2017, MOL ONCOL, V11, P1156, DOI 10.1002/1878-0261.12086; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Lothe RA, 1996, CANCER RES, V56, P4778; Lothe RA, 2001, GENE CHROMOSOME CANC, V30, P202, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1079>3.3.CO;2-X; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; McCoughan A, 2007, J MED GENET, V44, P463, DOI 10.1136/jmg.2006.048140; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mertens F, 2000, J PATHOL, V190, P31, DOI 10.1002/(SICI)1096-9896(200001)190:1<31::AID-PATH505>3.0.CO;2-#; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Murahashi M, 2016, CLIN IMMUNOL, V166, P48, DOI 10.1016/j.clim.2016.03.015; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; Nielsen GP, 2013, WHO CLASSIFICATION T, P187; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Nonaka D, 2008, J CUTAN PATHOL, V35, P1014, DOI 10.1111/j.1600-0560.2007.00953.x; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Rieske P, 1999, J EXP CLIN CANC RES, V18, P403; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Skotheim RI, 2003, J CLIN ONCOL, V21, P4586, DOI 10.1200/JCO.2003.07.067; Storlazzi CT, 2006, J PATHOL, V209, P492, DOI 10.1002/path.1998; Sveen A, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006225; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Verdijk RM, 2010, J NEUROPATH EXP NEUR, V69, P16, DOI 10.1097/NEN.0b013e3181c55d55; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallander ML, 2012, ARCH PATHOL LAB MED, V136, P95, DOI 10.5858/arpa.2010-0729-OA; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Xie Y, 2017, J DRUG TARGET, V25, P112, DOI 10.1080/1061186X.2016.1258568; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	56	0	0	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1694	1707		10.1038/s41379-018-0074-y			14	Pathology	Pathology	GY9FA	WOS:000448943600007	29946184				2019-10-28	
J	Angelova, EA; Medeiros, LJ; Wang, W; Muzzafar, T; Lu, XY; Khoury, JD; Ravandi, F; Patel, KP; Hu, ZH; Kanagal-Shamanna, R				Angelova, Evgeniya A.; Medeiros, L. Jeffrey; Wang, Wei; Muzzafar, Tariq; Lu, Xinyan; Khoury, Joseph D.; Ravandi, Farhad; Patel, Keyur P.; Hu, Zhihong; Kanagal-Shamanna, Rashmi			Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience	MODERN PATHOLOGY			English	Article							SPLENIC MARGINAL-ZONE; LYMPHOMA; INVOLVEMENT; VALIDATION; MUTATIONS; DIAGNOSIS; DELETION; TRIAL; FORM	Hairy cell leukemia-variant is rare. Only a small number of cases have been reported in the literature with little cytogenetic or molecular data available. In this study, we describe the clinicopathologic and genetic features of 23 patients with hairy cell leukemia-variant (16 men and 7 women) with a median age of 70 years. Most patients had splenomegaly (90%), leukocytosis (77%), and lymphocytosis (82%); no patients had monocytopenia. Histologically, the bone marrow biopsy specimens showed a mixed pattern of predominantly interstitial and lesser intrasinusoidal infiltration by leukemic cells. In bone marrow aspirate smears most cells had villous cytoplasmic features and a small nucleolus. We describe unusual sites of hairy cell leukemia-variant involvement in 4 patients, including brain, omentum, terminal ileum, and skin at the time of initial presentation. Immunophenotyping showed monotypic B-cells positive for pan B-cell antigens, CD11c, and CD103, and negative for CD25 and annexin A1. Conventional cytogenetic or fluorescence in situ hybridization analysis showed deletions of 17p13/TP53 and 11q22/ATM gene in 5/12 (42%) and 2/9 (22%) cases, respectively. Sequencing of the variable region of IGVH showed mutations (> 2% deviation from germline) in 40% of the cases assessed. MAP2K1 mutation (p. C121S) was seen in 1 of 14 (7%) patients tested. No BRAF V600E mutations were detected. The patients were treated in a heterogeneous manner, but most often with therapies designed for classical hairy cell leukemia and the 5-year overall survival was 84%. In summary, hairy cell leukemia-variant exhibits a heterogeneous spectrum of clinical, morphologic, immunophenotypic, and genetic features that may overlap with classic hairy cell leukemia and other hairy cell-like B-cell neoplasms. A subset of patients can have an aggressive clinical course. In our experience MAP2K1 mutations are uncommon in this disease.	[Angelova, Evgeniya A.; Medeiros, L. Jeffrey; Wang, Wei; Muzzafar, Tariq; Khoury, Joseph D.; Patel, Keyur P.; Hu, Zhihong; Kanagal-Shamanna, Rashmi] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Lu, Xinyan] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Clin Cytogenet Lab, Chicago, IL 60611 USA; [Ravandi, Farhad] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Kanagal-Shamanna, R (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	rkanagal@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019		NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA016672]		Alayed K, 2016, HUM PATHOL, V52, P61, DOI 10.1016/j.humpath.2015.12.029; Andritsos LA, 2018, LEUKEMIA LYMPHOMA, V59, P1008, DOI 10.1080/10428194.2017.1365853; Arons E, 2009, BLOOD, V114, P4687, DOI 10.1182/blood-2009-01-201731; Boddu PC, 2018, LEUKEMIA RES, V66, P73, DOI 10.1016/j.leukres.2018.01.013; CAWLEY JC, 1980, LEUKEMIA RES, V4, P547, DOI 10.1016/0145-2126(80)90066-1; Cessna MH, 2005, AM J CLIN PATHOL, V123, P132, DOI 10.1309/8QYT-YQ1C-LQMH-Q9CL; Chandana SR, 2013, J CLIN ONCOL, V31, pE186, DOI 10.1200/JCO.2012.44.8787; Charin YI, 2005, ARCH PATHOL LAB MED, V129, P395; Chihara D, 2016, BRIT J HAEMATOL, V174, P760, DOI 10.1111/bjh.14129; Dong HY, 2009, AM J CLIN PATHOL, V131, P586, DOI 10.1309/AJCPL13YDUHFKPJU; Durham BH, 2017, BLOOD, V130, P1644, DOI [10.1182/blood-2017-01765107, 10.1182/blood-2017-01-765107]; Falini B, 2004, LANCET, V363, P1869, DOI 10.1016/S0140-6736(04)16356-3; Foucar K, 2001, WHO CLASSIFICATION T, P138; Getta BM, 2016, BRIT J HAEMATOL, V175, P402, DOI 10.1111/bjh.14207; Hockley SL, 2011, LEUKEMIA, V25, P1189, DOI 10.1038/leu.2011.47; Hockley SL, 2012, BRIT J HAEMATOL, V158, P347, DOI 10.1111/j.1365-2141.2012.09163.x; Hu Z, 2016, AM J HEMATOL, V92, P1398; Hu ZH, 2018, MODERN PATHOL, V31, P327, DOI 10.1038/modpathol.2017.135; ISCN, 2016, ISCN 2016 AN INT SYS, V149, P1; Jain P, 2018, BRIT J HAEMATOL, V180, P33, DOI 10.1111/bjh.15018; Khoury JD, 2018, CLIN CANCER RES, V24, P521, DOI 10.1158/1078-0432.CCR-17-1597; Mason EF, 2017, LEUKEMIA LYMPHOMA, V58, P233, DOI 10.1080/10428194.2016.1185786; Matutes E, 2001, LEUKEMIA, V15, P184, DOI 10.1038/sj.leu.2401999; Matutes E, 2006, HEMATOL ONCOL CLIN N, V20, P1051, DOI 10.1016/j.hoc.2006.06.012; Matutes E, 2015, BEST PRACT RES CL HA, V28, P253, DOI 10.1016/j.beha.2015.09.002; McKay MJ, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.85; Piris M, 2017, SPLENIC B CELL LYMPH, P229; Ponzoni M, 2012, AM J SURG PATHOL, V36, P1609, DOI 10.1097/PAS.0b013e318271243d; SAINATI L, 1990, BLOOD, V76, P157; Shao HP, 2013, LEUKEMIA RES, V37, P401, DOI 10.1016/j.leukres.2012.11.021; Tadmor T, 2015, BEST PRACT RES CL HA, V28, P193, DOI 10.1016/j.beha.2015.10.020; Vallianatou K, 1999, LEUKEMIA RES, V23, P1041, DOI 10.1016/S0145-2126(99)00127-7; Waterfall JJ, 2014, NAT GENET, V46, P8, DOI 10.1038/ng.2828; Watkins AJ, 2010, J PATHOL, V220, P461, DOI 10.1002/path.2665; ZINZANI PL, 1990, HAEMATOLOGICA, V75, P54	35	2	2	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1717	1732		10.1038/s41379-018-0093-8			16	Pathology	Pathology	GY9FA	WOS:000448943600009	29955146				2019-10-28	
J	Bell, A; Bell, D; Chakravarti, N; Ma, JS; Henton, N; Prieto, VG				Bell, Achim; Bell, Diana; Chakravarti, Nitin; Ma, Junsheng; Henton, Nicholas; Prieto, Victor G.			Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin	MODERN PATHOLOGY			English	Article							MELANOMA; EXPRESSION; MIGRATION; INVASION; MIR-145; CANCER; YB-1	How melanocytes transform into melanoma cells remains largely unknown. However, prolonged ultraviolet radiation exposure is linked with melanoma, and the DNA of melanomas arising in chronically sun-exposed skin is characterized by an elevated number of pyrimidine transitions, mainly C>T (predominantly caused by ultraviolet B), and transversions of GC>TA or AT>CG (caused by ultraviolet A over indirect mechanisms). Since ultraviolet penetrates mostly only the superficial dermis, we sought to determine the extent to which superficial and deep melanocytes of nevi in sun-exposed skin differ in their miRNA expression and consider the changes as likely secondary to ultraviolet radiation-induced damage. The differentially expressed miRNAs were analyzed for known potential oncomiRs or linked to potential oncogenes or tumor suppressors. Superficial and deep melanocytes were microdissected from the nevi of 14 patients. The suspensions were processed for hybridization to a ribonucleotide protection system with 2280 total probes, including 2256 miRNA probes targeting 2083 human miRNAs. A comprehensive analysis of all human miRNAs registered in miRBase 11.0 was performed using the HTG Molecular Diagnostic database. Statistical analysis of these data yielded for 14 samples a statistically relevant profile of 39 miRNA species at FDR< 0.1 that were differentially expressed between superficial and deep melanocytes. Ingenuity Pathway Analysis based on the expression data of these 39 miRNAs suggested the gene transcripts AR, MDM2, SMAD2/3, and YBX1 as the most probable miRNA targets, which were validated at the protein level. Our findings suggest that superficial ultraviolet radiation-damaged melanocytes can be differentiated from deep melanocytes on the basis of the expression of 39 miRNAs, the most probable gene transcript and protein targets of which are AR, MDM2, SMAD2/3, and YBX1, with YBX1 expression validating the best the molecular signature in immunohistochemical analysis.	[Bell, Achim; Bell, Diana; Henton, Nicholas; Prieto, Victor G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol & Dermatopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Chakravarti, Nitin] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, 700 Childrens Dr,WA4112, Columbus, OH 43205 USA; [Ma, Junsheng] Univ Texas MD Anderson Canc Ctr, Dept Biostat, 1515 Holcombe Blvd, Houston, TX 77030 USA	Prieto, VG (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol & Dermatopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	vprieto@mdanderson.org	Chakravarti, Nitin/O-8232-2019	Chakravarti, Nitin/0000-0002-6619-953X	University of Texas MD Anderson Cancer Center; Dermatopathology section of the Pathology Department; Department of Biostatistics	We thank at The University of Texas MD Anderson Cancer Center, the Dermatopathology section of the Pathology Department and Dr. Jing Ning of the Department of Biostatistics for their support, the Laboratory of the Translational Molecular Pathology for facilitating the immunohistochemical study, and Mr. Joseph Munch from the Department of Scientific Publications, for his helpful editing input.	Babapoor S, 2017, LAB INVEST, V97, P636, DOI 10.1038/labinvest.2017.5; Baptista MS, 2017, PHOTOCHEM PHOTOBIOL, V93, P912, DOI 10.1111/php.12716; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Boyd AS, 2015, J AM ACAD DERMATOL, V73, P500, DOI 10.1016/j.jaad.2015.06.013; Catalanotto C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101712; Cymerman RM, 2016, JNCI-J NATL CANCER I, V108, P1; Dadras SS, 2011, ARCH PATHOL LAB MED, V135, P860, DOI 10.1043/2009-0623-RAR1.1; Edwards PAW, 2010, J PATHOL, V220, P244, DOI 10.1002/path.2632; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Holst LMB, 2011, EXP DERMATOL, V20, P278, DOI 10.1111/j.1600-0625.2010.01163.x; Howell PM, 2010, OCHSNER J, V10, P83; Jia JJ, 2017, MOL MED REP, V15, P240, DOI 10.3892/mmr.2016.5978; Jiang ZJ, 2017, ONCOL RES, V25, P1081, DOI 10.3727/096504016X14831120463349; Lall RK, 2015, PHOTOCHEM PHOTOBIOL, V91, P173, DOI 10.1111/php.12346; Lei C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.493; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Matsumoto Ken, 2005, J Mol Genet Med, V1, P11; McGovern VJ, 1983, MELANOMA HISTOLOGICA; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Mitchell D, 2012, PHOTOCH PHOTOBIO SCI, V11, P69, DOI 10.1039/c1pp05146f; Prieto VG, 2015, PATHOLOGY CHALLENGIN, P35; Rogers T, 2016, GIORN ITAL DERMAT V, V151, P365; Roh MR, 2015, PIGM CELL MELANOMA R, V28, P661, DOI 10.1111/pcmr.12412; Sengupta D, 2018, FEBS LETT, V592, P446, DOI 10.1002/1873-3468.12974; Sha JF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154915; Simanovich Elina, 2017, Front Immunol, V8, P1931, DOI 10.3389/fimmu.2017.01931; Sun XY, 2016, EXP DERMATOL, V25, P708, DOI 10.1111/exd.13057; Syed DN, 2013, CURR DRUG TARGETS, V14, P1128, DOI 10.2174/13894501113149990184; Coelho MMV, 2016, CLIN DERMATOL, V34, P563, DOI 10.1016/j.clindermatol.2016.05.022; Wei K, 2017, CELL PHYSIOL BIOCHEM, V44, P1545, DOI 10.1159/000485650; Wotschofsky Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148746; Wu HJ, 2013, BIOCHEM BIOPH RES CO, V441, P693, DOI 10.1016/j.bbrc.2013.10.053; Wu SL, 2015, NUCLEIC ACIDS RES, V43, P8516, DOI 10.1093/nar/gkv779	34	2	2	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1744	1755		10.1038/s41379-018-0088-5			12	Pathology	Pathology	GY9FA	WOS:000448943600011	29955145				2019-10-28	
J	Hissong, E; Crowe, EP; Yantiss, RK; Chen, YT				Hissong, Erika; Crowe, Elizabeth P.; Yantiss, Rhonda K.; Chen, Yao-Tseng			Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing	MODERN PATHOLOGY			English	Article							4 ANTIBODY PANEL; LYNCH-SYNDROME; COLON-CANCER; BETHESDA GUIDELINES; SOMATIC MUTATIONS; IMMUNOHISTOCHEMISTRY; DEFICIENCY; CARCINOMAS; ADENOCARCINOMA; TUMORS	Results of DNA mismatch repair testing are used to detect Lynch syndrome and have prognostic and therapeutic implications among patients with sporadic colorectal carcinomas. Immunohistochemistry for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6) and PCR for microsatellite instability are two established methods for assessing mismatch repair function. Older literature suggested a discordance rate of approximately 5% between these assays, leading some institutions to perform dual testing on all cases. Although universal mismatch repair testing is now recommended by multiple professional organizations, none provide guidelines regarding preferred assays. We surveyed 96 academic and nonacademic institutions to assess Lynch syndrome screening practices and evaluated discordance rates between immunohistochemistry and PCR among 809 colorectal cancers tested in our own institution. Our survey demonstrated no significant differences between academic and nonacademic practices with respect to testing strategies. Eighty six percent performed universal screening, and usually (76%) employed immunohistochemistry on initial biopsy samples. Only 20% employed PCR; these were mostly academic practices that used both immunohistochemistry and PCR (p < 0.01 compared with the nonacademic groups). Loss of MLH1/PMS2 staining was often (90%) followed by either BRAF mutational analysis or MLH1 methylation assays. Only 24% adhered to WHO recommendations to assign histologic grade based on mismatch repair status. We found only 3 cases (0.4%) with discordant immunohistochemistry and PCR results in our own practice: 1 reflected decreased MSH-6 staining in a neoadjuvantly treated microsatellite stable tumor, 1 MLH1-deficient tumor showed diminished MLH1/ PMS2 in the tumor compared with internal control, and 1 case reflected an error in the molecular laboratory. Overall, our results showed extremely low discordance between methods assessing mismatch repair status and would suggest immunohistochemistry as the preferred single screening test. PCR can be reserved for cases that show equivocal immunostaining patterns.	[Hissong, Erika; Crowe, Elizabeth P.; Yantiss, Rhonda K.; Chen, Yao-Tseng] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA	Chen, YT (reprint author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.	ytchen@med.cornell.edu			Weill Cornell Department of Pathology-Translational Research Program	The authors would like to thank the Weill Cornell Department of Pathology-Translational Research Program for funding and support, as well as the respondents for their participation in the survey and their thoughtful comments.	Bao F, 2010, AM J SURG PATHOL, V34, P1798, DOI 10.1097/PAS.0b013e3181f906cc; Bartley AN, 2012, CANCER PREV RES, V5, P320, DOI 10.1158/1940-6207.CAPR-11-0288; Beamer LC, 2012, J CLIN ONCOL, V30, P1058, DOI 10.1200/JCO.2011.38.4719; Bellizzi AM, 2009, ADV ANAT PATHOL, V16, P405, DOI 10.1097/PAP.0b013e3181bb6bdc; Benatti P, 2005, CLIN CANCER RES, V11, P8332, DOI 10.1158/1078-0432.CCR-05-1030; Boland CR, 1998, CANCER RES, V58, P5248; Boland CR, 2010, GASTROENTEROLOGY, V138; Boland CR, 2010, GASTROENTEROLOGY, V138, P2191; Bosman FT, 2010, WHO CLASSIF TUMOURS, V3, P417; Bouzourene H, 2010, FAM CANCER, V9, P167, DOI 10.1007/s10689-009-9302-4; Buza N, 2016, EXPERT REV MOL DIAGN, V16, P591, DOI 10.1586/14737159.2016.1156533; Cawkwell L, 1999, GUT, V45, P409, DOI 10.1136/gut.45.3.409; Cohen SA, 2016, CANCER-AM CANCER SOC, V122, P393, DOI 10.1002/cncr.29758; de la Chapelle A, 2009, INT J CANCER, V125, P1492, DOI 10.1002/ijc.24491; Debniak T, 2000, EUR J CANCER, V36, P49, DOI 10.1016/S0959-8049(99)00208-7; Dieumegard B, 2000, BRIT J CANCER, V82, P871, DOI 10.1054/bjoc.1999.1014; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Fadhil W, 2012, HISTOPATHOLOGY, V60, P653, DOI 10.1111/j.1365-2559.2011.04021.x; Funkhouser WK, 2012, J MOL DIAGN, V14, P91, DOI 10.1016/j.jmoldx.2011.11.001; Gavin PG, 2013, CLIN CANCER RES, V19, P1301, DOI 10.1158/1078-0432.CCR-13-0020; Goldberg KB, 2018, EXP BIOL MED, V243, P308, DOI 10.1177/1535370217740861; Gologan A, 2005, ARCH PATHOL LAB MED, V129, P1390; Guastadisegni C, 2010, EUR J CANCER, V46, P2788, DOI 10.1016/j.ejca.2010.05.009; Hall G, 2010, PATHOLOGY, V42, P409, DOI 10.3109/00313025.2010.493871; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hampel H, 2014, J NATL COMPR CANC NE, V12, P829, DOI 10.6004/jnccn.2014.0200; Hampel H, 2010, J NATL COMPR CANC NE, V8, P597, DOI 10.6004/jnccn.2010.0044; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Hicks SC, 2011, PATHOLOGY, V43, P84, DOI 10.1097/PAT.0b013e3283410b26; Huang MN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13321; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044; Johncilla ME, 2018, MODERN PATHOL, V31, P272; Klarskov L, 2010, HUM PATHOL, V41, P1387, DOI 10.1016/j.humpath.2010.03.003; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Murphy KM, 2006, J MOL DIAGN, V8, P305, DOI 10.2353/jmoldx.2006.050092; Mvundura M, 2010, GENET MED, V12, P93, DOI 10.1097/GIM.0b013e3181cd666c; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Nowak JA, 2017, J MOL DIAGN, V19, P84, DOI 10.1016/j.jmoldx.2016.07.010; Orimo H, 2000, J HUM GENET, V45, P228, DOI 10.1007/s100380070031; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Pai RK, 2016, AM J SURG PATHOL, V40, pE17, DOI 10.1097/PAS.0000000000000620; Parsons MT, 2012, J MED GENET, V49, P151, DOI 10.1136/jmedgenet-2011-100714; Pino MS, 2010, EXPERT REV MOL DIAGN, V10, P651, DOI 10.1586/ERM.10.45; Plazzer JP, 2013, FAM CANCER, V12, P175, DOI 10.1007/s10689-013-9616-0; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Rosty C, 2014, HUM PATHOL, V45, P2077, DOI 10.1016/j.humpath.2014.06.020; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Sepulveda AR, 2017, AM J CLIN PATHOL, V147, P221, DOI 10.1093/ajcp/aqw209; Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031; Shia JR, 2009, AM J SURG PATHOL, V33, P1639, DOI 10.1097/PAS.0b013e3181b15aa2; Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Vilkin A, 2014, HUM PATHOL, V45, P2029, DOI 10.1016/j.humpath.2014.07.005; Wahlberg SS, 2002, CANCER RES, V62, P3485; Watson N, 2007, J MOL DIAGN, V9, P472, DOI 10.2353/jmoldx.2007.060162; Weissman SM, 2012, J GENET COUNS, V21, P484, DOI 10.1007/s10897-011-9465-7; Wright CL, 2003, AM J SURG PATHOL, V27, P1393, DOI 10.1097/00000478-200311000-00001; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612; Yuan L, 2015, INT J CLIN EXP MED, V8, P20988; Zhang XC, 2013, WORLD J GASTRO ONCOL, V5, P12, DOI 10.4251/wjgo.v5.i2.12	67	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	NOV	2018	31	11					1756	1766		10.1038/s41379-018-0094-7			11	Pathology	Pathology	GY9FA	WOS:000448943600012	29955148				2019-10-28	
J	El-Zimaity, H; Choi, WT; Lauwers, GY; Riddell, R				El-Zimaity, Hala; Choi, Won-Tak; Lauwers, Gregory Y.; Riddell, Robert			The differential diagnosis of Helicobacter pylori negative gastritis	VIRCHOWS ARCHIV			English	Review						H.pylori negative; Gastric atrophy; Infections; Autoimmune; Drugs; Medication; Gastropathy; Lymphocytic gastritis	VERSUS-HOST-DISEASE; METAPLASTIC ATROPHIC GASTRITIS; GASTROINTESTINAL-TRACT INJURY; FOCALLY ENHANCED GASTRITIS; BARR-VIRUS GASTRITIS; COLLAGENOUS GASTRITIS; LYMPHOCYTIC GASTRITIS; PERNICIOUS-ANEMIA; CELIAC-DISEASE; EMPHYSEMATOUS GASTRITIS	Gastric biopsies are often submitted with as clinical question Helicobacter pylori (HP) infection. Regularly, the morphology suggests a HP infection but the organism is not detected in special stains. This review presents a practical approach to deal with such biopsies. The first step is to exclude a false negative result of the search for HP, by ensuring that both antral and oxyntic mucosa are present, by the use of sensitive stains, identification of marked reactive changes, such as intestinal, pseudo-pyloric, pancreatic metaplasia that may suggest a diagnosis of (HP associated or autoimmune) atrophic gastritis, and finally identification of signs of the use of proton pump inhibitors (PPI) as in such biopsies, HP may sometimes be found only within parietal cells. The differential diagnosis should include lymphocytic gastritis, other diseases affecting the stomach, such as inflammatory bowel disease (IBD), vasculitis, granulomatous disease, viral infection, such as cytomegalovirus (CMV) or more rarely Epstein-Barr virus (EBV) infection, or other bacterial infections, such as Enterococcus and Treponema pallidum. Clinical input may be required to ensure the patient is not taking medication that may cause gastritis, such as antibiotics used for HP eradication or common medications that cause a form of gastropathy. When these have been excluded, a known cause has not been found and in such a case, the term idiopathic focal/diffuse gastritis can be used.	[El-Zimaity, Hala] Dynacare Labs, Toronto, ON, Canada; [Choi, Won-Tak] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Anat Pathol, Tampa, FL 33612 USA; [Lauwers, Gregory Y.] Univ S Florida, Morsani Coll Med, Oncol Sci, Tampa, FL 33612 USA; [Riddell, Robert] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; [Riddell, Robert] Mt Sinai Hosp, Toronto, ON, Canada	El-Zimaity, H (reprint author), Dynacare Labs, Toronto, ON, Canada.	hzimaity@gmail.com					Abraham SC, 2001, AM J SURG PATHOL, V25, P637, DOI 10.1097/00000478-200105000-00011; Abraham SC, 1999, AM J SURG PATHOL, V23, P1241, DOI 10.1097/00000478-199910000-00009; Affolter K, 2017, HUM PATHOL, V66, P212, DOI 10.1016/j.humpath.2017.02.011; Al-Kandari Asma, 2014, J Med Case Rep, V8, P278, DOI 10.1186/1752-1947-8-278; Allan K, 2005, AM J MED SCI, V329, P205, DOI 10.1097/00000441-200504000-00007; Antico A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/520970; Anwar MS, 2017, GASTROENTEROL RES, V10, P126, DOI 10.14740/gr748w; Appelman MH, 2016, J CASE REP, V7, P7; Arnason T, 2015, MODERN PATHOL, V28, P533, DOI 10.1038/modpathol.2014.119; Bajwa Raza U, 2015, WMJ, V114, P271; Bektas M, 2012, ANN GASTROENTEROL, V25, P123; Bettington M, 2013, PATHOLOGY, V45, P145, DOI 10.1097/PAT.0b013e32835cc22c; Billiemaz K, 2009, ENDOSCOPY, V41, pE233, DOI 10.1055/s-2008-1077440; Broide E, 2017, CLIN EXP GASTROENTER, V10, P195, DOI 10.2147/CEG.S133421; Chen ZME, 2007, AM J SURG PATHOL, V31, P1446, DOI 10.1097/PAS.0b013e318050072f; Chlumska A, 2005, Cesk Patol, V41, P137; Cianferoni A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0558-5; Collins MH, 2009, IMMUNOL ALLERGY CLIN, V29, P109, DOI 10.1016/j.iac.2008.10.005; Cote JF, 1998, HUM PATHOL, V29, P883, DOI 10.1016/S0046-8177(98)90461-0; Dahshan A, 2001, ARCH PEDIAT ADOL MED, V155, P609, DOI 10.1001/archpedi.155.5.609; DAVIDSON RJL, 1989, J CLIN PATHOL, V42, P1092, DOI 10.1136/jcp.42.10.1092; De Re V, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0133-x; De Witte C, 2016, HELICOBACTER, V21, P62, DOI 10.1111/hel.12343; DEGIACOMO C, 1994, J PEDIATR-US, V124, P57, DOI 10.1016/S0022-3476(94)70254-3; DIXON MF, 1986, J CLIN PATHOL, V39, P524, DOI 10.1136/jcp.39.5.524; ECTORS NL, 1993, HISTOPATHOLOGY, V23, P55, DOI 10.1111/j.1365-2559.1993.tb01183.x; EISENSTAT DDR, 1995, GASTROENTEROLOGY, V109, P592, DOI 10.1016/0016-5085(95)90349-6; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; El-Zimaity H, 2013, CAN J GASTROENTEROL, V27, pE25, DOI 10.1155/2013/897423; El-Zimaity HMT, 1999, HUM PATHOL, V30, P72, DOI 10.1016/S0046-8177(99)90303-9; El-Zimaity HMT, 2002, CANCER-AM CANCER SOC, V94, P1428, DOI 10.1002/cncr.10375; El-Zimaity HMT, 1998, MODERN PATHOL, V11, P288; El-Zimaity HMT, 2001, AM J GASTROENTEROL, V96, P666; ElZimaity HMT, 1996, HUM PATHOL, V27, P1348, DOI 10.1016/S0046-8177(96)90349-4; ELZIMAITY HMT, 1995, AM J GASTROENTEROL, V90, P1962; Gabrieli D, 2017, UNITED EUR GASTROENT, V5, P805, DOI 10.1177/2050640616684698; Garcia Diaz E, 2001, Gastroenterol Hepatol, V24, P191; Genta RM, 2015, ALIMENT PHARM THER, V41, P218, DOI 10.1111/apt.13007; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; Goto K, 2016, INT J SURG PATHOL, V24, P89, DOI 10.1177/1066896915613434; GREENSON JK, 1993, AM J SURG PATHOL, V17, P45, DOI 10.1097/00000478-199301000-00005; GREENSTEIN DB, 1994, J CLIN GASTROENTEROL, V18, P4, DOI 10.1097/00004836-199401000-00003; Grin A, 2012, AM J SURG PATHOL, V36, P935, DOI 10.1097/PAS.0b013e31824babc2; Guilloteau M, 2007, GASTROEN CLIN BIOL, V31, P1155, DOI 10.1016/S0399-8320(07)78357-4; Hachem Christine Yeh, 2007, MedGenMed, V9, P64; Haesebrouck F, 2009, CLIN MICROBIOL REV, V22, P202, DOI 10.1128/CMR.00041-08; Hayat M, 1999, J CLIN PATHOL, V52, P815, DOI 10.1136/jcp.52.11.815; HENSON D, 1972, ARCH PATHOL, V93, P477; HRUBAN RH, 1989, CANCER, V63, P1944, DOI 10.1002/1097-0142(19890515)63:10<1944::AID-CNCR2820631013>3.0.CO;2-#; Huang CT, 2009, SCAND J INFECT DIS, V41, P317, DOI 10.1080/00365540902744774; Iacobuzio-Donahue CA, 2001, AM J SURG PATHOL, V25, P1067, DOI 10.1097/00000478-200108000-00012; Jhala NC, 2003, ARCH PATHOL LAB MED, V127, P854; Jin XY, 2013, DIGEST ENDOSC, V25, P547, DOI 10.1111/j.1443-1661.2012.01391.x; JOHNSTONE JM, 1978, HISTOPATHOLOGY, V2, P335, DOI 10.1111/j.1365-2559.1978.tb01726.x; Jun DW, 2007, GASTROINTEST ENDOSC, V65, P1092, DOI 10.1016/j.gie.2006.11.003; Jy C, 2016, PATHOLOGY, P48; Kamada T, 2015, HELICOBACTER, V20, P192, DOI 10.1111/hel.12193; Kamimura K, 2007, DIGEST DIS SCI, V52, P995, DOI 10.1007/s10620-006-9278-y; Kamimura K, 2015, WORLD J GASTROINTEST, V7, P265, DOI 10.4253/wjge.v7.i3.265; Kaneki T, 2001, HEPATO-GASTROENTEROL, V48, P1209; KEKKI M, 1991, SCAND J GASTROENTERO, V26, P109, DOI 10.3109/00365529109103997; Kim GY, 2005, GASTROINTEST ENDOSC, V61, P168, DOI 10.1016/S0016-5107(04)02217-5; Kim YJ, 2017, PEDIATR INT, V59, P234, DOI 10.1111/ped.13175; Kobayashi M, 2016, PATHOL INT, V66, P120, DOI 10.1111/pin.12349; Kocsmar E, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12387; Lagorce-Pages C, 2001, AM J SURG PATHOL, V25, P1174, DOI 10.1097/00000478-200109000-00008; Lauwers GY, 2010, J GASTROENTEROL, V45, P131, DOI 10.1007/s00535-009-0146-3; Leber A, 2012, GASTROENTEROL RES, V5, P236, DOI 10.4021/gr498w; Lebwohl B, 2015, ALIMENT PHARM THER, V42, P180, DOI 10.1111/apt.13249; Lee BS, 2005, ENDOSCOPY, V37, P490, DOI 10.1055/s-2005-861254; Leung ST, 2009, AM J SURG PATHOL, V33, P788, DOI 10.1097/PAS.0b013e318196a67f; Madisch A, 2006, ALIMENT PHARM THER, V23, P473, DOI 10.1111/j.1365-2036.2006.02778.x; Magro F, 2013, J CROHNS COLITIS, V7, P827, DOI 10.1016/j.crohns.2013.06.001; Maguilnik I, 2012, ALIMENT PHARM THER, V36, P736, DOI 10.1111/apt.12031; Makino M, 2015, PATHOL INT, V65, P33, DOI 10.1111/pin.12227; Mandaliya R, 2016, INDIAN J GASTROENTER, V35, P133, DOI 10.1007/s12664-016-0633-4; Marginean EC, 2006, AM J SURG PATHOL, V30, P514, DOI 10.1097/00000478-200604000-00013; Matsukuma K, 2016, AM J SURG PATHOL, V40, P1550, DOI 10.1097/PAS.0000000000000706; McHugh JB, 2013, AM J SURG PATHOL, V37, P295, DOI 10.1097/PAS.0b013e31826b2a94; Montalban-Arques A, 2016, J PATHOL, V240, P425, DOI 10.1002/path.4782; Murakami TT, 2017, PREV MED, V100, P216, DOI 10.1016/j.ypmed.2017.04.021; Nohr EW, 2017, INT J SURG PATHOL, V25, P449, DOI 10.1177/1066896917696751; Nordenstedt H, 2013, AM J GASTROENTEROL, V108, P65, DOI 10.1038/ajg.2012.372; Okamura T, 2013, CLIN J GASTROENTEROL, V6, P38, DOI 10.1007/s12328-012-0355-9; Owens SR, 2011, INT J SURG PATHOL, V19, P196, DOI 10.1177/1066896908316905; Papadopoulos AA, 2005, GUT, V54, P1822, DOI 10.1136/gut.2005.075077; Parfitt JR, 2007, HUM PATHOL, V38, P527, DOI 10.1016/j.humpath.2007.01.014; Peixoto A, 2016, ACTA GASTRO-ENT BELG, V79, P271; Pittman ME, 2015, AM J SURG PATHOL, V39, P1611, DOI 10.1097/PAS.0000000000000481; Poley JW, 2004, GASTROINTEST ENDOSC, V60, P372, DOI 10.1016/S0016-5107(04)01722-5; Polydorides AD, 2014, SEMIN DIAGN PATHOL, V31, P114, DOI 10.1053/j.semdp.2014.02.008; Pulimood AB, 2011, WORLD J GASTROENTERO, V17, P433, DOI 10.3748/wjg.v17.i4.433; ROSE MS, 1969, BRIT MED J, V1, P468, DOI 10.1136/bmj.1.5642.468; Rostami K, 2017, GUT, V66, P2080, DOI 10.1136/gutjnl-2017-314297; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Rudi J, 1997, DIGEST DIS SCI, V42, P1652, DOI 10.1023/A:1018849112533; Ruiz AR, 2001, AIDS PATIENT CARE ST, V15, P1, DOI 10.1089/108729101460047; Saraswati S, 2015, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00764; Seve P, 2005, J INTERN MED, V258, P191, DOI 10.1111/j.1365-2796.2005.01525.x; Shapiro JL, 1996, AM J SURG PATHOL, V20, P462, DOI 10.1097/00000478-199604000-00009; Sharif F, 2002, AM J GASTROENTEROL, V97, P1415, DOI 10.1016/S0002-9270(02)04141-2; Shiota S, 2017, CLIN GASTROENTEROL H, V15, P1037, DOI 10.1016/j.cgh.2017.01.006; Shiotani A, 2018, DIGESTION, V97, P154, DOI 10.1159/000484688; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; SNOVER DC, 1985, HUM PATHOL, V16, P387, DOI 10.1016/S0046-8177(85)80232-X; Srivastava A, 2007, HISTOPATHOLOGY, V50, P15, DOI 10.1111/j.1365-2559.2006.02553.x; STRAYER DS, 1981, CANCER, V48, P1478, DOI 10.1002/1097-0142(19810915)48:6<1478::AID-CNCR2820480633>3.0.CO;2-D; Takano Y, 2015, INTERNAL MED, V54, P195, DOI 10.2169/internalmedicine.54.3337; Venerito M, 2016, J CLIN PATHOL, V69, P677, DOI 10.1136/jclinpath-2015-203405; Vesoulis Z, 2000, MODERN PATHOL, V13, P591, DOI 10.1038/modpathol.3880101; Vieth M, 2017, VIRCHOWS ARCH, V470, P245, DOI 10.1007/s00428-017-2077-3; Vorobjova T, 2008, APMIS, V116, P465, DOI 10.1111/j.1600-0463.2008.00934.x; Walker C, 2016, GUT, V65, DOI 10.1136/gutjnl-2015-310564; Washington K, 1997, AM J SURG PATHOL, V21, P1037, DOI 10.1097/00000478-199709000-00008; WASHINGTON K, 1991, MODERN PATHOL, V4, P707; WEISDORF DJ, 1990, BLOOD, V76, P624; Winslow JL, 2001, AM J CLIN PATHOL, V116, P753; Wolf EM, 2014, DIGEST LIVER DIS, V46, P412, DOI 10.1016/j.dld.2013.12.017; Wright CL, 1998, AM J SURG PATHOL, V22, P383, DOI 10.1097/00000478-199804000-00001; Wu TT, 1999, AM J SURG PATHOL, V23, P153, DOI 10.1097/00000478-199902000-00003; Yamaguchi Eriko, 2017, Nihon Shokakibyo Gakkai Zasshi, V114, P248, DOI 10.11405/nisshoshi.114.248; Zafad S, 2007, PEDIATR BLOOD CANCER, V49, P1017, DOI 10.1002/pbc.20896; Zhang HJ, 2017, SCAND J GASTROENTERO, V52, P150, DOI 10.1080/00365521.2016.1236397; 2007, J PEDIATR GASTR NUTR, V44, P653, DOI DOI 10.1097/MPG.0b013e31805563f3	124	1	1	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					533	550		10.1007/s00428-018-2454-6			18	Pathology	Pathology	GY8GR	WOS:000448861800001	30255340				2019-10-28	
J	Kirmizi, A; Kalkan, C; Yuksel, S; Gencturk, Z; Savas, B; Soykan, I; Cetinkaya, H; Ensari, A				Kirmizi, Ayca; Kalkan, Cagdas; Yuksel, Seher; Gencturk, Zeynep; Savas, Berna; Soykan, Irfan; Cetinkaya, Hulya; Ensari, Arzu			Discriminant value of IEL counts and distribution pattern through the spectrum of gluten sensitivity: a simple diagnostic approach	VIRCHOWS ARCHIV			English	Article						Celiac disease; Intraepithelial lymphocytosis; Discriminant analysis	INTRAEPITHELIAL LYMPHOCYTE-COUNT; CELIAC-DISEASE; VILLOUS ARCHITECTURE; CLASSIFICATION; QUANTITATION; ENTEROPATHY; TIP	Intraepithelial lymphocytosis (IELosis) with or without villous abnormality is a characteristic feature of gluten sensitivity (GS) including celiac disease (CD) and non-celiac-GS, although various conditions may also be associated with IELosis. In order to distinguish GS from the other causes of IELosis, a threshold for IEL counts is necessary. We aimed to determine a cut-off value for IELs and monitor its value in the spectrum of GS in a large cohort. For this purpose, the duodenal biopsies from four groups of individuals including Types 1 (n=88) and 3 (n=92) CD, non-CD IELosis (n=112), and control (n=82) cases, all strictly defined by their clinical, laboratory, and serologic features, were evaluated. The number of IELs/100 enterocytes and their distribution pattern on H&E- and CD3-immunostained sections were assessed for each group. Kruskal-Wallis test and ROC curve analysis for discriminant value were employed for statistics. The IEL counts showed an increasing trend through the spectrum of mucosal pathology including controls (12.06; 21.40), non-CD IELosis (28.62; 39.46), Type 1 CD (49.27; 60.15), and Type 3 CD (58.53; 71.74) both on H&E- and CD3-immunostained sections, respectively (p<0.001). ROC analysis revealed 20.5 on H&E and 28.5 on CD3 as the IEL cut-off values with a sensitivity of 95.9 and 87.7% and a specificity of 98.8% and 93.9%, respectively, for controls. IELs showed a diffuse distribution pattern per biopsy piece and per villus (90.9%, 100%, respectively) in nearly all of Type 1 CD cases (p<0.001). An IEL cut-off value of 20.5 on H&E together with a diffuse distribution pattern seem to be the most discriminant features for the diagnosis of CD, even for the milder forms of the disease.	[Kirmizi, Ayca; Yuksel, Seher; Savas, Berna; Ensari, Arzu] Ankara Univ, Dept Pathol, Fac Med, TR-06100 Ankara, Turkey; [Kalkan, Cagdas; Soykan, Irfan; Cetinkaya, Hulya] Ankara Univ, Fac Med, Dept Gastroenterol, TR-06100 Ankara, Turkey; [Gencturk, Zeynep] Ankara Univ, Fac Med, Dept Biostat, TR-06100 Ankara, Turkey	Ensari, A (reprint author), Ankara Univ, Dept Pathol, Fac Med, TR-06100 Ankara, Turkey.	ensariarzu@gmail.com					Bardella Maria Teresa, 2016, Curr Gastroenterol Rep, V18, P63, DOI 10.1007/s11894-016-0536-7; Bhatnagar S, 2005, J PEDIATR GASTR NUTR, V41, P204, DOI 10.1097/01.mpg.0000172261.24115.29; Biagi F, 2004, J CLIN PATHOL, V57, P835, DOI 10.1136/jcp.2003.013607; Cabanne Ana, 2007, Acta Gastroenterologica Latinoamericana, V37, P20; Ensari Arzu, 2016, Gastroenterol Hepatol Bed Bench, V9, P73; Ensari A, 2010, ARCH PATHOL LAB MED, V134, P826, DOI 10.1043/1543-2165-134.6.826; FERGUSON A, 1971, GUT, V12, P988, DOI 10.1136/gut.12.12.988; Goldstein NS, 2004, HISTOPATHOLOGY, V44, P199, DOI 10.1111/j.1365-2559.2004.01775.x; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P63; Hayat M, 2002, J CLIN PATHOL, V55, P393, DOI 10.1136/jcp.55.5.393; Jarvinen TT, 2004, SCAND J GASTROENTERO, V39, P428, DOI 10.1080/00365520310008773; Kirmizi A, 2017, PATHOLOGY GASTROINTE, P641; Mahadeva S, 2002, J CLIN PATHOL, V55, P424, DOI 10.1136/jcp.55.6.424; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Mino M, 2003, AM J SURG PATHOL, V27, P1237, DOI 10.1097/00000478-200309000-00007; Nasseri-Moghaddam S, 2008, ARCH IRAN MED, V11, P136, DOI 08112/AIM.003; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Ozakinci H, 2016, PATHOL RES PRACT, V212, P1174, DOI 10.1016/j.prp.2016.08.012; Pellegrino S, 2011, ALIMENT PHARM THER, V33, P697, DOI 10.1111/j.1365-2036.2011.04578.x; Rostami K, 2017, GUT, V66, P2080, DOI 10.1136/gutjnl-2017-314297; Rostami K, 2015, WORLD J GASTROENTERO, V21, P2593, DOI 10.3748/wjg.v21.i9.2593; Veress B, 2004, SCAND J GASTROENTERO, V39, P138, DOI 10.1080/00365520310007675; Walker Marjorie M, 2015, Gastroenterol Hepatol Bed Bench, V8, P309; Watkins RD, 2017, PEDIATR CLIN N AM, V64, P563, DOI 10.1016/j.pcl.2017.01.013; Zanini B, 2018, VIRCHOWS ARCH, V473, P229, DOI 10.1007/s00428-018-2346-9	25	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					551	558		10.1007/s00428-018-2430-1			8	Pathology	Pathology	GY8GR	WOS:000448861800002	30094491				2019-10-28	
J	Kanayama, K; Imai, H; Usugi, E; Shiraishi, T; Hirokawa, YS; Watanabe, M				Kanayama, Kazuki; Imai, Hiroshi; Usugi, Eri; Shiraishi, Taizo; Hirokawa, Yoshifumi S.; Watanabe, Masatoshi			Association of HER2 gene amplification and tumor progression in early gastric cancer	VIRCHOWS ARCHIV			English	Article						Early gastric cancer; HER2 gene amplification; HER2 homogeneity; HER2 heterogeneity; Tumor progression	INVASIVE BREAST-CANCER; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; INTESTINAL METAPLASIA; GROWTH; CARCINOMA; NEOPLASIA; ADENOCARCINOMA; EXPRESSION; INDEFINITE	Overexpression of human epidermal growth factor receptor 2 (HER2) protein in association with HER2 gene amplification is found in 7-34% of gastric cancers. In breast cancer, HER2 overexpression is a prognostic factor in advanced cases and is associated with tumor progression in ductal carcinoma in situ. However, the biological and clinical significance of HER2 status in early gastric cancer is unknown. Here, we aimed to examine the correlation between HER2 gene amplification and tumor progression in early gastric cancer. The HER2 status was evaluated in 149 lesions from 141 consecutive patients with early gastric cancer who underwent endoscopic resection by immunohistochemistry and dual color in situ hybridization. HER2 gene amplification was detected in 35 (23.5%) of 149 lesions, and of those, 26 cases (74.3%) showed intratumoral heterogeneity. HER2 gene amplification was found in noninvasive carcinoma, and there was a significant correlation between HER2 status and T factor (P=0.0290). Our study demonstrated that HER2 gene amplification occurred during the early stages of gastric cancer and showed heterogeneity in several cases. HER2 gene amplification may be involved in tumor progression in early gastric cancer.	[Kanayama, Kazuki] Suzuka Univ Med Sci, Dept Clin Nutr, 1001-1 Kishioka, Suzuka, Mie 5100293, Japan; [Kanayama, Kazuki; Usugi, Eri; Shiraishi, Taizo; Hirokawa, Yoshifumi S.; Watanabe, Masatoshi] Mie Univ, Dept Oncol Pathol, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan; [Imai, Hiroshi] Mie Univ Hosp, Div Pathol, 2-174 Edobashi, Tsu, Mie 5148507, Japan; [Shiraishi, Taizo] Kuwana City Med Ctr, Div Pathol, Kotobukicho, Kuwana, Mie 5110061, Japan	Imai, H (reprint author), Mie Univ Hosp, Div Pathol, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	qchan@doc.medic.mie-u.ac.jp			Foundation for Promotion of Cancer Research in Japan	This work was supported in part by the Foundation for Promotion of Cancer Research in Japan.	BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; Cassaro M, 2007, J CLIN PATHOL, V60, P615, DOI 10.1136/jcp.2006.040386; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Fassan M, 2012, HISTOPATHOLOGY, V61, P769, DOI 10.1111/j.1365-2559.2012.04272.x; Fassan M, 2012, AM J CLIN PATHOL, V137, P727, DOI 10.1309/AJCPEU41HTGXSJDQ; Garcia-Garcia E, 2011, HISTOPATHOLOGY, V59, P8, DOI 10.1111/j.1365-2559.2011.03894.x; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; Kanayama K, 2016, CANCER SCI, V107, P536, DOI 10.1111/cas.12886; Kataoka Y, 2013, GASTRIC CANCER, V16, P84, DOI 10.1007/s10120-012-0150-9; Kurozumi S, 2016, BREAST CANCER RES TR, V158, P99, DOI 10.1007/s10549-016-3856-2; Lee S, 2011, HISTOPATHOLOGY, V59, P832, DOI 10.1111/j.1365-2559.2011.04017.x; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Nakashima Y, 2011, HISTOPATHOLOGY, V59, P841, DOI 10.1111/j.1365-2559.2011.04035.x; Silva TCR, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-85; Roses RE, 2009, CANCER EPIDEM BIOMAR, V18, P1386, DOI 10.1158/1055-9965.EPI-08-1101; Rugge M, 2010, ALIMENT PHARM THER, V31, P1104, DOI 10.1111/j.1365-2036.2010.04277.x; Rugge M, 2011, DIGEST LIVER DIS, V43, pS373, DOI 10.1016/S1590-8658(11)60593-8; Sawaki A, 2012, GASTRIC CANCER, V15, P313, DOI 10.1007/s10120-011-0118-1; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Seol H, 2012, MODERN PATHOL, V25, P938, DOI 10.1038/modpathol.2012.36; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Yoshida H, 2014, VIRCHOWS ARCH, V465, P145, DOI 10.1007/s00428-014-1597-3; Zheng Y, 2010, WORLD J GASTROENTERO, V16, P339, DOI 10.3748/wjg.v16.i3.339	25	3	3	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					559	565		10.1007/s00428-018-2433-y			7	Pathology	Pathology	GY8GR	WOS:000448861800003	30120594				2019-10-28	
J	Nortunen, M; Huhta, H; Helminen, O; Parkkila, S; Kauppila, JH; Karttunen, TJ; Saarnio, J				Nortunen, Minna; Huhta, Heikki; Helminen, Olli; Parkkila, Seppo; Kauppila, Joonas H.; Karttunen, Tuomo J.; Saarnio, Juha			Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma	VIRCHOWS ARCHIV			English	Article						CAII; CAIX; CAXII; Esophageal adenocarcinoma; Barrett's esophagus	SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; GASTRIC-CANCER; THERAPEUTIC APPLICATIONS; INTRACELLULAR PH; ISOENZYME-II; MN/CA IX; CA II; EXPRESSION; GROWTH	The aim of our retrospective study was to investigate the expression and clinical significance of the cancer-associated carbonic anhydrases (CAs) II, IX, and XII in Barrett's esophagus and esophageal adenocarcinoma (EAC). We evaluated 101 archival specimens from patients with EAC as well as seven and 26 samples from patients with high-and low-grade dysplasia, respectively. In addition, normal esophageal squamous epithelium, gastric, and intestinal metaplasia were analyzed when present. The expression patterns of isozymes were detected by immunohistochemistry. CAII and CIX expression levels were lower in the squamous epithelium than in the columnar cells while CAXII showed an opposite pattern and was present mainly in squamous epithelium. Expression patterns in benign, dysplastic, or malignant esophageal columnar lesions were not significantly different. The assessment of clinicopathological associations showed that CAII was significantly downregulated in metastatic disease (p=0.026). CAIX showed no association with prognosis, although there appeared to be an association (p=0.056) between high expression and nodal spread. In conclusion, CAII, CAIX, and CAXII do not serve as biomarkers for different phases in the development of EAC.	[Nortunen, Minna; Huhta, Heikki; Helminen, Olli; Kauppila, Joonas H.; Karttunen, Tuomo J.; Saarnio, Juha] Univ Oulu, Canc & Translat Med Res Unit, Med Res Ctr Oulu, Oulu 90014, Finland; [Nortunen, Minna; Huhta, Heikki; Helminen, Olli; Kauppila, Joonas H.; Karttunen, Tuomo J.; Saarnio, Juha] Oulu Univ Hosp, Oulu 90014, Finland; [Parkkila, Seppo] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Parkkila, Seppo] Tampere Univ Hosp, Fimlab Ltd, Tampere 33520, Finland; [Kauppila, Joonas H.] Karolinska Inst, Dept Mol Med & Surg, Upper Gastrointestinal Surg, S-17176 Stockholm, Sweden; [Kauppila, Joonas H.] Karolinska Univ Hosp, S-17176 Stockholm, Sweden	Nortunen, M (reprint author), Univ Oulu, Canc & Translat Med Res Unit, Med Res Ctr Oulu, Oulu 90014, Finland.; Nortunen, M (reprint author), Oulu Univ Hosp, Oulu 90014, Finland.	minna.nortunen@gmail.com	Kauppila, Joonas H/P-1363-2015	Kauppila, Joonas H/0000-0001-6740-3726; Parkkila, Seppo/0000-0001-7323-8536; Nortunen, Minna/0000-0003-0928-150X	Sigrid Juselius FoundationSigrid Juselius Foundation; Orion Research Foundation; Finnish Cancer Foundation; Mary and Georg C. Ehrnroots Foundation; Thelma Makikyro Foundation; Paivikki and Sakari Sohlberg's foundation; Finnish medical foundation	This study was funded by Sigrid Juselius Foundation (JHK), Orion Research Foundation (JHK), The Finnish Cancer Foundation (JHK, HH), Mary and Georg C. Ehrnroots Foundation (JHK, HH), Thelma Makikyro Foundation (JHK, HH), Paivikki and Sakari Sohlberg's foundation (HH), and Finnish medical foundation (HH).	Becker HM, 2011, P NATL ACAD SCI USA, V108, P3071, DOI 10.1073/pnas.1014293108; Birner P, 2011, ANN SURG ONCOL, V18, P3330, DOI 10.1245/s10434-011-1730-3; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Chien MH, 2012, ORAL ONCOL, V48, P417, DOI 10.1016/j.oraloncology.2011.11.015; Christie KN, 1997, J HISTOCHEM CYTOCHEM, V45, P35, DOI 10.1177/002215549704500105; Driessen A, 2006, ANN SURG, V243, P334, DOI 10.1097/01.sla.0000201452.09591.f3; Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Helminen O, 2014, VIRCHOWS ARCH, V464, P11, DOI 10.1007/s00428-013-1505-2; HONG MK, 1995, CANCER, V75, P423, DOI 10.1002/1097-0142(19950115)75:2<423::AID-CNCR2820750202>3.0.CO;2-5; Hu XT, 2014, INT J CLIN EXP PATHO, V7, P6716; Huber AR, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0310-6; Huhta H, 2017, ONCOTARGET, V8, P22894, DOI 10.18632/oncotarget.15284; Huhta H, 2016, ONCOTARGET, V7, P23658, DOI 10.18632/oncotarget.8151; Hulikova A, 2014, J BIOL CHEM, V289, P25418, DOI 10.1074/jbc.M114.547844; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; Ilie MI, 2011, INT J CANCER, V128, P1614, DOI 10.1002/ijc.25491; Jin MS, 2016, VIRCHOWS ARCH, V469, P183, DOI 10.1007/s00428-016-1953-6; Jung JH, 2013, INT J MED SCI, V10, P1217, DOI 10.7150/ijms.6054; Karhumaa P, 2000, MOL HUM REPROD, V6, P68, DOI 10.1093/molehr/6.1.68; Kivela AJ, 2005, WORLD J GASTROENTERO, V11, P155, DOI 10.3748/wjg.v11.i2.155; Lauwers GY, 1997, MODERN PATHOL, V10, P1201; Leppilampi M, 2003, WORLD J GASTROENTERO, V9, P1398, DOI 10.3748/wjg.v9.i7.1398; Li T, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12923; Li XJ, 2012, CHINESE J CANCER RES, V24, P196, DOI 10.1007/s11670-012-0196-6; Lim CH, 2007, ENDOSCOPY, V39, P581, DOI 10.1055/s-2007-966592; Nakamura J, 2011, AM J PATHOL, V178, P515, DOI 10.1016/j.ajpath.2010.10.010; Njei B, 2016, J GASTROEN HEPATOL, V31, P1141, DOI 10.1111/jgh.13289; Ochi F, 2015, J CANCER, V6, P922, DOI 10.7150/jca.11269; PARKKILA AK, 1993, HISTOCHEMISTRY, V99, P37, DOI 10.1007/BF00268018; PARKKILA S, 1994, GUT, V35, P646, DOI 10.1136/gut.35.5.646; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540; Qi C, 2016, ONCOL LETT, V11, P568, DOI 10.3892/ol.2015.3956; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; Senol S, 2016, J ENVIRON PATHOL TOX, V35, P206, DOI 10.1615/JEnvironPatholToxicolOncol.2016016099; Sheng WW, 2013, J SURG ONCOL, V107, P536, DOI 10.1002/jso.23282; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; Swietach P, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0099; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; Turner JR, 1997, HUM PATHOL, V28, P740, DOI 10.1016/S0046-8177(97)90185-4; van Kuijk SJA, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00069; Viikila P, 2016, WORLD J GASTROENTERO, V22, P8168, DOI 10.3748/wjg.v22.i36.8168; Waheed A, 2017, GENE, V623, P33, DOI 10.1016/j.gene.2017.04.027; WARBURG O, 1956, SCIENCE, V124, P269; Watson PH, 2003, BRIT J CANCER, V88, P1065, DOI 10.1038/sj.bjc.6600796; Xie HL, 2010, J DIGEST DIS, V11, P167, DOI 10.1111/j.1751-2980.2010.00432.x; Zhou R, 2013, INT J ONCOL, V43, P611, DOI 10.3892/ijo.2013.1972	50	1	1	2	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					567	575		10.1007/s00428-018-2424-z			9	Pathology	Pathology	GY8GR	WOS:000448861800004	30066203	Green Accepted			2019-10-28	
J	Christgen, M; Bartels, S; Luft, A; Persing, S; Henkel, D; Lehmann, U; Kreipe, H				Christgen, Matthias; Bartels, Stephan; Luft, Angelina; Persing, Sascha; Henkel, Daniel; Lehmann, Ulrich; Kreipe, Hans			Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer	VIRCHOWS ARCHIV			English	Article						Breast cancer; Bone metastasis; HER2; Mutation	ERBB2; AMPLIFICATION; CARCINOMA; PATTERNS; TUMORS; WOMEN	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer. The prevalence of ERBB2/HER2 mutation in bone metastasis of breast cancer and the associated phenotype are not known. In this study, bone metastases from breast cancer patients (n=231) were analyzed for ERBB2/HER2 mutation. In 7 patients (3%; median age 70years, range 50-83years), gain-of-function mutations of ERBB2/HER2 were detected. The most frequent mutation was p.L755S (71%). In 29% of mutated cases, p.V777L was found. Lobular breast cancer was present in 71% of mutated cases (n=5) and in 49% of all samples (n=231; p=0.275). Mutation frequency was 4.4% in the lobular subgroup and 17.4% in the pleomorphic subtype of lobular cancer (n=23), respectively. All but one mutated lobular cancers were of the pleomorphic subtype (p=0.006). Mutated cancers belonged either to the luminal (n=4) or to the triple-negative types (n=3). With regard to protein expression and gene amplification, HER2 was negative in all mutated cases. Among the 14% of metastatic luminal cancers with estrogen receptor gene (ESR1) mutation, conveying resistance against aromatase inhibitors, no concomitant ERBB2/HER2 mutation occurred. We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer. Since mutated cases appear to be HER2-negative by conventional testing, the opportunity for specific anti-HER2 therapy may be missed.	[Christgen, Matthias; Bartels, Stephan; Luft, Angelina; Persing, Sascha; Henkel, Daniel; Lehmann, Ulrich; Kreipe, Hans] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany	Kreipe, H (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kreipe.Hans@MH-Hannover.de		Bartels, Stephan/0000-0002-8903-2345	Deutsche KrebshilfeDeutsche Krebshilfe [1097154]	The study was supported by a grant from the Deutsche Krebshilfe to HK (Grant Number 1097154).	Ali SM, 2014, J CLIN ONCOL, V32, pE88, DOI 10.1200/JCO.2013.49.0599; Bartels S, 2018, MODERN PATHOL, V31, P56, DOI 10.1038/modpathol.2017.95; Bartels S, 2016, ONCOTARGET, V7, P30084, DOI 10.18632/oncotarget.8310; Bartels S, 2015, METHODS MOL BIOL, V1315, P103, DOI 10.1007/978-1-4939-2715-9_8; BORST MJ, 1993, SURGERY, V114, P637; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Chmielecki J, 2015, ONCOLOGIST, V20, P7, DOI 10.1634/theoncologist.2014-0234; Choritz H, 2011, VIRCHOWS ARCH, V459, P283, DOI 10.1007/s00428-011-1132-8; Deniziaut G, 2016, ONCOTARGET, V7, P73337, DOI 10.18632/oncotarget.11819; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Fang Y, 2014, TUMOR BIOL, V35, P11851, DOI 10.1007/s13277-014-2414-y; Gaedcke J, 2007, MODERN PATHOL, V20, P864, DOI 10.1038/modpathol.3800830; Gluz O, 2016, J CLIN ONCOL, V34, P2341, DOI 10.1200/JCO.2015.63.5383; Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109; Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; JAIN SJ, 1993, EUR J CANCER, V29A, P2155, DOI 10.1016/0959-8049(93)90053-I; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krop I, 2017, J CLIN ONCOL, V35, P2838, DOI 10.1200/JCO.2017.74.0472; Lien HC, 2015, BREAST CANCER RES TR, V150, P447, DOI 10.1007/s10549-015-3336-0; Petrelli F, 2017, BREAST CANCER RES TR, V166, P339, DOI 10.1007/s10549-017-4419-x; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Ross JS, 2016, CANCER-AM CANCER SOC, V122, P2654, DOI 10.1002/cncr.30102; Ross JS, 2013, CLIN CANCER RES, V19, P2668, DOI 10.1158/1078-0432.CCR-13-0295; Si PL, 2017, CANCER MED-US, V6, P2832, DOI 10.1002/cam4.1236; Yardley DA, 2016, BREAST CANCER-TARGET, V8, P73, DOI 10.2147/BCTT.S97963	26	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					577	582		10.1007/s00428-018-2414-1			6	Pathology	Pathology	GY8GR	WOS:000448861800005	30094493				2019-10-28	
J	Ptakova, N; Miesbauerova, M; Kost'un, J; Grossmann, P; Sidlova, H; Pavelka, J; Presl, J; Alaghehbandan, R; Bouda, J; Ondic, O				Ptakova, Nikola; Miesbauerova, Marketa; Kost'un, Jan; Grossmann, Petr; Sidlova, Henrieta; Pavelka, Jaroslav; Presl, Jiri; Alaghehbandan, Reza; Bouda, Jiri; Ondic, Ondrej			Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors	VIRCHOWS ARCHIV			English	Article						IMT; ALK; STUMP; Leiomyosarcoma; Molecular genetics	INFLAMMATORY MYOFIBROBLASTIC TUMOR; MYXOID-LEIOMYOSARCOMA; MOLECULAR ANALYSIS; UTERUS	We examined the value of targeted molecular screening for the identification of uterine anaplastic lymphoma kinase (ALK)-rearranged mesenchymal tumors, including ALK immunohistochemistry followed by molecular genetic testing, in all uterine leiomyosarcomas and STUMPs (smooth muscle tumors of uncertain malignant potential). All leiomyosarcoma and STUMP cases diagnosed in a 10-year period (2006-2016) at Charles University Faculty of Medicine in Pilsen were retrieved and reviewed. Of 23 cases, one case (LMS [leiomyosarcoma]) was positive for ALK rearrangement, namely, PPP1CB-ALK fusion gene. No specific histologic features (i.e., lymphocytic infiltrate and stromal edema) were observed in this case. This suggests that inflammatory myofibroblastic tumor (IMT)-like histologic features may not be an initial reliable screening tool in identifying uterine IMT cases. Thus, we proposed a two-step IHC and molecular genetic testing (as a reflex test) for IMT in all uterine LMS and STUMP cases. This will enhance the proper detection of such tumors at the population level and ultimately offer patients available targeted therapies.	[Ptakova, Nikola; Miesbauerova, Marketa; Grossmann, Petr; Ondic, Ondrej] Charles Univ Prague, Med Fac Pilsen, Dept Pathol, Plzen 30460, Czech Republic; [Ptakova, Nikola; Miesbauerova, Marketa; Kost'un, Jan; Grossmann, Petr; Presl, Jiri; Bouda, Jiri; Ondic, Ondrej] Charles Univ Hosp Pilsen, Plzen 30460, Czech Republic; [Ptakova, Nikola; Miesbauerova, Marketa; Grossmann, Petr; Pavelka, Jaroslav; Ondic, Ondrej] Biopt Lab Sro, Plzen, Czech Republic; [Kost'un, Jan; Presl, Jiri; Bouda, Jiri] Charles Univ Prague, Med Fac Pilsen, Dept Gynecol & Obstet, Plzen, Czech Republic; [Sidlova, Henrieta] Cytopathos Sro, Bratislava, Slovakia; [Sidlova, Henrieta] Slovak Med Univ Bratislava, Dept Pathol, Bratislava, Slovakia; [Pavelka, Jaroslav] Univ West Bohemia, Fac Educ, Plzen, Czech Republic; [Alaghehbandan, Reza] Univ British Columbia, Royal Columbian Hosp, Dept Pathol, Vancouver, BC, Canada	Ondic, O (reprint author), Charles Univ Prague, Med Fac Pilsen, Dept Pathol, Plzen 30460, Czech Republic.; Ondic, O (reprint author), Charles Univ Hosp Pilsen, Plzen 30460, Czech Republic.; Ondic, O (reprint author), Biopt Lab Sro, Plzen, Czech Republic.	ondic@medima.cz		Ondic, Ondrej/0000-0002-4038-5641			Aghajan Yasmin, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-217189; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Boi M, 2015, BRIT J HAEMATOL, V168, P771, DOI 10.1111/bjh.13265; Bosse T, 2018, AM J SURG PATHOL, V42, P561, DOI 10.1097/PAS.0000000000001020; Coffin CM, 2001, MODERN PATHOL, V14, P569, DOI 10.1038/modpathol.3880352; Croce S, 2018, MODERN PATHOL, V31, P816, DOI 10.1038/modpathol.2017.185; Devereaux KA, 2019, AM J SURG PATHOL, V43, P64, DOI 10.1097/PAS.0000000000001083; Fletcher C, 2013, WHO CLASSIFICATION T; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Griffin B, 2018, MODERN PATHOL, V31, P421; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; Pickett JL, 2017, AM J SURG PATHOL, V41, P1433, DOI 10.1097/PAS.0000000000000909; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	16	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					583	590		10.1007/s00428-018-2428-8			8	Pathology	Pathology	GY8GR	WOS:000448861800006	30116888				2019-10-28	
J	Versluis, MAC; Plat, A; de Bruyn, M; Matias-Guiu, X; Trovic, J; Krakstad, C; Nijman, HW; Bosse, T; de Bock, GH; Hollema, H				Versluis, M. A. C.; Plat, A.; de Bruyn, M.; Matias-Guiu, X.; Trovic, J.; Krakstad, C.; Nijman, H. W.; Bosse, T.; de Bock, G. H.; Hollema, H.			L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition	VIRCHOWS ARCHIV			English	Article						Endometrial neoplasm; Neural cell adhesion molecule L1; L1CAM; Epithelial-mesenchymal transition; Histology	ENDOMETRIAL CANCER; ADHESION MOLECULE; UP-REGULATION; CARCINOMAS; SURVIVAL; PROGRESSION; PREDICTOR; EMT; PATHOLOGY; TUMORS	Uterine carcinosarcoma (UCS) has been proposed as a model for epithelial-mesenchymal transition (EMT), a process characterized by a functional change facilitating migration and metastasis in many types of cancer. L1CAM is an adhesion molecule that has been involved in EMT as a marker for mesenchymal phenotype. We examined expression of L1CAM in UCS in a cohort of 90 cases from four different centers. Slides were immunohistochemically stained for L1CAM and scored in four categories (0%, <10%, 10-50%, and >50%). A score of more than 10% was considered positive for L1CAM. The median age at presentation was 68.6years, and half of the patients (53.3%) presented with FIGO stage 1 disease. Membranous L1CAM expression was positive in the epithelial component in 65.4% of cases. Remarkably, expression was negative in the mesenchymal component. In cases where both components were intermingled, expression limited to the epithelial component was confirmed by a double stain for L1CAM and keratin. Expression of L1CAM did not relate to overall or disease-free survival. Our findings suggest L1CAM is either not a marker for the mesenchymal phenotype in EMT, or UCS is not a good model for EMT.	[Versluis, M. A. C.; Plat, A.; de Bruyn, M.; Nijman, H. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol, POB 30-001, NL-9700 RB Groningen, Netherlands; [Matias-Guiu, X.] Univ Lleida, Arnau de Vilanova Univ Hosp, Dept Pathol & Mol Genet, Oncol Pathol Grp, Lleida, Spain; [Matias-Guiu, X.] Ctr Invest Biomed Red Oncol CIBERONC, Madrid, Spain; [Matias-Guiu, X.] Univ Hosp Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Catalonia, Spain; [Trovic, J.; Krakstad, C.] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway; [Trovic, J.; Krakstad, C.] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers, Bergen, Norway; [Bosse, T.] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; [de Bock, G. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Hollema, H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands	Versluis, MAC (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol, POB 30-001, NL-9700 RB Groningen, Netherlands.	m.a.c.versluis@umcg.nl	matias-guiu, xavier/C-3039-2009	matias-guiu, xavier/0000-0002-7201-6605; Krakstad, Camilla/0000-0002-0174-8139			Altevogt P, 2016, INT J CANCER, V138, P1565, DOI 10.1002/ijc.29658; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Boll D, 2012, INT J GYNECOL CANCER, V22, P599, DOI 10.1097/IGC.0b013e318244cedc; Bosse T, 2014, EUR J CANCER, V50, P2602, DOI 10.1016/j.ejca.2014.07.014; Cantrell LA, 2015, GYNECOL ONCOL, V137, P581, DOI 10.1016/j.ygyno.2015.03.041; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Colas E, 2012, CLIN TRANSL ONCOL, V14, P715, DOI 10.1007/s12094-012-0866-3; de Jong RA, 2011, MOD PATHOL; Dellinger TH, 2016, GYNECOL ONCOL, V141, P336, DOI 10.1016/j.ygyno.2016.02.003; Doberstein K, 2015, INT J CANCER, V136, pE326, DOI 10.1002/ijc.29222; Fadare O, 2018, HISTOPATHOLOGY, V72, P532, DOI 10.1111/his.13405; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673; Kiefel H, 2012, CARCINOGENESIS, V33, P1919, DOI 10.1093/carcin/bgs220; Kiefel H, 2012, CELL ADHES MIGR, V6, P374, DOI 10.4161/cam.20832; Matias-Guiu X, 2013, HISTOPATHOLOGY, V62, P111, DOI 10.1111/his.12053; McCluggage WG, 2002, J CLIN PATHOL, V55, P321, DOI 10.1136/jcp.55.5.321; McCluggage WGRS, 2009, PATHOLOGY FEMALE REP, P427; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; Piulats JM, 2017, GYNECOL ONCOL, V145, P200, DOI 10.1016/j.ygyno.2016.12.015; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P31, DOI 10.1111/his.12057; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; van der Putten LJM, 2016, BRIT J CANCER, V115, P716, DOI 10.1038/bjc.2016.235; van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057; Versluis MAC, 2018, ONCOLOGY, P1; Vorgias G, 2010, ARCH GYNECOL OBSTET, V282, P659, DOI 10.1007/s00404-010-1649-0; Zeimet AG, 2013, JNCI-J NATL CANCER I, V105, P1142, DOI 10.1093/jnci/djt144	29	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					591	598		10.1007/s00428-018-2444-8			8	Pathology	Pathology	GY8GR	WOS:000448861800007	30140948	Other Gold, Green Published			2019-10-28	
J	Arean-Cuns, C; Mercado-Gutierrez, M; Paniello-Alastruey, I; Mallor-Gimenez, F; Cordoba-Iturriagagoitia, A; Lozano-Escario, M; Santamaria-Martinez, M				Arean-Cuns, Carolina; Mercado-Gutierrez, Maria; Paniello-Alastruey, Irene; Mallor-Gimenez, Fermin; Cordoba-Iturriagagoitia, Alicia; Lozano-Escario, Maria; Santamaria-Martinez, Mercedes			Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women	VIRCHOWS ARCHIV			English	Article						Cervical cancer; Cytology; Human papillomavirus (HPV); Screening; Dual immunostaining	CERVICAL INTRAEPITHELIAL NEOPLASIA; PAP CYTOLOGY; BASE-LINE; FOLLOW-UP; CANCER PRECURSORS; AGED 30; POPULATION; P16(INK4A); RISK; DNA	Globally, cervical cancer (CC) screening is moving from cytology-based to HPV screening or a combination of both (co-testing). Most HPV-positive women clear the virus and do not develop relevant disease. Additional triage approaches are needed to reduce unnecessary colposcopy referrals. The p16/Ki67 dual stain cytology test (DSCT) is one of the most promising, but it has not (yet) been included as a recommendation in European guidelines. Previous studies in Spain on this issue are lacking. We studied the performance of p16/Ki67 DSCT for the triage of HPV-positive women in Navarra to detect precursor lesions (PLs) and CC compared to cytology only. We selected 1865 HPV-positive women with p16/Ki67 DSCT results and 304 women with an available biopsy result. Sensitivity, specificity and predictive values of the p16/Ki67 DSCT to detect underlying PLs and CC compared to cytology were calculated, using the biopsy as the gold standard. Cytology and p16/Ki67 DSCT showed similar sensitivity (99.0% vs. 98.0%), but cytology had significantly lower specificity (6.9 vs. 39.1%). Of the CIN2+/HPV+ women, triage using cytology only would have resulted in 40.2% true PLs and CC, while using p16/Ki67 DSCT this was 98.0% qualifying the women for colposcopy referral. Our results show that p16/Ki67 DSCT detects more than twice as many true PLs and CC than cytology only in this population. Thus, this test can be considered as an important additional tool in HPV testing-based screening strategies, to avoid unnecessary colposcopy referrals and to reduce health care costs.	[Arean-Cuns, Carolina; Mercado-Gutierrez, Maria; Cordoba-Iturriagagoitia, Alicia; Santamaria-Martinez, Mercedes] Complejo Hosp Navarra, Dept Pathol, Serv Anat Patol, Calle Irunlarrea 3,Pabellon F, Pamplona 31008, Spain; [Paniello-Alastruey, Irene; Mallor-Gimenez, Fermin] Univ Publ Navarra, Dept Stat & Operat Invest, Pamplona, Spain; [Lozano-Escario, Maria] Clin Univ Navarra, Dept Pathol, Pamplona, Spain	Arean-Cuns, C (reprint author), Complejo Hosp Navarra, Dept Pathol, Serv Anat Patol, Calle Irunlarrea 3,Pabellon F, Pamplona 31008, Spain.	carolina.arean.cuns@navarra.es			AEI, FEDER, UE [MTM2016-77015-R];  [MTM2017-83506-C2-1-P]	F. Mallor partially supported by MTM2016-77015-R (AEI, FEDER, UE).; I. Paniello partially supported by MTM2017-83506-C2-1-P. The other authors made no disclosures.	Ascunce N, 2008, CITOLOGIAS GINECOLOG, P1; Benevolo M, 2017, CANCER CYTOPATHOL, V125, P212, DOI 10.1002/cncy.21800; Bergeron C, 2015, CANCER CYTOPATHOL, V123, P373, DOI 10.1002/cncy.21542; Bergeron C, 2015, INT J CANCER, V136, P2741, DOI 10.1002/ijc.28900; Blade AT, 2014, PROG OBSTET GINEC S1, V14, P1, DOI DOI 10.1016/S0304-5013(14)73068-7; Blatt AJ, 2015, CANCER CYTOPATHOL, V123, P282, DOI 10.1002/cncy.21544; Carozzi F, 2013, LANCET ONCOL, V14, P168, DOI 10.1016/S1470-2045(12)70529-6; Carozzi FM, 2007, COLLEGIUM ANTROPOL, V31, P103; Ebisch RMF, 2017, MODERN PATHOL, V30, P1021, DOI 10.1038/modpathol.2017.16; Edgerton N, 2013, DIAGN CYTOPATHOL, V41, P35, DOI 10.1002/dc.21757; Guo M, 2017, CANCER CYTOPATHOL, V125, P644, DOI 10.1002/cncy.21877; Iftner T, 2015, J CLIN MICROBIOL, V53, P2509, DOI 10.1128/JCM.01013-15; Ikenberg H, 2013, JNCI-J NATL CANCER I, V105, P1550, DOI 10.1093/jnci/djt235; Killeen JL, 2014, J LOW GENIT TRACT DI, V18, P1, DOI 10.1097/LGT.0b013e31828aeb39; Kisser A, 2015, BJOG-INT J OBSTET GY, V122, P64, DOI 10.1111/1471-0528.13076; Loghavi S, 2013, DIAGN CYTOPATHOL, V41, P582, DOI 10.1002/dc.22900; Luttmer R, 2016, MODERN PATHOL, V29, P870, DOI 10.1038/modpathol.2016.80; Gutierrez MDM, 2017, REV ESP SALUD PUBLIC, V91; Ordi J, 2014, CANCER CYTOPATHOL, V122, P227, DOI 10.1002/cncy.21366; Ovestad IT, 2017, CANCER CYTOPATHOL, V125, P283, DOI 10.1002/cncy.21807; Petry KU, 2011, GYNECOL ONCOL, V121, P505, DOI 10.1016/j.ygyno.2011.02.033; Rossi P, 2015, PATHOLOGICA, V107, P185; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Tao X, 2017, CANCER CYTOPATHOL, V125, P947, DOI 10.1002/cncy.21914; Tracht JM, 2017, CANCER CYTOPATHOL, V125, P795, DOI 10.1002/cncy.21905; Uijterwaal MH, 2014, BRIT J CANCER, V110, P1579, DOI 10.1038/bjc.2014.34; Uijterwaal MH, 2015, INT J CANCER, V136, P2361, DOI 10.1002/ijc.29290; von Karsa L, 2015, EUROPEAN GUIDELINE S; Waldstrom M, 2013, CANCER CYTOPATHOL, V121, P136, DOI 10.1002/cncy.21233; Wentzensen N, 2006, CANCER, V111, P58, DOI 10.1002/cncr.22420; Wentzensen N, 2017, INT J CANCER, V140, P2192, DOI 10.1002/ijc.30579; Wentzensen N, 2016, J CLIN VIROL, V76, pS49, DOI 10.1016/j.jcv.2015.11.015; Wentzensen N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv257; Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270; White C, 2016, CYTOPATHOLOGY, V27, P269, DOI 10.1111/cyt.12317; You K, 2013, EUR J GYNAECOL ONCOL, V34, P535; Yu LL, 2016, ONCOTARGET, V7, P21181, DOI 10.18632/oncotarget.8307	38	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					599	606		10.1007/s00428-018-2432-z			8	Pathology	Pathology	GY8GR	WOS:000448861800008	30094492				2019-10-28	
J	Kuasne, H; Barros, MC; Marchi, FA; Drigo, SA; Scapulatempo-Neto, C; Faria, EF; Rogatto, SR				Kuasne, Hellen; Barros-Filho, Mateus C.; Marchi, Fabio A.; Drigo, Sandra A.; Scapulatempo-Neto, Cristovam; Faria, Eliney F.; Rogatto, Silvia R.			Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor	VIRCHOWS ARCHIV			English	Article						Penile carcinoma; Androgen receptor; Cytoplasmic AR expression; Immunohistochemistry	SQUAMOUS-CELL CARCINOMA; PROSTATE-CANCER PROGRESSION; HUMAN-PAPILLOMAVIRUS; P16(INK4A); MARKER; IDENTIFICATION; METASTASIS; PATHOLOGY; VARIANTS; CLONING	Androgen receptor (AR) is a member of the steroid and nuclear family receptor that acts as transcription factor. AR signaling plays pivotal role in the development and progression of prostate cancer. However, the role of AR in penile cancer (PeCa) is poorly explored. Our previous molecular studies unveiled frequent AR mRNA loss in PeCa, which was further predicted as a major driver alteration in this neoplasm. Herein, we assessed the AR protein expression in 59 usual PeCa tissues and 42 surrounding normal tissues (SNT) by immunohistochemistry using a tissue microarray. In a paired analysis, we found a total absence of nuclear AR expression in PeCa while 95.2% of SNT samples presented strong nuclear AR expression (P<0.001). Interestingly, 17 of 42 PeCa presented weak or moderate cytoplasmic AR staining, contrasting with 5 of 42 SNT (P=0.008). Increased levels of AR cytoplasmic expression were related with poor prognosis features including advanced clinical staging (P=0.044), compromised surgical margins (P=0.005), and pathological inguinal node status (P=0.047). Furthermore, AR cytoplasmic expression was also related with shorter overall survival (P=0.032). In conclusion, the frequent loss of nuclear AR protein levels suggests a potential function in PeCa development. Based on this result, the androgen deprivation therapy is not indicated for PeCa patients. In addition, the AR cytoplasmic expression found in a significant number of cases (40.5%) showed prognostic value and pathways activated by the non-genomic AR signaling may represent a promising therapeutic strategy.	[Kuasne, Hellen] Sao Paulo State Univ UNESP, Dept Urol, Fac Med, Botucatu, SP, Brazil; [Kuasne, Hellen; Barros-Filho, Mateus C.; Marchi, Fabio A.] CIPE AC, Camargo Canc Ctr, Sao Paulo, Brazil; [Drigo, Sandra A.] UNESP, Sch Vet Med & Anim Sci, Dept Surg & Orthoped, Botucatu, SP, Brazil; [Drigo, Sandra A.] UNESP, Sch Vet Med & Anim Sci, Dept Vet Clin, Botucatu, SP, Brazil; [Scapulatempo-Neto, Cristovam] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos & Diagnost Amer DASA, Sao Paulo, SP, Brazil; [Faria, Eliney F.] Barretos Canc Hosp, Dept Urol, Barretos, SP, Brazil; [Rogatto, Silvia R.] Univ Southern Denmark, Inst Reg Hlth Res, Vejle Hosp, Dept Clin Genet, Beriderbakken 4, DK-7100 Vejle, Denmark	Rogatto, SR (reprint author), Univ Southern Denmark, Inst Reg Hlth Res, Vejle Hosp, Dept Clin Genet, Beriderbakken 4, DK-7100 Vejle, Denmark.	silvia.regina.rogatto@rsyd.dk	Drigo, Sandra A/I-6514-2012; LINDE, SANDRA/S-3128-2019; Albuquerque Marchi, Fabio/N-9288-2018	Drigo, Sandra A/0000-0001-6747-6642; LINDE, SANDRA/0000-0001-6747-6642; Albuquerque Marchi, Fabio/0000-0001-5815-8423			Alemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007; Ali SM, 2016, ONCOLOGIST, V21, P33, DOI 10.1634/theoncologist.2015-0241; Alves G, 2001, GENE CHROMOSOME CANC, V31, P48, DOI 10.1002/gcc.1117.abs; Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Backes DM, 2009, CANCER CAUSE CONTROL, V20, P449, DOI 10.1007/s10552-008-9276-9; Baskin LS, 1997, J UROLOGY, V158, P1113, DOI 10.1016/S0022-5347(01)64400-8; Busso-Lopes AF, 2015, CANCER PREV RES, V8, P149, DOI 10.1158/1940-6207.CAPR-14-0284; Campos RSM, 2006, UROLOGY, V67, P797, DOI 10.1016/j.urology.2005.10.026; Christodoulidou M, 2015, CURR PROB CANCER, V39, P126, DOI 10.1016/j.currproblcancer.2015.03.010; Cubilla AL, 2018, HISTOPATHOLOGY, V72, P893, DOI 10.1111/his.13429; Cubilla AL, 2011, AM J SURG PATHOL, V35, P253, DOI 10.1097/PAS.0b013e318203cdba; Cubilla AL, 2010, AM J SURG PATHOL, V34, P104, DOI 10.1097/PAS.0b013e3181c76a49; Cutress ML, 2008, J CELL SCI, V121, P957, DOI 10.1242/jcs.022103; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Do HTT, 2013, BRIT J CANCER, V108, P229, DOI 10.1038/bjc.2012.583; Eisermann K, 2013, TRANSL ANDROL UROL, V2, P137, DOI 10.3978/j.issn.2223-4683.2013.09.15; El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974; Feber A, 2015, CLIN CANCER RES, V21, P1196, DOI 10.1158/1078-0432.CCR-14-1656; Ferrandiz-Pulido C, 2015, GENE CHROMOSOME CANC, V54, P629, DOI 10.1002/gcc.22274; Ferrandiz-Pulido C, 2013, J AM ACAD DERMATOL, V68, P73, DOI 10.1016/j.jaad.2012.05.029; GREGOIRE L, 1995, J NATL CANCER I, V87, P1705, DOI 10.1093/jnci/87.22.1705; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hartz JM, 2016, J UROLOGY, V196, P570, DOI 10.1016/j.juro.2016.01.115; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Hernandez BY, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00009; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu JP, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692259; Huang PX, 2010, ANNU REV PHYSIOL, V72, P247, DOI 10.1146/annurev-physiol-021909-135917; Kidd LC, 2017, TRANSL ANDROL UROL, V6, P791, DOI 10.21037/tau.2017.06.27; Kroon BK, 2008, BJU INT, V102, P510, DOI 10.1111/j.1464-410X.2008.07697.x; Kuasne H, 2017, ONCOTARGET, V8, P15294, DOI 10.18632/oncotarget.14783; Kuasne H, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0082-4; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Leung JK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00002; Li H, 2018, EUR UROL FOCUS, V4, P529, DOI 10.1016/j.euf.2017.01.004; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Luo J, 2016, ASIAN J ANDROL, V18, P580, DOI 10.4103/1008-682X.178490; Marchi FA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06659-1; McDaniel AS, 2015, CANCER RES, V75, P5219, DOI 10.1158/0008-5472.CAN-15-1004; Miralles-Guri C, 2009, J CLIN PATHOL, V62, P870, DOI 10.1136/jcp.2008.063149; Munoz JJ, 2016, TUMOR BIOL, V37, P11375, DOI 10.1007/s13277-016-4951-z; Prigge ES, 2017, INT J CANCER, V140, P1186, DOI 10.1002/ijc.30516; Roy AK, 1999, VITAM HORM, V55, P309; Rubin MA, 2001, AM J PATHOL, V159, P1211, DOI 10.1016/S0002-9440(10)62506-0; Termini L, 2015, BMC CLIN PATHOL, V15, DOI 10.1186/s12907-015-0003-7; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; Zarif JC, 2016, CELL SIGNAL, V28, P348, DOI 10.1016/j.cellsig.2016.01.013; Zhan Y, 2017, MOL CANCER RES, V15, P59, DOI 10.1158/1541-7786.MCR-16-0236; Zhang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131336	50	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					607	614		10.1007/s00428-018-2404-3			8	Pathology	Pathology	GY8GR	WOS:000448861800009	30099587	Green Published			2019-10-28	
J	Andreasen, S; Bishop, JA; Hellquist, H; Hunt, J; Kiss, K; Rinaldo, A; Skalova, A; Willems, SM; Williams, M; Ferlito, A				Andreasen, Simon; Bishop, Justin A.; Hellquist, Henrik; Hunt, Jennifer; Kiss, Katalin; Rinaldo, Alessandra; Skalova, Alena; Willems, Stefan M.; Williams, Michelle; Ferlito, Alfio			Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity	VIRCHOWS ARCHIV			English	Article						Biphenotypic sinonasal sarcoma; Prognosis; Recurrence; Sinonasal sarcoma; PAX3-MAML3; PAX3-NCOA1	MALIGNANT TRITON TUMOR; BETA-CATENIN; SOFT-TISSUE; MYOGENIC FEATURES; ALVEOLAR RHABDOMYOSARCOMA; DIAGNOSTIC CHALLENGE; PAX GENES; FUSION; HEAD; NECK	Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized type of sarcoma arising exclusively in the sinonasal tract displaying unique clinical course, histopathology, and genetics. Due to its rarity, only case series and case reports are available. In order to provide an overview of the current understanding of this disease, we present a comprehensive review of the literature and present three previously unreported cases of BSNS. A total of 55 genetically characterized and 41 cases without molecular data were identified in the literature. Two-thirds of patients were female and the peak incidence was in the fifth decade. Fatal outcome was rare (two cases with intracranial extension) and local recurrence occurred in 31.6%, all occurring within 5years after initial treatment. Histologically, BSNS is highly cellular in the majority of cases and composed of fascicles of spindle cells, with entrapped hyperplastic surface epithelium being a frequent finding. The immunohistochemical profile is characteristic due to the biphasic nature of this lesion, with shared features of both myogenic and neural origin. Rhabdomyoblastic differentiation is apparent in a subset of cases. The most common genetic event is the PAX3-MAML3 fusion (58.6%) but isolated PAX3 rearrangement (19.2%), absence of rearrangements (9.1%), PAX3-FOXO1 (8.1%), PAX3-NCOA1 (4%), and isolated MAML3 rearrangement (2%) have also been reported. In conclusion, the recognition of BSNS is crucial due to its relatively indolent clinical course. A selected immunohistochemical panel and/or molecular confirmation can be used to aid in appropriate diagnosis and consequently in prognostication and to avoid overtreatment with chemotherapy regimens used in its mimics.	[Andreasen, Simon] Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Andreasen, Simon; Kiss, Katalin] Rigshosp, Dept Pathol, Copenhagen, Denmark; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Hellquist, Henrik] Univ Algarve, Epigenet & Human Dis Lab, Dept Biomed Sci, CBMR,Algarve Biomed Ctr, Faro, Portugal; [Hunt, Jennifer] Univ Arkansas Med Sci, Dept Pathol & Lab Med, Little Rock, AR 72205 USA; [Rinaldo, Alessandra] Univ Udine, Sch Med, Udine, Italy; [Skalova, Alena] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Willems, Stefan M.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Williams, Michelle] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Ferlito, Alfio] Int Head & Neck Sci Grp, Padua, Italy	Andreasen, S (reprint author), Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.; Andreasen, S (reprint author), Rigshosp, Dept Pathol, Copenhagen, Denmark.	Simon@Andreasen.pm		Williams, Michelle D./0000-0002-9133-7332; Andreasen, Simon/0000-0002-1528-4988			Agaimy A, 2018, PATHOLOGE, V39, P18, DOI 10.1007/s00292-018-0415-0; Andreasen S, 2018, AM J SURG PATHOL, V42, P985, DOI 10.1097/PAS.0000000000001069; Andreasen S, 2015, APMIS, V123, P706, DOI 10.1111/apm.12407; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Casali PG, 2014, ANN ONCOL, V25, P102, DOI 10.1093/annonc/mdu254; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; DAVIS RJ, 1994, CANCER RES, V54, P2869; Fletcher C, 2013, WORLD HLTH CLASSIFIC; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; HEFFNER DK, 1992, CANCER, V70, P1089, DOI 10.1002/1097-0142(19920901)70:5<1089::AID-CNCR2820700513>3.0.CO;2-J; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Jo VY, 2018, AM J SURG PATHOL, V42, P1275, DOI 10.1097/PAS.0000000000001092; Kakkar A, 2018, ANN DIAGN PATHOL, V33, P6, DOI 10.1016/j.anndiagpath.2017.11.005; Kang YN, 2014, MODERN PATHOL, V27, P55, DOI 10.1038/modpathol.2013.115; KRAUS DH, 1994, CANCER, V74, P697, DOI 10.1002/1097-0142(19940715)74:2<697::AID-CNCR2820740224>3.0.CO;2-A; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Lin Y, 2017, INT J CLIN EXP PATHO, V10, P11743; Lu PPY, 2011, J NEUROSCI, V31, P16651, DOI 10.1523/JNEUROSCI.3015-11.2011; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Mikkelsen LH, 2016, APMIS, V124, P475, DOI 10.1111/apm.12529; NEEL HB, 1973, AM J SURG, V126, P547, DOI 10.1016/S0002-9610(73)80048-0; Powers KA, 2015, OR SURG OR MED OR PA, V119, pE265, DOI 10.1016/j.oooo.2014.10.007; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Senger JL, 2016, JSM SURG ONCOL RES, V1, P1; Siegfried A, 2018, GENE CHROMOSOME CANC, V57, P203, DOI 10.1002/gcc.22521; Smith SC, 2017, AM J SURG PATHOL, V41, P1642, DOI 10.1097/PAS.0000000000000940; Snyder ML, 2002, HEAD NECK-J SCI SPEC, V24, P52, DOI 10.1002/hed.10007.abs; Sturgis EM, 2003, CURR OPIN ONCOL, V15, P239, DOI 10.1097/00001622-200305000-00011; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Szablewski V, 2015, LARYNGOSCOPE, V125, P615, DOI 10.1002/lary.24910; Terzic A, 2009, HEAD NECK-J SCI SPEC, V31, P679, DOI 10.1002/hed.21051; Thompson LDR, 2003, AM J SURG PATHOL, V27, P737, DOI 10.1097/00000478-200306000-00004; Triki M, 2017, ARCH PATHOL LAB MED, V141, P718, DOI 10.5858/arpa.2016-0133-RS; Victoria L, 1999, HEAD NECK-J SCI SPEC, V21, P663, DOI 10.1002/(SICI)1097-0347(199910)21:7<663::AID-HED12>3.0.CO;2-4; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang QY, 2008, J CELL MOL MED, V12, P2281, DOI 10.1111/j.1582-4934.2008.00427.x; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295; Zhao M, 2017, Zhonghua Bing Li Xue Za Zhi, V46, P841, DOI 10.3760/cma.j.issn.0529-5807.2017.12.006	44	4	4	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					615	626		10.1007/s00428-018-2426-x			12	Pathology	Pathology	GY8GR	WOS:000448861800010	30109475				2019-10-28	
J	Hysek, M; Paulsson, JO; Wang, N; Jatta, K; Lindh, C; Fuentes-Martinez, N; Shabo, I; Zedenius, J; Juhlin, CC				Hysek, Martin; Paulsson, Johan O.; Wang, Na; Jatta, Kenbugul; Lindh, Claes; Fuentes-Martinez, Nelson; Shabo, Ivan; Zedenius, Jan; Juhlin, C. Christofer			TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine	VIRCHOWS ARCHIV			English	Article						TERT; Thyroid cancer; Mutation; Clinical practice	TELOMERASE; NODULES	Follicular thyroid adenomas (FTAs) and carcinomas (FTCs), collectively the most common thyroid neoplasms, constitute a significant clinical challenge since histological evidence of invasive behaviour is required for a malignant diagnosis. Small subsets of FTAs relapse as manifest malignant FTCs, indicating that histology is not always adequate to predict malignant potential. Lately, recurrent mutations in the promoter of the Telomerase reverse transcriptase (TERT) gene have been coupled to FTCs, whereas FTAs usually lack this aberrancy. We describe three patients with follicular thyroid tumours in which TERT promoter mutational screening was employed as part of the clinical work-up to pinpoint malignant potential. In two retrospective analyses of seemingly benign lesions, the detected mutations predicted future skeletal metastases, and in one prospective case, the mutational screening led to a different clinical management of the afflicted patient. We therefore consider TERT promoter mutational screening an adjunct tool of value in equivocal cases.	[Hysek, Martin; Jatta, Kenbugul; Lindh, Claes; Fuentes-Martinez, Nelson; Juhlin, C. Christofer] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden; [Paulsson, Johan O.; Wang, Na; Lindh, Claes; Juhlin, C. Christofer] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska CCK R8 04, S-17176 Stockholm, Sweden; [Shabo, Ivan; Zedenius, Jan] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Shabo, Ivan; Zedenius, Jan] Karolinska Univ Hosp, Dept Breast Endocrine Tumors & Sarcoma, Stockholm, Sweden	Juhlin, CC (reprint author), Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden.; Juhlin, CC (reprint author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska CCK R8 04, S-17176 Stockholm, Sweden.	christofer.juhlin@ki.se	Juhlin, Carl Christofer/C-1125-2016; Shabo, Ivan/K-8456-2018	Juhlin, Carl Christofer/0000-0002-5945-9081; Shabo, Ivan/0000-0002-9866-4192; Paulsson, Johan/0000-0003-0390-6740	Swedish Cancer SocietySwedish Cancer Society	This work was supported grants provided by the Swedish Cancer Society.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Asa SL, 2017, PATHOLOGY, V49, P229, DOI 10.1016/j.pathol.2017.01.001; Asa SL, 2015, THYROID, V25, P1, DOI 10.1089/thy.2014.0540; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cheng HH, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0299-8; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Landa I, 2013, J CLIN ENDOCR METAB, V98, pE1562, DOI 10.1210/jc.2013-2383; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu XL, 2013, ENDOCR-RELAT CANCER, V20, P603, DOI 10.1530/ERC-13-0210; Lloyd RO RY, 2017, WHO CLASSIFICATION T, V10; Nikiforov YE, 2015, THYROID, V25, P1217, DOI 10.1089/thy.2015.0305; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wang N, 2014, CANCER-AM CANCER SOC, V120, P2965, DOI 10.1002/cncr.28800	14	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					639	643		10.1007/s00428-018-2386-1			5	Pathology	Pathology	GY8GR	WOS:000448861800012	29860621	Other Gold			2019-10-28	
J	Lecumberri, B; Pozo-Kreilinger, JJ; Esteban, I; Gomes, M; Royo, A; de la Riva, AG; de Nanclares, GP				Lecumberri, Beatriz; Juan Pozo-Kreilinger, Jose; Esteban, Isabel; Gomes, Mariana; Royo, Aranzazu; Gomez de la Riva, Alvaro; Perez de Nanclares, Guiomar			Head and neck manifestations of an undiagnosed McCune-Albright syndrome: clinicopathological description and literature review	VIRCHOWS ARCHIV			English	Review						Gigantism; Fibrous dysplasia; Headache; McCune-Albright syndrome	POLYOSTOTIC FIBROUS DYSPLASIA; MUTATION; MANAGEMENT; DISEASE	Craniofacial fibrous dysplasia, characteristic of McCune-Albright syndrome (MAS), is usually present in patients with MAS-related acromegaly. We report here the first case of a patient with an undiagnosed MAS presenting with an acute hydrocephalus. A 21-year-old male with gigantism and craniofacial fibrous dysplasia consulted for rapidly progressive headache. An acute obstructive hydrocephalus due to a 39x35-mm cystic lesion in the third ventricle was discovered and operated, obtaining hydrocephalus resolution. Pathology described a colloid cyst material and a growth hormone-secreting pituitary adenoma. Genetic study revealed the mosaic GNAS R201H mutation in the pituitary tissue, confirming a MAS diagnosis. Adequate hormonal control was achieved postoperatively. Our results suggest that long-term untreated growth hormone excess in patients with MAS-related craniofacial fibrous dysplasia might end compromising cerebrospinal fluid flow. A prompt diagnosis and coordinated multidisciplinary treatment may help to avoid long-term deleterious impact of hyperfunctioning endocrinopathies in these patients.	[Lecumberri, Beatriz; Gomes, Mariana] La Paz Univ Hosp, Endocrinol & Nutr Dept, Madrid, Spain; [Juan Pozo-Kreilinger, Jose; Esteban, Isabel] La Paz Univ Hosp, Dept Pathol, Madrid, Spain; [Royo, Aranzazu] La Paz Univ Hosp, Dept Radiol, Madrid, Spain; [Gomez de la Riva, Alvaro] La Paz Univ Hosp, Neurosurg Dept, Madrid, Spain; [Perez de Nanclares, Guiomar] Araba Univ Hosp, BioAraba Natl Hlth Inst, Mol Epi Genet Lab, Vitoria, Spain	Lecumberri, B (reprint author), La Paz Univ Hosp, Endocrinol & Nutr Dept, Madrid, Spain.	lecum74@hotmail.com	Perez de Nanclares, Guiomar/P-1057-2018	Perez de Nanclares, Guiomar/0000-0002-2424-5294			Boyce AM, 2016, PLAST RECONSTR SURG, V137, P1833, DOI 10.1097/PRS.0000000000002151; Galland F, 2006, J CLIN ENDOCR METAB, V91, P4957, DOI 10.1210/jc.2006-0561; NERLICH A, 1991, LANCET, V338, P886, DOI 10.1016/0140-6736(91)91542-3; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Okamoto S, 2000, VIRCHOWS ARCH, V437, P133, DOI 10.1007/s004280000217; Pamir MN, 2004, ZBL NEUROCHIR, V65, P108, DOI 10.1055/s-2004-822846; Salenave S, 2014, J CLIN ENDOCR METAB, V99, P1955, DOI 10.1210/jc.2013-3826; Shin SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03093-1; Vasilev V, 2014, J CLIN ENDOCR METAB, V99, pE2029, DOI 10.1210/jc.2014-1291; Vortmeyer AO, 2012, J CLIN ENDOCR METAB, V97, P2404, DOI 10.1210/jc.2012-1274; Wood LD, 2017, VIRCHOWS ARCH, V470, P391, DOI 10.1007/s00428-017-2086-2; Yao Y, 2017, EUR J ENDOCRINOL, V176, P295, DOI 10.1530/EJE-16-0715	12	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					645	648		10.1007/s00428-018-2396-z			4	Pathology	Pathology	GY8GR	WOS:000448861800013	29984378				2019-10-28	
J	Kwon, JH; Kim, HJ; Park, DH; Lee, YJ; Heaphy, CM; Kloppel, G; Hruban, RH; Hong, SM				Kwon, Jeong-Hwa; Kim, Hyoung Jung; Park, Do Hyun; Lee, Young-Joo; Heaphy, Christopher M.; Kloeppel, Guenter; Hruban, Ralph H.; Hong, Seung-Mo			Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis	VIRCHOWS ARCHIV			English	Article						Pancreas; Neuroendocrine; Microadenoma; Lymph node; Metastasis; Malignant	TUMORS; TELOMERES; EXPRESSION; SURVIVAL; ATRX; MEN1; DAXX	Pancreatic neuroendocrine microadenomas (NEMAs) are non-functioning neuroendocrine tumors <0.5cm with a low proliferation rate and are considered benign. We report on a pancreatic NEMA with lymph node metastasis. A male in his 70s had pylorus-preserving pancreaticoduodenectomy for a distal bile duct carcinoma, which was a 2.1 cm well-differentiated-infiltrating adenocarcinoma with invasion limited to the bile duct wall. An incidental separate 0.4 cm well-differentiated NEMA was found in the pancreatic head with metastatic well-differentiated neuroendocrine tumor in one peripancreatic lymph node. Both neuroendocrine tumors in the pancreatic head and in the lymph node were composed of nests of uniform neoplastic cells with a fine chromatin pattern. The Ki-67 labeling index of NEMA was 0.85%. The neoplastic neuroendocrine cells in both the pancreas and node were diffusely positive for synaptophysin, chromogranin, and insulin. Therefore, this unusual case provides an exception to the current classification system which regards NEMAs as benign lesions.	[Kwon, Jeong-Hwa; Hong, Seung-Mo] Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea; [Kim, Hyoung Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea; [Kim, Hyoung Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Radiol, Seoul, South Korea; [Park, Do Hyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea; [Lee, Young-Joo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea; [Heaphy, Christopher M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Heaphy, Christopher M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Kloeppel, Guenter] Tech Univ Munich, Dept Pathol, Munich, Germany; [Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA	Hong, SM (reprint author), Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.	smhong28@gmail.com		Hong, Seung-Mo/0000-0002-8888-6007	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2016R1A2B4009381]; Asan Institute for Life Sciences, Seoul, Republic of Korea [2013-554]; 2016 Basic/Translational Science Investigator Award from the North American Neuroendocrine Tumor Society - Neuroendocrine Tumor Research Foundation (CMH); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA62924]	The study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2016R1A2B4009381), a grant (2013-554) from the Asan Institute for Life Sciences, Seoul, Republic of Korea (SMH), the 2016 Basic/Translational Science Investigator Award from the North American Neuroendocrine Tumor Society supported by the Neuroendocrine Tumor Research Foundation (CMH), and NIH grant CA62924 (RHH).	Anlauf M, 2008, AM J SURG PATHOL, V32, P1101, DOI 10.1097/PAS.0b013e3181655811; Bosman FT, 2010, WHO CLASSIFICATION T; de Wilde RF, 2012, MODERN PATHOL, V25, P1033, DOI 10.1038/modpathol.2012.53; Dogeas E, 2014, J AM COLL SURGEONS, V218, P628, DOI 10.1016/j.jamcollsurg.2014.01.001; Falconi M, 2016, NEUROENDOCRINOLOGY, V103, P153, DOI 10.1159/000443171; Hackeng WM, 2016, HUM PATHOL, V56, P93, DOI 10.1016/j.humpath.2016.06.006; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kim JY, 2017, CLIN CANCER RES, V23, P1598, DOI 10.1158/1078-0432.CCR-16-1147; Kim JY, 2015, AM J SURG PATHOL, V39, P592, DOI 10.1097/PAS.0000000000000383; KIMURA W, 1991, DIGEST DIS SCI, V36, P933, DOI 10.1007/BF01297144; Lloyd RV, 2017, WHO CLASSIFICATION T; Marinoni I, 2014, GASTROENTEROLOGY, V146, P453, DOI 10.1053/j.gastro.2013.10.020; Singhi AD, 2017, CLIN CANCER RES, V23, P600, DOI 10.1158/1078-0432.CCR-16-1113	14	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					649	653		10.1007/s00428-018-2407-0			5	Pathology	Pathology	GY8GR	WOS:000448861800014	30003325				2019-10-28	
J	Banz, Y; Berezowska, S; de Leval, L; Rubbia-Brandt, L; Tolnay, M; Moch, H; Perren, A; Hewer, E				Banz, Yara; Berezowska, Sabina; de Leval, Laurence; Rubbia-Brandt, Laura; Tolnay, Markus; Moch, Holger; Perren, Aurel; Hewer, Ekkehard			Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach	VIRCHOWS ARCHIV			English	Letter									[Banz, Yara; Berezowska, Sabina; Perren, Aurel; Hewer, Ekkehard] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland; [de Leval, Laurence] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland; [Rubbia-Brandt, Laura] Geneva Univ Hosp, Div Clin Pathol, Geneva, Switzerland; [Rubbia-Brandt, Laura] Fac Med Geneva, Geneva, Switzerland; [Tolnay, Markus] Univ Hosp Basel, Inst Med Genet & Pathol, Basel, Switzerland; [Moch, Holger] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland	Hewer, E (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	ekkehard.hewer@pathology.unibe.ch	Hewer, Ekkehard/W-8670-2019; Perren, Aurel/A-9383-2018	Hewer, Ekkehard/0000-0002-9128-0364; Perren, Aurel/0000-0002-6819-6092; Berezowska, Sabina/0000-0001-5442-9791	Swiss National Science Foundation SNFSwiss National Science Foundation (SNSF) [31BL30_172718]	The work was supported by the Swiss National Science Foundation SNF: 31BL30_172718.	Ellis DW, 2016, VIRCHOWS ARCH, V468, P51, DOI 10.1007/s00428-015-1834-4	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					655	656		10.1007/s00428-018-2431-0			2	Pathology	Pathology	GY8GR	WOS:000448861800015	30088082				2019-10-28	
J	Bal, M; Rane, S; Talole, S; Ramadwar, M; Deodhar, K; Patil, P; Goel, M; Shrikhande, SV				Bal, Munita; Rane, Swapnil; Talole, Sanjay; Ramadwar, Mukta; Deodhar, Kedar; Patil, Prachi; Goel, Mahesh; Shrikhande, Shailesh V.			Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting (vol 473, pg 293, 2018)	VIRCHOWS ARCHIV			English	Correction									[Bal, Munita; Rane, Swapnil; Ramadwar, Mukta; Deodhar, Kedar] Tata Mem Hosp, Dept Pathol, Bombay 400012, Maharashtra, India; [Talole, Sanjay] Tata Mem Hosp, Dept Epidemiol & Stat, Bombay, Maharashtra, India; [Patil, Prachi] Tata Mem Hosp, Dept Digest Dis & Nutr, Bombay, Maharashtra, India; [Goel, Mahesh; Shrikhande, Shailesh V.] Tata Mem Hosp, Dept Surg Oncol, Bombay, Maharashtra, India	Bal, M (reprint author), Tata Mem Hosp, Dept Pathol, Bombay 400012, Maharashtra, India.	munitamenon@gmail.com	rane, swapnil/H-4694-2011	rane, swapnil/0000-0002-5374-3903			Bal M, 2018, VIRCHOWS ARCH, V473, P293, DOI 10.1007/s00428-018-2429-7	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	NOV	2018	473	5					659	659		10.1007/s00428-018-2465-3			1	Pathology	Pathology	GY8GR	WOS:000448861800016	30284030				2019-10-28	
J	McKenney, JK; Hornick, JL				McKenney, Jesse K.; Hornick, Jason L.			Immunohistochemistry in Surgical Pathology	ADVANCES IN ANATOMIC PATHOLOGY			English	Editorial Material									[McKenney, Jesse K.] Cleveland Clin, Cleveland, OH 44106 USA; [Hornick, Jason L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	McKenney, JK (reprint author), Robert J Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	mckennj@ccf.org						0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					373	373		10.1097/PAP.0000000000000212			1	Pathology	Pathology	GX4IE	WOS:000447692000001	30179894				2019-10-28	
J	Schaefer, IM; Hornick, JL				Schaefer, Inga-Marie; Hornick, Jason L.			Diagnostic Immunohistochemistry for Soft Tissue and Bone Tumors: An Update	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						sarcoma; CAMTA1; FOSB; SMARCB1; PAX3; histone 3	BIPHENOTYPIC SINONASAL SARCOMA; ROUND-CELL SARCOMAS; WELL-DIFFERENTIATED LIPOSARCOMA; CIC-FOXO4 GENE FUSION; EWING-LIKE-SARCOMA; PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; EPITHELIOID HEMANGIOENDOTHELIOMA; LIPOMATOUS TUMOR; MARKER; CHONDROBLASTOMA	Although some soft tissue and bone tumors can be identified based on histologic features alone, immunohistochemistry plays a critical diagnostic role for most mesenchymal tumor types. The discovery of recurrent genomic alterations in many benign and malignant mesenchymal neoplasms has added important biologic insights and expanded the spectrum of some diagnostic subgroups. Some tumors are defined by unique genomic alterations, whereas others share abnormalities that are not tumor-specific and can be observed in a sometimes broad range of biologically unrelated neoplasms. We herein focus on novel immunohistochemical markers, based on molecular genetic alterations, which are particularly useful in the diagnostic workup of selected groups of soft tissue and bone tumors, including recently described entities, specifically round cell sarcomas (Ewing sarcoma, CIC-rearranged sarcoma, and BCOR-rearranged sarcoma), vascular tumors (epithelioid hemangioma, epithelioid hemangioendothelioma, and pseudomyogenic hemangioendothelioma), SMARCB1-deficient neoplasms, adipocytic tumors (spindle cell/pleomorphic lipoma, atypical spindle cell lipomatous tumor, and conventional atypical lipomatous tumor), giant cell-rich bone tumors (giant cell tumor of bone and chondroblastoma), and biphenotypic sinonasal sarcoma. Given the complex nature of sarcoma classification, and the rarity of many mesenchymal tumor types, careful integration of clinical presentation, imaging features, histology, immunophenotype, and cytogenetic/molecular alterations is crucial for accurate diagnosis of soft tissue and bone tumors.	[Schaefer, Inga-Marie; Hornick, Jason L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	Hornick, JL (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	jhornick@bwh.harvard.edu		, Inga-Marie/0000-0001-9710-5500	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007627]		Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P951, DOI 10.1002/gcc.22206; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Calderaro J, 2016, EUR UROL, V69, P1055, DOI 10.1016/j.eururo.2015.09.027; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; Cohen-Gogo S, 2014, PEDIATR BLOOD CANCER, V61, P2191, DOI 10.1002/pbc.25210; Creytens D, 2014, VIRCHOWS ARCH, V465, P97, DOI 10.1007/s00428-014-1568-8; DalCin P, 1997, HISTOPATHOLOGY, V31, P222, DOI 10.1046/j.1365-2559.1997.2450851.x; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; Deyrup AT, 2013, AM J SURG PATHOL, V37, P1373, DOI 10.1097/PAS.0b013e31829562ed; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Huang SC, 2015, AM J SURG PATHOL, V39, P1313, DOI 10.1097/PAS.0000000000000469; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Italiano A, 2008, INT J CANCER, V122, P2233, DOI 10.1002/ijc.23380; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Jo V, 2018, AM J SURG PATHOL; Jo VY, 2017, AM J SURG PATHOL, V41, P1013, DOI 10.1097/PAS.0000000000000849; Jo VY, 2015, AM J SURG PATHOL, V39, P673, DOI 10.1097/PAS.0000000000000379; Kao YC, 2018, AM J SURG PATHOL, V42, P604, DOI 10.1097/PAS.0000000000000965; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Laurino L, 2001, SEMIN DIAGN PATHOL, V18, P258, DOI 10.1053/sdia.2001.28254; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; LUCAS DR, 1994, AM J CLIN PATHOL, V102, P677, DOI 10.1093/ajcp/102.5.677; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019; Mentzel T, 2010, MODERN PATHOL, V23, P729, DOI 10.1038/modpathol.2010.66; Nohr E, 2017, HUM PATHOL, V68, P119, DOI 10.1016/j.humpath.2017.08.030; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Rosai J, 1996, AM J SURG PATHOL, V20, P1182, DOI 10.1097/00000478-199610000-00002; Schaefer I. M., 2018, CANC CYTOPATHOL; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Shih AR, 2018, MOD PATHOL; Solomon DA, 2014, AM J SURG PATHOL, V38, P1724, DOI 10.1097/PAS.0000000000000335; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; Templeton SF, 1996, J CUTAN PATHOL, V23, P546, DOI 10.1111/j.1600-0560.1996.tb01447.x; Tos APD, 2000, J PATHOL, V190, P531; van IJzendoorn DGP, 2015, GENE CHROMOSOME CANC, V54, P565, DOI 10.1002/gcc.22269; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295; Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c	59	5	5	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					400	412		10.1097/PAP.0000000000000204			13	Pathology	Pathology	GX4IE	WOS:000447692000004	30134255	Green Accepted			2019-10-28	
J	Myles, JL; Synovec, M; Klemp, T; Black-Schaffer, WS				Myles, Jonathan L.; Synovec, Mark; Klemp, Todd; Black-Schaffer, William S.			Current CPT Coding and Payment Policy Implications for Immunohistology Services	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						immunohistochemistry; immunofluorescence; CPT coding; payment policy	SOCIETY	Immunohistology is essential to the practice of modern surgical and cytopathology. There are 3 major types of immunohistologic services provided in clinical practice: traditional immunohistochemistry, morphometric analysis of tumor immunohistochemistry, and immunofluorescence. Proper Current Procedural Terminology coding for these services has been updated to reflect current medical practice. Subsequent to changes in the Current Procedural Terminology coding structure for these services, the valuation of these services have been reviewed by the American Medical Association/Specialty Society Relative Value Update Committee and new valuations instituted by the Centers for Medicare and Medicaid Services. Although valuations for services may be established, the circumstances of payment may be affected by Medicare Contractor's Local Coverage Determinations or service limits imposed by the National Correct Coding Initiative.	[Myles, Jonathan L.] Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Dept Pathol, Cleveland, OH 44106 USA; [Synovec, Mark] Topeka Pathol Grp LLC, Topeka, KS USA; [Klemp, Todd] Coll Amer Pathologists, Washington, DC USA; [Black-Schaffer, William S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Black-Schaffer, William S.] Harvard Med Sch, Boston, MA USA	Myles, JL (reprint author), Cleveland Clin, Dept Pathol, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	mylesj@ccf.org					Ahlman JT, 2017, CURRENT PROCEDURAL T, P591; Arber DA, 2017, ARCH PATHOL LAB MED, V141, P1342, DOI 10.5858/arpa.2016-0504-CP; Centers for Medicare and Medicaid Services, 2018, 2018 NAT CORR COD IN; CMS Website, MED PROGR INT MAN; CMS Website, 2018, MED UNL ED; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Fiegl C, 2014, CAP TODAY; Hsi ED, 2008, LEUKEMIA LYMPHOMA, V49, P2081, DOI 10.1080/10428190802419640; Myles JL, 2017, ADV ANAT PATHOL, V24, P222, DOI 10.1097/PAP.0000000000000156	9	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	NOV	2018	25	6					430	433		10.1097/PAP.0000000000000207			4	Pathology	Pathology	GX4IE	WOS:000447692000006	30130265				2019-10-28	
J	Saeki, K; Ohishi, Y; Matsuda, R; Mochidome, N; Miyasaka, Y; Yamamoto, H; Koga, Y; Maehara, Y; Nakamura, M; Oda, Y				Saeki, Kiyoshi; Ohishi, Yoshihiro; Matsuda, Ryota; Mochidome, Naoki; Miyasaka, Yoshihiro; Yamamoto, Hidetaka; Koga, Yutaka; Maehara, Yoshihiko; Nakamura, Masafumi; Oda, Yoshinao			"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pancreatic adenosquamous carcinoma; mucoepidermoid carcinoma; CRTC1/3-MAML2 fusion gene	MAML2 FUSION; TRANSLOCATION; REARRANGEMENT; CRTC3-MAML2; STATISTICS; TRANSCRIPT; EXPRESSION; MUC5AC; MUC2	"Mucoepidermoid carcinoma (MEC)" has been accepted as a synonym for pancreatic adenosquamous carcinoma (ASC). Pancreatic ASC can show salivary gland-type MEC-like morphology. CRTC1/3-MAML2 fusion gene is a characteristic molecular feature of MEC of the salivary gland. We conducted this study to clarify whether the pancreatic ASC with salivary gland-type MEC-like morphology (Pan-MEC) is a pancreatic counterpart of salivary gland-type MEC (Sal-MEC). We retrospectively analyzed 37 pancreatic ASCs including 16 Pan-MECs and 21 tumors without MEC-like features (ASC-NOS [not otherwise specified]), and we investigated (1) clinicopathologic features, (2) the presence of CRTC1/3-MAML2 fusion gene by reverse transcription polymerase chain reaction, (3) the presence of rearrangement of MAML2 gene by fluorescence in situ hybridization, and (4) mucin core proteins by immunohistochemistry. We also compared 16 Pan-MECs with 20 Sal-MECs by immunohistochemistry for mucin core protein. There were no significant differences of any clinicopathologic characteristics and survival analysis between the Pan-MECs and ASCs-NOS. Of note, the pancreatic ASCs (including Pan-MEC and ASC-NOS) were significantly more aggressive than conventional pancreatic ductal adenocarcinoma. In addition, all Pan-MECs were histologically high-grade. CRTC1/3-MAML2 fusion gene and MAML2 gene rearrangement were not detected in any ASCs including Pan-MECs. There were significant differences of MUC5AC and MUC6 between the Pan-MECs and Sal-MECs, but no significant differences of mucin core protein between the Pan-MECs and pancreatic ASCs-NOS. Pan-MEC is histologically and biologically high-grade and unrelated to CRTC1/3-MAML2 fusion gene, unlike Sal-MEC which is related to CRTC1/3-MAML2 fusion gene. Pan-MEC is not a pancreatic counterpart of CRTC1/3-MAML2 fusion gene-related Sal-MEC.	[Saeki, Kiyoshi; Ohishi, Yoshihiro; Matsuda, Ryota; Mochidome, Naoki; Yamamoto, Hidetaka; Koga, Yutaka; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Fukuoka, Japan; [Miyasaka, Yoshihiro; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Fukuoka, Japan; [Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp		Saeki, Kiyoshi/0000-0002-1214-3215			Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Alos L, 2005, AM J SURG PATHOL, V29, P806, DOI 10.1097/01.pas.0000155856.84553.c9; Bhattacharyya N, 2005, AM J OTOLARYNG, V26, P39, DOI 10.1016/j.amjoto.2004.06.017; Bosman F.T., 2010, WHO CLASSIFICATION T, P281; Brandwein MS, 2001, AM J SURG PATHOL, V25, P835, DOI 10.1097/00000478-200107000-00001; Brandwein-Gensler M, 2017, WHO CLASSIFICATION H, P163; Ellis GL, 2008, AFIP ATLAS TUMOR PAT, P173; ElNaggar AK, 1996, CANCER GENET CYTOGEN, V87, P29, DOI 10.1016/0165-4608(95)00266-9; Fehr A, 2008, GENE CHROMOSOME CANC, V47, P203, DOI 10.1002/gcc.20522; FISHER ER, 1983, AM J SURG PATHOL, V7, P15, DOI 10.1097/00000478-198301000-00002; Fukushima N, 2010, WHO CLASSIFICATION T, P292; Goode RK, 2005, WHO CLASSIFICATION T, P219; Handra-Luca A, 2005, AM J SURG PATHOL, V29, P881, DOI 10.1097/01.pas.0000159103.95360.e8; Hsu JT, 2005, DIGESTION, V72, P104, DOI 10.1159/000088364; Jee KJ, 2013, MODERN PATHOL, V26, P213, DOI 10.1038/modpathol.2012.154; Kardon DE, 2001, MODERN PATHOL, V14, P443, DOI 10.1038/modpathol.3880332; Kuma Y, 2017, HUM PATHOL, V70, P55, DOI 10.1016/j.humpath.2017.10.004; Lennerz JKM, 2009, AM J SURG PATHOL, V33, P835, DOI 10.1097/PAS.0b013e318190cf5b; Ma R, 2012, J RES MED SCI, V17, P886; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Nakano T, 2013, HISTOPATHOLOGY, V63, P378, DOI 10.1111/his.12183; Nakayama T, 2009, MODERN PATHOL, V22, P1575, DOI 10.1038/modpathol.2009.126; OHTSUKI Y, 1987, ACTA PATHOL JAPON, V37, P1175; Okabe M, 2006, CLIN CANCER RES, V12, P3902, DOI 10.1158/1078-0432.CCR-05-2376; ONODA N, 1995, SURG TODAY, V25, P843, DOI 10.1007/BF00311465; Pandey P, 2016, AM J DERMATOPATH, V38, P852, DOI 10.1097/DAD.0000000000000604; Roden AC, 2013, HUM PATHOL, V44, P2799, DOI 10.1016/j.humpath.2013.07.031; Salem A, 2017, VIRCHOWS ARCH, V470, P619, DOI 10.1007/s00428-017-2104-4; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; STEWART FW, 1945, ANN SURG, V122, P820, DOI 10.1097/00000658-194511000-00005; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; YAMAGUCHI K, 1991, J SURG ONCOL, V47, P109, DOI 10.1002/jso.2930470210	33	2	2	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1419	1428		10.1097/PAS.0000000000001135			10	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800001	30138216				2019-10-28	
J	Murdock, T; Orr, B; Allen, S; Ibrahim, J; Sharma, R; Ronnett, BM; Rodriguez, FJ				Murdock, Tricia; Orr, Brent; Allen, Sariah; Ibrahim, Junaid; Sharma, Rajni; Ronnett, Brigitte M.; Rodriguez, Fausto J.			Central Nervous System-type Neuroepithelial Tumors and Tumor-like Proliferations Developing in the Gynecologic Tract and Pelvis Clinicopathologic Analysis of 23 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						central nervous system tumors; central type primitive neuroectodermal tumor; gynecologic tract; pelvis	MATURE CYSTIC TERATOMA; OF-THE-LITERATURE; OVARIAN EPENDYMOMA; BROAD LIGAMENT; BRAIN-TUMORS; MYXOPAPILLARY EPENDYMOMA; NEUROECTODERMAL TUMORS; EXTRASPINAL EPENDYMOMA; PILOCYTIC ASTROCYTOMA; CENTRAL NEUROCYTOMA	Central nervous system (CNS)-type tumors and tumor-like proliferations arising in the gynecologic tract and pelvis are rare. Clinicopathologic features of 23 cases are reported using the current WHO classification system for CNS tumors, with selected relevant immunohistochemical and molecular genetic analyses when possible. There were 12 embryonal tumors, including 7 medulloepitheliomas, 2 embryonal tumors (not otherwise specified), 1 embryonal tumor with multilayered rosettes, 1 embryonal tumor with features of nodular desmoplastic medulloblastoma, and 1 medulloblastoma with extensive nodularity, with primary sites including ovary (7), uterus/endometrium (3), and pelvis (2). Six ovarian tumors had associated germ cell tumors (3 immature teratomas [1 also with yolk sac tumor], 2 mature cystic teratomas, and 1 yolk sac tumor). These tumors typically had some expression of synaptophysin (10/10), GFAP (5/9), S100 (3/6), and NeuN (3/3) and were negative for C19MC amplicon by fluorescence in situ hybridization (0/5). There were 6 glial tumors, including 3 ependymomas (1 anaplastic), 1 oligodendroglioma, not otherwise specified, 1 pilocytic astrocytoma, and 1 atypical glial proliferation after therapy of a high-grade high-stage immature teratoma, with primary sites including ovary (4), fallopian tube (1), and pelvic sidewall (1). Four ovarian tumors had associated teratomas (2 immature and 2 mature). These tumors expressed GFAP (5/6), OLIG2 (2/3), and S100 (1/1), and the pilocytic astrocytoma was negative for BRAF (V600E) mutant protein. There were 4 neuronal or mixed glioneuronal tumors, including 3 neurocytomas and 1 malignant (high-grade) glioneuronal neoplasm, all primary ovarian and associated with teratomas (3 mature, 1 immature). These tumors expressed synaptophysin (4/4), GFAP (1/3), NeuN (1/2), and OLIG2 (1/2). Single-nucleotide polymorphism microarray analysis of the malignant glioneuronal neoplasm demonstrated a partial deletion at location (1)(p36.23p35.2) on chromosome 1p, and 2 regions of deletion at locations (19)(q11q13.12) and (19)(q13.41qter) on 19q. One neurocytoma had no 1p and 19q co-deletions. There was 1 meningioma in the pelvis. For 10 patients with embryonal tumors and follow-up, 5 were alive with no evidence of disease (mean/median: 60/52 mo), 4 were alive with recurrent disease (mean/median: 32/31 mo), and 1 died of disease (13 mo). For 5 patients with other tumor types and follow-up, all were alive without evidence of disease (mean/median: 33/30 mo). Diagnostic evaluation and classification per systems used for primary CNS tumors are recommended for the wide spectrum of CNS-type neuroepithelial tumors that can occur in the female genital tract and pelvis.	[Murdock, Tricia; Ibrahim, Junaid; Sharma, Rajni; Ronnett, Brigitte M.; Rodriguez, Fausto J.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Orr, Brent; Allen, Sariah] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA	Murdock, T (reprint author), Johns Hopkins Med, Sibley Mem Hosp, Div Gynecol Pathol, 5255 Loughboro Rd NW, Washington, DC 20016 USA.	tmurdoc8@jhmi.edu					AUERBACH R, 1988, OBSTET GYNECOL, V71, P1043; Bar EE, 2008, J NEUROPATH EXP NEUR, V67, P878, DOI 10.1097/NEN.0b013e3181845622; Bay SB, 2010, PEDIATR HEMAT ONCOL, V27, P636, DOI 10.3109/08880018.2010.505633; BELL DA, 1984, AM J SURG PATHOL, V8, P203, DOI 10.1097/00000478-198403000-00006; BERGER N, 1969, AMER J ROENTGENOL RA, V107, P647, DOI 10.2214/ajr.107.3.647; Caltabiano R, 2008, PATHOLOGICA, V100, P420; Capper D, 2009, ACTA NEUROPATHOL, V118, P599, DOI 10.1007/s00401-009-0595-z; CARR KA, 1992, HUM PATHOL, V23, P962, DOI 10.1016/0046-8177(92)90414-X; Chiang S, 2017, AM J SURG PATHOL, V41, P761, DOI 10.1097/PAS.0000000000000831; Clinkard DJ, 2011, GYNECOL ONCOL, V120, P311, DOI 10.1016/j.ygyno.2010.10.022; Deshmukh H, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-57; Deval B, 2014, OBSTET GYNECOL, V123, P488, DOI 10.1097/AOG.0000000000000077; Din NU, 2012, J CLIN PATHOL, V65, P631, DOI 10.1136/jclinpath-2012-200714; Djordjevic B, 2007, AM J SURG PATHOL, V31, P1913, DOI 10.1097/PAS.0b013e318073cf44; Donner LR, 2003, AM J SURG PATHOL, V27, P1008, DOI 10.1097/00000478-200307000-00018; DUGGAN MA, 1989, CANCER, V64, P2565, DOI 10.1002/1097-0142(19891215)64:12<2565::AID-CNCR2820641226>3.0.CO;2-I; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Erdogan G, 2005, APMIS, V113, P301, DOI 10.1111/j.1600-0463.2005.apm_10.x; Ersoz S, 2011, FETAL PEDIATR PATHOL, V30, P275, DOI 10.3109/15513815.2011.572955; Fan F, 2006, ACTA CYTOL, V50, P709; FIGARELLABRANGER D, 1992, NEUROPATH APPL NEURO, V18, P408, DOI 10.1111/j.1365-2990.1992.tb00802.x; FRIEDMAN HD, 1991, ARCH PATHOL LAB MED, V115, P941; Friedrichs N, 2003, VIRCHOWS ARCH, V443, P217, DOI 10.1007/s00428-003-0852-9; Garcia-Barriola V, 2000, PATHOL RES PRACT, V196, P595, DOI 10.1016/S0344-0338(00)80035-7; Harada S, 2011, J MOL DIAGN, V13, P541, DOI 10.1016/j.jmoldx.2011.05.009; Harieaswer S, 2006, J Obstet Gynaecol, V26, P710; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hirahara F, 1997, EUR J OBSTET GYN R B, V75, P221, DOI 10.1016/S0301-2115(97)00134-6; Hirschowitz L, 1997, INT J GYNECOL PATHOL, V16, P176, DOI 10.1097/00004347-199704000-00016; Idowu MO, 2008, AM J SURG PATHOL, V32, P710, DOI 10.1097/PAS.0b013e318159a2b4; Ilhan I, 1998, MED PEDIATR ONCOL, V30, P81; KLEINMAN GM, 1993, AM J SURG PATHOL, V17, P764, DOI 10.1097/00000478-199308000-00002; Komuro Y, 2001, CANCER, V92, P3165, DOI 10.1002/1097-0142(20011215)92:12<3165::AID-CNCR10111>3.0.CO;2-Y; Korshunov A, 2014, ACTA NEUROPATHOL, V128, P279, DOI 10.1007/s00401-013-1228-0; Korshunov A, 2010, ACTA NEUROPATHOL, V120, P253, DOI 10.1007/s00401-010-0688-8; Li MH, 2009, CANCER CELL, V16, P533, DOI 10.1016/j.ccr.2009.10.025; Liang L, 2016, AM J SURG PATHOL, V40, P847, DOI 10.1097/PAS.0000000000000635; LOGOTHETIS CJ, 1982, CANCER, V50, P1629, DOI 10.1002/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO;2-1; Louis DN, 2016, WHO CLASSIFICATION T; Mandal S, 2010, PATHOL RES PRACT, V206, P322, DOI 10.1016/j.prp.2009.05.011; Matsuyama A, 2010, PATHOL INT, V60, P241, DOI 10.1111/j.1440-1827.2009.02509.x; Mogler C, 2009, VIRCHOWS ARCH, V454, P475, DOI 10.1007/s00428-009-0744-8; Morovic A, 2008, HISTOL HISTOPATHOL, V23, P765, DOI 10.14670/HH-23.765; Nobusawa S, 2012, BRAIN PATHOL, V22, P689, DOI 10.1111/j.1750-3639.2012.00574.x; Nur S, 2006, GYNECOL ONCOL, V103, P745, DOI 10.1016/j.ygyno.2006.05.050; Opris I, 2009, INT J GYNECOL PATHOL, V28, P367, DOI 10.1097/PGP.0b013e318196c4c0; Panesar NK, 2007, ANN DIAGN PATHOL, V11, P293, DOI 10.1016/j.anndiagpath.2006.03.019; Pfister S, 2009, ACTA NEUROPATHOL, V117, P457, DOI 10.1007/s00401-008-0467-y; Poulos C, 2006, MODERN PATHOL, V19, P766, DOI 10.1038/modpathol.3800596; Rodriguez FJ, 2006, ACTA NEUROPATHOL, V112, P727, DOI 10.1007/s00401-006-0129-x; SHIRLEY RL, 1971, OBSTET GYNECOL, V37, P402; Skopelitou A, 2002, VIRCHOWS ARCH, V440, P105, DOI 10.1007/s00428-001-0546-0; Snir OL, 2017, MODERN PATHOL, V30, P1467, DOI 10.1038/modpathol.2017.66; Soylemezoglu F, 1997, J NEUROPATH EXP NEUR, V56, P551; Spaulding R, 2014, CASE REP OBSTET GYNE, V2014; Spence T, 2014, ACTA NEUROPATHOL, V128, P291, DOI 10.1007/s00401-014-1291-1; Stolnicu S, 2017, INT J GYNECOL PATHOL, V36, P222, DOI 10.1097/PGP.0000000000000319; Stolnicu S, 2011, HUM PATHOL, V42, P403, DOI 10.1016/j.humpath.2010.07.017; Takano T, 2005, INT J GYNECOL CANCER, V15, P1138, DOI 10.1111/j.1525-1438.2005.00187.x; Takeshima Y, 2004, PATHOL INT, V54, P543, DOI 10.1111/j.1440-1827.2004.01662.x; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; TIMMERMAN W, 1984, DIS COLON RECTUM, V27, P114, DOI 10.1007/BF02553989; Trabzonlu L, 2017, PATHOL RES PRACT, V213, P518, DOI 10.1016/j.prp.2017.01.016; Tran HH, 2016, INT J CLIN EXP PATHO, V9, P345; Verdun TP, 2015, PATHOL RES PRACT, V211, P268, DOI 10.1016/j.prp.2014.10.007; Wei SZ, 2015, ENDOCR PATHOL, V26, P342, DOI 10.1007/s12022-015-9396-1; Wey SL, 2013, INT J SURG PATHOL, V21, P427, DOI 10.1177/1066896912464048; Whittemore DE, 2005, ARCH PATHOL LAB MED, V129, P1338; Yadav A, 1999, HISTOPATHOLOGY, V35, P170, DOI 10.1046/j.1365-2559.1999.00695.x; Yu JH, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0406-x; Zannoni GF, 2002, ACTA OBSTET GYN SCAN, V81, P896, DOI 10.1034/j.1600-0412.2002.810918.x; Zhou F, 2015, INT J GYNECOL PATHOL, V34, P450, DOI 10.1097/PGP.0000000000000156	72	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1429	1444		10.1097/PAS.0000000000001131			16	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800002	30074494				2019-10-28	
J	Skalova, A; Vanecek, T; Uro-Coste, E; Bishop, JA; Weinreb, I; Thompson, LDR; de Sanctis, S; Schiavo-Lena, M; Laco, J; Badoual, C; Conceicao, TS; Ptakova, N; Baneckova, M; Miesbauerova, M; Michal, M				Skalova, Alena; Vanecek, Tomas; Uro-Coste, Emmanuelle; Bishop, Justin A.; Weinreb, Ilan; Thompson, Lester D. R.; de Sanctis, Stefano; Schiavo-Lena, Marco; Laco, Jan; Badoual, Cecile; Conceicao, Thalita Santana; Ptakova, Nikola; Baneckova, Martina; Miesbauerova, Marketa; Michal, Michal			Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions A Report of 17 cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						salivary gland neoplasm; intraductal carcinoma; cystadenocarcinoma; mammary analogue secretory carcinoma; MASC; NCOA4-RET; TRIM27-RET; RET-targeted therapy	ANALOG SECRETORY CARCINOMA; DUCT CARCINOMA; IN-SITU; GENE REARRANGEMENTS; CELL-CARCINOMA; PAROTID-GLAND; TRANSLOCATION; IMMUNOHISTOCHEMISTRY; DIAGNOSIS	Intraductal carcinoma (IC) is the new World Health Organization designation for tumors previously called "low-grade cribriform cystadenocarcinoma" and "low-grade salivary duct carcinoma." The relationship of IC to salivary duct carcinoma is controversial, but they now are considered to be distinct entities. IC is a rare low-grade malignant salivary gland neoplasm with features similar to mammary atypical ductal hyperplasia or ductal carcinoma in situ, that shows diffuse S100 protein and mammaglobin positivity and is only partially defined genetically. (Mammary analogue) secretory carcinoma harboring ETV6-NTRK3, and in rare cases ETV6-RET fusion, shares histomorphologic and immunophenotypical features with IC. Recently, RET rearrangements and NCOA4-RET have been described in IC, suggesting a partial genetic overlap with mammary analogue secretory carcinoma. Here, we genetically characterize the largest cohort of IC to date to further explore this relationship. Seventeen cases of IC were analyzed by next-generation sequencing using the FusionPlex Solid Tumor kit (ArcherDX). Identified fusions were confirmed using fluorescence in situ hybridization break apart and, in some cases, fusion probes, and a reverse transcription polymerase chain reaction designed specifically to the detected breakpoints. All analyzed cases were known to be negative for ETV6 rearrangement by fluorescence in situ hybridization and for ETV6-NTRK3 fusion by reverse transcription polymerase chain reaction. Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC. A total of 47% of IC harbored a fusion involving RET. In conclusion, we have confirmed the presence of NCOA4-RET as the dominant fusion in intercalated duct type IC. A novel finding in our study has been a discovery of a subset of IC patients with apocrine variant IC harboring a novel TRIM27-RET.	[Skalova, Alena; Vanecek, Tomas; Baneckova, Martina; Miesbauerova, Marketa; Michal, Michal] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Vanecek, Tomas; Ptakova, Nikola] Biopticka Lab Ltd, Mol & Genet Lab, Plzen, Czech Republic; [Laco, Jan] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Laco, Jan] Univ Hosp, Hradec Kralove, Czech Republic; [Uro-Coste, Emmanuelle] Toulouse Univ Hosp, Dept Pathol, Toulouse, France; [Uro-Coste, Emmanuelle] INSERM, U1037, CRCT, Toulouse, France; [Badoual, Cecile] Paris Descartes Univ, AP HP, G Pompidou Hosp, Dept Pathol, Paris, France; [Bishop, Justin A.] UT Southwestern Med Ctr, Dept Pathol, Dallas, TX USA; [Weinreb, Ilan] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Woodland Hills, CA USA; [de Sanctis, Stefano] Cambridge Univ Hosp NHS Trust, Addenbrooke Hosp, Histopathol Dept, Cambridge, England; [Schiavo-Lena, Marco] IRCCS San Raffaele Sci Inst, Dept Pathol, Milan, Italy; [Conceicao, Thalita Santana] Univ Sao Paulo, Fac Dent, Dept Oral Pathol, Sao Paulo, Brazil	Skalova, A (reprint author), Charles Univ Prague, Med Fac, Fac Hosp, Sikls Dept Pathol, E Benese 13, Plzen 30599, Czech Republic.	skalova@fnplzen.cz	Laco, Jan/L-9715-2017	Laco, Jan/0000-0002-9602-7501	Ministry of Education Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [260 391]	Supported in parts by the grant SVV-2018 No. 260 391 provided by the Ministry of Education Youth and Sports of the Czech Republic. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Bishop JA, 2013, HUM PATHOL, V44, P1982, DOI 10.1016/j.humpath.2013.03.017; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Brandwein-Gensler M, 2004, AM J SURG PATHOL, V28, P1040, DOI 10.1097/01.pas.0000128662.66321.be; Brandwein-Gensler MS, 2005, PATHOLOGY GENETICS H, P233; CHEN KTK, 1983, J LARYNGOL OTOL, V97, P189, DOI 10.1017/S002221510009397X; Cheuk W, 2004, AM J SURG PATHOL, V28, P266, DOI 10.1097/00000478-200402000-00017; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Delgado R, 1996, CANCER, V78, P956; Dogan S, 2017, MOD PATHOL S, p323A; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Laco J, 2010, INT J SURG PATHOL, V18, P369, DOI 10.1177/1066896910367649; Loening T, 2017, WHO CLASSIFICATION H, P170; Nagao T, 2017, WHO CLASSIFICATION H, P173; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Simpson RHW, 2008, HISTOPATHOLOGY, V53, P416, DOI 10.1111/j.1365-2559.2008.03135.x; Simpson RHW, 2013, HEAD NECK PATHOL, V7, pS48, DOI 10.1007/s12105-013-0456-x; Skalova A, 2017, WHO CLASSIFICATION H, P177; Skalova A, 2018, AM J SURG PATHOL, V42, P234, DOI 10.1097/PAS.0000000000000972; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568; Weinreb I, 2006, AM J SURG PATHOL, V30, P1014, DOI 10.1097/00000478-200608000-00013; Weinreb I, 2018, AM J SURG PATHOL, V42, P442, DOI 10.1097/PAS.0000000000000952; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195	29	10	10	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1445	1455		10.1097/PAS.0000000000001133			11	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800003	30045065				2019-10-28	
J	Lezcano, C; Jungbluth, AA; Nehal, KS; Hollmann, TJ; Busam, KJ				Lezcano, Cecilia; Jungbluth, Achim A.; Nehal, Kishwer S.; Hollmann, Travis J.; Busam, Klaus J.			PRAME Expression in Melanocytic Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						PRAME; immunohistochemistry; melanoma; nevus	MALIGNANT-MELANOMA; UVEAL MELANOMA; ANTIGEN PRAME; CANCER; IMMUNOTHERAPY; LIPOSARCOMA; BIOMARKER; SIGNATURE; NY-ESO-1; RECEPTOR	PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen that was isolated by autologous T cells in a melanoma patient. While frequent PRAME mRNA expression is well documented in cutaneous and ocular melanomas, little is known about PRAME protein expression in melanocytic tumors. In this study we examined the immunohistochemical expression of PRAME in 400 melanocytic tumors, including 155 primary and 100 metastatic melanomas, and 145 melanocytic nevi. Diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83.2% of primary melanomas. Among melanoma subtypes, PRAME was diffusely expressed in 94.4% of acral melanomas, 92.5% of superficial spreading melanomas, 90% of nodular melanomas, 88.6% of lentigo maligna melanomas, and 35% of desmoplastic melanomas. When in situ and nondesmoplastic invasive melanoma components were present, PRAME expression was seen in both. Of the 140 cutaneous melanocytic nevi, 86.4% were completely negative for PRAME. Immunoreactivity for PRAME was seen, albeit usually only in a minor subpopulation of lesional melanocytes, in 13.6% of cutaneous nevi, including dysplastic nevi, common acquired nevi, traumatized/recurrent nevi, and Spitz nevi. Rare isolated junctional melanocytes with immunoreactivity for PRAME were also seen in solar lentigines and benign nonlesional skin. Our results suggest that immunohistochemical analysis for PRAME expression may be useful for diagnostic purposes to support a suspected diagnosis of melanoma. It may also be valuable for margin assessment of a known PRAME-positive melanoma, but its expression in nevi, solar lentigines, and benign nonlesional skin can represent a pitfall and merits further investigations to better assess the potential clinical utility of this marker.	[Lezcano, Cecilia; Jungbluth, Achim A.; Hollmann, Travis J.; Busam, Klaus J.] Mem Sloan Kettering Canc, Dept Pathol, New York, NY USA; [Nehal, Kishwer S.] Mem Sloan Kettering Canc, Dept Med, New York, NY USA	Busam, KJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.	busamk@mskcc.org			Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]	Supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Chang AY, 2017, J CLIN INVEST, V127, P2705, DOI 10.1172/JCI92335; Clarke LE, 2017, CANCER-AM CANCER SOC, V123, P617, DOI 10.1002/cncr.30385; Ferris LK, 2017, JAMA DERMATOL, V153, P675, DOI 10.1001/jamadermatol.2017.0473; Field MG, 2016, ONCOTARGET, V7, P59209, DOI 10.18632/oncotarget.10962; Field MG, 2016, CLIN CANCER RES, V22, P1234, DOI 10.1158/1078-0432.CCR-15-2071; Gezgin G, 2017, JAMA OPHTHALMOL, V135, P541, DOI 10.1001/jamaophthalmol.2017.0729; Goodison S, 2012, BIOMARK MED, V6, P629, DOI [10.2217/BMM.12.65, 10.2217/bmm.12.65]; Gutzmer R, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000068; Hemminger JA, 2014, MODERN PATHOL, V27, P1238, DOI 10.1038/modpathol.2013.244; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Iura K, 2017, HUM PATHOL, V61, P130, DOI 10.1016/j.humpath.2016.12.006; Iura K, 2015, J PATHOL CLIN RES, V1, P144, DOI 10.1002/cjp2.16; Ko JS, 2017, CANCER EPIDEM BIOMAR, V26, P1107, DOI 10.1158/1055-9965.EPI-16-0958; Neumann E, 1998, CANCER RES, V58, P4090; Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813; Pujol JL, 2016, J THORAC ONCOL, V11, P2208, DOI 10.1016/j.jtho.2016.08.120; Roszik J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.11067; Salmaninejad A, 2016, IMMUNOL INVEST, V45, P619, DOI 10.1080/08820139.2016.1197241; Sanchez MI, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-4861; Wadelin F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-226; Westekemper H, 2010, BRIT J OPHTHALMOL, V94, P1322, DOI 10.1136/bjo.2009.167445; Zhang W, 2016, ONCOTARGET, V7, P45352, DOI 10.18632/oncotarget.9977	22	1	1	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1456	1465		10.1097/PAS.0000000000001134			10	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800004	30045064	Green Accepted			2019-10-28	
J	Shimono, J; Miyoshi, H; Yoshida, N; Kato, T; Sato, K; Sugio, T; Miyawaki, K; Kurita, D; Sasaki, Y; Kawamoto, K; Imaizumi, Y; Kato, K; Nagafuji, K; Akashi, K; Seto, M; Teshima, T; Ohshima, K				Shimono, Joji; Miyoshi, Hiroaki; Yoshida, Noriaki; Kato, Takeharu; Sato, Kensaku; Sugio, Takeshi; Miyawaki, Kohta; Kurita, Daisuke; Sasaki, Yuya; Kawamoto, Keisuke; Imaizumi, Yoshitaka; Kato, Koji; Nagafuji, Koji; Akashi, Koichi; Seto, Masao; Teshima, Takanori; Ohshima, Koichi			Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						follicular lymphoma; GNA13; poor prognosis	B-CELL LYMPHOMA; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; 1ST-LINE IMMUNOCHEMOTHERAPY; TUMOR-SUPPRESSOR; CANCER CELLS; HIGH-RISK; IN-VIVO; EXPRESSION; CONFINEMENT; VINCRISTINE	GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.	[Shimono, Joji; Miyoshi, Hiroaki; Yoshida, Noriaki; Sato, Kensaku; Kurita, Daisuke; Sasaki, Yuya; Kawamoto, Keisuke; Seto, Masao; Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan; [Nagafuji, Koji] Kurume Univ, Sch Med, Dept Hematol, Div Hematol & Oncol, Kurume, Fukuoka, Japan; [Shimono, Joji; Teshima, Takanori] Hokkaido Univ, Fac Med, Dept Hematol, Sapporo, Hokkaido, Japan; [Kato, Takeharu] Sasebo City Gen Hosp, Dept Hematol, Sasebo, Japan; [Kato, Takeharu; Imaizumi, Yoshitaka] Nagasaki Univ, Atom Bomb Dis Inst, Dept Hematol, Atom Bomb Dis & Hibakusha Med Unit, Nagasaki, Japan; [Sugio, Takeshi; Miyawaki, Kohta; Kato, Koji; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Fukuoka, Japan; [Yoshida, Noriaki] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA	Miyoshi, H (reprint author), Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan.	miyoshi_hiroaki@med.kurume-u.ac.jp		Sugio, Takeshi/0000-0002-4270-1943			Casulo C, 2015, J CLIN ONCOL, V33, P2516, DOI 10.1200/JCO.2014.59.7534; Dubois S, 2016, CLIN CANCER RES, V22, P2919, DOI 10.1158/1078-0432.CCR-15-2305; Federico M, 2009, J CLIN ONCOL, V27, P4555, DOI 10.1200/JCO.2008.21.3991; Green JA, 2012, IMMUNOL REV, V247, P36, DOI 10.1111/j.1600-065X.2012.01114.x; Green JA, 2011, NAT IMMUNOL, V12, P672, DOI 10.1038/ni.2047; Grzelinski M, 2010, CLIN CANCER RES, V16, P1402, DOI 10.1158/1078-0432.CCR-09-1873; Healy JA, 2016, BLOOD, V127, P2723, DOI [10.1182/blood-2015-07659938, 10.1182/blood-2015-07-659938]; Jurinovic V, 2016, BLOOD, V128, P1112, DOI 10.1182/blood-2016-05-717355; Kahl BS, 2016, BLOOD, V127, P2055, DOI 10.1182/blood-2015-11-624288; Miyoshi H, 2014, PATHOL INT, V64, P95, DOI 10.1111/pin.12145; Morin RD, 2013, BLOOD, V122, P1256, DOI 10.1182/blood-2013-02-483727; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Murakami S, 2016, ANN HEMATOL, V95, P1259, DOI 10.1007/s00277-016-2690-2; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856; Oricchio E, 2011, CELL, V147, P554, DOI 10.1016/j.cell.2011.09.035; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Pastore A, 2015, LANCET ONCOL, V16, P1111, DOI 10.1016/S1470-2045(15)00169-2; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Swerdlow SH, 2008, WHO CLASSIFICATION T; Xu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35948; Zhang JX, 2014, ANN ONCOL, V25, P2196, DOI 10.1093/annonc/mdu439; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780	25	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1466	1471		10.1097/PAS.0000000000000969			6	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800005	30307409	Green Published			2019-10-28	
J	Pittman, ME; Milsom, J; Yantiss, RK				Pittman, Meredith E.; Milsom, Jeffrey; Yantiss, Rhonda K.			Treatment Effects Can Mimic Recurrent Extramammary Paget Disease in Perianal Skin	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cytokeratin 7; CK7; skin graft; therapy-related atypia; extramammary Paget disease; perianal skin	BOWENS-DISEASE; CYTOKERATIN 7; MAMMARY; IMMUNOHISTOCHEMISTRY; MANAGEMENT; IMIQUIMOD; EXCISION; THERAPY; REGION	The histologic differential diagnosis of perianal Paget disease includes malignant melanoma, pagetoid spread of squamous cell carcinoma, and secondary involvement by colorectal carcinoma. While consideration of these entities is useful when establishing a diagnosis, it does not apply when patients with Paget disease undergo surveillance for recurrent disease. Treatment of perianal Paget disease consists of a combination of surgical excision with skin grafts and topical chemotherapeutic agents that induce cytologic alterations in benign cells and simulate recurrent malignancy. To evaluate the therapy-related changes and possible diagnostic pitfalls in patients with Paget disease, we reviewed 412 posttreatment tissue samples from 3 women with primary perianal Paget disease who underwent wide excision, skin grafting, and topical 5-fluorouracil therapy. Biopsy samples from engrafted skin often displayed single and clustered cells with hyperchromatic nuclei dispersed in the deep epidermis. Similar cells were scattered throughout all levels of the epidermis in biopsy samples following topical chemotherapy. The abnormal cells were negative for cytokeratin 7 (CK7) and mucicarmine in both situations. Disease ultimately recurred in all patients; some Paget cells showed classic features with eosinophilic or mucinous cytoplasm and eccentric nuclei, whereas others were smaller with less conspicuous atypia. All Paget cells showed strong, membranous CK7 staining. In short, treatment of perianal Paget disease can elicit cytologic abnormalities in benign epithelial cells that simulate the cytologic features of recurrent disease, and can diminish the atypia of Paget cells. Immunohistochemical stains for CK7 can be helpful when evaluating surveillance samples from these patients.	[Pittman, Meredith E.; Yantiss, Rhonda K.] Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr1031A, New York, NY 10065 USA; [Milsom, Jeffrey] Weill Cornell Med, Dept Surg, Div Colon & Rectal Surg, New York, NY USA	Pittman, ME (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St,Starr1031A, New York, NY 10065 USA.	mep9071@med.cornell.edu					Bie MJ, 2013, DERMATOL SURG, V39, P69, DOI 10.1111/dsu.12019; Chandawarkar Rajiv Y, 2003, Can J Plast Surg, V11, P205; Cowan RA, 2016, GYNECOL ONCOL, V142, P139, DOI 10.1016/j.ygyno.2016.04.028; Dawson H, 2015, J CLIN PATHOL, V68, P971, DOI 10.1136/jclinpath-2015-203056; Goldblum JR, 1998, AM J SURG PATHOL, V22, P170, DOI 10.1097/00000478-199802000-00004; Hata M, 2015, BRIT J DERMATOL, V172, P1014, DOI 10.1111/bjd.13357; Isik O, 2016, INT J COLORECTAL DIS, V31, P29, DOI 10.1007/s00384-015-2342-3; Jabir Shehab, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-200504; Kanitakis J, 2007, J EUR ACAD DERMATOL, V21, P581, DOI 10.1111/j.1468-3083.2007.02154.x; LeBoit P. E., 2006, PATHOLOGY GENETICS S; Liegl B, 2007, HISTOPATHOLOGY, V50, P439, DOI 10.1111/j.1365-2559.2007.02633.x; Lloyd J, 2000, J CLIN PATHOL, V53, P742, DOI 10.1136/jcp.53.10.742; Lundquist K, 1999, AM J SURG PATHOL, V23, P212, DOI 10.1097/00000478-199902000-00011; Machida H, 2015, GYNECOL ONCOL, V139, P165, DOI 10.1016/j.ygyno.2015.07.097; Marchesa P, 1997, ANN SURG ONCOL, V4, P475, DOI 10.1007/BF02303671; Moller MG, 2014, AM J SURG, V207, P485, DOI 10.1016/j.amjsurg.2013.04.005; Perrotto J, 2010, AM J DERMATOPATH, V32, P137, DOI 10.1097/DAD.0b013e3181b71481; Raju RR, 2003, INT J GYNECOL PATHOL, V22, P127, DOI 10.1097/01.PGP.0000055171.04957.F4; Sah SP, 2013, HISTOPATHOLOGY, V62, P511, DOI 10.1111/his.12003; Smith RF, 2008, J CELL MOL MED, V12, P1605, DOI 10.1111/j.1582-4934.2007.00188.x; St Peter SD, 2004, AM J SURG, V187, P413, DOI 10.1016/j.amjsurg.2003.12.021; Williamson JD, 2000, ARCH PATHOL LAB MED, V124, P427; Yanagi T, 2007, CLIN EXP DERMATOL, V32, P506, DOI 10.1111/j.1365-2230.2007.02425.x	23	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1472	1479		10.1097/PAS.0000000000001130			8	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800006	30045063				2019-10-28	
J	Panni, RZ; Gonzalez, I; Hartley, CP; Williams, GA; Liu, JX; Hawkins, WG; Chatterjee, D				Panni, Roheena Z.; Gonzalez, Ivan; Hartley, Christopher P.; Williams, Gregory A.; Liu, Jingxia; Hawkins, William G.; Chatterjee, Deyali			Residual Tumor Index A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pancreatic ductal adenocarcinoma; PDAC; neoadjuvant therapy; NAT; NAT-PDAC; PDAC staging status post NAT; residual tumor	DUCTAL ADENOCARCINOMA; PREOPERATIVE CHEMORADIATION; RECTAL-CANCER; THERAPY; CHEMORADIOTHERAPY; VALIDATION; RESECTION; SURVIVAL	In the setting of neoadjuvant therapy (NAT) for pancreatic ductual adenocarcinoma (PDAC), accurate measurement of tumor size, and consequently, staging based on AJCC eighth edition, is difficult. Attempts to address the limitations of tumor size in the NAT setting have included correlation of residual tumor percent with survival. However, only cases with complete pathologic response or minimal residual disease have shown better prognosis compared with all other groups. To date, no studies have simultaneously evaluated the prognostic value of tumor size and tumor regression in the setting of PDAC status post NAT (NAT-PDAC). Our aim was to study the prognostic value of residual tumor index (RTI), a metric combining residual tumor percent and tumor bed size as an interaction term (% residual tumorxtumor bed size [cm]). In a cohort of 105 cases of NAT-PDAC, we show that RTI supersedes the prognostic value of AJCC eighth edition T staging via multivariate cox regression. At a binary cutoff of 0.35 for RTI, the hazard ratio for recurrence-free survival is 3.26 (95% confidence interval, 1.51-7.04), P < 0.01. We further identified cutoffs of <= 0.2, 0.2 to 2 and >2 that stratified our cases into 3 groups via RTI, which were statistically significant in Kaplan-Meier curve analysis of recurrence-free survival (P < 0.01) and overall survival (P < 0.01). RTI represents a novel metric for combining the prognostic value of tumor size and residual tumor in NAT-P DAC.	[Panni, Roheena Z.; Williams, Gregory A.; Hawkins, William G.] Washington Univ, Dept Surg, Div HPB & GI Surg, St Louis, MO USA; [Gonzalez, Ivan; Hartley, Christopher P.; Chatterjee, Deyali] Washington Univ, Dept Pathol & Immunol, Sect Oncol Biostat, Div Publ Hlth, St Louis, MO USA; [Liu, Jingxia] Washington Univ, Dept Surg, Div Publ Hlth, Sect Oncol Biostat, St Louis, MO USA	Chatterjee, D (reprint author), Washington Univ, Sch Med, BJC Inst Hlth, Dept Pathol & Immunol, 425 S Euclid Ave,Campus Box 8118,Room 3419, St Louis, MO 63110 USA.	deyali@wustl.edu			SPORE grant [5P50CA196510-02]; Clinical and Translational Science Award (CTSA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000448]; Siteman Comprehensive Cancer Center; NCI Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA091842];  [NIH5T32CA00962128]	Supported by the SPORE grant 5P50CA196510-02 (W.G.H., G.A.W., J.L.). Supported by NIH 5T32CA00962128 (R.Z.P.). REDCap Supported by Clinical and Translational Science Award (CTSA) Grant (UL1 TR000448) and Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant P30 CA091842. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abbott DE, 2013, ANN SURG ONCOL, V20, pS500, DOI 10.1245/s10434-013-2882-0; Allen PJ, 2017, ANN SURG, V265, P185, DOI 10.1097/SLA.0000000000001763; Chatterjee D, 2017, AM J SURG PATHOL, V41, P1097, DOI 10.1097/PAS.0000000000000887; Chatterjee D, 2013, HISTOPATHOLOGY, V63, P841, DOI 10.1111/his.12234; Chatterjee D, 2012, CANCER-AM CANCER SOC, V118, P3182, DOI 10.1002/cncr.26651; Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; Ishikawa O, 1988, Nihon Gan Chiryo Gakkai Shi, V23, P720; Kamarajah SK, 2017, ANN SURG ONCOL, V24, P2023, DOI 10.1245/s10434-017-5810-x; Lee SM, 2016, AM J SURG PATHOL, V40, P1653, DOI 10.1097/PAS.0000000000000738; Raimondi S, 2010, BEST PRACT RES CL GA, V24, P349, DOI 10.1016/j.bpg.2010.02.007; Ryan R, 2005, HISTOPATHOLOGY, V47, P141, DOI 10.1111/j.1365-2559.2005.02176.x; Satoi S, 2009, PANCREAS, V38, P282, DOI 10.1097/MPA.0b013e31819438c3; Strasberg SM, 2012, J GASTROINTEST SURG, V16, P1048, DOI 10.1007/s11605-012-1841-6; Varadhachary GR, 2006, ANN SURG ONCOL, V13, P1035, DOI 10.1245/ASO.2006.08.011; Verbeke CS, 2011, HISTOPATHOLOGY, V59, P1111, DOI 10.1111/j.1365-2559.2011.04056.x; Washington K, 2011, COLL AM PATHOLOGIST; White RR, 2005, ANN SURG ONCOL, V12, P214, DOI 10.1245/ASO.2005.03.105; Zhan HX, 2017, CANCER MED-US, V6, P1201, DOI 10.1002/cam4.1071	19	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1480	1487		10.1097/PAS.0000000000001144			8	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800007	30179901				2019-10-28	
J	Schrader, AMR; Jansen, PM; Vermeer, MH; Kleiverda, JK; Vermaat, JSP; Willemze, R				Schrader, Anne M. R.; Jansen, Patty M.; Vermeer, Maarten H.; Kleiverda, Johanna K.; Vermaat, Joost S. P.; Willemze, Rein			High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						primary cutaneous diffuse large B-cell lymphoma; leg type; primary cutaneous follicle center lymphoma; MYC rearrangements; double hits; double expression; fluorescence in situ hybridization; immunohistochemistry; prognosis; survival	WHO-EORTC CLASSIFICATION; BCL6 REARRANGEMENTS; PROGNOSTIC-FACTORS; POOR-PROGNOSIS; EXPRESSION; DLBCL; IDENTIFICATION; COEXPRESSION; SURVIVAL; FEATURES	Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary cutaneous follicle center lymphoma (PCFCL) are cutaneous B-cell lymphomas (CBCL) with different clinical characteristics and behavior. PCDLBCL-LT is the most aggressive CBCL with a relatively poor prognosis. In nodal diffuse large B-cell lymphoma (DLBCL), rearrangements of the MYC gene, especially in combination with a second hit in BCL2 and/or BCL6, and double protein expression of MYC and BCL2 (DE) are adverse prognostic factors. As the clinical significance of these factors in CBCL is largely unknown, we studied the frequency and prognostic value of MYC rearrangements and DE in a cohort of 44 patients with PCDLBCL-LT and 17 patients with PCFCL. Compared with nodal DLBCL (9% to 14%), the PCDLBCL-LT patients had a high incidence of MYC rearrangements (32%), but only 2 patients (4%) had a second hit, both with BCL6. PCDLBCL-LT patients with a MYC rearrangement showed an inferior disease-specific survival (Log-rank, P=0.036) and disease-free survival (Log-rank, P=0.028), but no significant adverse effect on overall survival (Log-rank, P=0.157) at 5 years compared with patients without a MYC rearrangement. DE, present in 65% of the PCDLBCL-LT patients, was not associated with reduced survival. In the PCFCL group, MYC rearrangements and DE were not detected. In conclusion, this study identifies a high incidence of MYC rearrangements in PCDLBCL-LT compared to nodal DLBCL and further shows that a MYC rearrangement is an inferior prognostic marker in these patients. Therefore, our data suggest that it is useful to perform MYC-FISH in all newly diagnosed PCDLBCL-LT patients.	[Schrader, Anne M. R.; Jansen, Patty M.; Kleiverda, Johanna K.] Leiden Univ, Med Ctr, Dept Pathol, POB 9600, NL-2300 RC Leiden, Netherlands; [Vermeer, Maarten H.; Willemze, Rein] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Vermaat, Joost S. P.] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands	Schrader, AMR (reprint author), Leiden Univ, Med Ctr, Dept Pathol, POB 9600, NL-2300 RC Leiden, Netherlands.	a.m.r.schrader@lumc.nl					Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Brunn A, 2013, ACTA NEUROPATHOL, V126, P603, DOI 10.1007/s00401-013-1169-7; Cady FM, 2008, J CLIN ONCOL, V26, P4814, DOI 10.1200/JCO.2008.16.1455; Casey SC, 2018, BLOOD, V131, P2007, DOI 10.1182/blood-2017-11-742577; Clipson A, 2015, J PATHOL CLIN RES, V1, P125, DOI 10.1002/cjp2.10; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Dunleavy K, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0374-0; Gill KZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114398; Grange F, 2001, J CLIN ONCOL, V19, P3602, DOI 10.1200/JCO.2001.19.16.3602; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Green TM, 2012, AM J SURG PATHOL, V36, P612, DOI 10.1097/PAS.0b013e318244e2ba; Hallermann C, 2004, J INVEST DERMATOL, V123, P213, DOI 10.1111/j.0022-202X.2004.22720.x; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kim S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2397-8; Kodama K, 2005, BLOOD, V106, P2491, DOI 10.1182/blood-2005-03-1175; Koens L, 2014, J INVEST DERMATOL, V134, P290, DOI 10.1038/jid.2013.265; Lucioni M, 2016, CANCER MED-US, V5, P2740, DOI 10.1002/cam4.865; Mareschal S, 2017, J INVEST DERMATOL, V137, P1984, DOI 10.1016/j.jid.2017.04.010; Menguy S, 2018, MODERN PATHOL, V31, P1332, DOI 10.1038/s41379-018-0041-7; Pham-Ledard A, 2014, JAMA DERMATOL, V150, P1173, DOI 10.1001/jamadermatol.2014.821; Pham-Ledard A, 2014, MODERN PATHOL, V27, P402, DOI 10.1038/modpathol.2013.156; Rosenthal A, 2017, BLOOD REV, V31, P37, DOI 10.1016/j.blre.2016.09.004; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Scott DW, 2018, BLOOD, V131, P2060, DOI 10.1182/blood-2017-12-820605; Senff NJ, 2007, J CLIN ONCOL, V25, P1581, DOI 10.1200/JCO.2006.09.6396; Senff NJ, 2009, J INVEST DERMATOL, V129, P1149, DOI 10.1038/jid.2008.357; Shi QY, 2017, J NEUROPATH EXP NEUR, V76, P942, DOI 10.1093/jnen/nlx083; Swerdlow SH, 2017, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Tapia G, 2015, APMIS, V123, P596, DOI 10.1111/apm.12390; Tzankov A, 2014, MODERN PATHOL, V27, P958, DOI 10.1038/modpathol.2013.214; Wiesner T, 2005, AM J SURG PATHOL, V29, P666, DOI 10.1097/01.pas.0000155163.40668.e7; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Ye Q, 2016, ONCOTARGET, V7, P2401, DOI 10.18632/oncotarget.6262	38	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1488	1494		10.1097/PAS.0000000000001132			7	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800008	30113335				2019-10-28	
J	Gagne, A; Racine, E; Orain, M; Meziou, S; Simard, S; Couture, C; Page, S; Trahan, S; Ugalde, P; Lacasse, Y; Joubert, D; Joubert, P				Gagne, Andreanne; Racine, Etienne; Orain, Michele; Meziou, Salma; Simard, Serge; Couture, Christian; Page, Sylvain; Trahan, Sylvain; Ugalde, Paula; Lacasse, Yves; Joubert, David; Joubert, Philippe			Identification of Grossing Criteria for Intraoperative Evaluation by Frozen Section of Lung Cancer Resection Margins	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						lung oncologic resection; frozen section; surgical margins	MICROSCOPIC RESIDUAL DISEASE; BRONCHIAL MARGINS; SPECIMENS; SURVIVAL; IMPACT; TUMOR; ADENOCARCINOMA; SURGERY; UTILITY	Because of a lack of official guidelines, systematic use of intraoperative frozen section for the evaluation of surgical margins in lung oncology constitutes standard practice in many pathology departments. This costly and time-consuming procedure seems unjustified as reported rates of positive margins remain low. We aimed to evaluate clinicopathologic criteria associated with positive margins and establish evidence-based recommendations regarding the use of frozen sections. This retrospective cohort included 1903 consecutive patients with a lung resection for malignant neoplasm between 2006 and 2015. Clinicopathologic data were retrieved from medical files. Univariate and multivariate analyses were used to identify variables associated with a positive margin. Receiver operating characteristic curves and a probability table of positive margins based on tumor-margin distance were created. Our results were confirmed in a validation cohort of 27 patients with positive margins. The rate of positive margins was 3.8%. A positive margin status changed the surgical management in 48.6% of patients. A short macroscopic tumor-margin distance was associated with a higher risk of positive bronchovascular and parenchymal margins in univariate and multivariate analyses. Selecting a 2.0 cm tumor-margin distance cut-off for performing a frozen section would result in a 55.3% reduction of intraoperative evaluations, with a risk of missing a positive margin of 0.61%. Overall, we showed that systematic use of frozen section for intraoperative evaluation of surgical margins is unnecessary. A better selection of patients with a higher risk of a positive margin can be achieved with tumor-margin distance as a simple gross evaluation parameter.	[Gagne, Andreanne; Racine, Etienne; Orain, Michele; Meziou, Salma; Simard, Serge; Ugalde, Paula; Lacasse, Yves; Joubert, Philippe] Quebec Heart & Lung Inst, Inst Univ Cardiol & Pneumol Quebec, Res Ctr, Quebec City, PQ, Canada; [Couture, Christian; Page, Sylvain; Trahan, Sylvain; Joubert, Philippe] Laval Univ, Dept Pathol & Cytol, Quebec City, PQ, Canada; [Ugalde, Paula] Laval Univ, Dept Thorac Surg, Quebec City, PQ, Canada; [Lacasse, Yves] Laval Univ, Dept Pneumol, Quebec City, PQ, Canada; [Couture, Christian; Joubert, Philippe] Laval Univ, Mol Biol Med Biochem & Pathol Dept, Quebec City, PQ, Canada; [Joubert, David] Univ Ottawa, Fac Social Sci, Ottawa, ON, Canada	Joubert, P (reprint author), Quebec Heart & Lung Inst, Inst Univ Cardiol & Pneumol Quebec, Dept Pathol, Pavillon Cent,Porte C2259,2725 Chemin St Foy, Quebec City, PQ G1V 4G5, Canada.	philippe.joubert.1@ulaval.ca		Gagne, Andreanne/0000-0002-3833-4159	Fondation J.D. Begin	Supported by the Fondation J.D. Begin. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Borczuk AC, 2017, ARCH PATHOL LAB MED, V141, P932, DOI 10.5858/arpa.2016-0415-RA; Goldstein NS, 2003, AM J CLIN PATHOL, V120, P720, DOI 10.1309/P47FYW5U4CRQ0WFE; Hancock JG, 2015, ANN THORAC SURG, V99, P406, DOI 10.1016/j.athoracsur.2014.09.033; Kara M, 2000, LUNG CANCER-J IASLC, V30, P161, DOI 10.1016/S0169-5002(00)00140-9; KAYSER K, 1993, THORAC CARDIOV SURG, V41, P308, DOI 10.1055/s-2007-1013878; Lacasse Y, 1998, ANN THORAC SURG, V65, P220, DOI 10.1016/S0003-4975(97)01190-9; Lequaglie C, 2003, EUR J CARDIO-THORAC, V23, P229, DOI 10.1016/S1010-7940(02)00750-9; Lin CC, 2017, ANN THORAC SURG, V104, P1161, DOI 10.1016/j.athoracsur.2017.04.033; Maygarden SJ, 2004, MODERN PATHOL, V17, P1080, DOI 10.1038/modpathol.3800154; Osarogiagbon RU, 2016, J THORAC ONCOL, V11, pE5, DOI 10.1016/j.jtho.2015.08.002; Owen RM, 2013, ANN THORAC SURG, V95, P1859, DOI 10.1016/j.athoracsur.2012.12.016; Poullis Michael, 2012, Asian Cardiovasc Thorac Ann, V20, P432, DOI 10.1177/0218492312443231; Riquet M, 2010, ANN THORAC SURG, V89, P870, DOI 10.1016/j.athoracsur.2009.11.052; Sawabata N, 2004, ANN THORAC SURG, V77, P415, DOI 10.1016/S0003-4975(03)01511-X; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sienko A, 2005, ARCH PATHOL LAB MED, V129, P1602; Smeltzer MP, 2017, J THORAC CARDIOV SUR, V154, P661, DOI 10.1016/j.jtcvs.2017.03.085; Snijder RJ, 1998, ANN THORAC SURG, V65, P212, DOI 10.1016/S0003-4975(97)01114-4; The National Comprehensive Cancer Network, 2017, NONSMALL CELL LUNG C; Thunnissen FBJM, 2005, HISTOPATHOLOGY, V47, P638, DOI 10.1111/j.1365-2559.2005.02263.x; Travis WD, 2015, WHO CLASSIFICATION T; Warth A, 2015, AM J SURG PATHOL, V39, P793, DOI 10.1097/PAS.0000000000000409; Wind J, 2007, EUR J CARDIO-THORAC, V32, P29, DOI 10.1016/j.ejcts.2007.04.003	23	1	1	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1495	1502		10.1097/PAS.0000000000001138			8	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800009	30124484				2019-10-28	
J	La Rosa, S; Uccella, S; Molinari, F; Savio, A; Mete, O; Vanoli, A; Maragliano, R; Frattini, M; Mazzucchelli, L; Sessa, F; Bongiovanni, M				La Rosa, Stefano; Uccella, Silvia; Molinari, Francesca; Savio, Antonella; Mete, Ozgur; Vanoli, Alessandro; Maragliano, Roberta; Frattini, Milo; Mazzucchelli, Luca; Sessa, Fausto; Bongiovanni, Massimo			Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN)	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mixed neuroendocrine non-neuroendocrine neoplasm; MiNEN; digestive system; MANET; mixed adenoneuroendocrine carcinoma; mixed adenoma well-differentiated tumor	CARCINOID-TUMORS; INTESTINAL ADENOMAS; COLORECTAL-CANCER; COLON; MICRODISSECTION; MUTATIONS; RECTUM; LASER; BRAF	Mixed neuroendocrine-nonneuroendocrine neoplasm (MiNEN) consisting of adenoma and well-differentiated neuroendocrine tumor (NET) has been recently defined as "MANET." However, the clinico-pathologic and pathogenetic features of this entity are not thoroughly studied. We examined the clinico-pathologic features of 12 MANETs by expanding their p53 and beta-catenin expression profiles as well as the presence of microsatellite instability and KRAS, BRAF, and PIK3CA mutations in the 2 tumor components. In all cases, the adenomatous component represented the larger part of the lesions and the NET was localized in the deep central portion of polyps. In 9 cases the latter was represented by NET G1, in 2 by NET G2, and in 1 by NET G3. In all cases, the glandular and NET components were intimately admixed, with zone of transition between the tumor components. The NET component was p53 negative in all cases and 3 of 8 cases showed variable nuclear positivity for beta-catenin. All patients with follow-up data were alive and free of disease after a mean follow-up time of 9 years. No mutations in KRAS, BRAF, and PIK3CA genes and no microsatellite instability were found in both tumor components. Review of the literature also identified 59 previously reported MANETs and no tumor-related death has been found. Like mixed adenoneuroendocrine carcinomas, a high-grade malignant form of MiNENs with a poorly differentiated neuroendocrine carcinoma component, a common origin for both tumor constituents may be hypothesized. Moreover, the current series provides evidence that MANET is an indolent disease that needs to be distinguished from aggressive high-grade MiNENs.	[La Rosa, Stefano; Bongiovanni, Massimo] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, Lausanne, Switzerland; [Molinari, Francesca; Frattini, Milo; Mazzucchelli, Luca] Inst Pathol, Locarno, Switzerland; [Uccella, Silvia; Maragliano, Roberta; Sessa, Fausto] Univ Insubria, Dept Med & Surg, Varese, Italy; [Savio, Antonella] Fdn Poliambulanza Ist Osped, Dept Histopathol, Brescia, Italy; [Vanoli, Alessandro] Univ Pavia, Dept Mol Med, Unit Anat Pathol, Pavia, Italy; [Vanoli, Alessandro] IRCCS San Matteo Hosp, Pavia, Italy; [Mete, Ozgur] Univ Hlth Network, Dept Pathol, Lab Med Program, Toronto, ON, Canada; [Mete, Ozgur] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	La Rosa, S (reprint author), CHU Vaudois, Inst Univ Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland.	stefano.larosa@chuv.ch	; Vanoli, Alessandro/J-4469-2016	uccella, silvia/0000-0002-5714-7295; Vanoli, Alessandro/0000-0002-2976-7032			Bazerbachi Fateh, 2015, Ochsner J, V15, P97; Chetty R, 2012, VIRCHOWS ARCH, V461, P483, DOI 10.1007/s00428-012-1318-8; Coyne JD, 2010, HISTOPATHOLOGY, V57, P492, DOI 10.1111/j.1365-2559.2010.03630.x; De Marco L, 2003, Pathologica, V95, P214; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Estrella JS, 2014, HUM PATHOL, V45, P2051, DOI 10.1016/j.humpath.2014.07.001; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; Gilbert JA, 2010, ENDOCR-RELAT CANCER, V17, P623, DOI 10.1677/ERC-09-0318; Harada T, 2001, GASTROINTEST ENDOSC, V53, P804, DOI 10.1067/mge.2001.114960; Hui CK, 2012, SINGAP MED J, V53, pE195; ITO H, 1989, HISTOPATHOLOGY, V15, P96, DOI 10.1111/j.1365-2559.1989.tb03046.x; July LV, 1999, AM J GASTROENTEROL, V94, P1091; Kloppel G, 2017, WHO CLASSIFICATION T, P211; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa Stefano, 2012, Cancers (Basel), V4, P11, DOI 10.3390/cancers4010011; Lee SM, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-102; Lin JM, 2012, AM J SURG PATHOL, V36, P292, DOI 10.1097/PAS.0b013e318236e4d2; Lyda MH, 1998, ARCH PATHOL LAB MED, V122, P262; Milione M, 2018, ENDOCR-RELAT CANCER, V25, P583, DOI 10.1530/ERC-17-0557; Mitsuhashi K, 2015, ONCOTARGET, V6, P22114, DOI 10.18632/oncotarget.4294; MORI K, 1978, DIS COLON RECTUM, V21, P506, DOI 10.1007/BF02586737; MOYANA TN, 1988, AM J SURG PATHOL, V12, P607, DOI 10.1097/00000478-198808000-00001; Niyaz Y, 2005, METH MOLEC MED, V114, P1; Pulitzer M, 2006, AM J SURG PATHOL, V30, P1531, DOI 10.1097/01.pas.0000213295.88778.00; Rindi G, 2010, WHO CLASSIFICATION T, V4, P13; Salaria SN, 2013, J CLIN PATHOL, V66, P302, DOI 10.1136/jclinpath-2012-201314; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; SOGA J, 1971, CANCER-AM CANCER SOC, V28, P990, DOI 10.1002/1097-0142(1971)28:4<990::AID-CNCR2820280424>3.0.CO;2-K; Tyner JW, 2009, BLOOD, V113, P1749, DOI 10.1182/blood-2008-04-152157; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vandewoestyne M, 2013, ANAL BIOCHEM, V439, P88, DOI 10.1016/j.ab.2013.04.023; VARGHESE NM, 1994, J CLIN PATHOL, V47, P427, DOI 10.1136/jcp.47.5.427	32	0	0	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1503	1512		10.1097/PAS.0000000000001123			10	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800010	30001239				2019-10-28	
J	Tregnago, AC; Epstein, JI				Tregnago, Aline C.; Epstein, Jonathan I.			Skene's Glands Adenocarcinoma A Series of 4 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Skene's gland; adenocarcinoma; paraurethral gland adenocarcinoma	PROSTATE-SPECIFIC ANTIGEN; PARAURETHRAL GLANDS; ACID-PHOSPHATASE; CANCER; SERUM	Skene's (periurethral) gland adenocarcinoma is very rare, with only 7 cases reported in the literature. This is the first series of cases on this entity. We describe the histologic, immunohistochemical, and clinical findings of 4 patients with Skene's gland adenocarcinoma retrieved from the Johns Hopkins Urologic Pathology Consult Service from 1984 to 2017. The average age at diagnosis of the 4 women was 74.5 years (range, 61 to 87 y). Tumors were treated by limited resections with negative margins. Tumor size ranged from 1.0 to 2.0 cm (mean, 1.5 cm). Average follow-up time was 40.7 months (range, 4 to 132 mo). Three of our cases were morphologically consistent with prostatic acinar adenocarcinoma with variable cribriform, fused, and poorly formed glands, analogous to Gleason score 4+4=8. Of these, one had mixed ductal features with neoplastic cells showing papillary carcinoma with columnar cytology. These 3 lesions were positive for PSA, P501S, NKX3.1, and AMACR. Focal goblet cells positive for CK20 and negative for prostatic markers were seen in one of these cases, suggesting intestinal differentiation (although negative for CDX2 and SATB2). A fourth case had glandular and papillary formations with pseudostratified columnar epithelium and mucin secretion, showing positivity for CK7, ER, and P16, and negativity for prostatic markers, suggesting serous differentiation (although negative for PAX8 and WT1). PIN4 cocktail confirmed the origin in preexisting paraurethral glands in 3 of the cases. All patients were alive and free of recurrence or metastatic disease at the time of last follow-up. Because of the rarity of Skene's gland adenocarcinomas, there is no consensus regarding their treatment. Our findings demonstrate that Skene's gland adenocarcinomas recapitulate morphologies and immunohistochemical markers seen in prostatic adenocarcinoma. However, it is unknown whether applying the same grading criteria for prostatic adenocarcinomas to Skene's gland adenocarcinoma is valid given the small number of cases with variable treatment and limited follow-up.	[Tregnago, Aline C.] Johns Hopkins Med Inst, Dept Pathol, 401 N Broadway St,Room 2242, Baltimore, MD 21231 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA; [Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	Epstein, JI (reprint author), Johns Hopkins Med Inst, Dept Pathol, 401 N Broadway St,Room 2242, Baltimore, MD 21231 USA.	jepstein@jhmi.edu	Tregnago, Aline C/L-7239-2018	Tregnago, Aline C/0000-0001-7370-3370			Borchert GH, 1997, BRIT J CANCER, V76, P1087, DOI 10.1038/bjc.1997.512; BOVA GS, 1993, CANCER RES, V53, P3869; Bowen C, 2010, CANCER RES, V70, P3089, DOI 10.1158/0008-5472.CAN-09-3138; CHAN DW, 1987, CLIN CHEM, V33, P1916; DODSON MK, 1994, GYNECOL ONCOL, V55, P304, DOI 10.1006/gyno.1994.1294; HUFFMAN JW, 1948, AM J OBSTET GYNECOL, V55, P86; KLEIN M, 1962, Scalpel (Brux), V115, P109; Korytko TP, 2012, UROL ONCOL-SEMIN ORI, V30, P602, DOI 10.1016/j.urolonc.2010.06.015; Moch H, 2016, WHO CLASSIFICATION T; Murphy DP, 1999, J UROLOGY, V161, P1881, DOI 10.1016/S0022-5347(05)68833-7; POLLEN JJ, 1984, UROLOGY, V23, P303, DOI 10.1016/S0090-4295(84)90053-0; Pongtippan A, 2004, INT J GYNECOL PATHOL, V23, P71, DOI 10.1097/01.pgp.0000101144.79462.39; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Skene AJC, 1880, AM J OBSTET DIS WOME, V13, P265; Sloboda J, 1998, PATHOL RES PRACT, V194, P129, DOI 10.1016/S0344-0338(98)80080-0; SVANHOLM H, 1987, VIRCHOWS ARCH A, V411, P395, DOI 10.1007/BF00713386; TEPPER SL, 1984, ARCH PATHOL LAB MED, V108, P423; Virchow R, 1853, ARCH PATHOL ANAT PHY, V5, P403; ZAVIACIC M, 1993, VIRCHOWS ARCH A, V423, P503, DOI 10.1007/BF01606542	19	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1513	1521		10.1097/PAS.0000000000001108			9	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800011	29901570				2019-10-28	
J	Trpkov, K; Sangkhamanon, S; Yilmaz, A; Medlicott, SAC; Donnelly, B; Gotto, G; Shea-Budgell, M				Trpkov, Kiril; Sangkhamanon, Sakkarn; Yilmaz, Asli; Medlicott, Shaun A. C.; Donnelly, Bryan; Gotto, Geoffrey; Shea-Budgell, Melissa			Concordance of "Case Level" Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						global Gleason Score; highest Gleason score; Grade Group; needle biopsy; prostate cancer; concordance; kappa	2005 INTERNATIONAL-SOCIETY; ISUP CONSENSUS-CONFERENCE; GLEASON-SCORE; PROSTATIC-CARCINOMA; SYSTEM; PATHOLOGY; SPECIMENS; UPGRADE; VALIDATION; AGREEMENT	The practice of assigning "case level" biopsy Grade Group (GG) or Gleason Score is variable. To our knowledge, a comparison of the concordance of different biopsy "case level" GG with the prostatectomy GG has not been done in a post-2005 prostate cancer cohort. We evaluated the GG in 2527 patients who had biopsy and radical prostatectomy performed at our institution between 2005 and 2014. We compared the agreements, the upgrades, and the downgrades of 3 different "case level" biopsy GG, with the final GG: (1) Global GG (sum of most prevalent and highest Gleason grade in any biopsy part/site-specific specimen); (2) Highest GG (found in any biopsy part/site-specific specimen); and (3) Largest Volume Cancer GG (found in any biopsy part/site-specific specimen). The concordance between the biopsy and the final GG were evaluated using weighted kappa (kappa) coefficient. The biopsy Global GG, Highest GG, and Largest Volume Cancer GG were the same as the final GG in 60.4%, 57.1%, and 54.3% cases, respectively (weighted kappa values: 0.49, 0.48, and 0.44, respectively). When final GG contained tertiary 5, the overall GG agreement decreased: Global GG 41.5%, Highest GG 40.3%, and Largest Volume Cancer GG 37.1% (weighted kappa: 0.22, 0.21, and 0.18, respectively). A subset analysis for cases in which the biopsy Global GG and Highest GG were different (n = 180) showed an agreement of 62.4% (weighted kappa: 0.37) and 18.8% (weighted kappa: 0.16), respectively. In patients without a tertiary Gleason pattern on radical prostatectomy, the Global GG and the Highest GG were identical in 92.4% of biopsies. Assigning a biopsy "case level" Global GG versus using the Highest GG and the Largest Volume Cancer GG resulted in comparable and slightly improved agreement with the final GG in this cohort.	[Trpkov, Kiril; Sangkhamanon, Sakkarn; Yilmaz, Asli; Medlicott, Shaun A. C.] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Calgary, AB, Canada; [Donnelly, Bryan; Gotto, Geoffrey] Univ Calgary, Div Urol, Calgary, AB, Canada; [Shea-Budgell, Melissa] Univ Calgary, Charbonneau Canc Inst, Calgary, AB, Canada; [Shea-Budgell, Melissa] Univ Calgary, Dept Oncol, Cumming Sch Med, Calgary, AB, Canada; [Sangkhamanon, Sakkarn] Khon Kaen Univ, Fac Med, Dept Pathol, Preclin Sci Bldg,5th Floor, Khon Kaen, Thailand	Trpkov, K (reprint author), Calgary Lab Serv, Dept Pathol & Lab Med, 7007 14 St, Calgary, AB T2V 1P9, Canada.; Trpkov, K (reprint author), Univ Calgary, Rockyview Gen Hosp, 7007 14 St, Calgary, AB T2V 1P9, Canada.	kiril.trpkov@cls.ab.ca		Sangkhamanon, Sakkarn/0000-0002-5203-8700	Calgary Laboratory Services; Southern Alberta Urology Institute	Supported in part by Calgary Laboratory Services and Southern Alberta Urology Institute. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Arias-Stella JA, 2015, AM J SURG PATHOL, V39, P1213, DOI 10.1097/PAS.0000000000000499; Athanazio D, 2017, HISTOPATHOLOGY, V70, P1098, DOI 10.1111/his.13179; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284; Cohen MS, 2008, EUR UROL, V54, P371, DOI 10.1016/j.eururo.2008.03.049; Danneman D, 2017, BJU INT, V119, P50, DOI 10.1111/bju.13458; de Lima NG, 2013, CLINICS, V68, P820, DOI 10.6061/clinics/2013(06)16; Delahunt B, 2015, PATHOLOGY, V47, P520, DOI 10.1097/PAT.0000000000000318; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Epstein JI, 2012, EUR UROL, V61, P1019, DOI 10.1016/j.eururo.2012.01.050; Forman JD, 2000, INT J RAD ONCOL B S3, V48, P1; Helpap B, 2006, VIRCHOWS ARCH, V449, P622, DOI 10.1007/s00428-006-0310-6; Kasivisvanathan V, 2018, NEW ENGL J MED, V378, P1767, DOI 10.1056/NEJMoa1801993; Kunju LP, 2009, HUM PATHOL, V40, P558, DOI 10.1016/j.humpath.2008.07.020; Kunz GM, 2003, HUM PATHOL, V34, P911, DOI 10.1016/S0046-8177(03)00338-1; Kuroiwa K, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.05.030; Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036; Moch H, 2016, WHO CLASSIFICATION T; Ozok HU, 2010, INT J SURG PATHOL, V18, P248, DOI 10.1177/1066896909346272; Park HK, 2006, UROLOGY, V67, P110, DOI 10.1016/j.urology.2005.07.018; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302; Reis LO, 2013, ADV UROL, V2013, P1; Rubin MA, 2004, AM J SURG PATHOL, V28, P946, DOI 10.1097/00000478-200407000-00016; Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315; Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029; Sfoungaristos S, 2013, CUAJ-CAN UROL ASSOC, V7, pE722, DOI 10.5489/cuaj.374; Suer E, 2014, SCAND J UROL, V48, P177, DOI 10.3109/21681805.2013.829519; Tolonen TT, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-21; Trpkov K, 2015, GENITOURINARY PATHOL, P13; Trpkov K, 2009, AM J SURG PATHOL, V33, P233, DOI 10.1097/PAS.0b013e31817fb3bd; Uemura H, 2009, BJU INT, V103, P1190, DOI 10.1111/j.1464-410X.2008.08197.x; Van Praet C, 2014, CLIN GENITOURIN CANC, V12, P160, DOI 10.1016/j.clgc.2013.11.008; Zareba P, 2009, HISTOPATHOLOGY, V55, P384, DOI 10.1111/j.1365-2559.2009.03405.x	37	5	5	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1522	1529		10.1097/PAS.0000000000001137			8	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800012	30080706				2019-10-28	
J	Michal, M; Agaimy, A; Contreras, AL; Svajdler, M; Kazakov, DV; Steiner, P; Grossmann, P; Martinek, P; Hadravsky, L; Michalova, K; Svajdler, P; Szep, Z; Michal, M; Fetsch, JF				Michal, Michael; Agaimy, Abbas; Contreras, Alejandro Luina; Svajdler, Marian; Kazakov, Dmitry V.; Steiner, Petr; Grossmann, Petr; Martinek, Petr; Hadravsky, Ladislav; Michalova, Kvetoslava; Svajdler, Peter; Szep, Zoltan; Michal, Michal; Fetsch, John F.			Dysplastic Lipoma A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH: A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						anisometric cell lipoma; atypical lipoma; atypical lipomatous tumor; dysplastic lipoma; lipoma with fat necrosis; p53; RB1 gene; retinoblastoma; soft tissue tumor; well-differentiated liposarcoma	WELL-DIFFERENTIATED LIPOSARCOMA; ANISOMETRIC CELL LIPOMA; SPINDLE-CELL; MALIGNANT NEOPLASMS; SOFT-TISSUE; FOLLOW-UP; TUMORS; EXPRESSION; MDM2; IMMUNOHISTOCHEMISTRY	In our routine and consultative pathology practices, we have repeatedly encountered an unusual subcutaneous fatty tumor with notable anisocytosis, single-cell fat necrosis, and patchy, often mild, adipocytic nuclear atypia. Because of the focal atypia, consultative cases have most often been received with concern for a diagnosis of atypical lipomatous tumor. Similar tumors have been described in small series under the designations "subcutaneous minimally atypical lipomatous tumors" and "anisometric cell lipoma." Sixty-six cases of this tumor type were collected and reviewed. Immunohistochemistry for p53, MDM2, CDK4, Retinoblastoma 1 (RB1) protein, CD34, S100, and CD163 was performed. Cases were tested for MDM2 gene amplification and RB1 gene deletion with fluorescence in situ hybridization (FISH) and for TP53 mutations by Sanger sequencing. Next-generation sequencing analysis using a panel of 271 cancer-related genes, including TP53, RB1, and MDM2, was also carried out. Our patient cohort included 57 male patients, 8 female patients, and 1 patient of unstated sex, who ranged in age from 22 to 87 years (mean: 51.2 y). All tumors were subcutaneous, with most examples occurring on the upper back, shoulders, or posterior neck (86.4%). Ten patients had multiple (2 to 5) lipomatous tumors, and the histology was confirmed to be similar in the different sites in 4 of them, including 1 patient who had a retinoblastoma diagnosed at age 1. The tumors were generally well circumscribed. At low magnification, there was notable adipocytic size variation with single-cell fat necrosis in the background associated with reactive histiocytes. Adipocytic nuclear atypia was typically patchy and characterized by chromatin coarsening, nuclear enlargement, and focal binucleation or multinucleation. Focal Lochkern change was frequent. In most instances, the degree of atypia was judged to be mild, but in 3 instances, it was more pronounced. Spindle cells were sparse or absent, and when present, cytologically bland. Thick ropy collagen bundles were absent. In all cases, p53 immunoexpression was noted (range: 2% to 20% of adipocytic nuclei), characteristically highlighting the most atypical cells. Twenty of 50 cases had MDM2 immunoreactivity, usually in <1% of the neoplastic cells, but in 4 cases, up to 10% of the cells were positive. Of 32 cases tested, 22 showed a near total loss of RB1 immunoexpression, and the remainder showed partial loss. Three of 13 cases showed RB1 gene deletion in >45% of the cells by FISH (our threshold value for reporting a positive result) with an additional 3 cases being very close to the required cutoff value. MDM2 gene amplification was absent in all 60 cases tested, including those with the greatest MDM2 immunoexpression and most pronounced atypia. All 5 tested cases showed no TP53 mutation with Sanger sequencing. Because of material quality issues, next-generation sequencing analysis could be performed in only 3 cases, and this did not reveal any recurrent mutations. All tumors were managed by simple local excision. Follow-up was available for 47 patients (range: 1 to 192 mo; mean: 27 mo) and revealed 2 local recurrences and no metastases. Dysplastic lipoma is a distinctive atypical fatty tumor variant that has p53 overexpression and RB1 gene abnormalities and lacks MDM2 gene amplification by FISH. These tumors have a strong male predominance and a notable tendency to involve the subcutaneous tissue of the shoulders, upper back and posterior neck. Multifocality is frequent (18. 9% of patients with follow-up information), and there is a rare association with retinoblastoma. This tumor warrants separation from ordinary lipoma with fat necrosis, fat-rich spindle cell lipoma and the conventional form of atypical lipomatous tumor that features MDM2 gene amplification.	[Michal, Michael; Svajdler, Marian; Kazakov, Dmitry V.; Steiner, Petr; Grossmann, Petr; Martinek, Petr; Michalova, Kvetoslava; Michal, Michal] Charles Univ Prague, Dept Pathol, Prague, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Prague, Czech Republic; [Michal, Michael; Svajdler, Marian; Kazakov, Dmitry V.; Steiner, Petr; Grossmann, Petr; Martinek, Petr; Michalova, Kvetoslava; Michal, Michal] Biopt Lab Ltd, Plzen, Czech Republic; [Hadravsky, Ladislav] Charles Univ Prague, Fac Med 1, Dept Pathol, Prague, Czech Republic; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp, Inst Pathol, Erlangen, Germany; [Contreras, Alejandro Luina; Fetsch, John F.] Joint Pathol Ctr, Silver Spring, MD USA; [Svajdler, Peter] Louis Pasteur Univ Hosp, Dept Pathol, Kosice, Slovakia; [Szep, Zoltan] Cytopathos Ltd, Bratislava, Slovakia	Michal, M (reprint author), Charles Univ Prague, Dept Pathol, Med Fac, Alej Svobody 80, Plzen 32300, Czech Republic.; Michal, M (reprint author), Charles Univ Prague, Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 32300, Czech Republic.	michael.michal@medima.cz	Svajdler, Marian/N-5600-2019; Michal, Michael/I-3497-2017	Svajdler, Marian/0000-0001-8052-4741; Michal, Michael/0000-0003-4403-7027	National Sustainability Program I (NPU I) [LO1503]; Ministry of Education Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [SVV-2017, 260 391]	Supported in parts by the National Sustainability Program I (NPU I) Nr. LO1503 and by the grant SVV-2017 No. 260 391 provided by the Ministry of Education Youth and Sports of the Czech Republic. The Joint Pathology Center contributions are covered by research protocol IRB17-0099. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2017, ANN DIAGN PATHOL, V29, P52, DOI 10.1016/j.anndiagpath.2017.04.012; Allen PW, 1998, PATHOLOGY, V30, P123, DOI 10.1080/00313029800169066; Arbiser ZK, 2001, AM J CLIN PATHOL, V116, P473; AZUMI N, 1987, AM J SURG PATHOL, V11, P161, DOI 10.1097/00000478-198703000-00001; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Billing V, 2008, J BONE JOINT SURG BR, V90B, P929, DOI 10.1302/0301-620X.90B7.20348; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Clay MR, 2016, AM J SURG PATHOL, V40, P1647, DOI 10.1097/PAS.0000000000000713; Creytens D, 2018, HUM PATHOL, V74, P188, DOI 10.1016/j.humpath.2017.11.023; Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Creytens D, 2014, VIRCHOWS ARCH, V465, P97, DOI 10.1007/s00428-014-1568-8; Debelenko LV, 2010, PEDIATR DEVEL PATHOL, V13, P218, DOI 10.2350/09-08-0694-OA.1; Dei Tos A P, 2000, Ann Diagn Pathol, V4, P252, DOI 10.1053/adpa.2000.8133; Deyrup AT, 2013, AM J SURG PATHOL, V37, P1373, DOI 10.1097/PAS.0b013e31829562ed; ENZINGER FM, 1975, CANCER, V36, P1852, DOI 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U; Evans H, 2015, MODERN PATHOL, V28, p17A; Evans HL, 2007, AM J SURG PATHOL, V31, P1, DOI 10.1097/01.pas.0000213406.95440.7a; Evans HL, 2016, AJSP-REV REP, V21, P195, DOI 10.1097/PCR.0000000000000153; EVANS HL, 1979, CANCER, V43, P574, DOI 10.1002/1097-0142(197902)43:2<574::AID-CNCR2820430226>3.0.CO;2-7; Evans HL, 1988, SURG PATHOL, V1, P41; Fletcher C, 2013, WHO CLASSIFICATION T; Fletcher CDM, 2002, WHO CLASSIFICATION T; Gonzalez RS, 2013, HISTOPATHOLOGY, V62, P1109, DOI 10.1111/his.12112; Kashima T, 2012, MODERN PATHOL, V25, P1384, DOI 10.1038/modpathol.2012.90; Kazakov DV, 2009, AM J DERMATOPATH, V31, P236, DOI 10.1097/DAD.0b013e3181984f10; KINDBLOM LG, 1982, ACTA PATH MICRO IM A, V90, P27; Ko JS, 2017, AM J SURG PATHOL, V41, P1267, DOI 10.1097/PAS.0000000000000915; Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; LUCAS DR, 1994, AM J CLIN PATHOL, V102, P677, DOI 10.1093/ajcp/102.5.677; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; Mentzel T, 2010, MODERN PATHOL, V23, P729, DOI 10.1038/modpathol.2010.66; Michal M, 2018, HUM PATHOL, V74, P189, DOI 10.1016/j.humpath.2017.11.024; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006; Miettien M, 2010, MODERN SOFT TISSUE P; Pilotti S, 1997, J PATHOL, V181, P14; Resnik KS, 2004, AM J DERMATOPATH, V26, P493, DOI 10.1097/00000372-200412000-00009; Rosai J, 1996, AM J SURG PATHOL, V20, P1182, DOI 10.1097/00000478-199610000-00002; SHMOOKLER BM, 1981, CANCER, V47, P126, DOI 10.1002/1097-0142(19810101)47:1<126::AID-CNCR2820470121>3.0.CO;2-K; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Steiner P, 2018, VIRCHOWS ARCH, V473, P471, DOI 10.1007/s00428-018-2349-6; Thway Khin, 2015, Sarcoma, P812089, DOI 10.1155/2015/812089; TOS APD, 1993, HISTOPATHOLOGY, V22, P45, DOI 10.1111/j.1365-2559.1993.tb00068.x; Valverde JR, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-53; Ware PL, 2014, AM J CLIN PATHOL, V141, P334, DOI 10.1309/AJCPLYU89XHSNHQO; WEISS SW, 1992, AM J SURG PATHOL, V16, P1051, DOI 10.1097/00000478-199211000-00003; Zhang HY, 2010, AM J SURG PATHOL, V34, P1304, DOI 10.1097/PAS.0b013e3181e92d0b	48	5	5	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1530	1540		10.1097/PAS.0000000000001129			11	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800013	30001242				2019-10-28	
J	Lilo, MT; Chen, Y; LeBlanc, RE				Lilo, Mohammed T.; Chen, Youdinghuan; LeBlanc, Robert E.			INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Merkel cell carcinoma; neuroendocrine carcinoma; INSM1; immunohistochemistry	NEUROENDOCRINE CARCINOMA; DIFFERENTIAL-DIAGNOSIS; TRABECULAR CARCINOMA; PROTEIN-1 INSM1; EXPRESSION; MARKER; POLYOMAVIRUS; TUMORS; SKIN; VIRUS	Merkel cell carcinoma (MCC) is an extremely aggressive skin cancer that must be distinguished from other basaloid cutaneous neoplasms that have different treatments and prognoses. This is sometimes challenging in small shave specimens, crushed samples, lymph nodes, and core needle biopsies. Insulinoma-associated protein 1 (INSM1) immunohistochemistry is a sensitive nuclear marker of neuroendocrine differentiation. INSM1 staining was performed on 56 MCC (47 primary tumors, 9 nodal metastases), 50 skin control cases that included basal cell carcinomas, basaloid squamous cell carcinomas, Bowen disease, sebaceous neoplasms, melanoma, and B-cell lymphomas, and 28 lymph node control cases that included metastatic neuroendocrine neoplasms, melanomas, squamous cell carcinomas, lymphomas, and adenocarcinomas. Percent of staining nuclei (0, <25%, 25% to 50%, 50% to 75%, >75%) and intensity (weak, moderate, strong) were recorded for each sample. All 56 MCC expressed INSM1. By comparison, synaptophysin, CK20, and chromogranin were expressed in 96%, 92%, and 32% of MCC, respectively. While the 3 conventional markers showed significant variability in staining intensity and distribution, INSM1 stained >75% tumor nuclei in 89% of MCC and 50% to 75% of tumor nuclei in 11%. Staining intensity was strong in 85% and moderate in 15%. None of the 50 cutaneous basaloid non-MCC neoplasms in the control group stained with INSM1, and among the lymph node controls 5 of 5 neuroendocrine neoplasms expressed INSM1, confirming that INSM1 staining cannot distinguish MCC from metastatic extracutaneous neuroendocrine carcinoma. INSM1 holds promise as a neuroendocrine marker that can distinguish MCC from its mimickers in the skin and improve detection of sentinel lymph node metastases.	[Lilo, Mohammed T.; LeBlanc, Robert E.] Dartmouth Hitchcock Med Ctr, Div Dermatopathol, Dept Pathol & Lab Med, Lebanon, NH 03766 USA; [Lilo, Mohammed T.; LeBlanc, Robert E.] Dartmouth Geisel Sch Med, Hanover, NH USA; [Chen, Youdinghuan] Dartmouth Geisel Sch Med, Dept Epidemiol, Hanover, NH USA	LeBlanc, RE (reprint author), Dartmouth Hitchcock Med Ctr, Dartmouth Geisel Sch Med, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03756 USA.	robert.e.leblanc@hitchcock.org		Chen, David/0000-0002-5451-0482			Becker JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.77; Becker JC, 2009, J INVEST DERMATOL, V129, P248, DOI 10.1038/jid.2008.198; Beer TW, 2009, J CUTAN PATHOL, V36, P385, DOI 10.1111/j.1600-0560.2008.01062.x; Bobos M, 2006, AM J DERMATOPATH, V28, P99, DOI 10.1097/01.dad.0000183701.67366.c7; Buck CB, 2009, J INVEST DERMATOL, V129, P9, DOI 10.1038/jid.2008.302; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Calder KB, 2007, J CUTAN PATHOL, V34, P918, DOI 10.1111/j.1600-0560.2007.00759.x; Chan JKC, 1997, AM J SURG PATHOL, V21, P226, DOI 10.1097/00000478-199702000-00014; Chen CC, 2015, ONCOTARGET, V6, P36700, DOI 10.18632/oncotarget.5485; Cimino PJ, 2014, MODERN PATHOL, V27, P1073, DOI 10.1038/modpathol.2013.235; Ezaldein Harib H, 2017, Oncoscience, V4, P106, DOI 10.18632/oncoscience.358; GEORGE E, 1989, AM J DERMATOPATH, V11, P131, DOI 10.1097/00000372-198911020-00004; Gong J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00274; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Hodgson NC, 2005, J SURG ONCOL, V89, P1, DOI 10.1002/jso.20167; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Houcine Yoldez, 2017, J Immunoassay Immunochem, V38, P487, DOI 10.1080/15321819.2017.1331170; Kassem A, 2008, CANCER RES, V68, P5009, DOI 10.1158/0008-5472.CAN-08-0949; Ko JS, 2016, MODERN PATHOL, V29, P122, DOI 10.1038/modpathol.2015.109; Kuji S, 2017, GYNECOL ONCOL, V144, P384, DOI 10.1016/j.ygyno.2016.11.020; Le MD, 2017, AM J DERMATOPATH, V39, P208, DOI 10.1097/DAD.0000000000000700; Mahmoodi M, 2005, J CUTAN PATHOL, V32, P491, DOI 10.1111/j.0303-6987.2005.00370.x; Malli T, 2018, MOL CYTOGENET, V11, DOI 10.1186/s13039-018-0355-7; Matsushita M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-65; McCalmont TH, 2010, J CUTAN PATHOL, V37, P821, DOI 10.1111/j.1600-0560.2010.01567_1.x; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Osipovich AB, 2014, DEVELOPMENT, V141, P2939, DOI 10.1242/dev.104810; Panse G, 2017, J CUTAN PATHOL, V44, P553, DOI 10.1111/cup.12950; Ptaszynski K, 2009, POL J PATHOL, V60, P151; Pulitzer Melissa, 2017, Surg Pathol Clin, V10, P399, DOI 10.1016/j.path.2017.01.013; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Reddi DM, 2013, J CUTAN PATHOL, V40, P431, DOI 10.1111/cup.12079; Rooper LM, 2018, AM J SURG PATHOL, V42, P665, DOI 10.1097/PAS.0000000000001037; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Rosenbaum JN, 2015, AM J CLIN PATHOL, V144, P579, DOI 10.1309/AJCPGZWXXBSNL4VD; Rush PS, 2018, J CUTAN PATHOL, V45, P129, DOI 10.1111/cup.13079; Singh B, 2018, J AM ACAD DERMATOL, V79, P126, DOI 10.1016/j.jaad.2018.01.041; Skelton HG, 1997, J AM ACAD DERMATOL, V37, P734, DOI 10.1016/S0190-9622(97)70110-5; Sunshine JC, 2018, ONCOGENE, V37, P1409, DOI 10.1038/s41388-017-0073-3; TANG CK, 1978, CANCER, V42, P2311, DOI 10.1002/1097-0142(197811)42:5<2311::AID-CNCR2820420531>3.0.CO;2-L; Tanigawa M, 2018, MED MOL MORPHOL, V51, P32, DOI 10.1007/s00795-017-0167-6; Terada T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0444-0; TOKER C, 1972, ARCH DERMATOL, V105, P107, DOI 10.1001/archderm.105.1.107; VISSCHER D, 1989, MODERN PATHOL, V2, P331; Yoshida A, 2018, MODERN PATHOL, V31, P744, DOI 10.1038/modpathol.2017.189	45	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1541	1548		10.1097/PAS.0000000000001136			8	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800014	30080705				2019-10-28	
J	Ju, JY; Mills, AM; Mahadevan, MS; Fan, JB; Culp, SH; Thomas, MH; Cathro, HP				Ju, Jennifer Y.; Mills, Anne M.; Mahadevan, Mani S.; Fan, Jinbo; Culp, Stephen H.; Thomas, Martha H.; Cathro, Helen P.			Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						upper tract; urothelial; Lynch syndrome; mismatch repair; microsatellite instability	UPPER URINARY-TRACT; MISMATCH-REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY ANALYSIS; NONPOLYPOSIS COLORECTAL-CANCER; TRANSITIONAL-CELL CARCINOMA; ENDOMETRIAL CANCERS; RISK; EXPRESSION; MUTATIONS; PROTEINS	Lynch syndrome (LS) is defined by germline mutations in DNA mismatch repair (MMR) genes, and affected patients are at high risk for multiple cancers. Reflexive testing for MMR protein loss by immunohistochemistry (IHC) is currently only recommended for colorectal and endometrial cancers, although upper tract urothelial carcinoma (UTUC) is the third-most common malignancy in patients with LS. To study the suitability of universal MMR IHC screening for UTUC, we investigated MMR expression and microsatellite status in UTUC in comparison to bladder UC (BUC), and evaluated the clinicopathologic features of UTUC. We found that 9% of UTUC showed MMR IHC loss (8 MSH6 alone; 1 MSH2 and MSH6; 1 MLH1 and PMS2; n = 117) compared with 1% of BUC (1 MSH6 alone; n = 160) (P = 0.001). Of these, 4/10 (40%) of UTUC (3% overall; 3 MSH6 alone; 1 MLH1 and PMS2) and none (0%) of BUC had high microsatellite instability on molecular testing (P = 0.03). The only predictive clinicopathologic feature for MMR loss was a personal history of colorectal cancer (P = 0.0003). However, UTUC presents at a similar age to colon carcinoma in LS and thus UTUC may be the sentinel event in some patients. Combining our results with those of other studies suggests that 1% to 3% of all UTUC cases may represent LS-associated carcinoma. LS accounts for 2% to 6% of both colorectal and endometrial cancers. As LS likely accounts for a similar percentage of UTUC, we suggest that reflexive MMR IHC screening followed by microsatellite instability testing be included in diagnostic guidelines for all UTUC.	[Ju, Jennifer Y.; Mills, Anne M.; Mahadevan, Mani S.; Fan, Jinbo; Cathro, Helen P.] Univ Virginia, Dept Pathol, 1215 Lee St,POB 800214,Off 3028, Charlottesville, VA 22908 USA; [Culp, Stephen H.] Univ Virginia, Dept Urol, Charlottesville, VA USA; [Thomas, Martha H.] Univ Virginia, Emily Cour Canc Ctr, Charlottesville, VA USA	Cathro, HP (reprint author), Univ Virginia, Dept Pathol, 1215 Lee St,POB 800214,Off 3028, Charlottesville, VA 22908 USA.	hpc4f@virginia.edu			Department of Pathology at the University of Virginia	Supported by the Department of Pathology at the University of Virginia. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Aarnio M, 2012, FAM CANCER, V11, P395, DOI 10.1007/s10689-012-9526-6; Acher P, 2010, BJU INT, V106, P300, DOI 10.1111/j.1464-410X.2010.09443.x; Audenet F, 2012, BJU INT, V110, pE583, DOI 10.1111/j.1464-410X.2012.11298.x; Bao F, 2010, AM J SURG PATHOL, V34, P1798, DOI 10.1097/PAS.0b013e3181f906cc; Barrow PJ, 2013, FAM CANCER, V12, P57, DOI 10.1007/s10689-012-9573-z; Blaszyk H, 2002, MODERN PATHOL, V15, P790, DOI 10.1097/01.MP.0000024263.25043.0C; Brennan B, 2017, THER ADV GASTROENTER, V10, P361, DOI 10.1177/1756283X17690990; Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; Crockett DG, 2011, J UROLOGY, V185, P1627, DOI 10.1016/j.juro.2010.12.102; Gibson J, 2014, CLIN GASTROENTEROL H, V12, P161, DOI 10.1016/j.cgh.2013.11.001; Goodfellow PJ, 2015, J CLIN ONCOL, V33, P4301, DOI 10.1200/JCO.2015.63.9518; Gylling AHS, 2008, CARCINOGENESIS, V29, P1351, DOI 10.1093/carcin/bgn133; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Harper HL, 2017, MODERN PATHOL, V30, P146, DOI 10.1038/modpathol.2016.171; Hartmann A, 2003, HUM PATHOL, V34, P222, DOI 10.1053/hupa.2003.22; Hartmann A, 2002, CANCER RES, V62, P6796; Joost P, 2015, UROLOGY, V86, P1212, DOI 10.1016/j.urology.2015.08.018; Leenen CHM, 2016, GENET MED, V18, P966, DOI 10.1038/gim.2015.206; Metcalfe MJ, 2018, J UROLOGY, V199, P60, DOI 10.1016/j.juro.2017.08.002; Mills AM, 2016, AM J SURG PATHOL, V40, P155, DOI 10.1097/PAS.0000000000000544; Mills AM, 2014, AM J SURG PATHOL, V38, P1501, DOI 10.1097/PAS.0000000000000321; O'Kane GM, 2017, CANCER MED-US, V6, P1465, DOI 10.1002/cam4.1025; Olagui GS, 2014, B CANCER, V101, P144, DOI 10.1684/bdc.2014.1896; Patel N, 2014, UROL ONCOL, V32, P28; Perez-Carbonell L, 2012, GUT, V61, P865, DOI 10.1136/gutjnl-2011-300041; Pradere B, 2016, CURR OPIN UROL, V27, P48, DOI 10.1097/MOU.0000000000000340; Radu OM, 2011, HUM PATHOL, V42, P1247, DOI 10.1016/j.humpath.2010.11.016; Roupret M, 2008, EUR UROL, V54, P1226, DOI 10.1016/j.eururo.2008.08.008; Sijmons RH, 1998, J UROLOGY, V160, P466, DOI 10.1016/S0022-5347(01)62926-4; Stoehr R, 2004, ONCOL REP, V11, P137; Tiwari AK, 2016, QJM-INT J MED, V109, P151, DOI 10.1093/qjmed/hcv137; Urakami S, 2018, INT J UROL, V25, P151, DOI 10.1111/iju.13481; van der Post RS, 2010, J MED GENET, V47, P464, DOI 10.1136/jmg.2010.076992; Vilkin A, 2014, HUM PATHOL, V45, P2029, DOI 10.1016/j.humpath.2014.07.005; Wang Y, 2017, J MOL DIAGN, V19, P57, DOI 10.1016/j.jmoldx.2016.07.008; Watkins JC, 2017, INT J GYNECOL PATHOL, V36, P115, DOI 10.1097/PGP.0000000000000312; Watson P, 2008, INT J CANCER, V123, P444, DOI 10.1002/ijc.23508; Yuan L, 2015, INT J CLIN EXP MED, V8, P20988; Zhang B, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0941-2	40	3	3	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1549	1555		10.1097/PAS.0000000000001141			7	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800015	30148743				2019-10-28	
J	Hutchings, D; Waters, KM; Weiss, MJ; Wolfgang, CL; Makary, MA; He, J; Cameron, JL; Wood, LD; Hruban, RH				Hutchings, Danielle; Waters, Kevin M.; Weiss, Matthew J.; Wolfgang, Christopher L.; Makary, Martin A.; He, Jin; Cameron, John L.; Wood, Laura D.; Hruban, Ralph H.			Cancerization of the Pancreatic Ducts Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cancerization of ducts; pancreatic ductal adenocarcinoma; pancreatic intraepithelial neoplasia; p53; Smad4	ACINAR-CELL-CARCINOMA; INTRAEPITHELIAL NEOPLASIA; PRECURSOR LESIONS; ADENOCARCINOMA; PROGRESSION; CANCER; SPREAD; GROWTH; EXPRESSION; SURVIVAL	Invasive pancreatic ductal adenocarcinoma (PDAC) can infiltrate back into and spread along preexisting pancreatic ducts and ductules in a process known as cancerization of ducts (COD). Histologically COD can mimic high-grade pancreatic intraepithelial neoplasia (HG-PanIN). We reviewed pancreatic resections from 100 patients with PDAC for the presence or absence of ducts with histologic features of COD. Features supporting COD included adjacent histologically similar invasive PDAC and an abrupt transition between markedly atypical intraductal epithelium and normal duct epithelium or circumferential involvement of a duct. As the TP53 and SMAD4 genes are frequently targeted in invasive PDAC but not HG-PanIN, paired PDAC and histologically suspected COD lesions were immunolabeled with antibodies to the p53 and Smad4 proteins. Suspected COD was identified on hematoxylin and eosin sections in 89 (89%) of the cases. Immunolabeling for p53 and Smad4 was performed in 68 (76%) of 89 cases. p53 was interpretable in 55 cases and all 55 (100%) cases showed concordant labeling between COD and invasive PDAC. There was matched aberrant p53 immunolabeling in 37 (67%) cases including overexpression in 30 (55%) cases and lack of expression in 7 (13%) cases. Smad4 immunolabeling was interpretable in 61 cases and 59 (97%) cases showed concordant labeling between COD and invasive PDAC. Matched loss of Smad4 was seen in 28 (46%) cases. The immunolabeling of invasive PDAC and COD for p53 and Smad4 supports the high prevalence of COD observed on hematoxylin and eosin and highlights the utility of p53 and Smad4 immunolabeling in differentiating COD and HG-PanIN.	[Hutchings, Danielle; Wood, Laura D.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Weiss, Matthew J.; Wolfgang, Christopher L.; Makary, Martin A.; He, Jin; Cameron, John L.] Johns Hopkins Univ, Sch Med, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Weiss, Matthew J.; Wolfgang, Christopher L.; Makary, Martin A.; He, Jin; Cameron, John L.; Wood, Laura D.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Waters, Kevin M.] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA	Hruban, RH (reprint author), Carnegie 415,600 North Wolfe St, Baltimore, MD 21287 USA.	rhruban@jhmi.edu			NIH SPORE grant [P50 CA62924]; NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK107781]; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; Gerald O Mann Charitable Foundation	Supported by the NIH SPORE grant P50 CA62924; NIH/NIDDK K08 DK107781; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; The Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Andea A, 2003, MODERN PATHOL, V16, P996, DOI 10.1097/01.MP.0000087422.24733.62; Basturk O, 2007, AM J SURG PATHOL, V31, P363, DOI 10.1097/01.pas.0000213376.09795.9f; Basturk O, 2015, ANN SURG ONCOL, V22, pS1187, DOI 10.1245/s10434-015-4861-0; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; BOSCHMAN CR, 1994, AM J PATHOL, V145, P1291; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; Chen JWC, 2010, HPB, V12, P101, DOI 10.1111/j.1477-2574.2009.00140.x; Fabre A, 2001, VIRCHOWS ARCH, V438, P312, DOI 10.1007/s004280000342; Garcea G, 2007, EJSO-EUR J SURG ONC, V33, P892, DOI 10.1016/j.ejso.2007.02.024; Hong SM, 2012, AM J SURG PATHOL, V36, P235, DOI 10.1097/PAS.0b013e3182376e36; Hosoda W, 2017, J PATHOL, V242, P16, DOI 10.1002/path.4884; Hruban RH, 2007, MODERN PATHOL, V20, pS61, DOI 10.1038/modpathol.3800685; Imamura M, 2009, SURG TODAY, V39, P1006, DOI 10.1007/s00595-009-3968-y; Ishii M, 2015, PANCREATOLOGY, V15, P681, DOI 10.1016/j.pan.2015.09.017; KLOPPEL G, 1980, VIRCHOWS ARCH A, V387, P221, DOI 10.1007/BF00430702; Lennon AM, 2014, CANCER RES, V74, P3381, DOI 10.1158/0008-5472.CAN-14-0734; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Matthaei H, 2011, ANN SURG ONCOL, V18, P3493, DOI 10.1245/s10434-011-1745-9; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Riopel MA, 1997, AM J SURG PATHOL, V21, P1030, DOI 10.1097/00000478-199709000-00007; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Strobel O, 2015, ANN SURG, V261, P961, DOI 10.1097/SLA.0000000000000814; Toll AD, 2011, INT J SURG PATHOL, V19, P795, DOI 10.1177/1066896909339912; Wilentz RE, 2000, CANCER RES, V60, P2002; Yamasaki S, 2002, PANCREATOLOGY, V2, P407, DOI 10.1159/000065089; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85	26	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1556	1561		10.1097/PAS.0000000000001148			6	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800016	30212393	Green Published			2019-10-28	
J	Argani, P; Reuter, VE; Kapur, P; Brown, JE; Sung, YS; Zhang, L; Williamson, R; Francis, G; Sommerville, S; Swanson, D; Dickson, BC; Antonescu, CR				Argani, Pedram; Reuter, Victor E.; Kapur, Payal; Brown, James E.; Sung, Yun-Shao; Zhang, Lei; Williamson, Richard; Francis, Glen; Sommerville, Scott; Swanson, David; Dickson, Brendan C.; Antonescu, Cristina R.			Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						renal neoplasm; sarcoma; MEIS1; NCOA2; translocation	SOFT-TISSUE ANGIOFIBROMA; CONGENITAL MESOBLASTIC NEPHROMA; ACUTE MYELOID-LEUKEMIA; SYNOVIAL SARCOMA; MOLECULAR ANALYSIS; STROMAL TUMOR; MEIS1; RHABDOMYOSARCOMA; REARRANGEMENTS; FIBROSARCOMA	We describe 2 cases of a distinct sarcoma characterized by a novel MEIS1-NCOA2 gene fusion. This gene fusion was identified in the renal neoplasms of 2 adults (21-y-old male, 72-y-old female). Histologically, the resected renal neoplasms had a distinctively nodular appearance, and while one renal neoplasm was predominantly cystic, the other demonstrated solid architecture, invasion of perirenal fat, and renal sinus vasculature invasion. The neoplasms were characterized predominantly by monomorphic plump spindle cells arranged in vague fascicles with a whorling pattern; however, a more primitive small round cell component was also noted. Both neoplasms were mitotically active and one case showed necrosis. The neoplasms did not have a distinctive immunohistochemical profile, though both labeled for TLE1. The morphologic features are distinct from other sarcomas associated with NCOA2 gene fusions, including mesenchymal chondrosarcoma, congenital/infantile spindle cell rhabdomyosarcoma, and soft tissue angiofibroma. While we have minimal clinical follow-up, the aggressive histologic features of these neoplasms indicate malignant potential, thus warranting classification as a novel subtype of sarcoma.	[Argani, Pedram] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Argani, Pedram] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Reuter, Victor E.; Sung, Yun-Shao; Zhang, Lei; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Kapur, Payal] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Brown, James E.] West Jefferson Med Ctr, Dept Pathol, Marrero, LA USA; [Williamson, Richard; Francis, Glen] Medlab Pathol, Brisbane, Qld, Australia; [Sommerville, Scott] Joint Space, Orthoped Surg, Auchenflower, Qld, Australia; [Swanson, David; Dickson, Brendan C.] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada	Argani, P (reprint author), Johns Hopkins Univ Hosp, Surg Pathol, Weinberg Bldg,Room 2242,401 N Broad Way, Baltimore, MD 21231 USA.	pargani@jhmi.edu			Cycle for Survival; Kristin Ann Carr Foundation; Dahan Translocation Carcinoma Fund; Joey's Wings;  [P50 CA 140146-01];  [P30-CA008748]	Supported in part by: P50 CA 140146-01 (C.R.A.), P30-CA008748 (C.R.A.), Cycle for Survival (C.R.A.), Kristin Ann Carr Foundation (C.R.A.), Dahan Translocation Carcinoma Fund (P.A.), Joey's Wings (P.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Aksoz M, 2018, CURR DRUG TARGETS, V19, P181, DOI 10.2174/1389450118666170724165514; Alaggio R, 2016, AM J SURG PATHOL, V40, P224, DOI 10.1097/PAS.0000000000000538; Antonescu CR, 2018, AM J SURG PATHOL, V42, P553, DOI 10.1097/PAS.0000000000001010; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Argani P, 2000, AM J SURG PATHOL, V24, P917, DOI 10.1097/00000478-200007000-00003; Argani P, 2000, MODERN PATHOL, V13, P29, DOI 10.1038/modpathol.3880006; Argani P, 2018, AM J SURG PATHOL, V42, P1128, DOI 10.1097/PAS.0000000000001089; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Argani P, 2015, AM J SURG PATHOL, V39, P365, DOI 10.1097/PAS.0000000000000338; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Argani P, 2009, AM J SURG PATHOL, V33, P609, DOI 10.1097/PAS.0b013e31818fbdff; Bekers EM, 2017, GENE CHROMOSOME CANC, V56, P750, DOI 10.1002/gcc.22478; Blasi F, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201600245; Calio A, 2016, AM J SURG PATHOL, V40, P1538, DOI 10.1097/PAS.0000000000000733; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Collins CT, 2016, CURR OPIN HEMATOL, V23, P354, DOI 10.1097/MOH.0000000000000245; Crijns APG, 2007, EUR J CANCER, V43, P2495, DOI 10.1016/j.ejca.2007.08.025; Fine SW, 2006, AM J SURG PATHOL, V30, P593, DOI 10.1097/01.pas.0000194298.19839.b4; He X, 2016, INT J CLIN EXP PATHO, V9, P4339; Jimenez RE, 2002, AM J SURG PATHOL, V26, P320, DOI 10.1097/00000478-200203000-00005; Jin YS, 2012, GENE CHROMOSOME CANC, V51, P510, DOI 10.1002/gcc.21939; Jones TA, 2000, EUR J CANCER, V36, P2368, DOI 10.1016/S0959-8049(00)00332-4; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Knezevich SR, 1998, CANCER RES, V58, P5046; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Li YJ, 2017, AM J SURG PATHOL, V41, P472, DOI 10.1097/PAS.0000000000000816; Liu JY, 2017, ANN HEMATOL, V96, P567, DOI 10.1007/s00277-016-2913-6; Mangray S, 2018, AM J SURG PATHOL, V42, P1360, DOI 10.1097/PAS.0000000000001098; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; O'Meara E, 2012, J PATHOL, V227, P72, DOI 10.1002/path.3985; Panagopoulos I, 2016, ONCOL REP, V36, P2455, DOI 10.3892/or.2016.5096; Patel AV, 2016, EBIOMEDICINE, V9, P110, DOI 10.1016/j.ebiom.2016.06.007; Quezado M, 1997, HUM PATHOL, V28, P767, DOI 10.1016/S0046-8177(97)90147-7; Rad A, 2016, TUMOR BIOL, V37, P1715, DOI 10.1007/s13277-015-3780-9; Rosales-Avina JA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-112; Rubin BP, 1999, AM J SURG PATHOL, V23, P589, DOI 10.1097/00000478-199905000-00014; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Strehl S, 2008, CLIN CANCER RES, V14, P977, DOI 10.1158/1078-0432.CCR-07-4022; Sugita S, 2014, HUM PATHOL, V45, P1588, DOI 10.1016/j.humpath.2013.12.022; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Troke PJF, 2006, BIOCHEM SOC SYMP, V73, P23; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Wang LL, 2007, AM J SURG PATHOL, V31, P576, DOI 10.1097/01.pas.0000213432.14740.14; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yamada Y, 2016, HISTOPATHOLOGY, V69, P459, DOI 10.1111/his.12943; Zhu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3155-2	51	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2018	42	11					1562	1570		10.1097/PAS.0000000000001140			9	Pathology; Surgery	Pathology; Surgery	GX4KI	WOS:000447699800017	30179902				2019-10-28	
J	Peterson, JF; Van Dyke, DL; Hoppman, NL; Kearney, HM; Sukov, WR; Greipp, PT; Ketterling, RP; Baughn, LB				Peterson, Jess F.; Van Dyke, Daniel L.; Hoppman, Nicole L.; Kearney, Hutton M.; Sukov, William R.; Greipp, Patricia T.; Ketterling, Rhett P.; Baughn, Linda B.			The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Hematologic neoplasms; Chromosomal microarray; Array-based comparative genomic hybridization (aCGH); Single nucleotide polymorphism (SNP)	ACUTE LYMPHOBLASTIC-LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; MYELODYSPLASTIC SYNDROMES; IKZF1 DELETION; ARRAY; ABERRATIONS; RECURRENT; KARYOTYPE; CLASSIFICATION; MALIGNANCIES	Objectives: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. Chromosomal microarray can detect copy number aberrations (CNAs) with greater resolution when compared to G-banding and FISH, and can also identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. Methods: A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. Results: Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. Microarray studies could not detect balanced rearrangements, low-level clones, or distinguish independent clones. Conclusions: When utilized appropriately, chromosomal microarray can provide clinically significant information that complements traditional cytogenetic testing methodologies.	[Peterson, Jess F.; Van Dyke, Daniel L.; Hoppman, Nicole L.; Kearney, Hutton M.; Sukov, William R.; Greipp, Patricia T.; Ketterling, Rhett P.; Baughn, Linda B.] Mayo Clin, Dept Lab Med & Pathol, Div Lab Genet & Genom, 200 First St SW, Rochester, MN 55905 USA	Peterson, JF (reprint author), Mayo Clin, Dept Lab Med & Pathol, Div Lab Genet & Genom, 200 First St SW, Rochester, MN 55905 USA.	peterson.jess@mayo.edu					Arenillas L, 2013, GENE CHROMOSOME CANC, V52, P1167, DOI 10.1002/gcc.22112; Baughn LB, 2015, CANCER GENET-NY, V208, P1, DOI 10.1016/j.cancergen.2014.11.003; Clappier E, 2015, LEUKEMIA, V29, P2154, DOI 10.1038/leu.2015.134; Cooley LD, 2013, GENET MED, V15, P484, DOI 10.1038/gim.2013.49; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Gangat N, 2016, AM J HEMATOL, V91, P76, DOI 10.1002/ajh.24253; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Gunn SR, 2008, J MOL DIAGN, V10, P442, DOI 10.2353/jmoldx.2008.080033; Gunnarsson R, 2011, HAEMATOL-HEMATOL J, V96, P1161, DOI 10.3324/haematol.2010.039768; Harrison CJ, 2014, LEUKEMIA, V28, P1015, DOI 10.1038/leu.2013.317; Harrison CJ, 2004, BRIT J HAEMATOL, V125, P552, DOI 10.1111/j.1365-2141.2004.04948.x; Hartmann L, 2014, CLIN CHEM, V60, P1558, DOI 10.1373/clinchem.2014.227785; Iacobucci I, 2017, J CLIN ONCOL, V35, P975, DOI 10.1200/JCO.2016.70.7836; Kolquist KA, 2011, CANCER GENET-NY, V204, P603, DOI 10.1016/j.cancergen.2011.10.004; Loghavi S, 2015, AM J CLIN PATHOL, V144, P393, DOI 10.1309/AJCPAN7BH5DNYWZB; Malek SN, 2013, ONCOGENE, V32, P2805, DOI 10.1038/onc.2012.411; Manning M, 2010, GENET MED, V12, P742, DOI 10.1097/GIM.0b013e3181f8baad; Martin CL, 2015, ANNU REV GENOM HUM G, V16, P309, DOI 10.1146/annurev-genom-090413-025346; Moorman AV, 2014, BLOOD, V124, P1434, DOI 10.1182/blood-2014-03-562918; Moorman AV, 2010, LANCET ONCOL, V11, P429, DOI 10.1016/S1470-2045(10)70066-8; Muhlbacher V, 2014, GENE CHROMOSOME CANC, V53, P524, DOI 10.1002/gcc.22163; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nachman JB, 2007, BLOOD, V110, P1112, DOI 10.1182/blood-2006-07-038299; Patel S, 2017, LEUKEMIA RES, V56, P44, DOI 10.1016/j.leukres.2017.01.034; Pienkowska-Grela B, 2011, MED ONCOL, V28, P1589, DOI 10.1007/s12032-010-9614-0; Puiggros A, 2014, BIOMED RES INT, DOI 10.1155/2014/435983; Roberts KG, 2015, NAT REV CLIN ONCOL, V12, P344, DOI 10.1038/nrclinonc.2015.38; Salaverria I, 2014, BLOOD, V123, P1187, DOI 10.1182/blood-2013-06-507996; Sargent R, 2009, J MOL DIAGN, V11, P25, DOI 10.2353/jmoldx.2009.080037; Schoumans J, 2016, GENE CHROMOSOME CANC, V55, P480, DOI 10.1002/gcc.22350; Shaffer LG, 2012, CURR OPIN GENET DEV, V22, P264, DOI 10.1016/j.gde.2012.01.005; Stevens-Kroef MJ, 2017, GENE CHROMOSOME CANC, V56, P524, DOI 10.1002/gcc.22455; Swerdlow SH, 2017, WHO CLASSIFICATION T; Taylor J, 2017, BLOOD, V130, P410, DOI 10.1182/blood-2017-02-734541; Thiel A, 2011, LEUKEMIA, V25, P387, DOI 10.1038/leu.2010.293; Tiu RV, 2011, BLOOD, V117, P4552, DOI 10.1182/blood-2010-07-295857; van der Veer A, 2013, BLOOD, V122, P2622, DOI 10.1182/blood-2012-10-462358; Zhang LS, 2011, CANCER GENET-NY, V204, P654, DOI 10.1016/j.cancergen.2011.10.012; Zhang P, 2017, INT J GENOMICS, DOI 10.1155/2017/1926304; Zhou Y, 2016, ANN DIAGN PATHOL, V23, P43, DOI 10.1016/j.anndiagpath.2016.02.002	40	2	2	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					375	384		10.1093/ajcp/aqy076			10	Pathology	Pathology	GV4PB	WOS:000446081500001	30052716				2019-10-28	
J	Austin, RM; Onisko, A; Zhao, CQ				Austin, R. Marshall; Onisko, Agnieszka; Zhao, Chengquan			Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cervical cancer screening; Risk assessment; Cotesting; HPV; Imaged liquid-based cytology	CONVENTIONAL PAPANICOLAOU SMEARS; RANDOMIZED CONTROLLED-TRIAL; SCREENING-PROGRAM; BETHESDA SYSTEM; FOLLOW-UP; WOMEN; RISK; ACCURACY; PERFORMANCE; PREVENTION	Objectives: Cervical screening strives to prevent cervical cancer (CxCa), minimizing morbidity and mortality. Most large US reports on cytology and human papillomavirus (HPV) cotesting of women aged 30 years and older are from one laboratory, which used conventional Papanicolaou (Pap) smears from 2003 to 2009. Methods: We quantified detection of CxCa and precancer (cervical intraepithelial neoplasia 31adenocarcinoma in situ [CIN3/AIS]) in 300,800 cotests at Magee Womens Hospital since 2005. Screening histories preceding CxCa and CIN3/AIS diagnoses were examined to assess the contribution of cytology and HPV testing Cotesting utilized Food and Drug Administration-approved imaged liquid-based cytology (LBC) and from-the-vial HPV tests. Results: LBC identified more women subsequently diagnosed with CxCa and CIN3/AIS than HPV testing HPV-negative/cytology-positive results preceded 13.1% of CxCa and 7.2% of CIN3/AIS diagnoses. Conclusions: LBC enhanced cotesting detection of CxCa and CIN3/AIS to a greater extent than previously reported with conventional Pap smear and HPV cotesting.	[Austin, R. Marshall; Onisko, Agnieszka; Zhao, Chengquan] Univ Pittsburgh, Med Ctr, Dept Pathol, 300 Halket St, Pittsburgh, PA 15213 USA; [Onisko, Agnieszka] Bialystok Tech Univ, Fac Comp Sci, Bialystok, Poland	Austin, RM (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 300 Halket St, Pittsburgh, PA 15213 USA.	raustin@magee.edu					Abulafia O, 2003, GYNECOL ONCOL, V90, P137, DOI 10.1016/S0090-8258(03)00176-8; Austin R Marshall, 2016, J Am Soc Cytopathol, V5, P9, DOI 10.1016/j.jasc.2015.05.001; Austin RM, 2010, ARCH PATHOL LAB MED, V134, P744, DOI 10.1043/1543-2165-134.5.744; Austin RM, 2011, AJSP-REV REP, V16, P73, DOI 10.1097/PCR.0b013e31820fff8a; Bernstein SJ, 2001, AM J OBSTET GYNECOL, V185, P308, DOI 10.1067/mob.2001.116736; Blatt AJ, 2015, CANCER CYTOPATHOL, V123, P282, DOI 10.1002/cncy.21544; Castanon A, 2012, CYTOPATHOLOGY, V23, P13, DOI 10.1111/j.1365-2303.2011.00948.x; Castle PE, 2018, ANN INTERN MED, V168, P20, DOI 10.7326/M17-1609; Castle PE, 2017, GYNECOL ONCOL, V146, P546, DOI 10.1016/j.ygyno.2017.06.003; Committee on Practice BulletinsGynecology, 2016, Obstet Gynecol, V128, pe111, DOI 10.1097/AOG.0000000000001708; Davey E, 2007, BRIT MED J, V335, P31, DOI 10.1136/bmj.39219.645475.55; de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357; Dijkstra MG, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4924; Einstein MH, 2010, GYNECOL ONCOL, V118, P116, DOI 10.1016/j.ygyno.2010.04.013; Gage JC, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju153; HUTCHINSON ML, 1994, AM J CLIN PATHOL, V101, P215, DOI 10.1093/ajcp/101.2.215; Iftner T, 2015, J CLIN MICROBIOL, V53, P2509, DOI 10.1128/JCM.01013-15; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS50, DOI 10.1097/LGT.0b013e3182854282; Kinney W, 2015, OBSTET GYNECOL, V125, P311, DOI 10.1097/AOG.0000000000000632; Kinney W, 2011, GYNECOL ONCOL, V121, P309, DOI 10.1016/j.ygyno.2010.12.361; Kitchener HC, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13510; Lee KR, 1997, OBSTET GYNECOL, V90, P278, DOI 10.1016/S0029-7844(97)00228-7; Malila N, 2013, INT J CANCER, V132, P2141, DOI 10.1002/ijc.27850; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Nance KV, 2007, DIAGN CYTOPATHOL, V35, P148, DOI 10.1002/dc.20607; Onisko Agnieszka, 2015, Foundations of Biomedical Knowledge Representation. Methods and Applications. LNCS 9521, P207, DOI 10.1007/978-3-319-28007-3_13; Onisko Agnieszka, 2016, J Pathol Inform, V7, P50, DOI 10.4103/2153-3539.197191; Ronco G, 2007, BRIT MED J, V335, P28, DOI 10.1136/bmj.39196.740995.BE; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Saslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139; Schiffman M, 2018, JNCI-J NATL CANCER I, V110, P501, DOI 10.1093/jnci/djx225; Siebers AG, 2009, JAMA-J AM MED ASSOC, V302, P1757, DOI 10.1001/jama.2009.1569; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Stoler MH, 2015, J CLIN MICROBIOL, V53, P2798, DOI 10.1128/JCM.01087-15; Tainio K, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k499; Tao X, 2015, ACTA CYTOL, V59, P445, DOI 10.1159/000443679; Terry G, 2001, J MED VIROL, V65, P155, DOI 10.1002/jmv.2015.abs; US Department of Health and Human Services Food and Drug Administration, 2011, GUID IND FOOD DRUG A; Wright TC, 2014, INT J CANCER, V134, P1835, DOI 10.1002/ijc.28514; Zhao CQ, 2009, GYNECOL ONCOL, V114, P383, DOI 10.1016/j.ygyno.2009.05.019; Zheng BW, 2015, ARCH PATHOL LAB MED, V139, P373, DOI 10.5858/arpa.2014-0070-OA	41	3	3	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					385	392		10.1093/AJCP/AQY114			8	Pathology	Pathology	GV4PB	WOS:000446081500002	30137189	Other Gold			2019-10-28	
J	Merzianu, M; Groman, A; Hutson, A; Cotta, C; Brynes, RK; Orazi, A; Reddy, V; Teruya-Feldstein, J; Amre, R; Balasubramanian, M; Brandao, G; Cherian, S; Courville, E; Czuchlewski, D; Fan, G; Grier, D; Hoehn, D; Inamdar, KV; Juskevicius, R; Kaur, P; Lazarchick, J; Lewis, MR; Miles, RR; Myers, JB; Nasr, MR; Qureishi, HN; Olteanu, H; Robu, VG; Salaru, G; Vajpayee, N; Vos, J; Zhang, L; Zhang, SX; Aye, L; Brega, E; Coad, JE; Grantham, J; Ivelja, S; McKenna, R; Sultan, K; Wilding, G; Hutchison, R; Peterson, L; Cheney, RT				Merzianu, Mihai; Groman, Adrienne; Hutson, Alan; Cotta, Claudiu; Brynes, Russell K.; Orazi, Attilio; Reddy, Vishnu; Teruya-Feldstein, Julie; Amre, Ramila; Balasubramanian, Manjula; Brandao, Guilherme; Cherian, Sindhu; Courville, Elizabeth; Czuchlewski, David; Fan, Guang; Grier, David; Hoehn, Daniela; Inamdar, Kedar, V; Juskevicius, Ricks; Kaur, Prabhjot; Lazarchick, John; Lewis, Michael R.; Miles, Rodney R.; Myers, Jerome B.; Nasr, Michel R.; Qureishi, Hina N.; Olteanu, Horatiu; Robu, Valentin G.; Salaru, Gratian; Vajpayee, Neerja; Vos, Jeffrey; Zhang, Ling; Zhang, Shanxiang; Aye, Le; Brega, Elisa; Coad, James E.; Grantham, John; Ivelja, Sinisa; McKenna, Robert; Sultan, Kieran; Wilding, Gregory; Hutchison, Robert; Peterson, LoAnn; Cheney, Richard T.			Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada A Multicenter Study	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Bone marrow biopsy; Bone marrow biopsy indications; Core biopsy length; Bone marrow adequacy; Bone marrow quality; Bone marrow biopsy; Bone marrow biopsy indications; Core biopsy length; Bone marrow adequacy; Bone marrow quality	B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; TREPHINE BIOPSIES; FLOW-CYTOMETRY; FOLLICULAR LYMPHOMA; 2-NEEDLE TECHNIQUE; RESPONSE CRITERIA; MYELOMA PATIENTS; WORKING-GROUP; INVOLVEMENT	Objectives: To assess bone marrow (BM) sampling in academic medical centers. Methods: Data from 6,374 BM samples obtained in 32 centers in 2001 and 2011, including core length (CL), were analyzed. Results: BM included a biopsy (BMB; 93%) specimen, aspirate (BMA; 92%) specimen, or both (83%). The median (SD) CL was 12 (8.5) mm, and evaluable marrow was 9 (7.6) mm. Tissue contraction due to processing was 15%. BMB specimens were longer in adults younger than 60 years men, and bilateral, staging, and baseline samples. Only 4% of BMB and 2% of BMB/BMA samples were deemed inadequate for diagnosis. BM for plasma cell dyscrasias nonphysician operators, and ancillary studies usage increased while bilateral sampling decreased over the decade. BM-related quality assurance programs are infrequent. Conclusions: CL is shorter than recommended and varies with patient age and sex, clinical circumstances and center experience While pathologists render diagnoses on most cases irrespective of CL, BMB yield improvement is desirable.	[Merzianu, Mihai] Roswell Pk Comprehens Canc Ctr, Pathol & Lab Med, Buffalo, NY 14263 USA; [Groman, Adrienne; Hutson, Alan; Wilding, Gregory] Roswell Pk Comprehens Canc Ctr, Biostat & Bioinformat, Buffalo, NY 14263 USA; [Cotta, Claudiu] Cleveland Clin, Lab Med, Cleveland, OH 44106 USA; [Brynes, Russell K.; Aye, Le] USC, Keck Sch Med, Pathol, Los Angeles, CA USA; [Orazi, Attilio] Weill Cornell Med Coll, Pathol, New York, NY USA; [Reddy, Vishnu] Univ Alabama Birmingham, Pathol, Birmingham, AL USA; [Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Pathol, 1275 York Ave, New York, NY 10021 USA; [Amre, Ramila] McGill Univ, Hlth Ctr, Pathol, Royal Victoria Hosp, Montreal, PQ, Canada; [Balasubramanian, Manjula] Albert Einstein Med Ctr, Clin Pathol, Philadelphia, PA 19141 USA; [Brandao, Guilherme; Brega, Elisa] McGill Univ, Pathol, Jewish Gen Hosp, Montreal, PQ, Canada; [Cherian, Sindhu] Univ Washington, Lab Med, Seattle, WA 98195 USA; [Courville, Elizabeth; McKenna, Robert] Univ Minnesota, Lab Med & Pathol, Minneapolis, MN USA; [Czuchlewski, David] Univ New Mexico, Pathol, Albuquerque, NM 87131 USA; [Fan, Guang] Oregon Hlth & Sci Univ, Pathol, Portland, OR 97201 USA; [Grier, David] Wake Forest Baptist Med Ctr, Pathol, Winston Salem, NC USA; [Hoehn, Daniela] Columbia Univ, Pathol & Cell Biol, Med Ctr, New York, NY USA; [Inamdar, Kedar, V] Henry Ford Hlth Syst, Pathol, Detroit, MI USA; [Juskevicius, Ricks] East Carolina Univ, Brody Sch Med, Pathol, Greenville, NC 27858 USA; [Kaur, Prabhjot] Dartmouth Hitchcock Med Ctr, Pathol, Lebanon, NH 03766 USA; [Lazarchick, John] Med Univ South Carolina, Pathol & Lab Med, Charleston, SC 29425 USA; [Lewis, Michael R.] Univ Vermont, Pathol & Lab Med, Burlington, VT USA; [Miles, Rodney R.] Univ Utah, Pathol, Salt Lake City, UT USA; [Myers, Jerome B.] Penrose St Francis Hlth Serv, Pathol, Colorado Springs, CO USA; [Nasr, Michel R.; Sultan, Kieran] Univ Manitoba, Pathol, Winnipeg, MB, Canada; [Qureishi, Hina N.] Univ Nebraska, Med Ctr, Pathol & Microbiol, Omaha, NE USA; [Olteanu, Horatiu] Med Coll Wisconsin, Pathol, Milwaukee, WI 53226 USA; [Robu, Valentin G.] Fox Chase Canc Ctr, Pathol, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Salaru, Gratian] Rutgers Robert Wood Johnson Med Sch, Clin Pathol, New Brunswick, NJ USA; [Ivelja, Sinisa] Rutgers Robert Wood Johnson Med Sch, Pathol, New Brunswick, NJ USA; [Vajpayee, Neerja; Hutchison, Robert] SUNY Upstate Med Univ, Pathol, Syracuse, NY 13210 USA; [Vos, Jeffrey; Coad, James E.; Grantham, John] West Virginia Univ, Pathol, Morgantown, WV USA; [Zhang, Ling] H Lee Moffitt Canc Ctr & Res Inst, Hematopathol & Lab Med, Tampa, FL USA; [Zhang, Shanxiang] Indiana Univ, Pathol & Lab Med, Indianapolis, IN 46204 USA; [Peterson, LoAnn] Northwestern Mem Hosp, Pathol, Chicago, IL 60611 USA; [Cheney, Richard T.] Univ Buffalo State Univ New York, Pathol & Anat Sci, Buffalo, NY USA; [Teruya-Feldstein, Julie] Mt Sinai Hosp, New York, NY 10029 USA; [Amre, Ramila] Morton Plant North Bay Hosp, New Port Richey, FL USA; [Brandao, Guilherme] Hop Reg St Jerome, St Jerome, PQ, Canada; [Hoehn, Daniela] Janssen Sci Affairs, Horsham, PA USA; [Juskevicius, Ricks] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Olteanu, Horatiu] Mayo Clin, Rochester, MN USA; [Robu, Valentin G.] Bon Secours St Francis Hlth Syst, Greenville, SC USA; [Vajpayee, Neerja] Oneida Healthcare Hosp, Oneida, NY USA; [Brega, Elisa] Hop Pierre Le Gardeur, Terrebonne, PQ, Canada; [Grantham, John] Ohio State Univ, Columbus, OH 43210 USA	Merzianu, M (reprint author), Roswell Pk Comprehens Canc Ctr, Dept Pathol & Lab Med, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Mihai.Merzianu@RoswellPark.org	Vos, Jeffrey/W-7374-2019	Vos, Jeffrey/0000-0002-6715-1415	Roswell Park Comprehensive Cancer Center; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016056]	This work was supported by Roswell Park Comprehensive Cancer Center and National Cancer Institute (grant P30CA016056).	Al-Ibraheemi A, 2013, ARCH PATHOL LAB MED, V137, P974, DOI 10.5858/arpa.2012-0046-OA; Arber DA, 2005, AM J SURG PATHOL, V29, P1549, DOI 10.1097/01.pas.0000182405.65041.8b; Arber DA, 2017, WHO CLASSIFICATION T, P16; Barekman CL, 1997, AM J HEMATOL, V56, P37, DOI 10.1002/(SICI)1096-8652(199709)56:1<37::AID-AJH8>3.0.CO;2-3; BEARDEN JD, 1974, J CLIN PATHOL, V27, P738, DOI 10.1136/jcp.27.9.738; Bennett JM, 2009, HAEMATOL-HEMATOL J, V94, P264, DOI 10.3324/haematol.13755; BISHOP PW, 1992, J CLIN PATHOL, V45, P1105, DOI 10.1136/jcp.45.12.1105; BOONSTRA H, 1983, VIRCHOWS ARCH A, V402, P195, DOI 10.1007/BF00695061; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brudno J, BLOOD; BRUNNING RD, 1975, ANN INTERN MED, V82, P365, DOI 10.7326/0003-4819-82-3-365; Burchill SA, 2017, CANCER-AM CANCER SOC, V123, P1095, DOI 10.1002/cncr.30380; Campbell J, 2006, EUR J HAEMATOL, V76, P473, DOI 10.1111/j.1600-0609.2006.00644.x; Campbell JK, 2003, ANN ONCOL, V14, P273, DOI 10.1093/annonc/mdg055; Charles KS, 2004, CLIN LAB HAEMATOL, V26, P403, DOI 10.1111/j.1365-2257.2004.00646.x; Check W., CAP TODAY; Chen-Liang TH, 2015, AM J HEMATOL, V90, P686, DOI 10.1002/ajh.24044; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chigrinova E, 2011, HEMATOL ONCOL, V29, P38, DOI 10.1002/hon.953; Chung R, 2007, BLOOD, V110, P1278, DOI 10.1182/blood-2007-01-070300; Coad JE, 1997, AM J SURG PATHOL, V21, P1047, DOI 10.1097/00000478-199709000-00009; COLLER BS, 1977, AM J HEMATOL, V3, P105, DOI 10.1002/ajh.2830030201; Dayton VJ, 2014, ARCH PATHOL LAB MED, V138, P860, DOI 10.5858/arpa.2013-0528-LE; Duggan PR, 2000, CANCER, V88, P894, DOI 10.1002/(SICI)1097-0142(20000215)88:4<894::AID-CNCR21>3.3.CO;2-F; George TB, 2004, MOD PATHOL, V248; Hostenkamp G, 2015, SOC SCI MED, V130, P162, DOI 10.1016/j.socscimed.2015.02.003; Hussong JW, 2013, PROTOCOL EXAMINATION; Iancu D, 2007, ARCH PATHOL LAB MED, V131, P282; Jackson AE, 2014, AM J HEMATOL, V89, P865, DOI 10.1002/ajh.23760; Joshi R, 2008, J CLIN PATHOL, V61, P213, DOI 10.1136/jcp.2007.049130; JUNEJA SK, 1990, J CLIN PATHOL, V43, P630, DOI 10.1136/jcp.43.8.630; Kidd PG, 1997, MED PEDIATR ONCOL, V29, P541, DOI 10.1002/(SICI)1096-911X(199712)29:6<541::AID-MPO4>3.0.CO;2-K; Kvasnicka HM, 2016, HISTOPATHOLOGY, V68, P905, DOI 10.1111/his.12871; LANE J, 1983, CALCIFIED TISSUE INT, V35, P1, DOI 10.1007/BF02404997; Lawson S, 1999, J CLIN PATHOL, V52, P154, DOI 10.1136/jcp.52.2.154; Lee SH, 2008, INT J LAB HEMATOL, V30, P349, DOI 10.1111/j.1751-553X.2008.01100.x; Loureiro G, 2014, CANCER-AM CANCER SOC, V120, P1441, DOI 10.1002/cncr.28602; Maes B, 2000, J CLIN PATHOL, V53, P835, DOI 10.1136/jcp.53.11.835; Moid F, 2005, ARCH PATHOL LAB MED, V129, P497; Naegele M, 2015, ANN HEMATOL, V94, P1577, DOI 10.1007/s00277-015-2405-0; NCCN, 2018, B CELL LYMPH; Odejide OO, 2013, CANCER-AM CANCER SOC, V119, P3472, DOI 10.1002/cncr.28249; Pittaluga S, 1999, AM J CLIN PATHOL, V111, P179; Pozdnyakova O, 2014, MODERN PATHOL, V27, P1447, DOI 10.1038/modpathol.2014.69; Purz S, 2011, J CLIN ONCOL, V29, P3523, DOI 10.1200/JCO.2010.32.4996; Reid MM, 1999, J CLIN PATHOL, V52, P851, DOI 10.1136/jcp.52.11.851; Reid MM, 1996, J CLIN PATHOL, V49, P226, DOI 10.1136/jcp.49.3.226; Rimmer EK, 2008, BLOOD, V112, P4702; ROATH S, 1991, J CLIN PATHOL, V44, P350, DOI 10.1136/jcp.44.4.350; Rudzki Zbigniew, 2005, Polish Journal of Pathology, V56, P187; Schmidt B, 2006, LEUKEMIA LYMPHOMA, V47, P1857, DOI 10.1080/10428190600709127; Sehn LH, 2011, J CLIN ONCOL, V29, P1452, DOI 10.1200/JCO.2010.33.3419; Sovani V, 2014, J CLIN PATHOL, V67, P389, DOI 10.1136/jclinpath-2013-201520; Talaulikar D, 2008, J HISTOCHEM CYTOCHEM, V56, P893, DOI 10.1369/jhc.2008.951087; Tefferi A, 2006, BLOOD, V108, P1497, DOI 10.1182/blood-2006-03-009746; Thiele J, 2005, HAEMATOL-HEMATOL J, V90, P1128; TUZUNER N, 1994, LEUKEMIA RES, V18, P559, DOI 10.1016/0145-2126(94)90036-1; Wang J, 2002, CANCER, V94, P1522, DOI 10.1002/cncr.10364	59	1	1	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					393	405		10.1093/AJCP/AQY066			13	Pathology	Pathology	GV4PB	WOS:000446081500003	30052721	Bronze			2019-10-28	
J	Lin, CY; Levy, D; Higgins, JPT; Kunder, CA; Kao, CS				Lin, Chieh-Yu; Levy, David; Higgins, John P. T.; Kunder, Christian A.; Kao, Chia-Sui			Adrenal Myelolipomas Involved by Plasma Cell Myeloma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Myelolipoma; Adrenal gland; Plasma cell neoplasm; Myeloma; Lymphoma	LIPOMATOUS TUMORS; EXPERIENCE; LYMPHOMA	Objectives: To report the presence and evaluate the frequency of plasma cell neoplasms within adrenal myelolipomas. Methods: Adrenal myelolipomas within our institution were reviewed for the presence of hematologic neoplasia, and a review of the literature was performed. Results: Two (9%) of 23 adrenal myelolipomas were involved by plasma cell myeloma. The patients were 71 and 81 years old, one woman and one man, with tumors measuring 7 cm and 8.5 cm, respectively. Both tumors contained large aggregates of dysplastic plasma cells occupying at least one x10 field and demonstrated light chain restriction. Neither had an established diagnosis of plasma cell neoplasm previously. After receiving therapy, one patient exhibited a stable clinical course 1 year after diagnosis while the other died of disease 3 years later. Conclusions: We report the first two cases of adrenal myelolipoma involved by plasma cell myeloma, a rare and subtle finding that has significant clinical implications.	[Lin, Chieh-Yu; Levy, David; Higgins, John P. T.; Kunder, Christian A.; Kao, Chia-Sui] Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr,L235, Stanford, CA 94305 USA	Kao, CS (reprint author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr,L235, Stanford, CA 94305 USA.	cicao2@stanford.edu	Kunder, Christian/K-3212-2019				Arora K, 2016, CASE REP HEMATOL, DOI 10.1155/2016/7364951; BURROWS S, 1969, AM J CLIN PATHOL, V52, P733; Campbell MJ, 2017, ENDOCRINE, V58, P289, DOI 10.1007/s12020-017-1410-6; Jimenez MSC, 2014, ENDOCRINOL NUTR, V61, pE7, DOI 10.1016/j.endonu.2013.04.002; Dan D, 2012, G CHIR, V33, P62; Daneshmand Siamak, 2006, Urol J, V3, P71; Geng CY, 2013, ONCOL LETT, V5, P862, DOI 10.3892/ol.2012.1085; George SK, 2012, J TISSUE ENG REGEN M, V6, P127, DOI 10.1186/1752-1947-6-127; Gheith S, 2009, INT J CLIN EXP PATHO, V2, P95; Gurbuz E, 2013, BMJ CASE REP, V2013; Hagspiel KD, 2005, EUR RADIOL, V15, P1757, DOI 10.1007/s00330-004-2523-x; Hajiran Ali, 2014, World J Clin Cases, V2, P279, DOI 10.12998/wjcc.v2.i7.279; Han M, 1997, J UROLOGY, V157, P1213, DOI 10.1016/S0022-5347(01)64926-7; Hsu SW, 2012, KAOHSIUNG J MED SCI, V28, P377, DOI 10.1016/j.kjms.2012.02.005; Kenney PJ, 1998, RADIOLOGY, V208, P87, DOI 10.1148/radiology.208.1.9646797; Lam KY, 2001, J CLIN PATHOL, V54, P707, DOI 10.1136/jcp.54.9.707; Mitsui Yozo, 2014, Can Urol Assoc J, V8, pE104, DOI 10.5489/cuaj.1610; Montone KT, 2009, ENDOCR PRACT, V15, P128, DOI 10.4158/EP.15.2.128; Noll A, 2013, ANN CLIN LAB SCI, V43, P441; OLSSON CA, 1973, SURGERY, V73, P665; Pan Z, 2007, INTERNET J PATHOL, V7; Suarez-Penaranda JM, 2014, INT J SURG PATHOL, V22, P473, DOI 10.1177/1066896914521289; Wang J, 2014, INT J SURG PATHOL, V22, P731, DOI 10.1177/1066896914532538; Yamada S, 2011, PATHOL RES PRACT, V207, P192, DOI 10.1016/j.prp.2010.07.008; Zeng Y, 2016, INT J SURG PATHOL, V24, P177, DOI 10.1177/1066896915617027; Zhang XF, 2011, INT J GYNECOL PATHOL, V30, P460, DOI 10.1097/PGP.0b013e31821643a3; Zhao JP, 2014, CUAJ-CAN UROL ASSOC, V8, pE132, DOI 10.5489/cuaj.977	27	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					406	414		10.1093/AJCP/AQY068			9	Pathology	Pathology	GV4PB	WOS:000446081500004	30052719				2019-10-28	
J	Rudolf, J; Baron, J; Branda, J; Lee-Lewandrowski, E				Rudolf, Joseph; Baron, Jason; Branda, John; Lee-Lewandrowski, Elizabeth			Laboratory Testing for Tick-Borne Infections in a Large Northeastern Academic Medical Center An 11-Year Experience	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Lyme disease; Babesiosis; Anaplasmosis; Erlichiosis; Tick-borne infection	BORRELIA-MIYAMOTOI; UNITED-STATES; DISEASE	Objectives: We evaluated changes in the testing menu, volume, and positivity rates for tick-borne illnesses in a New England medical center over an 11-year time frame. Methods: Testing data were obtained by a retrospective review utilizing searchable data from a laboratory information system archive. Results: Testing for tick-borne infections (TBI) increased 5.3-fold over an 11-year time period and the number of positive test results increased threefold Annual rates for Lyme serology positivity varied from 14% to 29% and for western blot confirmation from 26% to 48%. Test volumes and the number of positive results increased for all TBI endemic to our region. Conclusions: Our results confirm national trends suggesting increasing rates of TBI and substantially increased testing This may reflect a greater incidence of TBI in our region andlor increased awareness of these infections.	[Rudolf, Joseph] Univ Minnesota, Dept Lab Med & Pathol, Med Sch, Minneapolis, MN 55455 USA; [Baron, Jason; Branda, John; Lee-Lewandrowski, Elizabeth] Massachusetts Gen Hosp, Dept Pathol, Div Clin Labs & Mol Med, Boston, MA 02114 USA; [Baron, Jason; Branda, John; Lee-Lewandrowski, Elizabeth] Harvard Med Sch, Boston, MA USA	Lee-Lewandrowski, E (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Gray 5 Chem, Boston, MA 02114 USA.	elewandrowski@partners.org					[Anonymous], LYM DIS GRAPHS; Berger KA, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-181; Centers for Disease Control and Prevention, LYM DIS; Centers for Disease Control and Prevention, TICKB DIS US; Centers for Disease Control and Prevention, BORR MAYON; Doucleff M, FORBIDDING FORECAST; Gugliotta JL, 2013, NEW ENGL J MED, V368, P240, DOI 10.1056/NEJMoa1209039; Hinckley AF, 2014, CLIN INFECT DIS, V59, P676, DOI 10.1093/cid/ciu397; Massachusetts Department of Public Health, TULAR; Massachusetts Health and Human Services, TICKB DIS GEN INF FA; Molloy PJ, 2015, ANN INTERN MED, V163, P91, DOI 10.7326/M15-0333	11	1	1	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					415	420		10.1093/AJCP/AQY067			6	Pathology	Pathology	GV4PB	WOS:000446081500005	30032283				2019-10-28	
J	Fang, H; Ketterling, RP; Hanson, CA; Pardanani, A; Kurtin, PJ; Chen, D; Greipp, PT; Howard, MT; King, RL; Van Dyke, DL; Reichard, KK				Fang, Hong; Ketterling, Rhett P.; Hanson, Curtis A.; Pardanani, Animesh; Kurtin, Paul J.; Chen, Dong; Greipp, Patricia T.; Howard, Matthew T.; King, Rebecca L.; Van Dyke, Daniel L.; Reichard, Kaaren K.			A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow A Single Institutional Experience	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Eosinophilia; Bone marrow; Hypereosinophilia; Algorithm; Test utilization	IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; TYROSINE KINASE INHIBITORS; SYSTEMIC MASTOCYTOSIS; IMATINIB MESYLATE; MYELOID/LYMPHOID NEOPLASM; FIP1L1-PDGFRA FUSION; MYELOID NEOPLASMS; LEUKEMIA; TRANSLOCATION; PREVALENCE	Objectives: Determine ancillary test utilization for the workup of isolated eosinophilia in otherwise morphologically unremarkable bone marrow (BM). Methods: We evaluated BM ancillary testing performed in cases with isolated eosinophilia and otherwise morphologically unremarkable BM. Cases with abnormal morphology (eg, dysplasia, basophilia) and/or findings suggestive of a disorder (eg, unexplained thromboses, lymphoma) are specifically excluded. Results: A total of 132 cases met inclusion criteria. Ten cases had an ancillary testing abnormality that warranted a more specific hematologic diagnosis: four cases of lymphocytic variant of hypereosinophilic syndrome, three cases of myeloid neoplasm with PDGFRA rearrangement, and one case each of myeloid neoplasm with PDGFRB rearrangement, chronic eosinophilic leukemia, and morphologically occult systemic mastocytosis. No cases revealed a cryptic PDGFRB or BCR/ABL1 rearrangement or JAK2 V617F mutation. Conclusions: Findings from our institutional experience support initial testing in isolated eosinophilia with otherwise unremarkable BM to include PDGFRA rearrangement, tryptase/CD25 immunohistochemistry, cytogenetics, and T-cell flow cytometry/receptor gene rearrangement. This approach achieves diagnostic quality and test utilization efficiency in our clinical practice.	[Fang, Hong; Hanson, Curtis A.; Kurtin, Paul J.; Chen, Dong; Howard, Matthew T.; King, Rebecca L.; Reichard, Kaaren K.] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA; [Ketterling, Rhett P.; Greipp, Patricia T.; Van Dyke, Daniel L.] Mayo Clin, Div Lab Genet & Genom, Rochester, MN 55905 USA; [Pardanani, Animesh] Mayo Clin, Div Hematol, Rochester, MN 55905 USA	Reichard, KK (reprint author), Mayo Clin, Hilton 8-00C,200 First St SW, Rochester, MN 55905 USA.	reichard.kaaren@mayo.edu	Chen, Dong/V-8825-2019				Ault P, 2002, LEUKEMIA RES, V26, P881, DOI 10.1016/S0145-2126(02)00046-2; Boyer DF, 2016, ARCH PATHOL LAB MED, V140, P1060, DOI 10.5858/arpa.2016-0223-RA; Butt NM, 2017, BRIT J HAEMATOL, V176, P553, DOI 10.1111/bjh.14488; Chonabayashi K, 2014, ANN HEMATOL, V93, P535, DOI 10.1007/s00277-013-1843-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cortes J, 2003, BLOOD, V101, P4714, DOI 10.1182/blood-2003-01-0081; Falchi L, 2014, LEUKEMIA, V28, P2090, DOI 10.1038/leu.2014.168; Foucar K., 2010, BONE MARROW PATHOLOG; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Gotlib J, 2017, HEMATOL ONCOL CLIN N, V31, P643, DOI 10.1016/j.hoc.2017.04.009; Gotlib J, 2015, AM J HEMATOL, V90, P1078, DOI 10.1002/ajh.24196; Grand FH, 2007, EXP HEMATOL, V35, P1723, DOI 10.1016/j.exphem.2007.07.002; Greipp PT, 2004, CANCER GENET CYTOGEN, V153, P170, DOI 10.1016/j.cancergencyto.2004.01.013; Hanson CA, 2008, AM J CLIN PATHOL, V129, P478, DOI 10.1309/2VQLDHVJB9YW83KB; Helbig G, 2016, EUR J INTERN MED, V32, pE19, DOI 10.1016/j.ejim.2016.02.024; Helbig G, 2012, MED ONCOL, V29, P1073, DOI 10.1007/s12032-011-9831-1; Jawhar M, 2017, LEUKEMIA, V31, P2271, DOI 10.1038/leu.2017.240; Johnson Ryan C, 2013, Surg Pathol Clin, V6, P767, DOI 10.1016/j.path.2013.08.008; Jurgens DJ, 2004, HAEMATOLOGICA, V89, P1394; Khoury P, 2018, J ALLER CL IMM-PRACT, V6, P190, DOI 10.1016/j.jaip.2017.06.006; Klion AD, 2015, BLOOD, V126, P1069, DOI 10.1182/blood-2014-11-551614; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Meltzer E, 2008, AM J TROP MED HYG, V78, P702, DOI 10.4269/ajtmh.2008.78.702; Silva PM, 2015, EUR ANN ALLERGY CLIN, V47, P15; Pardanani A, 2004, BLOOD, V104, P3038, DOI 10.1182/blood-2004-03-0787; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Patterer V, 2013, ANN HEMATOL, V92, P759, DOI 10.1007/s00277-013-1695-3; Reiter A, 2017, BLOOD, V129, P704, DOI 10.1182/blood-2016-10-695973; Roufosse F, 2007, IMMUNOL ALLERGY CLIN, V27, P389, DOI 10.1016/j.iac.2007.07.002; Shaffer LG, 2009, INT SYSTEM HUMAN CYT; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tefferi A, 2006, BRIT J HAEMATOL, V133, P468, DOI 10.1111/j.1365-2141.2006.06038.x; Tirado CA, 2016, BIOMARK RES, V4, DOI 10.1186/s40364-016-0070-7; Ustun C, 2011, LEUKEMIA RES, V35, P1143, DOI 10.1016/j.leukres.2011.05.006; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Verstovsek S, 2008, CLIN CANCER RES, V14, P3906, DOI 10.1158/1078-0432.CCR-08-0366; Verstovsek S, 2013, EUR J HAEMATOL, V90, P89, DOI 10.1111/ejh.12043; Vu H, 2006, LEUKEMIA, V20, P1414, DOI 10.1038/sj.leu.2404266; Walz C, 2011, BLOOD, V118, P2239, DOI 10.1182/blood-2011-03-343426; Wang SA, 2017, HAEMATOLOGICA, V102, P1352, DOI 10.3324/haematol.2017.165340; Wang SA, 2016, MODERN PATHOL, V29, P854, DOI 10.1038/modpathol.2016.75; Wiktor AE, 2011, LEUKEMIA RES, V35, P1297, DOI 10.1016/j.leukres.2011.05.002; Zaliova M, 2016, HAEMATOLOGICA, V101, P1082, DOI 10.3324/haematol.2016.144345	44	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					421	431		10.1093/AJCP/AQY064			11	Pathology	Pathology	GV4PB	WOS:000446081500006	30032299				2019-10-28	
J	Rodriguez-Trujillo, A; Marti, C; Angeles, MA; Sierra, A; Esteve, R; Saco, A; Barnadas, E; Marimon, L; Nicolas, I; Torne, A; Ordi, J; del Pino, M				Rodriguez-Trujillo, Adriano; Marti, Cristina; Angeles, Martina Aida; Sierra, Adriana; Esteve, Roser; Saco, Adela; Barnadas, Esther; Marimon, Lorena; Nicolas, Inmaculada; Torne, Aureli; Ordi, Jaume; del Pino, Marta			Value of HPV 16/18 Genotyping and p16/Ki-67 Dual Staining to Predict Progression to HSIL/CIN2+in Negative Cytologies From a Colposcopy Referral Population	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cervical cancer; HPV genotyping; p16/Ki-67 dual staining; Colposcopy; Random biopsy; HSIL/CIN2+	CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS GENOTYPE; CLINICAL-PRACTICE; CANCER; WOMEN; RISK; TERMINOLOGY; LESIONS; BIOPSY; PERFORMANCE	Objectives: To assess the prognostic value of human papillomavirus (HPV) 16/18 genotyping and p161Ki-67 dual staining cytology in high-risk HPV (hrHPV)-positive women with no lesion or minor abnormalities. Methods: We evaluated progression to high-grade squamous intraepithelial lesionlcervical intraepithelial neoplasia grades 2 to 3 or cervical cancer (HSIL/CIN2+), persistencelregression of hrHPV infection in women referred to colposcopy showing hrHPV infection, histology diagnosis different from HSIL/CIN2+, and negative cytology. HPV 16/18 genotyping and dual staining were performed in liquid-based cytologic specimens obtained on the first visit. Results: Progression was observed in 16 (8.0%) of 200 women. Those with HPV 16/18 infection had an increased risk of progression compared with women infected by other hrHPV types, and they also showed more persistence. However, no association was observed between progression or persistence and the result of the dual staining. Conclusions: HPV 16/18-positive women with no lesions or minor abnormalities are at high risk of progression to HSIL/CIN2+ and hrHPV persistence.	[Rodriguez-Trujillo, Adriano; Marti, Cristina; Angeles, Martina Aida; Nicolas, Inmaculada; Torne, Aureli; del Pino, Marta] Univ Barcelona, Inst Clin Gynaecol Obstet & Neonatol, Hosp Clin, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain; [Sierra, Adriana; Esteve, Roser; Saco, Adela; Ordi, Jaume] Univ Barcelona, Hosp Clin, Dept Pathol, Barcelona, Spain; [Barnadas, Esther; Marimon, Lorena; Nicolas, Inmaculada; Ordi, Jaume] Inst Salut Global Barcelona ISGlobal, Barcelona, Spain	del Pino, M (reprint author), Univ Barcelona, Dept Gynecol & Obstet, Hosp Clin Prov, Villarroel 170-Esc 5 3, E-08036 Barcelona, Spain.	mdelpino@clinic.ub.es	Ordi, Jaume/X-4524-2018	Ordi, Jaume/0000-0002-4820-7954; , Inmaculada/0000-0001-9600-8434	Instituto de Salud Carlos III (ICSIII)-Fondo de Investigacion Sanitaria; ERDF "One Way to Europe" [PI15/00546, PI17/00772]	This work was supported by Instituto de Salud Carlos III (ICSIII)-Fondo de Investigacion Sanitaria and ERDF "One Way to Europe" (PI15/00546 and PI17/00772).	Blade AT, 2014, PROG OBSTET GINEC S1, V14, P1, DOI DOI 10.1016/S0304-5013(14)73068-7; Bornstein J, 2012, OBSTET GYNECOL, V120, P166, DOI 10.1097/AOG.0b013e318254f90c; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Cuzick J, 2000, BRIT J CANCER, V83, P561, DOI 10.1054/bjoc.2000.1375; Cuzick J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/ijc.21955; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; del Pino M, 2010, OBSTET GYNECOL, V116, P1324, DOI 10.1097/AOG.0b013e3181f74885; Dijkstra MG, 2014, ANN ONCOL, V25, P927, DOI 10.1093/annonc/mdt538; Geraets DT, 2009, J CLIN VIROL, V46, pS21, DOI 10.1016/S1386-6532(09)70297-5; Halfon P, 2013, ARCH VIROL, V158, P1143, DOI 10.1007/s00705-012-1584-4; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS56, DOI 10.1097/LGT.0b013e318285437b; Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0; Khan MJ, 2005, JNCI-J NATL CANCER I, V97, P1072, DOI 10.1093/jnci/dji187; Loghavi S, 2013, DIAGN CYTOPATHOL, V41, P582, DOI 10.1002/dc.22900; Massad LS, 2003, GYNECOL ONCOL, V89, P424, DOI 10.1016/S0090-8258(03)00082-9; Nam K, 2010, J LOW GENIT TRACT DI, V14, P346, DOI 10.1097/LGT.0b013e3181e9635b; Ordi J, 2014, CANCER CYTOPATHOL, V122, P227, DOI 10.1002/cncy.21366; Petry KU, 2011, GYNECOL ONCOL, V121, P505, DOI 10.1016/j.ygyno.2011.02.033; Rijkaart DC, 2012, INT J CANCER, V130, P602, DOI 10.1002/ijc.26056; Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Tatti S, 2013, OBSTET GYN CLIN N AM, V40, P235, DOI 10.1016/j.ogc.2013.02.002; Thomsen LT, 2015, INT J CANCER, V137, P193, DOI 10.1002/ijc.29374; Tjalma WAA, 2017, EUR J OBSTET GYN R B, V210, P275, DOI 10.1016/j.ejogrb.2017.01.009; Uijterwaal MH, 2015, INT J CANCER, V136, P2361, DOI 10.1002/ijc.29290; van der Marel J, 2014, GYNECOL ONCOL, V135, P201, DOI 10.1016/j.ygyno.2014.08.040; van der Marel J, 2015, J LOW GENIT TRACT DI, V19, P282, DOI 10.1097/LGT.0000000000000124; Vrdoljak-Mozetic D, 2015, CYTOPATHOLOGY, V26, P10, DOI 10.1111/cyt.12121; Waldstrom M, 2013, CANCER CYTOPATHOL, V121, P136, DOI 10.1002/cncy.21233; Wentzensen N, 2017, J LOW GENIT TRACT DI, V21, P230, DOI 10.1097/LGT.0000000000000334; Wentzensen N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv257; Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; Wright TC, 2015, GYNECOL ONCOL, V136, P189, DOI 10.1016/j.ygyno.2014.11.076	36	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					432	440		10.1093/AJCP/AQY071			9	Pathology	Pathology	GV4PB	WOS:000446081500007	30052715				2019-10-28	
J	Khoury, T; Peng, X; Yan, L; Wang, D; Nagrale, V				Khoury, Thaer; Peng, Xuan; Yan, Li; Wang, Dan; Nagrale, Vidya			Tumor-Infiltrating Lymphocytes in Breast Cancer Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Tumor infiltrating lymphocytes; Breast cancer; Heterogeneity; Interobserver variability; Core needle biopsy; Full-face section	PROGNOSTIC VALUE; FREE SURVIVAL; T-CELLS; CHEMOTHERAPY; TRASTUZUMAB; RELIABILITY; RECURRENCE; AGREEMENT; TRIAL	Objectives: The aims were to evaluate breast cancer (BC) tumor-infiltrating lymphocytes (TILs ) interobserver variability, heterogeneity, and the fidelity of scoring TILs in core needle biopsy (CNB). Methods: Matching CNB and two full-face sections (FFSs) of BC cases (n = 100) were independently reviewed by two pathologists. Percentage of stromal lymphocytes (TIL-str) and intratumoral lymphocytes (iTu-Ly) were recorded. Results: The weighted lti values for the degree of agreement between both raters were 0.53 to 0.71. However, there was a slight improvement in the interobserver variability for TIL-str and slight decline in iTu-Ly when ER+/HER2- cases were excluded The intraclass correlation coefficient for FFS1 vs FFS2 was 0.91 for TIL-str and 0.96 for iTu-Ly. Spearman correlation coefficient for CNB vs FFS1/FFS2 was 0.81 for TIL-str and 0.79 for iTu-Ly. Conclusions: We conclude that the agreement in TILs scoring between the raters is acceptable. Caution should be practiced when scoring iTu-Ly in CNBs.	[Khoury, Thaer; Nagrale, Vidya] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Peng, Xuan; Yan, Li; Wang, Dan] Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA	Khoury, T (reprint author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA.	khoury@roswellpark.org					Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Buisseret L, 2017, MODERN PATHOL, V30, P1204, DOI 10.1038/modpathol.2017.43; Denkert C, 2016, MODERN PATHOL, V29, P1155, DOI 10.1038/modpathol.2016.109; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Issa-Nummer Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079775; Khoury T, 2018, APPL IMMUNOHISTO M M, V26, P523, DOI 10.1097/PAI.0000000000000466; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mani NL, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0737-x; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276; Ocana A, 2015, J CLIN ONCOL, V33, P1298, DOI 10.1200/JCO.2014.59.7286; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Perez EA, 2016, JAMA ONCOL, V2, P56, DOI 10.1001/jamaoncol.2015.3239; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Salgado R, 2015, JAMA ONCOL, V1, P448, DOI 10.1001/jamaoncol.2015.0830; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Tramm T, 2018, ACTA ONCOL, V57, P90, DOI 10.1080/0284186X.2017.1403040; Wang K, 2017, HUM PATHOL, V69, P110, DOI 10.1016/j.humpath.2017.09.012; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	23	0	0	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					441	450		10.1093/AJCP/AQY069			10	Pathology	Pathology	GV4PB	WOS:000446081500008	30052720				2019-10-28	
J	Jialal, I; Pahwa, R				Jialal, Ishwarlal; Pahwa, Roma			Therapeutic Monoclonal Antibodies and the Value of the Free Light Chain Assay in Myeloma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Letter									[Jialal, Ishwarlal] VA Med Ctr, Sect Clin Chem, Mather, CA 95655 USA; [Jialal, Ishwarlal] Calif Northstate Univ, Coll Med, Elk Grove, CA 95757 USA; [Pahwa, Roma] NCI, Bethesda, MD 20892 USA	Jialal, I (reprint author), VA Med Ctr, Sect Clin Chem, Mather, CA 95655 USA.; Jialal, I (reprint author), Calif Northstate Univ, Coll Med, Elk Grove, CA 95757 USA.						Carr-Smith HD, 2016, CLIN CHEM LAB MED, V54, P997, DOI 10.1515/cclm-2015-1068; Jialal I, 2017, CLIN CHEM LAB MED, V55, pE27, DOI 10.1515/cclm-2016-0679; Rosenberg AS, 2016, CLIN BIOCHEM, V49, P1202, DOI 10.1016/j.clinbiochem.2016.07.016; Tang F, 2018, AM J CLIN PATHOL, V150, P121, DOI [10.1093/AJCP/AQY037, 10.1093/ajcp/aqy037]	4	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					468	468		10.1093/ajcp/aqy110			1	Pathology	Pathology	GV4PB	WOS:000446081500011	30184092				2019-10-28	
J	Rodriguez-Trujillo, A; Marti, C; Angeles, MA				Rodriguez-Trujillo, A.; Marti, C.; Angeles, M. A.			Value of HPV 16/18 genotyping and p16/Ki-67 dual staining to predict progression to HSIL/CIN2+ in negative cytologies from a colposcopy referral population (vol 150, pg 432, 2018)	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Correction																TRUJILLO R, 2018, AM J CLIN PATHOL, V150, P432	1	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	NOV	2018	150	5					470	470		10.1093/ajcp/aqy145			1	Pathology	Pathology	GV4PB	WOS:000446081500013					2019-10-28	
J	Kurose, N; Takenaka, M; Yamashita, M; Shimaguchi, C; Nakano, M; Britni, B; Guo, X; Futatsuya, C; Shioya, A; Yamada, S				Kurose, Nozomu; Takenaka, Michiho; Yamashita, Manabu; Shimaguchi, Chie; Nakano, Mariko; Britni, Bryant; Guo, Xin; Futatsuya, Chizuru; Shioya, Akihiro; Yamada, Sohsuke			A case report of infantile cystic nephroblastoma	DIAGNOSTIC PATHOLOGY			English	Article						Cyst; Nephroblastoma (NB); Infant; Peritoneal fluid; Cytology	CHILDRENS ONCOLOGY GROUP; HISTOLOGY WILMS-TUMOR; RUPTURE	Background: Nephroblastoma (NB) is a malignant embryonal neoplasm derived from nephrogenic blastemal cells. NB usually forms a solid mass, but in extremely rare cases, it may show cystic changes. Case presentation: A six-month-old girl with persistent high fevers was found to have pyuria and bacteriuria. Ultrasonography revealed multilocular cysts in the right kidney. Right nephrectomy was performed with cyst wall rupture during surgery. An intraoperative rapid diagnosis, based on peritoneal fluid cytology, confirmed three components of blastemal, stromal, and epithelial cells. The blastemal cells were dyshesive, with scant to no cytoplasm and were the predominant cell type. The spindle-shaped stromal cells were arranged in fascicles. The epithelial cells demonstrated tubular structures. Macroscopically, the resected cystic tumor measured 80 mm in maximum diameter with a prominently thin cyst wall, but solid areas were also apparent. Histologically, the tumor was diagnosed as cystic NB (blastemal-predominant) displaying a triphasic pattern. Hyperchromatic nuclei and apoptotic bodies were found. The clinical stage classification of Japan Wilms Tumor Study group was 3. The patient was treated with chemotherapy and radiotherapy. Tumor recurrence and metastasis have not been observed in the 8 months since surgery. Conclusion: This is an extremely rare case of infantile cystic NB. We diagnosed the NB cells that appeared in the peritoneal fluid by intraoperative rapid cytology. Cytological examination proved to be a very useful technique for determining the clinical stage of NB. Additionally, we propose that massive tumor degeneration and necrosis be considered as a pathogenic mechanism of cyst formation in NB.	[Kurose, Nozomu; Guo, Xin; Futatsuya, Chizuru; Shioya, Akihiro; Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan; [Takenaka, Michiho; Yamashita, Manabu; Shimaguchi, Chie; Nakano, Mariko] Kanazawa Med Univ, Dept Pathol, Uchinada, Ishikawa, Japan; [Britni, Bryant] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT USA	Kurose, N; Yamada, S (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	k-nozomu@kanazawa-med.ac.jp; sohsuke@kanazawa-med.ac.jp					Adjei O N, 1996, Radiat Med, V14, P287; BABUT JM, 1993, EUR J PEDIATR SURG, V3, P157, DOI 10.1055/s-2008-1063533; BECKWITH JB, 1993, MED PEDIATR ONCOL, V21, P158, DOI 10.1002/mpo.2950210303; Bindhu J, 2010, J POSTGRAD MED, V56, P28, DOI 10.4103/0022-3859.62436; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; Ehrlich PF, 2013, J CLIN ONCOL, V31, P1196, DOI 10.1200/JCO.2011.41.1165; Fujita K, 2003, INT J UROL, V10, P492, DOI 10.1046/j.1442-2042.2003.00668.x; Fukuzawa H, 2017, PEDIATR SURG INT, V33, P91, DOI 10.1007/s00383-016-4000-4; Gow KW, 2013, J PEDIATR SURG, V48, P34, DOI 10.1016/j.jpedsurg.2012.10.015; HUSER J, 1990, MODERN PATHOL, V3, P321; Khanna G, 2013, RADIOLOGY, V266, P610, DOI 10.1148/radiol.12120670; Moch H, 2016, WHO CLASSIFICATION T; William MM, 2004, TUMORS KIDNEY BLADDE, P38	13	0	0	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 27	2018	13								84	10.1186/s13000-018-0761-5			5	Pathology	Pathology	GY2WP	WOS:000448405500001	30368245	DOAJ Gold, Green Published			2019-10-28	
J	Flores, LC; Roman, MG; Cunningham, GM; Cheng, C; Dube, S; Allen, C; Van Remmen, H; Hubbard, GB; Saunders, TL; Ikeno, Y				Flores, Lisa C.; Roman, Madeline G.; Cunningham, Geneva M.; Cheng, Christie; Dube, Sara; Allen, Colton; Van Remmen, Holly; Hubbard, Gene B.; Saunders, Thomas L.; Ikeno, Yuji			Continuous overexpression of thioredoxin 1 enhances cancer development and does not extend maximum lifespan in male C57BL/6 mice	PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES			English	Article						Thioredoxin (Trx); transgenic mouse (Tg); oxidative stress; aging; cancer	FATAL NEOPLASTIC DISEASES; EARLY EMBRYONIC LETHALITY; ENZYMATIC REDUCTION; MAMMALIAN PEROXIREDOXIN; MITOCHONDRIAL-FUNCTION; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; DELAYED OCCURRENCE; OXIDATIVE STRESS; BINDING-ACTIVITY	We examined the effects of continuous overexpression of thioredoxin (Trx) 1 on aging in Trx1 transgenic mice [Tg(TXN)(+/0)]. This study was conducted to test whether increased thioredoxin expression over the lifespan in mice would alter aging and age-related pathology because our previous study demonstrated that Tg(act-TXN)(+/0) mice had no significant maximum life extension, possibly due to the use of actin as a promoter, which may have resulted in loss of Trx1 overexpression during aging. To test this hypothesis, we generated new Trx1 transgenic mice using a fragment of the human genome containing the TXN gene with an endogenous promoter to ensure continuous overexpression of Trx1 throughout the lifespan. Universal overexpression of Trx1 was observed, and Trx1 overexpression was maintained during aging (up to 22-24months old) in the Tg(TXN)(+/0) mice. The levels of Trx1 are significantly higher (approximately 4 to 31 fold) in all of the tissues examined in the Tg(TXN)(+/0) mice compared to the wild-type (WT) littermates. The overexpression of Trx1 did not cause any changes in the levels of Trx2, glutaredoxin, glutathione, or other major antioxidant enzymes. The survival study demonstrated that male Tg(TXN)(+/0) mice slightly extended the earlier part of the lifespan compared to WT littermates, but no significant life extension was observed over the lifespan. The cross-sectional pathological analysis (22-25months old) showed that Tg(TXN)(+/0) mice had a significantly higher severity of lymphoma and more tumor burden than WT mice, which was associated with the suppression of the apoptosis signal-regulating kinase 1 (ASK1) pathway. Our findings suggest that the increased levels of Trx1 over the lifespan in Tg(TXN)(+/0) mice showed some beneficial effects (slight extension of lifespan) in the earlier part of life but had no significant effects on median or maximum lifespans, and increased Trx1 levels enhanced tumor development in old mice.	[Flores, Lisa C.; Roman, Madeline G.; Cunningham, Geneva M.; Cheng, Christie; Dube, Sara; Allen, Colton; Hubbard, Gene B.; Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA; [Van Remmen, Holly] Oklahoma Med Res Fdn, Aging & Metab Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Hubbard, Gene B.; Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Saunders, Thomas L.] Univ Michigan, Transgen Anim Model Core, Ann Arbor, MI 48109 USA; [Ikeno, Yuji] South Texas Vet Hlth Care Syst, GRECC, Audie L Murphy VA Hosp, San Antonio, TX USA	Ikeno, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.	ikeno@uthscsa.edu		Saunders, Thom/0000-0003-2015-101X	VA Merit Review grant from the Department of Veteran Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG13319]; American Federation for Aging Research AFAR; Glenn Foundation	This research was supported by the VA Merit Review grant from the Department of Veteran Affairs (Y.I.), NIH grant [AG13319] (Y.I.), The American Federation for Aging Research AFAR) grant (Y.I.), and a grant from the Glenn Foundation (Y.I.).	ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Andersen P. K., 1993, STAT MODELS BASED CO; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; ASAHI T, 1961, J BIOL CHEM, V236, P1830; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BLACK S, 1960, J BIOL CHEM, V235, P2910; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Brot N, 2000, BIOPOLYMERS, V55, P288, DOI 10.1002/1097-0282(2000)55:4<288::AID-BIP1002>3.0.CO;2-M; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; Hsieh CC, 2006, FASEB J, V20, P259, DOI 10.1096/fj.05-4376com; Ikeno Y, 2005, J GERONTOL A-BIOL, V60, P1510, DOI 10.1093/gerona/60.12.1510; Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; KIM KW, 1988, J BIOL CHEM, V263, P4704; Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; Miranda-Vizuete A, 2006, FEBS LETT, V580, P484, DOI 10.1016/j.febslet.2005.12.046; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Perez VI, 2008, FREE RADICAL BIO MED, V44, P882, DOI 10.1016/j.freeradbiomed.2007.11.018; Perez VI, 2011, J GERONTOL A-BIOL, V66, P1286, DOI 10.1093/gerona/glr125; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Rebrin I, 2007, BRAIN RES, V1127, P10, DOI 10.1016/j.brainres.2006.10.040; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; Svensson MJ, 2007, HEREDITAS, V144, P25, DOI 10.1111/j.2007.0018-0661.01990.x; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87; Yoshihara E, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00514	46	1	1	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2001-0001			PATHOBIOL AGING AGE	Pathobiol. Aging Age-relat. Dis.	OCT 23	2018	8								1533754	10.1080/20010001.2018.1533754			12	Pathology	Pathology	GY5GU	WOS:000448601100001	30370017	DOAJ Gold, Green Published			2019-10-28	
J	Bailey, DN; Cohen, S; Gotlieb, A; Lipscomb, MF; Sanfilippo, F				Bailey, David N.; Cohen, Stanley; Gotlieb, Avrum; Lipscomb, Mary F.; Sanfilippo, Fred			What Advice Current Pathology Chairs Seek From Former Chairs	ACADEMIC PATHOLOGY			English	Article						consultation; advice; pathology chairs; senior fellows; former chairs		The 2018 Association of Pathology Chairs annual meeting included a panel discussion of Association of Pathology Chairs senior fellows (former chairs of academic departments of pathology who have remained active in Association of Pathology Chairs) about the type of advice that current (sitting) pathology chairs ask them. To inform the panel discussion, information was obtained from the senior fellows by e-mail and subsequent conference call. Of the 33 respondents, 24 (73%) had provided consultation advice (9, <5; 11, 5-10; 2, 10-20; and 2, >20). Most (>75%) of the consultations were provided face-to-face and outside the framework of Association of Pathology Chairs, with 70% of those seeking advice being well known by the consultant(s). Of the senior fellows providing advice, 71% had themselves sought consultation from former pathology chairs and 75% from nonpathology chairs. Modest correlation was found between the number of consultations senior fellows sought when they were chairs and the number of consultations they subsequently provided. The most frequent topics of consultation were strategic planning, balancing the missions, setting department priorities, recruitment of faculty and staff, conflict management, issues specific to new chairs, and resource (money/space) issues. Those who had provided such advice the longest and to the most people indicated that there was no significant change in the type of questions asked over time. Former department chairs can be a valuable source of counseling for current chairs, and organizations of department chairs should consider formalizing the use of these individuals as consultants to sitting chairs.	[Bailey, David N.] Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Cohen, Stanley] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ USA; [Gotlieb, Avrum] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Lipscomb, Mary F.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Sanfilippo, Fred] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Bailey, DN (reprint author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dnbailey@ucsd.edu					[Anonymous], G WASH U AC LEAD POR; Bailey DN, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516673651; Bailey DN, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517733734; Benoit P, DEP CHAIR ONLINE RES; DeLander GE, 2017, AM J PHARM EDUC, V81, DOI 10.5688/ajpe81343; Lieff S, 2013, ACAD MED, V88, P960, DOI 10.1097/ACM.0b013e318294ff36; Sanfilippo F, 2018, ACAD PATHOL, V5, DOI 10.1177/2374289518765462; Stanford University, TOM PROF POST ADV FU; Wolverton M, 2005, J HIGH EDUC POLICY M, V27, P227, DOI 10.1080/13600800500120126	9	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	OCT 22	2018	5								2374289518807397	10.1177/2374289518807397			4	Pathology	Pathology	HC9GW	WOS:000452115000001	30364779	DOAJ Gold, Green Published			2019-10-28	
J	Hartmann, K; Schlombs, K; Laible, M; Gurtler, C; Schmidt, M; Sahin, U; Lehr, HA				Hartmann, Kerstin; Schlombs, Kornelia; Laible, Mark; Guertler, Claudia; Schmidt, Marcus; Sahin, Ugur; Lehr, Hans-Anton			Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue	DIAGNOSTIC PATHOLOGY			English	Article						Breast cancer; MammaTyper; RT-qPCR; DCIS; Tumor cell content; Non-neoplastic tissue; Tissue heterogeneity	EXPRESSION; RNA; ESTROGEN; RECOMMENDATIONS; PROGESTERONE; PROGRESSION; SAMPLES; PCR; ER	BackgroundTissue heterogeneity in formalin-fixed paraffin-embedded (FFPE) breast cancer specimens may affect the accuracy of reverse transcription quantitative real-time PCR (RT-qPCR). Herein, we tested the impact of tissue heterogeneity of breast cancer specimen on the RT-qPCR-based gene expression assay MammaTyper (R).MethodsMammaTyper (R) quantifies the mRNA expression of the four biomarkers ERBB2, ESR1, PGR, and MKI67. Based on pre-defined cut-off values, this molecular in vitro diagnostic assay permits binary marker classification and determination of breast cancer subtypes as defined by St Gallen 2013. In this study, we compared data from whole FFPE sections with data obtained in paired RNA samples after enrichment for invasive carcinoma via macro- or laser-capture micro-dissection.ResultsCompared to whole sections, removal of surrounding adipose tissue by macrodissection generated mean absolute 40-ddCq differences of 0.28-0.32cycles for all four markers, with 90% concordant binary classifications. The mean raw marker Cq values in the adipose tissue were delayed by 6 to 7cycles compared with the tumor-enriched sections, adding a trivial linear fold change of 1.0078 to 1.0156. Comparison of specimens enriched for invasive tumor with whole sections with as few as 20% tumor cell content resulted in mean absolute differences that remained on average below 0.59 Cq. The mean absolute difference between whole sections containing up to 60% ductal carcinoma in situ (DCIS) and specimens after dissection of DCIS was only 0.16-0.25cycles, although there was a tendency for higher gene expression in DCIS. Observed variations were related to small size of samples and proximity of values to the limit of detection.ConclusionExpression of ESR1, PGR, ERBB2 and MKI67 by MammaTyper (R) is robust in clinical FFPE samples. Assay performance was unaffected by adipose tissue and was stable in samples with as few as 20% tumor cell content and up to 60% DCIS.	[Hartmann, Kerstin; Schlombs, Kornelia; Laible, Mark; Guertler, Claudia] BioNTech Diagnost GmbH, Goldgrube 12, D-55131 Mainz, Germany; [Schmidt, Marcus] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Langenbeckstr 1, D-55131 Mainz, Germany; [Sahin, Ugur] BioNTech AG, Goldgrube 12, D-55131 Mainz, Germany; [Lehr, Hans-Anton] Inst Pathol, Med Campus Bodensee,Rontgenstr 2, D-88048 Friedrichshafen, Germany	Hartmann, K (reprint author), BioNTech Diagnost GmbH, Goldgrube 12, D-55131 Mainz, Germany.	kerstin.hartmann@biontech.de	Schmidt, Marcus/H-3383-2013	Schmidt, Marcus/0000-0003-1365-2414			Duffy MJ, 2017, EUR J CANCER, V75, P284, DOI 10.1016/j.ejca.2017.01.017; Elloumi F, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-54; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fountzilas G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-212; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Graham K, 2011, CLIN CANCER RES, V17, P236, DOI 10.1158/1078-0432.CCR-10-1369; Gupta S, 2018, LAB INVEST, V98, P1076, DOI 10.1038/s41374-018-0064-1; Hagemann IS, 2016, ARCH PATHOL LAB MED, V140, P815, DOI 10.5858/arpa.2016-0051-RA; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI 10.1043/1543-2165-134.6.907; Kennedy S, 2011, PCR TROUBLESHOOTING AND OPTIMIZATION: THE ESSENTIAL GUIDE, P1; Kohrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188; Kotoula V, 2013, VIRCHOWS ARCH, V462, P141, DOI 10.1007/s00428-012-1357-1; Laible M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2476-x; LCUa J, 2005, BASIC HISTOLOGY, P123; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mee BC, 2011, BIOPRESERV BIOBANK, V9, P389, DOI 10.1089/bio.2011.0034; Nielsen T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-177; Palmieri C, 2004, J MOL ENDOCRINOL, V33, P35, DOI 10.1677/jme.0.0330035; Pandey PR, 2010, FRONT BIOSCI-LANDMRK, V15, P226, DOI 10.2741/3617; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Poremba C, 2014, VIRCHOWS ARCH, V465, P409, DOI 10.1007/s00428-014-1652-0; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Schleifman EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088401; Schobesberger M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-343; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sinn HP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3111-1; Stahlberg A, 2014, EXPERT REV MOL DIAGN, V14, P323, DOI 10.1586/14737159.2014.901154; Tamimi RM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2128; Tramm T, 2013, VIRCHOWS ARCH, V463, P775, DOI 10.1007/s00428-013-1486-1; Varga Z, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0848-z; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Viale G, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.27_suppl.32; Waldmann A, 2014, GEBURTSH FRAUENHEILK, V74, P361, DOI 10.1055/s-0033-1360263; Wilson TR, 2014, BREAST CANCER RES TR, V148, P315, DOI 10.1007/s10549-014-3163-8; Wirtz RM, 2016, BREAST CANCER RES TR, V157, P437, DOI 10.1007/s10549-016-3835-7	36	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 20	2018	13								83	10.1186/s13000-018-0760-6			10	Pathology	Pathology	GX7GO	WOS:000447933500002	30342538	DOAJ Gold, Green Published			2019-10-28	
J	Wang, XG; Ng, CS; Chen, CM; Yu, GY; Yin, WH				Wang, Xingen; Ng, Chi-Sing; Chen, Cuimin; Yu, Guangyin; Yin, Weihua			An unusual case report of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression involving the gastrointestinal tract and bone marrow	DIAGNOSTIC PATHOLOGY			English	Article						Indolent T-cell lymphoproliferative disorder; Gastrointestinal tract; Aberrant CD20 expression	LYMPHOMA; INFILTRATION; FEATURES; DISEASE	BackgroundIndolent T-cell proliferative disorder of the GIT is a rare and provisional entity in the revised WHO 2016 classification. The patients usually have prolonged survival with persistent disease even without any treatment.Case presentationThe 46years old male patient has been followed up for more than 6years without chemotherapy. Repeated gastrointestinal biopsies showed expansion of the lamina propria extending to the submucosa by small to medium sized lymphocytes with minimal cytologic atypia. The lymphoid cells were positive for CD3, CD43, TIA-1, CD2, CD7 and the B-cell marker CD20; but negative for CD4, CD8, PAX5, CD56, cyclinD1, granzyme (GraB) and Epstein Barr virus-encoded RNA (EBER). Ki-67(MIB1) index was less than 10%. Molecular tests demonstrated a clonal rearrangement for T-cell receptor (TCR ) gene but immunoglobulin chain (IgH, IgK, IgL) gene remained germline. Recognition of possible aberrant CD20 expression in indolent T-cell LPD is important to avoid potential diagnostic pitfall and improper treatment.ConclusionsWe present an unusual case of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression, Recognition of this unusual immunophenotype of indolent T-cell LPD of GI helps to eschew misdiagnosis of B-cell and other high grade lymphomas and inappropriate aggressive treatment.	[Wang, Xingen; Chen, Cuimin; Yu, Guangyin; Yin, Weihua] Peking Univ, Dept Pathol, Shenzhen Hosp, Lianhua Rd 1120, Shenzhen 518036, Peoples R China; [Ng, Chi-Sing] St Teresas Hosp, Dept Pathol, Ma Tau Wai, Hong Kong, Peoples R China	Yin, WH (reprint author), Peking Univ, Dept Pathol, Shenzhen Hosp, Lianhua Rd 1120, Shenzhen 518036, Peoples R China.	wangxg_77@163.com					Anamarija M, 2013, BLOOD, V122, P3599, DOI [10.1182/blood-2013-07-512830, DOI 10.1182/BLOOD-2013-07-512830]; Carbonnel F, 1999, GUT, V45, P662, DOI 10.1136/gut.45.5.662; Delabie J, 2011, BLOOD, V118, P148, DOI 10.1182/blood-2011-02-335216; Edison N, 2016, HUM PATHOL, V57, P45, DOI 10.1016/j.humpath.2016.06.021; EGAWA N, 1995, CANCER, V75, P1728, DOI 10.1002/1097-0142(19950401)75:7<1728::AID-CNCR2820750727>3.0.CO;2-9; Howell JM, 2012, CAN J GASTROENTEROL, V26, P452, DOI 10.1155/2012/480160; Kabul S, 2018, TURK J SURG, V34, P253, DOI 10.5152/turkjsurg.2017.3278; Kim SJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-321; Leventaki V, 2014, HUM PATHOL, V45, P421, DOI 10.1016/j.humpath.2013.08.003; Malamut G, 2014, CLIN GASTROENTEROL H, V12, P599, DOI 10.1016/j.cgh.2013.11.028; Margolskee E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068343; Matnani R, 2017, HEMATOL ONCOL, V35, P3, DOI 10.1002/hon.2317; Rahemtullah A, 2008, AM J SURG PATHOL, V32, P1593, DOI 10.1097/PAS.0b013e31817d7452; Swerdlow SH, 2017, WHO CLASSIFICATION T, P379; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tse E, 2012, AM J HEMATOL, V87, P663, DOI 10.1002/ajh.23213	16	0	0	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 20	2018	13								82	10.1186/s13000-018-0762-4			7	Pathology	Pathology	GX7GO	WOS:000447933500001	30342536	DOAJ Gold, Green Published			2019-10-28	
J	Esposito, MJ; Roychoudhury, S; Fornari, A				Esposito, Michael J.; Roychoudhury, Sudarshana; Fornari, Alice			A Professionalism and Mentoring Curriculum for Pathology Residents in Training	ACADEMIC PATHOLOGY			English	Article						professionalism; mentoring; structured curriculum; Accreditation Council for Graduate Medical Education core competency; pathology residency training	MEDICINE; BURNOUT	Professionalism is a core Accreditation Council for Graduate Medical Education competency. The Mentoring and Professionalism in Training Program was developed to promote humanism in health-care professionals in our health system. A modified version was implemented in the pathology residency program for professionalism competency. Twenty-one trainees were divided into 3 groups, with a facilitator who was a graduate of the system Mentoring and Professionalism in Training Program. Five sessions included topics on appreciative inquiry, active role modeling, conflict resolution, team building, feedback, mindfulness, and physician well-being. Participants completed pre- and postsurveys. Qualitative responses were very positive, for example, one participant felt the sessions helped "understand intricacies of workplace relationships and ways of effective, respectful, communication." The Mentoring and Professionalism in Training is a curriculum that teaches team building, conflict resolution, and feedback along with strategies to balance well-being with professional commitments and growth. It is an effective educational tool that can satisfy the Accreditation Council for Graduate Medical Education professionalism curriculum.	[Esposito, Michael J.; Roychoudhury, Sudarshana] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol, 6 Ohio Dr,Suite 202, New Hyde Pk, NY 11042 USA; [Fornari, Alice] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Sci Educ, Hempstead, NY USA	Roychoudhury, S (reprint author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol, 6 Ohio Dr,Suite 202, New Hyde Pk, NY 11042 USA.	madhua83@gmail.com			Society of '67	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The article processing fee for this article was supported by an Open Access Award given by the Society of '67, which supports the mission of the Association of Pathology Chairs to produce the next generation of outstanding investigators and educational scholars in the field of pathology. This award helps to promote the publication of high-quality original scholarship in Academic Pathology by authors at an early stage of academic development.	Arnold L, 2006, MEASURING MED PROFES, P15; Becker JL, 2006, AM J OBSTET GYNECOL, V195, P1444, DOI 10.1016/j.ajog.2006.06.075; Bell HS, 2007, FAM MED, V39, P13; Bing-You RG, 2009, JAMA-J AM MED ASSOC, V302, P1330, DOI 10.1001/jama.2009.1393; Branch WT, 2009, ACAD MED, V84, P117, DOI 10.1097/ACM.0b013e3181900f8a; Cruess SR, 2008, BRIT MED J, V336, P718, DOI 10.1136/bmj.39503.757847.BE; Duda Rosemary B, 2004, Curr Surg, V61, P325, DOI 10.1016/S0149-7944(03)00298-8; Dyrbye L, 2016, MED EDUC, V50, P132, DOI 10.1111/medu.12927; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Fornari A, 2018, J CONTIN EDUC HEALTH, V38, P66, DOI 10.1097/CEH.0000000000000184; Gaiser RR, 2009, ANESTH ANALG, V108, P948, DOI 10.1213/ane.0b013e3181935ac1; Gaufberg E, 2007, CLIN TEACH, V4, P78, DOI 10.1111/j.1743-498X.2007.00151.x; HAINES SL, 2014, AM J PHARM EDUC, V78; Hammond S., 2013, THIN BOOK APPRECIATI; Hardavella G, 2017, BREATHE, V13, P327, DOI 10.1183/20734735.009917; Jackevicius CA, 2014, AM J PHARM EDUC, V78, DOI 10.5688/ajpe785100; Levinson W, 2014, UNDERSTANDING MED PR; Logio LS, 2011, ACAD MED, V86, P1019, DOI 10.1097/ACM.0b013e318221fb9c; Ratanawongsa N, 2008, PATIENT EDUC COUNS, V72, P194, DOI 10.1016/j.pec.2008.04.010; Ratanawongsa N, 2007, MED EDUC, V41, P273, DOI 10.1111/j.1365-2929.2007.02687.x; Romani M, 2014, LIBYAN J MED, V9, DOI 10.3402/ljm.v9.23556; Roth LM, 2012, HUM PATHOL, V43, P165, DOI 10.1016/j.humpath.2011.08.016; Sambunjak D, 2006, JAMA-J AM MED ASSOC, V296, P1103, DOI 10.1001/jama.296.9.1103; Shanafelt TD, 2005, J GEN INTERN MED, V20, P559, DOI 10.1111/j.1365-1497.2005.0108.x; Skeff KM, 1998, NEW ENGL J MED, V339, P2015, DOI 10.1056/NEJM199812313392710; Straus SE, 2013, ACAD MED, V88, P82, DOI 10.1097/ACM.0b013e31827647a0; Swing SR, 2007, MED TEACH, V29, P648, DOI 10.1080/01421590701392903; van der Leeuw RM, 2013, MED TEACH, V35, P348, DOI 10.3109/0142159X.2013.769676	28	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	OCT 18	2018	5								2374289518805062	10.1177/2374289518805062			7	Pathology	Pathology	HC9GT	WOS:000452114600001	30364429	DOAJ Gold, Green Published			2019-10-28	
J	Dai, WG; Ye, JN; Zhang, ZM; Yang, L; Ren, H; Wu, H; Chen, JH; Ma, JY; Zhai, ET; Cai, SR; He, YL				Dai, Weigang; Ye, Jinning; Zhang, Zhimei; Yang, Liang; Ren, Hui; Wu, Hui; Chen, Jianhui; Ma, Jieyi; Zhai, Ertao; Cai, Shirong; He, Yulong			Increased expression of heat shock factor 1 (HSF1) is associated with poor survival in gastric cancer patients	DIAGNOSTIC PATHOLOGY			English	Article						HSF1; Gastric cancer; Prognosis	UP-REGULATION; FACTOR-I; PROMOTES; OVEREXPRESSION; METASTASIS; STATISTICS; PROGNOSIS; INVASION; STRESS	BackgroundHeat shock factor 1 (HSF1) was initially identified as a transcription factor encoding heat shock proteins, which assist in refolding or degrading damaged proteins. Recent studies have reported that HSF1 can act as an oncogene that regulates tumour progression. The present study aimed to elucidate the clinicopathological significance and prognostic value of HSF1 expression in gastric cancer (GC).MethodsThe data from The Cancer Genome Atlas (TCGA) were used to analyse HSF1 expression in GC and normal tissues, while 8 pairs of freshly frozen tissue samples were used to investigate HSF1 expression at the mRNA and protein levels in GC tissues and adjacent normal tissues using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting assays. The correlations between HSF1 expression and clinicopathological parameters, including the survival rate, were investigated in 117 GC tissue samples by immunohistochemical analysis.ResultsThe results of bioinformatics analysis, qRT-PCR, and western blot showed that HSF1 expression was higher in GC tissues than in normal tissues. High HSF1 expression was found in 54.7% (64/117) patients. Patients with high HSF1 expression had larger tumour size (P=0.001), advanced Bornmann classification (P=0.002), advanced depth of invasion (P=0.015), lymph node metastasis (P<0.001), distant metastasis (P=0.011) and tumour-node-metastasis (P<0.001). Moreover, the Kaplan-Meier and Cox proportional hazards analyses indicated that high HSF1 expression was significantly associated with poor overall survival and recurrence-free survival in GC patients and that high HSF1 expression was an independent prognostic factor for the long-term survival in GC patients.ConclusionsTaken together, our results show that high HSF1 expression is significantly correlated with advanced tumour progression and poor prognosis. In addition, HSF1 expression can serve as a biomarker for the prognosis of patients with GC.	[Dai, Weigang; Ye, Jinning; Yang, Liang; Wu, Hui; Chen, Jianhui; Zhai, Ertao; Cai, Shirong; He, Yulong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Zhimei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Ren, Hui] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gen Surg, Shenzhen, Peoples R China; [Ma, Jieyi; Zhai, Ertao] Sun Yat Sen Univ, Affiliated Hosp 1, Gen Surg Lab, Guangzhou, Guangdong, Peoples R China	Zhai, ET; He, YL (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	zhaiert@mail2.sysu.edu.cn; heyulong001@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81772579]; Science and Technology Planning Project of Guangdong Province [2016A020213002, 2012B060300011]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017 M622878]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2017A030313513, S2013020012724, 2017A030313861]; Science and Technology Planning Project of Guangzhou [201707010125, 201510010146]; Medical Scientific Research Foundation of Guangdong Province [A2017058, A2018022]; "3 & 3" Project of The First Affiliated Hospital of Sun Yat-sen University	This study was supported by grants from the National Natural Science Foundation of China (81772579), Science and Technology Planning Project of Guangdong Province (2016A020213002 and 2012B060300011), China Postdoctoral Science Foundation (2017 M622878), the Natural Science Foundation of Guangdong Province (2017A030313513, S2013020012724 and 2017A030313861), the Science and Technology Planning Project of Guangzhou (201707010125 and 201510010146), the Medical Scientific Research Foundation of Guangdong Province (A2017058 and A2018022), "3 & 3" Project of The First Affiliated Hospital of Sun Yat-sen University (Yulong He).	Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Aziz F, 2016, TOXICOL IN VITRO, V31, P158, DOI 10.1016/j.tiv.2015.09.025; Barna J, 2018, CELL MOL LIFE SCI, V75, P2897, DOI 10.1007/s00018-018-2836-6; Chen K, 2017, MOL ONCOL, V11, P1475, DOI 10.1002/1878-0261.12116; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chiang MC, 2009, HUM MOL GENET, V18, P2929, DOI 10.1093/hmg/ddp230; Cui JJ, 2015, ANN THORAC SURG, V100, P465, DOI 10.1016/j.athoracsur.2015.03.021; Fang F, 2012, CANCER-AM CANCER SOC, V118, P1782, DOI 10.1002/cncr.26482; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Huang LL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0676-8; Leach MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11704; Li JQ, 2018, MOL THER, V26, P1828, DOI 10.1016/j.ymthe.2018.04.014; Li SL, 2014, MOL MED REP, V10, P2313, DOI 10.3892/mmr.2014.2547; Liao YH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0703-x; Liu DH, 2016, DISCOV MED, V22, P87; Musiani D, 2014, FASEB J, V28, P4055, DOI 10.1096/fj.13-247924; Powell CD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168389; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Song SM, 2010, INT J BIOCHEM CELL B, V42, P1856, DOI 10.1016/j.biocel.2010.07.021; Tong YX, 2018, BBA-MOL BASIS DIS, V1864, P1104, DOI 10.1016/j.bbadis.2018.01.011; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsukao Y, 2017, ONCOL LETT, V13, P1819, DOI 10.3892/ol.2017.5637; Vilborg A, 2017, P NATL ACAD SCI USA, V114, pE8362, DOI 10.1073/pnas.1711120114; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wan T, 2018, ONCOTARGETS THER, V11, P383, DOI 10.2147/OTT.S153682; Wu PS, 2017, HISTOPATHOLOGY, V71, P711, DOI 10.1111/his.13284; Xia Y, 2012, CANCER LETT, V318, P145, DOI 10.1016/j.canlet.2011.09.043; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Zhai ET, 2018, CELL PHYSIOL BIOCHEM, V47, P879, DOI 10.1159/000490080; Zhang JB, 2013, BRIT J CANCER, V109, P1648, DOI 10.1038/bjc.2013.488; Zhang N, 2017, CANCER LETT, V409, P81, DOI 10.1016/j.canlet.2017.08.039; Zhou ZH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12346	32	1	1	4	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 17	2018	13								80	10.1186/s13000-018-0755-3			9	Pathology	Pathology	GX3VN	WOS:000447655300001	30326922	DOAJ Gold, Green Published			2019-10-28	
J	Mihaly, D; Nagy, N; Papp, G; Papai, Z; Sapi, Z				Mihaly, Dora; Nagy, Noemi; Papp, Gergo; Papai, Zsuzsanna; Sapi, Zoltan			Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma	DIAGNOSTIC PATHOLOGY			English	Article						Liquid biopsy; Synovial sarcoma; SS18-SSX fusion transcript; Droplet digital PCR; Nested PCR	POLYMERASE-CHAIN-REACTION; FUSION GENE; ALVEOLAR RHABDOMYOSARCOMA; PERIPHERAL-BLOOD; EWING SARCOMA; BONE-MARROW; RT-PCR; SYT; SSX; RISK	BackgroundSynovial sarcoma is a rare soft tissue tumor which contains the unique SS18-SSX1, SS18-SSX2 - or, rarely, SS18-SSX4 - fusion transcripts. It is well known that some soft tissue tumors, like Ewing sarcomas and myxoid liposarcomas, can spread via the blood with free circulating tumor cells (CTC); this can be detected by several sensitive molecular biology methods. Here we report a study of fifteen synovial sarcoma patients with varied clinical backgrounds.MethodAfter blood withdrawal and nucleic acid isolation, we attempted to detect the SS18-SSX fusion genes from circulating tumor cells or cell-free nucleic acids with nested PCR and droplet digital PCR.ResultsSS18-SSX2 fusion transcript was identified in a small copy number with droplet digital PCR in one case. Nested PCR could not detect any of the fusion transcripts in the examined 15 synovial sarcoma cases.ConclusionsHeretofore two case reports could detect CTCs in synovial sarcoma - in the first paper, the patient was diagnosed with poorly differentiated type while the other had a rare primary gastric synovial sarcoma. However, until now, no other studies have detected CTCs in the peripheral blood of synovial sarcoma patients. Based on our findings, we can conclude that detection of the chimeric SS18-SSX fusion gene after surgical excision and/or chemotherapy/radiotherapy is a rare circumstance and hence in itself is not sufficient for monitoring the tumor recurrence. Therefore, monitoring of other possible biomarkers - for example synovial sarcoma specific miRNAs - is recommended.	[Mihaly, Dora; Nagy, Noemi; Papp, Gergo; Sapi, Zoltan] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary; [Papai, Zsuzsanna] Mil Hosp Budapest, Dept Oncol, Podmaniczky Utca 111, H-1062 Budapest, Hungary	Sapi, Z (reprint author), Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary.	sapi.zoltan.dr@gmail.com			Hungarian Scientific Research Fund (OTKA)Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K-112993]; Hungarian National Research, Development and Innovation Office (NFKIH) [NVKP_16-1-2016-0004]	This work was financially supported by the Hungarian Scientific Research Fund (OTKA) https://nkfih.gov.hu/funding/otka, [No: K-112993]; and the [NVKP_16-1-2016-0004] grant of the Hungarian National Research, Development and Innovation Office (NFKIH).	Amary MF, 2007, INC SEP, V4, P482; Benini S, 2018, CANCER MANAG RES, V10, P49, DOI 10.2147/CMAR.S141623; Butler TM, 2017, CURR OPIN GENET DEV, V42, P14, DOI 10.1016/j.gde.2016.12.003; Chang L, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0430-9; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dimitriadis E, 2009, CANCER GENET CYTOGEN, V195, P54, DOI 10.1016/j.cancergencyto.2009.06.012; Eilber FC, 2008, J SURG ONCOL, V97, P314, DOI 10.1002/jso.20974; Fricke A, 2016, STEM CELLS INT, DOI 10.1155/2016/6146047; Hashimoto N, 2001, AM J SURG PATHOL, V25, P406, DOI 10.1097/00000478-200103000-00017; Herzog CE, 2005, J PEDIAT HEMATOL ONC, V27, P215, DOI 10.1097/01.mph.0000161762.53175.e4; Hou JM, 2009, AM J PATHOL, V175, P808, DOI 10.2353/ajpath.2009.090078; Kelly KM, 1996, CANCER, V78, P1320, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1320::AID-CNCR22>3.0.CO;2-1; Krumbholz M, 2016, CLIN CANCER RES, V22, P4356, DOI 10.1158/1078-0432.CCR-15-3028; Leung CT, 2009, CELL, V139, P1226, DOI 10.1016/j.cell.2009.12.013; Mehle N, 2018, ANAL BIOANAL CHEM; Mihaly D, 2017, CANCER GENET-NY, V216, P52, DOI 10.1016/j.cancergen.2017.07.003; Ogino S, 2018, WORLD J GASTROENTERO, V24, P949, DOI 10.3748/wjg.v24.i8.949; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Przybyl J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0109-2; Schleiermacher G, 2003, J CLIN ONCOL, V21, P85, DOI 10.1200/JCO.2003.03.006; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sun B, 2008, CANCER SCI, V99, P1355, DOI 10.1111/j.1349-7006.2008.00830.x; Tatrai P, 2012, BIOCHEM BIOPH RES CO, V422, P28, DOI 10.1016/j.bbrc.2012.04.088; Thomson B, 1999, BONE MARROW TRANSPL, V24, P527, DOI 10.1038/sj.bmt.1701939; Uotani K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12660-5; Verbeek BM, 2018, J SURG ONCOL, V117, P788, DOI 10.1002/jso.24889; Wei YK, 2002, CHINESE MED J-PEKING, V115, P1043; West DC, 1997, J CLIN ONCOL, V15, P583, DOI 10.1200/JCO.1997.15.2.583	29	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 17	2018	13								81	10.1186/s13000-018-0756-2			7	Pathology	Pathology	GX3VN	WOS:000447655300002	30326929	DOAJ Gold, Green Published			2019-10-28	
J	Brajkovic, S; Pelz, B; Procopio, MG; Leblond, AL; Repond, G; Schaub-Clerigue, A; Dupouy, DG; Soltermann, A				Brajkovic, Saska; Pelz, Benjamin; Procopio, Maria-Giuseppina; Leblond, Anne-Laure; Repond, Gregoire; Schaub-Clerigue, Ariane; Dupouy, Diego G.; Soltermann, Alex			Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma	DIAGNOSTIC PATHOLOGY			English	Article						Microfluidic tissue processor; Immunofluorescence; Anaplastic lymphoma kinase; Lung adenocarcinoma	PLATFORM LUNGSCAPE PROJECT; CANCER; IMMUNOHISTOCHEMISTRY	BackgroundAnaplastic lymphoma kinase (ALK) is a key oncogenic driver in lung adenocarcinoma patients and its fusion proteins are routinely assessed. The microfluidic tissue processor (MTP) device is based on a chip-confined low-volume technology allowing for rapid immunohistochemistry/immunofluorescence (IHC/IF) stainings of formalin-fixed paraffin-embedded (FFPE) or frozen tissue samples.MethodsA novel ALK IF protocol was developed for the MTP device using the primary mouse anti-human ALK antibody clone 5A4. FFPE tumor whole sections from 14 resected lung adenocarcinoma patients documented to be ALK positive (ALK+) by automated chromogenic IHC and/or FISH were used. MTP-derived IF immunoreactivity was measured by computerized analysis of digitalized images on individual frames of tumor epithelia and surrounding stroma, using an ImageJ plug-in.ResultsThe 5A4 antibody yielded saturated immunoreactivity at an incubation time of 4min on a titration curve ranging from 2 to 32min. Total staining time on the MTP device was 18min including secondary IgG Alexa Fluor 647. MTP-based ALK IF confirmed all 12 cases; with epithelial signal above stromal staining based on computerized pixel-based measurement. MTP-IF (mean intensity levels 458 to 1301) and chromogenic IHC (H-score 120 to 300) showed an equal range of variation of 2.8 and 2.5 folds, respectively, and a trend for direct correlation (p-value 0.051).ConclusionThe newly developed protocol for immunofluorescent detection of ALK protein with the MTP device confirms chromogenic IHC results on FFPE lung adenocarcinoma specimens. MTP-based IF is fast and reliable. We foresee this study to be a first step opening the road for further realization of microfluidic-based assays for rapid simultaneous detection of targetable oncogenic and immune-system related markers in their topographical context to investigate tumour heterogeneity and micro-environmental interactions.	[Brajkovic, Saska; Repond, Gregoire; Schaub-Clerigue, Ariane; Dupouy, Diego G.] Ecole Polytech Fed Lausanne, Lunaphore Technol SA, Innovat Pk,Bldg A, CH-1015 Lausanne, Switzerland; [Pelz, Benjamin] Swiss Fed Inst Technol, Microsyst Lab 2, CH-1015 Lausanne, Switzerland; [Procopio, Maria-Giuseppina; Leblond, Anne-Laure; Soltermann, Alex] Univ Hosp Zurich, Inst Pathol & Mol Pathol, CH-8091 Zurich, Switzerland	Brajkovic, S (reprint author), Ecole Polytech Fed Lausanne, Lunaphore Technol SA, Innovat Pk,Bldg A, CH-1015 Lausanne, Switzerland.	saska.brajkovic@lunaphore.com			Swiss National Science Foundation SystemsX [M-87704-01-02]; Swiss Commission of Technology and Innovation CTI [25736-1]	This work was supported by grants from the Swiss National Science Foundation SystemsX (reference number M-87704-01-02) to A.S. and from the Swiss Commission of Technology and Innovation CTI (reference number 25736-1) to D.G.D. and A.S.	Blackhall FH, 2014, J CLIN ONCOL, V32, P2780, DOI 10.1200/JCO.2013.54.5921; Ciftlik AT, 2013, P NATL ACAD SCI USA, V110, P5363, DOI 10.1073/pnas.1211273110; Dagogo-Jack I, 2016, ONCOLOGIST, V21, P662, DOI 10.1634/theoncologist.2016-0179; Dupouy DG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20277; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Hofman P, 2017, CANCERS, V9, DOI 10.3390/cancers9080107; Kim Hyojin, 2014, Korean J Pathol, V48, P1, DOI 10.4132/KoreanJPathol.2014.48.1.1; Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692; Letovanec I, 2018, J THORAC ONCOL, V13, P413, DOI 10.1016/j.jtho.2017.11.117; Lovchik RD, 2012, LAB CHIP, V12, P1040, DOI 10.1039/c2lc21016a; Marchetti A, 2016, J THORAC ONCOL, V11, P487, DOI 10.1016/j.jtho.2015.12.111; Paik JH, 2011, J THORAC ONCOL, V6, P466, DOI 10.1097/JTO.0b013e31820b82e8; Perner S, 2008, NEOPLASIA, V10, P298, DOI 10.1593/NEO.07878; Roussel H, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1286437; Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Volpatti LR, 2014, TRENDS BIOTECHNOL, V32, P347, DOI 10.1016/j.tibtech.2014.04.010; Walker PD, 2009, ARCH PATHOL LAB MED, V133, P181, DOI 10.1043/1543-2165-133.2.181; Yi ES, 2011, J THORAC ONCOL, V6, P459, DOI 10.1097/JTO.0b013e318209edb9	19	1	1	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 16	2018	13								79	10.1186/s13000-018-0757-1			10	Pathology	Pathology	GX3VK	WOS:000447655000001	30326973	DOAJ Gold, Green Accepted, Green Published			2019-10-28	
J	Abdullah, N; Hajeer, M; Abudalu, L; Sughayer, M				Abdullah, Niveen; Hajeer, Manar; Abudalu, Loay; Sughayer, Maher			Correlation study of thyroid nodule cytopathology and histopathology at two institutions in Jordan	CYTOJOURNAL			English	Article						Bethesda system for reporting thyroid cytopathology; cytohistological correlation; diagnostic test performance; fine needle aspiration	FINE-NEEDLE-ASPIRATION; BETHESDA SYSTEM; MANAGEMENT; DIAGNOSIS; BIOPSY	Background: Fine-needle aspiration (FNA) plays a fundamental role in determining the appropriate management for patients presenting with thyroid nodules. Aims: The aims of this study are to evaluate thyroid FNA test performance parameters through a cytohistological correlation. Materials and Methods: A retrospective analysis of all thyroid FNAs received over a period of 18 months was carried out. The findings were compared to their subsequent definite diagnoses on surgical specimens as well as to their follow-up repeat FNA results. A total of 499 thyroid FNAs were collected and reviewed against The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The percentage of each diagnostic category was calculated, and the implied risk of malignancy was determined by comparing the cytology results to their definite diagnoses obtained on the resection specimens. Analytical procedures were performed using Microsoft Excel. Results: Out of 499 thyroid FNAs, a benign interpretation was found in 273 patients (54.7%), atypia of undetermined significance in 81 (16.2%), follicular neoplasm in 20 (4%), suspicious for malignancy in 36 (7.2%), malignant in 32 (6.4%) and were nondiagnostic in 57 patients (11.4%). Only 101 patients (20.2%) underwent surgical resection and 47 (9.4%) underwent a follow-up FNA. After cytohistological correlation, FNA test performance, calculated by excluding the inadequate and undetermined categories revealed test sensitivity, specificity, and diagnostic accuracy of 95.6%, 54.8%, and 78.9%, respectively. The positive predictive value was 75.4%, and the negative predictive value was 89.5%. Conclusions: Our results are comparable to those previously published figures. The rate of atypia of undetermined significance/follicular lesion of undetermined significance is higher than what is currently recommended in TBSRTC.	[Abdullah, Niveen; Abudalu, Loay; Sughayer, Maher] King Hussein Canc Ctr, Dept Pathol & Lab Med, Amman 11941, Jordan; [Hajeer, Manar] Jordan Univ Hosp, Dept Pathol & Lab Med, Amman, Jordan	Sughayer, M (reprint author), King Hussein Canc Ctr, Dept Pathol & Lab Med, Amman 11941, Jordan.	niveenabdullah@yahoo.com; m.hajeer83@hotmail.com; luaiemad@hotmail.com; msughayer@khcc.jo		Sughayer, Maher/0000-0002-9185-9616			Ali SZ, 2016, ACTA CYTOL, V60, P397, DOI 10.1159/000451071; Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Cibas Edmund S, 2017, J Am Soc Cytopathol, V6, P217, DOI 10.1016/j.jasc.2017.09.002; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; Ghossein R, 2009, HEAD NECK PATHOL, V3, P86, DOI 10.1007/s12105-009-0109-2; Guth S, 2009, EUR J CLIN INVEST, V39, P699, DOI 10.1111/j.1365-2362.2009.02162.x; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; MCHENRY CR, 1993, AM SURGEON, V59, P415; Mondal SK, 2013, J CYTOL, V30, P94, DOI 10.4103/0970-9371.112650; Pusztaszeri M, 2016, ACTA CYTOL, V60, P399, DOI 10.1159/000451020; Ravetto C, 2000, CANCER CYTOPATHOL, V90, P357, DOI 10.1002/1097-0142(20001225)90:6<357::AID-CNCR6>3.0.CO;2-4; Sinna EA, 2012, J EGYPT NATL CANCER, V24, P63, DOI 10.1016/j.jnci.2012.01.001; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; Wang CCC, 2011, THYROID, V21, P243, DOI 10.1089/thy.2010.0243; Wong LQ, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.139725; Yassa L, 2007, CANCER CYTOPATHOL, V111, P508, DOI 10.1002/cncr.23116	17	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	OCT 15	2018	15								24	10.4103/cytojournal.cytojournal_53_17			8	Pathology	Pathology	HI1AG	WOS:000456175500001	30410561	DOAJ Gold, Green Published			2019-10-28	
J	Dehuri, P; Gochhait, D; Rangarajan, V; Sathiah, P; Siddaraju, N; Govindarajalou, R				Dehuri, Priyadarshini; Gochhait, Debasis; Rangarajan, Vidhyalakshmi; Sathiah, Prasath; Siddaraju, Neelaiah; Govindarajalou, Ramkumar			Cytologic examination of ascitic fluid in a patient with pleural-based mass: A unique presentation of a rare tumor	CYTOJOURNAL			English	Editorial Material							DIFFUSE MALIGNANT MESOTHELIOMA; DIAGNOSIS		[Dehuri, Priyadarshini; Gochhait, Debasis; Rangarajan, Vidhyalakshmi; Sathiah, Prasath; Siddaraju, Neelaiah; Govindarajalou, Ramkumar] Jawaharlal Inst Postgrad Med Educ & Res, Dept Pathol & Radiol, Pondicherry, India	Gochhait, D (reprint author), Jawaharlal Inst Postgrad Med Educ & Res, Dept Pathol & Radiol, Pondicherry, India.	drpriya.dehuri@gmail.com; debasis.go@gmail.com; drvidhyarangarajan@gmail.com; drprasasmc@gmail.com; rajusiddaraju@gmail.com; gramk80@gmail.com					Attanoos RL, 2003, HISTOPATHOLOGY, V43, P387, DOI 10.1046/j.1365-2559.2003.01685.x; Baker PM, 2005, AM J CLIN PATHOL, V123, P724, DOI 10.1309/2HONVRERPP2LJDUA; Bianchi C, 2007, TUMORI J, V93, P19; Churg A, PATHOLOGY GENETICS T; Davidson B, 2011, CYTOPATHOLOGY, V22, P5, DOI 10.1111/j.1365-2303.2010.00829.x; Del Gobbo A, 2014, INT J CLIN EXP PATHO, V7, P2484; Hammar SP, 2008, DAIL HAMMARS PULMONA, P558; Hida T, 2016, PATHOL INT, V66, P563, DOI 10.1111/pin.12453; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Trupiano JK, 2004, MODERN PATHOL, V17, P476, DOI 10.1038/modpathol.3800067; Whitaker D, 2000, CYTOPATHOLOGY, V11, P139, DOI 10.1046/j.1365-2303.2000.00247.x	11	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	OCT 15	2018	15								26	10.4103/cytojournal.cytojournal_7_18			4	Pathology	Pathology	HI1AG	WOS:000456175500003	30410563	DOAJ Gold, Green Published			2019-10-28	
J	Kishore, M; Kaushal, M; Ahuja, A				Kishore, Manjari; Kaushal, Manju; Ahuja, Arvind			Endometrial carcinoma with pleural fluid metastasis: A rare phenomenon	CYTOJOURNAL			English	Letter									[Kishore, Manjari] Post Grad Inst Med Educ & Res, Dept Pathol, New Delhi, India; Dr Ram Manohar Lohia Hosp, New Delhi, India	Kishore, M (reprint author), Post Grad Inst Med Educ & Res, Dept Pathol, New Delhi, India.	drmanjarik@gmail.com; manju_kaushal@yahoo.com; drarvindahuja@gmail.com					Avdalovic M, 2004, CLIN CHEST MED, V25, P379, DOI 10.1016/j.ccm.2004.01.009; Bouros D, 1996, ONCOLOGY, V53, P360; Dowdy SC, 2007, GYNECOL ONCOL, V107, P242, DOI 10.1016/j.ygyno.2007.06.030; Halperin R, COMP Z, V22, P122; Semczuk A, 2006, ACTA CYTOL, V50, P697, DOI 10.1159/000326045	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	OCT 15	2018	15								25	10.4103/cytojournal.cytojournal_28_18			3	Pathology	Pathology	HI1AG	WOS:000456175500002	30410562	DOAJ Gold, Green Published			2019-10-28	
J	Choi, SM; Andea, AA; Wang, M; Behdad, A; Shao, LN; Zhang, YM; Lu, XY; Dittmann, D; Castro, J; Chen, YH; Gao, JH				Choi, Sarah M.; Andea, Aleodor A.; Wang, Min; Behdad, Amir; Shao, Lina; Zhang, Yanming; Lu, Xinyan; Dittmann, David; Castro, Juan; Chen, Yi-Hua; Gao, Juehua			KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma	DIAGNOSTIC PATHOLOGY			English	Article						KRAS; Transdifferentiation; Langerhans cell sarcoma; Follicular lymphoma	B-CELL LYMPHOMA; LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA; CLONAL RELATIONSHIP; SOMATIC MUTATIONS; METASTATIC MELANOMA; LANGERHANS CELLS; SARCOMA; RAS; TRANSFORMATION; TRANSDIFFERENTIATION	BackgroundTransformation of follicular lymphoma most typically occurs as diffuse large B-cell lymphoma, however other forms of transformation such as classic Hodgkin lymphoma and lymphoblastic transformation can occur. Secondary malignant histiocytosis also represents a rare form of transformation, which is thought to occur due to a process of transdifferentiation whereby the lymphoma cells exhibit lineage plasticity and lose all evidence of B-cell phenotype and instead acquire the phenotype of a histiocytic neoplasm. Little is known about the underlying genetic alterations that occur during this unusual process. Comparative genetic analysis of pre- and post-transformation/transdifferentiation would be one tool by which we could better understand how this phenomenon occurs.Case presentationHere we report the clinical, immunophenotypic and genetic features of a rare case of secondary malignant histiocytosis, Langerhans cell-type (Langerhans cell sarcoma) arising from a previous low grade follicular lymphoma. FISH analysis confirmed the presence of IgH/BCL2 rearrangement in both the low grade follicular lymphoma (FL) and transformed Langerhans cells sarcoma (LCS) samples, demonstrating a clonal relationship. Comparative whole exome sequencing was then performed, which identified a KRAS p.G13D mutation in the LCS that was not present in the FL.ConclusionsThis report highlights genetic alterations, in particular an acquired somatic KRAS mutation, that may occur during transdifferentiation, with additional significance of KRAS mutation as a possible therapeutic target in cases which otherwise would have limited treatment options.	[Choi, Sarah M.; Behdad, Amir; Lu, Xinyan; Chen, Yi-Hua; Gao, Juehua] Northwestern Univ, Dept Pathol, Feinberg Sch Med, 251 E Huron St, Chicago, IL 60611 USA; [Choi, Sarah M.; Andea, Aleodor A.; Wang, Min; Shao, Lina] Univ Michigan, Dept Pathol, 5242 Med Sci Bldg 1,1301 Catherine St, Ann Arbor, MI 48109 USA; [Zhang, Yanming] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Dittmann, David; Castro, Juan] Northwestern Mem Hosp, Diagnost Mol Biol Lab, 251 E Huron St, Chicago, IL 60611 USA	Gao, JH (reprint author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 251 E Huron St, Chicago, IL 60611 USA.	j-gao@northwestern.edu					Abla O, 2015, HEMATOL-AM SOC HEMAT, P565, DOI 10.1182/asheducation-2015.1.565; Ambrosio MR, 2015, VIRCHOWS ARCH, V467, P471, DOI 10.1007/s00428-015-1814-8; Anjuere F, 2000, BLOOD, V96, P1633, DOI 10.1182/blood.V96.5.1633.h8001633_1633_1637; Badalian-Very G, 2012, BRIT J HAEMATOL, V156, P163, DOI 10.1111/j.1365-2141.2011.08915.x; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Carter MD, 2018, HUM PATHOL, V71, P117, DOI 10.1016/j.humpath.2017.10.014; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Chan WC, 1997, BLOOD, V89, P3909; Chapman PB, 2017, ANN ONCOL, V28, P2581, DOI 10.1093/annonc/mdx339; Chen W, 2009, AM J SURG PATHOL, V33, P863, DOI 10.1097/PAS.0b013e31819287b8; Chen Weiwei, 2013, N Am J Med Sci, V5, P386, DOI 10.4103/1947-2714.114172; Clark HM, 1996, LEUKEMIA, V10, P844; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642; Elenitoba-Johnson KSJ, 2003, P NATL ACAD SCI USA, V100, P7259, DOI 10.1073/pnas.1137463100; Feldman AL, 2005, LANCET ONCOL, V6, P435, DOI 10.1016/S1470-2045(05)70211-4; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Foster JM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0079-z; Fraser CR, 2009, AM J CLIN PATHOL, V132, P928, DOI 10.1309/AJCPWQ0I0DGXBMHO; Gajate P, 2012, CLIN COLORECTAL CANC, V11, P291, DOI 10.1016/j.clcc.2012.02.003; Garcia-Ramirez I, 2017, BLOOD, V129, P2645, DOI 10.1182/blood-2016-08-733469; Green MR, 2018, BLOOD, V131, P595, DOI 10.1182/blood-2017-08-737361; Green MR, 2015, P NATL ACAD SCI USA, V112, pE1116, DOI 10.1073/pnas.1501199112; Green MR, 2013, BLOOD, V121, P1604, DOI 10.1182/blood-2012-09-457283; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heritier S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0690-z; Hou YH, 2005, BLOOD, V105, P3488, DOI 10.1182/blood-2004-07-2839; Kamata T, 2017, BLOOD, V130, P514, DOI 10.1182/blood-2017-02-770149; Kim J, 2016, NATURE, V538, P114, DOI 10.1038/nature19771; Korfi K, 2017, EPIGENETICS-US, V12, P370, DOI 10.1080/15592294.2017.1282587; Kridel R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002197; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Magni M, 2002, LEUKEMIA RES, V26, P1131, DOI 10.1016/S0145-2126(02)00009-7; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750; Mourah S, 2016, EUR RESPIR J, V47, P1785, DOI 10.1183/13993003.01677-2015; Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856; Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Sahm F, 2012, BLOOD, V120, pE28, DOI 10.1182/blood-2012-06-429597; Schmitt-Graeff AH, 2012, LEUKEMIA, V26, P1707, DOI 10.1038/leu.2012.27; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shanmugam V, 2018, RAS MAPK PATHWAY ACT; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Swerdlow SH, 2008, WHO CLASSIFICATION T; Thakral B, 2016, BLOOD, V128, P2475, DOI 10.1182/blood-2016-08-735795; Vaque JP, 2014, HAEMATOLOGICA, V99, P222, DOI 10.3324/haematol.2013.096248; Wang ED, 2011, AM J SURG PATHOL, V35, P457, DOI 10.1097/PAS.0b013e3182098799; Wang ED, 2010, LEUKEMIA LYMPHOMA, V51, P802, DOI 10.3109/10428191003699845; Wang Y, 2012, CANCER GENET-NY, V205, P341, DOI 10.1016/j.cancergen.2012.06.005; Ward AF, 2012, BLOOD, V120, P3397, DOI 10.1182/blood-2012-05-378596; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; Yuan LWC, 2002, ONCOGENE, V21, P2253, DOI 10.1038/sj.onc.1205283; Zarnegar S, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26699	59	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 15	2018	13								78	10.1186/s13000-018-0758-0			13	Pathology	Pathology	GX1UE	WOS:000447503100001	30322385	DOAJ Gold, Green Published			2019-10-28	
J	Hicks, JK; Henderson-Jackson, E; Duggan, J; Joyce, DM; Brohl, AS				Hicks, J. Kevin; Henderson-Jackson, Evita; Duggan, Julia; Joyce, David M.; Brohl, Andrew S.			Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma	DIAGNOSTIC PATHOLOGY			English	Article						Soft tissue sarcoma; RAF1; MTAP; Fusion; Next generation sequencing; Molecular diagnostics	CLEAR-CELL SARCOMA; MTAP EXPRESSION; TUMORS; GENE; MELANOMA	Background: RAF family activating fusions have been described as a potentially targetable molecular finding in a subset of soft tissue sarcomas. To further expand upon the landscape of this genetic feature, we describe a novel MTAP-RAF1 activating fusion identified in a S100 positive soft tissue sarcoma. Case presentation: A 51 year old man underwent excision of a soft tissue mass in his foot. Pathology revealed a spindle cell neoplasm with S100 positivity, ultimately classified as a soft tissue sarcoma, not otherwise specified. Comprehensive molecular profiling was performed to help establish the diagnosis and revealed a novel MTAP-RAF1 fusion that includes the tyrosine kinase domain of RAF1. Conclusions: Our report adds to the spectrum of fusion-driven RAF activation observed in soft tissue sarcomas and lends additional evidence that RAF activation plays an important role in some soft tissue sarcomas. Identification of novel fusions involving the MAPK/ERK pathway in sarcomas may provide new avenues for precision medicine strategies involving targeted kinase inhibitors.	[Hicks, J. Kevin] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, DeBartolo Family Personalized Med Inst, Tampa, FL USA; [Henderson-Jackson, Evita] H Lee Moffitt Canc Ctr & Res Inst, Dept Anat Pathol, Tampa, FL USA; [Duggan, Julia] Fdn Med Inc, Cambridge, MA USA; [Joyce, David M.; Brohl, Andrew S.] H Lee Moffitt Canc Ctr & Res Inst, Sarcoma Dept, 12902 Magnolia Dr,FOB1, Tampa, FL 33612 USA; [Brohl, Andrew S.] H Lee Moffitt Canc Ctr & Res Inst, Chem Biol & Mol Med Program, Tampa, FL 33612 USA	Brohl, AS (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Sarcoma Dept, 12902 Magnolia Dr,FOB1, Tampa, FL 33612 USA.; Brohl, AS (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Chem Biol & Mol Med Program, Tampa, FL 33612 USA.	James.Hicks@moffitt.org; Andrew.Brohl@Moffitt.Org					Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Kao YC, 2018, AM J SURG PATHOL, V42, P28, DOI 10.1097/PAS.0000000000000938; Kao YC, 2017, AM J SURG PATHOL, V41, P1456, DOI 10.1097/PAS.0000000000000899; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Li CF, 2014, ONCOTARGET, V5, P11428, DOI 10.18632/oncotarget.2552; Park BM, 2013, BRIT J DERMATOL, V169, P1346, DOI 10.1111/bjd.12480; Protsenko SA, 2015, INVEST NEW DRUG, V33, P1136, DOI 10.1007/s10637-015-0280-0; Schmid M, 2000, ONCOGENE, V19, P5747, DOI 10.1038/sj.onc.1203942; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Xie HP, 2016, ONCOTARGET, V7, P16490, DOI 10.18632/oncotarget.7503	11	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	OCT 12	2018	13								77	10.1186/s13000-018-0759-z			4	Pathology	Pathology	GY2WL	WOS:000448405100001	30314519	DOAJ Gold, Green Published			2019-10-28	
J	Petriceks, AH; Olivas, JC; Salmi, D				Petriceks, Aldis H.; Olivas, John C.; Salmi, Darren			Educational Case: Symptomatic but Unruptured Abdominal Aortic Aneurysm	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; abdominal aortic aneurysm; aortic dissection; aneurysm risk factors; unruptured aneurysm; ruptured aneurysm; complications of abdominal aortic aneurysms; classification of aortic dissections	EXPANSION; RISK	The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies,	[Petriceks, Aldis H.; Olivas, John C.; Salmi, Darren] Stanford Univ, Sch Med, Div Clin Anat, 269 Campus Dr,CCSR 0135A, Stanford, CA 94305 USA; [Salmi, Darren] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Salmi, D (reprint author), Stanford Univ, Sch Med, Div Clin Anat, 269 Campus Dr,CCSR 0135A, Stanford, CA 94305 USA.	dsalmi@stanford.edu		Petriceks, Aldis/0000-0001-5136-1023			Acosta S, 2006, J VASC SURG, V44, P237, DOI 10.1016/j.jvs.2006.04.037; Assar AN, 2009, POSTGRAD MED J, V85, P268, DOI 10.1136/pgmj.2008.074666; Beales L, 2011, BRIT J SURG, V98, P1517, DOI 10.1002/bjs.7628; Bhak RH, 2015, JAMA SURG, V150, P44, DOI 10.1001/jamasurg.2014.2025; Black JH, 2018, UPTODATE; Brady AR, 2004, CIRCULATION, V110, P16, DOI 10.1161/01.CIR.0000133279.07468.9F; Chaikof EL, 2018, J VASC SURG, V67, P2, DOI 10.1016/j.jvs.2017.10.044; Chung J, 2018, UPTODATE; Dalman RL, 2018, UPTODATE; Forbes TL, 2006, ANN VASC SURG, V20, P564, DOI 10.1007/s10016-006-9079-y; Hagan PG, 2000, JAMA-J AM MED ASSOC, V283, P897, DOI 10.1001/jama.283.7.897; Jim J, 2018, UPTODATE; Kumar VAA, 2018, ROBBINS BASIC PATHOL; Norman PE, 2013, ARTERIOSCL THROM VAS, V33, P1473, DOI 10.1161/ATVBAHA.112.300158; Oliver-Williams C, 2018, BRIT J SURG, V105, P68, DOI 10.1002/bjs.10715; Skibba AA, 2015, J VASC SURG, V62, P1429, DOI 10.1016/j.jvs.2015.07.079; Takagi H, 2017, ANN VASC SURG, V39, P74, DOI 10.1016/j.avsg.2016.04.019	17	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	OCT 9	2018	5								UNSP 2374289518798560	10.1177/2374289518798560			7	Pathology	Pathology	GW4AW	WOS:000446853500001	30327791	DOAJ Gold, Green Published			2019-10-28	
J	Mrak, RE; Parslow, TG; Ducatman, BS				Mrak, Robert E.; Parslow, Tristram G.; Ducatman, Barbara S.			Benchmarking Subspecialty Practice in Academic Anatomic Pathology: The 2017 Association of Pathology Chairs Survey	ACADEMIC PATHOLOGY			English	Article						anatomic pathology; benchmarking; clinical effort; salary; subspecialty practice; work relative value units	WORKLOAD MEASUREMENT; SURGICAL PATHOLOGY	Assessment of physician workloads has become increasingly important in modern academic physician practice, where it is commonly used to allocate resources among departments, to determine staffing, and to set the compensation of individual physicians. The physician work relative value unit system is a frequently used metric in this regard. However, the application of this system to the practice of pathology has proven problematic. One area of uncertainty is the validity of using work relative value unit norms that were derived from general surgical pathology practice to assess the various subspecialties within anatomic pathology. Here, we used data from the 2017 Association of Pathology Chairs practice survey to assess salary and work relative value unit data for single-subspecialty practitioners in US academic pathology departments in the prior year (2016). Five subspecialties were evaluated: dermatopathology, gastrointestinal pathology, hematopathology/hematology, renal pathology, and neuropathology. Data for general surgical pathologists and cytopathologists were included for comparison. For this analysis, survey data were available for 168 practitioners in 43 US academic departments of pathology. Salary ranges varied little among subspecialties, with the exception of dermatopathology, where salaries were higher. In contrast, work relative value unit productivity varied widely among different subspecialties, with median values differing as much as 4- to 7-fold between subspecialties. These results suggest that the use of a single overall work relative value unit standard is not appropriate for specialty- or subspecialty-based anatomic pathology practice, and that either the benchmark norms should be tailored to individual practice patterns, or an alternative system of workload measurement should be developed.	[Mrak, Robert E.] Univ Toledo, Dept Pathol, Coll Med & Life Sci, 3000 Arlington Ave, Toledo, OH 43614 USA; [Parslow, Tristram G.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Ducatman, Barbara S.] Oakland Univ, Dept Pathol, William Beaumont Sch Med, Rochester, MI 48063 USA; [Ducatman, Barbara S.] Beaumont Hlth, Royal Oak, MI USA	Mrak, RE (reprint author), Univ Toledo, Dept Pathol, Coll Med & Life Sci, 3000 Arlington Ave, Toledo, OH 43614 USA.	robert.mrak@utoledo.edu					Cheung CC, 2015, MODERN PATHOL, V28, P324, DOI 10.1038/modpathol.2014.123; Cloetingh D, 2017, AM J CLIN PATHOL, V148, P16, DOI [10.1093/AJCP/AQX022, 10.1093/ajcp/aqx022]; Ducatman BS, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516666832; Horne GJ, 2009, J CLIN PATHOL, V62, P435, DOI 10.1136/jcp.2008.061150; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; Meijer GA, 2009, VIRCHOWS ARCH, V454, P623, DOI 10.1007/s00428-009-0768-0; Sinard JH, 2013, ARCH PATHOL LAB MED, V137, P228, DOI 10.5858/arpa.2012-0012-CP; The Royal College of Pathologists, 2015, GUID STAFF WORKL HIS	8	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	OCT 9	2018	5								UNSP 2374289518798556	10.1177/2374289518798556			9	Pathology	Pathology	GW4BC	WOS:000446854200001	30327790	DOAJ Gold, Green Published			2019-10-28	
J	Oest, SER; Hightower, M; Krasowski, MD				Oest, Sarah E. R.; Hightower, Maia; Krasowski, Matthew D.			Activation and Utilization of an Electronic Health Record Patient Portal at an Academic Medical Center-Impact of Patient Demographics and Geographic Location	ACADEMIC PATHOLOGY			English	Article						health information technology; electronic health records; patient portals; personal health information; computers/utilization	US HOSPITALS; CARE; DISPARITIES; ADOPTION; EHR	The advent of the online electronic health record patient portal has provided an efficient and practical means for patients to become more involved in their health care. In this report, we analyze how demographic variables such as age, gender, race, and geographic location affect patient portal activation and usage at the University of Iowa Hospitals and Clinics, the sole academic medical center in the state of Iowa, a predominantly rural state. Our primary end points were activation of the patient portal (MyChart, Epic, Inc) and access of outpatient laboratory and radiology results, among the most commonly accessed and popular features of the patient portal. We thus analyzed data from 536 378 patients to determine rates of patient portal activation and data from 219 671 patient encounters to determine the frequency at which patients access their online diagnostic test results. Higher rates of patient portal activation and usage were associated with female gender, Caucasians/non-underrepresented minorities, geographic location in closer proximity to the medical center (Iowa City and neighboring cities/suburbs), and nonelderly adults. For underrepresented minority and rural patients, opportunities for improvement exist for both activation and more robust use of online patient portal accounts. Overall, these data highlight existing disparities with online patient portal usage and provide a base on which further studies and interventions can help to improve utilization of these systems.	[Oest, Sarah E. R.; Krasowski, Matthew D.] Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA; [Oest, Sarah E. R.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Hightower, Maia] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA; [Hightower, Maia] Univ Iowa Hosp & Clin, Hlth Care Informat Syst, Iowa City, IA 52242 USA	Krasowski, MD (reprint author), Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA.	matthew-krasowski@uiowa.edu					Adler-Milstein J, 2015, HEALTH AFFAIR, V34, P2174, DOI 10.1377/hlthaff.2015.0992; Adler-Milstein J, 2014, J AM MED INFORM ASSN, V21, P984, DOI 10.1136/amiajnl-2014-002708; Agency for Healthcare Research and Quality, 2014, GUID PAT FAM ENG; Ammenwerth E, 2012, J MED INTERNET RES, V14, P325, DOI 10.2196/jmir.2238; Ancker JS, 2016, AM J MANAG CARE, V22, P539; Campanella P, 2016, EUR J PUBLIC HEALTH, V26, P60, DOI 10.1093/eurpub/ckv122; Centers for Disease Control and Prevention, 2017, MEAN US; Centers for Disease Control and Prevention, 2017, EL MED REC EL HLTH R; Diviani N, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4018; Evans R S, 2016, Yearb Med Inform, VSuppl 1, pS48, DOI 10.15265/IYS-2016-s006; Goel MS, 2011, J GEN INTERN MED, V26, P1112, DOI 10.1007/s11606-011-1728-3; Gordon NP, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5105; Grieme CV, 2017, CLIN LAB, V63, P561, DOI 10.7754/Clin.Lab.2016.160932; Griffin A, 2016, APPL CLIN INFORM, V7, P489, DOI 10.4338/ACI-2016-01-RA-0003; Hassol A, 2004, J AM MED INFORM ASSN, V11, P505, DOI 10.1197/jamia.M1593; Herrin J, 2012, HEALTH SERV RES, V47, P1522, DOI 10.1111/j.1475-6773.2011.01370.x; Jhamb M, 2015, CLIN J AM SOC NEPHRO, V10, P2013, DOI 10.2215/CJN.01640215; Kern LM, 2016, AM J MED QUAL, V31, P301, DOI 10.1177/1062860615572439; Kim EH, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1256; Krasowski Matthew D, 2016, J Pathol Inform, V7, P7, DOI 10.4103/2153-3539.175798; Krasowski MD, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0137-7; Krasowski MD, 2017, J PATHOL INFORM, V8, P45; Luque AE, 2013, JMIR RES PROTOC, V2, DOI 10.2196/resprot.2302; Miller Holly, 2007, J Healthc Inf Manag, V21, P44; Mook PJ, 2018, CIN-COMPUT INFORM NU, V36, P18, DOI 10.1097/CIN.0000000000000392; Peacock S, 2017, J AM MED INFORM ASSN, V24, pE173, DOI 10.1093/jamia/ocw095; Perzynski AT, 2017, J AM MED INFORM ASSN, V24, P927, DOI 10.1093/jamia/ocx020; Pillemer F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154743; Reed M, 2012, ANN INTERN MED, V157, P482, DOI 10.7326/0003-4819-157-7-201210020-00004; Reicher JJ, 2016, J DIGIT IMAGING, V29, P337, DOI 10.1007/s10278-015-9845-x; Sarkar U, 2011, J AM MED INFORM ASSN, V18, P318, DOI 10.1136/amiajnl.2010.006015; Sorondo Barbara, 2016, EGEMS (Wash DC), V4, P1262, DOI 10.13063/2327-9214.1262; Sorondo Barbara, 2016, EGEMS (Wash DC), V4, P1237, DOI 10.13063/2327-9214.1237; The Nation's Report Card, 2015, MATH READ ASS; United States Department of Health and Human Services, 2017, HITECH ACT ENF INT F; United States Office of Management and Budget, 2018, SHAR DAT CTR METR MI; Wallace LS, 2016, J AM BOARD FAM MED, V29, P592, DOI 10.3122/jabfm.2016.05.160046; Weingart SN, 2006, J AM MED INFORM ASSN, V13, P91, DOI 10.1197/jamia.M1833; Woods SS, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7895	39	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	OCT 4	2018	5								2374289518797573	10.1177/2374289518797573			9	Pathology	Pathology	GZ0PS	WOS:000449067500001	30302394	DOAJ Gold, Green Published			2019-10-28	
J	Sharma, K; Darvas, M; Keene, CD; Niedernhofer, LJ; Ladiges, W				Sharma, Kavita; Darvas, Martin; Keene, C. Dirk; Niedernhofer, Laura J.; Ladiges, Warren			Modeling Alzheimer's disease in progeria mice. An age-related concept	PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES			English	Article						Alzheimer's disease; aging; progeria; mouse models	MOUSE MODEL; COGNITIVE DECLINE; DNA-DAMAGE; PARADIGM	The prevalence of Alzheimer's disease (AD) is expected to dramatically increase in older people worldwide. Efforts to find disease-modifying treatments have been largely unsuccessful because of the focus on disease-specific pathogenesis, and lack of animal models to study AD in the context of aging and age-related co-morbidities. The geroscience approach to studying AD would suggest that modulation of aging per se would be a useful strategy, but a mammalian model system that combines both aging and AD is not available. One approach to study old age and AD is to utilize murine models of progeroid syndrome, which can provide a number of advantages not only for basic aging biology but also for preclinical drug testing. A progeria background, such as the Ercc1 mutant mouse (Ercc1(-/Delta)), provides an aging component not seen in current murine models of AD that lack age-related co-morbidities typical of AD patients. Ercc1(-/Delta) mice experience the same types of stochastic endogenous DNA damage as WT mice, but accumulate lesions faster due to impaired DNA repair, which accelerates the normal aging process by 6-fold. These mice do not show frank AD pathology but represent a predisposed or hypersensitive environment for AD pathology, where pathogenic elements of AD can be introduced, either by crossing with well-established AD transgenic mouse lines, or transcranial stereotaxic delivery directly into the brain. Since Ercc1(-/Delta) mice age five to six times faster than WT mice, very rapid characterization and testing of therapeutic interventions is possible. Studies are urgently needed to capitalize on the highly informative potential of this novel AD mouse model.	[Sharma, Kavita; Ladiges, Warren] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; [Darvas, Martin; Keene, C. Dirk] Univ Washington, Sch Med, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA; [Niedernhofer, Laura J.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Inst Biol Aging & Metab, Minneapolis, MN USA	Ladiges, W (reprint author), Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA.	wladiges@u.washington.edu					Ahmad A, 2008, MOL CELL BIOL, V28, P5082, DOI 10.1128/MCB.00293-08; Albin RL, 2016, NEUROBIOL DIS, V85, P73, DOI 10.1016/j.nbd.2015.10.014; Bhagwat N, 2009, MOL CELL BIOL, V29, P6427, DOI 10.1128/MCB.00086-09; Borgesius NZ, 2011, J NEUROSCI, V31, P12543, DOI 10.1523/JNEUROSCI.1589-11.2011; Darvas M, 2015, NEUROSCIENCE, V284, P934, DOI 10.1016/j.neuroscience.2014.11.011; Dillin A., 2011, COLD SPRING HARBOR P, V3, P1; Dolle MET, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7219; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Gordon LB, 2014, CELL, V156, P400, DOI 10.1016/j.cell.2013.12.028; Goss JR, 2011, MECH AGEING DEV, V132, P437, DOI [10.1016/j.mad,2011.04.010, 10.1016/j.mad.2011.04.010]; Gregg SQ, 2012, HEPATOLOGY, V55, P609, DOI 10.1002/hep.24713; Gurkar AU, 2015, EXP GERONTOL, V68, P43, DOI 10.1016/j.exger.2015.01.045; Harkema L, 2016, VET PATHOL, V53, P366, DOI 10.1177/0300985815625169; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Keene CD, 2016, PATHOBIOL AGING AGE, V6, DOI 10.3402/pba.v6.32397; Keller JN, 2006, AGEING RES REV, V5, P1, DOI 10.1016/j.arr.2005.06.002; Ladiges W, 2014, PATHOBIOL AGING AGE, V4, DOI 10.3402/pba.v4.24835; Ladiges W, 2017, J GERONTOL A-BIOL, V72, P760, DOI 10.1093/gerona/glx019; Ladiges W, 2016, PATHOBIOL AGING AGE, V6, DOI 10.3402/pba.v6.31478; Lavasani M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1611; Lawlor PA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-11; Longo VD, 2015, AGING CELL, V14, P497, DOI 10.1111/acel.12338; Lovell MA, 2007, NUCLEIC ACIDS RES, V35, P7497, DOI 10.1093/nar/gkm821; Montine TJ, 2014, NEUROLOGY, V83, P851, DOI 10.1212/WNL.0000000000000733; Moore G, 2008, MECH AGEING DEV, V129, P201, DOI 10.1016/j.mad.2007.12.009; Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456; Pettan-Brewer C, 2013, PATHOBIOL AGING AGE, V3, DOI 10.3402/pba.v3i0.20679; Ramos FJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003802; Robinson AR, 2018, REDOX BIOL, V17, P259, DOI 10.1016/j.redox.2018.04.007; Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785; Vo N, 2010, J ORTHOP RES, V28, P1600, DOI 10.1002/jor.21153; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wiley JC, 2011, AGING CELL, V10, P418, DOI 10.1111/j.1474-9726.2011.00680.x; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	35	0	0	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2001-0001			PATHOBIOL AGING AGE	Pathobiol. Aging Age-relat. Dis.	OCT 4	2018	8								1524815	10.1080/20010001.2018.1524815			4	Pathology	Pathology	GV8AA	WOS:000446355800001	30319737	DOAJ Gold, Green Published			2019-10-28	
J	Badoual, C				Badoual, Cecile			Editorial	ANNALES DE PATHOLOGIE			French	Editorial Material									[Badoual, Cecile] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Anatomopathol, 20 Rue Leblanc, F-75015 Paris, France	Badoual, C (reprint author), Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Anatomopathol, 20 Rue Leblanc, F-75015 Paris, France.	cecile.badoual@aphp.fr	Davim, Joao Paulo/D-2314-2009	Davim, Joao Paulo/0000-0002-5659-3111			El-Naggar AK, 2017, WHO CLASSIFICATION T	1	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					257	257		10.1016/j.annpat.2018.09.002			1	Pathology	Pathology	HU8CP	WOS:000465510300001	30309452				2019-10-28	
J	Martineau, VC				Martineau, Valerie Costes			ENT benign lesions and pseudo-tumors: Case No. 1	ANNALES DE PATHOLOGIE			French	Editorial Material							UNKNOWN PRIMARY; CARCINOMA; NECK; HEAD		[Martineau, Valerie Costes] CHU Montpellier, Dept Biopathol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France	Martineau, VC (reprint author), CHU Montpellier, Dept Biopathol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	v-costes_martineau@chu-montpellier.fr					Bishop JA, 2018, AM J SURG PATHOL, V42, P130, DOI 10.1097/PAS.0000000000000932; Bishop JA, 2015, AM J SURG PATHOL, V39, P1591, DOI 10.1097/PAS.0000000000000521; Cao DF, 2010, HUM PATHOL, V41, P535, DOI 10.1016/j.humpath.2009.09.006; Chernock RD, 2015, HEAD NECK PATHOL, V9, P6, DOI 10.1007/s12105-015-0616-2; Durmus K, 2014, HEAD NECK-J SCI SPEC, V36, P848, DOI 10.1002/hed.23385; Jalaly JB, 2015, CANCER CYTOPATHOL, V123, P723, DOI 10.1002/cncy.21600; Koch WM, 2001, OTOLARYNG HEAD NECK, V124, P331, DOI 10.1067/mhn.2001.114309; Layfield L, 2016, DIAGN CYTOPATHOL, V44, P151; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Moatamed NA, 2009, DIAGN CYTOPATHOL, V37, P720, DOI 10.1002/dc.21088; Pai R, 2009, CANCER, V117; Pazaitou-Panayiotou K, 2008, THYROID RES, V1, DOI 10.1186/1756-6614-1-8; Prosser JD, 2015, OTOLARYNG CLIN N AM, V48, P1, DOI 10.1016/j.otc.2014.09.002; Radkay-Gonzalez L, 2016, HEAD NECK PATHOL, V10, P167, DOI 10.1007/s12105-015-0653-x; Regauer S, 1997, APMIS, V105, P623, DOI 10.1111/j.1699-0463.1997.tb05063.x; RICKLES NH, 1967, AM J PATHOL, V50, P765; Seven H, 2004, AM J OTOLARYNG, V25, P11, DOI 10.1016/j.amjoto.2003.10.002; Thompson LDR, 1998, CANCER, V82, P944, DOI 10.1002/(SICI)1097-0142(19980301)82:5<944::AID-CNCR21>3.0.CO;2-#	18	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					263	268		10.1016/j.annpat.2018.07.006			6	Pathology	Pathology	HU8CP	WOS:000465510300002	30107935				2019-10-28	
J	Martineau, VC				Martineau, Valerie Costes			ENT benign lesions and pseudo-tumors: Case No. 2	ANNALES DE PATHOLOGIE			French	Editorial Material							KERATOCYSTIC ODONTOGENIC-TUMOR; UNICYSTIC AMELOBLASTOMA; CYST; EXPRESSION		[Martineau, Valerie Costes] CHU Montpellier, Dept Biopathol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France	Martineau, VC (reprint author), CHU Montpellier, Dept Biopathol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	v-costes_martineau@chu-montpellier.fr					Agaram NP, 2004, ARCH PATHOL LAB MED, V128, P313; Aragaki T, 2010, HUM PATHOL, V41, P1718, DOI 10.1016/j.humpath.2010.05.007; Boffano P, 2010, J ORAL MAXIL SURG, V68, P2994, DOI 10.1016/j.joms.2010.05.068; Cairns L, 2010, HISTOPATHOLOGY, V57, P544, DOI 10.1111/j.1365-2559.2010.03658.x; Carter LC, 1996, ORAL SURG ORAL MED O, V81, P210, DOI 10.1016/S1079-2104(96)80417-3; Dong Q, 2010, ARCH PATHOL LAB MED, V134, P271, DOI 10.1043/1543-2165-134.2.271; Fowler CB, 2011, HEAD NECK PATHOL, V5, P364, DOI 10.1007/s12105-011-0298-3; Henley J, 2005, HISTOPATHOLOGY, V47, P582, DOI 10.1111/j.1365-2559.2005.02267.x; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Li TJ, 2000, AM J SURG PATHOL, V24, P1385, DOI 10.1097/00000478-200010000-00008; Philipsen HP, 1998, ORAL ONCOL, V34, P317, DOI 10.1016/S1368-8375(98)00012-8; Gurgel CAS, 2008, J MOL HISTOL, V39, P311, DOI 10.1007/s10735-008-9167-0; Takeda Yasunori, 2005, J Oral Sci, V47, P77, DOI 10.2334/josnusd.47.77; Wooo SB., 2012, ORAL PATHOLOGY COMPR, P328; Zhang LL, 2010, INT J ORAL MAX SURG, V39, P878, DOI 10.1016/j.ijom.2010.04.048	15	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					269	273		10.1016/j.annpat.2018.07.007			5	Pathology	Pathology	HU8CP	WOS:000465510300003	30126763				2019-10-28	
J	Wassef, M				Wassef, Michel			ENT benign lesions and pseudo-tumors: Case No. 3	ANNALES DE PATHOLOGIE			French	Editorial Material							MIDDLE-EAR ADENOMA; CARCINOID-TUMOR		[Wassef, Michel] Univ Paris Diderot, Hop Lariboisiere, AP HP, 2 Rue Ambroise Pare, F-75475 Paris 10, France	Wassef, M (reprint author), Univ Paris Diderot, Hop Lariboisiere, AP HP, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	michel.wassef@aphp.fr					Agaimy A, 2015, HISTOPATHOLOGY, V66, P182, DOI 10.1111/his.12447; Bell D, 2017, VIRCHOWS ARCH, V471, P667, DOI 10.1007/s00428-017-2155-6; Et-Naggar AK, 2017, WHO CLASSIFICATION H; Fundakowski CE, 2013, LARYNGOSCOPE, V123, P779, DOI 10.1002/lary.23434; Liu G, 2014, INT J CLIN EXP PATHO, V7, P7105; Muller M, 2010, J LARYNGOL OTOL, V124, P108, DOI 10.1017/S0022215109990442; Ramsey MJ, 2005, LARYNGOSCOPE, V115, P1660, DOI 10.1097/01.mlg.0000175069.13685.37; Torske KR, 2002, MODERN PATHOL, V15, P543, DOI 10.1038/modpathol.3880561; WASSEF M, 1993, ANN PATHOL, V13, P170; WASSEF M, 1989, AM J SURG PATHOL, V13, P838, DOI 10.1097/00000478-198910000-00003	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					274	278		10.1016/j.annpat.2018.07.008			5	Pathology	Pathology	HU8CP	WOS:000465510300004	30100190				2019-10-28	
J	Wassef, M				Wassef, Michel			ENT benign lesions and pseudo-tumors: Case No. 4	ANNALES DE PATHOLOGIE			French	Editorial Material									[Wassef, Michel] Univ Paris Diderot, Hop Lariboisiere, AP HP, 2 Rue Ambroise Pare, F-75475 Paris 10, France	Wassef, M (reprint author), Univ Paris Diderot, Hop Lariboisiere, AP HP, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	michel.wassef@aphp.fr					BATSAKIS JG, 1992, ANN OTO RHINOL LARYN, V101, P623, DOI 10.1177/000348949210100716; Ding CW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001196; Gupta R, 2013, INDIAN J OTOLARYNGOL, V65, P52, DOI 10.1007/s12070-012-0602-x; Tam YY, 2016, INT J GEN MED, V9, P207, DOI 10.2147/IJGM.S104628; Wang YZ, 2012, AM J NEURORADIOL, V33, P767, DOI 10.3174/ajnr.A2856; Wenig BM, 2017, NONNEOPLASTIC DIS HE; Yokoi Hidenori, 2014, Ear Nose Throat J, V93, pE23; 2012, VIRCHOWS ARCH, V460, P203, DOI DOI 10.1007/S00428-011-1192-9; ARCH PATHOL LAB MED, V124, P406	9	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					279	282		10.1016/j.annpat.2018.07.009			4	Pathology	Pathology	HU8CP	WOS:000465510300005	30126764				2019-10-28	
J	Uro-Coste, E				Uro-Coste, Emmanuelle			ENT benign lesions and pseudo-tumors: Case No. 5	ANNALES DE PATHOLOGIE			French	Editorial Material									[Uro-Coste, Emmanuelle] CHU Toulouse, Inst Univ Canc Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Uro-Coste, E (reprint author), CHU Toulouse, Inst Univ Canc Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.	uro-coste.e@chu-toulouse.fr					Asa SL, 2018, HISTOPATHOLOGY, V72, P133, DOI 10.1111/his.13295; Lopes MBS, 2017, ACTA NEUROPATHOL, V134, P521, DOI 10.1007/s00401-017-1769-8; Osamura RY, IARC WHO CLASSIFICAT, P14; Vasiljevic A, 2016, MINERVA ENDOCRINOL, V41, P377	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					283	287		10.1016/j.annpat.2018.07.010			5	Pathology	Pathology	HU8CP	WOS:000465510300006	30201430				2019-10-28	
J	Uro-Coste, E				Uro-Coste, Emmanuelle			ENT benign lesions and pseudo-tumors: Case No. 6	ANNALES DE PATHOLOGIE			French	Editorial Material									[Uro-Coste, Emmanuelle] CHU Toulouse, Inst Univ Canc Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Uro-Coste, E (reprint author), CHU Toulouse, Inst Univ Canc Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.	uro-coste.e@chu-toulouse.fr					El-Naggar AK, 2017, WHO CLASS HEAD NECK, V9; Evrard SM, 2017, CYTOPATHOLOGY, V28, P312, DOI 10.1111/cyt.12427; Malzone MG, 2015, DIAGN CYTOPATHOL, V43, P654, DOI 10.1002/dc.23275; Uro-Coste Emmanuelle, 2011, Ann Pathol, V31, pS100, DOI 10.1016/j.annpat.2011.08.004	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					288	292		10.1016/j.annpat.2018.07.011			5	Pathology	Pathology	HU8CP	WOS:000465510300007	30224268				2019-10-28	
J	Badoual, C				Badoual, Cecile			ENT benign lesions and pseudo-tumors: Case No. 7	ANNALES DE PATHOLOGIE			French	Editorial Material							EX-PLEOMORPHIC ADENOMA; EXPRESSION; PLAG1		[Badoual, Cecile] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Anatomopathol, F-75015 Paris, France	Badoual, C (reprint author), Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Anatomopathol, F-75015 Paris, France.	cecile.badoual@aphp.fr					[Anonymous], 2017, B ACAD INT PATHOLOGI; Antony J, 2012, HEAD NECK PATHOL, V6, P1, DOI 10.1007/s12105-011-0281-z; de Brito BS, 2016, HUM PATHOL, V57, P152, DOI 10.1016/j.humpath.2016.07.011; El-Naggar AK, 2017, WHO CLASSIFICATION T; Ellis G. L., 2008, ATLAS TUMOR PATHOLOG; Ihrler S, 2007, HISTOPATHOLOGY, V51, P362, DOI 10.1111/j.1365-2559.2007.02736.x; Martins C, 2005, MODERN PATHOL, V18, P1048, DOI 10.1038/modpathol.3800386; ROSE GE, 1992, BRIT J OPHTHALMOL, V76, P395, DOI 10.1136/bjo.76.7.395; Salzman R, 2014, VIRCHOWS ARCH, V464, P29, DOI 10.1007/s00428-013-1502-5; Seethala RR, 2017, HEAD NECK PATHOL, V11, P55, DOI 10.1007/s12105-017-0795-0; Skalova A, 2012, AM J SURG PATHOL, V36, P1674, DOI 10.1097/PAS.0b013e3182690afe; Sobin LH, 2010, TNM CLASSIFICATION M; Thompson LDR, 2013, HEAD NECK PATHOLOGY; Weinreb I, 2013, ADV ANAT PATHOL, V20, P367, DOI 10.1097/PAP.0b013e3182a92cc3	14	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					293	298		10.1016/j.annpat.2018.08.002			6	Pathology	Pathology	HU8CP	WOS:000465510300008	30220544				2019-10-28	
J	Badoual, C				Badoual, Cecile			ENT benign lesions and pseudo-tumors: Case no 8	ANNALES DE PATHOLOGIE			French	Editorial Material									[Badoual, Cecile] Univ Paris 05, Hop Europeen G Pompidou, AP HP, Serv Anatomopathol, 20 Rue Leblanc, F-75015 Paris, France	Badoual, C (reprint author), Univ Paris 05, Hop Europeen G Pompidou, AP HP, Serv Anatomopathol, 20 Rue Leblanc, F-75015 Paris, France.	cecile.badoual@aphp.fr					[Anonymous], 2017, B ACAD INT PATHOLOGI; El-Naggar AK, 2017, WHO CLASSIFICATION T; Ellis G. L., 2008, ATLAS TUMOR PATHOLOG; Seethala RR, 2017, HEAD NECK PATHOL, V11, P55, DOI 10.1007/s12105-017-0795-0; Thompson LDR, 2013, HEAD NECK PATHOLOGY; Zarbo RJ, 2002, MODERN PATHOL, V15, P298, DOI 10.1038/modpathol.3880525	6	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					299	304		10.1016/j.annpat.2018.08.001			6	Pathology	Pathology	HU8CP	WOS:000465510300009	30217402				2019-10-28	
J	Moulonguet, I				Moulonguet, Isabelle			Dermatopathology histoseminar. Interstitial granuloma annulare, case 8	ANNALES DE PATHOLOGIE			French	Editorial Material							MYCOSIS-FUNGOIDES; DERMATITIS		[Moulonguet, Isabelle] Cabinet Dermatopathol Mathurin Moreau, 35 Ave Mathurin Moreau, F-75019 Paris, France	Moulonguet, I (reprint author), Cabinet Dermatopathol Mathurin Moreau, 35 Ave Mathurin Moreau, F-75019 Paris, France.	imoulonguetmichau@gmail.com					Coutinho I, 2015, AM J DERMATOPATH, V37, P614, DOI 10.1097/DAD.0000000000000288; Hartman RI, 2013, AM J DERMATOPATH, V35, P601, DOI 10.1097/DAD.0b013e31827e2fc1; Lenormand C, 2016, J AM ACAD DERMATOL, V74, P685, DOI 10.1016/j.jaad.2015.10.046; Peroni A, 2012, BRIT J DERMATOL, V166, P775, DOI [10.1111/j.1365-2133.2012.10727.x, 10.1111/j.1365-2133.2011.10727.x]; Piette EW, 2016, J AM ACAD DERMATOL, V75, P457, DOI 10.1016/j.jaad.2015.03.054; Reggiani C, 2016, AM J SURG PATHOL, V40, P1360, DOI 10.1097/PAS.0000000000000679; Rongioletti F, 2016, J AM ACAD DERMATOL, V74, P1194, DOI 10.1016/j.jaad.2015.12.021; Sezer E, 2011, J CUTAN PATHOL, V38, P439, DOI 10.1111/j.1600-0560.2010.01657.x; Su LD, 2002, J CUTAN PATHOL, V29, P135, DOI 10.1034/j.1600-0560.2002.290302.x; 2003, J AM ACAD DERMATOL, V48, P376, DOI DOI 10.1067/MJD.2003.90	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					305	313		10.1016/j.annpat.2018.09.001			9	Pathology	Pathology	HU8CP	WOS:000465510300010	30236823				2019-10-28	
J	Sabour, S				Sabour, Siamak			The 2015 classification of lung adenocarcinomas: Methodological issue on reproducibility	ANNALES DE PATHOLOGIE			English	Letter									[Sabour, Siamak] Shahid Beheshti Univ Med Sci, Dept Clin Epidemiol, Sch Publ Hlth, Tehran, Iran; [Sabour, Siamak] Shahid Beheshti Univ Med Sci, Safety Promot & Injury Prevent Res Ctr, Tehran, Iran	Sabour, S (reprint author), Shahid Beheshti Univ Med Sci, Dept Clin Epidemiol, Sch Hlth, Safety Promot & Injury Prevent Res Ctr, Chamran Highway,Daneshjoo Blvd, Tehran, Iran.	s.sabour@sbmu.ac.ir		Sabour, Siamak/0000-0002-1928-992X			Mlika M, 2017, ANN PATHOL, V37, P467, DOI 10.1016/j.annpat.2017.09.002; Sabour S, 2017, BLOOD PRESS MONIT, V22, P244, DOI 10.1097/MBP.0000000000000263; Sabour S, 2016, GRAEF ARCH CLIN EXP, V254, P2073, DOI 10.1007/s00417-016-3420-0; Sabour S, 2015, CORNEA, V34, pE14, DOI 10.1097/ICO.0000000000000401; Sabour S, 2015, AM J ROENTGENOL, V204, pW493, DOI 10.2214/AJR.14.13870; Szklo M., 2007, EPIDEMIOLOGY BASICS	6	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					314	315		10.1016/j.annpat.2018.04.004			2	Pathology	Pathology	HU8CP	WOS:000465510300011	29866533				2019-10-28	
J	Doh, K; Thiam, I; Takin, RCA; Sonhaye, K; Woto-Gaye, G				Doh, Kwame; Thiam, Ibou; Takin, Romulus Carmen Adechina; Sonhaye, Khaled; Woto-Gaye, Gisele			A rare parotid tumor	ANNALES DE PATHOLOGIE			French	Article						Sebaceous lymphadenoma; Parotid; Histopathology; Immunohistochemistry	LYMPHADENOMA; GLAND	Introduction. - Sebaceous lymphadenoma of the parotid (SLP) is a rare, benign tumor with similar epidemiological and macroscopic characteristics with other sebaceous differentiated tumors of the parotid (SDTP). The authors report a case of SLP in an 80-year-old woman. They then recall the distinctive histological and immunohistochemical criteria of SDTP. Observation. - Mrs P. D. was received during a surgical consultation for the management of a painless right parotid swelling that has evolved for 10 years, increasing slightly in volume. At admission, the mass was movable, firm with a healthy skin without facial paralysis or satellite lymphadenopathy. The surgical intervention performed removed a nodular mass measuring 7 cm, encapsulated, yellowish. It was made of regular epithelial cells without atypia or mitoses organized in nests, trabeculae and massifs. This tumor also included small canalicular cystic dilatations associated with several islands of sebaceous glands. The stroma was dense lymphoid with follicles and germinal centers. The tumor cells were CK7+, P63+, MSA+ and had a Ki67 < 5%. The diagnosis of an SLP was retained. No additional therapy was performed. One year after surgery, the patient had no local recurrence or metastatic foci. Conclusion. - SLP is a rare tumor with a particular histological and immunohistochemical profile. It is an epithelial tumor with sebaceous islands, a dense reactional lymphoid stroma, expression of luminal and basal epithelial markers and a low proliferation index. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Doh, Kwame; Thiam, Ibou; Woto-Gaye, Gisele] Hop Aristide Le Dantec, Lab Anat & Cytol Pathol, Pavillon Bichat,Ave Pasteur,BP 3001, Dakar, Senegal; [Sonhaye, Khaled] Hop Reg Ziguinchor, Serv ORL & CCF, BP 535, Ziguinchor, Senegal; [Takin, Romulus Carmen Adechina] Hop Gen Troyes, Lab Anat & Cytol Pathol, Hop Reg Troyes, 101 Ave Anatole France, F-10000 Troyes, France	Doh, K (reprint author), Hop Aristide Le Dantec, Lab Anat & Cytol Pathol, Pavillon Bichat,Ave Pasteur,BP 3001, Dakar, Senegal.	kwame.doh@ucad.edu.sn; dribouthiam@yahoo.fr; rtakin@yahoo.fr; ksonhaye@yahoo.fr		DOH, Kwame/0000-0002-9894-985X			Khmou M, 2016, BMC CLIN PATHOL, V16, P1; Liu GL, 2014, ONCOL LETT, V7, P1097, DOI 10.3892/ol.2014.1827; Mariappan AR, 2004, ARCH PATHOL LAB MED, V128, P245; Rawlinson NJ, 2010, HEAD NECK PATHOL, V4, P144, DOI 10.1007/s12105-010-0167-5; Seethala RR, 2012, MODERN PATHOL, V25, P26, DOI 10.1038/modpathol.2011.135	5	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					321	324		10.1016/j.annpat.2018.04.005			4	Pathology	Pathology	HU8CP	WOS:000465510300013	29880294				2019-10-28	
J	Zehani, A; Chelly, I; Ben Said, I; Jmel, H; Haouet, S; Kchir, N				Zehani, Alia; Chelly, Ines; Ben Said, Imed; Jmel, Hafedh; Haouet, Slim; Kchir, Nidhameddine			A misleading oncocytic tumor of the pituitary gland	ANNALES DE PATHOLOGIE			French	Editorial Material							SPINDLE-CELL ONCOCYTOMA; ADENOHYPOPHYSIS		[Zehani, Alia; Chelly, Ines; Haouet, Slim; Kchir, Nidhameddine] Hop La Rabta, Serv Anat Pathol, Tunis, Tunisia; [Ben Said, Imed; Jmel, Hafedh] Inst Neurol Tunis, Serv Neurochirurg, Tunis, Tunisia	Zehani, A (reprint author), Rue Mohamed Rached Beji,Residence Ichbilia 1, Tunis, Tunisia.	alia.zehanikassar@gmail.com					Asa SL, 2018, HISTOPATHOLOGY, V72, P133, DOI 10.1111/his.13295; Lopes MBS, 2016, WHO CLASSIFICATION T, P334; Mete O, 2013, AM J SURG PATHOL, V37, P1694, DOI 10.1097/PAS.0b013e31829723e7; Osman M, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.903702; Roncaroli F, 2002, AM J SURG PATHOL, V26, P1048, DOI 10.1097/01.PAS.0000020480.56467.9B; Vuong HG, 2016, PATHOL RES PRACT, V212, P222, DOI 10.1016/j.prp.2015.07.014; 2011, BRAIN TUMOR PATHOL, V28, P359, DOI DOI 10.1007/S10014-011-0051-3	7	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					325	327		10.1016/j.annpat.2018.04.002			3	Pathology	Pathology	HU8CP	WOS:000465510300014	29866532				2019-10-28	
J	Tredez, E; Attencourt, C; Le Mouel, JP; Fumery, M; Chatelain, D				Tredez, Estelle; Attencourt, Christophe; Le Mouel, Jean-Philippe; Fumery, Mathurin; Chatelain, Denis			Ring mitoses	ANNALES DE PATHOLOGIE			French	Editorial Material									[Tredez, Estelle; Attencourt, Christophe; Chatelain, Denis] CHU Amiens Nord, Serv Anat Pathol, Pl Victor Pauchet, F-80000 Amiens, France; [Le Mouel, Jean-Philippe; Fumery, Mathurin] CHU Amiens Sud, Serv Gastroenterol, Ave Laennec, F-80480 Salouel, France	Tredez, E (reprint author), CHU Amiens Nord, Serv Anat Pathol, Pl Victor Pauchet, F-80000 Amiens, France.	tredez.estelle@chu-amiens.fr					Daniels JA, 2008, AM J SURG PATHOL, V32, P473, DOI 10.1097/PAS.0b013e3181582331; Iacobuzio-Donahue CA, 2001, AM J SURG PATHOL, V25, P1067, DOI 10.1097/00000478-200108000-00012; Ma C, 2014, DIAGN HISTOPATHOL, V20, P46; STEMMERMANN GN, 1971, HUM PATHOL, V2, P321, DOI 10.1016/S0046-8177(71)80040-0; Wollersen H, 2009, LEG MED, V11, pS498	5	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	OCT	2018	38	5					328	330		10.1016/j.annpat.2018.05.002			3	Pathology	Pathology	HU8CP	WOS:000465510300015	29907342				2019-10-28	
J	Lu, NH; Du, YR; Li, HY; Luo, Y; Ouyang, B; Chen, YJ; Yang, YR; Yang, LX				Lu, Nihong; Du, Yingrong; Li, Haiyuan; Luo, Yu; Ouyang, Bing; Chen, Yangjun; Yang, Yongrui; Yang, Lixia			Omega-6 fatty acids down-regulate matrix metalloproteinase expression in a coronary heart disease-induced rat model	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						antioxidant; enzymes; matrix metalloproteinases; omega-6 fatty acids; rats	CEREBRAL-ISCHEMIA; FISH-OIL; PARAMETERS; LIVER	The present study investigated the therapeutic potential of omega-6 fatty acids, according to their effects on antioxidant markers and matrix metalloproteinases (MMPs), in coronary heart disease-induced rats. Rats were grouped into group I (sham control), group II (control), group III (0.5 g/kg bwt of omega-6 fatty acids) and group IV (1 g/kg bwt of omega-6 fatty acids). Reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), reduced glutathione (GSH), catalase, glutathione peroxidase (Gpx) and acetylcholinesterase (AChE) enzyme activities were determined. ROS and MDA were substantially reduced, whereas SOD, catalase, Gpx and AChE were significantly increased, following supplementation with omega-6 fatty acids. MMP-2 mRNA expression was drastically increased by 95% in group II. Treatment significantly reduced MMP-2 mRNA expression by 12.3% and 26.7% in groups III and IV respectively. MMP-9 mRNA expression drastically increased, by 121%, in group II. Treatment significantly reduced MMP-9 mRNA expression by 22.6% and 29.4% in groups III and IV respectively. MMP-2 protein expression was drastically increased, by 81%, in group II. Treatment significantly reduced MMP-2 protein expression by 9.4% and 26% in groups III and IV respectively. MMP-9 protein expression was drastically increased, by 100%, in group II. Treatment significantly reduced MMP-9 protein expression by 18.9% and 26.9% in groups III and IV respectively. In summary, the consumption of omega-6 fatty acids significantly decreased MDA and ROS, while SOD, catalase, GHS, Gpx and AChE were increased. Furthermore, omega-6 fatty acids significantly downregulated MMP-2 and MMP-9 expression in our coronary heart disease-induced rat model.	[Lu, Nihong; Ouyang, Bing; Chen, Yangjun] Kunming Med Univ, Peoples Hosp 3, Dept Resp Med, Kunming, Yunnan, Peoples R China; [Du, Yingrong; Luo, Yu; Chen, Yangjun] Third Peoples Hosp Kunming, Dept Cardiol, Kunming, Yunnan, Peoples R China; [Li, Haiyuan] Kunming Med Univ, Affiliated Hosp 1, Dept Urol Med, Kunming, Yunnan, Peoples R China; [Yang, Lixia] Kunming Med Univ, Kunming Gen Hosp, Chengdu Mil Area, Dept Cardiol, Kunming, Yunnan, Peoples R China	Yang, LX (reprint author), Kunming Med Univ, Kunming Gen Hosp, Chengdu Mil Area, Dept Cardiol, Kunming, Yunnan, Peoples R China.	LoriwHallqc@yahoo.com			Project of Yunnan Science and Technology Department [2017FB147]	This study was supported by Project of Yunnan Science and Technology Department (2017FB147)	Arutyunyan TV, 2016, B EXP BIOL MED+, V160, P635, DOI 10.1007/s10517-016-3236-2; Bas O, 2007, NEUROCHEM INT, V50, P548, DOI 10.1016/j.neuint.2006.11.005; Dmitriev AD, 2005, CLIN CHIM ACTA, V356, P76, DOI 10.1016/j.cccn.2004.12.019; Erden Inal Mine, 2003, J Am Aging Assoc, V26, P55, DOI 10.1007/s11357-003-0005-8; Evilsizor MN, 2015, JOVE-J VIS EXP, V99, P52293; Gaiva MH, 2003, NUTRITION, V19, P144, DOI 10.1016/S0899-9007(02)00909-7; Guo X, 2018, EBIOMEDICINE, V27, P214, DOI 10.1016/j.ebiom.2017.12.013; Hammamieh R, 2007, BREAST CANCER RES TR, V101, P7, DOI 10.1007/s10549-006-9269-x; Harris MA, 2001, PROSTAG LEUKOTR ESS, V65, P23, DOI 10.1054/plef.2001.0283; Kaddour T., 2016, J ACUTE DIS, V5, P470, DOI DOI 10.1016/J.JOAD.2016.08.028; Khandelwal Shweta, 2013, J Preventive Cardiol, V2, P325; McCabe AJ, 1999, LIPIDS, V34, pS217, DOI 10.1007/BF02562295; Merendino N, 2013, BIOMED RES INT, DOI 10.1155/2013/310186; Mittal B, 2014, ADV CLIN CHEM, V64, P1, DOI 10.1016/B978-0-12-800263-6.00001-X; Ozen OA, 2008, NEUROL SCI, V29, P147, DOI 10.1007/s10072-008-0926-1; Patel SP, 2006, INDIAN J CLIN BIOCHE, V21, P48, DOI 10.1007/BF02913066; Popovic T, 2012, J ANIM PHYSIOL AN N, V96, P1020, DOI 10.1111/j.1439-0396.2011.01216.x; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P1515, DOI 10.1161/01.ATV.13.10.1515; Salvati S, 2006, MINI-REV MED CHEM, V6, P1201, DOI 10.2174/138955706778742740; Simopoulos AP, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030128; Smi CK, 2004, DEV BRAIN RES, V152, P11, DOI 10.1016/j.debrainres.2004.05.004; Songur A, 2004, PROG NEURO-PSYCHOPH, V28, P693, DOI 10.1016/j.pnpbp.2004.05.006; Verschuren L, 2011, J NUTR, V141, P863, DOI 10.3945/jn.110.133751; Yan L, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-33; Yang DY, 2007, NEUROTOXICOLOGY, V28, P1220, DOI 10.1016/j.neuro.2007.08.003; Zurmanova J, 2008, PHYSIOL RES, V57, P973; 2005, INDIAN J PEDIATR, V72, P239	27	0	0	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					210	217		10.1111/iep.12293			8	Pathology	Pathology	HF3DY	WOS:000454116900001	30443948				2019-10-28	
J	Latini, JTP; Vicente, GC; Velarde, LGC; Benedicto, HG; Resende, AD; Teixeira, MT; de Almeida, KCL; Boaventura, GT				Pacheco Latini, Juliana Tomaz; Vicente, Gabriela Camara; Coca Velarde, Luis Guillermo; Benedicto, Hildebrando Gomes; Resende, Angela de Castro; Teixeira, Michelle Teixeira; Lenzi de Almeida, Katia Calvi; Boaventura, Gilson Teles			Can the indicators of chronic ethanol consumption be minimized by a continuous flaxseed intake?	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						ethanol; flaxseed; hepatotoxicity; liver; rats	LINUM-USITATISSIMUM; RATS; PROFILE; IMPACT; DAMAGE; DIET; OIL	The aim of this study was to evaluate the use of flaxseed in animals subjected to ethanol-induced hepatotoxicity. Twenty-four male rats were divided into four groups (n = 6): control group (CG) which received a control diet and water ad libitum; flaxseed group (FG) which received control diet with an addition of 25% flaxseed flour and water ad libitum; ethanol control group (ECG) which received control diet and a solution of 10% ethanol (v/v) as the only liquid source; and ethanol flaxseed group (EFG) which received control diet with an addition of 25% flaxseed flour and a solution of 10% ethanol (v/v) as the only liquid source. The animals were euthanized at 60 days, when blood was collected for biochemical analysis and liver was collected for histomorphometric analysis. Rats fed with diets containing flaxseed showed lower values of alkaline phosphatase (P = 0.020) and lower concentration of total bilirubin (P = 0.006), direct bilirubin (P = 0.013) and indirect bilirubin (P = 0.018) compared to ECG and EFG. The groups receiving flaxseed diets demonstrated higher expression of superoxide dismutase (SOD) enzyme (P < 0.001) than CG and ECG but did not affect thiobarbituric acid (TBARS) expression (P = 0.055). Regarding liver analysis, the ECG and EFG showed larger hepatocyte nuclei and paler cytoplasm than the groups who had not received ethanol, and less in fluid accumulation (oedema) in the cytoplasm than was seen in the FG and EFG livers. These latter two groups showed fewer fatty cells than was seen in the groups that had not been given flaxseed, so that the diagnosis of hepatic steatosis was not justified. In conclusion, therefore, this study showed that the indicators of ethanol chronic consumption can be reduced by the introduction of continuous flaxseed dietary intake.	[Pacheco Latini, Juliana Tomaz] Univ Fed Rio de Janeiro, Pharm Coll, Macae Campus, Rio De Janeiro, RJ, Brazil; [Vicente, Gabriela Camara; Boaventura, Gilson Teles] Fed Fluminense Univ, Nutr Coll, Dept Nutr & Dietet, Lab Expt Nutr, Niteroi, RJ, Brazil; [Coca Velarde, Luis Guillermo] Fed Fluminense Univ, Stat Dept, Niteroi, RJ, Brazil; [Benedicto, Hildebrando Gomes] Fed Fluminense Univ, Dept Morphol, Niteroi, RJ, Brazil; [Resende, Angela de Castro] Univ Estado Rio De Janeiro, Dept Pharmacol & Psychobiol, Rio De Janeiro, RJ, Brazil; [Lenzi de Almeida, Katia Calvi] Univ Fed Rio de Janeiro, Med Coll, Macae Campus, Rio De Janeiro, RJ, Brazil; [Teixeira, Michelle Teixeira] Fed Univ State Rio De Janeiro, Sch Nutr, Dept Nutr & Publ Hlth, Rio De Janeiro, RJ, Brazil	Latini, JTP (reprint author), Univ Fed Rio De Janeiro, Campus Macae, Rio De Janeiro, Brazil.	julianatomaz@yahoo.com.br		Vicente, Gabriela/0000-0001-5486-3416	Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior	Aguiar AS, 2008, BIOL RES, V42, P31; Brant LHC, 2012, ACTA CIR BRAS, V27, P537, DOI 10.1590/S0102-86502012000800004; Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1; Clapauch Ruth, 2002, Arq Bras Endocrinol Metab, V46, P679, DOI 10.1590/S0004-27302002000600013; Correia-Santos AM, 2017, NUTR FOOD SCI, V47, P477, DOI 10.1108/NFS-03-2017-0041; Daleprane JB, 2010, FOOD RES INT, V43, P2052, DOI 10.1016/j.foodres.2010.06.004; Dugani A, 2008, LIBYAN J MED, V3, P166, DOI 10.4176/080612; Leite CDFC, 2011, NUTR HOSP, V26, P415, DOI [10.3305/nh.2011.26.2.5188, 10.1590/S0212-16112011000200026]; Flower G, 2013, MEAT SCI, V96, P541; Haliga RE, 2013, SCI WORLD J, DOI 10.1155/2013/303950; Hu C, 2007, FOOD CHEM TOXICOL, V45, P2219, DOI 10.1016/j.fct.2007.05.017; Kajla P, 2015, J FOOD SCI TECH MYS, V52, P1857, DOI 10.1007/s13197-014-1293-y; Kasote DM, 2012, J PHARM BIOALLIED SC, V4, P231, DOI 10.4103/0975-7406.99064; Keshavarzian A, 2009, J HEPATOL, V50, P538, DOI 10.1016/j.jhep.2008.10.028; Almeida KCL, 2011, NUTR HOSP, V26, P991, DOI [10.3305/nh.2011.26.5.5149, 10.1590/S0212-16112011000500011]; Mallikarjuna K, 2009, ALCOHOL, V43, P59, DOI 10.1016/j.alcohol.2008.09.003; Cardozo LFMD, 2010, NUTR HOSP, V25, P250, DOI 10.3305/nh.2010.25.2.4289; Cardozo LFMD, 2012, FOOD CHEM TOXICOL, V50, P4092, DOI 10.1016/j.fct.2012.08.039; Morris D. H., 2007, LINAZA RECOPILACION; National Research Council (US) Institute for Laboratory Animal Research, 2011, GUIDANCE DESCRIPTION; Pacheco JT, 2011, NUTR HOSP, V26, P798, DOI [10.1590/S0212-16112011000400019, 10.3305/nh.2011.26.4.5045]; Prasad K, 2016, CURR PHARM DESIGN, V22, P141, DOI 10.2174/1381612822666151112151230; Rajesha J, 2006, J AGR FOOD CHEM, V54, P3794, DOI 10.1021/jf053048a; REEVES PG, 1993, J NUTR, V123, P1939; Riediger ND, 2008, EUR J NUTR, V47, P153, DOI 10.1007/s00394-008-0709-8; Shim YY, 2014, TRENDS FOOD SCI TECH, V38, P5, DOI 10.1016/j.tifs.2014.03.011; da Costa CA, 2016, FOOD FUNCT, V7, P698, DOI 10.1039/c5fo01598g; Takenaka A, 2003, BIOSCI BIOTECH BIOCH, V67, P278, DOI 10.1271/bbb.67.278; Yang HY, 2012, J NUTR BIOCHEM, V23, P679, DOI 10.1016/j.jnutbio.2011.03.016; Yang SF, 2009, J AGR FOOD CHEM, V57, P5078, DOI 10.1021/jf900499v	30	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					218	225		10.1111/iep.12288			8	Pathology	Pathology	HF3DY	WOS:000454116900002	30338600				2019-10-28	
J	Costa, KCT; de Sousa, BB; Dias, EHV; Pereira, DFD; Matias, MS; Oliveira, WJ; Mundim, AV; Mamede, CCN; Izidoro, LFM; Costa, JD; de Oliveira, F				Torres Costa, Kellen Cristina; de Sousa, Bruna Barbosa; Vaz Dias, Edigar Henrique; da Cunha Pereira, Deborah Fernanda; Matias, Mariana Santos; Oliveira, Wilson Junior; Mundim, Antonio Vicente; Neves Mamede, Carla Cristine; Moreira Izidoro, Luiz Fernando; Costa, Junia de Oliveira; de Oliveira, Fabio			Systemic alterations induced by phospholipase A(2), BmooTX-I, isolated from Bothrops moojeni snake venom	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						biochemical parameters; Bothrops moojeni; phospholipase A(2); snake venom; systemic alterations; urinalysis	HEMORRHAGIC STROKE; BILIRUBIN; MYOTOXINS; CHILDREN	Ophidic accidents are among the problems of public health in Brazil. The components from bothropic venom are responsible for many systemic clinical complications resulting from envenomation. The present work aimed to analyse the systemic changes induced in mice after intraperitoneal administration of BmooTX-I, a myotoxic acidic phospholipase A(2) isolated from Bothrops moojeni venom. Urinalysis was performed and the following plasma biochemical markers were documented: urea, creatinine and uric acid (renal function); glucose and amylase (pancreatic function); alanine aminotransferase, alkaline phosphatase and gamma-GT (intra- and extrahepatic function); creatine kinase and enzymatic lactate (muscle function). Our results showed that after the intraperitoneal injection of BmooTX-I the urine of these animals showed glycosuria, proteinuria, haematuria, bacteriuria, bilirubinuria, polyuria and nitrite. The plasma biochemical analysis showed alterations in levels of urea, creatinine and uric acid. Amylase concentration was not altered significantly, but the plasma glucose increased significantly compared to controls. The plasma levels of alanine aminotransferase and alkaline phosphatase decreased and increased, respectively, in these same animals. On the other hand, the plasma gamma GT concentration did not undergo significant modification compared to the control group. The plasma concentration of CK increased, while the enzymatic lactate concentration decreased after the injection of the BmooTX-I. Therefore, in mice BmooTX-I is capable of causing systemic alterations which manifest as renal, muscular, hepatic and pancreatic impairment.	[Torres Costa, Kellen Cristina; de Oliveira, Fabio] Univ Fed Uberlandia, Inst Ciencias Biomed, Uberlandia, MG, Brazil; [Torres Costa, Kellen Cristina; de Sousa, Bruna Barbosa; Vaz Dias, Edigar Henrique; da Cunha Pereira, Deborah Fernanda; Matias, Mariana Santos] Univ Fed Uberlandia, Inst Genet & Bioquim, Uberlandia, MG, Brazil; [Torres Costa, Kellen Cristina; Neves Mamede, Carla Cristine; de Oliveira, Fabio] Inst Nacl Ciencia & Tecnol Nanobiofarmaceut N Bio, Belo Horizonte, MG, Brazil; [Oliveira, Wilson Junior; Mundim, Antonio Vicente] Univ Fed Uberlandia, Fac Med Vet, Uberlandia, MG, Brazil; [Neves Mamede, Carla Cristine] Univ Fed Uberlandia, Inst Ciencias Agr, Monte Carmelo, MG, Brazil; [Moreira Izidoro, Luiz Fernando] Univ Fed Uberlandia, Fac Med, Uberlandia, MG, Brazil; [Costa, Junia de Oliveira] Inst Fed Educ Ciencia & Tecnol Triangulo Mineiro, Campus Ituiutaba, Ituiutaba, MG, Brazil	de Oliveira, F (reprint author), Univ Fed Uberlandia, Inst Ciencias Biomed, Uberlandia, MG, Brazil.; Costa, JD (reprint author), Inst Fed Educ Ciencia & Tecnol Triangulo Mineiro, Campus Ituiutaba, Ituiutaba, MG, Brazil.	juniacosta@iftm.edu.br; fabio@ufu.br			Fundacao de Amparo a Pesquisa do Estado deMinas Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES)CAPES; Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes (MCTIC) of Brazil	This work was supported by Fundacao de Amparo a Pesquisa do Estado deMinas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES) and Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes (MCTIC) of Brazil.	Amaral CF, 1985, REV INST MED TROP SP, V28, P220; Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0; Baptistella MF, 2009, ANU PRODUCAO INICIAC, V13, P33; Barbosa PSF, 2002, TOXICON, V40, P1427, DOI 10.1016/S0041-0101(02)00156-3; Barraviera B, 1999, OFIDIOS ESTUDOS CLIN; BERNILS R.S., 2012, REPTEIS BRASILEIROS; Beutler E, 2000, WILLIAMS HEMATOLOGY; Boer-Lima PA, 2002, AM J TROP MED HYG, V67, P217, DOI 10.4269/ajtmh.2002.67.217; Calhelha RC, 2014, BIOMED RES INT, DOI 10.1155/2014/897361; CAMPBELL JA, 2004, VENOMOUS REPTILES W; Cavalli Vera Lúcia de Liz Oliveira, 2007, Rev. bras. farmacogn., V17, P64, DOI 10.1590/S0102-695X2007000100014; Coelho JCU, 1996, APARELHO DIGESTIVO C; Pardal PPD, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0052-5; de Souza Carlos At, 2012, J Venom Res, V3, P28; Devgun MS, 2015, CLIN BIOCHEM, V48, P93, DOI 10.1016/j.clinbiochem.2014.10.011; Dhungana Neha, 2017, Pract Lab Med, V8, P77, DOI 10.1016/j.plabm.2017.05.004; Estevao-Costa MI, 2016, TOXICON, V122, P67, DOI 10.1016/j.toxicon.2016.09.010; Fevery J, 2008, LIVER INT, V28, P592, DOI 10.1111/j.1478-3231.2008.01716.x; Fox JW, 2009, J PROTEOMICS, V72, P200, DOI 10.1016/j.jprot.2009.01.015; Franca FOS, 2009, ANIMAIS PECONHENTOS, P81; Gay CC, 2005, TOXICON, V46, P546, DOI 10.1016/j.toxicon.2005.06.019; Gonzalez FHD, 2006, INTRO BIOQUIMICA CLI, P358; Gutierrez JM, 2003, TOXICON, V42, P915, DOI 10.1016/j.toxicon.2003.11.005; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Harrison GJ, 1994, AVIAN MED PRINCIPLES, P148; Higgins T, 2012, TIETZ TXB CLIN CHEM, P1016; Kanaan S, 2014, BIOQUIMICA CLIN; Kini RM, 2003, TOXICON, V42, P827; Konda Venugopala Rao, 2016, J Tradit Complement Med, V6, P347; Lerco Mauro Masson, 2003, Acta Cir. Bras., V18, P132, DOI 10.1590/S0102-86502003000200010; Linardi A, 2011, BBA-GEN SUBJECTS, V1810, P895, DOI 10.1016/j.bbagen.2011.06.006; Luciano PM, 2009, MEDICINA, V42, P61; Gutierrez JM, 2009, TOXICON, V54, P958, DOI 10.1016/j.toxicon.2009.01.038; Marks CS, 2007, BIOQUIMICA MED BASIC; Mattos AA, 2001, COMPENDIO HEPATOLOGI; Mello SM, 2010, TOXICON, V55, P470, DOI 10.1016/j.toxicon.2009.09.018; MOHAMED AH, 1981, TOXICON, V19, P605, DOI 10.1016/0041-0101(81)90098-2; Moneim AEA, 2013, TOXICOL MECH METHOD, V23, P624, DOI 10.3109/15376516.2013.823634; Motta VT, 2003, BIOQUIMICA CLIN LAB; Mukherjee AK, 1998, COMP BIOCHEM PHYS A, V119, P621, DOI 10.1016/S1095-6433(97)00475-3; Nelson D.L., 2014, PRINCIPIOS BIOQUIMIC; NISENBOM HE, 1986, TOXICON, V24, P259, DOI 10.1016/0041-0101(86)90151-0; Nogueira C, 2003, J HERPETOL, V37, P653, DOI 10.1670/120-02A; Otero R, 2002, TOXICON, V40, P1107, DOI 10.1016/S0041-0101(02)00104-6; Ramos OHP, 2006, COMP BIOCHEM PHYS C, V142, P328, DOI 10.1016/j.cbpc.2005.11.005; Ribeiro C, 2007, MOTRIZ, V13, P72; ROBERTSON AW, 1988, OBSTET GYNECOL, V71, P878; Santos MF, 2009, J BRAS NEFROL, V31, P132; Santos NA, 2008, TOXICON, V52, P908, DOI 10.1016/j.toxicon.2008.08.020; Sato Andréa de Fátima, 2005, J. Bras. Patol. Med. Lab., V41, P397, DOI 10.1590/S1676-24442005000600005; Schrier RW, 2004, J CLIN INVEST, V114, P598, DOI [10.1172/JCI200422353C1, 10.1172/JC1200422353]; Shashidharamurthy R, 2010, EXP TOXICOL PATHOL, V62, P587, DOI 10.1016/j.etp.2009.08.002; Sitprija V, 2006, NEPHROLOGY, V11, P442, DOI 10.1111/j.1440-1797.2006.00599.x; Soares AM, 2004, CURR ORG CHEM, V8, P1677, DOI 10.2174/1385272043369610; Sodré Fábio L., 2007, J. Bras. Patol. Med. Lab., V43, P329, DOI 10.1590/S1676-24442007000500005; Strasinger SK, 2014, URINALYSIS BODY FLUI; Talwer GP, 1989, TXB BIOCH HUMAN BIOL; Delgado ABT, 2017, TOXICON, V132, P6, DOI 10.1016/j.toxicon.2017.03.015; Tohamy Amany A., 2014, Journal of King Saud University Science, V26, P205, DOI 10.1016/j.jksus.2014.01.003; Warrell D.A., 2004, VENOMOUS REPTILES W, V1, P705; Yoshida CS, 2006, REV BRASILEIRA ANAL, V38, P255	61	0	0	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					226	235		10.1111/iep.12290			10	Pathology	Pathology	HF3DY	WOS:000454116900003	30456925				2019-10-28	
J	Scarim, CB; de Andrade, CR; da Rosa, JA; dos Santos, JL; Chin, CM				Scarim, Caue B.; de Andrade, Cleverton R.; da Rosa, Joao A.; dos Santos, Jean L.; Chin, Chung M.			Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						benznidazole; Chagas disease; chronic phase; hydroxymethylnitrofurazone; indeterminate form; Trypanosoma cruzi	TRYPANOSOMA-CRUZI INFECTION; MICE MUS-MUSCULUS; CHRONIC PHASE; IN-VIVO; AGGRESSIVE-BEHAVIOR; ADULT PATIENTS; ANIMAL-MODELS; MURINE MODEL; BENZNIDAZOLE; POSACONAZOLE	Hydroxymethylnitrofurazone (NFOH) is a nitrofurazone prodrug effective in vivo during acute infections, and it has less hepatotoxicity effect than the standard drug benznidazole (BZN) which has been used during short- and long-term treatment. In the present study, we induced the indeterminate form of Chagas disease in mice with a Y strain of Trypanosoma cruzi and analysed the histopathological data about the effects of NFOH and BZN on different tissues, including the heart, skeletal muscle, liver, kidney, colon, spleen and brain. After infection, BALB/c mice were treated with NFOH (150 mg/kg) and BZN (60 mg/kg) for 60 days and then submitted to immunosuppression using dexamethasone (5 mg/kg) for 14 days. Two trained analysts, as part of a blind evaluation, examined the results using serial sections of 3 mm diameter in two different moments. The results showed reactivation of the disease only in the infected nontreated group (POS). After treatment, amastigote nests were found in the heart, colon, liver and skeletal muscle in the POS group and in the heart and liver of the BZN group. Interestingly, amastigote nests were not found in the NFOH and NEG groups. The histopathological analysis showed fewer tissue lesions and parasite infiltrates in the NFOH group when compared with the BZN and POS groups. We have not observed any increase in the levels of hepatocellular injury biomarkers (AST/ALT) in the NFOH group. These in vivo studies show the potential for NFOH as an effective and safe compound useful as an anti-T. cruzi agent.	[Scarim, Caue B.; dos Santos, Jean L.; Chin, Chung M.] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, Lapdesf Lab Res & Dev Drugs, Araraquara, SP, Brazil; [de Andrade, Cleverton R.] Sao Paulo State Univ UNESP, Fac Dent, Dept Physiol & Pathol, Araraquara, SP, Brazil; [da Rosa, Joao A.] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Biol Sci, Araraquara, SP, Brazil	Scarim, CB; Chin, CM (reprint author), Univ Estadual Paulista, UNESP, Fac Ciencias Farmaceut, Dept Farm & Medicamentos, Araraquara, SP, Brazil.	cauebenitos@gmail.com; chung@fcfar.unesp.br	de+Andrade, Cleverton/AAA-6683-2019; Chin, Chung Man/W-2762-2019; de Andrade, Cleverton Roberto Roberto/D-9138-2012; Santos, Jean Dos/O-9111-2019; Man Chin, Chung/C-2259-2013; Santos, Jean Leandro/E-8753-2016	de+Andrade, Cleverton/0000-0001-7015-7175; de Andrade, Cleverton Roberto Roberto/0000-0001-7015-7175; Man Chin, Chung/0000-0003-4141-0455; Scarim, Caue Benito/0000-0002-2540-6395; Santos, Jean Leandro/0000-0002-2460-2829	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/14980-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq) [312404/2013-1]; Programa de Apoio ao Desenvolvimento Cientifico da Faculdade de Ciencias Farmaceuticas da UNESP (PADC/FCF-UNESP); Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES)CAPES	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Grant/Award Number: 2014/14980-0; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Grant/Award Number: 312404/2013-1; Programa de Apoio ao Desenvolvimento Cientifico da Faculdade de Ciencias Farmaceuticas da UNESP (PADC/FCF-UNESP); Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES)	Adad SJ, 1992, REV SOC BRAS MED TRO, V25, P101; Andrade MC, 2013, REV SOC BRAS MED TRO, V46, P776, DOI 10.1590/0037-8682-1646-2013; Andrade S.G., 1974, REV PATOLOGIA TROPIC, V3, P65; Andrade SG, 1997, INT J EXP PATHOL, V78, P391, DOI 10.1046/j.1365-2613.1997.390370.x; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33; Bermejo DA, 2011, IMMUNOLOGY, V132, P123, DOI 10.1111/j.1365-2567.2010.03347.x; Bosquesi PL, 2009, AVALIACAO PRESENCA G; Bustamante JM, 2003, CLIN SCI, V104, P415, DOI 10.1042/CS20020245; Bustamante JM, 2007, INT J ANTIMICROB AG, V29, P733, DOI 10.1016/j.ijantimicag.2007.01.014; Calabrese KS, 2000, IMMUNOPHARMACOLOGY, V47, P1, DOI 10.1016/S0162-3109(99)00179-4; Caldas IS, 2013, TROP MED INT HEALTH, V18, P75, DOI 10.1111/tmi.12002; Camandaroba Edson L.P., 2003, Rev. Soc. Bras. Med. Trop., V36, P201, DOI 10.1590/S0037-86822003000200002; Castro JA, 2006, HUM EXP TOXICOL, V25, P471, DOI 10.1191/0960327106het653oa; Cencig S, 2012, INT J ANTIMICROB AG, V40, P527, DOI 10.1016/j.ijantimicag.2012.08.002; Chung MC, 2003, BIOORGAN MED CHEM, V11, P4779, DOI 10.1016/j.bmc.2003.07.004; CLANCY AN, 1984, J NEUROSCI, V4, P2222; Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018; Coura JR, 2012, REV SOC BRAS MED TRO, V45, P286, DOI 10.1590/S0037-86822012000300002; Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; Crema E, 2007, REV SOC BRAS MED TRO, V40, P15, DOI 10.1590/S0037-86822007000100003; Davies C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003231; Davies C, 2010, ANTIMICROB AGENTS CH, V54, P3584, DOI 10.1128/AAC.01451-09; de Oliveira GM, 2008, PARASITOL RES, V102, P747, DOI 10.1007/s00436-007-0829-8; deAndrade ALSS, 1996, LANCET, V348, P1407; Dickerson MF, 2014, COMPARATIVE MED, V64, P323; Maya JD, 2010, BIOL RES, V43, P323, DOI [10.4067/S0716-97602010000300009, /S0716-97602010000300009]; dos Santos FM, 2008, EXP PARASITOL, V120, P385, DOI 10.1016/j.exppara.2008.09.007; Ekins S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003878; Esperandim VR, 2010, PARASITOL RES, V106, P1471, DOI 10.1007/s00436-010-1780-7; Estani SS, 1998, AM J TROP MED HYG, V59, P526, DOI 10.4269/ajtmh.1998.59.526; Fauro R, 2013, PARASITOLOGY, V140, P917, DOI 10.1017/S0031182013000103; de Lima VMF, 2012, VET PARASITOL, V184, P147, DOI 10.1016/j.vetpar.2011.08.024; Fernandes CD, 2009, MEM I OSWALDO CRUZ, V104, P27, DOI 10.1590/S0074-02762009000100004; Ferraz ML, 2007, ANTIMICROB AGENTS CH, V51, P1359, DOI 10.1128/AAC.01170-06; FERREIRA MS, 1991, AM J TROP MED HYG, V45, P723, DOI 10.4269/ajtmh.1991.45.723; Francisco AF, 2007, EFEITO TRATAMENTO CO; Francisco AF, 2016, SCI REP-UK, V6, DOI 10.1038/srep35351; Francisco AF, 2015, ANTIMICROB AGENTS CH, V59, P4653, DOI 10.1128/AAC.00520-15; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Garcia S, 2005, ANTIMICROB AGENTS CH, V49, P1521, DOI 10.1128/AAC.49.4.1521-1528.2005; Trossini GHG, 2010, LETT DRUG DES DISCOV, V7, P528; Guido M. C., 2001, REV CIEN FARM, V22, P319; Hasslocher-Moreno AM, 2012, J ANTIMICROB CHEMOTH, V67, P1261, DOI 10.1093/jac/dks027; Higuchi M L, 1995, Arq Bras Cardiol, V64, P251; HIGUCHI MD, 1987, CLIN CARDIOL, V10, P665; Jelicks LA, 2011, ADV PARASIT, V75, P193, DOI 10.1016/B978-0-12-385863-4.00009-5; Khare S, 2015, ANTIMICROB AGENTS CH, V59, P6385, DOI 10.1128/AAC.00689-15; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; Koberle F, 1957, REV GOIANA MED, V3, P155; Koberle F, 1963, REV GOIANA MED, V9, P79; Lewis MD, 2015, J BIOMOL SCREEN, V20, P36, DOI 10.1177/1087057114552623; LIBOW LF, 1991, CUTIS, V48, P37; Fernandez ML, 2016, MEM I OSWALDO CRUZ, V111, P218, DOI 10.1590/0074-02760150401; Maldonado IRSC, 2004, HISTOL HISTOPATHOL, V19, P85, DOI 10.14670/HH-19.85; Pereira PCM, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-34; Martinez I, 2004, THESIS FACULTY PHARM; Martinez-Diaz RA, 2001, MEM I OSWALDO CRUZ, V96, P53, DOI 10.1590/S0074-02762001000100006; Matsuda NM, 2009, CLINICS, V64, P1219, DOI 10.1590/S1807-59322009001200013; Melo MFF, 2006, PREPARACAO DETERMINA; Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574; Nogueira Filho MAF, 2014, DRUG METAB LETT, V7, P58; Nogueira-Paiva NC, 2014, MEM I OSWALDO CRUZ, V109, P51, DOI 10.1590/0074-0276130216; Okumura M, 1996, Rev Hosp Clin Fac Med Sao Paulo, V51, P166; Oliveira Luiz Carlos Marques De, 1997, Arquivos de Gastroenterologia, V34, P222; Serafim EOP, 2013, ANTIMICROB AGENTS CH, V57, P6106, DOI 10.1128/AAC.02522-12; Pedrosa R C, 1993, Rev Soc Bras Med Trop, V26, P163; Pereira Adriano, 2008, Rev Bras Parasitol Vet, V17 Suppl 1, P292; Pereira IR, 2015, PLOS NEGLECT TROP D, V9, P1; Pereira SAD, 2002, AM J TROP MED HYG, V66, P401; Pereira-da Silva L. H., 1953, Folia Clinica et Biologica Sao Paulo, V20, P191; Ferreira LRP, 2017, J INFECT DIS, V215, P387, DOI 10.1093/infdis/jiw540; PINTO FH, 1986, REV SAUDE PUBL, V20, P133, DOI 10.1590/S0034-89101986000200004; Pittella J E, 1993, Arq Neuropsiquiatr, V51, P8; POOLE TB, 1976, ANIM BEHAV, V24, P476, DOI 10.1016/S0003-3472(76)80056-5; POOLE TB, 1975, ANIM BEHAV, V23, P470, DOI 10.1016/0003-3472(75)90096-2; POOLE TB, 1973, ANIM BEHAV, V21, P788, DOI 10.1016/S0003-3472(73)80105-8; Ribeiro AR, 2016, REV SOC BRAS MED TRO, V49, P183, DOI 10.1590/0037-8682-0366-2015; Scarim CB, 2018, REV SOC BRAS MED TRO, V51, P133, DOI 10.1590/0037-8682-0337-2017; Soy D, 2015, ANTIMICROB AGENTS CH, V59, P3342, DOI 10.1128/AAC.05018-14; da Silva GMS, 2014, ANTIMICROB AGENTS CH, V58, P6371, DOI 10.1128/AAC.02842-14; STOLF NAG, 1987, J HEART TRANSPLANT, V6, P307; Taniwaki NN, 2011, PARASITOL RES, V109, P431, DOI 10.1007/s00436-011-2273-z; Toledo MJD, 2003, ANTIMICROB AGENTS CH, V47, P223, DOI 10.1128/AAC.47.1.223-230.2003; Torres Argenis, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P219, DOI 10.1590/S0036-46652000000400007; Trossini GHG, 2010, LETT ORG CHEM, V7, P191; Trossini GHG, 2010, J ENZYM INHIB MED CH, V25, P62, DOI 10.3109/14756360902941058; Uhrich J, 1938, J COMP PSYCHOL, V25, P373, DOI 10.1037/h0056350; Vizcaino-Castillo A, 2014, BIOMED RES INT, V2014, P1; WHO, 2002, CONTR CHAG DIS 2 REP, V905, P109; Zaidenberg A, 2006, BASIC CLIN PHARMACOL, V98, P351, DOI 10.1111/j.1742-7843.2006.pto_253.x	91	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					236	248		10.1111/iep.12289			13	Pathology	Pathology	HF3DY	WOS:000454116900004	30320480				2019-10-28	
J	Pacheco, CMS; Flores, GVA; Ferreira, AF; Ochoa, WS; da Matta, VLR; Valeriano, CZ; Corbett, CEP; Laurenti, MD				Sandoval Pacheco, Carmen Maria; Araujo Flores, Gabriela Venicia; Favero Ferreira, Aurea; Sosa Ochoa, Wilfredo; Ribeiro da Matta, Vania Lucia; Valeriano, Concepcion Zuniga; Pereira Corbett, Carlos Eduardo; Dalastra Laurenti, Marcia			Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						Atypical cutaneous leishmaniasis; Diagnosis; Honduras; Leishmania (L.) infantum chagasi; Pathology	CHAGASI; DIAGNOSIS; SERIES; SPP.	In Honduras visceral leishmaniasis and non-ulcerated or atypical cutaneous leishmaniasis (NUCL) are caused by the species Leishmania (L.) infantum chagasi. NUCL is the most common clinical form in the southern regions of the country, mainly affecting the young. In view of the lack of knowledge about the pathogenesis of the disease pattern caused by L. (L) infantum chagasi in individuals affected by NUCL, the aim of the present study was to describe in detail the histopathological features of the skin lesion caused by the parasite. Biopsies from human NUCL lesions with a positive parasitological diagnosis were collected and processed using standard histological techniques. Paraffin sections stained by haematoxylin and eosin were used to examine the histopathological alterations seen in the skin. The lesions varied between 3 and 5 mm, and the majority of the patients (60%) had a single lesion. Lesions were more frequently seen in females (65%), with an average age of 33.4 years. Microscopically, the skin lesions were characterized by mononuclear inflammatory infiltrate in the dermis composed of lymphocytes, macrophages and a few plasma cells. The intensity of the infiltration varied from discrete to intense. In both cases, the parasitic infection was discrete. Granulomas were present in 60% of cases and were associated with intense inflammation. The data revealed by the histopathological alterations in the skin of individuals affected by NUCL suggest activation of a cellular immune response that potentially controls parasite spreading.	[Sandoval Pacheco, Carmen Maria; Araujo Flores, Gabriela Venicia; Sosa Ochoa, Wilfredo; Pereira Corbett, Carlos Eduardo; Dalastra Laurenti, Marcia] Univ Sao Paulo, Med Sch, Lab Pathol Infect Dis, Sao Paulo, SP, Brazil; [Favero Ferreira, Aurea; Ribeiro da Matta, Vania Lucia] Univ Sao Paulo, Clin Hosp HCFMUSP, Med Sch, Lab Pathol Infect Dis,LIM50, Sao Paulo, SP, Brazil; [Sosa Ochoa, Wilfredo] Natl Autonomous Univ Honduras, Microbiol Res Inst, Tegucigalpa, Honduras; [Valeriano, Concepcion Zuniga] Univ Sch Hosp, Dept Hlth Surveillance, Tegucigalpa, Honduras	Laurenti, MD (reprint author), Univ Sao Paulo, Fac Med FMUSP, Dept Patol, Lab Patol Molestias Infecciosas, Sao Paulo, SP, Brazil.	mdlauren@usp.br	Laurenti, Marcia Dalastra/C-4734-2012	Laurenti, Marcia Dalastra/0000-0002-1080-2440	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/50315-0, 2015/01154-7]; Direccion de Investigacion y Posgrados de la UNAH con grant [02-2015]; Gabriela Venicia Araujo Flores Scholarship from CAPES (Social Demand); Laboratorio de Patologia de Molestias Infecciosas (LIM50 HC-FMUSP); National Research Council (CNPq), BrazilNational Council for Scientific and Technological Development (CNPq) [303098/2014-7]	This researcher was supported by Sao Paulo Research Foundation (FAPESP) grants #2014/50315-0, #2015/01154-7, Direccion de Investigacion y Posgrados de la UNAH con grant #02-2015, Gabriela Venicia Araujo Flores Scholarship from CAPES (Social Demand) and Laboratorio de Patologia de Molestias Infecciosas (LIM50 HC-FMUSP). Dalastra Laurenti M was supported by a Research Fellowship from National Research Council (CNPq) grant #303098/2014-7, Brazil.	Aguado M, 2013, ACTAS DERMO-SIFILOGR, V104, P334, DOI [10.1016/j.adengl.2013.03.005, 10.1016/j.ad.2012.11.005]; Aquino TA, 2014, J CLIN EXP DERMATOL, V5, P1; Araujo Flores GV, 2018, MEDIAT INFLAMM, V2018, P1; Araujo Flores GV, 2017, THESIS U SAO PAULO; Belli A, 1999, AM J TROP MED HYG, V61, P380, DOI 10.4269/ajtmh.1999.61.380; Campino L, 2006, ACTA MEDICA PORT, V18, P475; Campos-Ponce M, 2005, EXP PARASITOL, V109, P209, DOI 10.1016/j.exppara.2004.11.013; Gomes CMC, 2017, PARASITOL RES, V116, P1423, DOI 10.1007/s00436-017-5403-4; Castro LS, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658023, 10.1590/s1678-9946201658023]; Cedillos RA, 2014, MINERVA REV LINEA CI, V4, P33; Couppie P, 2004, AM J TROP MED HYG, V71, P558, DOI 10.4269/ajtmh.2004.71.558; del Giudice P, 1998, ARCH DERMATOL, V134, P193, DOI 10.1001/archderm.134.2.193; Francino O, 2006, VET PARASITOL, V137, P214, DOI 10.1016/j.vetpar.2006.01.011; Garcia-Almagro D, 2005, ACTAS DERMO-SIFILOGR, V96, P1, DOI 10.1016/S0001-7310(05)73027-1; González Kadir, 2018, Rev. Inst. Med. trop. S. Paulo, V60, pe8, DOI 10.1590/s1678-9946201860008; Instituto Nacional de Estadistica Honduras (INE), 2016, EST HOND; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; LIEW FY, 1990, J IMMUNOL, V144, P4794; Lyra MR, 2015, REV INST MED TROP SP, V57, P451, DOI 10.1590/S0036-46652015000500016; Martin-Ezquerra G, 2009, BRIT J DERMATOL, V161, P320, DOI 10.1111/j.1365-2133.2009.09282.x; Matute N, 2009, REV MED HONDUR, V77, P7; Mehregan DR, 1999, CLIN DERMATOL, V17, P297, DOI 10.1016/S0738-081X(99)00048-6; Mondal D, 2011, CURR OPIN INFECT DIS, V24, P418, DOI 10.1097/QCO.0b013e32834a8ba1; Moreira MAB, 2007, VET PARASITOL, V145, P245, DOI 10.1016/j.vetpar.2006.12.012; Noyes H, 1997, EXP PARASITOL, V85, P264, DOI 10.1006/expr.1996.4133; Nylen S, 2012, PARASITE IMMUNOL, V34, P551, DOI 10.1111/pim.12007; OPS, 2009, MAN MAN ENF PAR PRIO; PONCE C, 1991, LANCET, V337, P67, DOI 10.1016/0140-6736(91)90734-7; RIDLEY DS, 1983, J PATHOL, V141, P83, DOI 10.1002/path.1711410109; Salvioni OD, 2017, J DERMATOL CLIN RES, V5, P1104; Sandoval Pacheco CM, 2017, THESIS U SAO PAULO; Santos KE, 2006, REV MED POSTGRADOS M, V9, P47; Scott P, 2005, CELL MICROBIOL, V7, P1707, DOI 10.1111/j.1462-5822.2005.00626.x; Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x; Silveira F T., 2008, REV PARA MED, V22, P9; Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001; Singh A, 2015, INDIAN J DERMATOL VE, V81, P29, DOI 10.4103/0378-6323.148562; SOTTO MN, 1989, ACTA TROP, V46, P121, DOI 10.1016/0001-706X(89)90006-5; ZELEDON R, 1989, T ROY SOC TROP MED H, V83, P786, DOI 10.1016/0035-9203(89)90328-3; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6; Zijlstra EE, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1721-0	41	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					249	257		10.1111/iep.12295			9	Pathology	Pathology	HF3DY	WOS:000454116900005	30478864				2019-10-28	
J	Pacheco, VN; Langie, R; Benfica, JRD; Munaretto, JC; Etges, A; Ponzoni, D; Puricelli, E				Pacheco, Viviane N.; Langie, Renan; Benfica, Jules R. D.; Munaretto, Jessica C.; Etges, Adriana; Ponzoni, Deise; Puricelli, Edela			Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						bisphosphonate-associated osteonecrosis of the jaw; bisphosphonates; bone density conservation agents; inflammation; zoledronic acid	ZOLEDRONIC ACID; OSTEONECROSIS; MECHANISMS; JAWS	This study aimed to evaluate the alveolar bone tissue inflammatory response in rats undergoing zoledronic acid therapy. The study sample was composed of 28 Wistar rats. Animals from the test group GTa received a weekly intraperitoneal dose of 0.2 mg/kg of zoledronic acid for 3 weeks, while test group GTb received the same dose for 8 weeks. A physiological saline dose, equivalent to that of the medication, was administered to the controls in groups GCa and GCb. A defect was created in the dental crown of the lower first molars using a drill to simulate pulp and periapical injury. Data were evaluated regarding image grey levels by cone-beam computed tomography and histologically by assigning scores for the presence of inflammatory infiltrate, type of infiltrate, vascularization, bone necrosis and dental resorption. Grey levels in the 3-week therapy group (GTa) showed more pronounced changes in comparison with those seen in the GCa group (P < 0.05). Evaluation of the scores demonstrated no association between any of the variables amongst the groups (>0.05). However, bone remodelling decreased in the groups receiving the medication. Bone necrosis was present more frequently in group GTb than in the control group GCb. The results suggest that the drug interfered in the reaction capacity of the alveolar bone tissue as test group GTa showed higher grey levels in comparison to the control group GCa. In addition, there was less bone remodelling activity, with the appearance of bone necrosis zones and intense acute inflammatory infiltrate associated with the 8-week therapy group GTb.	[Pacheco, Viviane N.; Langie, Renan; Benfica, Jules R. D.; Munaretto, Jessica C.; Etges, Adriana; Ponzoni, Deise; Puricelli, Edela] Fed Univ Rio Grande Sul UFRGS, Clin Hosp Porto Alegre HCPA, Sch Dent, Oral & Maxillofacial Surg Unit, Porto Alegre, RS, Brazil	Pacheco, VN; Ponzoni, D (reprint author), Fed Univ Rio Grande Sul UFRGS, Clin Hosp Porto Alegre HCPA, Sch Dent, Oral & Maxillofacial Surg Unit, Porto Alegre, RS, Brazil.	vivi.npacheco@hotmail.com; deponzoni@yahoo.com			Clinical Hospital of Porto Alegre (HCPA)	Clinical Hospital of Porto Alegre (HCPA)	Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592; Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312; Cankaya AB, 2011, INT J MED SCI, V8, P667, DOI 10.7150/ijms.8.667; Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482; Harkness J. E., 1993, BIOL CLIN COELHOS RO; Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23; Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774-009-0128-9; Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054; Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010; Metcalf S, 2011, FUTURE ONCOL, V7, P1325, DOI [10.2217/fon.11.113, 10.2217/FON.11.113]; Pacheco VN, 2015, INT J EXP PATHOL, V96, P255, DOI 10.1111/iep.12133; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078-0432.CCR-06-0843; Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P13, DOI 10.1016/j.joms.2008.10.005; Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8; Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013	16	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					258	263		10.1111/iep.12291			6	Pathology	Pathology	HF3DY	WOS:000454116900006	30457199				2019-10-28	
J	Moura, LDAD; de Lima, MDM; Lima, CCB; Bandeira, AVL; de Moura, MS; Conde, AMC; Rizzo, MD				Almeida de Deus Moura, Lucia de Fatima; Moura de Lima, Marina de Deus; Branco Lima, Cacilda Castelo; Lopes Bandeira, Ana Victoria; de Moura, Marcoeli Silva; Conde Junior, Airton Mendes; Rizzo, Marcia dos Santos			Cellular profile of primary molars with pulp necrosis after treatment with antibiotic paste	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						cytology; leucocytes; paediatric dentistry; primary teeth; root canal filling materials	ENDODONTIC TREATMENT; PRIMARY TEETH	The interradicular region of primary molars is permeated by many foramina, channels and accessories that connect the pulp cavity with the periapical tissues anatomically. Thus, pulp decomposition products or drugs used in endodontic treatment can trigger inflammatory reactions. The aim of this study was to evaluate the blood cell profile of the alveolar region after extraction of primary molars treated with CTZ paste. Forty-eight primary molars were selected with clinical and radiographic signs of extraction. The sample was divided into three groups with 16 teeth each: Group 1-healthy teeth; Group 2-untreated decayed teeth; and Group 3-teeth treated with CTZ paste. Immediately after the extraction, blood from the interface of the tooth socket was collected and smears were performed for further evaluation. The slides were stained by the Fast Panoptic((R)) method and analysed by two previously trained examiners who counted the leucocytes in sets of 100 cells/slide, differentiating them into neutrophils, lymphocytes, monocytes, eosinophils and basophils. The data were analysed statistically by the MANOVA test. The blood samples from Group 2 differed significantly from Group 1 samples for all classes of leucocytes, except basophils, with higher average for lymphocytes (62.56), monocytes (7.81) and eosinophils (2.31). For Group 3, there was a relative difference (P < 0.05) to Group 2, of monocytes and eosinophils values. The blood cellularity interface in the tooth socket of primary teeth treated with CTZ paste is similar to those of healthy, exfoliated teeth and physiologically different from untreated decayed teeth.	[Almeida de Deus Moura, Lucia de Fatima; Moura de Lima, Marina de Deus; Branco Lima, Cacilda Castelo; de Moura, Marcoeli Silva] Univ Fed Piaui, Sch Dent, Dept Pathol & Dent Clin, Teresina, Piaui, Brazil; [Lopes Bandeira, Ana Victoria] Univ Fed Piaui, Postgrad Program Dent, Teresina, Piaui, Brazil; [Conde Junior, Airton Mendes; Rizzo, Marcia dos Santos] Univ Fed Piaui, Dept Morphol, Teresina, Piaui, Brazil	Lima, CCB (reprint author), Univ Fed Piaui, Sch Dent, Dept Pathol & Dent Clin, Teresina, PI, Brazil.	cacildacb@hotmail.com	Rizzo, Marcia dos Santos/N-3760-2019; Santos Rizzo, Marcia/M-4322-2015; Moura, Marcoeli/G-4720-2011	Rizzo, Marcia dos Santos/0000-0003-4276-3113; Santos Rizzo, Marcia/0000-0003-4276-3113; Lima, Cacilda/0000-0002-2977-6035; Moura, Marcoeli/0000-0002-9044-9025; Lima, Marina/0000-0002-7641-6331			Barja-Fidalgo Fernanda, 2011, ISRN Dent, V2011, P367318, DOI 10.5402/2011/367318; Bruno GB, 2007, BRAZ J ORAL SCI, V6, P1397, DOI [10.20396/bjos.v6i22.8642999, DOI 10.20396/BJOS.V6I22.8642999]; Cappiello J, 1964, REV CIRC ODONTOL ROS, V52, P138; Chan YK, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-558; Cordeiro Mabel Mariela Rodriguez, 2005, J Clin Pediatr Dent, V29, P193; Cruvinel WD, 2010, REV BRAS REUMATOL, V50, P434, DOI 10.1590/S0482-50042010000400008; Grond-Ginsbach C, 2013, EUR J NEUROL, V20, P1405, DOI 10.1111/ene.12201; Huang DC, 2012, J SYST SOFTWARE, V85, P2104, DOI 10.1016/j.jss.2012.04.012; Kayalvizhi G, 2013, J DENT CHILD, V80, P71; Lima CCB, 2015, INT ENDOD J, V48, P405, DOI 10.1111/iej.12328; Stadelmann J. V., 2012, Biomedical Engineering, V46, P83, DOI 10.1007/s10527-012-9273-x; Takushige T, 2004, INT ENDOD J, V37, P132, DOI 10.1111/j.0143-2885.2004.00771.x; Thachil J, 2014, HAEMATOLOGY IN CRITICAL CARE: A PRACTICAL HANDBOOK, P1, DOI 10.1002/9781118869147; Trairatvorakul C, 2012, INT J PAEDIATR DENT, V22, P217, DOI 10.1111/j.1365-263X.2011.01181.x; Zaldivar F, 2006, INT J OBESITY, V30, P906, DOI 10.1038/sj.ijo.0803227	15	0	0	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	OCT	2018	99	5					264	268		10.1111/iep.12292			5	Pathology	Pathology	HF3DY	WOS:000454116900007	30324690				2019-10-28	
J	Tse, KY; Chiu, KWH; Chan, KKL; Chu, MMY; Ngu, SF; Cheung, ANY; Ngan, HYS; Ip, PPC				Tse, Ka Yu; Chiu, Keith Wan Hang; Chan, Karen Kar Loen; Chu, Mandy Man Yee; Ngu, Siew Fei; Cheung, Annie Nga Yin; Ngan, Hextan Yuen Sheung; Ip, Philip Pun Ching			A Case Series of Five Patients With Pure or Mixed Gestational Epithelioid Trophoblastic Tumors and a Literature Review on Mixed Tumors	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Gestational; Epithelioid; Trophoblastic; Tumors	OF-THE-LITERATURE; PLACENTAL-SITE; DISEASE CENTER; DIFFERENTIAL-DIAGNOSIS; CHORIOCARCINOMA; PATHOGENESIS; MANAGEMENT; NEOPLASIA; CARCINOMA; PATHOLOGY	Objectives: To review the clinicopathologic features of five patients with epithelioid trophoblastic tumor (ETT). Methods: Characteristics of patients diagnosed with ETT in 2000 to 2012 were reviewed. Results: Among 190 patients with gestational trophoblastic neoplasia (GTN), two had pure ETT and three had mixed ETT and choriocarcinoma. The median age was 32.5 years. All the patients had localized disease in the uterus. One patient with pure ETT had a recurrence in the ureter 6 years after the initial treatment. Another patient with pure ETT had two full-term deliveries after fertility-sparing surgery. The three patients with mixed tumors had chemotherapy for GTN before their diseases were completely treated by hysterectomy. At a median follow-up of 102 months, all patients survived. Conclusions: ETT is indolent. Recurrence can happen, but the risk factors are not clear. When patients with GTN fail to respond to chemotherapy, the possibility of mixed GTN should be considered.	[Tse, Ka Yu; Chan, Karen Kar Loen; Chu, Mandy Man Yee; Ngan, Hextan Yuen Sheung] Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Chiu, Keith Wan Hang] Univ Hong Kong, Dept Radiol, Hong Kong, Hong Kong, Peoples R China; [Ngu, Siew Fei; Cheung, Annie Nga Yin; Ip, Philip Pun Ching] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Tse, KY (reprint author), Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, 6-F Professorial Block,102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	tseky@hku.hk	Chiu, Keith/Z-3985-2019; Ngu, Siew Fei/C-4497-2009; Cheung, Annie Nga Yin/C-4231-2009	Chiu, Keith/0000-0002-7930-1193; Ngu, Siew Fei/0000-0001-9314-5468; Ngan, Hextan Y S/0000-0003-3945-159X; Ip, Philip Pun-Ching/0000-0002-0493-9838; Tse, Ka Yu/0000-0001-8330-0970; Cheung, Annie Nga Yin/0000-0002-1584-7568			Baergen RN, 2006, GYNECOL ONCOL, V100, P511, DOI 10.1016/j.ygyno.2005.08.058; Bower M, 1997, J CLIN ONCOL, V15, P2636, DOI 10.1200/JCO.1997.15.7.2636; Chen BJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-85; Cheung ANY, 2003, BEST PRACT RES CL OB, V17, P849, DOI 10.1016/S1521-6934(03)00094-4; Chu MMY, 2015, INT J GYNECOL CANCER, V25, P498, DOI 10.1097/IGC.0000000000000383; Cole ME, 2008, NAT CLIN PRACT ONCOL, V5, P171, DOI 10.1038/ncponc1042; Coulson LE, 2000, AM J SURG PATHOL, V24, P1558, DOI 10.1097/00000478-200011000-00014; Davis MR, 2015, GYNECOL ONCOL, V137, P456, DOI 10.1016/j.ygyno.2015.03.006; Fadare O, 2006, MODERN PATHOL, V19, P75, DOI 10.1038/modpathol.3800485; Feltmate CM, 2001, GYNECOL ONCOL, V82, P415, DOI 10.1006/gyno.2001.6265; Horowitz NS, 2017, GYNECOL ONCOL, V144, P208, DOI 10.1016/j.ygyno.2016.10.024; Hui P., 2014, WHO CLASSIFICATION T, P156; Imamura Y, 2015, GYNECOL ONCOL REP, V14, P31, DOI 10.1016/j.gore.2015.10.002; JONES WB, 1993, CANCER, V72, P2175, DOI 10.1002/1097-0142(19931001)72:7<2175::AID-CNCR2820720718>3.0.CO;2-K; Jordan S, 2011, INT J GYNECOL CANCER, V21, P918, DOI 10.1097/IGC.0b013e31821a278d; Kalhor N, 2009, AM J SURG PATHOL, V33, P633, DOI 10.1097/PAS.0b013e318191f2eb; Knox S, 2002, GYNECOL ONCOL, V85, P204, DOI 10.1006/gyno.2002.6583; Li JQ, 2011, MED ONCOL, V28, P294, DOI 10.1007/s12032-010-9419-1; Luk WY, 2013, CASE REP OBSTET GYNE, V2013; Mao TL, 2007, AM J SURG PATHOL, V31, P1726, DOI 10.1097/PAS.0b013e318058a529; MAZUR MT, 1989, CANCER-AM CANCER SOC, V63, P1370, DOI 10.1002/1097-0142(19890401)63:7<1370::AID-CNCR2820630723>3.0.CO;2-G; MAZUR MT, 1982, CANCER, V50, P1833, DOI 10.1002/1097-0142(19821101)50:9<1833::AID-CNCR2820500930>3.0.CO;2-4; Mazur MT, 1994, BLAUSTEINS PATHOLOGY, P1049; Nagai Y, 2007, GYNECOL ONCOL, V106, P446, DOI 10.1016/j.ygyno.2007.04.025; Narita F, 2003, INT J GYNECOL CANCER, V13, P551, DOI 10.1046/j.1525-1438.2003.13311.x; Ngan HYS, 2015, INT J GYNECOL OBSTET, V131, pS123, DOI 10.1016/j.ijgo.2015.06.008; Palmer JE, 2008, J REPROD MED, V53, P465; Ramondetta LM, 2002, INT J GYNECOL CANCER, V12, P312, DOI 10.1046/j.1525-1438.2002.01110.x; Shen Dan-Hua, 2003, Arch Pathol Lab Med, V127, pe291; Shih IM, 2007, LANCET ONCOL, V8, P642, DOI 10.1016/S1470-2045(07)70204-8; Shih IM, 2001, INT J GYNECOL PATHOL, V20, P31, DOI 10.1097/00004347-200101000-00004; Shih IM, 1998, AM J SURG PATHOL, V22, P1393, DOI 10.1097/00000478-199811000-00010; Shih IM, 1998, HUM PATHOL, V29, P27, DOI 10.1016/S0046-8177(98)90386-0; Sun PM, 2016, ONCOL LETT, V12, P3135, DOI 10.3892/ol.2016.5074; Sung WJ, 2013, KOREAN J PATHOL, V47, P67, DOI 10.4132/KoreanJPathol.2013.47.1.67; Surveillance and Epidemiology Branch Centre for Health Protection of the Department of Health, 2013, BEH RISK FACT SURV O; Taylor JS, 2013, OBSTET GYNECOL, V121, P465, DOI [10.1097/AOG.0b013e31826d7da6, http://10.1097/AOG.0b013e31826d7da6]; Tse KY, 2012, BEST PRACT RES CL OB, V26, P357, DOI 10.1016/j.bpobgyn.2011.11.009; Yazaki-Sun S, 2006, J OBSTET GYNAECOL RE, V32, P265, DOI 10.1111/j.1447-0756.2006.00397.x; Zavadil M, 2003, Ceska Gynekol, V68, P420; Zhang XF, 2015, INT J CLIN EXP PATHO, V8, P7254; Zhang XF, 2013, INT J GYNECOL CANCER, V23, P1334, DOI 10.1097/IGC.0b013e31829ea023	42	1	1	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	OCT	2018	150	4					318	332		10.1093/AJCP/AQY039			15	Pathology	Pathology	GS3SN	WOS:000443541200006	29897391				2019-10-28	
J	Sircar, M; Rosales, IA; Selig, MK; Xu, DH; Zsengeller, ZK; Stillman, IE; Libermann, TA; Karumanchi, SA; Thadhani, RI				Sircar, Monica; Rosales, Ivy A.; Selig, Martin K.; Xu, Dihua; Zsengeller, Zsuzsanna K.; Stillman, Isaac E.; Libermann, Towia A.; Karumanchi, S. Ananth; Thadhani, Ravi I.			Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MEMBRANE ATTACK COMPLEX; GENE-EXPRESSION; PLASMA-PROTEINS; NEPHROPATHY; ACTIVATION; SYSTEM; INJURY; CELLS; C7; GLOMERULOSCLEROSIS	There is a temporal window from the time diabetes is diagnosed to the appearance of overt kidney disease during which time the disease progresses quietly without detection. Currently, there is no way to detect early diabetic nephropathy (EDN). Herein, we performed an unbiased assessment of gene-expression analysis of postmortem human kidneys to identify candidate genes that may contribute to EDN. We then studied one of the most promising differentially expressed genes in both kidney tissue and blood samples. Differential transcriptome analysis of EDN kidneys and matched nondiabetic controls showed alterations in five canonical pathways, and among them the complement pathway was the most significantly altered. One specific complement pathway gene, complement 7 (C7), was significantly elevated in EDN kidney. Real-time PCR confirmed more than a twofold increase of C7 expression in EDN kidneys compared with controls. Changes in C7 gene product level were confirmed by immunohistochemistry. C7 protein levels were elevated in proximal tubules of EDN kidneys. Serum C7 protein levels were also measured in EDN and control donors. C7 levels were significantly higher in EDN serum than control serum. This latter finding was independently confirmed in a second set of blood samples from a previously collected data set. Together, our data suggest that C7 is associated with EDN, and can be used as a molecular target for detection and/or treatment of EDN.	[Sircar, Monica; Rosales, Ivy A.; Selig, Martin K.; Xu, Dihua; Thadhani, Ravi I.] Massachusetts Gen Hosp, Div Nephrol, 55 Fruit St, Boston, MA 02114 USA; [Sircar, Monica; Rosales, Ivy A.; Selig, Martin K.; Xu, Dihua; Thadhani, Ravi I.] Partners Hlth Care, Boston, MA USA; [Zsengeller, Zsuzsanna K.; Stillman, Isaac E.; Karumanchi, S. Ananth] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA USA; [Zsengeller, Zsuzsanna K.; Stillman, Isaac E.; Karumanchi, S. Ananth] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; [Zsengeller, Zsuzsanna K.; Stillman, Isaac E.; Karumanchi, S. Ananth] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; [Libermann, Towia A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Genom Prote Bioinformat & Syst Biol Ctr, Dept Med, Boston, MA USA; [Karumanchi, S. Ananth] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Sircar, M (reprint author), Massachusetts Gen Hosp, Div Nephrol, 55 Fruit St, Boston, MA 02114 USA.	msircar@partners.org	Sircar, Monica/W-1023-2019	Zsengeller, Zsuzsanna/0000-0002-4540-5728	NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 5 7540]; Massachusetts General Hospital NIH/NIDDK [K24 DK094872-04]; American Society of Nephrology Ben J. Lipps Research Fellowship	Supported by NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) T32 grant DK 5 7540 (principal investigator: R.I.T; trainee: M.S.), Massachusetts General Hospital NIH/NIDDK grant K24 DK094872-04 (principal investigator: R.I.T.), and American Society of Nephrology Ben J. Lipps Research Fellowship (M.S.).	[Anonymous], 2000, AM J KIDNEY DIS, V36, pS1; Axelgaard E, 2017, J DIABETES RES, DOI 10.1155/2017/6368780; Baelde HJ, 2004, AM J KIDNEY DIS, V43, P636, DOI 10.1053/j.ajkd.2003.12.028; Bossi F, 2009, BLOOD, V113, P3640, DOI 10.1182/blood-2008-03-146472; Brennan EP, 2012, BBA-MOL BASIS DIS, V1822, P589, DOI 10.1016/j.bbadis.2012.01.008; BURKHOLD.PM, 1965, DIABETES, V14, P755, DOI 10.2337/diab.14.12.755; Chevalier RL, 2016, AM J PHYSIOL-RENAL, V311, pF145, DOI 10.1152/ajprenal.00164.2016; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; FALK RJ, 1987, AM J KIDNEY DIS, V9, P121, DOI 10.1016/S0272-6386(87)80089-6; Fearn Amy, 2015, World J Nephrol, V4, P31, DOI 10.5527/wjn.v4.i1.31; Fineberg D, 2013, NAT REV ENDOCRINOL, V9, P713, DOI 10.1038/nrendo.2013.184; Flyvbjerg A, 2017, NAT REV NEPHROL, V13, P311, DOI 10.1038/nrneph.2017.31; Fu FM, 2015, RENAL FAILURE, V37, P1219, DOI 10.3109/0886022X.2015.1061887; Fujita T, 1999, NEPHRON, V81, P208, DOI 10.1159/000045278; Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g; Hsieh TJ, 2006, KIDNEY INT, V69, P1005, DOI 10.1038/sj.ki.5000206; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; Klessens CQF, 2016, KIDNEY INT, V90, P149, DOI 10.1016/j.kint.2016.01.023; Krolewski AS, 2015, DIABETES CARE, V38, P954, DOI 10.2337/dc15-0184; Lahoria R, 2016, BRAIN, V139, P1891, DOI 10.1093/brain/aww122; Lim SC, 2009, DIABETOLOGIA, V52, P1343, DOI 10.1007/s00125-009-1368-x; Mazzucco G, 2002, AM J KIDNEY DIS, V39, P713, DOI 10.1053/ajkd.2002.31988; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; OSTERBY R, 1993, DIABETOLOGIA, V36, P1064, DOI 10.1007/BF02374500; Penning M, 2015, HYPERTENSION, V66, P117, DOI 10.1161/HYPERTENSIONAHA.115.05484; PODACK ER, 1977, J IMMUNOL, V119, P2024; Rajakumar A, 2012, HYPERTENSION, V59, P256, DOI 10.1161/HYPERTENSIONAHA.111.182170; Reimold FR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056389; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Rosoklija GB, 2000, ACTA NEUROPATHOL, V99, P55, DOI 10.1007/PL00007406; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344; Serna M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10587; SEWRY CA, 1987, J NEUROL SCI, V81, P141, DOI 10.1016/0022-510X(87)90091-8; Stoltzner SE, 2000, AM J PATHOL, V156, P489, DOI 10.1016/S0002-9440(10)64753-0; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Thadhani R, 2012, JAMA-J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120; Thadhani R, 2011, AM J NEPHROL, V33, P139, DOI 10.1159/000323551; Thurman JM, 2017, NEPHROL DIAL TRANSPL, V32, P57, DOI 10.1093/ndt/gfw228; Uesugi N, 2004, AM J KIDNEY DIS, V44, P224, DOI 10.1053/j.ajkd.2004.04.027; Vasil KE, 2007, J AM ACAD DERMATOL, V56, P96, DOI 10.1016/j.jaad.2006.05.013; Wang SC, 2015, FISH SHELLFISH IMMUN, V45, P672, DOI 10.1016/j.fsi.2015.05.042; Wang ZK, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0343-2; WESTBERG NG, 1972, DIABETES, V21, P163, DOI 10.2337/diab.21.3.163; Wetmore JB, 2015, J AM SOC NEPHROL, V26, P2601, DOI 10.1681/ASN.2015060660; White KE, 2000, J AM SOC NEPHROL, V66, P1596; Woroniecka KI, 2011, DIABETES, V60, P2354, DOI 10.2337/db10-1181; Wu T, 2014, EXP CLIN ENDOCR DIAB, V122, P587, DOI 10.1055/s-0034-1382033; Yang L, 2011, NEPHRON EXP NEPHROL, V119, pE8, DOI 10.1159/000324407; Zhang A, 2002, DIABETES, V51, P3499; Zheng SR, 2011, NEPHRON EXP NEPHROL, V119, pE21, DOI 10.1159/000327586	51	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2147	2154		10.1016/j.ajpath.2018.06.018			8	Pathology	Pathology	GV8SN	WOS:000446415800002	30253844				2019-10-28	
J	Chang, L; Zhang, L; Xu, JJ; Meyers, CA; Li, Z; Yan, N; Zou, E; James, AW				Chang, Leslie; Zhang, Lei; Xu, Jiajia; Meyers, Carolyn A.; Li, Zhu; Yan, Noah; Zou, Erin; James, Aaron W.			Lineage-Specific Wnt Reporter Elucidates Mesenchymal Wnt Signaling during Bone Repair	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FRACTURE; CELLS; INFLAMMATION; GROWTH; TUMORS	beta-Catenin-dependent Wnt signaling controls numerous aspects of skeletal development and postnatal bone repair. Currently available transgenic Wnt reporter mice allow for visualization of global canonical Wnt signaling activity within skeletal tissues, without delineation of cell. type. This is particularly important in a bone repair context, in which the inflammatory phase can obscure the visualization of mesenchymal cell types of interest. To tackle the issue of tissue-specific Wnt signaling, we have generated and characterized a transgenic mouse strain [termed paired related homeobox 1 (Prx1)-Wnt-green fluorescent protein (GFP), by crossing a previously validated Prx1-Cre strain with a nuclear fluorescent reporter driven by T-cell factor/lymphoid enhancer factor activity (Rosa26-Tcf/Lef-LSL-H2B-GFP)]. Prx1-Wnt-GFP animals were subject to three models of tong bone and membranous bone repair (displaced forelimb fracture, tibial cortical defect, and frontal bone defect). Results showed that, irrespective of bone type, locoregional mesenchymal cell activation of Wnt signaling occurs in a defined temporospatial pattern among Prx1-Wnt-GFP mice. In summary, Prx1-Wnt-GFP reporter animals allow for improved visualization, spatial discrimination, and facile quantification of Wnt-activated mesenchymal cells within models of adult bone repair.	[Chang, Leslie; Zhang, Lei; Xu, Jiajia; Meyers, Carolyn A.; Yan, Noah; Zou, Erin; James, Aaron W.] Johns Hopkins Univ, Dept Pathol, Ross Res Bldg,Room 524A,720 Rutland Ave, Baltimore, MD 21205 USA; [Li, Zhu] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA; [Zhang, Lei] China Med Univ, Dept Oral & Maxillofacial Surg, Sch Stomatol, Shenyang, Liaoning, Peoples R China	James, AW (reprint author), Johns Hopkins Univ, Dept Pathol, Ross Res Bldg,Room 524A,720 Rutland Ave, Baltimore, MD 21205 USA.	awjames@jhmi.edu		Meyers, Carolyn/0000-0002-0734-029X; James, Aaron/0000-0002-2002-622X; Xu, Jiajia/0000-0002-6084-2029	NIH/National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR070773, K08 AR068316]; US Army Medical Research Acquisition Activity through the Peer Reviewed Medical Research Program [W81XWH-180109121]; American Cancer Society Research ScholarAmerican Cancer Society [RSG-18-027-01-CSM]; Orthopedic Research and Education Foundation; Musculoskeletal Transplant Foundation; Maryland Stem Cell Research Foundation	Supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases grants R01 AR070773 (A.W.J.) and K08 AR068316 (A.W.J.), US Army Medical Research Acquisition Activity through the Peer Reviewed Medical Research Program W81XWH-180109121 (A.W.J.), American Cancer Society Research Scholar grant RSG-18-027-01-CSM (A.W.J.), the Orthopedic Research and Education Foundation (with funding provided by the Musculoskeletal Transplant Foundation; A.W.J.), the Maryland Stem Cell Research Foundation (A.W.J.), and the Musculoskeletal Transplant Foundation (A.W.J.).	Al Alam D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023139; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Cho C, 2017, NEURON, V95, P1056, DOI 10.1016/j.neuron.2017.07.031; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Davidson ENB, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4573; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Kroner J, 2017, J BONE MINER RES, V32, P2431, DOI 10.1002/jbmr.3234; Loi F, 2016, BONE, V86, P119, DOI [10.1016/j.bone.2016.02.0208756-3282, 10.1016/j.bone.2016.02.020]; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Martinez MD, 2010, BONE, V46, P1604, DOI 10.1016/j.bone.2010.02.030; Maruyama T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10526; Murao H, 2013, J BONE MINER METAB, V31, P390, DOI 10.1007/s00774-013-0429-x; Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116; Sagi HC, 2014, J ORTHOP TRAUMA, V28, P377, DOI 10.1097/BOT.0000000000000049; Seo HS, 2007, DEV BIOL, V310, P304, DOI 10.1016/j.ydbio.2007.07.040; Taniguchi Y, 2017, ARTHRITIS RHEUMATOL, V69, P598, DOI 10.1002/art.39976; Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002; Zhang XL, 2011, TISSUE ENG PT A, V17, P2497, DOI [10.1089/ten.TEA.2010.0705, 10.1089/ten.tea.2010.0705]	21	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2155	2163		10.1016/j.ajpath.2018.07.003			9	Pathology	Pathology	GV8SN	WOS:000446415800003	30031726	Bronze			2019-10-28	
J	Suff, N; Karda, R; Diaz, JA; Ng, J; Baruteau, J; Perocheau, D; Tangney, M; Taylor, PW; Peebles, D; Buckley, SMK; Waddington, SN				Suff, Natalie; Karda, Rajvinder; Diaz, Juan A.; Ng, Joanne; Baruteau, Julien; Perocheau, Dany; Tangney, Mark; Taylor, Peter W.; Peebles, Donald; Buckley, Suzanne M. K.; Waddington, Simon N.			Ascending Vaginal Infection Using Bioluminescent Bacteria Evokes Intrauterine Inflammation, Preterm Birth, and Neonatal Brain Injury in Pregnant Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NECROSIS-FACTOR-ALPHA; WHITE-MATTER LESIONS; MICROGLIAL ACTIVATION; FETAL MEMBRANES; LABOR; DAMAGE; MODEL; INTERLEUKIN-1-BETA; EPIDEMIOLOGY; PARTURITION	Preterm birth is a serious global health problem and the Leading cause of infant death before 5 years of age. At least 40% of cases are associated with infection. The most common way for pathogens to access the uterine cavity is by ascending from the vagina. Bioluminescent pathogens have revolutionized the understanding of infectious diseases. We hypothesized that bioluminescent Escherichia coli can be used to track and monitor ascending vaginal infections. Two bioluminescent strains were studied: E. coli K12 MG1655-lux, a nonpathogenic laboratory strain, and E. coli K1 A192PP-lux2, a pathogenic strain capable of causing neonatal meningitis and sepsis in neonatal rats. On embryonic day 16, mice received intravaginal E. coli K12, E. coli K1, or phosphate-buffered saline followed by whole-body bioluminescent imaging. In both cases, intravaginal delivery of E. coli K12 or E. coli K1 led to bacterial ascension into the uterine cavity, but only E. coli K1 induced preterm parturition. Intravaginal administration of E. coli K1 significantly reduced the proportion of pups born alive compared with E. coli K12 and phosphate-buffered saline controls. However, in both groups of viable pups born after bacterial inoculation, there was evidence of comparable brain inflammation by postnatal day 6. This study ascribes specific mechanisms by which exposure to intrauterine bacteria leads to premature delivery and neurologic inflammation in neonates.	[Suff, Natalie; Karda, Rajvinder; Diaz, Juan A.; Ng, Joanne; Baruteau, Julien; Perocheau, Dany; Buckley, Suzanne M. K.; Waddington, Simon N.] UCL, Gene Transfer Technol Grp, Dept Maternal & Fetal Med, Inst Womens Hlth, 86-96 Chenies Mews, London WC1E 6HX, England; [Suff, Natalie; Peebles, Donald] UCL, Preterm Birth Grp, Dept Maternal & Fetal Med, Inst Womens Hlth, London, England; [Taylor, Peter W.] UCL, Sch Pharm, London, England; [Baruteau, Julien] Great Ormond St Hosp Children NHS Fdn Trust, Dept Metab Med, London, England; [Tangney, Mark] Univ Coll Cork, SynBio Ctr, Cork, Ireland; [Waddington, Simon N.] Univ Witwatersrand, Fac Hlth Sci, MRC Antiviral Gene Therapy Res Unit, Johannesburg, South Africa	Buckley, SMK (reprint author), UCL, Gene Transfer Technol Grp, Dept Maternal & Fetal Med, Inst Womens Hlth, 86-96 Chenies Mews, London WC1E 6HX, England.	suzy.buckley@ucl.ac.uk	Waddington, Simon/G-3778-2011; Antinao Diaz, Juan/C-3209-2014	Waddington, Simon/0000-0003-4970-4730; Baruteau, Julien/0000-0003-0582-540X; Tangney, Mark/0000-0002-6314-1260; Antinao Diaz, Juan/0000-0001-7295-2738	Wellbeing of Women Research training fellowshipWellbeing of Women (WoW) [RT414]; Priory Foundation; UK Medical Research CouncilMedical Research Council UK (MRC) [G1000709, MR/N026101/1, MR/R015325/1, MR/P026494/1, MR/N019075/1]; Sport Aiding Medical Research for Kids (SPARKS) [17UCL01]; Research Training Fellowship from Action Medical Research [GN2137]; Action Medical Research grant [GN2075];  [SPARKS 17UCL01];  [MR/K02342X/1];  [GOSHCCV1284];  [Rosetrees M576]	Supported by the Wellbeing of Women Research training fellowship RT414 and the Priory Foundation (N.S.); UK Medical Research Council grants G1000709 and MR/N026101/1, MR/R015325/1, MR/P026494/1, and MR/N019075/1, and Sport Aiding Medical Research for Kids (SPARKS) 17UCL01 (S.N.W.); MR/P026494/1 and SPARKS 17UCL01 (R.K.); MR/K02342X/1, GOSHCCV1284, and Rosetrees M576 (J.N.); and Research Training Fellowship GN2137 from Action Medical Research. Production of Escherichia coli A192PP-lux2 was funded by Action Medical Research grant GN2075.	Agrawal V, 2012, SEMIN FETAL NEONAT M, V17, P12, DOI 10.1016/j.siny.2011.09.001; Akgul Y, 2014, J CLIN INVEST, V124, P5481, DOI 10.1172/JCI78765; Backhed F, 2003, MICROBES INFECT, V5, P1057, DOI 10.1016/S1286-4579(03)00207-7; Becher N, 2009, ACTA OBSTET GYN SCAN, V88, P502, DOI 10.1080/00016340902852898; Bell MJ, 2004, PEDIATR RES, V56, P541, DOI 10.1203/01.PDR.0000139407.89883.6B; Bell MJ, 2002, J NEUROSCI RES, V70, P570, DOI 10.1002/jnr.10423; Birchenough GMH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00123-w; Blencowe H, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-S1-S2; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Bollopragada S, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.032; Bonacorsi S, 2005, INT J MED MICROBIOL, V295, P373, DOI 10.1016/j.ijmm.2005.07.011; Boyle AK, 2017, J REPROD IMMUNOL, V119, P62, DOI 10.1016/j.jri.2016.11.008; Browning DF, 2013, MOL MICROBIOL, V87, P939, DOI 10.1111/mmi.12144; Burd I, 2012, AM J REPROD IMMUNOL, V67, P287, DOI 10.1111/j.1600-0897.2012.01110.x; Cronin M, 2014, MOL THER, V22, P1188, DOI 10.1038/mt.2014.23; Cronin M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030940; Dalgakiran F, 2014, JOVE-J VIS EXP, DOI 10.3791/52018; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Edey LF, 2016, BIOL REPROD, V95, DOI 10.1095/biolreprod.116.143289; Elovitz MA, 2011, INT J DEV NEUROSCI, V29, P663, DOI 10.1016/j.ijdevneu.2011.02.011; Espinoza J, 2003, J Matern Fetal Neonatal Med, V13, P2, DOI 10.1080/713605751; Fidel P, 2003, J Matern Fetal Neonatal Med, V14, P57, DOI 10.1080/713605934; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gomez-Lopez N, 2017, AM J OBSTET GYNECOL, V217; Gomez-Lopez N, 2017, REPROD SCI, V24, P1139, DOI 10.1177/1933719116678690; Grigsby PL, 2010, REPROD SCI, V17, P85, DOI 10.1177/1933719109348025; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hein M, 2002, AM J OBSTET GYNECOL, V187, P137, DOI 10.1067/mob.2002.123034; Helderman JB, 2010, EARLY HUM DEV, V86, P509, DOI 10.1016/j.earlhumdev.2010.06.006; Inanlou MR, 2005, DEV DYNAM, V233, P772, DOI 10.1002/dvdy.20381; Jones HE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008205; Karda R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06696-w; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X; Kenyon S, 2008, LANCET, V372, P1319, DOI 10.1016/S0140-6736(08)61203-9; Kim CJ, 2015, AM J OBSTET GYNECOL, V213, pS29, DOI 10.1016/j.ajog.2015.08.040; Kim MJ, 2009, LAB INVEST, V89, P924, DOI 10.1038/labinvest.2009.49; Kindinger LM, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0223-9; Leviton A, 2010, PEDIATR RES, V67, P95, DOI 10.1203/PDR.0b013e3181bf5fab; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyall K, 2017, ANNU REV PUBL HEALTH, V38, P81, DOI 10.1146/annurev-publhealth-031816-044318; MacIntyre DA, 2014, FASEB J, V28, P2358, DOI 10.1096/fj.13-247783; MCDONALD HM, 1991, BRIT J OBSTET GYNAEC, V98, P427, DOI 10.1111/j.1471-0528.1991.tb10335.x; McGlasson SL, 2017, EUR J IMMUNOL, V47, P658, DOI 10.1002/eji.201646799; Mendz GL, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00058; Meyer U, 2006, J NEUROSCI, V26, P4752, DOI 10.1523/JNEUROSCI.0099-06.2006; Meyer U, 2009, SCHIZOPHRENIA BULL, V35, P959, DOI 10.1093/schbul/sbn022; Migale R, 2015, AM J PATHOL, V185, P2390, DOI 10.1016/j.ajpath.2015.05.015; Modi BP, 2017, MOL GENET GENOM MED, V5, P720, DOI 10.1002/mgg3.330; Moore T, 2012, BMJ-BRIT MED J, V345, P217; Nadeau-Vallee M, 2017, J IMMUNOL, V198, P2047, DOI 10.4049/jimmunol.1601600; Oh KJ, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.035; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Paton MCB, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00200; Patterson PH, 2009, BEHAV BRAIN RES, V204, P313, DOI 10.1016/j.bbr.2008.12.016; Racicot K, 2013, J IMMUNOL, V191, P934, DOI 10.4049/jimmunol.1300661; Randis TM, 2014, J INFECT DIS, V210, P265, DOI 10.1093/infdis/jiu067; RIENDEAU D, 1979, J BIOL CHEM, V254, P7488; Rinaldi SF, 2015, AM J PATHOL, V185, P1201, DOI 10.1016/j.ajpath.2015.01.009; Rinaldi SF, 2014, J IMMUNOL, V192, P2315, DOI 10.4049/jimmunol.1302891; Romero R, 2001, PAEDIATR PERINAT EP, V15, P41, DOI 10.1046/j.1365-3016.2001.00007.x; Sadowsky DW, 2006, AM J OBSTET GYNECOL, V195, P1578, DOI 10.1016/j.ajog.2006.06.072; Samejima T, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.029; Shi LM, 2009, BRAIN BEHAV IMMUN, V23, P116, DOI 10.1016/j.bbi.2008.07.012; Shynlova O, 2014, J CELL MOL MED, V18, P1816, DOI 10.1111/jcmm.12307; Shynlova O, 2013, J CELL MOL MED, V17, P90, DOI 10.1111/j.1582-4934.2012.01650.x; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vogt C, 2008, J NEUROSCI RES, V86, P3314, DOI 10.1002/jnr.21792; Vornhagen J, 2016, MBIO, V7, DOI 10.1128/mBio.00781-16; Wang XY, 2007, BRAIN RES, V1144, P180, DOI 10.1016/j.brainres.2007.01.083; Witcomb LA, 2015, INFECT IMMUN, V83, P4528, DOI 10.1128/IAI.00953-15; Yoon BH, 2003, BJOG-INT J OBSTET GY, V110, P124, DOI 10.1016/S1470-0328(03)00063-6; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P19, DOI 10.1016/S0002-9378(97)70432-0; Yoon BH, 1996, AM J OBSTET GYNECOL, V174, P1433, DOI 10.1016/S0002-9378(96)70585-9; Young A, 2002, BIOL REPROD, V66, P445, DOI 10.1095/biolreprod66.2.445; Zanoni I, 2012, IMMUNOL LETT, V142, P41, DOI 10.1016/j.imlet.2011.12.002; Zaretsky MV, 2004, OBSTET GYNECOL, V103, P546, DOI 10.1097/01.AOG.0000114980.40445.83; Zerrate MC, 2007, J PHARMACOL EXP THER, V322, P16, DOI 10.1124/jpet.107.121483	80	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2164	2176		10.1016/j.ajpath.2018.06.016			13	Pathology	Pathology	GV8SN	WOS:000446415800004	30036519	Green Published, Other Gold			2019-10-28	
J	Sidler, M; Aitken, KJ; Jiang, JX; Sotiropoulos, C; Aggarwal, P; Anees, A; Chong, C; Siebenaller, A; Thanabalasingam, T; White, JM; Choufani, S; Weksberg, R; Sangiorgi, B; Wrana, J; Delgado-Olguin, P; Bagli, DJ				Sidler, Martin; Aitken, Karen J.; Jiang, Jia-Xin; Sotiropoulos, Chris; Aggarwal, Prateek; Anees, Arsalan; Chong, Cynthia; Siebenaller, Aliza; Thanabalasingam, Thenuka; White, J. Maxwell; Choufani, Sanaa; Weksberg, Rosanna; Sangiorgi, Bruno; Wrana, Jeff; Delgado-Olguin, Paul; Bagli, Darius J.			DNA Methylation Reduces the Yes-Associated Protein 1/WW Domain Containing Transcription Regulator 1 Pathway and Prevents Pathologic Remodeling during Bladder Obstruction by Limiting Expression of BDNF	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NEUROTROPHIC FACTOR; MUSCLE; PROLIFERATION; INDUCTION; COMPLEX	Chronic bladder obstruction and bladder smooth muscle cell (SMC) stretch provide fibrotic and mechanical environments that can lead to epigenetic change. Therefore, we examined the role of DNA methylation in bladder pathology and transcriptional control. Sprague-Dawley female rats underwent partial bladder obstruction by ligation of a silk suture around the proximal urethra next to a 0.9-mm steel rod. Sham operation comprised passing the suture around the urethra. After 2 weeks, rats were randomized to normal saline or DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (DAC) at 1 mg/kg, three times/week intraperitoneally. After 6 weeks, bladders were weighed and divided for histology and RNA analysis by high-throughput real-time quantitative PCR arrays. DAC treatment during obstruction in vivo profoundly augmented brain-derived neurotrophic factor (BDNF) expression compared with the obstruction with vehicle group, which was statistically correlated with pathophysiologic parameters. BDNF, cysteine rich angiogenic inducer 61 (CYR61), and connective tissue growth factor (CTGF) expression clustered tightly together using Pearson's correlation analysis. Their promoters were associated with the TEA domain family member 1 (TEAD1) and Yes-associated protein 1/WW domain containing transcription regulator 1 pathways. Interestingly, DAC treatment increased BDNF expression in bladder SMCs (P < 0.0002). Stretch-induced BDNF was inhibited by the YAP/WWTR1 inhibitor verteporfin. Verteporfin improved the SMC phenotype (proliferative markers and SMC marker expression), in part by reducing BDNF. Expression of BDNF is limited by DNA methylation and associated with pathophysiologic changes during partial bladder outlet obstruction and SMC phenotypic change in vitro.	[Sidler, Martin; Aitken, Karen J.; Jiang, Jia-Xin; Sotiropoulos, Chris; Aggarwal, Prateek; Siebenaller, Aliza; Thanabalasingam, Thenuka; White, J. Maxwell; Bagli, Darius J.] Hosp Sick Children, Res Inst, Dev & Stem Cell Biol, Toronto, ON, Canada; [Choufani, Sanaa; Weksberg, Rosanna] Hosp Sick Children, Res Inst, Genet & Genome Biol, Toronto, ON, Canada; [Delgado-Olguin, Paul] Hosp Sick Children, Res Inst, Translat Med, Toronto, ON, Canada; [Sidler, Martin; Aitken, Karen J.; Bagli, Darius J.] Hosp Sick Children, Dept Surg, Div Urol, Toronto, ON, Canada; [Sidler, Martin; Bagli, Darius J.] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada; [Jiang, Jia-Xin; Sotiropoulos, Chris; Anees, Arsalan; Bagli, Darius J.] Univ Toronto, Dept Physiol, Fac Arts & Sci, Toronto, ON, Canada; [Chong, Cynthia; Thanabalasingam, Thenuka] Univ Toronto, Human Biol Program, Toronto, ON, Canada; [Weksberg, Rosanna; Sangiorgi, Bruno; Wrana, Jeff; Delgado-Olguin, Paul] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [White, J. Maxwell] Queens Univ, Sch Business, Kingston, ON, Canada; [Sangiorgi, Bruno; Wrana, Jeff] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Sangiorgi, Bruno; Wrana, Jeff] Wolf Lebov Hlth Complex, Toronto, ON, Canada; [Delgado-Olguin, Paul] Heart & Stroke Richard Leward Ctr Excellence Card, Toronto, ON, Canada	Bagli, DJ (reprint author), Hosp Sick Children, 555 Univ Ave,M299, Toronto, ON M5G 1X8, Canada.	darius.bagli@sickkids.ca	Olguin, Paul Delgado/H-9293-2019; Aitken, KJ/AAC-5383-2019	Olguin, Paul Delgado/0000-0002-5355-247X; 	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Strategic Training program in regenerative medicine (TPRM); Research Training competition, SickKids Hospital Research Institute; Department of Physiology at the University of Toronto; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; YMCA Canada; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada	Supported by the Canadian Institutes of Health Research (D.J.B., P.D.-O.), the Strategic Training program in regenerative medicine (TPRM) (K.J.A.), the Research Training competition, SickKids Hospital Research Institute (J.-X.J.), the Department of Physiology at the University of Toronto (J.-X.J.), the Heart and Stroke Foundation of Canada (P.D.-O.), YMCA Canada (A.S.), and the Natural Sciences and Engineering Research Council of Canada (P.D.-O.).	Aitken KJ, 2010, AM J PATHOL, V176, P304, DOI 10.2353/ajpath.2010.080834; Antunes-Lopes T, 2013, J UROLOGY, V189, P359, DOI 10.1016/j.juro.2012.08.187; Chen KW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030571; Chowdhury B, 2015, SCI REP-UK, V5, DOI 10.1038/srep09281; Cruz CD, 2014, NEUROUROL URODYNAM, V33, P39, DOI 10.1002/nau.22438; Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578; Feng N, 2015, P NATL ACAD SCI USA, V112, P1880, DOI 10.1073/pnas.1417949112; Frias B, 2015, J NEUROSCI, V35, P2146, DOI 10.1523/JNEUROSCI.0373-14.2015; Ganz ML, 2010, UROLOGY, V75, P526, DOI 10.1016/j.urology.2009.06.096; Gheinani AH, 2015, J BIOL CHEM, V290, P7067, DOI 10.1074/jbc.M114.618694; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; Imamura M, 2007, AM J PHYSIOL-RENAL, V293, pF1007, DOI 10.1152/ajprenal.00107.2007; Jiang JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069089; Karagiannis TC, 2012, ANTIOXID REDOX SIGN, V17, P192, DOI 10.1089/ars.2012.4562; Liu RJ, 2015, BBA-GENE REGUL MECH, V1849, P448, DOI 10.1016/j.bbagrm.2014.06.004; Liu RJ, 2013, CIRCULATION, V128, P2047, DOI 10.1161/CIRCULATIONAHA.113.002887; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; Martin KA, 2004, AM J PHYSIOL-CELL PH, V286, pC507, DOI 10.1152/ajpcell.00201.2003; Metcalfe PD, 2010, BJU INT, V106, P1686, DOI 10.1111/j.1464-410X.2010.09445.x; Ochodnicky P, 2012, NAT REV UROL, V9, P628, DOI 10.1038/nrurol.2012.178; Pardo PS, 2011, J BIOL CHEM, V286, P2559, DOI 10.1074/jbc.M110.149153; Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2; Sampathkumar C, 2016, ELIFE, V5, DOI 10.7554/eLife.19374; Santos D, 2016, NEURAL PLAST, DOI 10.1155/2016/4969523; Schroder A, 2013, J UROLOGY, V189, P2377, DOI 10.1016/j.juro.2012.12.110; Sidler M, 2018, BLADDER, V5, pe33; Sidler M, 2017, UROLOGY, V105, DOI 10.1016/j.urology.2017.03.032; Sidler M, 2017, JOVE-J VIS EXP, DOI 10.3791/55288; Song QX, 2014, NAT REV UROL, V11, P579, DOI 10.1038/nrurol.2014.244; Tao H, 2014, TOXICOLOGY, V323, P125, DOI 10.1016/j.tox.2014.07.002; Tolg C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059413; Tureyen K, 2008, J NEUROCHEM, V105, P1313, DOI 10.1111/j.1471-4159.2008.05233.x; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Yuk SM, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0036-3; Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461; Zhuang JH, 2017, ARTERIOSCL THROM VAS, V37, P84, DOI 10.1161/ATVBAHA.116.307923	37	0	0	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2177	2194		10.1016/j.ajpath.2018.06.024			18	Pathology	Pathology	GV8SN	WOS:000446415800005	30121256				2019-10-28	
J	Tsagianni, A; Mars, WM; Bhushan, B; Bowen, WC; Orr, A; Stoops, J; Paranjpe, S; Tseng, GC; Liu, S; Michalopoulos, GK				Tsagianni, Anastasia; Mars, Wendy M.; Bhushan, Bharat; Bowen, William C.; Orr, Anne; Stoops, John; Paranjpe, Shirish; Tseng, George C.; Liu, Silvia; Michalopoulos, George K.			Combined Systemic Disruption of MET and Epidermal Growth Factor Receptor Signaling Causes Liver Failure in Normal Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEPATOCYTE GROWTH; PARTIAL-HEPATECTOMY; TYROSINE KINASE; REGENERATION; PATHWAY; CELLS; PROLIFERATION; ACTIVATION; EXPRESSION; INITIATION	MET and epidermal growth factor receptor (EGFR) tyrosine kinases are crucial for liver regeneration and normal hepatocyte function. Recently, we demonstrated that in mice, combined inhibition of these two signaling pathways abolished liver regeneration after hepatectomy, with subsequent hepatic failure and death at 15 to 18 days after resection. Morbidity was associated with distinct and specific alterations in important downstream signaling pathways that led to decreased hepatocyte volume, reduced proliferation, and shutdown of many essential hepatocyte functions, such as fatty acid synthesis, urea cycle, and mitochondrial functions. Herein, we explore the role of MET and EGFR signaling in resting mouse livers that are not subjected to hepatectomy. Mice with combined disruption of MET and EGFR signaling were noticeably sick by 10 days and died at 12 to 14 days. Mice with combined disruption of MET and EGFR signaling mice showed decreased liver/body weight ratios, increased apoptosis in nonparenchymal cells, impaired liver metabolic functions, and activation of distinct downstream signaling pathways related to inflammation, cell death, and survival. The present study demonstrates that, in addition to controlling the regenerative response, MET and EGFR synergistically control baseline liver homeostasis in normal mice in such a way that their combined disruption leads to liver failure and death.	[Tsagianni, Anastasia; Mars, Wendy M.; Bhushan, Bharat; Bowen, William C.; Orr, Anne; Stoops, John; Paranjpe, Shirish; Michalopoulos, George K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Tseng, George C.; Liu, Silvia] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA	Michalopoulos, GK (reprint author), 200 Lothrop St,S BST S410, Pittsburgh, PA 15261 USA.	michalopoulosgk@upmc.edu		Mars, Wendy/0000-0003-4495-1054	NIH/National Institute of Diabetes and Digestive and Kidney Diseases Program Project [P01 DK096690]; Cleveland Foundation; Menten Endowment Foundation of the University of Pittsburgh	Supported by the NIH/National Institute of Diabetes and Digestive and Kidney Diseases Program Project grant P01 DK096690 (G.K.M.), the Cleveland Foundation (G.K.M.), and the Menten Endowment Foundation of the University of Pittsburgh (G.K.M.).	[Anonymous], 2011, COMMITTEE UPDATE GUI; Bale SS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25329; Baumann C, 2017, MOL ONCOL, V11, P1430, DOI 10.1002/1878-0261.12109; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Carver RS, 2002, GASTROENTEROLOGY, V123, P2017, DOI 10.1053/gast.2002.37060; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Kaidanovich-Beilin O, 2006, J PHARMACOL EXP THER, V316, P17, DOI 10.1124/jpet.105.090266; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Michalopoulos GK, 2007, J CELL PHYSIOL, V213, P286, DOI 10.1002/jcp.21172; Michalopoulos GK, 2001, AM J PATHOL, V159, P1877, DOI 10.1016/S0002-9440(10)63034-9; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Natarajan A, 2007, P NATL ACAD SCI USA, V104, P17081, DOI 10.1073/pnas.0704126104; Nejak-Bowen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059836; Norris CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096053; OLSEN PS, 1988, HEPATOLOGY, V8, P992, DOI 10.1002/hep.1840080503; Organ Shawna Leslie, 2011, Ther Adv Med Oncol, V3, pS7, DOI 10.1177/1758834011422556; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Paranjpe S, 2016, HEPATOLOGY, V64, P1711, DOI 10.1002/hep.28721; Paranjpe S, 2010, AM J PATHOL, V176, P2669, DOI 10.2353/ajpath.2010.090605; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Presnell SC, 1997, MOL CARCINOGEN, V18, P244, DOI 10.1002/(SICI)1098-2744(199704)18:4<244::AID-MC8>3.0.CO;2-D; Rayasam GV, 2009, BRIT J PHARMACOL, V156, P885, DOI 10.1111/j.1476-5381.2008.00085.x; Runge DM, 1999, J HEPATOL, V30, P265, DOI 10.1016/S0168-8278(99)80073-7; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; Stabile LP, 2013, CLIN CANCER RES, V19, P380, DOI 10.1158/1078-0432.CCR-12-1555; Stolz DB, 1999, CANCER RES, V59, P3954; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Taub R, 1996, FASEB J, V10, P413; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tseng GC, 2005, BIOMETRICS, V61, P10, DOI 10.1111/j.0006-341X.2005.031032.x; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wu JW, 2013, ACS MED CHEM LETT, V4, P974, DOI 10.1021/ml4002437; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang MJ, 2017, COMP BIOCHEM PHYS C, V195, P52, DOI 10.1016/j.cbpc.2017.02.008; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	43	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2223	2235		10.1016/j.ajpath.2018.06.009			13	Pathology	Pathology	GV8SN	WOS:000446415800008	30031724				2019-10-28	
J	Jang, BG; Kim, HS; Chang, WY; Bae, JM; Kim, WH; Kang, GH				Jang, Bo Gun; Kim, Hye Sung; Chang, Weon Young; Bae, Jeong Mo; Kim, Woo Ho; Kang, Gyeong Hoon			Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PROTEIN-COUPLED RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-LIKE CELLS; WNT/BETA-CATENIN; COLON-CANCER; POOR-PROGNOSIS; MARKER; SURVIVAL; TUMOR; OVEREXPRESSION	We investigated the expression profile of leucine-rich, repeat-containing, G-protein-coupled receptor 5 (LGR5) during colorectal cancer (CRC) progression and determined the prognostic impact of LGR5 in a large cohort of CRC samples. LGR5 expression was higher in CRCs than in normal mucosa, and was not associated with other cancer stem cell markers. LGR5 positivity was observed in 68% of 788 CRCs and was positively correlated with older age, moderately to well-differentiated cells, and nuclear D-catenin expression. Enhanced LGR5 expression remained persistent during the adenoma-carcinoma transition, but markedly declined in the budding cancer cells at the invasive fronts, which was not due to altered wingless-type mouse mammary tumor virus integration site family (Wnt) or epithelial-mesenchymal transition signaling. LGR5 showed negative correlations with microsatellite instability and CpG island methylator phenotype, and was not associated with KRAS or BRAF mutation. Notably, LGR5 positivity was an independent prognostic marker for better clinical outcomes in CRC patients. LGR5 overexpression attenuated tumor growth by decreasing ERK phosphorylation along with decreased colony formation and migration abilities in DLD1 cells. Likewise, knockdown of LGR5 expression resulted in a decline in the colony-forming and migration capacities in LoVo cells. Taken together, our data suggest a suppressive role of LGR5 in CRC progression.	[Jang, Bo Gun; Kim, Hye Sung] Jeju Natl Univ, Sch Med, Dept Pathol, Jeju, South Korea; [Chang, Weon Young] Jeju Natl Univ, Sch Med, Dept Gen Surg, Jeju, South Korea; [Bae, Jeong Mo; Kim, Woo Ho; Kang, Gyeong Hoon] Seoul Natl Univ, Coll Med, Dept Pathol, Canc Res Inst, Seoul, South Korea; [Bae, Jeong Mo; Kang, Gyeong Hoon] Seoul Natl Univ, Coll Med, Canc Res Inst, Lab Epigenet, Seoul, South Korea	Kang, GH (reprint author), Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 110799, South Korea.	ghkang@snu.ac.kr	Kang, Gyeong Hoon/F-1051-2010	Kang, Gyeong Hoon/0000-0003-2380-6675	National Research Foundation of Korea (NRF) Basic Science Research Program, Ministry of Science, ICT & Future Planning [NRF-2017R1C1B5017468, NRF-2017R1C1B1004912]; Korea government NRFKorean Government [2011-0030049]	Supported by National Research Foundation of Korea (NRF) Basic Science Research Program, Ministry of Science, ICT & Future Planning grants NRF-2017R1C1B5017468 (B.G.J.) and NRF-2017R1C1B1004912 (H.S.K.); and the Korea government NRF grant 2011-0030049 (G.H.K.).	Al-Kharusi MRA, 2013, CARCINOGENESIS, V34, P1150, DOI 10.1093/carcin/bgt020; Baker AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep08654; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Becker L, 2008, THESCIENTIFICWORLDJO, V8, P1168, DOI 10.1100/tsw.2008.148; Boland CR, 1998, CANCER RES, V58, P5248; Bosman FT, 2010, WHO CLASSIFICATION T; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Chen Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107013; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Fan XS, 2010, INT J COLORECTAL DIS, V25, P583, DOI 10.1007/s00384-010-0903-z; Galvan JA, 2015, BRIT J CANCER, V112, P1944, DOI 10.1038/bjc.2015.177; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Han Y, 2015, CLIN RES HEPATOL GAS, V39, P267, DOI 10.1016/j.clinre.2014.07.008; He SB, 2014, BIOMED PHARMACOTHER, V68, P507, DOI 10.1016/j.biopha.2014.03.016; Hirsch D, 2014, CARCINOGENESIS, V35, P849, DOI 10.1093/carcin/bgt377; Hsu HC, 2013, INT J COLORECTAL DIS, V28, P1535, DOI 10.1007/s00384-013-1721-x; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jang BG, 2016, HISTOPATHOLOGY, V68, P567, DOI 10.1111/his.12787; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jiang YY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1986-2; Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233; Kim JH, 2014, MODERN PATHOL, V27, P443, DOI 10.1038/modpathol.2013.160; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nakata S, 2013, BRAIN PATHOL, V23, P60, DOI 10.1111/j.1750-3639.2012.00618.x; Ng A, 2014, NAT CELL BIOL, V16, P745, DOI 10.1038/ncb3000; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Saigusa S, 2013, J CANCER RES CLIN, V139, P131, DOI 10.1007/s00432-012-1308-x; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Sobin LH, 2010, CANCER-AM CANCER SOC, V116, P5336, DOI 10.1002/cncr.25537; Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434-010-1373-9; Tanese K, 2008, AM J PATHOL, V173, P835, DOI 10.2353/ajpath.2008.071091; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; Vieira GC, 2015, ONCOTARGET, V6, P40053, DOI 10.18632/oncotarget.5548; Walker F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022733; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Wu XS, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-244; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Yang L, 2015, STEM CELLS, V33, P2913, DOI 10.1002/stem.2083; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Zhou XL, 2017, CANCER RES, V77, P6589, DOI 10.1158/0008-5472.CAN-17-0219; Ziskin JL, 2013, GUT, V62, P1012, DOI 10.1136/gutjnl-2011-301195; Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199	51	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2236	2250		10.1016/j.ajpath.2018.06.012			15	Pathology	Pathology	GV8SN	WOS:000446415800009	30036518	Bronze			2019-10-28	
J	Yu, J; Francisco, AMC; Patel, BG; Cline, JM; Zou, E; Berga, SL; Taylor, RN				Yu, Jie; Francisco, Antonio M. C.; Patel, Bansari G.; Cline, J. Mark; Zou, Eric; Berga, Sarah L.; Taylor, Robert N.			IL-1 beta Stimulates Brain-Derived Neurotrophic Factor Production in Eutopic Endometriosis Stromal Cell Cultures A Model for Cytokine Regulation of Neuroangiogenesis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							KAPPA-B PATHWAY; NERVE-FIBERS; PROTEIN EXPRESSION; GENE-EXPRESSION; PELVIC PAIN; IN-VITRO; WOMEN; ACTIVATION; RANTES; RECEPTOR	Endometriosis implants are comprised of glandular and stromal elements, macrophages, nerves, and blood vessels and are commonly accompanied by pelvic pain. We propose that activated macrophages are recruited to and infiltrate nascent lesions, where they secrete proinflammatory cytokines, promoting the production of chemokines, neurotrophins, and angiogenic growth factors that sustain an inflammatory microenvironment. Immunohistochemical evaluation of endometriosis lesions reveals in situ colocalization of concentrated macrophages, brain-derived neurotrophic factor (BDNF), and nerve fibers. These observations were coupled with biochemical analyses of primary eutopic endometriosis stromal cell (EESC) cultures, which allowed defining potential pathways leading to the neuroangiogenic phenotype of these lesions. Our findings indicate that IL-1 beta potently (EC50 = 7 +/- 2 ng/mL) stimulates production of EESC BDNF at the mRNA and protein levels in an IL-1 receptor-dependent fashion. Selective kinase inhibitors demonstrate that this IL-1 beta effect is mediated by c-Jun N-terminal kinase (JNK), NE-kappa B, and mechanistic target of rapamycin signal transduction pathways. IL-1 beta regulation of regulated on activation normal T cell expressed and secreted (RANTES), a prominent EESC chemokine, also relies on JNK and NE-kappa B. An important clinical implication of the study is that interference with BDNF and RANTES production, by selectively targeting the JNK and NE-kappa B cascades, may offer a tractable therapeutic strategy to mitigate the pain and inflammation associated with endometriosis.	[Yu, Jie; Francisco, Antonio M. C.; Patel, Bansari G.; Zou, Eric; Berga, Sarah L.; Taylor, Robert N.] Wake Forest Sch Med, Dept Obstet & Gynecol, Winston Salem, NC USA; [Cline, J. Mark] Wake Forest Sch Med, Dept Comparat Med, Winston Salem, NC USA; [Cline, J. Mark; Taylor, Robert N.] Wake Forest Sch Med, Mol Med & Translat Sci Program, Winston Salem, NC USA; [Taylor, Robert N.] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA; [Francisco, Antonio M. C.] Univ Vale Sapucai, Hlth Sci Sch, Pouso Alegre, Brazil	Taylor, RN (reprint author), Univ Utah, Sch Med, Dept Obstet & Gynecol, 30 N 1900 East,Ste 2A242, Salt Lake City, UT 84132 USA.	rob.taylor@hsc.utah.edu		Taylor, Robert/0000-0002-1423-6351; Francisco, Antonio/0000-0002-8228-3379; Berga, Sarah/0000-0003-1885-0401	NIH Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD78818]	Supported by the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development grant R21 HD78818 (R.N.T.).	Adamson GD, 2010, J ENDOMETR PELVIC PA, V2, P3, DOI 10.1177/228402651000200102; Akoum A, 2007, HUM REPROD, V22, P1464, DOI 10.1093/humrep/dem021; Anaf V, 2011, GYNECOL OBSTET INVES, V71, P112, DOI 10.1159/000320750; Anger DL, 2007, ENDOCRINE, V31, P167, DOI 10.1007/s12020-007-0025-8; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; As-Sanie S, 2016, J PAIN, V17, P1, DOI 10.1016/j.jpain.2015.09.008; Asante A, 2011, ANNU REV PHYSIOL, V73, P163, DOI 10.1146/annurev-physiol-012110-142158; Becker CM, 2017, FERTIL STERIL, V108, P125, DOI 10.1016/j.fertnstert.2017.05.004; Berkley KJ, 2005, SCIENCE, V308, P1587, DOI 10.1126/science.1111445; Beste MT, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007988; Bokor A, 2009, HUM REPROD, V24, P3025, DOI 10.1093/humrep/dep283; Bondza Patrick Kibangou, 2009, Front Biosci (Elite Ed), V1, P415; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Borghese B, 2010, GYNECOL OBSTET FERTI, V38, P442, DOI 10.1016/j.gyobfe.2010.05.005; Browne AS, 2012, FERTIL STERIL, V98, P713, DOI 10.1016/j.fertnstert.2012.05.027; Canis M, 1997, FERTIL STERIL, V67, P817; Guzeloglu-Kayisli O, 2015, J PATHOL, V237, P423, DOI 10.1002/path.4589; HANEY AF, 1981, FERTIL STERIL, V35, P696; Hornung D, 1997, J CLIN ENDOCR METAB, V82, P1621, DOI 10.1210/jc.82.5.1621; Hornung D, 2001, AM J PATHOL, V158, P1949, DOI 10.1016/S0002-9440(10)64664-0; Hussein M, 2016, FERTIL STERIL, V105, P815, DOI 10.1016/j.fertnstert.2015.11.022; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Koninckx PR, 2012, FERTIL STERIL, V98, P564, DOI 10.1016/j.fertnstert.2012.07.1061; Kyama Cleophas M, 2009, Front Biosci (Elite Ed), V1, P444; Lebovic DI, 2000, MOL HUM REPROD, V6, P269, DOI 10.1093/molehr/6.3.269; Lebovic DI, 2004, J CLIN ENDOCR METAB, V89, P1397, DOI 10.1210/jc.2003-031010; Lebovic DI, 2001, J CLIN ENDOCR METAB, V86, P4759, DOI 10.1210/jc.86.10.4759; LEVIMONTALCINI R, 1995, J NEUROL SCI, V130, P119, DOI 10.1016/0022-510X(95)00007-O; Louis GMB, 2011, FERTIL STERIL, V96, P360, DOI 10.1016/j.fertnstert.2011.05.087; Malek AM, 1996, J CELL SCI, V109, P713; Matsuda S, 2012, J CELL PHYSIOL, V227, P2123, DOI 10.1002/jcp.22942; Medina MG, 2009, ACTA OBSTET GYN SCAN, V88, P968, DOI 10.1080/00016340903176826; Meigs JV, 1922, BOSTON MED SURG J, V187, P1; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Morotti M, 2017, EUR J OBSTET GYN R B, V209, P8, DOI 10.1016/j.ejogrb.2016.07.497; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Ponce C, 2009, REPRODUCTION, V137, P727, DOI 10.1530/REP-08-0407; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Reis FM, 2013, HUM REPROD UPDATE, V19, P406, DOI 10.1093/humupd/dmt010; Rocha AL, 2017, BIOMARK MED, V11, P313, DOI 10.2217/bmm-2016-0327; Ross JL, 2018, PAIN, V159, P380, DOI 10.1097/j.pain.0000000000001094; RYAN IP, 1994, J CLIN ENDOCR METAB, V78, P642, DOI 10.1210/jc.78.3.642; Sampson JA, 1921, ARCH SURG-CHICAGO, V3, P245, DOI 10.1001/archsurg.1921.01110080003001; Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073; Taylor R, 2014, YEN JAFFES REPROD EN, P565; Taylor RN, 2012, MIDDLE EAST FERTIL S, V17, P221, DOI 10.1016/j.mefs.2012.09.002; Taylor RN, 2015, SEMIN REPROD MED, V33, P246, DOI 10.1055/s-0035-1554920; Tokushige N, 2006, HUM REPROD, V21, P3001, DOI 10.1093/humrep/del260; Tseng JF, 1996, J CLIN ENDOCR METAB, V81, P1118, DOI 10.1210/jc.81.3.1118; Wang GY, 2009, HUM REPROD, V24, P827, DOI 10.1093/humrep/den464; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wessels JM, 2016, FERTIL STERIL, V105, P119, DOI 10.1016/j.fertnstert.2015.09.003; Wieser F, 2005, J CLIN ENDOCR METAB, V90, P6441, DOI 10.1210/jc.2005-0972; Wood CE, 2004, VET PATHOL, V41, P108, DOI 10.1354/vp.41-2-108; Wu JJ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0828-3; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF806; Yu J, 2017, ENDOCRINOLOGY, V158, P4270, DOI 10.1210/en.2017-00495; Yu J, 2016, ENDOCRINOLOGY, V157, P2432, DOI 10.1210/en.2015-1942; Yu J, 2014, MOL REPROD DEV, V81, P666, DOI 10.1002/mrd.22334; Yu J, 2014, MOL HUM REPROD, V20, P260, DOI 10.1093/molehr/gat087; Yu J, 2011, MOL CELL ENDOCRINOL, V344, P25, DOI 10.1016/j.mce.2011.04.011; Zhao D, 2002, J CLIN ENDOCR METAB, V87, P2514, DOI 10.1210/jc.87.6.2514	63	2	2	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2281	2292		10.1016/j.ajpath.2018.06.011			12	Pathology	Pathology	GV8SN	WOS:000446415800012	30031725				2019-10-28	
J	Wong, OGW; Cheung, CLY; Ip, PPC; Ngan, HYS; Cheung, ANY				Wong, Oscar G. W.; Cheung, Claire L. Y.; Ip, Philip P. C.; Ngan, Hextan Y. S.; Cheung, Annie N. Y.			Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN PLACENTAL DEVELOPMENT; HOUSEKEEPING GENES; EXPRESSION; TRISOMY-21; DIFFERENTIATION; INVASION; DISEASE; PREGNANCIES; APOPTOSIS	The placentas of Down syndrome (DS) pregnancies exhibit morphologic and functional abnormalities. Although the increase in dosage of certain genes on chromosome 21 has been associated with the DS phenotype, the effects on placenta have seldom been studied. Herein, we examine the expression of four dosage-sensitive genes (APP, ETS2, SOD1, and HMGN1) in normal and DS placentas. We demonstrated significant overexpression of amyloid precursor protein (APP) in DS placentas at RNA and protein levels by real-time quantitative PCR, Western blot analysis, and immunohistochemistry. Inducible APP overexpression trophoblast cell line models were established using a Tet-On system. APP induction in HTR-8/SVneo dose-dependently decelerated cell growth, enhanced apoptosis, and reduced cell migration and invasion when compared with the uninduced controls. Concomitantly, decreased beta-human chorionic gonadotropin in the culture medium was also detected on induction. Moreover, although forskolin treatment induced alpha/beta-human chorionic gonadotropin and syncytin expression in BeWo cells, such induction of syncytialization was inhibited by APP overexpression. E-cadherin immunofluorescence also demonstrated a decrease in syncytia formation in forskolin-treated BeWo-overexpressing APP. By liquid chromatography-tandem mass spectrometry, proteins related to cell-cell adhesion, protein translation, processing, and folding were found to be up-regulated in APP-induced HTR-8/SVneo clones. Our data demonstrated, for the first time, the effects of increased APP expression in DS placenta.	[Wong, Oscar G. W.; Cheung, Claire L. Y.; Ip, Philip P. C.; Cheung, Annie N. Y.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ngan, Hextan Y. S.] Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Wong, OGW; Cheung, ANY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, 7-F,Block T, Pokfulam, Hong Kong, Peoples R China.	wonggw@pathology.hku.hk; anycheun@pathology.hku.hk	Cheung, Annie Nga Yin/C-4231-2009	Cheung, Annie Nga Yin/0000-0002-1584-7568; Ip, Philip Pun-Ching/0000-0002-0493-9838; Ngan, Hextan Y S/0000-0003-3945-159X	Health and Medical Research Fund, Food and Health Bureau, Hong Kong Special Administrative Region [01120936]	Supported by the Health and Medical Research Fund, Food and Health Bureau, Hong Kong Special Administrative Region project number 01120936 (A.N.Y.C.).	Antonarakis SE, 2004, NAT REV GENET, V5, P725, DOI 10.1038/nrg1448; Banerjee S, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-25; Benosman S, 2011, J BIOL CHEM, V286, P43013, DOI 10.1074/jbc.M111.261271; Castro P, 2017, J NEUROL, V264, P804, DOI 10.1007/s00415-016-8308-8; Cheng N, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0150-16.2016; Fan XX, 2010, ACTA BIOCH BIOPH SIN, V42, P318, DOI 10.1093/abbs/gmq026; Frendo JL, 2004, J CLIN ENDOCR METAB, V89, P727, DOI 10.1210/jc.2003-030668; Govoni S, 1996, NEUROLOGY, V47, P1069, DOI 10.1212/WNL.47.4.1069; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Gupta SK, 2016, AM J REPROD IMMUNOL, V75, P361, DOI 10.1111/aji.12436; Haynes HR, 2018, J CLIN PATHOL, V71, P695, DOI 10.1136/jclinpath-2017-204969; Kaitu'u-Lino TJ, 2014, PLACENTA, V35, P1106, DOI 10.1016/j.placenta.2014.10.003; Lana-Elola E, 2011, DIS MODEL MECH, V4, P586, DOI 10.1242/dmm.008078; Lunghi L, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-6; Mak VCY, 2015, AM J PATHOL, V185, P2038, DOI 10.1016/j.ajpath.2015.03.011; Meller M, 2005, PLACENTA, V26, P601, DOI 10.1016/j.placenta.2004.09.009; Moncaster JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010659; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; Pallister C, 1997, NEUROBIOL AGING, V18, P97, DOI 10.1016/S0197-4580(96)00207-2; Pidoux G, 2004, PLACENTA, V25, pS79, DOI 10.1016/j.placenta.2004.01.007; Pidoux G, 2012, PLACENTA, V33, pS81, DOI 10.1016/j.placenta.2011.11.007; Pidoux G, 2007, ENDOCRINOLOGY, V148, P5403, DOI 10.1210/en.2007-0589; Qureshi F, 1997, FETAL DIAGN THER, V12, P210, DOI 10.1159/000264470; Ricco R, 2009, ANAL QUANT CYTOL, V31, P41; Roberts L, 2000, PLACENTA, V21, P678, DOI 10.1053/plac.2000.0553; Rozovski U, 2007, HUM REPROD, V22, P2538, DOI 10.1093/humrep/dem214; Scifres CM, 2009, J PHYSIOL-LONDON, V587, P3453, DOI 10.1113/jphysiol.2009.173252; Siu MKY, 2008, AM J PATHOL, V173, P1165, DOI 10.2353/ajpath.2008.080288; Sosa LJ, 2017, J NEUROCHEM, V143, P11, DOI 10.1111/jnc.14122; Weksler ME, 2013, AUTOIMMUN REV, V12, P670, DOI 10.1016/j.autrev.2012.10.013; WICE B, 1990, EXP CELL RES, V186, P306, DOI 10.1016/0014-4827(90)90310-7; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wong SYY, 1999, MODERN PATHOL, V12, P1025; Wright A, 2004, AM J MED GENET A, V130A, P354, DOI 10.1002/ajmg.a.30254; Yoshie M, 2008, HUM REPROD, V23, P2766, DOI 10.1093/humrep/den317; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	36	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2307	2317		10.1016/j.ajpath.2018.07.004			11	Pathology	Pathology	GV8SN	WOS:000446415800014	30031727				2019-10-28	
J	van der Waals, LM; Jongen, JMJ; Elias, SG; Veremiyenko, K; Trumpi, K; Trinh, A; Laoukili, J; Ubink, I; Schenning-van Schelven, SJ; van Diest, PJ; Rinkes, IHMB; Kranenburg, O				van der Waals, Lizet M.; Jongen, Jennifer M. J.; Elias, Sjoerd G.; Veremiyenko, Kateryna; Trumpi, Kari; Trinh, Anne; Laoukili, Jamila; Ubink, Inge; Schenning-van Schelven, Susanne J.; van Diest, Paul J.; Rinkes, Inne H. M. Borel; Kranenburg, Onno			Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors Association with Molecular Subtype and Prior Treatment	AMERICAN JOURNAL OF PATHOLOGY			English	Article							REACTIVE OXYGEN; ANTICANCER DRUGS; CANCER; STRESS; CELLS; DNA; ANTIOXIDANT; NRF2	High levels of oxidative stress in disseminated colorectal cancer tumor cells may form a therapeutically exploitable vulnerability. However, it is unclear whether oxidative stress and damage persist in metastases. Therefore, we analyzed markers of oxidative damage in primary colorectal tumors and their corresponding liver metastases. Markers of generic and oxidative DNA damage [phosphorylated histone H2AX (gamma H2AX) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)] were significantly higher in liver metastases compared with their corresponding primary tumors. Chemotherapy and/or radiotherapy before tumor resection was associated with increased persistent oxidative DNA damage, and this effect was more pronounced in metastases. Immunohistochemistry-based molecular classification into epithelial-and mesenchymal-like molecular subtypes revealed that untreated mesenchymal-like tumors contained lower levels of oxidative DNA damage compared with epitheliat-like tumors. Treated mesenchymal-like tumors, but not epithelial-like tumors, showed significantly higher levels of gamma H2AX and 8-OHdG. Mesenchymal-like tumors expressed significantly lower levels of phosphorylated nuclear factor erythroid 2-related factor 2, a master regulator of the antioxidant response, and nuclear factor erythroid 2-related factor 2-controlled genes. Of interest, a positive 8-OHdG status identified a subgroup of mesenchymal-like metastases with a poor overall survival. An increased capacity to tolerate therapy-induced oxidative damage in mesenchymal-like colorectal cancer may explain, at least in part, the poor responsiveness of these tumors to chemotherapy, which could contribute to the poor survival of this patient subgroup.	[van der Waals, Lizet M.; Jongen, Jennifer M. J.; Veremiyenko, Kateryna; Trumpi, Kari; Laoukili, Jamila; Ubink, Inge; Schenning-van Schelven, Susanne J.; Rinkes, Inne H. M. Borel; Kranenburg, Onno] Univ Utrecht, UMC Utrecht Canc Ctr, Dept Surg Oncol, Utrecht, Netherlands; [Elias, Sjoerd G.] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Trinh, Anne] Univ Utrecht, Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [van Diest, Paul J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Kranenburg, O (reprint author), Univ Med Ctr Utrecht, Div Biomed Genet, POB 85500, NL-3508 GA Utrecht, Netherlands.	o.kranenburg@umcutrecht.nl	Elias, Sjoerd G/E-6057-2011	Elias, Sjoerd G/0000-0003-3903-4024	Gieskes-Strijbis Foundation; Dutch Cancer SocietyKWF Kankerbestrijding [UU2013-5865, 2015-8088, 2014-6617]; Vrienden van het UMC Utrecht	Supported by the Gieskes-Strijbis Foundation (L.M.W.); Dutch Cancer Society grants UU2013-5865 (J.M.J.J.), 2015-8088 (J.L. and S.J.S.), and 2014-6617 (I.U.); and Vrienden van het UMC Utrecht (K.T.).	Alexandre J, 2006, J NATL CANCER I, V98, P236, DOI 10.1093/jnci/djj049; Arifa RDN, 2014, AM J PATHOL, V184, P2023, DOI 10.1016/j.ajpath.2014.03.012; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Coebergh JWW on behalf of the FMWV Society, 2011, BEHALF FMWV SOC FEDE; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Emmink BL, 2014, CANCER RES, V74, P6717, DOI 10.1158/0008-5472.CAN-14-1645; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827; Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453; Kuo LJ, 2008, IN VIVO, V22, P305; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Preston TJ, 2009, MOL CANCER THER, V8, P2015, DOI 10.1158/1535-7163.MCT-08-0929; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Siomek A, 2006, INT J CANCER, V119, P2228, DOI 10.1002/ijc.22088; Snoeren N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049442; Song N, 2016, JAMA ONCOL, V2, P1162, DOI 10.1001/jamaoncol.2016.2314; Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trinh A, 2017, CLIN CANCER RES, V23, P387, DOI 10.1158/1078-0432.CCR-16-0680; Trumpi K, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.48; Tulard A, 2003, FREE RADICAL BIO MED, V35, P68, DOI 10.1016/S0891-5849(03)00243-0; van Diest PJ, 2002, BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017	30	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2369	2377		10.1016/j.ajpath.2018.06.008			9	Pathology	Pathology	GV8SN	WOS:000446415800019	30031728				2019-10-28	
J	Dickson, BC; Antonescu, CR; Argyris, PP; Bilodeau, EA; Bullock, MJ; Freedman, PD; Gnepp, DR; Jordan, RC; Koutlas, IG; Lee, CH; Leong, I; Merzianu, M; Purgina, BM; Thompson, LDR; Wehrli, B; Wright, JM; Swanson, D; Zhang, L; Bishop, JA				Dickson, Brendan C.; Antonescu, Cristina R.; Argyris, Prokopios P.; Bilodeau, Elizabeth A.; Bullock, Martin J.; Freedman, Paul D.; Gnepp, Douglas R.; Jordan, Richard C.; Koutlas, Ioannis G.; Lee, Cheng-Han; Leong, Iona; Merzianu, Mihai; Purgina, Bibianna M.; Thompson, Lester D. R.; Wehrli, Bret; Wright, John M.; Swanson, David; Zhang, Lei; Bishop, Justin A.			Ectomesenchymal Chondromyxoid Tumor A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ectomesenchymal chondromyxoid tumor; tongue; gene rearrangement; RREB1; MKL2; EWSR1; CREM	ANTERIOR TONGUE; ONCOGENE; FUSION	Ectomesenchymal chondromyxoid tumor is a rare and benign neoplasm with a predilection for the anterior dorsal tongue. Despite morphologic heterogeneity, most cases are characterized by a proliferation of bland spindle cells with a distinctive reticular growth pattern and myxoid stroma. The immunophenotype of these neoplasms is likewise variable; most cases express glial fibrillary acid protein and S100 protein, with inconsistent reports of keratin and myoid marker expression. The molecular pathogenesis is poorly understood; however, a subset of cases has been reported to harbor EWSR1 gene rearrangement. Following identification of an RREB1-MKL2 fusion gene by RNA Sequencing in an index patient, a retrospective review of additional cases of ectomesenchymal chondromyxoid tumors was performed to better characterize the clinical, immunohistochemical, and molecular attributes of this neoplasm. A total of 21 cases were included in this series. A marked predisposition for the dorsal tongue was confirmed. Most cases conformed to prior morphologic descriptions; however, hypercellularity, hyalinized stroma, and necrosis were rare attributes not previously emphasized. The neoplastic cells frequently coexpressed glial fibrillary acid protein, S100 protein, keratin, smooth muscle actin, and/or desmin; a single case was found to contain significant myogenin expression. An RREB1-MKL2 fusion product was identified in 19 tumors (90%), a single tumor (5%) had an EWSR1-CREM fusion product, and the remaining case lacked any known fusion gene by RNA Sequencing. The latter 2 cases subtly differed morphologically from many in the cohort. This series illustrates that recurrent RREB1-MKL2 fusions occur in most, perhaps all, cases of ectomesenchymal chondromyxoid tumor.	[Dickson, Brendan C.; Leong, Iona; Swanson, David] Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada; [Dickson, Brendan C.] Univ Toronto, Fac Dent, Dept Lab Med, Toronto, ON, Canada; [Dickson, Brendan C.] Univ Toronto, Fac Dent, Dept Pathobiol, Toronto, ON, Canada; [Leong, Iona] Univ Toronto, Dept Oral Pathol & Oral Med, Fac Dent, Toronto, ON, Canada; [Purgina, Bibianna M.] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Wehrli, Bret] Western Univ, London Hlth Sci Ctr, Dept Pathol & Lab Med, London, ON, Canada; [Bullock, Martin J.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Lee, Cheng-Han] BC Canc Agcy, Vancouver, BC, Canada; [Antonescu, Cristina R.; Zhang, Lei] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Freedman, Paul D.] New York Presbyterian Queens, Sect Oral Pathol, Flushing, NY USA; [Merzianu, Mihai] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Argyris, Prokopios P.] Univ Minnesota, Div Oral & Maxillofacial Pathol, Sch Dent, Minneapolis, MN USA; [Argyris, Prokopios P.] Univ Minnesota, Coll Biol Sci, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA; [Bilodeau, Elizabeth A.] Univ Pittsburgh, Sch Dent Med, Dept Diagnost Sci, Pittsburgh, PA USA; [Jordan, Richard C.] Univ Calif San Francisco, Dept Orofacial Sci Pathol & Radiat Oncol, San Francisco, CA 94143 USA; [Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Woodland Hills, CA USA; [Gnepp, Douglas R.] Brown Univ, Warren Alpert Sch Med, Dept Pathol, Providence, RI 02912 USA; [Wright, John M.] Texas A&M Coll Dent, Dallas, TX USA; [Bishop, Justin A.] UT Southwestern Med Ctr, Dept Pathol, Dallas, TX USA	Dickson, BC (reprint author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave,Suite 6-500-12-5, Toronto, ON M5G 1X5, Canada.	brendan.dickson@sinaihealthsystem.ca			Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30-CA008748]	Supported in part by P50 CA140146-01 (C.R.A.); P30-CA008748 (C.R.A.); Kristen Ann Carr Foundation (C.R.A.); Cycle for Survival (C.R.A.). The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Aldojain A, 2015, HEAD NECK PATHOL, V9, P315, DOI 10.1007/s12105-014-0578-9; Allen CM, 2008, ORAL DIS, V14, P390, DOI 10.1111/j.1601-0825.2008.01447.x; Argyris PP, 2016, HISTOPATHOLOGY, V69, P607, DOI 10.1111/his.12973; Bishop J, 2017, WHO CLASS HEAD NECK, P119; Cardin MJ, 2014, HEAD NECK PATHOL, V8, P329, DOI 10.1007/s12105-013-0500-x; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; de Visscher JGAM, 2003, ORAL ONCOL, V39, P83, DOI 10.1016/S1368-8375(01)00117-8; Flucke U, 2013, HISTOPATHOLOGY, V62, P925, DOI 10.1111/his.12100; Garcia CB, 2012, ONCOGENE, V31, P2323, DOI 10.1038/onc.2011.418; Gouvea AF, 2012, OR SURG OR MED OR PA, V114, P154, DOI 10.1016/j.oooo.2011.11.005; Huang DL, 2010, GENE CHROMOSOME CANC, V49, P810, DOI 10.1002/gcc.20788; Ide F, 2003, VIRCHOWS ARCH, V442, P302, DOI 10.1007/s00428-003-0781-7; Ide F, 2006, J ORAL PATHOL MED, V35, P523, DOI 10.1111/j.1600-0714.2006.00452_1.x; Kao YC, 2017, AM J SURG PATHOL, V41, P482, DOI 10.1097/PAS.0000000000000788; Kato MG, 2017, ORAL ONCOL, V67, P192, DOI 10.1016/j.oraloncology.2017.02.021; Laco J, 2016, INT J SURG PATHOL, V24, P586, DOI 10.1177/1066896916652221; Liu S, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1234; Mokalled MH, 2010, DEVELOPMENT, V137, P2365, DOI 10.1242/dev.047605; Nigam S, 2006, J ORAL PATHOL MED, V35, P126, DOI 10.1111/j.1600-0714.2006.00368.x; Nikitakis NG, 2010, ORAL SURG ORAL MED O, V110, pE48, DOI 10.1016/j.tripleo.2010.05.074; Pires FR, 2009, ORAL SURG ORAL MED O, V108, P914, DOI 10.1016/j.tripleo.2009.07.007; Portnof JE, 2009, ORAL SURG ORAL MED O, V108, pE20, DOI 10.1016/j.tripleo.2009.05.040; Schep LA, 2016, CASE REP OTOLARYNGOL, DOI 10.1155/2016/7342910; Selvaraj A, 2003, J BIOL CHEM, V278, P41977, DOI 10.1074/jbc.M305679200; Seo SH, 2010, AM J DERMATOPATH, V32, P660, DOI 10.1097/DAD.0b013e3181d7d3bf; Siegfried A, 2018, GENE CHROMOSOME CANC, V57, P203, DOI 10.1002/gcc.22521; SMITH BC, 1995, AM J SURG PATHOL, V19, P519, DOI 10.1097/00000478-199505000-00003	28	5	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1297	1305		10.1097/PAS.0000000000001096			9	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300003	29912715				2019-10-28	
J	Bennett, JA; Braga, AC; Pinto, A; Van de Vijver, K; Cornejo, K; Pesci, A; Zhang, L; Morales-Oyarvide, V; Kiyokawa, T; Zannoni, GF; Carlson, J; Slavik, T; Tornos, C; Antonescu, CR; Oliva, E				Bennett, Jennifer A.; Braga, Ana C.; Pinto, Andre; Van de Vijver, Koen; Cornejo, Kristine; Pesci, Anna; Zhang, Lei; Morales-Oyarvide, Vicente; Kiyokawa, Takako; Zannoni, Gian Franco; Carlson, Joseph; Slavik, Tomas; Tornos, Carmen; Antonescu, Cristina R.; Oliva, Esther			Uterine PEComas A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						perivascular epithelioid cell tumor; PEComa; uterus; tuberous sclerosis; diagnostic criteria; TFE3; RAD51B	EPITHELIOID CELL NEOPLASM; TFE3 GENE REARRANGEMENT; CATHEPSIN-K IMMUNOREACTIVITY; TUMOR PECOMA; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TUBEROUS SCLEROSIS; EXTRAPULMONARY LYMPHANGIOLEIOMYOMATOSIS; MESENCHYMAL NEOPLASMS; URINARY-BLADDER; UTERUS	Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms that may show overlapping morphology and immunohistochemistry with uterine smooth muscle tumors. In this study, we evaluated the morphologic, immunohistochemical, and molecular features of 32 PEComas, including 11 with aggressive behavior. Two distinct morphologies were observed: classic (n = 30) and those with a lymphangioleiomyomatosis appearance (n = 2). In the former, patients ranged from 32 to 77 (mean: 51) years and 13% had tuberous sclerosis. Tumors ranged from 0.2 to 17 (mean: 5.5)cm with 77% arising in the corpus. Epithelioid cells were present in 100% and a spindled component was seen in 37%. Nuclear atypia was low (53%), intermediate (17%), or high (30%). Mitoses ranged from 0 to 36 (mean: 6) and 0 to 133 (mean: 19) per 10 and 50 high-power fields, with atypical mitoses present in 30%. Thin and delicate vessels were noted in 100%, clear/eosinophilic and granular cytoplasm in 93%, stromal hyalinization in 73%, necrosis in 30%, and lymphovascular invasion in 10%. All tumors were positive for HMB-45, cathepsin K, and at least one muscle marker, with most expressing melan-A (77%) and/or MiTF (79%). A PSF-TFE3 fusion was identified in one while another showed a RAD51B-OPHN1 fusion. Follow-up ranged from 2 to 175 (mean: 41) months, with 63% of patients alive and well, 20% dead of disease, 13% alive with disease, and 3% dead from other causes. In the latter group (n = 2), patients were 39 and 49 years old, one had tuberous sclerosis, while the other had pulmonary lymphangioleiomyomatosis. Both tumors expressed HMB-45, cathepsin K, and muscle markers, but lacked TFE3 and RAD51B rearrangements. The 2 patients are currently alive and well. Application of gynecologic-specific criteria (4 features required for malignancy: size >= 5 cm, high-grade atypia, mitoses > 1/50 high-power fields, necrosis, and lymphovascular invasion) for predicting outcome misclassified 36% (4/11) of aggressive tumors; thus, a modified algorithm with a threshold of 3 of these features is recommended to classify a PEComa as malignant.	[Bennett, Jennifer A.] Lahey Hosp & Med Ctr, Dept Pathol & Lab Med, Burlington, MA USA; [Cornejo, Kristine] Univ Massachusetts, Dept Pathol, Mem Med Ctr, Worcester, MA 01605 USA; [Morales-Oyarvide, Vicente] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Braga, Ana C.] EPE, Hosp Prof Doutor Fernando Fonseca, Dept Pathol, Amadora, Portugal; [Pinto, Andre] Univ Miami, Miller Sch Med, Dept Pathol & Lab Med, Miami, FL 33136 USA; [Van de Vijver, Koen] Canc Res Inst Ghent, Dept Pathol, Ghent, Belgium; [Van de Vijver, Koen] Univ Hosp Ghent, Ghent, Belgium; [Pesci, Anna] Sacred Heart Hosp, Dept Pathol, Negrar, Italy; [Zannoni, Gian Franco] Univ Cattolica Sacro Cuore, Dept Pathol, Rome, Italy; [Zhang, Lei; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Tornos, Carmen] Stony Brook Univ Hosp, Dept Pathol, Stony Brook, NY USA; [Kiyokawa, Takako] Jikei Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Carlson, Joseph] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Carlson, Joseph] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden; [Slavik, Tomas] Univ Pretoria, Ampath Private Pathol Labs, Pretoria, South Africa; [Slavik, Tomas] Univ Pretoria, Dept Anat Pathol, Pretoria, South Africa	Bennett, JA (reprint author), Univ Chicago Med, Dept Pathol, 5841 S Maryland Ave,MC 6101, Chicago, IL 60637 USA.	jabennett@uchicago.edu	Van de Vijver, Koen/N-7895-2019	Van de Vijver, Koen/0000-0002-2026-9790; Carlson, Joseph/0000-0002-3006-4107	Vickery Grant from the Massachusetts General Hospital; Cycle for Survival;  [P50-CA140146-01];  [P30-CA008748]	Supported by the Vickery Grant from the Massachusetts General Hospital (E.O.), and in part by P50-CA140146-01 (C.R.A.), P30-CA008748 (C.R.A.), and Cycle for Survival (C.R.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaram NP, 2015, AM J SURG PATHOL, V39, P813, DOI 10.1097/PAS.0000000000000389; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Choi YJ, 2016, J PATHOL TRANSL MED, V50, P469, DOI 10.4132/jptm.2016.04.20; Clay MR, 2011, INT J GYNECOL PATHOL, V30, P71, DOI 10.1097/PGP.0b013e3181efe08d; D'Angelo E, 2014, SEMIN DIAGN PATHOL, V31, P216, DOI 10.1053/j.semdp.2014.03.003; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011; GYURE KA, 1995, INT J GYNECOL PATHOL, V14, P344, DOI 10.1097/00004347-199510000-00010; Han Jung-Mi, 2008, J Gynecol Oncol, V19, P195, DOI 10.3802/jgo.2008.19.3.195; Hayashi T, 2011, AM J SURG PATHOL, V35, P1776, DOI 10.1097/PAS.0b013e318235edbd; Howitt BE, 2013, MODERN PATHOL, V26, p279A; Hurrell DP, 2005, HISTOPATHOLOGY, V47, P540, DOI 10.1111/j.1365-2559.2005.02147.x; Hyrcza MD, 2017, ENDOCR PATHOL, V28, P22, DOI 10.1007/s12022-016-9434-7; Kampjarvi K, 2014, HUM MUTAT, V35, P1136, DOI 10.1002/humu.22612; Kim YS, 2011, KOREAN J RADIOL, V12, P261, DOI 10.3348/kjr.2011.12.2.261; LACK EE, 1986, AM J SURG PATHOL, V10, P650, DOI 10.1097/00000478-198609000-00007; Lee SE, 2012, HUM PATHOL, V43, P1126, DOI 10.1016/j.humpath.2011.10.008; LeGallo RD, 2012, AM J SURG PATHOL, V36, P1410, DOI 10.1097/PAS.0b013e31826277a9; Lim GSD, 2011, INT J GYNECOL PATHOL, V30, P121, DOI 10.1097/PGP.0b013e3181fa5a99; Liu FF, 2014, INT J CLIN EXP PATHO, V7, P6409; Longacre TA, 1996, GYNECOL ONCOL, V63, P404, DOI 10.1006/gyno.1996.0344; Lu BY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000393; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Mehine M, 2016, P NATL ACAD SCI USA, V113, P1315, DOI 10.1073/pnas.1518752113; Mehine M, 2013, NEW ENGL J MED, V369, P43, DOI 10.1056/NEJMoa1302736; Michal M, 2000, INT J SURG PATHOL, V8, P323, DOI 10.1177/106689690000800411; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Oliva E, 2006, MODERN PATHOL, V19, p191A; Pradhan B, 2016, GENE CHROMOSOME CANC, V55, P215, DOI 10.1002/gcc.22317; Rabban JT, 2015, AM J SURG PATHOL, V39, P1015, DOI 10.1097/PAS.0000000000000416; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2013, HISTOPATHOLOGY, V62, P642, DOI 10.1111/his.12059; Rolim I, 2018, MODERN PATHOL, V31, P748; Russell CM, 2014, ANN CLIN LAB SCI, V44, P91; Sato T, 2004, J INTERN MED, V256, P166, DOI 10.1111/j.1365-2796.2004.01356.x; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P1404, DOI 10.1097/PAS.0000000000000470; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P394, DOI 10.1097/PAS.0000000000000349; Schoolmeester JK, 2014, AM J SURG PATHOL, V38, P176, DOI 10.1097/PAS.0000000000000133; Shen Q, 2014, VIRCHOWS ARCH, V465, P607, DOI 10.1007/s00428-014-1655-x; Shon W, 2016, BRIT J DERMATOL, V174, P617, DOI 10.1111/bjd.14173; Silva EG, 2004, AM J SURG PATHOL, V28, P244, DOI 10.1097/00000478-200402000-00013; Sinipson KW, 2007, AM J SURG PATHOL, V31, P95; Szpurek D, 2015, TAIWAN J OBSTET GYNE, V54, P603, DOI 10.1016/j.tjog.2015.08.015; Tanaka M, 2009, AM J SURG PATHOL, V33, P1416, DOI 10.1097/PAS.0b013e3181a9cd6c; Thibodeau ML, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001628; TORRES VE, 1995, MAYO CLIN PROC, V70, P641, DOI 10.4065/70.7.641; Toyoshima M, 2005, GYNECOL ONCOL, V97, P957, DOI 10.1016/j.ygyno.2005.02.028; Vang R, 2002, AM J SURG PATHOL, V26, P1, DOI 10.1097/00000478-200201000-00001; Williamson SR, 2013, AM J SURG PATHOL, V37, P1619, DOI 10.1097/PAS.0b013e318293729d; Zamecnik M, 2006, HISTOPATHOLOGY, V48, P463, DOI 10.1111/j.1365-2559.2005.02251.x; Zamecnik M, 2001, INT J SURG PATHOL, V9, P341, DOI 10.1177/106689690100900415; Zheng G, 2013, AM J CLIN PATHOL, V139, P151, DOI 10.1309/AJCPDTRTO2Z4UEXD	54	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1370	1383		10.1097/PAS.0000000000001119			14	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300011	30001237				2019-10-28	
J	Koperski, L; Pihowicz, P; Fus, LP; Bogdanska, M; Gornicka, B				Koperski, Lukasz; Pihowicz, Pawel; Fus, Lukasz Piotr; Bogdanska, Magdalena; Gornicka, Barbara			Non-neoplastic adrenal pseudocysts: A clinicopathologic study of 44 cases with potential insights into pathogenesis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Adrenal cysts; Adrenal pseudocysts; Vascular cysts; Non-neoplastic adrenal lesions	CYSTS	Background: Literature on non-neoplastic adrenal pseudocysts (NNAPC) remains limited and to date no large series have been reported. The pathogenesis of these lesions remains poorly defined, however a vascular origin is most often suggested in the literature. We aimed to evaluate the clinicopathological features and the spectrum of vascular changes within NNAPC, in order to better understand the mechanisms and circumstances of their pathogenesis. Methods and results: We reviewed 44 cases of surgically resected NNAPC. There were 30 females and 14 males ranging from 23 to 82 years (median, 53 years). On the basis of histopathologic and immunohistochemical analysis of the vascular changes the following types were defined: pseudocysts with lymphatic-related changes (type 1, n = 16), pseudocysts with large vein-related changes (type 2, n = 15) and pseudocysts with blood vessel microvasculature-related changes (type 3, n = 13). The median patient age of the latter group was higher than that of type 1 and 2 (64 years versus 51 and 50 years, respectively; p = 0.0002). Type 3 pseudocysts were more frequently associated with a history of systemic vascular and vascular-related disorders than type 1 and type 2 pseudocysts (92% versus 33% and 64%, respectively; p = 0.008). Type 1 pseudocysts were more frequently connected with a history of previous intra-abdominal surgical procedures than type 2 and 3 pseudocysts (60% versus 7% and 25%, respectively; p = 0.0079). Conclusions: NNAPC are clinically heterogenous and can arise on a background of various vascular changes. They may represent end-stage processes related to lymphangiomatous lesions, changes in adrenal venous structures or microvasculature.	[Koperski, Lukasz; Pihowicz, Pawel; Fus, Lukasz Piotr; Bogdanska, Magdalena; Gornicka, Barbara] Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland	Koperski, L (reprint author), Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland.	lkoperski@wum.edu.pl	Koperski, Lukasz/U-4594-2018	Koperski, Lukasz/0000-0001-8163-1813	Medical University of Warsaw [1M11/N/16-17]	This study was supported by the Medical University of Warsaw Statutory Grant 1M11/N/16-17.	ABESHOUSE GA, 1959, J UROLOGY, V81, P711, DOI 10.1016/S0022-5347(17)66099-3; Carney JA, 2012, HISTOLOGY PATHOLOGIS, P1231; Chien HP, 2008, ENDOCR PATHOL, V19, P274, DOI 10.1007/s12022-008-9046-y; Diolombi ML, 2016, HUM PATHOL, V53, P63, DOI 10.1016/j.humpath.2016.02.017; Ellis CL, 2011, HUM PATHOL, V42, P1013, DOI 10.1016/j.humpath.2010.10.023; Erickson LA, 2004, CANCER, V101, P1537, DOI 10.1002/cncr.20555; FOSTER DG, 1966, ARCH SURG-CHICAGO, V92, P131; GAFFEY MJ, 1989, AM J SURG PATHOL, V13, P740, DOI 10.1097/00000478-198909000-00003; Gao L, 2015, INT J CLIN EXP MED, V8, P4212; Goldblum JR, 2014, ENZINGER WEISSS SOFT, P733; GROBEN PA, 1986, ARCH PATHOL LAB MED, V110, P121; INCZE JS, 1979, AM J PATHOL, V95, P423; Jennings TA, 1998, ENDOCR PATHOL, V9, P353, DOI 10.1007/BF02739696; Lack EE, 2007, AFIP ATLAS TUMOR PAT, V8, P185; Laforga JBM, 2000, DIAGN CYTOPATHOL, V22, P110, DOI 10.1002/(SICI)1097-0339(200002)22:2<110::AID-DC11>3.0.CO;2-I; MEDEIROS LJ, 1989, HUM PATHOL, V20, P660, DOI 10.1016/0046-8177(89)90153-6; Mitchell R. N., 2010, ROBBINS COTRAN PATHO, P487; Scioli MG, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-19; Simon Daniel R, 2009, Curr Urol Rep, V10, P78; Torres C, 1997, MODERN PATHOL, V10, P530	20	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						5	11		10.1016/j.anndiagpath.2018.06.006			7	Pathology	Pathology	GW8OU	WOS:000447239200002	29966833				2019-10-28	
J	Awad, H; Bratasz, A; Nuovo, G; Burry, R; Meng, XM; Kelani, H; Brown, M; Ramadan, ME; Williams, J; Bouhliqah, L; Popovich, PG; Guan, Z; Mcallister, C; Corcoran, SE; Kaspar, B; Basso, DM; Otero, JJ; Kirsch, C; Davis, IC; Croce, CM; Michaille, JJ; Tili, E				Awad, Hamdy; Bratasz, Anna; Nuovo, Gerard; Burry, Richard; Meng, Xiaomei; Kelani, Hesham; Brown, Melissa; Ramadan, Mohamed E.; Williams, Jim; Bouhliqah, Lamia; Popovich, Phillip G.; Guan, Zhen; Mcallister, Cynthia; Corcoran, Sarah E.; Kaspar, Brian; Basso, D. Michele; Otero, Jose J.; Kirsch, Claudia; Davis, Ian C.; Croce, Carlo Maria; Michaille, Jean-Jacques; Tili, Esmerina			MiR-155 deletion reduces ischemia-induced paralysis in an aortic aneurysm repair mouse model: Utility of immunohistochemistry and histopathology in understanding etiology of spinal cord paralysis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Ischemia; Spinal cord; microRNA; Immunohistochemistry; Histopathology	BLOOD-BRAIN-BARRIER; REPERFUSION INJURY; ENDOTHELIAL-CELLS; MICRORNAS; INFLAMMATION; MFSD2A; MICE; TRANSPORTER; INHIBITION; DISEASE	Spinal cord paralysis is relatively common after surgical repair of thoraco-abdominal aortic aneurysm (TAAA) and its etiology is unknown. The present study was designed to examine the histopathology of the disease and investigate whether miR-155 ablation would reduce spinal cord ischemic damage and delayed hindlimb paralysis induced by aortic cross-clamping (ACC) in our mouse model. The loss of locomotor function in ACC-paralyzed mice correlated with the presence of extensive gray matter damage and central cord edema, with minimal white matter histopathology. qRTPCR and Western blotting showed that the spinal cords of wild-type ACC mice that escaped paralysis showed lower miR-155 expression and higher levels of transcripts encoding Mfsd2a, which is implicated in the maintenance of blood-brain barrier integrity. In situ based testing demonstrated that increased miR-155 detection in neurons was highly correlated with the gray matter damage and the loss of one of its targets, Mfsd2a, could serve as a good biomarker of the endothelial cell damage. In vitro, we demonstrated that miR-155 targeted Mfsd2a in endothelial cells and motoneurons and increased endothelial cell permeability. Finally, miR-155 ablation slowed the progression of central cord edema, and reduced the incidence of paralysis by 40%. In sum, the surgical pathology findings clearly indicated that the epicenter of the ischemic-induced paralysis was the gray matter and that endothelial cell damage correlated to Mfsd2a loss is a good biomarker of the disease. MiR-155 targeting therefore offers new therapeutic opportunity for edema caused by traumatic spinal cord injury and diagnostic pathologists, by using immunohistochemistry, can clarify if this mechanism also is important in other ischemic diseases of the CNS, including stroke.	[Awad, Hamdy; Kelani, Hesham; Brown, Melissa; Ramadan, Mohamed E.; Tili, Esmerina] Ohio State Univ, Wexner Med Ctr, Dept Anesthesiol, Columbus, OH 43210 USA; [Bratasz, Anna] OSU, Wexner Med Ctr, Small Anim Imaging Ctr Shared Resource, Columbus, OH 43210 USA; [Nuovo, Gerard; Williams, Jim] Phylogeny Inc, Powell, OH 43065 USA; [Burry, Richard; Popovich, Phillip G.; Guan, Zhen] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Meng, Xiaomei] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Bouhliqah, Lamia] OSU, Wexner Med Ctr, Dept ENT, Columbus, OH 43210 USA; [Mcallister, Cynthia; Corcoran, Sarah E.; Kaspar, Brian] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA; [Basso, D. Michele] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA; [Otero, Jose J.] OSU, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA; [Kirsch, Claudia] NSUH, Dept Radiol, 300 Community Dr, Manhasset, NY 11030 USA; [Davis, Ian C.] Coll Vet Med, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA; [Croce, Carlo Maria; Michaille, Jean-Jacques; Tili, Esmerina] Ohio State Univ, Dept Canc Biol & Genet, Wexner Med Ctr, Columbus, OH 43210 USA; [Croce, Carlo Maria; Michaille, Jean-Jacques; Tili, Esmerina] Ctr Comprehens Canc, Columbus, OH 43210 USA; [Michaille, Jean-Jacques] Univ Bourgogne Franche Comte, Fac Gabriel, BioPerox IL, UB INSERM IFR 100, 6 Bd Gabriel, F-21000 Dijon, France	Nuovo, G (reprint author), Phylogeny Inc, Powell, OH 43065 USA.	Nuovo.1@osu.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO3NS102861]; OSU College of Medicine Office of Research Discovery Funding Program; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [UL1TR001070];  [IRG-67-003-50];  [P30-NS04758];  [P30CA16058]	This work was supported by The National Institutes of Health (RO3NS102861 to E.T., H.A. and A.B.); IRG-67-003-50 to E.T.; OSU College of Medicine Office of Research Discovery Funding Program to E.T. and H.A.; P30-NS04758 to Center for Brain and SC Repair, P30CA16058 to Genomics Facility; and P30-MRI Pilot Project proposal/OSU/CCTS UL1TR001070 to H.A. by National Institute of Neurological Disorders and Stroke.	Acher C, 2012, ANN CARDIOTHORAC SUR, V1, P365, DOI 10.3978/j.issn.2225-319X.2012.08.06; Alakbarzade V, 2015, NAT GENET, V47, P814, DOI 10.1038/ng.3313; Andreoli Chiara, 2005, Radiol Med, V110, P636; Asatryan A, 2017, J BIOL CHEM, V292, P12390, DOI 10.1074/jbc.R117.783076; Awad H, 2017, CAN J ANESTH, V64, P1218, DOI 10.1007/s12630-017-0974-1; Awad H, 2010, ANESTHESIOLOGY, V113, P880, DOI 10.1097/ALN.0b013e3181ec61ee; Balconi G, 2000, ARTERIOSCL THROM VAS, V20, P1443, DOI 10.1161/01.ATV.20.6.1443; Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421; Bell MT, 2013, CIRCULATION, V128, pS152, DOI 10.1161/CIRCULATIONAHA.112.000024; Ben-Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006; Ge SJ, 2006, J NEUROIMMUNOL, V177, P209, DOI 10.1016/j.jneuroim.2006.05.012; Hamilton JA, 2007, J MOL NEUROSCI, V33, P12, DOI 10.1007/s12031-007-0050-3; Kim EH, 2015, CNS NEUROSCI THER, V21, P385, DOI 10.1111/cns.12326; Kim M, 2013, KIDNEY INT, V84, P90, DOI 10.1038/ki.2013.43; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; McDonald RA, 2012, CARDIOVASC RES, V93, P594, DOI 10.1093/cvr/cvr299; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Nguyen LN, 2014, NATURE, V509, P503, DOI 10.1038/nature13241; Nuovo GJ, 2009, BIOTECHNIQUES, V46, P115, DOI [10.2144/00011-3068, 10.2144/000113068]; Pascal JM, 2015, DNA REPAIR, V32, P10, DOI 10.1016/j.dnarep.2015.04.008; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; Smith PD, 2012, CIRCULATION, V126, pS110, DOI 10.1161/CIRCULATIONAHA.111.080275; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tili E, 2017, CURR OPIN PHARMACOL, V37, P142, DOI 10.1016/j.coph.2017.10.010; Tili E, 2013, IMMUNOL REV, V253, P167, DOI 10.1111/imr.12050; Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018; Ungaro F, 2017, GASTROENTEROLOGY, V153, P1363, DOI 10.1053/j.gastro.2017.07.048; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang XJ, 2010, NEUROPATHOLOGY, V30, P131, DOI 10.1111/j.1440-1789.2009.01061.x; Winkler EA, 2014, P NATL ACAD SCI USA, V111, pE1035, DOI 10.1073/pnas.1401595111	36	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						12	20		10.1016/j.anndiagpath.2018.06.002			9	Pathology	Pathology	GW8OU	WOS:000447239200003	29966831	Green Accepted			2019-10-28	
J	Chistyakov, DV; Astakhova, AA; Sergeeva, MG				Chistyakov, Dmiry V.; Astakhova, Alina A.; Sergeeva, Marina G.			Resolution of inflammation and mood disorders	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Depression; Inflammation; Resolution; Mood disorders; Innate immunity; Cytokines; Signaling pathways; Bipolar disorders; Resolvins; Toll-like receptors	TOLL-LIKE RECEPTORS; PRORESOLVING LIPID MEDIATORS; MAJOR DEPRESSIVE DISORDER; RAT-BRAIN ASTROCYTES; POSTTRAUMATIC-STRESS-DISORDER; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CENTRAL-NERVOUS-SYSTEM; BIPOLAR I DISORDER; C-REACTIVE PROTEIN; PHOSPHOLIPASE A(2)	Relationship between mood disorders and inflammation is now well-documented, although molecular mechanisms are not understood. Previously mostly pro-inflammatory cytokines of immune system (IL-6, TNF, etc.) were taken into account. However, recent understanding of resolution of inflammation as an active process drew attention to mediators of resolution, which include both proteins and omega-3 and omega-6 polyunsaturated fatty acids derivatives (resolvins, cyclopentenone prostaglandins, etc.). This review takes into account new data on resolution of inflammation and action of mediators of resolution in models of depression. New facts and ideas about mechanisms of chronic inflammation onset are considered in relation to mood disorders. Basic control mechanisms of inflammation at the cellular level and the role of resolution substances in regulation of depression and other mood disorders are discussed. Signaling systems of innate immunity located in non-immune cells and their ability to generate substances that affect an onset of depression are reviewed. A novel hypothesis of depression as a type of abnormal resolution is proposed.	[Chistyakov, Dmiry V.; Astakhova, Alina A.; Sergeeva, Marina G.] Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; [Chistyakov, Dmiry V.] Pirogov Russian Natl Res Med Univ, Moscow, Russia	Sergeeva, MG (reprint author), Moscow Lomonosov State Univ, Belozersky Inst Physicochem Biol, Leninskie Gory 1,Build 40, Moscow 119992, Russia.	mg.sergeeva@gmail.com	Sergeeva, Marina/G-3439-2012		Russian Science FoundationRussian Science Foundation (RSF) [16-15-10298]	This work was supported by Russian Science Foundation grant No16-15-10298	Akil E, 2015, NEUROL SCI, V36, P423, DOI 10.1007/s10072-014-1976-1; Akira Shizuo, 2010, Cornea, V29 Suppl 1, pS13; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Ataka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081744; Azab B, 2010, AM J CARDIOL, V106, P470, DOI 10.1016/j.amjcard.2010.03.062; Baker DG, 2001, NEUROIMMUNOMODULAT, V9, P209, DOI 10.1159/000049028; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Boeschoten RE, 2017, J NEUROL SCI, V372, P331, DOI 10.1016/j.jns.2016.11.067; Bogatcheva NV, 2005, MICROVASC RES, V69, P107, DOI 10.1016/j.mvr.2005.01.007; Bomasang-Layno E, 2015, PARKINSONISM RELAT D, V21, P833, DOI 10.1016/j.parkreldis.2015.04.018; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Cai SL, 2015, NEUROSCI BULL, V31, P61, DOI 10.1007/s12264-014-1486-4; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; Chamorro A, 2004, CEREBROVASC DIS, V17, P1, DOI 10.1159/000075297; Chan MMY, 2010, J IMMUNOL, V184, P6418, DOI 10.4049/jimmunol.0903816; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; Chen Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00609-7; Chistyakov DV, 2018, BIOCHEM BIOPH RES CO, V500, P204, DOI 10.1016/j.bbrc.2018.04.040; Chistyakov DV, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010113; Chistyakov DV, 2015, J NEUROCHEM, V134, P113, DOI 10.1111/jnc.13101; Chistyakov DV, 2014, J NEUROCHEM, V130, P563, DOI 10.1111/jnc.12757; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Chu CL, 2017, INT J NEUROPSYCHOPH, V20, P731, DOI 10.1093/ijnp/pyx044; Cojocaru DC, 2015, MED-SURG J, V119, P974; Colas RA, 2014, AM J PHYSIOL-CELL PH, V307, pC39, DOI 10.1152/ajpcell.00024.2014; Costabile M, 2017, PROSTAG LEUKOTR ESS, V122, P7, DOI 10.1016/j.plefa.2017.06.010; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Cristiano C, 2018, FRONT PHYSIOL, V9, DOI [10.3339/fphys.2018.00184, 10.3389/fphys.2018.00184]; Dalli J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01940; Dantzer R, 2001, ANN NY ACAD SCI, V933, P222; Dantzer R., 2016, INFLAMMATION ASS DEP; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2018, PHYSIOL REV, V98, P477, DOI 10.1152/physrev.00039.2016; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; Dantzer R, 2009, IMMUNOL ALLERGY CLIN, V29, P247, DOI 10.1016/j.iac.2009.02.002; Deak T, 2017, DIALOGUES CLIN NEURO, V19, P37; Dean J, 2017, ASIAN J PSYCHIATR, V27, P101, DOI 10.1016/j.ajp.2017.01.025; Dennis EA, 2016, J BIOL CHEM, V291, P24431, DOI 10.1074/jbc.X116.723791; Dennis EA, 2015, NAT REV IMMUNOL, V15, P511, DOI 10.1038/nri3859; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Duman CH, 2010, VITAM HORM, V82, P1, DOI 10.1016/S0083-6729(10)82001-1; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Eyre HA, 2015, PROG NEURO-PSYCHOPH, V57, P11, DOI 10.1016/j.pnpbp.2014.10.003; Falsig J, 2006, J NEUROCHEM, V96, P893, DOI 10.1111/j.1471-4159.2005.03622.x; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fenton WS, 2006, CURR OPIN PSYCHIATR, V19, P421, DOI 10.1097/01.yco.0000228765.33356.9f; Fiedorowicz JG, 2015, J AFFECT DISORDERS, V187, P172, DOI 10.1016/j.jad.2015.08.036; Fornaro M, 2013, J AFFECT DISORDERS, V145, P300, DOI 10.1016/j.jad.2012.08.007; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Fu X, 2017, ONCOTARGET, V8, P53623, DOI 10.18632/oncotarget.17323; Furuyashiki T, 2009, CURR OPIN PHARMACOL, V9, P31, DOI 10.1016/j.coph.2008.12.010; Gadek-Michalska A, 2013, PHARMACOL REP, V65, P1655; Garate I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-151; Bueno BG, 2016, NEUROSCI BIOBEHAV R, V64, P134, DOI 10.1016/j.neubiorev.2016.02.013; Gardner SE, 2015, ARTERIOSCL THROM VAS, V35, P1963, DOI 10.1161/ATVBAHA.115.305896; Ghosal A, 2014, AM J PHYSIOL-GASTR L, V307, pG365, DOI 10.1152/ajpgi.00157.2014; Gill J, 2008, J TRAUMA STRESS, V21, P530, DOI 10.1002/jts.20372; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505; Griffiths J, 2000, MOL PSYCHIATR, V5, P242, DOI 10.1038/sj.mp.4000697; Haapakoski R, 2015, BRAIN BEHAV IMMUN, V49, P206, DOI 10.1016/j.bbi.2015.06.001; Haeggstrom JZ, 2013, CHEM BIOL, V20, P138, DOI 10.1016/j.chembiol.2013.02.003; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hanly JG, 2005, J RHEUMATOL, V32, P1459; Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7; Hayley S, 2016, CURR OPIN PHARMACOL, V29, P42, DOI 10.1016/j.coph.2016.06.001; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Herculano-Houzel S, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00038; Hernandez ME, 2008, EUR NEUROPSYCHOPHARM, V18, P917, DOI 10.1016/j.euroneuro.2008.08.001; Herrera AJ, 2015, CURR TOP MED CHEM, V15, P2193, DOI 10.2174/1568026615666150610142027; Hodes GE, 2015, NAT NEUROSCI, V18, P1386, DOI 10.1038/nn.4113; Hodes GE, 2014, P NATL ACAD SCI USA, V111, P16136, DOI 10.1073/pnas.1415191111; Hohlfeld R, 2007, NEUROLOGY, V68, pS58, DOI 10.1212/01.wnl.0000275234.43506.9b; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535; Ishikawa Y, 2017, BEHAV BRAIN RES, V332, P233, DOI 10.1016/j.bbr.2017.06.010; Ivkovic M, 2016, COMPR PSYCHIAT, V66, P87, DOI 10.1016/j.comppsych.2016.01.005; Iyengar RL, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2013.02.037; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Jiang MD, 2014, J AFFECT DISORDERS, V166, P22, DOI 10.1016/j.jad.2014.04.027; Jung SJ, 2017, BRIT J PSYCHIAT, V211, P14, DOI 10.1192/bjp.bp.116.186726; Kalelioglu T, 2015, PSYCHIAT RES, V228, P925, DOI 10.1016/j.psychres.2015.05.110; Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kelley KW, 2003, BRAIN BEHAV IMMUN, V17, P1, DOI 10.1016/S0889-1591(02)00053-3; Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x; Kohler CA, 2018, MOL NEUROBIOL, V55, P4195, DOI 10.1007/s12035-017-0632-1; Kohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611; Kohli P, 2009, BRIT J PHARMACOL, V158, P960, DOI 10.1111/j.1476-5381.2009.00290.x; Kondo T, 2012, TRENDS IMMUNOL, V33, P449, DOI 10.1016/j.it.2012.05.002; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455; Krishnan V, 2010, AM J PSYCHIAT, V167, P1305, DOI 10.1176/appi.ajp.2009.10030434; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Laye S, 2018, PHARMACOL REV, V70, P12, DOI 10.1124/pr.117.014092; Ledeboer A, 2002, EUR J NEUROSCI, V16, P1175, DOI 10.1046/j.1460-9568.2002.02200.x; Leonard Brian E, 2018, Acta Neuropsychiatr, V30, P1, DOI 10.1017/neu.2016.69; Liu Q, 2014, EXP BIOL MED, V239, P376, DOI 10.1177/1535370213517620; Luppino FS, 2010, ARCH GEN PSYCHIAT, V67, P220, DOI 10.1001/archgenpsychiatry.2010.2; Ma Y, 2007, CELL CYCLE, V6, P2859, DOI 10.4161/cc.6.23.5018; MAES M, 1995, PROG NEURO-PSYCHOPH, V19, P11, DOI 10.1016/0278-5846(94)00101-M; MAES M, 1991, ACTA PSYCHIAT SCAND, V84, P379, DOI 10.1111/j.1600-0447.1991.tb03163.x; Manabe I, 2011, CIRC J, V75, P2739, DOI 10.1253/circj.CJ-11-1184; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Massart R, 2012, PHILOS T R SOC B, V367, P2485, DOI 10.1098/rstb.2012.0212; Maurer J, 2008, CHEST, V134, p43S, DOI 10.1378/chest.08-0342; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Menard C, 2017, NEUROPSYCHOPHARMACOL, V42, P62, DOI 10.1038/npp.2016.90; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Miller LS, 2007, J INVEST DERMATOL, V127, P262, DOI 10.1038/sj.jid.5700559; Miyaso H, 2005, J GASTROEN HEPATOL, V20, P1859, DOI 10.1111/j.1440-1746.2005.03953.x; Modabbernia A, 2013, BIOL PSYCHIAT, V74, P15, DOI 10.1016/j.biopsych.2013.01.007; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Muller N, 2017, DIALOGUES CLIN NEURO, V19, P55; Muller N, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00372; Mueller Norbert, 2010, Current Immunology Reviews, V6, P213; Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392; Nadeau S, 2011, J NEUROSCI, V31, P12533, DOI 10.1523/JNEUROSCI.2840-11.2011; Nadjar A, 2017, PROG NEURO-PSYCHOPH, V79, P19, DOI 10.1016/j.pnpbp.2016.07.004; Nanni MG, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-014-0530-4; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nazimek K, 2017, IMMUNOBIOLOGY, V222, P823, DOI 10.1016/j.imbio.2016.07.001; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049; Newton TL, 2014, BIOL PSYCHOL, V99, P150, DOI 10.1016/j.biopsycho.2014.03.009; Nguyen CM, 2016, CLIN COSMET INVESTI, V9, P383, DOI 10.2147/CCID.S76088; Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382; Parker G, 2006, AM J PSYCHIAT, V163, P969, DOI 10.1176/appi.ajp.163.6.969; Passos IC, 2015, LANCET PSYCHIAT, V2, P1002, DOI 10.1016/S2215-0366(15)00309-0; Patel H, 2012, CARDIOL RES PRACT, DOI 10.1155/2012/121237; Pawelec G, 2014, CURR OPIN IMMUNOL, V29, P23, DOI 10.1016/j.coi.2014.03.007; Perucci LO, 2017, EXPERT OPIN THER TAR, V21, P879, DOI 10.1080/14728222.2017.1364363; Pfau ML, 2015, NEUROBIOL STRESS, V1, P66, DOI 10.1016/j.ynstr.2014.09.004; Portou MJ, 2015, VASC PHARMACOL, V71, P31, DOI 10.1016/j.vph.2015.02.007; Quan N, 1999, J NEUROIMMUNOL, V93, P72, DOI 10.1016/S0165-5728(98)00193-3; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Rajakariar R, 2006, MOL INTERV, V6, P199, DOI 10.1124/mi.6.4.6; Rembach A, 2014, J NEUROIMMUNOL, V273, P65, DOI 10.1016/j.jneuroim.2014.05.005; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Rietdijk C. D., 2016, NEUROL-NEUROIMMUNOL, V3, P27, DOI [10.20517/2347-8659.2015.28, DOI 10.20517/2347-8659.2015.28]; Rosenblat JD, 2014, PROG NEURO-PSYCHOPH, V53, P23, DOI 10.1016/j.pnpbp.2014.01.013; Rothhammer V, 2015, SEMIN IMMUNOPATHOL, V37, P625, DOI 10.1007/s00281-015-0515-3; Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381; Russo SJ, 2012, NAT NEUROSCI, V15, P1475, DOI 10.1038/nn.3234; Saitoh T, 2010, J CELL BIOL, V189, P925, DOI 10.1083/jcb.201002021; Sarvas Jessica L, 2013, J Diabetes Metab, VSuppl 13, DOI 10.4172/2155-6156.S13-003; Schroder M, 2003, J IMMUNOL, V170, P5260, DOI 10.4049/jimmunol.170.10.5260; Seligman F, 2015, ANN NY ACAD SCI, V1345, P25, DOI 10.1111/nyas.12738; Sergeeva M, 2005, REPROD NUTR DEV, V45, P633, DOI 10.1051/rnd:2005050; Sergeeva MG, 2010, J NEUROCHEM, V115, P399, DOI 10.1111/j.1471-4159.2010.06931.x; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2017, MOL ASPECTS MED, V58, P1, DOI 10.1016/j.mam.2017.03.001; Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Shechter R, 2013, TRENDS MOL MED, V19, P135, DOI 10.1016/j.molmed.2012.11.007; Sheng WW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-121; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sommer IE, 2014, SCHIZOPHRENIA BULL, V40, P181, DOI 10.1093/schbul/sbt139; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; Stables MJ, 2011, PROG LIPID RES, V50, P35, DOI 10.1016/j.plipres.2010.07.005; Stefanovic MP, 2016, J PSYCHIATR RES, V73, P45, DOI 10.1016/j.jpsychires.2015.11.002; Strokin M, 2004, INT J DEV NEUROSCI, V22, P551, DOI 10.1016/j.ijdevneu.2004.07.002; Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326; Strokin M, 2007, J NEUROCHEM, V102, P1771, DOI 10.1111/j.1471-4159.2007.04663.x; Strokin M, 2011, AM J PHYSIOL-CELL PH, V300, pC542, DOI 10.1152/ajpcell.00428.2010; Sutcigil L, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/76396; Swardfager W, 2018, NEUROSCI BIOBEHAV R, V87, P56, DOI 10.1016/j.neubiorev.2018.01.010; Takeda Kiyoshi, 2015, Curr Protoc Immunol, V109, DOI 10.1002/0471142735.im1412s109; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Traki L, 2014, CLIN RHEUMATOL, V33, P1055, DOI 10.1007/s10067-014-2609-z; Trepanier MO, 2017, J NEUROCHEM, V140, P766, DOI 10.1111/jnc.13934; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Ulivi V, 2008, J CELL PHYSIOL, V217, P433, DOI 10.1002/jcp.21516; Uyanik V, 2015, PSYCHIAT RES, V228, P386, DOI 10.1016/j.psychres.2015.05.078; VANDAM AM, 1992, BRAIN RES, V588, P291, DOI 10.1016/0006-8993(92)91588-6; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Warner-Schmidt JL, 2011, P NATL ACAD SCI USA, V108, P9262, DOI 10.1073/pnas.1104836108; Watanabe S, 2017, CANCER SCI, V108, P563, DOI 10.1111/cas.13184; Wetzel HH, 2011, PSYCHIAT RES, V188, P372, DOI 10.1016/j.psychres.2011.05.006; Willrich MAV, 2015, TRANSL RES, V165, P270, DOI 10.1016/j.trsl.2014.09.006; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yagami T, 2016, MOL NEUROBIOL, V53, P4754, DOI 10.1007/s12035-015-9355-3; Yui K, 2015, CURR NEUROPHARMACOL, V13, P776, DOI 10.2174/1570159X13666151102103305; Yuk JM, 2011, NAT IMMUNOL, V12, P742, DOI 10.1038/ni.2064; Zhao P, 2009, J CELL MOL MED, V13, P1513, DOI 10.1111/j.1582-4934.2009.00798.x; Zhao QF, 2016, J AFFECT DISORDERS, V190, P264, DOI 10.1016/j.jad.2015.09.069	207	5	5	3	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					190	201		10.1016/j.yexmp.2018.08.002			12	Pathology	Pathology	GW8NM	WOS:000447235600005	30098318				2019-10-28	
J	Lv, CY; Zhao, ZY; Yang, TL; Wang, YL; Li, B; Lv, J; Ding, WJ				Lv Chun-yan; Zhao Zi-yi; Yang Tian-lin; Wang Yi-li; Li Bao; Lv Jiao; Ding Wei-jun			Liquid biopsy biomarkers of renal interstitial fibrosis based on urinary exosome	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Epithelial mesenchymal transition (EMT); Renal interstitial fibrosis(RIF); Urinary exosome (UExo); Liquid biopsy markers; Area under the curve (AUC)	TO-MESENCHYMAL TRANSITION; EXTRACELLULAR VESICLES; THERAPEUTIC RESPONSE; MESSENGER-RNA; E-CADHERIN; EXPRESSION; MARKERS; DAMAGE	Renal interstitial fibrosis (RIF) is difficult to diagnose. This paper explored liquid biopsy markers in urinary exosomes derived from RIF patients. Urine samples from 32 patients with various degrees of RIF and 20 non-RIF patients were collected. The size and morphology of urinary exosomes isolated by polyethylene glycol were observed with electron microscopy. Protein biomakers of exosomes were analyzed by Western blot. qRT-PCR was used to detect the levels of biomarkers (miR-29c, miR-21, E-cadherin, and vimentin) of epithelial mesenchymal transition in urinary exosomes. The diagnostic value was detected with ROC curves. Results displayed successfully isolated urinary exosomes. The examined miRNAs and mRNAs were checked from all urinary exosomes samples, except for two cases of RIF which lacked E-cadherin mRNA. RNA levels were different in patients with diverse degrees of RIF. Urinary miR-29c was decreased with the progress of fibrosis. Levels of E-cadherin mRNA were first decreased and then increased. The contents of miR-21 and vimentin mRNA were also depended on the degrees of RIF. ROC curve analysis showed that the area under the curve (AUC) of miR-29c was 0.8621, statistically significant compared with the non-RIF group (P < 0.05). The miR-29c level within the urinary exosomes is a promising marker for the diagnosis of RIF.	[Lv Chun-yan; Zhao Zi-yi; Yang Tian-lin; Li Bao; Lv Jiao] Chengdu Univ TCM, Affiliated Hosp, Clin Med Coll, Chengdu 610072, Sichuan, Peoples R China; [Wang Yi-li; Ding Wei-jun] Chengdu Univ TCM, Dept Fundamental Med, Chengdu 610072, Sichuan, Peoples R China	Lv, CY (reprint author), Chengdu Univ TCM, Affiliated Hosp, Clin Med Coll, Chengdu 610072, Sichuan, Peoples R China.; Ding, WJ (reprint author), Chengdu Univ TCM, Dept Fundamental Med, Chengdu 610072, Sichuan, Peoples R China.	lllcccyyyy@126.com; dingwj123@163.com			School fund of Chengdu University of Traditional Chinese Medicine [CGPY1601]; Experimental technology project of Chengdu University of Traditional Chinese Medicine [SYZD2017002]	School fund of Chengdu University of Traditional Chinese Medicine (CGPY1601), Experimental technology project of Chengdu University of Traditional Chinese Medicine (SYZD2017002). The funding sources had no involvement in study design, the collection, analysis and interpretation of data, the writing of the report; and the decision to submit the article for publication.	Aqil F, 2016, EXP MOL PATHOL, V101, P12, DOI 10.1016/j.yexmp.2016.05.013; Arora H, 2016, J CLIN DIAGN RES, V10, pZC48, DOI 10.7860/JCDR/2016/20808.8271; Aroune D, 2017, SAUDI J BIOL SCI, V24, P843, DOI 10.1016/j.sjbs.2016.05.009; Berchtold L, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14442; Cao YH, 2015, AM J PHYSIOL-RENAL, V309, pF514, DOI 10.1152/ajprenal.00449.2014; Charytan DM, 2014, INT J CARDIOL, V176, P99, DOI 10.1016/j.ijcard.2014.06.062; Chun-Yan Lu, 2018, CHIN J MOD MED, V28, P20; Chun-Yan Lv, 2016, MED J W CHINA, V28, P208; Chun-Yan Lv, 2017, J PRACTICAL MED, V33, P2799; Chun-Yan Lv, 2017, CHIN J TISSUE ENG RE, V21, P4685; Gangoda L, 2015, PROTEOMICS, V15, P260, DOI 10.1002/pmic.201400234; Ge XX, 2017, ONCOTARGET, V8, P69995, DOI 10.18632/oncotarget.19547; Glowacki F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058014; He JH, 2013, CLIN EXP NEPHROL, V17, P488, DOI 10.1007/s10157-013-0781-0; Hosper NA, 2013, EXP CELL RES, V319, P3000, DOI 10.1016/j.yexcr.2013.07.014; Jeon YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136442; Kitao T, 2015, J UROLOGY, V194, P766, DOI 10.1016/j.juro.2015.04.091; Kitterer D, 2015, CLIN NEPHROL, V84, P311, DOI 10.5414/CN108591; Lee SJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-99; Leung N, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfv294; Li Q, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0435-5; Liang S, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0482-0; Loboda A, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/8319283; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lv CY, 2018, INT UROL NEPHROL, V50, P973, DOI 10.1007/s11255-017-1779-4; Lv Chun-Yan, 2018, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V34, P110, DOI 10.13865/j.cnki.cjbmb.2018.01.15; Lv LL, 2014, CLIN CHIM ACTA, V428, P26, DOI 10.1016/j.cca.2013.10.003; Lv LL, 2013, AM J PHYSIOL-RENAL, V305, pF1220, DOI 10.1152/ajprenal.00148.2013; Mengel M, 2017, KIDNEY INT, V92, P553, DOI 10.1016/j.kint.2017.04.041; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Musial K, 2015, BIOMARKERS, V20, P177, DOI 10.3109/1354750X.2015.1061598; National Center for clinical medicine for kidney disease General Hospital of Nanjing, 2017, CHIN J PRACT INTERN, V37, P810; Papasotiriou M, 2015, NEPHROL DIAL TRANSPL, V30, P1112, DOI 10.1093/ndt/gfv063; Santiago-Dieppa DR, 2014, EXPERT REV MOL DIAGN, V14, P819, DOI 10.1586/14737159.2014.943193; Sethi S, 2017, KIDNEY INT, V91, P787, DOI 10.1016/j.kint.2017.01.002; Wan JX, 2016, ONCOTARGET, V7, P67748, DOI 10.18632/oncotarget.11682; Xiong J, 2014, MOL BIOL REP, V41, P241, DOI 10.1007/s11033-013-2857-z; Xiu-Rong Tang, 2016, JILIN MED J, V37, P2389; Zeniya M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13486-x	39	6	7	2	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					223	228		10.1016/j.yexmp.2018.08.004			6	Pathology	Pathology	GW8NM	WOS:000447235600010	30121168				2019-10-28	
J	Sent-Doux, KN; Mackinnon, C; Lee, JC; Folpe, AL; Habeeb, O				Sent-Doux, Kimberley N.; Mackinnon, Craig; Lee, Jen-Chieh; Folpe, Andrew L.; Habeeb, Omar			Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the "nonphosphaturic" variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization	HUMAN PATHOLOGY			English	Article						Phosphaturic mesenchymal tumor; Nonphosphaturic; FGF23; FN1-FGFR1; Tumor-induced osteomalacia (TIO)	SOFT-TISSUE TUMORS; EXPRESSION; FUSION; BONE	Phosphaturic mesenchymal tumor (PMT) is a rare, histologically distinctive neoplasm that classically presents with phosphaturia and tumor-induced osteomalacia (TIO; ie, oncogenic osteomalacia). Both the phosphaturia and the TIO are due to paraneoplastic production of FGF23 (a phosphatonin) by the neoplastic cells, which are genetically characterized by rearrangements of FN1 (most often with FGFR1, and less frequently with FGF1). However, rare cases of PMT present without phosphaturia and TIO (ie, the "nonphosphaturic" variant) and are therefore much more challenging to diagnose. Here, we report the first case of a genetically confirmed, nonphosphaturic PMT, in which the correct diagnosis was established through a combination of careful histologic evaluation, FGF23 chromogenic in situ hybridization, and fluorescence in situ hybridization testing for FN1-FGFR1. (C) 2018 Elsevier Inc. All rights reserved.	[Sent-Doux, Kimberley N.; Mackinnon, Craig] Hutt Valley Dist Hlth Board, Dept Plast Surg, Wellington 5010, New Zealand; [Lee, Jen-Chieh] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Grad Inst, Coll Med, Taipei, Taiwan; [Lee, Jen-Chieh] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pathol, Coll Med, Taipei, Taiwan; [Folpe, Andrew L.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Habeeb, Omar] Hutt Valley Dist Hlth Board, Dept Pathol, Wellington 5010, New Zealand	Habeeb, O (reprint author), Hutt Valley Dist Hlth Board, Dept Pathol, Wellington 5010, New Zealand.	kimberley.sentdoux@gmail.com; craig.mackinnon@huttvalleydhb.org.nz; leejenchieh@ntuh.gov.tw; folpe.andrew@mayo.edu; dromarhabeeb@gmail.com					Agaimy A, 2017, AM J SURG PATHOL, V41, P1371, DOI 10.1097/PAS.0000000000000890; Bahrami A, 2009, AM J SURG PATHOL, V33, P1348, DOI 10.1097/PAS.0b013e3181aa2311; Carter JM, 2015, AM J SURG PATHOL, V39, P75, DOI 10.1097/PAS.0000000000000290; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Folpe AL, 2004, AM J SURG PATHOL, V28, P1, DOI 10.1097/00000478-200401000-00001; Folpe AL, 2013, WHO CLASSIFICATION T; Honda R, 2014, J DERMATOL, V41, P845, DOI 10.1111/1346-8138.12602; Lee JC, 2016, MODERN PATHOL, V29, P1335, DOI 10.1038/modpathol.2016.137; Lee JC, 2015, J PATHOL, V235, P539, DOI 10.1002/path.4465; Sauder A, 2016, INT J SURG PATHOL, V24, P116, DOI 10.1177/1066896915617828; Shiba E, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0477-3; Shon W, 2015, J CLIN PATHOL, V68, P125, DOI 10.1136/jclinpath-2014-202601; WEIDNER N, 1987, CANCER, V59, P1442, DOI 10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q; Yamada Y, 2018, HISTOPATHOLOGY, V72, P460, DOI 10.1111/his.13377; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105	15	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						94	98		10.1016/j.humpath.2018.02.022			5	Pathology	Pathology	GX5US	WOS:000447817100011	29514106				2019-10-28	
J	Hong, KO; Oh, KY; Shin, WJ; Yoon, HJ; Lee, JI; Hong, SD				Hong, Kyoung-Ok; Oh, Kyu-Young; Shin, Wui-Jung; Yoon, Hye-Jung; Lee, Jae-Il; Hong, Seong-Doo			Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process	HUMAN PATHOLOGY			English	Article						Tumor budding; Epithelial-mesenchymal transition (EMT); Snail; Twist; Oral squamous cell carcinoma	COLORECTAL-CANCER; RECTAL-CANCER; STEM-CELLS; METASTASIS; EXPRESSION; INVASION; MARKER; RECURRENCE; INTERFACE; PHENOTYPE	In this study, we aimed to identify whether tumor budding is associated with the progression and prognosis of oral squamous cell carcinoma (OSCC) and investigate the correlation between tumor budding and regulators of epithelial-mesenchymal transition (EMT). Fifty-six cases of OSCC were selected and their tumor budding status was reviewed using archived hematoxylin and eosin stained slides. In addition, the expression of EMT regulators was evaluated by immunohistochemistry using antibodies against Snail and Twist. Tumor budding was observed in 19 (33.9%) of the 56 cases of OSCC. Tumor budding was strongly associated with lymph node metastasis (P = .001) and shorter overall survival (P = .002). The expression of Snail and Twist was correlated with lymph node metastasis (P < .001 and .002, respectively) and poorer overall survival (P = .024 and .024, respectively). Tumor budding was significantly associated with the expression of Snail (P = .003) and showed a tendency toward higher expression of Twist (P = .08). Therefore, our results suggest that tumor budding is significantly associated with poor prognosis in patients with OSCC and histologically represents an EMT process in OSCC. (C) 2018 Elsevier Inc. All rights reserved.	[Hong, Seong-Doo] Seoul Natl Univ, Sch Dent, Dept Oral Pathol, Seoul 03080, South Korea; Seoul Natl Univ, Dent Res Inst, Seoul 03080, South Korea	Hong, SD (reprint author), Seoul Natl Univ, Sch Dent, Dept Oral Pathol, Seoul 03080, South Korea.	hongsd@snu.ac.kr			Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT, and Future Planning [2017R1D1A1B03029317]	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2017R1D1A1B03029317).	Amin MB, 2018, AJCC CANC STAGING MA; Angadi PV, 2015, INT J SURG PATHOL, V23, P102, DOI 10.1177/1066896914565022; Attramadal CG, 2015, ANTICANCER RES, V35, P6111; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; DiTroia J F, 1972, Otolaryngol Clin North Am, V5, P333; El-Naggar A, 2017, WHO CLASSIFICATION H; Galvan JA, 2015, BRIT J CANCER, V112, P1944, DOI 10.1038/bjc.2015.177; Galvan JA, 2015, ONCOTARGET, V6, P874, DOI 10.18632/oncotarget.2716; Hayes BD, 2010, AM J SURG PATHOL, V34, P746, DOI 10.1097/PAS.0b013e3181da76b6; Jensen DH, 2015, J ORAL PATHOL MED, V44, P674, DOI 10.1111/jop.12321; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kanazawa H, 2008, COLORECTAL DIS, V10, P41, DOI 10.1111/j.1463-1318.2007.01240.x; Karamitopoulou E, 2010, HISTOPATHOLOGY, V57, P233, DOI 10.1111/j.1365-2559.2010.03615.x; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Niwa Y, 2014, J SURG ONCOL, V110, P764, DOI 10.1002/jso.23694; Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Prall F, 2009, HUM PATHOL, V40, P1510, DOI 10.1016/j.humpath.2009.06.015; Tanaka M, 2003, DIS COLON RECTUM, V46, P1054, DOI 10.1097/01.DCR.0000074867.87213.D1; Teramoto H, 2013, J SURG ONCOL, V108, P42, DOI 10.1002/jso.23341; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Ueno H, 2004, ANN SURG, V240, P832, DOI 10.1097/01.sla.0000143243.81014.f2; Wang C, 2011, J ORAL PATHOL MED, V40, P545, DOI 10.1111/j.1600-0714.2011.01041.x; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Yusra, 2012, INT J ONCOL, V41, P201, DOI 10.3892/ijo.2012.1459; Zhong LP, 2013, J CLIN ONCOL, V31, P744, DOI 10.1200/JCO.2012.43.8820; Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199; Zlobec I, 2009, WORLD J GASTROENTERO, V15, P5898, DOI 10.3748/wjg.15.5898	31	4	4	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						123	129		10.1016/j.humpath.2018.06.012			7	Pathology	Pathology	GX5US	WOS:000447817100015	29936060				2019-10-28	
J	Harbhajanka, A; Chahar, S; Miskimen, K; Silverman, P; Harris, L; Williams, N; Varadan, V; Gilmore, H				Harbhajanka, Aparna; Chahar, Satyapal; Miskimen, Kristy; Silverman, Paula; Harris, Lyndsay; Williams, Nicole; Varadan, Vinay; Gilmore, Hannah			Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma	HUMAN PATHOLOGY			English	Article						Triple-negative breast cancer; Basal-like; SOX10; Androgen receptor; WT1; Molecular subtypes	SALIVARY-GLAND TUMORS; CANCER; MARKER; CELLS; GENE; DIFFERENTIATION; SUPPRESSOR; PROTEINS; FAMILY; GATA3	The transcription factor SOX10 mediates the differentiation of neural crest derived cells, and SOX10 by immunohistochemistry (IHC) is used primarily for the diagnosis of melanoma. SOX10 expression has been previously documented in benign breast myoepithelial cells. However there is limited literature on its expression in triple-negative breast carcinoma (TNBC). The aim was to study the clinical, pathologic and molecular profiles of SOX10+ tumors in TNBC. Tissue microarrays of TNBC were evaluated for SOX10 expression in 48 cases. SOX10 expression was correlated with clinical and pathologic features such as age, grade, and stage. Gene expression was analyzed on RNA extracted from formalin-fixed paraffin-embedded (FFPE) specimens with Affymetrix 2.0 HTA. Co-expression of SOX10 with androgen receptor (AR), WT1, gross cystic disease fluid protein-15 (GCDFP-15), mammaglobin, epidermal growth factor receptor (EGFR), CK5/6 and GATA transcription factor 3 (GATA3) were also assessed. The mean age was 59.38 (range, 28-90 years). Overall, 37.5% cases (18/48) were SOX10+. There was no association between SOX10 expression and age, grade or stage of patients; 6 of 10 (60%) cases of basal-like 1 (BL1), and 5 of 8 cases of unstable (UNS) molecular subtype were SOX10+. One of 5 basal-like-2 (BL2), 1 of 6 immunomodulatory (IM), 1 of 4 mesenchymal (M), 1 of 5 luminal androgen receptor (LAR) and 2 of 8 mesenchymal stem cell (MSL) showed lower frequencies of SOX10 expression. There was negative correlation between SOX10 and AR+ subtypes (P < .002). SOX10 was positively correlated with WT1 (P = .05). SOX10 did not show significant correlation with mammaglobin, GCDFP15, EGFR, CK5/6 and GATA3. SOX10 expression in the basal-like and unstable molecular subtypes supports the concept that these neoplasms show myoepithelial differentiation. Published by Elsevier Inc.	[Harbhajanka, Aparna; Chahar, Satyapal; Gilmore, Hannah] Univ Hosp Cleveland Med Ctr, Dept Pathol, Cleveland, OH 44106 USA; [Miskimen, Kristy] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; [Silverman, Paula] Univ Hosp Cleveland Med Ctr, Dept Med, Cleveland, OH 44106 USA; [Harris, Lyndsay] Natl Canc Inst, Rockville, MD 20850 USA; [Williams, Nicole] Ohio State Univ Hosp, Dept Med, Columbus, OH 43210 USA; [Varadan, Vinay] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Harbhajanka, A (reprint author), 23220 Chagrin Blv,Apt 114, Beachwood, OH 44122 USA.	aparna_medi@yahoo.com					de la Rocha AMA, 2014, AM J CANCER RES, V4, P312; Artibani M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45255; Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chen X, 2012, CANCER INFORM, V11, P147, DOI 10.4137/CIN.S9983; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dravis C, 2015, CELL REP, V12, P2035, DOI 10.1016/j.celrep.2015.08.040; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gobbi H, 2003, MODERN PATHOL, V16, P893, DOI 10.1097/01.MP.0000085027.75201.B5; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Haldin CE, 2010, INT J BIOCHEM CELL B, V42, P441, DOI 10.1016/j.biocel.2009.11.014; Harris ML, 2010, PIGM CELL MELANOMA R, V23, P496, DOI 10.1111/j.1755-148X.2010.00711.x; Hong CS, 2005, SEMIN CELL DEV BIOL, V16, P694, DOI 10.1016/j.semcdb.2005.06.005; Hsieh MS, 2016, HUM PATHOL, V56, P134, DOI 10.1016/j.humpath.2016.05.021; Ivanov SV, 2013, BRIT J CANCER, V109, P444, DOI 10.1038/bjc.2013.326; Kelsh RN, 2006, BIOESSAYS, V28, P788, DOI 10.1002/bies.20445; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kwon AY, 2016, VIRCHOWS ARCH, V468, P597, DOI 10.1007/s00428-016-1918-9; Lewis GH, 2011, AM J CLIN PATHOL, V135, P587, DOI 10.1309/AJCPMFR6OA8ICHNH; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Mollaaghababa R, 2003, ONCOGENE, V22, P3024, DOI 10.1038/sj.onc.1206442; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Ohtomo R, 2013, MODERN PATHOL, V26, P1041, DOI 10.1038/modpathol.2013.54; Rakha E, 2009, ARCH PATHOL LAB MED, V133, P860, DOI 10.1043/1543-2165-133.6.860; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Stolt CC, 2010, INT J BIOCHEM CELL B, V42, P437, DOI 10.1016/j.biocel.2009.07.014; Subhawong AP, 2009, AM J SURG PATHOL, V33, P163, DOI 10.1097/PAS.0b013e31817f9790; Tong X, 2014, ONCOTARGET, V5, P10571, DOI 10.18632/oncotarget.2512; Weigelt B, 2009, BREAST CANCER RES TR, V117, P273, DOI 10.1007/s10549-008-0197-9; Zhao Y, 2016, ONCOTARGETS THER, V9, P1671, DOI 10.2147/OTT.S101344; Zhong WD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-248; Zhou DJ, 2014, TUMOR BIOL, V35, P9935, DOI 10.1007/s13277-014-1893-1; Zhu YT, 2010, BIOCHEM J, V425, P435, DOI 10.1042/BJ20091237	38	5	5	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						163	169		10.1016/j.humpath.2018.06.007			7	Pathology	Pathology	GX5US	WOS:000447817100020	29894722				2019-10-28	
J	Yousif, MQ; Salih, ZT; DeYoung, BR; Qasem, SA				Yousif, Mustafa Q.; Salih, Ziyan T.; DeYoung, Barry R.; Qasem, Shadi A.			Differentiating Intrarenal Ectopic Adrenal Tissue From Renal Cell Carcinoma in the Kidney	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						adrenal rest; renal cell carcinoma; PAX2; PAX8; inhibin	WILMS-TUMOR; PAX2; EXPRESSION; INHIBIN; MARKER; ADENOMA; GENE	Background. Adrenal rest (AR) is the presence of ectopic adrenal cortical tissue, often identified incidentally during autopsy (20% of postmortem examination). In the kidney, AR can be found in 6% of the general population. Ectopic adrenal tissue is of no functional significance but may in some cases, pose a diagnostic challenge for the pathologist, especially in the context of renal clear cell renal cell carcinoma (RCC) and small needle biopsies. Aim. To investigate the utility of immunohistochemical stains in distinguishing AR from RCC. Methods. Archival cases of AR, in our institution, were reviewed and compared with a cohort of RCC cases using a panel of immunohistochemical stains, including PAX2, PAX8, calretinin, and inhibin. Results. Nine of 10 (90%) cases of AR showed positive staining for inhibin and negative staining for calretinin, PAX2 and PAX8. One AR case was positive for PAX2 and PAX8 in addition to inhibin. All (100%) RCC cases were positive for PAX2 and PAX8, but negative for inhibin and calretinin. Conclusions. A panel of PAX2, PAX8 and inhibin may be useful markers for distinguishing AR from RCC. Calretinin was noncontributory in our study.	[Yousif, Mustafa Q.; Salih, Ziyan T.; DeYoung, Barry R.; Qasem, Shadi A.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; [Qasem, Shadi A.] Univ Kentucky, Coll Med, Lexington, KY USA	Yousif, MQ (reprint author), Wake Forest Univ, Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	yousif.mustafa@outlook.com					Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Browning L, 2008, J CLIN PATHOL, V61, P293, DOI 10.1136/jcp.2007.049544; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Doglioni C, 1996, AM J SURG PATHOL, V20, P1037, DOI 10.1097/00000478-199609000-00001; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; Erickson LA., 2014, ATLAS ENDOCRINE PATH, P567; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Li HM, 2015, VIRCHOWS ARCH, V466, P581, DOI 10.1007/s00428-015-1732-9; Mazal PR, 2002, NEW ENGL J MED, V347, P653, DOI 10.1056/NEJMoa013413; McCluggage WG, 1998, J CLIN PATHOL, V51, P114, DOI 10.1136/jcp.51.2.114; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Ordonez NG, 1998, AM J SURG PATHOL, V22, P1203, DOI 10.1097/00000478-199810000-00005; POLEEV A, 1992, DEVELOPMENT, V116, P611; Rosai J, 2011, ROSAI ACKERMANS SURG, P1059; Szumera Anna, 2003, Pol J Pathol, V54, P273; Tong AL, 2014, INT J CLIN EXP PATHO, V7, P4415; Tong GX, 2006, MODERN PATHOL, V19, P356, DOI 10.1038/modpathol.3800535; Zhang HY, 2008, APPL IMMUNOHISTO M M, V16, P32; Zheng WX, 2003, ADV ANAT PATHOL, V10, P27, DOI 10.1097/00125480-200301000-00003; Zhu J, 2012, J BIOL CHEM, V287, P8060, DOI 10.1074/jbc.M111.293381	22	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					588	592		10.1177/1066896918779449			5	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000001	29873281				2019-10-28	
J	Efared, B; Sidibe, IS; Gamrani, S; El Otmani, I; Erregad, F; Hammas, N; Bennis, S; Chbani, L; El Fatemi, H				Efared, Boubacar; Sidibe, Ibrahim S.; Gamrani, Sana; El Otmani, Ihsane; Erregad, Fatimazahra; Hammas, Nawal; Bennis, Sanae; Chbani, Laila; El Fatemi, Hinde			The Assessment of HER2 Gene Status by Fluorescence In Situ Hybridization in Invasive Breast Carcinomas With Equivocal HER2 Immunostaining: Experience From a Single Institution	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast carcinoma; HER2; equivocal immunohistochemistry; FISH	PATHOLOGISTS GUIDELINE RECOMMENDATIONS; CLINICAL-ONCOLOGY/COLLEGE; AMERICAN-SOCIETY; IMMUNOHISTOCHEMISTRY IHC; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; TESTING INCREASE; CANCER; FISH; AMPLIFICATION	Background. A subset of breast carcinomas harbors overexpression of the human epidermal growth factor receptor 2 (HER2). Fluorescence in situ hybridization (FISH) should be performed in breast carcinomas with equivocal HER2 immunostaining (immunohistochemistry [IHC] HER2 2+). The aim of our study is to investigate clinicopathologic factors associated with HER2 status in breast invasive carcinomas with IHC HER2 2+ through FISH analysis. Methods. This is a retrospective study including the FISH analysis of 111 patients with invasive breast carcinomas with equivocal HER2 immunostaining. Results. The mean age was 49.51 +/- 10.48 years, and invasive breast carcinoma of no special type was the most histological type in our study (96.4%). Most patients had tumors positive for hormones receptors (88.2% positive for estrogen receptor and 81.4% for progesterone receptor). On FISH, the HER2 amplification rate was 22.5%. There was no significant association of HER2 status with any clinicopathologic factors (P > .05). Conclusions. Our study shows that there are no reliable clinicopathologic factors to predict the HER2 status in breast tumors with equivocal HER2 immunostaining, supporting the necessary usage of FISH in such circumstances.	[Efared, Boubacar; Sidibe, Ibrahim S.; Gamrani, Sana; El Otmani, Ihsane; Erregad, Fatimazahra; Hammas, Nawal; Bennis, Sanae; Chbani, Laila; El Fatemi, Hinde] Hassan II Univ Hosp, Fes, Morocco; [Hammas, Nawal; Bennis, Sanae; Chbani, Laila; El Fatemi, Hinde] Sidi Mohamed Ben Abdellah Univ, Fes, Morocco	Efared, B (reprint author), CHU Hassan II Fes, BP 1835,Route Sidi Harazem, Fes, Morocco.	befared2013@gmail.com	Boubacar, Efared/J-7439-2019	Boubacar, Efared/0000-0002-8623-4005; El Otmani, Ihsane/0000-0002-2031-3640			Bahreini F, 2015, BREAST CANCER-TOKYO, V22, P615, DOI 10.1007/s12282-014-0528-0; Bethune GC, 2015, HISTOPATHOLOGY, V67, P880, DOI 10.1111/his.12723; Calhoun BC, 2015, SEMIN DIAGN PATHOL, V32, P362, DOI 10.1053/j.semdp.2015.02.011; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fan YS, 2016, BREAST CANCER RES TR, V155, P457, DOI 10.1007/s10549-016-3717-z; Gown AM, 2008, MODERN PATHOL, V21, pS8, DOI 10.1038/modpathol.2008.34; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Han XH, 2014, CHINESE MED J-PEKING, V127, P246, DOI 10.3760/cma.j.issn.0366-6999.20120938; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Ji YL, 2014, J THORAC DIS, V6, P896, DOI 10.3978/j.issn.2072-1439.2014.07.27; Lakhani SREI, 2012, WHO CLASSIFICATION T; Li-Ning-T E, 2005, INT J SURG PATHOL, V13, P343, DOI 10.1177/106689690501300406; Lim TH, 2016, ARCH PATHOL LAB MED, V140, P140, DOI 10.5858/arpa.2015-0108-OA; Mohsin SK, 2004, MODERN PATHOL, V17, P1545, DOI 10.1038/modpathol.3800229; Mostafa NAE, 2011, J EGYPT NATL CANCER, V23, P41, DOI 10.1016/j.jnci.2011.07.006; Muller KE, 2015, AM J CLIN PATHOL, V144, P247, DOI 10.1309/AJCPE5NCHWPSMR5D; Ning SF, 2014, INT J CLIN EXP PATHO, V7, P8740; Nitta H, 2016, PATHOL INT, V66, P313, DOI 10.1111/pin.12407; Patnayak R, 2015, INDIAN J MED PAEDIAT, V36, P117, DOI 10.4103/0971-5851.158844; Tchrakian N, 2016, VIRCHOWS ARCH, V468, P207, DOI 10.1007/s00428-015-1871-z; Varga Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140652; Varga Z, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-615; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yamashita Hiroko, 2006, Breast Cancer, V13, P74, DOI 10.2325/jbcs.13.74; Zhang H, 2012, BREAST CANCER RES TR, V134, P743, DOI 10.1007/s10549-012-2101-x	26	1	1	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					593	599		10.1177/1066896918767546			7	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000002	29629604				2019-10-28	
J	Ng, DWJ; Tan, GHC; Soon, JJY; Zhao, DY; Shannon, NB; Selvarajan, S; Soo, KC; Teo, MCC				Ng, Deanna Wan Jie; Tan, Grace Hwei Ching; Soon, Joel Jia Yi; Zhao, David Yue; Shannon, Nicholas Brian; Selvarajan, Sathiyamoorthy; Soo, Khee Chee; Teo, Melissa Ching Ching			The Approach to Solitary Fibrous Tumors: Are Clinicopathological Features and Nomograms Accurate in the Prediction of Prognosis?	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						solitary fibrous tumors; nomogram	SOFT-TISSUE TUMORS; EVOLVING CLASSIFICATION; PLEURA; MULTICENTER	Introduction. Currently, factors such as size, mitotic rate, and degree of necrosis have been shown to influence survival in patients with solitary fibrous tumors (SFTs); however, there remains no consensus regarding the associations between tumor characteristics and the malignant nature of these tumors. The aim of this article was to identify factors that would help in prognosticating SFTs and to validate the MD Anderson Cancer Center (MDACC) SFT nomogram in the largest known series of SFTs treated in an Asian population. Methods. A retrospective review of all patients with a diagnosis of SFT treated surgically in our institution between 2005 and 2015 was carried out. Basic demographics, clinicopathological, and surgical factors were analyzed for association with clinical outcomes. Factors that predicted for distant recurrence (DR) and poor survival were identified as high-risk features. The MDACC nomogram was validated by assessing the extent of discrimination, quantified using Harrell's concordance index (C-index). Results. Fifty-nine patients were included in analysis. Significant univariate associations for DR were found for mitotic rate (P = .05) and presence of necrosis (P = .04). Significant univariate associations for overall survival were found for presence of recurrence (P = .035), presence of necrosis (P = .072), and mitotic rate (P = .033). The C-index associated with the nomogram was 0.75. Conclusion. There is a negative association for DR and overall survival, with the mitotic rate and presence of necrosis. We propose that SFTs with these features should be regarded as high risk. The MDACC nomogram generally predicts well for patients in an Asian population.	[Ng, Deanna Wan Jie; Tan, Grace Hwei Ching; Soon, Joel Jia Yi; Zhao, David Yue; Shannon, Nicholas Brian; Soo, Khee Chee; Teo, Melissa Ching Ching] Natl Canc Ctr Singapore, 11 Hosp Dr, Singapore 169610, Singapore; [Selvarajan, Sathiyamoorthy] Singapore Gen Hosp, Singapore, Singapore	Teo, MCC (reprint author), Natl Canc Ctr Singapore, 11 Hosp Dr, Singapore 169610, Singapore.	Melissa.Teo.C.C@singhealth.com.sg		Shannon, Nicholas/0000-0001-8742-8285			Boddaert G, 2015, ANN THORAC SURG, V99, P1025, DOI 10.1016/j.athoracsur.2014.10.035; Cardillo G, 2009, ANN THORAC SURG, V88, P1632, DOI 10.1016/j.athoracsur.2009.07.026; de Perrot M, 2002, ANN THORAC SURG, V74, P285, DOI 10.1016/S0003-4975(01)03374-4; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; ENGLAND DM, 1989, AM J SURG PATHOL, V13, P640, DOI 10.1097/00000478-198908000-00003; Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x; Fletcher CDM, 2014, HISTOPATHOLOGY, V64, P2, DOI 10.1111/his.12267; Franzen D, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-138; Gengler C, 2006, HISTOPATHOLOGY, V48, P63, DOI 10.1111/j.1365-2559.2005.02290.x; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Lahon B, 2012, ANN THORAC SURG, V94, P394, DOI 10.1016/j.athoracsur.2012.04.028; Li XM, 2014, WORLD J GASTROENTERO, V20, P5066, DOI 10.3748/wjg.v20.i17.5066; Park MS, 2009, CURR OPIN ONCOL, V21, P327, DOI 10.1097/CCO.0b013e32832c9532; Pasquali S, 2016, EJSO-EUR J SURG ONC, V42, P1064, DOI 10.1016/j.ejso.2016.01.023; Robinson Lary A, 2006, Cancer Control, V13, P264; van Houdt WJ, 2013, ANN SURG ONCOL, V20, P4090, DOI 10.1245/s10434-013-3242-9; Wang H, 2014, ONCOL LETT, V7, P1067, DOI 10.3892/ol.2014.1872; Wilky BA, 2013, ANN SURG ONCOL, V20, P4080, DOI 10.1245/s10434-013-3241-x; Yanke BV, 2005, J UROLOGY, V173, P421, DOI 10.1097/01.ju.0000150522.82760.00	19	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					600	608		10.1177/1066896918772339			9	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000003	29772933				2019-10-28	
J	AbdullGaffar, B; Waslewski, K				AbdullGaffar, Badr; Waslewski, Krysztof			Myxoid Emboli	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						emboli; myxoid; myxoma; plaque; thrombi; tumor	LEFT ATRIAL-MYXOMA; CARDIAC MYXOMA; TUMOR; CALRETININ; EXPRESSION; THROMBUS; PATIENT	Emboli are common clinicopathologic findings. Recognition of the type of arterial emboli could be the first clue to the original source. Emboli with myxomatous changes are rare. Myxoma-like features in mural organizing thrombi have been reported. The most challenging differential diagnosis is between embolic cardiac myxomas and myxomatous thromboemboli. Emboli from sarcomas and arteriosclerotic plaques with myxoid features are also potential pitfalls. There is scarcity of studies focusing on myxoid emboli and their clinical and pathologic importance. We performed a retrospective study over 12 years. We retrieved all of the embolectomy specimens. We histologically screened the emboli for myxoid stroma, myxomatous changes, and mucinous degeneration. We retrieved 12 cases (3%) of myxoid emboli out of 391 embolectomy specimens. We found 4 cases of thromboemboli, 5 cases of atrial myxomas, 2 cases of atheromatous plaques, and a myxoid liposarcoma. The age range was between 35 and 71 years, with a mean age of 51 years. The male-to-female ratio was 3:2. Myxoid thromboemboli and myxomas were large, while atheromatous plaque emboli were small. Myxoid emboli arising from organizing mural thrombi can be histologically confused with cardiac myxomas and vice versa. Myxoid emboli from atheromatous plaque and myxoid sarcomas can mimic embolizing myxomas. Certain histologic features are helpful hints to differentiate between myxoid emboli. In doubtful cases, immunohistochemistry is helpful. Correct histologic recognition of the different types of myxoid emboli helps guide the clinicians to the most likely etiology and appropriate management in occlusive peripheral vascular diseases with clinically unrecognized lesions.	[AbdullGaffar, Badr; Waslewski, Krysztof] Rashid Hosp, Oud Metha Rd, Dubai 4545, U Arab Emirates	AbdullGaffar, B (reprint author), Rashid Hosp, Oud Metha Rd, Dubai 4545, U Arab Emirates.	gaffarbadr@hotmail.com		AbdullGaffar, Badr/0000-0001-6350-1214			Acebo E, 2003, CHEST, V123, P1379, DOI 10.1378/chest.123.5.1379; Acebo E, 2001, HISTOL HISTOPATHOL, V16, P1031, DOI 10.14670/HH-16.1031; CHOPRA P, 1981, JPN HEART J, V22, P353; Dogan R, 2007, ANADOLU KARDIYOL DER, V7, P105; Grass H, 2003, PATHOL RES PRACT, V199, P349, DOI 10.1078/0344-0338-00429; GUTHRIE J, 1963, BRIT HEART J, V25, P137; Jardine DL, 1997, HEART, V78, P512, DOI 10.1136/hrt.78.5.512; Mitchell RN, 2005, ROBBINS COTRAN PATHO, P130; Odim J, 2003, CARDIOVASC PATHOL, V12, P267, DOI 10.1016/S1054-8807(03)00087-5; Orlandi A, 2005, AM J PATHOL, V166, P1619, DOI 10.1016/S0002-9440(10)62472-8; Pinede L, 2001, MEDICINE, V80, P159, DOI 10.1097/00005792-200105000-00002; REYNEN K, 1995, NEW ENGL J MED, V333, P1610, DOI 10.1056/NEJM199512143332407; SALYER WR, 1975, ARCH PATHOL, V99, P307; SALYER WR, 1975, AM HEART J, V89, P4, DOI 10.1016/0002-8703(75)90003-4; TEJADA E, 1991, CLIN CARDIOL, V14, P425, DOI 10.1002/clc.4960140512; Terracciano LM, 2000, AM J CLIN PATHOL, V114, P754; Val-Bernal JF, 2003, PATHOL INT, V53, P489, DOI 10.1046/j.1440-1827.2003.01504.x; Vogel B, 2011, CASE REP MED, DOI 10.1155/2011/159024; WAKASA K, 1990, CANCER-AM CANCER SOC, V66, P583, DOI 10.1002/1097-0142(19900801)66:3<583::AID-CNCR2820660329>3.0.CO;2-5; WENKER JC, 1986, INVEST RADIOL, V21, P928, DOI 10.1097/00004424-198612000-00008; WHITFORD EG, 1982, AUST NZ J MED, V12, P543, DOI 10.1111/j.1445-5994.1982.tb03844.x	21	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					609	616		10.1177/1066896918768029			8	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000004	29623727				2019-10-28	
J	Al-Obaidy, KI; Kao, CS; Idrees, MT				Al-Obaidy, Khaleel I.; Kao, Chia-Sui; Idrees, Muhammad T.			P16 Expression in Extramammary Paget's Disease of the Vulva and Scrotum Is Not Human Papillomavirus Related	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						p16; extramammary Paget disease; EMPD; HPV; HPV-ISH	SQUAMOUS-CELL CARCINOMA; CONDYLOMA ACUMINATUM; LESIONS; P53	Introduction. Extramammary Paget disease (EMPD) of the vulva has been shown to express p16 by immunohistochemistry (IHC), however, p16 expression in the vulva and scrotum has not been extensively studied in relation to human papillomavirus (HPV) within EMPD of both the vulva and scrotum. Design. Twenty-two cases of EMPD (vulva, 16; scrotum, 6) were found in our laboratory information system. P16 and HPV IHC were performed. Any p16 reactivity less than 10% was considered negative. HPV in situ hybridization for both low- and high-risk HPV was also performed on all cases. Results. Of the 6 scrotal EMPD, 3 (50%) showed weak to moderate positive reactivity for p16 by IHC. Of the 16 vulvar EMPD, 13 (81%) were positive for p16, with at least moderate (2+) intensity with a mean expression of 33.3% (range = 10% to 80%) and 62% (range = 20% to 95%) in scrotal and vulvar EMPD, respectively. None of the scrotal or vulvar cases showed positive reactivity for HPV either by IHC or in situ hybridization. Conclusion. Both vulvar and scrotal EMPD can express p16 by IHC, more commonly vulvar than scrotal; however, no HPV was detected either by IHC or in situ hybridization. EMPD of vulva and scrotum does not appear to be related to HPV, and p16 expression may be regulated through a different mechanism.	[Al-Obaidy, Khaleel I.; Idrees, Muhammad T.] Indiana Univ, Indianapolis, IN 46204 USA; [Kao, Chia-Sui] Stanford Univ, Stanford, CA 94305 USA	Al-Obaidy, KI (reprint author), Indiana Univ, Hlth Pathol Lab, Dept Pathol & Lab Med, 350 W 11th St,Room 4014, Indianapolis, IN 46202 USA.	dr.khaleel.alobaidy@gmail.com	Al-Obaidy, Khaleel/Q-4731-2019	Al-Obaidy, Khaleel/0000-0001-9890-8751			Alexander RE, 2012, MODERN PATHOL, V25, P1526, DOI 10.1038/modpathol.2012.103; Brainard JA, 2000, AM J SURG PATHOL, V24, P543, DOI 10.1097/00000478-200004000-00008; Egawa K, 2005, AM J DERMATOPATH, V27, P439, DOI 10.1097/01.dad.0000157463.57087.6a; Honda Y, 2005, DERMATOLOGY, V210, P315, DOI 10.1159/000084756; Isrow D, 2014, CLIN MED INSIGHTS-ON, V8, P87, DOI 10.4137/CMO.S13107; Langendijk JA, 2010, ANN ONCOL, V21, P1931, DOI 10.1093/annonc/mdq439; Orlandi A, 2001, INT J GYNECOL CANCER, V11, P224, DOI 10.1046/j.1525-1438.2001.01016.x; Riethdorf S, 2004, HUM PATHOL, V35, P1477, DOI 10.1016/j.humpath.2004.09.004; Santos M, 2004, INT J GYNECOL PATHOL, V23, P206, DOI 10.1097/01.pgp.0000130108.03231.89; SNOW SN, 1992, CANCER, V69, P249, DOI 10.1002/1097-0142(19920101)69:1<249::AID-CNCR2820690140>3.0.CO;2-O; Stephen Josena K, 2013, Cancer Clin Oncol, V2, P51; Taddei G. L., 1993, Pathologica (Genoa), V85, P645; Takata M, 1997, BRIT J CANCER, V76, P904, DOI 10.1038/bjc.1997.482; van der Linden M, 2016, CRIT REV ONCOL HEMAT, V101, P60, DOI 10.1016/j.critrevonc.2016.03.008	14	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					617	620		10.1177/1066896918775513			4	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000005	29745285				2019-10-28	
J	Boylan, KE; Larsen, BT; Young, BA; Downs-Kelly, E; Panchabhai, TS; Collum, ES; Jensen, L; Emerson, LL				Boylan, Katherine E.; Larsen, Brandon T.; Young, Brittany A.; Downs-Kelly, Erinn; Panchabhai, Tanmay S.; Collum, Earle S.; Jensen, Leif; Emerson, Lyska L.			Pulmonary Mycobacterial Spindle Cell Pseudotumor: A Report of 3 Cases Including a Practical Approach to Histopathologic Recognition of This Unusual Entity	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						atypical mycobacteria; Mycobacterium avium-intracellulare; pulmonary nontuberculous mycobacteria; pseudotumor; histoid; immunosuppression	NONTUBERCULOUS MYCOBACTERIA; AVIUM-INTRACELLULARE; COMPLEX INFECTION; LUNG; TUBERCULOSIS; DIAGNOSIS; PATIENT; TISSUES; TUMORS; DISEASE	Mycobacterial spindle cell pseudotumor (MSP) is a rare benign spindle cell lesion containing acid-fact mycobacteria. These lesions are most commonly identified in the lymph nodes, skin, spleen, or bone marrow of immunocompromised patients and only rarely involve the lungs. We report 3 cases of pulmonary MSP, which include 2 patients who are known to be HIV-positive. The histopathological diagnosis of MSP in the lung lends itself to many challenges due to its rare incidence and its spindled tumor-like appearance. The differential diagnosis is broad and includes both benign and malignant entities. We highlight the importance of the clinical context in which these lesions typically present and the morphologic spectrum of features seen, and we offer a practical approach to the workup of pulmonary mycobacterial pseudotumor. Appropriate recognition of this entity should lead to an accurate diagnosis of a treatable benign condition despite the clinical presentation often favoring malignancy.	[Boylan, Katherine E.; Young, Brittany A.; Downs-Kelly, Erinn; Emerson, Lyska L.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; [Boylan, Katherine E.; Young, Brittany A.; Downs-Kelly, Erinn; Emerson, Lyska L.] Associated Reg & Univ Pathologists Labs, Salt Lake City, UT USA; [Larsen, Brandon T.] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ USA; [Panchabhai, Tanmay S.] St Josephs Hosp, John & Doris Norton Thorac Inst, Phoenix, AZ USA; [Collum, Earle S.] St Josephs Hosp, Dept Pathol, Phoenix, AZ USA; [Jensen, Leif] Univ Utah, Dept Radiol, Div Chest Imaging, Salt Lake City, UT 84132 USA	Emerson, LL (reprint author), Huntsman Canc Inst, Dept Pathol, 2000 Circle Hope Dr,Room 3100, Salt Lake City, UT 84112 USA.	lyska.emerson@hsc.utah.edu			University of Utah Department of Pathology; Associated Regional and University Pathologists (ARUP) Laboratories	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We would like to thank the University of Utah Department of Pathology and Associated Regional and University Pathologists (ARUP) Laboratories, for their financial and technical support.	Azov AG, 2005, APMIS, V113, P586, DOI 10.1111/j.1600-0463.2005.apm_234.x; CHADWICK EG, 1990, JAMA-J AM MED ASSOC, V263, P3182, DOI 10.1001/jama.263.23.3182; Gomez-Roman JJ, 2001, AM J SURG PATHOL, V25, P624, DOI 10.1097/00000478-200105000-00009; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Khoor A, 2001, AM J CLIN PATHOL, V115, P755; Kim Ho Cheol, 2007, Korean J Intern Med, V22, P215; Kim YN, 2015, J MOL DIAGN, V17, P597, DOI 10.1016/j.jmoldx.2015.04.005; Lee HS, 2011, J MOL DIAGN, V13, P390, DOI 10.1016/j.jmoldx.2011.02.004; Leslie KO, 2011, PRACTICAL PULMONARY, V2011, P651; Logani S, 1999, AM J SURG PATHOL, V23, P656, DOI 10.1097/00000478-199906000-00004; McShane PJ, 2015, CHEST, V148, P1517, DOI 10.1378/chest.15-0458; Morrison A, 1999, AM J SURG PATHOL, V23, P1294, DOI 10.1097/00000478-199910000-00017; Philip J, 2012, CHEST, V142, P783, DOI 10.1378/chest.11-2503; ROVIARO G, 1983, THORAX, V38, P942, DOI 10.1136/thx.38.12.942; Schulz S, 2005, MODERN PATHOL, V18, P274, DOI 10.1038/modpathol.3800289; SEKOSAN M, 1994, AM J SURG PATHOL, V18, P1065, DOI 10.1097/00000478-199410000-00010; UMLAS J, 1991, AM J SURG PATHOL, V15, P1181, DOI 10.1097/00000478-199112000-00009; WADE H W, 1963, Int J Lepr, V31, P129; WOOD C, 1985, AM J CLIN PATHOL, V83, P524, DOI 10.1093/ajcp/83.4.524; YOGANATHAN K, 1994, THORAX, V49, P179, DOI 10.1136/thx.49.2.179	20	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					629	634		10.1177/1066896918770010			6	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000010	29720005				2019-10-28	
J	Hashimoto, H; Hashikata, T; Shindo, A; Horiuchi, H				Hashimoto, Hirotsugu; Hashikata, Takehiro; Shindo, Akito; Horiuchi, Hajime			Eosinophilic Myocarditis With Hypersegmented Granulocytes and Neutrophilia Without Eosinophilia: A Case Mimicking Neutrophilic Myocarditis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						eosinophilic myocarditis; hypersegmentation; eosinophil; neutrophilia; Giemsa stain		We report a case of a 78-year-old woman with neutrophilia without eosinophilia who was pathologically diagnosed with eosinophilic myocarditis by myocardial biopsy. The biopsy specimen showed infiltrating granulocytes with hypersegmentation, mimicking neutrophils; however, they were confirmed to be eosinophils by Giemsa staining.	[Hashimoto, Hirotsugu; Hashikata, Takehiro; Shindo, Akito; Horiuchi, Hajime] NTT Med Ctr Tokyo, Tokyo, Japan	Hashimoto, H (reprint author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Shinagawa Ku, 5-9-22 Higashi Gotanda, Tokyo 1418625, Japan.	hhashimoto-tki@umin.ac.jp					Chan YK, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-558; CHIHARA J, 1989, ALLERGY PROC, V10, P27, DOI 10.2500/108854189778968515; HERZOG CA, 1984, BRIT HEART J, V52, P343; Morimoto SI, 2003, HEART VESSELS, V18, P193, DOI 10.1007/s00380-003-0721-0; Yamamoto Akemi, 2001, Allergology International, V50, P325, DOI 10.1046/j.1440-1592.2001.00234.x	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					635	636		10.1177/1066896918766669			2	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000011	29623745				2019-10-28	
J	Rekhi, B; Kosemehmetoglu, K; Rane, S; Soylemezoglu, F; Bulut, E				Rekhi, Bharat; Kosemehmetoglu, Kemal; Rane, Swapnil; Soylemezoglu, Figen; Bulut, Elif			Poorly Differentiated Chordomas Showing Loss of INI1/SMARCB1: A Report of 2 Rare Cases With Diagnostic Implications	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						poorly differentiated chordoma; brachyury; INI1; immunohistochemistry of soft tissue tumors; sarcomas	GROWTH-FACTOR RECEPTOR; BRACHYURY EXPRESSION; SMARCB1/INI1 EXPRESSION; SOFT-TISSUE; TUMORS; VALIDATION; MARKER; BASE; INI1	Poorly differentiated chordomas are rare musculoskeletal tumors. Case 1. A 42-year-old lady presented with quadriparesis of 2 months' duration. Radiologic imaging disclosed a soft tissue mass in her left prevertebral- and paravertebral cervical region. Case 2. A 4-year-old male child presented with neck pain and restricted head movements of 1-year duration. Radiologic imaging revealed a contrast enhancing, paraspinal soft tissue mass in his cervical region. Microscopic examination in both the cases revealed a cellular malignant tumor composed of moderate to markedly pleomorphic cells with interspersed mitotic figures, along with focal myxoid change and necrosis. By immunohistochemistry, tumor cells in both cases were diffusely positive for pan cytokeratin (AE1/AE3) and brachyury, whereas these were negative for INI1/SMARCB1. Tumor cells in the second case were also positive for glypican3. The first case developed pulmonary metastasis, while the second case developed recurrence. Poorly differentiated chordomas are uncommon tumors, invariably characterized by loss of INI1. These tumors can be rarely seen in adults and need to be differentiated from their diagnostic mimics, in view of treatment implications and their relatively aggressive clinical outcomes.	[Rekhi, Bharat; Rane, Swapnil] Tata Mem Hosp, Bombay, Maharashtra, India; [Kosemehmetoglu, Kemal; Soylemezoglu, Figen; Bulut, Elif] Hacettepe Univ, Ankara, Turkey	Rekhi, B (reprint author), Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.; Kosemehmetoglu, K (reprint author), Hacettepe Univ, Tip Fak, TR-06100 Ankara, Turkey.	rekhi.bharat@gmail.com; dokemal@hotmail.com	Rane, Swapnil U/H-4694-2011; Kosemehmetoglu, Kemal/A-2423-2016	Rane, Swapnil U/0000-0002-5374-3903; Rekhi, Bharat/0000-0002-3509-4794; Kosemehmetoglu, Kemal/0000-0002-7747-0460			Cha YJ, 2018, NEUROPATHOLOGY, V38, P47, DOI 10.1111/neup.12407; Chavez JA, 2014, CLIN NEUROPATHOL, V33, P418, DOI 10.5414/NP300724; de Castro CV, 2013, HUM PATHOL, V44, P1747, DOI 10.1016/j.humpath.2012.11.024; Flanagan A, 2013, WHO CLASSIFICATION T, P326; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; Hoch BL, 2006, AM J SURG PATHOL, V30, P811, DOI 10.1097/01.pas.0000209828.39477.ab; Jambhekar NA, 2010, ARCH PATHOL LAB MED, V134, P1181, DOI 10.1043/2009-0476-OA.1; Kohashi K, 2013, HUM PATHOL, V44, P526, DOI 10.1016/j.humpath.2012.06.014; Lauer SR, 2013, AM J SURG PATHOL, V37, P719, DOI 10.1097/PAS.0b013e31827813e7; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144; Owosho AA, 2018, GENE CHROMOSOME CANC, V57, P89, DOI 10.1002/gcc.22511; Rekhi B, 2017, INDIAN J PATHOL MICR, V60, P350, DOI 10.4103/IJPM.IJPM_409_16; Rekhi B, 2016, APMIS, V124, P238, DOI 10.1111/apm.12468; Rekhi B, 2013, PATHOL RES PRACT, V209, P758, DOI 10.1016/j.prp.2013.08.008; Sangoi AR, 2011, MODERN PATHOL, V24, P425, DOI 10.1038/modpathol.2010.196; Stacchiotti S, 2009, ANN ONCOL, V20, P1886, DOI 10.1093/annonc/mdp210; Tamborini E, 2006, CLIN CANCER RES, V12, P6920, DOI 10.1158/1078-0432.CCR-06-1584; Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Yadav R, 2014, NEURO-ONCOLOGY, V16, P372, DOI 10.1093/neuonc/not228	22	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					637	643		10.1177/1066896918768043			7	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000012	29623728				2019-10-28	
J	Gialamas, E; Mormont, M; Bagetakos, I; Frossard, JL; Morel, P; Puppa, G				Gialamas, Eleftherios; Mormont, Murielle; Bagetakos, Ilias; Frossard, Jean-Louis; Morel, Philippe; Puppa, Giacomo			Combination of Adenomyoma and Adenomyomatous Hyperplasia of the Ampullary System: A First Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						adenomyoma; adenomyomatous hyperplasia; major papilla; ampulla of Vater; duodenopancreatectomy	COMMON BILE-DUCT; VATERIAN SYSTEM; PAPILLA	Adenomyoma and adenomyomatous hyperplasia are benign tumor-like lesions that rarely involve the major or minor duodenal papilla. We report the case of a 73-year-old patient who underwent a cephalic duodenopancreatectomy due to clinical and radiological evidence of underlying malignant neoplasm. The histopathology results revealed the unusual association of a major duodenal papilla adenomyoma and an adenomyomatous hyperplasia of the minor papilla. Because of their resemblance to pancreatic malignancy, the diagnosis of these lesions is particularly challenging. In most cases, it is established postoperatively, after histopathological examination of the surgical specimen.	[Gialamas, Eleftherios; Mormont, Murielle; Morel, Philippe] Geneva Univ Hosp, Dept Surg, Div Abdominal Surg, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland; [Bagetakos, Ilias] Geneva Univ Hosp, Dept Radiol, Geneva, Switzerland; [Frossard, Jean-Louis] Geneva Univ Hosp, Div Gastroenterol & Hepatol, Geneva, Switzerland; [Puppa, Giacomo] Geneva Univ Hosp, Fac Med, Dept Clin Pathol, Geneva, Switzerland	Gialamas, E (reprint author), Geneva Univ Hosp, Dept Surg, Div Abdominal Surg, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.	eleftherios.gialamas@hcuge.ch					Albores-Saavedra J, 1991, WHO HISTOLOGICAL CLA, P204; Aoun N, 2005, ABDOM IMAGING, V30, P86, DOI 10.1007/s00261-004-0224-1; Bravet G., 1913, TUMEURS BENIGNES VOI; Choi Yong Hyeok, 2013, Korean J Gastroenterol, V62, P352; Colovic R, 2002, HPB (Oxford), V4, P187, DOI 10.1080/13651820260503864; Fukuda A, 2005, GASTROINTEST ENDOSC, V61, P475, DOI 10.1016/S0016-5107(04)02784-1; Handra-Luca A, 2003, MODERN PATHOL, V16, P530, DOI 10.1097/01.MP.0000073525.71096.8F; Higashi M, 2010, J HEPATO-BIL-PAN SCI, V17, P275, DOI 10.1007/s00534-009-0176-5; Kayahara M, 2001, DIGEST SURG, V18, P139, DOI 10.1159/000050115; Kumari N, 2011, J Surg Case Rep, V2011, P6, DOI 10.1093/jscr/2011.8.6; Kwon TH, 2007, WORLD J GASTROENTERO, V13, P2892; Lauffer JM, 1998, DIGEST DIS SCI, V43, P1200, DOI 10.1023/A:1018843421292; Lehwald Nadja, 2010, J Med Case Rep, V4, P402, DOI 10.1186/1752-1947-4-402; Masoom S, 2006, APMIS, V114, P559, DOI 10.1111/j.1600-0463.2006.apm_476.x; Narita T, 1999, Ann Diagn Pathol, V3, P174, DOI 10.1016/S1092-9134(99)80045-8; Odze RD, 2014, ODZE GOLDBLUM SURG P; Parthasarathy S, 2008, J PANCREAS, V9, P332; Rafiullah, 2014, BMJ CASE REP, V2014, DOI 10.1136/bcr-2013-203151.; Tsukamoto T, 1999, HEPATO-GASTROENTEROL, V46, P1627; ULICH TR, 1987, ARCH PATHOL LAB MED, V111, P388	20	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					644	648		10.1177/1066896918767561			5	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000013	29618230				2019-10-28	
J	Chen, SH; Zheng, ZY; Wang, HLL; Yu, YH; Zeng, DH; Qu, LJ; Ye, XZ				Chen, Shao-hua; Zheng, Zhi-yong; Wang, Hanlin L.; Yu, Ying-hao; Zeng, De-hua; Qu, Li-juan; Ye, Xian-zong			Thyroid-Like Intrahepatic Cholangiocarcinoma: Report of a Case and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						intrahepatic cholangiocarcinoma; thyroid neoplasm; thyroid-like; follicular; papillary	FOLLICULAR CARCINOMA; VARIANT; GLAND	Intrahepatic cholangiocarcinoma is a relatively uncommon malignant neoplasm. We recently encountered an unusual case of intrahepatic cholangiocarcinoma that histologically resembled a thyroid carcinoma. A thorough review of the English literature revealed only 2 similar cases that have been previously reported. Immunohistochemical studies are imperative to confirm the diagnosis of cholangiocarcinoma and to exclude the possibility of metastatic thyroid carcinoma and other malignancies with thyroid-like features.	[Chen, Shao-hua; Zheng, Zhi-yong; Yu, Ying-hao; Zeng, De-hua; Qu, Li-juan; Ye, Xian-zong] Fujian Med Univ, Fuzhou Gen Hosp PLA, Fuzong Clin Med Coll, Dept Pathol, Fuzhou 350025, Fujian, Peoples R China; [Chen, Shao-hua] Fujian Med Univ, Affiliated Hosp 2, Dept Pathol, Quanzhou City, Fujian, Peoples R China; [Wang, Hanlin L.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA	Qu, LJ; Ye, XZ (reprint author), Fujian Med Univ, Fuzhou Gen Hosp PLA, Fuzong Clin Med Coll, Dept Pathol, Fuzhou 350025, Fujian, Peoples R China.	qljuan6516@sina.com; yexianzong@126.com	ye, xianzong/G-6079-2011	ye, xianzong/0000-0002-3640-0570	Natural Science Foundation of Fujian Province in ChinaNatural Science Foundation of Fujian Province [2016J05199]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Natural Science Foundation of Fujian Province in China (No. 2016J05199).	Aishima S, 2011, AM J SURG PATHOL, V35, P590, DOI 10.1097/PAS.0b013e31820ffdf1; Alessandrini L, 2012, VIRCHOWS ARCH, V461, P345, DOI 10.1007/s00428-012-1298-8; Aosasa S, 2015, INT SURG, V100, P689, DOI 10.9738/INTSURG-D-14-00117.1; Bosman FT, 2010, WHO CLASSIFICATION T, P217; Chable-Montero F, 2012, ANN HEPATOL, V11, P961, DOI 10.1016/S1665-2681(19)31427-9; Colella R, 2015, INT J SURG PATHOL, V23, P217, DOI 10.1177/1066896914536222; Dawane R, 2015, AM J CLIN PATHOL, V144, P796, DOI 10.1309/AJCP6P0STAAHOTTG; DEVANEY K, 1993, INT J GYNECOL PATHOL, V12, P333, DOI 10.1097/00004347-199310000-00008; Farina E, 2016, ENDOCR PATHOL, V27, P55, DOI 10.1007/s12022-015-9410-7; Fornelli A, 2010, VIRCHOWS ARCH, V456, P339, DOI 10.1007/s00428-009-0874-z; Ghanem N, 2003, THYROID, V13, P503, DOI 10.1089/105072503322021188; Guerra G, 2014, INT J SURG, V12, pS3, DOI 10.1016/j.ijsu.2014.05.076; Haas S, 2007, AM J SURG PATHOL, V31, P902, DOI 10.1097/PAS.0b013e31802c0c8a; Nakanuma Y, 2010, WORLD J HEPATOL, V2, P419, DOI 10.4254/wjh.v2.i12.419; Oishi N, 2014, PATHOL RES PRACT, V210, P1142, DOI 10.1016/j.prp.2014.04.020; Rosai J., 2011, ROSAI ACKERMANS SURG; Sato Y, 2013, J GASTROEN HEPATOL, V28, P1422, DOI 10.1111/jgh.12247	17	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					649	654		10.1177/1066896918769381			6	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000014	29665738				2019-10-28	
J	Miyaoka, M; Hatanaka, K; Iwazaki, M; Nakamura, N				Miyaoka, Masashi; Hatanaka, Kazuhito; Iwazaki, Masayuki; Nakamura, Naoya			Pulmonary Adenocarcinoma Mimicking Desquamative Interstitial Pneumonia: Report of 2 Cases With Genetic Analysis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						adenocarcinoma; intra-alveolar; discohesive; EGFR; ALK; PD-L1	LUNG ADENOCARCINOMA; EXPRESSION; CANCER	We report 2 cases of pulmonary adenocarcinoma mimicking desquamative interstitial pneumonia (DIP) with genetic analysis occurring in a 74-year-old woman and a 76-year-old woman. In both cases, the tumor was mainly composed of discohesive tumor cells, which filled and floated in the alveolar space in a DIP-like pattern. The tumor cells had abnormally large round to oval nuclei with fine chromatin and relatively abundant eosinophilic cytoplasm lacking pigmentation. Immunohistochemically, tumor cells in both cases were positive for CK7, TTF-1, napsin A, E-cadherin, -catenin, and PD-L1 (one case had high expression and the other had low expression), and negative for CK5/6, CK20, p40, and ALK. However, the positive pattern of E-cadherin and -catenin was incomplete on the circumference of the cell membrane in both cases and in one case, respectively. On genetic analysis, EGFR alteration (exon 21, L858R mutation) was observed in one case and ALK translocation was not observed in either. To the best of our knowledge, this is the first report of pulmonary adenocarcinoma mimicking DIP with genetic analysis.	[Miyaoka, Masashi; Hatanaka, Kazuhito; Nakamura, Naoya] Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan; [Iwazaki, Masayuki] Tokai Univ, Div Gen Thorac Surg, Dept Surg, Sch Med, Isehara, Kanagawa, Japan	Hatanaka, K (reprint author), Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	kazhatanaka@tokai.ac.jp					Cha YJ, 2016, LUNG CANCER, V97, P73, DOI 10.1016/j.lungcan.2016.05.001; Colby TV, 1995, TUMORS LOWER RESP TR; Hirsch E, 2018, INT J SURG PATHOL, V26, P185, DOI 10.1177/1066896917729436; Kase S, 2000, CLIN CANCER RES, V6, P4789; Kozu Y, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-89; Raparia K, 2014, AM J SURG PATHOL, V38, P921, DOI 10.1097/PAS.0000000000000227; Travis WD, 2015, WHO CLASSIFICATION T; Yanagawa N, 2014, ANN THORAC SURG, V98, P453, DOI 10.1016/j.athoracsur.2014.04.108; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06	9	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					655	659		10.1177/1066896918773180			5	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000015	29720004				2019-10-28	
J	Savari, O; Hastings, H; Rayes, R; Tomashefski, JF				Savari, Omid; Hastings, Hope; Rayes, Rania; Tomashefski, Joseph F., Jr.			Neuroendocrine Neoplasia in Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Lung: A Case Report and Immunohistochemistry Analysis of Eight Pulmonary MALT Lymphomas	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						lung; MALT lymphoma; carcinoid tumorlet	LYMPHOPLASMACYTIC LYMPHOMA; TUMORLET	Carcinoid tumorlets are peribronchiolar proliferations of neuroendocrine cells often associated with lung scars. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a non-Hodgkin's lymphoma that frequently involves the gastrointestinal tract but less commonly is described in the lung. Simultaneous occurrence of neuroendocrine neoplasms and MALT lymphoma is extraordinarily rare and has predominately been reported in the gastrointestinal tract. In this article, we describe the case of a 73-year-old female with coexisting pulmonary MALT lymphoma and carcinoid tumorlets of the right middle lobe. Retrospective series of 8 pulmonary MALT lymphomas are evaluated for neuroendocrine neoplasia by immunohistochemistry. No correlation between MALT lymphoma and neuroendocrine neoplasia was identified in this case series. While the concurrence of these distinctive neoplasms is most likely coincidental, the presence of a common risk factor, or one neoplasm as a risk factor for the other, deserves study of a larger group of pulmonary MALT lymphomas.	[Savari, Omid; Hastings, Hope; Rayes, Rania; Tomashefski, Joseph F., Jr.] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH 44109 USA	Savari, O (reprint author), Case Western Reserve Univ, Metrohlth Med Ctr, Dept Pathol, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.	oxs54@case.edu					Agarwal Tanu, 2006, Indian J Gastroenterol, V25, P213; Aigelsreiter A, 2011, AM J CLIN PATHOL, V135, P70, DOI 10.1309/AJCPXMDRT1SY6KIV; Czapiewski P, 2010, PATHOL RES PRACT, V206, P508, DOI 10.1016/j.prp.2010.01.004; Fisseler-Eckhoff Annette, 2012, Cancers (Basel), V4, P777, DOI 10.3390/cancers4030777; Ganguly S, 2006, AM J CLIN ONCOL-CANC, V29, P104, DOI 10.1097/01.coc.0000162442.54674.46; He P, 2012, J THORAC DIS, V4, P655, DOI 10.3978/j.issn.2072-1439.2012.06.11; Isaacson PG, 2004, NAT REV CANCER, V4, P644, DOI 10.1038/nrc1409; List AF, 2001, ONCOLOGIST, V6, P24; Naderi N, 2013, ARCH PATHOL LAB MED, V137, P580, DOI 10.5858/arpa.2012-0034-RS; Rekhtman N, 2010, ARCH PATHOL LAB MED, V134, P1628, DOI 10.1043/2009-0583-RAR.1; Rubenstein JN, 2015, J CLIN EXP PATHOL, V5, P208; Sartelet H, 2004, HUM PATHOL, V35, P1210, DOI 10.1016/j.humpath.2004.07.009; Taylor WSJ, 2013, ANN THORAC SURG, V95, P1086, DOI 10.1016/j.athoracsur.2012.06.051; Troppan K, 2015, GASTROENT RES PRACT, DOI 10.1155/2015/102656	14	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					660	663		10.1177/1066896918769745			4	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000016	29673288				2019-10-28	
J	Moodley, J; Cutz, JC; Schell, M				Moodley, Jinesa; Cutz, Jean-Claude; Schell, Miranda			Reactive Nodular Fibrous Pseudotumor Mimicking Metastatic Gastrointestinal Stromal Tumor to Perigastric Lymph Node: A Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						reactive nodular fibrous pseudotumor; gastrointestinal stromal tumor; pseudotumor; postsurgical change; myofibroblast	TRACT; MESENTERY	Gastrointestinal stromal tumors (GIST) are the most common mesenchymal lesions of the gastrointestinal tract. Many are treated surgically with or without the use of adjuvant tyrosine kinase inhibitors. Metastases to lymph nodes are infrequent. In this article, we present a case of a perigastric nodule presenting 3 years postsurgical treatment for biopsy-proven GIST, clinically suspicious for a recurrent/metastatic GIST. The patient had also received adjuvant tyrosine kinase inhibitor therapy. Microscopic sections from the perigastric lesion showed a spindle cell nodule felt initially to represent a GIST with posttherapeutic changes. Together with morphology, immunohistochemical workup supported the myofibroblastic origin of the spindle cells, consistent with a reactive nodular fibrous pseudotumor, and definitively excluded metastatic GIST. This case highlights an important diagnostic pitfall and is the first known case of a GIST preceding a reactive nodular fibrous pseudotumor.	[Moodley, Jinesa; Cutz, Jean-Claude; Schell, Miranda] McMaster Univ, Hamilton, ON, Canada	Schell, M (reprint author), McMaster Univ, Dept Pathol & Mol Med, 1200 Main St West,HSC-2N33, Hamilton, ON L8N 3Z5, Canada.	schellm@hhsc.ca		Schell, Miranda/0000-0003-3135-666X			Ciftci Birgul, 2015, Iran J Pathol, V10, P149; Daum O, 2004, INT J SURG PATHOL, V12, P365, DOI 10.1177/106689690401200409; Gauchotte G, 2009, GASTROEN CLIN BIOL, V33, P1076, DOI 10.1016/j.gcb.2009.04.012; Loughrey MB, 2006, HISTOPATHOLOGY, V49, P99, DOI 10.1111/j.1365-2559.2006.02336.x; McAteer J, 2012, J PEDIATR SURG, V47, P795, DOI 10.1016/j.jpedsurg.2012.01.001; Saglam EA, 2005, VIRCHOWS ARCH, V447, P879, DOI 10.1007/s00428-005-0027-y; Salihi R, 2014, CASE REP OBSTET GYNE, V2014; Virgilio E, 2012, AM SURGEON, V78, pE262; Yan F, 2015, ONCOL LETT, V9, P1343, DOI 10.3892/ol.2015.2882; Yantiss RK, 2003, AM J SURG PATHOL, V27, P532, DOI 10.1097/00000478-200304000-00015; Yi Xiao-Jiang, 2014, World J Clin Cases, V2, P111, DOI 10.12998/wjcc.v2.i4.111; Yin SS, 2011, AM SURGEON, V77, P790	12	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					664	670		10.1177/1066896918771192			7	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000017	29681220				2019-10-28	
J	Meindl, A; Rao, MS; Yang, GY				Meindl, Amanda; Rao, M. Sambasiva; Yang, Guang-Yu			Extranodal Rosai-Dorfman Disease With Mucosal Involvement of the Stomach in a Background of Autoimmune Atrophic Gastritis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						Rosai-Dorfman disease; extranodal disease; gastrointestinal tract; autoimmune atrophic gastritis; carcinoid tumor	OF-THE-LITERATURE; MASSIVE LYMPHADENOPATHY; SINUS HISTIOCYTOSIS; TUMOR	Rosai-Dorfman disease (RDD), or sinus histiocytosis with massive lymphadenopathy, has been described involving both lymph nodes and extranodal sites, but extranodal RDD rarely involves the gastrointestinal tract. Although the etiology is unclear, several risk factors have been shown to be highly associated with this disease process, including viral infection and immune alterations. In this article, we present a case of a 79-year-old male with a history of autoimmune atrophic gastritis and multiple carcinoid tumors of the stomach presenting with a new stomach mass. An additional large sigmoid colon mass and adjacent enlarged lymph node was identified through imaging, prior to surgery. Through extensive pathologic analysis, we identified the first case of predominant extranodal RDD involving gastric mucosa and submucosa in a background of atrophic gastritis, with additional involvement of the sigmoid colon. Based on this case and literature review, we further discuss possible risk factors and pathogenesis of this disease process.	[Meindl, Amanda; Rao, M. Sambasiva; Yang, Guang-Yu] Northwestern Mem Hosp, Chicago, IL 60611 USA	Yang, GY (reprint author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave,Ward 4-115, Chicago, IL 60611 USA.	g-yang@northwestern.edu		Meindl, Amanda/0000-0003-4513-7919	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DKI107767]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by NIH (DKI107767).	Alatassi H, 2006, INT J SURG PATHOL, V14, P95, DOI 10.1177/106689690601400119; Anders Robert A, 2003, Arch Pathol Lab Med, V127, pE74; Arabadzhieva E, 2015, INT J SURG CASE REP, V12, P140, DOI 10.1016/j.ijscr.2015.06.001; Baran B, 2013, EUR J GASTROEN HEPAT, V25, P869, DOI 10.1097/MEG.0b013e32836019f8; Dalia S, 2014, CANCER CONTROL, V21, P322, DOI 10.1177/107327481402100408; Garces S, 2017, MODERN PATHOL, V30, P1367, DOI 10.1038/modpathol.2017.55; Ide M, 2010, RARE TUMORS, V2, P5, DOI 10.4081/rt.2010.e2; Ioannidis I, 2015, DIAGN CYTOPATHOL, V43, P40, DOI 10.1002/dc.23112; Lauwers GY, 2000, HUM PATHOL, V31, P380, DOI 10.1016/S0046-8177(00)80254-3; Long E, 2007, PATHOL RES PRACT, V203, P233, DOI 10.1016/j.prp.2007.01.008; Horvat NDMR, 2015, ABDOM IMAGING, V40, P2738, DOI 10.1007/s00261-015-0449-1; Mantilla JG, 2016, AM J CLIN PATHOL, V145, P211, DOI 10.1093/ajcp/aqv029; OSBORNE BM, 1981, AM J SURG PATHOL, V5, P603, DOI 10.1097/00000478-198109000-00010; Podberezin M, 2010, ARCH PATHOL LAB MED, V134, P276, DOI 10.1043/1543-2165-134.2.276; Zhao M, 2013, INT J CLIN EXP PATHO, V6, P2569	15	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					671	675		10.1177/1066896918773399			5	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000018	29720012				2019-10-28	
J	Wolfe, S; Sullivan, J; Kahn, L				Wolfe, Scott; Sullivan, James; Kahn, Leonard			Perivascular Leiomyomatosis: A Unique Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						smooth muscle tumor; intravascular leiomyomatosis; benign metastasizing leiomyoma; leiomyomatosis peritonealis desseminata; leiomyoma	SMOOTH-MUSCLE TUMORS; DISSEMINATED PERITONEAL LEIOMYOMATOSIS; UNUSUAL GROWTH-PATTERNS; INTRAVASCULAR LEIOMYOMATOSIS; CARDIAC EXTENSION; HYSTERECTOMY; EXPRESSION; UTERUS	There are 3 histologically benign smooth muscle neoplasms that have unusual growth patterns. These include intravascular leiomyomatosis, benign metastasizing leiomyoma, and leiomyomatosis peritonealis desseminata. We report a unique case of perivascular leiomyomatosis. The tumor showed multiple nodules of benign smooth muscle with some of the nodules closely associated with the periphery of the medial muscle layer of venous channels. All the neoplastic nodules were located on the outer surface of venous channels, thus precluding a diagnosis of intravascular leiomyomatosis. To the best of our knowledge, this is the first documentation of such an entity.	[Wolfe, Scott; Sullivan, James; Kahn, Leonard] Northwell Hlth, Lake Success, NY 11042 USA	Wolfe, S (reprint author), Northwell Hlth, Dept Pathol & Lab Med, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA.	swolfe@northwell.edu					Anila KR, 2014, INT J SURG PATHOL, V22, P158, DOI 10.1177/1066896913507600; Barnas E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175875; Bayrak Savas, 2014, J Med Case Rep, V8, P114, DOI 10.1186/1752-1947-8-114; Birch-Hirschfeld FV, 1896, LEHRBUCH PATHOLOGISC; Calvo-Rodriguez D, 2016, CIR ESPAN, V94, P306, DOI 10.1016/j.ciresp.2015.11.007; Cohen DT, 2007, AM J ROENTGENOL, V188, P246, DOI 10.2214/AJR.05.1070; Cornelis F, 2012, J THORAC CARDIOV SUR, V144, pE3, DOI 10.1016/j.jtcvs.2012.03.022; Diakomanolis E., 2003, Archives of Gynecology and Obstetrics, V267, P256; Du J, 2011, HUM PATHOL, V42, P1240, DOI 10.1016/j.humpath.2010.10.015; Vaquero ME, 2009, J MINIM INVAS GYN, V16, P263, DOI 10.1016/j.jmig.2009.01.013; Fasih N, 2008, RADIOGRAPHICS, V28, P1931, DOI 10.1148/rg.287085095; Fukuyama A, 2011, PATHOL ONCOL RES, V17, P171, DOI 10.1007/s12253-010-9265-7; Galajda Z, 2010, J VASC SURG, V51, P1000, DOI 10.1016/j.jvs.2009.09.061; Kir G, 2004, EUR J GYNAECOL ONCOL, V25, P362; Le Bouedec G, 1999, PRESSE MED, V28, P1463; Lin J, 2014, INT J GYNECOL PATHOL, V33, P140, DOI 10.1097/PGP.0b013e31828def26; Magyar Eva, 2007, Lege Artis Med, V17, P694; Nucci MR, 2001, AM J SURG PATHOL, V25, P455, DOI 10.1097/00000478-200104000-00004; Rosica G, 2011, CLIN EXP OBSTET GYN, V38, P84	19	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	OCT	2018	26	7					676	679		10.1177/1066896918772340			4	Pathology; Surgery	Pathology; Surgery	GS5TF	WOS:000443733000019	29692211				2019-10-28	
J	Serra, S; Chetty, R				Serra, Stefano; Chetty, Runjan			p16	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TUMOR-SUPPRESSOR P16(INK4A); HPV STATUS; EXPRESSION; CANCER; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; PROTEIN; UTILITY; LESIONS; CDKN2A	The p16 gene belongs to INK4 family of genes and is made up of four members: p16(INK4A), p15(INK4B), p18(INK4C), and p19(INK4D), all of which share biological properties, namely, inhibition of cell growth and tumour suppression. After p53, p16 is the second most common tumour suppressor gene. It has been regarded as the familial melanoma gene. Immunohistochemistry for p16 has a well-defined role in distinct pathological scenarios. It is used to distinguish desmoplastic melanoma from reactive fibrous proliferation, with former showing strong nuclear positivity. In other types of melanoma, p16 protein expression is lost. Spitz nevi show retention of nuclear staining for p16. Benign mesothelial proliferations tend to retain nuclear p16 immunoreactivity, while malignant mesotheliomas lose expression. However, p16 fluorescent in-situ hybridisation analysis is recommended in the workup of malignant mesothelioma. Another common application of p16 immunohistochemistry is as an indicator for human papillomavirus (HPV) infection and p16 protein is overexpressed in HPV-associated tumours. In this context, p16 immunopositivity should be strong, diffuse, nuclear or nuclear and cytoplasmic in location. Another use for p16 is demonstration of p16 immunopositivity in well-differentiated and dedifferentiated liposarcoma.	Univ Hlth Network, Dept Anat Pathol, Lab Med Program, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada	Chetty, R (reprint author), Univ Hlth Network, Toronto Gen Hosp, Dept Anat Pathol, Lab Med Program, Toronto, ON M5G 2C4, Canada.	runjan.chetty@gmail.com		Chetty, Runjan/0000-0002-2124-515X			Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Cameron RI, 2002, HISTOPATHOLOGY, V41, P313, DOI 10.1046/j.1365-2559.2002.01465.x; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harms PW, 2016, HUM PATHOL, V58, P152, DOI 10.1016/j.humpath.2016.07.029; He M, 2009, APPL IMMUNOHISTO M M, V17, P51, DOI 10.1097/PAI.0b013e3181719223; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Jordan RC, 2012, AM J SURG PATHOL, V36, P945, DOI 10.1097/PAS.0b013e318253a2d1; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Li JN, 2011, BIOCHEMISTRY-US, V50, P5566, DOI 10.1021/bi200642e; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lin YC, 2007, ONCOGENE, V26, P7017, DOI 10.1038/sj.onc.1210507; Mahajan A, 2016, HUM PATHOL, V51, P64, DOI 10.1016/j.humpath.2015.12.021; McCarthy AJ, 2018, J CLIN PATHOL, V71, P483, DOI 10.1136/jclinpath-2017-204975; Ng W, 2015, INT J SURG PATHOL, V23, P544, DOI 10.1177/1066896915595465; O'Neill CJ, 2006, ADV ANAT PATHOL, V13, P8, DOI 10.1097/01.pap.0000201828.92719.f3; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Thway K, 2012, AM J SURG PATHOL, V36, P462, DOI 10.1097/PAS.0b013e3182417330; Uguen A, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0431-9	24	5	6	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					853	858		10.1136/jclinpath-2018-205216			6	Pathology	Pathology	GV4QG	WOS:000446084700004	30076191	Bronze			2019-10-28	
J	Shiroma, N; Arihiro, K; Oda, M; Orita, M				Shiroma, Noriyuki; Arihiro, Koji; Oda, Miyo; Orita, Makoto			KRAS fluorescence in situ hybridisation testing for the detection and diagnosis of pancreatic adenocarcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							K-RAS MUTATIONS; EUS-GUIDED FNA; DUCTAL ADENOCARCINOMA; GENOMIC INSTABILITY; GENE AMPLIFICATION; CANCER; CARCINOMA; ABNORMALITIES; PROGRESSION; LESIONS	Aims The aim of our study was to analyse correlations between KRAS mutation status, chromosomal changes that affect KRAS status in cells from pancreatic tumours. Methods We collected 69 cases of surgically resected pancreatic ductal adenocarcinoma (PDA) and seven cases of chronic pancreatitis (CP). Chromosomal abnormalities of KRAS and CEP12 were detected using fluorescence in situ hybridisation (FISH). Results The number of CEP12 signals per cell ranged from 1.78 to 2.04 and 1.46 to 4.88 in CP and PDA samples, respectively, while the number of KRAS signals per cell ranged from 1.94 to 2.06 and 1.88 to 8.18 in CP and PDA samples, respectively. The 'chromosomal instability index', which was defined as the percentage of cells with any chromosomal abnormality, was over 5.7 times greater in PDA than in CP. We performed KRAS mutation analysis by direct sequencing and found that tumours with KRAS mutations have a significantly higher mean KRAS signal per cell from PDA samples compared with tumours with wild-type KRAS. KRAS amplification was noted in 10% of cases. Although we found that lymph node metastasis and distal metastasis of PDA were more frequent in cases with KRAS amplification, this was not correlated with overall survival. Using a threshold of 40%, we found that the chromosomal instability index robustly discriminated PDA cells from CP cells. Conclusions Based on these findings, we concluded that FISH testing of KRAS using cytology samples may represent an accurate approach for the diagnosis of PDA.	[Shiroma, Noriyuki; Arihiro, Koji; Oda, Miyo; Orita, Makoto] Hiroshima Univ Hosp, Dept Anat Pathol, Hiroshima 7348551, Japan	Shiroma, N (reprint author), Hiroshima Univ Hosp, Dept Anat Pathol, Hiroshima 7348551, Japan.	nshiroma@hiroshima-u.ac.jp					Adsay NV, 1999, PANCREAS, V18, P111, DOI 10.1097/00006676-199903000-00001; Arihiro K, 2016, PATHOL RES PRACT, V212, P1126, DOI 10.1016/j.prp.2016.09.014; Baumgart M, 2010, PANCREAS, V39, P1093, DOI 10.1097/MPA.0b013e3181dc62f6; Birkeland E, 2012, BRIT J CANCER, V107, P1997, DOI 10.1038/bjc.2012.477; Botti C, 2000, J AM COLL SURGEONS, V190, P530, DOI 10.1016/S1072-7515(00)00252-0; Brat DJ, 1997, AM J PATHOL, V150, P383; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Dewald GW, 2009, MAYO CLIN PROC, V84, P801, DOI 10.1016/S0025-6196(11)60490-4; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fritcher EGB, 2009, GASTROENTEROLOGY, V136, P2180, DOI 10.1053/j.gastro.2009.02.040; Gagos S, 2005, INT J BIOCHEM CELL B, V37, P1014, DOI 10.1016/j.biocel.2005.01.003; Genevay M, 2010, PANCREAS, V39, P543, DOI 10.1097/MPA.0b013e3181bbff44; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Immervoll H, 2006, VIRCHOWS ARCH, V448, P788, DOI 10.1007/s00428-006-0191-8; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Kamisawa T, 2009, PANCREAS, V38, P890, DOI 10.1097/MPA.0b013e3181b65a1c; Kawesha A, 2000, INT J CANCER, V89, P469, DOI 10.1002/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L; Kowalski J, 2007, CANCER GENET CYTOGEN, V178, P26, DOI 10.1016/j.cancergencyto.2007.06.004; Krasinskas AM, 2013, MODERN PATHOL, V26, P1346, DOI 10.1038/modpathol.2013.71; Kubiliun N, 2011, GASTROINTEST ENDOSC, V74, P541, DOI 10.1016/j.gie.2011.04.043; Levy MJ, 2007, GASTROINTEST ENDOSC, V66, P483, DOI 10.1016/j.gie.2007.03.1053; Lohr M, 2005, NEOPLASIA, V7, P17, DOI 10.1593/neo.04445; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathol.3.121806.154305; Muzumdar MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00942-5; Pikor L, 2013, CANCER METAST REV, V32, P341, DOI 10.1007/s10555-013-9429-5; Qiu WL, 2011, ONCOTARGET, V2, P862; Scarlett CJ, 2011, PATHOLOGY, V43, P183, DOI 10.1097/PAT.0b013e3283445e3a; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Smith G, 2010, BRIT J CANCER, V102, P693, DOI 10.1038/sj.bjc.6605534; Takahashi K, 2005, GASTROINTEST ENDOSC, V61, P76, DOI 10.1016/S0016-5107(04)02224-2; Tanno Y, 2015, SCIENCE, V349, P1237, DOI 10.1126/science.aaa2655; Xia XM, 2010, ONCOL LETT, V1, P1045, DOI 10.3892/ol.2010.164; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215	37	2	2	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					865	873		10.1136/jclinpath-2018-205002			9	Pathology	Pathology	GV4QG	WOS:000446084700009	29695486				2019-10-28	
J	Liang, J; Malherbe, JAJ; Fuller, KA; Mirzai, B; George, C; Carter, TL; Cole, CH; Guo, BB; Meehan, K; Erber, WN				Liang, James; Malherbe, Jacques A. J.; Fuller, Kathryn A.; Mirzai, Bob; George, Carly; Carter, Tina L.; Cole, Catherine H.; Guo, Belinda B.; Meehan, Katie; Erber, Wendy N.			Automated enumeration of lymphoid and plasma cells in bone marrow to establish normal reference ranges	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DIGITAL-IMAGE-ANALYSIS; FLOW-CYTOMETRIC ANALYSIS; AGE-RELATED-CHANGES; MULTIPLE-MYELOMA; NORMAL HEMATOPOIESIS; TISSUE MICROARRAYS; PROTEIN EXPRESSION; TREPHINE BIOPSY; QUANTIFICATION; CRITERIA	Aims The number of precursor and mature lymphoid cells and plasma cells in normal bone marrow trephine (BMT) biopsies throughout the human lifespan is unknown. Reference ranges have been established from aspirated marrow, but due to haemodilution errors, these do not accurately reflect the native marrow milieu. We aimed to define age-specific, normal reference ranges for lymphoid and plasma cells in BMT biopsy specimens using a combined immunophenotyping and digital enumeration approach. Methods Morphologically normal BMT biopsy specimens (n=483) were obtained from patients aged 1 month to 90 years of age. Immunohistochemistry was performed to identify lymphoid progenitors , T-lymphocytes (CD3), B-lymphocytes (CD20) and plasma cells (CD138 and MUM1). Positive cells were counted using digital enumeration software, and the percent positivity for each antigen was determined per case. Mean values were generated for specific age groups, and age-defined reference ranges were determined for each antigen using normalised data. Results A mean of 16 609 cells (range: 7210-34 097) were counted per biopsy. Infant marrows showed a predominance of immature lymphoid progenitors and B cells. With increasing age, an increase in mean T cell and plasma cell numbers were observed. The results showed the same trends to flow cytometry references for aspirate material although the absolute values differed. Conclusions Combined immunohistochemistry and automated enumeration gives an accurate, reproducible number of antigen-positive cells and has generated normal reference ranges for these cell types in BMT biopsies. The method and ranges we have established have the potential to be applied in routine clinical practice.	[Liang, James; Malherbe, Jacques A. J.; Fuller, Kathryn A.; Mirzai, Bob; George, Carly; Cole, Catherine H.; Guo, Belinda B.; Meehan, Katie; Erber, Wendy N.] Univ Western Australia, Sch Biomed Sci, Fac Hlth & Med Sci, Crawley, WA, Australia; [Liang, James] Sir Charles Gairdner Hosp, Dept Haematol, Nedlands, WA, Australia; [Malherbe, Jacques A. J.; Cole, Catherine H.; Erber, Wendy N.] Univ Western Australia, Med Sch, Fac Hlth & Med Sci, Crawley, WA, Australia; [Fuller, Kathryn A.; Mirzai, Bob; Carter, Tina L.; Cole, Catherine H.; Erber, Wendy N.] PathWest Lab Med, Nedlands, WA, Australia; [George, Carly; Carter, Tina L.; Cole, Catherine H.] Princess Margaret Hosp, Dept Haematol, Subiaco, WA, Australia	Erber, WN (reprint author), Univ Western Australia, Fac Hlth & Med Sci, M500, Crawley, WA 6009, Australia.	wendy.erber@uwa.edu.au	Fuller, Kathy A/C-5454-2011	Fuller, Kathy A/0000-0002-3462-7501; Guo, Belinda/0000-0003-2146-8561; Erber, Wendy/0000-0002-1028-9376	WA Cancer and Palliative Care Network Health; WA Health Department; Cancer Council Western AustraliaCancer Council Western Australia; Sir Charles Gairdner Group grant	JL received fellowships from the WA Cancer and Palliative Care Network Health and the WA Health Department. BBG received a Translational Cancer Pathology Postdoctoral Fellowship from Cancer Council Western Australia. KAF and WNE received a Sir Charles Gairdner Group grant for part of this study.	ANDREONI C, 1990, BLUT, V61, P271, DOI 10.1007/BF01732876; Bain BJ, 1996, BRIT J HAEMATOL, V94, P206, DOI 10.1046/j.1365-2141.1996.d01-1786.x; Bain BJ, 2001, J CLIN PATHOL, V54, P737, DOI 10.1136/jcp.54.10.737; Braun M, 2013, HISTOL HISTOPATHOL, V28, P605, DOI 10.14670/HH-28.605; Brooimans RA, 2009, CYTOM PART B-CLIN CY, V76B, P18, DOI 10.1002/cyto.b.20439; CALDWELL CW, 1991, AM J CLIN PATHOL, V95, P816, DOI 10.1093/ajcp/95.6.816; CLARK P, 1986, BLOOD, V67, P1600; Diebold J, 2000, HISTOPATHOLOGY, V37, P199, DOI 10.1046/j.1365-2559.2000.00965.x; Erber W. N., 2010, DIAGNOSTIC TECHNIQUE, P28; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; FAULKNERJONES BE, 1988, J CLIN PATHOL, V41, P768, DOI 10.1136/jcp.41.7.768; GLASER K, 1950, PEDIATRICS, V6, P789; Glover SJ, 2008, BONE, V42, P623, DOI 10.1016/j.bone.2007.12.218; Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438; HIRSCH K, 1993, ANN NY ACAD SCI, V677, P410, DOI 10.1111/j.1749-6632.1993.tb38801.x; Ilyas M, 2013, HISTOPATHOLOGY, V62, P827, DOI 10.1111/his.12118; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Kyle RA, 2009, LEUKEMIA, V23, P3, DOI 10.1038/leu.2008.291; LANIER LL, 1992, J IMMUNOL, V149, P1876; Laurinavicius A, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3639; Lee SH, 2008, INT J LAB HEMATOL, V30, P349, DOI 10.1111/j.1751-553X.2008.01100.x; Liu JYW, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-72; LOKEN MR, 1987, BLOOD, V69, P255; Malherbe JAJ, 2016, J CLIN PATHOL, V69, P155, DOI 10.1136/jclinpath-2015-203177; Matsue K, 2017, HEMATOL ONCOL, V35, P323, DOI 10.1002/hon.2300; MCCOY JP, 1994, CYTOMETRY, V18, P129, DOI 10.1002/cyto.990180304; Mohammed ZMA, 2012, HISTOPATHOLOGY, V61, P675, DOI 10.1111/j.1365-2559.2012.04280.x; Natkunam Y, 2001, MODERN PATHOL, V14, P686, DOI 10.1038/modpathol.3880373; Ng AP, 2006, HAEMATOL-HEMATOL J, V91, P972; Osgood EE, 1944, PHYSIOL REV, V24, P0046; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rego EM, 1998, CYTOMETRY, V34, P22, DOI 10.1002/(SICI)1097-0320(19980215)34:1<22::AID-CYTO4>3.0.CO;2-G; Riley RS, 2009, J CLIN LAB ANAL, V23, P259, DOI 10.1002/jcla.20305; Rizzardi AE, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-42; Salama ME, 2014, APPL IMMUNOHISTO M M, V22, P550, DOI 10.1097/PAI.0b013e318294cb61; SANDKUHLER S, 1956, BLOOD, V11, P856, DOI 10.1182/blood.V11.9.856.856; Smock KJ, 2007, ARCH PATHOL LAB MED, V131, P951; Stalhammar G, 2016, MODERN PATHOL, V29, P318, DOI 10.1038/modpathol.2016.34; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Travlos GS, 2006, TOXICOL PATHOL, V34, P548, DOI 10.1080/01926230600939856; Tuominen VJ, 2012, HISTOPATHOLOGY, V60, P758, DOI 10.1111/j.1365-2559.2011.04142.x; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; Went P, 2006, HISTOL HISTOPATHOL, V21, P951, DOI 10.14670/HH-21.951; WILKINS BS, 1992, J CLIN PATHOL, V45, P645, DOI 10.1136/jcp.45.8.645	45	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					916	925		10.1136/jclinpath-2018-205168			10	Pathology	Pathology	GV4QG	WOS:000446084700017	29858232				2019-10-28	
J	Wolf, JC; Smith, SA; Jortner, BS; McMaster, ME				Wolf, J. C.; Smith, S. A.; Jortner, B. S.; McMaster, M. E.			Putative Rodlet Cell Neoplasms in the Livers of Two White Suckers (Catostomus commersonii)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						Catostomus commersonii; liver neoplasia; rodlet cell; white sucker	DICENTRARCHUS-LABRAX L.; CELLS/EOSINOPHILIC GRANULE CELLS; FRESH-WATER TELEOSTS; NUCLEAR-DNA CONTENT; CYPRINUS-CARPIO L; ULTRASTRUCTURAL OBSERVATIONS; INFLAMMATORY CELLS; PHOXINUS-PHOXINUS; LEPOMIS-MACROCHIRUS; CIRRHINUS-MRIGALA	Although discovered more than a century ago, piscine rodlet cells (RCs) remain somewhat of a mystery to scientists in terms of their origin and function. Initially described as parasites, and later as potential secretory cells, the prevailing theory is that RCs are leucocyte-like cells that possess pathogen defence capabilities. The current case report involves a novel type of neoplasm discovered in the livers of two adult female white suckers (Gatostomus commersonii) that were collected as part of a survey of fish from the St. Mary's River Area of Concern, in which sediment contaminated by polyaromatic hydrocarbons has been associated historically with a high prevalence ofliver neoplasms in white suckers. The two tumours in this study were investigated by light microscopy, histochemical staining, immunohistochemical labelling for S100 protein and transmission electron microscopy. The evidence from these investigations suggests that these neoplasms may be derived from de-differentiated RCs or RC precursors. The unanticipated existence of these solid mesenchymal-like tumours may prompt a reassessment of the current dogma regarding the physiological function of RCs. (C) 2018 Elsevier Ltd. All rights reserved.	[Wolf, J. C.] Expt Pathol Labs Inc, Sterling, VA 20166 USA; [Smith, S. A.; Jortner, B. S.] Virginia Tech, Virginia Maryland Coll Vet Med, Blacksburg, VA USA; [McMaster, M. E.] Environm & Climate Change Canada, Burlington, ON, Canada	Wolf, JC (reprint author), Expt Pathol Labs Inc, Sterling, VA 20166 USA.	jwolf@cpl-inc.com					Abd El-Hamid H. T., 2016, J GEOGRAPHICAL ENV E, V7, P1, DOI DOI 10.9734/JGEESI/2016/26887; ABRAHAM R, 1969, HISTOCHEMISTRY, V18, P195, DOI 10.1007/BF00306166; Arellano JM, 2001, HISTOL HISTOPATHOL, V16, P511, DOI 10.14670/HH-16.511; BARBER DL, 1986, CAN J ZOOL, V64, P801, DOI 10.1139/z86-120; BARBER DL, 1983, J FISH BIOL, V22, P477, DOI 10.1111/j.1095-8649.1983.tb04768.x; BARBER DL, 1985, J FISH BIOL, V27, P817, DOI 10.1111/j.1095-8649.1985.tb03223.x; BARBER DL, 1979, J FISH BIOL, V14, P277, DOI 10.1111/j.1095-8649.1979.tb03519.x; Baumann PC, 1996, J GREAT LAKES RES, V22, P131, DOI 10.1016/S0380-1330(96)70946-2; Bielek E., 2002, Journal of Submicroscopic Cytology and Pathology, V34, P271; Blazer VS, 2006, DIS AQUAT ORGAN, V72, P19, DOI 10.3354/dao072019; Bosi G, 2018, J FISH DIS, V41, P475, DOI 10.1111/jfd.12751; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; DAWE JC, 1964, CANCER RES, V24, P1194; DePasquale JA, 2014, ACTA ZOOL-STOCKHOLM, V95, P209, DOI 10.1111/azo.12020; DePasquale JA, 2014, ACTA ZOOL-STOCKHOLM, V95, P144, DOI 10.1111/azo.12013; DESSER SS, 1975, CAN J ZOOL, V53, P1483, DOI 10.1139/z75-182; Dezfuli BS, 2006, CHEMOSPHERE, V64, P1684, DOI 10.1016/j.chemosphere.2006.01.023; Dezfuli BS, 2016, FISH SHELLFISH IMMUN, V50, P274, DOI 10.1016/j.fsi.2016.02.002; Dezfuli BS, 2010, VET PARASITOL, V174, P359, DOI 10.1016/j.vetpar.2010.08.024; Dezfuli BS, 2007, FISH SHELLFISH IMMUN, V23, P300, DOI 10.1016/j.fsi.2006.11.003; Dezfuli BS, 2010, FISH SHELLFISH IMMUN, V28, P476, DOI 10.1016/j.fsi.2009.12.012; Dezfuli BS, 2007, DIS AQUAT ORGAN, V75, P51, DOI 10.3354/dao075051; Dezfuli BS, 2007, ANAT REC, V290, P367, DOI 10.1002/ar.20507; Dezfuli BS, 2002, J FISH DIS, V25, P7, DOI 10.1046/j.1365-2761.2002.00332.x; Dezfuli BS, 2003, DIS AQUAT ORGAN, V53, P257, DOI 10.3354/dao053257; Dezfuli BS, 2000, DIS AQUAT ORGAN, V43, P61, DOI 10.3354/dao043061; FLOOD MT, 1975, J FISH BIOL, V7, P129, DOI 10.1111/j.1095-8649.1975.tb04582.x; Frost W. E., 1959, Journal du Conseil International Exploration Mer, V24, P314; Giari L, 2007, CHEMOSPHERE, V67, P1171, DOI 10.1016/j.chemosphere.2006.10.061; Giari L, 2006, J FISH BIOL, V69, P590, DOI 10.1111/j.1095-8649.2006.01130.x; HAYES MA, 1990, SCI TOTAL ENVIRON, V94, P105, DOI 10.1016/0048-9697(90)90367-4; Iger Y, 1997, TISSUE CELL, V29, P431, DOI 10.1016/S0040-8166(97)80029-8; Imagawa T, 1998, J FISH DIS, V21, P153, DOI 10.1046/j.1365-2761.1998.00084.x; IMAGAWA T, 1990, J FISH DIS, V13, P537, DOI 10.1111/j.1365-2761.1990.tb00814.x; Jordanova M, 2007, FISH SHELLFISH IMMUN, V23, P473, DOI 10.1016/j.fsi.2006.11.004; Jovanovic B, 2014, NANOTOXICOLOGY, V8, P755, DOI 10.3109/17435390.2013.828794; Kramer CR, 2002, CAN J ZOOL, V80, P1422, DOI 10.1139/Z02-125; Laura R, 2012, MICROSC RES TECHNIQ, V75, P1321, DOI 10.1002/jemt.22067; Lee MW, 2002, INT J DERMATOL, V41, P168, DOI 10.1046/j.1365-4362.2002.01373_2.x; LEINO RL, 1974, CELL TISSUE RES, V155, P367; Leino RL, 1996, CAN J ZOOL, V74, P217, DOI 10.1139/z96-027; Leknes IL, 2001, FISH SHELLFISH IMMUN, V11, P433, DOI 10.1006/fsim.2000.0325; Lin SH, 1998, J FISH BIOL, V53, P560, DOI 10.1111/j.1095-8649.1998.tb01001.x; MACCUBBIN AE, 1991, HYDROBIOLOGIA, V219, P301, DOI 10.1007/BF00024762; Manera M, 2004, J FISH BIOL, V65, P597, DOI 10.1111/j.1095-8649.2004.00511.x; Manera M, 2009, J FISH BIOL, V74, P474, DOI 10.1111/j.1095-8649.2008.02096.x; Matisz CE, 2010, INT J PARASITOL, V40, P307, DOI 10.1016/j.ijpara.2009.08.013; Mazon AF, 2007, FISH SHELLFISH IMMUN, V22, P27, DOI 10.1016/j.fsi.2006.03.012; Mbuthia PG, 1996, DISCOV INNOVAT, V8, P219; Mendonca Ivete, 2005, Brazilian Journal of Morphological Sciences, V22, P187; Milani D, 2006, DIRECTION GEN SCI TE, P53; Miyajima R, 2001, J VET MED SCI, V63, P449, DOI 10.1292/jvms.63.449; MORRISON CM, 1978, J FISH RES BOARD CAN, V35, P101, DOI 10.1139/f78-014; NOGA EJ, 1989, VET PATHOL, V26, P429, DOI 10.1177/030098588902600508; Poltronieri C, 2009, VET RES COMMUN, V33, P619, DOI 10.1007/s11259-009-9211-x; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Reite OB, 2006, FISH SHELLFISH IMMUN, V20, P192, DOI 10.1016/j.fsi.2005.01.012; Reite OB, 2005, FISH SHELLFISH IMMUN, V19, P253, DOI 10.1016/j.fsi.2005.01.002; Reite OB, 1998, FISH SHELLFISH IMMUN, V8, P489, DOI 10.1006/fsim.1998.0162; Schultz AG, 2014, J FISH DIS, V37, P219, DOI 10.1111/jfd.12099; Siderits D, 2009, FISH SHELLFISH IMMUN, V27, P539, DOI 10.1016/j.fsi.2009.06.020; Silphaduang U, 2006, DIS AQUAT ORGAN, V72, P241, DOI 10.3354/dao072241; Smith IR, 1995, CANADIAN TECHNICAL R, P2050; SMITH SA, 1995, J FISH BIOL, V46, P241, DOI 10.1111/j.1095-8649.1995.tb05965.x; Smith Stephen A., 1995, Journal of Aquatic Animal Health, V7, P63, DOI 10.1577/1548-8667(1995)007<0063:OORCAA>2.3.CO;2; Srivastava N, 2012, ACTA HISTOCHEM, V114, P626, DOI 10.1016/j.acthis.2011.11.009; Thelohan P, 1892, J ANAT PHYSL PARIS, V28, P163; VALLEJO AN, 1989, DEV COMP IMMUNOL, V13, P133, DOI 10.1016/0145-305X(89)90028-1; Vigliano FA, 2009, FISH SHELLFISH IMMUN, V26, P146, DOI 10.1016/j.fsi.2008.02.016; Wolf JC, 2005, TOXICOL PATHOL, V33, P75, DOI 10.1080/01926230590890187; Wolf JC, 2015, TOXICOL PATHOL, V43, P297, DOI 10.1177/0192623314540229; Xie R, 2011, J HISTOCHEM CYTOCHEM, V59, P356, DOI 10.1369/0022155411398488; Yashpal M, 2014, ANAT HISTOL EMBRYOL, V43, P116, DOI 10.1111/ahe.12055	73	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						1	16		10.1016/j.jcpa.2018.08.002			16	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800001	30360907				2019-10-28	
J	Kim, KY; Lewis, JS; Chen, Z				Kim, Kelly Y.; Lewis, James S., Jr.; Chen, Zhong			Current status of clinical testing for human papillomavirus in oropharyngeal squamous cell carcinoma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Review						oropharyngeal cancer; oropharyngeal squamous cell carcinoma; OPSCC; head and neck cancer; human papillomavirus; HPV; p16; molecular diagnostics; biomarkers	RISK HUMAN-PAPILLOMAVIRUS; IN-SITU HYBRIDIZATION; ROCHE COBAS 4800; ADENOID CYSTIC CARCINOMA; ACTIVE HPV INFECTION; E6/E7 MESSENGER-RNA; NECK-CANCER; P16 IMMUNOHISTOCHEMISTRY; PATIENT OUTCOMES; TUMOR-ORIGIN	While a variety of human papillomavirus (HPV) tests and surrogate markers are available, currently there is no consensus on the best detection method(s) that should be used to identify HPV-related oropharyngeal squamous cell carcinomas and serve as a standard test (or tests) for routine diagnostic use. As we begin to consider using the results of HPV testing for clinical purposes beyond simple prognostication, such as making decisions on treatment dose or duration or for targeted therapies that may be highly dependent on viral-mediated pathways, we need to be more rigorous in assessing and ensuring the performance of the test (or tests) used. Here we provide an overview of the platforms and technologies, including the strengths and limitations of each test, and discuss what steps are needed to generate confidence in their performance for use in clinical practice.	[Kim, Kelly Y.] NCI, Canc Diag Program, Div Canc Treatment & Diag, NIH, Rockville, MD USA; [Lewis, James S., Jr.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Lewis, James S., Jr.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, TN 37232 USA; [Chen, Zhong] Natl Inst Deafness & Other Commun Disorders, Clin Genom Unit, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA	Chen, Z (reprint author), Natl Inst Deafness & Other Commun Disorders, NIH, Bldg 10,Room 7N240,10 Ctr Dr, Bethesda, MD 20892 USA.	chenz@nidcd.nih.gov			Intramural Research Program of The National Institute on Deafness and Other Communication Disorders [ZIA-DC-000016]; Extramural Cancer Diagnosis Program of National Cancer Institute (NCI) [1R21CA179327-01A1]		Abreu ALP, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-262; Ahn SM, 2014, JAMA OTOLARYNGOL, V140, P846, DOI 10.1001/jamaoto.2014.1338; Al-Swiahb JN, 2010, ARCH OTOLARYNGOL, V136, P502, DOI 10.1001/archoto.2010.47; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Baldassarri R, 2015, AM J CLIN PATHOL, V143, P694, DOI 10.1309/AJCPCZA4PSZCFHQ4; Barasch S, 2016, AM J SURG PATHOL, V40, P1261, DOI 10.1097/PAS.0000000000000666; Begum S, 2007, CLIN CANCER RES, V13, P1186, DOI 10.1158/1078-0432.CCR-06-1690; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Bishop JA, 2011, AM J SURG PATHOL, V35, P1679, DOI 10.1097/PAS.0b013e3182299cde; Boland JM, 2012, MODERN PATHOL, V25, P529, DOI 10.1038/modpathol.2011.186; Cao DF, 2010, HUM PATHOL, V41, P535, DOI 10.1016/j.humpath.2009.09.006; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chera BS, 2018, CANCER-AM CANCER SOC, V124, P2347, DOI 10.1002/cncr.31338; Dayyani F, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-15; Fakhry C, 2014, J CLIN ONCOL, V32, P3365, DOI 10.1200/JCO.2014.55.1937; Fischer CA, 2010, INT J CANCER, V126, P1256, DOI 10.1002/ijc.24842; Fonmarty D, 2015, EUR ANN OTORHINOLARY, V132, P135, DOI 10.1016/j.anorl.2015.01.003; Gao G, 2013, INT J CANCER, V132, P882, DOI 10.1002/ijc.27739; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Guo M, 2014, CANCER CYTOPATHOL, V122, P96, DOI 10.1002/cncy.21375; Hakima L, 2015, DIAGN CYTOPATHOL, V43, P683, DOI 10.1002/dc.23278; Han Min, 2016, J Am Soc Cytopathol, V5, P221, DOI 10.1016/j.jasc.2016.05.001; Huho AN, 2018, J MOL DIAGN, V20, P232, DOI 10.1016/j.jmoldx.2017.11.008; Jordan RC, 2012, AM J SURG PATHOL, V36, P945, DOI 10.1097/PAS.0b013e318253a2d1; Jung AC, 2010, INT J CANCER, V126, P1882, DOI 10.1002/ijc.24911; Kerr DA, 2016, ARCH PATHOL LAB MED, V140, P844, DOI 10.5858/arpa.2015-0272-OA; Kerr DA, 2014, CANCER CYTOPATHOL, V122, P167, DOI 10.1002/cncy.21372; Kraft S, 2012, AM J SURG PATHOL, V36, P321, DOI 10.1097/PAS.0b013e31823f2f17; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Marklund L, 2012, CANCER MED-US, V1, P82, DOI 10.1002/cam4.2; Marur S, 2017, J CLIN ONCOL, V35, P490, DOI 10.1200/JCO.2016.68.3300; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; McDowell LJ, 2016, CANCER-AM CANCER SOC, V122, P1201, DOI 10.1002/cncr.29901; Mehanna H, 2013, HEAD NECK-J SCI SPEC, V35, P747, DOI 10.1002/hed.22015; Mirghani H, 2016, ORAL ONCOL, V62, P101, DOI 10.1016/j.oraloncology.2016.10.009; Mirghani H, 2014, ORAL ONCOL, V50, P1, DOI 10.1016/j.oraloncology.2013.10.008; Morbini P, 2015, HUM PATHOL, V46, P681, DOI 10.1016/j.humpath.2014.12.014; Munger K, 2015, J VIROL, V89, P4708, DOI 10.1128/JVI.03486-14; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; Nauta IH, 2018, ANN ONCOL, V29, P1273, DOI 10.1093/annonc/mdy060; NCCN, 2017, NCCN GUID VERS 2 201; OSullivan B, 2016, AJCC CANC STAGING MA; Pettus JR, 2017, EXP MOL PATHOL, V102, P47, DOI 10.1016/j.yexmp.2016.12.004; Ragin CCR, 2007, INT J CANCER, V121, P1813, DOI 10.1002/ijc.22851; Reimers N, 2007, INT J CANCER, V120, P1731, DOI 10.1002/ijc.22355; Rischin D, 2010, J CLIN ONCOL, V28, P4142, DOI 10.1200/JCO.2010.29.2904; Rooper LM, 2016, ORAL ONCOL, V55, P11, DOI 10.1016/j.oraloncology.2016.02.008; Roy-Chowdhuri S, 2015, SEMIN DIAGN PATHOL, V32, P250, DOI 10.1053/j.semdp.2014.12.006; Schache AG, 2011, CLIN CANCER RES, V17, P6262, DOI 10.1158/1078-0432.CCR-11-0388; Shelton J, 2017, MODERN PATHOL, V30, P1194, DOI 10.1038/modpathol.2017.31; Shi W, 2009, J CLIN ONCOL, V27, P6213, DOI 10.1200/JCO.2009.23.1670; Singhi AD, 2010, CANCER-AM CANCER SOC, V116, P2166, DOI 10.1002/cncr.25033; Smith DF, 2014, ORAL ONCOL, V50, P600, DOI 10.1016/j.oraloncology.2014.02.011; Stevens TM, 2011, APPL IMMUNOHISTO M M, V19, P1574, DOI 10.1097/PAI.0b013e318215248a; Thavaraj S, 2011, J CLIN PATHOL, V64, P308, DOI 10.1136/jcp.2010.088450; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; Volpi CC, 2018, HUM PATHOL, V74, P32, DOI 10.1016/j.humpath.2017.09.011; Weinberger PM, 2009, OTOLARYNG HEAD NECK, V141, P382, DOI 10.1016/j.otohns.2009.04.014; Westra W, 2017, WHO CLASSIFICATION H; Westra WH, 2015, SEMIN DIAGN PATHOL, V32, P42, DOI 10.1053/j.semdp.2015.02.023	68	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					213	226		10.1002/cjp2.111			14	Pathology	Pathology	GW0OS	WOS:000446567600002	30058293	DOAJ Gold, Green Published			2019-10-28	
J	Rambau, PF; Vierkant, RA; Intermaggio, MP; Kelemen, LE; Goodman, MT; Herpel, E; Pharoah, PD; Kommoss, S; Jimenez-Linan, M; Karlan, BY; Gentry-Maharaj, A; Menon, U; Polo, SH; Candido dos Reis, FJ; Doherty, JA; Gayther, SA; Sharma, R; Larson, MC; Harnett, PR; Hatfield, E; de Andrade, JM; Nelson, GS; Steed, H; Schildkraut, JM; Carney, ME; Hogdall, E; Whittemore, AS; Widschwendter, M; Kennedy, CJ; Wang, F; Wang, Q; Wang, C; Armasu, SM; Daley, F; Coulson, P; Jones, ME; Anglesio, MS; Chow, C; de Fazio, A; Garcia-Closas, M; Brucker, SY; Cybulski, C; Harris, HR; Hartkopf, AD; Huzarski, T; Jensen, A; Lubinski, J; Oszurek, O; Benitez, J; Mina, F; Staebler, A; Taran, FA; Pasternak, J; Talhouk, A; Rossing, MA; Hendley, J; Edwards, RP; Fereday, S; Modugno, F; Ness, RB; Sieh, W; El-Bahrawy, MA; Winham, SJ; Lester, J; Kjaer, SK; Gronwald, J; Sinn, P; Fasching, PA; Chang-Claude, J; Moysich, KB; Bowtell, DD; Hernandez, BY; Luk, H; Behrens, S; Shah, M; Jung, A; Ghatage, P; Alsop, J; Alsop, K; Garcia-Donas, J; Thompson, PJ; Swerdlow, AJ; Karpinskyj, C; Cazorla-Jimenez, A; Garcia, MJ; Deen, S; Wilkens, LR; Palacios, J; Berchuck, A; Koziak, JM; Brenton, JD; Cook, LS; Goode, EL; Huntsman, DG; Ramus, SJ; Kobel, M				Rambau, Peter F.; Vierkant, Robert A.; Intermaggio, Maria P.; Kelemen, Linda E.; Goodman, Marc T.; Herpel, Esther; Pharoah, Paul D.; Kommoss, Stefan; Jimenez-Linan, Mercedes; Karlan, Beth Y.; Gentry-Maharaj, Aleksandra; Menon, Usha; Polo, Susanna Hernando; Candido dos Reis, Francisco J.; Doherty, Jennifer Anne; Gayther, Simon A.; Sharma, Raghwa; Larson, Melissa C.; Harnett, Paul R.; Hatfield, Emma; de Andrade, Jurandyr M.; Nelson, Gregg S.; Steed, Helen; Schildkraut, Joellen M.; Carney, Micheal E.; Hogdall, Estrid; Whittemore, Alice S.; Widschwendter, Martin; Kennedy, Catherine J.; Wang, Frances; Wang, Qin; Wang, Chen; Armasu, Sebastian M.; Daley, Frances; Coulson, Penny; Jones, Micheal E.; Anglesio, Micheal S.; Chow, Christine; de Fazio, Anna; Garcia-Closas, Montserrat; Brucker, Sara Y.; Cybulski, Cezary; Harris, Holly R.; Hartkopf, Andreas D.; Huzarski, Tomasz; Jensen, Allan; Lubinski, Jan; Oszurek, Oleg; Benitez, Javier; Mina, Fady; Staebler, Annette; Taran, Florin Andrei; Pasternak, Jana; Talhouk, Aline; Rossing, Mary Anne; Hendley, Joy; Edwards, Robert P.; Fereday, Sian; Modugno, Francesmary; Ness, Roberta B.; Sieh, Weiva; El-Bahrawy, Mona A.; Winham, Stacey J.; Lester, Jenny; Kjaer, Susanne K.; Gronwald, Jacek; Sinn, Peter; Fasching, Peter A.; Chang-Claude, Jenny; Moysich, Kirsten B.; Bowtell, David D.; Hernandez, Brenda Y.; Luk, Hugh; Behrens, Sabine; Shah, Mitul; Jung, Audrey; Ghatage, Prafull; Alsop, Jennifer; Alsop, Kathryn; Garcia-Donas, Jesus; Thompson, Pamela J.; Swerdlow, Anthony J.; Karpinskyj, Chloe; Cazorla-Jimenez, Alicia; Garcia, Maria J.; Deen, Susha; Wilkens, Lynne R.; Palacios, Jose; Berchuck, Andrew; Koziak, Jennifer M.; Brenton, James D.; Cook, Linda S.; Goode, Ellen L.; Huntsman, David G.; Ramus, Susan J.; Koebel, Martin		AOCS Group	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						ovary; immunocytochemistry; RT-QPCR	GRADE SEROUS CARCINOMA; BRCA2 MUTATION CARRIERS; CANCER RISK; GROWTH-FACTOR; GENE-PRODUCT; SURVIVAL; P16(INK4A); THERAPY; PATHWAY; PROTEIN	We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.	[Rambau, Peter F.; Hatfield, Emma; Mina, Fady; Koebel, Martin] Univ Calgary, Dept Pathol & Lab Med, Foothills Med Ctr, Calgary, AB, Canada; [Rambau, Peter F.] Cathol Univ Hlth & Allied Sci Bugando, Pathol Dept, Mwanza, Tanzania; [Vierkant, Robert A.; Larson, Melissa C.; Armasu, Sebastian M.; Winham, Stacey J.] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA; [Intermaggio, Maria P.; Ramus, Susan J.] Univ NSW Sydney, Sch Womens & Childrens Hlth, Fac Med, Sydney, NSW, Australia; [Kelemen, Linda E.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA; [Goodman, Marc T.; Thompson, Pamela J.] Cedars Sinai Med Ctr, Canc Prevent & Genet Program, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Herpel, Esther] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany; [Pharoah, Paul D.; Shah, Mitul; Alsop, Jennifer] Univ Cambridge, Dept Oncol, Ctr Canc Genet Epidemiol, Cambridge, England; [Pharoah, Paul D.; Wang, Qin] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England; [Kommoss, Stefan; Hartkopf, Andreas D.; Taran, Florin Andrei; Pasternak, Jana] Tubingen Univ Hosp, Dept Womens Hlth, Tubingen, Germany; [Jimenez-Linan, Mercedes] Addenbrookes Hosp, Dept Histopathol, Cambridge, England; [Karlan, Beth Y.; Lester, Jenny] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA; [Gentry-Maharaj, Aleksandra; Menon, Usha; Widschwendter, Martin; Karpinskyj, Chloe] UCL, Inst Womens Hlth, Gynaecol Canc Res Ctr, Womens Canc, London, England; [Polo, Susanna Hernando] Hosp Univ Fdn Alcorcon, Med Oncol Serv, Alcorcon, Spain; [Candido dos Reis, Francisco J.; de Andrade, Jurandyr M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ribeirao Preto, Brazil; [Doherty, Jennifer Anne] Univ Utah, Huntsman Canc Inst, Dept Populat Hlth Sci, Salt Lake City, UT USA; [Gayther, Simon A.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA; [Gayther, Simon A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Ctr Canc Prevent & Translat Genom, Los Angeles, CA 90048 USA; [Gayther, Simon A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Sharma, Raghwa] Univ Sydney, Westmead Hosp, Pathol West ICPMR Westmead, Sydney, NSW, Australia; [Sharma, Raghwa] Univ Western Sydney, Westmead Hosp, Westmead, NSW, Australia; [Harnett, Paul R.; Kennedy, Catherine J.; de Fazio, Anna] Univ Sydney, Westmead Inst Med Res, Ctr Canc Res, Sydney, NSW, Australia; [Harnett, Paul R.] Westmead Hosp, Sydney West Canc Network, Crown Princess Mary Canc Ctr Westmead, Sydney, NSW, Australia; [Nelson, Gregg S.; Ghatage, Prafull] Univ Calgary, Cumming Sch Med, Div Gynecol Oncol, Dept Oncol, Calgary, AB, Canada; [Steed, Helen] Royal Alexandra Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Edmonton, AB, Canada; [Schildkraut, Joellen M.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA; [Carney, Micheal E.] Univ Hawaii, Dept Obstet & Gynecol, John A Burns Sch Med, Honolulu, HI 96822 USA; [Hogdall, Estrid; Jensen, Allan; Kjaer, Susanne K.] Danish Canc Soc Res Ctr, Dept Virus Lifestyle & Genes, Copenhagen, Denmark; [Hogdall, Estrid] Univ Copenhagen, Herlev Hosp, Dept Pathol, Mol Unit, Copenhagen, Denmark; [Whittemore, Alice S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy Epidemiol, Stanford, CA USA; [Whittemore, Alice S.] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA USA; [Kennedy, Catherine J.; de Fazio, Anna] Westmead Hosp, Dept Gynaecol Oncol, Sydney, NSW, Australia; [Wang, Frances] Duke Canc Inst, Canc Control & Populat Sci, Durham, NC USA; [Wang, Frances] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA; [Wang, Chen] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Daley, Frances] Inst Canc Res, Div Breast Canc Res, London, England; [Daley, Frances] Brunel Univ, Div Biosci, London, England; [Coulson, Penny; Jones, Micheal E.; Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, London, England; [Anglesio, Micheal S.; Huntsman, David G.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Chow, Christine] Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada; [Chow, Christine] Univ British Columbia, Vancouver, BC, Canada; [Garcia-Closas, Montserrat] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Brucker, Sara Y.] Univ Tubingen, Dept Gynecol & Obstet, Tubingen, Germany; [Cybulski, Cezary; Huzarski, Tomasz; Lubinski, Jan; Gronwald, Jacek] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland; [Harris, Holly R.; Rossing, Mary Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1124 Columbia St, Seattle, WA 98104 USA; [Harris, Holly R.] Karolinska Inst, Div Nutr Epidemiol, Dept Environm Med, Stockholm, Sweden; [Oszurek, Oleg] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Szczecin, Poland; [Benitez, Javier; Garcia, Maria J.] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Programme, Madrid, Spain; [Benitez, Javier; Garcia, Maria J.] Biomed Network Rare Dis CIBERER, Madrid, Spain; [Staebler, Annette] Univ Tubingen Hosp, Inst Pathol, Tubingen, Germany; [Talhouk, Aline; Huntsman, David G.] Vancouver Gen Hosp, BC Canc Agcy, British Columbias Ovarian Canc Res OVCARE Program, Vancouver, BC, Canada; [Talhouk, Aline; Huntsman, David G.] Univ British Columbia, Vancouver, BC, Canada; [Rossing, Mary Anne] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Hendley, Joy; Fereday, Sian; Bowtell, David D.; Alsop, Kathryn] Peter MacCallum Canc Ctr, Dept Res Canc Genom & Genet, Melbourne, Vic, Australia; Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [AOCS Group] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia; [Edwards, Robert P.] Magee Womens Res Inst, Womens Canc Res Program, Ovarian Canc Ctr Excellence, Pittsburgh, PA USA; [Edwards, Robert P.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Edwards, Robert P.; Modugno, Francesmary] Univ Pittsburgh, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Modugno, Francesmary] Magee Womens Res Inst, Womens Canc Res Ctr, Pittsburgh, PA USA; [Modugno, Francesmary] Hillman Canc Ctr, Pittsburgh, PA USA; [Ness, Roberta B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Sieh, Weiva] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Dept Genet & Genom Sci, New York, NY 10029 USA; [El-Bahrawy, Mona A.] Imperial Coll London, Hammersmith Hosp, Dept Histopathol, London, England; [Kjaer, Susanne K.] Univ Copenhagen, Dept Gynaecol, Rigshosp, Copenhagen, Denmark; [Sinn, Peter] Univ Hosp Heidelberg, Inst Pathol, Dept Pathol, Heidelberg, Germany; [Fasching, Peter A.] Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, David Geffen Sch Med, Los Angeles, CA 90024 USA; [Fasching, Peter A.] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr ER EMN, Dept Gynecol & Obstet, Erlangen, Germany; [Chang-Claude, Jenny; Behrens, Sabine; Jung, Audrey] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany; [Chang-Claude, Jenny] Univ Med Ctr Hamburg Eppendorf, UCCH, Canc Epidemiol Grp, Hamburg, Germany; [Moysich, Kirsten B.] Roswell Pk Canc Inst, Div Canc Prevent & Control, Buffalo, NY 14263 USA; [Bowtell, David D.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Hernandez, Brenda Y.; Luk, Hugh; Wilkens, Lynne R.] Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA; [Garcia-Donas, Jesus] HM Hosp, Ctr Integral Oncol HM Clara Campal, Med Oncol Serv, Madrid, Spain; [Swerdlow, Anthony J.] Inst Canc Res, Div Genet & Epidemiol, London, England; [Swerdlow, Anthony J.] Inst Canc Res, Div Breast Canc Res, London, England; [Cazorla-Jimenez, Alicia] Fdn Jimenez Diaz Quiron Salud, Pathol Dept, Madrid, Spain; [Deen, Susha] Nottingham Univ Hosp NHS Trust, Dept Histopathol, Queens Med Ctr, Nottingham, England; [Palacios, Jose] Univ Alcala De Henares, Hosp Univ Ramon y Cajal, Pathol Dept, IRYCIS,CIBERONC, Madrid, Spain; [Berchuck, Andrew] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; [Koziak, Jennifer M.] Alberta Hlth Serv Canc Care, Calgary, AB, Canada; [Brenton, James D.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Cook, Linda S.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Cook, Linda S.] Alberta Hlth Serv, Dept Canc Epidemiol & Prevent Res, Calgary, AB, Canada; [Goode, Ellen L.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA; [Huntsman, David G.] BC Canc Agcy Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada; [Ramus, Susan J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW, Australia	Kobel, M (reprint author), Univ Calgary & Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB 2TN 2T9, Canada.; Kobel, M (reprint author), Univ Calgary, Dept Pathol & Lab Med, 1304 S29 St NW, Calgary, AB 2TN 2T9, Canada.; Kobel, M (reprint author), Calgary Lab Serv, 1304 S29 St NW, Calgary, AB 2TN 2T9, Canada.	martin.koebel@cls.ab.ca	Harnett, Paul R/D-4090-2014; Andrade, Jurandyr M/B-2025-2013; Sinn, Hans-Peter/C-5661-2008; Reis, Francisco Jose Candido dos/K-7024-2016; Brenton, James D/B-3174-2008; Menon, Usha/C-4716-2008; Wang, Chen/B-3244-2011; Garcia, Maria/G-1361-2016; Pharoah, Paul/V-6658-2019; DeFazio, Anna/O-2385-2019; benitez, javier/H-5232-2015; Bowtell, David/H-1007-2016	Harnett, Paul R/0000-0001-7021-0642; Andrade, Jurandyr M/0000-0003-3619-0582; Sinn, Hans-Peter/0000-0003-2836-6699; Reis, Francisco Jose Candido dos/0000-0001-5758-5917; Brenton, James D/0000-0002-5738-6683; Menon, Usha/0000-0003-3708-1732; Wang, Chen/0000-0003-2638-3081; Garcia, Maria/0000-0002-2236-9912; Pharoah, Paul/0000-0001-8494-732X; DeFazio, Anna/0000-0003-0057-4744; Hogdall, Estrid/0000-0003-4689-5658; Jung, Audrey/0000-0003-0875-6673; benitez, javier/0000-0002-0923-7202; Bowtell, David/0000-0001-9089-7525; Jensen, Allan/0000-0001-8124-4880; Swerdlow, Anthony/0000-0001-5550-4159	Agar family, Ovarian Cancer Action (UK); Ovarian Cancer Australia; Peter MacCallum Foundation; Institute of Cancer Research; Ovarian Cancer ActionOvarian Cancer Action; NHS; Royal Marsden/ICR NIHR Biomedical Research Centre; National Center for Tumor Diseases (NCT, Heidelberg, Germany); Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group; NCI/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA168758]; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0729]; Cancer Council Victoria, Queensland Cancer FundCancer Council VictoriaCanadian Institutes of Health Research (CIHR); Cancer Council New South WalesCancer Council New South Wales; Cancer Council South AustraliaCancer Council South Australia; Cancer Foundation of Western AustraliaCancer Council Western Australia; Cancer Council TasmaniaCancer Council Tasmania; NHMRCNational Health and Medical Research Council of Australia [ID400413, ID400281]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [310670, 628903]; United States Department of Defence (DoD) Ovarian Cancer Transitional Leverage Award [W81XWH-12-1-0104]; Ministerio de Economia y CompetitividadSpanish Ministry of Economy & Competitiveness [SAF2012]; Huntsman Cancer Foundation; National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA042014]; German Cancer Research Center (DKFZ)Helmholtz Association; Department of DefenseUnited States Department of Defense [DAMD17-02-1-0669]; NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07-CA080668, R01-CA95023, P50-CA159981, MO1-RR000056, R01-CA126841]; National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124]; Danish Cancer SocietyDanish Cancer Society [R01-CA122443, P30-CA15083, P50-CA136393]; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Cancer Research UKCancer Research UK [C490/A16561]; UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Cambridge Cancer Centre; NHS in the East of England through the Clinical Academic Reserve; Pomeranian Medical University; TVA; Canadian Institutes of Health Research grantCanadian Institutes of Health Research (CIHR) [MOP-86727]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1 R01CA160669-01A1]; Oak Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Janet D. Cottrelle Foundation Scholars fund; BC Cancer Foundation; UBC Hospital Foundation; Cancer Institute NSW [15/RIG/1-16]; Breast Cancer Now; Thomas E. Feasby PhD student fund; Cancer Council VictoriaCancer Council VictoriaCanadian Institutes of Health Research (CIHR); Queensland Cancer FundCancer Council Queensland; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [APP1092856]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-86727]; ELAN Funds of the University of Erlangen-Nuremberg; Cancer Research Society [19319]; CLS Internal Research [RS11-508]; Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI 12/01319]; German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research [01GB9401]; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA58598, N01-CN-55424, N01-PC-67001]; American Cancer Society Early Detection ProfessorshipAmerican Cancer Society [SIOP-06-258-01-COUN]; Danish Cancer Society, Copenhagen, DenmarkDanish Cancer Society [9422252]; Mermaid I project; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA122443, P30-CA15083, P50-CA136393]	We would like to thank all of the women who participated in these research programs. We thank Marjorie J. Riggan (OCAC) for coordination. Acknowledgements for individual studies: The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. AOV: We thank Mie Konno, Michelle Darago, Faye Chambers. BGS: We thank Breast Cancer Now and the Institute of Cancer Research for support and funding of the Generations Study, Ovarian Cancer Action for funding of work on ovarian cancer within the Study, and the study participants, study staff, and the doctors, nurses and other health care providers and health information sources who have contributed to the study and Professor Robert Brown for advice and help. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. CAL: We thank Taryn Burghardt for study coordination and Thomas Kryton (BFA, digital imaging specialist for Calgary Laboratory Services) for creating figures. GER: tissue samples were provided by the tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the ethics committee of the University of Heidelberg. SEA: SEARCH team, Craig Luccarini, Caroline Baynes, Don Conroy. UKO: We particularly thank I. Jacobs, E. Wozniak, A. Ryan, J. Ford and N. Balogun. WMH: We thank the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group. Peter F. Rambau was supported by a Thomas E. Feasby PhD student fund. NCI/NIH R01CA172404 to Susan J Ramus. Funding for individual studies: AOC: The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the NHMRC (ID400413 and ID400281). Professor David Bowtell is supported by the National Health and Medical Research Council of Australia (NHMRC; APP1092856) and the United States Department of Defence (DoD) Ovarian Cancer Transitional Leverage Award (W81XWH-12-1-0104); AOV: Canadian Institutes of Health Research (MOP-86727).; BAV: ELAN Funds of the University of Erlangen-Nuremberg; CAL: Cancer Research Society (19319) and CLS Internal Research support RS11-508; CNI: Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economia y Competitividad (SAF2012); DOV: NCI/NIH R01CA168758, and NCI/NIH R01CA168758. Huntsman Cancer Foundation and the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014.; The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH; GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01GB9401) and the German Cancer Research Center (DKFZ); HAW: US National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: Department of Defense (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, P50-CA159981, MO1-RR000056, R01-CA126841); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; MAL: NCI R01-CA61107, research grant 9422252 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; SEA: Cancer Research UK C490/A16561, the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Cambridge Cancer Centre. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. POC: Pomeranian Medical University; TVA: This work was supported by Canadian Institutes of Health Research grant (MOP-86727) and by NIH/NCI 1 R01CA160669-01A1; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre; VAN: The Janet D. Cottrelle Foundation Scholars fund provides support to M.S. Anglesio. OVCARE receives core funding from The BC Cancer Foundation and the VGH and UBC Hospital Foundation. WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 and ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 and 15/RIG/1-16.	Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216; Anglesio MS, 2011, GYNECOL ONCOL, V121, P407, DOI 10.1016/j.ygyno.2011.01.005; Au-Yeung G, 2017, CLIN CANCER RES, V23, P1862, DOI 10.1158/1078-0432.CCR-16-0620; Ayhan A, 2017, MODERN PATHOL, V30, P297, DOI 10.1038/modpathol.2016.160; Balogun N, 2011, J CLIN EPIDEMIOL, V64, P525, DOI 10.1016/j.jclinepi.2010.07.008; Baxter SW, 2002, CANCER EPIDEM BIOMAR, V11, P211; Beirne JP, 2016, HISTOPATHOLOGY, V68, P615, DOI 10.1111/his.12777; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bromley AB, 2012, INT J GYNECOL PATHOL, V31, P397, DOI 10.1097/PGP.0b013e31824c2372; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakravarti A, 2007, J CLIN ONCOL, V25, P3082, DOI 10.1200/JCO.2006.08.4152; Christine M, 2012, EVOLUTION TRANSLATIO, P65; Clinton LK, 2015, AM J CLIN PATHOL, V144, P844, DOI 10.1309/AJCPUXLP7XD8OQYY; Cook LS, 2016, GYNECOL ONCOL, V140, P277, DOI 10.1016/j.ygyno.2015.12.005; Dickson MA, 2014, CLIN CANCER RES, V20, P3379, DOI 10.1158/1078-0432.CCR-13-1551; Dong Y, 1997, INT J CANCER, V74, P57, DOI 10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F; Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655; Emmanuel C, 2014, CLIN CANCER RES, V20, P6618, DOI 10.1158/1078-0432.CCR-14-1292; Ferguson DC, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0163-1; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Closas M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-60; Garsed DW, 2018, CLIN CANCER RES, V24, P569, DOI 10.1158/1078-0432.CCR-17-1621; Glud E, 2004, ARCH INTERN MED, V164, P2253, DOI 10.1001/archinte.164.20.2253; Goode EL, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.3290; Goode EL, 2011, CANCER EPIDEM BIOMAR, V20, P1638, DOI 10.1158/1055-9965.EPI-11-0455; Goodman MT, 2008, ENDOCR-RELAT CANCER, V15, P1055, DOI 10.1677/ERC-08-0104; Hein A, 2013, EUR J CANCER PREV, V22, P52, DOI 10.1097/CEJ.0b013e328355ec22; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hunter SM, 2015, ONCOTARGET, V6, P37663, DOI 10.18632/oncotarget.5438; IMAI Y, 1991, J VIROL, V65, P4966; Kamieniak MM, 2015, MOL ONCOL, V9, P422, DOI 10.1016/j.molonc.2014.09.010; Kelemen LE, 2016, GYNECOL ONCOL, V140, P124, DOI 10.1016/j.ygyno.2015.11.008; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kabel M, 2014, BRIT J CANCER, V111, P2297, DOI 10.1038/bjc.2014.567; Kobel M, 2010, J PATHOL, V222, P191, DOI 10.1002/path.2744; Kobel M, 2010, INT J GYNECOL PATHOL, V29, P203, DOI 10.1097/PGP.0b013e3181c042b6; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kommoss S, 2007, BRIT J CANCER, V96, P306, DOI 10.1038/sj.bjc.6603531; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Kudoh K, 2002, INT J CANCER, V99, P579, DOI 10.1002/ijc.10331; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Lo-Ciganic WH, 2012, EPIDEMIOLOGY, V23, P311, DOI 10.1097/EDE.0b013e3182456ad3; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lurie G, 2008, CANCER EPIDEM BIOMAR, V17, P2070, DOI 10.1158/1055-9965.EPI-08-0145; McGuire V, 2004, AM J EPIDEMIOL, V160, P613, DOI 10.1093/aje/kwh284; McIntyre JB, 2017, HISTOPATHOLOGY, V70, P347, DOI 10.1111/his.13071; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Merritt MA, 2008, INT J CANCER, V122, P170, DOI 10.1002/ijc.23017; Milea A, 2014, MODERN PATHOL, V27, P991, DOI 10.1038/modpathol.2013.218; Peterlongo P, 2015, CANCER EPIDEM BIOMAR, V24, P308, DOI 10.1158/1055-9965.EPI-14-0532; Prentice LM, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-33; QUELLE DE, 1995, CELL, V83, P993; Rambau P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030515; Ramus SJ, 2012, HUM MUTAT, V33, P690, DOI 10.1002/humu.22025; Ryland GL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0210-y; Sieh W, 2013, LANCET ONCOL, V14, P853, DOI 10.1016/S1470-2045(13)70253-5; Soegaard M, 2007, CANCER EPIDEM BIOMAR, V16, P1160, DOI 10.1158/1055-9965.EPI-07-0089; Song HL, 2006, CARCINOGENESIS, V27, P2235, DOI 10.1093/carcin/bgl089; Swenerton KD, 2011, ANN ONCOL, V22, P341, DOI 10.1093/annonc/mdq383; Talhouk A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153844; Williams E, 2012, VIRCHOWS ARCH, V461, P33, DOI 10.1007/s00428-012-1252-9; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776	63	3	3	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					250	261		10.1002/cjp2.109			12	Pathology	Pathology	GW0OS	WOS:000446567600005	30062862	DOAJ Gold, Green Published, Green Accepted			2019-10-28	
J	Bejnordi, BE; Mullooly, M; Pfeiffer, RM; Fan, S; Vacek, PM; Weaver, DL; Herschorn, S; Brinton, LA; van Ginneken, B; Karssemeijer, N; Beck, AH; Gierach, GL; van der Laak, JAWM; Sherman, ME				Bejnordi, Babak Ehteshami; Mullooly, Maeve; Pfeiffer, Ruth M.; Fan, Shaoqi; Vacek, Pamela M.; Weaver, Donald L.; Herschorn, Sally; Brinton, Louise A.; van Ginneken, Bram; Karssemeijer, Nico; Beck, Andrew H.; Gierach, Gretchen L.; van der Laak, Jeroen A. W. M.; Sherman, Mark E.			Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies	MODERN PATHOLOGY			English	Article							CARCINOMA IN-SITU; MICROENVIRONMENTAL REGULATION; CANCER; FIBROBLASTS; PROGRESSION; RECURRENCE; FEATURES; AREAS; GRADE; DCIS	The breast stromal microenvironment is a pivotal factor in breast cancer development, growth and metastases. Although pathologists often detect morphologic changes in stroma by light microscopy, visual classification of such changes is subjective and non-quantitative, limiting its diagnostic utility. To gain insights into stromal changes associated with breast cancer, we applied automated machine learning techniques to digital images of 2387 hematoxylin and eosin stained tissue sections of benign and malignant image-guided breast biopsies performed to investigate mammographic abnormalities among 882 patients, ages 40-65 years, that were enrolled in the Breast Radiology Evaluation and Study of Tissues (BREAST) Stamp Project. Using deep convolutional neural networks, we trained an algorithm to discriminate between stroma surrounding invasive cancer and stroma from benign biopsies. In test sets (928 whole-slide images from 330 patients), this algorithm could distinguish biopsies diagnosed as invasive cancer from benign biopsies solely based on the stromal characteristics (area under the receiver operator characteristics curve = 0.962). Furthermore, without being trained specifically using ductal carcinoma in situ as an outcome, the algorithm detected tumor-associated stroma in greater amounts and at larger distances from grade 3 versus grade 1 ductal carcinoma in situ. Collectively, these results suggest that algorithms based on deep convolutional neural networks that evaluate only stroma may prove useful to classify breast biopsies and aid in understanding and evaluating the biology of breast lesions.	[Bejnordi, Babak Ehteshami; van Ginneken, Bram; Karssemeijer, Nico; van der Laak, Jeroen A. W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Nijmegen, Netherlands; [Bejnordi, Babak Ehteshami; Beck, Andrew H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Mullooly, Maeve; Pfeiffer, Ruth M.; Fan, Shaoqi; Brinton, Louise A.; Gierach, Gretchen L.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Mullooly, Maeve] NCI, Canc Prevent Fellowship Program, Div Canc Prevent, Bethesda, MD 20892 USA; [Vacek, Pamela M.] Univ Vermont, Dept Med Biostat, Burlington, VT USA; [Weaver, Donald L.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; [Herschorn, Sally] Univ Vermont, Canc Ctr, Burlington, VT USA; [Herschorn, Sally] Univ Vermont, Dept Radiol, Burlington, VT USA; [Beck, Andrew H.] PathAI Inc, Cambridge, MA USA; [van der Laak, Jeroen A. W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [Sherman, Mark E.] Mayo Clin, Jacksonville, FL 32224 USA	van der Laak, JAWM (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Nijmegen, Netherlands.; van der Laak, JAWM (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands.	Jeroen.vanderLaak@radboudumc.nl	van der Laak, Jeroen AWM/D-3057-2015; van Ginneken, Bram/A-3728-2012; Bejnordi, Babak Ehteshami/P-9534-2015	van der Laak, Jeroen AWM/0000-0001-7982-0754; Bejnordi, Babak Ehteshami/0000-0002-6258-5687	Intramural Research Program of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; European Union FP7 funded VPHPRISM project [n601040]; U01 exploring stromal contributions to tumor progression [U01 CA196383]	This project was funded in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland and a competitive award to MES and LAB funded through the sale of breast cancer awareness postage stamps. The authors wish to acknowledge the financial support by the European Union FP7 funded VPHPRISM project under the grant agreement n601040. Pamela Vacek and Donald Weaver are currently funded under a U01 exploring stromal contributions to tumor progression (U01 CA196383).	Bagnall MJC, 2001, CLIN RADIOL, V56, P828, DOI 10.1053/crad.2001.0779; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564; Bejnordi BE, 2017, J MED IMAGING, V4, DOI 10.1117/1.JMI.4.4.044504; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Bejnordi BE, 2017, 2017 IEEE 14TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2017), P929, DOI 10.1109/ISBI.2017.7950668; Bejnordi BE, 2016, IEEE T MED IMAGING, V35, P2141, DOI 10.1109/TMI.2016.2550620; Benson JR, 2016, LANCET ONCOL, V17, pE442, DOI 10.1016/S1470-2045(16)30367-9; Bombonati A, 2011, J PATHOL, V223, P307, DOI 10.1002/path.2808; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Dong F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114885; Dundar MM, 2011, IEEE T BIO-MED ENG, V58, P1977, DOI 10.1109/TBME.2011.2110648; DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Ehteshami Bejnordi B, 2015, P SPIE MED IMAGING 2; Elshof LE, 2015, EUR J CANCER, V51, P1497, DOI 10.1016/j.ejca.2015.05.008; Felix AS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0746-9; Francis A, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-OT2-3-01; Gierach GL, 2016, CANCER PREV RES, V9, P149, DOI 10.1158/1940-6207.CAPR-15-0282; Gierach GL, 2014, CANCER EPIDEM BIOMAR, V23, P2338, DOI 10.1158/1055-9965.EPI-14-0257; Glasziou P, 2005, STAT MED, V24, P2582; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Naik S, 2008, I S BIOMED IMAGING, P284, DOI 10.1109/ISBI.2008.4540988; Okabe A., 1992, SPATIAL TESSELATIONS, P532; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pinder SE, 2010, MODERN PATHOL, V23, pS8, DOI 10.1038/modpathol.2010.40; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Silver SA, 1998, CANCER, V82, P2382, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2382::AID-CNCR12>3.0.CO;2-L; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; Simonyan K, 2014, VERY DEEP CONVOLUTIO; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Trivedi MA, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-1; Wallis MG, 2012, BRIT J CANCER, V106, P1611, DOI 10.1038/bjc.2012.151; Youngwirth Linda M, 2017, Bull Am Coll Surg, V102, P62	45	7	7	4	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1502	1512		10.1038/s41379-018-0073-z			11	Pathology	Pathology	GV3XJ	WOS:000446031300002	29899550				2019-10-28	
J	Noe, M; Pea, A; Luchini, C; Felsenstein, M; Barbi, S; Bhaijee, F; Yonescu, R; Ning, Y; Adsay, NV; Zamboni, G; Lawlor, RT; Scarpa, A; Offerhaus, GJA; Brosens, LAA; Hruban, RH; Roberts, NJ; Wood, LD				Noe, Michael; Pea, Antonio; Luchini, Claudio; Felsenstein, Matthaus; Barbi, Stefano; Bhaijee, Feriyl; Yonescu, Raluca; Ning, Yi; Adsay, N. Volkan; Zamboni, Giuseppe; Lawlor, Rita T.; Scarpa, Aldo; Offerhaus, G. Johan A.; Brosens, Lodewijk A. A.; Hruban, Ralph H.; Roberts, Nicholas J.; Wood, Laura D.			Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1	MODERN PATHOLOGY			English	Article							NERVE SHEATH TUMORS; GASTROINTESTINAL STROMAL TUMORS; SOMATIC MUTATION; NF1 INACTIVATION; MULTIPLE; DISEASE; GENE; PHEOCHROMOCYTOMA; PANCREATITIS; LANDSCAPE	Neurofibromatosis type 1 (NF1) is a hereditary cancer predisposition syndrome characterized by frequent cutaneous and nervous system abnormalities. Patients with NF1 also have an increased prevalence of multiple gastrointestinal and peripancreatic neoplasms-neuroendocrine tumors of the ampulla that express somatostatin are particularly characteristic of NF1. In this study, we characterize the genetic alterations of a clinically well-characterized cohort of six NFl-associated duodenal neuroendocrine tumors using whole-exome sequencing. We identified inactivating somatic mutations in the NF1 gene in three of six tumors; the only other gene altered in more than one tumor was IFNBJ. Copy number analysis revealed deletion/loss of heterozygosity of chromosome 22 in three of six patients. Analysis of germline variants revealed germline deleterious NF1 variants in four of six patients, as well as deleterious variants in other tumor suppressor genes in two of four patients with deleterious NF1 variants. Taken together, these data confirm the importance of somatic inactivation of the wildtype NF1 allele in the formation of NF1-associated duodenal neuroendocrine tumors and suggest that loss of chromosome 22 is important in at least a subset of cases. However, we did not identify any genes altered in the majority of NF1-associated duodenal neuroendocrine tumors that uniquely characterize the genomic landscape of this tumor. Still, the genetic alterations in these tumors are distinct from sporadic neuroendocrine tumors occurring at these sites, highlighting that unique genetic alterations drive syndromic tumors.	[Noe, Michael; Luchini, Claudio; Felsenstein, Matthaus; Bhaijee, Feriyl; Yonescu, Raluca; Ning, Yi; Brosens, Lodewijk A. A.; Hruban, Ralph H.; Roberts, Nicholas J.; Wood, Laura D.] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Noe, Michael; Offerhaus, G. Johan A.; Brosens, Lodewijk A. A.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Pea, Antonio] Johns Hopkins Univ, Sch Med, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Pea, Antonio] Univ & Hosp Trust Verona, Dept Surg, Verona, Italy; [Luchini, Claudio; Barbi, Stefano; Zamboni, Giuseppe; Scarpa, Aldo] Univ Verona, Dept Diagnost & Publ Hlth, Sect Pathol, Verona, Italy; [Adsay, N. Volkan] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Zamboni, Giuseppe] Sacro Cuore Don Calabria Hosp, I-37024 Verona, Italy; [Lawlor, Rita T.; Scarpa, Aldo] Univ Verona, ARC Net Res Ctr, Verona, Italy; [Brosens, Lodewijk A. A.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands; [Hruban, Ralph H.; Roberts, Nicholas J.; Wood, Laura D.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA	Wood, LD (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA.; Wood, LD (reprint author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA.	ldwood@jhmi.edu	Luchini, Claudio/O-2187-2019; Giuseppe, Zamboni/L-6029-2019; Luchini, Claudio/Q-4922-2016; Adsay, Volkan/N-7130-2017	Luchini, Claudio/0000-0003-4901-4908; Giuseppe, Zamboni/0000-0001-7428-4673; Luchini, Claudio/0000-0003-4901-4908; Adsay, Volkan/0000-0002-1308-3701; Roberts, Nicholas/0000-0002-8709-0664; Noe, Michael/0000-0002-5336-4508	NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA62924, R00 CA190889]; NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK107781]; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; Gerald O Mann Charitable Foundation; Lisa Waller Hayes Foundation; Nijbakker Morra Foundation; Dutch Digestive Foundation [CDG 14-02]; German Research Foundation (DFG)German Research Foundation (DFG); Associazione Italiana Ricerca CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [12182]; FP7 European Community Grant Cam-Pac [602783]; Italian Ministry of UniversityMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [FIRB RBAP10AHJB]	We acknowledge the following sources of support: NIH/NCI P50 CA62924; NIH/NIDDK K08 DK107781; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; The Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees); Lisa Waller Hayes Foundation; Nijbakker Morra Foundation; Dutch Digestive Foundation (CDG 14-02); German Research Foundation (DFG); Associazione Italiana Ricerca Cancro (grant number: 12182); FP7 European Community Grant Cam-Pac (no: 602783); Italian Ministry of University (FIRB RBAP10AHJB); NIH/NCI R00 CA190889.	Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Burnichon N, 2012, HUM MOL GENET, V21, P5397, DOI 10.1093/hmg/dds374; Cao YN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3810; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Garbrecht N, 2008, ENDOCR-RELAT CANCER, V15, P229, DOI 10.1677/ERC-07-0157; Gutmann DH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.4; Gutmann DH, 2013, GENOME RES, V23, P431, DOI 10.1101/gr.142604.112; Hosoda W, 2017, J PATHOL, V242, P16, DOI 10.1002/path.4884; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Jett K, 2010, GENET MED, V12, P1, DOI 10.1097/GIM.0b013e3181bf15e3; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Klimstra D. S., 2010, WHO CLASSIFICATION T; Kloppel G, 2017, AJSP-REV REP, V22, P233, DOI 10.1097/PCR.0000000000000211; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; LaRusch J, 2012, J PANCREAS, V13, P258; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lie JT, 1998, CARDIOVASC PATHOL, V7, P97, DOI 10.1016/S1054-8807(97)00081-1; Maertens O, 2006, HUM MOL GENET, V15, P1015, DOI 10.1093/hmg/ddl016; Pemov A, 2017, ONCOGENE, V36, P3168, DOI 10.1038/onc.2016.464; Pfutzer RH, 2000, GASTROENTEROLOGY, V119, P615, DOI 10.1053/gast.2000.18017; Relles D, 2010, J GASTROINTEST SURG, V14, P1052, DOI 10.1007/s11605-009-1123-0; Roberts NJ, 2016, CANCER DISCOV, V6, P166, DOI 10.1158/2159-8290.CD-15-0402; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sohier P, 2017, GENE CHROMOSOME CANC, V56, P421, DOI 10.1002/gcc.22446; Stenman A, 2015, ENDOCR PATHOL, V26, P9, DOI 10.1007/s12022-014-9348-1; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Usui M, 2002, J GASTROENTEROL, V37, P947, DOI 10.1007/s005350200159; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116	31	4	4	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1532	1538		10.1038/s41379-018-0082-y			7	Pathology	Pathology	GV3XJ	WOS:000446031300005	29849115	Green Accepted			2019-10-28	
J	Hashimoto, T; Tanaka, Y; Ogawa, R; Mori, T; Yoshida, H; Taniguchi, H; Hiraoka, N; Kojima, M; Oono, Y; Saito, Y; Sekine, S				Hashimoto, Taiki; Tanaka, Yusaku; Ogawa, Reiko; Mori, Taisuke; Yoshida, Hiroshi; Taniguchi, Hirokazu; Hiraoka, Nobuyoshi; Kojima, Motohiro; Oono, Yasuhiro; Saito, Yutaka; Sekine, Shigeki			Superficially serrated adenoma: a proposal for a novel subtype of colorectal serrated lesion	MODERN PATHOLOGY			English	Article							HYPERPLASTIC POLYPS; KRAS MUTATIONS; PATHWAY; CANCER; GENE; TUMORIGENESIS; DEFICIENCY; DYSPLASIA; FUSIONS; RNF43	We describe a series of colorectal polyps characterized by mixed adenomatous and serrated features, herein referred to as superficially serrated adenomas. Twenty superficially serrated adenomas were obtained from 11 female and 9 male patients aged 62-87 years. Most lesions endoscopically appeared as small sessile polyps, but larger lesions were plaque-like (2-20 mm; median, 5 mm). Eighteen lesions (90%) were located in the sigmoid colon or rectum. They consisted primarily of straight, adenomatous glands but showed serration confined to the superficial layer. Immunohistochemistry revealed CK20 expression in the upper layer. Proliferating cells, determined by their expression of Ki-67, were localized to the middle to bottom layers. Genetic analyses identified KRAS mutations in 19 lesions and a BRAF mutation in one lesion. Furthermore, RSPO fusions and/or overexpression were observed in 18 lesions and truncating APC mutations were observed in the two remaining lesions. Consistent with the presence of WNT pathway gene alterations, all superficially serrated adenomas showed focal or diffuse nuclear beta-catenin accumulation. Since concurrent KRAS mutations and RSPO fusions are reportedly common in traditional serrated adenomas, we reviewed 129 traditional serrated adenomas and found 15 lesions (12%) that were associated with superficially serrated adenoma components. Remarkably, all but one superficially serrated adenoma-associated traditional serrated adenoma exhibited concurrent KRAS mutations and RSPO fusions/overexpression. The present study suggests that superficially serrated adenoma is a morphologically and molecularly distinct type of colorectal serrated polyp that is histogenetically related to traditional serrated adenoma.	[Hashimoto, Taiki; Mori, Taisuke; Yoshida, Hiroshi; Taniguchi, Hirokazu; Hiraoka, Nobuyoshi; Sekine, Shigeki] Natl Canc Ctr, Div Pathol & Clin Labs, Tokyo, Japan; [Tanaka, Yusaku; Saito, Yutaka] Natl Canc Ctr, Endoscopy Div, Tokyo, Japan; [Ogawa, Reiko; Mori, Taisuke; Hiraoka, Nobuyoshi; Sekine, Shigeki] Natl Canc Ctr, Div Mol Pathol, Res Inst, Tokyo, Japan; [Kojima, Motohiro] Natl Canc Ctr, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba, Japan; [Oono, Yasuhiro] Natl Canc Ctr Hosp East, Endoscopy Div, Kashiwa, Chiba, Japan	Sekine, S (reprint author), Natl Canc Ctr, Div Pathol & Clin Labs, Tokyo, Japan.; Sekine, S (reprint author), Natl Canc Ctr, Div Mol Pathol, Res Inst, Tokyo, Japan.	ssekine@ncc.go.jp	Yoshida, Hiroshi/J-2900-2019	Saito, Yutaka/0000-0003-2296-8373; Hashimoto, Taiki/0000-0003-3148-9243	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K19097]	We thank Ms. Sachiko Miura, Ms. Toshiko Sakaguchi, Ms. Chizu Kina, and Ms. Yuka Nakamura for their skillful technical assistance. This work was supported by JSPS KAKENHI grant number JP16K19097.	Bettington M, 2017, GUT, V66, P97, DOI 10.1136/gutjnl-2015-310456; Bettington M, 2016, HISTOPATHOLOGY, V68, P578, DOI 10.1111/his.12788; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Bettington ML, 2015, MODERN PATHOL, V28, P414, DOI 10.1038/modpathol.2014.122; Chan CWM, 2009, P NATL ACAD SCI USA, V106, P1936, DOI 10.1073/pnas.0812904106; Chetty R, 2015, J CLIN PATHOL, V68, P270, DOI 10.1136/jclinpath-2014-202827; Davenport A, 2003, J CLIN PATHOL, V56, P200, DOI 10.1136/jcp.56.3.200; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Hashimoto T, 2017, AM J SURG PATHOL, V41, P1188, DOI 10.1097/PAS.0000000000000877; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Kim MJ, 2013, AM J CLIN PATHOL, V140, P898, DOI 10.1309/AJCPDJC9VC5KTYUS; Lee EJ, 2005, VIRCHOWS ARCH, V447, P597, DOI 10.1007/s00428-005-1226-2; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sekine S, 2017, HISTOPATHOLOGY, V71, P601, DOI 10.1111/his.13265; Sekine S, 2017, MODERN PATHOL, V30, P1144, DOI 10.1038/modpathol.2017.39; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Sheridan TB, 2006, AM J CLIN PATHOL, V126, P564, DOI 10.1309/C7JE88VL8420V5VT; Snover DC, 2010, WHO CLASSIFICATION T, P160; Torlakovic EE, 2008, AM J SURG PATHOL, V32, P21, DOI 10.1097/PAS.0b013e318157f002; Tsai JH, 2016, AM J SURG PATHOL, V40, P1352, DOI 10.1097/PAS.0000000000000664; Tsai JH, 2014, MODERN PATHOL, V27, P1375, DOI 10.1038/modpathol.2014.35; Wiland HO, 2014, AM J SURG PATHOL, V38, P1290, DOI 10.1097/PAS.0000000000000253; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a	27	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1588	1598		10.1038/s41379-018-0069-8			11	Pathology	Pathology	GV3XJ	WOS:000446031300011	29789649				2019-10-28	
J	Qin, H; Cheng, YQ; Ling, C; Du, MZ; Wang, YH; Xu, GF; Jiong, S; Fan, XS; Zhou, XL; Zhang, YF; Guo, LC; Liu, TY; Dan, Z; Mashimo, H; Gold, JS; Zou, XP				Qin Huang; Cheng, Yuqing; Ling Chen; Du Mingzhan; Wang, Yaohui; Xu, Guifang; Jiong Shi; Fan, Xiangshan; Zhou, Xiaoli; Zhang, Yifeng; Guo, Linchuan; Liu, Tianyun; Dan Zhou; Mashimo, Hiroshi; Gold, Jason S.; Zou, Xiaoping		Jiangsu Prov Early Gastric Carcino	Low risk of lymph node metastasis in 495 early gastric cardiac carcinomas: a multicenter clinicopathologic study of 2101 radical gastrectomies for early gastric carcinoma	MODERN PATHOLOGY			English	Article							ENDOSCOPIC SUBMUCOSAL DISSECTION; ESOPHAGOGASTRIC JUNCTION; CHINESE PATIENTS; PREDICTIVE FACTORS; CANCER; ADENOCARCINOMA; ESOPHAGUS; EXPERIENCE; FEATURES; STOMACH	Clinical decision-making on endoscopic vs. surgical resection of early gastric cardiac carcinoma remains challenging because of uncertainty on risk of lymph node metastasis. The aim of this multicenter study was to investigate risk factors of lymph node metastasis in early gastric cardiac carcinoma. Guided with the World Health Organization diagnostic criteria, we studied 2101 radical resections of early gastric carcinoma for risk factors associated with lymph node metastasis, including tumor location, gross pattern, size, histology type, differentiation, invasion depth, lymphovascular, and perineural invasion. We found that the risk of lymph node metastasis was significantly lower in early gastric cardiac carcinomas (6.7%, 33/495), compared with early gastric non-cardiac carcinomas (17.1%, 275/1606) (p < 0.0001). In early gastric cardiac carcinoma, no lymph node metastasis was identified in intramucosal carcinoma (0/193) and uncommon types of carcinomas (0/24), irrespective of the gross pattern, size, histologic type, differentiation, and invasion depth. Ulceration, size > 3 cm, and submucosal invasion were not significant independent risk factors for lymph node metastasis. In 33 early gastric cardiac carcinomas with lymph node metastasis, either lymphovascular invasion or poor differentiation was present in 16 (48.5%) cases and together in six cases. By multivariate analysis, independent risk factors of lymph node metastasis in early gastric cardiac carcinoma included lymphovascular invasion (Odds Ratio (OR): 7.6, 95% Confidence Interval (CI): 2.8-20.2) (p < 0.0001) and poor differentiation (OR: 6.0, 95% CI: 1.4-25.9) (p < 0.05). In conclusion, lymph node metastasis was not identified in early gastric cardiac intramucosal carcinoma and uncommon types of carcinoma. The risk of lymph node metastasis was also significantly lower in tumors with submucosal invasion, especially for cases without lymphovascular invasion or poor differentiation. These results lend support to the role of endoscopic therapy in the treatment of patients with early gastric cardiac carcinoma.	[Qin Huang; Cheng, Yuqing; Zhou, Xiaoli] Changzhou Second Hosp, Dept Pathol, Changzhou, Peoples R China; [Qin Huang; Ling Chen; Jiong Shi; Fan, Xiangshan; Liu, Tianyun] Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Qin Huang] Boston VA Healthcare Syst, Pathol & Lab Med, West Roxbury, MA 02132 USA; [Qin Huang; Mashimo, Hiroshi; Gold, Jason S.] Harvard Med Sch, West Roxbury, MA 02132 USA; [Du Mingzhan; Guo, Linchuan] Soochow Univ First Hosp, Dept Pathol, Suzhou, Peoples R China; [Wang, Yaohui; Zhang, Yifeng] Jiangsu Prov Hosp Tradit Chinese Med, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Xu, Guifang; Zou, Xiaoping] Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China; [Dan Zhou] Qual Healthcare Consultant, Lexington, MA USA; [Mashimo, Hiroshi] Boston VA Healthcare Syst, Dept Gastroenterol, West Roxbury, MA USA; [Gold, Jason S.] Boston VA Healthcare Syst, Dept Surg, West Roxbury, MA USA	Qin, H (reprint author), Changzhou Second Hosp, Dept Pathol, Changzhou, Peoples R China.; Qin, H (reprint author), Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China.; Qin, H (reprint author), Boston VA Healthcare Syst, Pathol & Lab Med, West Roxbury, MA 02132 USA.; Qin, H (reprint author), Harvard Med Sch, West Roxbury, MA 02132 USA.	qinhuang0122@gmail.com	Gold, Jason S./O-5112-2014	Gold, Jason S./0000-0002-2925-4755	Science and Technology Development Project of the Nanjing City [ZKX05013, ZKX07011]; special grant from the Nanjing Drum Tower Hospital in Nanjing, China	The study was partially financed by research grants from the Science and Technology Development Project of the Nanjing City (ZKX05013, ZKX07011 to QH) and a special grant from the Nanjing Drum Tower Hospital in Nanjing, China.	Aida J, 2011, AM J SURG PATHOL, V35, P1140, DOI 10.1097/PAS.0b013e3182206c0e; Ajani JA, 2015, J NATL COMPR CANC NE, V13, P194, DOI 10.6004/jnccn.2015.0028; American Joint Committee on Cancer, 2009, AJCC CANC STAGING MA, P129; [Anonymous], 2014, CHIN J DIG ENDOSC, V31, P361; Colquhoun A, 2015, GUT, V64, P1881, DOI 10.1136/gutjnl-2014-308915; Fang C, 2016, J DIGEST DIS, V17, P526, DOI 10.1111/1751-2980.12385; Gotoda T, 2000, GASTRIC CANCER, V3, P219, DOI DOI 10.1007/PL00011720; Hahn KY, 2018, SURG ENDOSC, V32, P73, DOI 10.1007/s00464-017-5640-8; Hanaoka N, 2009, ENDOSCOPY, V41, P427, DOI 10.1055/s-0029-1214495; Huang Q, 2016, J DIGEST DIS, V17, P421, DOI 10.1111/1751-2980.12355; Huang Q, 2015, PATHOLOGY, V47, P526, DOI 10.1097/PAT.0000000000000276; Huang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep13439; Huang Q, 2012, HUM PATHOL, V43, P2138, DOI 10.1016/j.humpath.2012.02.018; Huang Q, 2011, J DIGEST DIS, V12, P420, DOI 10.1111/j.1751-2980.2011.00535.x; Huang Q, 2011, HISTOPATHOLOGY, V59, P188, DOI 10.1111/j.1365-2559.2011.03924.x; Huang Q, 2011, ARCH PATHOL LAB MED, V135, P384, DOI 10.1043/2010-0162-RA.1; Huh CW, 2016, J SURG ONCOL, V114, P769, DOI 10.1002/jso.24385; Japanese Gastric Canc Assoc, 2017, GASTRIC CANCER, V20, P1, DOI 10.1007/s10120-016-0622-4; Kakeji Y, 2012, SURG TODAY, V42, P351, DOI 10.1007/s00595-011-0114-4; Kang HJ, 2010, GASTROINTEST ENDOSC, V72, P508, DOI 10.1016/j.gie.2010.03.1077; Kim JK, 2018, SURG ENDOSC, V32, P760, DOI 10.1007/s00464-017-5735-2; Kumagai K, 1985, Gan No Rinsho, V31, P31; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Lim H, 2017, GASTRIC CANCER, V20, P793, DOI 10.1007/s10120-017-0703-z; Lim MS, 2011, J GASTROINTEST SURG, V15, P1783, DOI 10.1007/s11605-011-1624-5; Maeda H, 2008, J AM COLL SURGEONS, V206, P306, DOI 10.1016/j.jamcollsurg.2007.06.306; Matsuda T, 2014, WORLD J SURG, V38, P2337, DOI 10.1007/s00268-014-2573-4; Nam MJ, 2010, J GASTRIC CANCER, V10, P162, DOI 10.5230/jgc.2010.10.4.162; Nesi G, 2009, IN VIVO, V23, P337; Okabayashi T, 2000, CANCER, V89, P2555, DOI 10.1002/1097-0142(20001215)89:12<2555::AID-CNCR6>3.3.CO;2-I; Okholm C, 2014, SURG ONCOL, V23, P140, DOI 10.1016/j.suronc.2014.06.001; Ronellenfitsch U, 2016, ONCOTARGET, V7, P10676, DOI 10.18632/oncotarget.7221; Sano T, 2017, GASTRIC CANCER, V20, P217, DOI 10.1007/s10120-016-0601-9; Sekiguchi M, 2016, J GASTROENTEROL, V51, P961, DOI 10.1007/s00535-016-1180-6; Siewert JR, 2005, J SURG ONCOL, V90, P139, DOI 10.1002/jso.20218; Tajima Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055345; TANAKA T, 1990, Kurume Medical Journal, V37, P265; van Sandick JW, 2000, CANCER-AM CANCER SOC, V88, P2429, DOI 10.1002/1097-0142(20000601)88:11<2429::AID-CNCR1>3.0.CO;2-H; Verdecchia A, 2004, INT J CANCER, V109, P737, DOI 10.1002/ijc.20047; Yamashita H, 2017, GASTRIC CANCER, V20, pS69, DOI 10.1007/s10120-016-0663-8; Zhao BW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129531; Zhao XD, 2017, J GASTROINTEST SURG, V21, P700, DOI 10.1007/s11605-017-3364-7; [钟芸诗 ZHONG Yunshi], 2011, [中华消化外科杂志, Chinese Journal of Digestive Surgery], V10, P185	43	2	3	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1599	1607		10.1038/s41379-018-0063-1			9	Pathology	Pathology	GV3XJ	WOS:000446031300012	29802360				2019-10-28	
J	Allanson, BM; Weber, MA; Jackett, LA; Chan, C; Lau, L; Ziegler, DS; Warby, M; Mayoh, C; Cowley, MJ; Tucker, KM; Long, GV; Maher, A; Anazodo, A; Scolyer, RA				Allanson, Benjamin M.; Weber, Martin A.; Jackett, Louise A.; Chan, Charles; Lau, Loretta; Ziegler, David S.; Warby, Meera; Mayoh, Chelsea; Cowley, Mark J.; Tucker, Katherine M.; Long, Georgina V.; Maher, Annabelle; Anazodo, Antoinette; Scolyer, Richard A.			Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma	PATHOLOGY			English	Article						Gastrointestinal neuroectodermal tumour; clear cell sarcoma; melanoma; pathology; diagnosis; treatment; clear cell sarcoma-like tumour of the gastrointestinal tract	CLEAR-CELL SARCOMA; OF-THE-LITERATURE; SMALL-BOWEL; SOFT PARTS; TRACT; ILEUM; ASSOCIATION; FEATURES; STOMACH; PITFALL	Malignant gastrointestinal neuroectodermal tumour (GNET) is a recently characterised rare and aggressive tumour that typically arises in association with the small intestine of adults. We present a novel case of this entity and expand the spectrum of its reported morphological features. The patient was a 5-year-old female, the youngest reported patient affected by the condition, and presented with extra-abdominal disease. The histopathological features included the presence of a junctional component of the palatal tumour, which mimicked mucosal melanoma, a feature that has not been previously reported in GNET. Whole genome and RNA sequencing was performed that demonstrated the EWSR1-ATF1 translocation characteristic of GNET. Knowledge of this entity and its features, together with careful morphological assessment supplemented by judicious immunohistochemical and molecular studies should enable the correct diagnosis to be established.	[Allanson, Benjamin M.; Jackett, Louise A.; Maher, Annabelle; Scolyer, Richard A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Weber, Martin A.] Sydney Childrens Hosp, Prince Wales Hosp, NSW Hlth Pathol East, Dept Anat Pathol, Randwick, NSW, Australia; [Weber, Martin A.] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia; [Jackett, Louise A.; Chan, Charles; Long, Georgina V.; Maher, Annabelle; Scolyer, Richard A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Jackett, Louise A.; Long, Georgina V.; Scolyer, Richard A.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Chan, Charles] Concord Repatriat Gen Hosp, Dept Anat Pathol, NSW Hlth Pathol, Sydney, NSW, Australia; [Lau, Loretta; Ziegler, David S.; Anazodo, Antoinette] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Lau, Loretta; Ziegler, David S.; Anazodo, Antoinette] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Lau, Loretta; Ziegler, David S.; Mayoh, Chelsea; Cowley, Mark J.] Univ New South Wales, Childrens Canc Inst, Sydney, NSW, Australia; [Warby, Meera; Tucker, Katherine M.; Anazodo, Antoinette] Prince Wales Hosp, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia; [Cowley, Mark J.] Garvan Inst, Kinghorn Ctr Clin Genom, Sydney, NSW, Australia; [Cowley, Mark J.] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Tucker, Katherine M.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Long, Georgina V.] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia	Allanson, BM (reprint author), Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia.	Benjamin.Allanson@health.nsw.gov.au	Long, Georgina/Z-2044-2019; Lau, Loretta MS/B-1565-2008; Cowley, Mark/K-8731-2019	Long, Georgina/0000-0001-8894-3545; Lau, Loretta MS/0000-0002-3172-0970; Cowley, Mark/0000-0002-9519-5714; Anazodo, Antoinette/0000-0002-5495-6062; Scolyer, Richard/0000-0002-8991-0013; Ziegler, David/0000-0001-7451-7916			Alali BM, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0659-7; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; Boland JM, 2016, HUM PATHOL, V57, P13, DOI 10.1016/j.humpath.2016.05.026; Comin CE, 2007, VIRCHOWS ARCH, V451, P839, DOI 10.1007/s00428-007-0454-z; D'Amico FE, 2012, INT J SURG PATHOL, V20, P401, DOI 10.1177/1066896911428073; Donner LR, 1998, AM J SURG PATHOL, V22, P121, DOI 10.1097/00000478-199801000-00016; Feasel PC, 2016, J CUTAN PATHOL, V43, P838, DOI 10.1111/cup.12755; Fletcher C, 2013, WHO CLASSIFICATION T; Friedrichs N, 2005, INT J SURG PATHOL, V13, P313, DOI 10.1177/106689690501300402; Gahanbani Ardakani A, 2016, Ann R Coll Surg Engl, V98, pe37, DOI 10.1308/rcsann.2016.0073; Granville L, 2006, ULTRASTRUCT PATHOL, V30, P111, DOI 10.1080/01913120500406400; Inoue S, 2013, J PEDIAT HEMATOL ONC, V35, P402, DOI 10.1097/MPH.0b013e3182580d1f; Insabato L, 2015, PATHOL RES PRACT, V211, P688, DOI 10.1016/j.prp.2015.06.001; Joo M, 2009, ANN DIAGN PATHOL, V13, P30, DOI 10.1016/j.anndiagpath.2008.10.003; Kansal S, 2017, INDIA J SURG ONCOL, V8, P630, DOI 10.1007/s13193-017-0654-1; Kato T, 2017, DIAGN CYTOPATHOL, V45, P1137, DOI 10.1002/dc.23786; Keditsu KK, 2017, INDIAN J SURG, V79, P166, DOI 10.1007/s12262-016-1499-5; Kim SB, 2015, WORLD J GASTROENTERO, V21, P5739, DOI 10.3748/wjg.v21.i18.5739; Kong J, 2014, ONCOL LETT, V8, P2687, DOI 10.3892/ol.2014.2524; Kraft S, 2013, ARCH PATHOL LAB MED, V137, P1680, DOI 10.5858/arpa.2012-0467-CR; Lagmay JP, 2009, PEDIATR BLOOD CANCER, V53, P214, DOI 10.1002/pbc.22014; Lee Y, 2010, HISTOPATHOLOGY, V67, P927; Pauwels P, 2002, HISTOPATHOLOGY, V41, P526, DOI 10.1046/j.1365-2559.2002.01509.x; Prado G, 2017, J GASTROINTEST CANC, V2, P5; Shenjere P, 2012, INT J SURG PATHOL, V20, P378, DOI 10.1177/1066896911425485; Sidiropoulos M, 2013, J CUTAN PATHOL, V40, P265, DOI 10.1111/cup.12058; Singh M, 2014, HISTOPATHOLOGY, V64, P750, DOI 10.1111/his.12299; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Suarez-Vilela D, 2012, AM J SURG PATHOL, V36, P1905, DOI 10.1097/PAS.0b013e31826f5b28; Syed Kowsar A, 2015, INT J ORAL MAXILLOF, V44, pe294; Thway K, 2014, CASE REP MED, V2014, P1; US National Library of Medicine, 2017, GEN HOM REF LZTRI GE; US National Library of Medicine, 2016, GEN HOM REF PEND SYN; Ustundag N, 2015, ORAL MAXILLOFAC PATH, V199, P194; Venkataraman G, 2005, APMIS, V113, P716, DOI 10.1111/j.1600-0463.2005.apm_243.x; Washimi K, 2017, PATHOL INT, V67, P534, DOI 10.1111/pin.12573; Yang JC, 2012, J PEDIATR SURG, V47, P1943, DOI 10.1016/j.jpedsurg.2012.08.014; Yegen G, 2015, INT J SURG PATHOL, V23, P61, DOI 10.1177/1066896914547046; Zambrano E, 2003, INT J SURG PATHOL, V11, P75, DOI 10.1177/106689690301100202; Zhao ZH, 2014, INT J CLIN EXP PATHO, V7, P8967	40	0	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	OCT	2018	50	6					648	653		10.1016/j.pathol.2018.07.002			6	Pathology	Pathology	GU7XB	WOS:000445543400010	30177220				2019-10-28	
J	Nishimura, Y; Yoshida, A; Yonemori, K; Motoi, N; Tamura, K; Hiraoka, N; Mori, T				Nishimura, Yuuki; Yoshida, Akihiko; Yonemori, Kan; Motoi, Noriko; Tamura, Kenji; Hiraoka, Nobuyoshi; Mori, Taisuke			SMARCB-1 deficient squamous cell carcinoma of a mediastinal cyst	PATHOLOGY INTERNATIONAL			English	Article						mediastinal cyst; SMARCB1; squamous cell carcinoma	MESOTHELIOMA; FEATURES; TUMORS	SMARCB1-deficiency has been found in a variety of tumors. Here, we report a SMARCB1-deficient squamous cell carcinoma of a mediastinal cyst. A 53-year-old man was diagnosed with a cyst of the pericardial region in his twenties. As a symptom at this time, he complained of severe pain and dyspnea in the right chest. Following investigation using imaging and histological examination of the biopsy specimen, he was diagnosed with a SMARCB1 deficient malignant neoplasm. As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC). The patient died six months after initial presentation. The autopsy showed the most part of the tumor with anaplastic cytomorphology, loss of SMARCB1, diffusely positive immunostaining for pancytokeratin, and negative immunostaining for p40 and CK5/6. To our knowledge, this is the first report of SMARCB1-deficient SCC of mediastinal cyst.	[Nishimura, Yuuki; Yoshida, Akihiko; Motoi, Noriko; Hiraoka, Nobuyoshi; Mori, Taisuke] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan; [Yonemori, Kan; Tamura, Kenji] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan	Mori, T (reprint author), Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 10040045, Japan.	tamori@ncc.go.jp		mori, taisuke/0000-0003-1838-7883			Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Kimura N, 2018, PATHOL INT, V68, P128, DOI 10.1111/pin.12623; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Lloyd RV, 2017, WHO CLASSIFICATION T; Mills S. E., 2012, HISTOLOGY PATHOLOGIS; Sahni DR, 2017, OXF MED CASE REP, P229, DOI 10.1093/omcr/omx075; Tanaka H, 2018, HISTOPATHOLOGY, V72, P1216, DOI 10.1111/his.13482; Tower-Rader A, 2017, PROG CARDIOVASC DIS, V59, P389, DOI [10.1016/j.pcad.2016.12.0.11, 10.1016/j.pcad.2016.12.011]; Travis WD, 2015, WHO CLASSIFICATION T; Tsuta K, 2011, J THORAC ONCOL, V6, P1190, DOI 10.1097/JTO.0b013e318219ac78; Yoshida K, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4321-x; Yoshimura M, 2017, HISTOPATHOLOGY, V71, P1011, DOI 10.1111/his.13321	13	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					563	566		10.1111/pin.12720			4	Pathology	Pathology	GV9EJ	WOS:000446457500004	30216599				2019-10-28	
J	Ji, DL; Zhong, XY; Jiang, XM; Leng, KM; Xu, Y; Li, ZL; Huang, LN; Li, JL; Cui, YF				Ji, Daolin; Zhong, Xiangyu; Jiang, Xingming; Leng, Kaiming; Xu, Yi; Li, Zhenglong; Huang, Lining; Li, Jinglin; Cui, Yunfu			The role of long non-coding RNA AFAP1-AS1 in human malignant tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Long non-coding RNA; AFAP1-AS1; Carcinoma; Biomarker; Carcinogene	SQUAMOUS-CELL CARCINOMA; PREDICTS POOR-PROGNOSIS; CANCER STATISTICS; HEPATOCELLULAR-CARCINOMA; OVARIAN-CANCER; LUNG-CANCER; NASOPHARYNGEAL CARCINOMA; CHROMOSOME 3P21; HIGH EXPRESSION; DOWN-REGULATION	Objectives: Long non-coding RNAs (LncRNAs) are a type Table of endogenous RNA longer than 200 nucleotides in length, and this kind of RNAs lack or possess limited ability of coding proteins. A large number of studies have demonstrated that lncRNAs could take part in massive biological processes, such as transcriptional activation and interference, cellular differentiation, proliferation, migration, invasion and apoptosis. The abnormal expression of lncRNAs has been clarified to play extremely important roles in various diseases, especially in human cancers. LncRNA actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is a newly recognized cancer related lncRNA deriving from the antisense strand of DNA at the AFAP1 coding gene locus. A slew of new studies suggest that AFAP1-AS1 is involved in many kinds of malignant tumors. Moreover, in recent years, the dysregulated expression of AFAP1-AS1 has been confirmed to be associated with oncogenesis and tumor progression. Evidence has increasingly shown that AFAP1-AS1 could probably serve as a novel potential molecular biomarker in tumor diagnosis and therapeutic target in tumor treatment. In this review, we sum up present stage new hottest research issues in respect of the biological functions and molecular mechanisms of AFAP1-AS1 in occurrence and progression of human tumors. Materials and methods: In this review, we summarize the recent researches about the expression and molecular biological mechanisms of LncRNA AFAP1-AS1 in tumor development. Existing relevant studies are acquired and analyzed by searching Pubmed, BioMedNet, GEO database and Academic Search Elit systematically. Results: Long non-coding RNA AFAP1-AS1 is an important tumor-associated LncRNA and its aberrant expression has been found in many malignancies so far, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, esophageal cancer, nasopharyngeal carcinoma, lung cancer, ovarian cancer, breast cancer, retinoblastoma, laryngeal cancer, tongue squamous cell carcinoma and thyroid cancer. In addition, the dysregulated expression of AFAP1-AS1 is related to carcinogensis, overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and tumor progression containing lymph node metastasis, distant metastasis, histological grade, tumor size and tumor stage. Conclusions: A series of studies provide detailed information to understand LncRNA AFAP1-AS1 role in various human cancers. LncRNA AFAP1-AS1 is an oncogene in tumors that have been studied so far, and it may act as a useful tumor biomarker and therapeutic target.	[Ji, Daolin; Zhong, Xiangyu; Jiang, Xingming; Leng, Kaiming; Xu, Yi; Li, Zhenglong; Huang, Lining; Li, Jinglin; Cui, Yunfu] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, 246 XueFu Ave, Harbin 150086, Heilongjiang, Peoples R China	Cui, YF (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, 246 XueFu Ave, Harbin 150086, Heilongjiang, Peoples R China.	yfcui777@hotmail.com			Postgraduate Innovative Research Project of Harbin Medical University [YJSCX2016-21HYD]; Foundation of Key Laboratory of Myocardial Ischemia, Ministry of Education [KF201810]	This study was funded by Postgraduate Innovative Research Project of Harbin Medical University (Grant No. YJSCX2016-21HYD), Foundation of Key Laboratory of Myocardial Ischemia, Ministry of Education (Grant No. KF201810).	Aggarwal C, 2014, ANN PALLIAT MED, V3, P229, DOI 10.3978/j.issn.2224-5820.2014.06.01; Agulnik M, 2008, ORAL ONCOL, V44, P617, DOI 10.1016/j.oraloncology.2007.08.003; Al Bakir M, 2014, BRIT MED BULL, V112, P57, DOI 10.1093/bmb/ldu034; Bartsch R, 2017, MEMO-MAG EUR MED ONC, V10, P228, DOI 10.1007/s12254-017-0368-7; Bauer JA, 2005, MOL CANCER THER, V4, P1096, DOI 10.1158/1535-7163.MCT-05-0081; Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057; Broaddus E, 2009, BRIT J OPHTHALMOL, V93, P21, DOI 10.1136/bjo.2008.138750; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Carroll MRR, 2014, CLIN BIOCHEM, V47, P921, DOI 10.1016/j.clinbiochem.2014.04.019; Chen WQ, 2014, CHIN J CANCER, V33, P402, DOI 10.5732/cjc.014.10084; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Costabile V, 2015, INT J ONCOL, V46, P1913, DOI 10.3892/ijo.2015.2911; Dai WC, 2018, BIOMED PHARMACOTHER, V99, P191, DOI 10.1016/j.biopha.2017.12.105; Deng J, 2015, BIOMED PHARMACOTHER, V75, P8, DOI 10.1016/j.biopha.2015.07.003; Dianatpour A, 2018, CANCER BIOMARK, V22, P49, DOI 10.3233/CBM-170831; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; El-Serag HB, 2014, HEPATOLOGY, V60, P1767, DOI 10.1002/hep.27222; Fabian ID, 2018, ONCOGENE, V37, P1551, DOI 10.1038/s41388-017-0050-x; Feng JH, 2014, MOL MED REP, V10, P867, DOI 10.3892/mmr.2014.2316; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goetze TO, 2015, WORLD J GASTROENTERO, V21, P12211, DOI 10.3748/wjg.v21.i43.12211; Gomes CC, 2017, OR SURG OR MED OR PA, V123, P235, DOI 10.1016/j.oooo.2016.10.006; Gong ZJ, 2012, SCI CHINA LIFE SCI, V55, P1120, DOI 10.1007/s11427-012-4413-9; Guo JQ, 2017, DIGEST DIS SCI, V62, P2004, DOI 10.1007/s10620-017-4584-0; Han X, 2016, BIOL RES, V49, DOI 10.1186/s40659-016-0094-3; Hao FQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180384; Hay ID, 2013, SURGERY, V154, P1448, DOI 10.1016/j.surg.2013.07.007; He BY, 2017, ONCOTARGET, V8, P41166, DOI 10.18632/oncotarget.17083; Herszenyi L, 2010, EUR REV MED PHARMACO, V14, P249; Hoffman HT, 2006, LARYNGOSCOPE, V116, P1, DOI 10.1097/01.mlg.0000236095.97947.26; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Huang B, 2014, SCI CHINA LIFE SCI, V57, P643, DOI 10.1007/s11427-014-4669-3; Invernizzi F, 2016, LIVER INT, V36, P100, DOI 10.1111/liv.13006; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jin H, 2017, MOL MED REP, V16, P3475, DOI 10.3892/mmr.2017.6989; Karatas OF, 2017, ORAL ONCOL, V67, P124, DOI 10.1016/j.oraloncology.2017.02.015; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Li L, 2016, HEPATOLOGY, V63, P1900, DOI 10.1002/hep.28508; Liu FT, 2016, ONCOTARGETS THER, V9, P4247, DOI 10.2147/OTT.S107188; Liu Rui-Hua, 2018, Oncotarget, V9, P8100, DOI 10.18632/oncotarget.23568; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Low SK, 2018, CANCER SCI, V109, P497, DOI 10.1111/cas.13463; Lu JY, 2014, PROG BIOCHEM BIOPHYS, V41, P41, DOI 10.3724/SP.J.1206.2013.00386; Lu X, 2017, CELL PHYSIOL BIOCHEM, V42, P222, DOI 10.1159/000477319; Lu X, 2016, TUMOR BIOL, V37, P9699, DOI 10.1007/s13277-016-4858-8; Luo HL, 2016, CANCER MED-US, V5, P2879, DOI 10.1002/cam4.848; Ma DC, 2019, BREAST CANCER-TOKYO, V26, P74, DOI 10.1007/s12282-018-0891-3; Ma F, 2016, BIOMED PHARMACOTHER, V84, P1249, DOI 10.1016/j.biopha.2016.10.064; Ma JM, 2013, FUTURE ONCOL, V9, P917, DOI [10.2217/fon.13.76, 10.2217/FON.13.76]; Maher B, 2012, NATURE, V489, P46, DOI 10.1038/489046a; Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1; Mendoza PR, 2016, CANCER CONTROL, V23, P99, DOI 10.1177/107327481602300203; Meng X, 2014, CANCER RES, V74, P7161, DOI 10.1158/0008-5472.CAN-14-1446; Miller G, 2008, EJSO-EUR J SURG ONC, V34, P306, DOI 10.1016/j.ejso.2007.07.206; Molina-Castro S, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12412; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Rao R, 2017, INDIAN J PEDIATR, V84, P937, DOI 10.1007/s12098-017-2395-0; Rinella ME, 2015, JAMA-J AM MED ASSOC, V313, P2263, DOI 10.1001/jama.2015.5370; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Rustin G, 2011, LANCET, V377, P380, DOI 10.1016/S0140-6736(11)60126-8; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; She WH, 2015, WORLD J HEPATOL, V7, P2147, DOI 10.4254/wjh.v7.i18.2147; Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sirica AE, 2008, HEPATOLOGY, V48, P2040, DOI 10.1002/hep.22623; Sugimachi K, 2001, J HEPATOL, V35, P74, DOI 10.1016/S0168-8278(01)00079-4; Tang YY, 2017, ONCOTARGET, V8, P39001, DOI 10.18632/oncotarget.16545; Thin KZ, 2018, PATHOL RES PRACT, V214, P801, DOI 10.1016/j.prp.2018.04.003; Wang F, 2016, BIOMED PHARMACOTHER, V81, P152, DOI 10.1016/j.biopha.2016.04.009; Wang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112662; Wang Y., 2017, ONCOTARGET, V8; Wang Zhan-shan, 2018, Huanjing Kexue, V39, P1, DOI 10.13227/j.hjkx.201705276; Wang ZH, 2012, BIOMED PHARMACOTHER, V66, P161, DOI 10.1016/j.biopha.2011.09.008; Watson ME, 2015, J GASTROINTEST LIVER, V24, P349, DOI 10.15403/jgld.2014.1121.243.mew; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Xiang GZ, 2016, PATHOL RES PRACT, V212, P1102, DOI 10.1016/j.prp.2016.10.006; Xiao ZD, 2014, INT J CLIN EXP PATHO, V7, P4039; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Yan HC, 2014, EUR REV MED PHARMACO, V18, P3497; Yang HX, 2016, MOL MED REP, V13, P5255, DOI 10.3892/mmr.2016.5170; Yang JP, 2011, CHINESE MED J-PEKING, V124, P1055, DOI 10.3760/cma.j.issn.0366-6999.2011.07.020; Yang SL, 2016, EUR REV MED PHARMACO, V20, P5107; Ye YB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0490-4; Yoon JH, 2015, BIOCHIMIE, V117, P15, DOI 10.1016/j.biochi.2015.03.001; Youlden DR, 2008, J THORAC ONCOL, V3, P819, DOI 10.1097/JTO.0b013e31818020eb; Yu H, 2015, J THORAC ONCOL, V10, P645, DOI 10.1097/JTO.0000000000000470; Yuan ZN, 2018, J CELL MOL MED, V22, P4253, DOI 10.1111/jcmm.13707; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zeng ZY, 2006, GENET MED, V8, P156, DOI 10.1097/01.gim.0000196821.87655.d0; Zhai XH, 2012, MOL MED REP, V6, P444, DOI 10.3892/mmr.2012.923; Zhang JY, 2016, INT J ONCOL, V48, P1590, DOI 10.3892/ijo.2016.3385; Zhang XL, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-64; Zhou XL, 2016, MOL CARCINOGEN, V55, P2095, DOI 10.1002/mc.22454; Zhou YP, 2018, CLIN CHIM ACTA, V481, P147, DOI 10.1016/j.cca.2018.03.006; Zhuang Y, 2017, AM J TRANSL RES, V9, P2997	104	5	5	2	11	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1524	1531		10.1016/j.prp.2018.08.014			8	Pathology	Pathology	GY0SD	WOS:000448231000002	30173945				2019-10-28	
J	Pallua, JD; Brunner, A; Zelger, B; Stalder, R; Unterberger, SH; Schirmer, M; Tappert, MC				Pallua, J. D.; Brunner, A.; Zelger, B.; Stalder, R.; Unterberger, S. H.; Schirmer, M.; Tappert, M. C.			Clinical infrared microscopic imaging: An overview	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Mid-infrared microscopic imaging; Molecular fingerprint; Chemical as well as physical sample properties; Statistical classification; Three-dimensional image data cube; Histopathology	HUMAN TISSUE; IR SPECTROSCOPY; MICRO-SPECTROSCOPY; COLON-CANCER; MICROSPECTROSCOPY; RAMAN; FTIR; CELLS; CLASSIFICATION; DIAGNOSIS	New developments in Mid-infrared microscopic imaging instrumentation and data analysis have turned this method into a conventional technique. This imaging method offers a global analysis of samples, with a resolution close to the cellular level enabling the acquisition of local molecular expression profiles. It is possible to get chemo-morphological information about the tissue status, which represents an essential benefit for future analytical interpretation of pathological changes of tissue. In this review, we give an overview of Mid-infrared microscopic imaging and its applications in clinical research.	[Pallua, J. D.; Brunner, A.; Zelger, B.] Med Univ Innsbruck, Dept Pathol, Mullerstr 44, A-6020 Innsbruck, Austria; [Pallua, J. D.] Med Univ Innsbruck, Inst Legal Med, Mullerstr 44, A-6020 Innsbruck, Austria; [Stalder, R.] Leopold Franzens Univ Innsbruck, Inst Mineral & Petrog, Innrain 52, A-6020 Innsbruck, Austria; [Unterberger, S. H.] Leopold Franzens Univ Innsbruck, Mat Technol, Technikerstr 13, A-6020 Innsbruck, Austria; [Schirmer, M.] Med Univ Innsbruck, Dept Internal Med, Clin 2, Anichstr 35, A-6020 Innsbruck, Austria; [Tappert, M. C.] Hyperspectral Intelligence Inc, Box 851, Gibsons, BC V0N 1V0, Canada	Pallua, JD (reprint author), Med Univ Innsbruck, Dept Pathol, Mullerstr 44, A-6020 Innsbruck, Austria.	Johannes.Pallua@i-med.ac.at	Schirmer, Michael/B-1893-2012; Unterberger, Seraphin Hubert/K-9736-2015	Schirmer, Michael/0000-0001-9208-7809; Stalder, Roland/0000-0003-1066-5340; Unterberger, Seraphin Hubert/0000-0002-4155-2421			Argov S, 2004, BIOPOLYMERS, V75, P384, DOI 10.1002/bip.20154; Baker MJ, 2014, NAT PROTOC, V9, P1771, DOI 10.1038/nprot.2014.110; Bhargava R, 2005, SHEFF ANALY CHEM, P1, DOI 10.1002/9780470988541; Bhargava R, 2007, ANAL BIOANAL CHEM, V389, P1155, DOI 10.1007/s00216-007-1511-9; Bowley H. J., 2012, PRACTICAL RAMAN SPEC; Boydston-White S, 1999, BIOSPECTROSCOPY, V5, P219, DOI 10.1002/(SICI)1520-6343(1999)5:4<219::AID-BSPY2>3.0.CO;2-O; Buckley K, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.11.111602; Bunaciu AA, 2017, CRIT REV ANAL CHEM, V47, P194, DOI 10.1080/10408347.2016.1253454; Byrne HJ, 2015, ANALYST, V140, P2066, DOI 10.1039/c4an02036g; Carney PA, 2018, J CUTAN PATHOL, V45, P478, DOI 10.1111/cup.13147; Chan KLA, 2006, VIB SPECTROSC, V42, P130, DOI 10.1016/j.vibspec.2005.10.005; Chew SF, 2007, TISSUE ANTIGENS, V69, P252, DOI 10.1111/j.1399-0039.2006.00775.x; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; Chiriboga L, 1998, BIOSPECTROSCOPY, V4, P55, DOI 10.1002/(SICI)1520-6343(1998)4:1<55::AID-BSPY6>3.3.CO;2-Y; Chiriboga L, 1998, BIOSPECTROSCOPY, V4, P47, DOI 10.1002/(SICI)1520-6343(1998)4:1<47::AID-BSPY5>3.3.CO;2-1; Cohenford MA, 1998, P NATL ACAD SCI USA, V95, P15327, DOI 10.1073/pnas.95.26.15327; Cohenford MA, 1997, GYNECOL ONCOL, V66, P59, DOI 10.1006/gyno.1997.4627; Creagh D, 2017, RADIAT PHYS CHEM, V137, P225, DOI 10.1016/j.radphyschem.2016.03.007; De Oliveira J.V., 2007, ADV FUZZY CLUSTERING; Diem M, 2016, FARADAY DISCUSS, V187, P9, DOI 10.1039/c6fd00023a; Dumas P, 2004, FARADAY DISCUSS, V126, P289, DOI 10.1039/b305065c; Edwards HGM, 2007, ANAL BIOANAL CHEM, V387, P821, DOI 10.1007/s00216-006-0791-9; Fabian H, 2004, METHODS, V34, P28, DOI 10.1016/j.ymeth.2004.03.004; Fabian H, 2006, BBA-BIOMEMBRANES, V1758, P874, DOI 10.1016/j.bbamem.2006.05.015; Fernandez DC, 2005, NAT BIOTECHNOL, V23, P469, DOI 10.1038/nbt1080; Foreman L., 2015, ASSESSING DYSPLASIA; Gamsjaeger S, 2014, CURR OSTEOPOROS REP, V12, P454, DOI 10.1007/s11914-014-0238-8; Gazi E, 2003, J PATHOL, V201, P99, DOI 10.1002/path.1421; Geladi P. L. M., 2007, TECHNIQUES APPL HYPE; Gendrin C, 2008, J PHARMACEUT BIOMED, V48, P533, DOI 10.1016/j.jpba.2008.08.014; Giinzler H., 1996, IR SPEKTROSKOPIE EIN, V3; Goodacre R, 2016, FARADAY DISCUSS, V187, P429, DOI 10.1039/C6FD90013E; Grenko RT, 2000, AM J CLIN PATHOL, V114, P735; Griffiths P. R., 2007, FOURIER TRANSFORM IN; Halcrow SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098462; Holland-Moritz K., 1980, INFRARED RAMAN SPECT; Holley Stephanie, 2008, Archiv fuer Kriminologie, V221, P175; Huang RY, 2003, BONE, V33, P514, DOI 10.1016/S8756-3282(03)00233-3; Jamin N, 1998, CELL MOL BIOL, V44, P9; Khanmohammadi M, 2009, MED ONCOL, V26, P292, DOI 10.1007/s12032-008-9118-3; Kidder LH, 1997, OPT LETT, V22, P742, DOI 10.1364/OL.22.000742; Kirsch M, 2010, ANAL BIOANAL CHEM, V398, P1707, DOI 10.1007/s00216-010-4116-7; Kleiner Oleg, 2002, BMC Gastroenterol, V2, P3, DOI 10.1186/1471-230X-2-3; Klinkert I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2737770; KLINKHAMER PJJM, 1988, ACTA CYTOL, V32, P794; Kohler M, 2009, ANAL BIOANAL CHEM, V393, P1513, DOI 10.1007/s00216-008-2592-9; Krafft C, 2006, BIOPOLYMERS, V82, P301, DOI 10.1002/bip.20492; Krishna CM, 2007, ANAL BIOANAL CHEM, V387, P1649, DOI 10.1007/s00216-006-0827-1; Kuepper C, 2016, FARADAY DISCUSS, V187, P105, DOI 10.1039/c5fd00157a; Kwak JT, 2015, SCI REP-UK, V5, DOI 10.1038/srep08758; Lasch P, 2004, BBA-MOL BASIS DIS, V1688, P176, DOI 10.1016/j.bbadis.2003.12.006; Lasch P, 2002, BIOPOLYMERS, V67, P335, DOI 10.1002/bip.10095; Lasch P, 1998, CELL MOL BIOL, V44, P189; Lasch P., 2007, BIOMEDICAL VIBRATION; Li QB, 2005, CLIN CHEM, V51, P346, DOI 10.1373/clinchem.2004.037986; Longato S, 2015, ANAL METHODS-UK, V7, P2917, DOI 10.1039/c4ay02943g; Malins DC, 2002, P NATL ACAD SCI USA, V99, P5937, DOI 10.1073/pnas.082111199; Mantsch H. H., 1996, INFRARED SPECTROSCOP; McDonnell LA, 2007, MASS SPECTROM REV, V26, P606, DOI 10.1002/mas.20124; McLaughlin G, 2011, ANAL BIOANAL CHEM, V401, P2511, DOI 10.1007/s00216-011-5338-z; Miller LM, 2000, CELL MOL BIOL, V46, P1035; MIZUSHIMA SI, 1954, ADV PROTEIN CHEM, V9, P299, DOI 10.1016/S0065-3233(08)60209-0; Mourant JR, 2003, BIOPHYS J, V85, P1938, DOI 10.1016/S0006-3495(03)74621-9; Nagy G, 2008, FORENSIC SCI INT, V175, P55, DOI 10.1016/j.forsciint.2007.05.008; Painter P. C., 1982, THEORY VIBRATIONAL S; Pallua JD, 2012, ANALYST, V137, P3965, DOI 10.1039/c2an35483g; Pallua JD, 2012, CURR PROTEOMICS, V9, P132; Pallua J.D., 2011, CURR BIOACT COMPD, V7, P106; Paluszkiewicz C, 1998, CELL MOL BIOL, V44, P65; Parker F. S., 1983, APPL INFRARED RAMAN; Patel II, 2011, ANAL BIOANAL CHEM, V401, P969, DOI 10.1007/s00216-011-5123-z; Petibois C, 2005, CELL BIOL INT, V29, P709, DOI 10.1016/j.cellbi.2005.04.007; Petibois C, 2006, TRENDS BIOTECHNOL, V24, P455, DOI 10.1016/j.tibtech.2006.08.005; Pezzei C, 2010, MOL BIOSYST, V6, P2287, DOI 10.1039/c0mb00041h; Podshyvalov A, 2005, APPL OPTICS, V44, P3725, DOI 10.1364/AO.44.003725; Pollock H. M., 2006, MICROSPECTROSCOPY MI; RIGAS B, 1990, P NATL ACAD SCI USA, V87, P8140, DOI 10.1073/pnas.87.20.8140; Salzer R., 2009, INFRARED RAMAN SPECT; Sammon C, 2016, FARADAY DISCUSS, V187, P155, DOI 10.1039/C6FD90011A; Shimanouchi T., 1963, STRUCTURE PROPERTIES; Siebert F., 2008, VIBRATIONAL SPECTROS; Sobottka SB, 2009, ANAL BIOANAL CHEM, V393, P187, DOI 10.1007/s00216-008-2443-8; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Villmann T, 2008, BRIEF BIOINFORM, V9, P129, DOI 10.1093/bib/bbn009; Walch A, 2008, HISTOCHEM CELL BIOL, V130, P421, DOI 10.1007/s00418-008-0469-9; Wang TD, 2007, P NATL ACAD SCI USA, V104, P15864, DOI 10.1073/pnas.0707567104; Woess C, 2015, ANALYST, V140, P6363, DOI 10.1039/c5an01072a; Wood BR, 2004, GYNECOL ONCOL, V93, P59, DOI 10.1016/j.ygyno.2003.12.028; Yano K, 1996, CANCER LETT, V110, P29, DOI 10.1016/S0304-3835(96)04450-3; Yano K, 2000, ANAL BIOCHEM, V287, P218, DOI 10.1006/abio.2000.4872; Yeh K, 2015, ANAL CHEM, V87, P485, DOI 10.1021/ac5027513	91	0	0	4	12	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1532	1538		10.1016/j.prp.2018.08.026			7	Pathology	Pathology	GY0SD	WOS:000448231000003	30220435				2019-10-28	
J	Chen, CL; Ke, Q; Luo, M; Gao, ZY; Li, ZJ; Luo, ZG; Liu, DB				Chen, Chun-Li; Ke, Qing; Luo, Ming; Gao, Zi-Ye; Li, Zhi-Jiu; Luo, Zhi-Guo; Liu, Dong-Bo			Loss of LINC01939 expression predicts progression and poor survival in gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gastric cancer; Long non-coding RNAs; LINC01939; Progression; Survival	LONG NONCODING RNAS; CHEMOTHERAPY; STATISTICS; BIOMARKER; PROGNOSIS; DISEASE	As highly tissue-specific genes, it is increasingly recognized that long non-coding RNAs (lncRNAs) are considered as promising prognostic biomarkers for multiple human cancers. However, lack of tissue-specific lncRNAs in gastric cancer (GC) still exist. In this study, we identified a novel IncRNA LINC01939 which showed the largest fold change in GC than other human cancers from lnCAR database by bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction (qPCR) assay confirmed that LINC01939 was significantly downregulated in GC tissues compared with matched normal tissues. Low expression of LINC01939 was positively associated with advanced TNM stage and lymphatic metastasis. Patients with low LINC01939 expression have remarkably shorter overall survival (OS) and progression-free survival (PFS) than those with high LINC01939 expression. Univariate and multivariate analysis showed that LINC01939 is an independent protective predictor of OS and PFS in GC patients. Therefore, our data suggest that the newly identified IncRNA LINC01939 might act as a potential prognostic biomarker for GC.	[Chen, Chun-Li; Ke, Qing; Luo, Ming; Gao, Zi-Ye; Li, Zhi-Jiu; Luo, Zhi-Guo] Hubei Univ Med, Taihe Hosp, Dept Clin Oncol, 32 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China; [Liu, Dong-Bo] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Ctr Canc, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China	Luo, ZG (reprint author), Hubei Univ Med, Taihe Hosp, Dept Clin Oncol, 32 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China.; Liu, DB (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Ctr Canc, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.	dori419@163.com; keqing@taihehospital.com; heavry@126.com; gaoziye613@163.com; lzjhsh@126.com; camelwhite@163.com; dbliutj@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602391]; Natural Science Foundation of Hubei ProvinceNatural Science Foundation of Hubei Province [2018CFB405]	This present study was supported by the National Natural Science Foundation of China (grant no. 81602391) and the Natural Science Foundation of Hubei Province (grant no. 2018CFB405).	Chen DL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0420-1; Chen JS, 2016, NEOPLASMA, V63, P223, DOI 10.4149/207_150821N454; Chen MM, 2017, ADV MECH ENG, V9, DOI 10.1177/1687814017727973; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077070; Hajjari M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0670-0; Jandura A, 2017, TRENDS GENET, V33, P665, DOI 10.1016/j.tig.2017.08.002; Li ZW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.245; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Qi Y, 2016, ONCOTARGET, V7, P12693, DOI 10.18632/oncotarget.7281; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wu XL, 2017, ONCOTARGET, V8, P76015, DOI 10.18632/oncotarget.18638; Wu XL, 2017, ONCOL RES TREAT, V40, P370, DOI 10.1159/000464465; Yang XZ, 2017, AGING-US, V9, P914, DOI 10.18632/aging.101200; Zhang J, 2015, TUMOR BIOL, V36, P7465, DOI 10.1007/s13277-015-3460-9; Zhang M, 2016, WORLD J GASTROENTERO, V22, P6610, DOI 10.3748/wjg.v22.i29.6610; Zhao W, 2015, AM J TRANSL RES, V7, P1295; Zhou JP, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0250-6; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	27	1	1	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1539	1543		10.1016/j.prp.2018.07.007			5	Pathology	Pathology	GY0SD	WOS:000448231000004	30017335				2019-10-28	
J	Magro, G; Spadola, S; Motta, F; Palazzo, J; Catalano, F; Vecchio, GM; Salvatorelli, L				Magro, Gaetano; Spadola, Saveria; Motta, Fabio; Palazzo, Juan; Catalano, Francesca; Vecchio, Giada Maria; Salvatorelli, Lucia			STAT6 expression in spindle cell lesions of the breast: An immunohistochemical study of 48 cases	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Key words; STAT 6; Breast; Itnmunohistochemistry; Spindle cell lesions; Solitary fibrous tumor	SOLITARY FIBROUS TUMOR; MAMMARY MYOFIBROBLASTOMA; NUCLEAR EXPRESSION; NAB2-STAT6 FUSION; DIAGNOSIS; FIBROMATOSIS; EMPHASIS; DISTINCTION; CARCINOMA; MIMICS	The diagnosis of spindle cell lesions of the breast parenchyma is challenging. Some of these lesions share the expression of CD34, posing differential diagnostic problems, especially in core biopsies. Recently, antibodies against the STAT6 C-terminal, are being used in paraffin-embedded tissues as a surrogate for identifying the NAB2-STA6 fusion gene which is considered a specific molecular marker for solitary fibrous tumor. Accordingly, we investigated the expression of STAT6 in a large series of uncommon spindle cell tumor-like and tumor lesions occurring primarily in the breast parenchyma. We collected 10 classic-type myofibroblastomas, 9 desmoid-type fibromatosis, 6 spindle cell metaplastic carcinoma, 5 benign fibroblastic spindle cell tumors, 3 solitary fibrous tumors, 7 pseudoangiomatous stromal hyperplasias, 2 reactive spindle cell nodules, 1 leiomyoma, 1 spindle cell lipoma, 1 case of inflammatory pseudotumor, 1 nodular fasciitis, 1 myxoma and 1 dermatofibrosarcoma pro-tuberans. A diffuse and strong nuclear STAT6 expression was restricted only to solitary fibrous tumors, while the other lesions were negative or showed only weak cytoplasmic expression. The present study confirms that the demonstration of a diffuse and strong STAT6 nuclear staining is very helpful in distinguishing solitary fibrous tumor from other spindle cell mimics arising in the breast.	[Magro, Gaetano; Spadola, Saveria; Motta, Fabio; Vecchio, Giada Maria; Salvatorelli, Lucia] Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Anat Pathol Sect,Sch Med, I-95123 Catania, Italy; [Palazzo, Juan] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Catalano, Francesca] Azienda Osped Cannizzaro Catania, UOC Multidisciplinare Senol, Catania, Italy	Magro, G (reprint author), Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Anat Pathol Sect,Sch Med, I-95123 Catania, Italy.	g.magro@unict.it	Spadola, Saveria/AAC-2451-2019	Spadola, Saveria/0000-0003-0387-5921; motta, fabio/0000-0002-9034-6958; Magro, Gaetano Giuseppe/0000-0003-3244-6827	Centro Studi Senologia di Siracusa (CSS)	This research was supported by the Centro Studi Senologia di Siracusa (CSS).	Bombonati Alessandro, 2003, Breast J, V9, P251, DOI 10.1046/j.1524-4741.2003.09315.x; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Chen HC, 2010, J IMMUNOL, V185, P64, DOI 10.4049/jimmunol.0903323; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Creytens D, 2015, APPL IMMUNOHISTO M M, V23, P462, DOI 10.1097/PAI.0000000000000081; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Dwyer JB, 2015, ARCH PATHOL LAB MED, V139, P552, DOI 10.5858/arpa.2013-0555-RS; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kuba MG, 2017, AM J CLIN PATHOL, V148, P243, DOI [10.1093/AJCP/AQX065, 10.1093/ajcp/aqx065]; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lee AHS, 2008, HISTOPATHOLOGY, V52, P45, DOI 10.1111/j.1365-2559.2007.02893.x; Lusby K, 2013, ANN SURG ONCOL, V20, P2364, DOI 10.1245/s10434-012-2834-0; Magro G, 1998, PATHOL RES PRACT, V194, P867, DOI 10.1016/S0344-0338(98)80092-7; Magro G, 2002, VIRCHOWS ARCH, V440, P249, DOI 10.1007/s00428-001-0572-y; Magro G, 1998, Ann Diagn Pathol, V2, P306, DOI 10.1016/S1092-9134(98)80023-3; Magro G, 2000, HISTOPATHOLOGY, V37, P189, DOI 10.1046/j.1365-2559.2000.00985-3.x; Magro G., 2002, Pathologica (Genoa), V94, P238, DOI 10.1007/s102420200039; Magro G, 2001, PATHOL RES PRACT, V197, P453, DOI 10.1078/0344-0338-00112; Magro G, 2008, ARCH PATHOL LAB MED, V132, P1813, DOI 10.1043/1543-2165-132.11.1813; Magro Gaetano, 2018, Surg Pathol Clin, V11, P91, DOI 10.1016/j.path.2017.09.005; Magro G, 2016, PATHOL RES PRACT, V212, P463, DOI 10.1016/j.prp.2015.12.013; Magro G, 2016, HISTOL HISTOPATHOL, V31, P1, DOI 10:14670; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015; Magro G, 2010, VIRCHOWS ARCH, V456, P581, DOI 10.1007/s00428-010-0902-z; Ouladan S, 2015, INT J ONCOL, V46, P2595, DOI 10.3892/ijo.2015.2975; Rakha EA, 2016, HISTOPATHOLOGY, V68, P33, DOI 10.1111/his.12865; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Sanders M.E., 2018, PRACTICAL SURG PATHO, P255; Tai HC, 2015, MODERN PATHOL, V28, P1324, DOI 10.1038/modpathol.2015.90; Tay TKY, 2017, SEMIN DIAGN PATHOL, V34, P400, DOI 10.1053/j.semdp.2017.05.012; Vecchio GM, 2013, PATHOLOGICA, V105, P122; Vecchio GM, 2011, PATHOL RES PRACT, V207, P322, DOI 10.1016/j.prp.2011.01.009; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	37	2	2	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1544	1549		10.1016/j.prp.2018.07.011			6	Pathology	Pathology	GY0SD	WOS:000448231000005	30072169				2019-10-28	
J	Song, IH; Kim, KR; Lim, S; Kim, SH; Sung, CO				Song, In Hye; Kim, Kyu-Rae; Lim, Sehun; Kim, Seok-Hyung; Sung, Chang Ohk			Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ovarian neoplasms; Epithelial-mesenchymal transition; SLUG; Phenotype	ADHESION MOLECULES; CARCINOMA INVASION; METASTASIS; SLUG; INVASIVENESS; PATHOGENESIS; CADHERIN; TUMORS; SNAIL; CELLS	The epithelial-mesenchymal transition (EMT) is known to be associated with carcinoma invasion and metastasis. Previous studies have demonstrated that the expression of EMT-related proteins in carcinoma cells in many organs is associated with a higher histologic grade and a poor prognosis. However, the clinical significance of EMT in ovarian cancers is controversial. Formalin-fixed and paraffin-embedded tumor samples of 198 high-grade serous carcinomas (HGSCs) and 13 serous borderline tumors or low-grade serous carcinomas (SBT/LGSCs) of the ovary were analyzed. EMT phenotype marker expression, including claudin 4, E-cadherin, N-cadherin, alpha-smooth muscle actin (alpha-SMA) and vimentin, and EMT related transition factor expression, including paired-related homeobox 1 (PRRX1), SLUG, SNAIL, and TWIST1, were evaluated by immunohistochemistry. EMT phenotype was classified into three groups including complete EMT phenotype, incomplete EMT phenotype, and epithelial phenotype according to epithelial and mesenchymal marker expression. EMT phenotypes varied in HGSC (Complete phenotype, 32.3%; Incomplete phenotype, 42.9%; epithelial phenotype, 24.7%) compared with SBT/LGSC. EMT phenotype and each EMT phenotype markers were not significantly associated with patient survival of HGSCs in multivariate analysis. However transition factor, SLUG expression, correlated with advanced disease and SLUG expression was an independent predictor of poor overall survival in HGSC. EMT related transition factor expression like SLUG is more important in association with clinical outcome than EMT phenotype itself in HGSC.	[Song, In Hye] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hosp Pathol, Coll Med, Seoul, South Korea; [Song, In Hye; Kim, Kyu-Rae; Sung, Chang Ohk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Lim, Sehun] Inje Univ, Coll Med, Busan Paik Hosp, Dept Anesthesiol & Pain Med, Busan, South Korea; [Kim, Seok-Hyung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 50 Ilwon Dong, Seoul 135710, South Korea; [Sung, Chang Ohk] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Canc Genome Discovery,Asan Inst Life Sci, Seoul, South Korea	Sung, CO (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Kim, SH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 50 Ilwon Dong, Seoul 135710, South Korea.	platoshkim@daum.net; co.sung@amc.seoul.kr		Sung, Chang Ohk/0000-0002-8567-456X	National Research Foundation of Korea (NRF) - Korean Government (MSIP) [2016R1A5A2945889]	This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP) (2016R1A5A2945889).	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Cho EY, 2006, PATHOL INT, V56, P62, DOI 10.1111/j.1440-1827.2006.01925.x; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Gu AX, 2017, REPROD SCI, V24, P291, DOI 10.1177/1933719116654989; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Kim Kyungbin, 2014, Korean J Pathol, V48, P283, DOI 10.4132/KoreanJPathol.2014.48.4.283; Kim MK, 2014, BIOMED RES INT, DOI 10.1155/2014/495754; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; LaGamba D, 2005, DEV DYNAM, V234, P132, DOI 10.1002/dvdy.20489; Mise BP, 2014, PATHOL ONCOL RES; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Olmeda D, 2008, ONCOGENE, V27, P4690, DOI 10.1038/onc.2008.118; R.C. Team, 2015, R LANG ENV STAT COMP; Ryabtseva O. D., 2013, Experimental Oncology, V35, P211; ShihIe M, 2010, AM J OBSTET GYNECOL, V203, DOI DOI 10.1016/J.AJ0G.2010.08.003; Sung CO, 2013, J CLIN PATHOL, V66, P601, DOI 10.1136/jclinpath-2012-201271; Sung CO, 2011, MODERN PATHOL, V24, P1060, DOI 10.1038/modpathol.2011.59; Takai M, 2014, J OVARIAN RES, V7, DOI [10.1186/1757-2215-7-76, 10.1186/1757-2215-7-38]; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Yuan H, 2015, ONCOTARGET, V6, P13359, DOI 10.18632/oncotarget.3673; Zhu YH, 2006, INT J CANCER, V118, P1884, DOI 10.1002/ijc.21506	27	2	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1564	1571		10.1016/j.prp.2018.07.016			8	Pathology	Pathology	GY0SD	WOS:000448231000008	30082157				2019-10-28	
J	Dai, SJ; Zhang, JY; Bao, YT; Zhou, XJ; Lin, LN; Fu, YB; Zhang, YJ; Li, CY; Yang, YX				Dai, Shi Jie; Zhang, Jie Ying; Bao, Yu Ting; Zhou, Xiao Jie; Lin, Lu Ning; Fu, Yun Bo; Zhang, Yu Jia; Li, Chang Yu; Yang, Yuan Xiao			Intracerebroventricular injection of A beta(1-42) combined with two-vessel occlusion accelerate Alzheimer's disease development in rats	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Alzheimer's disease; A beta 1-42; Two-vessel occlusion; Cerebral ischemia	CEREBRAL-BLOOD-FLOW; VASCULAR DEMENTIA; SYNAPTIC PLASTICITY; ANIMAL-MODELS; RISK-FACTORS; WATER-MAZE; MEMORY; DEFICITS; STAGE; HYPERPHOSPHORYLATION	Numerous experimental studies and clinical observations suggest that cerebral ischemia may contribute to the pathogenesis of Alzheimer's disease (AD). Two-vessel occlusion caused cerebral ischemia model is often used in the study of vascular dementia (VaD). But how cerebral ischemia works on AD rat model which induced by intracerebroventricular injection of A beta(1-42) remains unclear. In the following study, we investigated the characteristics of rat model caused by intracerebroventricular injection of A beta(1-42) or two-vessel occlusion (2-VO) only and by both of the two operations. The animal cognitive functions were accessed by the Morris water maze. Regional cerebral blood flow was detected by Laser Doppler Blood Flowmeter. HE&Nissl staining, Congo red staining and immunohistochemistry were used to observe the status of neuronal loss, A beta deposition and the phosphorylated tau expression in hippocampus, respectively. We also measured the contents of AchE and ChAT in serum and hippocampus by Enzyme Linked Immunosorbent Assay. The MWM results showed that rats of A beta(1-42) + 2-VO group had a disorder in cognitive functions, at an early stage of one week after modeling, comparing with rats of sham group. The regional cerebral blood flow (rCBF) was significantly reduced in A beta(1-42) + 2-VO and 2-VO group one week after modeling, and still maintained low perfusion levels four weeks after modeling. HE and Nissl staining showed that A beta(1-42) + 2-VO rats' hippocampal CA1 neurons were in disorder, degeneration and necrosis, severe neuronal loss from the first week to the fourth week, while this phenomenon only appeared in the fourth week after modeling in rats of A beta(1-42) group and 2-VO group. Congo red staining showed that A beta(1-42) + 2-VO group rats' hippocampus CA1 had amyloid deposits from the first week to the fourth week, A beta(1-42) group were not find amyloid deposition significantly until four weeks after modeling, however, 2-VO group had no significant amyloid deposition all the time. Notably, IHC showed that, two weeks after modeling, the p-tau positive total area and integrated optical density of hippocampal CA1 region were significantly increased in A beta(1-42) + 2-VO group rats, while 2-VO group and A beta(1-42) group rats had no significantly changes all the time. We also found that the content of AchE was increased both in serum and hippocampus of A beta(1-42) + 2-VO group rats, and ChAT was decreased. However, there was no significantly change in cortex of content of AchE: acetylcholinesterase (AchE) and choline acetylase (ChAT) all three groups. Together, our study suggest that intracerebroventricular injection of A beta(1-42) combined with two-vessel occlusion may accelerate Alzheimer's disease development in rats. Also, this may serve as a less-time consuming new model to study the Alzheimer's disease and especially AD accompanied by cerebral ischemia.	[Dai, Shi Jie; Zhang, Jie Ying; Bao, Yu Ting; Zhou, Xiao Jie; Lin, Lu Ning; Fu, Yun Bo; Zhang, Yu Jia; Li, Chang Yu] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China; [Yang, Yuan Xiao] Hangzhou Med Coll, Sch Basic Med Sci & Forens Med, Hangzhou, Zhejiang, Peoples R China	Yang, YX (reprint author), Hangzhou Med Coll, Sch Basic Med Sci & Forens Med, Hangzhou, Zhejiang, Peoples R China.	597383375@qq.com; cecezone@163.com; 674552915@qq.com; 1053144865@qq.com; 603297331@qq.com; 782531142@qq.com; 393635423@qq.com; lcyzcmu@sina.com; yyx104475@163.com		Zhang, Jieying/0000-0001-5153-0472	Zhejiang Experimental Animal Project [2018C37081]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81403128]	This work was supported by Zhejiang Experimental Animal Project (Grant no. 2018C37081), the National Natural Science Foundation of China (no. 81403128).	Anderson P., 2006, HIPPOCAMPUS BOOK, P581; Ando K, 2010, BIOCHEM SOC T, V38, P1001, DOI 10.1042/BST0381001; Asle-Rousta M, 2013, J MOL NEUROSCI, V50, P524, DOI 10.1007/s12031-013-9979-6; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Bjerke M, 2011, J ALZHEIMERS DIS, V27, P665, DOI 10.3233/JAD-2011-110566; Brouillette J, 2012, J NEUROSCI, V32, P7852, DOI 10.1523/JNEUROSCI.5901-11.2012; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Clark RE, 2013, P NATL ACAD SCI USA, V110, P10365, DOI 10.1073/pnas.1301225110; Cuello AC, 2010, NEURODEGENER DIS, V7, P96, DOI 10.1159/000285514; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; de la Torre JC, 2016, BRAIN PATHOL, V26, P618, DOI 10.1111/bpa.12405; de la Torre JC, 2012, J ALZHEIMERS DIS, V32, P553, DOI 10.3233/JAD-2012-120793; de la Torre JC, 2003, NEUROL RES, V25, P635, DOI 10.1179/016164103101201931; DELATORRE JC, 1992, BRAIN RES, V582, P186, DOI 10.1016/0006-8993(92)90132-S; DELATORRE JC, 1995, J NEUROSCI RES, V41, P238, DOI 10.1002/jnr.490410211; Di Marco LY, 2015, NEUROBIOL DIS, V82, P593, DOI 10.1016/j.nbd.2015.08.014; Dong DW, 2014, BRAIN RES, V1543, P280, DOI 10.1016/j.brainres.2013.11.004; Epis R, 2010, EUR J PHARMACOL, V626, P57, DOI 10.1016/j.ejphar.2009.10.020; Ferreira ST, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00191; Foley AM, 2015, J ALZHEIMERS DIS, V44, P787, DOI 10.3233/JAD-142208; Fujii H., 2016, J CEREB BLOOD FLOW M; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Iturria-Medina Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11934; Jaworski T, 2010, BBA-MOL BASIS DIS, V1802, P808, DOI 10.1016/j.bbadis.2010.03.005; Kumar S, 2013, ACTA NEUROPATHOL, V125, P699, DOI 10.1007/s00401-013-1107-8; Liu H, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.05.027; Liu JM, 2016, CNS NEUROSCI THER, V22, P220, DOI 10.1111/cns.12495; Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008; Mantzavinos V, 2017, CURR ALZHEIMER RES, V14, P1149, DOI 10.2174/1567205014666170203125942; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morrissette DA, 2009, J BIOL CHEM, V284, P6033, DOI 10.1074/jbc.R800030200; Mortimer JA, 2012, CURR ALZHEIMER RES, V9, P621; Paxinos G, 2009, RAT BRAIN STEREOTAXI; Philipson O, 2010, FEBS J, V277, P1389, DOI 10.1111/j.1742-4658.2010.07564.x; Plouffe V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036873; Pluta R, 2013, MOL NEUROBIOL, V48, P500, DOI 10.1007/s12035-013-8439-1; Pluta R, 2013, MOL NEUROBIOL, V47, P425, DOI 10.1007/s12035-012-8360-z; Pratico D, 2002, FASEB J, V16, P1138, DOI 10.1096/fj.02-0012fje; Puzzo D, 2008, J NEUROSCI, V28, P14537, DOI 10.1523/JNEUROSCI.2692-08.2008; Qiu LF, 2016, SCI REP-UK, V6, DOI 10.1038/srep23964; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Schneider LS, 2014, J INTERN MED, V275, P251, DOI 10.1111/joim.12191; Schneider L, 2017, LANCET NEUROL, V16, P4, DOI 10.1016/S1474-4422(16)30356-8; Solfrizzi V, 2010, J NEUROL NEUROSUR PS, V81, P433, DOI 10.1136/jnnp.2009.181743; Sun XJ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00221; Terry AV, 2009, FRONT NEUROSCI, P267; TSUCHIYA M, 1992, EXP BRAIN RES, V89, P87; Van Dam D, 2011, BRIT J PHARMACOL, V164, P1285, DOI 10.1111/j.1476-5381.2011.01299.x; Vorhees CV, 2014, ILAR J, V55, P310, DOI 10.1093/ilar/ilu013; Wang Y. Q., 2005, EXPT STUDY EFFECTS C; West MJ, 2004, NEUROBIOL AGING, V25, P1205, DOI 10.1016/j.neurobiolaging.2003.12.005; Wierenga CE, 2014, J ALZHEIMERS DIS, V42, pS411, DOI 10.3233/JAD-141467; Wollenweber FA, 2016, STROKE, V47, P2645, DOI 10.1161/STROKEAHA.116.013778; Yamada K, 2000, PHARMACOL THERAPEUT, V88, P93, DOI 10.1016/S0163-7258(00)00081-4; Yang S., 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/215798; Yang S, 2013, BIOMED RES INT, DOI 10.1155/2013/215798; Zhang N, 2015, NEUROSCIENCE, V311, P284, DOI 10.1016/j.neuroscience.2015.10.038; Zhang QL, 2012, INT J IMMUNOPATH PH, V25, P49, DOI 10.1177/039463201202500107	60	0	0	0	6	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1583	1595		10.1016/j.prp.2018.07.020			13	Pathology	Pathology	GY0SD	WOS:000448231000011	30087036				2019-10-28	
J	Wada, N; Nojima, S; Tahara, S; Ohshima, K; Kurashige, M; Kawasaki, K; Tone, M; Kusumoto, S; Ikeda, J; Morii, E				Wada, Naoki; Nojima, Satoshi; Tahara, Shin-ichiro; Ohshima, Kenji; Kurashige, Masako; Kawasaki, Keisuke; Tone, Mitsuyo; Kusumoto, Shinya; Ikeda, Jun-ichiro; Morii, Eiichi			Effect of glutamine on lymphoplasmacytic lymphoma, especially on the viewpoint of the differentiation into vulnerable subpopulation	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glutamine; Lymphoplasmacytic lymphoma; CD138; Differentiation	MACROGLOBULINEMIA CELL-LINE; B-CELL; METABOLISM; GROWTH	Glutamine (Gin) is important not only for cell proliferation but also for differentiation. Although Gln is essential for plasmacytic differentiation of lymphocytes, no study has been done on the effect of Gln on differentiation of tumor cells, such as lymphoma. Here we examined the effect of Gln on plasmacytic differentiation of lympho-plasmacytic lymphoma (LPL) with its cell lines, MWCL-1 and RPCI-WM1. Gln promoted plasmacytic differentiation of LPL, and p38 MAPK signaling pathway mediated such differentiation. We previously reported that the subpopulation with plasmacytic differentiation was vulnerable to apoptosis in LPL. Although it is difficult to lead these findings to the radical therapy, they might help the treatment of LPL, in which stimulation of p38 MAPK by Gln induced differentiation of LPL into vulnerable subpopulation.	[Wada, Naoki; Nojima, Satoshi; Tahara, Shin-ichiro; Ohshima, Kenji; Kurashige, Masako; Kawasaki, Keisuke; Tone, Mitsuyo; Kusumoto, Shinya; Ikeda, Jun-ichiro; Morii, Eiichi] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Morii, E (reprint author), Osaka Univ, Grad Sch Med, Dept Pathol C3, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morii@molpath.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [T18K070680, T16K086490, T17K195550, T18K150780, T18K151220]	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (T18K070680, T16K086490, T17K195550, T18K150780, and T18K151220).	Chitta KS, 2013, LEUKEMIA LYMPHOMA, V54, P387, DOI 10.3109/10428194.2012.713481; CRAWFORD J, 1985, J CELL PHYSIOL, V124, P275, DOI 10.1002/jcp.1041240216; Curi R, 1999, BRAZ J MED BIOL RES, V32, P15, DOI 10.1590/S0100-879X1999000100002; Curi R, 2005, J CELL PHYSIOL, V204, P392, DOI 10.1002/jcp.20339; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Hodge LS, 2011, BLOOD, V117, pE190, DOI 10.1182/blood-2010-12-326868; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Konoplev S, 2005, AM J CLIN PATHOL, V124, P414, DOI 10.1309/3G1XDX0DVHBNVKB4; Morice WG, 2009, MODERN PATHOL, V22, P807, DOI 10.1038/modpathol.2009.34; Owen RG, 2003, SEMIN ONCOL, V30, P110, DOI 10.1053/sonc.2003.50082; Swerdlow SH, 2017, WHO CLASSIFICATION T, P232; Tanaka G, 2004, INT CONGR SER, V1259, P15, DOI 10.1016/S0531-5131(03)01668-6; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Wada N, 2017, PATHOL RES PRACT, V213, P773, DOI 10.1016/j.prp.2017.04.003; Wada N, 2014, LAB INVEST, V94, P79, DOI 10.1038/labinvest.2013.129; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wiren M, 1998, INT J BIOCHEM CELL B, V30, P1331, DOI 10.1016/S1357-2725(98)00104-6; Yasuda T, 2012, J IMMUNOL, V188, P6127, DOI 10.4049/jimmunol.1103039; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151	19	0	0	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1667	1674		10.1016/j.prp.2018.08.019			8	Pathology	Pathology	GY0SD	WOS:000448231000022	30173943				2019-10-28	
J	Vicentini, C; Cantu, C; Antonello, D; Simbolo, M; Mafficini, A; Luchini, C; Rusev, B; Porcaro, AB; Lacovelli, R; Fassan, M; Corbo, V; Brunelli, M; Artibani, W; Scarpa, A; Lawlor, RT				Vicentini, Caterina; Cantu, Cinzia; Antonello, Davide; Simbolo, Michele; Mafficini, Andrea; Luchini, Claudio; Rusev, Borislav; Porcaro, Antonio Benito; Lacovelli, Roberto; Fassan, Matteo; Corbo, Vincenzo; Brunelli, Matteo; Artibani, Walter; Scarpa, Aldo; Lawlor, Rita T.			ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Prostate cancer; Bone metastasis; Castration resistance; Next-generation sequencing; Multigene panels	GENE FUSIONS; CANCER; CHEMOTHERAPY; SURVIVAL; THERAPY; ENZALUTAMIDE; ABIRATERONE; DISCOVERY	Introduction: One of the most common sites of distant metastasization of prostate cancer is bone, but to date reliable biomarkers able to predict the risk and timing of bone metastasization are still lacking. Patients and methods: Surgically resected paraffin embedded samples from 12 primary prostate cancers that developed metachronous bone metastasis at different time points were studied (six cases within 2 years, six cases after 5 years from surgery). A targeted next-generation DNA and RNA sequencing able to assess simultaneously mutations, copy number alterations and fusion events of multiple genes was used. Immunohistochemistry was used to assess mTOR pathway activation. Results: Rearrangements of ETS family genes, molecular alterations in PTEN and 7P53 genes were detected in 10, 6 and 5 cancers, respectively. Nine samples showed TMPRSS2-ERG fusions, which were associated with increased ERG expression at immunohistochemistry. mTOR pathway activation was documented in 6 patients, with a clear trend of prevalence in late-metastatic patients (p = 0.08). Conclusions: A simultaneous next-generation targeted DNA and RNA sequencing is applicable on routine formalin-fixed paraffin-embedded tissues to assess the multigene molecular asset of individual prostate cancers. This approach, coupled with immunohistochemistry for ERG and mTOR pathway proteins, may help to better characterize prostate cancer molecular features with a potential impact on clinical decisions.	[Vicentini, Caterina; Cantu, Cinzia; Antonello, Davide; Simbolo, Michele; Mafficini, Andrea; Rusev, Borislav; Corbo, Vincenzo; Scarpa, Aldo; Lawlor, Rita T.] Univ Verona, ARC NET Res Ctr, Verona, Italy; [Vicentini, Caterina; Simbolo, Michele; Luchini, Claudio; Rusev, Borislav; Corbo, Vincenzo; Brunelli, Matteo; Scarpa, Aldo] Univ Verona, Sect Anat Pathol, Dept Diagnost & Publ Hlth, Verona, Italy; [Vicentini, Caterina; Simbolo, Michele; Luchini, Claudio; Rusev, Borislav; Corbo, Vincenzo; Brunelli, Matteo; Scarpa, Aldo] Hosp Trust Verona, Piazzale LA Scuro 10,Piastra Odontoiatr 2 Floor, I-37134 Verona, VR, Italy; [Antonello, Davide] Univ Verona, Dept Surg, Gen Surg B, Verona, Italy; [Artibani, Walter] AOUI, Urol Unit, Verona, Italy; [Porcaro, Antonio Benito] APOUI, Dept Internal Med, Verona, Italy; [Lacovelli, Roberto] AOUI, Oncol Unit, Verona, Italy; [Fassan, Matteo] Univ Padua, Dept Med DIMED, Padua, PD, Italy	Scarpa, A (reprint author), Hosp Trust Verona, Piazzale LA Scuro 10,Piastra Odontoiatr 2 Floor, I-37134 Verona, VR, Italy.; Scarpa, A (reprint author), Univ Verona, Dept Diagnost & Publ Hlth, Sect Pathol, ARC Net Res Ctr, Piazzale LA Scuro 10,Piastra Odontoiatr 2 Floor, I-37134 Verona, VR, Italy.	aldo.scarpa@univr.it	Simbolo, Michele/AAB-1851-2019; Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016; Brunelli, Matteo/AAA-7679-2019; Fassan, Matteo/F-5152-2012	Simbolo, Michele/0000-0002-0866-4499; Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; Mafficini, Andrea/0000-0002-7471-3121; Fassan, Matteo/0000-0001-6515-5482	Associazione Italiana Ricerca sul Cancro (AIRC 5x1000)Associazione Italiana per la Ricerca sul Cancro (AIRC) [12182]	This research was supported by Associazione Italiana Ricerca sul Cancro (AIRC 5x1000 n. 12182). The funding agencies had no role in the collection, analysis and interpretation of data and in the writing of the manuscript.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barry M, 2007, UROLOGY, V70, P630, DOI 10.1016/j.urology.2007.08.032; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bitting RL, 2013, ENDOCR-RELAT CANCER, V20, pR83, DOI 10.1530/ERC-12-0394; Carles J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw372.24; Chaux A, 2011, AM J SURG PATHOL, V35, P1014, DOI 10.1097/PAS.0b013e31821e8761; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Hong MKH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7605; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; La Manna F, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a033688; Malvezzi M, 2017, ANN ONCOL, V28, P1117, DOI 10.1093/annonc/mdx033; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; National Cancer Institute, SURV EP END REPROG; Owari T., 2018, ONCOLOGY, P1; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Seidenfeld J, 2000, ANN INTERN MED, V132, P566, DOI 10.7326/0003-4819-132-7-200004040-00009; Simbolo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062692; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Yap TA, 2016, NAT REV DRUG DISCOV, V15, P699, DOI 10.1038/nrd.2016.120; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018	40	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1675	1680		10.1016/j.prp.2018.08.031			6	Pathology	Pathology	GY0SD	WOS:000448231000023	30190183	Other Gold			2019-10-28	
J	Yang, HY; Wang, C; Guo, MZ; Zhou, YH; Feng, ZH; Yin, ZY				Yang, Haiyan; Wang, Chun; Guo, Meizi; Zhou, Yihua; Feng, Zhenhua; Yin, Zhenyu			RETRACTION: Correlations between peroxisome proliferator activator receptor gamma, Cystatin C, or advanced oxidation protein product, and atherosclerosis in diabetes patients (Retraction of Vol 211, Pg 235, 2014)	PATHOLOGY RESEARCH AND PRACTICE			English	Retraction									[Yang, Haiyan; Wang, Chun; Guo, Meizi; Yin, Zhenyu] Nanjing Univ Sch, Affiliated Hosp, Nanjing Drum Tower Hosp, Cadre Hlth Care Ward, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Yihua; Feng, Zhenhua] Nanjing Univ Sch, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China	Wang, C (reprint author), Nanjing Drum Tower Hosp, Cadre Hlth Care Ward, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	chunwangdr@163.com					Yang HY, 2015, PATHOL RES PRACT, V211, P235, DOI 10.1016/j.prp.2014.11.006	1	0	0	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1747	1747		10.1016/j.prp.2018.08.025			1	Pathology	Pathology	GY0SD	WOS:000448231000035	30249418				2019-10-28	
J	Janas, MM; Harbison, CE; Perry, VK; Carito, B; Sutherland, JE; Vaishnaw, AK; Keirstead, ND; Warner, G				Janas, Maja M.; Harbison, Carole E.; Perry, Victoria K.; Carito, Brenda; Sutherland, Jessica E.; Vaishnaw, Akshay K.; Keirstead, Natalie D.; Warner, Garvin			The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies	TOXICOLOGIC PATHOLOGY			English	Review						cell(ular) pathology; drug development; liver; monkey pathology; preclinical research and development; preclinical safety assessment/risk management; rat pathology	NUCLEIC-ACID LNA; ANTISENSE OLIGONUCLEOTIDES; LIPID NANOPARTICLES; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GROWTH-FACTOR; GENE; DELIVERY; HEPATOTOXICITY; RECEPTORS; SEQUENCE	Short interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are the most clinically advanced oligonucleotide-based platforms. A number of N-acetylgalactosamine (GalNAc)-conjugated siRNAs (GalNAc-siRNAs), also referred to as RNA interference (RNAi) therapeutics, are currently in various stages of development, though none is yet approved. While the safety of ASOs has been the subject of extensive review, the nonclinical safety profiles of GalNAc-siRNAs have not been reported. With the exception of sequence differences that confer target RNA specificity, GalNAc-siRNAs are largely chemically uniform, containing limited number of phosphorothioate linkages, and 2'-O-methyl and 2'-deoxy-2'-fluoro ribose modifications. Here, we present the outcomes of short-term (3-5 week) rat and monkey weekly repeat-dose toxicology studies of six Enhanced Stabilization Chemistry GalNAc-siRNAs currently in clinical development. In nonclinical studies at supratherapeutic doses, these molecules share similar safety signals, with histologic findings in the organ of pharmacodynamic effect (liver), the organ of elimination (kidney), and the reticuloendothelial system (lymph nodes). The majority of these changes are nonadverse, partially to completely reversible, correlate well with pharmacokinetic parameters and tissue distribution, and often reflect drug accumulation. Furthermore, all GalNAc-siRNAs tested to date have been negative in genotoxicity and safety pharmacology studies.	[Janas, Maja M.; Harbison, Carole E.; Perry, Victoria K.; Carito, Brenda; Sutherland, Jessica E.; Vaishnaw, Akshay K.; Keirstead, Natalie D.; Warner, Garvin] Alnylam Pharmaceut, 300 Third St, Cambridge, MA 02142 USA	Janas, MM (reprint author), Alnylam Pharmaceut, 300 Third St, Cambridge, MA 02142 USA.	mjanas@alnylam.com			Alnylam Pharmaceuticals	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article is funded by Alnylam Pharmaceuticals.	ADITYANJEE, 1987, ACTA PSYCHIAT SCAND, V76, P603, DOI 10.1111/j.1600-0447.1987.tb02927.x; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; Berman CL, 2016, NUCLEIC ACID THER, V26, P73, DOI 10.1089/nat.2015.0534; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Bramsen JB, 2010, NUCLEIC ACIDS RES, V38, P5761, DOI 10.1093/nar/gkq341; BROWN DA, 1994, J BIOL CHEM, V269, P26801; Burdick AD, 2014, NUCLEIC ACIDS RES, V42, P4882, DOI 10.1093/nar/gku142; Burel SA, 2016, NUCLEIC ACIDS RES, V44, P2093, DOI 10.1093/nar/gkv1210; Chan A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.36; Chery Jessica, 2016, Postdoc J, V4, P35; Crooke ST, 2017, NUCLEIC ACID THER, V27, P121, DOI 10.1089/nat.2016.0650; Cummings R. D., 2009, C TYPE LECTINS; Dancygier H, 2010, CLINICAL HEPATOLOGY, VOL 1, P75, DOI 10.1007/978-3-540-93842-2_6; Deleavey GF, 2012, CHEM BIOL, V19, P937, DOI 10.1016/j.chembiol.2012.07.011; Dias N, 2002, MOL CANCER THER, V1, P347; Eckstein F, 2000, ANTISENSE NUCLEIC A, V10, P117, DOI 10.1089/oli.1.2000.10.117; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elmen J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193; Engelhardt JA, 2015, TOXICOL PATHOL, V43, P935, DOI 10.1177/0192623315570341; Ennulat D, 2010, TOXICOL SCI, V116, P397, DOI 10.1093/toxsci/kfq144; Ferdinandi ES, 2011, CANCER CHEMOTH PHARM, V68, P193, DOI 10.1007/s00280-010-1473-z; Foster DJ, 2018, MOL THER, V26, P708, DOI 10.1016/j.ymthe.2017.12.021; Frazier KS, 2015, TOXICOL PATHOL, V43, P78, DOI 10.1177/0192623314551840; Frazier KS, 2014, TOXICOL PATHOL, V42, P923, DOI 10.1177/0192623313505781; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Hagedorn PH, 2013, NUCLEIC ACID THER, V23, P302, DOI 10.1089/nat.2013.0436; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harris Rebecca Louise, 2012, Mol Biol Int, V2012, P283974, DOI 10.1155/2012/283974; Hartmann G, 1996, MOL MED, V2, P429, DOI 10.1007/BF03401902; Henry SP, 2017, NUCLEIC ACID THER, V27, P197, DOI 10.1089/nat.2017.0666; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; Hsu SH, 2012, J CLIN INVEST, V122, P2871, DOI 10.1172/JCI63539; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Janas MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02989-4; Janas MM, 2017, NUCLEIC ACID THER, V27, P11, DOI 10.1089/nat.2016.0639; Janas MM, 2016, NUCLEIC ACID THER, V26, P363, DOI 10.1089/nat.2016.0622; Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263; Kakiuchi-Kiyota S, 2014, TOXICOL SCI, V138, P234, DOI 10.1093/toxsci/kft278; Masuda Shigeo, 2017, N Engl J Med, V376, pe38, DOI 10.1056/NEJMc1703361; Lee HS, 2015, NAT COMMUN, V6; Liebow A, 2017, J AM SOC NEPHROL, V28, P494, DOI 10.1681/ASN.2016030338; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; Martin P., 1995, HELV CHIM ACTA, V78, P486, DOI DOI 10.1002/HLCA.19950780219; Martinez T, 2015, EXCLI J, V14, P714, DOI 10.17179/excli2015-297; Mook O, 2010, ARTIF DNA PNA XNA, V1, P36, DOI DOI 10.4161/ADNA.1.1.12204; Nair JK, 2017, NUCLEIC ACIDS RES, V45, P10969, DOI 10.1093/nar/gkx818; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1708483, 10.1056/NEJMoa1616569]; Perry K., 2016, PRESENTED AT 12TH AN; Prakash TP, 2007, CURR TOP MED CHEM, V7, P641, DOI 10.2174/156802607780487713; Ray KK, 2017, NEW ENGL J MED, V376, P1430, DOI 10.1056/NEJMoa1615758; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; Sehgal A, 2015, NAT MED, V21, P492, DOI 10.1038/nm.3847; Senn JJ, 2005, J PHARMACOL EXP THER, V314, P972, DOI 10.1124/jpet.105.084004; Seok H, 2016, BMB REP, V49, P135; Seow YYT, 2002, NEPHRON, V91, P431, DOI 10.1159/000064283; Sewing S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187574; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Stanton R, 2012, NUCLEIC ACID THER, V22, P344, DOI 10.1089/nat.2012.0366; Swayze EE, 2007, NUCLEIC ACIDS RES, V35, P687, DOI 10.1093/nar/gkl1071; Vaish N, 2011, NUCLEIC ACIDS RES, V39, P1823, DOI 10.1093/nar/gkq961; Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993; Wen J, 2012, J CLIN INVEST, V122, P2773, DOI 10.1172/JCI63966; Wu J, 2002, FRONT BIOSCI, V7, pD717, DOI 10.2741/wu2; Zanardi TA, 2018, NUCLEIC ACID THER, V28, P233, DOI 10.1089/nat.2017.0706; Zatsepin TS, 2016, INT J NANOMED, V11, P3077, DOI 10.2147/IJN.S106625; Zimmermann TS, 2017, MOL THER, V25, P71, DOI 10.1016/j.ymthe.2016.10.019; Zlatev I, 2018, NAT BIOTECHNOL, V36, P509, DOI 10.1038/nbt.4136	72	5	5	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					735	745		10.1177/0192623318792537			11	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300002	30139307	Green Published, Other Gold			2019-10-28	
J	Mecklenburg, L				Mecklenburg, Lars			A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists	TOXICOLOGIC PATHOLOGY			English	Review						payload; auristatin; maytansinoid; calicheamicin; duocarmycin; pyrrolobenzodiazepine; amanitin; antibody-drug conjugates; ADCs; antibody	ALPHA-AMANITIN; TOXICITY; RATS; DUOCARMYCIN; MAYTANSINE; PROFILE; MICE	Antibody-drug conjugates (ADCs) are an emerging class of anticancer therapeutics, delivering highly cytotoxic molecules directly to cancer cells. ADCs are composed of an antibody, a small molecule drug, and a linker attaching one to another. Antibodies are directed to a large variety of antigens overexpressed on tumor cells, tumor vasculature, or tumor-supporting stroma. After internalization, the ADC is transferred to lysosomes where the cytotoxic component is released, finally killing the target cell. All ADCs are administered via intravenous injection. Once in the circulation, linker stability in plasma is of high importance. In vivo studies in animals address the release of payload over time and typically measure total antibody, conjugated ADC, and free drug. ADC development is driven by ICH (International Council for Harmonisation) guidelines S6(R1) and S9. Dose-limiting toxicities of current ADCs are mainly associated with the payload and correlate well between clinical trials and nonclinical studies in rodents and nonrodents. This mini review is intended to provide general information about ADCs in oncology and shall assist the toxicologic pathologist in correctly interpreting morphological findings acquired in toxicity studies with this entity.	[Mecklenburg, Lars] Covance Preclin Serv GmbH, Kesselfeld 29, D-48163 Munster, Germany	Mecklenburg, L (reprint author), Covance Preclin Serv GmbH, Kesselfeld 29, D-48163 Munster, Germany.	lars.mecklenburg@covance.com					Dokter W, 2014, MOL CANCER THER, V13, P2618, DOI 10.1158/1535-7163.MCT-14-0040-T; European Medicines Agency, 2012, EMA7023902012; European Medicines Agency, 2008, EMA7023902012; European Medicines Agency, 2013, EMA7492282013; European Medicines Agency, 2017, EMA2890462017; Fang T, 2016, ANGEW CHEM INT EDIT, V55, P2416, DOI 10.1002/anie.201509432; Hedrich WD, 2018, CLIN PHARMACOKINET, V57, P687, DOI 10.1007/s40262-017-0619-0; Hinrichs MJM, 2015, AAPS J, V17, P1055, DOI 10.1208/s12248-015-9790-0; KOBAYASHI E, 1994, CANCER RES, V54, P2404; Kraynov E, 2016, DRUG METAB DISPOS, V44, P617, DOI 10.1124/dmd.115.068049; Lin J. H., 2018, CURR PHARM REP, V4, P10, DOI DOI 10.1007/S40495-018-0122-9; Lucas AT, 2018, ANTIBODIES, V7, DOI 10.3390/antib7010010; Masters JC, 2018, INVEST NEW DRUG, V36, P121, DOI 10.1007/s10637-017-0520-6; Miller ML, 2016, MOL CANCER THER, V15, P1870, DOI 10.1158/1535-7163.MCT-16-0184; Mirsalis JC, 1999, CANCER CHEMOTH PHARM, V44, P395, DOI 10.1007/s002800050995; MUGERA GM, 1977, CANCER TREAT REP, V61, P1333; Pillow TH, 2017, MOL CANCER THER, V16, P871, DOI 10.1158/1535-7163.MCT-16-0641; Poon KA, 2013, TOXICOL APPL PHARM, V273, P298, DOI 10.1016/j.taap.2013.09.003; Sellmann C, 2016, J BIOL CHEM, V291, P25106, DOI 10.1074/jbc.M116.753491; Staudacher AH, 2017, BRIT J CANCER, V117, P1736, DOI 10.1038/bjc.2017.367; VOGEL G, 1979, AGENTS ACTIONS, V9, P221, DOI 10.1007/BF02024739; WHITE RD, 1983, CANCER TREAT REP, V67, P183; Zhao J, 2006, PEPTIDES, V27, P3047, DOI 10.1016/j.peptides.2006.08.015	23	1	1	3	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					746	752		10.1177/0192623318803059			7	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300003	30295169				2019-10-28	
J	Rojas, JM; Bolze, F; Thorup, I; Nowak, J; Dalsgaard, CM; Skydsgaard, M; Berthelsen, LO; Keane, KA; Soeborg, H; Sjogren, I; Jensen, JT; Fels, JJ; Offenberg, HK; Andersen, LW; Dalgaard, M				Rojas, Jennifer M.; Bolze, Florian; Thorup, Inger; Nowak, Jette; Dalsgaard, Charlotte M.; Skydsgaard, Mikala; Berthelsen, Line O.; Keane, Kevin A.; Soeborg, Henrik; Sjogren, Ingrid; Jensen, Jes T.; Fels, Johannes J.; Offenberg, Hanne K.; Andersen, Laerke W.; Dalgaard, Majken			The Effect of Diet-induced Obesity on Toxicological Parameters in the Polygenic Sprague-Dawley Rat Model	TOXICOLOGIC PATHOLOGY			English	Article						Sprague-Dawley rat; diet-induced obesity; toxicology parameters; bone toxicity; reproductive toxicity; nonclinical safety assessment	HIGH-FAT DIET; METABOLICALLY HEALTHY OBESITY; ADIPOSE-TISSUE DEPOTS; INSULIN-RESISTANCE; BODY-WEIGHT; CANCELLOUS BONE; ANIMAL-MODELS; LABORATORY RODENTS; PANCREATIC-ISLETS; SAFETY ASSESSMENT	The obese rodent serves as an indispensable tool for proof-of-concept efficacy and mode-of-action pharmacology studies. Yet the utility of this disease model as an adjunct to the conventional healthy animal in the nonclinical safety evaluation of anti-obesity pharmacotherapies has not been elucidated. Regulatory authorities have recommended employing disease models in toxicology studies when necessary. Our study investigated standard and exploratory toxicology parameters in the high-fat diet (HFD)-induced obese, polygenic Sprague-Dawley rat model in comparison to chow diet (CD)-fed controls. We sought to establish feasibility of the model for safety testing and relevance to human obesity pathophysiology. We report that both sexes fed a 45% kcal HFD for 29 weeks developed obesity and metabolic derangements that mimics to a certain extent, common human obesity. Minor clinical pathologies were observed in both sexes and considered related to CD versus HFD differences. Histopathologically, both sexes exhibited mild obesity-associated findings in brown and subcutaneous white fat, bone, kidneys, liver, lung, pancreas, salivary parotid glands, and skeletal muscle. We conclude that chronic HFD feeding in both sexes led to the development of an obese but otherwise healthy rat. Therefore, the diet-induced obese Sprague-Dawley rat may serve as a suitable model for evaluating toxicity findings encountered with anti-obesity compounds.	[Rojas, Jennifer M.; Dalgaard, Majken] Novo Nordisk AS, Early Regulatory Toxicol, DK-2760 Malov, Denmark; [Bolze, Florian; Andersen, Laerke W.] Novo Nordisk AS, Toxicol Dev Projects, Malov, Denmark; [Thorup, Inger; Nowak, Jette; Dalsgaard, Charlotte M.; Skydsgaard, Mikala; Berthelsen, Line O.; Keane, Kevin A.; Soeborg, Henrik; Sjogren, Ingrid; Offenberg, Hanne K.] Novo Nordisk AS, Toxicopathol, Malov, Denmark; [Jensen, Jes T.] CiToxLAB Scantox AS, Lille Skensved, Denmark; [Fels, Johannes J.] Novo Nordisk AS, Res Bioanal, Malov, Denmark	Dalgaard, M (reprint author), Novo Nordisk AS, Early Regulatory Toxicol, DK-2760 Malov, Denmark.	mjda@novonordisk.com			Novo Nordisk R&D STAR Programme; Novo Nordisk A/SNovo Nordisk	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publications of this article: This study was funded by the Novo Nordisk R&D STAR Programme (JR, FB) and by Novo Nordisk A/S.	Abdelaal M, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.107; Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Agahi A, 2014, VET PATHOL, V51, P695, DOI 10.1177/0300985813492801; Altunkaynak ME, 2008, J ANAT, V212, P845, DOI 10.1111/j.1469-7580.2008.00902.x; Archer ZA, 2003, OBES RES, V11, P1376, DOI 10.1038/oby.2003.186; Aubin MC, 2008, J PHARMACOL EXP THER, V325, P961, DOI 10.1124/jpet.107.135061; Axelsen LN, 2010, AM J PHYSIOL-REG I, V298, pR1560, DOI 10.1152/ajpregu.00392.2009; BAGDADE JD, 1967, J CLIN INVEST, V46, P1549, DOI 10.1172/JCI105646; Bailey SA, 2004, TOXICOL PATHOL, V32, P448, DOI 10.1080/01926230490465874; Barrett P, 2016, DIS MODEL MECH, V9, P1245, DOI 10.1242/dmm.026443; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35047145; Berryman DE, 2011, GROWTH HORM IGF RES, V21, P113, DOI 10.1016/j.ghir.2011.03.002; Betz Matthias J, 2011, Front Endocrinol (Lausanne), V2, P86, DOI 10.3389/fendo.2011.00086; Blundell JE, 2000, BRIT J NUTR, V83, pS33; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; Cacho J, 2008, AM J PHYSIOL-ENDOC M, V295, pE1269, DOI 10.1152/ajpendo.90207.2008; Cao JJ, 2015, CALCIFIED TISSUE INT, V97, P145, DOI 10.1007/s00223-015-9992-6; Cao JJ, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749-799X-6-30; Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017; Chao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096969; Chusyd DE, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00010; Cinti S, 2012, DIS MODEL MECH, V5, P588, DOI 10.1242/dmm.009662; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cora MC, 2015, TOXICOL PATHOL, V43, P776, DOI 10.1177/0192623315570339; Cordain L, 2005, AM J CLIN NUTR, V81, P341; Creasy D, 2012, TOXICOL PATHOL, V40, p40S, DOI 10.1177/0192623312454337; Dallak M, 2019, ARCH PHYSIOL BIOCHEM, V125, P79, DOI 10.1080/13813455.2018.1437749; Darvall KAL, 2007, EUR J VASC ENDOVASC, V33, P223, DOI 10.1016/j.ejvs.2006.10.006; De Pergola G, 2002, J ENDOCRINOL INVEST, V25, P899, DOI 10.1007/BF03344054; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Dixit R, 2007, DRUG DISCOV TODAY, V12, P336, DOI 10.1016/j.drudis.2007.02.018; Dong XL, 2016, J NUTR, V146, P1172, DOI 10.3945/jn.115.225474; El-Gendy AA, 2014, J PHYSIOL BIOCHEM, V70, P809, DOI 10.1007/s13105-014-0350-3; Eshet R, 2004, J ENDOCRINOL, V182, P165, DOI 10.1677/joe.0.1820165; Everds NE, 2013, TOXICOL PATHOL, V41, P560, DOI 10.1177/0192623312466452; Fernandes TAP, 2017, J DIABETES RES, DOI 10.1155/2017/9021314; Frayn KN, 2002, DIABETOLOGIA, V45, P1201, DOI 10.1007/s00125-002-0873-y; Gao MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119784; Garg A, 2004, J CLIN ENDOCR METAB, V89, P4206, DOI 10.1210/jc.2004-0631; Gautam J, 2014, BRIT J NUTR, V111, P1811, DOI 10.1017/S0007114514000051; Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gower BA, 2013, J CLIN DENSITOM, V16, P450, DOI 10.1016/j.jocd.2013.08.010; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P1; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hamer M, 2012, J CLIN ENDOCR METAB, V97, P2482, DOI 10.1210/jc.2011-3475; Hill AA, 2014, IMMUNOL REV, V262, P134, DOI 10.1111/imr.12216; Howard C. V., 2010, UNBIASED STEREOLOGY, P53; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Imaoka M, 2007, TOXICOL PATHOL, V35, P388, DOI 10.1080/01926230701230304; Imaoka M, 2009, TOXICOL PATHOL, V37, P218, DOI 10.1177/0192623308329283; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Guidelines, 1997, ICH HARM TRIP GUID P; Inzana JA, 2013, BONE, V57, P174, DOI 10.1016/j.bone.2013.08.003; Iwaniec UT, 2016, J ENDOCRINOL, V230, pR115, DOI 10.1530/JOE-16-0089; Jarvis P, 2011, PHARM STAT, V10, P477, DOI 10.1002/pst.527; Jensen T, 2018, J HEPATOL, V68, P1063, DOI 10.1016/j.jhep.2018.01.019; Jung CH, 2017, KOREAN J INTERN MED, V32, P611, DOI 10.3904/kjim.2016.259; Jungheim ES, 2012, OBSTET GYN CLIN N AM, V39, P479, DOI 10.1016/j.ogc.2012.09.002; Kaji N, 2013, J VET MED SCI, V75, P1245, DOI 10.1292/jvms.13-0029; Kawai M, 2010, J CELL BIOCHEM, V111, P14, DOI 10.1002/jcb.22678; Keenan KP, 2005, TOXICOL PATHOL, V33, P650, DOI 10.1080/01926230500311222; Kern PA, 2003, DIABETES, V52, P1779, DOI 10.2337/diabetes.52.7.1779; Kim GW, 2014, CLIN PHARMACOL THER, V95, P53, DOI 10.1038/clpt.2013.204; Kleinert M, 2018, NAT REV ENDOCRINOL, V14, P140, DOI 10.1038/nrendo.2017.161; Levin BE, 1997, AM J PHYSIOL-REG I, V273, pR725; Levin BE, 2000, AM J PHYSIOL-REG I, V278, pR231; Lutz Thomas A, 2012, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0561s58; Madsen AN, 2010, J ENDOCRINOL, V206, P287, DOI 10.1677/JOE-10-0004; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Marques C, 2016, ADIPOCYTE, V5, P11, DOI 10.1080/21623945.2015.1061723; Martin B, 2010, P NATL ACAD SCI USA, V107, P6127, DOI 10.1073/pnas.0912955107; Massy ZA, 2012, CLIN KIDNEY J, V5, P52, DOI 10.1093/ndtplus/sfr167; MATSUBARA T, 1982, JPN J PHARMACOL, V32, P999, DOI 10.1254/jjp.32.999; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McDyre BC, 2018, TOXICOL PATHOL, V46, P202, DOI 10.1177/0192623317747549; McInnes E. F., 2011, BACKGROUND LESIONS L; Mercer JG, 2005, BIOCHEM SOC T, V33, P1068, DOI 10.1042/BST0331068; Morgan SJ, 2013, TOXICOL PATHOL, V41, P508, DOI 10.1177/0192623312457273; Morton GJ, 2014, NAT REV NEUROSCI, V15, P367, DOI 10.1038/nrn3745; Mullur R, 2014, PHYSIOL REV, V94, P355, DOI 10.1152/physrev.00030.2013; Nicoll R, 2015, INT J MOL SCI, V16, P8861, DOI 10.3390/ijms16048861; Olivares A, 2010, GEN COMP ENDOCR, V166, P356, DOI 10.1016/j.ygcen.2009.12.007; Organization for Economic Cooperation and Development, 2017, OECD HLTH STAT OB UP; Palmisano BT, 2018, MOL METAB, V15, P45, DOI 10.1016/j.molmet.2018.05.008; Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023; Phillips CM, 2013, REV ENDOCR METAB DIS, V14, P219, DOI 10.1007/s11154-013-9252-x; Posey KA, 2009, AM J PHYSIOL-ENDOC M, V296, pE1003, DOI 10.1152/ajpendo.90377.2008; Raun K, 2007, DIABETES, V56, P8, DOI 10.2337/db06-0565; Recker RR, 1983, BONE HISTOMORPHOMETR; REEVES PG, 1993, J NUTR, V123, P1939; Reid IR, 2002, BONE, V31, P547, DOI 10.1016/S8756-3282(02)00864-5; Sackmann-Sala L, 2012, OBESITY, V20, P101, DOI 10.1038/oby.2011.235; Sakr Hussein F., 2018, Journal of Basic and Clinical Physiology and Pharmacology, V29, P61, DOI 10.1515/jbcpp-2017-0069; Sampey BP, 2011, OBESITY, V19, P1109, DOI 10.1038/oby.2011.18; Scheid MP, 2014, REV ENDOCR METAB DIS, V15, P157, DOI 10.1007/s11154-013-9265-5; Schwartz MW, 2017, ENDOCR REV, V38, P267, DOI 10.1210/er.2017-00111; Shapses S. A., 2015, NUTR BONE HLTH BODY; Shapses SA, 2012, ANNU REV NUTR, V32, P287, DOI 10.1146/annurev.nutr.012809.104655; Shimizu I, 2014, J CLIN INVEST, V124, P2099, DOI 10.1172/JCI71643; Rojas JXS, 2016, J GERONTOL A-BIOL, V71, P310, DOI 10.1093/gerona/glv117; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Smith S. Y., 2017, BONE TOXICOLOGY; Snel M., 2012, INT J ENDOCRINOL, V2012, P18; Srivastava G, 2018, CURR OBES REP, V7, P147, DOI 10.1007/s13679-018-0300-4; Suttie A. W., 2018, BOORMANS PATHOLOGY R; Tannenbaum BM, 1997, AM J PHYSIOL-ENDOC M, V273, pE1168; Tetri LH, 2008, AM J PHYSIOL-GASTR L, V295, pG987, DOI 10.1152/ajpgi.90272.2008; Tremmel M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040435; Tsonkova VG, 2018, MOL METAB, V8, P144, DOI 10.1016/j.molmet.2017.12.007; van Harmelen V, 2003, INT J OBESITY, V27, P889, DOI 10.1038/sj.ijo.0802314; Vickers SP, 2011, BRIT J PHARMACOL, V164, P1248, DOI 10.1111/j.1476-5381.2011.01245.x; Vidal JD, 2014, SPERMATOGENESIS, V4, pe979099, DOI [10.4161/21565562.2014.979099, DOI 10.4161/21565562.2014.979099]; Whalan JE, 2015, TOXICOLOGISTS GUIDE; Woods SC, 2003, J NUTR, V133, P1081; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463	116	1	1	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					777	798		10.1177/0192623318803557			22	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300006	30343647				2019-10-28	
J	Carroll, EE; Ippolito, DL; Permenter, MG; McDyre, BC; Baer, CE; Kumsher, DM; Boyle, MH; DiVito, VT; Lewis, JA; Koontz, JM				Carroll, Erica E.; Ippolito, Danielle L.; Permenter, Matthew G.; McDyre, B. Claire; Baer, Christine E.; Kumsher, David M.; Boyle, Molly H.; DiVito, Valerie T.; Lewis, John A.; Koontz, Jason M.			Utility of Serum miR-122, Liver Enzymes, and Hepatic Histopathology in Response to Hepatotoxicants in Sprague-Dawley Rats	TOXICOLOGIC PATHOLOGY			English	Article						biomarker; fibrosis; liver; miR-122; pathology; liver enzymes; hepatotoxicity	INJURY; BIOMARKERS; FIBROSIS; IDENTIFICATION; TOXICITY; MICE	More than 80,000 chemicals are in commercial use worldwide. Hepatic metabolism to toxic intermediates is often a key mechanism leading to tissue damage and organ dysfunction. Effective treatment requires prompt detection of hepatotoxicity, ideally with rapid, minimally invasive diagnostic assays. In this study, archetypal histologic features of chemically induced hepatic injury were compared with clinical chemistries (including liver enzymes) and serum concentrations of microRNA-122 (miR-122, the processed form miR-122-5p), a biomarker of liver injury. The hepatotoxicants 4,4'-methylenedianiline (4,4'-MDA), allyl alcohol (AA), or carbon tetrachloride (CCl4) were orally administered to male Sprague-Dawley rats for 1, 5, 14, or 28 days to induce liver damage. Formalin-fixed, paraffin-embedded liver sections were evaluated histologically for inflammation, fibrosis, necrosis, and lipid accumulation. Liver enzymes were measured in serum, and serum miR-122 concentrations were assessed by quantitative polymerase chain reaction (qPCR). Histologic features of hepatic injury dose-dependently increased in both severity and frequency. Increases in liver enzymes and bilirubin were more pronounced in response to AA or 4,4'-MDA than to CCl4 at early time points. Elevated serum miR-122 levels in animals administered CCl4, AA, or 4,4'-MDA were more strongly associated with degree of hepatic histopathology than with dosage. Given this sensitive expression pattern postexposure, liver-specific miR-122 may improve the diagnostic accuracy of early hepatic injury.	[Carroll, Erica E.] US Army, Publ Hlth Ctr, Gunpowder, MD USA; [Carroll, Erica E.] Covance Inc, Greenfield, IN USA; [Ippolito, Danielle L.; DiVito, Valerie T.; Lewis, John A.; Koontz, Jason M.] US Army, Environm Hlth Program, Ctr Environm Hlth Res USACEHR, Ft Detrick, MD USA; [Permenter, Matthew G.; Baer, Christine E.; Kumsher, David M.] Excet Inc, Frederick, MD USA; [McDyre, B. Claire] ORISE, Frederick, MD USA; [Boyle, Molly H.] Envigo, Somerset, NJ USA	Koontz, JM (reprint author), US Army, Ctr Environm Hlth Res, 568 Doughten Dr, Ft Detrick, MD 21702 USA.	jason.m.koontz6.civ@mail.mil					Arias IM, 1982, LIVER BIOL PATHOBIOL; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Burkhardt JE, 2011, TOXICOL PATHOL, V39, P1129, DOI 10.1177/0192623311422082; Cardenas-Gonzalez M, 2017, CLIN CHEM, V63, P1515, DOI 10.1373/clinchem.2017.274175; Casarett L. J., 2008, CASARETT DOULLS TOXI; Cheng YH, 2012, J MOL CELL CARDIOL, V53, P668, DOI 10.1016/j.yjmcc.2012.08.010; Church RJ, 2016, TOXICOL SCI, V150, P3, DOI 10.1093/toxsci/kfv260; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Ganter B, 2005, J BIOTECHNOL, V119, P219, DOI 10.1016/j.jbiotec.2005.03.022; Ippolito DL, 2016, TOXICOL SCI, V149, P67, DOI 10.1093/toxsci/kfv214; Ismail Mona H, 2009, Saudi J Gastroenterol, V15, P72, DOI 10.4103/1319-3767.45072; JAESCHKE H, 1987, BIOCHEM PHARMACOL, V36, P51, DOI 10.1016/0006-2952(87)90381-9; Lee GP, 2005, ANTICANCER RES, V25, P1029; Moustafa SA, 2001, INT J TOXICOL, V20, P15, DOI 10.1080/109158101750103332; National Research Council, 2011, GUIDE CARE USE LAB A; National Toxicology Program, 2010, DRUGMATRIX; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Orang AV, 2014, INT J GENOMICS, DOI 10.1155/2014/970607; Schafer KA, 2018, TOXICOL PATHOL, V46, P256, DOI 10.1177/0192623318761348; Sharapova T, 2016, VET PATHOL, V53, P211, DOI 10.1177/0300985815591076; Starckx S, 2013, TOXICOL PATHOL, V41, P795, DOI 10.1177/0192623312464436; Tan YW, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0094264, 10.1371/journal.pone.0105192]; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Vliegenthart ADB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15501; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Yu CD, 2002, AM J PATHOL, V161, P2003, DOI 10.1016/S0002-9440(10)64478-1; Zhang XY, 2006, J PHARMACOL EXP THER, V316, P289, DOI 10.1124/jpet.105.093302	27	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					835	846		10.1177/0192623318795435			12	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300009	30205766				2019-10-28	
J	Davidson, B				Davidson, Ben			Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies	VIRCHOWS ARCHIV			English	Review						Circulating tumor cells; Disseminated tumor cells; Cell-free DNA; Gynecological cancer; Diagnosis; Prognosis	CERVICAL-CANCER PATIENTS; EPITHELIAL OVARIAN-CANCER; PLATINUM-BASED CHEMOTHERAPY; PERIPHERAL-BLOOD; BONE-MARROW; FREE DNA; ENDOMETRIAL CARCINOMA; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; PROGNOSTIC-SIGNIFICANCE	The ability to detect cancer cells in the blood or in the bone marrow offers invaluable information which potentially impacts early diagnosis, monitoring of treatment, and prognosis. Accessing blood or other body fluids has the additional advantage of being less invasive than biopsy. Consequently, considerable effort has been invested in the last 20 years in optimizing assays which may identify malignant cells at these anatomic sites. Detection of nucleic acids has been applied as alternative approach in this context, first targeting single cancer-associated genes using PCR-based technology, and recently using assays which identify different DNA classes, as well as microRNAs and exosomes. The present review focuses on studies which applied these assays to the detection of cells or cellular components originating from gynecological cancers.	[Davidson, Ben] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, N-0310 Oslo, Norway; [Davidson, Ben] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway	Davidson, B (reprint author), Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, N-0310 Oslo, Norway.; Davidson, B (reprint author), Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway.	bend@medisin.uio.no					Aktas B, 2011, INT J GYNECOL CANCER, V21, P822, DOI 10.1097/IGC.0b013e318216cb91; Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223; Banys M, 2009, INT J GYNECOL CANCER, V19, P948, DOI 10.1111/IGC.0b013e3181a23c4c; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Blassl C, 2016, MOL ONCOL, V10, P1030, DOI 10.1016/j.molonc.2016.04.002; Braun S, 2001, J CLIN ONCOL, V19, P368, DOI 10.1200/JCO.2001.19.2.368; Carow K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102032; Chebouti I, 2017, ONCOTARGET, V8, P24303, DOI 10.18632/oncotarget.13286; Christie EL, 2017, J CLIN ONCOL, V35, P1274, DOI 10.1200/JCO.2016.70.4627; Chung TKH, 2017, GYNECOL ONCOL, V146, P334, DOI 10.1016/j.ygyno.2017.05.038; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; Cohen PA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0667-6; Cui L, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0168-9; Dobrzycka B, 2010, INT J CANCER, V127, P612, DOI 10.1002/ijc.25077; DORAN TA, 1966, AM J OBSTET GYNECOL, V94, P985, DOI 10.1016/0002-9378(66)90037-8; Fan T, 2009, GYNECOL ONCOL, V112, P185, DOI 10.1016/j.ygyno.2008.09.021; Farkkila A, 2017, J MOL DIAGN, V19, P126, DOI 10.1016/j.jmoldx.2016.08.005; Fehm T, 2014, INT J CANCER, V134, P925, DOI 10.1002/ijc.28417; Filippov-Levy N, 2018, GYNECOL ONCOL, V148, P559, DOI 10.1016/j.ygyno.2018.01.004; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; He W, 2008, INT J CANCER, V123, P1968, DOI 10.1002/ijc.23717; He W, 2007, P NATL ACAD SCI USA, V104, P11760, DOI 10.1073/pnas.0703875104; Ji XQ, 2006, GYNECOL ONCOL, V100, P355, DOI 10.1016/j.ygyno.2005.08.041; Judson PL, 2003, GYNECOL ONCOL, V91, P389, DOI 10.1016/S0090-8258(03)00571-7; Kamat AA, 2010, CANCER-AM CANCER SOC, V116, P1918, DOI 10.1002/cncr.24997; Kang ZG, 2017, CLIN CANCER RES, V23, P6856, DOI 10.1158/1078-0432.CCR-17-1553; Klein A, 2000, GYNECOL ONCOL, V78, P352, DOI 10.1006/gyno.2000.5918; Kommoss S, 2017, J CANCER RES CLIN, V143, P2183, DOI 10.1007/s00432-017-2474-7; Kumar P, 2017, MOL CANCER RES, V15, P1197, DOI 10.1158/1541-7786.MCR-17-0095; Lee M, 2017, GYNECOL ONCOL, V145, P361, DOI 10.1016/j.ygyno.2017.02.042; Lemech CR, 2016, ONCOLOGY-BASEL, V91, P48, DOI 10.1159/000445999; Lianidou ES, 2014, CRIT REV CL LAB SCI, V51, P160, DOI 10.3109/10408363.2014.896316; Liu JF, 2013, GYNECOL ONCOL, V131, P352, DOI 10.1016/j.ygyno.2013.08.006; Marth C, 2002, CANCER-AM CANCER SOC, V94, P707, DOI 10.1002/cncr.10250; Martignetti JA, 2014, NEOPLASIA, V16, P97, DOI 10.1593/neo.131900; Massard C, 2017, EUR J CANCER, V83, P185, DOI 10.1016/j.ejca.2017.05.016; Mitsuhashi A, 2003, GYNECOL ONCOL, V89, P480, DOI 10.1016/S0090-8258(03)00150-1; Morikawa Asuka, 2018, Oncotarget, V9, P15266, DOI 10.18632/oncotarget.24555; Nakamura K, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0536-0; Obermayr E, 2017, ONCOTARGET, V8, P106415, DOI 10.18632/oncotarget.22468; Obermayr E, 2013, GYNECOL ONCOL, V128, P15, DOI 10.1016/j.ygyno.2012.09.021; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Pao CC, 1997, J CLIN ONCOL, V15, P1008, DOI 10.1200/JCO.1997.15.3.1008; Park Yu Ran, 2018, Obstet Gynecol Sci, V61, P328, DOI 10.5468/ogs.2018.61.3.328; Parkinson CA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002198; Pearl ML, 2017, GYNECOL ONCOL, V147, P426, DOI 10.1016/j.ygyno.2017.08.018; Pearl ML, 2015, GYNECOL ONCOL, V137, P229, DOI 10.1016/j.ygyno.2015.03.002; Pearl ML, 2014, GYNECOL ONCOL, V134, P581, DOI 10.1016/j.ygyno.2014.06.013; Pecot CV, 2011, CANCER DISCOV, V1, P580, DOI 10.1158/2159-8290.CD-11-0215; Pfitzner C, 2014, SCI REP-UK, V4, DOI 10.1038/srep03970; Phallen J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2415; Poveda A, 2011, GYNECOL ONCOL, V122, P567, DOI 10.1016/j.ygyno.2011.05.028; Romero-Laorden N, 2014, GYNECOL ONCOL, V133, P632, DOI 10.1016/j.ygyno.2014.03.016; SONG J, 1969, AM J OBSTET GYNECOL, V104, P713, DOI 10.1016/0002-9378(69)90613-9; Speicher MR, 2014, NAT BIOTECHNOL, V32, P441, DOI 10.1038/nbt.2897; Steffensen KD, 2014, EUR J CANCER, V50, P2611, DOI 10.1016/j.ejca.2014.06.022; Stenman J, 1997, INT J CANCER, V74, P75, DOI 10.1002/(SICI)1097-0215(19970220)74:1<75::AID-IJC13>3.0.CO;2-H; Takakura M, 2018, CANCER SCI, V109, P231, DOI 10.1111/cas.13449; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Traver S, 2014, HUM REPROD UPDATE, V20, P905, DOI 10.1093/humupd/dmu031; Trejo-Becerril C, 2003, INT J CANCER, V104, P663, DOI 10.1002/ijc.11003; TURCHETTI G, 1968, GYNAECOLOGIA, V165, P252, DOI 10.1159/000302563; Vaksman O, 2014, CARCINOGENESIS, V35, P2113, DOI 10.1093/carcin/bgu130; Vanderstichele A, 2017, CLIN CANCER RES, V23, P2223, DOI 10.1158/1078-0432.CCR-16-1078; Walter CB, 2014, FUTURE ONCOL, V10, P41, DOI [10.2217/FON.13.174, 10.2217/fon.13.174]; Wang HX, 2017, ONCOTARGET, V8, P1884, DOI 10.18632/oncotarget.12242; Weigelt B, 2017, CLIN CANCER RES, V23, P6708, DOI 10.1158/1078-0432.CCR-17-0544; Widschwendter M, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0500-7; Wimberger P, 2011, INT J CANCER, V128, P2572, DOI 10.1002/ijc.25602; Wu YQ, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00234; YAGI M, 1963, J Jpn Obstet Gynecol Soc, V10, P69; Yuan CC, 2002, GYNECOL ONCOL, V85, P148, DOI 10.1006/gyno.2002.6587	72	0	0	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					395	403		10.1007/s00428-018-2447-5			9	Pathology	Pathology	GV8HP	WOS:000446380500001	30145616				2019-10-28	
J	Ferreira, C; Lobo, J; Antunes, L; Lopes, P; Jeronimo, C; Henrique, R				Ferreira, Catarina; Lobo, Joao; Antunes, Luis; Lopes, Paula; Jeronimo, Carmen; Henrique, Rui			Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features	VIRCHOWS ARCHIV			English	Article						Prostate cancer; E-cadherin; P-cadherin; Survival	RADICAL PROSTATECTOMY; BETA-CATENIN; MESENCHYMAL TRANSITION; ALPHA-CATENIN; HIGH-RISK; PROGNOSTIC VALUE; NATURAL-HISTORY; GAMMA-CATENIN; N-CADHERIN; SURVIVAL	Cadherins seem to play and important role in prostate cancer (PCa) progression. E-cadherin loss of expression has been associated with poor prognosis; P-cadherin's role is still elusive. Although pT3 PCa is often considered "high-risk cancer," it does not exhibit an uniformly poor prognosis. Herein, we assessed the prognostic value and survival impact of E-cadherin and P-cadherin immunoexpression in pT3 PCa. Radical prostatectomy (RP) specimens from 102 pT3 PCa patients treated between 1991 and 2014 in a single institution were designated for E-cadherin and P-cadherin immunoexpression analysis. A representative block from each specimen was selected for tissue micro-array (TMA) construction, using 3 cores per case. E-cadherin immunoexpression was assessed via a digital image analysis system. For P-cadherin, scoring criteria for HER2 in gastric cancer were used. Clinical records of all patients were reviewed for baseline clinical/pathologic characteristics and follow-up data. E-cadherin-low PCa patients displayed worse disease-specific survival (DSS), although not reaching statistical significance (HR 2.65, 95%CI 0.81-7.88). However, considering the pT3b group only, those with low E-cadherin immunoexpression displayed significantly worse overall-survival (OS) and DSS (HR 3.69, 95%CI 1.18-11.50; HR 5.90, 95%CI 1.40-24.81). No significant differences in survival were found for P-cadherin differential immunoexpression. Furthermore, an association between E-cadherin and P-cadherin immunoexpression (p = 0.019) was found, as among E-cadherin-low PCa, 96.6% were P-cadherin negative. We demonstrated that low E-cadherin immunoexpression discriminates among pT3b PCa patients those with poorer survival and which might benefit from specific therapy. The role of P-cadherin in PCa seems context-dependent deserving further investigation.	[Ferreira, Catarina; Lobo, Joao; Lopes, Paula; Henrique, Rui] IPOP, Dept Pathol, R Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal; [Lobo, Joao; Lopes, Paula; Jeronimo, Carmen; Henrique, Rui] Res Ctr Portuguese Oncol Inst Porto GEBC CI IPOP, Canc Biol & Epigenet Grp, R Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal; [Lobo, Joao; Jeronimo, Carmen; Henrique, Rui] Univ Porto ICBAS UP, Inst Biomed Sci Abel Salazar, Dept Pathol & Mol Immunol, Rua Jorge Viterbo Ferreira 228, P-4050513 Porto, Portugal; [Antunes, Luis] IPOP, Dept Epidemiol, R Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal	Henrique, R (reprint author), IPOP, Dept Pathol, R Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal.; Henrique, R (reprint author), Res Ctr Portuguese Oncol Inst Porto GEBC CI IPOP, Canc Biol & Epigenet Grp, R Dr Antonio Bernardino de Almeida, P-4200072 Porto, Portugal.; Henrique, R (reprint author), Univ Porto ICBAS UP, Inst Biomed Sci Abel Salazar, Dept Pathol & Mol Immunol, Rua Jorge Viterbo Ferreira 228, P-4050513 Porto, Portugal.	henrique@ipoporto.min-saude.pt	Lobo, Joao/K-5920-2019; Henrique, Rui/I-2757-2013; Antunes, Luis/A-8572-2014	Lobo, Joao/0000-0001-6829-1391; Henrique, Rui/0000-0003-3171-4666; Antunes, Luis/0000-0002-3098-0711	Research Centre of Portuguese Oncology Institute of Porto [CI-IPOP-17-2015]; FCT-Fundacao para a Ciencia e Tecnologia [SFRH/BD/132751/2017]	This study was supported by project CI-IPOP-17-2015 (Epigenetic signature of prostate cancer stem cells) funded by the Research Centre of Portuguese Oncology Institute of Porto. JL is supported by an FCT-Fundacao para a Ciencia e Tecnologia-fellowship (grant number SFRH/BD/132751/2017).	Abdelrahman AE, 2017, TURK J PATHOL, V33, P198, DOI 10.5146/tjpath.2016.01392; ADOLFSSON J, 1990, BRIT J UROL, V65, P611, DOI 10.1111/j.1464-410X.1990.tb14829.x; Albergaria A, 2011, INT J DEV BIOL, V55, P811, DOI 10.1387/ijdb.113382aa; Arenas MI, 2000, HISTOCHEM J, V32, P659, DOI 10.1023/A:1004111331752; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Bae KM, 2011, AM J CANCER RES, V1, P71; Barqawi A, 2012, ADV UROL, DOI 10.1155/2012/862639; Bauer JJ, 1998, J UROLOGY, V159, P929, DOI 10.1016/S0022-5347(01)63773-X; Behnsawy HM, 2013, BJU INT, V111, P30, DOI 10.1111/j.1464-410X.2012.11551.x; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; BOSTWICK DG, 1993, UROLOGY, V41, P403, DOI 10.1016/0090-4295(93)90497-X; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deng QK, 2016, MED SCI MONITOR, V22, P516, DOI 10.12659/MSM.897179; Drivalos A, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2015.10.016; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Etzioni R, 2002, J NATL CANCER I, V94, P981; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Howlader N, 2017, SEER CANC STAT REV 1; Hulpiau P, 2009, INT J BIOCHEM CELL B, V41, P349, DOI 10.1016/j.biocel.2008.09.027; Imai K, 2008, CLIN CANCER RES, V14, P6487, DOI 10.1158/1078-0432.CCR-08-1086; Isbarn H, 2013, DTSCH ARZTEBL INT, V110, P497, DOI 10.3238/arztebl.2013.0497; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; Jeong BC, 2015, EUR UROL, V67, P342, DOI 10.1016/j.eururo.2014.06.015; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Lazari P, 2013, UROL INT, V90, P109, DOI 10.1159/000345057; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Loric S, 2001, EUR J CANCER, V37, P1475, DOI 10.1016/S0959-8049(01)00143-5; Ma D, 2015, ONCOL LETT, V10, P2185, DOI 10.3892/ol.2015.3556; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Mareel M, 2009, VIRCHOWS ARCH, V454, P599, DOI 10.1007/s00428-009-0784-0; Miller GJ, 2001, EPIDEMIOL REV, V23, P14, DOI 10.1093/oxfordjournals.epirev.a000780; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1744; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Pontes J, 2010, APPL IMMUNOHISTO M M, V18, P179, DOI 10.1097/PAI.0b013e3181640bca; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Richmond PJM, 1997, CANCER RES, V57, P3189; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Soler AP, 1997, AM J PATHOL, V151, P471; Stephenson RA, 1996, CANCER, V77, P1342; Tang L. H., 2013, PROTOCOL EXAMINATION; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsaur I, 2015, CANCER RES TREAT, V47, P306, DOI 10.4143/crt.2014.015; Uchikado Y, 2011, GASTRIC CANCER, V14, P41, DOI 10.1007/s10120-011-0004-x; UMBAS R, 1994, CANCER RES, V54, P3929; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; van Oort IM, 2007, PROSTATE, V67, P1432, DOI 10.1002/pros.20626; Van Poppel H, 2008, EUR UROL, V53, P253, DOI 10.1016/j.eururo.2007.10.009; Vieira AF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0448-4; Whiteland H, 2013, EXP MOL PATHOL, V95, P220, DOI 10.1016/j.yexmp.2013.07.010; Yossepowitch O, 2007, J UROLOGY, V178, P493, DOI 10.1016/j.juro.2007.03.105	55	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					443	452		10.1007/s00428-018-2406-1			10	Pathology	Pathology	GV8HP	WOS:000446380500006	30006753				2019-10-28	
J	Almangush, A; Makitie, AA; Makinen, LK; Kauppila, JH; Pukkila, M; Hagstrom, J; Laranne, J; Soini, Y; Kowalski, LP; Grenman, R; Haglund, C; Coletta, RD; Salo, T; Leivo, I				Almangush, Alhadi; Makitie, Antti A.; Makinen, Laura K.; Kauppila, Joonas H.; Pukkila, Matti; Hagstrom, Jaana; Laranne, Jussi; Soini, Ylermi; Kowalski, Luiz Paulo; Grenman, Reidar; Haglund, Caj; Coletta, Ricardo D.; Salo, Tuula; Leivo, Ilmo			Small oral tongue cancers (ae<currency> 4 cm in diameter) with clinically negative neck: from the 7th to the 8th edition of the American Joint Committee on Cancer	VIRCHOWS ARCHIV			English	Article						Early-stage; Oral tongue cancer; Depth of invasion; 7th AJCC; 8th AJCC	SQUAMOUS-CELL-CARCINOMA; TUMOR-THICKNESS; CERVICAL METASTASIS; POOR-PROGNOSIS; STAGE; DEPTH; INVASION; INFILTRATION; CAVITY	One of the main changes in the 8th edition of the American Joint Committee on Cancer (AJCC) for staging of oral cancer is the inclusion of depth of invasion (DOI) in the T category. However, cancers in different oral subsites have variable behavior, with oral tongue squamous cell carcinoma (OTSCC) being the most aggressive one even at early stage. Thus, it is necessary to evaluate the performance of this new T category in homogenous cohort of early OTSCC. Therefore, we analyzed a large cohort of patients with a small (ae4 cm) OTSCC to demonstrate the differences in T stage between the AJCC 7th and 8th editions. A total of 311 early-stage cases (AJCC 7th) of OTSCC were analyzed. We used 5 mm and 10 mm DOI for upstaging from T1 to T2 and from T2 to T3 respectively, as in the AJCC 8th. We further reclassified the cases according to our own proposal suggesting 2 mm to upstage to T2 and 4 mm to upstage to T3. According to AJCC 7th, there were no significant differences in the survival analysis. When we applied the 8th edition, many cases were upstaged to T3 and thus associated with worse disease-specific survival (HR 2.37, 95% CI 1.12-4.99) and disease-free survival (HR 2.12, 95% CI 1.09-4.08). Based on our proposal, T3 cases were associated with even worse disease-specific survival (HR 4.19, 95% CI 2.27-7.74). The 8th edition provides better survival prediction for OTSCC than the 7th and can be further optimized by lowering the DOI cutoffs.	[Almangush, Alhadi; Hagstrom, Jaana; Salo, Tuula] Univ Helsinki, Dept Pathol, Haartmaninkatu 3,POB 21, FIN-00014 Helsinki, Finland; [Almangush, Alhadi; Leivo, Ilmo] Univ Turku, Dept Pathol, Turku, Finland; [Almangush, Alhadi] Univ Misurata, Inst Dent, Misurata, Libya; [Makitie, Antti A.; Makinen, Laura K.] Helsinki Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; [Makitie, Antti A.; Makinen, Laura K.] Univ Helsinki, Helsinki, Finland; [Makitie, Antti A.] Karolinska Inst, Karolinska Univ Hosp, Dept Clin Sci Intervent & Technol, Div Ear Nose & Throat Dis, Stockholm, Sweden; [Kauppila, Joonas H.; Salo, Tuula] Univ Oulu, Med Res Ctr Oulu, Canc & Translat Med Res Unit, Oulu, Finland; [Kauppila, Joonas H.; Salo, Tuula] Oulu Univ Hosp, Oulu, Finland; [Kauppila, Joonas H.] Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden; [Pukkila, Matti] Kuopio Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Kuopio, Finland; [Hagstrom, Jaana] Univ Helsinki, Helsinki Univ Hosp, Dept Pathol, HUSLAB, Helsinki, Finland; [Hagstrom, Jaana; Haglund, Caj] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland; [Laranne, Jussi] Tampere Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Tampere, Finland; [Soini, Ylermi] Univ Eastern Finland, Dept Pathol & Forens Med, Kuopio, Finland; [Kowalski, Luiz Paulo] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo, SP, Brazil; [Grenman, Reidar] Univ Turku, Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; [Haglund, Caj] Univ Helsinki, Dept Surg, Helsinki, Finland; [Haglund, Caj] Helsinki Univ Hosp, Helsinki, Finland; [Coletta, Ricardo D.] Univ Estadual Campinas, Sch Dent, Dept Oral Diag, Piracicaba, SP, Brazil; [Salo, Tuula] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland	Almangush, A (reprint author), Univ Helsinki, Dept Pathol, Haartmaninkatu 3,POB 21, FIN-00014 Helsinki, Finland.; Almangush, A (reprint author), Univ Turku, Dept Pathol, Turku, Finland.; Almangush, A (reprint author), Univ Misurata, Inst Dent, Misurata, Libya.	alhadi.almangush@helsinki.fi	Hagstrom, Jaana/G-1468-2018; Haglund, Caj/N-1240-2019; Kowalski, Luiz P/D-1701-2012; Coletta, Ricardo D./B-4909-2015; Kauppila, Joonas H/P-1363-2015	Hagstrom, Jaana/0000-0001-6079-7881; Kowalski, Luiz P/0000-0002-0481-156X; Coletta, Ricardo D./0000-0001-5285-3046; Kauppila, Joonas H/0000-0001-6740-3726; Salo, Tuula/0000-0001-6039-0088	Finnish Dental Society; Rauha Ahokas Foundation; K. Albin Johanssons Foundation; Helsinki University Hospital Research Fund; Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Cancer Society; Finska Lakaresallskapet; Maritza and Reino Salonen Foundation	This study received funding from the Finnish Dental Society, the Rauha Ahokas Foundation, K. Albin Johanssons Foundation, the Helsinki University Hospital Research Fund, the Sigrid Juselius Foundation, the Finnish Cancer Society, Finska Lakaresallskapet, and the Maritza and Reino Salonen Foundation.	Almangush A, 2018, VIRCHOWS ARCH, V472, P231, DOI 10.1007/s00428-017-2212-1; Almangush A, 2015, VIRCHOWS ARCH, V467, P39, DOI 10.1007/s00428-015-1758-z; Amin MB, 2017, AJCC CANC STAGING MA; Arora A, 2017, AM J SURG PATHOL, V41, P950, DOI 10.1097/PAS.0000000000000843; Dirven R, 2017, ORAL ONCOL, V74, P30, DOI 10.1016/j.oraloncology.2017.09.007; Edge SB, 2010, AJCC CANC STAGING MA; Ganly I, 2012, CANCER-AM CANCER SOC, V118, P101, DOI 10.1002/cncr.26229; Glastonbury CM, 2017, AM J NEURORADIOL, V38, P2231, DOI 10.3174/ajnr.A5409; Hakeem Arsheed Hussain, 2016, Ann Maxillofac Surg, V6, P235, DOI 10.4103/2231-0746.200331; Han MW, 2015, OTOLARYNG HEAD NECK, V152, P80, DOI 10.1177/0194599814556061; Huang SH, 2009, CANCER-AM CANCER SOC, V115, P1489, DOI 10.1002/cncr.24161; Iwai H, 2002, LARYNGOSCOPE, V112, P457, DOI 10.1097/00005537-200203000-00010; Jung J, 2009, INT J ORAL MAX SURG, V38, P653, DOI 10.1016/j.ijom.2009.01.004; Lodder WL, 2011, EUR RADIOL, V21, P98, DOI 10.1007/s00330-010-1891-7; Madana J, 2015, J OTOLARYNGOL-HEAD N, V44, DOI 10.1186/s40463-015-0089-z; Melchers LJ, 2012, ORAL ONCOL, V48, P337, DOI 10.1016/j.oraloncology.2011.11.007; Melkane AE, 2012, LARYNGOSCOPE, V122, P1782, DOI 10.1002/lary.23383; Mroueh R, 2017, HEAD NECK-J SCI SPEC, V39, P1306, DOI 10.1002/hed.24744; Okura M, 2008, AM J NEURORADIOL, V29, P45, DOI 10.3174/ajnr.A0749; Piazza C, 2014, CURR OPIN OTOLARYNGO, V22, P81, DOI 10.1097/MOO.0000000000000038; Preda L, 2006, EUR RADIOL, V16, P2242, DOI 10.1007/s00330-006-0263-9; Rusthoven K, 2008, CANCER-AM CANCER SOC, V112, P345, DOI 10.1002/cncr.23183; Taylor SM, 2010, ORAL ONCOL, V46, P38, DOI 10.1016/j.oraloncology.2009.10.005; Wang S, 2018, CLIN ORAL INVEST, V22, P1131, DOI 10.1007/s00784-017-2197-9; Xie N, 2015, J ORAL PATHOL MED, V44, P266, DOI 10.1111/jop.12242	25	3	3	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					481	487		10.1007/s00428-018-2417-y			7	Pathology	Pathology	GV8HP	WOS:000446380500010	30039390	Green Accepted, Green Published			2019-10-28	
J	Lapp, S; Bube, A; Colbatzky, FA; Ernst, H; Kellner, R; Nolte, T; Rinke, M				Lapp, Stefanie; Bube, Axel; Colbatzky, Florian A.; Ernst, Heinrich; Kellner, Rupert; Nolte, Thomas; Rinke, Matthias			Best Practice Approach for Assessment of Microchip-associated Tumors in Preclinical Safety Studies: Position of the Registry of Industrial Toxicology Animal-data (RITA)	TOXICOLOGIC PATHOLOGY			English	Review						microchip-associated tumors; implantation; soft tissue tumors; RITA; best practice recommendations; sampling; recording; INHAND	SOFT-TISSUE TUMORS; JOINT PUBLICATION; REVISED GUIDES; INDUCED SARCOMA; MICE; IDENTIFICATION; IMPLANT; RATS; FIBROSARCOMA; SITE	Microchip (passive radio-frequency identification device) implantation is a common and widely employed means of animal identification in laboratory animal facilities. However, these devices have been associated with tumors of the skin and subcutis in rodents. While microchip-associated tumors are rare, they pose a challenge for accurate diagnosis and documentation in preclinical toxicity studies. Documentation of these tumors should differentiate microchip-associated lesions with spontaneously occurring or test article-induced tumors. Standardizing criteria for microchip-associated lesions will aid the diagnostic process and allow for preclinical regulatory standardization. To this end, the Registry of Industrial Toxicology Animal-data have developed clear recommendations for diagnosis and documentation of microchip-associated lesions.	[Lapp, Stefanie; Colbatzky, Florian A.; Nolte, Thomas] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Bube, Axel] Sanofi, Frankfurt, Germany; [Ernst, Heinrich; Kellner, Rupert] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany	Lapp, S (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Nonclin Drug Safety, Birkendorfer Str 65, D-88397 Biberach, Germany.	stefanie.lapp@boehringer-ingelheim.com					Albrecht K., 2010, 2010 IEEEE INT S TEC; BAHNEMANN R, 1995, EXP TOXICOL PATHOL, V47, P247, DOI 10.1016/S0940-2993(11)80259-9; BALL DJ, 1991, LAB ANIM SCI, V41, P185; Blanchard KT, 1999, TOXICOL PATHOL, V27, P519, DOI 10.1177/019262339902700505; BRAND KG, 1976, CRC CR REV TOXICOL, V4, P353, DOI 10.1080/10408447609164018; Carminato A, 2011, VET DERMATOL, V22, P565, DOI 10.1111/j.1365-3164.2011.00975.x; Dahlborn K, 2013, LAB ANIM-UK, V47, P2, DOI 10.1177/002367712473290; Elcock LE, 2001, EXP TOXICOL PATHOL, V52, P483; Fletcher C. D. M., 2006, WHO CLASSIFICATION T; Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x; Greaves P, 2013, J TOXICOL PATHOL, V26, p1S, DOI 10.1293/tox.26.1S; Johnson K. A., 1996, VET PATHOL, V33, P619; Kirkpatrick CJ, 2000, AM J PATHOL, V156, P1455, DOI 10.1016/S0002-9440(10)65014-6; Kittel B, 2004, EXP TOXICOL PATHOL, V55, P413, DOI 10.1078/0940-2993-00349; Klein M., 2004, P 8 FELASA S, P92; Le Calvez S, 2006, EXP TOXICOL PATHOL, V57, P255, DOI 10.1016/j.etp.2005.10.007; Morawietz G, 2004, EXP TOXICOL PATHOL, V55, P433, DOI 10.1078/0940-2993-00350; Nolte T., 2006, CLASSIC EXAMPLES TOX; Palmer T. E., 1998, 16 INT S SOC TOX PAT, V26, P165; RAO GN, 1990, TOXICOL PATHOL, V18, P412, DOI 10.1177/019262339001800308; Ruehl-Fehlert C, 2003, EXP TOXICOL PATHOL, V55, P91, DOI 10.1078/0940-2993-00311; SACCO W, 1992, AM BIOTECHNOL LAB, V10, P16; Schutt LK, 2010, J AM ASSOC LAB ANIM, V49, P638; Tillmann T, 1997, EXP TOXICOL PATHOL, V49, P197, DOI 10.1016/S0940-2993(97)80007-3; Vascellari A, 2006, VET PATHOL, V43, P545, DOI 10.1354/vp.43-4-545	25	0	0	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					728	734		10.1177/0192623318792541			7	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300001	30176767				2019-10-28	
J	Catlin, NR; Willson, CJ; Creasy, DM; Rao, DB; Kissling, GE; McIntyre, BS; Wyde, M				Catlin, Natasha R.; Willson, Cynthia J.; Creasy, Dianne M.; Rao, Deepa B.; Kissling, Grace E.; McIntyre, Barry S.; Wyde, Michael			Differentiating between Testicular Toxicity and Sexual Immaturity in Ortho-phthalaldehyde Inhalation Toxicity Studies in Rats and Mice	TOXICOLOGIC PATHOLOGY			English	Article						juvenile rodents; peripuberty; testis; epididymis; reproductive; ortho-phthalaldehyde; sexual immaturity	ZERO-DOSE CONTROL; CELL APOPTOSIS; TESTIS; SPERMATOGENESIS; TESTOSTERONE; PATHOLOGISTS; INVOLVEMENT; IMPACT; ISSUES; WAVE	Early deaths of young or juvenile animals (before sexual maturation is achieved) in routine regulatory safety studies present pathologists and toxicologists with the challenge of interpreting findings in the male reproductive tract. Additionally, the advent of toxicity testing regulations has resulted in a growing need for the use of juvenile animals in toxicology studies. Here, we present the reproductive toxicity findings from a 13-week inhalation toxicity study with ortho-phthalaldehyde (OPA) in male rats and mice as a case example for working through this challenging task. In this study with OPA, survival was significantly reduced in the two highest exposure concentrations of OPA tested. Early deaths and histopathological lesions in the testes and epididymides were generally also limited to these two highest exposure groups. Therefore, there was concern that peripubertal morphological features could be a confounding factor for the histopathological evaluation of exposure-related testicular and epididymal findings. Although it can be difficult to differentiate exposure-related effects from the normal morphological features defining peripubertal changes in the testes and epididymides in animals that die early in a toxicity study, the use of age-matched controls in this case study with OPA provided a reference and aided in the differentiation of these effects.	[Catlin, Natasha R.; Kissling, Grace E.; McIntyre, Barry S.; Wyde, Michael] NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA; [Catlin, Natasha R.] Pfizer Inc, Groton, CT 06340 USA; [Willson, Cynthia J.; Rao, Deepa B.] Integrated Syst Lab, Morrisville, NC USA; [Creasy, Dianne M.] Dianne Creasy Consulting, Diss, Norfolk, England; [Rao, Deepa B.] US FDA, Silver Spring, MD USA	Wyde, M (reprint author), Natl Toxicol Program, POB 12233, Durham, NC 27709 USA.	wyde@niehs.nih.gov		, Cynthia/0000-0003-0942-3723	Intramural Research Program of the National Institutes of Health (NIH; National Institute of Environmental Health Sciences [NIEHS] Projects) [ZIA ES103319-01, ZIA ES103316-01]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [N01-ES-65406]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Intramural Research Program of the National Institutes of Health (NIH; National Institute of Environmental Health Sciences [NIEHS] Projects ZIA ES103319-01 and ZIA ES103316-01) and by NIEHS contract no. N01-ES-65406.	Adler ID, 1996, MUTAT RES-FUND MOL M, V352, P169, DOI 10.1016/0027-5107(95)00223-5; Campion SN, 2013, REPROD TOXICOL, V38, P16, DOI 10.1016/j.reprotox.2013.02.003; Catlin NR, 2017, INHAL TOXICOL, V29, P414, DOI 10.1080/08958378.2017.1390015; Chapin RE, 2012, TOXICOL PATHOL, V40, P1063, DOI 10.1177/0192623312443321; Creasy DM, 2001, TOXICOL PATHOL, V29, P64, DOI 10.1080/019262301301418865; Dixon W. J., 1957, INTRO STAT ANAL; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096; Environmental Protection Agency, 2011, PUB DEV THYR FUNCT I, P1500; European Medicines Agency, 2008, GUID NEED NONCL TEST; Everds NE, 2013, TOXICOL PATHOL, V41, P560, DOI 10.1177/0192623312466452; GART JJ, 1979, J NATL CANCER I, V62, P957; HIKIM APS, 1995, ENDOCRINOLOGY, V136, P2770, DOI 10.1210/en.136.6.2770; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; Lanning LL, 2002, TOXICOL PATHOL, V30, P507, DOI 10.1080/01926230290105695; Marty MS, 2001, TOXICOL SCI, V60, P285, DOI 10.1093/toxsci/60.2.285; Moffit JS, 2007, TOXICOL PATHOL, V35, P719, DOI 10.1080/01926230701481931; Morales A, 2007, ANAT REC, V290, P206, DOI 10.1002/ar.20417; National Toxicology Program, 2018, TOX 84 TOX REP TABL; ODONNELL L, 1994, ENDOCRINOLOGY, V135, P2608, DOI 10.1210/en.135.6.2608; Picut CA, 2017, TOXICOL PATHOL, V45, P195, DOI 10.1177/0192623316672744; Picut CA, 2015, TOXICOL PATHOL, V43, P326, DOI 10.1177/0192623314547279; Rehm S, 2008, TOXICOL PATHOL, V36, P687, DOI 10.1177/0192623308320275; Remick AK, 2015, TOXICOL PATHOL, V43, P1166, DOI 10.1177/0192623315595883; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; RUSSELL LD, 1987, ENDOCRINOLOGY, V120, P1615, DOI 10.1210/endo-120-4-1615; Rutala WA, 2001, EMERG INFECT DIS, V7, P348, DOI 10.3201/eid0702.010241; SHIRLEY E, 1977, BIOMETRICS, V33, P386, DOI 10.2307/2529789; The Food and Drug Administration, 2006, GUID IND NONCL SAF E; Whitney KM, 2012, SYST BIOL REPROD MED, V58, P51, DOI 10.3109/19396368.2011.647380; WILLIAMS DA, 1971, BIOMETRICS, V27, P103, DOI 10.2307/2528930; WILLIAMS DA, 1972, BIOMETRICS, V28, P519, DOI 10.2307/2556164; WILLIAMS DA, 1986, BIOMETRICS, V42, P183, DOI 10.2307/2531254; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4	34	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					753	763		10.1177/0192623318801790			11	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300004	30259793				2019-10-28	
J	Rahman, N; Pervin, M; Kuramochi, M; Karim, MR; Izawa, T; Kuwamura, M; Yamate, J				Rahman, Nahid; Pervin, Munmun; Kuramochi, Mizuki; Karim, Mohammad R.; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji			M1/M2-macrophage Polarization-based Hepatotoxicity in D-galactosamine-induced Acute Liver Injury in Rats	TOXICOLOGIC PATHOLOGY			English	Article						D-GalN; liver injury; hepatic macrophages; cytokines; rats	ACUTE VIRAL-HEPATITIS; MACROPHAGE ACTIVATION; THIOACETAMIDE TAA; CELL INJURY; FAILURE; HETEROGENEITY; DIFFERENTIATION; PATHOGENESIS; GALECTIN-3; DEPLETION	D-galactosamine (D-GalN) is a well-known hepatotoxic agent that causes liver injury. Conversely, hepatic macrophages play a crucial role in maintaining liver tissue integrity. Macrophage functions were investigated in hepatic lesions induced by a single intraperitoneal injection of D-GalN (800 mg/kg body weight [BW]) in 6-week-old F344 rats. Blood and liver samples were examined at 8 hr and on 1, 2, 3, and 5 days postsingle injection (PSI). Hepatic lesions consisting of degeneration/sporadic foci of coagulation necrosis, inflammatory cell reaction, and reparative fibrosis were seen on PSI days 1 and 2, reflected by significantly increased serum levels of aspartate transaminase and alanine transaminase and upregulation of CD68 M1 (tumor necrosis factor-alpha, interleukin [IL]-6, and interferon-gamma) and CD163 M2 (transforming growth factor-beta 1, IL-10, monocyte chemoattractant protein-1, and IL-4) macrophage-related factors. Double immunofluorescence staining on PSI day 2 demonstrated that 82% of hepatic macrophages expressed of CD163/CD68 simultaneously; 65-75% of MHC class II macrophages showed co-expression of CD163 or CD68 and 95% CD204-expressing macrophages reacted to CD163 or CD68. These findings showed that both M1- and M2-macrophages contributed to the development of hepatic lesions induced by D-GalN and provided information about macrophage activation, indicating the importance of analysis of macrophage phenotypes for hepatotoxicity based on M1/M2-polarization.	[Rahman, Nahid; Pervin, Munmun; Kuramochi, Mizuki; Karim, Mohammad R.; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Lab Vet Pathol, Izumisano, Osaka, Japan	Yamate, J (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Struct & Funct Biosci Anim Vet Pathol, Izumisano, Osaka 5988531, Japan.	yamate@vet.osakafu-u.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26292152]; Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED [3P18 am 0101123]; Otsuka Toshimi Scholarship FoundationOtsuka Pharmaceutical [16-S79, 17-S42]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported partly by JSPS KAKENHI Grant Numbers 26292152 (to Yamate), by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED and Grand Numbers 3P18 am 0101123 (to Yamate) and by The Otsuka Toshimi Scholarship Foundation (Number 16-S79, 17-S42 to N. Rahman).	Antoniades CG, 2012, HEPATOLOGY, V56, P735, DOI 10.1002/hep.25657; Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7; BOYER JL, 1970, NEW ENGL J MED, V283, P1063, DOI 10.1056/NEJM197011122832001; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Golbar HM, 2012, EXP TOXICOL PATHOL, V64, P1, DOI 10.1016/j.etp.2010.05.011; Golbar HM, 2016, TOXICOL PATHOL, V44, P246, DOI 10.1177/0192623315621191; Golbar HM, 2011, TOXICOL PATHOL, V39, P795, DOI 10.1177/0192623311413790; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; He P, 2001, BIOSCI BIOTECH BIOCH, V65, P670, DOI 10.1271/bbb.65.670; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; Hume DA, 2008, MUCOSAL IMMUNOL, V1, P432, DOI 10.1038/mi.2008.36; Hung MY, 2006, FOOD CHEM TOXICOL, V44, P1424, DOI 10.1016/j.fct.2006.03.009; Ide M, 2003, J COMP PATHOL, V128, P41, DOI 10.1053/jcpa.2002.0603; Ju C, 2016, CELL MOL IMMUNOL, V13, P316, DOI 10.1038/cmi.2015.104; KEPPLER D, 1968, EXP MOL PATHOL, V9, P279, DOI 10.1016/0014-4800(68)90042-7; Kmiec Z, 2000, ACTA BIOCHIM POL, V47, P349; Lee WM, 2008, HEPATOLOGY, V47, P1401, DOI 10.1002/hep.22177; Li Y., 1999, HEPATOLOGY, V31, P491; Liaskou E, 2013, HEPATOLOGY, V57, P385, DOI 10.1002/hep.26016; Martinez FO, 2011, EUR J IMMUNOL, V41, P1531, DOI 10.1002/eji.201141670; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Njoku DB, 2009, EUR J IMMUNOL, V39, P1652, DOI 10.1002/eji.200838135; Pello OM, 2011, IMMUNOBIOLOGY, V216, P1172, DOI 10.1016/j.imbio.2011.05.010; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; POPPER H, 1983, HEPATOLOGY, V3, P758; SHINOZUKA H, 1973, FED PROC, V32, P1516; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sugiyama K, 1998, BIOSCI BIOTECH BIOCH, V62, P609, DOI 10.1271/bbb.62.609; Takahashi K, 1996, PATHOL INT, V46, P473, DOI 10.1111/j.1440-1827.1996.tb03641.x; Tomokiyo R, 2002, ATHEROSCLEROSIS, V161, P123, DOI 10.1016/S0021-9150(01)00624-4; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Wang N, 2013, INT IMMUNOPHARMACOL, V15, P325, DOI 10.1016/j.intimp.2013.01.002; Wasley Annemarie, 2008, Morbidity and Mortality Weekly Report, V57, P1; Wijesundera KK, 2014, EXP MOL PATHOL, V96, P382, DOI 10.1016/j.yexmp.2014.04.003; Wijesundera KK, 2013, EXP TOXICOL PATHOL, V65, P799, DOI 10.1016/j.etp.2012.11.006; Wlodzimirow KA, 2012, ALIMENT PHARM THER, V35, P1245, DOI 10.1111/j.1365-2036.2012.05097.x; Zheng YB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041392	38	2	2	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					764	776		10.1177/0192623318801574			13	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300005	30253710				2019-10-28	
J	Langevin, NE; Schafer, KA; Turner, OC; McPherson, BJ; Rose, RE				Langevin, Nicholas E.; Schafer, Kenneth A.; Turner, Oliver C.; McPherson, Brittany J.; Rose, Robert E.			Historical Data: Histopathology Lesions Observed in the Eyes of Control Rabbits in Topical Ocular Administration and Contact Lens Studies	TOXICOLOGIC PATHOLOGY			English	Article						pathology; histopathology; rabbit; eye; toxicology; spontaneous; historical; control; lesion	EPITHELIUM; HISTOLOGY; GLAUCOMA	Information on background changes in the ocular tissues of rabbits (Oryctolagus cuniculus), a common species employed in ophthalmic toxicology studies, is sparse. This complicates interpretation of changes in light of small sample sizes on any single study. The purpose of this publication is to document the interstudy incidence of spontaneous or iatrogenic changes occurring in eyes of control rabbits. Photomicrographs of select lesions are provided. The data set was derived from a total of 54 studies conducted over an eleven-year period at Alcon Research Ltd., a Novartis Division, which featured topical ocular and contact lens routes of administration. It includes a total of 1,222 pigmented and albino New Zealand rabbits and a total of 2,084 eyes which were either untreated or treated with innocuous control articles. There were no noteworthy differences across routes of administration. Changes in anterior segment ocular and adnexal tissues were more common than in posterior segment ocular tissues. Overall, mononuclear cell infiltration was the most common finding. The retina was the posterior tissue most commonly observed with spontaneous changes, with folds and rosettes being the most common retinal finding. Retinal changes were more common in albino as compared to pigmented rabbits. Understanding the incidence and characteristics of spontaneous ocular lesions facilitates accurate and consistent diagnosis and data interpretation.	[Langevin, Nicholas E.] Novartis, Regulatory Affairs, 6201 S Freeway, Ft Worth, TX 76134 USA; [Langevin, Nicholas E.; McPherson, Brittany J.; Rose, Robert E.] Alcon Res Ltd, Preclin Dev, Ft Worth, TX USA; [Schafer, Kenneth A.] Vet Path Serv Inc, Mason, OH USA; [Turner, Oliver C.] Novartis Inst BioMed Res, Preclin Safety Pathol, E Hanover, NJ USA	Langevin, NE (reprint author), Novartis, Regulatory Affairs, 6201 S Freeway, Ft Worth, TX 76134 USA.	nicholas.langevin@novartis.com					Barthold S. W, 2016, PATHOLOGY LAB RODENT; BJORKMAN N, 1960, Z ZELLFORSCH MIK ANA, V52, P93, DOI 10.1007/BF00344641; Bradley A. E., 2012, BACKGROUND LESIONS L, P87; BRUCE AS, 1990, SURV OPHTHALMOL, V35, P25, DOI 10.1016/0039-6257(90)90046-X; Cain C, 2008, INVEST OPHTH VIS SCI, V49, P644, DOI 10.1167/iovs.07-0856; Casteleyn C, 2010, VET IMMUNOL IMMUNOP, V133, P212, DOI 10.1016/j.vetimm.2009.08.011; Davis F. A., 1929, T AM OPHTHAL SOC, V27; de Zafra CLZ, 2017, REGUL TOXICOL PHARM, V86, P221, DOI 10.1016/j.yrtph.2017.03.013; GREAVES DP, 1951, BRIT J OPHTHALMOL, V35, P232, DOI 10.1136/bjo.35.4.232; Holve DL, 2011, COMPARATIVE MED, V61, P436; Jeong MB, 2005, EXP ANIM TOKYO, V54, P395, DOI 10.1538/expanim.54.395; Knop N, 2008, ACTA OPHTHALMOL, V86, P243; KOLKER AE, 1963, INVEST OPHTH VISUAL, V2, P316; Ladage PM, 2001, OPHTHALMOLOGY, V108, P1279, DOI 10.1016/S0161-6420(01)00639-X; Lindsey J. R., 1994, BIOL LAB RABBIT, P239; Martin C. L., 2009, OPHTHALMIC DIS VET M, P401; MCMASTER PRB, 1960, ARCH OPHTHALMOL-CHIC, V64, P388; Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199; MOORE CP, 1987, VET PATHOL, V24, P28, DOI 10.1177/030098588702400106; Munger RJ, 2002, VET OPHTHALMOL, V5, P177, DOI 10.1046/j.1463-5224.2002.00245.x; Prince JH, 1964, RABBIT EYE RES; Ramos MF, 2018, J TOXICOL PATHOL, V31, p97S, DOI 10.1293/tox.31.97S; Schafer K. A., 2013, ASSESSING OCULAR TOX, P259; Schafer K. A., 2013, ASSESSING OCULAR TOX, P159; Schuh JCL, 2018, TOXICOL PATHOL, V46, P719, DOI 10.1177/0192623318791524; SHEPPARD LB, 1962, ARCH OPHTHALMOL-CHIC, V67, P87; TESLUK GC, 1982, LAB ANIM, V16, P234, DOI 10.1258/002367782780891679; Williams D., 2013, VET OPHTHALMOLOGY, P1725; Woicke J, 2018, TOXICOL PATHOL, V46, P273, DOI 10.1177/0192623318758619; YANOFF M, 2002, OCULAR PATHOLOGY	30	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					799	820		10.1177/0192623318803854			22	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300007	30348063				2019-10-28	
J	Gauthier, BE; Penard, L; Bordier, NF; Briffaux, JPJ; Ruty, BM				Gauthier, Beatrice E.; Penard, Laure; Bordier, Nicole F.; Briffaux, Jean-Paul J.; Ruty, Bernard M.			Specificities of the Skin Morphology in Juvenile Minipigs	TOXICOLOGIC PATHOLOGY			English	Article						juvenile; minipig; miniature swine; cartography; histology; skin		The Gottingen minipig is recognized by the scientific community and by health authorities as the animal model of choice to evaluate dermally applied drugs under development. Young adults of approximately 4 months of age are most generally chosen to participate in dermal pharmacology and toxicology studies, and recently, minipigs have been proved to be also suitable for juvenile studies. A complete anatomical cartography of the skin morphology of juvenile male and female minipigs from postnatal day 1 (PND1) to twelve weeks of age was performed measuring the thickness of skin layers for each anatomical location and time point. Overall, the neonatal skin of minipigs (PND1 and PND8) shows prominent cellularity, similar to that seen in human neonates, and the morphology of the skin of older animals is considered similar to that of young adult minipigs. Epidermal thickness varies only minimally over the period; whereas, the dermal and more markedly, the subcutaneous thicknesses increase over time.	[Gauthier, Beatrice E.; Bordier, Nicole F.; Ruty, Bernard M.] Galderma R&D, Biot, France; [Penard, Laure; Briffaux, Jean-Paul J.] Charles River, St Germain Nuelles, France	Penard, L (reprint author), Charles River, 327 Impasse Domaine Rozier, F-69210 Les Oncins, St Germain Nuel, France.	laure.penard@crl.com					Bode G, 2010, J PHARMACOL TOX MET, V62, P196, DOI 10.1016/j.vascn.2010.05.009; De Schaepdrijver L. M., 2010, GUIDE PAEDIAT DRUG D; De Schaepdrijver LM, 2013, PEDIATRIC DRUG DEVELOPMENT: CONCEPTS AND APPLICATIONS, 2ND EDITION, P201; Feyen B, 2016, REPROD TOXICOL, V64, P105, DOI 10.1016/j.reprotox.2016.04.019; Ganderup NC, 2012, INT J TOXICOL, V31, P507, DOI 10.1177/1091581812462039; Loomis C A, 2001, Adv Dermatol, V17, P183; Makin A, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P185; Penard L., 2016, ELLEGAARD NEWSLETTER; Qvist MH, 2000, EUR J PHARM SCI, V11, P59, DOI 10.1016/S0928-0987(00)00091-9; Stricker-Krongrad A, 2017, CUTAN OCUL TOXICOL, V36, P105, DOI 10.1080/15569527.2016.1178277; Swindle M., 1998, SCAND J LAB ANIM SCI, V25; Swindle MM, 2012, VET PATHOL, V49, P344, DOI 10.1177/0300985811402846; Tassinari MS, 2013, NONCLINICAL SAFETY ASSESSMENT: A GUIDE TO INTERNATIONAL PHARMACEUTICAL REGULATIONS, P297	13	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					821	834		10.1177/0192623318804520			14	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300008	30348062				2019-10-28	
J	Poitout, F; Colangelo, JL; Lavallee, S; Aulbach, AD; Piche, MS; Ennulat, D; Ameri, M; Boone, LI				Poitout, Florence; Colangelo, Jennifer L.; Lavallee, Simon; Aulbach, Adam D.; Piche, Marie-Soleil; Ennulat, Daniela; Ameri, Mehrdad; Boone, Laura I.			Current Practices and Challenges in Method Validation	TOXICOLOGIC PATHOLOGY			English	Article						assay validation; flow cytometry; multiplex assay; LC-MS; liquid chromatography-mass spectrometry; biological validation	BIOANALYTICAL METHOD VALIDATION; DRUG DEVELOPMENT; BIOMARKER QUALIFICATION; FLOW-CYTOMETRY; KIDNEY INJURY; RECOMMENDATIONS; SPECTROMETRY; TOXICITY; ASSAYS; RAT	Method validation is a cornerstone on which biomarker development and utilization rest. However, given the abundance of biomarker candidates that are being identified and characterized, validation of these entities for the use in nonclinical studies can be complex. The objective of this continuing education course was to review current practices and challenges encountered during the validation of methods for the analysis of novel biomarkers. Additionally, the importance of biological validation and correlation with pathology end points for biomarker candidates was discussed. This article is a summary of the materials presented at the 36th Annual Symposium of the Society of Toxicologic Pathology for a continuing education course titled "Current Practices and Challenges in Method Validation." The speakers were subject-matter experts in the validation of quantitative mass spectrometry, multiplex binding assays, biological biomarkers, and immunophenotyping and anatomic and clinical pathology considerations in biomarker qualification.	[Poitout, Florence; Lavallee, Simon; Piche, Marie-Soleil] Charles River Labs, Preclin Serv, Senneville, PQ, Canada; [Colangelo, Jennifer L.] Pfizer Inc, Drug Safety Res & Dev, Groton, CT 06340 USA; [Aulbach, Adam D.] MPI Res, Mattawan, MI USA; [Ennulat, Daniela; Ameri, Mehrdad] GlaxoSmithKline, King Of Prussia, PA USA; [Boone, Laura I.] Covance Labs Inc, 671 S Meridian, Greenfield, IN 46140 USA	Boone, LI (reprint author), Covance Labs Inc, 671 S Meridian, Greenfield, IN 46140 USA.	laura.boone@covance.com					Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041; Barnard RM, 2012, BIOANALYSIS, V4, P2471, DOI [10.4155/BIO.12.225, 10.4155/bio.12.225]; Bonventre JV, 2010, NAT BIOTECHNOL, V28, P436, DOI 10.1038/nbt0510-436; Bower JF, 2014, AAPS J, V16, P352, DOI 10.1208/s12248-014-9566-y; Burkhardt JE, 2011, TOXICOL PATHOL, V39, P1129, DOI 10.1177/0192623311422082; Cunliffe J, 2009, PHARM RES-DORDR, V26, P2551, DOI 10.1007/s11095-009-9972-5; EMA, 2011, GUID BIOAN METH VAL; FDA (Food and Drug Administration), 2018, FDA ISS LETT SUPP; FDA (Food and Drug Administration), 2016, LETT SUPP DRUG IND V; FDA (U. S. Food and Drug Administration) Center for Drug Evaluation and Research, 2016, LETT SUPP DRUG IND D; Food and Drug Administration, 2016, LETT SUPP DRUG IND L; Food and Drug Administration, 2013, GUID IND BIOAN METH; Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x; Harpur E, 2011, TOXICOL SCI, V122, P235, DOI 10.1093/toxsci/kfr112; Kruve A, 2015, ANAL CHIM ACTA, V870, P29, DOI 10.1016/j.aca.2015.02.017; Kruve A, 2015, ANAL CHIM ACTA, V870, P8, DOI 10.1016/j.aca.2015.02.016; Lee JW, 2006, PHARM RES, V23, P312, DOI 10.1007/s11095-005-9045-3; Lee JW, 2005, PHARM RES-DORDR, V22, P499, DOI 10.1007/s11095-005-2495-9; Lowes S, 2016, BIOANALYSIS, V8, P163, DOI 10.4155/bio.15.251; Moein MM, 2017, J CHROMATOGR B, V1043, P3, DOI 10.1016/j.jchromb.2016.09.028; O'Hara DM, 2011, J IMMUNOL METHODS, V363, P120, DOI 10.1016/j.jim.2010.09.036; Phillips JA, 2016, TOXICOL SCI, V151, P214, DOI 10.1093/toxsci/kfw038; Vaidya VS, 2010, NAT BIOTECHNOL, V28, P478, DOI 10.1038/nbt.1623; Van Eeckhaut A, 2009, J CHROMATOGR B, V877, P2198, DOI 10.1016/j.jchromb.2009.01.003; Wood B, 2013, CYTOM PART B-CLIN CY, V84, P315, DOI 10.1002/cyto.b.21108; Woodcock J, 2008, ANNU REV MED, V59, P1, DOI 10.1146/annurev.med.59.090506.155819; Woodcock Janet, 2011, Expert Opin Med Diagn, V5, P369, DOI 10.1517/17530059.2011.588947; Wu AHB, 2013, CLIN CHIM ACTA, V420, P4, DOI 10.1016/j.cca.2012.10.026; Wu DY, 2010, BIOANALYSIS, V2, P1617, DOI 10.4155/BIO.10.33	29	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	OCT	2018	46	7					847	856		10.1177/0192623318801571			10	Pathology; Toxicology	Pathology; Toxicology	HA3LP	WOS:000450153300010	30253718				2019-10-28	
J	Bertram, CA; Muller, K; Klopfleisch, R				Bertram, C. A.; Mueller, K.; Klopfleisch, R.			Genital Tract Pathology in Female Pet Rabbits (Oryctolagus cuniculus): a Retrospective Study of 854 Necropsy Examinations and 152 Biopsy Samples	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						endometrial hyperplasia; female genital pathology; rabbit; uterine adenocarcinoma	ENDOMETRIAL VENOUS ANEURYSMS; MIXED MULLERIAN TUMOR; DOMESTIC RABBIT; UTERINE ADENOCARCINOMA; RETE OVARII; HYPERPLASIA; HYDROMETRA; DISORDERS; METASTASIS; PYOMETRA	Genital tract disorders, especially uterine disorders, are the most common conditions of the female pet rabbit (Oryctolagus cuniculus); however, there have been few large studies of diseases of the female genital tract of this species. The present study examined diseases of the ovaries, Fallopian tubes, uterus and vagina, retrospectively over a period of 22 years, and included 854 full post-mortem examinations of female pet rabbits and 152 female genital tract biopsy samples. The age distribution of uterine neoplasia, endometrial hyperplasia and uterine inflammation was determined in the post-mortem cases. Uterine disorders were a common finding, occurring in 26.8% of all full necropsy examinations and in almost all genital tract biopsy samples. Uterine tumours (n = 205) were the most common uterine pathology, with adenocarcinoma being the most frequent tumour type. Metastasis was found in 4.6.2% of rabbits with uterine adenocarcinomas diagnosed at post-mortem examination, with metastatic spread to the lung occurring in 79.1% of these animals. The second most common uterine pathology was endometrial hyperplasia, which was glandular-cystic in most cases. The incidence of uterine tumours and endometrial hyperplasia increased with age, while endometrial hyperplasia was found more commonly in slightly younger animals. In contrast, uterine inflammation, the third most common finding, was found predominately in young to middle-aged rabbits. Ovarian disorders were found rarely at post-mortem examinations (3.3% of all animals), but comprised 16.9% of biopsy samples. Of these, ovarian cysts, especially follicular cysts, and secondary tumours were found most frequently. Disorders of the Fallopian tube and the vagina were found in <1% of cases and should be considered rare. (C) 2018 Elsevier Ltd. All rights reserved.	[Bertram, C. A.; Klopfleisch, R.] Free Univ Berlin, Inst Vet Pathol, Robert von Ostertagstr 15, Berlin, Germany; [Mueller, K.] Free Univ Berlin, Small Anim Clin, Oertzenweg 19b, Berlin, Germany	Klopfleisch, R (reprint author), Free Univ Berlin, Inst Vet Pathol, Robert von Ostertagstr 15, Berlin, Germany.	Robert.klopfleisch@fu-berlin.de		Klopfleisch, Robert/0000-0002-6308-0568			Allison N, 2003, LAB ANIMAL, V32, P23, DOI 10.1038/laban0203-23; Asakawa MG, 2008, VET PATHOL, V45, P217, DOI 10.1354/vp.45-2-217; Becha B, 2006, J VET ANIMAL SCI, V42, P84; Bertram C, 2016, KLEINTIERPRAXIS, V61, P374, DOI 10.2377/0023-2076-61-374; Bertram CA, 2017, J VET MED SCI, V79, P1994, DOI 10.1292/jvms.17-0358; BRAY MV, 1991, LAB ANIM SCI, V41, P628; BRAY MV, 1992, LAB ANIM SCI, V42, P360; Brown YK, 2010, JAVMA-J AM VET MED A, V237, P1257, DOI 10.2460/javma.237.11.1257; Chambers JK, 2014, J VET MED SCI, V76, P909, DOI 10.1292/jvms.14-0053; Cooper TK, 2006, VET PATHOL, V43, P377, DOI 10.1354/vp.43-3-377; DeSanto J, 1997, J AM VET MED ASSOC, V210, P1322; Dettweiler A, 2012, KLEINTIERPRAXIS, V57, P69; Fuchs-Baumgartinger A, 2009, WIENER TIERARZTLICHE, V96, P1; Goto M, 2006, VET PATHOL, V43, P560, DOI 10.1354/vp.43-4-560; GREENE HSN, 1947, CANCER RES, V7, P502; GREENE HSN, 1949, CANCER, V2, P673, DOI 10.1002/1097-0142(194907)2:4<673::AID-CNCR2820020414>3.0.CO;2-J; Haist V, 2010, BERL MUNCH TIERARZTL, V123, P346, DOI 10.2376/0005-9366-123-346; Harcourt-Brown Frances Margaret, 2017, Veterinary Clinics of North America Exotic Animal Practice, V20, P555, DOI 10.1016/j.cvex.2016.11.010; HOBBS BA, 1990, LAB ANIM SCI, V40, P535; HOFMANN JR, 1986, J AM VET MED ASSOC, V189, P1155; Hristov K, 2017, MEDINFORM, V3, P544; IYER PKR, 1979, INDIAN J ANIM SCI, V49, P242; JOHNSON JH, 1993, J AM VET MED ASSOC, V203, P667; Kaufmann-Bart M, 2008, VET PATHOL, V45, P77, DOI 10.1354/vp.45-1-77; Kunzel F, 2015, J AM ANIM HOSP ASSOC, V51, P8; Kurotaki T, 2007, J VET MED SCI, V69, P981, DOI 10.1292/jvms.69.981; Lode J, 2003, KLEINTIERPRAXIS, V48, P203; Meier W, 1994, VET J, V31, P606; MORRELL JM, 1989, VET REC, V125, P325, DOI 10.1136/vr.125.12.325; Nasrin Askari, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS1975; Reimnitz L, 2017, J EXOT PET MED, V26, P230, DOI 10.1053/j.jepm.2017.05.003; Saito K, 2002, J VET MED SCI, V64, P495, DOI 10.1292/jvms.64.495; Sebensteny A., 1972, Laboratory Animals, V6, P357, DOI 10.1258/002367772781006194; Sheppard EM, 1943, J ANAT, V77, P288; Sladakovic I, 2015, J EXOT PET MED, V24, P98, DOI 10.1053/j.jepm.2014.11.004; Sommerville LM, 1998, VET REC, V142, P550, DOI 10.1136/vr.142.20.550-b; Streicher M, 2006, KLEINTIERPRAXIS, V51, P309; Thode HP, 2009, VET REC, V164, P242, DOI 10.1136/vr.164.8.242; van Zeeland Yvonne, 2017, Vet Clin North Am Exot Anim Pract, V20, P135, DOI 10.1016/j.cvex.2016.07.005; Vinci A, 2010, J COMP PATHOL, V142, P323, DOI 10.1016/j.jcpa.2009.12.005; Walter B, 2010, VET REC, V166, P230, DOI 10.1136/vr.b4749; Woodhouse SJ, 2011, JAVMA-J AM VET MED A, V238, P289, DOI 10.2460/javma.238.3.289; Zadravec M, 2012, J VET DIAGN INVEST, V24, P418, DOI 10.1177/1040638711433324	43	1	1	3	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						17	26		10.1016/j.jcpa.2018.08.003			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800002	30360908				2019-10-28	
J	Walker, D; Gibbons, J; Harris, JD; Taylor, CS; Scott, C; Paterson, GK; Morrison, LR				Walker, D.; Gibbons, J.; Harris, J. D.; Taylor, C. S.; Scott, C.; Paterson, G. K.; Morrison, L. R.			Systemic Yersinia pseudotuberculosis as a Cause of Osteomyelitis in a Captive Ring-tailed Lemur (Lemur catta)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						lemur; osteomyelitis; Yersinia pseudotuberculosis; yersiniosis	REACTIVE ARTHRITIS; CLINICAL-FEATURES; SEPTIC ARTHRITIS; ENTEROCOLITICA; INFECTION; CELLS; OUTBREAK; MONKEYS; GOATS; SHEEP	Yersinia pseudotuberculosis and Yersinia enterocolitica are ubiquitous pathogens with wildlife and domestic animal reservoirs. Outbreaks of 'non-plague' yersiniosis in man and non-human primates are reported frequently (including zoological specimens and research breeding colonies) and are usually characterized by enteritis, mesenteric lymphadenitis and occasionally organ abscessation. In people, non-septic reactive arthritis is a common sequela to yersiniosis. However, there have been rare reports in people of septic arthritis and osteomyelitis because of active systemic infection with Y. pseudotuberculosis. Osteomyelitis has also been reported rarely in historical yersiniosis outbreaks in farmed turkeys in England and the USA. This paper reports the first case of osteomyelitis caused by systemic infection with Y. pseudotuberculosis 0:1 in a non-human primate, a captive ringtailed lemur (Lemur catta). The lemur had a short clinical history of hyporexia and weight loss with reduction in mobility, especially of the left hindlimb. On post-mortem examination there was evidence of multi-organ abscessation. In addition, severe necrosis, inflammation and large bacterial colonies were present in the musculature, periosteum and bone marrow in the hip, ribs and a vertebra at the cervicothoracic junction. Osteomyelitis should be considered as a rare clinical presentation in non-human primates with systemic Y. pseudotuberculosis infection. (C) 2018 Elsevier Ltd. All rights reserved.	[Walker, D.; Harris, J. D.; Taylor, C. S.; Paterson, G. K.; Morrison, L. R.] Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Gibbons, J.] Univ Coll Dublin, Sch Vet Med, Dublin 4, Ireland; [Scott, C.] Struthers & Scott Vet Practice, Doune FK16 6EH, Perth, Scotland	Walker, D (reprint author), Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.	dave.walker@ed.ac.uk	Paterson, Gavin/V-6725-2019	Paterson, Gavin/0000-0002-1880-0095			Barnes PD, 2006, J EXP MED, V203, P1591, DOI 10.1084/jem.20060905; Bonardi S, 2016, INT J FOOD MICROBIOL, V235, P125, DOI 10.1016/j.ijfoodmicro.2016.07.033; BUHLES WC, 1981, J CLIN MICROBIOL, V13, P519; Clark MA, 1998, INFECT IMMUN, V66, P1237; Crowe M, 1996, J MED MICROBIOL, V45, P302, DOI 10.1099/00222615-45-4-302; Galindo CL, 2011, J PATHOG, DOI 10.4061/2011/182051; Gaston JSH, 1999, ARTHRITIS RHEUM, V42, P2239; Giannitti F, 2014, J VET DIAGN INVEST, V26, P88, DOI 10.1177/1040638713516624; GRANFORS K, 1989, NEW ENGL J MED, V320, P216, DOI 10.1056/NEJM198901263200404; Ishihara T, 2016, JOINT BONE SPINE, V83, P727, DOI 10.1016/j.jbspin.2016.01.009; Iwata T, 2011, JARQ-JPN AGR RES Q, V45, P83, DOI 10.6090/jarq.45.83; Katamura K, 2001, PEDIATR INT, V43, P711, DOI 10.1046/j.1442-200X.2001.01452.x; Loftus CG, 2002, DIGEST DIS SCI, V47, P2805, DOI 10.1023/A:1021081911456; MACARTHUR JA, 1983, LAB ANIM, V17, P151, DOI 10.1258/002367783780959367; Mair N.S., 1973, Journal Wildl Dis, V9, P64; Milnes AS, 2008, EPIDEMIOL INFECT, V136, P739, DOI 10.1017/S0950268807009223; Nakamura S, 2010, J COMP PATHOL, V143, P150, DOI 10.1016/j.jcpa.2010.01.017; Schulte R, 2000, CELL MICROBIOL, V2, P173, DOI 10.1046/j.1462-5822.2000.00047.x; SEBES JI, 1976, CHEST, V69, P546, DOI 10.1378/chest.69.4.546; SLEE KJ, 1990, AUST VET J, V67, P396, DOI 10.1111/j.1751-0813.1990.tb03024.x; Smego RA, 1999, EUR J CLIN MICROBIOL, V18, P1, DOI 10.1007/s100960050219; SPIRA TJ, 1976, ARCH INTERN MED, V136, P1305, DOI 10.1001/archinte.136.11.1305; Stamm I, 2013, J CLIN MICROBIOL, V51, P887, DOI 10.1128/JCM.02506-12; TAFFS LF, 1983, LAB ANIM, V17, P311, DOI 10.1258/002367783781062280; van Zonneveld M, 2002, NEPHROL DIAL TRANSPL, V17, P2252, DOI 10.1093/ndt/17.12.2252; Vasala M, 2014, ANN RHEUM DIS, V73, P1793, DOI 10.1136/annrheumdis-2013-203431; Wacheck S, 2010, FOODBORNE PATHOG DIS, V7, P307, DOI 10.1089/fpd.2009.0367; WALLNERPENDLETON E, 1983, AVIAN DIS, V27, P524, DOI 10.2307/1590179; WISE DR, 1972, J MED MICROBIOL, V5, P128, DOI 10.1099/00222615-5-1-128	29	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						27	31		10.1016/j.jcpa.2018.08.004			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800003	30360909				2019-10-28	
J	Costa, RA; Casaux, ML; Caffarena, RD; Macias-Rioseco, M; Schild, CO; Fraga, M; Riet-Correa, F; Giannitti, F				Costa, R. A.; Casaux, M. L.; Caffarena, R. D.; Macias-Rioseco, M.; Schild, C. O.; Fraga, M.; Riet-Correa, F.; Giannitti, F.			Urocystitis and Ureteritis in Holstein Calves with Septicaemia Caused by Salmonella enterica Serotype Dublin	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cattle; pathology; salmonellosis; urinary tract infection	SEROVAR DUBLIN; INFECTION; CATTLE	Salmonellosis is an enteric or multisystemic disease of global distribution that affects numerous animal species. Although Salmonella enterica has been associated with urinary tract lesions in man, information on urocystitis/ ureteritis in cattle caused by salmonellae is lacking. This communication describes lesions oldie inferior urinary tract in four Holstein calves with septicaemia caused by S. enterica subsp. enlerica serotype Dublin. Examination of the urinary bladder revealed either diffuse irregular thickening (three cases) or petechiation (one case) of the mucosa. On histopathological examination, urocystitis with submucosal histiocytic, lymphocytic and plasmacytic infiltration and neutrophil transmigration through the urothelium was noted in all cases. In one case, a fibrinosuppurative ureteritis was detected. Salmonella Dublin was identified by culture, 16S rDNA sequencing and serotyping and Salmonella antigen was detected intralesionally by immunohistochemistry. Other lesions, indicative of septicaemia included hepatitis, enteritis, pericarditis, splenitis, lymphadcnitis and pneumonia. We conclude that S. Dublin can be uropathogenic in cattle with septicaemia. (C) 2018 Elsevier Ltd. All rights reserved.	[Costa, R. A.; Casaux, M. L.; Caffarena, R. D.; Macias-Rioseco, M.; Schild, C. O.; Fraga, M.; Riet-Correa, F.; Giannitti, F.] Inst Nacl Invest Agr, Ruta 50 Km 11, La Estanzuela, Colonia, Uruguay; [Giannitti, F.] Univ Minnesota, Coll Vet Med, Vet Populat Med Dept, St Paul, MN 55108 USA	Giannitti, F (reprint author), Inst Nacl Invest Agr, Ruta 50 Km 11, La Estanzuela, Colonia, Uruguay.; Giannitti, F (reprint author), Univ Minnesota, Coll Vet Med, Vet Populat Med Dept, St Paul, MN 55108 USA.	fgiannitti@inia.org.uy	Caffarena, Dario/F-2343-2017	Caffarena, Dario/0000-0002-2141-3264; Fraga, Martin/0000-0003-3390-9723; Giannitti, Federico/0000-0001-8799-6848	Uruguayan Instituto Nacional de Investigacion Agropecuaria [PL-015 N-15156]	The authors thank Y. Perdomo and C. Monesiglio from the Institute Nacional de Investigacion Agropecuaria; J. Shivers from the University of Minnesota Veterinary Diagnostic Laboratory (UMNVDL) and A. Martinez and L. Betancor from the Institute de Higiene, Univesidad de la Reptiblica, for technical assistance with the histological, immunohistochemical and bacteriological techniques, and Dr. A. Wuenschmann from the UMNVDL for assistance with photomicrographs. We also thank Dr. R. Moeller Jr., from the California Animal Health and Food Safety Laboratory, University of California, Davis, for critically reviewing this manuscript. This work was funded by the Uruguayan Instituto Nacional de Investigacion Agropecuaria (grant PL-015 N-15156).	Bazargani TT, 2015, IRAN J VET RES, V16, P114; Carrique-Mas JJ, 2010, VET REC, V167, P560, DOI 10.1136/vr.c4943; Cianciolo RE, 2016, JUBB KENNEDY PALMERS, P458; Costa LF, 2012, RES VET SCI, V93, P1, DOI 10.1016/j.rvsc.2012.03.002; Grimont P. A. D., 2007, WHO COLLABORATING CT, V9, P1; Na SK, 2013, KIDNEY RES CLIN PRAC, V32, P84, DOI 10.1016/j.krcp.2013.04.005; Octavia S, 2014, PROKARYOTES GAMMAPRO, P225; Pecoraro HL, 2017, J VET DIAGN INVEST, V29, P860, DOI 10.1177/1040638717712757; Polat HB, 2014, CASE REP MED, DOI 10.1155/2014/758583; Tena D, 2007, J INFECTION, V54, P245, DOI 10.1016/j.jinf.2006.05.007; Uzal FA, 2016, JUBB KENNEDY PALMERS, P167; Yim L, 2014, INFECT IMMUN, V82, P1465, DOI 10.1128/IAI.01336-13	12	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						32	36		10.1016/j.jcpa.2018.08.005			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800004	30360910				2019-10-28	
J	Tuan, YC; Wan, RC; Kao, JP; Chiou, HY; Takahashi, K; Liao, JW				Tuan, Y. C.; Wan, R. C.; Kao, J. P.; Chiou, H. Y.; Takahashi, K.; Liao, J. W.			Retrospective Pathological Studies of Splenic Lesions in Domestic Hamsters (Phodopus spp.)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						hamster; Phodopus spp.; spleen; tumours	HISTIOCYTIC SARCOMA; SPONTANEOUS TUMORS; SUNGORUS; CELLS; SKIN	Fifteen splenic biopsy specimens from a total of 212 biopsy specimens and necropsy cases of domestic hamsters (Phodopus spp.) from the Division of Wild (Exotic) Animal Medicine, Veterinary Medical Teaching Hospital, National Chung Hsing University, Taiwan, collected between 2010 and 2017, were studied retrospectively. The incidence of lesions in the spleen was 7.1% (15/212). The mean age of affected hamsters was 16.6 months and females were affected more than males. The lesions consisted of 10 neoplasms and five non-neoplastic lesions. The most common tumours were histiocytic sarcoma (HS), lymphoma, malignant fibrous histiocytoma (MFH) and hemangiosarcoma. Immunohistochemistry revealed the HSs and MFHs to express lysozyme. The lymphomas were negative for CD20; however, one case was positive for CD3 and another was positive for CD79a. The hemangiosarcoma expressed von Willebrand factor. The non-neoplastic lesions were all fibrotic nodules and these were all identified in ageing female hamsters. The nodules consisted of collagen fibres identified with Masson's trichrome stain, and they were related to repair of trauma in the spleen. (C) 2018 Elsevier Ltd. All rights reserved.	[Tuan, Y. C.; Chiou, H. Y.; Liao, J. W.] Natl Chung Hsing Univ, Grad Inst Vet Pathobiol, Taichung, Taiwan; [Wan, R. C.; Kao, J. P.] Natl Chung Hsing Univ, Vet Med Teaching Hosp, Taichung, Taiwan; [Kao, J. P.] Natl Chung Hsing Univ, Dept Vet Med, Taichung, Taiwan; [Takahashi, K.] Nippon Vet & Anim Sci Univ, Dept Vet Pathol, Tokyo, Japan; [Liao, J. W.] Natl Chung Hsing Univ, Anim Dis Diagnost Ctr, Taichung, Taiwan	Liao, JW (reprint author), Natl Chung Hsing Univ, Grad Inst Vet Pathobiol, Taichung, Taiwan.; Liao, JW (reprint author), Natl Chung Hsing Univ, Anim Dis Diagnost Ctr, Taichung, Taiwan.	jwliao@dragon.nchu.edu.tw			Ministry of Education, Taiwan, R.O.C., under the ATU planMinistry of Education, Taiwan	This work is supported in part by the Ministry of Education, Taiwan, R.O.C., under the ATU plan. The authors also thank I. Cochrane-Lusk for English revision of the manuscript.	Baba Y, 2003, COMPARATIVE MED, V53, P527; CHEN HC, 1992, TOXICOL PATHOL, V20, P260, DOI 10.1177/019262339202000213; Coble DJ, 2015, COMPARATIVE MED, V65, P127; Gill JR, 2012, J AM ASS LAB ANIMAL, V51, P653; GOODMAN DG, 1984, JNCI-J NATL CANCER I, V73, P265; Hosseininejad M, 2008, Pak J Biol Sci, V11, P2289; ISHMAEL J., 1967, J SMALL ANIM PRACT, V8, P501, DOI 10.1111/j.1748-5827.1967.tb06772.x; Jacobs RM, 2002, TUMORS DOMESTIC ANIM, P170; Kamino K, 2001, EXP TOXICOL PATHOL, V52, P539; Karolewski B, 2012, AM COLL LAB, P867, DOI 10.1016/B978-0-12-380920-9.00033-X; Kashida Y, 2003, VET PATHOL, V40, P548, DOI 10.1354/vp.40-5-548; Kondo H, 2008, VET PATHOL, V45, P674, DOI 10.1354/vp.45-5-674; Nakahira R, 2016, COMPARATIVE MED, V66, P25; Ogihara K, 2016, J COMP PATHOL, V155, P361, DOI 10.1016/j.jcpa.2016.09.001; POGOSIANZ HE, 1975, J NATL CANCER I, V54, P659, DOI 10.1093/jnci/54.3.659; RAPER AB, 1959, J PATHOL BACTERIOL, V78, P1, DOI 10.1002/path.1700780103; Santos Vitorino M., 2002, Medicina (Ribeirao Preto), V35, P179; Shirai T, 1997, TOXICOL PATHOL, V25, P453, DOI 10.1177/019262339702500504; Valli VE, 2002, TUMORS DOMESTIC ANIM, P48; Yang Chung-Chun, 2014, Taiwan Veterinary Journal, V40, P145, DOI 10.1142/S1682648514720020	20	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						37	43		10.1016/j.jcpa.2018.08.007			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800005	30360911				2019-10-28	
J	Tecilla, M; Bielli, M; Origgi, FC				Tecilla, M.; Bielli, M.; Origgi, F. C.			Polycystic Kidney-like Disease in a Red-ear Slider Turtle (Trachemys scripta elegans)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						kidney; pancreas; polycystic kidney-like disease; turtle	CILIA; EXPRESSION; MODELS; CELLS; PTEN	A 14-year-old red-ear slider turtle (Trachemys scripta elegans) with no history of pre-existing clinical disease died and was referred for necropsy examination. Grossly, oesophageal prolapse, bilateral renal cysts and a paraduodenal cystic mass were detected. Tissues were processed routinely for histology and immunohistochemistry (MC) with primary antibodies specific for Wilm's tumour suppressor gene-1 (WT-1), insulin, glucagon and pancytokeratins. Microscopically, renal medullar) , cysts and medullary atrophy resembled the changes associated with polycystic kidney disease (PKD). The cysts of the paraduodenal mass were lined by ciliated epithelial cells resembling embryonal cells and were intensely positive for glucagon and insulin by IHC. There was no cytokeratin expression in either lesion. WT-1 expression in the paraduodenal mass was cytoplasmic and appeared non-specific. Lesions were consistent with renal PKD-like disease and a pancreatic cystic hamartoma. (C) 2018 Elsevier Ltd. All rights reserved.	[Tecilla, M.] Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy; [Bielli, M.] Viale Buonarroti Michelangelo 20-A, I-28100 Novara, Italy; [Origgi, F. C.] Univ Bern, Dept Infect Dis & Pathobiol, Ctr Fish & Wildlife Hlth FIWI, Langgassstr 122, Bern, Switzerland	Tecilla, M (reprint author), Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy.	marco.tecilla@gmail.com	Tecilla, Marco/I-6167-2017	Tecilla, Marco/0000-0002-1214-8155			Bclyi VA, 2009, COLD SPRING HARB PER, V2; Cullen JM, 2016, JUBB KENNEDY PALMERS, V2, P264; Delling M, 2016, NATURE, V531, P656, DOI 10.1038/nature17426; Domanjko-Petric A, 2008, J FELINE MED SURG, V10, P115, DOI 10.1016/j.jfms.2007.07.004; Gonzalez-Granero S, 2011, NEUROGENESIS IN THE ADULT BRAIN I: NEUROBIOLOGY, P169, DOI 10.1007/978-4-431-53933-9_6; Guillaume R, 2000, MECH DEVELOP, V93, P179, DOI 10.1016/S0925-4773(00)00257-4; Harris PC, 1993, GENE REV, P1; Harris PC, 2009, ANNU REV MED, V60, P321, DOI 10.1146/annurev.med.60.101707.125712; Hobert JA, 2009, GENET MED, V11, P687, DOI 10.1097/GIM.0b013e3181ac9aea; Johnstone AC, 2005, NEW ZEAL VET J, V53, P307, DOI 10.1080/00480169.2005.36565; JORGENSEN JM, 1988, ACTA ZOOL-STOCKHOLM, V69, P169, DOI 10.1111/j.1463-6395.1988.tb00914.x; Lyons LA, 2004, J AM SOC NEPHROL, V15, P2548, DOI 10.1097/01.ASN.0000141776.38527.BB; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Marra AN, 2016, GENESIS, V54, P457, DOI 10.1002/dvg.22957; Maurer KJ, 2004, KIDNEY INT, V65, P482, DOI 10.1111/j.1523-1755.2004.00401.x; Nagao S, 2012, EXP ANIM TOKYO, V61, P477, DOI 10.1538/expanim.61.477; Newman SJ, 2000, J VET DIAGN INVEST, V12, P374, DOI 10.1177/104063870001200415; O'Leary CA, 1999, AUST VET J, V77, P361, DOI 10.1111/j.1751-0813.1999.tb10304.x; Palmer MV, 2004, J VET DIAGN INVEST, V16, P475, DOI 10.1177/104063870401600522; Parsai S, 2013, THESIS; Plesker R, 2006, AM J PRIMATOL, V68, P838, DOI 10.1002/ajp.20283; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Schou KB, 2015, EMBO REP, V16, P1099, DOI 10.15252/embr.201540530; Spotila LD, 1998, COMP BIOCHEM PHYS B, V119, P761, DOI 10.1016/S0305-0491(98)00053-4; Stacy BA, 2004, J COMP PATHOL, V130, P223, DOI 10.1016/j.jcpa.2003.09.009; Sutterlin GG, 1998, AM J PHYSIOL-REG I, V275, pR220; VANALSTINE WG, 1984, AVIAN DIS, V28, P758; Weissman T, 2003, CEREB CORTEX, V13, P550, DOI 10.1093/cercor/13.6.550; Wessely O, 2008, FRONT BIOSCI-LANDMRK, V13, P1866, DOI 10.2741/2806; Wyneken J., 2013, P ASREPTILIAN AMPH, P72	30	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						44	47		10.1016/j.jcpa.2018.08.006			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800006	30360912				2019-10-28	
J	Nordio, L; Fattori, S; Vascellari, M; Giudice, C				Nordio, L.; Fattori, S.; Vascellari, M.; Giudice, C.			Evidence of Vasculogenic Mimicry in a Palpebral Melanocytoma in a Dog (vol 162, pg 43, 2018)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Correction									[Nordio, L.; Giudice, C.] Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy; [Vascellari, M.] Ist Zooprofilatt Sperimentale Venezie, Lab Histopathol, Viale Univ 10, Legnaro, Italy	Nordio, L (reprint author), Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy.	laura.nordio@unimi.it		Vascellari, Marta/0000-0002-4537-4386			Nordio L, 2018, J COMP PATHOL, V162, P43, DOI 10.1016/j.jcpa.2018.06.003	1	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	OCT	2018	164						48	48		10.1016/j.jcpa.2018.08.008			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GZ5FO	WOS:000449444800007	30360913				2019-10-28	
J	Li, ZL; Jiang, XM; Su, ZL; Li, JL; Kang, PC; Li, CL; Cui, YF				Li, Zhenglong; Jiang, Xingming; Su, Zhilei; Li, Jinglin; Kang, Pengcheng; Li, Chunlong; Cui, Yunfu			Current insight into a cancer-implicated long noncoding RNA ZFAS1 and correlative functional mechanisms involved	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Long noncoding RNA ZFAS1; Cancer; Biomarker; Mechanism	EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; METASTASIS; OVEREXPRESSION; PROGRESSION; ACTIVATION; MORTALITY; LNCRNAS; GROWTH	Objectives: A vast of transcripts have been found aberrantly expressed in cancers functioning as mechanical factors. The association between the deregulation of long noncoding RNAs (lncRNAs) and clinicopathologic features is one of the most investigated in this field, and many lncRNAs have already been revealed to be potential biomarkers or therapeutic targets. Zinc finger antisense 1 (ZFAS1) has been found one promising lncRNA, initially discovered downregulated in human breast cancer and could regulate alveolar development and epithelial cell differentiation in mice mammary gland, however the subsequent investigation provided inverse outcomes as overexpressed in other human cancers. Further excavation of this transcript indicated that ZFAS1 could function as oncogenic factor via many approaches to contribute to the advance of cancers, including induction of epithelial-mesenchymal transition, sponging microRNAs, destabilization p53 gene and many others. Materials and Methods: In this work, we summarized current evidence regarding the biological functions and mechanisms of ZFAS1 in human cancers. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library. Results: LncRNA ZFAS1 is one cancer-implicated product with multiple functional mechanisms, and its potential clinical values is gradually unfolded in many types of cancers, including breast cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioma, ovarian cancer and many others. Conclusion: The multi-mechanisms of LncRNA ZFAS1 fertilizes its role of potential clinical biomarkers and therapeutic targets.	[Li, Zhenglong; Jiang, Xingming; Su, Zhilei; Li, Jinglin; Kang, Pengcheng; Li, Chunlong; Cui, Yunfu] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin 150086, Heilongjiang, Peoples R China	Cui, YF (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin 150086, Heilongjiang, Peoples R China.	yfcui777@hotmail.com		Li, Zhenglong/0000-0003-3720-3496	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602088]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M621305]; Heilongjiang Postdoctoral Science Foundation [LBH-Z16096]; Health and Family Planning Commission Research Project of Heilongjiang Province [2016-049]; Innovative Science Foundation of Harbin Medical University [2016LCZX09]	This work was supported by grants from the National Natural Science Foundation of China (No. 81602088), the China Postdoctoral Science Foundation (No. 2017M621305), the Heilongjiang Postdoctoral Science Foundation (No. LBH-Z16096), the Health and Family Planning Commission Research Project of Heilongjiang Province (No. 2016-049), and the Innovative Science Foundation of Harbin Medical University (No. 2016LCZX09).	Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Askarian-Amiri ME, 2011, RNA, V17, P878, DOI 10.1261/rna.2528811; Atianand MK, 2016, CELL, V165, P1672, DOI 10.1016/j.cell.2016.05.075; Baytak E, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701648; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bogacheva M, 2017, BIOORG MED CHEM LETT, V27, P4781, DOI 10.1016/j.bmcl.2017.10.001; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Butterfield GL, 2017, NATURE, V552, P415, DOI 10.1038/nature25157; Chen LJ, 2017, PATHOL RES PRACT, V213, P882, DOI 10.1016/j.prp.2017.06.012; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; Chen X, 2018, EUR REV MED PHARMACO, V22, P3423, DOI 10.26355/eurrev_201806_15165; Chrun ES, 2017, PATHOL RES PRACT, V213, P1329, DOI 10.1016/j.prp.2017.06.013; Costa FF, 2010, BIOESSAYS, V32, P599, DOI 10.1002/bies.200900112; Denzler R, 2014, MOL CELL, V54, P766, DOI 10.1016/j.molcel.2014.03.045; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Gao K, 2017, BIOMED PHARMACOTHER, V87, P555, DOI 10.1016/j.biopha.2017.01.014; Gu HF, 2017, EXP THER MED, V14, P647, DOI 10.3892/etm.2017.4535; Hansji H, 2016, BIOL DIRECT, V11, DOI 10.1186/s13062-016-0165-y; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Imai-Sumida M, 2017, ONCOTARGET, V8, P92032, DOI 10.18632/oncotarget.20734; Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Lee SH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061144; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li J, 2015, CELL PHYSIOL BIOCHEM, V37, P687, DOI 10.1159/000430387; Li N, 2017, ONCOTARGET, V8, P104160, DOI 10.18632/oncotarget.22032; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Li Z, 2016, CELL PROLIFERAT, V49, P471, DOI 10.1111/cpr.12269; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu DD, 2017, GENE DEV, V31, P1823, DOI 10.1101/gad.307439.117; Liu GF, 2017, AM J CANCER RES, V7, P1450; Liu R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00050-w; Luo CL, 2018, CANCER MANAG RES, V10, P1449, DOI 10.2147/CMAR.S164227; Lv Q. L., 2017, TUMOUR BIOL, V39; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Moffett HF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00505-8; Nie FQ, 2017, ONCOTARGET, V8, P38227, DOI 10.18632/oncotarget.9611; Pan L, 2017, J CANCER RES CLIN, V143, P991, DOI 10.1007/s00432-017-2361-2; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Sanders SJ, 2017, NAT NEUROSCI, V20, P1661, DOI 10.1038/s41593-017-0017-9; Shi HT, 2017, ONCOTARGET, V8, P59048, DOI 10.18632/oncotarget.19937; Smith RA, 2017, CA-CANCER J CLIN, V67, P100, DOI 10.3322/caac.21392; Thorenoor N, 2016, ONCOTARGET, V7, P622, DOI 10.18632/oncotarget.5807; Tian FM, 2016, EUR REV MED PHARMACO, V20, P5126; Ulz P, 2016, NAT GENET, V48, P1273, DOI 10.1038/ng.3648; Wang C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.493; Wang G, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12389; Wang WL, 2016, PATHOL RES PRACT, V212, P690, DOI 10.1016/j.prp.2016.05.003; Xia BR, 2017, ONCOTARGET, V8, P19534, DOI 10.18632/oncotarget.14663; Xie CR, 2017, MOL THER-NUCL ACIDS, V9, P440, DOI 10.1016/j.omtn.2017.10.018; Xie SP, 2018, CELL CYCLE, V17, P154, DOI 10.1080/15384101.2017.1407895; Xin Y, 2016, CELL PROLIFERAT, V49, P255, DOI 10.1111/cpr.12252; Xu Y, 2017, J EARTHQ ENG, V3, P1, DOI DOI 10.1038/cddis.2017.503; Yan HL, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0047-y; Yan Y., 2017, PATHOL RES PRACT, V213; Yang ZG, 2015, DIS MARKERS, DOI 10.1155/2015/191029; Yu H, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.7; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013; Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044; Zhang YY, 2016, AM J TRANSL RES, V8, P5035; Zhang ZW, 2016, J CLIN PATHOL, V69, P76, DOI 10.1136/jclinpath-2015-203275; Zheng J, 2016, MOL THER, V24, P1199, DOI 10.1038/mt.2016.71; Zhou H, 2016, AGING-US, V8, P2023, DOI 10.18632/aging.101048	66	2	2	0	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1517	1523		10.1016/j.prp.2018.07.032			7	Pathology	Pathology	GY0SD	WOS:000448231000001	30122315				2019-10-28	
J	Hong, WG; Pyo, JS				Hong, Won Gi; Pyo, Jung-Soo			The clinicopathological significance of SIRT1 expression in colon cancer: An immunohistochemical study and meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						SIRT1; Colorectal cancer; Prognosis; Immunohistochemistry; Meta-analysis	EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE EXPRESSION; MAMMALIAN SIRTUINS; COLORECTAL-CANCER; TUMOR INVASION; GROWTH; METASTASIS; INHIBITOR; PROGNOSIS; RADIATION	Objective: The aim of this study was to determine the clinicopathological significance and potential prognostic role of SIRT1 expression in colorectal cancer (CRC) using immunohistochemistry and meta-analysis. Methods: Immunohistochemistry was performed on 265 archival paraffin-embedded human CRC specimens to investigate the correlation between SIRT1 expression and clinicopathological characteristics, including patient survival. To elucidate the potential prognostic value of SIRT1 expression, a meta-analysis was performed using data on 2132 patients from eight eligible studies. Results: SIRT1 was highly expressed in 24.5% of the 265 CRC specimens analyzed. High SIRT1 expression correlated with vascular invasion (P = 0.041). High SIRT1 expression also significantly correlated with expression of SNAI (P = 0.001), but not E-cadherin (P = 0.958). However, there was no significant correlation between SIRT1 expression and other clinicopathological parameters. High SIRT1 expression in the CRC specimens significantly correlated with a worse overall survival rate, independent of SNAI expression. However, based on the meta-analysis, high SIRT1 expression was not significantly correlated with overall survival rates [hazard ratio (HR) 1.111, 95% confidential interval (CI) 0.799-1.544]. Conclusion: In our retrospective study, high SIRT1 expression significantly correlated with vascular invasion and a worse prognosis. However, because the results from the meta-analysis differed the retrospective arm of our study, additional cumulative studies are needed to determine the prognostic value of SIRT1 in CRC.	[Hong, Won Gi] Eulji Univ, Sch Med, Daejeon 34824, South Korea; [Pyo, Jung-Soo] Eulji Univ, Sch Med, Eulji Univ Hosp, Dept Pathol, 95 Dunsanseo Ro, Daejeon 35233, South Korea	Pyo, JS (reprint author), Eulji Univ, Sch Med, Eulji Univ Hosp, Dept Pathol, 95 Dunsanseo Ro, Daejeon 35233, South Korea.	anapyojs@gmail.com			National Research Foundation of Korea (NRF) - Korea government (Ministry of Science, ICT & Future Planning) [NRF-2017R1C1B5018063]	The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This study was supported by National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (NRF-2017R1C1B5018063).	Benard A, 2015, HISTOPATHOLOGY, V66, P270, DOI 10.1111/his.12534; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chen XJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07481; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Choupani J, 2018, J CELL PHYSIOL, V233, P4443, DOI 10.1002/jcp.26302; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685; Jin MS, 2016, TUMOR BIOL, V37, P4743, DOI 10.1007/s13277-015-4231-3; Jung W, 2013, KOREAN J PATHOL, V47, P332, DOI 10.4132/KoreanJPathol.2013.47.4.332; Li SQ, 2016, MED SCI MONITOR, V22, P1593; Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9; Matsushita N, 2005, GENES CELLS, V10, P321, DOI 10.1111/j.1365-2443.2005.00836.x; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PETO R, 1973, APPL STAT, V22, P86; Pyo JS, 2015, J CANCER RES CLIN, V141, P1181, DOI 10.1007/s00432-014-1890-1; REMMELE W, 1987, PATHOLOGE, V8, P138; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013; Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171; Wu SJ, 2017, ONCOTARGET, V8, P62589, DOI 10.18632/oncotarget.19880; Zhang XZ, 2015, INT J CLIN EXP MED, V8, P809; Zu G, 2016, INT J SURG, V26, P32, DOI 10.1016/j.ijsu.2016.01.002	28	2	3	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1550	1555		10.1016/j.prp.2018.07.022			6	Pathology	Pathology	GY0SD	WOS:000448231000006	30082156				2019-10-28	
J	Meng, JL; Li, WZ; Zhang, M; Hao, ZY; Fan, S; Zhang, L; Liang, CZ				Meng, Jialin; Li, Wanzhen; Zhang, Meng; Hao, Zongyao; Fan, Song; Zhang, Li; Liang, Chaozhao			An update meta-analysis and systematic review of TAP polymorphisms as potential biomarkers for judging cancer risk	PATHOLOGY RESEARCH AND PRACTICE			English	Review						TAP1; TAP2; Polymorphism; Cancer; Meta-analysis	PROCESSING MACHINERY COMPONENTS; GENE POLYMORPHISMS; CERVICAL-CARCINOMA; ASSOCIATION; TRANSPORTER; EXPRESSION; POPULATION; VARIANT	Objective: Transporter associated with antigen processing protein (TAP) is a heterodimer protein consist of TAP1 and TAP2, act a pivotal part in the immune surveillance. In recent days, controversial relationships were reported between TAP polymorphisms and cancer risk, thus, a systematic meta-analysis was performed to resolve this discrepancy. Methods: We searched the PubMed, EMbase, Web of Science, CNKI and Wanfang databases, the cited references were also manually searched again, covering all the papers published until March 25, 2018. Quality assessment was conducted using the Newcastle Ottawa Scale. All the meta-analysis was conducted with Stata version 12.0 software to assess the strength of the association. Results: 4719 cases and 4215 controls from 24 case-control studies related to TAP polymorphisms were enrolled. There was no significant association between TAP1-rs1135216, TAP1-rs4148873, TAP2-rs2228396, TAP2-rs241447 and TAP2-rs4148873 and cancer sensibility. Interestingly, a significant positive association was observed between TAP2 rs4148876 C/T polymorphism and increase cancer risk in homozygote and recessive models. Further in-silico results indicated the expression of TAP2 in cancer tissue is higher than that in normal tissue (cervical cancer, TPM = 70.2 vs. 24.0 respectively, P < 0.01; acute myeloid leukemia, TPM = 52.5 vs. 8.8 respectively, P < 0.01), and influence the survival time of acute myeloid leukemia patients (Log-rank P < 0.05). Conclusions: Our finding suggested that TAP1-rs1135216, TAP1-rs4148873, TAP2-rs2228396, TAP2-rs241447 and TAP2-rs4148873 might not be involved in cancer risk, but the T allele of TAP2-rs4148876 might be a potential biomarker for judging cancer risk, and larger-scale studies are required to confirm our findings.	[Meng, Jialin; Zhang, Meng; Hao, Zongyao; Fan, Song; Zhang, Li; Liang, Chaozhao] Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Affiliated Hosp 1, Dept Urol,Inst Urol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China; [Meng, Jialin; Li, Wanzhen; Zhang, Meng] Anhui Med Univ, Grad Sch, Hefei, Anhui, Peoples R China	Liang, CZ (reprint author), Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Affiliated Hosp 1, Dept Urol,Inst Urol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.	liang_chaozhao@ahmu.edu.cn	Meng, Jialin/L-8480-2019	Meng, Jialin/0000-0002-4622-833X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81630019]	This manuscript was supported by National Natural Science Foundation of China (81630019 to C Liang)	Bonferroni C. E., 1936, COMM FIRENZE, V1936, P216; Cao BW, 2005, CARCINOGENESIS, V26, P1280, DOI 10.1093/carcin/bgi071; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Dogru D, 2007, PEDIATR PULM, V42, P237, DOI 10.1002/ppul.20560; Feng ML, 2009, HUM IMMUNOL, V70, P257, DOI 10.1016/j.humimm.2009.01.028; Guo QH, 2016, INT J CLIN EXP MED, V9, P12097; Hasim A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044952; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mehta AM, 2007, GENE CHROMOSOME CANC, V46, P577, DOI 10.1002/gcc.20441; Mehta AM, 2015, IMMUNOGENETICS, V67, P267, DOI 10.1007/s00251-015-0834-5; Natter C, 2013, DIS MARKERS, P79, DOI 10.1155/2013/368732; Ozbas-Gerceker F, 2013, ASIAN PAC J CANCER P, V14, P5213, DOI 10.7314/APJCP.2013.14.9.5213; Parcej D, 2010, NAT CHEM BIOL, V6, P572, DOI [10.1038/nchembio.410, 10.1038/NCHEMBIO.410]; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Ritz U, 2001, MOL MED, V7, P149, DOI 10.1007/BF03401948; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Seagroatt V, 1998, BRIT MED J, V316, P470; Shinde V, 2013, HUM IMMUNOL, V74, P803, DOI 10.1016/j.humimm.2013.01.001; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tang ZF, 2017, BIOINFORMATICS, V33, P941, DOI 10.1093/bioinformatics/btw775; Vermeulen CFW, 2007, GYNECOL ONCOL, V105, P593, DOI 10.1016/j.ygyno.2007.02.016; Wang DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033051; Zou NJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0185-y	25	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1556	1563		10.1016/j.prp.2018.07.018			8	Pathology	Pathology	GY0SD	WOS:000448231000007	30082158				2019-10-28	
J	Hu, HC; Zhou, C; Li, B; Chen, YF; Dai, J; Mao, YY; Huang, TY; Yu, H; Chen, M; Zhao, J; Duan, SW				Hu, Haochang; Zhou, Cong; Li, Bin; Chen, Yanfei; Dai, Jie; Mao, Yiyi; Huang, Tianyi; Yu, Hang; Chen, Min; Zhao, Jun; Duan, Shiwei			Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						DNA methylation; Colorectal cancer; RASSF1A; Diagnosis; Meta-analysis	DNA METHYLATION; TUMOR-SUPPRESSOR; PROMOTER HYPERMETHYLATION; EPIGENETIC ALTERATIONS; UNITED-STATES; RAS; PATHWAY; BIOMARKERS; GENES; IDENTIFICATION	Purpose: Ras association domain family 1 isoform A (RASSF1A), a member of Ras association domain family, plays an important role in tumorigenesis. The goal of our meta-analysis was to assess the diagnostic value of RASSF1A hypermethylation in colorectal cancer (CRC). Methods: PubMed, Embase, CNKI and Wanfang databases were used to conduct literature selection. The association between RASSF1A methylation and CRC risk was evaluated by odds ratios (ORs) and 95% confidence intervals (CIs). Summary receiver operating characteristics (SROC) test was used to estimate the diagnostic value of RASSF1A methylation for CRC. Results: A total of 22 articles among 1736 CRC and 811 non-tumor samples were included in the current meta analysis. Our results showed that RASSF1A hypermethylation was found more frequently in CRC than non-tumor samples (OR = 6.02, 95% CI = 4.57-7.93, P < 0.001). Our SROC test showed that RASSF1A hypermethylation had an area under the curve (AUC) of 0.71 with a pooled sensitivity of 0.33 (95% CI = 0.31-0.36), a pooled specificity of 0.86 (95% CI = 0.84-0.89), a positive-likelihood ratio of 3.18 (95% CI = 1.99-5.09), a negative likelihood ratio of 0.71 (95% CI = 0.63-0.80), and a diagnostic odds ratio of 5.53 (95% CI = 3.40-9.00). Data mining study indicated that a trend of increased RASSF1A expression was found in the CRC cell line C2C12 after 5-AZA treatment. Conclusions: Our study established that RASSF1A hypermethylation might have a potential value in the clinical diagnosis of CRC.	[Hu, Haochang; Zhou, Cong; Li, Bin; Chen, Yanfei; Dai, Jie; Mao, Yiyi; Huang, Tianyi; Yu, Hang; Chen, Min; Zhao, Jun; Duan, Shiwei] Ningbo Univ, Sch Med, Ctr Med Genet, Ningbo, Zhejiang, Peoples R China	Duan, SW (reprint author), Ningbo Univ, Sch Med, Ctr Med Genet, Ningbo, Zhejiang, Peoples R China.	duanshiwei@nbu.edu.cn			K. C. Wong Magna Fund in Ningbo University	The research was supported by the grants from K. C. Wong Magna Fund in Ningbo University.	Abotchie PN, 2012, J WOMENS HEALTH, V21, P393, DOI 10.1089/jwh.2011.2992; Arnold CN, 2005, CANCER, V104, P2035, DOI 10.1002/cncr.21462; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Benton Sally C, 2015, Curr Gastroenterol Rep, V17, P428, DOI 10.1007/s11894-015-0428-2; Capuano V, 2015, J FR OPHTALMOL, V38, pE19, DOI 10.1016/j.jfo.2014.04.018; Chen C, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-199; Coppede F, 2014, EPIGENETICS-US, V9, P621, DOI 10.4161/epi.27956; Coppede F, 2014, CANCER LETT, V342, P238, DOI 10.1016/j.canlet.2011.12.030; Dallol A, 2012, CANCER EPIDEM BIOMAR, V21, P2069, DOI 10.1158/1055-9965.EPI-12-0755; Dammann R, 2000, NAT GENET, V25, P315; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Donninger H, 2016, SEMIN CELL DEV BIOL, V58, P86, DOI 10.1016/j.semcdb.2016.06.007; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; Freitas M, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1415-9; Gansler T, 2010, CA-CANCER J CLIN, V60, P345, DOI 10.3322/caac.20088; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hu HC, 2018, ONCOTARGET, V9, P5378, DOI 10.18632/oncotarget.23870; Hu HC, 2017, ONCOTARGET, V8, P84054, DOI 10.18632/oncotarget.21097; Jackson CS, 2016, J GASTROINTEST ONCOL, V7, pS32, DOI 10.3978/j.issn.2078-6891.2015.039; Carmona FJ, 2013, CANCER PREV RES, V6, P656, DOI 10.1158/1940-6207.CAPR-12-0501; Joo MK, 2015, MOL MED REP, V11, P3039, DOI 10.3892/mmr.2014.3055; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Li JY, 2017, GENE, V630, P1, DOI 10.1016/j.gene.2017.07.082; Li M, 2016, Zhonghua Yi Xue Za Zhi, V96, P456, DOI 10.3760/cma.j.issn.0376-2491.2016.06.010; Liu Y, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-74; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Matthaios D, 2016, ONCOL LETT, V12, P748, DOI 10.3892/ol.2016.4649; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Nilsson TK, 2013, INT J ONCOL, V42, P127, DOI 10.3892/ijo.2012.1682; Oh T, 2013, J MOL DIAGN, V15, P498, DOI 10.1016/j.jmoldx.2013.03.004; Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Overmeyer JH, 2011, FRONT BIOSCI-LANDMRK, V16, P1693, DOI 10.2741/3814; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rasmussen SL, 2016, COLORECTAL DIS, V18, P549, DOI 10.1111/codi.13336; Sakamoto N, 2004, ONCOGENE, V23, P8900, DOI 10.1038/sj.onc.1207993; Schirosi L, 2016, ONCOTARGET, V7, P67841, DOI 10.18632/oncotarget.12280; Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142; Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wahab AHA, 2011, TUMOR BIOL, V32, P845, DOI 10.1007/s13277-011-0156-7; Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Yoo W, 2016, ANN PUBLIC HLTH RES, V3; Yu W, 2016, MOL CLIN ONCOL, V4, P237, DOI 10.3892/mco.2015.702; Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335; Zhao LD, 2016, INT J ONCOL, V48, P1977, DOI 10.3892/ijo.2016.3414	57	4	4	2	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1572	1578		10.1016/j.prp.2018.07.031			7	Pathology	Pathology	GY0SD	WOS:000448231000009	30082160				2019-10-28	
J	Fu, J; Li, ZZ; Li, N				Fu, Jun; Li, Zhanzhan; Li, Na			The association between COX-2 gene rs5275 polymorphism and Nasopharyngeal carcinoma risk	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cyclooxygenase-2; Nasopharyngeal carcinoma; Single nucleotide polymorphism; Molecular epidemiology	CYCLOOXYGENASE-2 GENE; SUSCEPTIBILITY; IDENTIFICATION	The overexpression of cyclooxygenase-2 (COX-2) was correlated with the invasion and lymphatic metastasis and with the clinical stage of Nasopharyngeal carcinoma (NPC). The C allele of COX-2 gene rs5275 polymorphism disrupts miR-542-3p function to promote COX-2 overexpression. To examine the role of COX-2 gene rs5275 polymorphism in NPC, we determined COX-2 gene rs5275 polymorphism by using a custom-by-design 48-Plex single nucleotide polymorphism (SNP) Scan (TM) Kit. We found that C allele or CC genotype of rs5275 polymorphism in COX-2 gene was associated with an increased risk of NPC. In stratified analyses, COX-2 gene rs5275 polymorphism was associated with the risk of NPC among females, smokers, and drinkers. Based on these results, we concluded that COX-2 gene rs5275 variant contributes to NPC risk in a Chinese population. Larger studies with more diverse ethnic populations are needed to confirm these results.	[Fu, Jun; Li, Zhanzhan; Li, Na] Cent S Univ, Xiangya Hosp, Dept Oncol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China	Li, ZZ (reprint author), Cent S Univ, Xiangya Hosp, Dept Oncol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	liche4006@126.com					Bai Weiqi, 2012, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V26, P408; Catarino RJ, 2006, HEAD NECK-J SCI SPEC, V28, P603, DOI 10.1002/hed.20377; Chan OSH, 2014, ORAL ONCOL, V50, P791, DOI 10.1016/j.oraloncology.2014.01.004; Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100; Cui Dewei, 2008, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V22, P692; Gong J, 2018, NUCLEIC ACIDS RES, V46, pD971, DOI 10.1093/nar/gkx861; Gong J, 2012, HUM MUTAT, V33, P254, DOI 10.1002/humu.21641; Guo XC, 2008, CANCER EPIDEM BIOMAR, V17, P1760, DOI 10.1158/1055-9965.EPI-08-0149; HENDERSON BE, 1976, NEW ENGL J MED, V295, P1101, DOI 10.1056/NEJM197611112952003; Huang L, 2015, ROM J MORPHOL EMBRYO, V56, P1279; Kamran SC, 2015, SURG ONCOL CLIN N AM, V24, P547, DOI 10.1016/j.soc.2015.03.008; Kongruttanachok N, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-4; Li Gang, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P1111; Li Q, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0397-6; Li WW, 2014, PHARMAZIE, V69, P132, DOI 10.1691/ph.2014.3794; Li ZL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1044712; Mamoghli T, 2015, PATHOL BIOL, V63, P7, DOI 10.1016/j.patbio.2014.10.008; Moore AE, 2012, ONCOGENE, V31, P1592, DOI 10.1038/onc.2011.349; Peng QL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094790; Raab-Traub N, 2015, CURR TOP MICROBIOL, V390, P339, DOI 10.1007/978-3-319-22822-8_14; Shen JJ, 2015, GENET TEST MOL BIOMA, V19, P187, DOI 10.1089/gtmb.2014.0149; Sousa H, 2011, DNA CELL BIOL, V30, P99, DOI 10.1089/dna.2010.1086; Tan JY, 2017, ONCOTARGETS THER, V10, P909, DOI 10.2147/OTT.S126159; Tiwawech Danai, 2005, Asian Pac J Cancer Prev, V6, P270; U. S. National Science Foundation, ALLELE FREQUENCY DAT; Wang B, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0470-6; Wang JL, 2015, INT J CLIN EXP PATHO, V8, P7441; Wittekind C, 2012, STRAHLENTHER ONKOL, V188, P191, DOI 10.1007/s00066-011-0032-9; Zhang TC, 2015, INT J CLIN EXP PATHO, V8, P3168; Zhao ML, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-57	30	3	3	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1579	1582		10.1016/j.prp.2018.07.028			4	Pathology	Pathology	GY0SD	WOS:000448231000010	30087034				2019-10-28	
J	Sasso, S; Cruz, IR; Lorenzini, MS; Delwing-Dal Magro, D; Brueckheimer, MB; Maia, TP; Sala, GABN; Mews, MHR; Delwing-de Lima, D				Sasso, Simone; Cruz, Indianara Rodrigues; Lorenzini, Mariana Simonato; Delwing-Dal Magro, Debora; Brueckheimer, Maite Beatriz; Maia, Thayna Patachini; Bunick Neto Sala, Geraldo Antonio; Ruela Mews, Matheus Henrique; Delwing-de Lima, Daniela			Antioxidant effects on the intracerebroventricular galactose damage in rats	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Galactose; Antioxidants; Acetylcholinesterase; Oxidative stress; Intracerebroventricular injection	OXIDATIVE DAMAGE; VITAMIN-E; DROSOPHILA-MELANOGASTER; STRESS; BRAIN; MEMORY; ACID; MICE; ACETYLCHOLINESTERASE; HIPPOCAMPUS	We investigated the effects of the intracerebroventricular infusion of galactose and the influence of pretreatment with antioxidants on oxidative stress parameters and acethylcholinesterase (AChE) activity in the brain of 60 day-old Wistar rats (6 per group). The animals were divided into naive group (did not undergo surgery); procedure group (only underwent surgery); sham group (underwent surgery and received 5 mu L saline) and galactose group (received 5 mu L of galactose solution (5.0 mM) by intracerebroventricular injection), and were killed by decapitation after 1 h. Other groups were pretreated daily for 1 week with saline (sham and galactose groups) or antioxidants, a-tocopherol (40 mg/kg) plus ascorbic acid (100 mg/kg, i.p.) (antioxidants and galactose + antioxidants groups). Twelve hours after the last antioxidants injection, animals received an intracerebroventricular infusion of 5 mu L of galactose solution (galactose and galactose + antioxidants groups) or saline (sham and antioxidants groups) and were sacrificed 1 h later. Galactose elevated thiobarbituric acid reactive substances (TBA-RS), protein carbonyl content and glutathione peroxidase (GSH-Px) activity and decreased total sulfhydryl content and catalase (CAT) activity in the cerebral cortex. In the hippocampus, galactose enhanced TBA-RS, decreased total sulfhydryl content and increased AChE activity, while in the cerebellum it decreased total sulfhydryl content and increased CAT and superoxide dismutase (SOD) activities. Pretreatment with antioxidants prevented the majority of these alterations, indicating the participation of free radicals in these effects. Thus, intracerebroventricular galactose infusion impairs redox homeostasis in the brain; the administration of antioxidants should be considered as an adjuvant therapy to specific diets in galactosemia.	[Cruz, Indianara Rodrigues; Lorenzini, Mariana Simonato; Brueckheimer, Maite Beatriz; Maia, Thayna Patachini; Bunick Neto Sala, Geraldo Antonio; Delwing-de Lima, Daniela] Univ Regiao Joinville UNIVILLE, Dept Med, Rua Paulo Malschitzki,10 Zona Ind Norte, BR-89201972 Joinville, SC, Brazil; [Sasso, Simone; Delwing-de Lima, Daniela] Univ Regiao Joinville UNIVILLE, Programa Posgrad Saude & Meio Ambiente, Rua Paulo Malschitzki,10 Zona Ind Norte, BR-89201972 Joinville, SC, Brazil; [Delwing-Dal Magro, Debora] Univ Reg Blumenau, Ctr Ciencias Exatas & Nat, Dept Ciencias Nat, Rua Antonio da Veiga 140, BR-9012900 Blumenau, SC, Brazil; [Ruela Mews, Matheus Henrique] Univ Regiao Joinville UNIVILLE, Dept Farm, Rua Paulo Malschitzki,10 Zona Ind Norte, BR-89201972 Joinville, SC, Brazil	Delwing-de Lima, D (reprint author), Univ Regiao Joinville, Dept Med, Rua Paulo Malschitzki,10 Zona Ind Norte, BR-89201972 Joinville, SC, Brazil.	daniela.delwing@univille.br			Universidade da Regido de Joinville; Conselho Nacional de Desenvolvimento Cientifico e tecnologico -CNPq (Brazil)National Council for Scientific and Technological Development (CNPq)	This work was supported by grants from the Universidade da Regido de Joinville and Conselho Nacional de Desenvolvimento Cientifico e tecnologico -CNPq (Brazil).	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aksenov MY, 2001, NEUROSCI LETT, V302, P141, DOI 10.1016/S0304-3940(01)01636-6; Baradaran A, 2012, J HERBMED PLARMACOL, V1, P3; Berry GT, 2011, J INHERIT METAB DIS, V34, P345, DOI 10.1007/s10545-010-9260-x; Berry GT, 2006, INBORN METABOLIC DIS, P121; Bosch AM, 2006, J INHERIT METAB DIS, V29, P516, DOI 10.1007/s10545-006-0382-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budni J, 2016, BEHAV BRAIN RES, V302, P35, DOI 10.1016/j.bbr.2015.12.041; Castro MB, 2016, METAB BRAIN DIS, V31, P1381, DOI 10.1007/s11011-016-9865-3; Cui X, 2004, BIOGERONTOLOGY, V5, P317, DOI 10.1007/s10522-004-2570-3; Cui X, 2006, J NEUROSCI RES, V83, P1584, DOI 10.1002/jnr.20845; Delwing-de Lima D, 2017, BIOMED PHARMACOTHER, V86, P686, DOI 10.1016/j.biopha.2016.12.011; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fridovich-Keil JL, 2008, ONLINE METABOLIC MOL, P1; GITZELMANN R, 1995, EUR J PEDIATR, V154, pS45, DOI 10.1007/BF02143803; Gong YS, 2016, EXP GERONTOL, V74, P21, DOI 10.1016/j.exger.2015.11.020; Gubbels CS, 2011, J INHERIT METAB DIS, V34, P387, DOI 10.1007/s10545-010-9180-9; Hoffmann B, 2012, J INHERIT METAB DIS, V35, P1051, DOI 10.1007/s10545-012-9469-y; ISSELBACHER KJ, 1956, SCIENCE, V123, P635, DOI 10.1126/science.123.3198.635; Jumbo-Lucioni PP, 2013, DIS MODEL MECH, V6, P84, DOI 10.1242/dmm.010207; Jumbo-Lucioni PP, 2012, J INHERIT METAB DIS, V35, P1037, DOI 10.1007/s10545-012-9477-y; Lima D. Delwing-de, 2016, METAB BRAIN DIS, V32, P359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu J, 2006, BEHAV BRAIN RES, V171, P251, DOI 10.1016/j.bbr.2006.03.043; Lu J, 2007, BIOCHEM PHARMACOL, V74, P1078, DOI 10.1016/j.bcp.2007.07.007; Marklund S., 1985, HDB METHODS OXYGEN R, P243; Nwose EU, 2008, MED HYPOTHESES, V70, P1002, DOI 10.1016/j.mehy.2007.07.048; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pohanka M, 2011, BIOMED PAP, V155, P219, DOI 10.5507/bp.2011.036; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Rodrigues A. F., 2016, MOL NEUROBIOL, V11, P589; Rodrigues AF, 2016, INT J DEV NEUROSCI, V50, P1, DOI 10.1016/j.ijdevneu.2016.01.007; Shan Q, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/564737; Shen YX, 2002, J PINEAL RES, V32, P173, DOI 10.1034/j.1600-079x.2002.1o850.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; ten Hoedt AE, 2011, J INHERIT METAB DIS, V34, P391, DOI 10.1007/s10545-010-9267-3; Thomas SR, 2000, FREE RADICAL BIO MED, V28, P1795, DOI 10.1016/S0891-5849(00)00236-7; Timson DJ, 2014, INT J FOOD SCI NUTR, V65, P391, DOI 10.3109/09637486.2013.860586; Waisbren SE, 2012, J INHERIT METAB DIS, V35, P279, DOI 10.1007/s10545-011-9372-y; Wendel A, 1981, Methods Enzymol, V77, P325; Wyse ATS, 2002, NEUROCHEM RES, V27, P1685, DOI 10.1023/A:1021647329937; Young IS, 2001, J CLIN PATHOL, V54, P176, DOI 10.1136/jcp.54.3.176; Zou GM, 2007, J CELL PHYSIOL, V213, P440, DOI 10.1002/jcp.21140	43	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1596	1605		10.1016/j.prp.2018.07.034			10	Pathology	Pathology	GY0SD	WOS:000448231000012	30093085				2019-10-28	
J	Tang, GX; Tang, Q; Jia, LZ; Xia, SJ; Li, J; Chen, Y; Li, HQ; Ding, X; Wang, F; Hou, DQ; Kuai, XW; Feng, ZQ; Fan, Y				Tang, Genxiong; Tang, Qi; Jia, Lizhou; Xia, Shujing; Li, Jing; Chen, Yuan; Li, Huaiqi; Ding, Xu; Wang, Feng; Hou, Deqiang; Kuai, Xingwang; Feng, Zhenqing; Fan, Yuan			High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						TROP2; Oral squamous cell carcinoma; Prognosis; Oral potentially malignant lesion	POTENTIAL THERAPEUTIC TARGET; LUNG ADENOCARCINOMA; CANCER; OVEREXPRESSION; PROLIFERATION; EPITHELIUM; MARKER; PROMOTES; INVASION	Human trophoblastic cell-surface antigen 2 (TROP2) is a cell surface glycoprotein that exhibits high expression in various carcinomas but low or no expression in normal tissues. High TROP2 expression plays an important role in promoting tumor development and aggressiveness, which is correlated with reduced patient survival. However, there are few studies regarding TROP2 in relation to both oral squamous cell carcinoma (OSCC) and oral potentially malignant lesions. The expression of TROP2 protein and mRNA was investigated in OSCC tissues, oral potentially malignant lesion tissues, and normal oral tissues using immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR). The association between TROP2 expression and clin-icopathological characteristics of OSCC was also analyzed, and the prognostic value of TROP2 was evaluated. The expression of TROP2 protein and mRNA were both higher in OSCC tissues than in oral potentially malignant lesion tissues or normal oral tissues. Positive TROP2 expression was related to differentiation, lymph node metastases, TNM stage, perineural infiltration, and vascular invasion. Poor overall survival was associated with high TROP2 expression and other factors associated with poor overall survival including poor differentiation, lymph node metastasis, TNM stage, vascular invasion, and perineural invasion in univariate analyses. TROP2 expression as well as TNM stage and vascular invasion were independent prognostic factors associated with the overall survival of OSCC patients in multivariate analyses. In summary, High TROP2 expression is associated with poor overall survival and serves as an independent prognostic factor in OSCC. The results suggest that TROP2 expression could be an effective prognostic biomarker for OSCC.	[Tang, Genxiong] Nanjing Med Univ, Affiliated Childrens Hosp, Dept Stomatol, Nanjing 210008, Jiangsu, Peoples R China; [Tang, Genxiong; Wang, Feng; Feng, Zhenqing] Nanjing Med Univ, Dept Pathol, Nanjing 211166, Jiangsu, Peoples R China; [Tang, Genxiong; Li, Jing; Fan, Yuan] Nanjing Med Univ, Dept Oral Med, Affiliated Hosp Stomatol, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China; [Tang, Qi; Jia, Lizhou; Kuai, Xingwang; Feng, Zhenqing] Nanjing Med Univ, Minist Hlth, Key Lab Antibody Tech, Nanjing 211166, Jiangsu, Peoples R China; [Xia, Shujing] Yangzhou Univ, Affiliated Xinghua Peoples Hosp, Dept Gastroenterol, Xinghua 225700, Peoples R China; [Chen, Yuan] Nanjing Med Univ, Affiliated Hosp 2, Dept Otolaryngol, Nanjing 210011, Jiangsu, Peoples R China; [Li, Huaiqi; Ding, Xu] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China; [Hou, Deqiang] Jiangnan Univ, Affiliated Hosp, Dept Stomatol, Wuxi 214062, Peoples R China; [Feng, Zhenqing] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing 211166, Jiangsu, Peoples R China; [Feng, Zhenqing] Nanjing Med Univ, Key Lab Canc Biomarkers Prevent & Treatment, Ctr Canc, Nanjing 211166, Jiangsu, Peoples R China	Fan, Y (reprint author), Nanjing Med Univ, Dept Oral Med, Affiliated Hosp Stomatol, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.; Feng, ZQ (reprint author), Nanjing Med Univ, Dept Pathol, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing 211166, Jiangsu, Peoples R China.	fengzhenqing@njmu.edu.cn; fanyuan@njmu.edu.cn	Wang, Feng/F-2653-2015		Grant of Maternal and Child Health Research Projects of Jiangsu Province [F201607]	This work was supported by the Grant of Maternal and Child Health Research Projects of Jiangsu Province (grant numbers, F201607).	Bignotti E, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-22; Chen C, 2016, AM J CANCER RES, V6, P649; Chen CJ, 2012, HUM PATHOL, V43, P1119, DOI 10.1016/j.humpath.2011.09.003; Chen MB, 2014, TUMOR BIOL, V35, P11565, DOI 10.1007/s13277-014-2469-9; Chen X, 2014, INT J CLIN EXP PATHO, V7, P7907; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eckert AW, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0828-6; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; Guan GF, 2015, INT J CLIN EXP PATHO, V8, P10995; Ju XM, 2016, CANCER RES, V76, P6723, DOI 10.1158/0008-5472.CAN-15-3327; Kim SM, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1213-5; Kowalsky CA, 2015, J BIOL CHEM, V290, P26457, DOI 10.1074/jbc.M115.676635; Le Magnen C, 2013, CLIN CANCER RES, V19, P5361, DOI 10.1158/1078-0432.CCR-12-2857; Li XX, 2017, ONCOTARGET, V8, P47052, DOI 10.18632/oncotarget.16789; Li ZH, 2016, BIOCHEM BIOPH RES CO, V470, P197, DOI 10.1016/j.bbrc.2016.01.032; Lin JC, 2012, EMBO MOL MED, V4, P472, DOI 10.1002/emmm.201200222; Liu XQ, 2014, J CANCER RES CLIN, V140, P1331, DOI 10.1007/s00432-014-1696-1; McDougall ARA, 2015, DEV DYNAM, V244, P99, DOI 10.1002/dvdy.24242; McDougall ARA, 2011, AM J PHYSIOL-LUNG C, V301, pL478, DOI 10.1152/ajplung.00063.2011; Mustata RC, 2013, CELL REP, V5, P421, DOI 10.1016/j.celrep.2013.09.005; Ning SL, 2013, NEUROL SCI, V34, P1745, DOI 10.1007/s10072-013-1326-8; Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961; Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884; Shih SC, 2017, AM J TRANSL RES, V9, P1114; Sridevi Ugrappa, 2015, Eur J Dent, V9, P364, DOI 10.4103/1305-7456.163238; Trerotola M, 2012, J CELL PHYSIOL, V227, P3670, DOI 10.1002/jcp.24074; Tsukahara Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028607; Vallone VF, 2016, DEVELOPMENT, V143, P1452, DOI 10.1242/dev.131490; Vidmar T, 2013, PROTEIN EXPRES PURIF, V91, P69, DOI 10.1016/j.pep.2013.07.006; Wang XD, 2015, MOL MED REP, V12, P865, DOI 10.3892/mmr.2015.3485; Wanger TM, 2015, CELL SIGNAL, V27, P1325, DOI 10.1016/j.cellsig.2015.03.017; Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x; Wu H, 2013, HEAD NECK-J SCI SPEC, V35, P1373, DOI 10.1002/hed.23138; Xie JH, 2016, ONCOTARGET, V7, P44492, DOI 10.18632/oncotarget.9876; Xu N, 2016, INT J EXP PATHOL, V97, P150, DOI 10.1111/iep.12174; Yong HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28222; Zeng P, 2016, SCI REP-UK, V6, DOI 10.1038/srep33658; Zhao W., 2015, ONCOTARGET, V7, P6136; Zhao W, 2017, CANCER MED-US, V6, P994, DOI 10.1002/cam4.1018; Zheng Z., 2016, BIOMARKERS, V29, P1	43	1	1	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1606	1612		10.1016/j.prp.2018.07.017			7	Pathology	Pathology	GY0SD	WOS:000448231000013	30098828	Other Gold			2019-10-28	
J	Shang, YY; Zhang, F; Li, DH; Li, C; Li, HB; Jiang, YJ; Zhang, DL				Shang, Yuanyuan; Zhang, Fang; Li, Dehui; Li, Chang; Li, Hongbo; Jiang, Yingjian; Zhang, Dianliang			Overexpression of UQCRC2 is correlated with tumor progression and poor prognosis in colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						UQCRC2; Colorectal cancer; Prognosis; Proliferation; Apoptosis	CYTOCHROME BC(1) COMPLEX; BREAST-CANCER; OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL DYSFUNCTION; METABOLISM; THERAPY; STATISTICS; BIOMARKERS; MUTATION; CELLS	Ubiquinol-cytochrome c reductase complex core protein 2 (UQCRC2) is an important subunit of mitochondrial respiratory complex III. However, its role in tumorigenesis and tumor progression remains unknown, especially with regards to colorectal cancer (CRC). In this research, we measured the expression of UQCRC2 protein by immunohistochemistry assay in 89 paired paraffin-embedded tumor tissues and corresponding adjacent normal tissues from patients with colorectal adenocarcinoma and investigated possible correlations of UQCRC2 expression with clinicopathological parameters and prognosis. We found that UQCRC2 was significantly upregulated in CRC tissues compared with adjacent normal tissues, and immunohistochemical UQCRC2 status was correlated to the depth of invasion (T), lymph node metastasis (N), advanced TNM stage. Multivariate analysis indicated that UQCRC2 remained an independent prognostic factor for poorer overall survival. Furthermore, we determined the role of UQCRC2-knockdown in CRC cells (RKO and HCT116) using lentivirus-mediated small hairpin RNAs (shRNAs). The effects of UQCRC2 knockdown on CRC cells (RKO and HCT116) proliferation were analyzed by cell proliferation and colony formation assay, and cell cycle and apoptosis were assessed by flow cytometry. We found that silencing UQCRC2 suppressed cell proliferation and colony formation in RKO and HCT116 cells, led to a cell cycle arrest and induced cell apoptosis in vitro. These results provided novel insights into the potential role of UQCRC2 in the tumorigenesis and progression of CRC, and revealed that UQCRC2 may serve as a new prognostic and therapeutic target in CRC.	[Shang, Yuanyuan; Li, Dehui; Li, Chang; Li, Hongbo; Jiang, Yingjian; Zhang, Dianliang] Qingdao Univ, Qingdao Municipal Hosp, Ctr Colon & Rectum, 1 Jiaozhou Rd, Qingdao 266011, Shandong, Peoples R China; [Zhang, Fang] Qingdao Univ, Qingdao Municipal Hosp, Dept Pathol, Qingdao 266011, Shandong, Peoples R China	Zhang, DL (reprint author), Qingdao Univ, Qingdao Municipal Hosp, Ctr Colon & Rectum, 1 Jiaozhou Rd, Qingdao 266011, Shandong, Peoples R China.	phdzdl@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81270448, 81470890]	This work was supported by the National Natural Science Foundation of China, Nos. 81270448 and 81470890.	Aguilera-Aguirre L, 2009, J IMMUNOL, V183, P5379, DOI 10.4049/jimmunol.0900228; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cocco T, 1998, BIOCHEMISTRY-US, V37, P2037, DOI 10.1021/bi9724164; Deng K, 2001, J BIOL CHEM, V276, P6499, DOI 10.1074/jbc.M007128200; Ellinger J, 2016, ONCOTARGET, V7, P86490, DOI 10.18632/oncotarget.13275; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Gaignard P, 2017, J HUM GENET, V62, P729, DOI 10.1038/jhg.2017.22; Guinn BA, 2008, CANCER GENE THER, V15, P765, DOI 10.1038/cgt.2008.66; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Han Y., 2016, DIS MARKERS, V2016; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Karsa LV, 2010, BEST PRACT RES CL GA, V24, P381, DOI 10.1016/j.bpg.2010.06.004; Kwon WS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15654; Lin C. S., 2018, ONCOL REP, V36, P125; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Miyake N, 2013, HUM MUTAT, V34, P446, DOI 10.1002/humu.22257; Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Putignani L, 2008, BREAST CANCER RES TR, V110, P439, DOI 10.1007/s10549-007-9738-x; Putignani L, 2012, MITOCHONDRION, V12, P363, DOI 10.1016/j.mito.2012.02.003; Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P172, DOI 10.4161/cc.23058; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Shukla KK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076959; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Verschoor ML, 2013, BIOMED RES INT, DOI 10.1155/2013/612369; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Xu H., 2016, BRAZ J MED BIOL RES, P49; Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	33	1	1	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1613	1620		10.1016/j.prp.2018.08.012			8	Pathology	Pathology	GY0SD	WOS:000448231000014	30115536				2019-10-28	
J	Liu, J; Lu, CX; Zhang, F; Lv, W; Liu, CY				Liu, Jie; Lu, Chun-xiao; Zhang, Fang; Lv, Wei; Liu, Chuanyong			Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+T cells in patients with colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						ILT3; Colorectal cancer; Prognosis; CD45RO	CAPECITABINE PLUS OXALIPLATIN; INHIBITORY RECEPTOR ILT3; LUNG-CANCER; 1ST-LINE THERAPY; DENDRITIC CELLS; PHASE-III; FAMILY; TOLERIZATION; DOCETAXEL; NIVOLUMAB	Immunoglobulin like transcript 3 (ILT3) was previously identified as an inhibitory receptor to induce T cell anergy in tranplantation, autoimmunity and allergy. Here we aimed to investigate the expression of ILT3 in colorectal cancer, analyze the association between ILT3 expression and clinicopathological variables and prognosis, and evaluate the correlation between the expression of ILT3 and CD45RO + T cells density. Expression of ILT3 was identified on the cell membrane and/or in the cytoplasm. High expression ILT3 was identified in 55 of 85 (64.7%) tumor specimens, which was significantly higher than that in the adjacent normal tissues(5/30) (P < 0.001). High ILT3 expression was significantly associated with positive lymph node metastasis (N1-2; P = 0.03), advanced disease (stage III-IV; P = 0.03), and reduced OS in patients. The ILT3 expression level was an independent prognostic factor (P = 0.004) and inversely correlated with the number of CD45RO + T cells (P = 0.019). In the present study, high ILT3 expression was observed in colorectal cancer and inversely associated with CD45RO + T cells density and prognosis, suggesting that ILT3 played an important role in tumor progression by possible influence on CD45RO + T cells in the tumor microenvironment.	[Liu, Jie; Lv, Wei; Liu, Chuanyong] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Shandong, Peoples R China; [Lu, Chun-xiao] WeiFang Med Univ, Dept Oncol, Weifang, Shandong, Peoples R China; [Zhang, Fang] Shandong Univ, Jinan Cent Hosp, Dept Pharm, Jinan, Shandong, Peoples R China	Liu, CY (reprint author), Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Shandong, Peoples R China.	lcyatjn@126.com			Natural Science Foundation of Shandong provinceNatural Science Foundation of Shandong Province [ZR2010HM105]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81501989]	This work was supported by grants from the Natural Science Foundation of Shandong province (Grant No. ZR2010HM105) and National Natural Science Foundation of China (Grant No. 81501989)	Allan DSJ, 2000, IMMUNOBIOLOGY, V202, P34, DOI 10.1016/S0171-2985(00)80050-9; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Cao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053834; Cassidy J, 2004, J CLIN ONCOL, V22, P2084, DOI 10.1200/JCO.2004.11.069; Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Chui CSC, 2009, HUM IMMUNOL, V70, P686, DOI 10.1016/j.humimm.2009.06.003; Colonna M, 2000, SEMIN IMMUNOL, V12, P121, DOI 10.1006/smim.2000.0214; Colovai AI, 2007, CYTOM PART B-CLIN CY, V72B, P354, DOI 10.1002/cyto.b.20164; Dobrowolska H, 2013, CYTOM PART B-CLIN CY, V84B, P21, DOI 10.1002/cyto.b.21050; Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu GM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11122-2; Ingebrigtsen VA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-602; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Khan MF, 2012, TRANSL ONCOL, V5, P85, DOI 10.1593/tlo.11328; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Liu J, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-85; Manavalan JS, 2003, TRANSPL IMMUNOL, V11, P245, DOI 10.1016/S0966-3274(03)00058-3; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Razzak Mina, 2013, Nat Rev Clin Oncol, V10, P365, DOI 10.1038/nrclinonc.2013.98; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3; Sun YP, 2008, CHEST, V134, P783, DOI 10.1378/chest.07-1100; Sun YP, 2006, LUNG CANCER-J IASLC, V53, P143, DOI 10.1016/j.lungcan.2006.05.012; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vlad G, 2006, INT IMMUNOPHARMACOL, V6, P1889, DOI 10.1016/j.intimp.2006.07.017; Vlad G, 2008, HUM IMMUNOL, V69, P681, DOI 10.1016/j.humimm.2008.08.286; Zhang P, 2015, FEBS LETT, V589, P2248, DOI 10.1016/j.febslet.2015.06.037; Zhang P, 2015, ONCOTARGET, V6, P13550, DOI 10.18632/oncotarget.3624; Zhang Y, 2012, MOL MED REP, V5, P910, DOI 10.3892/mmr.2012.744	35	0	0	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1621	1625		10.1016/j.prp.2018.07.026			5	Pathology	Pathology	GY0SD	WOS:000448231000015	30126665				2019-10-28	
J	Yoon, HK; Kim, TH; Park, S; Jung, H; Quan, XG; Park, SJ; Han, J; Lee, A				Yoon, Hye Kyoung; Kim, Tae Hyun; Park, SaeGwang; Jung, Hana; Quan, Xingguo; Park, Seung Jae; Han, Jaewoong; Lee, Anbok			Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Chemoimmunotherapy; Cytotoxic drugs; Galectin-9; Programmed cell death ligand-1; Subtype; Triple-negative breast cancer	INFILTRATING LYMPHOCYTES; MOLECULAR SUBTYPES; KAPPA-B; CHEMOTHERAPY; BLOCKADE; IMMUNOTHERAPY; CARCINOMA; IMMUNITY; THERAPY; SYSTEM	This study identified chemotherapeutic agents that up-regulate programmed cell death ligand-1 (PD-L1) and galectin-9 (Gal-9) in breast cancer cells. Immunohistochemical (IHC) staining was used to evaluate changes in PD-L1 and Gal-9 expression in the tumor tissue of triple-negative breast cancer (TNBC) patients who received anthracycline- and taxane-based neoadjuvant chemotherapy. To determine whether PD-L1 and Gal-9 expression changes were attributable directly to chemotherapeutics, MDA-MB-231 cells and HS578T cells were treated with different concentrations of anthracycline and taxane. Expression levels of PD-L1 and Gal-9 were evaluated and the activation status of NF kappa B in MDA-MB-231 and HS578T cells was determined to identify the PD-L1 and Gal-9 up-regulation mechanism. Three cases of increased PD-L1 expression and two of increased Gal-9 expression were observed among the TNBC patients. PD-L1 and Gal-9 expression were up-regulated by anthracycline and taxane in MDA-MB-231 cells, but not in HS578T cells. Increased nuclear levels of NF kappa B were observed in MDA-MB-231 cells treated with 0.5 mu M epirubicin. Anthracycline and taxane up-regulated PD-L1 and Gal-9 expression in some subtypes of TNBC. This study provides useful reference data for clinical trials investigating combination treatments with immune checkpoint inhibitors and chemotherapy.	[Yoon, Hye Kyoung] Inje Univ, Coll Med, Busan Paik Hosp, Dept Pathol, Busan, South Korea; [Kim, Tae Hyun; Han, Jaewoong; Lee, Anbok] Inje Univ, Coll Med, Busan Paik Hosp, Dept Surg, 75 Bokjiro, Busan, South Korea; [Park, SaeGwang; Jung, Hana; Quan, Xingguo] Inje Univ, Coll Med, Dept Microbiol & Immunol, Busan, South Korea; [Park, Seung Jae] Inje Univ, Coll Med, Busan Paik Hosp, Dept Internal Med, Busan, South Korea	Lee, A (reprint author), Inje Univ, Coll Med, Busan Paik Hosp, Dept Surg, 75 Bokjiro, Busan, South Korea.	ab-lee@hanmail.net			2016 Inje University Busan Paik Hospital research grant	This work was supported by 2016 Inje University Busan Paik Hospital research grant.	Abramson VG, 2014, CURR BREAST CANCER R, V6, P154, DOI 10.1007/s12609-014-0152-1; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187; Chen G, 2013, CANCER IMMUNOL IMMUN, V62, P203, DOI 10.1007/s00262-012-1388-0; Chou FC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020430; Denkert C, 2014, ANN ONCOL, V25, P1453, DOI 10.1093/annonc/mdu235; Disis Mary L, 2015, Am Soc Clin Oncol Educ Book, pe25, DOI 10.14694/EdBook_AM.2015.35.e25; EHRKE MJ, 1984, CANCER RES, V44, P2497; Ercolini AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2; Irie A, 2005, CLIN CANCER RES, V11, P2962, DOI 10.1158/1078-0432.CCR-04-0861; Javeed A, 2009, EUR J PHARM SCI, V38, P283, DOI 10.1016/j.ejps.2009.08.009; Klibi J, 2009, BLOOD, V113, P1957, DOI 10.1182/blood-2008-02-142596; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Perez-Gracia JL, 2014, CURR OPIN IMMUNOL, V27, P89, DOI 10.1016/j.coi.2014.01.002; MACCUBBIN DL, 1992, CANCER RES, V52, P3572; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Mathew M, 2018, PHARMACOL THERAPEUT, V186, P130, DOI 10.1016/j.pharmthera.2018.01.003; Mattarollo SR, 2011, CANCER RES, V71, P4809, DOI 10.1158/0008-5472.CAN-11-0753; Melichar B, 2001, IMMUNOPHARM IMMUNOT, V23, P163, DOI 10.1081/IPH-100103857; Minn AJ, 2016, CELL, V165, P272, DOI 10.1016/j.cell.2016.03.031; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peng J, 2015, CANCER RES, V75, P5034, DOI 10.1158/0008-5472.CAN-14-3098; Polk A, 2018, CANCER TREAT REV, V63, P122, DOI 10.1016/j.ctrv.2017.12.008; Sau A, 2016, CELL STEM CELL, V19, P52, DOI 10.1016/j.stem.2016.05.003; Vandenabeele P, 2016, ADV EXP MED BIOL, V930, P133, DOI 10.1007/978-3-319-39406-0_6; Zeichner SB, 2016, BREAST CANCER-BASIC, V10, DOI 10.4137/BCBCR.S32783	34	1	1	2	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1626	1631		10.1016/j.prp.2018.08.009			6	Pathology	Pathology	GY0SD	WOS:000448231000016	30139555				2019-10-28	
J	Brkovic, V; Milinkovic, M; Kravljaca, M; Lausevic, M; Basta-Jovanovic, G; Markovic-Lipkovski, J; Naumovic, R				Brkovic, V.; Milinkovic, M.; Kravljaca, M.; Lausevic, M.; Basta-Jovanovic, G.; Markovic-Lipkovski, J.; Naumovic, R.			Does the pathohistological pattern of renal biopsy change during time?	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Renal biopsy; Glomerulopathy; Registry; Epidemiology	EPIDEMIOLOGIC DATA; REGISTRY; GLOMERULONEPHRITIS; DISEASES; EXPERIENCE	Biopsy registries are one of the most important sources of accurate epidemiological data and the clinical presentation of renal diseases. A detailed analysis of clinicopathologic correlations over a period of 20 years (1987-2006) was performed earlier by our centre. The aim of this study was to check the current state and to register possible changes in clinicopathologic findings recorded under better socioeconomical circumstances and new management. Records of 665 renal biopsies performed at our institution were prospectively followed from 2007 to 2014. The results were compared with our previously published data. The average annual incidence of renal biopsies increased by 10% and included more elderly patients. Nephrotic syndrome (NS) remained the most common clinical indication for biopsy, while acute kidney injury participated more frequently than in the previous study (p < 0.001). Membranous nephropathy (MN) was still the most common cause of NS. Primary glomerulonephritis (PGN) remained the most prevalent disease, while MN was the most prevalent PGN. In comparison with the earlier period, MN was a more common diagnosis (p = 0.002), while the prevalence of mesangioproliferative non-IgA nephropathy decreased significantly during the time (p = 0.012). LN remained the most frequent secondary glomerulonephritis. The pathohistological pattern of renal biopsy remained largely unchanged during time. However, acute kidney injury was more frequently an indication for biopsy in the current study. The significant increase of biopsied elderly patients is due to the rise in their relative numbers in our population.	[Brkovic, V.; Milinkovic, M.; Kravljaca, M.; Lausevic, M.; Naumovic, R.] Clin Ctr Serbia, Clin Nephrol, Belgrade, Serbia; [Basta-Jovanovic, G.; Markovic-Lipkovski, J.] Univ Belgrade, Inst Pathol, Sch Med, Belgrade, Serbia; [Brkovic, V.; Milinkovic, M.; Lausevic, M.; Naumovic, R.] Univ Belgrade, Sch Med, Belgrade, Serbia	Brkovic, V (reprint author), Clin Ctr Serbia, Clin Nephrol, Belgrade, Serbia.	voin.brkovic@gmail.com					Barr RG, 2003, NEPHROL DIAL TRANSPL, V18, P2039, DOI 10.1093/ndt/gfg345; Chang JH, 2009, NEPHROL DIAL TRANSPL, V24, P2406, DOI 10.1093/ndt/gfp091; Covic A, 2006, NEPHROL DIAL TRANSPL, V21, P419, DOI 10.1093/ndt/gfi207; Davison A M, 1985, Contrib Nephrol, V48, P24; Fuiano G, 2000, AM J KIDNEY DIS, V35, P448, DOI 10.1016/S0272-6386(00)70197-1; Gesualdo L, 2004, KIDNEY INT, V66, P890, DOI 10.1111/j.1523-1755.2004.00831.x; Hanko JB, 2009, NEPHROL DIAL TRANSPL, V24, P3050, DOI 10.1093/ndt/gfp254; Horvatic I, 2013, INT UROL NEPHROL, V45, P1577, DOI 10.1007/s11255-013-0397-z; Iversen P, 1997, J AM SOC NEPHROL, V8, P1778; Johnson RJ, 2003, AM J KIDNEY DIS, V42, P575, DOI 10.1016/S0272-6386(03)00801-1; Li LS, 2004, KIDNEY INT, V66, P920, DOI 10.1111/j.1523-1755.2004.00837.x; Malafronte P, 2006, NEPHROL DIAL TRANSPL, V21, P3098, DOI 10.1093/ndt/gfl237; Naumovic R, 2009, NEPHROL DIAL TRANSPL, V24, P877, DOI 10.1093/ndt/gfn564; Ozturk S, 2014, INT UROL NEPHROL, V46, P2347, DOI 10.1007/s11255-014-0838-3; Polenakovic MH, 2003, NEPHROL DIAL TRANSPL, V18, P26, DOI 10.1093/ndt/gfg1039; Rivera F, 2002, NEPHROL DIAL TRANSPL, V17, P1594, DOI 10.1093/ndt/17.9.1594; Rus V, 2007, DUBOIS LUPUS ERYTHEM, P34; Rychlik I, 2004, NEPHROL DIAL TRANSPL, V19, P3040, DOI 10.1093/ndt/gfh521; Scott DGI, 2013, CLIN EXP NEPHROL, V17, P607, DOI 10.1007/s10157-013-0830-8; Sugiyama H, 2011, CLIN EXP NEPHROL, V15, P493, DOI 10.1007/s10157-011-0430-4; Wirta O, 2008, NEPHROL DIAL TRANSPL, V23, P193, DOI 10.1093/ndt/gfm564; Zaza G, 2013, AM J NEPHROL, V37, P255, DOI 10.1159/000348566	22	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1632	1637		10.1016/j.prp.2018.07.027			6	Pathology	Pathology	GY0SD	WOS:000448231000017	30139556				2019-10-28	
J	Yang, CG; Ren, J; Li, BL; Zhang, DM; Ma, C; Cheng, C; Sun, YL; Fu, LN; Shi, XF				Yang, Chenggang; Ren, Jing; Li, Bangling; Zhang, Dongmei; Ma, Cui; Cheng, Cheng; Sun, Yaolan; Fu, Lina; Shi, Xiaofeng			Identification of clinical tumor stages related mRNAs and miRNAs in cervical squamous cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cervical squamous cell carcinoma; Clinical tumor stage; Differentially expressed mRNAs; Differentially expressed miRNAs	OF-THE-LITERATURE; PANCREATIC-CANCER; CIRCADIAN-CLOCK; GENE-EXPRESSION; GASTRIC-CANCER; MOUSE MODEL; MICRORNA-451; ENDOMETRIUM; GROWTH; PER1	Objectives: The aim of this study is to identify the clinical tumor stage related mRNAs and miRNAs, shedding light on the potential molecular mechanisms of cervical squamous cell carcinoma (CSCC). Methods: Firstly, the mRNA and miRNA next-generation sequencing data were downloaded. Secondly, clinical tumor stage correlation analysis of mRNAs and miRNA was performed, followed by the functional enrichment analysis of all clinical tumor stage related mRNAs. Thirdly, differentially expression analysis of mRNAs and miRNA between different clinical tumor stages was performed, followed by target gene prediction of these differentially expressed miRNAs. Results: 3 mRNAs (PER1, PRKAB1 and PMM2) and 5 miRNAs (hsa-mir-486, hsa-mir-451, hsa-mir-424, hsa-mir-144 and hsa-mir-450a-2) were overlapped from stage 1, stage 2, stage 3 and stage 4. Conclusions: Alterations of differentially expressed mRNAs and miRNAs may offer important insights into the molecular mechanisms in the pathology of CSCC.	[Yang, Chenggang; Ma, Cui; Shi, Xiaofeng] Guan Bojian Biotechnol Co LTD, Langfang, Peoples R China; [Yang, Chenggang; Ren, Jing; Li, Bangling; Zhang, Dongmei; Ma, Cui; Cheng, Cheng; Sun, Yaolan; Fu, Lina; Shi, Xiaofeng] Beijing Medintell Bioinformat Technol Co LTD, Dept BigData, 1 Shanyuan St, Beijing 100081, Peoples R China	Shi, XF (reprint author), Beijing Medintell Bioinformat Technol Co LTD, Dept BigData, 1 Shanyuan St, Beijing 100081, Peoples R China.	shi.xiaofeng@medintell.com					Agashe S R, 2007, Indian J Pathol Microbiol, V50, P375; Agresti A., 2013, CATEGORICAL DATA ANA; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Biewenga P, 2011, CANCER-AM CANCER SOC, V117, P768, DOI 10.1002/cncr.25658; Brinkmann O, 2011, ORAL ONCOL, V47, P51, DOI 10.1016/j.oraloncology.2010.10.009; Carvalho RH, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-9; Chan B, 2016, HUM MOL GENET, V25, P2182, DOI 10.1093/hmg/ddw085; Chen R, 2012, ONCOTARGETS THER, V5, P403, DOI 10.2147/OTT.S38508; Chen Zujian, 2017, Biomark Cancer, V9, P1, DOI 10.4137/BIC.S40981; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Ding H, 2014, ASIAN PAC J CANCER P, V15, P1675, DOI 10.7314/APJCP.2014.15.4.1675; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11; Forrest ARR, 2010, DIFFERENTIATION, V80, pS31, DOI 10.1016/j.diff.2010.09.048; Freeze HH, 2009, BBA-MOL BASIS DIS, V1792, P835, DOI 10.1016/j.bbadis.2009.01.004; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Gemoll T, 2015, ONCOTARGET, V6, P16517, DOI 10.18632/oncotarget.4140; Godlewski J, 2010, CELL CYCLE, V9, P2742, DOI 10.4161/cc.9.14.12248; Gomez-Gomez Y, 2013, BIOMED RES INT, DOI 10.1155/2013/407052; Goodman A, 1996, GYNECOL ONCOL, V61, P54, DOI 10.1006/gyno.1996.0096; Goodrich S, 2013, DIAGN CYTOPATHOL, V41, P817, DOI 10.1002/dc.22814; Gross SR, 2013, CELL ADHES MIGR, V7, P199, DOI 10.4161/cam.23176; Gungor T, 2011, ARCH GYNECOL OBSTET, V283, P323, DOI 10.1007/s00404-010-1672-1; Hothorn T, 2008, J STAT SOFTW, V28, P1; Hrushesky WJM, 2009, INTEGR CANCER THER, V8, P387, DOI 10.1177/1534735409352086; Huang Fang, 2011, Zhonghua Xin Xue Guan Bing Za Zhi, V39, P353, DOI 10.3760/cma.j.issn.0253-3758.2011.04.015; Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028; Intaraphet S, 2013, ASIAN PAC J CANCER P, V14, P5355, DOI 10.7314/APJCP.2013.14.9.5355; Jones TA, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0266-3; Lajer CB, 2012, BRIT J CANCER, V106, P1526, DOI 10.1038/bjc.2012.109; Landoni F, 2014, GYNECOL ONCOL, V132, P611, DOI 10.1016/j.ygyno.2013.12.010; Li AG, 2013, CLIN CANCER RES, V19, P3600, DOI 10.1158/1078-0432.CCR-12-3092; Li XQ, 2017, ONCOL LETT, V14, P2991, DOI 10.3892/ol.2017.6481; Li YY, 2015, AM J TRANSL RES, V7, P2775; Liu D, 2014, CANCER EPIDEMIOL, V38, P85, DOI 10.1016/j.canep.2013.12.005; Liu LP, 2012, MOL MED REP, V5, P753, DOI 10.3892/mmr.2011.696; Liu LX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0183-5; Liu YH, 2011, MOL IMMUNOL, V48, P1084, DOI 10.1016/j.molimm.2011.02.001; Lloyd KL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1101-8; Madka V, 2015, AM J CANCER RES, V5, P3030; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Rangel J, 2008, AM J SURG PATHOL, V32, P1207, DOI 10.1097/PAS.0b013e31816fd53c; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schiff M, 2017, J MED GENET, V54, P843, DOI 10.1136/jmedgenet-2017-104903; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shah FD, 2011, INDIAN J CLIN BIOCHE, V26, P326, DOI 10.1007/s12291-011-0149-8; Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402; Takeuchi K, 2012, EUR J GYNAECOL ONCOL, V33, P552; Tang HW, 2011, CANCER EPIDEM BIOMAR, V20, P779, DOI 10.1158/1055-9965.EPI-10-0845; Thomakos N, 2008, ARCH GYNECOL OBSTET, V278, P177, DOI 10.1007/s00404-008-0567-x; Varis A, 2002, CANCER RES, V62, P2625; Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642; Wang S. S., 2004, CANCER, V100; Wang SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008667; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; WANG XH, 2008, PLOS ONE, V3, DOI DOI 10.1371/JOURNAL.PONE.0002557; Wang YH, 2017, EUR J CANCER PREV, V26, P144, DOI 10.1097/CEJ.0000000000000221; Wei WF, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0077-5; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wong YF, 2006, INT J CANCER, V118, P2461, DOI 10.1002/ijc.21660; Xie HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034265; Xu J, 2013, ONCOGENE, V32, P976, DOI 10.1038/onc.2012.121; Yamada Y, 2018, CANCER SCI, V109, P1239, DOI 10.1111/cas.13526; Ye H., BIOMED PHARMACOTHER, V80; Zhang LF, 2014, BMC PEDIATR, V14, DOI [10.1186/1471-2407-14-885, 10.1186/1471-2431-14-4]; Zhang WJ, 2016, TUMOR BIOL, V37, P369, DOI 10.1007/s13277-015-3806-3; Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248; Zhao H, 2014, INT J CLIN EXP PATHO, V7, P619; Zhou H, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0072-4	72	0	0	1	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1638	1647		10.1016/j.prp.2018.07.035			10	Pathology	Pathology	GY0SD	WOS:000448231000018	30149901				2019-10-28	
J	He, ZX; Ni, XJ; Xia, LW; Shao, ZM				He, Zhixian; Ni, Xiaojian; Xia, Liuwan; Shao, Zhimin			Overexpression of NIMA-related kinase 6 (NEK6) contributes to malignant growth and dismal prognosis in Human Breast Cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; Nek6; Prognosis; Proliferation; Spheroid	MITOTIC SPINDLE FORMATION; CELL-CYCLE KINASES; PREMATURE SENESCENCE; PROTEIN-KINASES; PROLIFERATION; PHOSPHORYLATION; STATISTICS; SUPPRESSES; EXPRESSION; DIAGNOSIS	NIMA Related Kinase 6 (Nek6) is a protein kinase involved in various cellular processes, including cell cycle regulation, apopotosis, senescence, telomere maintainance and chemoresistance. In the present study, we investigated the role of Nek6 in breast tumorigenesis and the prognostic merit of Nek6 expression in breast cancer. Immunohistochemistry and Western blot analyses was conducted to determine the expression profile of Nek6 in 133 breast cancer specimens. Nek6 was overexpressed in a majority of breast cancer specimens, compared with the adjacent non-tumorous tissues. Furthermore, we revealed that high expression of Nek6 was associated with histologic grade, tumor size and TNM stage in breast cancer. Liner regression analysis showed a significant association between the levels of Nek6 and Ki-67. Cox regression analysis indicated that Nek6 expression was an independent prognostic predictor for breast cancer. Moreover, intracellular level of Nek6 was remarkably increased following the release from serum starvation in MCF-7 cells. EdU incorporation assay indicated that depletion of Nek6 remarkably impaired the proliferation of MCF-7 cells. Finally, spheroid formation assay revealed that interference of Nek6 led to diminished oncospheroid-forming capacity of breast cancer cells. In conclusion, our results imply that Nek6 plays a facilitating role in breast cancer cell proliferation and may serve as a promising therapeutic target for breast cancer.	[He, Zhixian; Shao, Zhimin] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, 270 Dongan St, Shanghai 200032, Peoples R China; [He, Zhixian; Xia, Liuwan] Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China; [Ni, Xiaojian] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China	Shao, ZM (reprint author), Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, 270 Dongan St, Shanghai 200032, Peoples R China.	shaozhiminfd@163.com					Anderson KN, 2014, BREAST CANCER RES TR, V144, P1, DOI 10.1007/s10549-014-2852-7; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690; Cao XL, 2012, PATHOL ONCOL RES, V18, P201, DOI 10.1007/s12253-011-9429-0; Chen J, 2006, BIOCHEM BIOPH RES CO, V341, P1059, DOI 10.1016/j.bbrc.2005.12.228; de Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Hadad SM, 2014, CLIN TRANSL ONCOL, V16, P746, DOI 10.1007/s12094-013-1144-8; Hirai Y, 2016, GENES CELLS, V21, P874, DOI 10.1111/gtc.12391; Jee HJ, 2013, CANCER LETT, V335, P175, DOI 10.1016/j.canlet.2013.02.012; Jee HJ, 2011, BIOCHEM BIOPH RES CO, V408, P669, DOI 10.1016/j.bbrc.2011.04.083; Jee HJ, 2010, CELL CYCLE, V9, P4703, DOI 10.4161/cc.9.23.14059; Jeon YJ, 2010, J BIOL CHEM, V285, P28126, DOI 10.1074/jbc.M110.137190; Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551; Li X, 2014, POULTRY SCI, V93, P1097, DOI 10.3382/ps.2013-03656; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Maurer M, 2009, ANN NY ACAD SCI, V1171, P250, DOI 10.1111/j.1749-6632.2009.04717.x; Mundt F, 2018, CANCER RES, V78, P2732, DOI [10.1158/0008-5472-CAN-17-1990, 10.1158/0008-5472.CAN-17-1990]; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; O'Regan L, 2009, MOL CELL BIOL, V29, P3975, DOI 10.1128/MCB.01867-08; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Rapley J, 2008, J CELL SCI, V121, P3912, DOI 10.1242/jcs.035360; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Shah R, 2014, WORLD J CLIN ONCOL, V5, P283, DOI 10.5306/wjco.v5.i3.283; Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6; Bertran MT, 2011, EMBO J, V30, P2634, DOI 10.1038/emboj.2011.179; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Yin MJ, 2003, J BIOL CHEM, V278, P52454, DOI 10.1074/jbc.M308080200	36	2	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1648	1654		10.1016/j.prp.2018.07.030			7	Pathology	Pathology	GY0SD	WOS:000448231000019	30153958				2019-10-28	
J	Hu, XY; Li, L; Wu, HT; Liu, Y; Wang, BD; Tang, Y				Hu, Xiang-Yu; Li, Li; Wu, Hong-Tao; Liu, Ying; Wang, Bei-Da; Tang, Ying			Serum miR-130b level, an ideal marker for monitoring the recurrence and prognosis of primary hepatocellular carcinoma after radiofrequency ablation treatment	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Primary hepatocellular carcinoma; miR-130b; Radiofrequency ablation; Recurrence; Prognosis	PERCUTANEOUS ETHANOL INJECTION; MICRORNA EXPRESSION; ALPHA-FETOPROTEIN; HEPATIC-TUMORS; LIVER-TUMORS; RISK-FACTORS; COMPLICATIONS; CANCER; CIRRHOSIS; RESECTION	Objective: This study was aimed to explore the potential roles of miR-130b for the efficacy of radiofrequency ablation (RFA) in patients with primary hepatocellular carcinoma (PHC). Methods: The serum sample of 110 PHC patients, which underwent RFA treatment, was collected on 1d pre-operation (Pre 1), 7d (POD 7) and 14d post-operation (POD 14). qRT-PCR was used to detect miR-130b expression. The relationship between miR-130b expression and clinicopathological features, postoperative recurrence and survival rate were analyzed. Results: The liver function of PHC patients was improved after RFA treatment. The level of alpha fetoprotein (AFP) was gradually reduced on POD 7 and POD 14 (all P < 0.05). Before RFA, the expression of miR-130b in PHC patients was upregulated, while the expression of miR-130b decreased significantly with time after RFA treatment. And high expression of miR-130b was closely related to cirrhosis (P = 0.027) and tumor differentiation degree (P < 0.01). Serum miR-130b levels were significantly higher in patients with recurrence than in patients without recurrence (P < 0.05). Patients were divided into two groups according to miR-130b expression level (median Delta Ct), compared with low Delta Ct group, the incidence of recurrence in high Delta Ct group was significantly higher after RFA (P = 0.020). Kaplan-Meier survival analysis showed that the survival rate of high Delta Ct group was significantly shorter than that of low Delta Ct group (P < 0.001). Conclusion: Our study provided evidence that serum miR-130b level may be used as an ideal marker for monitoring the recurrence and prognosis of PHC after RFA treatment.	[Hu, Xiang-Yu; Li, Li; Wu, Hong-Tao; Liu, Ying; Tang, Ying] Tianjin First Ctr Hosp, Dept Ultrasound, 24 Fukang Rd, Tianjin 300300, Peoples R China; [Wang, Bei-Da] Tianjin Dongli Hosp, Dept Ultrasound, Tianjin 300192, Peoples R China	Tang, Y (reprint author), Tianjin First Ctr Hosp, Dept Ultrasound, 24 Fukang Rd, Tianjin 300300, Peoples R China.	drtang2002@aliyun.com					Akahoshi K, 2016, J GASTROENTEROL, V51, P910, DOI 10.1007/s00535-015-1159-8; Baig Jawed Altaf, 2009, J Ayub Med Coll Abbottabad, V21, P72; Bosetti C, 2014, BEST PRACT RES CL GA, V28, P753, DOI 10.1016/j.bpg.2014.08.007; Braconi C, 2008, HEPATOLOGY, V47, P1807, DOI 10.1002/hep.22326; Burmistrova OA, 2007, BIOCHEMISTRY-MOSCOW+, V72, P578, DOI 10.1134/S0006297907050161; Cabibbo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070016; Chai S, 2013, CHIN J CANCER, V32, P419, DOI 10.5732/cjc.013.10038; Chang SKY, 2012, SINGAP MED J, V53, P32; Crocetti L, 2010, CARDIOVASC INTER RAD, V33, P11, DOI 10.1007/s00270-009-9736-y; Curley SA, 2004, ANN SURG, V239, P450, DOI 10.1097/01.sla.0000118373.31781.f2; Dodd GD, 2000, RADIOGRAPHICS, V20, P9, DOI 10.1148/radiographics.20.1.g00ja019; Goldberg S N, 2001, Eur J Ultrasound, V13, P129, DOI 10.1016/S0929-8266(01)00126-4; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; He XX, 2012, ONCOGENE, V31, P3357, DOI 10.1038/onc.2011.500; Ho DWH, 2016, LIVER CANCER, V5, P290, DOI 10.1159/000449340; Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x; Hung IFN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148493; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Jones EA, 2001, J ANAT, V198, P555, DOI 10.1046/j.1469-7580.2001.19850555.x; Koda M, 2012, HEPATOL RES, V42, P1058, DOI 10.1111/j.1872-034X.2012.01025.x; Kong WT, 2009, WORLD J GASTROENTERO, V15, P2651, DOI 10.3748/wjg.15.2651; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Lai KW, 2010, EUR J CANCER, V46, P1456, DOI 10.1016/j.ejca.2010.01.036; Lam VWT, 2008, ANN SURG ONCOL, V15, P782, DOI 10.1245/s10434-007-9733-9; Lee YH, 2015, J CLIN GASTROENTEROL, V49, P242, DOI 10.1097/MCG.0000000000000133; Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718; Li BL, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0484-0; Lin ZQ, 2009, P NATL ACAD SCI USA, V106, P12103, DOI 10.1073/pnas.0811371106; Liu A. M., BMJ OPEN, V2; Llovet JM, 2001, HEPATOLOGY, V33, P1124, DOI 10.1053/jhep.2001.24233; Ma WJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-212; N'Kontchou G, 2009, HEPATOLOGY, V50, P1475, DOI 10.1002/hep.23181; Negrini M, 2011, ANTI-CANCER AGENT ME, V11, P500, DOI 10.2174/187152011796011037; Ng KK, 2008, J GASTROINTEST SURG, V12, P183, DOI 10.1007/s11605-007-0276-y; Park W, 2013, HEPATOL RES, V43, P1304, DOI 10.1111/hepr.12083; Poggi G, 2015, WORLD J HEPATOL, V7, P2578, DOI 10.4254/wjh.v7.i25.2578; Rodriguez MAM, 2000, REV ESP ENFERM DIG, V92, P464; Sakhuja P., 2011, J CLIN EXP HEPATOL, V1; Shao YL, 2017, COMPUT BIOL MED, V89, P282, DOI 10.1016/j.compbiomed.2017.08.025; Shiina S, 2002, ONCOLOGY-BASEL, V62, P64, DOI 10.1159/000048278; Shiina S, 2012, AM J GASTROENTEROL, V107, P569, DOI 10.1038/ajg.2011.425; Tateishi R, 2005, CANCER-AM CANCER SOC, V103, P1201, DOI 10.1002/cncr.20892; Tavakolpour S, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.33537; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tu KS, 2014, INT J MOL SCI, V15, P20486, DOI 10.3390/ijms151120486; van der Fits L, 2011, J INVEST DERMATOL, V131, P762, DOI 10.1038/jid.2010.349; Wang WZ, 2011, INT J CANCER, V129, P1624, DOI 10.1002/ijc.25818; Wood TF, 2000, ANN SURG ONCOL, V7, P593, DOI 10.1007/BF02725339; Yang C, 2012, GYNECOL ONCOL, V124, P325, DOI 10.1016/j.ygyno.2011.10.013; Yang NN, 2015, ADV DRUG DELIVER REV, V81, P62, DOI 10.1016/j.addr.2014.10.029; Yip L, 2011, ANN SURG ONCOL, V18, P2035, DOI 10.1245/s10434-011-1733-0; Yu SJ, 2018, J CLIN GASTROENTEROL, V52, pE18, DOI 10.1097/MCG.0000000000000841	52	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1655	1660		10.1016/j.prp.2018.08.007			6	Pathology	Pathology	GY0SD	WOS:000448231000020	30153957				2019-10-28	
J	Uchihara, Y; Iwata, E; Papadimitriou-Olivgeri, I; Herrero-Charrington, D; Tanaka, Y; Athanasou, NA				Uchihara, Y.; Iwata, E.; Papadimitriou-Olivgeri, I.; Herrero-Charrington, D.; Tanaka, Y.; Athanasou, N. A.			Localised foot and ankle amyloid deposition	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Foot; Ankle; Amyloid; Transthyretin; Glycosaminoglycans	SENILE SYSTEMIC AMYLOIDOSIS; CARPAL-TUNNEL RELEASE; ARTICULAR-CARTILAGE; TRANSTHYRETIN DEPOSITION; PYROPHOSPHATE ARTHRITIS; PERIARTICULAR TISSUE; GLYCOSAMINOGLYCANS; KNEE; OSTEOARTHRITIS; JOINTS	Background: Localised (transthyretin-associated) amyloid is commonly seen in articular/periarticular tissues of elderly individuals. Whether age-associated, amyloid deposition occurs in foot and ankle (F&A) tissues has not previously been investigated. In this study we assessed the nature and frequency of F&A amyloid deposition and determined whether it is associated with age and/or specific articular/periarticular F&A lesions. Methods: Histological sections of twenty five normal F&A articular/periarticular tissues (16-71 years) and a range of F&A lesions were stained by Congo Red. The amyloid protein was identified by immunohistochemistry and type of matrix glycosaminoglycans determined by Alcian Blue (critical electrolyte concentration) histochemistry. Results: Amyloid deposits were found in the joint cartilage and capsule of 3/25 normal specimens (57, 62 and 78 years). Amyloid deposits were small, contained transthyretin, and found in areas of matrix degeneration associated with the presence of highly sulphated glycosaminoglycans. In patients older than 47 years, small amyloid deposits were noted in some F&A lesions, including osteoarthritis, Charcot arthropathy, bursa, ganglion, chondrocalcinosis, gout, calcific tendonitis and Achilles tendonitis. Conclusion: Small localised amyloid deposits in F&A tissues contain transthyretin and occur in areas of matrix degeneration associated with the presence of highly sulphated glycosaminoglycans; these deposits are age-associated and, although seen more commonly in some F&A lesions, are small and unlikely to be of pathogenic significance.	[Uchihara, Y.; Iwata, E.; Tanaka, Y.] Nara Med Univ, Dept Orthopaed Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan; [Papadimitriou-Olivgeri, I.; Herrero-Charrington, D.; Athanasou, N. A.] Univ Oxford, Nuffield Orthopaed Ctr, NDORMS, Dept Histopathol, Oxford OX3 7HE, England	Athanasou, NA (reprint author), Univ Oxford, Nuffield Orthopaed Ctr, NDORMS, Dept Histopathol, Oxford OX3 7HE, England.	nick.athanasou@ndorms.ox.ac.uk			European UnionEuropean Union (EU)	The authors thank Sarah Turton for typing the manuscript. I Papadimitriou-Olivgeri was a European Union-funded Erasmus Student.	Akasaki Y, 2015, ARTHRITIS RHEUMATOL, V67, P2097, DOI 10.1002/art.39178; Ando Y, 2012, CURR MED CHEM, V19, P2312, DOI 10.2174/092986712800269317; Ankarcrona M, 2016, J INTERN MED, V280, P177, DOI 10.1111/joim.12506; Athanasou N A, 1995, Eur Spine J, V4, P308, DOI 10.1007/BF00301041; ATHANASOU NA, 1992, HISTOPATHOLOGY, V20, P41, DOI 10.1111/j.1365-2559.1992.tb00914.x; ATHANASOU NA, 1995, HISTOPATHOLOGY, V26, P267, DOI 10.1111/j.1365-2559.1995.tb01441.x; ATHANASOU NA, 1995, NEPHROL DIAL TRANSPL, V10, P1672; Bourgault S, 2011, BIOCHEMISTRY-US, V50, P1001, DOI 10.1021/bi101822y; Christofi T, 2007, POSTGRAD MED J, V83, P749, DOI 10.1136/pgmj.2007.063578; Cole AS, 2001, J BONE JOINT SURG BR, V83B, P561, DOI 10.1302/0301-620X.83B4.11547; Cordiner-Lawrie S, 2001, J HAND SURG-BRIT EUR, V26, P380, DOI 10.1054/jhsb.2001.0571; Di Domizio J, 2012, J BIOL CHEM, V287, P736, DOI 10.1074/jbc.M111.238477; Foitschik T, 2005, AMYLOID, V12, P167, DOI 10.1080/13506120500222094; GOFFIN Y A, 1985, Applied Pathology, V3, P88; Goncalves NP, 2016, NEUROBIOL AGING, V47, P91, DOI 10.1016/j.neurobiolaging.2016.07.020; Gu YJ, 2014, J ZHEJIANG UNIV-SC B, V15, P92, DOI 10.1631/jzus.B1300046; Hou X, 2007, FEBS J, V274, P1637, DOI 10.1111/j.1742-4658.2007.05712.x; Iannuzzi C, 2015, MOLECULES, V20, P2510, DOI 10.3390/molecules20022510; Kisilevsky R, 2016, FRONT MOL BIOSCI, V3, DOI 10.3389/fmolb.2016.00017; KYLE RA, 1989, AM J CLIN PATHOL, V91, P393, DOI 10.1093/ajcp/91.4.393; KYLE RA, 1992, AM J CLIN PATHOL, V97, P250, DOI 10.1093/ajcp/97.2.250; LADEFOGED C, 1982, ACTA ORTHOP SCAND, V53, P587, DOI 10.3109/17453678208992263; LADEFOGED C, 1989, HISTOPATHOLOGY, V15, P289, DOI 10.1111/j.1365-2559.1989.tb03079.x; LINKER A, 1987, LAB INVEST, V57, P297; MOHR W, 1976, Z RHEUMATOL, V35, P412; MUNOZGOMEZ J, 1985, ANN RHEUM DIS, V44, P729, DOI 10.1136/ard.44.11.729; Niggemeyer O, 2011, ARCH ORTHOP TRAUM SU, V131, P637, DOI 10.1007/s00402-010-1187-z; PEITZMAN SJ, 1976, JAMA-J AM MED ASSOC, V235, P1345, DOI 10.1001/jama.235.13.1345; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; PRUZANSKI W, 1981, J RHEUMATOL, V8, P477; Sahin F, 2007, JOINT BONE SPINE, V74, P209, DOI 10.1016/j.jbspin.2006.04.009; Solomon A, 2006, ARTHRITIS RHEUM, V54, P3545, DOI 10.1002/art.22201; SORENSEN KH, 1981, ACTA ORTHOP SCAND, V52, P129, DOI 10.3109/17453678108991773; SORENSEN KH, 1973, ACTA ORTHOP SCAND, V44, P460, DOI 10.3109/17453677308989081; Sueyoshi T, 2011, HUM PATHOL, V42, P1259, DOI 10.1016/j.humpath.2010.11.017; TAGLIABUE JR, 1990, SKELETAL RADIOL, V19, P448; Takanashi T, 2013, AMYLOID, V20, P151, DOI 10.3109/13506129.2013.803190; TEGLBJAERG PS, 1979, ACTA PATH MICRO IM A, V87, P307; Uchiyama S, 2014, J ORTHOP SCI, V19, P913, DOI 10.1007/s00776-014-0635-y; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; Westermark P, 2003, AMYLOID, V10, P48; Yanagisawa A, 2016, AMYLOID, V23, P26, DOI 10.3109/13506129.2015.1115758; Yanagisawa A, 2015, MODERN PATHOL, V28, P201, DOI 10.1038/modpathol.2014.102	43	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1661	1666		10.1016/j.prp.2018.08.027			6	Pathology	Pathology	GY0SD	WOS:000448231000021	30173946				2019-10-28	
J	Acosta, AM; Vormittag, E; Al Rasheed, MRH; Sharif, A; Mon, KS; Kajdacsy-Balla, A; Mohapatra, G				Acosta, Andres M.; Vormittag, Erica; Al Rasheed, Mohamed R. Haroon; Sharif, Asma; Mon, Khin-Su; Kajdacsy-Balla, Andre; Mohapatra, Gayatry			Comparison of prostatic adenocarcinoma Gleason 5 and intraductal carcinoma of the prostate with tumor necrosis. A morphometric study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Intraductal carcinoma of the prostate; Tumor necrosis; Comedonecrosis; Gleason pattern 5; Prostatic adenocarcinoma	INTERNATIONAL SOCIETY; INVASIVE CRIBRIFORM; NEEDLE-BIOPSY; CANCER; PATTERNS; SPREAD	Intraductal carcinoma of the prostate(IDCP) is defined as a solid or cribriform neoplastic growth confined to ducts and acini, with preservation of the basal cell layer. Since IDCP can often present tumor necrosis (TN), it should be distinguished from Gleason 5 (GP5) invasive adenocarcinoma for staging and clinical purposes. In the present study we reviewed 344 radical prostatectomies performed at our institution and selected all cases with either > 5% GP5 or IDCP for assessment of TN on histology slides (n = 59). A total of 19 cases with TN were identified, and morphology, size, location, and histoarchitecture of the lesions with TN were recorded. Subsequently, the corresponding sections were stained with a basal cell immunomarker (P63), and lesions with TN were assigned to IDCP or invasive carcinoma GP5 for comparison. Our results show that a branched shape and size 501-1000 mu m are more common in IDCP, while a size > 1000 mu m and location within 1 mm of the periprostatic soft tissue are significantly more prevalent in invasive adenocarcinoma GP5. These features, however, usually cannot be assessed in core biopsies. In this setting, the utilization of immunohistochemistry is warranted to differentiate IDCP and GP5 with necrosis.	[Acosta, Andres M.; Vormittag, Erica; Al Rasheed, Mohamed R. Haroon; Sharif, Asma; Mon, Khin-Su; Kajdacsy-Balla, Andre; Mohapatra, Gayatry] Univ Illinois, Dept Pathol, Chicago, IL USA	Acosta, AM (reprint author), 820 S Wood St,Suite 130 CSN, Chicago, IL 60612 USA.	andresmartinacosta@gmail.com; gayamoha@uic.edu		Haroon Al Rasheed, Mohamed Rizwan/0000-0002-0572-0387; Acosta, Andres/0000-0003-0164-5911			Acosta AM, 2018, HUM PATHOL, V75, P1, DOI 10.1016/j.humpath.2017.11.015; Egevad L, 2018, PATHOLOGY, V50, P60, DOI 10.1016/j.pathol.2017.09.008; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Fine SW, 2018, AM J SURG PATHOL, V42, P1036, DOI 10.1097/PAS.0000000000001104; Gottipati S, 2012, AM J SURG PATHOL, V36, P900, DOI 10.1097/PAS.0b013e3182495dee; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054; Iczkowski KA, 2014, ANN DIAGN PATHOL, V18, P333, DOI 10.1016/j.anndiagpath.2014.08.010; KOVI J, 1985, CANCER, V56, P1566, DOI 10.1002/1097-0142(19851001)56:7<1566::AID-CNCR2820560717>3.0.CO;2-Y; Kweldam CF, 2017, MODERN PATHOL, V30, P1126, DOI 10.1038/modpathol.2017.29; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Lim SK, 2013, ANN SURG ONCOL, V20, P3127, DOI 10.1245/s10434-013-2996-4; Mahal BA, 2016, BJU INT, V118, P95, DOI 10.1111/bju.13239; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Wilcox G, 1998, HUM PATHOL, V29, P1119, DOI 10.1016/S0046-8177(98)90423-3; Young HH, 1909, ANN SURG, V50, P1144, DOI 10.1097/00000658-190912000-00015	17	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1681	1685		10.1016/j.prp.2018.08.030			5	Pathology	Pathology	GY0SD	WOS:000448231000024	30195638				2019-10-28	
J	Tang, B; Xuan, L; Tang, MM; Wang, HJ; Zhou, J; Liu, JJ; Wu, SL; Li, MN; Wang, XJ; Zhang, H				Tang, Bi; Xuan, Ling; Tang, Mingming; Wang, Hongju; Zhou, Jing; Liu, Jinjun; Wu, Shili; Li, Miaonan; Wang, Xiaojing; Zhang, Heng			miR-93-3p alleviates lipopolysaccharide-induced inflammation and apoptosis in H9c2 cardiomyocytes by inhibiting toll-like receptor 4	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Cardiomyocytes; Apoptosis; LPS; miR-93-3p; TLR4	MYOCARDIAL-INFARCTION; CARDIAC DYSFUNCTION; HEART-FAILURE; TLR4; INJURY; PHOSPHORYLATION; HYPERTROPHY; PATHWAY; SEPSIS; CELLS	Background: miR-93 is recently recognized to perform anti-inflammatory action in the pathological process of cardiomyocytes dysfunction. However, it remains unclear whether miR-93-3p involves in lipopolysaccharide (LPS)-induced inflammation and apoptosis in H9c2 cells. The present study aimed to investigate the functions of miR-93-3p and its target, toll-like receptor 4 (TLR4), in LPS-stimulated cardiomyocytes. Material and methods: Cell viability was analyzed by CCK-8 assay. AnnexinV-FITC/PI staining and lactate dehydrogenase (LDH) assay were used to evaluate the cell death. The mRNA and protein levels were assayed by RT-qPCR and western blotting, respectively. The targeted gene was predicted by a bioinformatics algorithm and confirmed by a dual luciferase reporter assay. Results: LDH stimulation resulted in the suppression of cell viability and the increase in apoptosis rate, inflammatory cytokines and LDH levels, while inhibition of TLR4 with TAK-242 or overexpression of miR-93-3p dramatically blocked LPS-induced inflammation and apoptosis in cardiomyocytes. Intriguingly, bioinformatics analysis and experimental data suggested that TLR4 was a direct target of miR-93-3p, which could inhibit TLR4 expression by transfected with miR-93-3p mimics or elevate the expression of TLR4 by transfected with miR-93-3p inhibitors. Overexpression of TLR4 carried out an opposite effect to miR-93-3p and positively regulated LPS-induced inflammation and apoptosis in cardiomyocytes. Conclusion: miR-93-3p showed the protective effects against LPS-induced inflammation and apoptosis in cardiomyocytes by inhibiting TLR4 expression.	[Tang, Bi; Xuan, Ling; Tang, Mingming; Wang, Hongju; Zhou, Jing; Liu, Jinjun; Wu, Shili; Li, Miaonan; Zhang, Heng] Bengbu Med Coll, Affiliated Hosp 1, Dept Cardiovasc Med, 287 Changhuai Rd, Bengbu 233004, Anhui, Peoples R China; [Wang, Xiaojing] Bengbu Med Coll, Affiliated Hosp 1, Clin & Basic Prov Lab Resp Syst Dis Anhui Prov, Bengbu 233004, Anhui, Peoples R China	Zhang, H (reprint author), Bengbu Med Coll, Affiliated Hosp 1, Dept Cardiovasc Med, 287 Changhuai Rd, Bengbu 233004, Anhui, Peoples R China.	heng_zhangfh@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81170046]; Key Project of Top-Notch Talent of Discipline (specialty) of the Higher Education Institute of Anhui Province 2016 [gxbjZD2016072]; Major projects of Natural Science Research in Colleges and Universities of Anhui Province [KJ2018ZD023]	This research was supported by the National Natural Science Foundation of China (No. 81170046), Key Project of Top-Notch Talent of Discipline (specialty) of the Higher Education Institute of Anhui Province 2016 (No. gxbjZD2016072) and Major projects of Natural Science Research in Colleges and Universities of Anhui Province (No. KJ2018ZD023).	Avlas O, 2016, EXP CELL RES, V348, P115, DOI 10.1016/j.yexcr.2016.07.020; Barba I, 2009, J PHYSIOL-LONDON, V587, P1331, DOI 10.1113/jphysiol.2008.163311; Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919; Bouras G, 2014, MED CHEM, V10, P682, DOI 10.2174/1573406410666140318113325; Braunwald E, 2013, JACC-HEART FAIL, V1, P1, DOI 10.1016/j.jchf.2012.10.002; Chen L, 2017, J CELL MOL MED, V21, P3178, DOI 10.1111/jcmm.12871; Chen TS, 2018, J CELL PHYSIOL, V233, P5869, DOI 10.1002/jcp.26386; Chen WP, 2010, N-S ARCH PHARMACOL, V382, P441, DOI 10.1007/s00210-010-0562-1; Emanueli C, 2013, CELL RES, V23, P866, DOI 10.1038/cr.2013.57; Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739; Gao M, 2015, J IMMUNOL, V195, P672, DOI 10.4049/jimmunol.1403155; Garikipati VNS, 2017, CARDIOVASC RES, V113, P938, DOI 10.1093/cvr/cvx052; Jenke A, 2013, CARDIOVASC RES, V99, P422, DOI 10.1093/cvr/cvt118; Jia ZQ, 2016, APOPTOSIS, V21, P174, DOI 10.1007/s10495-015-1201-6; Jing R, 2017, INT HEART J, V58, P422, DOI 10.1536/ihj.16-261; Li K, 2017, MED HYPOTHESES, V106, P23, DOI 10.1016/j.mehy.2017.07.003; Li WX, 2016, SCI REP-UK, V6, DOI 10.1038/srep24580; Li YW, 2018, EUR J PHARMACOL, V818, P508, DOI 10.1016/j.ejphar.2017.11.031; Liu L, 2015, J CELL MOL MED, V19, P2728, DOI 10.1111/jcmm.12659; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mangini S, 2015, INT J CARDIOL, V178, P55, DOI 10.1016/j.ijcard.2014.10.133; Pan Y, 2014, DIABETES, V63, P3497, DOI 10.2337/db13-1577; Perdomo L, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0237-9; Plociennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018-014-1762-5; Rouse M, 2014, J PHARMACOL EXP THER, V350, P341, DOI 10.1124/jpet.114.214742; Su Q, 2018, INFLAMMATION, V41, P1229, DOI 10.1007/s10753-018-0769-8; Velloso LA, 2015, ENDOCR REV, V36, P245, DOI 10.1210/er.2014-1100; Wahlquist C, 2014, NATURE, V508, P531, DOI 10.1038/nature13073; Wang H, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.80; Wang H, 2016, J MOL CELL CARDIOL, V94, P43, DOI 10.1016/j.yjmcc.2016.03.014; Wang XT, 2016, SCI REP-UK, V6, DOI 10.1038/srep27866; Wang YY, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0820-1; Wo Y, 2018, CARDIOVASC PATHOL, V35, P29, DOI 10.1016/j.carpath.2018.04.003; Xu Y, 2014, FEBS LETT, V588, P1692, DOI 10.1016/j.febslet.2014.03.013; Yan XT, 2017, INT IMMUNOPHARMACOL, V46, P156, DOI 10.1016/j.intimp.2017.01.027; Yao Y., 2018, BIOSCI REP, V38; Zhang HF, 2018, BIOMED PHARMACOTHER, V101, P663, DOI 10.1016/j.biopha.2018.02.129; Zhang YD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142456	38	0	0	1	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1686	1693		10.1016/j.prp.2018.08.024			8	Pathology	Pathology	GY0SD	WOS:000448231000025	30195636				2019-10-28	
J	Yang, JZ; Wu, XD; Meng, JB; Zhang, JQ; Sun, LX				Yang, Jian-Zhu; Wu, Xian-Da; Meng, Jian-Bo; Zhang, Jin-Qiao; Sun, Li-Xia			Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Multiple myeloma; Skeletal extramedullary disease relapse; Microvessel density; Predicting	TO-LYMPHOCYTE RATIO; POOR-PROGNOSIS; SURVIVAL; IMPACT; ERA; PLASMACYTOMAS; ANGIOGENESIS; METASTASIS; EXPRESSION; FEATURES	The aim of the study was to investigate whether microvessel density (MVD) could be associated with skeletal extramedullary disease relapse (skeletal-EMDR) in patients with multiple myeloma (MM) who have skeletal-EMD at diagnosis. Seventy-nine newly diagnosed MM patients who have skeletal-EMD were retrospectively enrolled in this study. The 4-year cumulative incidence of skeletal-EMDR was 35.0% +/- 8.3%. The 4-year probability of overall survival (OS) was 54.0% +/- 7.6%. Multivariate analysis showed that skeletal-EMDR (HR = 4.144; 95% CI: 1.608-10.685; P = 0.003) was independently associated with inferior OS for the MM patients who have skeletal-EMD at diagnosis. The factors associated with skeletal-EMDR were MVD (HR = 3.990, 95%CI:1.136-14.018; P = 0.031), white blood cell (WBC) (HR = 0.262, 95% CI:0.090-0.769; P = 0.015), and the EMD sites involved at onset (HR = 0.263, 95% CI: 0.074-0.937; P = 0.039). The MVD in patients with thoracic and lumbar vertebrae as the involved sites at diagnosis was significantly lower than those with other sites involved (41.59 +/- 14.39 vs. 60.82 +/- 35.14, P = 0.001). Our data suggest that increased MVD could be used to predict skeletal-EMDR, which is associated with inferior survival in patients with MM who have skeletal-EMD at diagnosis.	[Yang, Jian-Zhu] Hebei Med Univ, Affiliated Hosp 3, Dept Pathol, Shijiazhuang, Hebei, Peoples R China; [Wu, Xian-Da; Meng, Jian-Bo; Zhang, Jin-Qiao; Sun, Li-Xia] Hebei Med Univ, Affiliated Hosp 3, Dept Hematol, Shijiazhuang 050051, Hebei, Peoples R China	Sun, LX (reprint author), Hebei Med Univ, Affiliated Hosp 3, Dept Hematol, Shijiazhuang 050051, Hebei, Peoples R China.	sun2010@bjmu.edu.cn			science and technology Huimin Project from the Science and Technology Department of Hebei Province, China [16277750D]	This work was funded by science and technology Huimin Project from the Science and Technology Department of Hebei Province, China. (Project No.16277750D)	Andersen NF, 2005, BRIT J HAEMATOL, V128, P210, DOI 10.1111/j.1365-2141.2004.05299.x; Blade J, 2015, BRIT J HAEMATOL, V169, P763, DOI 10.1111/bjh.13384; Blade J, 2011, J CLIN ONCOL, V29, P3805, DOI 10.1200/JCO.2011.34.9290; Chantry A, 2017, BRIT J HAEMATOL, V178, P380, DOI 10.1111/bjh.14827; Deng Shuhui, 2015, Zhonghua Xue Ye Xue Za Zhi, V36, P501, DOI 10.3760/cma.j.issn.0253-2727.2015.06.012; Deng SH, 2015, CL LYMPH MYELOM LEUK, V15, P286, DOI 10.1016/j.clml.2014.12.013; Dimopoulos MA, 2015, J CLIN ONCOL, V33, P657, DOI 10.1200/JCO.2014.57.9961; Gagelmann N, 2018, HAEMATOLOGICA, V103, P890, DOI 10.3324/haematol.2017.178434; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Lee N, 2015, ANN LAB MED, V35, P563, DOI 10.3343/alm.2015.35.6.563; Lee SE, 2015, ANN HEMATOL, V94, P445, DOI 10.1007/s00277-014-2216-8; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Mangiacavalli S, 2017, ANN HEMATOL, V96, P73, DOI 10.1007/s00277-016-2847-z; Mantas D, 2016, ONCOL LETT, V12, P1610, DOI 10.3892/ol.2016.4760; Ntellas P, 2017, ACTA HAEMATOL-BASEL, V138, P77, DOI 10.1159/000478085; Sezer O, 2000, ANN HEMATOL, V79, P574, DOI 10.1007/s002770000236; Shi LH, 2017, ONCOTARGET, V8, P18792, DOI 10.18632/oncotarget.13320; Short KD, 2011, LEUKEMIA, V25, P906, DOI 10.1038/leu.2011.29; Tao LY, 2016, ONCOTARGET, V7, P74314, DOI 10.18632/oncotarget.11031; Tao LY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004932; Touzeau C, 2016, BLOOD, V127, P971, DOI 10.1182/blood-2015-07-635383; Usmani SZ, 2012, HAEMATOL-HEMATOL J, V97, P1761, DOI 10.3324/haematol.2012.065698; Varettoni M, 2010, ANN ONCOL, V21, P325, DOI 10.1093/annonc/mdp329; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang JZ, 2016, PATHOL RES PRACT, V212, P210, DOI 10.1016/j.prp.2015.12.011; Yang JZ, 2014, PATHOL RES PRACT, V210, P586, DOI 10.1016/j.prp.2014.04.018	26	0	0	3	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1694	1699		10.1016/j.prp.2018.08.018			6	Pathology	Pathology	GY0SD	WOS:000448231000026	30196985				2019-10-28	
J	Koletzko, L; Mahli, A; Hellerbrand, C				Koletzko, Leandra; Mahli, Abdo; Hellerbrand, Claus			Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatitis C; Genotype 1b; Hepatic steatosis; Oxidative stress; Lipogenesis	FATTY LIVER-DISEASE; INSULIN-RESISTANCE; STEATOSIS; EPIDEMIOLOGY; ACCUMULATION; EXPRESSION; NAFLD	Hepatic steatosis is common in patients infected with hepatitis C virus (HCV). Particularly in patients infected with non-genotype 3 HCV, hepatic steatosis is closely related to factors of the metabolic syndrome such as hyperlipidemia. However, the molecular mechanisms involved in this "metabolic" steatosis in non-3 genotype HCV infections are not well understood. Here, we aimed to develop an in vitro model to study the effect of genotype 1 HCV infection on hepatic lipotoxicity and lipid metabolism. Cellular lipid accumulation was induced in Huh-7 hepatoma cells transfected with HCV genotype 1b replicon (HCV+) by incubation with increasing doses of palmitic acid (C16:0) or oleic acid (C18:1 n-9) complexed to albumin mimicking hyperlipidemic conditions. Mock transfected hepatoma cells (HCV-) were used as controls. Incubation with oleic acid concentrations as high as 0.5 mM did not induce toxic effects in HCV+ or HCV- cells. In contrast, incubation with palmitic acid caused dose-dependently cytotoxic effects which were more pronounced in HCV+ compared to HCV- cells. Further analysis with subtoxic palmitic and oleic acid concentrations revealed a higher uptake of fatty acids and intracellular triglyceride accumulation in HCV+ compared to HCV- cells. Carnitine palmitoyltransferase I (CPT1) expression, indicative of mitochondrial beta-oxidation, was markedly stimulated by lipid exposure in HCV+ but not in HCV- cells. Furthermore, heme oxygenase 1 (HMOX1) expression levels increased in FA stimulated cells, and this increase was significantly higher in HCV+ compared to HCV- cells. In contrast, expression of the key enzymes of hepatic de novo lipogenesis fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD-1) was significantly reduced upon oleate exposure in HCV- but not in HCV+ cells. In summary, our newly developed cell culture model revealed effects of HCV genotype 1b infection on metabolic susceptibility to lipid accumulation and toxicity particularly to saturated lipids. These results may indicate that HCV (genotype 1b) infected individuals with hyperlipidemia may benefit from dietary or pharmacological intervention.	[Koletzko, Leandra] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany; [Koletzko, Leandra; Hellerbrand, Claus] Univ Hosp Regensburg, Dept Internal Med 1, Regensburg, Germany; [Mahli, Abdo; Hellerbrand, Claus] Friedrich Alexander Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany	Hellerbrand, C (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany.	claus.hellerbrand@fau.de		Mahli, Abdo/0000-0002-8333-7551	German Research Association (DFG)German Research Foundation (DFG) [FOR2127, KFO262]; Interdisciplinary Center for Clinical Research Erlangen (IZKF)	This study was supported by grants from the German Research Association (DFG) (FOR2127 and KFO262) and the Interdisciplinary Center for Clinical Research Erlangen (IZKF) to C.H.	Adinolfi LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060803; Asselah T, 2006, GUT, V55, P123, DOI 10.1136/gut.2005.069757; Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9; Czech B, 2013, INT J CLIN EXP PATHO, V6, P1585; de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009; Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519; Dorn C, 2014, LAB INVEST, V94, P394, DOI 10.1038/labinvest.2014.3; Dorn C, 2010, INT J CLIN EXP PATHO, V3, P505; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Esfeh JM, 2016, GASTROENTEROL REP, V4, P24, DOI 10.1093/gastro/gov040; Estadella D, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/137579; Gehrmann W, 2015, CELL PHYSIOL BIOCHEM, V36, P852, DOI 10.1159/000430261; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lonardo A, 2004, GASTROENTEROLOGY, V126, P586, DOI 10.1053/j.gastro.2003.11.020; Macaluso FS, 2013, BIOMED RES INT, DOI 10.1155/2013/564645; Mahli A, 2018, GUT, V67, P746, DOI 10.1136/gutjnl-2016-312485; Mahli A, 2015, ONCOTARGET, V6, P41464, DOI 10.18632/oncotarget.6203; McClain CJ, 2007, HEPATOLOGY, V45, P1343, DOI 10.1002/hep.21788; Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005; Oem J. K., 2008, J GEN VIROL PT 5, V89; Petta S, 2008, AM J GASTROENTEROL, V103, P1136, DOI 10.1111/j.1572-0241.2008.01813.x; Polyak SJ, 2001, J VIROL, V75, P6209, DOI 10.1128/JVI.75.13.6209-6211.2001; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Thompson AJ, 2012, GUT, V61, P128, DOI 10.1136/gut.2010.236158; Wobser H, 2009, CELL RES, V19, P996, DOI 10.1038/cr.2009.73; Wree A, 2013, NAT REV GASTRO HEPAT, V10, P627, DOI 10.1038/nrgastro.2013.149; Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431	29	1	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1700	1706		10.1016/j.prp.2018.08.013			7	Pathology	Pathology	GY0SD	WOS:000448231000027	30201523				2019-10-28	
J	Zhao, M; Sun, L; Lai, JZ; Shi, HY; Mei, KY; He, XL; Jin, XL; Lai, JP; Cao, DF				Zhao, Ming; Sun, Lu; Lai, Jenny Z.; Shi, Huaiyin; Mei, Kaiyong; He, Xianglei; Jin, Xiaolong; Lai, Jinping; Cao, Dengfeng			Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gastric hepatoid carcinoma; Fetal type gastrointestinal adenocarcinoma; liepatocellular carcinoma; LIN28; SALL4	GERM-CELL TUMORS; YOLK-SAC TUMORS; EMBRYONIC STEM-CELLS; CLINICOPATHOLOGICAL FEATURES; DIFFERENTIAL-DIAGNOSIS; SENSITIVE MARKER; CLEAR-CELL; STOMACH; UTILITY; CANCER	Introduction: Gastric hepatoid carcinomas (GHCs) include type I (classic) and type II (fetal type gastrointestinal adenocarcinoma). The classic type shows overlapping morphologic features with those of hepatocellular carcinoma (HCC). The aim of this study is to investigate expression of LIN28 in GHCs and explore its utility to distinguish classic GHC from HCC. Methods: We investigated immunohistochemical expression of LIN28 in 93 primary GHCs (47 type I, 46 type II) and 60 HCCs with comparison to SALL4, AFP, glypican-3, Hep Par1, p-CEA and CK7. We also stained LIN28 and SALL4 in 52 conventional gastric adenocarcinomas to assess their specificity in gastric carcinomas. Results: Classic GHCs and fetal type gastrointestinal adenocarcinomas showed positive LIN28 in 21/47 (45%) and 10/46 (22%), SALL4 in 41/47 (87%) and 36/46 (78%), AFP in 30/46 (65%) and 33/46 (72%), glypican-3 in 31/41 (76%) and 24/38 (63%), Hep Par1 in 27/41 (66%) and 28/37 (76%), and CK7 in 15/40 (38%) and 25/38 (66%), respectively. p-CEA staining was seen in 19/44 (43%) classic GHCs. Among HCCs, LIN28, SALL4, AFP, glypican-3, Hep Par1, p-CEA and CK7 was seen in 1/60 (2%), 0/60 (0%), 6/30 (20%), 23/30 (77%), 29/30 (97%), 28/30 (93%) and 21/30 (70%) cases, respectively. LIN28 and SALL4 staining was seen in 2/52 (4%) and 14/52 (27%) gastric conventional adenocarcinomas, respectively. The sensitivity and specificity of distinguishing classic GHCs from HCCs was 45% and 98% for LIN28, 87% and 100% for SALL4, 65% and 80% for AFP, 76% and 30% for glypican-3, 66% and 3% for Hep Par1, 43% and 7% for p-CEA, and 38% and 30% for CK7, respectively. Combining LIN28 and SALL4 increased the sensitivity to 96% with 98% specificity to distinguish classic GHCs from HCCs. Conclusions: LIN28 is a very specific marker (98% specificity) for distinguishing classic GHCs from HCCs though it is not as sensitive as SALL4. AFP, glypican-3, Hep Par1 and p-CEA are not useful in distinguishing classic GHCs from HCCs. Combining LIN28 and SALL4 increased the sensitivity to distinguish classic PHCs from HCCs.	[Zhao, Ming; He, Xianglei] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Zhao, Ming; He, Xianglei] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China; [Sun, Lu; Shi, Huaiyin] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing, Peoples R China; [Lai, Jenny Z.] Washington Univ, Univ Coll, St Louis, MO USA; [Mei, Kaiyong] Guangzhou Med Univ, Affiliated Hosp 2, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Jin, Xiaolong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Dept Pathol, Shanghai, Peoples R China; [Lai, Jinping] Univ Florida, Dept Pathol & Lab Med, Gainesville, FL USA; [Cao, Dengfeng] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S South Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA	Cao, DF (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S South Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	dcao@path.wustl.edu			department of pathology and immunology at Washington University School of Medicine, Saint Louis, MO, USA	This work was supported by the discretional fund from the department of pathology and immunology at Washington University School of Medicine, Saint Louis, MO 63110, USA.	Arora K, 2018, J CLIN PATHOL, V71, P221, DOI 10.1136/jclinpath-2017-204535; Cao DF, 2011, HUM PATHOL, V42, P710, DOI 10.1016/j.humpath.2010.09.007; Cao DF, 2011, MODERN PATHOL, V24, P288, DOI 10.1038/modpathol.2010.195; Cao DF, 2009, AM J SURG PATHOL, V33, P1065, DOI 10.1097/PAS.0b013e3181a13eef; Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; Cao DF, 2009, AM J SURG PATHOL, V33, P894, DOI 10.1097/PAS.0b013e318198177d; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P1293, DOI 10.1016/j.humpath.2012.10.017; Hishinuma M, 2006, HISTOPATHOLOGY, V49, P479, DOI 10.1111/j.1365-2559.2006.02522.x; Ikeda H, 2012, HUM PATHOL, V43, P1955, DOI 10.1016/j.humpath.2011.11.022; ISHIKURA H, 1985, CANCER-AM CANCER SOC, V56, P840, DOI 10.1002/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO;2-E; Kinjo T, 2012, AM J SURG PATHOL, V36, P56, DOI 10.1097/PAS.0b013e31823aafec; Kumashiro Y, 2007, HUM PATHOL, V38, P857, DOI 10.1016/j.humpath.2006.10.020; Liu AJ, 2010, AM J SURG PATHOL, V34, P697, DOI 10.1097/PAS.0b013e3181db84aa; Liu TC, 2014, AM J SURG PATHOL, V38, P966, DOI 10.1097/PAS.0000000000000218; Liu XW, 2012, J SURG ONCOL, V106, P299, DOI 10.1002/jso.23073; Liu XW, 2010, AM J SURG PATHOL, V34, P1465, DOI 10.1097/PAS.0b013e3181f0a873; Maitra A, 2001, AM J CLIN PATHOL, V115, P689; Mei KY, 2009, MODERN PATHOL, V22, P1628, DOI 10.1038/modpathol.2009.148; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; MOTOYAMA T, 1993, ACTA PATHOL JAPON, V43, P654; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; NAGAI E, 1993, CANCER, V72, P1827, DOI 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8; Osada M, 2014, HUM PATHOL, V45, P1243, DOI 10.1016/j.humpath.2014.02.003; Shibahara J, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-721; Su JS, 2013, WORLD J GASTROENTERO, V19, P321, DOI 10.3748/wjg.v19.i3.321; Terracciano LM, 2003, AM J SURG PATHOL, V27, P1302, DOI 10.1097/00000478-200310000-00002; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Ushiku T, 2009, CANCER SCI, V100, P626, DOI 10.1111/j.1349-7006.2009.01108.x; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang FH, 2009, AM J SURG PATHOL, V33, P1529, DOI 10.1097/PAS.0b013e3181ad25d5; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; West JA, 2009, NATURE, V460, P909, DOI 10.1038/nature08210; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Xu CY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0382-x; Xue DB, 2011, HISTOPATHOLOGY, V59, P452, DOI 10.1111/j.1365-2559.2011.03949.x	36	1	1	1	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1707	1712		10.1016/j.prp.2018.07.037			6	Pathology	Pathology	GY0SD	WOS:000448231000028	30196987				2019-10-28	
J	Mujtaba, H; Wang, Y; Duan, YX; Cao, M; Zhang, NN; Batool, I; Murtaza, A; Chen, XL; Wang, YL				Mujtaba, Hasan; Wang, Ying; Duan, Yixin; Cao, Meng; Zhang, Nana; Batool, Iffat; Murtaza, Ali; Chen, Xiaoli; Wang, Yili			Human papillomavirus in tonsillectomy specimen from China and Pakistan - Prevalence and genotype distribution	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Human papillomavirus; Tonsils; Polymerase chain reaction; Oropharyngeal squamous cell carcinoma; China; Pakistan	RISK HUMAN-PAPILLOMAVIRUS; SQUAMOUS-CELL CARCINOMA; ORAL HUMAN-PAPILLOMAVIRUS; HPV INFECTION; PALATINE TONSILS; UNITED-STATES; CANCER; DNA; CHILDREN; EPIDEMIOLOGY	Background: The expected corresponding increase in tonsillar human papillomavirus (HPV) infection associated with increasing incidence of oropharyngeal squamous cell carcinoma (OPSCC) substantiate the evaluation of normal tonsillar tissue in different population. The epidemiology of HPV in tonsillar tissue varies geographically. This study evaluated samples from two countries to determine the prevalence in respective samples. Objective: To characterize HPV infection in non-malignant tonsillar tissue from Shaanxi, China (herein after referred to as China) and Punjab, Pakistan (herein after referred to as Pakistan). Methodology: The DNA extracted from formalin-fixed, paraffin-embedded tumor free tonsillar tissue was evaluated using polymerase chain reaction (PCR). A total of 367 cases from China and 139 cases from Pakistan were screened for HPV DNA using GP5 + /GP6 + consensus primer. Genotype of the positive cases was determined for common HPV types (6, 11, 16, 18, 52, 58) simultaneously by type-specific PCR. Results: The mean age of cohorts in China was 13.42 (Median age 7, Range 2-72 years) while in Pakistan it was 10.77 (Median age 8, Range 3-42 years) the gender distribution was 61.6% male in China and in Pakistan they were 56.8%, rest were females. The overall prevalence of HPV in China was 2.45% and 2.16% in Pakistan. High risk human papillomavirus was 1.63% in China with 5 cases positive for HPV 16 and HPV 58 in 1 case. In Pakistan, 2 cases (1.43%) of HPV 16 were detected. Low-risk types include HPV 11 present in 2 cases from China, while HPV 6 was detected in 1 case each from both the countries. Conclusion: A low prevalence of HPV was found in China and Pakistan; high-risk and low-risk HPV were detectable in tonsillar tissue from both countries. Age stratification (< 5 years, 5-14 years, 15-25 years, > 25 years) suggest that sexual and non-sexual transmission of the virus can occur. The difference in the genotype distribution geographically within China and with Pakistan was observed in the case of HPV 58. The most common type in both the countries was HPV 16.	[Mujtaba, Hasan; Wang, Ying; Duan, Yixin; Cao, Meng; Zhang, Nana; Wang, Yili] Xi An Jiao Tong Univ, Sch Basic Med Sci, Inst Canc Res, Xian 710061, Shaanxi, Peoples R China; [Batool, Iffat] Fauji Fdn Hosp, Dept Pediat, Rawalpindi, Pakistan; [Murtaza, Ali] Ali Lab, Rawalpindi, Pakistan; [Chen, Xiaoli] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Pathol, Xian 710004, Shaanxi, Peoples R China	Wang, YL (reprint author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Inst Canc Res, Xian 710061, Shaanxi, Peoples R China.; Chen, XL (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Pathol, Xian 710004, Shaanxi, Peoples R China.	hasan2015@stu.xjtu.edu.cn; wangyingwa@stu.xjtu.edu.c; duanyx23@stu.xjtu.cn; caomeng@stu.xjtu.edu.cn; znn164503047@stu.xjtu.edu.cn; iffatb2004@hotmail.com; dralimurtaza@yahoo.com; chenxiaolixjtu@163.com; wangyili@mail.xjtu.edu.cn			Shaanxi Provincial Innovation Foundation [2011KTCL03-18]	This study was funded by the Shaanxi Provincial Innovation Foundation (No. 2011KTCL03-18). We are grateful to Ding Haiyan and Mr. Guo Shangwen for the tissue sections and assistance throughout the research work.	Adelstein D.J., 2009, NAT CANC I STAT SCI, DOI [10.1002/hed.21269, DOI 10.1002/HED.21269]; Andersen AS, 2014, INT J CANCER, V134, P2755, DOI 10.1002/ijc.28411; Baloglu H, 2010, TURK KLIN TIP BILIM, V30, P528, DOI 10.5336/medsci.2008-10230; Burd EM, 2016, CLIN MICROBIOL REV, V29, P291, DOI 10.1128/CMR.00013-15; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen RW, 2005, J CLIN MICROBIOL, V43, P1408, DOI 10.1128/JCM.43.3.1408-1410.2005; Chung CH, 2014, ORAL ONCOL, V50, P364, DOI 10.1016/j.oraloncology.2013.09.003; Cockerill CC, 2016, DIAGN MICR INFEC DIS, V86, P365, DOI 10.1016/j.diagmicrobio.2016.08.014; Combes JD, 2017, ORAL ONCOL, V66, P52, DOI 10.1016/j.oraloncology.2017.01.001; Czegledy Judit, 2001, Acta Microbiologica et Immunologica Hungarica, V48, P511; Duray A, 2011, OTOLARYNG HEAD NECK, V145, P230, DOI 10.1177/0194599811402944; Ernster JA, 2009, ARCH OTOLARYNGOL, V135, P554, DOI 10.1001/archoto.2009.49; Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101; Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2; Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149; Hahn HS, 2013, EUR J OBSTET GYN R B, V169, P202, DOI 10.1016/j.ejogrb.2013.02.024; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Ilmarinen T, 2017, ORAL ONCOL, V73, P77, DOI 10.1016/j.oraloncology.2017.08.010; Kim SH, 2007, INT J CANCER, V120, P1418, DOI 10.1002/ijc.22464; Komarov I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092409; Koskimaa HM, 2012, J PEDIATR-US, V160, P837, DOI 10.1016/j.jpeds.2011.10.027; Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738; Kreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682; Kreimer AR, 2010, SEX TRANSM DIS, V37, P386, DOI 10.1097/OLQ.0b013e3181c94a3b; Loya A, 2016, CANCERS, V8, DOI 10.3390/cancers8080072; Lu BB, 2012, CANCER EPIDEM BIOMAR, V21, P1542, DOI 10.1158/1055-9965.EPI-12-0483; Mammas IN, 2006, PEDIATR INFECT DIS J, V25, P1158, DOI 10.1097/01.inf.0000245094.15643.8c; Marques AEM, 2015, J ORAL PATHOL MED, V44, P453, DOI 10.1111/jop.12252; Marques AEM, 2013, PATHOL RES PRACT, V209, P291, DOI 10.1016/j.prp.2013.02.011; Miller DL, 2012, BIOCHEM J, V443, P339, DOI 10.1042/BJ20112017; Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1; Palmer E, 2014, INT J CANCER, V135, P2437, DOI 10.1002/ijc.28886; Ribeiro Kátia Moreira Xavier, 2006, Braz J Infect Dis, V10, P165, DOI 10.1590/S1413-86702006000300002; Rieth KKS, 2018, JAMA OTOLARYNGOL, V144, P231, DOI 10.1001/jamaoto.2017.2916; Rossi PG, 2016, CANCER CYTOPATHOL, V124, P66, DOI 10.1002/cncy.21622; Rusan M, 2015, EUR ARCH OTO-RHINO-L, V272, P2505, DOI 10.1007/s00405-014-3225-x; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Shah W, 2009, CLIN ONCOL-UK, V21, P768, DOI 10.1016/j.clon.2009.09.003; Sisk J, 2006, LARYNGOSCOPE, V116, P1372, DOI 10.1097/01.mlg.0000225973.21736.bc; Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.04.002, 10.1016/j.ygyno.2010.01.024]; Stokes A, 2012, J CLIN PATHOL, V65, P283, DOI 10.1136/jclinpath-2011-200454; Strome SE, 2002, CLIN CANCER RES, V8, P1093; Sun Yue-feng, 2012, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V47, P974; Syrjanen S, 2004, J CLIN PATHOL, V57, P449, DOI 10.1136/jcp.2003.008656; Xue XC, 2014, J MED VIROL, V86, P963, DOI 10.1002/jmv.23894; Yin Y, 2017, LANCET, V390, P1735, DOI 10.1016/S0140-6736(17)32606-5; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690	48	0	0	3	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1713	1718		10.1016/j.prp.2018.08.032			6	Pathology	Pathology	GY0SD	WOS:000448231000029	30217437				2019-10-28	
J	Li, J; Zhou, T; Liu, L; Ju, YC; Chen, YT; Tan, ZR; Wang, J				Li, Jie; Zhou, Tao; Liu, Liang; Ju, Ying Chao; Chen, Yue Tong; Tan, Zi Rui; Wang, Jing			The regulatory role of Annexin 3 in a nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						ANXA3; Breast cancer; Cell proliferation; Nude mice; Transplanted tumor	RNA INTERFERENCE; CANCER MORTALITY; TUMOR-CELL; A3; EXPRESSION; DOXORUBICIN; BINDING; TARGET; GROWTH	The following study investigated the effects of Annexin A3 (ANXA3) on breast cancer biological behavior in vivo, using nude mouse model bearing a subcutaneous tumor. A total of 18 female nude mice were randomly divided into three groups (n = 6): negative control group which was inoculated with MDA-MB-231 cells, blank control group which was inoculated with MDA-MB-231-NC cells, and the transfection group which was inoculated with MDA-MB-231-Sh cells. The experiment lasted for 4 weeks, during which mice conditions, diet and defecation were monitored on a daily basis. Body weight, as well as tumor diameters, which were assessed using standard caliper method, were measured once a week. In vivo imaging was performed to detect the activity of transplanted tumors. H&E staining was used to analyze the histological structure of tumor tissues in three groups, while flow cytometry and fluorescent RT-PCR were performed to measure cell proliferation and the expression of ANXA3 mRNA. Briefly, significantly slower tumor growth and tumor activity were observed in the transfection group compared to negative and blank controls, while the tumor weight and volume in this group were also significantly lower compared to the other two groups (P < 0.01). Sparse tumor cells accompanied with massive fibrous connective tissue proliferation, and lower new blood vessels formation were observed in transfection group compared to other groups. Moreover, mRNA and protein levels of ANXA3 were significantly lower in transfection group compared to the other two groups (P < 0.01). In addition, lower proliferation index and higher G(0/1) cell count were observed in transfection group compared to negative and blank controls (P < 0.01). To sum up, these results suggested that ANXA3 silencing regulates the proliferation and inhibits the growth of MDA-MB-231 breast cancer cells. Consequently, ANXA3 might be used as a potential target for gene therapy in breast cancer.	[Li, Jie; Tan, Zi Rui] Hebei Med Univ, Hosp 4, Div Med Affairs, Shijiazhuang 050011, Hebei, Peoples R China; [Zhou, Tao] Hebei Med Univ, Hosp 4, Breast Dis Ctr, Shijiazhuang 050011, Hebei, Peoples R China; [Liu, Liang; Chen, Yue Tong; Wang, Jing] Hebei Med Univ, Hosp 4, Tumor Inst, Shijiazhuang 050011, Hebei, Peoples R China; [Ju, Ying Chao] Hebei Med Univ, Hosp 4, Ctr Expt Anim, Shijiazhuang 050011, Hebei, Peoples R China	Liu, L (reprint author), Hebei Med Univ, Hosp 4, Tumor Inst, Shijiazhuang 050011, Hebei, Peoples R China.	aliangdaziran@163.com					Alam S, 2014, CANCER BIOL THER, V15, P1013, DOI 10.4161/cbt.29172; Amadou A, 2014, SALUD PUBLICA MEXICO, V56, P547; Beysebayev Eldar, 2015, Asian Pac J Cancer Prev, V16, P6795; CHEN JM, 1993, J BIOMOL STRUCT DYN, V10, P1067, DOI 10.1080/07391102.1993.10508696; Du RK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0143-z; Ekwueme DU, 2014, AM J PREV MED, V46, P71, DOI 10.1016/j.amepre.2013.08.016; Ewens A, 2006, CANCER RES, V66, P5419, DOI 10.1158/0008-5472.CAN-05-3963; Kluthcovsky ACGC, 2014, REV ASSOC MED BRAS, V60, P387, DOI 10.1590/1806-9282.60.04.019; Haslam Sandra Z, 2005, Breast Dis, V24, P71; Hofmann A, 2000, BIOCHEMISTRY-US, V39, P7712, DOI 10.1021/bi992359+; Hokaiwado N, 2008, IDRUGS, V11, P274; Imoukhuede PI, 2014, CANCER MED-US, V3, P225, DOI 10.1002/cam4.188; Ito H, 2016, BREAST CANCER-TOKYO, V23, P33, DOI 10.1007/s12282-015-0609-8; Jones LW, 2005, CLIN CANCER RES, V11, P6695, DOI 10.1158/1078-0432.CCR-05-0844; Karkare S, 2004, APPL BIOCHEM BIOTECH, V119, P1, DOI 10.1385/ABAB:119:1:01; Kim JY, 2018, CLIN BREAST CANCER, V18, pE713, DOI 10.1016/j.clbc.2017.11.009; Kollerrmann J, 2008, EUR UROL, V54, P1314, DOI 10.1016/j.eururo.2008.01.001; KOHLER BA, 2015, JNCI J NATL CANCER I, V107, DOI DOI 10.1093/JNCI/DJV048; Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004; Li CS, 2014, CANCER BIOL THER, V15, P443, DOI 10.4161/cbt.27825; Liu YF, 2009, J PATHOL, V217, P54, DOI 10.1002/path.2429; Liu YF, 2016, ANAL CELL PATHOL, DOI 10.1155/2016/4131403; Metildi CA, 2014, J SURG ONCOL, V109, P451, DOI 10.1002/jso.23507; Okal A, 2014, GENE THER, V21, P903, DOI 10.1038/gt.2014.70; Pan QZ, 2015, MOL CARCINOGEN, V54, P598, DOI 10.1002/mc.22126; Pan QZ, 2015, STEM CELLS, V33, P354, DOI 10.1002/stem.1850; Qu Y, 2015, CELL BIOCHEM FUNCT, V33, P320, DOI 10.1002/cbf.3117; Shi XJ, 2014, ASIAN PAC J CANCER P, V15, P2785, DOI 10.7314/APJCP.2014.15.6.2785; Sopkova J, 2002, PROTEIN SCI, V11, P1613, DOI 10.1110/ps.4230102; Storvold Gro Leite, 2006, Critical Reviews in Oncogenesis, V12, P127; Tong M, 2015, STEM CELL REP, V5, P45, DOI 10.1016/j.stemcr.2015.05.013; Wang K, 2016, ONCOTARGET, V7, P86972, DOI 10.18632/oncotarget.13493; Yang Q, 2018, ONCOTARGET, V9, P3996, DOI 10.18632/oncotarget.23583; Zhou T, 2017, ONCOL REP, V37, P388, DOI 10.3892/or.2016.5251	34	1	1	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1719	1725		10.1016/j.prp.2018.09.009			7	Pathology	Pathology	GY0SD	WOS:000448231000030	30236487				2019-10-28	
J	Baniak, N; Adams, S; Chibbar, R; Lee, CH; Kanthan, R				Baniak, Nick; Adams, Scott; Chibbar, Rajni; Lee, Cheng-Han; Kanthan, Rani			Hepatic endometrial stromal sarcoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Endometrial stromal sarcoma; Extra-pelvic; Metastases; JAZF1-SUZ12 rearrangement	CLINICOPATHOLOGICAL FEATURES; YWHAE-FAM22 REARRANGEMENT; GRADE; METASTASIS; LUNG; TUMOR	Endometrial stromal sarcomas are rare tumors that may recur or metastasize many years after their initial presentation. Though most recurrences are within the pelvis, distant metastases can occur, and are most common to the lungs. Metastases to the liver are extremely rare. Herein we report two cases of endometrial stromal sarcoma with metastases to the liver without a prior history of endometriosis, accompanied by their histology, immunohistochemistry, and molecular analysis in the context of a relevant literature review.	[Baniak, Nick; Chibbar, Rajni; Kanthan, Rani] Univ Saskatchewan, Coll Med, Dept Pathol & Lab Med, Saskatoon, SK, Canada; [Adams, Scott] Univ Saskatchewan, Coll Med, Dept Med Imaging, Saskatoon, SK, Canada; [Lee, Cheng-Han] BC Canc Agcy, Dept Pathol, Vancouver, BC, Canada	Baniak, N (reprint author), Univ Saskatchewan, Dept Pathol & Lab Med, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.	nmb509@mail.usask.ca; scott.adams@usask.ca; rajni.chibbar@saskhealthauthority.ca; chlee2@ualberta.ca; Rani.Kanthan@saskhealthauthority.ca					Akhavan A, 2012, BMJ CASE REP, V2012, P17; Alessandrini L, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0627-2; Asada Y, 2005, WORLD J GASTROENTERO, V11, P2367, DOI 10.3748/wjg.v11.i15.2367; Aubry MC, 2002, AM J SURG PATHOL, V26, P440, DOI 10.1097/00000478-200204000-00005; BAGGISH MS, 1972, OBSTET GYNECOL, V40, P487; Baker P, 2007, J CLIN PATHOL, V60, P235, DOI 10.1136/jcp.2005.031203; Batista LM, 2011, SURG ONCOL, V20, pE78, DOI 10.1016/j.suronc.2010.10.006; Centeno Barbara A, 2006, Cancer Control, V13, P13; CHANG KL, 1993, INT J GYNECOL PATHOL, V12, P282, DOI 10.1097/00004347-199310000-00002; Chu MC, 2003, GYNECOL ONCOL, V90, P170, DOI 10.1016/S0090-8258(03)00258-0; Cui R, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006584; Gunhan-Bilgen I, 2002, EUR RADIOL, V12, P3023, DOI 10.1007/s00330-001-1294-x; Huang CH, 2015, INT J CLIN EXP PATHO, V8, P967; Inayama Y, 2000, PATHOL RES PRACT, V196, P129, DOI 10.1016/S0344-0338(00)80045-X; Khan A W, 2002, HPB (Oxford), V4, P43, DOI 10.1080/136518202753598735; Kruse AJ, 2014, INT J GYNECOL CANCER, V24, P1616, DOI 10.1097/IGC.0000000000000278; Kunlun R. J., 2014, WHO CLASSIFICATION T, V6; Lauchlan S C, 1972, Obstet Gynecol Surv, V27, P133, DOI 10.1097/00006254-197203000-00001; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Masand RP, 2013, AM J SURG PATHOL, V37, P1635, DOI 10.1097/PAS.0000000000000083; Matsuura Y, 2004, GYNECOL ONCOL, V92, P995, DOI 10.1016/j.ygyno.2003.11.047; Morrison Carl, 2002, Ann Diagn Pathol, V6, P312, DOI 10.1053/adpa.2002.35746; Nakamura Yusuke, 2013, Tokai J Exp Clin Med, V38, P142; Park JY, 2013, HISTOPATHOLOGY, V63, P833, DOI 10.1111/his.12232; Ramia JM, 2012, WORLD J HEPATOL, V4, P415, DOI 10.4254/wjh.v4.i12.415; Thomas MB, 2009, INT J GYNECOL CANCER, V19, P253, DOI 10.1111/IGC.0b013e3181999c5f; Tian W, 2014, AM J SURG PATHOL, V38, P982, DOI 10.1097/PAS.0000000000000214; Yokosuka K, 2002, SOUTHERN MED J, V95, P1196	30	1	1	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1726	1731		10.1016/j.prp.2018.05.008			6	Pathology	Pathology	GY0SD	WOS:000448231000031	29843927				2019-10-28	
J	Carney, JM; Wang, L; Bentley, R; Cardona, DM; Zhang, XF				Carney, John M.; Wang, Lin; Bentley, Rex; Cardona, Diana M.; Zhang, Xuefeng			Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Pseudoangiosarcomatous; Squamous cell carcinoma; Angiosarcoma; Metastasis	TISSUE MICROARRAY; ANGIOSARCOMA; TUMORS; ANTIBODY; LESION; SKIN; P63	Squamous cell carcinoma with pseudoangiosarcomatous features is a rare but well-recognized variant of squamous cell carcinoma. These tumors exhibit complex anastomosing channels lined by neoplastic cells, histologically mimicking a vasoformative mesenchymal tumor. Immunohistochemically, the published cases expressed epithelial markers and were consistently negative for vascular markers. Squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers has never been reported. Herein, we report two cases of metastatic poorly-differentiated squamous cell carcinoma with pseudoangiosarcomatous morphologic features which showed immunoreactivity for vascular markers (CD31, Fli-1, and ERG). One case (left thigh skin squamous cell carcinoma with abdominal wall metastasis) showed strong and diffuse positivity for vascular markers, and the final diagnosis was confirmed with electron microscopy. The second case (squamous cell carcinoma of unknown primary site with bone metastasis) showed patchy positivity for both squamous and vascular markers. This is the first report of squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers, which resembles angiosarcoma both morphologically and immunohistochemically, and may represent a potential diagnostic pitfall. It is of crucial importance for pathologists to be aware of metastatic squamous cell carcinoma with such unique features, so that misdiagnosis and inappropriate treatment will be avoided.	[Carney, John M.; Bentley, Rex; Cardona, Diana M.; Zhang, Xuefeng] Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA; [Wang, Lin] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol, New York, NY USA	Zhang, XF (reprint author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	John.carney@dm.duke.edu; linwang240@gmail.com; Rex.bentley@duke.edu; Diana.cardona@duke.edu; Xuefeng.Zhang@duke.edu					BANERJEE SS, 1992, HISTOPATHOLOGY, V21, P13; Conde-Taboada A, 2005, AM J DERMATOPATH, V27, P142, DOI 10.1097/01.dad.0000145675.95549.f5; De Young BR, 1998, AM J CLIN PATHOL, V110, P374, DOI 10.1093/ajcp/110.3.374; Driemel Oliver, 2008, Head Face Med, V4, P17, DOI 10.1186/1746-160X-4-17; Horie Y, 1999, PATHOL INT, V49, P170, DOI 10.1046/j.1440-1827.1999.00841.x; Jo VY, 2011, AM J CLIN PATHOL, V136, P762, DOI 10.1309/AJCPXNUC7JZSKWEU; Kallen ME, 2012, PATHOL ONCOL RES, V18, P97, DOI 10.1007/s12253-011-9426-3; Koh Sung Hoon, 2014, Burns, V40, pe47, DOI 10.1016/j.burns.2014.02.019; Lin XY, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-118; Matoso A, 2015, AM J SURG PATHOL, V39, P1377, DOI 10.1097/PAS.0000000000000444; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P694, DOI 10.1136/jcp.2006.039230; Miettinen M, 2000, HUM PATHOL, V31, P1062, DOI 10.1053/hupa.2000.9843; MILCHGRUB S, 1991, CANCER-AM CANCER SOC, V67, P3087, DOI 10.1002/1097-0142(19910615)67:12<3087::AID-CNCR2820671225>3.0.CO;2-D; NAPPI O, 1992, AM J SURG PATHOL, V16, P429, DOI 10.1097/00000478-199205000-00001; NAPPI O, 1994, HUM PATHOL, V25, P373, DOI 10.1016/0046-8177(94)90145-7; Rao P, 2013, AM J DERMATOPATH, V35, P432, DOI 10.1097/DAD.0b013e318271295a; Yaskiv O, 2012, AM J CLIN PATHOL, V138, P803, DOI 10.1309/AJCP3K5VUFALZTKC; Zidar N, 2006, J CLIN PATHOL, V59, P1206, DOI 10.1136/jcp.2005.029553	18	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1732	1737		10.1016/j.prp.2018.06.006			6	Pathology	Pathology	GY0SD	WOS:000448231000032	29933892				2019-10-28	
J	Yang, LH; Ingersoll, K; Zhao, Y; Luedke, C; Sebastian, S; Wang, ED				Yang, Lian-He; Ingersoll, Kimberly; Zhao, Yue; Luedke, Catherine; Sebastian, Siby; Wang, Endi			CD3-positive diffuse large B-cell lymphoma relapses as CD3-negative large B-cell lymphoma: Loss of aberrant antigen expression in B-cell lymphoma after chemotherapy	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Diffuse large B-cell lymphoma; CD3; Aberrant expression; Antigen loss; Relapse	PYOTHORAX-ASSOCIATED LYMPHOMA; OF-THE-LITERATURE; T-CELL; GENE REARRANGEMENTS; DIAGNOSTIC PITFALL; MARKER EXPRESSION; CD3; NEOPLASMS; CLASSIFICATION; PHENOTYPE	Aberrant expression of CD3 on diffuse large B-cell lymphoma (DLBCL) is rare, and its mechanism and biological significance are currently unclear. Herein we report a case of Epstein-Barr virus-negative, CD3-positive DLBCL in a 53 year-old male, who had a remote history of renal transplantation. After standard chemotherapy, the patient was in clinical remission. He relapsed three years later, but at this time with apparent loss of CD3 expression. PCR-based IGK gene rearrangement studies demonstrated clonal amplicons with an identical nucleotide size between the primary and secondary DLBCL, confirming the clonal relationship despite their phenotypic differences. To our knowledge, this is the first case of CD3-positive DLBCL that demonstrated a loss of aberrant CD3 on relapse. The chronologic change in phenotype seen in this case suggests that the source of the patient's lymphoma relapse may arise from either a quiescent subclone without CD3 expression, or from an upstream neoplastic precursor cell.	[Yang, Lian-He; Zhao, Yue] China Med Univ, Coll Basic Sci, Affiliated Hosp 1, Dept Pathol, Shenyang 110013, Liaoning, Peoples R China; [Yang, Lian-He; Ingersoll, Kimberly; Zhao, Yue; Luedke, Catherine; Sebastian, Siby; Wang, Endi] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA	Wang, ED (reprint author), Duke Hosp South, Dept Pathol, DUMC Box 3712,M-345 Davison Bldg Green Zone, Durham, NC 27710 USA.	endi.wang@duke.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81301930]; General project of Education Department of Liaoning Province [L2015595]; Students' Innovation and Entrepreneurship Training Program [201610159000036]	This study was supported by National Natural Science Foundation of China (Grant No. 81301930 to L.-H. Yang), General project of Education Department of Liaoning Province (Grant No. L2015595 to L.-H. Yang), and Students' Innovation and Entrepreneurship Training Program (Grant No. 201610159000036 to L.-H. Yang). We thank Steven Colon in Department of Pathology, Duke University Medical Center for his assistance in the figure illustration of this manuscript.	ALSAATI T, 1992, BLOOD, V80, P209; Beaty MW, 1999, AM J SURG PATHOL, V23, P992, DOI 10.1097/00000478-199908000-00023; Ferry JA, 2018, ADV ANAT PATHOL, V25, P14, DOI 10.1097/PAP.0000000000000174; HARRIS NL, 1994, BLOOD, V84, P1361; HOLLINGSWORTH HC, 1994, AM J SURG PATHOL, V18, P1092, DOI 10.1097/00000478-199411000-00003; Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007; Lee M, 2013, BLOOD RES, V48, P156, DOI 10.5045/br.2013.48.2.156; Lombardo KA, 2017, BLOOD ADV, V1, P535, DOI 10.1182/bloodadvances.2016000794; Luo XD, 2016, PATHOLOGY, V48, P378, DOI 10.1016/j.pathol.2016.02.019; McClure RF, 2006, LEUKEMIA, V20, P176, DOI 10.1038/sj.leu.2404049; Mori N, 1996, AM J SURG PATHOL, V20, P760, DOI 10.1097/00000478-199606000-00015; Oliveira JL, 2012, AM J SURG PATHOL, V36, P1364, DOI 10.1097/PAS.0b013e31825e63a9; Pan ZG, 2018, MODERN PATHOL, V31, P718, DOI 10.1038/modpathol.2017.177; Payne K, 2011, BRIT J HAEMATOL, V155, P84, DOI 10.1111/j.1365-2141.2011.08803.x; Petitjean B, 2002, AM J SURG PATHOL, V26, P724, DOI 10.1097/01.PAS.0000015151.82934.6F; Sun JL, 2011, PATHOLOGY, V43, P54, DOI 10.1097/PAT.0b013e328340bbba; Suzuki Y., 2010, INTERN MED, V49; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tagawa H, 2005, BLOOD, V106, P1770, DOI 10.1182/blood-2005-02-0542; Tsuyama N, 2017, ONCOTARGET, V8, P33487, DOI 10.18632/oncotarget.16532; Wallentine JC, 2009, J PEDIAT HEMATOL ONC, V31, P124, DOI 10.1097/MPH.0b013e31818b354a; Wang E, 2010, INT J HEMATOL, V91, P509, DOI 10.1007/s12185-010-0501-4; Wang J, 2009, AM J SURG PATHOL, V33, P505, DOI 10.1097/PAS.0b013e318185d231; Went P, 2006, J CLIN ONCOL, V24, P2472, DOI 10.1200/JCO.2005.03.6327; Wu B, 2017, AM J CLIN PATHOL, V148, P136, DOI [10.1093/AJCP/AQX055, 10.1093/ajcp/aqx055]; Wu B, 2016, ANN HEMATOL, V95, P1671, DOI 10.1007/s00277-016-2749-0	26	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1738	1744		10.1016/j.prp.2018.07.003			7	Pathology	Pathology	GY0SD	WOS:000448231000033	30025593				2019-10-28	
J	Motta, F; Puzzo, L; Regis, F; Morgia, G; Magro, G				Motta, Fabio; Puzzo, Lidia; Regis, Federica; Morgia, Giuseppe; Magro, Gaetano			Mixofibrosarcoma of the kidney: An unusual site for a common soft tissue tumor	PATHOLOGY RESEARCH AND PRACTICE			English	Letter							MYXOFIBROSARCOMA		[Motta, Fabio; Puzzo, Lidia; Magro, Gaetano] Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, Dept Med & Surg Sci & Adv Technol, GF Ingrassia,Anat Pathol Sect,Sch Med, I-95131 Catania, Italy; [Regis, Federica; Morgia, Giuseppe] Univ Catania, Dept Surg, Urol Sect, Catania, Italy	Magro, G (reprint author), Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, Dept Med & Surg Sci & Adv Technol, GF Ingrassia,Anat Pathol Sect,Sch Med, I-95131 Catania, Italy.	g.magro@unict.it		Magro, Gaetano Giuseppe/0000-0003-3244-6827; motta, fabio/0000-0002-9034-6958			ANGERVALL L, 1977, ACTA PATH MICRO IM A, V85, P127; GRIGNON DJ, 1990, CANCER, V65, P1611, DOI 10.1002/1097-0142(19900401)65:7<1611::AID-CNCR2820650727>3.0.CO;2-G; Mentzel T., 2013, WHO CLASSIFICATION T, P93; Rosai J, 2003, SEMIN DIAGN PATHOL, V20, P247, DOI 10.1053/S0740-2570(03)00063-7; Val-Bernal JF, 2015, PATHOL RES PRACT, V211, P619, DOI 10.1016/j.prp.2015.04.004; Weiss S.W., 2008, ENZINGER WEISSS SOFT, P312	6	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	OCT	2018	214	10					1745	1746		10.1016/j.prp.2018.07.012			2	Pathology	Pathology	GY0SD	WOS:000448231000034	30078470				2019-10-28	
J	Shin, S; Park, HC; Kim, MS; Han, MR; Lee, SH; Jung, SH; Lee, SH; Chung, YJ				Shin, Sun; Park, Hyeon-Chun; Kim, Min Sung; Han, Mi-Ryung; Lee, Sung Hak; Jung, Seung Hyun; Lee, Sug Hyung; Chung, Yeun-Jun			Whole-exome sequencing identified mutational profiles of squamous cell carcinomas of anus	HUMAN PATHOLOGY			English	Article						Anus; Cancer; Squamous cell carcinoma; Mutation signature; Whole-exome sequencing; Copy number alteration	ANAL CANCER; HUMAN-PAPILLOMAVIRUS; COPY NUMBER; METAANALYSIS; EXPRESSION; SIGNATURES; LANDSCAPE; NEOPLASIA; HEAD; EGFR	Anal squamous cell carcinoma (ASCC), either with human papillomavirus (+) or (-), is a neoplastic disease with frequent recurrence and metastasis. To characterize ASCC genomes, we attempted to disclose novel alterations of ASCC genomes and other genetic features including mutation signatures. We performed whole-exome sequencing and copy number alteration (CNA) profiling for 8 ASCC samples from 6 patients (2 cases with primary and recurrent/metastatic tumors). We found known ASCC mutations (TP53, CDKN2A, and PIK3CA) and CNAs (gains on 3q and 19q and losses on 11q and 13q). In addition, we discovered novel mutations in HRAS and ARID1A and CNAs (gain on 8q and losses 5q, 9p, 10q, and 19p) that had not been reported in ASCCs. We identified 4 signature patterns of the mutations (signatures 1 and 2 with deamination of 5-methyl-cytosin, signature 3 with APOBEC, and signature 4 with mismatch repair) in the ASCCs. Although signatures 1 to 3 have been detected in other SCCs, signature 4 was first identified in ASCCs. In addition, we first found that ASCCs harbored chromothripsis, copy-neutral losses of heterozygosity, and focal amplification of KLF5 super-enhancer. Analyses of primary and recurrent/metastatic pair genomes revealed that driver events in development and progression of ASCC might not be uniform. Our data indicate that ASCCs may have similar mutation and CNA profiles to other SCCs, but that there are unique genomic features of ASCCs as well. Our data may provide useful information for ASCC pathogenesis and for developing clinical strategies for ASCC. (C) 2018 Elsevier Inc. All rights reserved.	[Shin, Sun; Chung, Yeun-Jun] Catholic Univ Korea, Dept Microbiol, Seoul 06591, South Korea; [Shin, Sun; Park, Hyeon-Chun; Han, Mi-Ryung; Jung, Seung Hyun; Chung, Yeun-Jun] Catholic Univ Korea, Integrated Res Ctr Genome Polymorphism, Seoul 06591, South Korea; [Shin, Sun; Park, Hyeon-Chun; Han, Mi-Ryung; Jung, Seung Hyun; Lee, Sug Hyung; Chung, Yeun-Jun] Catholic Univ Korea, Precis Med Res Ctr, Seoul 06591, South Korea; [Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Seoul 06591, South Korea; [Kim, Min Sung; Jung, Seung Hyun; Lee, Sug Hyung; Chung, Yeun-Jun] Catholic Univ Korea, Canc Evolut Res Ctr, Seoul 06591, South Korea; [Lee, Sung Hak] Catholic Univ Korea, Dept Hosp Pathol, Seoul 06591, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 222 Banpo Daero, Seoul 06591, South Korea.; Chung, YJ (reprint author), Catholic Univ Korea, Coll Med, Dept Microbiol, 222 Banpo Daero, Seoul 06591, South Korea.	suhulee@catholic.ac.kr; yejun@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2012R1A5A2047939, 2017R1D1A1B03027840, 2017R1E1A1A01074913]	This study was supported by grants from the National Research Foundation of Korea (2012R1A5A2047939, 2017R1D1A1B03027840, and 2017R1E1A1A01074913).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bernardi MP, 2015, LANCET ONCOL, V16, pE611, DOI 10.1016/S1470-2045(15)00292-2; Cacheux W, 2016, BRIT J CANCER, V114, P1387, DOI 10.1038/bjc.2016.144; Chung JH, 2016, ANN ONCOL, V27, P1336, DOI 10.1093/annonc/mdw152; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; De Schutter H, 2007, EUR J HUM GENET, V15, P734, DOI 10.1038/sj.ejhg.5201845; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Elorza Garazi, 2016, Rev. esp. enferm. dig., V108, P31; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Forment JV, 2012, NAT REV CANCER, V12, P663, DOI 10.1038/nrc3352; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Garcia-Alcalde F, 2012, BIOINFORMATICS, V28, P2678, DOI 10.1093/bioinformatics/bts503; Gehring JS, 2015, BIOINFORMATICS, V31, P3673, DOI 10.1093/bioinformatics/btv408; Heselmeyer K, 1997, BRIT J CANCER, V76, P1271, DOI 10.1038/bjc.1997.547; Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263; Johnson LG, 2004, CANCER-AM CANCER SOC, V101, P281, DOI 10.1002/cncr.20364; Jones CM, 2017, BRIT J CANCER, V116, P156, DOI 10.1038/bjc.2016.398; Kim TM, 2014, J PATHOL, V234, P365, DOI 10.1002/path.4401; Kuglik P, 2014, INT J CLIN EXP PATHO, V7, P5071; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Martin V, 2014, HISTOL HISTOPATHOL, V29, P513, DOI 10.14670/HH-29.10.513; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mouw KW, 2017, CLIN CANCER RES, V23, P3214, DOI 10.1158/1078-0432.CCR-16-2017; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Paliga A, 2012, BRIT J CANCER, V107, P1864, DOI 10.1038/bjc.2012.479; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Reed E, 2005, CLIN CANCER RES, V11, P6100, DOI 10.1158/1078-0432.CCR-05-1083; Rousseau DL, 2005, SURG ONCOL, V14, P121, DOI 10.1016/j.suronc.2005.07.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomas LK, 2014, EUR J CANCER, V50, P85, DOI 10.1016/j.ejca.2013.08.022; Trietsch MD, 2014, GYNECOL ONCOL, V135, P149, DOI 10.1016/j.ygyno.2014.07.094; Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470	37	1	1	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						1	10		10.1016/j.humpath.2018.03.008			10	Pathology	Pathology	GX5US	WOS:000447817100001	29555573				2019-10-28	
J	Prat, J; D'Angelo, E; Espinosa, I				Prat, Jaime; D'Angelo, Emanuela; Espinosa, Inigo			Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics	HUMAN PATHOLOGY			English	Article						Ovary; High-grade serous carcinoma; Low-grade serous carcinoma; Mucinous carcinoma; Endometrioid carcinoma; Clear cell carcinoma	GRADE SEROUS CARCINOMA; CLEAR-CELL CARCINOMA; TUBAL INTRAEPITHELIAL CARCINOMA; TERM-FOLLOW-UP; BORDERLINE TUMORS; FALLOPIAN-TUBE; CLINICOPATHOLOGICAL ANALYSIS; MUCINOUS TUMORS; BRAF MUTATION; MICROSATELLITE INSTABILITY	Based on histopathology and molecular genetics, ovarian carcinomas are divided into five main types: high-grade serous (70%), endometrioid (10%), clear cell (10%), mutinous (3%), and low-grade serous (<5%) carcinomas. These tumors, which account for over 95% of cases, represent distinct diseases with different prognoses and treatments. TP53 mutations are identified in almost all (96%) high-grade serous carcinomas (HGSCs). Early p53 loss followed by BRCA loss leads to deficiency in homologous recombination (DHR) repair, which in turn triggers chromosomal instability and widespread somatic copy number changes. An undetermined number of cases of HGSCs originate in the tubal fimbria; however, an origin from the ovarian surface epithelium cannot be totally excluded. Low-grade serous carcinomas (LGSCs) most likely represent progression of SBTs. BRAF or KRAS mutations occur in one-third to one-half of cases. Mucinous carcinomas (MCs) typically show benign-appearing, borderline, non-invasive and invasive components indicating tumor progression. KRAS mutations occur in 43.6% of cases and overexpression/amplification of HER2 in 18.8%. Endometrioid and clear cell carcinomas (EC and CCC) originate from ovarian endometriosis. Compared with their uterine counterparts, ECs have a similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability (MI) and PTEN alterations. ARID1A mutations occur in both ECs (30%) and CCCs (50%) and may be encountered in adjacent endometriosis. CCCs carry inactivating PTEN mutations and activating mutations in PIK3CA in 8% and 33% of cases, respectively. This review summarizes recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinomas and are also relevant to patient management. (C) 2018 Elsevier Inc. All rights reserved.	[Prat, Jaime; Espinosa, Inigo] Autonomous Univ Barcelona, Inst Biomed Res IIB St Pau, Hosp Santa Creu & St Pau, Dept Pathol, Barcelona 08041, Spain; [D'Angelo, Emanuela] Univ Aquila, Dept Pathol, Coppito, Italy; [Espinosa, Inigo] Clin Univ Navarra, Dept Pathol, Marquesado Sta Marta 3, Madrid 28022, Spain	Prat, J (reprint author), Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Pathol, St Quitin 87-89, Barcelona 08041, Spain.	jpratdl@gmail.com			Department of Health, Spain [FIS PI16-00902, RTICC RD06/0020/0015]; Fundacion AECC-Grupos Estables; Fondo Europeo de Desarrollo Regional (FEDER)European Union (EU); Instituto de Salud Carlos III, SpainInstituto de Salud Carlos III; Xarxa Banc de Tumors de Catalunya (XBTC)	This work was supported by Grants FIS PI16-00902 and RTICC RD06/0020/0015, Department of Health, Spain, Fundacion AECC-Grupos Estables. Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III, Spain. Tumor samples were obtained with the support of Xarxa Banc de Tumors de Catalunya (XBTC).	Ahn G, 2016, AM J SURG PATHOL, V40, P1165, DOI 10.1097/PAS.0000000000000693; Ali RH, 2012, INT J GYNECOL PATHOL, V31, P499, DOI 10.1097/PGP.0b013e31824d7445; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Anglesio MS, 2013, J PATHOL, V229, P111, DOI 10.1002/path.4088; [Anonymous], 2018, CANC FACTS FIG 2015; Avril S, 2012, GYNECOL ONCOL, V127, P516, DOI 10.1016/j.ygyno.2012.08.027; Back S. J, 2008, J GYNECOL ONCOL, V19, P223; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bell DA, 2004, HUM PATHOL, V35, P934, DOI 10.1016/j.humpath.2004.03.005; Bennett JA, 2015, HISTOPATHOLOGY, V66, P808, DOI 10.1111/his.12514; Bowtell DDL, 2010, NAT REV CANCER, V10, P803, DOI 10.1038/nrc2946; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Catasus L, 2008, MODERN PATHOL, V21, P131, DOI 10.1038/modpathol.3800992; Chan WY, 2000, AM J PATHOL, V156, P409, DOI 10.1016/S0002-9440(10)64744-X; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; Crum CP, 2013, J PATHOL, V231, P402, DOI 10.1002/path.4263; Cuatrecasas M, 2009, AM J SURG PATHOL, V33, P556, DOI 10.1097/PAS.0b013e318188b84c; Dehari R, 2007, AM J SURG PATHOL, V31, P1007, DOI 10.1097/PAS.0b013e31802cbbe9; DelaCuesta RS, 1996, GYNECOL ONCOL, V60, P238, DOI 10.1006/gyno.1996.0032; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Ducie J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01217-9; Emmanuel C, 2014, CLIN CANCER RES, V20, P6618, DOI 10.1158/1078-0432.CCR-14-1292; Espinosa I, 2011, MODERN PATHOL, V24, P846, DOI 10.1038/modpathol.2011.12; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Falconer H, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju410; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Folkins AK, 2013, HISTOPATHOLOGY, V62, P2, DOI 10.1111/his.12028; Geisler JP, 2002, J NATL CANCER I, V94, P61; George J, 2013, CLIN CANCER RES, V19, P3474, DOI 10.1158/1078-0432.CCR-13-0066; Gershenson DM, 2006, OBSTET GYNECOL, V108, P361, DOI 10.1097/01.AOG.0000227787.24587.d1; Gilks CB, 2015, AM J SURG PATHOL, V39, P357, DOI 10.1097/PAS.0000000000000353; Gilks CB, 2009, HUM PATHOL, V40, P1213, DOI 10.1016/j.humpath.2009.04.017; Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3; Grisham RN, 2013, CANCER-AM CANCER SOC, V119, P548, DOI 10.1002/cncr.27782; Guan B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju146; Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Hirst JE, 2009, INT J GYNECOL CANCER, V19, P826, DOI 10.1111/IGC.0b013e3181a1b5dc; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Hoskins PJ, 2012, J CLIN ONCOL, V30, P1656, DOI 10.1200/JCO.2011.40.1646; Howitt BE, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1277308; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jarboe E, 2008, INT J GYNECOL PATHOL, V27, P1, DOI 10.1097/pgp.0b013e31814b191f; Ji JX, 2018, J PATHOL, V244, P550, DOI 10.1002/path.5037; Jiang XX, 1998, CANCER RES, V58, P1707; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Karnezis AN, 2013, AM J SURG PATHOL, V37, P24, DOI 10.1097/PAS.0b013e31826a5399; Kato N, 2006, MODERN PATHOL, V19, P83, DOI 10.1038/modpathol.3800492; Kennedy AW, 1996, CANCER-AM CANCER SOC, V78, P278, DOI 10.1002/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T; Kim J, 2015, ENDOCRINOLOGY, V156, P1975, DOI 10.1210/en.2014-1977; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kobayashi H, 2009, INT J GYNECOL CANCER, V19, P471, DOI 10.1111/IGC.0b013e3181a19eca; Kobel M, 2013, CANCER EPIDEM BIOMAR, V22, P1677, DOI 10.1158/1055-9965.EPI-13-0391; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kobel M, 2009, AM J SURG PATHOL, V33, P14, DOI 10.1097/PAS.0b013e3181788546; Komiyama S, 1999, GYNECOL ONCOL, V72, P342, DOI 10.1006/gyno.1998.5284; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; KOONINGS PP, 1989, OBSTET GYNECOL, V74, P921; Kuhn E, 2010, AM J SURG PATHOL, V34, P829, DOI 10.1097/PAS.0b013e3181dcede7; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Kurman RJ, 2014, WHO CLASSIFICATION T, P11; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kurman RJ, 2016, INT J GYNECOL PATHOL, V35, P78, DOI 10.1097/PGP.0000000000000266; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lee KR, 2000, AM J SURG PATHOL, V24, P1447, DOI 10.1097/00000478-200011000-00001; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Longacre TA, 2005, AM J SURG PATHOL, V29, P707, DOI 10.1097/01.pas.0000164030.82810.db; Mackenzie R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1421-8; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; McAlpine JN, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2014.01.003; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; MOK SCH, 1993, CANCER RES, V53, P1489; Morrison JC, 2015, AM J SURG PATHOL, V39, P442, DOI 10.1097/PAS.0000000000000352; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Obata K, 1998, CANCER RES, V58, P2095; Onda T, 1998, CANCER, V83, P1555, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R; Palacios J, 1998, CANCER RES, V58, P1344; Park JY, 2011, GYNECOL ONCOL, V123, P511, DOI 10.1016/j.ygyno.2011.08.008; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Powell CB, 2005, J CLIN ONCOL, V23, P127, DOI 10.1200/JCO.2005.04.109; Prat J, 2002, AM J SURG PATHOL, V26, P1111, DOI 10.1097/01.PAS.0000022626.38542.66; Prat J., 2004, PATHOLOGY OVARY, P83; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Provenza C, 2008, AM J SURG PATHOL, V32, P383, DOI 10.1097/PAS.0b013e3181451b93; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Rabban JT, 2014, AM J SURG PATHOL, V38, P729, DOI 10.1097/PAS.0000000000000199; Rambau PF, 2017, AM J SURG PATHOL, V41, P685, DOI 10.1097/PAS.0000000000000812; Risch HA, 2006, J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Rodriguez IM, 2004, AM J SURG PATHOL, V28, P1311, DOI 10.1097/01.pas.0000138178.10829.b8; Rodriguez IM, 2002, AM J SURG PATHOL, V26, P139, DOI 10.1097/00000478-200202000-00001; Ronnett BM, 2008, AM J SURG PATHOL, V32, P1835, DOI 10.1097/PAS.0b013e3181758831; Rougemont AL, 2018, HUM PATHOL; Sato N, 2000, CANCER RES, V60, P7052; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Scott CL, 2015, J CLIN ONCOL, V33, P1397, DOI 10.1200/JCO.2014.58.8848; Scully RE, 1998, ATLAS TUMOR PATHOL, P27; Shappell HW, 2002, AM J SURG PATHOL, V26, P1529, DOI 10.1097/00000478-200212000-00001; Shvartsman HS, 2007, GYNECOL ONCOL, V105, P625, DOI 10.1016/j.ygyno.2007.01.030; Sieben NL, 2006, J PATHOL, V210, P405, DOI 10.1002/path.2074; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; SILVA EG, 1990, AM J CLIN PATHOL, V93, P457, DOI 10.1093/ajcp/93.4.457; Silverberg SG, 2004, HUM PATHOL, V35, P910, DOI 10.1016/j.humpath.2004.03.003; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Stewart CJR, 2017, HISTOPATHOLOGY, V70, P309, DOI 10.1111/his.13040; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Tan DSP, 2007, J CLIN PATHOL, V60, P355, DOI 10.1136/jcp.2006.040030; Tang SG, 2012, INT J GYNECOL PATHOL, V31, P103, DOI 10.1097/PGP.0b013e31822ea955; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Tsang YT, 2013, J PATHOL, V231, P449, DOI 10.1002/path.4252; Uzan C, 2014, ANN ONCOL, V25, P1312, DOI 10.1093/annonc/mdu139; Vang R, 2006, INT J GYNECOL PATHOL, V25, P83, DOI 10.1097/01.pgp.0000177125.31046.fd; Vang R, 2016, INT J GYNECOL PATHOL, V35, P48, DOI 10.1097/PGP.0000000000000207; Veras E, 2009, AM J SURG PATHOL, V33, P844, DOI 10.1097/PAS.0b013e31819c4271; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Willner J, 2007, HUM PATHOL, V38, P607, DOI 10.1016/j.humpath.2006.10.007; Wong KK, 2010, AM J PATHOL, V177, P1611, DOI 10.2353/ajpath.2010.100212; Yamaguchi K, 2014, INT J CANCER, V135, P585, DOI 10.1002/ijc.28701; Yamamoto S, 2008, J PATHOL, V216, P103, DOI 10.1002/path.2386; Yamamoto S, 2007, AM J SURG PATHOL, V31, P999, DOI 10.1097/01.pas.0000249449.13466.3c; Yamamoto S, 2011, J PATHOL, V225, P189, DOI 10.1002/path.2940; Zeppernick F, 2014, AM J SURG PATHOL, V38, P1603, DOI 10.1097/PAS.0000000000000313; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zuo T, 2018, MODERN PATHOL, V31, P350, DOI 10.1038/modpathol.2017.121	133	10	10	2	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						11	27		10.1016/j.humpath.2018.06.018			17	Pathology	Pathology	GX5US	WOS:000447817100002	29944973				2019-10-28	
J	Kwon, MJ; Rho, YS; Nam, ES; Cho, SJ; Park, HR; Min, SK; Seo, J; Choe, JY; Kim, ES; Park, B; Hong, M; Min, KW				Kwon, Mi Jung; Rho, Young-Soo; Nam, Eun Sook; Cho, Seong Jin; Park, Hye-Rim; Min, Soo Kee; Seo, Jinwon; Choe, Ji-Young; Kim, Eun Soo; Park, Bumjung; Hong, Mineui; Min, Kyueng-Whan			Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition	HUMAN PATHOLOGY			English	Article						Programmed cell death-1 ligand-1; Tonsil; Squamous cell carcinoma; Human papillomavirus; Epithelial-to-mesenchymal transition	PD-L1 EXPRESSION; C-MET; TUMOR; CANCER; PROGNOSIS; HEAD; ANTIBODY; OVEREXPRESSION; METASTASIS; IMPACT	Programmed cell death-1 ligand-1 (PD-L1), essential for immune evasion, is a potential candidate for pathogenesis and therapeutic target of human papillomavirus (HPV)-positive tonsillar squamous cell carcinomas (TSCCs). MET/hepatocyte growth factor signaling and transcription factors involved in epithelial-to-mesenchymal transition (EMT) upregulate PD-L1, which can contribute to clinical outcome. Intratumoral heterogeneity of PD-L1 expression is of clinical importance in selection bias due to false-negative patient enrollment. However, the clinicopathological features, prognostic value, and coexpressed molecules of PD-L1 remain unclear in TSCCs. PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP142) between whole-tissue and tissue microarray (TMA) sections of 79 tumors (5% cutoff value with weak staining). Expressions of EMT markers (TWIST1, Snail, and SNIP1) and MET/hepatocyte growth factor were also analyzed. Staining of the TMA sections showed 78.5% concordance rate to the whole section. PD-L1 positivity and its intratumoral heterogeneity were 29.1% and 15.2% of TSCCs by whole section, respectively. PD-L1 positivity was prevalent in females, HPV-positive tumors without base of tongue invasion, and SNIP1-overexpressed tumors. SNIP1 overexpression, unmethylated TWIST1, smoking, and poorly differentiated tumors were predictive for PD-L1 overexpression. PD-L1 positivity was a favorable independent prognostic factor. Subgroup analyses according to the coexpression of PD-L1 with HPV, SNIP], or unmethylated TWIST1 indicated the best clinical outcome than any other subgroups. In conclusion, intratumoral heterogeneity of PD-L1 expression was frequent, warranting a caution in punching TMA cores. A combined analysis of PD-L1 with EMT and HPV may define a characteristic subset of patients and prognostic group. (C) 2018 The Authors. Published by Elsevier Inc.	[Kwon, Mi Jung; Park, Hye-Rim; Min, Soo Kee; Seo, Jinwon; Choe, Ji-Young] Hallym Univ, Dept Pathol, Sacred Heart Hosp, Coll Med, 22 Gwanpyeong Ro,170beon Gil, Anyang Si 14068, Gyeonggi Do, South Korea; [Kwon, Mi Jung] Hallym Univ, Res Inst Complementary & Alternat Med, Hwaseong 445170, Gyeonggi Do, South Korea; [Rho, Young-Soo] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp,Head & Neck Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg,Ilsong Mem, Seoul 134701, South Korea; [Nam, Eun Sook; Cho, Seong Jin] Hallym Univ, Kangdong Sacred Heart Hosp, Dept Pathol, Coll Med, Seoul 134701, South Korea; [Kim, Eun Soo] Hallym Univ, Dept Radiol, Sacred Heart Hosp, Coll Med, Anyang Si 14068, Gyeonggi Do, South Korea; [Park, Bumjung] Hallym Univ, Dept Otorhinolaryngol Head & Neck surg, Sacred Heart Hosp, Coll Med, Anyang Si 14068, Gyeonggi Do, South Korea; [Hong, Mineui] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Pathol, Coll Med, Seoul 150950, South Korea; [Min, Kyueng-Whan] Hanyang Univ Guri Hosp, Hanyang Univ, Dept Pathol, Coll Med, Guri Si 11923, Gyeonggi Do, South Korea	Kwon, MJ (reprint author), Hallym Univ, Dept Pathol, Sacred Heart Hosp, Coll Med, 22 Gwanpyeong Ro,170beon Gil, Anyang Si 14068, Gyeonggi Do, South Korea.	mulank@hanmail.net			Hallym University Research Fund [HURF-2017-38]; National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2016R1D1A1B03935447]	This research was supported by the Hallym University Research Fund (HURF-2017-38) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1B03935447) to M. J. Kwon.	Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Betiol J, 2013, BRAZ J MED BIOL RES, V46, P217, DOI 10.1590/1414-431X20132703; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chen TC, 2015, ORAL ONCOL, V51, P1004, DOI 10.1016/j.oraloncology.2015.08.011; Cho YA, 2011, ORAL ONCOL, V47, P1148, DOI 10.1016/j.oraloncology.2011.08.007; Chow L.Q.B.B., 2014, ANN ONCOL, V25, P1, DOI DOI 10.1093/ANN0NC/MDU438; Cohan DM, 2009, CURR OPIN OTOLARYNGO, V17, P88, DOI 10.1097/MOO.0b013e32832984c0; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Edge SB, 2010, AJCC CANC STAGING MA, P41, DOI DOI 10.1007/978-0-387-88441-7_4; El Jabbour T, 2018, J CLIN PATHOL, V71, P46, DOI 10.1136/jclinpath-2017-204525; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hong AM, 2016, ONCOTARGET, V7, P77010, DOI 10.18632/oncotarget.12776; Jaber JJ, 2009, ARCH OTOLARYNGOL, V135, P1147, DOI 10.1001/archoto.2009.164; Kim HS, 2016, CANCER RES TREAT, V48, P527, DOI 10.4143/crt.2015.249; Kim R, 2016, WORLD J GASTROENTERO, V22, P8389, DOI 10.3748/wjg.v22.i37.8389; Kogashiwa Y, 2017, ANTICANCER RES, V37, P1417, DOI 10.21873/anticanres.11465; Kwon MJ, 2017, ONCOTARGET, V8, P82399, DOI 10.18632/oncotarget.19390; Kwon MJ, 2017, BIOMED RES INT, DOI 10.1155/2017/1056427; Kwon MJ, 2014, HUM PATHOL, V45, P1327, DOI 10.1016/j.humpath.2014.03.003; Kwon MJ, 2013, HUM PATHOL, V44, P1722, DOI 10.1016/j.humpath.2013.03.004; Lee DJ, 2013, KOREAN J PATHOL, V47, P203, DOI 10.4132/KoreanJPathol.2013.47.3.203; Lim YC, 2006, LARYNGOSCOPE, V116, P1148, DOI 10.1097/01.mlg.0000217543.40027.1d; Lin YK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137890; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Mezache L, 2015, MODERN PATHOL, V28, P1594, DOI 10.1038/modpathol.2015.108; Nakamura S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186192; Ock CY, 2016, ONCOTARGET, V7, P15901, DOI 10.18632/oncotarget.7431; Okada T, 2010, GENE CHROMOSOME CANC, V49, P452, DOI 10.1002/gcc.20755; Oliveira-Costa JP, 2015, ONCOTARGET, V6, P20902, DOI 10.18632/oncotarget.3939; Satgunaseelan L, 2016, PATHOLOGY, V48, P574, DOI 10.1016/j.pathol.2016.07.003; Shin SJ, 2016, ANN SURG ONCOL, V23, P694, DOI 10.1245/s10434-015-4903-7; Slootweg PJ, 2005, WHO CLASSIFICATION T, P166; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Yu GT, 2015, ONCOTARGET, V6, P42067, DOI 10.18632/oncotarget.5955	36	2	2	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						28	39		10.1016/j.humpath.2018.03.025			12	Pathology	Pathology	GX5US	WOS:000447817100003	29634978	Other Gold			2019-10-28	
J	Zhang, CX; Wang, EY; Liu, F; Sung, CJ; Quddus, MR; Ou, J; Lomme, M; Lawrence, WD				Zhang, Cunxian; Wang, Edmond Y.; Liu, Fang; Sung, C. James; Quddus, M. Ruhul; Ou, Joyce; Lomme, Michele; Lawrence, W. Dwayne			Routine histologic features in complex atypical hyperplasia can predict the presence of endometrial carcinoma: a clinicopathological study of 222 cases	HUMAN PATHOLOGY			English	Article						Complex atypical hyperplasia; Endometrial carcinoma; Routine histologic features; Predict; Clinicopathologic study	ADENOCARCINOMA IN-SITU; LONG-TERM; DIAGNOSIS; WOMEN; CURETTAGE; CANCER; RISK	There is a wide range of finding endometrial adenocarcinoma (ADCA) in the uterus after a diagnosis of complex atypical hyperplasia (CAH), likely due to a poor diagnostic reproducibility and an inherent heterogeneity in CAH. We evaluated whether histologic subtyping of CAH would help predict ADCA. Our study consisted of 222 cases of CAH diagnosed by endometrial biopsy or curettage. ADCA was seen in 38.3% of these cases at hysterectomy. We divided CAH into 2 subtypes: type A was defined as back-to-back glands in a focus smaller than 2.1 mm, and type B as crowded glands with cytologic atypia but with still-intervening stroma regardless of lesional size. Type A was associated with a significantly higher frequency of ADCA (75.9%) compared with type B (26.2%). Lesions containing neutrophilic/cellular debris showed a higher association of ADCA (60.0%) compared with those without neutrophilic/cellular debris (35.5%). CAH present outside endometrial polyp was associated with a higher frequency of ADCA (42.5%) than that confined to endometrial polyp (19.5%). Within type B cases, lesions greater than 3 mm had a higher association of ADCA (34.3%) than did smaller ones (13.6%). Patients older than 50 years were more likely to have ADCA in the uterus compared with younger women with a preoperative diagnosis of CAH (43.2% versus 28.3%). CAH made on office biopsy showed a higher association of ADCA (46.6%) compared with a diagnosis made on curettage (31.1%). Recognition of these clinicopathological features in CAH may prove useful in predicting the likelihood of ADCA in the uterus. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Cunxian] Kent Hosp, Dept Pathol, 455 Toll Gate Rd, Warwick, RI 02886 USA; [Zhang, Cunxian; Wang, Edmond Y.; Liu, Fang; Sung, C. James; Quddus, M. Ruhul; Ou, Joyce; Lomme, Michele; Lawrence, W. Dwayne] Women & Infants Hosp Rhode Isl, Dept Pathol, Providence, RI 02905 USA; [Zhang, Cunxian; Liu, Fang; Sung, C. James; Quddus, M. Ruhul; Ou, Joyce; Lomme, Michele; Lawrence, W. Dwayne] Brown Univ, Warren Alpert Med Sch, Dept Pathol, Providence, RI 02912 USA; [Wang, Edmond Y.] Meditech, One Constitut Way, Foxboro, MA 02035 USA; [Liu, Fang] St Vincent Hosp, Worcester Med Ctr, Dept Pathol, 123 Summer St, Worcester, MA 01608 USA	Zhang, CX (reprint author), Kent Hosp, Dept Pathol, 455 Toll Gate Rd, Warwick, RI 02886 USA.	czhang@kentri.org					Antonsen SL, 2012, GYNECOL ONCOL, V125, P124, DOI 10.1016/j.ygyno.2011.12.436; Chen YL, 2009, J FORMOS MED ASSOC, V108, P502, DOI 10.1016/S0929-6646(09)60098-X; Cramer DW, 2012, HEMATOL ONCOL CLIN N, V26, P1, DOI 10.1016/j.hoc.2011.10.009; Dunton CJ, 1996, AM J OBSTET GYNECOL, V174, P1518, DOI 10.1016/S0002-9378(96)70599-9; Emons G, 2015, GEBURTSH FRAUENHEILK, V75, P135, DOI 10.1055/s-0034-1396256; HUNTER JE, 1994, GYNECOL ONCOL, V55, P66, DOI 10.1006/gyno.1994.1249; JANICEK MF, 1994, GYNECOL ONCOL, V52, P373, DOI 10.1006/gyno.1994.1064; KURMAN RJ, 1982, CANCER, V49, P2547, DOI 10.1002/1097-0142(19820615)49:12<2547::AID-CNCR2820491224>3.0.CO;2-0; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Lacey JV, 2010, J CLIN ONCOL, V28, P788, DOI 10.1200/JCO.2009.24.1315; LAMBERT B, 1994, J REPROD MED, V39, P639; Leitao MM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.05.004; McKenney LK, 2009, ADV ANAT PATHOL, V16, P1, DOI 10.1097/PAP.0b013e3181919e15; Mittal K, 2007, INT J GYNECOL PATHOL, V27, P45; Mittal K, 2009, MODERN PATHOL, V22, P37, DOI 10.1038/modpathol.2008.138; Monte NM, 2010, CANCER RES, V70, P6225, DOI 10.1158/0008-5472.CAN-10-0149; Mutter GL, 2008, HUM PATHOL, V39, P866, DOI 10.1016/j.humpath.2007.09.023; Mutter GL, 2000, J PATHOL, V190, P462, DOI 10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D; Mutter GL, 2000, GYNECOL ONCOL, V76, P287, DOI 10.1006/gyno.1999.5580; Orbo A, 2000, J CLIN PATHOL, V53, P697, DOI 10.1136/jcp.53.9.697; Salman MC, 2010, J GYNECOL ONCOL, V21, P97, DOI 10.3802/jgo.2010.21.2.97; Shutter J, 2005, INT J GYNECOL PATHOL, V24, P313, DOI 10.1097/01.pgp.0000164598.26969.c3; Suh-Burgmann E, 2009, OBSTET GYNECOL, V114, P523, DOI 10.1097/AOG.0b013e3181b190d5; Trimble CL, 2006, CANCER-AM CANCER SOC, V106, P812, DOI 10.1002/cncr.21650; Valenzuela P, 2003, GYNECOL OBSTET INVES, V56, P163, DOI 10.1159/000073950; Ventura KC, 2004, INT J SURG PATHOL, V12, P225, DOI 10.1177/106689690401200303; Xie X, 2002, GYNECOL ONCOL, V84, P135, DOI 10.1006/gyno.2001.6476; Zhang CX, 2017, HUM PATHOL, V59, P120, DOI 10.1016/j.humpath.2016.09.021	28	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						40	46		10.1016/j.humpath.2018.03.009			7	Pathology	Pathology	GX5US	WOS:000447817100004	29559235				2019-10-28	
J	Zhang, L; Wang, XHI; Zhang, SL				Zhang, Lin; Wang, Xiaohong, I; Zhang, Songlin			Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer	HUMAN PATHOLOGY			English	Article						Triple-negative breast cancer (TNBC); Pathological complete response (pCR); Residual disease (RD); Neoadjuvant chemotherapy (NACT); Tumor-infiltrating lymphocytes (TILs); Tumor-infiltrating lymphocyte volume (TILV)	PATHOLOGICAL COMPLETE RESPONSE; PROGNOSTIC VALUE; CHEMOTHERAPY; SUBTYPES; TRIAL	Triple-negative breast cancer (TNBC) has an aggressive behavior, limited therapeutic options, and high mortality rate. Neoadjuvant chemotherapy is a standard treatment for TNBC, and patients with pathological complete response (pCR) have a favorable outcome. We conducted a comprehensive evaluation of cancer clinicopathological parameters and correlated these parameters with the pCR rate and the overall survival. Fifty-eight patients with TNBC of no special type who underwent breast biopsy, neoadjuvant therapy, and mastectomy in our institution during 2005-2016 were included in this study. Among the 58 TNBC patients, 26 (45%) achieved pCR, and 32 (55%) had residual disease. The study parameters included age, histologic grade, clinical stage, mitotic count, Ki-67 proliferation index, stromal ratio, stromal type, tumor necrosis, stromal tumor-infiltrating lymphocytes (TILs), tumor intraepithelial lymphocytes, and tumor-infiltrating lymphocytes volume (TILV). Whereas most factors did not affect pCR, stromal TILs and TILV showed significant correlation with pCR (P = .01 and P = .0008, respectively). In the residual disease group, all factors showed no significant differences before and after neoadjuvant chemotherapy, except for tumor sizes. Lastly, pCR, TILs, and TILV were all significantly correlated with the overall survival, with P = .028, .029, and .015, respectively. In summary, we proposed a new concept of TILV to precisely evaluate the tumor immunity, and our data showed that TILV had a better predictive value than TILs for the pCR and the overall survival in TNBC. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Lin; Wang, Xiaohong, I; Zhang, Songlin] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, Houston, TX 77030 USA	Zhang, SL (reprint author), 6431 Fannin St MSB 2-216, Houston, TX 77030 USA.	Songlin.Zhang@uth.tmc.edu			Department of Defense, Breast Cancer Idea Award, Port Detrick, MDUnited States Department of Defense [BC120177]; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX	The study was funded by Department of Defense, Breast Cancer Idea Award, grant BC120177, Port Detrick, MD, and the Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX.	Adamo B, 2017, ONCOTARGET, V8, P76974, DOI 10.18632/oncotarget.20293; Brown JR, 2014, CLIN CANCER RES, V20, P5995, DOI 10.1158/1078-0432.CCR-14-1622; Casbas-Hernandez P, 2015, CANCER EPIDEM BIOMAR, V24, P406, DOI 10.1158/1055-9965.EPI-14-0934; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Dieci MV, 2017, SEMIN CANC BIOL; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gamucci T, 2018, J CELL PHYSIOL, V233, P2313, DOI 10.1002/jcp.26103; Garcia-Teijido P, 2016, CLIN MED INSIGHTS-ON, V10, P31, DOI 10.4137/CMO.S34540; Guarneri V, 2006, J CLIN ONCOL, V24, P1037, DOI 10.1200/JCO.2005.02.6914; Jang N, 2018, ANN SURG ONCOL, V25, P937, DOI 10.1245/s10434-017-6332-2; Khaja ASS, 2017, ONCOTARGET, V8, P33159, DOI 10.18632/oncotarget.16565; Li XB, 2016, AM J CLIN PATHOL, V145, P871, DOI 10.1093/ajcp/aqw045; Liu YX, 2016, ONCOL LETT, V12, P1240, DOI 10.3892/ol.2016.4778; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Matsumoto H, 2015, J CLIN PATHOL, V68, P506, DOI 10.1136/jclinpath-2015-202944; Mitra S, 2012, CANCER SCI, V103, P400, DOI 10.1111/j.1349-7006.2011.02183.x; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Prowell TM, 2012, NEW ENGL J MED, V366, P2438, DOI 10.1056/NEJMp1205737; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; Pruneri G, 2016, BREAST CANCER RES TR, V158, P323, DOI 10.1007/s10549-016-3863-3; Ruffell B, 2012, P NATL ACAD SCI USA, V109, P2796, DOI 10.1073/pnas.1104303108; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Shao ZY, 2016, ONCOL RES, V23, P291, DOI 10.3727/096504016X14562725373879; Stanton SE, 2016, JAMA ONCOL, V2, P1354, DOI 10.1001/jamaoncol.2016.1061; Urru SAM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3969-y; Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013; Yeong J, 2017, BREAST CANCER RES TR, V163, P21, DOI 10.1007/s10549-017-4161-4	30	3	3	1	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						47	54		10.1016/j.humpath.2018.05.024			8	Pathology	Pathology	GX5US	WOS:000447817100005	29883779				2019-10-28	
J	Zinnall, U; Weyerer, V; Comperat, E; Camparo, P; Gaisa, NT; Knuechel-Clarke, R; Perren, A; Lugli, A; Toma, M; Baretton, G; Kristiansen, G; Wirtz, RM; Cheng, L; Wullich, B; Stoehr, R; Hartmann, A; Bertz, S				Zinnall, Ulrike; Weyerer, Veronika; Comperat, Eva; Camparo, Philippe; Gaisa, Nadine T.; Knuechel-Clarke, Ruth; Perren, Aurel; Lugli, Alessandro; Toma, Marieta; Baretton, Gustavo; Kristiansen, Glen; Wirtz, Ralph M.; Cheng, Liang; Wullich, Bernd; Stoehr, Robert; Hartmann, Arndt; Bertz, Simone			Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype	HUMAN PATHOLOGY			English	Article						Urothelial bladder cancer; Micropapillary variant; HER2; Molecular subtype; Targeted therapy	INVASIVE BLADDER-CANCER; GENE AMPLIFICATION; URINARY-BLADDER; BREAST-CANCER; VARIANT; OVEREXPRESSION; EXPRESSION; ASSOCIATION; TUMORS	Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC, alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed, and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, HER2 amplification status was assigned by chromogenic in situ hybridization. Sanger sequencing of exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was calculated to compare marker distribution between proportions of the MPUC component. HER2 2+/3+ staining scores were identified in 39.6% of 91 analyzed MPUCs and were not differentially distributed among the proportion of the MPUC component (P = .89). Additionally, CISH analysis revealed 30% of HER2-amplified tumors independently of the MPUC fraction. In 6/90 evaluable MPUCs, a p.S310F HER2 mutation was detected. Overexpression of luminal markers was observed in the majority of MPUC. Our investigations of the largest cohort of analyzed MPUC demonstrate that HER2 overexpression and amplifications are common genetic alterations and identification of overexpressed lumina] markers allows subclassification to the luminal subtype. These findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 status and the luminal molecular subtype for potential targeted therapeutic strategies. (C) 2018 Elsevier Inc. All rights reserved.	[Zinnall, Ulrike; Weyerer, Veronika; Stoehr, Robert; Hartmann, Arndt; Bertz, Simone] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Zinnall, Ulrike] Berlin Inst Med Syst Biol, Max Delbruck Ctr Mol Med Helmholtz Assoc, D-13125 Berlin, Germany; [Comperat, Eva] UPMC Paris VI, Dept Pathol, Hop Tenon, AP HP, F-75020 Paris, France; [Camparo, Philippe] Ctr Pathol Amiens Picardie, F-80000 Amiens, France; [Gaisa, Nadine T.; Knuechel-Clarke, Ruth] Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; [Perren, Aurel; Lugli, Alessandro] Univ Bern, Inst Pathol, CH-3008 Bern, Switzerland; [Toma, Marieta; Baretton, Gustavo] Univ Hosp Carl Gustav Carus, Inst Pathol, D-01307 Dresden, Germany; [Toma, Marieta; Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, D-53127 Bonn, Germany; [Wirtz, Ralph M.] STRATIFYER Mol Pathol GmbH, D-50935 Cologne, Germany; [Wirtz, Ralph M.] Inst Pathol, D-50935 Cologne, Germany; [Wirtz, Ralph M.] St Elisabeth Hosp Koln Hohenlind, D-50935 Cologne, Germany; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med & Urol, Indianapolis, IN 46202 USA; [Wullich, Bernd] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol & Pediat Urol, D-91054 Erlangen, Germany	Weyerer, V (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	veronika.weyerer@uk-erlangen.de	Perren, Aurel/A-9383-2018	Perren, Aurel/0000-0002-6819-6092	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Friedrich-AlexanderUniversitat Erlangen-Nurnberg (FAU)	We thank Rudolf Jung, Verena Popp, Stefanie Herlein, Claudia Giedl and Christa Winkelmann for their excellent technical support. Parts of this study were presented at the annual meeting of the German Association of Pathology; May, 2015; Berlin, Germany. We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-AlexanderUniversitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing.	AMIN MB, 1994, AM J SURG PATHOL, V18, P1224, DOI 10.1097/00000478-199412000-00005; Behzatoglu K, 2018, EUR UROL FOCUS, V4, P399, DOI 10.1016/j.euf.2016.06.007; Bertz S, 2016, VIRCHOWS ARCH, V469, P339, DOI 10.1007/s00428-016-1986-x; Caner V, 2008, PATHOL ONCOL RES, V14, P261, DOI 10.1007/s12253-008-9027-y; Ching CB, 2011, MODERN PATHOL, V24, P1111, DOI 10.1038/modpathol.2011.69; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Comperat E, 2010, PATHOLOGY, V42, P650, DOI 10.3109/00313025.2010.522173; Figueroa JD, 2014, HUM MOL GENET, V23, P1387, DOI 10.1093/hmg/ddt519; Gandour-Edwards R, 2002, CANCER, V95, P1009, DOI 10.1002/cncr.10808; Goodman AL, 2016, HUM PATHOL, V57, P160, DOI 10.1016/j.humpath.2016.07.014; Guo CC, 2009, ARCH PATHOL LAB MED, V133, P62, DOI 10.1043/1543-2165-133.1.62; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Hansel DE, 2008, AM J CLIN PATHOL, V130, P274, DOI 10.1309/41VLTFX3YPP1HF6F; Herter-Sprie GS, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00086; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Jackson BL, 2016, UROL INT, V96, P32, DOI 10.1159/000375411; Jimenez RE, 2001, CLIN CANCER RES, V7, P2440; Kiss B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42713; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Lae M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488; Layfield LJ, 2016, PATHOL RES PRACT, V212, P190, DOI 10.1016/j.prp.2015.11.016; Lerner SP, 2016, BLADDER CANCER, V2, P37, DOI 10.3233/BLC-150037; Lopez-Beltran A, 2010, HUM PATHOL, V41, P1159, DOI 10.1016/j.humpath.2009.11.018; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Moktefi A, 2018, MOD PATHOL; Nguyen D, 2016, VIRCHOWS ARCH, V469, P427, DOI 10.1007/s00428-016-2001-2; REMMELE W, 1987, PATHOLOGE, V8, P138; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Ross JS, 2014, CLIN CANCER RES, V20, P68, DOI 10.1158/1078-0432.CCR-13-1992; Schneider SA, 2014, MODERN PATHOL, V27, P758, DOI 10.1038/modpathol.2013.201; Stoehr R, 2005, EUR UROL, V47, P58, DOI 10.1016/j.eururo.2004.07.012; Tschui J, 2015, VIRCHOWS ARCH, V466, P703, DOI 10.1007/s00428-015-1729-4; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Willis DL, 2014, UROL ONCOL-SEMIN ORI, V32, P826, DOI 10.1016/j.urolonc.2014.01.020; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	35	0	0	2	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						55	64		10.1016/j.humpath.2018.05.022			10	Pathology	Pathology	GX5US	WOS:000447817100006	29885409				2019-10-28	
J	Tretiakova, MS				Tretiakova, Maria S.			Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases	HUMAN PATHOLOGY			English	Article						Eosinophilic; Solid; Cystic; RCC; Mimicking; Epithelioid; AML		Eosinophilic solid and cystic renal cell carcinoma (ESC-RCC) is a novel entity of rare tumors with rather unique morphology and immunohistochemical profile. Until recently these tumors were characterized by indolent behavior. Herein, we describe a series of six primary and metastatic ESC-RCCs morphologically and immunophenotypically mimicking epithelioid angiomyolipoma (eAML). Retrospective review of unclassified RCCs with oncocytic phenotype yielded several candidate cases, 4 of which fulfilled diagnostic criteria after additional work-up. Three female patients and one male (median age 46) presented with unifocal tumors ranging from 1.5 cm to 20.5 cm (median 5 cm). On follow-up (median 32 months), 2 younger patients had no signs of tumor recurrence, but older patients presented with advanced disease. A 50 year-old female developed numerous bone metastases and tumor progression despite aggressive treatment. Two of these metastases were analyzed showing morphology and immunoprofile similar to the primary tumor. 50 year-old male had locally aggressive tumor invading adrenal gland and retroperitoneum. All cases exhibited ESC-like architecture of solid sheets, tight nests and variably sized cysts with hobnailed lining, as well as foci of diffuse growth with poorly cohesive brightly eosinophilic cells. Characteristic cytoplasmic stippling and coarse granularity was present in all cases including compact cytoplasmic "Leishmaniasis-like" globules. Due to high suspicion of eAML, immunostaining panels included melanocytic markers, cytokeratins and RCC-specific markers. All ESC-RCC were positive for CK20 and melanocytic markers Melan-A, Cathepsin-K or HMB45, as well as PAX8, whereas EMA, pan-cytokeratin, CK7, CKIT, CD10, CAIX were negative. Comparison with 5 eAML cases including 2 malignant tumors showed similar morphology and immune reactivity except for more frequent expression of HMB45 and lack of PAX8 positivity. In conclusion, we report 2 cases of aggressive ESC-RCC course including widespread bone metastases in addition to 2 typical indolent tumors. ESC-RCC and eAML could present with overlapping morphology and immunophenotype causing diagnostic difficulty and expanding our understanding of these rare tumors. (C) 2018 Elsevier Inc. All rights reserved.	[Tretiakova, Maria S.] Univ Washington, Dept Pathol, Med Ctr, Seattle, WA 98105 USA	Tretiakova, MS (reprint author), Univ Washington, Dept Pathol, Sch Med, 325 9th Ave,Box 359791, Seattle, WA 98104 USA.	mariast@uw.edu					Brimo F, 2010, AM J SURG PATHOL, V34, P715, DOI 10.1097/PAS.0b013e3181d90370; Calio A, 2018, MODERN PATHOL, V31, P474, DOI 10.1038/modpathol.2017.144; Chuang CK, 2017, INT UROL NEPHROL, V49, P1527, DOI 10.1007/s11255-017-1629-4; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Delhorme JB, 2017, EJSO-EUR J SURG ONC, V43, P831, DOI 10.1016/j.ejso.2016.11.012; Giannikou K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006242; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Mantilla JG, 2017, HUM PATHOL, V66, P152, DOI 10.1016/j.humpath.2017.06.016; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; McKenney JK, 2018, HISTOPATHOLOGY, V72, P1066, DOI 10.1111/his.13457; Moch H, 2016, WHO CLASSIFICATION T; Nese N, 2011, AM J SURG PATHOL, V35, P161, DOI 10.1097/PAS.0b013e318206f2a9; Peckova K, 2014, ANN DIAGN PATHOL, V18, P351, DOI 10.1016/j.anndiagpath.2014.10.002; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Qu X, 2017, J CLIN MOL PATHOL, V1, P7; Smith NE, 2014, AM J SURG PATHOL, V38, P604, DOI 10.1097/PAS.0000000000000203; Tacha D, 2011, APPL IMMUNOHISTO M M, V19, P293, DOI 10.1097/PAI.0b013e3182025f66; Trpkov K, 2017, AM J SURG PATHOL, V41, P1299, DOI 10.1097/PAS.0000000000000838; Trpkov K, 2016, AM J SURG PATHOL, V40, P60, DOI 10.1097/PAS.0000000000000508	21	4	4	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						65	75		10.1016/j.humpath.2018.05.023			11	Pathology	Pathology	GX5US	WOS:000447817100007	29885406				2019-10-28	
J	Zhao, CHLS; Hui, Y; Wang, LJ; Yang, DF; Yakirevich, E; Mangray, S; Huang, CK; Lu, SL				Zhao, Chaohui Lisa; Hui, Yiang; Wang, Li Juan; Yang, Dongfang; Yakirevich, Evgeny; Mangray, Shamlal; Huang, Chiung-Kuei; Lu, Shaolei			Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas	HUMAN PATHOLOGY			English	Article						AGXT1; Hepatocellular carcinoma; Diagnostic marker; Arginase-1; Immunohistochemistry	IMMUNOHISTOCHEMICAL-MARKERS; SENSITIVE MARKER; ARGINASE-1; DIFFERENTIATION; HEPPAR-1; LIVER; GLYPICAN-3; MUTATIONS; DIAGNOSIS	Arginase-1 has been demonstrated as a marker for hepatocellular carcinoma (HCC) with higher sensitivity and specificity than HepPar-1 and glypican-3. However, its sensitivity is diminished in moderately and poorly differentiated HCCs. In the current study, we evaluated the utility of AGXT1 as a diagnostic marker. Immunostains for AGXT1 and arginase-1 were performed in tissue microarrays of 139 HCCs and 374 gastrointestinal and nongastrointestinal carcinomas. AGXT1 exhibited granular cytoplasmic immunoreactivity in contrast to the diffuse cytoplasmic staining characteristic of arginase-1 in nonneoplastic and neoplastic hepatocytes. Sensitivities of AGXT1 for all HCCs were 90.0% compared to 87.8% for arginase-1. A small number of tumors expressed only I of the 2 markers. Sensitivity increased to 92.1% when the presence of either marker was considered positive. Excepting 5 cases of cholangiocarcinoma, both AGXT1 and arginase-1 were negative in all non-HCC tumors with specificities of 98.7%. Our data support the consideration of AGXT1 as a novel hepatocellular marker with equally high specificity and slightly higher sensitivity as compared to arginase-1. AGXT1 may aid in diagnostic workup especially in conjunction with arginase-1 for HCCs that may otherwise defy conventional immunostaining patterns. (C) 2018 Elsevier Inc. All rights reserved.	[Zhao, Chaohui Lisa; Hui, Yiang; Wang, Li Juan; Yang, Dongfang; Yakirevich, Evgeny; Mangray, Shamlal; Lu, Shaolei] Brown Univ, Rhode Isl Hosp, Dept Pathol & Lab Med, Providence, RI 02903 USA; [Zhao, Chaohui Lisa; Hui, Yiang; Wang, Li Juan; Yang, Dongfang; Yakirevich, Evgeny; Mangray, Shamlal; Huang, Chiung-Kuei; Lu, Shaolei] Brown Univ, Warren Alpert Med Sch, Providence, RI 02903 USA; [Huang, Chiung-Kuei] Brown Univ, Rhode Isl Hosp, Liver Res Ctr, Providence, RI 02903 USA	Huang, CK (reprint author), Brown Univ, Rhode Isl Hosp, Liver Res Ctr, Warren Alpert Med Sch, 55 Claverick St, Providence, RI 02903 USA.; Lu, SL (reprint author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Pathol, APC12,593 Eddy St, Providence, RI 02903 USA.	chiung-kuei_huang@brown.edu; slu@lifespan.org			Rhode Island Foundation, Providence, RI [20144126]; AASLDF, Alexandria, VA Pinnacle Research Award	The study was supported by the Rhode Island Foundation, Providence, RI (20144126) and AASLDF, Alexandria, VA Pinnacle Research Award.	Boualla L, 2015, GENET TEST MOL BIOMA, V19, P623, DOI 10.1089/gtmb.2015.0136; Clark I, 2017, HUM PATHOL, V69, P90, DOI 10.1016/j.humpath.2017.09.007; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fujikura K, 2016, AM J SURG PATHOL, V40, P689, DOI 10.1097/PAS.0000000000000585; Fujiwara M, 2012, CANCER CYTOPATHOL, V120, P230, DOI 10.1002/cncy.21190; Hu XL, 2017, J MOL CELL CARDIOL, V113, P33, DOI 10.1016/j.yjmcc.2017.09.010; Kogiso T, 2015, HEPATOL RES, V45, P1251, DOI 10.1111/hepr.12494; Lee DH, 2017, EUR J RADIOL, V95, P349, DOI 10.1016/j.ejrad.2017.08.030; Lumb MJ, 2000, J BIOL CHEM, V275, P36415, DOI 10.1074/jbc.M006693200; PURDUE PE, 1991, GENOMICS, V10, P34, DOI 10.1016/0888-7543(91)90481-S; Salido E, 2012, BBA-MOL BASIS DIS, V1822, P1453, DOI 10.1016/j.bbadis.2012.03.004; Sang W, 2015, TUMOR BIOL, V36, P3881, DOI 10.1007/s13277-014-3030-6; Shahid M, 2015, AM J SURG PATHOL, V39, P25, DOI 10.1097/PAS.0000000000000343; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Nguyen T, 2015, ARCH PATHOL LAB MED, V139, P1028, DOI 10.5858/arpa.2014-0479-OA; Timek DT, 2012, AM J CLIN PATHOL, V138, P203, DOI 10.1309/AJCPK1ZC9WNHCCMU; Witjes CDM, 2013, J CLIN PATHOL, V66, P687, DOI 10.1136/jclinpath-2012-201156; Yan BC, 2010, AM J SURG PATHOL, V34, P1147, DOI 10.1097/PAS.0b013e3181e5dffa	18	0	0	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						76	81		10.1016/j.humpath.2018.05.025			6	Pathology	Pathology	GX5US	WOS:000447817100008	29883780				2019-10-28	
J	Coccaro, N; Zagaria, A; Orsini, P; Anelli, L; Tota, G; Casieri, P; Impera, L; Minervini, A; Minervini, CF; Cumbo, C; Parciante, E; Mestice, A; Delia, M; Brunetti, C; Specchia, G; Albano, F				Coccaro, Nicoletta; Zagaria, Antonella; Orsini, Paola; Anelli, Luisa; Tota, Giuseppina; Casieri, Paola; Impera, Luciana; Minervini, Angela; Minervini, Crescenzio F.; Cumbo, Cosimo; Parciante, Elisa; Mestice, Anna; Delia, Mario; Brunetti, Claudia; Specchia, Giorgina; Albano, Francesco			RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia	HUMAN PATHOLOGY			English	Article						APL-like leukemia; RARA; RARG; EZH2; NGS; Epigenetic silencing	ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; IN-VITRO; FUSION; PATIENT	Most acute promyelocytic leukemia (APL) patients express PML-RARA fusion; in rare cases, RARA is rearranged with partner genes other than PML. To date, only 2 patients presenting features similar to APL showing the RARG gene rearrangement have been described. We report an acute myeloid leukemia patient with morphology resembling APL without involvement of the RARA gene. Molecular and fluorescent in situ hybridization analyses excluded PML-RARA fusion and variant rearrangements involving RARA and RARG loci. Targeted next-generation sequencing showed EZH2- D185H mutation. As this mutation involved the region of interaction with DNA methyltransferases, we speculate an epigenetic alteration of genes involved in the APL-like phenotype. Expression analysis by droplet digital polymerase chain reaction revealed downregulation of the RARA and RARG genes. We hypothesize a novel mechanism of EZH2 function alteration, which may be responsible for an acute myeloid leukemia with APL-like phenotype featuring dysregulation of the RARA and RARG genes. (C) 2018 Elsevier Inc. All rights reserved.	[Coccaro, Nicoletta; Zagaria, Antonella; Orsini, Paola; Anelli, Luisa; Tota, Giuseppina; Casieri, Paola; Impera, Luciana; Minervini, Angela; Minervini, Crescenzio F.; Cumbo, Cosimo; Parciante, Elisa; Mestice, Anna; Delia, Mario; Brunetti, Claudia; Specchia, Giorgina; Albano, Francesco] Univ Bari, Dept Emergency & Organ Transplantat, Hematol Sect, I-70124 Bari, Italy	Coccaro, N (reprint author), Univ Bari, Dept Emergency & Organ Transplantat, Hematol Sect, I-70124 Bari, Italy.		Albano, Francesco/J-2352-2016; CUMBO, COSIMO/S-5834-2019	Albano, Francesco/0000-0001-7926-6052; CUMBO, COSIMO/0000-0002-2509-6200; Minervini, Crescenzio/0000-0002-4382-9906			Albano F, 2010, ONCOGENE, V29, P2509, DOI 10.1038/onc.2009.524; Cohen ASA, 2016, HUM MUTAT, V37, P301, DOI 10.1002/humu.22946; Gajendra S, 2011, EUR J HAEMATOL, DOI [10.1111/j.1600-0609.2011.01668.x, DOI 10.1111/J.1600-0609.2011.01668.X]; Glasow A, 2008, BLOOD, V111, P2374, DOI 10.1182/blood-2007-05-088344; Grimwade D, 2000, BLOOD, V96, P1297; Ha JS, 2017, LEUKEMIA, V31, P1992, DOI 10.1038/leu.2017.167; McKeown MR, 2017, CANCER DISCOV, V7, P1136, DOI 10.1158/2159-8290.CD-17-0399; Poddighe PJ, 2014, MOL CYTOGENET, V7, DOI 10.1186/s13039-014-0067-6; Qiu JJ, 2015, LEUKEMIA, V29, P1153, DOI 10.1038/leu.2014.334; Sashida G, 2017, INT J HEMATOL, V105, P23, DOI 10.1007/s12185-016-2124-x; Specchia G, 2004, GENE CHROMOSOME CANC, V41, P86, DOI 10.1002/gcc.20061; Such E, 2014, ANN HEMATOL, V93, P1931, DOI 10.1007/s00277-014-2073-5; Such E, 2011, BLOOD, V117, P242, DOI 10.1182/blood-2010-06-291658; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang HY, 2016, BRIT J HAEMATOL, V172, P987, DOI 10.1111/bjh.13552; Welch JS, 2011, BLOOD, V117, P2460, DOI 10.1182/blood-2010-08-300087; Yan WZ, 2016, ACTA HAEMATOL-BASEL, V136, P1, DOI 10.1159/000444514	17	3	3	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						82	86		10.1016/j.humpath.2018.02.023			5	Pathology	Pathology	GX5US	WOS:000447817100009	29530751				2019-10-28	
J	Zhao, ZH; Lu, JJ; Qu, HY; Wang, ZS; Liu, Q; Yang, XQ; Liu, S; Ge, JT; Xu, Y; Li, N; Yuan, YJ				Zhao, Zuohui; Lu, Jiaju; Qu, Hongyi; Wang, Zunsong; Liu, Qiang; Yang, Xiaoqing; Liu, Shuai; Ge, Juntao; Xu, Yue; Li, Na; Yuan, Yijiao			Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma	HUMAN PATHOLOGY			English	Article						MnSOD; Cancer-specific survival; Prognosis; Reactive oxygen species; Renal cell carcinoma	CANCER STATISTICS; MITOCHONDRIAL ROS; UP-REGULATION; GENE; PATHWAYS; MARKERS; MNSOD; PROGRESSION; METASTASIS; EXPRESSION	The antioxidant enzyme manganese superoxide dismutase (MnSOD) is up-regulated in renal cell carcinoma (RCC) and has been implicated in multiple stages of RCC tumorigenesis and progression. However, the prognostic significance of MnSOD in RCC has not been fully elucidated. This study aimed to investigate the expression profile of MnSOD in clear cell RCC (ccRCC) tissues and evaluate the clinical significance of this enzyme in ccRCC patients. MnSOD mRNA was assessed in 42 ccRCC and 33 normal kidney tissues using the Oncomine database, and its protein was detected in 145 ccRCCs and 3 normal tissues by immunohistochemistry staining. The Oncomine database confirmed higher MnSOD mRNA expression in ccRCC than in normal tissues, and immunohistochemistry analysis revealed that MnSOD protein expression was inversely associated with pathologic grade, clinical stage, tumor size, M status, and cancer-specific survival. In addition, univariate survival analysis demonstrated that high-grade, late-stage, large tumors, stage M-1, and low MnSOD expression were associated with a poorer prognosis for cancer-specific survival, and further multivariate analysis revealed that tumor grade, stage, M-1 stage, and MnSOD were identified as independent prognostic factors for cancer-specific survival in patients with ccRCC. Collectively, these findings imply that MnSOD is a promising prognostic marker in ccRCC and implies that oxidative stress might be involved in the tumorigenesis and progression of ccRCC. (C) 2018 Elsevier Inc. All rights reserved.	[Zhao, Zuohui; Qu, Hongyi; Ge, Juntao; Xu, Yue; Li, Na; Yuan, Yijiao] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Pediat Surg, Jingshi Rd 16766, Jinan 250014, Shandong, Peoples R China; [Lu, Jiaju; Liu, Shuai] Shandong Univ, Shandong Prov Hosp, Dept Urol, Jinan 250021, Shandong, Peoples R China; [Wang, Zunsong] Shandong Prov Qianfoshan Hosp, Dept Nephrol, Jinan 250014, Shandong, Peoples R China; [Liu, Qiang] Shandong Prov Qianfoshan Hosp, Med Res Ctr, Lab Microvasc Med, Jinan 250014, Shandong, Peoples R China; [Yang, Xiaoqing] Shandong Prov Qianfoshan Hosp, Dept Pathol, Jinan 250014, Shandong, Peoples R China	Zhao, ZH (reprint author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Pediat Surg, Jingshi Rd 16766, Jinan 250014, Shandong, Peoples R China.	zhaozuohui@126.com			Shandong Medical and Health Science and Technology Development Project [2016WS0481]	This work was supported by Shandong Medical and Health Science and Technology Development Project (No. 2016WS0481).	Atrih A, 2014, BRIT J CANCER, V110, P1622, DOI 10.1038/bjc.2014.24; Becuwe P, 2014, FREE RADICAL BIO MED, V77, P139, DOI 10.1016/j.freeradbiomed.2014.08.026; Bur H, 2014, HISTOPATHOLOGY, V65, P319, DOI 10.1111/his.12389; Chen PM, 2013, MOL CANCER RES, V11, P261, DOI 10.1158/1541-7786.MCR-12-0527; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kumar AP, 2014, ANTIOXID REDOX SIGN, V20, P2326, DOI 10.1089/ars.2013.5295; Liu XQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-365; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Miar A, 2015, FREE RADICAL BIO MED, V85, P45, DOI [10.1016/j.freebiomed.2015.04.001, 10.1016/j.freeradbiomed.2015.04.001]; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Shwetha SD, 2016, PATHOL RES PRACT, V212, P17, DOI 10.1016/j.prp.2015.11.002; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soini Y, 2006, HISTOL HISTOPATHOL, V21, P157, DOI 10.14670/HH-21.157; Sverko A, 2011, INT IMMUNOPHARMACOL, V11, P639, DOI 10.1016/j.intimp.2010.12.023; Tamai T, 2011, WORLD J GASTROENTERO, V17, P4890, DOI 10.3748/wjg.v17.i44.4890; Wettersten HI, 2015, CANCER RES, V75, P2541, DOI 10.1158/0008-5472.CAN-14-1703; White NMA, 2014, ONCOTARGET, V5, P506, DOI 10.18632/oncotarget.1529; Zhao ZH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020319; Zhao ZH, 2016, TUMOR BIOL, V37, P8121, DOI 10.1007/s13277-015-4720-4; Zhao ZH, 2015, TUMOR BIOL, V36, P939, DOI 10.1007/s13277-014-2694-2; Zou XH, 2017, J BIOENERG BIOMEMBR, V49, P325, DOI 10.1007/s10863-017-9718-8	29	0	0	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						87	93		10.1016/j.humpath.2017.12.032			7	Pathology	Pathology	GX5US	WOS:000447817100010	29935195				2019-10-28	
J	Fujimoto, M; Togashi, Y; Matsuzaki, I; Baba, S; Takeuchi, K; Inaba, Y; Jinnin, M; Murata, S				Fujimoto, Masakazu; Togashi, Yuki; Matsuzaki, Ibu; Baba, Satoko; Takeuchi, Kengo; Inaba, Yutaka; Jinnin, Masatoshi; Murata, Shin-ichi			A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results	HUMAN PATHOLOGY			English	Article						ALK-MLPH fusion; Melanophilin; Atypical Spitz tumor; Melanoma; Melanocytic nevus	FEATURES; NEOPLASMS; SYSTEM; NTRK1	Frequent kinase fusions have been reported in spitzoid neoplasms, approximately 10% of which involve ALK rearrangements. Herein, we report a case of atypical Spitz tumor with a novel MLPH-ALK fusion, which has not been previously reported to contribute to cancer development. The tumor was detected in the right arm of a 40-year-old woman. The novel ALK fusion was identified by a 5'-rapid amplification of cDNA ends-based system optimized for formalin-fixed, paraffin-embedded tissue. Initially, ALK expression was detected by immunohistochemistry using 5A4 antibodies for both sensitive and conventional polymer detection methods. However, the anti-ALK1 antibody, which is commonly used for the diagnosis of ALK-positive anaplastic large cell lymphoma, failed to confirm ALK expression. These results indicated that ALK immunohistochemistry results in ALK-rearranged atypical Spitz tumor may differ based on the type of primary antibody clone, which can be a potential diagnostic pitfall. (C) 2018 Elsevier Inc. All rights reserved.	[Fujimoto, Masakazu; Matsuzaki, Ibu; Murata, Shin-ichi] Wakayama Med Univ, Dept Diagnost Pathol, Wakayama 6418509, Japan; [Togashi, Yuki; Baba, Satoko; Takeuchi, Kengo] Japanese Fdn Canc Res, Canc Inst, Pathol Project Mol Targets, Tokyo 1358550, Japan; [Inaba, Yutaka; Jinnin, Masatoshi] Wakayama Med Univ, Dept Dermatol, Wakayama 6418509, Japan	Murata, S (reprint author), Wakayama Med Univ, Dept Pathol, 811-1 Kimiidera, Wakayama, Wakayama 6418510, Japan.	smurata@wakayama-med.ac.jp					Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Busam KJ, 2016, AM J SURG PATHOL, V40, P786, DOI 10.1097/PAS.0000000000000611; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Kiuru M, 2016, INT J SURG PATHOL, V24, P200, DOI 10.1177/1066896916630375; Lee CY, 2017, AM J DERMATOPATH, V39, P181, DOI 10.1097/DAD.0000000000000629; Ogawa K, 2017, J DERMATOL, V44, pe342, DOI 10.1111/1346-8138.14000; Rand AJ, 2018, J CUTAN PATHOL, V45, P136, DOI 10.1111/cup.13057; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Togashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031323; Van Gele M, 2009, PIGM CELL MELANOMA R, V22, P268, DOI 10.1111/j.1755-148X.2009.00558.x; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wu G, 2016, MODERN PATHOL, V29, P359, DOI 10.1038/modpathol.2016.37; Yeh I, 2016, J PATHOL, V240, P282, DOI 10.1002/path.4775; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387	15	2	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						99	103		10.1016/j.humpath.2018.02.021			5	Pathology	Pathology	GX5US	WOS:000447817100012	29514107				2019-10-28	
J	Park, JK; Otsuka, N; Tomaru, U; Suzuki, H; Azuma, M; Okamoto, K; Yamashiro, K; Kasahara, M				Park, Jong Kun; Otsuka, Noriyuki; Tomaru, Utano; Suzuki, Hiroaki; Azuma, Manabu; Okamoto, Kazuhira; Yamashiro, Katsushige; Kasahara, Masanori			Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas	HUMAN PATHOLOGY			English	Article						GINS complex; PSF3; Immunohistochemistry; Atypical endometrial hyperplasia; Endometrioid carcinoma; Ki-67	PROGNOSTIC BIOMARKER; CELL-PROLIFERATION; GINS COMPLEX; CANCER CELLS; LUNG-CANCER; HYPERPLASIA; DIAGNOSIS; ADENOCARCINOMA; CHEMOTHERAPY; RADIOTHERAPY	PSF3 (Partner of SLD Five 3) is a member of the heterotetrameric complex termed GINS. Previous studies have shown that PSF3 is up-regulated in several cancers and is associated with tumor malignancy. However, the clinicopathological significance of PSF3 expression in endometrial lesions is still poorly understood. To investigate whether PSF3 could serve as a useful biomarker for endometrial carcinomas, we performed immunohistochemical analysis of PSF3 expression. In 155 cases of endometrial carcinomas (ECs), the mean tumor proportion score of PSF3 expression was 30.7% in G1 endometrioid carcinoma, 55.0% in G2 endometrioid carcinoma, 59.0% in G3 endometrioid carcinoma, and 58.9% in nonendometrioid carcinomas. In 25 cases of atypical hyperplasia, the mean tumor proportion score of PSF3 expression was significantly lower (10.4%). High expression of PSF3 was associated with more advanced pathologic T stage (P = .000), lymphatic invasion (P = .001), and poor clinical outcomes such as shorter relapse-free survival (P = .000) and overall survival (P = .001). When we compared the immunostaining of PSF3 and Ki-67, the proportions of PSF3-positive cells in tumor epithelial cells were comparable to those of Ki-67-positive cells. However, PSF3-positive cells were selectively found in tumor cells, whereas Ki-67-positive cells were also found in tumor stromal cells. These results demonstrated that PSF3 immunostaining was valuable as a histopathologic marker for differential diagnosis between atypical hyperplasia and ECs, for tumor histologic grading, and for determining a patient's prognosis. PSF3 may play a crucial role in tumor progression in EC. (C) 2018 Elsevier Inc. All rights reserved.	[Park, Jong Kun; Otsuka, Noriyuki; Tomaru, Utano; Kasahara, Masanori] Hokkaido Univ, Grad Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan; [Park, Jong Kun; Suzuki, Hiroaki; Azuma, Manabu; Yamashiro, Katsushige] Hokkaido Canc Ctr, Natl Hosp Org, Dept Surg Pathol, Sapporo, Hokkaido 0030804, Japan; [Okamoto, Kazuhira] Hokkaido Canc Ctr, Natl Hosp Org, Gynecol Oncol, Sapporo, Hokkaido 0030804, Japan	Otsuka, N (reprint author), Hokkaido Univ, Grad Sch Med, Dept Pathol, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.	tsuka-p@med.hokudai.ac.jp	Kasahara, Masanori/G-7651-2011				Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Brierley JD, 2017, TNM CLASSIFICATION M; Fei OY, 2017, ONCOL REP, V37, P2652, DOI 10.3892/or.2017.5573; Fujimoto T, 2009, GYNECOL ONCOL, V112, P342, DOI 10.1016/j.ygyno.2008.10.019; Han YL, 2009, BIOCHEM BIOPH RES CO, V380, P609, DOI 10.1016/j.bbrc.2009.01.133; Hogberg T, 2010, EUR J CANCER, V46, P2422, DOI 10.1016/j.ejca.2010.06.002; Hokka D, 2013, LUNG CANCER, V79, P77, DOI 10.1016/j.lungcan.2012.10.001; Kamada K, 2007, NAT STRUCT MOL BIOL, V14, P388, DOI 10.1038/nsmb1231; Kurman RJ, 2014, WHO CLASSIFICATION T; Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914; Liu LC, 2016, J OBSTET GYNAECOL RE, V42, P1159, DOI 10.1111/jog.13040; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; MacNeill SA, 2010, BIOCHEM J, V425, P489, DOI 10.1042/BJ20091531; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Mutter GL, 2007, INT J GYNECOL PATHOL, V26, P103, DOI 10.1097/PGP.0b013e31802e4696; Mutter GL, 2000, INT J GYNECOL PATHOL, V19, P301, DOI 10.1097/00004347-200010000-00002; Mutter GL, 2002, J CLIN PATHOL, V55, P326, DOI 10.1136/jcp.55.5.326; Nagahama Y, 2010, BIOCHEM BIOPH RES CO, V392, P150, DOI 10.1016/j.bbrc.2009.12.174; Nakahara I, 2010, GENES CELLS, V15, P1015, DOI 10.1111/j.1365-2443.2010.01442.x; Orbo A, 2003, INT J GYNECOL PATHOL, V22, P141, DOI 10.1097/01.PGP.0000055170.26935.F8; Rakha E, 2012, AM J SURG PATHOL, V36, P1683, DOI 10.1097/PAS.0b013e31825dd4ff; Rasool N, 2010, GYNECOL ONCOL, V116, P10, DOI 10.1016/j.ygyno.2009.10.043; Robbe EJM, 2012, INT J GYNECOL CANCER, V22, P1264, DOI 10.1097/IGC.0b013e31826302a3; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; Silverberg SG, 2000, MODERN PATHOL, V13, P309, DOI 10.1038/modpathol.3880053; Susumu N, 2008, GYNECOL ONCOL, V108, P226, DOI 10.1016/j.ygyno.2007.09.029; Tahara H, 2015, PROSTATE CANCER P D, V18, P56, DOI 10.1038/pcan.2014.46; Tane S, 2015, CANCER SCI, V106, P1625, DOI 10.1111/cas.12770; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; Ueno M, 2009, BLOOD, V113, P555, DOI 10.1182/blood-2008-01-136879; Zhang JY, 2015, TUMOR BIOL, V36, P2163, DOI 10.1007/s13277-014-2826-8; Zheng M, 2014, BREAST CANCER RES TR, V148, P423, DOI 10.1007/s10549-014-3172-7	33	0	0	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						104	112		10.1016/j.humpath.2018.06.010			9	Pathology	Pathology	GX5US	WOS:000447817100013	29936059				2019-10-28	
J	Sato, N; Fujishima, F; Nakamura, Y; Aoyama, Y; Onodera, Y; Ozawa, Y; Ito, K; Ishida, H; Kamei, T; Watanabe, M; Sasano, H				Sato, Naomi; Fujishima, Fumiyoshi; Nakamura, Yasuhiro; Aoyama, Yayoi; Onodera, Yoshiaki; Ozawa, Yohei; Ito, Ken; Ishida, Hirotaka; Kamei, Takashi; Watanabe, Mika; Sasano, Hironobu			Myosin 5a regulates tumor migration and epithelial-mesenchymal transition in esophageal squamous cell carcinoma: utility as a prognostic factor	HUMAN PATHOLOGY			English	Article						Esophageal squamous cell carcinoma; Myosin 5a; Vimentin; E-cadherin; Immunohistochemistry; Epithelial-mesenchymal transition	GENE-EXPRESSION; SNAIL; VA; PROGRESSION; CANCER; MELANOMA; MOTILITY; TARGET; HEAD	Esophageal squamous cell carcinoma (ESCC) is highly malignant. Recently, the expression of myosin 5a, a member of the myosin superfamily, was reported to be associated with increased invasiveness and metastasis in many tumor types. Moreover, myosin 5a is upregulated by Snail and activated by Akt2, both of which are epithelial-mesenchymal transition (EMT) markers. In this study, we confirmed the expression of myosin 5a in ESCC surgical specimens and cell lines, revealing its correlation with tumor invasion, migration, patient prognosis, and expression of EMT-related proteins. The expression of myosin 5a, vimentin, and E-cadherin was immunohistochemically evaluated in 118 patients with ESCC who underwent esophagectomy without chemotherapy or irradiation therapy prior to surgery. We also investigated ESCC cell migration under myosin 5a silencing by siRNA induction. The high expression of myosin 5a was correlated with tumor depth, lymph node metastasis, pathological stage, high vimentin expression, and low Ecadherin expression. Patients with high expression of myosin 5a, including those with pT1 cancer, exhibited significantly worse survival. Moreover, the expression level of vimentin mRNA and the number of migrated ESCC cells decreased significantly following myosin 5a silencing. Our findings demonstrate that high expression of myosin 5a may be an independent prognostic factor in patients with ESCC, even in early invasive carcinoma, and indicate myosin 5a has a role in both cell migration and EMT. (C) 2018 Elsevier Inc. All rights reserved.	[Sato, Naomi; Fujishima, Fumiyoshi; Aoyama, Yayoi; Onodera, Yoshiaki; Watanabe, Mika; Sasano, Hironobu] Tohoku Univ Hosp, Dept Pathol, Sendai, Miyagi 9808574, Japan; [Sato, Naomi] Sendai City Hosp, Div Surg Pathol, Sendai, Miyagi 9828502, Japan; [Nakamura, Yasuhiro] Tohoku Med & Pharmaceut Univ, Dept Pathol, Sendai, Miyagi 9810905, Japan; [Nakamura, Yasuhiro] Tohoku Med & Pharmaceut Univ, Fac Med, Div Pathol, Sendai, Miyagi 9810905, Japan; [Ozawa, Yohei; Ito, Ken; Ishida, Hirotaka; Kamei, Takashi] Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Sendai, Miyagi 9808575, Japan	Sato, N (reprint author), Sendai City Hosp, Dept Pathol, Taihaku Ku, 1-1-1 Asutonagamachi, Sendai, Miyagi 9828502, Japan.	nasato@patholo2.med.tohoku.ac.jp					Alves CP, 2013, J INVEST DERMATOL, V133, P2809, DOI 10.1038/jid.2013.218; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bosman FT, 2010, WHO CLASSIFICATION T; Cagdas D, 2012, EUR J PEDIATR, V171, P1527, DOI 10.1007/s00431-012-1765-x; Du YCN, 2007, PLOS BIOL, V5, P2255, DOI 10.1371/journal.pbio.0050276; Eppinga RD, 2008, CELL MOTIL CYTOSKEL, V65, P197, DOI 10.1002/cm.20255; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Galland F, 2010, ENDOCR-RELAT CANCER, V17, P361, DOI 10.1677/ERC-10-0018; Guo W, 2014, CANCER-AM CANCER SOC, V120, P2412, DOI 10.1002/cncr.28764; Kim DH, 2014, SCAND J GASTROENTERO, V49, P1486, DOI 10.3109/00365521.2013.832369; Kuo KT, 2012, ANN SURG ONCOL, V19, pS549, DOI 10.1245/s10434-011-2043-2; Lan LX, 2010, INT J CANCER, V126, P53, DOI 10.1002/ijc.24641; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lin DC, 2009, DIS ESOPHAGUS, V22, P9, DOI 10.1111/j.1442-2050.2008.00845.x; Lindsay AJ, 2011, J BIOL CHEM, V286, P11519, DOI 10.1074/jbc.M110.182808; Lindsay AJ, 2009, CELL MOTIL CYTOSKEL, V66, P1057, DOI 10.1002/cm.20408; Mendez E, 2011, CLIN CANCER RES, V17, P2466, DOI 10.1158/1078-0432.CCR-10-0175; Nakamura Y, 2016, MOL CANCER THER, V15, P1988, DOI 10.1158/1535-7163.MCT-15-0737; Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112; Niwa Y, 2014, J SURG ONCOL, V110, P764, DOI 10.1002/jso.23694; Ozawa Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1450-3; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Fernandez-Perez MP, 2013, NEOPLASIA, V15, P826, DOI 10.1593/neo.13320; Sobin LH, 2009, TNM CLASSIFICATION M; Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365; Wang LS, 1999, AM J GASTROENTEROL, V94, P1933; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022	28	1	1	2	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						113	122		10.1016/j.humpath.2018.06.002			10	Pathology	Pathology	GX5US	WOS:000447817100014	29898384				2019-10-28	
J	Chen, QR; Wang, MX; Wang, MW; Jin, S; Xiao, SY; Tian, SF				Chen, Qiongrong; Wang, Manxiang; Wang, Mingwei; Jin, Su; Xiao, Shu-yuan; Tian, Sufang			Expansile invasive growth pattern is definite evidence for the diagnosis of small hepatocellular carcinomas: a comparative study of 37 cases	HUMAN PATHOLOGY			English	Article						Expansile invasive growth pattern; Small HCCs; Small and early HCCs; Small and progressed HCCs; Stomal invasion	DYSPLASTIC NODULES; GLUTAMINE-SYNTHETASE; FACTOR-RECEPTOR; ADENOMA; CLASSIFICATION; DISTINCTION; EXPRESSION; LESIONS; LIVER	Small HCCs, including seHCC and spHCC, are rarely encountered in daily practice. Definite diagnosis is difficult for general pathologists. In this study, we reviewed 1025 cases of HCC and examined the histologic characteristics of small HCCs to facilitate more accurate diagnosis. Slides of archived HCC cases were reviewed by 2 senior pathologists, and small HCCs were identified according to the canonical criteria. Additional immunohistochemical stains were performed. Thirty-seven cases of small HCC were identified, including 22 cases of seHCC and 15 cases of spHCC. We found 2 types of invasive growth patterns in these lesions. The first is the expansile invasive growth pattern, with monomorphic tumor cells penetrating through the incomplete fibrous capsules and expanding into the adjacent noncancerous liver with a spherical, hemispheric, or mushroom shape. The second is the classic stromal invasion pattern. At least one type of invasive pattern was observed in all of the 37 cases of small HCC, and the seHCCs exhibit the expansile invasive growth pattern more frequently than the classic stromal invasion pattern. On the contrary, stromal invasive pattern was more common in spHCC nodules. In conclusion, with the background of chronic hepatitis and cirrhosis, histologic features including crowdedness of hepatocytic trabeculae and the expansile invasive growth pattern are strong evidence for the diagnoses of small HCC. (C) 2018 Elsevier Inc. All rights reserved.	[Chen, Qiongrong; Xiao, Shu-yuan; Tian, Sufang] Wuhan Univ, Dept Pathol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Chen, Qiongrong; Xiao, Shu-yuan; Tian, Sufang] Wuhan Univ, Pathol Ctr, Wuhan 430071, Hubei, Peoples R China; [Wang, Manxiang; Wang, Mingwei; Jin, Su] Hubei Canc Hosp, Dept Pathol, Wuhan 430079, Hubei, Peoples R China	Tian, SF (reprint author), Wuhan Univ, Dept Pathol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.; Tian, SF (reprint author), Wuhan Univ, Pathol Ctr, Wuhan 430071, Hubei, Peoples R China.	usa2005tiansufang@hotmail.com			Wuhan Young and Mid-Career Medical Experts program 2014	This study was financially supported by the Wuhan Young and Mid-Career Medical Experts program 2014 (the principal investigator is Qiongrong Chen).	[Anonymous], 2015, Zhonghua Gan Zang Bing Za Zhi, V23, P321; Bosman FT, 2010, WHO CLASSIFICATION T; Desmet VJ, 2009, HEPATOLOGY, V49, P355, DOI 10.1002/hep.22681; Di Tommaso L, 2011, HEPATOLOGY, V53, P1549, DOI 10.1002/hep.24218; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Feng LH, 2017, ONCOTARGET, V8, P87329, DOI 10.18632/oncotarget.20607; Fukatsu A, 2013, AM J CLIN PATHOL, V140, P500, DOI 10.1309/AJCPIMPE6ZFT8AME; Hale G, 2016, MODERN PATHOL, V29, P1370, DOI 10.1038/modpathol.2016.122; Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131; Jin GZ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-161; Jin So-Young, 2011, Korean J Hepatol, V17, P238, DOI 10.3350/kjhep.2011.17.3.238; Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Kojiro Masamichi, 2004, Liver Transpl, V10, pS3, DOI 10.1002/lt.20042; Kondo F, 2011, INT J HEPATOL, DOI 10.4061/2011/241652; KURMAN RJ, 1982, CANCER, V49, P2547, DOI 10.1002/1097-0142(19820615)49:12<2547::AID-CNCR2820491224>3.0.CO;2-0; Kutami R, 2000, J HEPATOL, V33, P282, DOI 10.1016/S0168-8278(00)80369-4; Lee KR, 2003, INT J GYNECOL PATHOL, V22, P42, DOI 10.1097/01.PGP.0000040092.04359.E9; Lennerz JKM, 2011, AM J PATHOL, V179, P1015, DOI 10.1016/j.ajpath.2011.04.040; Luo Q, 2015, ONCOTARGET, V6, P6989, DOI 10.18632/oncotarget.3136; Margolskee E, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0475-5; Matsunobu T, 2006, INT J ONCOL, V28, P307; Ministry of Health of the People's Republic of China, 2012, Zhonghua Gan Zang Bing Za Zhi, V20, P419; Nakano M, 1997, LIVER, V17, P41; Nguyen TB, 2016, MODERN PATHOL, V29, P283, DOI 10.1038/modpathol.2015.162; Park YN, 2007, CANCER, V109, P915, DOI 10.1002/cncr.22460; Park YN, 2011, ARCH PATHOL LAB MED, V135, P704, DOI 10.1043/2010-0524-RA.1; Prall F, 2007, HISTOPATHOLOGY, V50, P318, DOI 10.1111/j.1365-2559.2007.02609.x; Ronealli M, 2011, DIG LIVER DIS S4, V43, P361; Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130; Sciarra A, 2016, J HEPATOL, V64, P87, DOI 10.1016/j.jhep.2015.08.031; You JS, 2015, HUM PATHOL, V46, P583, DOI 10.1016/j.humpath.2015.01.001	32	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						130	137		10.1016/j.humpath.2018.06.011			8	Pathology	Pathology	GX5US	WOS:000447817100016	29936057				2019-10-28	
J	Ferreira, CR; Zhao, SC; Sahoo, MK; Pinsky, B; Weber, J; Lage, LAPC; Pereira, J; Zerbini, MCN; Natkunam, Y				Ferreira, Cristiane R.; Zhao, Shuchun; Sahoo, Malaya K.; Pinsky, Benjamin; Weber, Jenna; Lage, Luis A. P. C.; Pereira, Juliana; Zerbini, Maria C. N.; Natkunam, Yasodha			FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype	HUMAN PATHOLOGY			English	Article						ATLL; FOXP3; PTCL-NOS; ALK-ALCL; Regulatory T-Cell; Lymphoma; Immunohistochemistry	LEUKEMIA-VIRUS; LYMPHOTROPIC VIRUS; PD-L1 EXPRESSION; FOXP3 EXPRESSION; LEUKEMIA/LYMPHOMA; LEUKAEMIA/LYMPHOMA; INFILTRATION; PROGNOSIS; FEATURES; IMMUNITY	Forkhead box P3 (FOXP3) is a specific marker for regulatory T-cells (Tregs). We report 6 cases of T-cell lymphomas with Treg phenotype based on diffuse positivity for FOXP3 in tumor cells. The patients showed a median age of 56 years with a male predominance. Sites of disease included lymph nodes (4), skin (2), subcutaneous tissue (1) and bone marrow (1). All cases showed monomorphic large cells, some with Hodgkin-like or anaplastic cells. All cases expressed pan T-cell markers and lacked cytotoxic markers; one case showed diffuse PD1 staining. Only one case harbored human T-lymphotrophic virus (HTLV)-1 DNA within tumor cells and was classified as adult T-cell leukemia/lymphoma (ATLL). Among 5 HTLV1-negative cases, 3 were classified as peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 2 fulfilled criteria for ALK-negative anaplastic large cell lymphoma (ALCL) with diffuse and strong CD30 positivity. We concluded that Treg phenotype may be rarely seen in HTLV1-negative cases, such as PTCL, NOS and ALK-negative ALCL. Our findings expand the spectrum of T-cell lymphomas with regulatory phenotype and suggest that consideration should be given to HTLV1 DNA testing in the appropriate clinical setting to rule out ATLL. (C) 2018 Elsevier Inc. All rights reserved.	[Ferreira, Cristiane R.; Zhao, Shuchun; Sahoo, Malaya K.; Pinsky, Benjamin; Weber, Jenna; Natkunam, Yasodha] Stanford Univ, Dept Pathol, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA; [Ferreira, Cristiane R.; Zerbini, Maria C. N.] Univ Sao Paulo, Dept Pathol, BR-01246 Sao Paulo, SP, Brazil; [Lage, Luis A. P. C.; Pereira, Juliana] Univ Sao Paulo, Dept Hematol, BR-01246 Sao Paulo, SP, Brazil	Natkunam, Y (reprint author), Stanford Univ, Dept Pathol, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA.	yaso@stanford.edu	PEREIRA, JULIANA/C-2742-2014; Zerbini, Maria Claudia/D-1586-2012	PEREIRA, JULIANA/0000-0002-0655-2821; Zerbini, Maria Claudia/0000-0002-7408-9816; Pinsky, Benjamin/0000-0001-8751-4810; Weber, Jenna/0000-0002-8192-7945; Sahoo, Malaya/0000-0001-9837-4032	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/09180-0]	Dr. Ferreira thanks Sao Paulo Research Foundation (FAPESP; grant: 2016/09180-0) for funding a one-year fellowship at Stanford University School of Medicine, Stanford, California, USA.	Attygalle AD, 2014, HISTOPATHOLOGY, V64, P171, DOI 10.1111/his.12251; Bangham CRM, 2011, ADV CANCER RES, V111, P163, DOI 10.1016/B978-0-12-385524-4.00004-0; Beltran BE, 2012, APPL IMMUNOHISTO M M, V20, P196, DOI 10.1097/PAI.0b013e318225189f; Bonzheim I, 2008, AM J CLIN PATHOL, V130, P613, DOI 10.1309/L65GWEQ803PP6VX1; Brunetto GS, 2014, J NEUROVIROL, V20, P341, DOI 10.1007/s13365-014-0249-3; Chtanova T, 2005, J IMMUNOL, V175, P7837, DOI 10.4049/jimmunol.175.12.7837; De Oliveira MSP, 1999, INT J CANCER, V83, P291; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gualco G, 2009, AM J CLIN PATHOL, V132, P28, DOI 10.1309/AJCP6Q7QMUVGMVMF; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang CT, 2014, INTERN MED J, V44, P374, DOI 10.1111/imj.12394; Jaffe E. S., 2017, WHO CLASSIFICATION T, P190; Kamihira S, 2005, CLIN LAB HAEMATOL, V27, P235, DOI 10.1111/j.1365-2257.2005.00698.x; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Karube K, 2008, MODERN PATHOL, V21, P617, DOI 10.1038/modpathol.2008.25; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Kozako T, 2009, LEUKEMIA, V23, P375, DOI 10.1038/leu.2008.272; Kubota T, 1996, AM J HEMATOL, V53, P133; Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549; Mills AM, 2013, AM J SURG PATHOL, V37, P995, DOI 10.1097/PAS.0b013e31827fcc33; OHSHIMA K, 1991, CANCER, V67, P1622, DOI 10.1002/1097-0142(19910315)67:6<1622::AID-CNCR2820670625>3.0.CO;2-1; Ohshima K, 2017, WHO CLASSIFICATION T, P363; Ohshima K, 2007, CANCER SCI, V98, P772, DOI 10.1111/j.1349-7006.2007.00456.x; Que Y, 2017, J CANCER, V8, P2018, DOI 10.7150/jca.18683; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965; Roychoudhuri R, 2015, CURR OPIN IMMUNOL, V33, P101, DOI 10.1016/j.coi.2015.02.003; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Satou A, 2016, HISTOPATHOLOGY, V68, P1099, DOI 10.1111/his.12885; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tzankov A, 2008, HAEMATOL-HEMATOL J, V93, P193, DOI 10.3324/haematol.11702; Vicente C, 2015, NAT GENET, V47, P1226, DOI 10.1038/ng.3428; Wilcox RA, 2009, BLOOD, V114, P2149, DOI 10.1182/blood-2009-04-216671; Woodland DL, 2003, CURR OPIN IMMUNOL, V15, P336, DOI 10.1016/S0952-7915(03)00037-2; Zhu YM, 2016, ONCOTARGET, V7, P71455, DOI 10.18632/oncotarget.12213	35	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						138	144		10.1016/j.humpath.2018.06.001			7	Pathology	Pathology	GX5US	WOS:000447817100017	29898383				2019-10-28	
J	Huang, HS; Liao, CK; Liu, TT; You, HL; Wang, MC; Huang, WT				Huang, Hui-Shan; Liao, Chun-Kai; Liu, Ting-Ting; You, Huey-Ling; Wang, Ming-Chung; Huang, Wan-Ting			TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression	HUMAN PATHOLOGY			English	Article						TP53 mutation; p53 expression; Angioimmunoblastic T-cell lymphoma; Peripheral T-cell lymphoma, not otherwise specified; Extranodal nasal-type NK/T-cell lymphoma; Intestinal T-cell lymphoma	GENE-MUTATIONS; BREAST-CANCER; IMPACT; CHEMOTHERAPY; POLYMORPHISM	Peripheral mature T and NK cell lymphomas consist of a heterogeneous group of neoplasms with cytogenetic and molecular diversities. TP53 mutation is involved in the events of tumorigenesis and present in a variety of cancer subtypes. However, TP53 mutation in peripheral mature T and NK cell lymphomas has not been extensively investigated. In this study, 57 formalin-fixed paraffin-embedded samples were collected for whole-exome sequencing and immunohistochemical study. Ten cases had TP53 mutation variant allele frequency (VAF) of more than 5%, predominantly in intestinal T-cell lymphoma (60%), peripheral T cell lymphoma, not otherwise specified (22.2%), and extranodal nasal-type NK/T-cell lymphoma (21.7%). Six of 16 (37.5%) cases with 72Pro homozygous genotype showed higher frequency of TP53 mutation VAF > 5% than did those with 72Arg homozygous genotype (P = .044). To a variable extent, overexpression of p53 was observed in 11 of 56 (19.6%) tumors. The percentage of tumor cells with strong p53 staining was positively correlated with TP53 mutation VAF (R-2 = 0.95, P <.001). TP53 mutation and p53 expression tended to indicate poor prognosis (P = .054 and P = .009, respectively). In conclusion, we demonstrated TP53 mutation and p53 expression in subtypes of peripheral mature T and NK cell lymphomas and found positive correlation of this immunostaing pattern with the status of TP53 mutation. (C) 2018 Elsevier Inc. All rights reserved.	[Huang, Hui-Shan; You, Huey-Ling; Huang, Wan-Ting] Kaohsiung Chang Gung Mem Hosp, Dept Lab Med, Kaohsiung 83301, Taiwan; [Huang, Hui-Shan; Liao, Chun-Kai; You, Huey-Ling; Wang, Ming-Chung; Huang, Wan-Ting] Chang Gung Univ, Coll Med, Kaohsiung 83301, Taiwan; [Huang, Hui-Shan; Liu, Ting-Ting; Huang, Wan-Ting] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 833031, Taiwan; [Huang, Hui-Shan; Liu, Ting-Ting; Huang, Wan-Ting] Chang Gung Univ, Coll Med, Kaohsiung 833031, Taiwan; [Liao, Chun-Kai; Wang, Ming-Chung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Hematol Oncol Div, Kaohsiung 83301, Taiwan; [You, Huey-Ling; Huang, Wan-Ting] Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung 83102, Taiwan	Huang, WT (reprint author), Chang Gung Mem Hosp, Dept Lab Med, Kaohsiung Med Ctr, 123 Ta Pei Rd, Kaohsiung, Taiwan.	maggie1211@cgmh.org.tw; jimwaterburg@gmail.com; liutt107@cgmh.org.tw; ouhling@cgmh.org.tw; wangmt@cgmh.org.tw; huangwanting5@gmail.com			Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG8F1241, CMRPG8F1242]	This study was supported by the Chang Gung Memorial Hospital (grant number CMRPG8F1241 and CMRPG8F1242).	Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Boldrini L, 2008, ONCOL REP, V19, P771; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CESARMAN E, 1992, BLOOD, V80, P3205; Deleeuw RJ, 2007, GASTROENTEROLOGY, V132, P1902, DOI 10.1053/j.gastro.2007.03.036; Kang HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072609; Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li T, 2000, LAB INVEST, V80, P493, DOI 10.1038/labinvest.3780055; Lin CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep17879; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Marrogi AJ, 1999, J CUTAN PATHOL, V26, P369, DOI 10.1111/j.1600-0560.1999.tb01860.x; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Petit B, 2001, HUM PATHOL, V32, P196, DOI 10.1053/hupa.2001.21569; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Phang BH, 2015, P NATL ACAD SCI USA, V112, pE6349, DOI 10.1073/pnas.1510043112; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Quintanilla-Martinez L, 2001, AM J PATHOL, V159, P2095, DOI 10.1016/S0002-9440(10)63061-1; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Swerdlow SH, 2017, WHO CLASSIFICATION T, P197; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Xu C, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3425-4; Xu PP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174809; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592	31	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						145	151		10.1016/j.humpath.2018.05.026			7	Pathology	Pathology	GX5US	WOS:000447817100018	29885407				2019-10-28	
J	Piao, LZ; Yang, ZT; Jin, JJ; Ni, WD; Qi, WB; Xuan, YH				Piao, Longzhen; Yang, Zhaoting; Jin, Jiajun; Ni, Weidong; Qi, Wenbo; Xuan, Yanhua			B7H4 is associated with sternness and cancer chTor, progression in esophageal squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						B7H4; Esophageal squamous cell carcinoma; Prognosis; Cancer sternness; Cell cycle; HIF-l alpha	STEM-LIKE CELLS; PANCREATIC-CANCER; TUMOR PROGRESSION; B7-H4 EXPRESSION; PROLIFERATION; POPULATION; BIOMARKER; SURVIVAL; INVASION; PATHWAY	B7H4 is overexpressed in human cancers and often correlates with poor clinical outcome. There is a lack of data on the role of B7H4 as a cancer stem cell (CSC) regulator in esophageal squamous cell carcinoma (ESCC) and its expression levels compared to other sternness genes in ESCC. In this study, we have assessed the expression of B7H4 and cancer sternness proteins in 156 paraffin-embedded ESCC tissue samples using immunohistochemistry as well as in ESCC cell lines using Western blotting and immunofluorescence imaging. The correlation of B7H4 expression with clinicopathological parameters, cell cycle regulating genes, and PI3K/Akt/NF-kappa B signaling genes was investigated. The expression of B7H4 in ESCC tissue was correlated with the primary tumor (pT) stage, stromal activity, and the expression of CD68 and HIF-1 alpha. However, B7H4 expression was negatively associated with CD8+ T cell infiltration in ESCC tissues. Moreover, B7H4 was found to be strongly linked to prognostic factors leading to poor clinical outcome. B7H4-expressing cancer cells also expressed known cancer sternness proteins (Sox9, LSD1, Oct4, and LGR5). Moreover, B7H4, Sox9, LSD1, Oct4, and LGR5 were highly expressed in more poorly differentiated ESCC cell lines. Notably, B7H4 expression was positively associated with the expression of cell cycle regulators such as cyclin D1, p27, and PI3K/Akt/NF/kappa B signaling proteins. B7H4 could be a novel cancer stem cell marker for the prognostic evaluation of ESCC patients as well as a potential therapeutic target against ESCC. (C) 2018 Elsevier Inc. All rights reserved.	[Piao, Longzhen] Yanbian Univ, Affiliated Hosp, Dept Oncol, Yanji 133002, Jilin, Peoples R China; [Yang, Zhaoting; Ni, Weidong; Qi, Wenbo; Xuan, Yanhua] Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Mol, Minist Educ, Yanji 133002, Jilin, Peoples R China; [Yang, Zhaoting; Ni, Weidong; Qi, Wenbo; Xuan, Yanhua] Yanbian Univ, Dept Pathol, Coll Med, Yanji 133002, Jilin, Peoples R China; [Jin, Jiajun] Shenyang Fifth People Hosp, Dept Oncol, Shenyang 110023, Jilin, Peoples R China	Xuan, YH (reprint author), Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Molecul, Minist Educ, 977 Gongyuan Rd, Yanji, Peoples R China.; Xuan, YH (reprint author), Yanbian Univ, Coll Med, Dept Pathol, 977 Gongyuan Rd, Yanji, Peoples R China.	plz1978@126.com; 945986163@qq.com; jjj126hz@163.com; 939819731@qq.com; 767623287@qq.com; xuanyh1@ybu.edu.cn			National Natural Science Funds of ChinaNational Natural Science Foundation of China [81460390, 81760531]	This study was supported by grants from National Natural Science Funds of China (No. 81460390, 81760531).	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Almozyan S, 2017, INT J CANCER, V141, P1402, DOI 10.1002/ijc.30834; Arigami T, 2011, WORLD J SURG, V35, P2051, DOI 10.1007/s00268-011-1186-4; Arigami T, 2010, J SURG ONCOL, V102, P748, DOI 10.1002/jso.21722; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Dangaj D, 2013, CANCER RES, V73, P4820, DOI 10.1158/0008-5472.CAN-12-3457; Galazka K, 2012, AM J REPROD IMMUNOL, V68, P85, DOI 10.1111/j.1600-0897.2012.01134.x; Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280; Jeon YK, 2015, BIOCHEM BIOPH RES CO, V459, P277, DOI 10.1016/j.bbrc.2015.02.098; Jiang L, 2017, ONCOTARGET, V8; Kim HK, 2014, PFLUG ARCH EUR J PHY, V466, P2323, DOI 10.1007/s00424-014-1493-3; Krambeck AE, 2006, P NATL ACAD SCI USA, V103, P10391, DOI 10.1073/pnas.0600937103; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Lee S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099452; Luan XY, 2013, TISSUE CELL, V45, P32, DOI 10.1016/j.tice.2012.09.002; Qian Y, 2013, CELL TISSUE RES, V353, P139, DOI 10.1007/s00441-013-1640-8; Rassouli FB, 2013, TUMOR BIOL, V34, P2909, DOI 10.1007/s13277-013-0853-5; Shen LW, 2017, HUM PATHOL, V66, P79, DOI 10.1016/j.humpath.2017.05.023; Simon I, 2006, CANCER RES, V66, P1570, DOI 10.1158/0008-5472.CAN-04-3550; Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991; Uemura N, 2015, BBA-PROTEINS PROTEOM, V1854, P687, DOI 10.1016/j.bbapap.2014.09.011; Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003; Yang ZT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145807; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Yu SC, 2009, STEM CELL REV REP, V5, P66, DOI 10.1007/s12015-008-9047-8; Zang XX, 2007, CLIN CANCER RES, V13, P5271, DOI 10.1158/1078-0432.CCR-07-1030; Zhang C, 2015, J SURG RES, V197, P301, DOI 10.1016/j.jss.2015.04.034; Zhang G, 2012, MOL MED REP, V6, P519, DOI 10.3892/mmr.2012.939; Zhang L, 2013, ONCOGENE, V32, P5347, DOI 10.1038/onc.2012.600; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419	32	1	2	3	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						152	162		10.1016/j.humpath.2018.05.021			11	Pathology	Pathology	GX5US	WOS:000447817100019	29885401				2019-10-28	
J	Tawfik, O; Kimler, BF; Karnik, T; Shehata, P				Tawfik, Ossama; Kimler, Bruce F.; Karnik, Tejashree; Shehata, Peter			Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells	HUMAN PATHOLOGY			English	Article						Breast cancer; Local and distant metastasis; Programmed cell death ligand-1; Tumor-infiltrating immune cells; Primary and metastatic breast cancer PD-L1	DEATH 1; LYMPHOCYTES; IMMUNOHISTOCHEMISTRY; MICROENVIRONMENT; PROGNOSIS; CARCINOMA; LEADS	Few studies have evaluated the expression of the programmed cell death-1 and its ligand-1 (PD-L1) in breast cancer. In this study, we correlated differential expression of PD-L1 in breast cancer (BC) and its microenvironment from a cohort of patients with BC, paired locally metastatic disease to regional lymph nodes (LNs) and nonpaired distantly metastatic disease (mets). PD-L1 expression was correlated with several pathologic and clinical parameters in tumor and tumor immune cells (ICs; CD3, CD4, CD8, CD20, and CD68) using the Ventana antibody (SP263) in 41 BCs, 46 paired mets in LNs, and 46 distant mets. There was 100% agreement for PD-L1 expression on tumor and ICs between BC and matched LN. PD-L1 is differentially expressed in primary BC and regional nodal disease. Expression correlated with higher grade, hormone receptor negativity, and highly proliferative tumors (P<.001). In LNs, the high positivity rate was driven by triple-negative status (70% versus 5%; P<.0001). In contrast, there was significantly near-total absence of PD-L1 expression in distant mets compared with BC and LNs (2%-4% in mets versus 17%-20% in BC and LN, P=.009). IC density varied in BC and metastatic tumors with predominance of CD3 and CD68 and near total absence of CD20 cells. PD-L1 expression was mainly associated with CD68 cells. There were consistent higher numbers of CD3 (CD8 > CD4) than CD20 cells in primary and metastatic tumors. Correlation of PD-L1 expression in BC and its microenvironment may be useful for the development of new treatment strategies. Published by Elsevier Inc.	[Tawfik, Ossama; Karnik, Tejashree; Shehata, Peter] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Kimler, Bruce F.] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66160 USA	Tawfik, O (reprint author), St Lukes Hosp Kansas City, Dept Pathol & Lab Med, MAWD Pathol Grp, 2750 Clay Edwards Dr,Suite 420 N, Kansas City, MO 64116 USA.	otawfik@mawdpathology.com					AiErken N, 2017, INT J BIOL SCI, V13, P1172, DOI 10.7150/ijbs.20868; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Baptista MZ, 2016, HUM PATHOL, V47, P78, DOI 10.1016/j.humpath.2015.09.006; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Beckers RK, 2016, HISTOPATHOLOGY, V69, P25, DOI 10.1111/his.12904; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Buisseret L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1257452; Butte MJ, 2008, MOL IMMUNOL, V45, P3567, DOI 10.1016/j.molimm.2008.05.014; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Duchnowska R, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0702-8; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Ghebeh H, 2006, NEOPLASIA, V8, P190, DOI 10.1593/neo.05733; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Karnik T, 2018, HUM PATHOL, V72, P28, DOI 10.1016/j.humpath.2017.08.010; Kim A, 2017, SCI REP, V7, P1167, DOI [10.1038/s41598-11905-7, DOI 10.1038/S41598-11905-7]; Kitano A, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2016-000150; Lanng C, 2007, EJSO-EUR J SURG ONC, V33, P281, DOI 10.1016/j.ejso.2006.09.032; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Muenst S, 2013, BREAST CANCER RES TR, V139, P667, DOI 10.1007/s10549-013-2581-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; RUFFIN WK, 1995, J AM COLL SURGEONS, V180, P245; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Soliman H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088557; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sun WY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0925-6; Wang ZQ, 2017, ONCOTARGET, V8, P51641, DOI 10.18632/oncotarget.18305; Yaziji H, 2017, APPL IMMUNOHISTO M M, V25, P1, DOI 10.1097/PAI.0000000000000472; Zhang MH, 2017, ONCOTARGET, V8, P31347, DOI 10.18632/oncotarget.15532	35	4	4	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						170	178		10.1016/j.humpath.2018.06.008			9	Pathology	Pathology	GX5US	WOS:000447817100021	29936058				2019-10-28	
J	Liu, ZF; Ma, CG; Ma, GH; Sun, XM; Liu, J; Li, S; Liu, K; Wang, JY; Yang, D				Liu, Zifeng; Ma, Changgeng; Ma, Guohui; Sun, Xiumei; Liu, Jin; Li, Shuang; Liu, Kang; Wang, Junye; Yang, Dong			High expression of tumor necrosis factor receptor 2 in tissue is associated with progression and prognosis of esophageal squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						Esophageal squamous cell carcinoma; Tumor necrosis factor receptor 2; Overall survival; Immunohistochemistry	INFLAMMATORY RESPONSES; CANCER-CELLS; TNF-ALPHA; PROGRANULIN; RADIOTHERAPY; ARTHRITIS; MOLECULE; SURVIVAL	In recent years, the role of TNFR2 has attracted much attention for its promotion role in several types of tumors. However, in ESCC, the clinical relevance of TNFR2 is still unknown. In this study, we detected TNFR2 expression in ESCC tissues using immunohistochemistry. The chi(2) test showed that TNFR2 was positively correlated with invasion depth, advanced clinical stage, and low differentiation; survival analysis showed that TNFR2 was positively correlated with poor OS; univariate Cox regression analysis showed that clinical stage, lymph node involvement, and invasion depth were all correlated with OS; and multivariate Cox regression analysis showed that lymph node involvement and invasion depth were independent prognostic factors. In male cases, TNFR2 was positively correlated with invasion depth, advanced clinical stage, low differentiation, and poor OS; univariate Cox regression analysis showed that clinical stage, lymph node involvement, and invasion depth were all associated with OS; and multivariate Cox regression analysis showed that lymph node involvement was an independent prognostic factor. In female cases, TNFR2 was positively correlated with invasion depth, advanced clinical stage, and poor OS; univariate Cox regression analysis showed that only lymph node involvement was associated with OS. All the results confirmed that TNFR2 in ESCC tissues was positively correlated with progression and poor prognosis of ESCC patients. Lymph node involvement and invasion depth can be treated as independent prognostic factors. (C) 2018 Elsevier Inc. All rights reserved.	[Liu, Zifeng] Jining Med Univ, Affiliated Hosp, Med Dept, Jining 272029, Shandong, Peoples R China; [Ma, Changgeng; Sun, Xiumei; Liu, Jin; Liu, Kang] Weifang Med Univ, Affiliated Hosp, Oncol Dept, Weifang 261000, Shandong, Peoples R China; [Ma, Guohui] Shandong Univ, Jinan Cent Hosp, Dept Breast & Thyroid, Jinan 250013, Shandong, Peoples R China; [Li, Shuang] Weifang Tradit Chinese Hosp, Radiotherapy Dept, Weifang 261041, Shandong, Peoples R China; [Wang, Junye; Yang, Dong] Jining Med Univ, Affiliated Hosp, Oncol Dept, 89 Guhuai Rd, Jining 272029, Shandong, Peoples R China	Wang, JY; Yang, D (reprint author), Jining Med Univ, Affiliated Hosp, Oncol Dept, 89 Guhuai Rd, Jining 272029, Shandong, Peoples R China.	junyewang1234@163.com; mike19840320@126.com					Dobrzycka B, 2009, EUR CYTOKINE NETW, V20, P131, DOI 10.1684/ecn.2009.0161; Dong QZ, 2017, ONCOTARGET, V8, P55135, DOI 10.18632/oncotarget.19069; Feng J, 2017, WORLD J GASTROENTERO, V23, P4243, DOI 10.3748/wjg.v23.i23.4243; Geary LA, 2014, MOL CANCER RES, V12, P607, DOI 10.1158/1541-7786.MCR-13-0469; Grotowski Maciej, 2003, Pol Merkur Lekarski, V14, P327; Han GJ, 2017, ONCOTARGET, V8, P61742, DOI 10.18632/oncotarget.18687; Jiang Q, 2017, MED SCI MONITOR, V23, P3200, DOI 10.12659/MSM.904992; Johrer K, 2004, CLIN CANCER RES, V10, P1901, DOI 10.1158/1078-0432.CCR-1053-03; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Li DJ, 2016, J BUON, V21, P1268; Lu J., 2015, BIOMED RES INT, V2015; Martin EM, 2014, INNATE IMMUN-LONDON, V20, P712, DOI 10.1177/1753425913506949; Mathieu LN, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.30_suppl.47; Nakamura N, 2013, EUR J HAEMATOL, V91, P322, DOI 10.1111/ejh.12139; Nan JL, 2017, CIRC RES, V121, P392, DOI 10.1161/CIRCRESAHA.117.311143; Nomura M, 2017, JPN J CLIN ONCOL, V47, P480, DOI 10.1093/jjco/hyx040; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tanimura Y, 2005, CANCER LETT, V219, P205, DOI 10.1016/j.canlet.2004.07.027; Wang LL, 2017, ONCOTARGET, V8, P26323, DOI 10.18632/oncotarget.15461; Yang D, 2015, AM J CANCER RES, V5, P3085; Yang FQ, 2017, ONCOL LETT, V14, P2393, DOI 10.3892/ol.2017.6410; Yang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182660; Yin H, 2017, CLIN TRANSL ONCOL, V19, P742, DOI 10.1007/s12094-016-1603-0; Zhang HF, 2017, CELL BIOL INT, V41, P415, DOI 10.1002/cbin.10735; Zhao YP, 2013, BIOMATERIALS, V34, P6412, DOI 10.1016/j.biomaterials.2013.05.030	25	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						179	185		10.1016/j.humpath.2018.03.027			7	Pathology	Pathology	GX5US	WOS:000447817100022	29920311				2019-10-28	
J	Chatterjee, D; Garg, C; Singla, N; Radotra, BD				Chatterjee, Debajyoti; Garg, Chandni; Singla, Navneet; Radotra, Bishan Dass			Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation	HUMAN PATHOLOGY			English	Article						BRAF V600E; Desmoplastic infantile ganglioglioma; Desmoplastic infantile astrocytoma; Immunohistochemistry; VEI	VE1 ANTIBODY; GANGLIOGLIOMA; ASTROCYTOMA; GLIOMAS; IMMUNOHISTOCHEMISTRY; EXPRESSION; PITUITARY; MELANOMA	Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) are rare primary glioneuronal tumors that comprise 0.5% to 1.0% of all intracranial tumors. While BRAF mutation is found in up to 50% of pediatric gangliogliomas, data for DIA/DIGs is limited. This study was carried out to evaluate the frequency of BRAF V600E mutation in DIA/DIG. All cases of DIA/DIGs diagnosed over 7 years (2010-2016) were reviewed retrospectively. The clinical, radiological and histopathological characteristics of these patients were evaluated along with immunohistochemical analysis for glial and neuronal markers. We evaluated presence of BRAF V600E mutation by Sanger sequencing and immunohistochemistry using monoclonal antibody against clone VE1. Eight cases of desmoplastic infantile astrocytoma/ganglioglioma (6 DIGs and 2 DIAs) were evaluated. Four cases were of infantile type (age 10 months-2 years) and 4 cases of non-infantile type (age 10-14 years). BRAF VEI immunohistochemistry (IHC) was positive in four cases (two DIG and two DIA). All these four cases also showed heterozygous BRAF V600E mutation (T replaced by A at nucleotide position 1799). Sequencing didn't detect BRAF mutation in any additional case. All four cases harboring this mutation were non-infantile (10-14 years). Cases with infantile presentation didn't carry this mutation. None of the cases showed recurrence on follow-up. Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis. Identification of BRAF status opens the possibility of targeted therapies for the subset of cases that clinically progress post-resection. (C) 2018 Elsevier Inc. All rights reserved.	[Chatterjee, Debajyoti; Garg, Chandni; Radotra, Bishan Dass] Postgrad Inst Med Educ & Res PGIMER, Dept Histopathol, Chandigarh 160012, India; [Singla, Navneet] Postgrad Inst Med Educ & Res PGIMER, Dept Neurosurg, Chandigarh 160012, India	Radotra, BD (reprint author), Postgrad Inst Med Educ & Res PGIMER, Dept Histopathol, Chandigarh 160012, India.	devchat1984@gmail.com; chandnigarg_88@yahoo.com; drnavi2007@yahoo.co.in; bishanradotra@gmail.com					Bergthold G, 2015, NEURO-ONCOLOGY, V17, P1486, DOI 10.1093/neuonc/nov045; Brat DJ, 2016, WHO CLASSIFICATION T, P144; Capper D, 2012, ACTA NEUROPATHOL, V123, P223, DOI 10.1007/s00401-011-0887-y; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Chatterjee Debajyoti, 2018, Surg Neurol Int, V9, P29, DOI 10.4103/sni.sni_284_17; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Donson AM, 2014, BRAIN PATHOL, V24, P173, DOI 10.1111/bpa.12103; Dougherty MJ, 2010, NEURO-ONCOLOGY, V12, P621, DOI 10.1093/neuonc/noq007; Gelabert-Gonzalez M, 2011, NEUROSURG REV, V34, P151, DOI 10.1007/s10143-010-0303-4; Gessi M, 2013, J NEUROPATH EXP NEUR, V72, P807, DOI 10.1097/NEN.0b013e3182a033a0; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hoving EW, 2008, J NEUROSURG-PEDIATR, V1, P95, DOI 10.3171/PED-08/01/095; Hummel TR, 2012, J PEDIAT HEMATOL ONC, V34, pE232, DOI 10.1097/MPH.0b013e3182580330; Hussain MRM, 2015, SAUDI J BIOL SCI, V22, P359, DOI 10.1016/j.sjbs.2014.10.002; Jones RT, 2015, MODERN PATHOL, V28, P596, DOI 10.1038/modpathol.2014.150; Karabagli P, 2014, BRAIN TUMOR PATHOL, V31, P282, DOI 10.1007/s10014-014-0179-z; Kleinschmidt-DeMasters BK, 2015, AM J SURG PATHOL, V39, P528, DOI 10.1097/PAS.0000000000000363; Koelsche C, 2014, NEUROPATH APPL NEURO, V40, P337, DOI 10.1111/nan.12072; Koelsche C, 2013, ACTA NEUROPATHOL, V125, P891, DOI 10.1007/s00401-013-1100-2; Kros JM, 2002, ACTA NEUROPATHOL, V104, P144, DOI 10.1007/s00401-002-0534-8; Long GV, 2013, AM J SURG PATHOL, V37, P61, DOI 10.1097/PAS.0b013e31826485c0; Machnicki MM, 2013, ACTA BIOCHIM POL, V60, P57; Mordes DA, 2014, AM J CLIN PATHOL, V141, P811, DOI 10.1309/AJCP37TLZLTUAOJL; Nicolaides TP, 2011, CLIN CANCER RES, V17, P7595, DOI 10.1158/1078-0432.CCR-11-1456; Prabowo AS, 2014, BRAIN PATHOL, V24, P52, DOI 10.1111/bpa.12081; Qaddoumi I, 2016, ACTA NEUROPATHOL, V131, P833, DOI 10.1007/s00401-016-1539-z; Rush S, 2013, J CLIN ONCOL, V31, pE159, DOI 10.1200/JCO.2012.44.1568; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Sperveslage J, 2013, ACTA NEUROPATHOL, V125, P911, DOI 10.1007/s00401-013-1118-5; TARATUTO AL, 1984, CANCER, V54, P2505, DOI 10.1002/1097-0142(19841201)54:11<2505::AID-CNCR2820541132>3.0.CO;2-G; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Trehan G, 2004, AM J NEURORADIOL, V25, P1028; VANDENBERG SR, 1987, J NEUROSURG, V66, P58, DOI 10.3171/jns.1987.66.1.0058; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Ziai J, 2012, EXPERT REV MOL DIAGN, V12, P127, DOI [10.1586/ERM.12.1, 10.1586/erm.12.1]	35	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						186	191		10.1016/j.humpath.2018.06.005			6	Pathology	Pathology	GX5US	WOS:000447817100023	29902580				2019-10-28	
J	Johnson, SM; Umakanthan, JM; Yuan, J; Fedoriw, Y; Bociek, RG; Kaiser-Rogers, K; Sanmann, JN; Montgomery, ND				Johnson, Steven M.; Umakanthan, Jayadev Manikkam; Yuan, Ji; Fedoriw, Yuri; Bociek, R. Gregory; Kaiser-Rogers, Kathleen; Sanmann, Jennifer N.; Montgomery, Nathan D.			Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations	HUMAN PATHOLOGY			English	Article						Double-hit lymphoma; High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; t(3;8)(q27;q24); Triple-hit lymphoma; Lymphoma cytogenetics	B-CELL LYMPHOMA; MYC TRANSLOCATIONS; HODGKIN-LYMPHOMA; BURKITT-LYMPHOMA; REARRANGEMENTS; PROGNOSIS; FEATURES; LYMPHOMA/LEUKEMIA; CLASSIFICATION; JUXTAPOSITION	High-grade B-cell lymphomas with MYC, BCL2, and/or BCL6 rearrangements, "double-hit" or "triple-hit" lymphomas (DTHL), are aggressive neoplasms associated with a poor prognosis. A t(3;8) (q27;q24) rarely occurs in B-cell lymphomas that results in a unique "pseudo double-hit" BCL6-MYC fusion, indistinguishable by interphase fluorescence in situ hybridization (FISH) from more conventional DTHL with independent MYC and BCL6 translocations. Reports of t(3;8)(q27;q24) lymphomas are sparse, and to better characterize their pathologic, cytogenetic, and clinical features, 6 new cases from 2 institutions and 19 previously published cases were reviewed. All new cases displayed aggressive morphologic features, and most previously published cases were classified as aggressive lymphomas. Collectively, all t(3;8)(q27; q24) cases had a germinal center (GC) phenotype, and most had complex karyotypes (22/24, 92%), including frequent concomitant BCL2 rearrangements (17/24, 71%). When compared to two large published DTHL cohorts, t(3;8)(q27;q24) lymphomas less often expressed BCL2 (P<.01), had a greater likelihood of extranodal involvement (P<.01), and more frequently appeared triple-hit by FISH analysis (P<.01). Despite presenting with aggressive clinicopathologic features, 100% (6/6) of t(3;8;)(q27;q24) patients achieved complete remission after intensive induction regimens, and 2- and 3-year overall survival rates were 63% (10/16) and 57% (8/14), respectively. These findings suggest that lymphomas with t (3;8)(q27;q24) may represent a subset of GC B-cell lymphomas distinct from conventional DTHL. Our results further highlight the value of routine karyotype assessment in aggressive B-cell lymphomas, and the importance of recognizing the t(3;8)(q27;q24) so that its clinical significance can be more fully explored. (C) 2018 Elsevier Inc. All rights reserved.	[Johnson, Steven M.; Fedoriw, Yuri; Kaiser-Rogers, Kathleen; Montgomery, Nathan D.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Umakanthan, Jayadev Manikkam; Bociek, R. Gregory] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; [Yuan, Ji] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Fedoriw, Yuri; Montgomery, Nathan D.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Kaiser-Rogers, Kathleen] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27514 USA; [Kaiser-Rogers, Kathleen] Univ N Carolina, Sch Med, Dept Genet, Genetics, NC 27514 USA; [Sanmann, Jennifer N.] Univ Nebraska Med Ctr, Munroe Meyer Inst, Human Genet Lab, Omaha, NE 68131 USA	Johnson, SM (reprint author), Dept Pathol & Lab Med, CB 7525, Chapel Hill, NC 27599 USA.	Steven.Johnson@unchealth.unc.edu					Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 2000, J CLIN ONCOL, V18, P510, DOI 10.1200/JCO.2000.18.3.510; Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bacher U, 2011, GENE CHROMOSOME CANC, V50, P43, DOI 10.1002/gcc.20831; Bernell P, 1998, BRIT J HAEMATOL, V101, P487; Bertrand P, 2008, LEUKEMIA, V22, P1064, DOI 10.1038/sj.leu.2404999; Bertrand P, 2007, LEUKEMIA, V21, P515, DOI 10.1038/sj.leu.2404529; Clipson A, 2015, J PATHOL CLIN RES, V1, P125, DOI 10.1002/cjp2.10; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kallen ME, 2016, INT J SURG PATHOL, V24, P709, DOI 10.1177/1066896916657409; Landsburg DJ, 2016, CANCER-AM CANCER SOC, V122, P559, DOI 10.1002/cncr.29781; Le Gouill S, 2007, HAEMATOL-HEMATOL J, V92, P1335, DOI 10.3324/haematol.11305; Li SY, 2016, HISTOPATHOLOGY, V68, P1090, DOI 10.1111/his.12884; Mitelman F, 2018, MITELMAN DATABASE CH; Montgomery ND, 2016, CANCER GENET-NY, V209, P408, DOI 10.1016/j.cancergen.2016.08.006; Motllo C, 2010, CANCER GENET CYTOGEN, V203, P328, DOI 10.1016/j.cancergencyto.2010.08.018; Ohno H, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.59; Oki Y, ANN M 2013, P1776; Oki Y, 2014, BRIT J HAEMATOL, V166, P891, DOI 10.1111/bjh.12982; Petrich AM, 2014, BLOOD, P1, DOI 10.1182/blood-2014-05-578963.A.M.P; Pillai RK, 2013, AM J SURG PATHOL, V37, P323, DOI 10.1097/PAS.0b013e31826cebad; Rosenthal A, 2017, BLOOD REV, V31, P37, DOI 10.1016/j.blre.2016.09.004; Ryan RJH, 2015, CANCER DISCOV, V5, P1058, DOI 10.1158/2159-8290.CD-15-0370; Sanders L, 2014, CASE REP HEMATOL, DOI 10.1155/2014/120714; Sandlund JT, 2006, CANCER GENET CYTOGEN, V168, P69, DOI 10.1016/j.cancergencyto.2005.12.013; Sonoki T, 2007, INT J HEMATOL, V86, P196, DOI 10.1532/IJH97.07083; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Tomita N, 2009, HAEMATOL-HEMATOL J, V94, P935, DOI 10.3324/haematol.2008.005355; Wang HY, 2007, CANCER GENET CYTOGEN, V172, P45, DOI 10.1016/j.cancergencyto.2006.07.016; Wang W, 2015, AM J SURG PATHOL, V39, P1132, DOI 10.1097/PAS.0000000000000434; Ye Q, 2016, ONCOTARGET, V7, P2401, DOI 10.18632/oncotarget.6262	35	1	1	2	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						192	200		10.1016/j.humpath.2018.06.006			9	Pathology	Pathology	GX5US	WOS:000447817100024	29902576				2019-10-28	
J	Liu, ML; Qi, Y; Zhao, LL; Chen, DD; Zhou, Y; Zhou, HR; Lv, YM; Zhang, L; Jin, S; Li, SG; Zou, H; Jia, W; Wang, CC; Jiang, JF; Liang, WH; Pang, LJ; Li, F				Liu, Manli; Qi, Yan; Zhao, Lili; Chen, Dongdong; Zhou, Yang; Zhou, Hongrun; Lv, Yanmin; Zhang, Lu; Jin, Shan; Li, Shugang; Zou, Hong; Jia, Wei; Wang, Cuicui; Jiang, Jinfang; Liang, Weihua; Pang, Lijuan; Li, Feng			Matrix metalloproteinase-14 induces epithelial-to-mesenchymal transition in synovial sarcoma	HUMAN PATHOLOGY			English	Article						Epithelial-to-mesenchymal transition; Matrix metalloproteinase-14; Synovial sarcoma; SW982 cells; Invasive ability	PROGNOSTIC-FACTORS; POOR-PROGNOSIS; EXPRESSION; CARCINOMA; CANCER; TISSUE; ANGIOGENESIS; PROGRESSION; EXTREMITIES; NEOPLASMS	Synovial sarcoma (SS) is a highly aggressive malignant soft tissue sarcoma with typical characteristics of both epithelial and mesenchymal differentiation. Matrix metalloproteinase-14 (MMP-14) is reported to play an important role in some of these tumors. It induces epithelial-to-mesenchymal transition (EMT) in some carcinomas, such as breast and prostate cancers. However, the role of MMP-14 in the pathogenesis of SS remains unclear. Therefore, we investigated the role of MMP-14 and EMT/mesenchymal-to-epithelial transition in SS. The expression of MMP-14 and EMT-related proteins was determined in 37 SS cases and transfected cells by immunohistochemistry staining and Western blotting. The invasion ability of transfected cells was determined by transwell invasion assay. The expression rates of MMP-14, E-cadherin, N-cadherin, and vimentin were 75.7%, 54.1%, 75.7%, and 100%, respectively, in the cases of SS. The expression of MMP-14 correlated negatively with E-cadherin and positively with N-cadherin in monophasic fibrous SS. The MMP-14 protein expression was higher in stage III/IV than in stage After MMP-14 was transfected into SW982 cells, MMP-14, N-cadherin, and vimentin expression was up-regulated, and E-cadherin expression was down-regulated. High expression of MMP-14 enhanced the invasive ability of SW982 cells. Our findings suggest that MMP-14 enhances the invasive ability of SW982 cells by inducing EMT. By this action, it may play an important role in the occurrence and development of SS. (C) 2018 Published by Elsevier Inc.	[Liu, Manli; Qi, Yan; Zhao, Lili; Chen, Dongdong; Zhou, Yang; Zhou, Hongrun; Lv, Yanmin; Zhang, Lu; Jin, Shan; Zou, Hong; Jia, Wei; Wang, Cuicui; Jiang, Jinfang; Liang, Weihua; Pang, Lijuan; Li, Feng] Shihezi Univ, Sch Med, Minist Educ, Dept Pathol, Shihezi 832002, Xinjiang, Peoples R China; [Liu, Manli; Qi, Yan; Zhao, Lili; Chen, Dongdong; Zhou, Yang; Zhou, Hongrun; Lv, Yanmin; Zhang, Lu; Jin, Shan; Zou, Hong; Jia, Wei; Wang, Cuicui; Jiang, Jinfang; Liang, Weihua; Pang, Lijuan; Li, Feng] Shihezi Univ, Sch Med, Minist Educ, Key Lab Xinjiang Endem & Ethn Dis, Shihezi 832002, Xinjiang, Peoples R China; [Li, Shugang] Shihezi Univ, Sch Med, Dept Publ Hlth, Shihezi 832002, Xinjiang, Peoples R China; [Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing 100020, Peoples R China	Li, F (reprint author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing 100020, Peoples R China.; Pang, LJ; Li, F (reprint author), Shihezi Univ, Sch Med, Dept Pathol, North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.; Pang, LJ (reprint author), Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, North 2nd Rd, Shihezi 832002, Xinjiang, Peoples R China.	ocean123456@163.com; lifeng7855@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81560053]; Corps Doctor Foundation [2014BB018]; One Thousand Youth Talents Plan; Pairing Program of Shihezi University with Eminent Scholar in Elite University [SDJDZ201508]	This work was supported by the National Natural Science Foundation of China (No. 81560053), the Corps Doctor Foundation (No. 2014BB018), One Thousand Youth Talents Plan, and the Pairing Program of Shihezi University with Eminent Scholar in Elite University (No. SDJDZ201508).	CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO;2-R; Cao J, 2008, J BIOL CHEM, V283, P6232, DOI 10.1074/jbc.M705759200; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Dong YC, 2015, GENE, V563, P29, DOI 10.1016/j.gene.2015.03.003; Fletcher CD, 2002, PATHOLOGY GENETICS T; Goldblum JR, 2013, ENZINGER WEISSS SOFT; Itoh Y, 2006, IUBMB LIFE, V58, P589, DOI 10.1080/15216540600962818; Koh KH, 2009, ORTHOPEDICS, V32, P824, DOI 10.3928/01477447-20090922-12; KRANSDORF MJ, 1995, AM J ROENTGENOL, V164, P129, DOI 10.2214/ajr.164.1.7998525; Laskin WB, 2002, ARCH PATHOL LAB MED, V126, P425; Li GS, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0478-6; Li WF, 2015, TUMOR BIOL, V36, P6883, DOI 10.1007/s13277-015-3381-7; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Mylona E, 2007, HISTOPATHOLOGY, V50, P338, DOI 10.1111/j.1365-2559.2007.02615.x; Nakagawa Y, 2006, J CANCER RES CLIN, V132, P444, DOI 10.1007/s00432-006-0089-5; Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585-008-9143-9; Pang LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22179; Peng CW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-153; Qi Y, 2013, INT J CLIN EXP PATHO, V6, P2787; Roebuck MM, 2005, AM J CLIN PATHOL, V123, P405, DOI 10.1309/LK1V7R99JL41WVKP; Roomi MW, 2013, INT J ONCOL, V43, P1787, DOI 10.3892/ijo.2013.2113; Sakabe T, 2008, MED SCI MONITOR, V14, pCR305; Subramaniam MM, 2011, ARCH PATHOL LAB MED, V135, P1001, DOI 10.5858/2010-0071-OAR1; Takeuchi T, 2011, VIRCHOWS ARCH, V459, P291, DOI 10.1007/s00428-011-1125-7; Tetu B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1503; Trudel D, 2014, MODERN PATHOL, V27, P1394, DOI 10.1038/modpathol.2014.32; Wang HY, 2014, CELL BIOCHEM BIOPHYS, V70, P729, DOI 10.1007/s12013-014-9974-8; Yan TH, 2015, ARCH MED RES, V46, P186, DOI 10.1016/j.arcmed.2015.03.006; Yang CC, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-171; Zhou HY, 2014, ONCOL LETT, V7, P1395, DOI 10.3892/ol.2014.1920	31	1	1	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						201	209		10.1016/j.humpath.2017.12.031			9	Pathology	Pathology	GX5US	WOS:000447817100025	29935194				2019-10-28	
J	Huang, M; Song, Q; Wang, H; Wang, HX; Xu, C; Wang, X; Jiang, ZZ; Wang, YQ; Xu, YF; Su, J; Zeng, HY; Tan, LJ; Zhu, HG; Jiang, DX; Hou, YY				Huang, Me; Song, Qi; Wang, Hao; Wang, Haixing; Xu, Chen; Wang, Xin; Jiang, Zhengzeng; Wang, Yanqiu; Xu, Yifan; Su, Jieakesu; Zeng, Haiying; Tan, Lijie; Zhu, Hongguang; Jiang, Dongxian; Hou, Yingyong			Poor prognostic impact of FGF4 amplification in patients with esophageal squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						FGF4 amplification; Clinical stage; Esophageal squamous cell carcinoma (ESCC); Poor prognosis; Fluorescence in situ hybridization (FISH)	CANCER; GENE; EXPRESSION; TRENDS; HST-1; EGFR; EMS1	In the present study, we aimed to determine the prognostic impact and clinicopathological feature of FGF4 amplification in patients with esophageal squamous cell carcinoma (ESCC). Fluorescence in situ hybridization with FGF4 probe was analyzed using tissue microarray consisting of representative cores of 267 ESCC cases. FGF4 amplification was observed in 52.8% (141/267) of patients. Patients with FGF4 amplification showed a significantly shorter disease-free survival (DFS) or disease-specific overall survival (OS) compared with those without FGF4 amplification (both P<.05). Moreover, FGF4 amplification was an independent prognostic factor (DFS, P=.036; OS, P=.021) along with clinical stage and lymph node metastasis in multivariate analysis. Among stage I-II or III patients whose DFS was greater than or equal to 24 months (n=125 or 32), patients with FGF4 amplification showed a significantly worse prognosis (OS, P=.027 or P=.010). Moreover, the survival curve of stage I-II patients with FGF4 amplification was identical to stage III patients without FGF4 amplification (DFS, P=.643; OS, P=.707). Taken together, FGF4 amplification was an independent prognostic factor in ESCC patients, and ESCC might have potentially been upstaged by FGF4 amplification. Therefore, FGF4 amplification in combination with clinical stage could be used as a relatively accurate predictor for the 5-year probability of death and recurrence for ESCC patients. (C) 2018 Published by Elsevier Inc.	[Huang, Me; Song, Qi; Wang, Haixing; Xu, Chen; Wang, Xin; Jiang, Zhengzeng; Wang, Yanqiu; Xu, Yifan; Su, Jieakesu; Zeng, Haiying; Jiang, Dongxian; Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China; [Wang, Hao; Tan, Lijie] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai 200032, Peoples R China; [Zhu, Hongguang; Hou, Yingyong] Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai 200032, Peoples R China; [Zhu, Hongguang; Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China; [Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Qingpu Branch, Dept Pathol, Shanghai 201700, Peoples R China	Jiang, DX; Hou, YY (reprint author), Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China.; Hou, YY (reprint author), Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai 200032, Peoples R China.; Hou, YY (reprint author), Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China.; Hou, YY (reprint author), Fudan Univ, Zhongshan Hosp, Qingpu Branch, Dept Pathol, Shanghai 201700, Peoples R China.	jiangdongxian3@aliyun.com; houyingyong@aliyun.com			Shanghai Municipal Commission of Health and Family Planning, Key-developing disciplines [2015ZB0201]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81702372]; Shanghai Natural Science Foundation of ChinaNational Natural Science Foundation of China [18ZR1406800]	This work was financially supported by Shanghai Municipal Commission of Health and Family Planning, Key-developing disciplines (No. 2015ZB0201); National Natural Science Foundation of China (No. 81702372); and Shanghai Natural Science Foundation of China (No. 18ZR1406800).	Ajani JA, 2015, J NATL COMPR CANC NE, V13, P194, DOI 10.6004/jnccn.2015.0028; Arao T, 2013, HEPATOLOGY, V57, P1407, DOI 10.1002/hep.25956; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cheng CX, 2016, AM J HUM GENET, V98, P256, DOI 10.1016/j.ajhg.2015.12.013; CHIKUBA K, 1995, BRIT J SURG, V82, P364, DOI 10.1002/bjs.1800820327; Cihoric N, 2014, BRIT J CANCER, V110, P2914, DOI 10.1038/bjc.2014.229; Gupta B, 2017, EUR J CANCER PREV, V26, P107, DOI 10.1097/CEJ.0000000000000249; Harding James J, 2014, Hepatobiliary Surg Nutr, V3, P168, DOI 10.3978/j.issn.2304-3881.2014.07.03; Jiang DX, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1393-8; Karlsson E, 2011, GENE CHROMOSOME CANC, V50, P775, DOI 10.1002/gcc.20900; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Lazar V, 2009, MODERN PATHOL, V22, P1367, DOI 10.1038/modpathol.2009.109; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Liu HD, 2017, SURG ONCOL, V26, P13, DOI 10.1016/j.suronc.2016.12.003; Malhotra GK, 2017, J SURG ONCOL, V115, P564, DOI 10.1002/jso.24592; Mariette C, 2015, LANCET ONCOL, V16, P1008, DOI 10.1016/S1470-2045(15)00127-8; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Perez EA, 2011, J CLIN ONCOL, V29, P651, DOI 10.1200/JCO.2010.30.2125; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shi Y, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-9; Song B, 2016, ONCOTARGET, V7, P3599, DOI 10.18632/oncotarget.6120; Song Qi, 2016, Zhonghua Bing Li Xue Za Zhi, V45, P209, DOI 10.3760/cma.j.issn.0529-5807.2016.03.016; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; SUGIMURA T, 1990, CIBA F SYMP, V150, P79; Sugimura T, 1990, CIBA F SYMP, V150, P89; Terada M, 1989, Princess Takamatsu Symp, V20, P71; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; Wang HX, 2016, TUMOR BIOL, V37, P9771, DOI 10.1007/s13277-015-4692-4; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; Yamasaki M, 2017, ANN ONCOL, V28, P116, DOI 10.1093/annonc/mdw439; Yasuda K, 2014, LAB INVEST, V94, P1355, DOI 10.1038/labinvest.2014.122; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	38	0	0	2	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						210	218		10.1016/j.humpath.2018.06.009			9	Pathology	Pathology	GX5US	WOS:000447817100026	29936056				2019-10-28	
J	Fararjeh, AFS; Tu, SH; Chen, LC; Liu, YR; Lin, YK; Chang, HL; Chang, HW; Wu, CH; Hwang-Verslues, WW; Ho, YS				Fararjeh, Abdul-Fattah Satah; Tu, Shih-Hsin; Chen, Li-Ching; Liu, Yun-Ru; Lin, Yen-Kuang; Chang, Hang-Lung; Chang, Hui-Wen; Wu, Chih-Hsiung; Hwang-Verslues, Wendy W.; Ho, Yuan-Soon			The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer	HUMAN PATHOLOGY			English	Article						GATA3; Breast cancer; Overall survival; Prognostic factor; Estrogen receptor	ESTROGEN-RECEPTOR; GENE-EXPRESSION; CELL-DIFFERENTIATION; T-CELLS; CARCINOMAS; SURVIVAL; IDENTIFICATION; MUTATION; MARKER; TUMORS	The transcription factor GATA3 plays a significant role in mammary gland development and differentiation. We analyzed expression of GATA3 in breast cancer (BC) cell lines and clinical specimens from BC patients in Taiwan. Semiquantitative reverse-transcription polymerase chain reaction (RT-PCR), quantitative real-time PCR were carried out to determine the mRNA level of GATA3 from 241 pairs of matched tumor and adjacent normal tissues from anonymous female donors. GATA3 immunohistochemistry (IHC) staining and H-score were performed (n = 25). Inducing and silencing of GATA3 were done by exposure MCF-7 cell line to nicotine or curcumin, respectively. GATA3 expression was detected in most of the estrogen receptor-positive (ER+) tumor specimens (176/241, 73%) compared with paired normal tissues (65/241, 27%) (P<.001). The GATA3 level was highest in Luminal A, and independent t-tests revealed higher GATA3 was associated with ER+ (P=.018) and BC stages (stage II, and stage IV). Nuclear protein expression of GATA3 was detected in tumor tissues (P<.001) with higher H-score in Luminal A patients (P=.012). Kaplan-Meier survival analyses showed that ER+/progesterone receptor (PgR)+ and lower grade BC patients with relatively high GATA3 had better clinical overall survival (OS). GATA3 regulates ER alpha and BCL-2 as BC lumina! subtype markers. Cox univariate and multivariate analyses demonstrated that the expression of GATA3 was an effective predictor of the risk of death. We demonstrated a correlation between GATA3 expression and only ER+ and suggest that a higher GATA3 expression is a good prognostic factor for OS for ER+ BC patients. (C) 2018 Elsevier Inc. All rights reserved.	[Fararjeh, Abdul-Fattah Satah] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 110, Taiwan; [Fararjeh, Abdul-Fattah Satah] Acad Sinica, Taipei 110, Taiwan; [Tu, Shih-Hsin; Chen, Li-Ching] Taipei Med Univ Hosp, Breast Med Ctr, Taipei, Taiwan; [Tu, Shih-Hsin; Chen, Li-Ching] Taipei Med Univ Hosp, Taipei Canc Ctr, Taipei, Taiwan; [Tu, Shih-Hsin; Wu, Chih-Hsiung] Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei, Taiwan; [Chen, Li-Ching; Ho, Yuan-Soon] Taipei Med Univ, TMU Res Ctr Canc Translat Med, Taipei, Taiwan; [Liu, Yun-Ru] Taipei Med Univ, Off Human Res, Joint Biobank, Taipei, Taiwan; [Lin, Yen-Kuang] Taipei Med Univ, Res Ctr Biostat, Taipei, Taiwan; [Chang, Hang-Lung; Wu, Chih-Hsiung] EnChun Kong Hosp, Dept Gen Surg, New Taipei, Taiwan; [Chang, Hui-Wen; Ho, Yuan-Soon] Taipei Med Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Hwang-Verslues, Wendy W.] Acad Sinica, Gen Res Ctr, Taipei, Taiwan; [Ho, Yuan-Soon] Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan; [Ho, Yuan-Soon] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan	Ho, YS (reprint author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.	hoyuansn@tmu.edu.tw		Tu, Shih-Hsin/0000-0002-4106-8146	Health and Welfare surcharge of tobacco products grant [MOHW107-TDU-B-212-114014]; TMU Research Center of Cancer Translational Medicine from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST105-2320-B-038-053-MY3, MOST106-2320-B-038-046, MOST106-2314-B-038-053-MY3, MOST 106-2320-B-038-061 -MY3, MOST104-2314-B-038-059-MY3]	This study was supported by the Health and Welfare surcharge of tobacco products grant (MOHW107-TDU-B-212-114014), by TMU Research Center of Cancer Translational Medicine from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan and by the Ministry of Science and Technology, Taiwan (MOST105-2320-B-038-053-MY3 and MOST106-2320-B-038-046 awarded to Dr. Ho, MOST106-2314-B-038-053-MY3 awarded to Dr. Tu, MOST 106-2320-B-038-061 -MY3 awarded to Dr. Chen, and MOST104-2314-B-038-059-MY3 awarded to Dr. Wu).	Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Cheng TC, 2015, ONCOTARGET, V6, P21283, DOI 10.18632/oncotarget.4238; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Halabi Susan, 2010, Semin Oncol, V37, pe9, DOI 10.1053/j.seminoncol.2010.04.001; Hallman K, 2017, BREAST CANCER-TARGET, V9, DOI 10.2147/BCTT.S125783; Inman D, 2008, REPROD SCI, V15, P83, DOI 10.1177/1933719107309690; Jenssen TK, 2002, HUM GENET, V111, P411, DOI 10.1007/s00439-002-0804-5; Joe S, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0292-5; Kikuchi H, 2008, NEUROSCI LETT, V432, P217, DOI 10.1016/j.neulet.2007.12.027; Lee CH, 2010, J NATL CANCER I, V102, P1322, DOI 10.1093/jnci/djq300; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Liu JJ, 2016, CANCER LETT, V376, P104, DOI 10.1016/j.canlet.2016.03.038; Martin LA, 2013, CANCER CELL, V24, P7, DOI 10.1016/j.ccr.2013.06.006; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Tominaga N, 2012, ANN ONCOL, V23, P3051, DOI 10.1093/annonc/mds120; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Voduc D, 2008, CANCER EPIDEM BIOMAR, V17, P365, DOI 10.1158/1055-9965.EPI-06-1090; Yagi R, 2011, INT IMMUNOL, V23, P415, DOI 10.1093/intimm/dxr029; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yang M, 2010, MODERN PATHOL, V23, P654, DOI 10.1038/modpathol.2010.38; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Yu KD, 2013, CLIN CANCER RES, V19, P2723, DOI 10.1158/1078-0432.CCR-12-2986; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223; Zheng WP, 2016, J IMMUNOL, V196, P4426, DOI 10.4049/jimmunol.160064; Zhou M, 2003, IMMUNOL RES, V28, P25, DOI 10.1385/IR:28:1:25	34	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						219	230		10.1016/j.humpath.2018.06.004			12	Pathology	Pathology	GX5US	WOS:000447817100027	29902578				2019-10-28	
J	Jepsen, RK; Novotny, GW; Klarskov, LL; Bang-Berthelsen, CH; Haakansson, IT; Hansen, A; Christensen, IJ; Riis, LB; Hogdall, E				Jepsen, Rikke Karlin; Novotny, Guy Wayne; Klarskov, Louise Laurberg; Bang-Berthelsen, Claus Heiner; Haakansson, Ida Trondhjem; Hansen, Anker; Christensen, Ib Jade; Riis, Lene Buhl; Hogdall, Estrid			Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front	HUMAN PATHOLOGY			English	Article						Colorectal cancer; pT1; Invasive tumor front; Metastases; Microarray; MicroRNA; MiR-17/92	EPITHELIAL-MESENCHYMAL TRANSITION; KEY ONCOGENIC COMPONENT; LYMPH-NODE METASTASIS; PI3K/AKT PATHWAY; MICRORNAS; MIR-92A; PTEN; PROGNOSIS; REVEALS	Accurate prediction of regional lymph node metastases (LNM) in endoscopically resected pT1 colorectal cancer (CRC) is crucial in treatment stratification for subsequent radical surgery. Several miRNAs have been linked to CRC invasion and metastasis, including the oncogenic miR-17/92 cluster, and expression levels might have predictive value in the risk assessment of early metastatic progression in CRC. We performed global miRNA microarray using tissue samples from the invasive front of pT1 CRC and investigated associations of the miR-17/92 cluster and presence of LNM. In total, 56 matched pT1 CRCs were thoroughly clinicopathologically characterized, and miRNA microarrays were performed on invasive front tissue samples. Global miRNA intensities were screened using paired t-tests between pT1pN+ and pT1pN0. Associations between miR-17/92 and histopathological features were analyzed using general linear models and tumor cell adjusted expression intensities. miR-17-3p and miR-92a were significantly higher expressed in the invasive front of tumors with LNM compared to those without, corresponding to 1.53-fold higher expression of miR-17-3p (95%CI: 1.04-2.24, P=.030) and 1.28-fold higher expression of miR-92a (95%CI: 1.01-1.68, P=.042). An inverse association between miR-19a and presence of high-grade tumor budding was observed (1.55-fold, 95%CI: 1.13-2.12, P=.008). We provide evidence for associations between early regional LNM and high expression levels of the miR-17/92 cluster members: miR-17-3p and miR-92a, in the invasive front of CRC. Our results support a role for the miR-17/92 cluster in early metastatic progression of CRC and calls for further investigation. (C) 2018 Elsevier Inc. All rights reserved.	[Jepsen, Rikke Karlin; Novotny, Guy Wayne; Klarskov, Louise Laurberg; Christensen, Ib Jade; Riis, Lene Buhl; Hogdall, Estrid] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol & Mol Unit, DK-2730 Herlev, Denmark; [Haakansson, Ida Trondhjem; Hansen, Anker] Med Prognosis Inst AS, DK-2970 Harsholm, Denmark; [Bang-Berthelsen, Claus Heiner] Tech Univ Denmark, Natl Food Inst, Res Grp Microbial Biotechnol & Biorefining, DK-2800 Lyngby, Denmark	Jepsen, RK (reprint author), Univ Copenhagen, Rigshosp, Dept Pathol, Copenhagen, Denmark.	rikke.karlin.jepsen.01@regionh.dk; guy.wayne.novotny@regionh.dk; louise.laurberg.klarskov@regionh.dk; claban@food.dtu.dk; ith@medical-prognosis.com; ah@medical-prognosis.com; Ib.Jarle.Christensen@regionh.dk; Lene.Buhl.Riis@regionh.dk; Estrid.Hoegdall@regionh.dk		/0000-0003-4541-2538; Hogdall, Estrid/0000-0003-4689-5658	Beckett Foundation [38069/38079]; A.P. Moller Foundation for the Advancement of Medical Science [14-187]; Krista and Viggo Petersens Foundation [5793/44]; Fabrikant Einer Willumsen Foundation [6000073]; Vald Foersom and Thyra Foersoms Foundation [41452-001]	This work was funded by Beckett Foundation [38069/38079], The A.P. Moller Foundation for the Advancement of Medical Science [14-187], Krista and Viggo Petersens Foundation [5793/44], Fabrikant Einer Willumsen Foundation [6000073] and Vald Foersom and Thyra Foersoms Foundation [41452-001]. Funding sources had no influence in any part of the study.	Alves A, 2005, ARCH SURG-CHICAGO, V140, P278, DOI 10.1001/archsurg.140.3.278; de Krijger I, 2011, J PATHOL, V224, P438, DOI 10.1002/path.2922; De Smedt L, 2017, BRIT J CANCER, V116, P58, DOI 10.1038/bjc.2016.382; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Eriksen AHM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156919; Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Gill MD, 2012, BRIT J CANCER, V107, P417, DOI 10.1038/bjc.2012.305; Huang LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13350; Jepsen RK, 2016, EXP MOL PATHOL, V101, P187, DOI 10.1016/j.yexmp.2016.08.003; Jepsen RK, 2018, GEO SERIES ACCESSION; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Jung CK, 2016, ONCOTARGET, V7, P32902, DOI 10.18632/oncotarget.8766; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karamitopoulou E, 2013, MODERN PATHOL, V26, P295, DOI 10.1038/modpathol.2012.155; Ke TW, 2015, ANN SURG ONCOL, V22, P2649, DOI 10.1245/s10434-014-4305-2; Knudsen KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140503; Lu WD, 2014, INT J CLIN EXP PATHO, V7, P7286; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Ma YL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2276; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Petrovic N, 2017, MOL DIAGN THER, V21, P511, DOI 10.1007/s40291-017-0285-9; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Suzuki T, 2003, DIS COLON RECTUM, V46, P203, DOI 10.1097/01.DCR.0000044728.97664.CB; Toh EW, 2015, DIS COLON RECTUM, V58, P393, DOI 10.1097/DCR.0000000000000315; Tsuchida A, 2011, CANCER SCI, V102, P2264, DOI 10.1111/j.1349-7006.2011.02081.x; von Karsa L, 2013, ENDOSCOPY, V45, P51, DOI 10.1055/s-0032-1325997; Zhang GJ, 2014, DIGEST DIS SCI, V59, P98, DOI 10.1007/s10620-013-2858-8; Zhou T, 2013, INT J COLORECTAL DIS, V28, P19, DOI 10.1007/s00384-012-1528-1	34	0	0	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						231	238		10.1016/j.humpath.2018.05.027			8	Pathology	Pathology	GX5US	WOS:000447817100028	29902577				2019-10-28	
J	Zuo, T; Wilson, P; Cicek, AF; Harigopal, M				Zuo, Tao; Wilson, Parker; Cicek, Ali Fuat; Harigopal, Malini			Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers	HUMAN PATHOLOGY			English	Article						Biomarkers; Androgen receptor; Triple-negative breast cancers; Basal-like breast cancers; Cytokeratin 5/6 (CK5/6)	SUBTYPE	Androgen receptor (AR) expression is an emerging prognostic marker that has been observed in 25% to 75% of triple-negative breast cancers (TNBCs) that lack estrogen receptor, progesterone receptor and HER2 overexpression. TNBCs are treated with AR-targeted therapies and standardized evaluation of AR expression may help guide patient management. Basal-like TNBCs are a subgroup of TNBCs defined by positive immunoreactivity for CK5/6 or EGFR that carry a worse prognosis. However, it's unclear whether basal-like TNBCs have a different rate of AR positivity or if AR expression is predictive of disease-free survival (DFS) in this patient group. Here, we examined a total of 185 TNBCs for AR and CK5/6 using tissue microarrays (TMAs). Among all samples, 32% were AR positive using a 1% cutoff, and 24% were AR positive using a 10% cutoff. Ninety (49%) TNBCs were CK5/6 positive with lower intensity of AR expression compared to CK5/6-negative cases. There was no significant difference in pathologic stage, tumor size, histologic grade and type, or lymph node stage after stratifying by AR and CK5/6 positivity. AR-positive TNBCs had better overall survival (OS) and DFS compared to AR-negative TNBCs. In addition, increased AR expression carried a dose-dependent effect on DFS. AR expression, nodal status and tumor size were significant predictors of disease-free and overall survival in a multivariable model adjusted for CK5/6 expression, age, histologic grade, and mitotic rate. In conclusion, our data demonstrated that AR positivity is a favorable prognostic factor for triple-negative breast cancers. Published by Elsevier Inc.	[Zuo, Tao; Wilson, Parker; Harigopal, Malini] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Cicek, Ali Fuat] Grad Sch Med, Dept Pathol, Ankara, Turkey; [Cicek, Ali Fuat] Training Hosp, Ankara, Turkey	Zuo, T; Harigopal, M (reprint author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.	tao.zuo@yale.edu					Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gasparini P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088525; Gucalp A, 2016, CURR PROB CANCER, V40, P141, DOI 10.1016/j.currproblcancer.2016.09.004; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lindner R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071915; McGhan LJ, 2014, ANN SURG ONCOL, V21, P361, DOI 10.1245/s10434-013-3260-7; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Qu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082650; Rampurwala M, 2016, CLIN ADV HEMATOL ONC, V14, P186; Safarpour D, 2015, ARCH PATHOL LAB MED, V139, P612, DOI 10.5858/arpa.2014-0122-RA; Safarpour D, 2014, AM J CANCER RES, V4, P353; Sutton LM, 2012, AM J CLIN PATHOL, V138, P511, DOI 10.1309/AJCP8AVF8FDPTZLH; Szekely B, 2017, ONCOLOGY-NY, V31, P130; Thike AA, 2014, MODERN PATHOL, V27, P352, DOI 10.1038/modpathol.2013.145; Thike AA, 2010, AM J SURG PATHOL, V34, P956, DOI 10.1097/PAS.0b013e3181e02f45; Thike AA, 2010, MODERN PATHOL, V23, P123, DOI 10.1038/modpathol.2009.145; Yue Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149661	21	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						239	245		10.1016/j.humpath.2018.06.003			7	Pathology	Pathology	GX5US	WOS:000447817100029	29902579				2019-10-28	
J	Wang, QQ; Dai, HF				Wang, Qianqian; Dai, Hongfeng			SASH1, a potential therapeutic target for cancer	HUMAN PATHOLOGY			English	Letter							PROGNOSIS; INVASION		[Wang, Qianqian; Dai, Hongfeng] Anhui Univ Chinese Med, Dept TCM Pharm, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China	Wang, QQ (reprint author), Anhui Univ Chinese Med, Dept TCM Pharm, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China.	1154080308@qq.com					Burgess JT, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.364; Burgess JT, 2016, ONCOTARGET, V7, P72807, DOI 10.18632/oncotarget.12020; Chen EG, 2012, TUMOR BIOL, V33, P1393, DOI 10.1007/s13277-012-0387-2; He P, 2016, ONCOL RES, V24, P25, DOI 10.3727/096504016X14575597858609; Stubblefield K, 2017, EXP CELL RES, V359, P384, DOI 10.1016/j.yexcr.2017.08.022; Sun CY, 2017, INT J BIOCHEM CELL B, V89, P95, DOI 10.1016/j.biocel.2017.06.006; Xie J, 2017, EUR REV MED PHARMACO, V21, P3781; Zhou N, 2018, HUM PATHOL, V74, P83, DOI 10.1016/j.humpath.2018.01.008	8	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						246	246		10.1016/j.humpath.2018.03.028			1	Pathology	Pathology	GX5US	WOS:000447817100030	29936055				2019-10-28	
J	Cihan, YB				Cihan, Yasemin Benderli			Does ezrin play a predictive role in cancer patients undergoing radiotherapy and/or chemotherapy?	HUMAN PATHOLOGY			English	Letter							LUNG-CANCER; EXPRESSION		[Cihan, Yasemin Benderli] Kayseri Educ & Res Hosp, Dept Radiat Oncol, TR-38010 Kocasinan Kayseri, Turkey	Cihan, YB (reprint author), Kayseri Educ & Res Hosp, Dept Radiat Oncol, TR-38010 Kocasinan Kayseri, Turkey.	cihany@erciyes.edu.tr					Celik H, 2016, J BIOL CHEM, V291, P13257, DOI 10.1074/jbc.M116.718189; Chen QY, 2013, MOL CELL BIOCHEM, V377, P207, DOI 10.1007/s11010-013-1586-x; Karmakar S, 2004, J REPROD IMMUNOL, V64, P9, DOI 10.1016/j.jri.2004.04.005; Korkeila EA, 2011, HUM PATHOL, V42, P384, DOI 10.1016/j.humpath.2010.08.004; Li JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep17903; Li Qiong, 2006, Ai Zheng, V25, P363; Liang F, 2017, ONCOTARGET, V8, P93186, DOI 10.18632/oncotarget.21473; Palmerini E, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-014-0222-5; Zhang XQ, 2012, CLIN LUNG CANCER, V13, P196, DOI 10.1016/j.cllc.2011.04.002	9	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						247	248		10.1016/j.humpath.2018.04.029			2	Pathology	Pathology	GX5US	WOS:000447817100032	29940285				2019-10-28	
J	Zhou, N				Zhou, Nan			SASH1, a potential therapeutic target for cancer-reply	HUMAN PATHOLOGY			English	Letter							PROLIFERATION; INVASION; PATHWAY; CELLS		[Zhou, Nan] Nantong Univ, Dept Oncol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China	Zhou, N (reprint author), Nantong Univ, Dept Oncol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.	15160075@yjs.ntu.edu.cn					Chen H, 2016, MOL MED REP, V13, P3613, DOI 10.3892/mmr.2016.4946; Sun DW, 2015, INT J CLIN EXP PATHO, V8, P12276; Zhou N, 2018, HUM PATHOL, V74, P83, DOI 10.1016/j.humpath.2018.01.008; Zong W, 2016, ONCOL RES, V24, P17, DOI 10.3727/096504016X14570992647203	4	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	OCT	2018	80						247	247		10.1016/j.humpath.2018.03.029			1	Pathology	Pathology	GX5US	WOS:000447817100031	29940287				2019-10-28	
J	Agrawal, R				Agrawal, Ranjan			From Editor's desk	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Agrawal, Ranjan] Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India	Agrawal, R (reprint author), Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India.	chiefeditor.ijpm@gmail.com					Elkady N, 2018, INDIAN J PATHOL MICR, V61, P526, DOI 10.4103/IJPM.IJPM_588_17; Grover S, 2018, INDIAN J PATHOL MICR, V61, P537, DOI 10.4103/IJPM.IJPM_297_17; Jafarian AH, 2018, INDIAN J PATHOL MICR, V61, P500, DOI 10.4103/IJPM.IJPM_67_18; Jagtap SV, 2018, INDIAN J PATHOL MICR, V61, P477, DOI [10.4103/IJPM.IJPM_201_18, 10.4103/IJPM.IJPM_277_16]; Nayak SS, 2018, INDIAN J PATHOL MICR, V61, P520, DOI 10.4103/IJPM.IJPM_430_17; Neeha S, 2018, INDIAN J PATHOL MICR, V61, P495, DOI 10.4103/IJPM.IJPM_461_17; Pradhan S, 2018, INDIAN J PATHOL MICR, V61, P583, DOI 10.4103/IJPM.IJPM_423_17; Tiwari N, 2018, INDIAN J PATHOL MICR, V61, P489, DOI 10.4103/IJPM.IJPM_318_17	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					475	476		10.4103/0377-4929.243011			2	Pathology	Pathology	GW7WJ	WOS:000447182900001	30303131	DOAJ Gold			2019-10-28	
J	Jagtap, SV				Jagtap, Sunil Vitthalrao			Evaluation of CD4+T-cells and CD8+T-cells in triple-negative invasive breast cancer	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							TUMOR-INFILTRATING LYMPHOCYTES; CARCINOMA; MARKER		[Jagtap, Sunil Vitthalrao] KIMS Univ, Dept Pathol, Karad, Maharashtra, India	Jagtap, SV (reprint author), KIMS Univ, Dept Pathol, Karad, Maharashtra, India.	drsvjagtap@gmail.com	jagtap, sunil v/I-9965-2019				Cancello G, 2010, ANN ONCOL, V21, P1974, DOI 10.1093/annonc/mdq072; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Helal TEA, 2013, INDIAN J PATHOL MICR, V56, P89, DOI 10.4103/0377-4929.118676; Jagtap SV, 2016, JR EVIDENCE BASED ME, V3, P1666; Jana SH, 2014, INDIAN J PATHOL MICR, V57, P530, DOI 10.4103/0377-4929.142639; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Schmidt M, 2012, CLIN CANCER RES, V18, P2695, DOI 10.1158/1078-0432.CCR-11-2210; Wang K, 2017, HUM PATHOL, V69, P110, DOI 10.1016/j.humpath.2017.09.012; West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072	9	5	5	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					477	478		10.4103/IJPM.IJPM_201_18			2	Pathology	Pathology	GW7WJ	WOS:000447182900002	30303132	DOAJ Gold			2019-10-28	
J	Ravi, M; Boaz, K; Natarajan, S; Lewis, A; Prasad, M; Yellapurkar, S				Ravi, Mahalakshini; Boaz, Karen; Natarajan, Srikant; Lewis, Amitha; Prasad, Mukul; Yellapurkar, Swetha			Expression of alpha-smooth muscle actin in benign and malignant salivary gland tumors: An immunohistochemical study	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adenoid cystic carcinoma; alpha smooth muscle actin; histogenesis; myoepithelial cells; tumour patterning	PLEOMORPHIC ADENOMA; NEOPLASMS; BREAST; CELLS	Background and Objectives: Myoepithelial cells (ME) are known to contribute in the patterning of salivary gland neoplasms (SGN) and possess cytoplasmic smooth muscle actin (SMA) revealed by alpha SMA (alpha-SMA). The present study aimed to assess the expression of alpha-SMA in selected benign and malignant SGN (pleomorphic adenoma [PA], mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (ACC), and polymorphous low-grade adenocarcinoma (PLGA). Materials and Methods: The intensity and pattern of expression of a-SMA were studied in 25 cases of SGN's ACC (n = 7), MEC (n = 8), PA (n = 8), and PLGA (n = 2), and correlated with the histological patterns. Results: Maximum expression of alpha-SMA in the epithelial compartment was seen in ACC, followed by PA, whereas MEC and PLGA showed completely negative staining. The connective tissue expression was mild in ACC and MEC. The myxoid stroma of PA with "melting" pattern was weakly positive for alpha-SMA. The stroma in PLGA showed complete negativity. In ACC, alpha-SMA-positive cells were lining the cribriform spaces, small islands, and dispersed within large islands. Small nests showed complete positivity for alpha-SMA. Interpretation and Conclusion: In ACC, alpha-SMA expression supports the involvement of ME in epithelial organization explaining the histological patterns seen. In PA, the expression correlates with the predominantly secretory nature of ME. The absence of epithelial positivity in MEC and PLGA suggest that ME has less role to play in their histogenesis. The weak stromal positivity observed in MEC and ACC may be attributed to the positive immunoreactivity of myofibroblasts playing a role in modulating the course of SGN's.	[Ravi, Mahalakshini; Boaz, Karen; Natarajan, Srikant; Lewis, Amitha; Prasad, Mukul; Yellapurkar, Swetha] Manipal Acad Higher Educ, Manipal Coll Dent Sci, Dept Oral Pathol & Microbiol, Mangalore, Karnataka, India	Boaz, K (reprint author), Manipal Acad Higher Educ, Manipal Coll Dent Sci, Dept Oral Pathol & Microbiol, Mangalore, Karnataka, India.	karen.boaz@manipal.edu		NATARAJAN, SRIKANT/0000-0002-2686-0397; Boaz, Karen/0000-0001-6033-9581			Chitturi RT, 2015, J CLIN DIAGN RES, V9, pZE14, DOI 10.7860/JCDR/2015/11372.5707; Cirri P, 2011, AM J CANCER RES, V1, P482; Dardick I, 1996, COLOR ATLAS TEXT SAL, P24; DARDICK I, 1991, SURG PATHOLOGY SALIV, P108; Deyhimi P, 2006, DENT RES J, V3, P1; Dwivedi N, 2013, INDIAN J CANCER, V50, P361, DOI 10.4103/0019-509X.123629; Edwards PC, 2003, ORAL SURG ORAL MED O, V95, P586, DOI 10.1067/moe.2003.31; Gabbiani G, 1998, CARDIOVASC RES, V38, P545, DOI 10.1016/S0008-6363(98)00065-0; Gudjonsson T, 2002, J CELL SCI, V115, P39; Gupta V, 2012, INT J ORAL MAXILLOF, V3, P15; HIRANO T, 1990, ARCH OTOLARYNGOL, V116, P692; Lehman W, 2012, J MUSCLE RES CELL M, V33, P461, DOI 10.1007/s10974-012-9283-z; Margaritescu C, 2004, J CELL MOL MED, V8, P369, DOI 10.1111/j.1582-4934.2004.tb00326.x; Pia-Foschini M, 2003, J CLIN PATHOL, V56, P497, DOI 10.1136/jcp.56.7.497; Prasad AR, 1999, ARCH PATHOL LAB MED, V123, P801; Rasheed FS, 2011, ORAL DIAG, V23, P51; Savera AT, 1997, MODERN PATHOL, V10, P1093	17	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					479	484		10.4103/IJPM.IJPM_482_17			6	Pathology	Pathology	GW7WJ	WOS:000447182900003	30303133	DOAJ Gold			2019-10-28	
J	Yadav, M; Agrawal, V; Pani, KC; Verma, R; Jaiswal, S; Mishra, A; Pandey, R				Yadav, Mahima; Agrawal, Vinita; Pani, Krushna Chandra; Verma, Ritu; Jaiswal, Sushila; Mishra, Anjali; Pandey, Rakesh			C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						C-cell; familial; medullary; sporadic	PROGNOSTIC-FACTORS; MICROCARCINOMA	C-cell hyperplasia (CCH) is characterized by increased mass of C-cells and has been identified as a precursor condition for medullary thyroid carcinoma (MTC). Varying proportion of MTCs is associated with CCH in different studies. This could be due to the lack of uniformity of the definitions and techniques used to identify CCH in these studies. Aims: This study aims to study the occurrence, clinicopathological, and immunohistochemical features of CCH in MTC diagnosed during a 22-year period at a tertiary care center in North India and to review the available literature on CCH. Materials and Methods: Eighty-seven consecutive cases of MTC were included in the study. Histological evaluation for the presence of CCH and neoplastic CCH was performed. Confirmation of CCH was done by immunohistochemistry for calcitonin and chromogranin. The presence of neoplastic CCH was correlated with clinical factors and prognostic factors. Results: Of 87 cases of MTC included in the study, 71 (82%) patients were sporadic and 16 (18%) had familial MTC. Neoplastic CCH was seen in 12 (75%) familial and in 9 (13%) sporadic MTC. Patients with familial MTC were more frequently associated with neoplastic CCH than sporadic MTC (P < 0.001), were younger (P < 0.001), and had more often bilateral and multifocal tumors (P < 0.001). However, there was no significant difference in mean survival time and progression-free survival in patients with and without CCH. Conclusion: CCH, though more common in familial MTC, can also be seen in sporadic tumors. CCH is not associated with patient survival and disease progression.	[Yadav, Mahima; Agrawal, Vinita; Pani, Krushna Chandra; Verma, Ritu; Jaiswal, Sushila; Pandey, Rakesh] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India; [Mishra, Anjali] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrine Surg, Lucknow, Uttar Pradesh, India	Yadav, M (reprint author), D63-13 A,6 Annapoorna Nagar, Varanasi 221010, Uttar Pradesh, India.	mahima.yadav@gmail.com					Albores-Saavedra J, 2001, ENDOCR PATHOL, V12, P365, DOI 10.1385/EP:12:4:365; ALBORESSAAVEDRA J, 1988, HUM PATHOL, V19, P795, DOI 10.1016/S0046-8177(88)80262-4; Borda A, 1999, Rom J Morphol Embryol, V45, P53; BUSSOLATI G, 1967, J ENDOCRINOL, V37, P205, DOI 10.1677/joe.0.0370205; Carney J A, 1978, Pathobiol Annu, V8, P105; Chan JK, 2001, DIAGNOSTIC HISTOPATH, P959; Desai Saral S, 2005, Indian J Cancer, V42, P25; Etit D, 2008, ARCH PATHOL LAB MED, V132, P1767, DOI 10.1043/1543-2165-132.11.1767; Guyetant S, 1997, J CLIN ENDOCR METAB, V82, P42, DOI 10.1210/jc.82.1.42; Guyetant S, 2003, MODERN PATHOL, V16, P756, DOI 10.1097/01.MP.0000081727.75778.0C; Kaserer K, 2001, AM J SURG PATHOL, V25, P1245, DOI 10.1097/00000478-200110000-00004; Kebebew E, 2000, CANCER-AM CANCER SOC, V88, P1139, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z; KOMMINOTH P, 1994, AM J SURG PATHOL, V18, P399, DOI 10.1097/00000478-199404000-00008; LiVolsi VA, 1997, J CLIN ENDOCR METAB, V82, P39, DOI 10.1210/jc.82.1.39; LIVOLSI VA, 1979, AM J CLIN PATHOL, V71, P595; Matias-Guiu X, 2004, PATHOLOGY GENETICS T, V8, P86; Perry A, 1996, CANCER-AM CANCER SOC, V77, P750, DOI 10.1002/(SICI)1097-0142(19960215)77:4<750::AID-CNCR22>3.0.CO;2-Z; Randolph G W, 2000, Cancer Control, V7, P253; Moreno MJR, 2011, ENDOCR PATHOL, V22, P35, DOI 10.1007/s12022-010-9145-4; ROSAI J, 1992, ATLAS TUMOR PATHOLOG; Scopsi L, 1996, CANCER, V78, P2173, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2173::AID-CNCR20>3.3.CO;2-D; Stewart BW, 2003, WORLD CANC REPORT, P257	22	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					485	488		10.4103/IJPM.IJPM_478_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900004	30303134	DOAJ Gold			2019-10-28	
J	Tiwari, N; Srivastava, AN; Tandon, N; Lal, N; Yadav, S; Kant, S; Jain, M				Tiwari, Neema; Srivastava, Anand N.; Tandon, Nishi; Lal, Nirupma; Yadav, Shailendra; Kant, Surya; Jain, Manoj			A prospective study of association of cancer stem cell marker aldehyde dehydrogenase 1 with clinicopathological profile in lung carcinoma patients	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Lung cancer; staging; stem cells	EXPRESSION; DIAGNOSIS; CD133; PROGNOSIS; SYMPTOMS; ALDH1	Context: In India, lung carcinoma is the fifth-most common tumor and second-most common tumor in the males as per the Indian Council of Medical Research registry of 2002. It has been seen that ALDH1 expression in non-small cell lung cancer (NSCLC) and the presence of marker was linked to a more tumorigenic potential in the in vivo assessment and shorter disease-free survival in NSCLC patients with platinum treatment. Aims: Hence, our objective was to detect association of cancer stem cell (CSC) marker aldehyde dehydrogenase 1 (ALDH1) with clinicopathological profile in lung carcinoma patients. Settings and Design: This is a Pilot study. Subjects and Methods: It was a Pilot study where biopsies from 55 fresh previously untreated lung cancer patients visiting the Pulmonary Medicine Department of Era's Lucknow Medical College and Hospital Lucknow and King George's Medical University were taken for 18 months November 2014-April 2016, after taking proper informed consent from them. Paraffin blocks were taken and stained by hematoxylin and eosin (Sigma) to make the histopathological diagnosis and immunohistochemistry was done for detection of CSC marker ALDH1 (Daco). Statistical Analysis Used: The statistical analysis was done using Statistical Package for Social Sciences Version 15.0 Statistical Analysis Software. The values were represented in number (%) and mean +/- standard deviation. Results: Expression of stem cell marker ALDH1 with the staging of the tumor was observed in 62.5% of Stage I, 80% of Stage II, 94.1% of Stage Ill, and 100% of Stage IV cases. Statistically, there was a significant association between ALDH1expression and stage of disease (P < 0.001). Diagnostic efficacy of ALDH1 expression in the detection of any positive clinical stage, it was found to be 88.6% sensitive and 90.9% specific. Conclusions: Strong ALDH1 expression correlates with higher stage of lung carcinoma making it a prognostic marker needing in-depth study.	[Tiwari, Neema; Srivastava, Anand N.; Tandon, Nishi; Lal, Nirupma] Eras Lucknow Med Coll & Hosp, Dept Pathol, Lucknow, Uttar Pradesh, India; [Yadav, Shailendra; Kant, Surya] King George Med Univ, Dept CTVS & Pulm Med, Lucknow, Uttar Pradesh, India; [Jain, Manoj] SGPGI, Dept Pathol, Lucknow, Uttar Pradesh, India	Tiwari, N (reprint author), 5-69 Vinay Khand, Lucknow 226010, Uttar Pradesh, India.	nehaneemat@yahoo.co.in					Alamgeer M, 2013, RESPIROLOGY, V18, P757, DOI 10.1111/resp.12094; Behera D., 2012, J INDIAN ACAD CLIN M, V13, P131; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Birring SS, 2005, THORAX, V60, P268, DOI 10.1136/thx.2004.032698; Corner J, 2005, THORAX, V60, P314, DOI 10.1136/thx.2004.029264; Dimou A, 2012, AM J PATHOL, V181, P1436, DOI 10.1016/j.ajpath.2012.06.037; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fargeas CA, 2007, TISSUE ANTIGENS, V69, P602, DOI 10.1111/j.1399-0039.2007.00825.x; Feng W, 2010, IDENTIFICATION HUMAN; Hamilton G, 2010, J BIOANAL BIOMED S, VS9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; van Voss MRH, 2011, CELL ONCOL, V34, P3, DOI 10.1007/s13402-010-0007-3; Herpel E, 2011, ANTICANCER RES, V31, P4491; Hou HW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01259; HYDE L, 1974, CHEST, V65, P299, DOI 10.1378/chest.65.3.299; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jensen AR, 2002, ACTA ONCOL, V41, P147, DOI 10.1080/028418602753669517; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Loewen G, 2004, CHEST, V125, p163S, DOI 10.1378/chest.125.5_suppl.163S-a; Malik PS, 2015, INDIAN J MED RES, V141, P5; Miyata T, 2016, AACR 107 ANN M 15 JU; Mohan A, 2016, INDIAN J CANCER, V53, P92, DOI 10.4103/0019-509X.180819; Moreira AL, 2010, MODERN PATHOL, V23, P889, DOI 10.1038/modpathol.2010.68; Myrdal G, 2004, THORAX, V59, P45; NIEBURGS HE, 1968, ACTA CYTOL, V12, P445; Noronha V, 2012, INDIAN J CANCER, V49, P74, DOI 10.4103/0019-509X.98925; Phuc PV, 2011, ONCOTARGETS THER, V4, P71, DOI 10.2147/OTT.S21431; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roudi R, 2015, CANCER INVEST, V33, P294, DOI 10.3109/07357907.2015.1034869; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Wang PH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052088; Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015; [徐跃华 Xu Yuehua], 2011, [江苏医药, Jiangsu Medical Journal], V37, P412; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932	38	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					489	494		10.4103/IJPM.IJPM_318_17			6	Pathology	Pathology	GW7WJ	WOS:000447182900005	30303135	DOAJ Gold			2019-10-28	
J	Neeha, S; Kattimani, SR; Mahanta, AA; Patil, AG				Neeha, Saara; Kattimani, Santosh Rao; Mahanta, Anita A.; Patil, Anuradha G.			An autopsy based descriptive study of the spectrum of pulmonary lesions encountered in fetal deaths at a tertiary care center	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Congenital lung malformation; fetal autopsy; pulmonary lesions	MECONIUM ASPIRATION SYNDROME; RISK-FACTORS	Background: Fetal autopsy has been an indispensable tool in evaluating the cause of death. The most common cause for fetal deaths is associated with respiratory disorders accounting for around 60%. This study was undertaken to evaluate the gross and microscopic features of lungs in fetal autopsies and estimate the incidence of deaths attributable to pulmonary causes. Materials and Methods: All fetuses received for autopsy at our institute were included in the study with prior consent. Gross and microscopic findings along with relevant clinical data were recorded. Results: A total of 426 autopsies were conducted from January 2011 to August 2016. Of those, 184 had abnormal pulmonary findings constituting 43.19%. Aspiration pneumonia was the most common finding with 67 cases (36.4%), followed by atelectasis 54 cases (29.3%), congenital cystic adenomatoid malformation in 13 cases (7.1%), lung hypoplasia 12 cases (6.5%), pulmonary hemorrhage 21 (11.4%),15 cases (8.15%) of hyaline membrane disease, one case (0.5%) of heterotaxy, and one case of extralobar pulmonary sequestration (0.5%). Congenital malformations of lungs were seen in 27 (14.67%) cases and 38 cases (20.65%) had other associated anomalies. Conclusion: Pulmonary pathology is the most common finding in fetal deaths with aspiration pneumonitis being the most common avoidable cause. Accurate fetal autopsy along with clinical data are important in evaluating fetal deaths and can help in reduction of unexplained stillbirths.	[Neeha, Saara; Kattimani, Santosh Rao; Mahanta, Anita A.; Patil, Anuradha G.] Mahadevappa Rampure Med Coll, Dept Pathol, Kalaburagi, Karnataka, India	Neeha, S (reprint author), 5-739 Roza Khurd, Kalaburagi 585104, Karnataka, India.	drsaara.neha@gmail.com					Aghabiklooei A, 2009, INDIAN J PEDIATR, V76, P1137, DOI 10.1007/s12098-009-0229-4; Agrons GA, 2005, RADIOGRAPHICS, V25, P1047, DOI 10.1148/rg.254055019; Askin FB, 2007, POTTERS PATHOLOGY FE; Becroft DMO, 2005, PEDIATR DEVEL PATHOL, V8, P448, DOI 10.1007/s10024-005-0033-8; D'costa GF, 2006, BOMBAY HOSP J, V48, P547; Dargaville PA, 2006, PEDIATRICS, V117, P1712, DOI 10.1542/peds.2005-2215; Finkbeiner WE, 2009, AUTOPSY PATHOLOGY MA, P9; Hakverdi S, 2012, TURK J PATHOL, V28, P154, DOI 10.5146/tjpath.2012.01115; Kamakeri NS, 2017, INT J REPROD CONTRAC, V6, P2914; Liu WF, 2002, AM J PERINAT, V19, P367, DOI 10.1055/s-2002-35611; Naik V, 2015, INT J RES MED SCI, V3, P1114; Pradhan R, 2013, J INDIAN ACAD FORENS, V35, P10; Zodpey S, 2014, PHFI AIIMS SC STATE	13	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					495	499		10.4103/IJPM.IJPM_461_17			5	Pathology	Pathology	GW7WJ	WOS:000447182900006	30303136	DOAJ Gold			2019-10-28	
J	Jafarian, AH; Tasbandi, A; Gilan, H; Sheikhi, M; Roshan, NM				Jafarian, Amir Hossein; Tasbandi, Aida; Gilan, Hamed; Sheikhi, Maryam; Roshan, Nema Mohamadian			Evaluation of CD30/CD4/CD8 in triple-negative invasive ductal carcinoma of breast in association with clinicopathological prognostic factors	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast; CD30; CD4; CD8; ductal carcinoma; triple negative	TUMOR-INFILTRATING LYMPHOCYTES; FAVORABLE PROGNOSIS; CD30 EXPRESSION; CELL LYMPHOMA; T-CELL; CANCER; PATTERN	Background: Triple-negative breast cancer (TNBC) lacks the benefits of receptor-targeted therapeutic strategies. The limitations in treatment options along with poor patients' outcome heighten the need for novel approaches. Due to recent concentration on the role of biomarkers in prognosis, treatment, and survival of various cancer subtypes, this study involves an investigation of CD4, CD8, and CD30 markers detected by immunohistochemistry in TNBCs and their association with clinicopathological and prognostic factors. Materials and Methods: Tissue samples of 85 hormone receptor- and human epidermal growth factor receptor-2-negative ductal breast carcinomas extracted from the archive of pathology department. Regarding CD4/CD8 ratio, the infiltrated T-lymphocytes were investigated. The tumoral tissue regions were also identified to be immunohistochemically assessed for the CD30 expression levels. Results: With an elevated CD4/CD8 ratio, a significant increase in lymph node involvement was observed (P < 0.05); in contrast, increased expression levels of CD8 were related to significant reduction of lymph node involvement. CD30 overexpression was found to be significantly associated with shortened overall survival (OS) and highly involvement of lymph nodes. Conclusion: Following the progression in stage and grade of tumor, CD4/CD8 ratio and CD30 expression levels are increased and are accompanied by adverse prognosis and poor OS, while CD8-enhanced expression carries a favorable prognostic impact as it improves OS status. Therefore, all these findings could be of interest in the field of target therapy.	[Jafarian, Amir Hossein; Roshan, Nema Mohamadian] Mashhad Univ Med Sci, Dept Pathol & Lab Med, Fac Med, Mashhad, Iran; [Sheikhi, Maryam] Mashhad Univ Med Sci, Canc Mol Pathol Res Ctr, Fac Med, Mashhad, Iran; [Tasbandi, Aida; Gilan, Hamed] Mashhad Univ Med Sci, Dept Pathol, Fac Med, Mashhad, Iran	Roshan, NM (reprint author), Mashhad Univ Med Sci, Dept Pathol, Fac Med, Mashhad, Iran.	mohamadian_nema@yahoo.com			Research Deputyship of Mashhad University of Medical Sciences	This work is supported by Research Deputyship of Mashhad University of Medical Sciences.	Akhtar M, 2015, BREAST CANCER-TARGET, V7, P239, DOI 10.2147/BCTT.S85442; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Eerola AK, 2000, CLIN CANCER RES, V6, P1875; Engert A, 2013, HAEMATOLOGICA, V98, P1165, DOI 10.3324/haematol.2013.091561; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Funada Y, 2003, ONCOL REP, V10, P309; Hu SM, 2013, BLOOD, V121, P2715, DOI 10.1182/blood-2012-10-461848; Iwase H, 2010, BREAST CANCER-TOKYO, V17, P118, DOI 10.1007/s12282-009-0113-0; Li PF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-890; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; Macchetti Alexandre Henrique, 2006, Clinics, V61, P203, DOI 10.1590/S1807-59322006000300004; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mirzania Mehrzad, 2017, Int J Hematol Oncol Stem Cell Res, V11, P37; Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Stagg J, 2013, THER ADV MED ONCOL, V5, P169, DOI 10.1177/1758834012475152; Taheri NS, 2012, ASIAN PAC J CANCER P, V13, P4517, DOI 10.7314/APJCP.2012.13.9.4517; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; vonWasielewski R, 1997, AM J PATHOL, V150, P793; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775	25	1	1	0	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					500	504		10.4103/IJPM.IJPM_67_18			5	Pathology	Pathology	GW7WJ	WOS:000447182900007	30303137	DOAJ Gold			2019-10-28	
J	Wijesinghe, HD; Thuvarakan, P; Samarasekera, A; Lokuhetty, MDS				Wijesinghe, Harshima Disvini; Thuvarakan, Poobalasinghain; Samarasekera, Anandi; Lokuhetty, Menaka Dilani S.			Prognostic indices predictive of short-term disease-free survival of breast carcinoma patients receiving primary surgical treatment in Sri Lanka	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast carcinoma; prognostic indices; short-term survival; Sri Lanka	PRACTICE GUIDELINE UPDATE; CLINICAL-PRACTICE; CANCER RECURRENCE; AMERICAN SOCIETY; FOLLOW-UP; THERAPY; POPULATION; EXPERIENCE; WOMEN; ASSAY	Background: Breast carcinoma (BCa) is the commonest malignancy among women worldwide and in Sri Lanka. Several prognostic indices are described for BCa. Aims: To assess clinicopathological features and prognostic indices derived from routine clinical, histopathological and immunohistochemical (INC) data, in a cohort of patients undergoing primary surgery for BCa and to determine their prognostic impact on short-term disease free survival. Setting and Design: This is a bidirectional cohort study of 208 women undergoing primary surgery for BCa at the National Hospital of Sri Lanka, from 2012-2014, excluding post-neoadjuvant chemotherapy cases. Material and Methods: Clinical details, tumor size and nodal status were obtained from histopathology reports. Histopathology and estrogen/progesterone receptor and HER2 status were reviewed. Molecular subtype based on IHC was determined. Nodal ratio (number of positive nodes/total number retrieved) and Nottingham prognostic index were calculated. Follow up information was obtained by patient interviews and record review. Statistical Analysis: Data was analyzed by univariate and multivariate Cox regression using SPSS19.0. Results: Mean follow-up duration was 27.16 months (0.5-52 months, s = 9.35 months). 174 (82.9%) remained disease free with 19 (9%) deaths. Thirteen (6.2%) survived with metastasis and 4 (1.9%) with recurrences. On univariate Cox regression, tumor, nodal and TNM stages, nodal ratio and lymphovascular invasion (LVI) were predictive of disease free survival (DFS) (P = 0.001, P = 0.021, P = 0.022, P = 0.002, P = 0.018). On multivariate analysis TNM stage and LVI were predictive of DFS. Conclusion: TNM stage and LVI were the most important predictors of short-term disease free survival in this study population, confirming that early detection of BCa at a lower stage has a significant impact on short-term outcomes.	[Wijesinghe, Harshima Disvini; Thuvarakan, Poobalasinghain; Lokuhetty, Menaka Dilani S.] Univ Colombo, Fac Med, Dept Pathol, Colombo, Sri Lanka; [Samarasekera, Anandi] Natl Hosp Sri Lanka, Dept Pathol, Colombo, Sri Lanka	Wijesinghe, HD (reprint author), Univ Colombo, Fac Med, Dept Pathol, Colombo, Sri Lanka.	harshima@hotmail.com			National Research Council of Sri Lanka [NRC 11:51]; Kumi and Heram Bilmoria Trust Fund	This study received financial support from the National Research Council of Sri Lanka Grant NRC 11:51 and the Kumi and Heram Bilmoria Trust Fund.	Ajaikumar BS, 2012, J CLIN ONCOL, V30; Bhatti AH, 2014, ASIAN PAC J CANCER P, V15, P5331, DOI 10.7314/APJCP.2014.15.13.5331; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carlson JJ, 2013, BREAST CANCER RES TR, V141, P13, DOI 10.1007/s10549-013-2666-z; DeFrank JT, 2013, PUBLIC HEALTH GENOM, V16, P215, DOI 10.1159/000353518; Dinshaw KA, 2005, INT J RADIAT ONCOL, V63, P1132, DOI 10.1016/j.ijrobp.2005.03.071; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Geradts J, 2010, CANCER INVEST, V28, P969, DOI 10.3109/07357907.2010.512600; Green AR, 2013, BRIT J CANCER, V109, P1886, DOI 10.1038/bjc.2013.528; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Jamshed A, 2015, INDIAN J CANCER, V52, P119, DOI 10.4103/0019-509X.175599; Khatcheressian JL, 2013, J CLIN ONCOL, V31, P961, DOI 10.1200/JCO.2012.45.9859; Lakhani SREI, 2012, WHO CLASSIFICATION T; Martin FT, 2013, BREAST J, V19, P388, DOI 10.1111/tbj.12122; National Cancer Control Programme, 2013, CANC INC DAT SRI LAN; NHS Cancer Screening Programmes and the Royal College of Pathologists, 2005, NHSBSP PUBL, V58, P41; Ni YB, 2014, ANN SURG ONCOL, V21, P2928, DOI 10.1245/s10434-014-3691-9; Raina Vinod, 2005, Indian J Cancer, V42, P40; Rakha EA, 2014, BRIT J CANCER, V110, P1688, DOI 10.1038/bjc.2014.120; Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607; Sathwara J, 2016, INT J RES MED SCI, V4, P3102; Sobin LH, 2009, INT UNION CANC UICC; Soria D, 2010, COMPUT BIOL MED, V40, P318, DOI 10.1016/j.compbiomed.2010.01.003; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sundquist M, 1999, BREAST CANCER RES TR, V53, P1, DOI 10.1023/A:1006052115874; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Xue Cheng, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P245	29	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					505	509		10.4103/IJPM.IJPM_321_17			5	Pathology	Pathology	GW7WJ	WOS:000447182900008	30303138	DOAJ Gold			2019-10-28	
J	Singha, J; Khan, K; Chatterjee, S				Singha, Joydeb; Khan, Kalyan; Chatterjee, Souvik			Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Canalicular; CD10; cellblock; fine-needle aspiration cytology; hepatocellular carcinoma; metastatic malignancy of liver	LYMPHOBLASTIC-LEUKEMIA ANTIGEN; NEEDLE-ASPIRATION-CYTOLOGY; METASTATIC CARCINOMA; BIOPSY; HEPATOCYTE; IMMUNOCYTOCHEMISTRY; NEPRILYSIN; EXPRESSION; ANTIBODY; MARKER	Background: Differentiation of hepatocellular carcinoma (HCC) from metastatic malignancy in liver may be difficult at times on fine-needle aspiration cytology, especially in case of moderate-to-poorly differentiated tumors. The benefit of cell-block technique is the recognition of histologic pattern of diseases along with application of a wide variety of immunohistochemical (IHC) stains to differentiate hepatic malignancies. In this study, CD10IHC staining was done on cellblocks prepared from aspirates of clinicoradiologically/cytologically suspected malignant liver neoplasms to differentiate HCC from malignancies metastasizing to liver. Objective: The objective of the study was to assess the diagnostic utility of CD10 IHC stain on cell-block preparation for differentiating primary from Secondary malignancies of liver. Materials and Methods: Formalin-fixed, paraffin-embedded cellblocks of 61 cases (25 cases of HCC and 36 cases of metastatic carcinoma) were prepared from a fine-needle aspirate of the suspected malignant liver neoplasm and immunostained using monoclonal antibody against CD10. Results: Twenty-two (88%) of 25 cases of HCC were positive for CD10 with a canalicular staining pattern. Two (8%) were positive for CD10 with membranous and one (4%) with cytoplasmic staining pattern. Conclusion: CD10 immunostaining on cellblock is useful in discriminating HCC and metastatic carcinoma of the liver with a diagnostic accuracy of 88.52%.	[Singha, Joydeb; Khan, Kalyan] North Bengal Med Coll, Dept Pathol, Siliguri, India; [Chatterjee, Souvik] CNMCH, Dept Urol, Kolkata, W Bengal, India	Singha, J (reprint author), PO Ghoshpara, Howrah 711227, W Bengal, India.	joydeb453enigma@gmail.com					Bales CE, 2006, KOSS DIAGNOSTIC CYTO, P1591; Borscheri N, 2001, AM J SURG PATHOL, V25, P1297, DOI 10.1097/00000478-200110000-00011; BRET PM, 1988, GASTROINTEST RADIOL, V13, P253, DOI 10.1007/BF01889073; Chu PGG, 2002, AM J SURG PATHOL, V26, P978, DOI 10.1097/01.PAS.0000020482.56467.09; Crawford J, 2010, PATHOLOGIC BASIS DIS, P877; Dragovic T, 1997, ANTICANCER RES, V17, P3233; Guo ZW, 2002, DIAGN CYTOPATHOL, V26, P283, DOI 10.1002/dc.10097; Kumar M, 2007, J GASTROEN HEPATOL, V22, P1104, DOI 10.1111/j.1440-1746.2007.04908.x; Lin F, 2004, DIAGN CYTOPATHOL, V30, P92, DOI 10.1002/dc.10419; METZGAR RS, 1981, J EXP MED, V154, P1249, DOI 10.1084/jem.154.4.1249; Miller K, 2002, THEORY PRACTICAL HIS, P424; Morrison C, 2002, MODERN PATHOL, V15, P1279, DOI 10.1097/01.MP.0000037312.69565.24; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PISHARODI LR, 1995, DIAGN CYTOPATHOL, V12, P364; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; Saad RS, 2004, DIAGN CYTOPATHOL, V30, P1, DOI 10.1002/dc.10345; Salomao DR, 1997, DIAGN CYTOPATHOL, V16, P8, DOI 10.1002/(SICI)1097-0339(199701)16:1<8::AID-DC3>3.0.CO;2-F; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; Tan CH, 2011, INT J HEPATOL, DOI 10.4061/2011/519783; Turner AJ, 1997, FASEB J, V11, P355; Wee Aileen, 2005, Cytojournal, V2, P7, DOI 10.1186/1742-6413-2-7; Xiao SY, 2001, AM J PATHOL, V159, P1415, DOI 10.1016/S0002-9440(10)62528-X; Zaakook M, 2013, J EGYPT NATL CANCER, V25, P173, DOI 10.1016/j.jnci.2013.07.004; Zimmerman RL, 2001, CANCER CYTOPATHOL, V93, P288, DOI 10.1002/cncr.9043	24	0	0	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					510	515		10.4103/IJPM.IJPM_788_16			6	Pathology	Pathology	GW7WJ	WOS:000447182900009	30303139	DOAJ Gold			2019-10-28	
J	Hazarika, P; Sharma, MK				Hazarika, Prabir; Sharma, Manoj Kumar			Intracholecystic papillary-tubular neoplasm of gallbladder: A 5-year retrospective pathological study	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Biliary; intracholecystic papillary-tubular neoplasm; papillary; papillary-tubular; pyloric	CARCINOMA	Background: Intracholecystic papillary-tubular neoplasm (ICPN) is a relatively new entity which includes neoplastic polyps, adenomas, and papillary neoplasms that are >= 1.0 cm. This study is done to evaluate the pathological features of ICPN and to find out the factors associated with invasion. Materials and Methods: This is a 5-year retrospective study in a referral pathology center. A total of 19 cases of ICPN are found. The cases are analyzed for age and sex distribution, clinical suspicion, stages, histological architecture, differentiation, and grade of dysplasia. Descriptive statistics and test of significance by Chi-square and t-test are used in the study. Results: ICPN comprises 23.5% of all gallbladder neoplasms. Two-thirds of the cases were suspected radiologically. Age range is 26-65 years with mean age of 50 years. They are 2.8 times more common in female. Approximately one-third of the cases show invasion. The most common histological pattern is papillary, followed by papillary-tubular and finally by tubular pattern. Pyloric and biliary are the most common differentiation pattern followed by oncocytic and intestinal pattern. About three-fourths of the cases are associated with high-grade dysplasia mostly diffuse high-grade dysplasia. Conclusion: We have found the younger age of presentation, less proportion of invasive tumors, fewer tumors with biliary phenotypes, and fewer tumors with high-grade dysplasia as compared to previous studies. Factors significantly associated with invasion are grade and extent of dysplasia particularly diffuse high-grade dysplasia.	[Hazarika, Prabir] Jorhat Med Coll, Dept Pathol, Jorhat, Assam, India; [Sharma, Manoj Kumar] Alcare Diagnost & Res Ctr, Gauhati, Assam, India	Hazarika, P (reprint author), Jorhat Med Coll & Hosp, Dept Pathol, Jorhat 785001, Assam, India.	prabirhazarika@gmail.com					Adsay V, 2012, AM J SURG PATHOL, V36, P1279, DOI 10.1097/PAS.0b013e318262787c; Albores-Saavedra J, 2005, ARCH PATHOL LAB MED, V129, P905; Argon A, 2016, INT J SURG PATHOL, V24, P504, DOI 10.1177/1066896916644781; Balci S, 2014, AJSP-REV REP, V19, P283, DOI 10.1097/PCR.0000000000000069; Bennett S, 2015, HPB, V17, P811, DOI 10.1111/hpb.12460; Hamdani NH, 2012, ASIAN PAC J CANCER P, V13, P5613, DOI 10.7314/APJCP.2012.13.11.5613; Hashimoto S, 2014, INTERNAL MED, V53, P2313, DOI 10.2169/internalmedicine.53.2778; ISOZAKI M, 2014, SHOWA U J MED SCI, V26, P17; Poudel R, 2016, J SOC SURG NEPAL, V18, P46; Seretis Charalampos, 2014, J Clin Med Res, V6, P26, DOI 10.4021/jocmr1689w; Singh V, 2001, J GASTROEN HEPATOL, V16, P560, DOI 10.1046/j.1440-1746.2001.02484.x; Unisa S, 2011, HPB, V13, P117, DOI 10.1111/j.1477-2574.2010.00255.x; Wan XS, 2013, WORLD J GASTROENTERO, V19, P8595, DOI 10.3748/wjg.v19.i46.8595; Wan XS, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000131; Xiao SY, 2012, SCIENTIFICA, DOI 10.6064/2012/893632; Yamamoto K, 2014, WORLD J GASTROENTERO, V20, P8736, DOI 10.3748/wjg.v20.i26.8736	16	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					516	519		10.4103/IJPM.IJPM_489_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900010	30303140	DOAJ Gold			2019-10-28	
J	Nayak, SS; Roy, P; Arora, N; Arun, I; Roy, MK; Banerjee, S; Mahide, I; Mallath, MK				Nayak, Sonali Susinita; Roy, Paromita; Arora, Neeraj; Arun, Indu; Roy, Manas Kumar; Banerjee, Sudeep; Mahide, Indranil; Mallath, Moliandas K.			Prevalence estimation of microsatellite instability in colorectal cancers using tissue microarray based methods-A tertiary care center experience	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Colorectal carcinoma; microsatellite instability; mismatch repair protein	MISMATCH REPAIR STATUS; LYNCH-SYNDROME; COLON-CANCER; MOLECULAR PATHWAYS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROGNOSIS; CARCINOMA; DIAGNOSIS; SURVIVAL	Aim: Microsatellite instability (MSI) pathway is known to be implicated in carcinogenesis of 15% colorectal carcinomas (CRC), including 2%-3% of cases of Lynch syndrome, as per western literature. MSI status has important prognostic and therapeutic implications. The prevalence of MSI in Indian CRC patients is unknown. We aimed to determine the prevalence by studying 231 consecutive unselected cases of CRC. Methods: Tissue microarrays using duplicate cores per case for 141 cases, and whole tissue sections for 90 cases, were used. Immunohistochemistry with four mismatch repair (MMR) markers - MLH1, MSH2, MSH6, and PMS2 was performed. Molecular analysis for MSI status was performed in 18 randomly selected cases. Correlation with various clinical and histopathological features was done using univariate and multivariate analysis. Results: Loss of MMR immunohistochemical (INC) was seen in 53/231 cases, i.e. 22.94% (95% confidence interval 17.52%-28.36%). MLH1-PMS2 dual loss comprised 13.9%, MSH2-MSH6 7.4%, and isolated PMS2 loss in 1.73% of cases. Univariate analysis showed significant association with age (<60 years), right-sided tumor location, histologic type, high grade, the presence of severe intratumoral lymphocytic (ITL) and peri-tumoral lymphocytic response, and NO nodal stage. On multivariate analysis, independent variables were age < 60 years, right-sided location, and severe ITL. Molecular testing for MSI corroborated with the IHC results. Conclusion: The study results show a slightly higher prevalence of MSI-H phenotype, compared to Western literature, stressing the need for more widespread testing for better clinical management and identification of possible hereditary colon cancer syndrome.	[Nayak, Sonali Susinita; Roy, Paromita; Arun, Indu] Tata Med Ctr, Dept Pathol, Kolkata, W Bengal, India; [Arora, Neeraj] Tata Med Ctr, Dept Lab Med & Mol Genet, Kolkata, W Bengal, India; [Roy, Manas Kumar; Banerjee, Sudeep] Tata Med Ctr, Dept Surg Oncol, Kolkata, W Bengal, India; [Mahide, Indranil] Tata Med Ctr, Dept Radiat Oncol, Kolkata, W Bengal, India; [Mallath, Moliandas K.] Tata Med Ctr, Dept GI Med, Kolkata, W Bengal, India	Roy, P (reprint author), Tata Med Ctr, 14 MAR E-W, Kolkata 700160, W Bengal, India.	paromita.roy@tmckolkata.com					Al-Sohaily S, 2012, J GASTROEN HEPATOL, V27, P1423, DOI 10.1111/j.1440-1746.2012.07200.x; Bacher JW, 2004, DIS MARKERS, V20, P237, DOI 10.1155/2004/136734; Bartley AN, 2014, ARCH PATHOL LAB MED, V138, P166, DOI 10.5858/arpa.2013-0231-CP; Chew MH, 2013, WORLD J SURG, V37, P2468, DOI 10.1007/s00268-013-2134-2; Cicek MS, 2011, J MOL DIAGN, V13, P271, DOI 10.1016/j.jmoldx.2010.12.004; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; Greenson JK, 2003, AM J SURG PATHOL, V27, P563, DOI 10.1097/00000478-200305000-00001; Hughes LAE, 2012, BBA-REV CANCER, V1825, P77, DOI 10.1016/j.bbcan.2011.10.005; Kanth VVR, 2014, TUMOR BIOL, V35, P4347, DOI 10.1007/s13277-013-1570-9; LeGolvan MP, 2012, HUM PATHOL, V43, P1157, DOI 10.1016/j.humpath.2012.03.003; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Merok MA, 2013, ANN ONCOL, V24, P1274, DOI 10.1093/annonc/mds614; National Cancer Registry Programme (India), 3 YEAR REP POP BAS C; Ohrling K, 2010, ACTA ONCOL, V49, P797, DOI 10.3109/02841861003705786; Pandey V, 2007, INT J COLORECTAL DIS, V22, P777, DOI 10.1007/s00384-006-0241-3; Rajkumar T, 2004, GENET TEST, V8, P157, DOI 10.1089/1090657041797211; Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917; Shia J, 2005, AM J SURG PATHOL, V29, P96, DOI 10.1097/01.pas.0000146009.85309.3b; Shia J, 2003, AM J SURG PATHOL, V27, P1407, DOI 10.1097/00000478-200311000-00002; Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031; Singh P, 2015, INDIAN J MED RES PHA, V2, P9; Sinicrope FA, 2012, CLIN CANCER RES, V18, P1506, DOI 10.1158/1078-0432.CCR-11-1469; Sinicrope FA, 2011, JNCI-J NATL CANCER I, V103, P863, DOI 10.1093/jnci/djr153; Tang LH, 2016, PROTOCOL EXAMINATION; Toon CW, 2014, MODERN PATHOL, V27, P644, DOI 10.1038/modpathol.2013.200; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Yoon YS, 2011, J GASTROEN HEPATOL, V26, P1733, DOI 10.1111/j.1440-1746.2011.06784.x	31	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					520	525		10.4103/IJPM.IJPM_430_17			6	Pathology	Pathology	GW7WJ	WOS:000447182900011	30303141	DOAJ Gold			2019-10-28	
J	Elkady, N; Sultan, M; Elkhouly, E				Elkady, Noha; Sultan, Mohamed; Elkhouly, Enas			Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						KI-67; non-muscle-invasive urothelial carcinoma; P53; recurrence; topoisomerase II	SUPERFICIAL BLADDER-CANCER; DNA TOPOISOMERASES; PREDICTIVE-VALUE; STAGE TA; RISK; CLASSIFICATION; CHEMOTHERAPY; INSTILLATION; EPIRUBICIN; RECURRENCE	Background: Transurethral resection of tumor is the main treatment of non-muscle-invasive urothelial carcinoma, but it is associated with high rate of recurrence and/or progression and this arouses the need for adjuvant therapy. Topoisomerase II (Top II), KI-67, and P53 are proliferation and cell cycle regulation markers that may predict tumor response to therapy. Aim: This study aimed to assess Top II, KI-67, and P53 expression and their effect on clinical outcome and response to therapy of non-muscle-invasive urothelial carcinoma. Materials and Methods: Fifty cases of non-muscle invasive urothelial carcinoma were collected; Top II, KI-67, and P53 expression was evaluated. Patients received treatment then tumor recurrence was correlated with the expression of previous markers. Results: There was a significant association between high Top II score, P53, and KI-67 and high tumor grade (P=0.0001, 0.001, and 0.0001), submucosal infiltration (P=0.0001 and 0.01), and recurrence (P=0.01, 0.001, and 0.001). Conclusion: Top II, P53, and KI-67 may predict tumor response to therapy and the clinical outcome in non-muscle-invasive urothelial carcinoma.	[Elkady, Noha] Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm, Egypt; [Sultan, Mohamed] Menoufia Univ, Fac Med, Dept Urol, Shibin Al Kawm, Egypt; [Elkhouly, Enas] Menoufia Univ, Fac Med, Dept Clin Oncol, Shibin Al Kawm, Egypt	Elkady, N (reprint author), Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm, Egypt.	Nohalkdy@yahoo.com					AlielDein B, 1997, J UROLOGY, V158, P68, DOI 10.1097/00005392-199707000-00018; Brake M, 2000, UROLOGY, V55, P673, DOI 10.1016/S0090-4295(99)00591-9; Chaux A, 2012, HUM PATHOL, V43, P115, DOI 10.1016/j.humpath.2011.04.013; Chekerov R, 2009, MOL MED REP, V2, P1011, DOI 10.3892/mmr_00000207; Chen JS, 2002, JTUA, V13, P114; COLE SPC, 1991, CANCER RES, V51, P3345; Colombel M, 2008, EUR UROL SUPPL, V7, P618, DOI 10.1016/j.eursup.2008.08.002; Delbridge AR, 2012, COLD SPRING HARB PER, V4; Feng CC, 2014, SCI REP-UK, V4, DOI 10.1038/srep04015; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kim EJ, 2010, UROLOGY, V75, DOI 10.1016/j.urology.2009.08.055; Kumar V, 2013, ROBBINS BASIC PATHOL, P177; Menendez Lopez V, 2000, Actas Urol Esp, V24, P530; Millan-Rodriguez F, 2000, J UROLOGY, V164, P680, DOI 10.1016/S0022-5347(05)67280-1; Mokhtar N, 2004, CANC PATHOLOGY REGIS, P32; Mukherjee A, 2010, BRIT J CANCER, V103, P1794, DOI 10.1038/sj.bjc.6605960; Nakopoulou L, 2001, J CLIN PATHOL, V54, P309, DOI 10.1136/jcp.54.4.309; Nakopoulou L, 1998, BRIT J CANCER, V77, P2267; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; OOSTERLINCK W, 1993, J UROLOGY, V149, P749, DOI 10.1016/S0022-5347(17)36198-0; Pasin Erik, 2008, Rev Urol, V10, P31; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Quintero A, 2006, J CLIN PATHOL, V59, P83, DOI 10.1136/jcp.2004.022939; Salem HK, 2012, UROLOGY, V79, P379, DOI 10.1016/j.urology.2011.08.072; Santos L, 2003, INT J CANCER, V105, P267, DOI 10.1002/ijc.11049; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sylvester RJ, 2004, J UROLOGY, V171, P2186, DOI 10.1097/01.ju.0000125486.92260.b2; THAKUR DS, 2011, INT J PHARM SCI NANO, V3, P1173; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831	30	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					526	531		10.4103/IJPM.IJPM_588_17			6	Pathology	Pathology	GW7WJ	WOS:000447182900012	30303142	DOAJ Gold			2019-10-28	
J	Bibi, A; Java, S; Chaudhary, S; Joshi, S; Mascerhenas, R; Rabade, N; Tembhare, P; Subramanian, PG; Gujral, S; Menon, H; Khattry, N; Sengar, M; Bagal, B; Jain, H; Patkar, N				Bibi, Asina; Java, Shrutika; Chaudhary, Shruti; Joshi, Swapnali; Mascerhenas, Russel; Rabade, Nikhil; Tembhare, Prashant; Subramanian, Papagudi Ganesan; Gujral, Smneet; Menon, Hari; Khattry, Navin; Sengar, Manju; Bagal, Bhausaheb; Jain, Hasmukh; Patkar, Nikhil			BRAFV600E mutation in hairy cell leukemia: A single-center experience	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Amplification refractory mutation system-polymerase chain reaction; BRAFV600E; hairy cell leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; BRAF V600E MUTATION; RING SIDEROBLASTS; SF3B1 MUTATION; VARIANT; NEOPLASMS; DIAGNOSIS; LYMPHOMA	Background: BRAFV600E mutation has been reported as a unique genetic lesion of hairy cell leukemia (HCL), a subset of which lacks this lesion and shows adverse outcomes. Aims: To determine the prevalence of BRAFV600E in HCL from our center and derive clinicopathological correlation, if any. Materials and Methods: A 9-year retrospective analysis of 46 consecutive cases of HCL diagnosed on morphology and immunophenotyping was done. Stained smears were used as samples for amplification refractory mutation system polymerase-chain reaction using fluorescent primers for mutation detection. Results: BRAFV600E mutation was detected in 41/46 patients (89.1%) while anent in control samples of chronic lymphocytic leukemia. Cases mimicking HCL-variant clinically or immunophenotypically too showed the presence of this mutation. HCL with mutated BRAF presented at a younger age. No statistical difference in blood counts, tumor bad, and immunophenotype patterns existed among BRAF mutated and unmutated group. Nine patients (45%) with mutated BRAF had residual disease following treatment with cladribine. Conclusion: BRAFV600E mutation analysis has a definitive role in the diagnosis of HCL.	[Bibi, Asina; Java, Shrutika; Chaudhary, Shruti; Joshi, Swapnali; Mascerhenas, Russel; Rabade, Nikhil; Tembhare, Prashant; Subramanian, Papagudi Ganesan; Gujral, Smneet; Menon, Hari; Khattry, Navin; Sengar, Manju; Bagal, Bhausaheb; Jain, Hasmukh] Tata Mem Hosp, Hematopathol Lab, Bombay, Maharashtra, India; [Patkar, Nikhil] Tata Mem Hosp, Mol Div, Hematopathol Lab, Bombay, Maharashtra, India	Patkar, N (reprint author), Tata Mem Hosp, Hematopathol Lab, ACTREC, KS-231, Bombay 410210, Maharashtra, India.	nvpatkar@gmail.com	TEMBHARE, PRASHANT R/J-6813-2019	Patkar, Nikhil/0000-0001-9234-2857			Arber DA, 2008, WHO CLASSIFICATION T, P110; Arcaini L, 2012, BLOOD, V119, P188, DOI 10.1182/blood-2011-08-368209; Arons E, 2011, LEUKEMIA LYMPHOMA, V52, P99, DOI 10.3109/10428194.2011.565841; Arons E, 2009, BLOOD, V114, P4687, DOI 10.1182/blood-2009-01-201731; Blombery PA, 2012, HAEMATOL-HEMATOL J, V97, P780, DOI 10.3324/haematol.2011.054874; Boyd EM, 2011, BRIT J HAEMATOL, V155, P609, DOI 10.1111/j.1365-2141.2011.08868.x; Chen YH, 2006, AM J CLIN PATHOL, V125, P251, DOI 10.1309/PMQXVY619Q8Y43AR; Craig FE, 2008, BLOOD, V111, P3941, DOI 10.1182/blood-2007-11-120535; Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124; Forconi F, 2011, LEUKEMIA LYMPHOMA, V52, P103, DOI 10.3109/10428194.2011.569620; Forconi F, 2009, BLOOD, V114, P4696, DOI 10.1182/blood-2009-03-212449; Foucar K., 2008, WHO CLASSIFICATION T, P188; Grever MR, 2010, BLOOD, V115, P21, DOI 10.1182/blood-2009-06-195370; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Huang TG, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-3; Jebaraj BMC, 2013, LEUKEMIA LYMPHOMA, V54, P1177, DOI 10.3109/10428194.2012.742525; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Kridel R, 2012, BLOOD, V119, P1963, DOI 10.1182/blood-2011-11-391474; Langabeer SE, 2012, LEUKEMIA RES, V36, P483, DOI 10.1016/j.leukres.2011.12.015; Lennerz JK, 2012, BRIT J HAEMATOL, V157, P267, DOI 10.1111/j.1365-2141.2011.08963.x; Malcovati L, 2015, BLOOD, V126, P233, DOI 10.1182/blood-2015-03-633537; Matutes E, 2006, HEMATOL ONCOL CLIN N, V20, P1051, DOI 10.1016/j.hoc.2006.06.012; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pettirossi V, 2015, BLOOD, V125, P1207, DOI 10.1182/blood-2014-10-603100; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Raess PW, 2013, BLOOD, V122, P3084, DOI 10.1182/blood-2013-07-513523; Shao HP, 2013, LEUKEMIA RES, V37, P401, DOI 10.1016/j.leukres.2012.11.021; Sharpe RW, 2006, HEMATOL ONCOL CLIN N, V20, P1023, DOI 10.1016/j.hoc.2006.06.010; Stetler-Stevenson M, 2011, LEUKEMIA LYMPHOMA, V52, P11, DOI 10.3109/10428194.2011.570820; Tallman MS, 1999, CLIN CANCER RES, V5, P1665; Tiacci E, 2015, NEW ENGL J MED, V373, P1733, DOI 10.1056/NEJMoa1506583; Tiacci E, 2006, NAT REV CANCER, V6, P437, DOI 10.1038/nrc1888; Tiacci E, 2013, HAEMATOLOGICA, V98, P635, DOI 10.3324/haematol.2012.078071; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Tschernitz S, 2014, BRIT J HAEMATOL, V165, P529, DOI 10.1111/bjh.12735; Waterfall JJ, 2014, NAT GENET, V46, P8, DOI 10.1038/ng.2828; Xi LQ, 2012, BLOOD, V119, P3330, DOI 10.1182/blood-2011-09-379339	38	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					532	536		10.4103/IJPM.IJPM_484_16			5	Pathology	Pathology	GW7WJ	WOS:000447182900013	30303143	DOAJ Gold			2019-10-28	
J	Grover, S; Sood, N; Chaudhary, A				Grover, Sumit; Sood, Neena; Chaudhary, Anurag			Student perception of peer teaching and learning in pathology: A qualitative analysis of modified seminar fishbowls, and interactive classroom activities	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Aspects; interactive; peer-led seminars; peer teaching and learning; qualitative study; small group	MEDICAL-STUDENTS; EDUCATION	Context: Peer-assisted teaching and learning (PTL) is being experimented in different medical universities worldwide. It is a learner-centered approach involving students through active learning strategies. Aims: To study the student perception of PTL in methods such as group-led seminars and fishbowls, in classroom through various interactive activities: compare and find out the student acceptability and efficacy of each of these methods in learning conceptual topics such as various types of anemia. Subjects and Methods: Medical students of second-year professional course were subjected to PTL in classroom during allotted teaching hours for 10 successive sessions using group-led modified seminars, fishbowls, and different formality-level interactive activities such as street plays, prop sessions, quiz sessions, to make them understand the clinical features and presentation of different types of anemia through understanding of etio-pathogenesis. To ascertain the aspects that influenced learning, focus group discussions were conducted in small groups consisting of 14 students and one facilitator in each group. Qualitative thematic analysis was performed on transcripts of the audio recordings by authors. Results: The emerging themes from qualitative analysis of transcripts were pertaining to teacher, student, and organization. We found motivation, interest, and involvement of peer teacher, student behavior and collaboration, contact time between students and facilitator, preparation time, coherence with other curricular activities, group size and composition, suitability of topic for the kind of activity, and availability of material for preparation as few sub-aspects affecting learning. Conclusion: For PTL to be effective, adequate transfer of knowledge through good peer teacher involvement, learner receptiveness, and adequate contact time is needed. Proper preparation with suitability of topics for the type of activity, alignment of seminars with other activities, and course coherence are prerequisites for the same.	[Grover, Sumit; Sood, Neena] Dayanand Med Coll & Hosp, Dept Pathol, Ludhiana, Punjab, India; [Chaudhary, Anurag] Dayanand Med Coll & Hosp, Dept Social & Prevent Med, Ludhiana, Punjab, India	Grover, S (reprint author), Dayanand Med Coll & Hosp, Dept Pathol, Ludhiana, Punjab, India.	sumitgrover1204@gmail.com					Asghar A, 2010, ASSESS EVAL HIGH EDU, V35, P403, DOI 10.1080/02602930902862834; Burgess A, 2014, ADV MED EDUC PRACT, V5, P403, DOI 10.2147/AMEP.S72653; Burgess A, 2013, MED TEACH, V35, P58, DOI 10.3109/0142159X.2012.731101; Chou CL, 2011, ACAD MED, V86, P1560, DOI 10.1097/ACM.0b013e31823595fd; de Jong Z, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-79; de Menezes S, 2016, INT J MED EDUC, V7, P160, DOI 10.5116/ijme.5738.3c28; Dennick R, 2011, MED ED THEORY PRACTI, P131; Edmunds S, 2010, MED TEACH, V32, P715, DOI 10.3109/0142159X.2010.505454; Greenstock L, 2013, J INTERPROF CARE, V27, P537, DOI 10.3109/13561820.2013.816272; Harden RM, 2001, MED TEACH, V23, P123, DOI 10.1080/01421590120036547; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jaarsma ADC, 2008, MED EDUC, V42, P1178, DOI 10.1111/j.1365-2923.2008.03170.x; Krippendorff K, 1980, CONTENT ANAL INSTRUC; McCrorie P., 2010, UNDERSTANDING MED ED, p[124, 128], DOI DOI 10.1080/01421590802109834; Spruijt A, 2015, J VET MED EDUC, V42, P259, DOI 10.3138/jvme.1114-119R2; Spruijt A, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-22; Sprvijt A., 2012, MED TEACH, V34, P129; Wolff M, 2015, J EMERG MED, V48, P85, DOI 10.1016/j.jemermed.2014.09.010; Yardley S, 2012, MED TEACH, V34, P161, DOI 10.3109/0142159X.2012.643264	19	1	1	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					537	544		10.4103/IJPM.IJPM_297_17			8	Pathology	Pathology	GW7WJ	WOS:000447182900014	30303144	DOAJ Gold			2019-10-28	
J	Raja, K; Antony, M; Harikrishnan, S				Raja, Kavita; Antony, Molly; Harikrishnan, S.			Infective endocarditis due to Streptococci and Enterococci: A 3-year retrospective study	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Alpha lytic streptococci; enterococci; Infective endocarditis	VALVES	Introduction: Infective endocarditis (IE) is an infection of the heart valves with an aggregation of bacteria in a fibrin plaque called vegetation. Aims and Objectives: This is a retrospective study of all infective endocarditis cases due to alpha haemolytic streptococci and enterococci. Methods: AM cases of infective endocarditis cases due to alpha haemolytic streptococci and enterococci in a period of three years from 1st January 2010 to 31st December 2012 were included. Isolation of the same organism from more than one set of blood cultures was taken as a confirmed case of infective endocarditis. Clinical and serological parameters were recorded using a proforma. Results: Native valve endocarditis was more common with only five prosthetic valves being involved. Out of 89 clinically suspected cases of IE in the three years from Jan 2010 to Dec 2012, for which blood was sent for culture, 63(70.78%) samples were positive by culture. Of these, 42/63(66.66%) were due to alpha-lytic Streptococci, enterococci and rare gram positive cocci. The rare ones included Enterococcus gallinarum, abiotropha defective, Vagococcus fluvialis and Nutritionally Variant Streptococci(NVS). High level Aminoglycoside resistance(HLAR) was also encountered. The varied and important features of these isolates are discussed. Complications and treatment are described. Conclusion: From a clinical microbiology point of view, the major challenge faced by the microbiologist in diagnosis of IE is proper aseptic collection of sample before starting antibiotics with a need for multiple samples to detect and also to prove the causative organism. Sensitivity reporting can be a difficult task in the context of NVS, HLAR and gram positives that are slow growing. Congestive failure and embolisation occurs even when the antibiotic treatment is successful.When patients go in for complications, it is very rarely due to wrong antibiotics.	[Raja, Kavita; Antony, Molly] Sree Chithra Tirunal Inst Med Sci & Technol, Dept Microbiol, Thiruvananthapuram, Kerala, India; [Harikrishnan, S.] Sree Chithra Tirunal Inst Med Sci & Technol, Dept Cardiol, Thiruvananthapuram, Kerala, India	Raja, K (reprint author), Sree Chithra Tirunal Inst Med Sci & Technol, Dept Microbiol, Thiruvananthapuram, Kerala, India.	kavita_raja@yahoo.com					Brusch JL., 2007, INFECT DIS CRITICAL, P242; Clinical and Laboratory Standards Institute, 2014, PERFORMANCE STANDARD; Dargere S, 2002, J CLIN MICROBIOL, V40, P2308, DOI 10.1128/JCM.40.6.2308-2310.2002; Greenwood D, 2006, MED MICROBIOLOGY GUI, P183; Guerrero MLF, 2007, MEDICINE, V86, P363, DOI 10.1097/MD.0b013e31815d5386; Mocchegiani R., 2009, Cardiovascular & Hematological Disorders - Drug Targets, V9, P240; Senthilkumar Subramaniam, 2010, Indian J Med Sci, V64, P187, DOI 10.4103/0019-5359.97358	7	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					545	548		10.4103/IJPM.IJPM_205_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900015	30303145	DOAJ Gold			2019-10-28	
J	Huang, ZY; Zhang, SS; Zhang, YZ; An, JH; Luo, J; Liao, PJ; Chen, Q; Shen, H				Huang, Zhuo-Ya; Zhang, Sisi; Zhang, Yao-Zhong; An, Jian-Hong; Luo, Jiao; Liao, Peng-Juan; Chen, Qing; Shen, Hong			The clinicopathologic and immunohistochemical features of villoglandular adenocarcinoma of uterine cervix	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Clinical stage; clinicopathologic feature; human papillomavirus infections; outcome; villoglandular adenocarcinoma	OF-THE-LITERATURE; PAPILLARY ADENOCARCINOMA; CANCER; EXPRESSION; PROGESTERONE; RECURRENCE; RECEPTORS; ESTROGEN; THERAPY; LESIONS	Aim: Villoglandular adenocarcinoma (VGA) of the uterine cervix is a variant of endocervical adenocarcinoma. However, the clinicopathologic and immunohistochemical features of VGA are still unclear. The aim of this study was to investigate the clinicopathologic and immunohistochemical features of VGA. Materials and Methods: A total of 20 VGA patients were identified among 852 patients diagnosed with cervical cancer and enrolled in this study. The immunohistochemical levels of Ki-67, P53, P16, progesterone receptor (PR), carcinoembryonic antigen (CEA), vimentin (Vim), and estrogen receptor (ER) were measured by immunohistochemistry. Results: VGA was prevalent in younger women and presented favorable prognosis. Ki-67, P16, and CEA were highly expressed in VGA tissues, while PR expression was hardly to be detected. The positive rates of Ki-67, CEA, and P16 were 90.0%, 90.0%, and 85.0%, respectively, which were significantly higher compared with PR (5.0%, P < 0.001). In addition, the positive rates of P53, Vim, and ER in VGA tissues were 55.0%, 50.0%, and 40.0%, respectively. However, the expression levels of Ki-67, P53, P16, PR, CEA, Vim, and ER were not significantly associated with clinical features (P > 0.05). Conclusion: These data indicate that VGA is a rare cervical adenocarcinoma, which is prevalent in younger women, and presents favorable prognosis. Detection of Ki-67, P53, P16, PR, CEA, Vim, and ER would be beneficial for the diagnosis of VGA.	[Huang, Zhuo-Ya; Zhang, Sisi; Zhang, Yao-Zhong; An, Jian-Hong; Luo, Jiao; Shen, Hong] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Huang, Zhuo-Ya; Zhang, Sisi; Zhang, Yao-Zhong; An, Jian-Hong; Luo, Jiao; Shen, Hong] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Chen, Qing] Southern Med Univ, Dept Epidemiol, Sch Publ & Trop Med, Guangzhou, Guangdong, Peoples R China; [Huang, Zhuo-Ya; Liao, Peng-Juan] Huizhou Municipal Cent Hosp, Dept Pathol, Huizhou, Peoples R China	Shen, H (reprint author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Shen, H (reprint author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.	shenhong2013168@163.com					Ballo MS, 1996, ACTA CYTOL, V40, P536; Chen CC, 2016, ANN SAUDI MED, V36, P245, DOI 10.5144/0256-4947.2016.245; Chung SH, 2015, TRENDS ENDOCRIN MET, V26, P399, DOI 10.1016/j.tem.2015.06.004; Collinet P, 1999, EUR J OBSTET GYN R B, V86, P101, DOI 10.1016/S0301-2115(99)00047-0; Leite PMD, 2017, REV BRAS GINECOL OBS, V39, P288, DOI 10.1055/s-0037-1598643; Dede M, 2004, TOHOKU J EXP MED, V202, P305, DOI 10.1620/tjem.202.305; Falcon O, 2006, GYNECOL ONCOL, V101, P168, DOI 10.1016/j.ygyno.2005.09.059; Freier CP, 2016, ANTICANCER RES, V36, P3131; Gonzalez-Bosquet E, 2009, EUR J GYNAECOL ONCOL, V30, P211; Hoffman JS, 2001, GYNECOL ONCOL, V81, P310, DOI 10.1006/gyno.2001.6129; HOPSON L, 1990, GYNECOL ONCOL, V39, P221, DOI 10.1016/0090-8258(90)90437-P; Kawaguchi G, 2010, INT J CLIN ONCOL, V15, P104, DOI 10.1007/s10147-009-0005-5; Kleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-X; Korach J, 2009, ACTA OBSTET GYN SCAN, V88, P355, DOI 10.1080/00016340902730359; Lakhtakia R, 2000, J SURG ONCOL, V74, P297, DOI 10.1002/1096-9098(200008)74:4<297::AID-JSO12>3.3.CO;2-V; Lataifeh IM, 2013, INT J GYNECOL CANCER, V23, P900, DOI 10.1097/IGC.0b013e31828efcaa; Lei B, 2015, J UROLOGY, V194, P1491, DOI 10.1016/j.juro.2015.04.116; Lei B, 2013, HISTOPATHOLOGY, V63, P696, DOI 10.1111/his.12215; Lin JY, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0450-6; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MONSONEGO J, 1991, INT J CANCER, V48, P533, DOI 10.1002/ijc.2910480410; Rubesa-Mihaljevic R, 2010, COLLEGIUM ANTROPOL, V34, P291; Spurgeon ME, 2014, AM J PATHOL, V184, P530, DOI 10.1016/j.ajpath.2013.10.013; Takai N, 2010, EUR J GYNAECOL ONCOL, V31, P573; Yamazawa K, 2000, GYNECOL ONCOL, V77, P473, DOI 10.1006/gyno.2000.5804; YOUNG RH, 1989, CANCER, V63, P1773; Zhao LP, 2016, ONCOL LETT, V11, P2164, DOI 10.3892/ol.2016.4172; Zhou QY, 2016, ONCOL LETT, V11, P837, DOI 10.3892/ol.2015.3944	28	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					549	552		10.4103/IJPM.IJPM_144_18			4	Pathology	Pathology	GW7WJ	WOS:000447182900016	30303146	DOAJ Gold			2019-10-28	
J	Goyal, M; Dinaker, M; Gayathri, K				Goyal, Manu; Dinaker, M.; Gayathri, K.			Adult T-cell leukemia/lymphoma and acquired immunodeficiency syndrome-CD4+T-cell malignancy in CD4+T-cell deficient status: A paradox	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adult T-cell leukemia/lymphoma; CD4; human immunodeficiency virus; human T-cell lymphotropic virus type I; thalassemia; viral load	LYMPHOTROPIC VIRUS TYPE; HIV-INFECTION; IN-VIVO; HTLV-I; COINFECTION; SUBSETS; DISEASE	CD4 counts along with viral loads are important parameters in the monitoring of human immunodeficiency virus (HIV) infection. Human T-cell lymphotropic virus type I (HTLV-1) is known to be an etiological agent for adult T-cell leukemia/lymphoma (ATLL). Coinfection of HTLV-1 and HIV is well known in regions with high seroprevalence, and there is no published data in the Indian scenario. We present an interesting case of occurrence of CD4+ T-cell proliferation in a known beta thalassemia major with acquired HIV seropositivity accompanied by simultaneously increasing CD4+ counts and viral loads. Further workup revealed ATLL with an underlying HTLV infection.	[Goyal, Manu] Sunshine Hosp, Dept Hematopathol, AmPath, Hyderabad, Telangana, India; [Gayathri, K.] Sunshine Hosp, Dept Hematopathol, Lifeline Tapadia Diagnost Ctr, Hyderabad, Telangana, India; [Dinaker, M.] Sunshine Hosp, Dept Med, Hyderabad, Telangana, India	Goyal, M (reprint author), AOI & Citizens Hosp, Ampath, Dept Hematopathol, Hyderabad 500019, Telangana, India.	dr_manu31@yahoo.com	Goyal, Manu/N-5073-2019		Lifeline Tapadia Diagnostic Center	We sincerely thank Dr. R.S. Tapadia, Lifeline Tapadia Diagnostic Center for providing financial support to perform additional tests for confirmation of the diagnosis.	Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; CLEGHORN FR, 1992, ARCH INTERN MED, V152, P1372, DOI 10.1001/archinte.152.7.1372; Dunham RM, 2008, J IMMUNOL, V180, P5582, DOI 10.4049/jimmunol.180.8.5582; Fantry L, 1995, CLIN INFECT DIS, V21, P1466, DOI 10.1093/clinids/21.6.1466; Fathalla SE, 1998, ANN SAUDI MED, V18, P366, DOI 10.5144/0256-4947.1998.366; Harrison LH, 1997, J INFECT DIS, V175, P438, DOI 10.1093/infdis/175.2.438; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; Kumar Harsh, 2006, Indian J Pathol Microbiol, V49, P532; Marsh BJ, 1997, J INFECT DIS, V176, P543, DOI 10.1086/517289; Moon HS, 2006, MOL CELLS, V21, P7; Nadler JP, 1996, CLIN INFECT DIS, V23, P415, DOI 10.1093/clinids/23.2.415; Nixon DF, 2005, MICROBES INFECT, V7, P1063, DOI 10.1016/j.micinf.2005.03.026; Ohshima K, 2008, WHO CLASSIFICATION T, P281; Scapellato PG, 2003, JAIDS-J ACQ IMM DEF, V33, P279, DOI 10.1097/00126334-200306010-00028; SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353	15	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					553	556		10.4103/IJPM.IJPM_119_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900017	30303147	DOAJ Gold			2019-10-28	
J	Chari, PS; Chandra, P; Prasad, S; Bhattad, S				Chari, Preethi S.; Chandra, Prathap; Prasad, Sujay; Bhattad, Sagar			Chronic granulomatous disease presenting with small bone osteomyelitis in a young child: A case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Chronic granulomatous disease; dihydrorhodamine; nitroblue tetrazolium	DIAGNOSIS; OXIDASE	Chronic granulomatous disease (CGD) is a life threatening inherited disorder with varied clinical presentations often characterized by recurrent bacterial and fungal infections along with widespread granulomatous tissue response. The disease results from phagocytic defects characterized by deficiencies in oxidative burst of neutrophils. Nitroblue tetrazolium reduction test (NBT) and Dihydrorhodamine (DHR) with PMA stimulation by flow cytometry are quick, simple, sensitive and specific laboratory tests that help establish early and reliable diagnosis of CGD with an overall improvement in survival and disease prognosis. We report a case of 2-year old child who presented with small bone osteomyelitis involving bilateral feet and was later diagnosed to have autosomal recessive CGD due to mutation in NCF1 gene.	[Chari, Preethi S.; Prasad, Sujay] Anand Diagnost Lab, Hematopathol & Immunohematol, Bengaluru, Karnataka, India; [Chandra, Prathap] Motherhood Hosp, Dept Pediat, Bengaluru, Karnataka, India; [Bhattad, Sagar] Aster CMI Hosp, Dept Pediat Immunol, Bengaluru, Karnataka, India	Chari, PS (reprint author), 54 Bowring Tower,Bowring Hosp Rd, Bengaluru 560001, Karnataka, India.	preethichari@gmail.com					Abraham RS, 2016, CLIN VACCINE IMMUNOL, V23, P254, DOI 10.1128/CVI.00001-16; Afzal MM, 2014, INT J RES HLTH SCI, V2, P581; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2011.00054, 10.3389/fimmu.2014.00162]; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; EMMENDORFFER A, 1994, CYTOMETRY, V18, P147, DOI 10.1002/cyto.990180306; Golightly C, 2011, NEUTROPHIL OXIDATIVE; JANEWAY CA, 1954, AMA AM J DIS CHILD, V88, P388; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Leiding JW, 1993, GENEREVIEWS; Madkaikar M, 2013, INDIAN PEDIATR, V50, P579, DOI 10.1007/s13312-013-0171-4; Rawat A, 2014, J CLIN IMMUNOL, V34, P58, DOI 10.1007/s10875-013-9963-5; Rezaei N, 2017, PHAGOCYTIC DEFECTS, P245; Roos D, 2014, CLIN EXP IMMUNOL, V175, P139, DOI 10.1111/cei.12202; Vowells SJ, 1996, J PEDIATR-US, V128, P104, DOI 10.1016/S0022-3476(96)70437-7; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	15	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					557	560		10.4103/IJPM.IJPM_458_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900018	30303148	DOAJ Gold			2019-10-28	
J	Bajpai, M; Pardhe, N; Kumar, M				Bajpai, Manas; Pardhe, Nilesh; Kumar, Manish			mmunohistochemical differentiation between spindle cell lipoma and neurofibroma of oral cavity using CD34 and SOX10	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						CD34; connective tissue tumor; neurofibroma; soft-tissue tumor; SOX10; spindle cell lipoma	TONGUE	Spindle cell lipoma (SCL), also called as pleomorphic adenoma, is a rare variant of lipoma histopathologically characterized by an admixture of mature fat cells with spindle cells and occasionally mast cells with myxoid connective tissue stroma and thick bends of birefringent collagen. Although buccal mucosa is the most common location for oral lipomas, for SCL, it is an exceedingly rare location. We report a case of an asymptomatic swelling of buccal mucosa that simulated the features of neurofibroma on histopathological examination, and the final diagnosis of SCL was made on the basis of immunohistochemical features. This is the first documentation of oral SCL using SOX10 to achieve the final diagnosis.	[Bajpai, Manas; Pardhe, Nilesh] NIMS Dent Coll, Dept Oral & Maxillofacial Pathol, Jaipur, Rajasthan, India; [Kumar, Manish] SP Med Coll, Dept Dent, Bikaner, Rajasthan, India	Bajpai, M (reprint author), NIMS Dent Coll, Dept Oral & Maxillofacial Pathol, Jaipur, Rajasthan, India.	dr.manasbajpai@gmail.com					Bajpai M, 2017, JCPSP-J COLL PHYSICI, V27, P252, DOI 2600; Bajpai M, 2016, JCPSP-J COLL PHYSICI, V26, P1003, DOI 2507; Bajpai Manas, 2014, Natl J Maxillofac Surg, V5, P250, DOI 10.4103/0975-5950.154856; Billings SD, 2006, AM J DERMATOPATH, V28, P28, DOI 10.1097/01.dad.0000189615.13641.4b; Chandrashekhar P, 2012, Kathmandu Univ Med J (KUMJ), V10, P92; Darling M, 2002, ORAL SURG ORAL MED O, V93, P171, DOI 10.1067/moe.2002.120520; ENZINGER FM, 1975, CANCER, V36, P1852, DOI 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U; FLETCHER CDM, 1987, HISTOPATHOLOGY, V11, P803, DOI 10.1111/j.1365-2559.1987.tb01884.x; Mentzel T, 2016, VIRCHOWS ARCH, V469, P435, DOI 10.1007/s00428-016-1996-8; Stokes SM, 2011, J ORAL MAXIL SURG, V69, pE131, DOI 10.1016/j.joms.2011.01.043	10	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					561	563		10.4103/IJPM.IJPM_473_7			3	Pathology	Pathology	GW7WJ	WOS:000447182900019	30303149	DOAJ Gold			2019-10-28	
J	Rani, P; Singh, M; Mehrol, C; Gupta, AJ; Khurana, N; Meher, R				Rani, Poonam; Singh, Meeta; Mehrol, Chetna; Gupta, Amita Jain; Khurana, Nita; Meher, Ravi			Dedifferentiation of oncocytic epithelial-myoepithelial carcinoma to mucoepidermoid carcinoma in parotid gland: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Mucoepidermoid carcinoma; myoepithelial carcinoma; oncocytic	SALIVARY-GLANDS	Epithelial-myoepithelial carcinomas (EMCs) account for <1% of all salivary gland malignancies. Till now, 23 cases of dedifferentiated EMC have been reported to the best of our knowledge. However, dedifferentiation of oncocytic EMC to mucoepiderrnoid carcinoma is extremely rare. A 38-year-old female presented with right post aural swelling 4 cm x 2 cm in size for 6 months. Surgical excision was carried out, and we received partly skin-covered tissue 5 cm x 2 cm in size. Sections examined showed features of oncocytic EMC dedifferentiating into mucoepidermoid carcinoma. Myoepithelial component showed oncocytic change which was highlighted by p63.	[Rani, Poonam; Singh, Meeta; Mehrol, Chetna; Gupta, Amita Jain; Khurana, Nita] Maulana Azad Med Coll & Associated Lok Nayak Hosp, Dept Pathol, New Delhi, India; [Meher, Ravi] Maulana Azad Med Coll & Associated Lok Nayak Hosp, Dept ENT, New Delhi, India	Singh, M (reprint author), K-171, New Delhi 110076, India.	meetamamc@gmail.com					Alos L, 1999, VIRCHOWS ARCH, V434, P291, DOI 10.1007/s004280050344; Aydin S, 2014, CASE REP OTOLARYNGOL, DOI 10.1155/2014/629054; Baker AR, 2013, INT J SURG PATHOL, V21, P514, DOI 10.1177/1066896912468153; Ellis GL AP, 2008, TUMORS SALIVARY GLAN; Gnepp DR., 2001, DIAGNOSTIC SURG PATH; Kainuma K, 2010, ACTA OTO-LARYNGOL, V130, P185, DOI 10.3109/00016480902930458; Nagao T, 2002, MODERN PATHOL, V15, P724, DOI 10.1097/01.MP.0000018977.18942.FD; Seethala RR, 2007, AM J SURG PATHOL, V31, P44, DOI 10.1097/01.pas.0000213314.74423.d8; Seethala RR, 2013, HEAD NECK PATHOL, V7, pS77, DOI 10.1007/s12105-013-0461-0; Yang S, 2012, INT J ORAL MAX SURG, V41, P810, DOI 10.1016/j.ijom.2011.12.012	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					564	566		10.4103/IJPM.IJPM_64_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900020	30303150	DOAJ Gold			2019-10-28	
J	Kumar, A; Deka, L; Varshney, B; Aiyer, HM				Kumar, Abhishek; Deka, Lopamudra; Varshney, Bharti; Aiyer, Hema Malini			Cutaneous melanoma in childhood presenting as intraparotid lymph node metastasis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Cutaneous; malignancy; melanoma; pediatric	CHILDREN	Cutaneous melanoma in childhood is a rare disease. Rendering a clinical diagnosis of melanoma in pediatric patients is confounded by the fact that pigmented lesions in pediatric patients do not conform to the ABCDE rules applicable to adult patients. Furthermore, making a histologic diagnosis of cutaneous melanoma in childhood is also difficult with no universally accepted criteria applicable to pediatric melanomas. We report the case of a 5-year-old child presenting with intraparotid lymph node metastasis who was later found to have melanoma involving periorbital region. It is proposed that careful analysis of histologic features as well as the additional information provided by immunohistochemistry should allow for a correct diagnosis in most cases of melanoma in children.	[Kumar, Abhishek; Deka, Lopamudra; Varshney, Bharti; Aiyer, Hema Malini] Natl Reference Lab, Dr Lal PathLabs, Dept Pathol, Sect 18, New Delhi 110085, India	Kumar, A (reprint author), Natl Reference Lab, Dr Lal PathLabs, Dept Pathol, Sect 18, New Delhi 110085, India.	pathosapiens@gmail.com					Averbook BJ, 2013, CANCER-AM CANCER SOC, V119, P4012, DOI 10.1002/cncr.28289; BARNHILL R, 2004, PATHOLOGY MELANOCYTI; Brenn T., 2008, DIAGN HISTOPATHOL, V14, P18, DOI DOI 10.1016/J.MPDHP.2007.11.004; Cordoro KM, 2013, J AM ACAD DERMATOL, V68, P913, DOI 10.1016/j.jaad.2012.12.953; Ferrari A, 2014, J PEDIATR-US, V164, P376, DOI 10.1016/j.jpeds.2013.10.012; Paradela S, 2011, ARCH PATHOL LAB MED, V135, P307, DOI 10.1043/2009-0503-RA.1; Rao TN, 2009, INDIAN J PATHOL MICR, V52, P524, DOI 10.4103/0377-4929.56149	7	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					567	569		10.4103/IJPM.IJPM_43_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900021	30303151	DOAJ Gold			2019-10-28	
J	Medhe, AS; Mandale, SS; Deshpande, PU; Bhavthankar, JD				Medhe, Apurva Sonu; Mandale, Sonal S.; Deshpande, Preeti U.; Bhavthankar, Jyoti D.			Bilateral submandibular swelling diagnosed as tuberculous lymphadenitis in an asymptomatic patient A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Bilaterally; extrapulmonary; lymphadenitis; submandibular tuberculosis		In India, tuberculosis (TB) is a prevalent systemic disease and number of people who die with TB is increasing year by year. TB can be life-threatening, and there is a high mortality rate of systemic infection with TB. Although extrapulmonary TB (EPTB) is a rare form of TB, its prevalence is increasing day-by-day. Reported here is a case of a 28-year-old female patient with a painless swelling bilaterally in the submandibular region. She was diagnosed with bilateral submandibular tuberculous lymphadenitis. Tuberculous lymphadenitis, when occurring in the cervical region, continues to be a common cause of EPTB. Thorough knowledge of this condition is important as it can help in early diagnosis leading to prompt treatment of the patient and prevent further complications.	[Medhe, Apurva Sonu; Bhavthankar, Jyoti D.] Govt Dent Coll & Hosp, Dept Oral Pathol & Microbiol, Room 133,Ghati Campus, Aurangabad 431001, Maharashtra, India; [Mandale, Sonal S.] Rural Hlth Ctr, Aurangabad, Maharashtra, India; [Deshpande, Preeti U.] King Edward Mem Hosp, Dept Microbiol, Bombay, Maharashtra, India	Medhe, AS (reprint author), Govt Dent Coll & Hosp, Dept Oral Pathol & Microbiol, Room 133,Ghati Campus, Aurangabad 431001, Maharashtra, India.	apurva921989@gmail.com					Chao SS, 2002, OTOLARYNG HEAD NECK, V126, P176, DOI 10.1067/mhn.2002.121912; Dixit Ramakant, 2008, Indian J Tuberc, V55, P51; HASHIMOTO Y, 1989, J ORAL MAXIL SURG, V47, P744, DOI 10.1016/S0278-2391(89)80019-9; KRISHNASWAMI H, 1972, Tubercle, V53, P215, DOI 10.1016/0041-3879(72)90019-0; MANOLIDIS S, 1993, OTOLARYNG HEAD NECK, V109, P427, DOI 10.1177/019459989310900307; Martynaik D, 2010, UWO MED J, V78, P66; Mohapatra Prasanta Raghab, 2009, J Assoc Physicians India, V57, P585; RAUCH DM, 1978, J ORAL SURG, V36, P387; Sarwar A, 2004, INT J PATH, V2, P85; TAN K K, 1988, SMJ Singapore Medical Journal, V29, P441	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					570	572		10.4103/IJPM.IJPM_655_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900022	30303152	DOAJ Gold			2019-10-28	
J	Hui, M; Harshavardhana, KR; Uppin, SG				Hui, Monalisa; Harshavardhana, K. R.; Uppin, Shantveer G.			Pericardial mesothelioma presenting as chronic constrictive pericarditis. A series of three cases from a in single institution	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Chronic constrictive pericarditis; imaging; immunohistochemistry; mesothelioma; morphology; pericardium	OF-THE-LITERATURE; PATIENT	Pericardial mesotheliomas are rare tumors which often present with features of constrictive pericarditis. We present clinical, imaging, histological, and immunohistochemical findings of three cases presenting with chronic constrictive pericarditis. Two of these cases were initially treated as tuberculous pericarditis. Histologically, all the three cases were of an epithelioid type and showed positivity for more than one mesothelial markers. Two patients had a fatal outcome, and one was lost to follow-up.	[Hui, Monalisa; Uppin, Shantveer G.] Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Telangana, India; [Harshavardhana, K. R.] Nizams Inst Med Sci, Dept Radiol & Imageol, Hyderabad, Telangana, India	Uppin, SG (reprint author), Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Telangana, India.	drsguppin@yahoo.co.in					Bendek M, 2010, CARDIOVASC PATHOL, V19, P377, DOI 10.1016/j.carpath.2009.08.003; Choi Won-Suk, 2012, J Cardiovasc Ultrasound, V20, P57, DOI 10.4250/jcu.2012.20.1.57; Godar M, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/283601; GOSSINGER HD, 1988, AM HEART J, V115, P1321, DOI 10.1016/0002-8703(88)90033-6; Janes SM, 2007, CHEST, V131, P1232, DOI 10.1378/chest.06-2353; Kainuma S, 2008, ANN THORAC CARDIOVAS, V14, P396; Karadzic R, 2005, ARCH ONCOL, V13, P152; Makarawate P, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/356901; NAMBIAR CA, 1992, AM HEART J, V124, P802, DOI 10.1016/0002-8703(92)90301-B; Nilsson A, 2009, CASE REP ONCOL, V2, P125, DOI 10.1159/000228894; Ohnishi J, 1996, JPN CIRC J, V60, P898, DOI 10.1253/jcj.60.898; Papi M, 2005, TUMORI, V91, P276; Rizzardi C, 2010, ANTICANCER RES, V30, P1323; ROSE DSC, 1992, POSTGRAD MED J, V68, P137, DOI 10.1136/pgmj.68.796.137; Sardar MR, 2012, TEX HEART I J, V39, P261; Suman S, 2004, HEART, V90, DOI 10.1136/heart.90.1.e4	16	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					573	576		10.4103/IJPM.IJPM_711_1			4	Pathology	Pathology	GW7WJ	WOS:000447182900023	30303153	DOAJ Gold			2019-10-28	
J	Narla, SL; Stephen, P; Kurian, A; Annapurneswari, S				Narla, Swetha Lakshmi; Stephen, Punitha; Kurian, Ann; Annapurneswari, S.			Well-differentiated liposarcoma of the breast arising in a background of malignant phyllodes tumor in a pregnant woman: A rare case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Breast; liposarcoma; phyllodes tumor; sarcomatous	SARCOMA	Pure mesenchymal sarcomas and phyllodes tumor with sarcomatous differentiation of the breast are rare tumors. Primary breast sarcomas are a heterogenous group of neoplasms which include malignant fibrous histiocytoma, fibrosarcoma, angiosarcoma, leiomyosarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma. Sarcomatous differentiation in phyllodes tumor is seen in the form of angiosarcoma, chondrosarcoma, leiomyosarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma. Here, we report a case of a 28-year-old pregnant woman with a breast lump during her second trimester which drastically increased in size in the postpartum period. Wide local excision revealed a malignant phyllodes tumor with liposarcomatous differentiation. Later, the patient underwent completion mastectomy which showed residual tumor.	[Narla, Swetha Lakshmi; Stephen, Punitha; Kurian, Ann; Annapurneswari, S.] Apollo Canc Inst, Dept Histopathol, 320 Anna Salai, Madras 600035, Tamil Nadu, India	Narla, SL (reprint author), Apollo Canc Inst, Dept Histopathol, 320 Anna Salai, Madras 600035, Tamil Nadu, India.	drswetha.gmc2k2@gmail.com					Adem C, 2004, BRIT J CANCER, V91, P237, DOI 10.1038/sj.bjc.6601920; Argaez Cime Noel Lorenzo, 2005, Ginecol Obstet Mex, V73, P145; Carter BA, 2004, HUM PATHOL, V35, P1051, DOI 10.1016/j.humpath.2004.08.001; FOOTE FW, 1946, SURGERY, V19, P74; Isotalo PA, 2005, ARCH PATHOL LAB MED, V129, P421; Neumann E., 1862, VIRCHOWS ARCH PATH A, V24, P316; Pant I, 2008, DIAGN CYTOPATHOL, V36, P674, DOI 10.1002/dc.20913; PIETRUSZKA M, 1978, CANCER, V41, P1974, DOI 10.1002/1097-0142(197805)41:5<1974::AID-CNCR2820410543>3.0.CO;2-C; POLLARD SG, 1990, CANCER, V66, P941, DOI 10.1002/1097-0142(19900901)66:5<941::AID-CNCR2820660522>3.0.CO;2-B; Scala M, 1999, Minerva Chir, V54, P355; Tiffany W, 2011, GRAND ROUNDS, V11, P87; Voutsadakis IA, 2011, BREAST, V20, P199, DOI 10.1016/j.breast.2011.02.016	12	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					577	579		10.4103/IJPM.IJPM_238_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900024	30303154	DOAJ Gold			2019-10-28	
J	Bakshi, N; Rao, S; Dhawan, S; Singla, V				Bakshi, Neha; Rao, Seema; Dhawan, Shashi; Singla, Vikas			Duodenal gangliocytic paraganglioma: A rare cause for gastrointestinal polyp	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Differential diagnosis; duodenal polyp; gangliocytic paraganglioma	DIAGNOSIS	Duodenal gangliocytic paragangliomas are rare neoplasms often arising in the duodenum in close proximity to the ampulla of Vater. These neoplasms are considered to have a benign behavior with lymph node metastases being a rare phenomenon and distant metastases even more so. Although a standardized treatment has not been determined, a margin-free tumor resection seems to be the best treatment modality. We report herein the case of a 36-year-old female who presented with abdominal pain and was found to have a polyp in the second part of duodenum which was excised endoscopically. Histopathology and immunohistochemistry revealed characteristic features of this rare tumor.	[Bakshi, Neha; Rao, Seema; Dhawan, Shashi] Sir Ganga Ram Hosp, Dept Histopathol, New Delhi, India; [Singla, Vikas] Sir Ganga Ram Hosp, Inst Liver Gastroenterol & Pancreat Biliary Sci, New Delhi, India	Rao, S (reprint author), Sir Ganga Ram Hosp, Dept Histopathol, New Delhi, India.	seemarao1974@yahoo.co.in					DAHL EV, 1957, AM J PATHOL, V33, P953; Hechtman JF, 2015, ARCH PATHOL LAB MED, V139, P133, DOI 10.5858/arpa.2013-0431-RS; Hoffmann KM, 2005, BEST PRACT RES CL GA, V19, P675, DOI 10.1016/j.bpg.2005.05.009; Li B, 2014, WORLD J GASTROENTERO, V20, P15454, DOI 10.3748/wjg.v20.i41.15454; Okubo Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-187; Okubo Y, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-27; Park HK, 2016, ARCH PATHOL LAB MED, V140, P94, DOI 10.5858/arpa.2014-0456-RS; PERRONE T, 1985, AM J SURG PATHOL, V9, P31, DOI 10.1097/00000478-198501000-00007; SCHEITHAUER BW, 1986, AM J CLIN PATHOL, V86, P559, DOI 10.1093/ajcp/86.5.559; Sharma S, 2015, INT J SURG PATHOL, V23, P561, DOI 10.1177/1066896915589969	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					580	582		10.4103/IJPM.IJPM_479_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900025	30303155	DOAJ Gold			2019-10-28	
J	Pradhan, S; Sherpa, M				Pradhan, Supriya; Sherpa, Mingma			Gastric carcinoma and acute myeloid leukemia: A case report of a double malignancy	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Gastric carcinoma; leukemia; multiple primary cancer	CANCER	A double malignancy involving a solid organ and hematopoieteic system is rare. We report an interesting case of gastric adenocarcinoma with subsequent development of acute myeloid leukemia, in the absence of any therapeutic intervention.	[Pradhan, Supriya; Sherpa, Mingma] Sikkim Manipal Inst Med Sci, Dept Pathol, 5th Mile Tadong, Gangtok 737101, Sikkim, India	Sherpa, M (reprint author), Sikkim Manipal Inst Med Sci, Dept Pathol, 5th Mile Tadong, Gangtok 737101, Sikkim, India.	mingma_sherpa@yahoo.com					Bauer-Wu S, 2014, INTEGR CANCER THER, V13, P502, DOI 10.1177/1534735414549624; BUTALA A, 1989, J NATL MED ASSOC, V81, P457; Cui YH, 2012, CANCER RES TREAT, V44, P63, DOI 10.4143/crt.2012.44.1.63; Fraumeni J, 2006, NEW MALIGNANCIES CAN; Kim WJ, 2001, KOREAN J CLIN PATHOL, V21, P323; Lawniczak M, 2014, WORLD J GASTROENTERO, V20, P7480, DOI 10.3748/wjg.v20.i23.7480; Meher Lakshmi K, 2015, J MED SCI RES, V3, P134; NAGURA EI, 1985, JPN J CLIN ONCOL, V15, P211; Smith MA, 1996, JNCI-J NATL CANCER I, V88, P407, DOI 10.1093/jnci/88.7.407; Verma Y, 2012, BRIT J CANCER, V106, P962, DOI 10.1038/bjc.2011.598	10	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					583	584		10.4103/IJPM.IJPM_423_17			2	Pathology	Pathology	GW7WJ	WOS:000447182900026	30303156	DOAJ Gold			2019-10-28	
J	Khurana, A; Mukherjee, U; Patil, N				Khurana, Anuj; Mukherjee, Urmi; Patil, Nayana			An unusual case of hepatic lymphoma with multiple epithelial malignancies	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Dual malignancy; liver; mucosa-associated lymphoid tissue lymphoma	LIVER	Primary hepatic mucosa-associated lymphoid tissue lymphoma (MALToma) is a rare entity. Its coexistence with other malignancies is even rarer. Only few case reports of its association with other malignancies mostly gastric and colon cancer have been published. We report a case of primary MALToma of liver in an unusual setting of dual solid malignancy.	[Khurana, Anuj; Mukherjee, Urmi; Patil, Nayana] Max Super Special Hosp, Dept Lab Med, New Delhi 110017, India	Patil, N (reprint author), Max Super Special Hosp, Dept Lab Med, New Delhi 110017, India.	dr.nayana04@gmail.com					Dong SL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006305; Gherlan George S, 2016, Maedica (Buchar), V11, P250; Kwon YK, 2015, WORLD J HEPATOL, V7, P2696, DOI 10.4254/wjh.v7.i26.2696; Li LX, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0817-5; Nagata S, 2015, SURG CASE REP, V1, DOI 10.1186/s40792-015-0091-8; Obiorah IE, 2017, WORLD J HEPATOL, V9, P155, DOI [10.4254/wjh.v9.i3.155, 10.4254/wjh.v9.i13.155]; Prabhu RM, 1998, MODERN PATHOL, V11, P404; Taguchi K, 2015, SURG CASE REP, V1, DOI 10.1186/s40792-015-0110-9	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					585	586		10.4103/IJPM.IJPM_509_17			2	Pathology	Pathology	GW7WJ	WOS:000447182900027	30303157	DOAJ Gold			2019-10-28	
J	Gupta, L; Bhatt, AS; Mallya, V; Khurana, N; Lal, P				Gupta, Latika; Bhatt, Anusha S.; Mallya, Varuna; Khurana, Nita; Lal, Pawanindra			Adrenal medullary hyperplasia with coexistent cerebral angiomas	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Adrenal medullary hyperplasia; cerebral angioma; pheochromocytoma	LAPAROSCOPIC ADRENALECTOMY; PHEOCHROMOCYTOMA	Sporadic adrenal medullary hyperplasia (AMH) is a rare entity and mimics pheochromocytoma clinically as well as pharmacologically. It is characterized by increase in adrenal medullary cells with the expansion of cells into areas normally not seen. A 59-year-old male presented with chronic hypertension and raised 24-h urinary normetanephrine levels. Radiological and clinical possibility of pheochromocytoma led to left transperitoneal laparoscopic adrenalectomy. Histopathology, however, showed increase in adrenal medullary to cortical ratio, further confirmed by immunohistochemistry. The absence of any well-defined lesion led to the diagnosis of AMH. Furthermore, on routine imaging, two asymptomatic cavernous hemangiomas were seen. We present this case to reiterate that AMH is an entity which should be considered as a differential for pheochromocytoma. Furthermore, the presence of asymptomatic cavernous hemangiomas in the cerebrum, in this case, makes it rarer since this sporadic association is seldom seen.	[Gupta, Latika; Bhatt, Anusha S.; Mallya, Varuna; Khurana, Nita] Maulana Azad Med Coll, Dept Pathol, New Delhi 110091, India; [Lal, Pawanindra] Maulana Azad Med Coll, Dept Surg, New Delhi, India	Mallya, V (reprint author), Maulana Azad Med Coll, Dept Pathol, New Delhi 110091, India.	varunamallya@gmail.com					CARNEY JA, 1976, AM J CLIN PATHOL, V66, P279; DRALLE H, 1990, WORLD J SURG, V14, P308, DOI 10.1007/BF01658512; Grogan RH, 2011, J CLIN ONCOL, V29, pE200, DOI 10.1200/JCO.2010.32.2156; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; Lubikowski J, 2011, ENDOKRYNOL POL, V62, P512; MONTALBANO FP, 1962, JAMA-J AM MED ASSOC, V182, P264, DOI 10.1001/jama.1962.03050420040010; Rinaldi E, 2016, ENDOCRINOL DIABETES, V2, P1; RUDY FR, 1980, HUM PATHOL, V11, P650, DOI 10.1016/S0046-8177(80)80076-1; Marin MR, 2013, JSLS-J SOC LAPAROEND, V17, P433, DOI 10.4293/108680813X13693422521476; Valdes G, 2006, ENDOCRINE, V30, P389, DOI 10.1007/s12020-006-0019-y	10	2	2	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					587	589		10.4103/IJPM.IJPM_707_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900028	30303158	DOAJ Gold			2019-10-28	
J	Akbarzadeh-Jahromi, M; Aslani, FS; Najib, F; Hosseini, S				Akbarzadeh-Jahromi, Mojgan; Aslani, Fatemeh Sari; Najib, Fatemesadat; Hosseini, Shahla			Primary intrauterine dysgerminoma in a pregnant woman: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Dysgerminoma; extraovarian germ cell tumor; uterus	GERM-CELL TUMORS	Primary extraovarian dysgerminoma is very rare. Nearly all reported uterine germ cell tumors are nondysgerminoma. Herein, we reported a primary intrauterine dysgerminoma. A 21-year-old pregnant woman G2 L1 with a gestational age of 33 weeks referred to an obstetric ward with a chief complaint of labor pain and membrane rupture. Ultrasonography showed a large hypoechoic lobulated area adjacent to the lower part of her uterus. She underwent an operation and a huge mass was detected in her uterus, which was extended to her pelvic floor. Histopathological and immunohistochemical examinations were consistent with dysgerminoma.	[Akbarzadeh-Jahromi, Mojgan] Shiraz Univ Med Sci, Dept Pathol, Maternal Fetal Med Res Ctr, Shiraz, Iran; [Aslani, Fatemeh Sari; Hosseini, Shahla] Shiraz Univ Med Sci, Dept Pathol, Shiraz, Iran; [Najib, Fatemesadat] Shiraz Univ Med Sci, Dept OB & GYN, Shiraz, Iran	Akbarzadeh-Jahromi, M (reprint author), Shiraz Univ Med Sci, Maternal Fetal Med Res Ctr, Sch Med, Dept Pathol, Zand St, Shiraz, Iran.	akbarzadeh@sums.ac.ir	Akbarzadeh-Jahromi, Mojgan/I-2353-2015; Sari Aslani, Fatemeh/U-1910-2018	Akbarzadeh-Jahromi, Mojgan/0000-0003-0874-3127; Sari Aslani, Fatemeh/0000-0002-6232-9923			Adekunle OO, 2013, CASE REP CLIN MED, V2, P170; da Silva JL, 2015, INT J GYNECOL CANCER, V25, P786, DOI 10.1097/IGC.0000000000000432; Gadducci A, 2014, GYNECOL ENDOCRINOL, V30, P467, DOI 10.3109/09513590.2014.907262; Pauniaho SL, 2012, CANCER CAUSE CONTROL, V23, P1921, DOI 10.1007/s10552-012-0069-9; Rusner C, 2013, CANCER EPIDEMIOL, V37, P370, DOI 10.1016/j.canep.2013.04.003; Shih IM, 2001, INT J GYNECOL PATHOL, V20, P31, DOI 10.1097/00004347-200101000-00004; Stang A, 2012, INT J ANDROL, V35, P616, DOI 10.1111/j.1365-2605.2011.01245.x; Vicus D, 2010, GYNECOL ONCOL, V117, P23, DOI 10.1016/j.ygyno.2009.12.024; von Eyben FE, 2003, CRIT REV CL LAB SCI, V40, P377, DOI 10.1080/10408360390247814; Yoo SH, 2011, PATHOL INT, V61, P248, DOI 10.1111/j.1440-1827.2010.02640.x	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					590	592		10.4103/IJPM.IJPM_598_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900029	30303159	DOAJ Gold			2019-10-28	
J	Pecorella, I; Monti, M; Dei Malatesta, MLF; Ciardi, G				Pecorella, Irene; Monti, Marco; Dei Malatesta, Maria Luisa Framarino; Ciardi, Gaia			Polyp of the uterine cervix with heterologous fatty tissue	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Cervical choristoma; cervical polyp; heterotopic adipose tissue	MULLERIAN MIXED TUMOR; LIPOADENOFIBROMA; ADENOFIBROMA; VARIANT	This report documents an uncommon case of choristomatous cervical polyp-containing fat tissue. The patient was a 24-year-old female who presented with irregular intermenstrual bleeding. On examination, a polypoid lesion with smooth outlines, measuring 1 cm in diameter was removed. Microscopic examination demonstrated abnormal fibrous stroma, devoid of endocervical glands, containing mature adipose tissue, and thick-walled blood vessels. The lesion was covered by a typical mature squamous cell outer lining. To the best of our knowledge, this is only the second report of an adipose tissue arising from the cervical wall. Further clinicopathologic considerations are needed to elucidate the origin of the fatty component in cervical polyps.	[Pecorella, Irene; Ciardi, Gaia] Univ Rome Sapienza, Dept Radiol Oncol & Anat Pathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy; [Monti, Marco; Dei Malatesta, Maria Luisa Framarino] Univ Rome Sapienza, Dept Gynecol & Urol Sci, Rome, Italy	Pecorella, I (reprint author), Univ Rome Sapienza, Dept Radiol Oncol & Anat Pathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy.	irene.pecorella@uniroma1.it		Monti, Marco/0000-0002-9592-1245			Akbulut M, 2008, ARCH GYNECOL OBSTET, V278, P283, DOI 10.1007/s00404-008-0572-0; Chu IL, 2012, TAIWAN J OBSTET GYNE, V51, P285, DOI 10.1016/j.tjog.2012.04.022; de Lima M A, 1998, Rev Hosp Clin Fac Med Sao Paulo, V53, P149; Doldan A, 2009, INT J GYNECOL PATHOL, V28, P396, DOI 10.1097/PGP.0b013e318192cd20; Hinge SA, 1975, J OBSTET GYNAECOL IN, P294; HORIE Y, 1995, ARCH PATHOL LAB MED, V119, P274; Ilhan R, 2001, PATHOL INT, V51, P305, DOI 10.1046/j.1440-1827.2001.01194.x; Mignogna C, 2009, ARCH GYNECOL OBSTET, V280, P1071, DOI 10.1007/s00404-009-1122-0	8	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					593	595		10.4103/IJPM.IJPM_105_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900030	30303160	DOAJ Gold			2019-10-28	
J	Agrawal, CR; Koyyala, VPB; Talwar, V; Tayal, J; Poonia, DR				Agrawal, Chaturbhuj Ramanand; Koyyala, Venkata Pradeep Babu; Talwar, Vineet; Tayal, Juhi; Poonia, Dharma Ram			Malignant Sertoli cell tumor of the testis masquerading as seminoma with bone metastasis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Seminoma; Sertoli cell tumor; sex cord-stromal tumor		Sex cord-stromal tumors of the testes are rare malignancies as compared to germ cell tumors. Pure Sertoli cell tumors are still rare representing <1% of testicular cancers and the malignant forms are too rare. Furthermore, the occurrence of metastasis in such cases is extremely rare with <30 cases reported in literature so far to the best of our knowledge. We present herein a case of malignant Sertoli cell tumor in a 48-year-old male who was initially misdiagnosed as seminoma based on histology and clinical presentation. Four months later, he presented with symptoms due to bony metastasis and found to have widespread metastatic disease which is a very rare presentation of Sertoli cell tumors. Diagnosis of sex cord-stromal tumor requires high index of suspicion as these tumors are most of the times misdiagnosed as germ cell tumors due to their rare incidence and atypical presentation leading to mismanagement. Timely diagnosis at an early stage can provide therapeutic benefit due to lack of well-defined treatment options at advanced stages.	[Agrawal, Chaturbhuj Ramanand; Koyyala, Venkata Pradeep Babu; Talwar, Vineet] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India; [Poonia, Dharma Ram] Rajiv Gandhi Canc Inst & Res Ctr, Dept Surg Oncol, New Delhi, India; [Tayal, Juhi] Rajiv Gandhi Canc Inst & Res Ctr, Dept Res, New Delhi, India	Agrawal, CR (reprint author), Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India.	chaturbhujagrawal06@rediffmail.com					Coleman Sarah, 2014, Rev Urol, V16, P191; DILWORTH JP, 1991, UROLOGY, V37, P399, DOI 10.1016/0090-4295(91)80100-L; Giglio M, 2003, UROL INT, V70, P205, DOI 10.1159/000068770; Halat SK, 2007, J UROLOGY, V177, P2338, DOI 10.1016/j.juro.2007.03.071; Huddart R, 2012, RARE TUMORS TESTIS P, P77; Idrees MT, 2017, HISTOPATHOLOGY, V70, P513, DOI 10.1111/his.13115; Kuhn AL, 2016, ULTRASONOGRAPHY, V35, P180, DOI 10.14366/usg.15075; MADSEN EL, 1990, ACTA ONCOL, V29, P946, DOI 10.3109/02841869009096396; Mosharafa AA, 2003, CANCER, V98, P753, DOI 10.1002/cncr.11573; Perrone F, 2014, AM J SURG PATHOL, V38, P66, DOI 10.1097/PAS.0b013e31829cdbc6; Shanks JH, 2002, CURRENT DIAGNOSTIC P, V8, P83; Sia SF, 2006, J U MALAYA MED CENT, V9, P18; Ulbright TM, 1999, AM REGIST PATHOL, V25, P149	13	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					596	599		10.4103/IJPM.IJPM_492_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900031	30303161	DOAJ Gold			2019-10-28	
J	Islam, N; Sinha, D; Ghosh, P; Datta, C; Chatterjee, U				Islam, Nelofar; Sinha, Debanjali; Ghosh, Parasar; Datta, Chhanda; Chatterjee, Uttara			Orchitis: An unusual presentation of polyarteritis nodosa	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Epididymo-orchitis; polyarteritis nodosa; vasculitis	VASCULITIS; CLASSIFICATION	Polyarteritis nodosa (PAN), a systemic necrotizing vasculitis with multiorgan development, is generally restricted to the medium-sized muscular arteries. The varied initial clinical presentations of PAN can lead to a delayed diagnosis. We present the case of a middle-aged male patient who presented with an acute onset right-sided testicular pain as the initial clinical symptom with ischemic changes on ultrasonogram, thereby requiring orchiectomy. This was reported to be a case of tubercular epididymo-orchitis. On review, the biopsy revealed features of necrotizing arteritis as seen in PAN with fibrinoid necrosis and giant cells, thus highlighting the fact that vasculitis due to PAN may have a localized presentation at the time of diagnosis. PAN should be distinguished from other causes of epididymo-orchitis and other vasculitis lesions, the most common being tubercular etiology in the Asian population.	[Islam, Nelofar; Datta, Chhanda; Chatterjee, Uttara] IPGME&R, Dept Pathol, Kolkata, W Bengal, India; [Sinha, Debanjali; Ghosh, Parasar] IPGME&R, Dept Rheumatol, Kolkata, W Bengal, India	Chatterjee, U (reprint author), IPGME&R, Dept Pathol, Kolkata, W Bengal, India.	uttarac1@gmail.com		chatterjee, Uttara/0000-0002-9346-1695			Abdulkader R, 2013, ANN RHEUM DIS, V72, P1888, DOI 10.1136/annrheumdis-2013-203511; DAHL EV, 1960, AM J MED, V28, P222, DOI 10.1016/0002-9343(60)90185-6; Fraenkel-Rubin M, 2002, ANN RHEUM DIS, V61, P362, DOI 10.1136/ard.61.4.362; Fulgham PF, 2006, J CLIN ULTRASOUND, V34, P99, DOI 10.1002/jcu.20205; Gervaise A, 2014, DIAGN INTERV IMAG, V95, P615, DOI 10.1016/j.diii.2014.02.007; Hernandez-Rodriguez J, 2014, J AUTOIMMUN, V48-49, P84, DOI 10.1016/j.jaut.2014.01.029; Jennette JC, 2013, CLIN EXP NEPHROL, V17, P603, DOI 10.1007/s10157-013-0869-6; Kolar P, 2007, RHEUMATOLOGY, V46, P1377, DOI 10.1093/rheumatology/kem165; Kussmaul A, 1866, DTSCH ARCH KLIN MED, V1, P484; Mahr A, 2015, CURR OPIN RHEUMATOL, V27, P1, DOI 10.1097/BOR.0000000000000134; Pagnoux C, 2006, FUTURE RHEUMATOL, V1, P729; Samarkos M, 2005, SEMIN ARTHRITIS RHEU, V35, P95, DOI 10.1016/j.semarthrit.2005.05.004; Stroup Sean P, 2007, Rev Urol, V9, P235; TEICHMAN JMH, 1993, J UROLOGY, V149, P1139, DOI 10.1016/S0022-5347(17)36322-X; TURKI S, 1994, ANN DERMATOL VENER, V121, P325; Watts RA, 2011, RHEUMATOLOGY, V50, P643, DOI 10.1093/rheumatology/keq229; Yoo Bin, 1996, Korean Journal of Internal Medicine (English Edition), V11, P165	17	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					600	603		10.4103/IJPM.IJPM_569_17			4	Pathology	Pathology	GW7WJ	WOS:000447182900032	30303162	DOAJ Gold			2019-10-28	
J	Saxena, P; Agarwal, R; Nain, G; Khurana, N; Lal, P; Tudu, SK				Saxena, Priyanka; Agarwal, Radhika; Nain, Gunjan; Khurana, Nita; Lal, Pawanindra; Tudu, Sanjeev Kumar			Synovial hemangiomas of wrist and ankle joint: A report of two rare cases	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Ankle; histopathology; joint; synovial hemangioma; wrist	FLEXOR TENDON SHEATH	Synovial hemangioma is a rare, benign, vascular tumor of synovium leading to joint pain and swelling. The most common site is the knee joint, but rare cases involving other sites have also been reported. We report two rare cases of synovial hemangioma, one involving the ankle joint and other involving the wrist joint. Histopathology is the gold standard for diagnosis of these cases. Early treatment is warranted to prevent the risk of permanent joint damage.	[Saxena, Priyanka; Agarwal, Radhika; Nain, Gunjan; Khurana, Nita] Maulana Azad Med Coll, Dept Pathol, New Delhi, India; [Lal, Pawanindra; Tudu, Sanjeev Kumar] Maulana Azad Med Coll, Dept Surg, New Delhi, India	Agarwal, R (reprint author), MAMC, Room 62,Pathol Block, New Delhi 110002, India.	agarwalradhika88@gmail.com					Chow LTC, 2004, APMIS, V112, P314, DOI 10.1111/j.1600-0463.2004.apm11204-0514.x; DEVANEY K, 1993, HUM PATHOL, V24, P737, DOI 10.1016/0046-8177(93)90010-E; George Robert, 2013, Open Orthop J, V7, P72, DOI 10.2174/1874325001307010072; GREENSPAN A, 1995, SKELETAL RADIOL, V24, P583; Kim JY, 2010, J HAND SURG-EUR VOL, V35E, P73, DOI 10.1177/1753193409347688; Lopez-Oliva CLL, 2015, INT ORTHOP, V39, P2037, DOI 10.1007/s00264-015-2930-4; Mahata M, 2015, INT J BIOMED RES, V6, P726; Narvaez JA, 2001, EUR RADIOL, V11, P2549, DOI 10.1007/s003300000759; Oumakhir S, 2010, Foot (Edinb), V20, P42, DOI 10.1016/j.foot.2009.12.003; Rajni, 2008, INDIAN J PATHOL MICR, V51, P257	10	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					604	606		10.4103/IJPM.IJPM_603_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900033	30303163	DOAJ Gold			2019-10-28	
J	Juyal, D; Pal, S; Sharma, M; Negi, V; Adekhandi, S; Tyagi, M				Juyal, Deepak; Pal, Shekhar; Sharma, Munesh; Negi, Vikrant; Adekhandi, Shamanth; Tyagi, Manoj			Keratomycosis due to Purpureocillium lilacinum: A case report from Sub-Himalayan region of Uttarakhand	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Keratitis; oculomycosis; Paecilomyces; Purpureocillium; voriconazole	PAECILOMYCES-LILACINUS; VORICONAZOLE; INFECTIONS	The fungus Purpureocillium lilacinum previously known as Paceliomyces lilacinus is an emerging pathogen that can cause severe human infections including devastating oculomycosis. Treatment with traditional antifungals often fails, and the organism shows variable susceptibility to novel triazoles. We hereby report a case of keratomycosis caused by Pur. lilacinum in an immunocompetent male patient following trauma. The patient was successfully treated with voriconazole. The drug shows good activity against Pur lilacinum and could be a promising therapeutic alternative to treat infections caused by this fungus, which generally shows resistance to conventional antifungal agents including novel triazoles.	[Juyal, Deepak; Pal, Shekhar] Govt Doon Med Coll, Dept Microbiol, Dehra Dun 248001, Uttarakhand, India; [Sharma, Munesh] Rajshree Med Res Inst, Dept Microbiol, Bareilly, Uttar Pradesh, India; [Negi, Vikrant] Dr Sampurnanand Med Coll, Dept Microbiol, Jodhpur, Rajasthan, India; [Adekhandi, Shamanth] Post Grad Inst Med Educ & Res, Dept Med Microbiol, Chandigarh, India; [Tyagi, Manoj] Bundelkhand Med Coll, Dept Ophthalmol, Sagar, Madhya Pradesh, India	Juyal, D (reprint author), Govt Doon Med Coll, Dept Microbiol, Dehra Dun 248001, Uttarakhand, India.	deepakk787@gmail.com					Garbino J, 2002, SCAND J INFECT DIS, V34, P701, DOI 10.1080/00365540210147642; Gower EW, 2010, OPHTHALMOLOGY, V117, P2263, DOI 10.1016/j.ophtha.2010.03.048; Gutierrez-Rodero F, 1999, EUR J CLIN MICROBIOL, V18, P814, DOI 10.1007/s100960050407; Hariprasad SM, 2008, BRIT J OPHTHALMOL, V92, P871, DOI 10.1136/bjo.2007.136515; Karsten E, 2012, OPEN OPHTHALMOL J, V6, P110, DOI 10.2174/1874364101206010110; Luangsa-Ard J, 2011, FEMS MICROBIOL LETT, V321, P141, DOI 10.1111/j.1574-6968.2011.02322.x; Naik M, 2014, MIDDLE EAST AFR J OP, V21, P92, DOI 10.4103/0974-9233.124121; Pastor FJ, 2006, CLIN MICROBIOL INFEC, V12, P948, DOI 10.1111/j.1469-0691.2006.01481.x; Perdomo H, 2013, MYCOLOGIA, V105, P151, DOI 10.3852/11-190; Yuan XY, 2009, AM J OPHTHALMOL, V147, P691, DOI 10.1016/j.ajo.2008.11.016	10	0	0	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					607	609		10.4103/IJPM.IJPM_404_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900034	30303164	DOAJ Gold			2019-10-28	
J	Matthai, SM; Valson, AT; Duhli, N; Rupali, P; Pulimood, AB; Varughese, T				Matthai, Smita Mary; Valson, Anna T.; Duhli, Neelaveni; Rupali, Priscilla; Pulimood, Anna B.; Varughese, Tosh			Fibrillary glomerulonephritis in a human immunodeficiency virus-positive, hepatitis C-negative Indian patient: Expanding the profile of renal involvement in human immunodeficiency virus infection	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Fibrillary glomerulonephritis; HIV associated immune complex mediated kidney disease; HIV associated nephropathy; HIV associated renal disease; Human Immunodeficiency virus infection	GLOMERULOPATHY; DISEASE	Highly active anti retroviral therapy (HAART) has dramatically improved life expectancy of human immunodeficiency virus (HIV) infected patients, converting HIV infection into a chronic illness with associated changes in its attendant renal complications. The past two decades have witnessed a decrease in the prevalence of HIV associated nephropathy (HIVAN), traditionally considered to be the hall mark of renal involvement in HIV infection. Simultaneously a host of other glomerular and tubulo-interstitial diseases have emerged, expanding the spectrum of HIV associated renal diseases, predominant among which is HIV associated immune complex mediated kidney diseases (HIVICK). Of the diverse glomerular diseases constituting HIVICK, fiprillary glomerulonephritis (FGN) remains a rarity, with only two existing reports to date, confined to patients co-infected with Hepatitis C virus (HCV). The pathogenetic role of HIV in these patients remains under a cloud because of previously well established association of HCV infection and FGN. We report a case of FGN in a HIV seropositive, HCV negative Indian patient, highlighting the diagnostic electron microscopy (EM) findings of FGN and strengthening the causal association of HIV with FGN. In view of increasing heterogeneity of renal complications in HIV infection, the diagnostic utility of a comprehensive renal biopsy evaluation inclusive of EM is emphasized for appropriate selection of treatment modalities.	[Matthai, Smita Mary; Pulimood, Anna B.] Christian Med Coll & Hosp, Cent Electron Microscopy Facil, Dept Pathol, Vellore, Tamil Nadu, India; [Valson, Anna T.; Varughese, Tosh] Christian Med Coll & Hosp, Dept Nephrol, Vellore 632004, Tamil Nadu, India; [Duhli, Neelaveni] Christian Med Coll & Hosp, Dept Gen Pathol, Vellore, Tamil Nadu, India; [Rupali, Priscilla] Christian Med Coll & Hosp, Dept Infect Dis, Vellore, Tamil Nadu, India	Valson, AT (reprint author), Christian Med Coll & Hosp, Dept Nephrol, Vellore 632004, Tamil Nadu, India.	ceruleus@gmail.com	SOUNDRARAJAN, JOYSON/I-1779-2019				Bridoux F, 2002, KIDNEY INT, V62, P1764, DOI 10.1046/j.1523-1755.2002.00628.x; Cohen SD, 2008, SEMIN NEPHROL, V28, P535, DOI 10.1016/j.semnephrol.2008.08.006; Haas M, 2000, NEPHROL DIAL TRANSPL, V15, P1679, DOI 10.1093/ndt/15.10.1679; Markowitz GS, 1998, J AM SOC NEPHROL, V9, P2244; Martin JL, 2003, AM J KIDNEY DIS, V42, DOI 10.1053/j.ajkd.2003.08.034; Swanepoel CR, 2018, KIDNEY INT, V93, P545, DOI 10.1016/j.kint.2017.11.007	6	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					610	613		10.4103/IJPM.IJPM_52_18			4	Pathology	Pathology	GW7WJ	WOS:000447182900035	30303165	DOAJ Gold			2019-10-28	
J	Yadav, S; Sagar, N; Mallya, V; Mandal, S; Khurana, N; Gupta, S				Yadav, Surekha; Sagar, Nishant; Mallya, Varuna; Mandal, Sharmana; Khurana, Nita; Gupta, Sangeeta			Extensive trophoblastic differentiation in case of an endometrial carcinoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Endometrium; serous carcinoma; trophoblast	OF-THE-LITERATURE; CHORIOCARCINOMATOUS DIFFERENTIATION	Trophoblastic differentiation of endometrial carcinoma is extremely rare, till date 18 cases reports are there in the literature. A 68-year-old postmenopausal female presented with abnormal vaginal bleeding. Histopathologically, there were areas of serous carcinoma with trophoblastic differentiation (similar to 90%). On immunohistochemistry, the trophoblastic component was positive for beta-human chorionic gonadotropin (hCG), HPL and EMA. IHC confirmed the diagnosis of serous carcinoma with trophoblastic differentiation. The clinicopathological features of 18 previously reported cases of trophoblastic differentiation in the uterine tumor were analyzed in addition to the present case.	[Yadav, Surekha; Sagar, Nishant; Mallya, Varuna; Mandal, Sharmana; Khurana, Nita] Dept Pathol & Obstet & Gynaecol, New Delhi, India; [Gupta, Sangeeta] Maulana Azad Med Coll, 269 Pathol Block, New Delhi, India	Mallya, V (reprint author), Maulana Azad Med Coll, 269 Pathol Block, New Delhi, India.	varunamallya@gmail.com					Akbulut M, 2008, ARCH GYNECOL OBSTET, V278, P79, DOI 10.1007/s00404-007-0526-y; CIVANTOS F, 1972, CANCER, V29, P789, DOI 10.1002/1097-0142(197203)29:3<789::AID-CNCR2820290337>3.0.CO;2-N; Horn LC, 2006, INT J GYNECOL PATHOL, V25, P247, DOI 10.1097/01.pgp.0000215294.45738.a4; Hubbard SA, 2010, REPRODUCTION, V140, P23, DOI 10.1530/REP-09-0411; Ishida M, 2013, ONCOL LETT, V6, P655, DOI 10.3892/ol.2013.1431; Ji ML, 2013, ONCOTARGETS THER, V6, P1515, DOI 10.2147/OTT.S51983; Le Bret T, 2005, J Gynecol Obstet Biol Reprod (Paris), V34, P85; Yamada T, 2009, GYNECOL ONCOL, V113, P291, DOI 10.1016/j.ygyno.2009.01.005	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					614	616		10.4103/IJPM.IJPM_228_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900036	30303166	DOAJ Gold			2019-10-28	
J	Vaideeswar, P; Karande, S; Kadiyani, L				Vaideeswar, Pradeep; Karande, Sunil; Kadiyani, Lamk			Bilateral renal fungal balls in an infant	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							MANAGEMENT; DIAGNOSIS		[Vaideeswar, Pradeep] Seth GS Med Coll & KEM Hosp, Dept Pathol, Div Cardiovasc & Thorac, Bombay 400012, Maharashtra, India; [Karande, Sunil; Kadiyani, Lamk] Seth GS Med Coll & KEM Hosp, Dept Pediat, Bombay, Maharashtra, India	Vaideeswar, P (reprint author), Seth GS Med Coll & KEM Hosp, Dept Pathol, Div Cardiovasc & Thorac, Bombay 400012, Maharashtra, India.	shreeprajai@yahoo.co.in	Karande, Sunil/F-1835-2013	Karande, Sunil/0000-0002-1170-325X			Basu Rajit K, 2011, Recent Pat Biomark, V1, P49; Bisht V, 2011, EUR J PEDIATR, V170, P1227, DOI 10.1007/s00431-011-1514-6; de Wall LL, 2015, J PEDIATR UROL, V11, DOI 10.1016/j.jpurol.2014.10.015; Dornbusch HJ, 2009, PEDIATR INFECT DIS J, V28, P734, DOI 10.1097/INF.0b013e3181b076b1; Kauffman CA, 2014, INFECT DIS CLIN N AM, V28, P61, DOI 10.1016/j.idc.2013.09.004; Sadegi BJ, 2009, J ULTRAS MED, V28, P507, DOI 10.7863/jum.2009.28.4.507	6	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					617	619		10.4103/IJPM.IJPM_57_18			3	Pathology	Pathology	GW7WJ	WOS:000447182900037	30303167	DOAJ Gold			2019-10-28	
J	Katiyar, R; Patne, SCU; Chowdhary, S				Katiyar, Richa; Patne, Shashikant C. U.; Chowdhary, Sarita			MiT family translocation-associated (TFE3 positive) renal cell carcinoma of childhood	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							EMPHASIS		[Katiyar, Richa; Patne, Shashikant C. U.] Banaras Hindu Univ, Inst Med Sci, Dept Pathol, Varanasi 221005, Uttar Pradesh, India; [Chowdhary, Sarita] Banaras Hindu Univ, Inst Med Sci, Dept Paediat Surg, Varanasi, Uttar Pradesh, India	Patne, SCU (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Pathol, Varanasi 221005, Uttar Pradesh, India.	scupatne@gmail.com			Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India	Revolving fund of the Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, Uttar Pradesh, India.	Armah HB, 2010, ARCH PATHOL LAB MED, V134, P124, DOI 10.1043/2008-0391-RSR.1; Liu N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166897; Magers MJ, 2015, ARCH PATHOL LAB MED, V139, P1224, DOI 10.5858/arpa.2015-0196-RA; Rao Q, 2010, INT J SURG PATHOL, V18, P458, DOI 10.1177/1066896910375565; Shemin Z, 2015, J HISTOL HISTOPATHOL, V2, P6, DOI [10.7243/2055-091X-2-6, DOI 10.7243/2055-091X-2-6]; Udager AM, 2016, ARCH PATHOL LAB MED, V140, P1026, DOI 10.5858/arpa.2016-0218-RA	6	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					620	622		10.4103/IJPM.IJPM_279_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900038	30303168	DOAJ Gold			2019-10-28	
J	Garg, N; Bansal, D; Mangla, G; Kotru, M				Garg, Neha; Bansal, Divya; Mangla, Gunjan; Kotru, Mrinalini			Bone marrow edema mimicking amyloid	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							TRANSFORMATION		[Garg, Neha; Bansal, Divya; Mangla, Gunjan; Kotru, Mrinalini] Univ Coll Med Sci & Guru Teg Bahadur Hosp, Dept Pathol, New Delhi 110095, India	Kotru, M (reprint author), Univ Coll Med Sci & Guru Teg Bahadur Hosp, Dept Pathol, New Delhi 110095, India.	mrinalini.kotru@gmail.com					Das S, 2014, TURK J HEMATOL, V31, P175, DOI 10.4274/Tjh.2012.0151; Nakanishi R, 2013, INT J CLIN EXP PATHO, V6, P1677; Patel S, 2014, RHEUMATOLOGY, V53, P785, DOI 10.1093/rheumatology/ket324; Paydas S, 2002, AM J HEMATOL, V70, P300, DOI 10.1002/ajh.10114; Thiryayi WA, 2008, EUR J RADIOL, V67, P62, DOI 10.1016/j.ejrad.2008.01.056	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					623	625		10.4103/IJPM.IJPM_89_18			3	Pathology	Pathology	GW7WJ	WOS:000447182900039	30303169	DOAJ Gold			2019-10-28	
J	Madakshira, MG; Kakkar, N; Menon, P				Madakshira, Manoj Gopal; Kakkar, Nandita; Menon, Prema			Partial "fetus-in-fetu"	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Madakshira, Manoj Gopal; Kakkar, Nandita] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India; [Menon, Prema] Postgrad Inst Med Educ & Res, Dept Paediat Surg, Chandigarh, India	Madakshira, MG (reprint author), Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India.	manoj.gopal@gmail.com		Madakshira, Manoj Gopal/0000-0002-7056-5096			Borges E, 2005, J ULTRAS MED, V24, P1313, DOI 10.7863/jum.2005.24.9.1313; Federici S, 2001, PEDIATR SURG INT, V17, P483, DOI 10.1007/s003830000476; Karaman Ibrahim, 2008, J Indian Assoc Pediatr Surg, V13, P30, DOI 10.4103/0971-9261.42572; Sewell E K, 2017, J Neonatal Perinatal Med, V10, P333, DOI 10.3233/NPM-16101; Sitharama SA, 2017, POL J RADIOL, V82, P46, DOI 10.12659/PJR.899956	5	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					626	627		10.4103/IJPM.IJPM_143_18			2	Pathology	Pathology	GW7WJ	WOS:000447182900040	30303170	DOAJ Gold			2019-10-28	
J	Saurabh, K; Nag, VL; Sharma, A; Maurya, AK; Hada, V				Saurabh, Kumar; Nag, Vijaya Lakshmi; Sharma, Anuradha; Maurya, Anand Kumar; Hada, Vivek			Abnormal morphological appearance of Klebsiella pneumoniae in blood culture: A microscopic observation	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							BETA-LACTAM ANTIBIOTICS; BACTERIA		[Saurabh, Kumar; Nag, Vijaya Lakshmi; Sharma, Anuradha; Maurya, Anand Kumar; Hada, Vivek] All India Inst Med Sci, Dept Microbiol, Jodhpur, Rajasthan, India	Nag, VL (reprint author), All India Inst Med Sci, Dept Microbiol, Jodhpur, Rajasthan, India.	vijayalakshmi005@gmail.com					Arshad HM, 2012, J APPL PHARM SCI, V2, P109; Bitterman R, 2017, CLIN MICROBIOL INFEC, V23, P26, DOI 10.1016/j.cmi.2016.09.026; HANBERGER H, 1991, EUR J CLIN MICROBIOL, V10, P927, DOI 10.1007/BF02005446; LORIAN V, 1982, J CLIN MICROBIOL, V16, P382; Mani R, 2008, INDIAN J MED MICROBI, V26, P283, DOI 10.4103/0255-0857.42060; Rajeshwari H, 2009, WORLD J MICROB BIOT, V25, P2263, DOI 10.1007/s11274-009-0126-z; Yao ZZ, 2012, MOL CELL, V48, P705, DOI 10.1016/j.molcel.2012.09.016	7	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					628	629		10.4103/IJPM.IJPM_447_17			2	Pathology	Pathology	GW7WJ	WOS:000447182900041	30303171	DOAJ Gold			2019-10-28	
J	Hui, M; Paul, TR; Uppin, SG; Jyothi, N				Hui, Monalisa; Paul, Tara Roshni; Uppin, Shantveer G.; Jyothi, Nirmala			Lipofibroadenoma with B1 thymoma: A case report of a rare thymic tumor	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							CLASSIFICATION		[Hui, Monalisa; Paul, Tara Roshni; Uppin, Shantveer G.; Jyothi, Nirmala] Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Telangana, India	Paul, TR (reprint author), Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Telangana, India.	troshnip@yahoo.co.in					Aydin Y, 2012, EURASIAN J MED, V44, P176, DOI 10.5152/eajm.2012.41; Chalabreysse L, 2002, AM J SURG PATHOL, V26, P1605, DOI 10.1097/00000478-200212000-00008; Chen G, 2015, WHO CLASSIFICATION T, P210; Kuo TT, 2001, INT J SURG PATHOL, V9, P29, DOI 10.1177/106689690100900106; Okumura M, 2002, CANCER-AM CANCER SOC, V94, P624, DOI 10.1002/cncr.10226; Qu GM, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-117; Zambudio AR, 2001, J THORAC CARDIOV SUR, V122, P825, DOI 10.1067/mtc.2001.114928	7	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					630	+		10.4103/IJPM.IJPM_443_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900042	30303172	DOAJ Gold			2019-10-28	
J	Ray, M; Sathe, P; Ghodke, R; Suryavanshi, M				Ray, Manjusha; Sathe, Pragati; Ghodke, Ratnaprabha; Suryavanshi, Monica			Canalicular adenoma arising from the nasal septum in a child: First case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Ray, Manjusha; Sathe, Pragati; Ghodke, Ratnaprabha; Suryavanshi, Monica] Seth GS Med Coll & KEM Hosp, Dept Pathol, Acharya Donde Marg, Bombay 400012, Maharashtra, India	Ray, M (reprint author), Seth GS Med Coll & KEM Hosp, Dept Pathol, Acharya Donde Marg, Bombay 400012, Maharashtra, India.	manjusharay@gmail.com					Azevedo Luciana Reis, 2008, J Contemp Dent Pract, V9, P91; Bajpai M, 2016, JCPSP-J COLL PHYSICI, V26, P946; El-Naggar AC, 2017, WHO CLASSIFICATION H, P160; MCKENNA RJ, 1984, CA-CANCER J CLIN, V34, P24, DOI 10.3322/canjclin.34.1.24; Ortega RM, 2018, HEAD NECK PATHOL, V12, P145, DOI 10.1007/s12105-017-0838-6; Sciandra D, 2008, ACTA OTORHINOLARYNGO, V28, P150; Thompson LDR, 2015, HEAD NECK PATHOL, V9, P181, DOI 10.1007/s12105-014-0560-6; Wang QY, 2015, INT J CLIN EXP PATHO, V8, P2176	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					632	+		10.4103/IJPM.IJPM_137_18			3	Pathology	Pathology	GW7WJ	WOS:000447182900043	30303173	DOAJ Gold			2019-10-28	
J	Raphael, V; Gogoi, BB; Mishra, J				Raphael, Vandana; Gogoi, Bidyut B.; Mishra, Jaya			Primary pulmonary pleomorphic adenoma: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Raphael, Vandana; Gogoi, Bidyut B.; Mishra, Jaya] North Eastern Indira Gandhi Reg Inst Hlth & Med S, Dept Pathol, Shillong, Meghalaya, India	Gogoi, BB (reprint author), North Eastern Indira Gandhi Reg Inst Hlth & Med S, Dept Pathol, Shillong, Meghalaya, India.	dr.gogoibidyut@gmail.com					Ali SR, 2016, OXF MED CASE REP, P300, DOI 10.1093/omcr/omw090; Fitchett J, 2008, ANN THORAC SURG, V86, P1025, DOI 10.1016/j.athoracsur.2008.02.073; Flieder DB, 2004, WHO PATHOLOGY GENETI, P86; Jin Heung-Yong, 2007, Korean Journal of Internal Medicine, V22, P122; MORAN CA, 1994, CANCER-AM CANCER SOC, V73, P2481, DOI 10.1002/1097-0142(19940515)73:10<2481::AID-CNCR2820731006>3.0.CO;2-A	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					634	+		10.4103/IJPM.IJPM_73_18			3	Pathology	Pathology	GW7WJ	WOS:000447182900044	30303174	DOAJ Gold			2019-10-28	
J	Agrawal, CR; Talwar, V; Tayal, J; Koyyala, VPB; Goyal, P				Agrawal, Chaturbhuj Ramanand; Talwar, Vineet; Tayal, Juhi; Koyyala, Venkata Pradeep Babu; Goyal, Pankaj			Primary pulmonary melanoma: An unexpected diagnosis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							PRIMARY MALIGNANT-MELANOMA; METASTATIC MELANOMA; LUNG		[Agrawal, Chaturbhuj Ramanand; Talwar, Vineet; Koyyala, Venkata Pradeep Babu; Goyal, Pankaj] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India; [Tayal, Juhi] Rajiv Gandhi Canc Inst & Res Ctr, Dept Res, New Delhi, India	Agrawal, CR (reprint author), Rajiv Gandhi Canc Inst, Dept Med Oncol, New Delhi 110085, India.	chaturbhujagrawal06@rediffmail.com					Abul Y, 2011, TURK KLIN TIP BILIM, V31, P468, DOI 10.5336/medsci.2010-18810; ALLEN MS, 1968, CANCER, V21, P154, DOI 10.1002/1097-0142(196801)21:1<154::AID-CNCR2820210123>3.0.CO;2-K; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Frenkel S, 2009, ISR MED ASSOC J, V11, P280; HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743; JENNINGS TA, 1990, AM J CLIN PATHOL, V94, P649, DOI 10.1093/ajcp/94.5.649; JENSEN OA, 1967, SCAND J RESPIR DIS, V48, P127; Seitelman Eric, 2011, J Thorac Dis, V3, P207, DOI 10.3978/j.issn.2072-1439.2011.04.02; SERNA MJ, 1994, CUTIS, V53, P305; Wilson RW, 1997, AM J SURG PATHOL, V21, P1196, DOI 10.1097/00000478-199710000-00010	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					636	+		10.4103/IJPM.IJPM_490_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900045	30303175	DOAJ Gold			2019-10-28	
J	Doshi, P; Ramdasi, R; Thorve, S; Khubchandani, S				Doshi, Paresh; Ramdasi, Raghvendra; Thorve, Smita; Khubchandani, Shaila			Tumefactive demyelination versus tumor; a diagnostic dilemma: Role of electron microscopy	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							LESIONS		[Doshi, Paresh; Ramdasi, Raghvendra; Thorve, Smita] Jaslok Hosp & Res Ctr, Dept Neurosurg, 15 Dr Deshmukh Marg,Pedder Rd, Bombay 400026, Maharashtra, India; [Khubchandani, Shaila] Jaslok Hosp & Res Ctr, Dept Pathol, Bombay, Maharashtra, India	Ramdasi, R (reprint author), Jaslok Hosp & Res Ctr, Dept Neurosurg, 15 Dr Deshmukh Marg,Pedder Rd, Bombay 400026, Maharashtra, India.	drraghavr@gmail.com					Gnanapavan S, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-68; Law M, 2002, NEURORADIOLOGY, V44, P986, DOI 10.1007/s00234-002-0872-1; Neelima R, 2012, INDIAN J PATHOL MICR, V55, P496, DOI 10.4103/0377-4929.107788; Rajasekharan C, 2012, BMJ CASE REP, V2012; Saindane AM, 2002, AM J NEURORADIOL, V23, P1378	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					638	+		10.4103/IJPM.IJPM_677_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900046	30303176	DOAJ Gold			2019-10-28	
J	Saha, A; Saha, K; Agrawal, V; Neyaz, Z; Jaiswal, AK				Saha, Arpita; Saha, Kaushik; Agrawal, Vinita; Neyaz, Zafar; Jaiswal, Awadesh Kumar			Isolated spinal epidural hydatid disease: A diagnostic challenge in a needle core biopsy	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Saha, Arpita; Saha, Kaushik] Hlth World Hosp, Dept Histopathol, Durgapur, W Bengal, India; [Agrawal, Vinita] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India; [Neyaz, Zafar] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow, Uttar Pradesh, India; [Jaiswal, Awadesh Kumar] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India	Agrawal, V (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India.	vinita.agrawal15@gmail.com					Berk C, 1998, NEURORADIOLOGY, V40, P390, DOI 10.1007/s002340050608; BRAITHWAITE PA, 1981, RADIOLOGY, V140, P763, DOI 10.1148/radiology.140.3.7280247; Fares Y, 2003, SCAND J INFECT DIS, V35, P394, DOI 10.1080/00365540310009040; Islekel S, 1998, SPINAL CORD, V36, P166, DOI 10.1038/sj.sc.3100512; Lam KS, 1997, SPINE, V22, P2050, DOI 10.1097/00007632-199709010-00023; PAMIR MN, 1984, SURG NEUROL, V21, P53, DOI 10.1016/0090-3019(84)90401-4	6	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					640	642		10.4103/IJPM.IJPM_764_17			3	Pathology	Pathology	GW7WJ	WOS:000447182900047	30303177	DOAJ Gold			2019-10-28	
J	Amita, K; Suma, MN; Shankar, SV; Premalata, CS; Sanjay, M				Amita, K.; Suma, M. N.; Shankar, S., V; Premalata, C. S.; Sanjay, M.			Primary follicular lymphoma of disguised as multiple miliary like lesions: A case report and review of literature (vol 61, pg 446, 2018)	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Correction																Amita K, 2018, INDIAN J PATHOL MICR, V61, P446, DOI 10.4103/IJPM.IJPM_126_17	1	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					643	643		10.4103/0377-4929.243009			1	Pathology	Pathology	GW7WJ	WOS:000447182900048		DOAJ Gold			2019-10-28	
J	Rekhi, B				Rekhi, Bharat			Catechism (Quiz 2)	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							MESENCHYMAL TUMORS; OSTEOMALACIA		[Rekhi, Bharat] Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India	Rekhi, B (reprint author), Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.	rekhi.bharat@gmail.com					El-Maouche D, 2016, J CLIN ENDOCR METAB, V101, P3575, DOI 10.1210/jc.2016-2052; Folpe A, 2013, WHO CLASSIFICATION T, P213; Folpe AL, 2004, AM J SURG PATHOL, V28, P1, DOI 10.1097/00000478-200401000-00001; WEIDNER N, 1987, CANCER, V59, P1442, DOI 10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q	4	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	OCT-DEC	2018	61	4					644	646		10.4103/IJPM.IJPM_433_18			3	Pathology	Pathology	GW7WJ	WOS:000447182900049		DOAJ Gold			2019-10-28	
J	Wang, YQ; Ding, Y; Qin, C; Gu, M; Wang, ZJ; Han, CH; Liu, X; Li, HX; Hua, HJ				Wang, Yiqiu; Ding, Ying; Qin, Chao; Gu, Min; Wang, Zengjun; Han, Conghui; Liu, Xia; Li, Hongxia; Hua, Hongjin			Expression of vitamin D receptor in clear cell papillary renal cell carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Clear cell papillary renal cell carcinoma; Vitamin D receptor	COLORECTAL-CANCER; BREAST-CANCER; SPECTRUM; TARGET; EMPHASIS; FEATURES; BEHAVIOR; DISTINCT; THERAPY; KIDNEY	Clear cell papillary renal cell carcinoma (ccpRCC) is a recently recognized subtype of renal cell carcinoma. In this study, we investigated the clinicopathological and immunohistochemical features in a group of 26 cases of ccpRCC, with a special emphasis on the expression of vitamin D receptor (VDR). The mean age of patients was 53.3 years (range 36-74 years), and the mean tumor size was 2.5 cm (range 0.5 to 6.5 cm). During follow-up (range 12-121 months, median 50 months), no recurrence or metastasis was observed. Histopathologically, all cases of ccpRCC exhibited a tubular and papillary architecture, covered by tumor cells with clear cytoplasm. Immunohistochemistry showed intermediate (5/26, 19%) to diffuse (21/26, 81%) and moderate (2/26, 8%) to strong (24/26, 92%) membranous staining for VDR in each case. All cases (26/26, 100%) were diffuse and strong cytoplasmic and fibrillar staining for cytokeratin 7 (CK7), but negative for alpha-methylacyl-CoA-racemase (AMACR). Each case showed diffuse (26/26, 100%) and moderate (4/26, 15%) to strong (22/26, 85%) membranous staining for carbonic anhydrase IX (CA IX). In addition, the majority of cases showed negative for cluster of differentiation 10 (CDIO) (20/26, 77%) and renal cell carcinoma maker (RCC-Ma) (24/26, 92%). This unique staining pattern is helpful for distinguishing ccpRCC from its mimics. Furthermore, VDR positive expression suggests that ccpRCC originates from the precursor epithelium of distal nephron.	[Wang, Yiqiu; Qin, Chao; Gu, Min; Wang, Zengjun] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Wang, Yiqiu] Southeast Univ, Dept Surg Oncol, Affiliated Xuzhou Hosp, Coll Med, Xuzhou, Jiangsu, Peoples R China; [Ding, Ying; Li, Hongxia; Hua, Hongjin] Nanjing Med Univ, Dept Pathol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Han, Conghui] Southeast Univ, Dept Urol, Affiliated Xuzhou Hosp, Coll Med, Xuzhou, Jiangsu, Peoples R China; [Liu, Xia] Southeast Univ, Dept Pathol, Affiliated Xuzhou Hosp, Coll Med, Xuzhou, Jiangsu, Peoples R China	Gu, M (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China.	lancetgu@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570676, 81672531]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); "333 high level talents project" in Jiangsu province [BRA2015469]; Six talents peak project in Jiangsu Province [WSN-056]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20151024]	This work was supported by the National Natural Science Foundation of China (grants number 81570676 and 81672531), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), "333 high level talents project" in Jiangsu province (grant number BRA2015469), Six talents peak project in Jiangsu Province (grants number WSN-056) and the Natural Science Foundation of Jiangsu Province (grant number BK20151024).	Alexiev BA, 2014, PATHOL RES PRACT, V210, P234, DOI 10.1016/j.prp.2013.12.009; Alomari AK, 2015, HUM PATHOL, V46, P1418, DOI 10.1016/j.humpath.2015.06.006; Aydin H, 2010, AM J SURG PATHOL, V34, P1608, DOI 10.1097/PAS.0b013e3181f2ee0b; Byers SW, 2012, REV ENDOCR METAB DIS, V13, P31, DOI 10.1007/s11154-011-9196-y; Cardus A, 2009, ATHEROSCLEROSIS, V204, P85, DOI 10.1016/j.atherosclerosis.2008.08.020; Carlberg C, 2007, DERMATOL CLIN, V25, P515, DOI 10.1016/j.det.2007.06.004; Chevarie-Davis M, 2014, AM J SURG PATHOL, V38, P887, DOI 10.1097/PAS.0000000000000247; Czarnecka AM, 2016, INT J ONCOL, V48, P2221, DOI 10.3892/ijo.2016.3460; Ditsch N, 2012, J HISTOCHEM CYTOCHEM, V60, P121, DOI 10.1369/0022155411429155; DROZ D, 1990, AM J PATHOL, V137, P895; Evans SRT, 1998, CLIN CANCER RES, V4, P1591; Gilani SM, 2012, PATHOLOGICA, V104, P101; Gobbo S, 2008, AM J SURG PATHOL, V32, P1239, DOI 10.1097/PAS.0b013e318164bcbb; Kato S, 2000, J BIOCHEM-TOKYO, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; Kittaka A, 2012, FUTURE MED CHEM, V4, P2049, DOI [10.4155/FMC.12.130, 10.4155/fmc.12.130]; Kuroda N, 2014, INT J CLIN EXP PATHO, V7, P7312; Liu WH, 2006, HUM PATHOL, V37, P1268, DOI 10.1016/j.humpath.2006.04.029; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Murray A, 2017, ENDOCR-RELAT CANCER, V24, P181, DOI 10.1530/ERC-16-0463; Nangia AK, 2007, J UROLOGY, V178, P1092, DOI 10.1016/j.juro.2007.05.009; Obara W, 2007, J UROLOGY, V178, P1497, DOI 10.1016/j.juro.2007.05.119; Seubwai W, 2007, CANCER, V109, P2497, DOI 10.1002/cncr.22716; Shi SS, 2013, INT J CLIN EXP PATHO, V6, P2936; STUMPF WE, 1980, P NATL ACAD SCI-BIOL, V77, P1149, DOI 10.1073/pnas.77.2.1149; Thorne J, 2008, P NUTR SOC, V67, P115, DOI 10.1017/S0029665108006964; Tickoo SK, 2006, AM J SURG PATHOL, V30, P141, DOI 10.1097/01.pas.0000185382.80844.b1; Wang KW, 2015, HISTOPATHOLOGY, V67, P386, DOI 10.1111/his.12663; Wang YJ, 2012, ARCH BIOCHEM BIOPHYS, V523, P123, DOI 10.1016/j.abb.2012.04.001; YOSHIDA SO, 1989, CANCER RES, V49, P1802; Zhang XH, 2006, CURR CANCER DRUG TAR, V6, P229, DOI 10.2174/156800906776842939; Zhou HJ, 2014, HUM PATHOL, V45, P59, DOI 10.1016/j.humpath.2013.08.004	31	0	0	3	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						1	4		10.1016/j.anndiagpath.2018.06.007			4	Pathology	Pathology	GW8OU	WOS:000447239200001	29966830				2019-10-28	
J	Nuovo, GJ; de Andrade, CV; Wells, SI; Brusadelli, M; Nicol, AF				Nuovo, Gerard J.; de Andrade, Cecilia Vianna; Wells, Susanne I.; Brusadelli, Marion; Nicol, Alcina F.			New biomarkers of human papillomavirus infection in acute cervical intraepithelial neoplasia	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Mcl1l cFLIP; Importin; Exportin; HPV; CIN; Productive	NF-KAPPA-B; NUCLEAR TRANSPORT; REV PROTEIN; COMPLEX; VIRUS; ONCOPROTEIN; ACTIVATION; PATHWAY; CELL; AMPLIFICATION	Acute human papillomavirus (HPV) infection of the cervix (cervical intraepithelial neoplasia, CIN) is marked by high copy episomal viral DNA and L1/L2 capsid protein expression (productive infection) in the cells towards the surface that facilitate sexual viral transmission. Viral DNA is low copy and not associated with viral capsid protein expression in the less differentiated lower part of the CIN (nonproductive infection). The purpose of this study was to examine the host response in these two areas. Serial section and co-localization analyses demonstrated that in 29/33 (88%) of cases the NF-kappa B pathway was activated and localized to the suprabasal nonproductively infected cells in the CIN lesions. There was a concomitant increased expression of importin-beta, exportin-5, Mcl1, p16, Ki67 and cFLIP in 32/33 (96%) of CIN lesions that likewise localized primarily to the nonproductively infected cells. Only Ki67 and exportin-5 were expressed, though much less so, in the adjacent, normal squamous epithelia. The viral proteins E1(boolean AND)E4 and L1 were localized to productively infected cells whereas E6/E7 protein/RNA was rarely present in early CIN. It is concluded that the host viral response to acute cervical HPV infection includes strong increased expression of proteins besides p16 and Ki67. These include importin-beta, exportin-5, Mcl1, and cFLIP in cells with low copy and relatively quiescent viral DNA that, in turn, may serve as new biomarkers of this disease.	[Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Nuovo, Gerard J.] Phylogeny Lab, Powell, OH USA; [de Andrade, Cecilia Vianna] Fernandes Figueira IFF FIOCRUZ, Natl Inst Hlth Women Children & Adolescents, Rio De Janeiro, Brazil; [Wells, Susanne I.; Brusadelli, Marion] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Nicol, Alcina F.] Natl Inst Infect Dis Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil; [Wells, Susanne I.; Brusadelli, Marion] Univ Cincinnati, Cincinnati, OH USA	Nuovo, GJ (reprint author), Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.	nuovo.1@osu.edu	ANDRADE, CECILIA/B-5916-2017	ANDRADE, CECILIA/0000-0001-7980-4367	Alzheimer's Drug Discovery Foundation [20160204]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA102357]	Alzheimer's Drug Discovery Foundation (# 20160204, GJN) and the National Institutes of Health R01-CA102357 to SIW.	Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; BEDELL MA, 1991, J VIROL, V65, P2254; Cheng YW, 2008, CLIN CANCER RES, V14, P4705, DOI 10.1158/1078-0432.CCR-07-4675; Crum CP, 2000, MODERN PATHOL, V13, P243, DOI 10.1038/modpathol.3880045; CRUM CP, 1988, J VIROL, V62, P84; Demart S, 2003, EXP CELL RES, V291, P484, DOI 10.1016/j.yexcr.2003.07.011; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hasan UA, 2013, J EXP MED, V210, P1369, DOI 10.1084/jem.20122394; Havard L, 2005, VIROLOGY, V331, P357, DOI 10.1016/j.virol.2004.10.030; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hoskins EE, 2009, ONCOGENE, V28, P674, DOI 10.1038/onc.2008.416; Hoskins EE, 2012, J VIROL, V86, P8131, DOI 10.1128/JVI.00408-12; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kim SH, 2009, CARCINOGENESIS, V30, P753, DOI 10.1093/carcin/bgp066; Krause E, 2014, J VIROL, V88, P9963, DOI 10.1128/JVI.00684-14; Leonard SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20847; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Malik P, 2012, J BIOL CHEM, V287, P12277, DOI 10.1074/jbc.M111.331777; Mezache L, 2017, APPL IMMUNOHISTO M M, V25, P100, DOI 10.1097/PAI.0000000000000298; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Nakahara T, 2015, J VIROL, V89, P5040, DOI 10.1128/JVI.00389-15; Nuovo G, 2016, ANN DIAGN PATHOL, V25, P54, DOI 10.1016/j.anndiagpath.2016.09.010; Nuovo GJ, 2018, ANN DIAGN PATHOL, V34, P36, DOI 10.1016/j.anndiagpath.2018.01.003; NUOVO GJ, 1991, AM J PATHOL, V139, P847; Nuovo GJ., 1994, CYTOPATHOLOGY LOWER; Nuovo GJ, 2013, SITU MOL PATHOLOGY C; Richards KH, 2015, SCI REP-UK, V5, DOI 10.1038/srep12922; RICHART RM, 1993, CANCER-AM CANCER SOC, V71, P1413, DOI 10.1002/cncr.2820710406; Samson A, 2016, GUT GUTJNL, DOI [10.1136/gutjn1-2016-312009, DOI 10.1136/GUTJN1-2016-312009]; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stoler MH, 2003, CANCER J, V9, P360, DOI 10.1097/00130404-200309000-00005; Tummers B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7537; Vandermark ER, 2012, VIROLOGY, V425, P53, DOI 10.1016/j.virol.2011.12.023; Wang W, 2011, APOPTOSIS, V16, P55, DOI 10.1007/s10495-010-0543-3; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x	36	5	6	3	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						21	27		10.1016/j.anndiagpath.2018.06.008			7	Pathology	Pathology	GW8OU	WOS:000447239200004	29966832				2019-10-28	
J	Straub, MM; Podoll, MB; David, SN; Wiesner, GL; Desouki, MM				Straub, Melissa M.; Podoll, Mirna B.; David, Stephanie N.; Wiesner, Georgia L.; Desouki, Mohamed M.			Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Risk-reducing salpingo-oophorectomy; Ovarian cancer; Breast cancer; BRCA; Mutation	OVARIAN-CANCER; SURGERY; POPULATION; MANAGEMENT	Risk-reducing salpingo-oophorectomy (RRSO) is a procedure to reduce the risk of adnexal cancer in BRCA mutation carriers and for hormonal manipulation in women with breast cancer (BC). The goal of the study is to report the frequency of subsequent BC and high-grade serous carcinoma (HGSC) following RRSO in BRCA1 and BRCA2 mutation carriers and in patients with personal history of BC with or without BRCA mutation. A series of 147 consecutive patients who received a RRSO were reviewed. Patient's age, clinical history, BC histotype, gene mutation data, incidence of post-RRSO BC and HGSC and time intervals were analyzed. The cases were followed for a mean of 49 months. Group 1 consists of 97 cases with pathogenic or likely pathogenic "deleterious" mutation BRCA1 (n = 49) or BRCA2 (n = 48). Group 2 consists of 50 cases with history of BC and no documented BRCA gene mutation. Prior to RRSO, 42 (43%) cases in group 1 had a history of BC and all cases in group 2 had a history of BC. There was no difference between the groups in the age at diagnosis for BC (Mean of 44 years). Following RRSO, 2/49 cases (4%) with BRCA1 mutation were found to have occult HGSC and none in BRCA2 cases. There were also 1 BC recurrence and 1 primary BC with BRCA1 mutation compared to 5 recurrent BC in Group 2 (10%). In conclusion, the risk of subsequent recurrent BC after RRSO appears to be higher (10%) in patients with history of BC with no BRCA mutation when compared to (2%) in BRCA mutation carriers.	[Straub, Melissa M.; Podoll, Mirna B.; David, Stephanie N.; Desouki, Mohamed M.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Wiesner, Georgia L.] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN USA	Desouki, MM (reprint author), Vanderbilt Univ, Sch Med, 1161 21st Ave South,MCN,C-2310A, Nashville, TN 37232 USA.	mokhtar.desouki@vanderbilt.edu					Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Berek JS, 2010, OBSTET GYNECOL, V116, P733, DOI 10.1097/AOG.0b013e3181ec5fc1; Chay WY, 2015, GYNECOL ONCOL REP, V12, P72, DOI 10.1016/j.gore.2015.03.007; Daly MB, 2016, J NATL COMPR CANC NE, V14, P153, DOI 10.6004/jnccn.2016.0018; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Finch APM, 2014, J CLIN ONCOL, V32, P1547, DOI 10.1200/JCO.2013.53.2820; Kramer JL, 2005, J CLIN ONCOL, V23, P8629, DOI 10.1200/JCO.2005.02.9199; Madalinska JB, 2005, J CLIN ONCOL, V23, P6890, DOI 10.1200/JCO.2005.02.626; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Obermair A, 2014, INT J CANCER, V134, P2211, DOI 10.1002/ijc.28537; Salvador S, 2017, J OBSTET GYNAECOL CA, V39, P480, DOI 10.1016/j.jogc.2016.12.005; Santen RJ, 2015, STEROIDS, V99, P61, DOI 10.1016/j.steroids.2014.08.003; Stan DL, 2013, J WOMENS HEALTH, V22, P825, DOI 10.1089/jwh.2013.4407; Tschernichovsky R, 2017, ONCOLOGIST, V22, P450, DOI 10.1634/theoncologist.2016-0444; Willsher P, 2008, ANZ J SURG, V78, P670, DOI 10.1111/j.1445-2197.2008.04614.x; Zakhour M, 2016, GYNECOL ONCOL, V143, P231, DOI 10.1016/j.ygyno.2016.08.336	16	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						28	30		10.1016/j.anndiagpath.2018.06.003			3	Pathology	Pathology	GW8OU	WOS:000447239200005	30055521				2019-10-28	
J	Aboulhagag, NA; El-Deek, HEM; Sherif, MF				Aboulhagag, Noha A.; El-Deek, Heba E. M.; Sherif, Mahmoud F.			Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Renal cell carcinoma; Galectin-1; Galectin-3; Immunohistochemistry	KIDNEY CANCER; CLINICAL-SIGNIFICANCE; PROGNOSTIC MARKER; TUMOR PROGRESSION; NEOPLASMS; CORRELATE	Background and aims: Galectins comprise a large family of calcium independent lectins. Galectin-1 and galectin-3 contribute to neoplastic transformation, angiogenesis, and tumor metastasis in some cancers. This study aimed at studying the immunohistochemical expression of both galectin-1 and galectin-3 in renal cell carcinoma (RCC) variants and detecting the possible association of galectins with various clinicopathological parameters. Materials and methods: Sections from 67 formalin-fixed paraffin-embedded tissue blocks of RCC variants were stained with galectin-1 and galectin-3. Expression was assessed in tumor tissue and adjacent renal parenchyma and was correlated with clinicopathological criteria. Results: In apparently normal renal parenchyma adjacent to tumor tissue, galectin-1 was expressed in 27 (40.2%) of specimens in renal tubules and glomeruli, while 34 (50.7%) of specimens showed galectin-3 expression in renal tubules sparing glomeruli. In tumor tissue, galectin-1 showed high expression in 47 (70.1%) and low expression in 20 (29.9%) of specimens. Galectin-3 had high expression in 15 (22.4%) and low expression in 52 (77.6%) of specimens. Significant association was detected between expression of galectin-1 and galectin-3 and the type of RCC (P = 0.032) and (P = 0.006), respectively. Significant inverse association was detected between the expression of galectin-3 and the presence of tumor haemorrhage and necrosis (P = 0.014) and (P = 0.039), respectively. Conclusion: Galectin-1 and galectin-3 are overexpressed in RCC with different percentage in different subtypes. Galactin-lexpression is more in tumor tissue than surrounding renal parenchyma suggesting that it has a carcinogenic role. Galectin-1 and galectin-3 overexpression in chromophobe RCC suggests that they may have diagnostic role.	[Aboulhagag, Noha A.; El-Deek, Heba E. M.; Sherif, Mahmoud F.] Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt	Aboulhagag, NA (reprint author), Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt.	nohah@aun.edu.eg		mohamed, noha/0000-0002-2574-9881			Ahmed H, 2015, CLIN MED INSIGHTS-ON, V9, P113, DOI [10.4137/CMO.S29462, 10.4137/CMO.S29462.]; Balan Vitaly, 2010, Cancers (Basel), V2, P592, DOI 10.3390/cancers2020592; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Dancer JY, 2010, ARCH PATHOL LAB MED, V134, P90, DOI 10.1043/2008-0392-OAR1.1; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Edge SB, 2010, AJCC CANC STAGING HD; Endo K, 2005, ANTICANCER RES, V25, P3117; Fischer S, 2015, TRANSL ANDROL UROL, V4, P310, DOI 10.3978/j.issn.2223-4683.2015.04.07; Fisher R, 2013, SEMIN CANCER BIOL, V23, P38, DOI 10.1016/j.semcancer.2012.06.004; Fukumori T, 2007, DRUG RESIST UPDATE, V10, P101, DOI 10.1016/j.drup.2007.04.001; Huang CS, 2014, J AM SOC NEPHROL, V25, P1486, DOI 10.1681/ASN.2013070773; Idikio HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026150; Kaneko N, 2013, INT J UROL, V20, P530, DOI 10.1111/j.1442-2042.2012.03206.x; Li P, 2015, EUR UROL, V67, P1134, DOI 10.1016/j.eururo.2014.11.001; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Merseburger AS, 2008, WORLD J UROL, V26, P637, DOI 10.1007/s00345-008-0294-8; Moch H, 2016, WHO CLASSIFICATION T; Nagy N, 2003, CANCER, V97, P1849, DOI 10.1002/cncr.11268; Pacis RA, 2000, PROSTATE, V44, P118; Sakaki M, 2010, J MED INVESTIG, V57, P152, DOI 10.2152/jmi.57.152; Shekhar MPV, 2004, AM J PATHOL, V165, P1931, DOI 10.1016/S0002-9440(10)63245-2; Tamaskar I, 2007, CANCER, V110, P776, DOI 10.1002/cncr.22838; van den Brule F, 2003, LAB INVEST, V83, P377, DOI 10.1097/01.LAB.0000059949.01480.40; VandenBrule FA, 1996, HUM PATHOL, V27, P1185, DOI 10.1016/S0046-8177(96)90313-5; von Klot CA, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-15; White NMA, 2017, BRIT J CANCER, V116, pE3, DOI 10.1038/bjc.2016.441; White NMA, 2014, BRIT J CANCER, V110, P1250, DOI 10.1038/bjc.2013.828; Yazawa EM, 2015, J INVEST DERMATOL, V135, P1849, DOI 10.1038/jid.2015.95; Zhou XS, 2014, GENE, V546, P403, DOI 10.1016/j.gene.2014.04.066; Zuniga E, 2001, J LEUKOCYTE BIOL, V70, P73	31	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						31	37		10.1016/j.anndiagpath.2018.06.005			7	Pathology	Pathology	GW8OU	WOS:000447239200006	30055522				2019-10-28	
J	Ronen, S; Narula, N; Koizumi, JH; Hunt, B; Giorgadze, T				Ronen, Shira; Narula, Navneet; Koizumi, June H.; Hunt, Bryan; Giorgadze, Tamara			Low-grade endometrial stromal sarcoma presenting as multiple pulmonary nodules: A potential pitfall in fine needle aspiration and core biopsy specimens - A Cytological - Pathological Correlation	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Low-grade endometrial stromal sarcoma; Solitary fibrous tumor; Synovial sarcoma; Neuroendocrine tumor; Leiomyosarcoma; Fine needle aspiration	SOLITARY FIBROUS TUMORS; SYNOVIAL SARCOMA; LUNG	Low-grade endometrial stromal sarcoma (LGESS) is the second most common malignant mesenchymal tumor of the uterus. The most common location is the uterine corpus, but it can also primarily arise in a variety of extrauterine locations such as pelvis, ovary, abdominal cavity, vagina, and vulva. We are reporting a case of a 47-year-old female with no significant medical history who presented with multiple pulmonary nodules. Fine needle aspiration (FNA) specimen revealed spindle cell neoplasm consistent with the diagnosis of LGESS. The differential diagnosis included neuroendocrine tumor, synovial sarcoma, solitary fibrous tumor, smooth muscle tumors, and peripheral nerve sheath tumors. The clinical, cytological, and histopathologic details of this case, as well as a discussion of the potential pitfalls and differential diagnosis of spindle cell lesions of the lung are described.	[Ronen, Shira; Hunt, Bryan] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Narula, Navneet; Koizumi, June H.; Giorgadze, Tamara] Weill Cornell Med Coll, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA	Giorgadze, T (reprint author), Med Coll Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	sronen@mcw.edu; nan9030@med.cornell.edu; jhkoizum@med.cornell.edu; bhunt@mcw.edu; tgiorgadze@mcw.edu					Ali RH, 2015, J CLIN PATHOL, V68, P325, DOI 10.1136/jclinpath-2014-202829; Aubry MC, 2002, AM J SURG PATHOL, V26, P440, DOI 10.1097/00000478-200204000-00005; Binesh F, 2013, BMJ CASE REP, V2013; Cho EY, 2007, CYTOPATHOLOGY, V18, P20, DOI 10.1111/j.1365-2303.2007.00378.x; Collins BT, 2009, ACTA CYTOL, V53, P105, DOI 10.1159/000325094; DAngelo E, 2014, ADV ANAT PATHOL, V21, P383; Field AS, 2017, PRACTICAL CYTOPATHOL; Goepel J., 2003, J CLIN PATHOL, V56, P160; Huang CC, 2014, DIAGN CYTOPATHOL, V42, P170, DOI 10.1002/dc.22912; Nuwal P, 2012, LUNG INDIA, V29, P384, DOI 10.4103/0970-2113.102841; Oliva E, 2007, AM J SURG PATHOL, V31, P1277, DOI 10.1097/PAS.0b013e318031f012; Park JY, 2013, HISTOPATHOLOGY, V63, P833, DOI 10.1111/his.12232; Policarpio-Nicolas ML, 2007, AM J CLIN PATHOL, V128, P265, DOI 10.1309/G13Y360MTXLN7KU9; Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	15	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						38	43		10.1016/j.anndiagpath.2018.06.004			6	Pathology	Pathology	GW8OU	WOS:000447239200007	30055523				2019-10-28	
J	Goulart, JAV; Montalli, VAM; Passador-Santos, F; Soares, AB; de Araujo, NS; de Araujo, VC				Vianna Goulart-Filho, Joao Augusto; Martins Montalli, Victor Angelo; Passador-Santos, Fabricio; Soares, Andresa Borges; de Araujo, Ney Soares; de Araujo, Vera Cavalcanti			Microvessel density and cell proliferation in juvenile ossifying fibroma: A comparative study with central ossifying fibroma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Juvenile ossifying fibroma; Ossifying fibroma; CD34; CD105; Ki-67; Mcm-2	RECURRENT PLEOMORPHIC ADENOMA; OF-THE-LITERATURE; MAXILLA	Considered as an aggressive counterpart of central ossifying fibroma (OF), juvenile ossifying fibroma (JOF) is a benign fibro-osseous neoplasm characterized by an unpredictable destructive behavior, elevated morbidity, mutilating treatment and high potential for local recurrences. The aim of this study is to compare the analysis for cell proliferation and vascular markers between JOF and OF. Cell proliferation index was measured by Ki-67 and Mcm-2 expression and microvessel density (MVD) was obtained by the immunoexpression of CD34/CD105. We observed a reduced expression of vascular markers, where MVD for CD34 was significantly higher in JOF than in OF (p = 0.009), but no statistical difference was found for CD105. JOF and OF showed low expression for Ki-67 and Mcm-2 and no difference was noted between both, suggesting that other mechanisms such as anti-apoptotic and/or pro-autophagic pathways or even increased expression of matrix metalloproteinases may be responsible for the aggressiveness of JOF.	[Vianna Goulart-Filho, Joao Augusto; Martins Montalli, Victor Angelo; Passador-Santos, Fabricio; Soares, Andresa Borges; de Araujo, Ney Soares; de Araujo, Vera Cavalcanti] Sao Leopoldo Mandic Inst & Res Ctr, Dept Oral Pathol, Rua Jose Rocha Junqueira 13, BR-13045610 Campinas, SP, Brazil	Goulart, JAV (reprint author), Sao Leopoldo Mandic Inst & Res Ctr, Dept Oral Pathol, Rua Jose Rocha Junqueira 13, BR-13045610 Campinas, SP, Brazil.	jgoulartf@hotmail.com; victor.montalli@slmandic.edu.br; fabricio.passador-santos@slmandic.edu.br; nsaraujo@usp.br; vcaraujo@usp.br		Goulart-Filho, Joao Augusto Vianna/0000-0001-8591-7798; Araujo, Vera/0000-0002-5860-3715			Abramovitch Kenneth, 2016, Dent Clin North Am, V60, P167, DOI 10.1016/j.cden.2015.08.010; Aggarwal S, 2012, CONTEMP CLIN DENT, V3, P330, DOI 10.4103/0976-237X.103630; Ariyasathitman S, 2012, AURIS NASUS LARYNX, V39, P314, DOI 10.1016/j.anl.2011.07.019; Babaji Harsh V, 2014, J Int Oral Health, V6, P108; Silva CAB, 2011, PEDIATR DENT, V33, P388; Bohn OL, 2011, HEAD NECK PATHOL, V5, P71, DOI 10.1007/s12105-010-0212-4; Breheret R, 2011, EUR ANN OTORHINOLARY, V128, P317, DOI 10.1016/j.anorl.2011.02.007; El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545; El-Naggar AK, 2017, WHO CLASSIFICATION H; Figueiredo LMG, 2014, ORAL MAXILLOFAC SURG, V18, P87, DOI 10.1007/s10006-013-0400-y; Gondivkar SM, 2011, ORAL ONCOL, V47, P804, DOI 10.1016/j.oraloncology.2011.06.014; Granados R, 2006, ORAL SURG ORAL MED O, V101, P614, DOI 10.1016/j.tripleo.2005.03.036; Han J, 2016, INT J ORAL MAX SURG, V45, P368, DOI 10.1016/j.ijom.2015.12.004; Hasselblatt M, 2005, J NEUROSURG, V102, P1151, DOI 10.3171/jns.2005.102.6.1151; Osunde OD, 2013, ANN MED HEALTH SCI R, V3, P288, DOI 10.4103/2141-9248.113685; Owosho AA, 2014, OR SURG OR MED OR PA, V118, P734, DOI 10.1016/j.oooo.2014.09.010; Patigaroo SA, 2011, J MAXILLOFAC ORAL SU, V10, P155, DOI 10.1007/s12663-010-0065-0; Patil Ravi S, 2013, Ann Maxillofac Surg, V3, P100, DOI 10.4103/2231-0746.110081; Peterson BR, 2015, HEAD NECK PATHOL, V9, P384, DOI 10.1007/s12105-014-0595-8; Ranganath K, 2014, J MAXILLOFAC ORAL SU, V13, P109, DOI 10.1007/s12663-013-0479-6; Sankaranarayanan S, 2011, J Oral Maxillofac Pathol, V15, P299, DOI 10.4103/0973-029X.86693; Slootweg PJ, 2012, VIRCHOWS ARCH, V461, P699, DOI 10.1007/s00428-012-1329-5; Smith SF, 2009, J ORAL MAXIL SURG, V67, P200, DOI 10.1016/j.joms.2007.12.009; Soares AB, 2009, J ORAL PATHOL MED, V38, P623, DOI 10.1111/j.1600-0714.2009.00794.x; Soares AB, 2011, J ORAL PATHOL MED, V40, P352, DOI 10.1111/j.1600-0714.2010.00956.x; Tabareau-Delalande F, 2015, MODERN PATHOL, V28, P48, DOI 10.1038/modpathol.2014.80; Tolentino ES, 2012, RADIO, V113, P40, DOI 10.1016/j.0000.2011.08.005; Urs AB, 2013, ANN DIAGN PATHOL, V17, P198, DOI 10.1016/j.anndiagpath.2012.06.003; Weidner N, 2008, METHOD ENZYMOL, V444, P305, DOI 10.1016/S0076-6879(08)02814-0; Yadav N, 2013, CONTEMP CLIN DENT, V4, P566, DOI 10.4103/0976-237X.123094	30	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						44	49		10.1016/j.anndiagpath.2018.08.001			6	Pathology	Pathology	GW8OU	WOS:000447239200008	30098514				2019-10-28	
J	Rekhi, B; Gupta, C; Chinnaswamy, G; Qureshi, S; Vora, T; Khanna, N; Laskar, S				Rekhi, Bharat; Gupta, Chhavi; Chinnaswamy, Girish; Qureshi, Sajid; Vora, Tushar; Khanna, Nehal; Laskar, Siddhartha			Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Rhabdomyosarcoma; Embryonal rhabdomyosarcoma; Alveolar rhabdomyosarcoma; Spindle cell/sclerosing rhabdomyosarcoma; Pleomorphic rhabdomyosarcoma; Myogenin; MyoD1	SPINDLE-CELL RHABDOMYOSARCOMA; CHILDRENS ONCOLOGY GROUP; TISSUE SARCOMA COMMITTEE; OF-THE-LITERATURE; INTERGROUP-RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; PROGNOSTIC-FACTORS; EMBRYONAL RHABDOMYOSARCOMA; PEDIATRIC RHABDOMYOSARCOMA; CLINICAL-OUTCOMES	The present study was aimed at evaluating clinicopathologic and immunohistochemical (IHC) features of 300 rhabdomyosarcomas (RMSs), including differential IHC expression and prognostic value of myogenin and MyoD1 across various subtypes of RMSs. IHC expression of myogenin and MyoD1 was graded on the basis of percentage of tumor cells displaying positive intranuclear immunostaining i.e. grade 1 (1-25%); grade 2 (26-50%); grade 3 (51-76%) and grade 4 (76-100%).Clinical follow-up was available in 238 (79.3%) patients. Various clinicopathologic parameters were correlated with 3-year disease free survival (DFS) and overall survival (OS). There were 140 cases (46.7%) of alveolar RMS (ARMS), 90 of embryonal RMS (ERMS) (30%), 61 (20.3%) of spindle cell/sclerosing RMS and 9 cases (3%) of pleomorphic RMS. Most cases, barring pleomorphic RMSs, occurred in the first two decades (228 cases) (76%), frequently in males, in the head and neck region (126) (42%). By immunohistochemistry, desmin was positive in 292/299 (97.6%) tumors; myogenin in 238/267 (89.1%) and MyoD1 in 192/266 (72.2%) tumors. High myogenin expression (in >= 51% positive tumor cells) was significantly associated with ARMSs (95/121, 78.5%), as compared to other subtypes (48/117, 41%) (p value < 0.001). High MyoD1 expression (>= 51% tumor cells) was seen in more cases of pure sclerosing, combined with spindle cell/sclerosing RMSs (10/10, 100%), as compared to the other subtypes (91/141, 67.4%) (p = 0.032). There was no significant difference between high myogenin expression and clinical outcomes. Patients without metastasis and harbouring tumors, measuring <= 5 cm showed a significant increase in OS, with p values = 0.01 and < 0.001, respectively. ARMS was the most frequent subtype. There was a significant association between high myogenin expression and ARMSs and high MyoD1 expression and spindle cell/sclerosing RMSs. High myogenin expression did not correlate with clinical outcomes. Patients with smaller sized tumors and without metastasis had significantly better clinical outcomes.	[Rekhi, Bharat; Gupta, Chhavi] Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India; [Chinnaswamy, Girish; Vora, Tushar] Tata Mem Hosp, Dept Med Oncol, Bombay, Maharashtra, India; [Qureshi, Sajid] Tata Mem Hosp, Dept Surg Oncol, Bombay, Maharashtra, India; [Khanna, Nehal; Laskar, Siddhartha] Tata Mem Hosp, Dept Radiat Oncol, Bombay, Maharashtra, India; Tata Mem Hosp, Bombay, Maharashtra, India	Rekhi, B (reprint author), Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.	rekhi.bharat@gmail.com					Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Ahmad Zubair, 2015, Asian Pac J Cancer Prev, V16, P757; ALTMANNSBERGER M, 1985, AM J PATHOL, V118, P85; Bahrami A, 2008, MODERN PATHOL, V21, P795, DOI 10.1038/modpathol.2008.86; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Carpentieri DF, 2002, MODERN PATHOL, V15, P1080, DOI 10.1097/01.MP.0000028646.03760.6B; CARTER RL, 1989, HISTOPATHOLOGY, V15, P585, DOI 10.1111/j.1365-2559.1989.tb01624.x; CAVAZZANA AO, 1992, AM J SURG PATHOL, V16, P229, DOI 10.1097/00000478-199203000-00002; Cerveira N, 2005, CANCER GENET CYTOGEN, V163, P138, DOI 10.1016/j.cancergencyto.2005.06.020; Cessna MH, 2001, AM J SURG PATHOL, V25, P1150, DOI 10.1097/00000478-200109000-00005; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; Cui S, 1999, PATHOL INT, V49, P62, DOI 10.1046/j.1440-1827.1999.00825.x; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DOWNING JR, 1995, AM J PATHOL, V146, P626; Folpe AL, 1997, MODERN PATHOL, V10, P895; Freeman A, 2004, MODERN PATHOL, V17, P765, DOI 10.1038/modpathol.3800078; Furlong MA, 2001, MODERN PATHOL, V14, P595, DOI 10.1038/modpathol.3880357; Heerema-McKenney A, 2008, AM J SURG PATHOL, V32, P1513, DOI 10.1097/PAS.0b013e31817a909a; HEYN RM, 1974, CANCER-AM CANCER SOC, V34, P2128, DOI 10.1002/1097-0142(197412)34:6<2128::AID-CNCR2820340638>3.0.CO;2-M; Joshi D, 2004, PEDIATR BLOOD CANCER, V42, P64, DOI 10.1002/pbc.10441; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Kumar S, 2000, MOD PATHOL, V13; La Starza R, 2015, PEDIATR BLOOD CANCER, V62, P2238, DOI 10.1002/pbc.25664; Lawrence W, 1997, CANCER, V80, P1165; LEADER M, 1989, BRIT J CANCER, V59, P106, DOI 10.1038/bjc.1989.21; Mentzel T, 2006, VIRCHOWS ARCH, V449, P554, DOI 10.1007/s00428-006-0284-4; Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801; Montgomery EA, 2013, WHO CLASSIFICATION T, P132; Morotti RA, 2006, AM J SURG PATHOL, V30, P962, DOI 10.1097/00000478-200608000-00005; Nascimento AF, 2005, AM J SURG PATHOL, V29, P1106; Nascimento AF, 2013, WHO CLASSIFICATION T, P134; NEWTON WA, 1995, CANCER-AM CANCER SOC, V76, P1073, DOI 10.1002/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L; Nishio J, 2006, LAB INVEST, V86, P547, DOI 10.1038/labinvest.3700416; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; Ordonez NG, 1998, AM J SURG PATHOL, V22, P1314, DOI 10.1097/00000478-199811000-00002; Parham DM, 2006, ARCH PATHOL LAB MED, V130, P1454; PARHAM DM, 1991, CANCER-AM CANCER SOC, V67, P3072, DOI 10.1002/1097-0142(19910615)67:12<3072::AID-CNCR2820671223>3.0.CO;2-Z; PARHAM DM, 1994, AM J SURG PATHOL, V18, P474, DOI 10.1097/00000478-199405000-00006; Parham DM, 2013, WHO CLASSIFICATION T, P127; Parham DM, 2013, WHO CLASSIFICATION T, P130; Rekhi B, 2016, MODERN PATHOL, V29, P1532, DOI 10.1038/modpathol.2016.144; Rekhi B, 2014, APMIS, V122, P1144, DOI 10.1111/apm.12272; Rekhi B, 2013, PATHOL RES PRACT, V209, P758, DOI 10.1016/j.prp.2013.08.008; Rubin BP, 1998, AM J SURG PATHOL, V22, P459, DOI 10.1097/00000478-199804000-00011; Rudzinski ER, 2013, AM J CLIN PATHOL, V140, P82, DOI 10.1309/AJCPA1WN7ARPCMKQ; Sebire NJ, 2005, APPL IMMUNOHISTO M M, V13, P1, DOI 10.1097/00129039-200503000-00001; Sebire NJ, 2003, J CLIN PATHOL, V56, P412, DOI 10.1136/jcp.56.6.412; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stock N, 2009, AM J SURG PATHOL, V33, P1850, DOI 10.1097/PAS.0b013e3181be6209; Sultan I, 2009, J CLIN ONCOL, V27, P3391, DOI 10.1200/JCO.2008.19.7483; Szuhai K, 2014, J PATHOL, V232, P300, DOI 10.1002/path.4307; Treetipsatit J, 2009, PEDIATR DEVEL PATHOL, V12, P383, DOI 10.2350/08-08-0518.1; TRUONG LD, 1990, AM J CLIN PATHOL, V93, P305, DOI 10.1093/ajcp/93.3.305; Wang P, 2008, AM J CLIN PATHOL, V129, P410, DOI 10.1309/EP3FRRY6GMP555QC; Yang LM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-654	57	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						50	60		10.1016/j.anndiagpath.2018.07.002			11	Pathology	Pathology	GW8OU	WOS:000447239200009	30098515				2019-10-28	
J	Flucke, U; Bekers, EM; Creytens, D; van Gorp, JM				Flucke, Uta; Bekers, Elise M.; Creytens, David; van Gorp, Joost M.			COL1A1 is a fusionpartner of USP6 in myositis ossificans - FISH analysis of six cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Letter							ANEURYSMAL BONE-CYST; REARRANGEMENTS		[Flucke, Uta; Bekers, Elise M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands; [Bekers, Elise M.] Jeroen Bosch Hosp, Dept Pathol Pathol DNA, Den Bosch, Netherlands; [Creytens, David] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [van Gorp, Joost M.] Diakonessenhuis Utrecht, Dept Pathol Pathol DNA, Utrecht, Netherlands	Flucke, U (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	uta.flucke@radboudumc.nl					Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Bekers EM, 2018, ANN DIAGN PATHOL, V34, P56, DOI 10.1016/j.anndiagpath.2018.01.006; Jacquot C, 2015, SKELETAL RADIOL, V44, P1695, DOI 10.1007/s00256-015-2205-6; Nielsen GP, 2002, AM J SURG PATHOL, V26, P64, DOI 10.1097/00000478-200201000-00007; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z	6	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	OCT	2018	36						61	62		10.1016/j.anndiagpath.2018.06.009			2	Pathology	Pathology	GW8OU	WOS:000447239200010	29980413				2019-10-28	
J	Szurian, K; Csala, I; Marosvari, D; Rajnai, H; Derso, K; Bodor, C; Piurko, V; Matolcsy, A; Reiniger, L				Szurian, Kinga; Csala, Iren; Marosvari, Dora; Rajnai, Hajnalka; Derso, Katalin; Bodor, Csaba; Piurko, Violetta; Matolcsy, Andras; Reiniger, Lilla			EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Proliferation center; CLL/SLL; EZH2; miR-26a; C-myc	CHRONIC LYMPHOCYTIC-LEUKEMIA; POLYCOMB-GROUP PROTEINS; MANTLE CELL LYMPHOMA; LOW MIR-150; EXPRESSION; MYC; MUTATIONS; CANCER; GENES; LOOP	Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is characterised by the diffuse infiltration of small neoplastic lymphocytes, which is accompanied by the presence of proliferation centres (PCs) comprising prolymphocytes and paraimmunoblasts. There is increasing evidence of accumulation of various molecular alterations in the tumour cells of PCs, which may explain why extended PCs are related to a less favourable prognosis. To further characterize PCs, we compared the expression level of EZH2 protein, the overexpression of which has recently been recognized as poor prognostic factor in CLL/SLL, in the PCs and the intervening small cell areas in lymph nodes of 15 patients with CLL/SLL. We also investigated the mutational profile of EZH2 and the expression of its upstream regulators c-Myc, E2F1, pRB and miR-26a. Our results showed a significantly increased expression of EZH2 in the PCs. No EZH2 mutations were detected, however, overexpression of c-Myc, E2F1 and pRb proteins as well as reduced expression of the tumor suppressor miR-26a were demonstrated in the PCs. In summary our findings indicate that EZH2 pathway is significantly upregulated in the PCs of CLL/SLL lymph nodes, providing further evidence for the distinguished biological features of the PCs.	[Szurian, Kinga; Marosvari, Dora; Rajnai, Hajnalka; Derso, Katalin; Matolcsy, Andras; Reiniger, Lilla] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary; [Csala, Iren] Semmelweis Univ, Inst Behav Sci, Budapest, Hungary; [Bodor, Csaba] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, MTA SE Lendulet Mol Oncohematol Res Grp, Budapest, Hungary; [Piurko, Violetta; Reiniger, Lilla] Semmelweis Univ, Dept Pathol 2, Budapest, Hungary; [Reiniger, Lilla] Hungarian Acad Sci, Brain Metastasis Res Grp, MTA SE NAP, Budapest, Hungary	Reiniger, L (reprint author), Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary.	reiniger.lilla@med.semmelweis-univ.hu	Bodor, Csaba/O-4524-2017	Bodor, Csaba/0000-0002-0729-692X	Hungarian National Research, Development and Innovation Office (NFKIH) [NVKP_16-1-2016-0004]; Hungarian Science FoundationOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [OTKA-PD115792, OTKA-K116151]; Hungarian Brain Research Program [2017-1.2.1-NKP-2017-00002]; Hungarian Academy of SciencesHungarian Academy of Sciences [LP-95021]	This work was supported by the Hungarian National Research, Development and Innovation Office (NFKIH) (Grant number: NVKP_16-1-2016-0004); the Hungarian Science Foundation (Grant numbers: OTKA-PD115792 and OTKA-K116151).; L.R. is funded by Hungarian Brain Research Program (Grant number: 2017-1.2.1-NKP-2017-00002); C.B is funded by the Hungarian Academy of Sciences (Grant number: LP-95021).	Balogh Z, 2011, LEUKEMIA LYMPHOMA, V52, P1080, DOI 10.3109/10428194.2011.555889; Beguelin W, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01029-x; Benetatos L, 2014, CELL MOL LIFE SCI, V71, P257, DOI 10.1007/s00018-013-1426-x; Bodor C, 2011, LEUKEMIA, V25, P726, DOI 10.1038/leu.2010.311; Bonato M, 1998, AM J SURG PATHOL, V22, P49, DOI 10.1097/00000478-199801000-00006; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Ciccone M, 2012, LEUKEMIA, V26, P499, DOI 10.1038/leu.2011.247; Coe BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071670; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Gibson SE, 2016, BRIT J HAEMATOL, V175, P173, DOI 10.1111/bjh.13844; Gine E, 2010, HAEMATOL-HEMATOL J, V95, P1526, DOI 10.3324/haematol.2010.022277; Gradowski JF, 2012, AM J CLIN PATHOL, V138, P132, DOI 10.1309/AJCPIVKZRMPF93ET; Kanduri M, 2013, EPIGENETICS-US, V8, P1280, DOI 10.4161/epi.26546; Kopparapu PK, 2016, EPIGENETICS-US, V11, P335, DOI 10.1080/15592294.2016.1164375; Lund K, 2014, LEUKEMIA, V28, P44, DOI 10.1038/leu.2013.288; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Papakonstantinou N, 2016, ONCOTARGET, V7, P35946, DOI 10.18632/oncotarget.9371; Papakonstantinou N, 2013, MOL MED, V19, P115, DOI 10.2119/molmed.2013.00005; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rabello DD, 2015, BLOOD CELL MOL DIS, V54, P97, DOI 10.1016/j.bcmd.2014.07.013; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Sander S, 2009, CELL CYCLE, V8, P556, DOI 10.4161/cc.8.4.7599; Schuh A, 2012, BLOOD, V120, P4191, DOI 10.1182/blood-2012-05-433540; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Swerdlow SH, 2017, WHO CLASSIFICATION T, V2; Szurian K, 2017, LEUKEMIA RES, V58, P39, DOI 10.1016/j.leukres.2017.04.002; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Wang M, 2008, J PATHOL, V215, P13, DOI 10.1002/path.2333; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94	33	1	1	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					161	165		10.1016/j.yexmp.2018.07.009			5	Pathology	Pathology	GW8NM	WOS:000447235600001	30031020				2019-10-28	
J	Chistiakov, DA; Chekhonin, VP				Chistiakov, Dimitry A.; Chekhonin, Vladimir P.			Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Circulating tumor cells; Epithelial-to-mesenchymal transition; Dormancy; Metastasis; Enrichment techniques; Glioblastoma multiforme	EPITHELIAL-MESENCHYMAL TRANSITION; NEURAL STEM-CELLS; NF-KAPPA-B; BREAST-CANCER; PROGNOSTIC VALUE; PERIPHERAL-BLOOD; MOLECULAR CHARACTERIZATION; TGF-BETA; MICROENVIRONMENTAL REGULATION; CLINICAL-IMPLICATIONS	In the late stages of their development, cancers can form metastases. Formation of metastases was found to be associated with the capacity of cancer cells to quit the tumor mass and journey through the circulation to distant organs. This cell population is called circulating tumor cells (CTCs). They exhibit several advanced properties such as epithelial-to-mesenchymal transition (EMT) and dormancy that are essential for supporting their survival in the bloodstream, radio- and chemoresistance, their escape from the anti-cancer immune response, and metastasis initiation. CTCs, and especially dormant tumor cells, are responsible for post-surgery tumor recurrence. CTCs were detected in the blood of patients affected with glioblastoma multiforme (GBM)-the most frequent, invasive, and deadly neoplasm among primary brain tumors. The identification of glioblastoma CTCs might have a promising clinical potential for early tumor diagnosis and prognosis. A variety of CTC enrichment and detection techniques have been developed to date. For several epithelial cancers, especially for breast carcinoma, a prognostic value of CTCs was reported. Similar efforts should be performed for GBM to evaluate clinical the significance of CTCs.	[Chistiakov, Dimitry A.; Chekhonin, Vladimir P.] VP Serbsky Fed Med Res Ctr Psychiat & Narcol, Dept Basic & Appl Neurobiol, Kropotkinsky Pereulok 23, Moscow 119991, Russia; [Chekhonin, Vladimir P.] NI Pirogov Russian State Med Univ RSMU, Dept Med Nanobiotechnol, Ulitsa Ostrovityanova 1, Moscow 117997, Russia	Chistiakov, DA (reprint author), VP Serbsky Fed Med Res Ctr Psychiat & Narcol, Dept Basic & Appl Neurobiol, Kropotkinsky Pereulok 23, Moscow 119991, Russia.	dimitry.chistiakov@gmail.com		Chekhonin, Vladimir P./0000-0003-4386-7897; Chistiakov, Dimitry/0000-0001-9869-3607			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Adamczyk LA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00174; Aggarwal C, 2013, ANN ONCOL, V24, P420, DOI 10.1093/annonc/mds336; Aguirre-Ghiso JA, 2004, CANCER RES, V64, P7336, DOI 10.1158/0008-5472.CAN-04-0113; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Alix-Panabieres Catherine, 2012, Recent Results Cancer Res, V195, P69, DOI 10.1007/978-3-642-28160-0_6; Amato RJ, 2013, UROLOGY, V81, P1303, DOI 10.1016/j.urology.2012.10.041; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Balbous A, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.5; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Barradas Ana M C, 2013, Cancers (Basel), V5, P1619, DOI 10.3390/cancers5041619; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chang K, 2015, ONCOTARGET, V6, P41825, DOI 10.18632/oncotarget.6167; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Coumans FAW, 2012, CLIN CANCER RES, V18, P5711, DOI 10.1158/1078-0432.CCR-12-1585; Crane CA, 2010, NEURO-ONCOLOGY, V12, P7, DOI 10.1093/neuonc/nop009; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Engstrom PG, 2012, GENOME MED, V4, DOI 10.1186/gm377; Gao XL, 2017, ONCOTARGETS THER, V10, P5219, DOI 10.2147/OTT.S140854; Gascoyne PRC, 2014, CANCERS, V6, P545, DOI 10.3390/cancers6010545; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Goffart N, 2015, NEURO-ONCOLOGY, V17, P81, DOI 10.1093/neuonc/nou144; Goodman OB, 2011, CLIN GENITOURIN CANC, V9, P31, DOI 10.1016/j.clgc.2011.04.001; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Grover PK, 2014, ANN ONCOL, V25, P1506, DOI 10.1093/annonc/mdu018; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Han SP, 2011, CELL MOL NEUROBIOL, V31, P489, DOI 10.1007/s10571-010-9643-4; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; Hou HW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01259; Howard EW, 2008, CLIN EXP METASTAS, V25, P497, DOI 10.1007/s10585-008-9157-3; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Hvichia GE, 2016, INT J CANCER, V138, P2894, DOI 10.1002/ijc.30007; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Islam SS, 2016, MOL CARCINOGEN, V55, P537, DOI 10.1002/mc.22300; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jackson EL, 2008, CELLS TISSUES ORGANS, V188, P212, DOI 10.1159/000114541; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698; Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010; Joseph JV, 2013, BIOCHEM PHARMACOL, V85, P478, DOI 10.1016/j.bcp.2012.11.005; Karabacak NM, 2014, NAT PROTOC, V9, P694, DOI 10.1038/nprot.2014.044; Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0; Kim Yong-Nyun, 2012, Int J Cell Biol, V2012, P306879, DOI 10.1155/2012/306879; Kleffel S, 2013, ADV EXP MED BIOL, V734, P145, DOI 10.1007/978-1-4614-1445-2_8; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Krishnamurthy S, 2010, CANCER-AM CANCER SOC, V116, P3330, DOI 10.1002/cncr.25145; Kuhnol CD, 2017, ONCOL LETT, V13, P3882, DOI 10.3892/ol.2017.5875; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lalmahomed ZS, 2015, BRIT J CANCER, V112, P556, DOI 10.1038/bjc.2014.651; Lawton CD, 2012, J NEUROSURG-SPINE, V17, P438, DOI 10.3171/2012.7.SPINE12212; Li XX, 2008, J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu L, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0305-z; Lombard A, 2015, STEM CELLS INT, DOI 10.1155/2015/182985; Lopez-Gines C, 2005, CLIN NEUROPATHOL, V24, P209; Lou XL, 2015, CHINESE J CANCER RES, V27, P450, DOI 10.3978/j.issn.1000-9604.2015.04.10; Lowes LE, 2014, CANCERS, V6, P595, DOI 10.3390/cancers6010595; Lu YJ, 2016, ONCOTARGET, V7, P37361, DOI 10.18632/oncotarget.8156; Lustberg MB, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3622; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Lv Q, 2016, CLIN TRANSL ONCOL, V18, P322, DOI 10.1007/s12094-015-1372-1; MacArthur KM, 2014, CANCER RES, V74, P2152, DOI 10.1158/0008-5472.CAN-13-0813; Maitah MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016068; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague Joan, 2003, Clin Adv Hematol Oncol, V1, P576; McInnes LM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00042; Moore N, 2012, STEM CELLS DEV, V21, P1822, DOI 10.1089/scd.2011.0477; Moro N, 2014, EUR J CELL BIOL, V93, P23, DOI 10.1016/j.ejcb.2014.01.002; Motta FJN, 2008, GENET MOL RES, V7, P295, DOI 10.4238/vol7-2gmr424; Muller C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009095; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Neves RPL, 2014, CLIN CHEM, V60, P1290, DOI 10.1373/clinchem.2014.222331; Nieswandt B, 1999, CANCER RES, V59, P1295; Ortensi B, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt166; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616; Patel SA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00906; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pierga JY, 2013, ANN ONCOL, V24, P2999, DOI 10.1093/annonc/mdt348; Purkait S, 2016, BRAIN TUMOR PATHOL, V33, P183, DOI 10.1007/s10014-016-0251-y; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695; ROSS AA, 1993, BLOOD, V82, P2605; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sakariassen PO, 2007, NEOPLASIA, V9, P882, DOI 10.1593/neo.07658; Saliba AE, 2010, P NATL ACAD SCI USA, V107, P14524, DOI 10.1073/pnas.1001515107; Sandberg CJ, 2013, EXP CELL RES, V319, P2230, DOI 10.1016/j.yexcr.2013.06.004; Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105; Shiomi-Mouri Y, 2016, BREAST CANCER-TOKYO, V23, P120, DOI 10.1007/s12282-014-0539-x; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sobrado VR, 2009, J CELL SCI, V122, P1014, DOI 10.1242/jcs.028241; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Sullivan JP, 2014, CANCER DISCOV, V4, P1299, DOI 10.1158/2159-8290.CD-14-0471; Sun SQ, 2013, J CANCER RES THER, V9, pS150, DOI 10.4103/0973-1482.122510; Takano S, 2010, J ONCOL, DOI 10.1155/2010/351908; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Talasaz AH, 2009, P NATL ACAD SCI USA, V106, P3970, DOI 10.1073/pnas.0813188106; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; VERTOSICK FT, 1990, NEUROSURGERY, V27, P516, DOI 10.1227/00006123-199010000-00002; Wang CH, 2017, CLIN BREAST CANCER, V17, P341, DOI 10.1016/j.clbc.2017.02.002; Wang H, 2013, EUR J PHARMACOL, V714, P48, DOI 10.1016/j.ejphar.2013.05.046; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Watanabe M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-143; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; White DE, 2006, CELL CYCLE, V5, P1756, DOI 10.4161/cc.5.16.2993; Wong TS, 2014, BIOMED RES INT, DOI 10.1155/2014/921564; Wu WS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18101-7; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00144; Xu CH, 2016, TUMOR BIOL, V37, P6091, DOI 10.1007/s13277-015-4481-0; Yan XW, 2011, P NATL ACAD SCI USA, V108, P1591, DOI 10.1073/pnas.1018696108; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang LL, 2012, CLIN CANCER RES, V18, P5701, DOI 10.1158/1078-0432.CCR-12-1587; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	138	4	4	2	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					166	174		10.1016/j.yexmp.2018.07.007			9	Pathology	Pathology	GW8NM	WOS:000447235600002	30028961				2019-10-28	
J	Ciriello, J; Tatomir, A; Hewes, D; Boodhoo, D; Anselmo, F; Rus, V; Rus, H				Ciriello, Jonathan; Tatomir, Alexandru; Hewes, Daniel; Boodhoo, Dallas; Anselmo, Freidrich; Rus, Violeta; Rus, Horea			Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						SIRT1; PBMCs; Multiple sclerosis; Histone trimethylation; Glatiramer acetate; Biomarker	CELL-CYCLE; METHYLATION; ENCEPHALOMYELITIS; DEACETYLATION; TRANSCRIPTION; ACTIVATION; REPRESSION; APOPTOSIS; SIRTUINS; TARGETS	We have previously shown that SIRT1 mRNA expression was significantly lower in relapsing MS patients compared to those in remission. Our goal was to longitudinally investigate the role of active, phosphorylated SIRT1 (p-SIRT1) as a potential biomarker of relapse and predictor for response to glatiramer acetate (GA) treatment in patients with relapsing remitting multiple sclerosis (MS). We also want to investigate the downstream effects of SIRT1 activation by measuring the trimethylation of histone 3 at lysine 9 (H3K9me3). A cohort of 15 GA-treated patients was clinically monitored using the Expanded Disability Status Scale (EDSS) and peripheral blood mononuclear cells (PBMCs) were collected at 0, 3, 6, and 12 months after initiation of the therapy. P-SIRT1 and H3K9me3 levels were assayed by Western blotting using specific antibodies. Statistically significant lower levels of p-SIRT1 protein (p < 0.0001) and H3K9me3 (p = 0.001) were found during relapses when compared to stable MS patients. Non-responders to GA treatment were defined as patients who exhibited at least two relapses following initiation of GA treatment. Statistically significant lower levels of p-SIRT1 protein (p = 0.02) and H3K9me3 (p = 0.004) were found in GA non-responders compared to responders. Using receiver operating characteristic analysis, area under the curve (AUC) for p-SIRT1 was 77% (p = 0.007) and for H3K9me3 was 81% (p = 0.002) for prediction of relapse. For predicting responsiveness to GA treatment, AUC was 75% (P = 0.01) for H3K9me3. Our data suggest that p-SIRT1 and H3K9me3 could serve as potential biomarkers for MS relapse. In addition, H3K9me3 could serve as possible biomarker to predict response to GA treatment.	[Ciriello, Jonathan; Tatomir, Alexandru; Hewes, Daniel; Boodhoo, Dallas; Anselmo, Freidrich; Rus, Horea] Univ Maryland, Sch Med, Dept Neurol, 655 W Baltimore St,BRB 12-033, Baltimore, MD 21201 USA; [Rus, Violeta] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA; [Rus, Violeta; Rus, Horea] Vet Adm Maryland Hlth Care Syst, Res Serv, Baltimore, MD USA; [Rus, Horea] Vet Adm Multiple Sclerosis Ctr Excellence East, Baltimore, MD USA	Rus, H (reprint author), Univ Maryland, Sch Med, Dept Neurol, 655 W Baltimore St,BRB 12-033, Baltimore, MD 21201 USA.	hrus@umaryland.edu			Teva Neuroscience grant [CNS-2014-175]; Veterans Administration Merit Award [I01BX001458]; Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future program; University of Maryland, School of Medicine Office of Student Research; Leslie B. Barnett Memorial Student Fellowship; University of Maryland School of Medicine Office of Student Research	We thank Dr. Deborah McClellan for editing this manuscript. This work was supported in part by a Teva Neuroscience grant CNS-2014-175 (to H.R.) and a Veterans Administration Merit Award I01BX001458 (to H.R.). Jonathan Ciriello was supported in part by a medical student research grant from the Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future program, the University of Maryland, School of Medicine Office of Student Research and the Leslie B. Barnett Memorial Student Fellowship. Daniel Hewes was supported in part by a medical student research grant from the Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future program and by the University of Maryland, School of Medicine Office of Student Research. Freidrich Anselmo was supported in part by the University of Maryland School of Medicine Office of Student Research.	Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Feige JN, 2008, CURR OPIN CELL BIOL, V20, P303, DOI 10.1016/j.ceb.2008.03.012; Flick F, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00029; Fonseca-Kelly Zoe, 2012, Front Neurol, V3, P84, DOI 10.3389/fneur.2012.00084; Graves MC, 2014, MULT SCLER J, V20, P1033, DOI 10.1177/1352458513516529; Guarente L, 2011, NEW ENGL J MED, V364, P2235, DOI 10.1056/NEJMra1100831; Hewes D, 2017, EXP MOL PATHOL, V102, P191, DOI 10.1016/j.yexmp.2017.01.014; Imler TJ, 2009, INT IMMUNOPHARMACOL, V9, P134, DOI 10.1016/j.intimp.2008.10.015; Johnson KP, 2012, EXPERT REV NEUROTHER, V12, P371, DOI [10.1586/ERN.12.25, 10.1586/ern.12.25]; Khan RS, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00063; Kulakova OG, 2016, ACTA NATURAE, V8, P103, DOI 10.32607/20758251-2016-8-3-103-110; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Nimmagadda VK, 2013, J IMMUNOL, V190, P4595, DOI 10.4049/jimmunol.1202584; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Shindler KS, 2010, J NEURO-OPHTHALMOL, V30, P328, DOI 10.1097/WNO.0b013e3181f7f833; Singh NP, 2007, MOL PHARMACOL, V72, P1508, DOI 10.1124/mol.107.038984; Tegla CA, 2015, EXP MOL PATHOL, V98, P328, DOI 10.1016/j.yexmp.2015.03.011; Tegla CA, 2014, EXP MOL PATHOL, V96, P139, DOI 10.1016/j.yexmp.2013.12.010; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Webb LM, 2017, TRENDS MOL MED, V23, P546, DOI 10.1016/j.molmed.2017.04.004; Yang G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14941; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang JN, 2009, J CLIN INVEST, V119, P3048, DOI 10.1172/JCI38902	29	3	3	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					175	180		10.1016/j.yexmp.2018.07.008			6	Pathology	Pathology	GW8NM	WOS:000447235600003	30028960				2019-10-28	
J	Dencic, TI; Bartolome, A; Selemetjev, S; Doric, I; Tatic, S; Zivaljevic, V; Cvejic, D				Dencic, Tijana Isic; Bartolome, Aleksandar; Selemetjev, Sonja; Doric, Ilona; Tatic, Svetislav; Zivaljevic, Vladan; Cvejic, Dubravka			High expression and localization of beta-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Papillary thyroid carcinoma; beta-Catenin; Epidermal growth factor receptor; Predictive biomarker; Risk stratification	CLINICOPATHOLOGICAL PARAMETERS; BRAF MUTATION; E-CADHERIN; OVEREXPRESSION; CONVERGENCE; MARKERS; WNT	We have evaluated the clinical significance of deregulated expression of beta-catenin and epidermal growth factor receptor (EGFR) during papillary thyroid carcinoma (PTC) progression. Immunohistochemical expression of beta-catenin and EGFR was analyzed in 104 archival tissues of PTC and 19 matched lymph node metastases (LNMs). beta-catenin (39/104, 37.5%) and EGFR (58/104, 55.7%) were co-expressed and co-localized in primary PTCs (p < .0001), which was confirmed by double immunofluorescent staining. The high expression of each molecule, as well as their high cytosolic co-expression, correlated with adverse clinicopathological features of the patients (p < .05). High expression of the proteins did not associate with the presence of BRAFV600E mutation (p > .05), tested by mutant allele-specific PCR amplification. Although nuclear localization of beta-catenin was found in a subset of PTC patients (16/104, 15.4%), no beta-catenin mutations were found in exon 3 of the CTNNB1 gene (screened by PCR in combination with denaturing gradient gel electrophoresis and confirmed by next generation sequencing). Cases with additional nuclear beta-catenin staining showed strong association with high EGFR expression (15/16, 93.7%), the presence of capsule invasion (12/16, 81.25%) and regional LNM (9/16, 52.3%). In corresponding LNMs, beta-catenin and EGFR expressions were maintained at high levels or further increased. Co-expression of high levels of beta-catenin and EGFR in association with clinicopathological features implicates their clinical utility in risk stratification of PTC patients, and supports the possibility of crosstalk between Wnt/beta-catenin and EGFR signaling during PTC progression.	[Dencic, Tijana Isic; Bartolome, Aleksandar; Selemetjev, Sonja; Doric, Ilona; Cvejic, Dubravka] Univ Belgrade, Dept Endocrinol & Radioimmunol, Inst Applicat Nucl Energy INEP, Banatska 31b, Belgrade, Serbia; [Tatic, Svetislav] Univ Belgrade, Inst Pathol, Fac Med, Belgrade, Serbia; [Zivaljevic, Vladan] Clin Ctr Serbia, Inst Endocrinol Diabet & Dis Metab, Ctr Endocrine Surg, Belgrade, Serbia; [Bartolome, Aleksandar] Fritz Lipmann Inst FLI, Leibniz Inst Aging, Jena, Germany	Dencic, TI (reprint author), Univ Belgrade, Dept Endocrinol & Radioimmunol, Inst Applicat Nucl Energy INEP, Banatska 31b, Belgrade, Serbia.	tijana@inep.co.rs		Isic Dencic, Tijana/0000-0001-8475-2266	Ministry of Education, Science and Technological Development, Republic of Serbia [173050]	This study was supported by grant no. 173050 from the Ministry of Education, Science and Technological Development, Republic of Serbia.	Abbosh PH, 2005, THYROID, V15, P551, DOI 10.1089/thy.2005.15.551; Bartolome A, 2016, APMIS, V124, P271, DOI 10.1111/apm.12505; Basolo F, 2010, J CLIN ENDOCR METAB, V95, P4197, DOI 10.1210/jc.2010-0337; Bhaijee F, 2011, ENDOCR PATHOL, V22, P126, DOI 10.1007/s12022-011-9170-y; Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; CLEVERS H, 2012, CELL, V13, P149; Edge S. B., 2010, REVIEW, P87; EDGE SB, 2010, SPRINGER, V7, P87; Elliott DD, 2008, HUM PATHOL, V39, P15, DOI 10.1016/j.humpath.2007.05.012; Fisher KE, 2013, J SURG RES, V185, P217, DOI 10.1016/j.jss.2013.05.003; Fujimoto J, 1997, EUR J GYNAECOL ONCOL, V18, P484; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Guan CN, 2012, ASIAN PAC J CANCER P, V13, P677, DOI 10.7314/APJCP.2012.13.1.677; Hu T., 2010, J BIOL CHEM, V9, P236; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Landriscina M, 2011, THYROID, V21, P1227, DOI 10.1089/thy.2011.0172; Latasa MU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052711; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; LIVOLSI VA, 2004, WHO CLASSIFICATION T, P50; Lou PJ, 1999, ONCOL REP, V6, P1065; Moon HS, 2001, GYNECOL ONCOL, V81, P355, DOI 10.1006/gyno.2001.6163; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Paskas S, 2014, OTOLARYNG HEAD NECK, V150, P201, DOI 10.1177/0194599813512781; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Schmid K, 2009, CLIN CANCER RES, V15, P4554, DOI 10.1158/1078-0432.CCR-09-0089; Sethi Kruttibas, 2011, J Exp Ther Oncol, V9, P187; Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687; Stojiljkovic M, 2006, CLIN GENET, V70, P151, DOI 10.1111/j.1399-0004.2006.00650.x; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xu HT, 2011, APMIS, V119, P750, DOI 10.1111/j.1600-0463.2011.02799.x; Yarden Y, 2001, EUR J CANCER, V37, pS3	35	0	0	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					181	189		10.1016/j.yexmp.2018.08.001			9	Pathology	Pathology	GW8NM	WOS:000447235600004	30077672				2019-10-28	
J	Orekhov, AN; Pushkarsky, T; Oishi, Y; Nikiforov, NG; Zhelankin, AV; Dubrovsky, L; Makeev, VJ; Foxx, K; Jin, XT; Kruth, HS; Sobenin, IA; Sukhorukov, VN; Zakiev, ER; Kontush, A; Le Goff, W; Bukrinsky, M				Orekhov, Alexander N.; Pushkarsky, Tatiana; Oishi, Yumiko; Nikiforov, Nikita G.; Zhelankin, Andrey V.; Dubrovsky, Larisa; Makeev, Vsevolod J.; Foxx, Kathy; Jin, Xueting; Kruth, Howard S.; Sobenin, Igor A.; Sukhorukov, Vasily N.; Zakiev, Emile R.; Kontush, Anatol; Le Goff, Wilfried; Bukrinsky, Michael			HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						HDL; Monocyte-derived macrophages; Cholesterol efflux; Transcriptome analysis; Lipid metabolism; Atherosclerosis	HIGH-DENSITY-LIPOPROTEIN; CELLULAR LIPID EFFLUX; APOLIPOPROTEIN-A-I; B TYPE-I; SCAVENGER RECEPTOR; PHOSPHOLIPID EFFLUX; ANALYSIS REVEALS; APOA-I; SR-BI; BINDING	High density lipoproteins (HDL) are key components of reverse cholesterol transport pathway. HDL removes excessive cholesterol from peripheral cells, including macrophages, providing protection from cholesterol accumulation and conversion into foam cells, which is a key event in pathogenesis of atherosclerosis. The mechanism of cellular cholesterol efflux stimulation by HDL involves interaction with the ABCA1 lipid transporter and ensuing transfer of cholesterol to HDL particles. In this study, we looked for additional proteins contributing to HDL-dependent cholesterol efflux. Using RNAseq, we analyzed mRNAs induced by HDL in human monocyte-derived macrophages and identified three genes, fatty acid desaturase 1 (FADS1), insulin induced gene 1 (INSIG1), and the low-density lipoprotein receptor (LDLR), expression of which was significantly upregulated by HDL. We individually knocked down these genes in THP-1 cells using gene silencing by siRNA, and measured cellular cholesterol efflux to HDL. Knock down of FADS1 did not significantly change cholesterol efflux (p = 0.70), but knockdown of INSIG1 and LDLR resulted in highly significant reduction of the efflux to HDL (67% and 75% of control, respectively, p < 0.001). Importantly, the suppression of cholesterol efflux was independent of known effects of these genes on cellular cholesterol content, as cells were loaded with cholesterol using acetylated LDL. These results indicate that HDL particles stimulate expression of genes that enhance cellular cholesterol transfer to HDL.	[Orekhov, Alexander N.; Nikiforov, Nikita G.; Sobenin, Igor A.; Sukhorukov, Vasily N.; Zakiev, Emile R.] Inst Gen Pathol & Pathophysiol, Moscow, Russia; [Orekhov, Alexander N.] Skolkovo Innovat Ctr, Atherosclerosis Res Inst, Moscow, Russia; [Pushkarsky, Tatiana; Dubrovsky, Larisa; Bukrinsky, Michael] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Oishi, Yumiko] Tokyo Med & Dent Univ, Med Res Inst, Dept Cellular & Mol Med, Tokyo, Japan; [Nikiforov, Nikita G.; Sobenin, Igor A.] Natl Med Res Ctr Cardiol, Inst Expt Cardiol, Med Genet Lab, Moscow, Russia; [Zhelankin, Andrey V.] Fed Res & Clin Ctr Phys Chem Med, Lab Postgen Res, Moscow, Russia; [Makeev, Vsevolod J.] Russian Acad Sci, Vavilov Inst Gen Genet, Moscow, Russia; [Makeev, Vsevolod J.] Res Inst Genet & Select Ind Microorganisms, Kurchatov Inst, Ctr Sci, Moscow, Russia; [Makeev, Vsevolod J.] State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, Moscow Region, Russia; [Makeev, Vsevolod J.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Foxx, Kathy] Kalen Biomed LLC, Montgomery Village, MD USA; [Jin, Xueting; Kruth, Howard S.] NHLBI, Expt Atherosclerosis Sect, NIH, Bldg 10, Bethesda, MD 20892 USA; [Sukhorukov, Vasily N.; Zakiev, Emile R.; Kontush, Anatol; Le Goff, Wilfried] Sorbonne Univ, INSERM, ICAN, Hop Pitie,UMR S1166, Paris, France; [Nikiforov, Nikita G.] Russian Acad Sci, Inst Gene Biol, Moscow, Russia	Bukrinsky, M (reprint author), George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.	mbukrins@gwu.edu	Sobenin, Igor A/J-4282-2013; Le Goff, Wilfried/N-7593-2019; Le Goff, Wilfried/N-6326-2017; Sukhorukov, Vasily/H-6545-2016; Zhelankin, Andrey/F-8247-2014; Kontush, Anatol/J-2198-2016	Sobenin, Igor A/0000-0003-0978-6444; Le Goff, Wilfried/0000-0002-7611-9644; Le Goff, Wilfried/0000-0002-7611-9644; Sukhorukov, Vasily/0000-0002-0312-3773; Zhelankin, Andrey/0000-0002-3014-2005; 	Russian Science FoundationRussian Science Foundation (RSF) [14-15-00112]; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL101274, P30AI117970]	This work was supported by Russian Science Foundation (grant #14-15-00112, supported all experiments on cells and statistical analysis), INSERM and NIH (grants R01HL101274 and P30AI117970 supported work on study design, data interpretation, and manuscript preparation).	Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carobbio S, 2013, DIABETES, V62, P3697, DOI 10.2337/db12-1748; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Das A, 2014, ELIFE, V3, DOI 10.7554/eLife.02882; De Nardo D, 2014, NAT IMMUNOL, V15, P152, DOI 10.1038/ni.2784; Du XM, 2015, CIRC RES, V116, P1133, DOI 10.1161/CIRCRESAHA.116.305485; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fu Y, 2013, CELL METAB, V18, P225, DOI 10.1016/j.cmet.2013.07.003; Gelissen IC, 2006, ARTERIOSCL THROM VAS, V26, P534, DOI 10.1161/01.ATV.0000200082.58536.e1; Genest J, 2018, CURR OPIN LIPIDOL, V29, P36, DOI 10.1097/MOL.0000000000000470; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Kannan Y, 2012, J BIOL CHEM, V287, P23479, DOI 10.1074/jbc.M111.320960; Kim WS, 2005, J BIOL CHEM, V280, P3989, DOI 10.1074/jbc.M412602200; Kockx M, 2008, ARTERIOSCL THROM VAS, V28, P1060, DOI 10.1161/ATVBAHA.108.164350; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI14011; Larrede S, 2009, ARTERIOSCL THROM VAS, V29, P1930, DOI 10.1161/ATVBAHA.109.194548; Lee SD, 2015, ATHEROSCLEROSIS, V242, P29, DOI 10.1016/j.atherosclerosis.2015.06.042; Lin CY, 1999, J LIPID RES, V40, P1618; Lin J, 2016, ARTERIOSCL THROM VAS, V36, P1434, DOI 10.1161/ATVBAHA.116.307573; Linsel-Nitschke P, 2005, J LIPID RES, V46, P86, DOI 10.1194/jlr.M400247-JLR200; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; Loewen CJR, 2002, CURR BIOL, V12, pR779, DOI 10.1016/S0960-9822(02)01292-7; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mendelson K, 2014, DEVELOPMENT, V141, P5, DOI 10.1242/dev.094805; Mineo C, 2013, J LIPID RES, V54, P2315, DOI 10.1194/jlr.R039479; Mukhamedova N, 2007, BIOCHEMISTRY-US, V46, P9388, DOI 10.1021/bi700473t; Nagao K, 2012, BBA-MOL CELL BIOL L, V1821, P530, DOI 10.1016/j.bbalip.2011.06.024; Nofer JR, 2015, HANDB EXP PHARMACOL, V224, P229, DOI 10.1007/978-3-319-09665-0_6; Oram JF, 2001, J LIPID RES, V42, P1173; Phillips MC, 2018, J LIPID RES, V59, P749, DOI 10.1194/jlr.R082313; Phillips MC, 2014, J BIOL CHEM, V289, P24020, DOI 10.1074/jbc.R114.583658; Qian HW, 2017, CELL, V169, P1228, DOI 10.1016/j.cell.2017.05.020; Qin XM, 2008, HEPATOLOGY, V48, P432, DOI 10.1002/hep.22334; Rodrigue-Way A, 2014, FASEB J, V28, P1910, DOI 10.1096/fj.13-240168; Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shen WJ, 2018, ANNU REV PHYSIOL, V80, P95, DOI 10.1146/annurev-physiol-021317-121550; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; van der Vorst EPC, 2017, CELL METAB, V25, P197, DOI 10.1016/j.cmet.2016.10.013; Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200; Vergeer M, 2011, NEW ENGL J MED, V364, P136, DOI 10.1056/NEJMoa0907687; Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang X, 2007, J CLIN INVEST, V117, P2216, DOI 10.1172/JCI32057; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Zhang Y, 2016, INT J BIOL SCI, V12, P569, DOI 10.7150/ijbs.14027; Zybarth G, 1999, J IMMUNOL, V162, P400	53	1	1	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					202	207		10.1016/j.yexmp.2018.08.003			6	Pathology	Pathology	GW8NM	WOS:000447235600006	30118702				2019-10-28	
J	Jia, XY; Yao, LM; Zhou, Y; Han, H; Tang, N; Wang, LR; Li, Y				Jia, Xingyuan; Yao, Limei; Zhou, Yan; Han, Han; Tang, Ning; Wang, Lirong; Li, Ying			Detection of three common mutations causing beta-thalassemia by using a closed-tube multiplex PCR	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Thalassemia; Point mutation; PCR; Molecular diagnosis	DISSOCIATION CURVE ANALYSIS; ALPHA-THALASSEMIA; CHINA	Small oligonucleotides mutations are the large majority causes of A-thalassemia. Dual priming oligonucleotide PCR has been used to detect point mutations and thus could be applied to diagnose A-thalassemia. The goal of this study was to establish a simple, quick and cost-effective screening assay by using modified dual priming oligonucleotide PCR for three most common mutations of 13-thalassemia [CD71-72 (+A), CD 41-42 (-CTTT), Pnt.-28 (A -> G)] in Southeast Asia and southern China. Man-made 5 tandem mismatched bases instead of poly (I) were used as the linker in the specific PCR primers. Single closed-tube multiplex PCRs followed by dissociation curve (DC) analysis were included in the molecular screening assay. Denaturing high-performance liquid chromatography analysis was applied to distinguish compound heterozygotes from single mutations. A blinded study of 91 samples was performed using this new assay. There were 41 samples detected as the above three mutations and it was concordant with the original methods. In conclusion, the modified dual priming oligonucleotide multiplex PCR/DC can detect these three genotypes of common mutation of 13-thalassemia; this method is simple, rapid and cost-effective, which makes it suitable for large-scale screening and diagnosis.	[Jia, Xingyuan; Zhou, Yan; Han, Han; Li, Ying] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, 8 GongTiNan St, Beijing 100020, Peoples R China; [Yao, Limei] Xingtai Peoples Hosp, Dept Internal Med, Xingtai 054001, Peoples R China; [Tang, Ning] Liuzhou Municipal Matern & Child Healthcare Hosp, Liuzhou 545001, Peoples R China; [Wang, Lirong] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Wang, Lirong] Peking Union Med Coll, Beijing 100730, Peoples R China	Jia, XY (reprint author), Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, 8 GongTiNan St, Beijing 100020, Peoples R China.	jiaxy@hotmail.com			Natural Science Foundation of Beijing, ChinaBeijing Natural Science Foundation [JS96004]	We thank Prof. Jingzhong Liu for his initiating the research. This work was financially supported by Grant JS96004 from the Natural Science Foundation of Beijing, China.	Chun JY, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm051; Jia XY, 2011, EXP MOL PATHOL, V91, P626, DOI 10.1016/j.yexmp.2011.06.013; Jia XY, 2011, EXP MOL PATHOL, V91, P429, DOI 10.1016/j.yexmp.2011.04.013; Li CG, 2009, HEMOGLOBIN, V33, P296, DOI [10.1080/03630260903211698, 10.3109/03630260903211698]; Liu JZ, 2006, TRANSL RES, V148, P6, DOI 10.1016/j.lab.2006.03.016; Origa R, 2017, GENET MED, V19, P609, DOI 10.1038/gim.2016.173; Shang X, 2017, BEST PRACT RES CL OB, V39, P3, DOI 10.1016/j.bpobgyn.2016.10.012; Xu LH, 2013, HEMOGLOBIN, V37, P307, DOI 10.3109/03630269.2013.789967	8	0	0	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					208	212		10.1016/j.yexmp.2018.08.005			5	Pathology	Pathology	GW8NM	WOS:000447235600007	30118703				2019-10-28	
J	Cohn, M				Cohn, Melvin			Exploring the elements for a successful immune offense against cancer	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Immune response; Cancer; Cytotoxic T-cell; Helper T-cell; Engineering epitopes	SELF-NONSELF DISCRIMINATION; PATHWAYS	A successful immune attack on a tumor requires two elements. First, a nonself (NS) epitope that can act as an effective target must be expressed uniquely and uniformly on the tumor. Second, the immune system must be induced to produce an appropriate ridding effector activity specific for the cell expressing that de novo displayed NS-epitope. Today, the major effort is directed toward nonspecifically increasing the horsepower of the immune system by relieving suppressive and resistance factors using checkpoint blockade. This is coupled to the hope that the cancer will display a unique nonself determinant and that tolerance to Self (S) will not be abrogated. Here, these two elements will be explored in order to see what a more defined approach to the immune system treatment of cancer entails. While a Hail Mary approach may, in the end, be our only alternative, defining the elements of a solution, attainable or not, based on basic immunology, can only be salutary.	[Cohn, Melvin] Salk Inst Biol Studies, Conceptual Immunol Grp, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA	Cohn, M (reprint author), Salk Inst Biol Studies, Conceptual Immunol Grp, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cohn@salk.edu					Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Chambers B, 2007, CANCER RES, V67, P8450, DOI 10.1158/0008-5472.CAN-07-1092; COHN M, 1992, RES IMMUNOL, V143, P323, DOI 10.1016/S0923-2494(92)80132-5; Cohn M, 2005, SPRINGER SEMIN IMMUN, V27, P3, DOI 10.1007/s00281-005-0199-1; Cohn M, 2005, IMMUNOL RES, V31, P133, DOI 10.1385/IR:31:2:133; Cohn M, 2017, IMMUNOL RES, V65, P573, DOI 10.1007/s12026-017-8908-0; Cohn M, 2012, EXP MOL PATHOL, V93, P354, DOI 10.1016/j.yexmp.2012.08.001; Cohn M, 2011, IMMUNOL RES, V50, P49, DOI 10.1007/s12026-010-8173-y; FRANKSSON L, 1993, J EXP MED, V177, P201, DOI 10.1084/jem.177.1.201; Gromme M, 1997, EUR J IMMUNOL, V27, P898, DOI 10.1002/eji.1830270415; Lampen MH, 2010, J IMMUNOL, V185, P6508, DOI 10.4049/jimmunol.1001774; Lee CH, 2018, TRENDS IMMUNOL, V39, P536, DOI 10.1016/j.it.2018.04.005; McCluskey J, 2004, CURR OPIN IMMUNOL, V16, P651, DOI 10.1016/j.coi.2004.07.016; Oliveira CC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00298; Osorio F, 2018, CURR OPIN IMMUNOL, V52, P100, DOI 10.1016/j.coi.2018.04.020	15	0	0	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					213	215		10.1016/j.yexmp.2018.08.006			3	Pathology	Pathology	GW8NM	WOS:000447235600008	30130493				2019-10-28	
J	Yang, ZT; Zhang, CY; Qi, WB; Cui, CA; Cui, Y; Xuan, YH				Yang, Zhaoting; Zhang, Chengye; Qi, Wenbo; Cui, Chunai; Cui, Yan; Xuan, Yanhua			Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Tenascin-C; Epithelial mesenchymal transition; Prognosis; Colorectal cancer	POOR-PROGNOSIS; CELLS; CARCINOMA; MICROENVIRONMENT; FIBROBLASTS; EXPRESSION; MIGRATION; CYTOKINE; MARKER	Although Tenascin-C (TNC) as an extracellular matrix protein involved in various cancers, the mechanisms by which TNC leads to decreased survival time remain to be clarified in CRC. We assessed the expression of TNC and its relationship with cancer associated fibroblasts (CAFs) markers, epithelial-to-mesenchymal transition (EMT) and cell cycle markers in 100 paraffin-embedded CRC tissue samples using immunohistochemistry. TNC expression was higher in CRC tissue samples than in adjacent non-tumor-tissues (P <.001). In addition, TNC was involved in clinical stage (P =.030), pT stage (P =.049), distant metastasis (P =.004), tumor recurrence (P =.007), and tumor budding (P <.001). TNC play crucial roles in regulating the poor 5-year CRC survival rate by Kaplan-Meier analysis, and was an independent predictor of poor overall survival (P =.007) and disease free survival (P =.004) in CRC. Moreover, it was postively correlated with CAF (SMA (P <.001) and FSP1 (P =.005)) and cell cycle marker p27 (P =.013) along with EMT (E-cadherin, P =.599; Snail, P <.001; vimentin, P =.012). TNC may promote EMT-like change and proliferation, which lead to poor prognosis for patients with CRC.	[Yang, Zhaoting; Qi, Wenbo; Xuan, Yanhua] Yanbian Univ, Minist Educ, Key Lab Nat Resources Changbai Mt & Funct Mol, Yanji, Peoples R China; [Yang, Zhaoting; Zhang, Chengye; Qi, Wenbo; Cui, Chunai; Xuan, Yanhua] Yanbian Univ, Inst Regenerat Med, Coll Med, 977 Gongyuan Rd, Yanji 133002, Peoples R China; [Cui, Yan] Yanbian Univ, Affiliate Hosp, Dept Oncol, Yanji, Peoples R China	Xuan, YH (reprint author), Yanbian Univ, Inst Regenerat Med, Coll Med, 977 Gongyuan Rd, Yanji 133002, Peoples R China.	xuanyh1@ybu.edu.cn			National Natural Science Funds of ChinaNational Natural Science Foundation of China [81460390, 81760531, 81660687]; Science and Technology Development Plan of Jilin Province Fund of China [20160101151JC]	This study was supported by grants from National Natural Science Funds of China (No. 81460390, 81760531, 81660687) and Science and Technology Development Plan of Jilin Province Fund (20160101151JC) of China.	Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Donnarumma E, 2017, ONCOTARGET, V8, P19592, DOI 10.18632/oncotarget.14752; Gallagher DJ, 2010, CLIN COLORECTAL CANC, V9, P205, DOI 10.3816/CCC.2010.n.030; Garden OJ, 2006, GUT, V55, P1, DOI 10.1136/gut.2006.098053; Gurzu S, 2016, WORLD J GASTROENTERO, V22, P6764, DOI 10.3748/wjg.v22.i30.6764; Gurzu S, 2015, WORLD J CLIN CASES, V3, P393, DOI 10.12998/wjcc.v3.i5.393; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Ishigaki T, 2011, J CELL PHYSIOL, V226, P2617, DOI 10.1002/jcp.22614; Kartha VK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154645; Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27; Kwak JM, 2010, WORLD J GASTROENTERO, V16, P3897, DOI 10.3748/wjg.v16.i31.3897; Ni WD, 2017, BIOCHEM BIOPH RES CO, V486, P607, DOI 10.1016/j.bbrc.2017.03.021; Nong YH, 2015, AM J CANCER RES, V5, P782; O'Brien P, 2008, BBA-PROTEINS PROTEOM, V1784, P1130, DOI 10.1016/j.bbapap.2008.01.006; Rabeneck L, 2015, CANC DIS CONTROL PRI, V3, DOI 10.1596/978-1-4648-0349-9_ch6; Wei SC, 2016, TRENDS CELL BIOL, V26, P111, DOI 10.1016/j.tcb.2015.09.009; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang ZT, 2017, INT J CLIN EXP PATHO, V10, P139; Yang ZT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145807; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332	22	4	4	4	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	OCT	2018	105	2					216	222		10.1016/j.yexmp.2018.08.009			7	Pathology	Pathology	GW8NM	WOS:000447235600009	30170017				2019-10-28	
J	Garland, SM; Dimech, W; Collignon, P; Cooley, L; Nimmo, GR; Smith, DW; Baird, R; Rawlinson, W; Costa, AM; Higgins, G				Garland, Suzanne M.; Dimech, Wayne; Collignon, Peter; Cooley, Louise; Nimmo, Graeme R.; Smith, David W.; Baird, Rob; Rawlinson, William; Costa, Anna-Maria; Higgins, Geoff		Australian Clinical Microbiologist	The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						HPV; nucleic acid technology; quality control; quality assurance	YOUNG AUSTRALIAN WOMEN; VACCINATION; VALIDATION; COVERAGE; VALGENT; TESTS	Along with the reduction in human papillomavirus (HPV) infection and cervical abnormalities as a result of the successful HPV vaccination program, Australia is adopting a new screening strategy. This involves a new paradigm moving from cervical cytological screening to molecular nucleic acid technology (NAT), using HPV DNA assays as primary screening methodology for cervical cancer prevention. These assays must strike a balance between sufficient clinical sensitivity to detect or predict high-grade cervical intraepithelial lesions, the precursor to cervical cancer, without being too sensitive and detecting transient infection not destined for disease. Ensuring the highest quality HPV NAT is thus a priority in order to reduce the possibility of falsely negative screens and manage the risk associated with false positive HPV NAT test results. How to do this needs informed discussion and on-going refinement of the screening algorithm. This is of relevance as more countries move to more sensitive HPV NAT tests for secondary prevention of cervical cancer and as more HPV assays become available.	[Garland, Suzanne M.; Costa, Anna-Maria] Royal Womens Hosp, Dept Microbiol & Infect Dis, Locked Bag 300, Parkville, Vic 3052, Australia; [Garland, Suzanne M.] Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic, Australia; [Garland, Suzanne M.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic, Australia; [Dimech, Wayne] Natl Serol Reference Lab Australia NRL, Fitzroy, Vic, Australia; [Collignon, Peter] Canberra Hosp, Infect Dis & Microbiol, Garran, ACT, Australia; [Collignon, Peter] Australian Natl Univ, Med Sch, Canberra, ACT, Australia; [Cooley, Louise] Royal Hobart Hosp, Dept Microbiol & Infect Dis, Hobart, Tas, Australia; [Nimmo, Graeme R.] Pathol Queensland Cent Lab, Dept Microbiol, Herston, Qld, Australia; [Nimmo, Graeme R.] Griffith Univ, Sch Med, Dept Microbiol, Southport, Qld, Australia; [Smith, David W.] PathWest Lab Med WA, Dept Microbiol, Nedlands, WA, Australia; [Smith, David W.] Univ Western Australia, Fac Hlth & Med Sci, Nedlands, WA, Australia; [Baird, Rob] Royal Darwin Hosp, Dept Hlth & Families, Infect Dis, Terr Pathol, Tiwi, Australia; [Rawlinson, William] NSW Hlth Pathol, Virol Serol & OTDS Labs, Randwick, NSW, Australia; [Costa, Anna-Maria] Royal Childrens Hosp, Dept Microbiol, Parkville, Vic, Australia; [Higgins, Geoff; Australian Clinical Microbiologist] South Australia Pathol, Microbiol & Infect Dis, North Terrace, Adelaide, SA, Australia	Garland, SM (reprint author), Royal Womens Hosp, Dept Microbiol & Infect Dis, Locked Bag 300, Parkville, Vic 3052, Australia.	suzanne.garland@thewomens.org.au					Ali H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-140; [Anonymous], 2013, SCREENING NATL CERVI; [Anonymous], 2017, NATL CERVICAL SCREEN; [Anonymous], 2013, REQUIREMENTS MED TES; [Anonymous], 2011, AUSTR REGULATORY GUI; [Anonymous], 2017, REQUIREMENTS LAB REP; Arbyn M, 2016, J CLIN VIROL, V76, pS14, DOI 10.1016/j.jcv.2015.09.014; Brotherton JML, 2017, MED J AUSTRALIA, V206, P262, DOI 10.5694/mja16.00958; Brotherton JML, 2016, MED J AUSTRALIA, V204, P184, DOI 10.5694/mja15.01038; Brotherton JML, 2014, VACCINE, V32, P592, DOI 10.1016/j.vaccine.2013.11.075; Canfell K, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002388; Costa AM, 2018, PATHOLOGY; Cuschieri K, 2018, INT J CANCER, V143, P735, DOI 10.1002/ijc.31261; Cuschieri K, 2016, J CLIN MICROBIOL, V54, P2337, DOI 10.1128/JCM.00897-16; Denham O, 2016, J FAM MED PREV, V2, P41; Dimech W, 2015, CLIN CHEM LAB MED, V53, P329, DOI 10.1515/cclm-2014-0546; Framework for the Execution of Cervical Cancer Population Screening National Institute for Public Health and the Environment (RIVM), 2017, FRAMEWORK EXECUTION; Franceschi S, 2011, INT J CANCER, V128, P2765, DOI 10.1002/ijc.25915; Garland SM, 2018, VACCINE, V36, P3221, DOI 10.1016/j.vaccine.2018.04.080; Garland SM, 2011, PREV MED, V53, pS29, DOI 10.1016/j.ypmed.2011.08.015; Garland SM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-104; Gertig DM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-227; Jayasinghe Y, 2016, J CLIN VIROL, V76, pS74, DOI 10.1016/j.jcv.2015.10.026; Machalek DA, 2017, J INFECT DIS, V215, P202, DOI 10.1093/infdis/jiw530; Meijer CJLM, 2009, INT J CANCER, V124, P516, DOI 10.1002/ijc.24010; Michalas SP, 1928, EUR J OBSTET GYN R B, V90, P135; National HPV Vaccination Program Register, 2017, NATL HPV VACCINATION; Poljak M, 2016, J CLIN VIROL, V76, pS3, DOI 10.1016/j.jcv.2015.10.023; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2; US Preventive Services Task Force, 2017, DRAFT REC STAT CERV; Walker S, 2009, VOX SANG, V97, P309, DOI 10.1111/j.1423-0410.2009.01218.x; Yap D, 2016, J CLIN VIROL, V76, pS81, DOI 10.1016/j.jcv.2015.11.018	34	2	2	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					207	212		10.1002/cjp2.110			6	Pathology	Pathology	GW0OS	WOS:000446567600001	30058126	DOAJ Gold, Green Published			2019-10-28	
J	Barnhill, R; Vermeulen, P; Daelemans, S; van Dam, PJ; Roman-Roman, S; Servois, V; Hurbain, I; Gardrat, S; Raposa, G; Nicolas, A; Dendale, R; Pierron, G; Desjardins, L; Cassoux, N; Piperno-Neumann, S; Mariani, P; Lugassy, C				Barnhill, Raymond; Vermeulen, Peter; Daelemans, Sofie; van Dam, Pieter-Jan; Roman-Roman, Sergio; Servois, Vincent; Hurbain, Ilse; Gardrat, Sophie; Raposa, Graca; Nicolas, Andre; Dendale, Remi; Pierron, Gaelle; Desjardins, Laurence; Cassoux, Nathalie; Piperno-Neumann, Sophie; Mariani, Pascale; Lugassy, Claire			Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						uveal melanoma; metastasis; liver; histopathological growth patterns; replacement; desmoplastic; vascular co-option; angiotropism	EXTRAVASCULAR MIGRATORY METASTASIS; PRIMARY CUTANEOUS MELANOMA; PERICYTIC-MIMICRY; OCULAR MELANOMA; INDEPENDENT PREDICTOR; MALIGNANT-MELANOMA; PROGNOSTIC FACTOR; CO-OPTION; ANGIOTROPISM; CANCER	Up to 50% of uveal melanomas (UM) metastasise to the liver within 10 years of diagnosis, and these almost always prove rapidly fatal. As histopathological growth patterns (HGPs) of liver metastases of the replacement and desmoplastic type, particularly from colon and breast carcinoma, may import valuable biological and prognostic information, we have studied HGP in a series of 41 UM liver metastases originating from 41 patients from the period 2006-2017. Twenty patients underwent enucleation while 21 had radiation therapy. Analysis of UM by array comparative genomic hybridisation revealed: 25 (64%) patients with high risk (monosomy3/8q gain); 13 (33%) intermediate risk (M3/8normal or disomy3/8q gain); and 1 low risk (disomy3/8normal). The principal HGP was replacement in 30 (73%) cases and desmoplastic in 11 (27%) cases. Cases with replacement demonstrated striking vascular co-option/angiotropism. With the development of liver metastasis, only the replacement pattern, largest primary tumour diameter, and R2 (incomplete resection) status predicted diminished overall survival (OS; p < 0.041, p < 0.017, p < 0.047, respectively). On multivariate analysis, only HGP (hazard ratio; HR = 6.51, p = 0.008) and resection status remained significant. The genomic high-risk variable had no prognostic value at this stage of liver metastasis. Chi-square test showed no association of HGP with monosomy 3 or 8q gain. Eighteen of 41 (44%) patients are alive with disease and 23 (56%) patients died with follow-up ranging from 12 to 318 months (mean: 70 months, median: 47 months). In conclusion, we report for the first time the frequency of the replacement and desmoplastic HGPs in liver UM metastases resected from living patients, and their potential important prognostic value for UM patients, as in other solid cancers. These results may potentially be utilised to develop radiological correlates and therapeutic targets for following and treating patients with UM metastases.	[Barnhill, Raymond; Gardrat, Sophie; Nicolas, Andre] Inst Curie, Dept Pathol, 26 Rue Ulm, F-75248 Paris 05, France; [Barnhill, Raymond; Cassoux, Nathalie] Univ Paris 05, Fac Med, Paris, France; [Vermeulen, Peter; Daelemans, Sofie; van Dam, Pieter-Jan] HistoGeneX, Antwerp, Belgium; [Vermeulen, Peter; Daelemans, Sofie; van Dam, Pieter-Jan] Univ Antwerp, Fac Med & Hlth Sci, MIPRO Ctr Oncol Res CORE, TCRU,GZA Sint Augustinus, Antwerp, Belgium; [Roman-Roman, Sergio; Lugassy, Claire] Inst Curie, Dept Translat Res, Paris, France; [Servois, Vincent] Inst Curie, Dept Radiol, Paris, France; [Hurbain, Ilse; Raposa, Graca] PSL Res Univ, CNRS, Inst Curie, Paris, France; [Hurbain, Ilse; Raposa, Graca] UPMC Univ Paris 06, Sorbonne Univ, CNRS, Paris, France; [Hurbain, Ilse; Raposa, Graca] Inst Curie, Cell & Tissue Imaging Core Facil PICT IBiSA, Paris, France; [Dendale, Remi] Inst Curie Orsay, Dept Radiotherapy, Paris, France; [Pierron, Gaelle] Inst Curie, Dept Somat Genet, Paris, France; [Desjardins, Laurence; Cassoux, Nathalie] Inst Curie, Dept Ophthalmol, Paris, France; [Piperno-Neumann, Sophie] Inst Curie, Dept Med Oncol, Paris, France; [Mariani, Pascale] Inst Curie, Dept Surg, Paris, France	Barnhill, R (reprint author), Inst Curie, Dept Pathol, 26 Rue Ulm, F-75248 Paris 05, France.	raymond.barnhill@curie.fr		van Dam, Pieter-Jan/0000-0001-9074-8271; Servois, Vincent/0000-0002-8378-8432	French National Research Agency through the "Investments for the Future' program (France-BioImaging)French National Research Agency (ANR) [ANR-10-INSB-04]; CelTisPhyBio Labex, IDEX PSL [ANR-10-LBX-0038, ANR-10-IDEX-0001-02 PSL]	This work was supported by the French National Research Agency through the "Investments for the Future' program (France-BioImaging, ANR-10-INSB-04). We acknowledge the PICT-IBiSA, member of the France-BioImaging national research infrastructure, supported by the CelTisPhyBio Labex (No ANR-10-LBX-0038) part of the IDEX PSL (No ANR-10-IDEX-0001-02 PSL).	AFFELDT JC, 1980, ARCH OPHTHALMOL-CHIC, V98, P1975; Allison KH, 2004, ARCH PATHOL LAB MED, V128, P1418; Amaro A, 2017, CANCER METAST REV, V36, P109, DOI 10.1007/s10555-017-9663-3; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Barnhill R, 2002, J INVEST DERMATOL, V119, P705, DOI 10.1046/j.1523-1747.2002.01871.x; Barnhill RL, 2017, LAB INVEST, V97, P746, DOI 10.1038/labinvest.2017.16; Barnhill RL, 2004, PATHOLOGY, V36, P485, DOI 10.1080/00313020412331282708; Bentolila LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep23834; Blanco PL, 2012, MELANOMA RES, V22, P334, DOI 10.1097/CMR.0b013e328357bea8; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Borthwick NJ, 2011, J CLIN PATHOL, V64, P666, DOI 10.1136/jcp.2010.087999; Cassoux N, 2014, BRIT J OPHTHALMOL, V98, P769, DOI 10.1136/bjophthalmol-2013-303867; Coupland SE, 2008, OPHTHALMOLOGY, V115, P1778, DOI 10.1016/j.ophtha.2008.04.025; Diener-West M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1639; Farquhar N, 2018, J PATHOL CLIN RES, V4, P26, DOI 10.1002/cjp2.86; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gritsenko P, 2017, HISTOCHEM CELL BIOL, V148, P395, DOI 10.1007/s00418-017-1604-2; Griveau A, 2018, CANCER CELL, V33, P874, DOI 10.1016/j.ccell.2018.03.020; Grossniklaus HE, 2016, HUM PATHOL, V57, P165, DOI 10.1016/j.humpath.2016.07.012; Grossniklaus HE, 2013, JAMA OPHTHALMOL, V131, P462, DOI 10.1001/jamaophthalmol.2013.2547; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kizhatil K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001912; Landsberg J, 2016, J INVEST DERMATOL, V136, P372, DOI 10.1016/j.jid.2015.11.013; Levy MJ, 2009, CLIN GASTROENTEROL H, V7, P246, DOI 10.1016/j.cgh.2008.09.010; Liao A, 2018, OPHTHALMOLOGY, V125, P597, DOI 10.1016/j.ophtha.2017.09.029; Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021; Lugassy C, 1999, J CUTAN PATHOL, V26, P78, DOI 10.1111/j.1600-0560.1999.tb01806.x; Lugassy C, 1997, J SUBMICR CYTOL PATH, V29, P19; Lugassy C, 2014, CANCER MICROENVIRON, V7, P139, DOI 10.1007/s12307-014-0156-4; Lugassy C, 2014, J CUTAN PATHOL, V41, P810, DOI 10.1111/cup.12355; Lugassy C, 2013, PIGM CELL MELANOMA R, V26, P746, DOI 10.1111/pcmr.12120; Mariani P, 2009, EJSO-EUR J SURG ONC, V35, P1192, DOI 10.1016/j.ejso.2009.02.016; McLean IW, 1994, ATLAS TUMOR PATHOLOG, P179; Nielsen K, 2014, MODERN PATHOL, V27, P1641, DOI 10.1038/modpathol.2014.4; Pourhoseingholi Mohamad Amin, 2012, Gastroenterol Hepatol Bed Bench, V5, P79; Recamier J. C. A., 1829, RECHERCHES TRAITEMEN; SEDDON JM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1894; SHAMMAS HF, 1977, ARCH OPHTHALMOL-CHIC, V95, P2002; Simone Christine, 2012, J Med Case Rep, V6, P402, DOI 10.1186/1752-1947-6-402; STARR HJ, 1962, INT OPHTHALMOL CLIN, V2, P369; Sykes AM, 2011, PEARLS PITFALLS THOR, P148; van Dam PJ, 2017, BRIT J CANCER, V117, P1427, DOI 10.1038/bjc.2017.334; Van den Eynden GG, 2013, CANCER RES, V73, P2031, DOI 10.1158/0008-5472.CAN-12-3931; Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1; Van Es SL, 2008, AM J SURG PATHOL, V32, P1396, DOI 10.1097/PAS.0b013e3181753a8e; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Wilmott J, 2012, HISTOPATHOLOGY, V61, P889, DOI 10.1111/j.1365-2559.2012.04279.x; Winkler F, 2017, J PATHOL, V242, P267, DOI 10.1002/path.4904; Zografos L, 2002, TUMEURS INTRAOCULAIR, P236	50	3	3	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					227	240		10.1002/cjp2.105			14	Pathology	Pathology	GW0OS	WOS:000446567600003	29917326	DOAJ Gold, Green Published			2019-10-28	
J	Coulson-Gilmer, C; Humphries, MP; Rajan, SS; Droop, A; Jackson, S; Condon, A; Cserni, G; Jordan, LB; Jones, LJ; Kanthan, R; Di Benedetto, A; Mottolese, M; Provenzano, E; Kulka, J; Shaaban, AM; Hanby, AM; Speirs, V				Coulson-Gilmer, Camilla; Humphries, Matthew P.; Rajan, Sreekumar Sundara; Droop, Alastair; Jackson, Sharon; Condon, Alexandra; Cserni, Gabor; Jordan, Lee B.; Jones, Louise J.; Kanthan, Rani; Di Benedetto, Anna; Mottolese, Marcella; Provenzano, Elena; Kulka, Janina; Shaaban, Abeer M.; Hanby, Andrew M.; Speirs, Valerie			Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						male breast cancer; stanniocalcin 2; immunohistochemistry; survival	PROGNOSTIC MARKERS; STC2; PROMOTES; CELLS; PROGRESSION; BIOMARKER; RECEPTOR; CLONING; SCREEN; GENES	Breast cancer can occur in either gender; however, it is rare in men, accounting for <1% of diagnosed cases. In a previous transcriptomic screen of male breast cancer (MBC) and female breast cancer (FBC) occurrences, we observed that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to confirm the expression of STC2 in MBC and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic screen, STC2 gene expression was confirmed by RT-qPCR in matched MBC and FBC samples as well as in tumour-associated fibroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohistochemically in tissue microarrays containing 477 MBC cases. Cumulative survival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-specific STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in MBC, also supported by data deposited in Oncomine. STC2 protein expression was a positive prognostic factor for disease-free survival (DFS; Log-rank; total p = 0.035, HR = 0.49; tumour cells p = 0.017, HR = 0.44; stroma p = 0.030, HR = 0.48) but had no significant impact on overall survival (Log-rank; total p = 0.23, HR = 0.71; tumour cells p = 0.069, HR = 0.59; stroma p = 0.650, HR = 0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging, tumour size, ER, and PR status revealed that total STC2 expression as well as expression in tumour cells was an independent prognostic factor for DFS (Cox regression; p = 0.018, HR = 0.983; p = 0.015, HR = 0.984, respectively). In conclusion, STC2 expression is abundant in MBC where it is an independent prognostic factor for DFS.	[Coulson-Gilmer, Camilla; Rajan, Sreekumar Sundara; Jackson, Sharon; Condon, Alexandra; Hanby, Andrew M.; Speirs, Valerie] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England; [Humphries, Matthew P.] Queens Univ, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [Droop, Alastair] Univ Leeds, MRC Med Bioinformat Ctr, Leeds, W Yorkshire, England; [Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Kecskemet, Hungary; [Jordan, Lee B.] Univ Dundee, NHS Tayside, Dundee, Scotland; [Jones, Louise J.] Barts Canc Inst, London, England; [Kanthan, Rani] Univ Saskatchewan, Dept Pathol & Lab Med, Saskatoon, SK, Canada; [Di Benedetto, Anna] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Mottolese, Marcella; Provenzano, Elena] Addenbrookes Hosp, Dept Histopathol, Cambridge, England; [Kulka, Janina] Semmelweis Univ, Dept Pathol 2, Budapest, Hungary; [Shaaban, Abeer M.] Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Birmingham, W Midlands, England; [Shaaban, Abeer M.] Univ Birmingham, Birmingham, W Midlands, England	Speirs, V (reprint author), Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England.	valerie.speirs@abdn.ac.uk		Cserni, Gabor/0000-0003-1344-7744; Shaaban, Abeer/0000-0001-5784-8705	Yorkshire Cancer Research [L378]; Breast Cancer Now [TBLEE2017]	This study was supported by Yorkshire Cancer Research (grant L378) and Breast Cancer Now (TBLEE2017). We are grateful to the Breast Cancer Now Tissue Bank and the Male Breast Cancer Consortium who kindly provided cases for this work.	Arigami T, 2013, ONCOL REP, V30, P2838, DOI 10.3892/or.2013.2775; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bouras T, 2002, CANCER RES, V62, P1289; Brantley KD, 2018, CANCER EPIDEM BIOMAR, V27, P653, DOI 10.1158/1055-9965.EPI-17-0905; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cardoso F, 2018, ANN ONCOL, V29, P405, DOI 10.1093/annonc/mdx651; Chen B, 2016, ONCOTARGET, V7, P71400, DOI 10.18632/oncotarget.12147; Esseghir S, 2007, CLIN CANCER RES, V13, P3164, DOI 10.1158/1078-0432.CCR-07-0224; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hou J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122179; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Humphries MP, 2017, CLIN CANCER RES, V23, P2575, DOI 10.1158/1078-0432.CCR-16-1952; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V250, P252, DOI 10.1006/bbrc.1998.9300; Jansen MPHM, 2015, MOL ONCOL, V9, P1218, DOI 10.1016/j.molonc.2015.02.006; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; Joensuu K, 2008, CANCER LETT, V265, P76, DOI 10.1016/j.canlet.2008.02.022; Johansson I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3116; Johansson I, 2011, BREAST CANCER RES TR, V129, P747, DOI 10.1007/s10549-010-1262-8; McBryan J, 2007, ONCOGENE, V26, P6406, DOI 10.1038/sj.onc.1210468; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Na SS, 2015, BBA-PROTEINS PROTEOM, V1854, P668, DOI 10.1016/j.bbapap.2014.11.002; Parris TZ, 2014, INT J CANCER, V134, P1617, DOI 10.1002/ijc.28497; Raulic S, 2008, J ENDOCRINOL, V197, P517, DOI 10.1677/JOE-08-0043; Roch GJ, 2011, GENOME BIOL EVOL, V3, P284, DOI 10.1093/gbe/evr020; Shin J, 2009, COMP BIOCHEM PHYS A, V153, P24, DOI 10.1016/j.cbpa.2008.11.014; Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702; Todd JR, 2016, ONCOTARGET, V7, P62939, DOI 10.18632/oncotarget.11307; Volland S, 2009, INT J CANCER, V125, P2049, DOI 10.1002/ijc.24564; Wu JJ, 2015, ONCOL REP, V34, P1494, DOI 10.3892/or.2015.4120; Yeung BHY, 2012, MOL CELL ENDOCRINOL, V349, P272, DOI 10.1016/j.mce.2011.11.007; Zubor P, 2015, MOL MED REP, V11, P1421, DOI 10.3892/mmr.2014.2863	31	3	3	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					241	249		10.1002/cjp2.106			9	Pathology	Pathology	GW0OS	WOS:000446567600004	29956502	DOAJ Gold, Green Published, Green Accepted			2019-10-28	
J	Dodson, A; Parry, S; Ibrahim, M; Bartlett, JMS; Pinder, S; Dowsett, M; Miller, K				Dodson, Andrew; Parry, Suzanne; Ibrahim, Merdol; Bartlett, John M. S.; Pinder, Sarah; Dowsett, Mitch; Miller, Keith			Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						breast cancer; clinical testing; biomarkers; oestrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; ER; PR; HER2; external quality assessment	HER2 ASSESSMENT; RECOMMENDATIONS; TRENDS	We describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together with clinicopathological parameters were collected. Our analyses focused on human epidermal growth factor receptor-2 (HER2), oestrogen receptor (ER) and progesterone receptor (PR), with the aim of the study being to provide robust confirmatory evidence on known associations in these biomarkers and to uncover new data on previously undescribed or unconfirmed associations, thus strengthening the evidence-base in clinical breast cancer testing. Overall, 13.1% of tumours were HER2-positive; 10.6% in ER-positive tumours, and 25.5% in ER-negative tumours. Higher rates of HER2 positivity were significantly associated with patient age <56 years versus age 56 years, symptomatic versus screen-detected tumours, testing of involved axillary node versus primary breast cancer, invasive ductal carcinoma (not otherwise specified) versus other histological types, higher histological grade, increasing tumour size, increasing nodal involvement, ER-negative versus ER-positive tumour status, PR-negative versus PR-positive tumour status. Where ER status was known, 82.7% of tumours were ER-positive; 80.9% in women age <56 years, and 83.6% in those age 56 years (ER-positive cut-off 1.0% positive tumour cells or equivalent). Where PR status was known, 64.9% of tumours were PR-positive; 65.8% in women age <56 years, and 64.4% in women age 56 years (PR-positive cut off 10.0% or equivalent). These analyses of clinical test results provide contemporary benchmarking data for HER2, ER and PR positive rates.	[Dodson, Andrew; Dowsett, Mitch] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, Wallace Wing,Fulham Rd, London SW3 6JJ, England; [Dodson, Andrew; Dowsett, Mitch] Inst Canc Res, London, England; [Parry, Suzanne; Ibrahim, Merdol; Miller, Keith] UCL, Canc Inst, UK NEQAS ICC, London, England; [Parry, Suzanne; Ibrahim, Merdol; Miller, Keith] UCL, Canc Inst, ISH, London, England; [Bartlett, John M. S.] Ontario Inst Canc Res, Toronto, ON, Canada; [Pinder, Sarah] Kings Coll London, Canc Studies, London, England	Dodson, A (reprint author), Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, Wallace Wing,Fulham Rd, London SW3 6JJ, England.	andrew.dodson@icr.ac.uk			Roche Products Ltd	The authors gratefully acknowledge the contribution made by all participating testing centres who entered data into the database. They thank Kate Herriot and Tasmeen Ahmed for their work in promoting the uptake and use of the database throughout the breast cancer testing community. The project was supported with funding from Roche Products Ltd but Roche Products Ltd was not involved in the preparation, drafting or editing of this article. Roche Products Limited has conducted a factual accuracy check on the final content, but any decisions to incorporate comments were made solely at the discretion of the authors.	Anderson WF, 2013, INT J CANCER, V133, P2201, DOI 10.1002/ijc.28222; Bartlett JMS, 2007, J CLIN ONCOL, V25, P4423, DOI 10.1200/JCO.2007.11.0973; IBRAHIM M, 2011, VIRCHOWS ARCH S1, V459, pS74; Kaufman PA, 2014, CANCER-AM CANCER SOC, V120, P2657, DOI 10.1002/cncr.28710; Lin CY, 2017, AM J CLIN PATHOL, V148, P199, DOI [10.1093/AJCP/AQX063, 10.1093/ajcp/aqx063]; Mullooly M, 2017, EUR J CANCER, V86, P326, DOI 10.1016/j.ejca.2017.08.031; Purdie CA, 2014, BRIT J CANCER, V110, P565, DOI 10.1038/bjc.2013.756; Purdie CA, 2010, HISTOPATHOLOGY, V56, P702, DOI 10.1111/j.1365-2559.2010.03533.x; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Rosenberg PS, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv159; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	11	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	OCT	2018	4	4					262	273		10.1002/cjp2.112			12	Pathology	Pathology	GW0OS	WOS:000446567600006	30066480	DOAJ Gold, Green Published			2019-10-28	
J	Pearsall, EA; Connor, KM				Pearsall, Elizabeth A.; Connor, Kip M.			Atypical Protein Kinase C Breaking Down Barriers in Ocular Disease?	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material							VASCULAR-PERMEABILITY; MACULAR DEGENERATION; INHIBITORS; ZETA		[Pearsall, Elizabeth A.; Connor, Kip M.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Angiogenesis Lab, 325 Cambridge St,4th Floor, Boston, MA 02114 USA	Pearsall, EA (reprint author), Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Angiogenesis Lab, 325 Cambridge St,4th Floor, Boston, MA 02114 USA.	elizabeth_moran@meei.harvard.edu		Connor, Kip/0000-0002-2048-9080; Pearsall, Elizabeth/0000-0003-1013-6238	National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [1R01EY027303]; Bright Focus FoundationBrightFocus Foundation; Massachusetts Lions Fund	Supported by National Eye Institute grant 1R01EY027303, the Bright Focus Foundation, and the Massachusetts Lions Fund (K.M.C.).	Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073; Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Campochiaro PA, 2012, OPHTHALMOLOGICA, V227, P30, DOI 10.1159/000337157; Claesson-Welsh L, 2015, UPSALA J MED SCI, V120, P135, DOI 10.3109/03009734.2015.1064501; Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009; Drummond ML, 2016, J MOL BIOL, V428, P1455, DOI 10.1016/j.jmb.2016.03.003; Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005; Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906; Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768; Ishizuka F, 2013, PHARMACOL RES PERSPE, V1, DOI 10.1002/prp2.6; Jaadane I, 2015, J CELL MOL MED, V19, P1646, DOI 10.1111/jcmm.12539; Lin CM, 2018, AM J PATHOL, V188, P2392, DOI 10.1016/j.ajpath.2018.06.020; Liu XW, 2016, AM J PATHOL, V186, P2486, DOI 10.1016/j.ajpath.2016.04.018; Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367; Muthusamy A, 2014, J CEREBR BLOOD F MET, V34, P522, DOI 10.1038/jcbfm.2013.230; Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009; Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115; Omri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081600; Rajapakse D, 2017, AGING-US, V9, P2051, DOI 10.18632/aging.101299; Song HB, 2014, BIOCHEM BIOPH RES CO, V444, P63, DOI 10.1016/j.bbrc.2014.01.002; Titchenell PM, 2013, BIOORG MED CHEM LETT, V23, P3034, DOI 10.1016/j.bmcl.2013.03.019; Titchenell PM, 2012, BIOCHEM J, V446, P455, DOI 10.1042/BJ20111961	23	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2142	2146		10.1016/j.ajpath.2018.07.006			5	Pathology	Pathology	GV8SN	WOS:000446415800001	30220553	Bronze			2019-10-28	
J	De Cunto, G; Bartalesi, B; Cavarra, E; Balzano, E; Lungarella, G; Lucattelli, M				De Cunto, Giovanna; Bartalesi, Barbara; Cavarra, Eleonora; Balzano, Emilia; Lungarella, Giuseppe; Lucattelli, Monica			Ongoing Lung Inflammation and Disease Progression in Mice after Smoking Cessation Beneficial Effects of Formyl-Peptide Receptor Blockade	AMERICAN JOURNAL OF PATHOLOGY			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; CIGARETTE-SMOKE; INDUCED EMPHYSEMA; COPD; OXIDANTS; MOUSE; ROFLUMILAST; PROTECTION; INHIBITOR; ENDOTOXIN	The most important risk factor for chronic obstructive pulmonary disease (COPD) is cigarette smoking. Until now, smoking cessation (SC) is the only treatment effective in slowing down the progression of the disease. However, in many cases SC may only relieve the airflow obstruction and inflammatory response. Consequently, a persistent lung inflammation in ex-smokers is associated smoking. Until now, smoking cessation (SC) is the only treatment effective in slowing down the with progressive deterioration of respiratory functions. This is an increasingly important clinical progression of the disease. However, in many cases SC may only relieve the airflow obstruction and problem whose mechanistic basis remains poorly understood. Available therapies do not adequately suppress inflammation and are not able to stop the vicious cycle that is at the basis of persistent inflammation. In addition, in mice after SC an ongoing inflammation and progressive lung deterioration is observed. After 4 months of smoke exposure mice show mild emphysematous changes. Lung inflammation is still present after SC, and emphysema progresses during the next 6-month period of observation. Destruction of alveolar walls is associated with airways remodeling (goblet cell metaplasia and peribronchiolar fibrosis). Modulation of formyl-peptide receptor signaling with antagonists mitigates inflammation and prevents deterioration of lung structures. This study suggests an important role for N-formylated peptides in the progression and exacerbation of COPD. Modulating formyl-peptide receptor signal should be explored as a potential new therapy for COPD.	[De Cunto, Giovanna; Bartalesi, Barbara; Cavarra, Eleonora; Balzano, Emilia; Lungarella, Giuseppe; Lucattelli, Monica] Univ Siena, Dept Mol & Dev Med, Via Aldo Moro 2, I-53100 Siena, Italy	Lucattelli, M (reprint author), Univ Siena, Dept Mol & Dev Med, Via Aldo Moro 2, I-53100 Siena, Italy.	monica.lucattelli@unisi.it		Bartalesi, Barbara/0000-0002-6792-5249; CAVARRA, ELEONORA/0000-0002-4600-0546; LUCATTELLI, MONICA/0000-0001-7372-9933; Balzano, Emilia/0000-0002-8498-9703; De Cunto, Giovanna/0000-0002-3869-4621; LUNGARELLA, Giuseppe/0000-0002-3796-7317	MIURMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [2008T5BLWA]; University of Siena [122004]	Supported by MIUR grant 2008T5BLWA (G.L.) and University of Siena grant 122004 (M.L.).	Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Atzori L, 2009, AM J RESP CELL MOL, V41, P680, DOI 10.1165/rcmb.2007-0386OC; Bartalesi B, 2005, EUR RESPIR J, V25, P15, DOI 10.1183/09031936.04.00067204; Braber S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-99; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Cardini S, 2012, AM J RESP CELL MOL, V47, P332, DOI 10.1165/rcmb.2012-0036OC; Cavarra E, 2001, AM J RESP CRIT CARE, V164, P886, DOI 10.1164/ajrccm.164.5.2010032; Cavarra E, 1999, AM J RESP CELL MOL, V20, P264, DOI 10.1165/ajrcmb.20.2.3235; Chen KQ, 2017, J AUTOIMMUN, V85, P64, DOI 10.1016/j.jaut.2017.06.012; Churg A, 2008, AM J PHYSIOL-LUNG C, V294, pL612, DOI 10.1152/ajplung.00390.2007; Churg A, 2006, AM J RESP CRIT CARE, V174, P1327, DOI 10.1164/rccm.200605-585OC; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Curtis JL, 2015, AM J RESP CRIT CARE, V192, P648, DOI 10.1164/rccm.201506-1230ED; De Cunto G, 2011, EUR RESPIR J, V37, P823, DOI 10.1183/09031936.00060210; De Cunto G, 2016, AM J PATHOL, V186, P1814, DOI 10.1016/j.ajpath.2016.03.002; Dorward DA, 2017, THORAX, V72, P928, DOI 10.1136/thoraxjnl-2017-210030; Dorward DA, 2015, AM J PATHOL, V185, P1172, DOI 10.1016/j.ajpath.2015.01.020; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Grommes J, 2014, J INNATE IMMUN, V6, P111, DOI 10.1159/000353229; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; Hatzelmann A, 2010, PULM PHARMACOL THER, V23, P235, DOI 10.1016/j.pupt.2010.03.011; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Lapperre TS, 2006, THORAX, V61, P115, DOI 10.1136/thx.2005.040519; Le YY, 2002, INT IMMUNOPHARMACOL, V2, P1, DOI 10.1016/S1567-5769(01)00150-3; Lucattelli M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-83; Lucattelli M, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0373-0; Lunghi B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119797; MacNee W, 1999, AM J RESP CRIT CARE, V160, pS58, DOI 10.1164/ajrccm.160.supplement_1.15; Mannino DM, 2006, EUR RESPIR J, V27, P627, DOI 10.1183/09031936.06.00024605; Martorana PA, 2005, AM J RESP CRIT CARE, V172, P848, DOI 10.1164/rccm.200411-1549OC; MARTORANA PA, 2006, DRUG DISCOV TODAY DI, V3, P225, DOI DOI 10.1016/J.DDM0D.2006.09.004; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rabiet MJ, 2005, EUR J IMMUNOL, V35, P2486, DOI 10.1002/eji.200526338; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Rahman I, 2017, AM J RESP CELL MOL, V57, P270, DOI 10.1165/rcmb.2017-0175ED; Rossi R, 2009, FREE RADICAL RES, V43, P538, DOI 10.1080/10715760902893332; Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381, DOI 10.1164/ajrccm.161.2.9901044; Simmons MS, 2005, EUR RESPIR J, V25, P1011, DOI 10.1183/09031936.05.00086804; STOCKLEY RA, 1994, AM J RESP CRIT CARE, V149, P464, DOI 10.1164/ajrccm.149.2.8306047; Tuder RM, 2012, J CLIN INVEST, V122, P2749, DOI 10.1172/JCI60324; Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; World Medical Association, 2002, Am J Physiol Regul Integr Comp Physiol, V283, pR281; Yu CD, 2003, AM J PATHOL, V163, P1653, DOI 10.1016/S0002-9440(10)63522-5	49	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2195	2206		10.1016/j.ajpath.2018.06.010			12	Pathology	Pathology	GV8SN	WOS:000446415800006	30031729	Other Gold			2019-10-28	
J	Nagaraja, MR; Tiwari, N; Shetty, SK; Marudamuthu, AS; Fan, L; Ostrom, RS; Fu, J; Gopu, V; Radhakrishnan, V; Idell, S; Shetty, S				Nagaraja, M. R.; Tiwari, Nivedita; Shetty, Shwetha K.; Marudamuthu, Amarnath S.; Fan, Liang; Ostrom, Rennolds S.; Fu, Jian; Gopu, Venkadesaperumal; Radhakrishnan, Vijay; Idell, Steven; Shetty, Sreerama			p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling	AMERICAN JOURNAL OF PATHOLOGY			English	Article							IDIOPATHIC PULMONARY-FIBROSIS; EPITHELIAL-MESENCHYMAL TRANSITION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FIBRINOLYTIC SYSTEM; EXTRACELLULAR-MATRIX; P53-MEDIATED CHANGES; CROSS-TALK; INJURY; PATHOGENESIS; CAVEOLIN-1	Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and Life-threatening disease. A cardinal feature of the pathogenesis of IPF is excessive extracellular matrix deposition attributable to proliferation of activated fibrotic lung fibroblasts (fLfs). To assess the underlying mechanism, we analyzed the status of the tumor suppressor protein p53 in fLfs from the lungs of IPF patients or mice with bleomycin-induced established PF. We report that basal expression of p53 is markedly reduced in fLfs. Forced expression of caveolin-1 in fLfs increased basal p53 and reduced profibrogenic proteins, including collagen-1. Transduction of fLfs with adenovirus expressing p53 reduced expression of these proteins. Conversely, inhibition of baseline p53 in control lung fibroblasts from lung tissues increased profibrogenic protein expression. Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice. Furthermore, treatment of fLfs or fibrotic lung tissues with caveotin-1 scaffolding domain peptide (CSP) or its fragment, CSP7, restored p53 and reduced profibrogenic proteins. Treatment of wild-type mice with i.p. CSP or CSP7 resolved bleomycin-induced PF. These peptides failed to resolve PF in inducible conditional knockout mice lacking p53 in fLfs, indicating the induction of baseline fLf p53 as the basis of the antifibrotic effects.	[Nagaraja, M. R.; Tiwari, Nivedita; Shetty, Shwetha K.; Marudamuthu, Amarnath S.; Fan, Liang; Gopu, Venkadesaperumal; Radhakrishnan, Vijay; Idell, Steven; Shetty, Sreerama] Univ Texas Hlth Sci Ctr Tyler, Texas Lung Injury Inst, Dept Med, 11937 US Hwy 271, Tyler, TX 75708 USA; [Ostrom, Rennolds S.] Chapman Univ, Sch Pharm, Dept Pharmacol, Irvine, CA USA; [Fu, Jian] Univ Kentucky, Coll Med, Ctr Res Environm Dis & Toxicol, Lexington, KY USA	Shetty, S (reprint author), Univ Texas Hlth Sci Ctr Tyler, Texas Lung Injury Inst, Dept Med, 11937 US Hwy 271, Tyler, TX 75708 USA.	sreerama.shetty@uthct.edu		Gopu, Venkadesaperumal/0000-0002-2123-5007	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL133067-01, R21ES025815]; Flight Attendant Medical Research Institute [150063]	Supported in part by NIH grants R01HL133067-01 (S.S.) and R21ES025815 (S.S.) and Flight Attendant Medical Research Institute, Clinical Investigator Award 150063 (S.S.).	Aoshiba K, 2003, TOB INDUC DIS, V1, P21; Bhandary YP, 2015, TOXICOL APPL PHARM, V283, P92, DOI 10.1016/j.taap.2015.01.007; Bhandary YP, 2013, AM J PATHOL, V183, P131, DOI 10.1016/j.ajpath.2013.03.022; Bhandary YP, 2012, AM J PHYSIOL-LUNG C, V302, pL463, DOI 10.1152/ajplung.00099.2011; Borensztajn K, 2013, RESPIRATION, V86, P441, DOI 10.1159/000357598; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; CROUCH E, 1990, AM J PHYSIOL, V259, pL159; Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Hughes G, 2016, J CLIN MED, V5, DOI 10.3390/jcm5090078; Johnson LN, 2009, ANTIOXID REDOX SIGN, V11, P355, DOI 10.1089/ars.2008.2183; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kendall RT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00123; KHALIL N, 1991, CIBA F SYMP, V157, P194; Khalil N, 1991, CIBA F SYMP, V157, P207; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kodama T, 2011, J CLIN INVEST, V121, P3343, DOI 10.1172/JCI44957; Lawson WE, 2011, AM J MED SCI, V341, P439, DOI 10.1097/MAJ.0b013e31821a9d7a; Lehtonen ST, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0328-5; Maher TM, 2013, CURR OPIN PULM MED, V19, P460, DOI 10.1097/MCP.0b013e328363f4b7; Margaritopoulos GA, 2016, CORE EVID, V11, P11, DOI 10.2147/CE.S76549; Markowski DN, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-2; Markowski DN, 2011, ANTICANCER RES, V31, P753; Marudamuthu AS, 2015, J BIOL CHEM, V290, P9428, DOI 10.1074/jbc.M114.601815; Marudamuthu AS, 2015, AM J PATHOL, V185, P55, DOI 10.1016/j.ajpath.2014.08.027; Meltzer EB, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-8; Moore BB, 2013, AM J RESP CELL MOL, V49, P167, DOI 10.1165/rcmb.2013-0094TR; Myllarniemi M, 2015, EUR CLIN RESPIR J, V2, DOI 10.3402/ecrj.v2.26385; Noble PW, 2004, CLIN CHEST MED, V25, P749, DOI 10.1016/j.ccm.2004.04.003; Okudela K, 1999, AM J PATHOL, V155, P1341, DOI 10.1016/S0002-9440(10)65236-4; Pardo A, 2016, ANN AM THORAC SOC, V13, pS417, DOI 10.1513/AnnalsATS.201605-341AW; Park SH, 2014, PULM CIRC, V4, P654, DOI 10.1086/678511; Prasad R, 2015, INTRACTABLE RARE DIS, V4, P65, DOI 10.5582/irdr.2015.01009; Puthusseri B, 2017, AM J PHYSIOL-LUNG C, V312, pL783, DOI 10.1152/ajplung.00291.2016; Raghu G, 2015, AM J RESP CRIT CARE, V191, P252, DOI 10.1164/rccm.201411-2044ED; Ramos C, 2001, AM J RESP CELL MOL, V24, P591, DOI 10.1165/ajrcmb.24.5.4333; Rockey DC, 2015, NEW ENGL J MED, V372, P1138, DOI 10.1056/NEJMra1300575; Sakai N, 2013, BBA-MOL BASIS DIS, V1832, P911, DOI 10.1016/j.bbadis.2013.03.001; Shetty SK, 2017, AM J PATHOL, V187, P1016, DOI 10.1016/j.ajpath.2016.12.020; Shimbori C, 2013, CURR OPIN PULM MED, V19, P446, DOI 10.1097/MCP.0b013e328363f4de; Shivshankar P, 2012, AM J RESP CELL MOL, V47, P28, DOI 10.1165/rcmb.2011-0349OC; Strippoli R, 2015, EMBO MOL MED, V7, P102, DOI 10.15252/emmm.201404127; Todd NW, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-11; Walter R, 2000, ENVIRON HEALTH PERSP, V108, P733, DOI 10.2307/3454410; Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536; Wilson MS, 2009, MUCOSAL IMMUNOL, V2, P103, DOI 10.1038/mi.2008.85; Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551	49	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2207	2222		10.1016/j.ajpath.2018.07.005			16	Pathology	Pathology	GV8SN	WOS:000446415800007	30253845				2019-10-28	
J	Sato, Y; Yamamura, M; Sasaki, M; Harada, K				Sato, Yasunori; Yamamura, Minako; Sasaki, Motoko; Harada, Kenichi			Blockade of Hedgehog Signaling Attenuates Biliary Cystogenesis in the Polycystic Kidney (PCK) Rat	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CONGENITAL HEPATIC-FIBROSIS; CAROLIS-DISEASE; CYSTIC CHOLANGIOCYTES; MOLECULAR-MECHANISMS; LIVER-DISEASES; PRIMARY CILIUM; INHIBITION; CELLS; TARGET; MODEL	Caroli disease represents a hepatic manifestation of autosomal recessive polycystic kidney disease, and belongs to a class of chotangiociliopathies. The role of Hedgehog signaling, a major pathway regulated by primary cilia, in biliary cystogenesis in Caroli disease remains unknown. Using the pots/cystic kidney (PCK) rat as an animal model of Caroli disease, this study investigated the involvement of Hedgehog signaling in its pathogenesis. In vitro experiments revealed that PCK cholangiocytes overexpressed Smoothened, Gli1, and Gli1's target molecule cyclin D1. The nuclear expression of Gli1 Gli2, and Gli3 was observed in PCK cholangiocytes by immunocytochemistry. An immunohistochemical analysis using liver sections confirmed the overexpression of Smoothened and cyclin D1, and the nuclear expression of the Gli proteins in the biliary epithelium of PCK rats as welt as human Caroli disease. The treatment of PCK cholangiocytes with cyclopamine inhibited cell proliferative activity that was associated with the inhibition of nuclear translocation of Gli1 and Gli2, and reduced cyclin D1 expression. The in vivo administration of cyclopamine to PCK rats decreased abnormally elevated serum liver enzymes, and significantly attenuated bile duct dilation as well as kidney cyst formation. These results suggest that cholangiocyte hyperproliferation is causally associated with the aberrant activation of Hedgehog signaling, and the inhibition of the signaling has potential as a therapeutic strategy for biliary cystogenesis in Caroli disease.	[Sato, Yasunori; Yamamura, Minako; Sasaki, Motoko; Harada, Kenichi] Kanazawa Univ, Grad Sch Med, Dept Human Pathol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan	Sato, Y (reprint author), Kanazawa Univ, Grad Sch Med, Dept Human Pathol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	sato-ya@med.kanazawa-u.ac.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [15K08342]	Supported in part by grant-in-aid for Scientific Research 15K08342 (Y.S.) from the Ministry of Education, Science, Sports and Culture of Japan.	Carpino G, 2015, J HEPATOL, V63, P1220, DOI 10.1016/j.jhep.2015.06.018; Cebotaru L, 2016, KIDNEY INT, V90, P90, DOI 10.1016/j.kint.2016.01.026; Dhanyamraju PK, 2015, MOL CANCER THER, V14, P727, DOI 10.1158/1535-7163.MCT-14-0481; Di Magno L, 2015, BBA-REV CANCER, V1856, P62, DOI 10.1016/j.bbcan.2015.06.003; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Ferretti E, 2008, EMBO J, V27, P2616, DOI 10.1038/emboj.2008.172; Furubo S, 2013, PEDIATR DEVEL PATHOL, V16, P177, DOI 10.2350/12-11-1267-OA.1; Gradilone SA, 2014, AM J PATHOL, V184, P600, DOI 10.1016/j.ajpath.2013.11.027; Harris PC, 2009, ANNU REV MED, V60, P321, DOI 10.1146/annurev.med.60.101707.125712; Hartung EA, 2014, PEDIATRICS, V134, pE833, DOI 10.1542/peds.2013-3646; Jiang QW, 2016, MED RES REV, V36, P119, DOI 10.1002/med.21346; Jung YM, 2007, HEPATOLOGY, V45, P1091, DOI 10.1002/hep.21660; Lee SO, 2008, J CLIN INVEST, V118, P3714, DOI 10.1172/JCI34922; Mansini AP, 2018, BBA-MOL BASIS DIS, V1864, P1245, DOI 10.1016/j.bbadis.2017.06.006; Maroni L, 2015, CELL MOL GASTROENTER, V1, P368, DOI 10.1016/j.jcmgh.2015.05.005; Masyuk AI, 2006, GASTROENTEROLOGY, V131, P911, DOI 10.1053/j.gastro.2006.07.003; Masyuk T, 2009, CURR OPIN GASTROEN, V25, P265, DOI 10.1097/MOG.0b013e328328f4ff; Masyuk TV, 2017, CURR DRUG TARGETS, V18, P950, DOI 10.2174/1389450116666150427161743; Masyuk TV, 2003, GASTROENTEROLOGY, V125, P1303, DOI 10.1016/j.gastro.2003.09.001; Matsushita S, 2014, CANCER SCI, V105, P272, DOI 10.1111/cas.12354; Perugorria MJ, 2014, NAT REV GASTRO HEPAT, V11, P750, DOI 10.1038/nrgastro.2014.155; Pisarello ML, 2018, AM J PATHOL, V188, P981, DOI 10.1016/j.ajpath.2017.12.016; Pratap A, 2011, MOL PHARMACEUT, V8, P958, DOI 10.1021/mp200115v; Razumilava N, 2014, J HEPATOL, V60, P599, DOI 10.1016/j.jhep.2013.11.005; Ren XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087660; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Sanzen T, 2001, AM J PATHOL, V158, P1605, DOI 10.1016/S0002-9440(10)64116-8; Sato Y, 2005, AM J PATHOL, V166, P49, DOI 10.1016/S0002-9440(10)62231-6; Sato Y, 2007, AM J PATHOL, V171, P1859, DOI 10.2353/ajpath.2007.070337; Sato Y, 2006, AM J PATHOL, V169, P1238, DOI 10.2353/ajpath.2006.051136; Tang L, 2013, CLIN CANCER RES, V19, P2014, DOI 10.1158/1078-0432.CCR-12-0349; Tran PV, 2014, J AM SOC NEPHROL, V25, P2201, DOI 10.1681/ASN.2013070735; Urribarri AD, 2014, GUT, V63, P1658, DOI 10.1136/gutjnl-2013-305281; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Wills ES, 2014, TRENDS MOL MED, V20, P261, DOI 10.1016/j.molmed.2014.01.003; Yasoshima M, 2009, J PATHOL, V217, P442, DOI 10.1002/path.2472; Yoshihara D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081480; Yu PP, 2017, MOL NEUROBIOL, V54, P212, DOI 10.1007/s12035-015-9639-7; Zhang MZ, 2004, P NATL ACAD SCI USA, V101, P2311, DOI 10.1073/pnas.0400073101	40	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2251	2263		10.1016/j.ajpath.2018.06.014			13	Pathology	Pathology	GV8SN	WOS:000446415800010	30036521	Other Gold			2019-10-28	
J	Wu, N; Meng, FY; Zhou, TH; Venter, J; Giang, TK; Kyritsi, K; Wu, CD; Alvaro, D; Onori, P; Mancinelli, R; Gaudio, E; Francis, H; Alpini, G; Glaser, S; Franchitto, A				Wu, Nan; Meng, Fanyin; Zhou, Tianhao; Venter, Julie; Giang, Thao K.; Kyritsi, Konstantina; Wu, Chaodong; Alvaro, Domenico; Onori, Paolo; Mancinelli, Romina; Gaudio, Eugenio; Francis, Heather; Alpini, Gianfranco; Glaser, Shannon; Franchitto, Antonio			The Secretin/Secretin Receptor Axis Modulates Ductular Reaction and Liver Fibrosis through Changes in Transforming Growth Factor-beta 1-Mediated Biliary Senescence	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PRIMARY SCLEROSING CHOLANGITIS; FUNCTIONAL-HETEROGENEITY; EPITHELIAL-CELLS; CELLULAR SENESCENCE; RAT CHOLANGIOCYTES; GENE-EXPRESSION; MDR2(-/-) MICE; SECRETIN; PROLIFERATION; LIGATION	Activation of the secretin (Sct)/secretin receptor (SR) axis stimulates ductular reaction and liver fibrosis, which are hallmarks of cholangiopathies. Our aim was to define the role of Sct-regulated cellular senescence, and we demonstrated that both ductular reaction and liver fibrosis are significantly reduced in Sct(-/-), SR-/-, and Sct(-/-)/SR (-/-) bile duct ligated (BDL) mice compared with BDL wild-type mice. The reduction in hepatic fibrosis in Sct(-/-), SR-/-, and Sct(-/-)/SR (-/-) BDL mice was accompanied by reduced transforming growth factor-beta 1 levels in serum and cholangiocyte supernatant, as well as decreased expression of markers of cellular senescence in cholangiocytes in contrast to enhanced cellular senescence in hepatic stellate cells compared with BDL wild-type mice. Secretin directly stimulated the senescence of cholangiocytes and regulated, by a paracrine mechanism, the senescence of hepatic stellate cells and liver fibrosis via modulation of transforming growth factor-beta 1 biliary secretion. Targeting senescent cholangiocytes may represent a novel therapeutic approach for ameliorating hepatic fibrosis during cholestatic liver injury.	[Wu, Nan; Zhou, Tianhao; Venter, Julie; Giang, Thao K.; Kyritsi, Konstantina; Francis, Heather; Alpini, Gianfranco; Glaser, Shannon] Texas A&M Univ, Coll Med, Dept Res, Dept Med Physio, Temple, TX 76508 USA; [Meng, Fanyin; Francis, Heather; Alpini, Gianfranco; Glaser, Shannon] Cent Texas Vet Hlth Care Syst, Temple, TX USA; [Meng, Fanyin; Francis, Heather; Alpini, Gianfranco; Glaser, Shannon] Baylor Scott & White Hlth Care, Baylor Scott & White Digest Dis Res Ctr, Temple, TX USA; [Wu, Chaodong] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA; [Alvaro, Domenico] Sapienza, Dept Gastroenterol, Rome, Italy; [Onori, Paolo; Mancinelli, Romina; Gaudio, Eugenio; Franchitto, Antonio] Sapienza, Dept Anat Histol Forens Med & Orthopaed Sci, Rome, Italy; [Franchitto, Antonio] Sapienza, Dept Med, Rome, Italy; [Franchitto, Antonio] Eleonora Lorillard Spencer Cenci Fdn, Rome, Italy	Alpini, G (reprint author), Cent Texas Vet Hlth Care Syst, Texas A&M Hlth Sci Ctr Coll Med, Olin E Teague Med Ctr, 1901 S First St,Bldg 205,1R60, Temple, TX 76504 USA.	galpini@medicine.tamhsc.edu	Onori, Paolo/J-9394-2013; Franchitto, Antonio/C-8095-2009	Onori, Paolo/0000-0002-7195-3760; 	Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology from Scott White; Veterans Affairs (VA) Research Career Scientist Award, US Department of Veterans Affairs Biomedical Laboratory Research and Development Service VA Merit Awards [5I01BX000574, 5I01BX002192, 1I01BX001724, 1I01BX003031]; University of Rome La SapienzaSapienza University Rome; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK054811, DK115184, DK076898, DK107310, DK062975, DK108959, DK095862]; American Diabetes AssociationAmerican Diabetes Association [1-17-IBS-145]; Central Texas Veterans Health Care System	Supported in part by the Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology from Scott & White, a Veterans Affairs (VA) Research Career Scientist Award, US Department of Veterans Affairs Biomedical Laboratory Research and Development Service VA Merit Awards 5I01BX000574 (G.A.), 5I01BX002192 (S.G.), 1I01BX001724 (F.M.), and 1I01BX003031 (H.F.), University of Rome La Sapienza (P.O.), NIH grants DK054811 (G.A., S.G., and F.M.), DK115184 (G.A., S.G., and F.M.), DK076898 (G.A., S.G., and F.M.), DK107310 (G.A., S.G., and F.M.), DK062975 (G.A., S.G., and F.M.), DK108959 (H.F.), and DK095862 (C.W.), American Diabetes Association grant 1-17-IBS-145 (C.W.), and the Central Texas Veterans Health Care System.	Alpini G, 1997, AM J PHYSIOL-GASTR L, V272, pG289; Alpini G, 1997, AM J PHYSIOL-GASTR L, V272, pG1064; Alpini G, 1998, AM J PHYSIOL-GASTR L, V274, pG767; ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; ALPINI G, 1994, AM J PHYSIOL, V266, pG922; Alpini G, 1996, GASTROENTEROLOGY, V110, P1636, DOI 10.1053/gast.1996.v110.pm8613073; ALVARO D, 1993, J CLIN INVEST, V92, P1314, DOI 10.1172/JCI116705; Alvaro D, 1997, AM J PHYSIOL-GASTR L, V273, pG303; Alvaro D, 2007, GASTROENTEROLOGY, V132, P415, DOI 10.1053/j.gastro.2006.07.023; Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602; Chen BY, 2010, J MEMBRANE BIOL, V235, P17, DOI 10.1007/s00232-010-9252-7; Dutta AK, 2013, AM J PHYSIOL-GASTR L, V304, pG87, DOI 10.1152/ajpgi.00154.2012; Dutta AK, 2011, J BIOL CHEM, V286, P766, DOI 10.1074/jbc.M110.164970; Feng XX, 2015, CANCER SCI, V106, P559, DOI 10.1111/cas.12632; Fiorotto R, 2011, GASTROENTEROLOGY, V141, P1498, DOI 10.1053/j.gastro.2011.06.052; Francis H, 2007, AM J PHYSIOL-CELL PH, V293, pC1252, DOI 10.1152/ajpcell.00031.2007; Glaser S, 2014, GASTROENTEROLOGY, V146, P1795, DOI 10.1053/j.gastro.2014.02.030; Glaser S, 2010, HEPATOLOGY, V52, P204, DOI 10.1002/hep.23657; Glaser SS, 2009, LAB INVEST, V89, P456, DOI 10.1038/labinvest.2009.6; Guerrier Micheleine, 2014, Hepatobiliary Surg Nutr, V3, P118, DOI 10.3978/j.issn.2304-3881.2014.04.04; Han YY, 2013, EXP BIOL MED, V238, P549, DOI 10.1177/1535370213489926; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; Jones H, 2016, HEPATOLOGY, V64, P1202, DOI 10.1002/hep.28704; Klein S, 2012, LAB INVEST, V92, P1440, DOI 10.1038/labinvest.2012.106; Korner M, 2006, J HEPATOL, V45, P825, DOI 10.1016/j.jhep.2006.06.016; Lan T, 2018, HEPATOLOGY, V68, P1070, DOI 10.1002/hep.29885; Lazaridis KN, 2004, GASTROENTEROLOGY, V127, P1565, DOI 10.1053/j.gastro.2004.08.006; LeSage GD, 1999, AM J PHYSIOL-GASTR L, V276, pG1289; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lunz JG, 2001, AM J PATHOL, V158, P1379, DOI 10.1016/S0002-9440(10)64089-8; Mancinelli R, 2010, AM J PATHOL, V176, P1790, DOI 10.2353/ajpath.2010.090677; MARTINEZANSO E, 1994, HEPATOLOGY, V19, P1400, DOI 10.1002/hep.1840190613; McDaniel K, 2017, HEPATOLOGY, V65, P544, DOI 10.1002/hep.28831; MCGILL JM, 1994, AM J PHYSIOL, V266, pG731; Meng LK, 2015, AM J PATHOL, V185, P602, DOI 10.1016/j.ajpath.2014.10.027; Moncsek A, 2018, HEPATOLOGY, V67, P247, DOI 10.1002/hep.29464; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakanuma Y, 2015, J HEPATOL, V62, P934, DOI 10.1016/j.jhep.2014.11.027; Puche JE, 2013, HEPATOLOGY, V57, P340, DOI 10.1002/hep.26053; Sato K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10694-3; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Spirli C, 2001, GASTROENTEROLOGY, V121, P156, DOI 10.1053/gast.2001.25516; Tabibian JH, 2014, HEPATOLOGY, V59, P2263, DOI 10.1002/hep.26993; Ueno Y, 2003, LIVER INT, V23, P449, DOI 10.1111/j.1478-3231.2003.00876.x; Valente R, 2016, NEW ENGL J MED, V375, P2500; Wan Y, 2017, HEPATOLOGY, V66, P528, DOI 10.1002/hep.29138; Wu N, 2016, HEPATOLOGY, V64, P865, DOI 10.1002/hep.28622; Yang H, 2018, ENVIRON SCI POLLUT R, V25, P867, DOI 10.1007/s11356-017-0344-0; Zerlanko BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035460	49	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2264	2280		10.1016/j.ajpath.2018.06.015			17	Pathology	Pathology	GV8SN	WOS:000446415800011	30036520	Bronze			2019-10-28	
J	Fernung, LEP; Jones, K; Mas, A; Kleven, D; Waller, JL; Al-Hendy, A				Fernung, Lauren E. Prusinski; Jones, Kimya; Mas, Aymara; Kleven, Daniel; Waller, Jennifer L.; Al-Hendy, Ayman			Expanding upon the Human Myometrial Stem Cell Hypothesis and the Role of Race, Hormones, Age, and Parity in a Profibroid Environment	AMERICAN JOURNAL OF PATHOLOGY			English	Article							UTERINE FIBROIDS; SIDE POPULATION; CANCER-RISK; LEIOMYOMA; DISPARITIES; PREGNANCY; EXPOSURE; WOMEN; TUMORIGENESIS; MECHANISMS	Uterine fibroids (UFs) are clonal, hormonally regulated, benign smooth-muscle myometrial tumors that severely affect female reproductive health, although their unknown etiology limits effective care. UFs occur fourfold more commonly in African American women than in Caucasian women, and African American women generally have earlier disease onset and greater UF tumor burden, although the mechanism of this ethnic disparity has not been identified. Recent findings have linked cancer (ie, tumor) risk to increased tissue-specific stem cell division and self-renewal and suggest that somatic mutations in myometrial stem cells (MyoSCs) convert them into tumor-initiating cells, leading to UF. Specifically, preliminary results in paraffin-embedded myometrial tissues have shown increased STRO-1(+)/CD44(+) MyoSCs in African American versus Caucasian women. Using specific methods of flow cytometry and automated quantitative pathology imaging, a large cohort of myometrial samples were investigated to determine how the STRO-1(+)/CD44(+) MyoSCs change with regard to a patient's race, age, parity, fibroid and hormone statuses, and the location of UFs within the uterus. We confirmed that the STRO-1(+)/CD44(+) MyoSC population is expanded in African American women, is correlated with parity and fibroid number, and fluctuates with cyclic menstrual cycle hormone changes and age. Our data suggest that an expanded MyoSC population increases the formation of tumor-initiating cells, ultimately contributing to increased UF prevalence and burden in African American women.	[Fernung, Lauren E. Prusinski] Augusta Univ, Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA USA; [Jones, Kimya; Kleven, Daniel] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA USA; [Waller, Jennifer L.] Augusta Univ, Med Coll Georgia, Dept Biostat & Data Sci, Augusta, GA USA; [Mas, Aymara] La Fe Hlth Res Inst, Reprod Med Res Grp, Valencia, Spain; [Al-Hendy, Ayman] Univ Illinois, Dept Obstet & Gynecol, 820 S Wood St,2nd Fl,M-C 808, Chicago, IL 60612 USA	Al-Hendy, A (reprint author), Univ Illinois, Dept Obstet & Gynecol, 820 S Wood St,2nd Fl,M-C 808, Chicago, IL 60612 USA.	aalhendy@uic.edu	Al-hendy, Ayman/J-9324-2019; Mas, Aymara/E-4409-2018		NIH National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES028615]; NIH National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F30 HD089585]; Augusta University Start-up Package from the Department of Obstetrics and Gynecology	Supported by NIH National Institute of Environmental Health Sciences grant R01 ES028615 (A.A.), NIH National Institute of Child Health and Human Development grant F30 HD089585 (L.E.P.F.), and the Augusta University Start-up Package from the Department of Obstetrics and Gynecology (A.A.). This work was conducted at Augusta University (Augusta, GA).	Albini A, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv213; Baird DD, 2003, EPIDEMIOLOGY, V14, P247; Bakas P, 2008, FERTIL STERIL, V90, P1878, DOI 10.1016/j.fertnstert.2007.09.019; Barbarisi A, 2001, J CELL PHYSIOL, V186, P414, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1040>3.0.CO;2-E; Borahay MA, 2015, MOL MED, V21, P242, DOI 10.2119/molmed.2014.00053; Cardozo ER, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.002; CDC/ NCEH (National Center for Environmental Health), 2005, NCEH PUB; Chakraborty J, 2007, J EPIDEMIOL COMMUN H, V61, P1074, DOI 10.1136/jech.2006.054130; Check JH, 2002, HUM REPROD, V17, P1244, DOI 10.1093/humrep/17.5.1244; Ciarmela P, 2011, J CLIN ENDOCR METAB, V96, P755, DOI 10.1210/jc.2010-0501; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Cramer SF, 2000, ARCH PATHOL LAB MED, V124, P1448; Fernung LEP, 2019, REPROD SCI, V26, P619, DOI 10.1177/1933719118783252; Fujimoto J, 1998, TUMOR BIOL, V19, P126, DOI 10.1159/000029983; HARRISONWOOLRYCH M, 1995, FERTIL STERIL, V64, P191, DOI 10.1016/S0015-0282(16)57679-1; Houston KD, 2001, TOXICOL PATHOL, V29, P100, DOI 10.1080/019262301301418900; Institute of Medicine Committee on Environmental Justice, 1999, COMM ENV JUST NAT AC; Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225; KATZ VL, 1989, OBSTET GYNECOL, V73, P593; KJERULFF KH, 1993, OBSTET GYNECOL, V82, P757; Klatsky PC, 2008, AM J OBSTET GYNECOL, V198, P357, DOI 10.1016/j.ajog.2007.12.039; Maruyama T, 2010, REPRODUCTION, V140, P11, DOI 10.1530/REP-09-0438; Mas A, 2017, BIOL REPROD, V96, P70, DOI 10.1095/biolreprod.116.143461; Mas A, 2017, STEM CELLS, V35, P666, DOI 10.1002/stem.2519; Mas A, 2015, FERTIL STERIL, V104, P225, DOI 10.1016/j.fertnstert.2015.04.021; Mas A, 2012, FERTIL STERIL, V98, P741, DOI 10.1016/j.fertnstert.2012.04.044; Meadows M, 2001, FDA Consum, V35, P21; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P1150, DOI 10.1289/ehp.8930; Moshesh M, 2014, J SEX MED, V11, P800, DOI 10.1111/jsm.12425; Narod SA, 2012, CURR ONCOL, V19, P9, DOI 10.3747/co.19.1003; Noor Shehla, 2009, J Ayub Med Coll Abbottabad, V21, P37; Ono M, 2007, P NATL ACAD SCI USA, V104, P18700, DOI 10.1073/pnas.0704472104; Ono M, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.114.127126; Ono M, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.123794; Ono M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036935; Othman EER, 2008, BEST PRACT RES CL OB, V22, P589, DOI 10.1016/j.bpobgyn.2008.01.014; PARAZZINI F, 1988, OBSTET GYNECOL, V72, P853, DOI 10.1097/00006250-198812000-00008; Prusinski Fernung LP, 2018, BIOL REPROD, DOI [10.1093/biolrefloy097, DOI 10.1093/BIOLREFLOY097]; Ramsey E., 1994, ANATOMY HUMAN UTERUS, P18; ROSS RK, 1986, BRIT MED J, V293, P359, DOI 10.1136/bmj.293.6543.359; Shynlova O, 2006, BIOL REPROD, V74, P839, DOI 10.1095/biolreprod.105.048124; Silbergeld EK, 2005, AM J OBSTET GYNECOL, V192, pS11, DOI 10.1016/j.ajog.2004.06.117; Stewart EA, 2017, BJOG-INT J OBSTET GY, V124, P1501, DOI 10.1111/1471-0528.14640; Stewart EA, 2013, J WOMENS HEALTH, V22, P807, DOI 10.1089/jwh.2013.4334; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Weintraub M, 2008, ENVIRON RES, V107, P412, DOI 10.1016/j.envres.2008.03.001; Yang QW, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00040; Yang QW, 2016, REPROD SCI, V23, P163, DOI 10.1177/1933719115584449	48	0	0	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2293	2306		10.1016/j.ajpath.2018.06.023			14	Pathology	Pathology	GV8SN	WOS:000446415800013	30075150	Bronze			2019-10-28	
J	Kim, T; Kim, S; Song, M; Lee, C; Yagita, H; Williams, DW; Sung, EC; Hong, C; Shin, KH; Kang, MK; Park, NH; Kim, RH				Kim, Terresa; Kim, Sol; Song, Minju; Lee, Cindy; Yagita, Hideo; Williams, Drake W.; Sung, Eric C.; Hong, Christine; Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.			Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BISPHOSPHONATE-RELATED OSTEONECROSIS; BONE METASTASES; ZOLEDRONIC ACID; BREAST-CANCER; DENOSUMAB; ANTIBODY; DISEASES; MODELS; COHORT	Medication-related osteonecrosis of the jaw (MRONJ) is a rare but detrimental intraoral lesion that predominantly occurs in patients with long-term use of antiresorptive agents, such as bisphosphonate and denosumab, a human anti-receptor activator of NF-kappa B ligand (RANKL) monoclonal antibody (Ab). Surgical intervention, such as tooth extraction, is a known risk factor for MRONJ, which is often performed to eliminate preexiting pathologic inflammatory conditions, such as periodontal diseases. Nonetheless, it remains unknown whether pre-existing periodontal disease condition exacerbates, or removal of such condition ameliorates, MRONJ development after tooth extraction. In this study, we combined the Ligature-induced periodontitis and the tooth extraction mouse models under the administration of zoledronic acid (ZOL) or anti-RANKL Ab, and provide experimental evidence that a pre-existing pathologic inflammatory condition exacerbates MRONJ development after tooth extraction in mice. Under ZOL administration, tooth extraction alone induced ONJ lesions; however, extraction of a ligature-placed tooth further exacerbated ONJ development. When the ligature was removed and the inflammatory condition was deescalated, ONJ development was ameliorated. Anti-RANKL Ab administration resulted in similar outcomes. Interestingly, unlike ZOL-administered mice, anti-RANKL Ab-administered mice exhibited complete absence of osteoclasts, suggesting that physical presence of osteocLasts is not directly involved in ONJ development. Collectively, our study demonstrated that periodontal disease is a functionally linked risk factor that predisposes ONJ development after tooth extraction in the presence of bisphosphonate and denosumab.	[Kim, Terresa; Kim, Sol; Song, Minju; Lee, Cindy; Williams, Drake W.; Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.] Univ Calif Los Angeles, Sch Dent, Shapiro Family Lab Viral Oncol & Aging Res, Los Angeles, CA 90024 USA; [Sung, Eric C.] Univ Calif Los Angeles, Sch Dent, Sect Special Patient Care, Los Angeles, CA 90024 USA; [Hong, Christine] Univ Calif Los Angeles, Sch Dent, Sect Orthodont, Los Angeles, CA 90024 USA; [Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Park, No-Hee] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Song, Minju] Dankook Univ, Sch Dent, Cheonan, South Korea; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo, Japan	Kim, RH (reprint author), Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, Room 43-009,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	rkim@dentistry.ucla.edu	; Williams, Drake/N-7788-2017	Song, Minju/0000-0001-7586-2359; Williams, Drake/0000-0002-7718-2098; Sung, Eric C./0000-0002-0725-1801	National Institute of Dental and Craniofacial Research/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE023348, F30DE025172]; UCLA School of Dentistry Dean's Faculty Research Seed grant	Supported by National Institute of Dental and Craniofacial Research/NIH grants R01DE023348 (R.H.K.) and F30DE025172 (D.W.W.), and UCLA School of Dentistry Dean's Faculty Research Seed grant (R.H.K.).	Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671; Akiyama T, 2012, WORLD J ORTHOP, V3, P142, DOI 10.5312/wjo.v3.i9.142; Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020; de Molon RS, 2015, J BONE MINER RES, V30, P1627, DOI 10.1002/jbmr.2490; Ferrari-Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198-010-1326-y; Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146; de Paula-Silva FWG, 2009, J ENDODONT, V35, P1234, DOI 10.1016/j.joen.2009.06.008; Graves DT, 2008, J CLIN PERIODONTOL, V35, P89, DOI 10.1111/j.1600-051X.2007.01172.x; Graves DT, 2012, FRONT ORAL BIOL, V15, P117, DOI 10.1159/000329675; Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549-010-0866-3; Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; JAMES WC, 1978, J PERIODONTOL, V49, P291, DOI 10.1902/jop.1978.49.6.291; Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565; Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098; Kim Reuben Han-Kyu, 2016, J Calif Dent Assoc, V44, P85; Martins AS, 2017, J CRANIO MAXILL SURG, V45, P1736, DOI 10.1016/j.jcms.2017.07.014; Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278-2391(03)00720-1; Muratsu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067906; Nair PNR, 2004, CRIT REV ORAL BIOL M, V15, P348, DOI 10.1177/154411130401500604; Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031; Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435; Sapna G, 2014, ORAL DIS, V20, P538, DOI 10.1111/odi.12159; Song MJ, 2016, J ENDODONT, V42, P1641, DOI 10.1016/j.joen.2016.07.020; Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101; Thumbigere-Math V, 2014, J PERIODONTOL, V85, P226, DOI 10.1902/jop.2013.130017; Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584; Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010; Yamazaki T, 2012, INT J ORAL MAX SURG, V41, P1397, DOI 10.1016/j.ijom.2012.06.020	29	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2318	2327		10.1016/j.ajpath.2018.06.019			10	Pathology	Pathology	GV8SN	WOS:000446415800015	30059656				2019-10-28	
J	Hudson, LE; Mendoza, P; Hudson, WH; Ziesel, A; Hubbard, GB; Wells, J; Dwivedi, B; Kowalski, J; Seby, S; Patel, V; Geisert, E; Specht, C; Grossniklaus, HE				Hudson, Lauren E.; Mendoza, Pia; Hudson, William H.; Ziesel, Alison; Hubbard, G. Baker, III; Wells, Jill; Dwivedi, Bhakti; Kowalski, Jeanne; Seby, Sandra; Patel, Viren; Geisert, Eldon; Specht, Charles; Grossniklaus, Hans E.			Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CLINICAL RISK-FACTORS; INTERNATIONAL CLASSIFICATION; INTRAARTERIAL CHEMOTHERAPY; INTRAOCULAR RETINOBLASTOMA; ENUCLEATED EYES; R-PACKAGE; PROMOTER; INVASION; COMPLEX; LECTURE	Morbidity and mortality associated with retinoblastoma have decreased drastically in recent decades, in large part owing to better prediction of high-risk disease and appropriate treatment stratification. High-risk histopathologic features and severe anaplasia both predict the need for more aggressive treatment; however, not all centers are able to assess tumor samples easily for the degree of anaplasia. Instead, identification of genetic signatures that are able to distinguish among anaplastic grades and thus predict high- versus low-risk retinoblastoma would facilitate appropriate risk stratification in a wider patient population. A better understanding of genes dysregulated in anaplasia also would yield valuable insights into pathways underlying the development of more severe retinoblastoma. Here, we present the histopathologic and gene expression analysis of 28 retinoblastoma cases using microarray analysis. Tumors of differing anaplastic grade show clear differential gene expression, with significant dysregulation of unique genes and pathways in severe anaplasia. Photoreceptor and nucleoporin expression in particular are identified as highly dysregulated in severe anaplasia and suggest particular cellular processes contributing to the development of increased retinoblastoma severity. A limited set of highly differentially expressed genes also are able to predict severe anaplasia accurately in our data set. Together, these data contribute to the understanding of the development of anaplasia and facilitate the identification of genetic markers of high risk retinoblastoma.	[Hudson, Lauren E.; Mendoza, Pia; Ziesel, Alison; Hubbard, G. Baker, III; Wells, Jill; Geisert, Eldon; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Dwivedi, Bhakti; Kowalski, Jeanne; Seby, Sandra] Emory Univ, Winship Canc Inst, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Kowalski, Jeanne] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Mendoza, Pia; Grossniklaus, Hans E.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Hudson, William H.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Patel, Viren] Emory Univ, Integrated Computat Core, Atlanta, GA 30322 USA; [Specht, Charles] Penn State Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA USA	Grossniklaus, HE (reprint author), Emory Eye Ctr, LF Montgomery Lab Ophthalm Pathol, Room BT 428,1365 Clifton Rd NE, Atlanta, GA 30322 USA.	ophtheg@emory.edu			National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [NEI P30EY06360]; Research to Prevent BlindnessResearch to Prevent Blindness (RPB)	Supported by National Eye Institute grant NEI P30EY06360 (H.E.G.) and a grant from Research to Prevent Blindness.	Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014; Abramson DH, 2010, BRIT J OPHTHALMOL, V94, P396, DOI 10.1136/bjo.2009.174268; Bodenhofer U, 2011, BIOINFORMATICS, V27, P2463, DOI 10.1093/bioinformatics/btr406; Broaddus E, 2009, BRIT J OPHTHALMOL, V93, P21, DOI 10.1136/bjo.2008.138750; Canturk S, 2010, BRIT J OPHTHALMOL, V94, P1432, DOI 10.1136/bjo.2009.168062; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Chow KH, 2012, NAT REV CANCER, V12, P196, DOI 10.1038/nrc3219; Eagle RC, 2009, ARCH PATHOL LAB MED, V133, P1203, DOI 10.1043/1543-2165-133.8.1203; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Frey BJ, 2007, SCIENCE, V315, P972, DOI 10.1126/science.1136800; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gobin YP, 2011, ARCH OPHTHALMOL-CHIC, V129, P732, DOI 10.1001/archophthalmol.2011.5; Grossniklaus HE, 2014, AM J OPHTHALMOL, V158, P875, DOI 10.1016/j.ajo.2014.07.025; HAIK BG, 1987, OPHTHALMOLOGY, V94, P367; Harbour JW, 2014, METHODS MOL BIOL, V1102, P427, DOI 10.1007/978-1-62703-727-3_22; Issaq SH, 2010, MOL CANCER RES, V8, P223, DOI 10.1158/1541-7786.MCR-09-0189; Jijelava KP, 2013, SAUDI J OPHTHALMOL, V27, P135, DOI 10.1016/j.sjopt.2013.06.006; Kabachinski G, 2015, J CELL SCI, V128, P423, DOI 10.1242/jcs.083246; Kaliki S, 2013, OPHTHALMOLOGY, V120, P997, DOI 10.1016/j.ophtha.2012.10.044; Kapatai G, 2013, BRIT J CANCER, V109, P512, DOI 10.1038/bjc.2013.283; Kooi IE, 2015, EBIOMEDICINE, V2, P660, DOI 10.1016/j.ebiom.2015.06.022; Le S, 2008, J STAT SOFTW, V25, P1; Li J., 2012, J LIPIDS, V2012, P1; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; Mabtum ED, 2013, ARQ BRAS OFTALMOL, V76, P247, DOI 10.1590/S0004-27492013000400013; Mendoza PR, 2015, AM J OPHTHALMOL, V159, P764, DOI 10.1016/j.ajo.2014.12.014; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Parplys AC, 2015, NUCLEIC ACIDS RES, V43, P9817, DOI 10.1093/nar/gkv859; Plotly Technologies Inc, 2015, COLL DAT SCI; Reese A, 1976, TUMORS EYE; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; Sastre X, 2009, ARCH PATHOL LAB MED, V133, P1199, DOI 10.1043/1543-2165-133.8.1199; Shields CL, 2011, ARCH OPHTHALMOL-CHIC, V129, P1399, DOI 10.1001/archophthalmol.2011.150; Shields CL, 2006, OPHTHALMOLOGY, V113, P2276, DOI 10.1016/j.ophtha.2006.06.018; Shields CL, 2008, OPHTHALMOLOGY, V115, P2253, DOI 10.1016/j.ophtha.2008.07.003; SHIELDS CL, 1993, BRIT J OPHTHALMOL, V77, P544, DOI 10.1136/bjo.77.9.544; SHIELDS CL, 1994, CANCER, V73, P692, DOI 10.1002/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8; Shields CL, 2002, AM J OPHTHALMOL, V133, P657, DOI 10.1016/S0002-9394(02)01348-X; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Stirzaker C, 1997, CANCER RES, V57, P2229; Strambio-De-Castillia C, 2010, NAT REV MOL CELL BIO, V11, P490, DOI 10.1038/nrm2928; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takai H, 2014, CELL REP, V9, P48, DOI 10.1016/j.celrep.2014.08.071; Wickham H., 2016, GGPLOT2 ELEGANT GRAP	46	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2328	2338		10.1016/j.ajpath.2018.06.013			11	Pathology	Pathology	GV8SN	WOS:000446415800016	30036517	Bronze			2019-10-28	
J	Aydin, Y; Stephens, CM; Chava, S; Heidari, Z; Panigrahi, R; Williams, DD; Wiltz, K; Bell, A; Wilson, W; Reiss, K; Dash, S				Aydin, Yucel; Stephens, Christopher M.; Chava, Srinivas; Heidari, Zahra; Panigrahi, Rajesh; Williams, Donkita D.; Wiltz, Kylar; Bell, Antoinette; Wilson, Wallace; Reiss, Krzysztof; Dash, Srikanta			Chaperone-Mediated Autophagy Promotes Beclin1 Degradation in Persistently Infected Hepatitis C Virus Cell Culture	AMERICAN JOURNAL OF PATHOLOGY			English	Article							UNFOLDED PROTEIN RESPONSE; HUMAN HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; ER STRESS; ACTIVATES STAT-3; IN-VITRO; CANCER; PATHWAY; PERK; CARCINOGENESIS	Liver cirrhosis is an independent risk factor for hepatocellular carcinoma (HCC). The mechanisms that contribute to HCC development in the cirrhotic microenvironment are unknown. We found that HCC grown in the highly stressed cirrhotic microenvironment undergoes autophagy switching from a protective state characterized by high macroautophagy with low chaperone-mediated autophagy (CMA) to an HCC-promoting state characterized by low macroautophagy with high CMA. This study examined how the stress response executes oncogenic cell programming through autophagy switching using hepatitis C virus cell culture. Protein kinase R-like endoplasmic reticulum kinase expression increased to high levels in hepatitis C virus culture. Protein kinase R-like endoplasmic reticulum kinase-dependent activation of nuclear factor erythroid 2-related factor (Nrf2) led to increased transcription of the cytoprotective genes: heat shock cognate 70 kDa protein and lysosome-associated membrane protein 2A (LAMP2A) and precipitated the induction of CMA. CMA selectively targeted beclin1 degradation, leading to accumulation of the autophagy flux protein p62 due to impaired autophagosome-endosome fusion. This impaired autophagosome-endosome fusion due to beclin1 degradation inhibited endocytosis and degradation of epidermal growth factor receptor. Silencing Nrf2 and LAMP2A reduced cell viability, suggesting that the stress response activates CMA as a compensatory mechanism of cell survival. We report a novel mechanism through which stress response triggers oncogenic Nrf2 signaling that promotes autophagy switching to favor cell survival.	[Aydin, Yucel; Stephens, Christopher M.; Chava, Srinivas; Panigrahi, Rajesh; Williams, Donkita D.; Wiltz, Kylar; Bell, Antoinette; Wilson, Wallace; Dash, Srikanta] Tulane Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, Box 8679,1430 Tulane Ave, New Orleans, LA 70112 USA; [Heidari, Zahra] Tulane Univ, Dept Chem & Biomed Engn, New Orleans, LA 70118 USA; [Reiss, Krzysztof] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA	Dash, S (reprint author), Tulane Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, Box 8679,1430 Tulane Ave, New Orleans, LA 70112 USA.	sdash@tulane.edu	AYDIN, YUCEL/AAA-8522-2019	AYDIN, YUCEL/0000-0001-6727-6296; Bell, Antoinette/0000-0002-9353-5615; Wilson, Wallace/0000-0002-9470-9445	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA089121, AI103106, 1P20 GM121288-01]; Louisiana Clinical and Translational Science Center [U54 GM104940]	Supported by NIH grants CA089121 (S.D.), AI103106 (S.D.), and 1P20 GM121288-01 (Y.A.) and Louisiana Clinical and Translational Science Center grant U54 GM104940.	Aydin Y, 2017, HEPATOL COMMUN, V1, P256, DOI [10.1002/hep4.1025/suppinfo, 10.1002/hep4.1025]; Aydin Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10087-6; Baiceanu A, 2016, NAT REV ENDOCRINOL, V12, P710, DOI 10.1038/nrendo.2016.124; Bao LL, 2014, EXP MOL PATHOL, V96, P149, DOI 10.1016/j.yexmp.2013.12.002; Bartenschlager R, 2011, TRENDS MICROBIOL, V19, P95, DOI 10.1016/j.tim.2010.11.005; Chandra PK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108616; Chandra PK, 2014, AM J PATHOL, V184, P214, DOI 10.1016/j.ajpath.2013.10.005; Chava S, 2017, ONCOTARGET, V8, P40019, DOI 10.18632/oncotarget.16685; Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Dash S, 2016, VIRUSES, V23, P8; Dreux M, 2010, CELL CYCLE, V9, P1295, DOI 10.4161/cc.9.7.11109; Florczyk U, 2011, FREE RADICAL BIO MED, V51, P1882, DOI 10.1016/j.freeradbiomed.2011.08.023; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Ji GR, 2015, INT J BIOL SCI, V11, P803, DOI 10.7150/ijbs.11100; Joyce MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000291; Karin M, 2016, CARCINOGENESIS, V37, P541, DOI 10.1093/carcin/bgw060; Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006; Ke PY, 2011, J CLIN INVEST, V121, P37, DOI 10.1172/JCI41474; Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Kurt R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125962; Levine B, 2015, TRENDS CELL BIOL, V25, P533, DOI 10.1016/j.tcb.2015.05.004; Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441; Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x; Lloyd-Lewis B, 2018, J BIOL CHEM, V293, P4244, DOI 10.1074/jbc.RA118.001777; Lu P, 2014, BIOL TRACE ELEM RES, V159, P434, DOI 10.1007/s12011-014-9988-5; Macri C, 2015, AUTOPHAGY, V11, P472, DOI 10.1080/15548627.2015.1017179; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002; Merquiol E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024660; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Munafo DB, 2001, J CELL SCI, V114, P3619; Petruzziello A, 2016, WORLD J GASTROENTERO, V22, P7824, DOI 10.3748/wjg.v22.i34.7824; Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rah B, 2015, AUTOPHAGY, V11, P314, DOI 10.1080/15548627.2015.1017182; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Rusyn I, 2014, CANCER LETT, V345, P210, DOI 10.1016/j.canlet.2013.06.028; Saeed M, 2011, J BIOL CHEM, V286, P37264, DOI 10.1074/jbc.M111.259085; Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003; Scheel TKH, 2013, NAT MED, V19, P837, DOI 10.1038/nm.3248; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Shang J, 2007, J CELL BIOL, V176, P605, DOI 10.1083/jcb.200607007; Shi YH, 2009, AUTOPHAGY, V5, P380, DOI 10.4161/auto.5.3.7658; Shinohara Y, 2013, BIOCHEM BIOPH RES CO, V432, P326, DOI 10.1016/j.bbrc.2013.01.103; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464; Sir D, 2008, AUTOPHAGY, V4, P830, DOI 10.4161/auto.6566; Sir D, 2012, J BIOL CHEM, V287, P18036, DOI 10.1074/jbc.M111.320085; Son YO, 2014, J BIOL CHEM, V289, P28660, DOI 10.1074/jbc.M114.595496; Sugiura K, 2009, J INVEST DERMATOL, V129, P2126, DOI 10.1038/jid.2009.51; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tardif KD, 2005, TRENDS MICROBIOL, V13, P159, DOI 10.1016/j.tim.2005.02.004; Tardif KD, 2004, J BIOL CHEM, V279, P17158, DOI 10.1074/jbc.M312144200; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006; Wang LY, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004764; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Waris G, 2005, J VIROL, V79, P1569, DOI 10.1128/JVI.79.3.1569-1580.2005	65	0	0	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2339	2355		10.1016/j.ajpath.2018.06.022			17	Pathology	Pathology	GV8SN	WOS:000446415800017	30075149				2019-10-28	
J	Caron, JM; Han, XH; Contois, L; Vary, CPH; Brooks, PC				Caron, Jennifer M.; Han, XiangHua; Contois, Liangru; Vary, Calvin P. H.; Brooks, Peter C.			The HU177 Collagen Epitope Controls Melanoma Cell Migration and Experimental Metastasis by a CDK5/YAP-Dependent Mechanism	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HUMANIZED ANTIBODY D93; TUMOR-GROWTH; EXTRACELLULAR-MATRIX; ANGIOGENESIS; INTEGRIN; PHOSPHORYLATION; INHIBITION; BINDING; CDK5; IDENTIFICATION	Stromal components not only help form the structure of neoplasms such as melanomas, but they also functionally contribute to their malignant phenotype. Thus, uncovering signaling pathways that integrate the behavior of both tumor and stromaL cells may provide unique opportunities for the development of more effective strategies to control tumor progression. In this regard, extracellular matrix-mediated signaling plays a role in coordinating the behavior of both tumor and stromal cells. Here, evidence is provided that targeting a cryptic region of the extracellular matrix protein collagen (HU177 epitope) inhibits melanoma tumor growth and metastasis and reduces angiogenesis and the accumulation of alpha-SMA-expressing stromal cell in these tumors. The current study suggests that the ability of the HU177 epitope to control melanoma cell migration and metastasis depends on the transcriptional coactivator Yes-associated protein (YAP). Melanoma cell interactions with the HU177 epitope promoted nuclear accumulation of YAP by a cyclin-dependent kinase-5-associated mechanism. These findings provide new insights into the mechanism by which the anti-HU177 antibody inhibits metastasis, and uncovers an unknown signaling pathway by which the HU177 epitope selectively reprograms melanoma cells by regulating nuclear localization of YAP. This study helps to define a potential new therapeutic strategy to control melanoma tumor growth and metastasis that might be used alone or in combination with other therapeutics.	[Caron, Jennifer M.; Han, XiangHua; Contois, Liangru; Vary, Calvin P. H.; Brooks, Peter C.] Maine Med Ctr Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA	Brooks, PC (reprint author), Maine Med Ctr Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	brookp1@mmc.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA196739, P20GM106391 COBRE]	Supported in part by NIH grant CA196739 (P.C.B.) and institutional support from Maine Medical Center. This work also utilized the services of the molecular phenotyping core facility at Maine Medical Center Research Institute, funded by NIH grant P20GM106391 COBRE in Stem and Progenitor Cell Biology and Regenerative Medicine.	Akaht A, 2007, CANCER RES, V67, P4353, DOI 10.1158/0008-5472.CAN-06-0482; Alexander J, 2016, CURR OPIN CELL BIOL, V42, P80, DOI 10.1016/j.ceb.2016.05.002; Ames JJ, 2016, J BIOL CHEM, V291, P2731, DOI 10.1074/jbc.M115.669614; Atkins MB, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv414; Bisht S, 2015, TRANSL ONCOL, V8, P295, DOI 10.1016/j.tranon.2015.06.002; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Caron JM, 2016, AM J PATHOL, V186, P1649, DOI 10.1016/j.ajpath.2016.01.015; Contois L, 2009, SEMIN CANCER BIOL, V19, P318, DOI 10.1016/j.semcancer.2009.05.002; Cretu A, 2007, J CELL PHYSIOL, V213, P391, DOI 10.1002/jcp.21222; Cretu A, 2007, CLIN CANCER RES, V13, P3068, DOI 10.1158/1078-0432.CCR-06-2342; Egnblad M, 2010, DEV CELL, V18, P884; Freimark B, 2007, MOL IMMUNOL, V44, P3741, DOI 10.1016/j.molimm.2007.03.027; Gagne PJ, 2005, AM J PATHOL, V167, P1349, DOI 10.1016/S0002-9440(10)61222-9; Hamilton HK, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-19; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang C, 2009, NAT CELL BIOL, V11, P624, DOI 10.1038/ncb1868; Inada M, 2015, J BIOL CHEM, V290, P29781, DOI 10.1074/jbc.M115.669481; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Lopez-Bergami P, 2011, PIGM CELL MELANOMA R, V24, P902, DOI 10.1111/j.1755-148X.2011.00908.x; Lydolph MC, 2009, EXP CELL RES, V315, P3312, DOI 10.1016/j.yexcr.2009.09.022; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Mulgrew K, 2006, MOL CANCER THER, V5, P3122, DOI 10.1158/1535-7163.MCT-06-0356; Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321; Ng B, 2008, CLIN CANCER RES, V14, P6253, DOI 10.1158/1078-0432.CCR-07-4992; Pernasetti F, 2006, INT J ONCOL, V29, P1371; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Raab-Westphal S, 2017, CANCERS, V9, DOI 10.3390/cancers9090110; Ramovs V, 2017, MATRIX BIOL, V57-58, P213, DOI 10.1016/j.matbio.2016.08.007; Reynolds AR, 2009, NAT MED, V15, P392, DOI 10.1038/nm.1941; ROBERT F, 2010, J CLIN ONCOL S, V28; Robinson SD, 2011, CURR OPIN CELL BIOL, V23, P630, DOI 10.1016/j.ceb.2011.03.014; Roth JM, 2006, AM J PATHOL, V168, P1576, DOI 10.2353/ajpath.2006.050176; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Shupp A, 2017, ONCOTARGET, V8, P17373, DOI 10.18632/oncotarget.14538; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Wenke AK, 2007, CELL ONCOL, V29, P373; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu JS, 2000, HYBRIDOMA, V19, P375, DOI 10.1089/02724570050198893; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	50	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2356	2368		10.1016/j.ajpath.2018.06.017			13	Pathology	Pathology	GV8SN	WOS:000446415800018	30118657				2019-10-28	
J	Romero, P; Benhamo, V; Deniziaut, G; Fuhrmann, L; Berger, F; Manie, E; Bhalshankar, J; Vacher, S; Laurent, C; Marangoni, E; Gruel, N; MacGrogan, G; Rouzier, R; Delattre, O; Popova, T; Reyal, F; Stern, MH; Stoppa-Lyonnet, D; Marchio, C; Bieche, I; Vincent-Salomon, A				Romero, Pierre; Benhamo, Vanessa; Deniziaut, Gabrielle; Fuhrmann, Laetitia; Berger, Frederique; Manie, Elodie; Bhalshankar, Jaydutt; Vacher, Sophie; Laurent, Cecile; Marangoni, Elisabetta; Gruel, Nadege; MacGrogan, Gaetan; Rouzier, Roman; Delattre, Olivier; Popova, Tatiana; Reyal, Fabien; Stern, Marc-Henri; Stoppa-Lyonnet, Dominique; Marchio, Caterina; Bieche, Ivan; Vincent-Salomon, Anne			Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GENE; IDENTIFICATION; LYMPHOCYTES; APOPTOSIS; MUTATION	Medullary breast carcinoma (MBC) is a rare subtype of triple-negative breast cancer with specific genomic features within the spectrum of basal-like carcinoma (BLC). In this study of 19 MBCs and 36 non-MBC BLCs, we refined the transcriptomic and genomic knowledge about this entity. Unsupervised and supervised analysis of transcriptomic profiles confirmed that MBC clearly differs from non-MBC BLC, with 92 genes overexpressed and 154 genes underexpressed in MBC compared with non-MBC BLC. Immunity-related pathways are the most differentially represented pathways in MBC compared with non-MBC BLC. The proapoptotic gene BCLG (official name BCL2L14) is by far the most intensely overexpressed gene in MBC. A quantitative RT-PCR validation study conducted in 526 breast tumors corresponding to all molecular subtypes documented the specificity of BCLG overexpression in MBC, which was confirmed at the protein level by immunohistochemistry. We also found that most MBCs belong to the immunomodulatory triple-negative breast cancer subtype. Using pan-genomic analysis, it was found that MBC harbors more losses of heterozygosity than non-MBC BLC. These observations corroborate the notion that MBC remains a distinct entity that could benefit from specific treatment strategies (such as deescalation or targeted therapy) adapted to this rare tumor type.	[Romero, Pierre; Deniziaut, Gabrielle; Fuhrmann, Laetitia; Stern, Marc-Henri; Stoppa-Lyonnet, Dominique; Marchio, Caterina; Vincent-Salomon, Anne] PSL Res Univ, Dept Pathol, Paris, France; [Benhamo, Vanessa; Laurent, Cecile; Marangoni, Elisabetta; Gruel, Nadege; Reyal, Fabien] PSL Res Univ, Dept Translat Res, Paris, France; [Rouzier, Roman; Reyal, Fabien] PSL Res Univ, Dept Surg, Paris, France; [Vacher, Sophie; Bieche, Ivan] PSL Res Univ, Pharmacogen Unit, Paris, France; [Benhamo, Vanessa; Fuhrmann, Laetitia; Manie, Elodie; Bhalshankar, Jaydutt; Gruel, Nadege; Delattre, Olivier; Popova, Tatiana; Stern, Marc-Henri; Stoppa-Lyonnet, Dominique; Vincent-Salomon, Anne] PSL Res Univ, Dept Genet, INSERM, U934, Paris, France; [Berger, Frederique] PSL Res Univ, Inst Curie, INSERM, Unit Biometry,U900, Paris, France; [MacGrogan, Gaetan] Inst Bergonie, Dept Biopathol, Bordeaux, France; [Stoppa-Lyonnet, Dominique] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Bieche, Ivan] Univ Paris 05, EA 7331, Paris, France; [Marchio, Caterina] Univ Turin, Inst Pathol, Dept Med Sci, Turin, Italy	Romero, P (reprint author), Inst Curie, Dept Pathol, 26 Rue Ulm, F-75248 Paris 05, France.	pierre.romero@curie.fr	BERGER, Frederique/A-8893-2008; Stern, Marc-Henri/A-2728-2011	BERGER, Frederique/0000-0002-3251-4060; Stern, Marc-Henri/0000-0002-8100-2272; delattre, olivier/0000-0002-8730-2276	Grand Prix Ruban Rose 2012; Mayent-Rothschild Foundation	Supported by the Grand Prix Ruban Rose 2012 (A.V.-S.) and in part by a grant from the Mayent-Rothschild Foundation (C.M.).	Abramson VG, 2015, CANCER-AM CANCER SOC, V121, P8, DOI 10.1002/cncr.28914; Balasubramanian D, 2012, GENOME MED, V4, DOI 10.1186/gm346; Bareche Y, 2018, ANN ONCOL, V29, P895, DOI 10.1093/annonc/mdy024; Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031; Bieche I, 2001, CANCER RES, V61, P1652; Bieche I, 1999, CLIN CHEM, V45, P1148; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coit P, 2013, J AUTOIMMUN, V43, P78, DOI 10.1016/j.jaut.2013.04.003; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Huober J, 2012, ANN ONCOL, V23, P2843, DOI 10.1093/annonc/mds105; Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; Jiang GL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2911-z; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; Luo N, 2009, CLIN IMMUNOL, V132, P349, DOI 10.1016/j.clim.2009.05.010; Manie E, 2009, CANCER RES, V69, P663, DOI 10.1158/0008-5472.CAN-08-1560; McPherson A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001138; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Nakamura M, 2015, IMMUNOL INVEST, V44, P1, DOI 10.3109/08820139.2014.909454; Pedersen L, 1995, EUR J CANCER, V31A, P2289, DOI 10.1016/0959-8049(95)00408-4; Pickard MR, 2011, BBA-MOL BASIS DIS, V1812, P1146, DOI 10.1016/j.bbadis.2011.04.009; Pickard MR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2350; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Popova T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r128; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Stirzaker C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6899; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; VINAYAK S, 2014, J CLIN ONCOL S, V32; Vincent-Salomon A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1666	36	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2378	2391		10.1016/j.ajpath.2018.06.021			14	Pathology	Pathology	GV8SN	WOS:000446415800020	30075151				2019-10-28	
J	Lin, CM; Titchenell, PM; Keil, JM; Garcia-Ocana, A; Bolinger, MT; Abcouwer, SF; Antonetti, DA				Lin, Cheng-mao; Titchenell, Paul M.; Keil, Jason M.; Garcia-Ocana, Adolfo; Bolinger, Mark T.; Abcouwer, Steven F.; Antonetti, David A.			Inhibition of Atypical Protein Kinase C Reduces Inflammation-Induced Retinal Vascular Permeability	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DIABETIC MACULAR EDEMA; ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B; TIGHT JUNCTION TRAFFICKING; PKC-ZETA; RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB; INFLIXIMAB; DEGENERATION	Changes in permeability of retinal blood vessels contribute to macular edema and the pathophysiology of numerous ocular diseases, including diabetic retinopathy, retinal vein occlusions, and macular degeneration. Vascular endothelial growth factor (VEGF) induces retinal permeability and macular thickening in these diseases. However, inflammatory agents, such as tumor necrosis factor-alpha (TNF-alpha), also may drive vascular permeability, specifically in patients unresponsive to anti-VEGF therapy. Recent evidence suggests VEGF and TNF-alpha induce permeability through distinct mechanisms; however, both require the activation of atypical protein kinase C (aPKC). We provide evidence, using genetic mouse models and therapeutic intervention with small molecules, that inhibition of aPKC prevented or reduced vascular permeability in animal models of retinal inflammation. Expression of a kinase-dead aPKC transgene, driven by a vascular and hematopoietic restricted promoter, reduced retinal vascular permeability in an ischemia-reperfusion model of retinal injury. This effect was recapitulated with a small-molecule inhibitor of aPKC. Expression of the kinase-dead aPKC transgene dramatically reduced the expression of inflammatory factors and blocked the attraction of inflammatory monocytes and granulocytes after ischemic injury. Coinjection of VEGF with TNF-alpha was sufficient to induce permeability, edema, and retinal inflammation, and treatment with an aPKC inhibitor prevented VEGF/TNF-alpha-induced permeability. These data suggest that aPKC contributes to inflammation-driven retinal vascular pathology and may be an attractive target for therapeutic intervention.	[Lin, Cheng-mao; Bolinger, Mark T.; Abcouwer, Steven F.; Antonetti, David A.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; [Keil, Jason M.] Univ Michigan, Dept Human Genet, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Keil, Jason M.] Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA; [Titchenell, Paul M.] Univ Penn, Inst Diabet Obes & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA; [Garcia-Ocana, Adolfo] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Antonetti, DA (reprint author), Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.	dantonet@umich.edu		Lin, Cheng-mao/0000-0003-2409-9423; Keil, Jason/0000-0002-3431-5540; Bolinger, Mark/0000-0001-7875-7570	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EY012021, R01 EY023725, R24 EY024868]; Research to Prevent Blindness grantsResearch to Prevent Blindness (RPB); JDRF grants; National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30 EY007003]; Morphology and Image Analysis Core of the Michigan Diabetes Research and Training Center [P30 DK020572]	Supported by NIH grants R01 EY012021 (D.A.A.), R01 EY023725 (D.A.A.), and R24 EY024868 (D.A.A. and S.F.A.), Research to Prevent Blindness grants (D.A.A.), and JDRF grants (D.A.A.). This work used the Vision Research Core at the Kellogg Eye Center, funded by National Eye Institute grant P30 EY007003 and Morphology and Image Analysis Core of the Michigan Diabetes Research and Training Center grant P30 DK020572.	Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149; Abcouwer SF, 2010, INVEST OPHTH VIS SCI, V51, P5920, DOI 10.1167/iovs.10-5264; Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x; Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073; Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942; Arita R, 2013, INVEST OPHTH VIS SCI, V54, P2373, DOI 10.1167/iovs.12-10757; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Bressler SB, 2017, JAMA OPHTHALMOL, V135, P558, DOI 10.1001/jamaophthalmol.2017.0821; Cai S, 2017, CURR OPIN OPHTHALMOL, V28, P636, DOI 10.1097/ICU.0000000000000424; Campochiaro PA, 2012, OPHTHALMOLOGICA, V227, P30, DOI 10.1159/000337157; de Kozak Y, 2007, AM J PATHOL, V170, P1241, DOI 10.2353/ajpath.2007.060236; Dimitrijevic OB, 2006, J CEREBR BLOOD F MET, V26, P797, DOI 10.1038/sj.jcbfm.9600229; Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005; Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768; Huang X, 2009, J IMMUNOL, V182, P5810, DOI 10.4049/jimmunol.0804073; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Johnson MW, 2009, AM J OPHTHALMOL, V147, P11, DOI 10.1016/j.ajo.2008.07.024; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; KLEIN R, 1995, OPHTHALMOLOGY, V102, P7; Knudsen LL, 2006, BRIT J OPHTHALMOL, V90, P1404, DOI 10.1136/bjo.2006.093393; Korot E, 2016, JAMA OPHTHALMOL, V134, P15, DOI 10.1001/jamaophthalmol.2015.3949; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Leslie KL, 2013, J BIOL CHEM, V288, P36426, DOI 10.1074/jbc.M113.483339; Markomichelakis NN, 2004, AM J OPHTHALMOL, V138, P648, DOI 10.1016/j.ajo.2004.04.066; Minshall RD, 2010, MICROVASC RES, V80, P240, DOI 10.1016/j.mvr.2010.04.007; Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823; Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Muthusamy A, 2014, J CEREBR BLOOD F MET, V34, P522, DOI 10.1038/jcbfm.2013.230; Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Sfikakis PP, 2010, DIABETES CARE, V33, P1523, DOI 10.2337/dc09-2372; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tang YF, 2010, GENESIS, V48, P563, DOI 10.1002/dvg.20654; Thomas G, 2015, ARTERIOSCL THROM VAS, V35, P1306, DOI 10.1161/ATVBAHA.114.304650; Titchenell PM, 2013, BIOORG MED CHEM LETT, V23, P3034, DOI 10.1016/j.bmcl.2013.03.019; Titchenell PM, 2012, BIOCHEM J, V446, P455, DOI 10.1042/BJ20111961; Vasavada RC, 2007, DIABETES, V56, P2732, DOI 10.2337/db07-0461	39	2	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2018	188	10					2392	2405		10.1016/j.ajpath.2018.06.020			14	Pathology	Pathology	GV8SN	WOS:000446415800021	30220554	Bronze			2019-10-28	
J	Kondo, T; Sasa, N; Yamada, H; Takagi, T; Iizuka, J; Kobayashi, H; Yoshida, K; Fukuda, H; Ishihara, H; Tanabe, K; Tsuzuki, T				Kondo, Tsunenori; Sasa, Naoto; Yamada, Hiroshi; Takagi, Toshio; Iizuka, Junpei; Kobayashi, Hirohito; Yoshida, Kazuhiko; Fukuda, Hironori; Ishihara, Hiroki; Tanabe, Kazunari; Tsuzuki, Toyonori			Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study	PATHOLOGY INTERNATIONAL			English	Article						cystic kidney disease; dialysis; end-stage renal disease; pathology; renal cell carcinoma	KIDNEY-DISEASE; HEMODIALYSIS; DIALYSIS; CANCER; PROGNOSIS; EMPHASIS; DURATION	New pathological subtypes of renal cell carcinoma (RCC) were designated in the 2016 World Health Organization (WHO) classification corresponding to the features commonly seen in patients with end-stage renal disease (ESRD). To determine the clinicopathological findings of new subtypes, we reanalyzed all sections from 315 kidneys in 291 ESRD patients bearing RCC tumors surgically resected in three Japanese institutes by the central pathologist. Clear cell RCC was diagnosed in 144 kidneys (45.7%), acquired cystic disease (ACD)-associated RCC in 100 (31.7%), papillary RCC in 41 (13.0%), and other minor subtypes in 30 (9.52%). Multivariate analysis showed that longer duration of dialysis, young age, and male sex were independent prognostic clinical factors for the occurrence of ACD-associated RCC. ACD-associated RCC included more WHO/International Society of Urologic Pathology (ISUP) grade 3/4 cases compared to other RCCs. In contrast, other unfavorable findings were less frequent in ACD-associated RCC, including the presence of a sarcomatoid component, lymphovascular invasion, and necrosis. In conclusion, ACD-associated RCC is a common histology in Japanese patients with ESRD. In addition, ACD-associated RCC showed more cases with a higher WHO/ISUP grade, but fewer cases with other unfavorable pathological features, suggesting a favorable prognosis of ACD-associated RCC.	[Kondo, Tsunenori; Takagi, Toshio; Iizuka, Junpei; Kobayashi, Hirohito; Yoshida, Kazuhiko; Fukuda, Hironori; Ishihara, Hiroki; Tanabe, Kazunari] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan; [Kondo, Tsunenori] Tokyo Womens Med Univ, Med Ctr East, Dept Urol, Tokyo, Japan; [Sasa, Naoto] Nagoya Univ, Dept Urol, Nagoya, Aichi, Japan; [Yamada, Hiroshi] Japanese Red Cross Nagoya Daini Hosp, Dept Urol, Nagoya, Aichi, Japan; [Tsuzuki, Toyonori] Aichi Med Univ, Dept Pathol, Nagakute, Aichi, Japan	Kondo, T (reprint author), Tokyo Womens Med Univ, Med Ctr East, Dept Urol, Arakawa ku, 2-1-10 Nishiogu, Tokyo 1168567, Japan.	tkondo@twmu.ac.jp		Yoshida, Kazuhiko/0000-0002-3834-0153; Ishihara, Hiroki/0000-0002-5146-656X			Aron M, 2015, AM J SURG PATHOL, V39, P873, DOI 10.1097/PAS.0000000000000446; Brierley JD, 2016, TNM CLASSIFICATION M, P199; Butler AM, 2015, AM J KIDNEY DIS, V65, P763, DOI 10.1053/j.ajkd.2014.12.013; DUNNILL MS, 1977, J CLIN PATHOL, V30, P868, DOI 10.1136/jcp.30.9.868; Hashimoto Y, 2015, INT J CLIN ONCOL, V20, P1035, DOI 10.1007/s10147-015-0812-9; Huang XB, 1999, NEPHRON, V81, P458, DOI 10.1159/000045340; International Agency for Research on Cancer, 2016, IARC WHO CLASS TUM; Ishikawa I, 2004, NEPHRON CLIN PRACT, V97, pC11, DOI 10.1159/000077590; Ito F, 2000, NEPHRON, V86, P192, DOI 10.1159/000045743; Kuroda N, 2017, POL J PATHOL, V68, P306, DOI [10.5114/PJP.2017.73926, 10.5114/pjp.2017.73926]; Kuroda N, 2010, MED MOL MORPHOL, V43, P231, DOI 10.1007/s00795-009-0465-8; Levine E, 1996, RADIOL CLIN N AM, V34, P947; Liang JA, 2011, JPN J CLIN ONCOL, V41, P752, DOI 10.1093/jjco/hyr051; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; MATSON MA, 1990, MEDICINE, V69, P217, DOI 10.1097/00005792-199007000-00003; NARASIMHAN N, 1986, KIDNEY INT, V30, P748, DOI 10.1038/ki.1986.251; Neuzillet Y, 2011, EUR UROL, V60, P366, DOI 10.1016/j.eururo.2011.02.035; Nouh MAAM, 2010, BJU INT, V105, P620, DOI 10.1111/j.1464-410X.2009.08817.x; Pan CC, 2009, HISTOPATHOLOGY, V55, P145, DOI 10.1111/j.1365-2559.2009.03361.x; Paner GP, 2010, AM J SURG PATHOL, V34, P1233, DOI 10.1097/PAS.0b013e3181e96f2a; Sassa N, 2011, NEPHROL DIAL TRANSPL, V26, P1677, DOI 10.1093/ndt/gfq529; Shi SS, 2013, INT J CLIN EXP PATHO, V6, P2936; Stewart JH, 2009, NEPHROL DIAL TRANSPL, V24, P3225, DOI 10.1093/ndt/gfp331; Tickoo SK, 2006, AM J SURG PATHOL, V30, P141, DOI 10.1097/01.pas.0000185382.80844.b1; Zhou HJ, 2014, HUM PATHOL, V45, P59, DOI 10.1016/j.humpath.2013.08.004	25	3	3	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					543	549		10.1111/pin.12718			7	Pathology	Pathology	GV9EJ	WOS:000446457500001	30187581				2019-10-28	
J	Bahadir, B; Behzatoglu, K; Hacihasanoglu, E; Koca, SB; Sigirci, BB; Tokat, F				Bahadir, Burak; Behzatoglu, Kemal; Hacihasanoglu, Ezgi; Koca, Sevim Baykal; Sigirci, Buket Bambul; Tokat, Fatma			Atypical spindle cell/pleomorphic lipomatous tumor: A clinicopathologic, immunohistochemical, and molecular study of 20 cases	PATHOLOGY INTERNATIONAL			English	Article						atypical pleomorphic lipomatous tumor; atypical spindle cell lipomatous tumor; dedifferentiated liposarcoma; dedifferentiation; liposarcoma	CELL LIPOMA; LIPOSARCOMA; NEOPLASM	Lipomatous tumors accompanied by spindle cell component are not frequently encountered, and there are still problems regarding their differential diagnosis, nature, and nomenclature. To contribute to ongoing efforts, we present the clinical, histologic, and immunohistochemical characteristics of 20 cases of spindle cell lipomatous tumors with atypical features that may also be called atypical spindle cell/pleomorphic lipomatous tumors. Of the patients, 13 were men and 7 were women with an average age of 57.5 years. The most commonly affected site was the extremities. Twelve tumors arose in the subcutaneous tissue, while eight cases were located in the deep soft tissues. Tumor margins were often ill-defined with invasion into the surrounding tissues. Microscopic examination revealed a wide spectrum of histologic features. All cases consisted of poorly marginated proliferation of mildly atypical spindle cells set in a fibrous or myxoid stroma with a variable amount of adipocytic component showing variation in adipocyte size and scattered nuclear atypia and frequent univacuolated or multivacuolated lipoblasts. Tumor cellularity and the relative proportion of the components were highly variable. One tumor showed morphologic features evocative of dedifferentiation and another one exhibited histological features resembling pleomorphic liposarcoma. None of the patients had recurrence or metastasis at follow-up.	[Bahadir, Burak] Bulent Ecevit Univ, Fac Med, Dept Pathol, Zonguldak, Turkey; [Behzatoglu, Kemal] Atakent Hosp, Acibadem Hlth Grp, Dept Pathol, Istanbul, Turkey; [Hacihasanoglu, Ezgi] Sirnak State Hosp, Minist Hlth, Dept Pathol, Sirnak, Turkey; [Koca, Sevim Baykal; Sigirci, Buket Bambul] Istanbul Educ & Res Hosp, Minist Hlth, Dept Pathol, Istanbul, Turkey; [Tokat, Fatma] Acibadem Mehmet Ali Aydinlar Univ, Subdiv Cytopathol, Dept Pathol, Istanbul, Turkey	Behzatoglu, K (reprint author), Acibadem Atakent Hastanesi, Patol Lab, Istanbul, Turkey.	kemal.behzatoglu@acibadem.com.tr					Billings SD, 2007, AM J DERMATOPATH, V29, P437, DOI 10.1097/DAD.0b013e31813735df; Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Creytens D, 2014, VIRCHOWS ARCH, V465, P97, DOI 10.1007/s00428-014-1568-8; Deyrup AT, 2013, AM J SURG PATHOL, V37, P1373, DOI 10.1097/PAS.0b013e31829562ed; ENZINGER FM, 1975, CANCER, V36, P1852, DOI 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U; ENZINGER FM, 1962, VIRCHOWS ARCH A, V335, P367, DOI 10.1007/BF00957030; Fletcher C, 2013, WHO CLASSIFICATION T; FLETCHER CDM, 1987, HISTOPATHOLOGY, V11, P803, DOI 10.1111/j.1365-2559.1987.tb01884.x; Howitt BE, 2016, AM J SURG PATHOL, V40, P361, DOI 10.1097/PAS.0000000000000540; Kryvenko ON, 2015, AM J SURG PATHOL, V39, P1219, DOI 10.1097/PAS.0000000000000426; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Mentzel T, 2005, VIRCHOWS ARCH, V446, P300, DOI 10.1007/s00428-004-1138-6; Mentzel T, 2016, VIRCHOWS ARCH, V469, P435, DOI 10.1007/s00428-016-1996-8; Mentzel T, 2010, MODERN PATHOL, V23, P729, DOI 10.1038/modpathol.2010.66; NAPOLITANO L, 1963, J CELL BIOL, V18, P663, DOI 10.1083/jcb.18.3.663; Rajasekhar C, 2005, CLIN ONCOL-UK, V17, P128, DOI 10.1016/j.clon.2004.11.005; RYDHOLM A, 1983, ACTA ORTHOP SCAND, V54, P929, DOI 10.3109/17453678308992936	17	6	6	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					550	556		10.1111/pin.12719			7	Pathology	Pathology	GV9EJ	WOS:000446457500002	30198097				2019-10-28	
J	Takahashi, Y; Yamamichi, N; Inada, K; Shiogama, K; Sakurai, K; Takeuchi, C; Mizutani, Y; Tsutsumi, Y; Koike, K				Takahashi, Yu; Yamamichi, Nobutake; Inada, Ken-ichi; Shiogama, Kazuya; Sakurai, Kouhei; Takeuchi, Chihiro; Mizutani, Yasuyoshi; Tsutsumi, Yutaka; Koike, Kazuhiko			Nectin1 expression is frequently decreased in gastric cancers	PATHOLOGY INTERNATIONAL			English	Article						gastric cancer; histological pattern; nectin1	E-CADHERIN; CELL-ADHESION; MUTATIONS; ROLES; MOLECULES; MOVEMENT	Gastric cancer (GC) is rich in many different histological types, but how the histological pattern is defined remains to be proved. The relation between GC histological types and the expression of nectinl, which is one of the cell adhesion molecules that composes adherens junction, has not been reported. According to a publicly available database of 406 GC patients, the median overall survival of Nectin1 high expression patients was 55.4 months and that of low expression patients was 25.6 months (P=0.0246). Using surgically or endoscopically resected GC samples, nectin1 expression was analyzed by immunohistochemistry. Nectin1 expressed at adherens junction in all the normal epithelial cells. However, nectin1 expressed not at adherens junction but at apical membrane in epithelial cells in intestinal metaplasia. The expression pattern of nectin1 in intestinal type GC resembled to intestinal metaplasia. In order to analyze the difference in nectin1 expression between GC histological types, a total of 116 intestinal type GC and 33 diffuse type GC. The expression of necitinl in diffuse type GC (3.0%) was remarkably decreased compared to that in intestinal type GC (65.5%) (P < 0.0001). In conclusion, this is the first report showing an association between nectin1 expression and histological subtypes of GC.	[Takahashi, Yu; Yamamichi, Nobutake; Takeuchi, Chihiro; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; [Inada, Ken-ichi; Sakurai, Kouhei] Fujita Hlth Univ, Dept Diagnost Pathol 2, Nagoya, Aichi, Japan; [Shiogama, Kazuya] Fujita Hlth Univ, Grad Sch Hlth Sci, Dept Clin Examinat, Toyoake, Aichi, Japan; [Mizutani, Yasuyoshi] Fujita Hlth Univ, Sch Med, Dept Mol Oncol, Toyoake, Aichi, Japan; [Tsutsumi, Yutaka] Pathos Tsutsumi, Toyoake, Aichi, Japan	Takahashi, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yutakahashi-tky@umin.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25460381]; Ministry of Health, Labor and WelfareMinistry of Health, Labour and Welfare, Japan [H20-genome-g-006]	We are grateful to Ms. Mika Maeshima and Ms. Sayaka Takeuchi for their cooperation in our research. This work was supported in part by Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (Grant number: 25460381), and in part by a grant-in-aid for pioneering basic research from the Ministry of Health, Labor and Welfare (H20-genome-g-006).	Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; [Anonymous], SEER CANC STAT FACTS; Baek H, 2011, MOL THER, V19, P507, DOI 10.1038/mt.2010.207; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BECKER KF, 1994, CANCER RES, V54, P3845; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coradini D, 2011, ACTA PHARMACOL SIN, V32, P552, DOI 10.1038/aps.2011.20; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kaneko S, 2001, BRIT J CANCER, V84, P400, DOI 10.1054/bjoc.2000.1602; Liu X, 2014, BIOMED RES INT, DOI 10.1155/2014/637308; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Ogita H, 2006, IUBMB LIFE, V58, P334, DOI 10.1080/15216540600719622; Ooshio' T, 2007, J CELL SCI, V120, P2352, DOI 10.1242/jcs.03470; Peng YF, 2002, ONCOGENE, V21, P4108, DOI 10.1038/sj.onc.1205517; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; Stiekema J, 2013, EJSO-EUR J SURG ONC, V39, P686, DOI 10.1016/j.ejso.2013.02.026; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601	25	0	0	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					557	562		10.1111/pin.12721			6	Pathology	Pathology	GV9EJ	WOS:000446457500003	30221498				2019-10-28	
J	Tanaka, S; Hitotsumatsu, T; Sugita, Y; Ishido, K; Ito, O; Hatae, R; Akagi, Y; Yoshimoto, K; Iihara, K				Tanaka, Shunya; Hitotsumatsu, Tsutomu; Sugita, Yasuo; Ishido, Katsuya; Ito, Osamu; Hatae, Ryusuke; Akagi, Yojiro; Yoshimoto, Koji; Iihara, Koji			Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses	PATHOLOGY INTERNATIONAL			English	Article						gliosarcoma; oligodendroglioma; oligosarcoma; 1p/19q co-deletion	CENTRAL-NERVOUS-SYSTEM; MESENCHYMAL TRANSITION; TUMORS; CLASSIFICATION; PROGRESSION; EVOLUTION; GLIOMAS; BRAIN	Gliosarcomas are a type of bimorphic tumor composed of glial and sarcomatous elements, and are considered to be a variant of glioblastoma, WHO grade IV. To date, only rare cases of gliosarcoma with oligodendroglial components (oligosarcoma) have been reported. We report a case of oligosarcoma consisting of gliosarcoma arising from recurrent oligodendroglioma. A 53-year-old man, who had undergone a gross total resection of oligodendroglioma (WHO grade II) 11 years earlier, presented with a local tumor recurrence. The patient underwent a second gross total resection, whereupon a histopathological examination further revealed residual features of classical oligodendroglioma, and newly-developed sarcomatous characteristics. Both the primary and recurrent tumors showed 1p/19q co-deletion and mutation of the isocitrate dehydrogenase 1 (IDH1) gene, consistent with being oligodendroglial in nature. Loss of heterozygosity (LOH) of chromosome 1p/19q and IDH1 mutation have seldom been analyzed in previous reports of oligosarcomas. We report a rare case study supported by the results of genetic analyses. Our analyses have revealed that the sarcomatous component represents a metaplastic change occurring in the oligodendroglial element.	[Tanaka, Shunya; Hitotsumatsu, Tsutomu; Ishido, Katsuya; Ito, Osamu] Shin Koga Hosp, Stroke & Neurol Ctr, Dept Neurosurg, 120 Tenjin Machi, Kurume, Fukuoka 8308577, Japan; [Sugita, Yasuo] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan; [Hatae, Ryusuke; Akagi, Yojiro; Yoshimoto, Koji; Iihara, Koji] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan	Tanaka, S (reprint author), Shin Koga Hosp, Stroke & Neurol Ctr, Dept Neurosurg, 120 Tenjin Machi, Kurume, Fukuoka 8308577, Japan.	shumu1114@yahoo.co.jp					Agozzino L, 1983, Pathologica, V75, P501; Brandner S, 2015, NEUROPATH APPL NEURO, V41, P694, DOI 10.1111/nan.12246; Campbell BA, 2008, J NEURO-ONCOL, V89, P37, DOI 10.1007/s11060-008-9597-2; Cheong JH, 2010, CLIN NEUROL NEUROSUR, V112, P701, DOI 10.1016/j.clineuro.2010.04.012; Codispoti KET, 2014, BRAIN TUMOR PATHOL, V31, P40, DOI 10.1007/s10014-012-0132-y; Fallon KB, 2004, J NEUROPATH EXP NEUR, V63, P314, DOI 10.1093/jnen/63.4.314; FEIGIN I, 1976, J NEUROPATH EXP NEUR, V35, P679, DOI 10.1097/00005072-197611000-00006; Hiniker A, 2013, CLIN NEUROPATHOL, V32, P165, DOI 10.5414/NP300577; Kanamori M, 2013, BRAIN TUMOR PATHOL, V30, P151, DOI 10.1007/s10014-012-0119-8; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Riemenschneider MJ, 2010, ACTA NEUROPATHOL, V120, P567, DOI 10.1007/s00401-010-0736-4; Rodriguez FJ, 2007, AM J SURG PATHOL, V31, P351, DOI 10.1097/01.pas.0000213378.94547.ae; Shoji T, 2016, BRAIN TUMOR PATHOL, V33, P255, DOI 10.1007/s10014-016-0268-2; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Vajtai I, 2012, PATHOL RES PRACT, V208, P750, DOI 10.1016/j.prp.2012.09.009; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Yasuda T, 2018, NEUROPATHOLOGY, V38, P41, DOI 10.1111/neup.12406; Yoshimoto K, 2002, JPN J CANCER RES, V93, P284, DOI 10.1111/j.1349-7006.2002.tb02170.x	20	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					567	573		10.1111/pin.12723			7	Pathology	Pathology	GV9EJ	WOS:000446457500005	30246385				2019-10-28	
J	Komatsu, M; Hashimoto, T; Hanioka, K; Itoh, T; Hirose, T				Komatsu, Masato; Hashimoto, Tetsuya; Hanioka, Keisuke; Itoh, Tomoo; Hirose, Takanori			A rare autopsy case of epithelioid angiosarcoma arising in the aorta in a patient with massive multi-organ embolization	PATHOLOGY INTERNATIONAL			English	Letter									[Komatsu, Masato; Itoh, Tomoo] Kobe Univ Hosp, Dept Diagnost Pathol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan; [Komatsu, Masato; Hirose, Takanori] Hyogo Canc Ctr, Dept Pathol, 13-70 Kitaooji Cho, Akashi, Hyogo 6730021, Japan; [Hashimoto, Tetsuya] Akashi City Hosp, Dept Cardiol, 1033 Takasho Machi, Akashi, Hyogo 6738501, Japan; [Hanioka, Keisuke] Akashi City Hosp, Dept Diagnost Pathol, 1033 Takasho Machi, Akashi, Hyogo 6738501, Japan; [Hirose, Takanori] Kobe Univ, Sch Med, Div Pathol Reg Commun, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan	Komatsu, M (reprint author), Kobe Univ Hosp, Dept Diagnost Pathol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.; Komatsu, M (reprint author), Hyogo Canc Ctr, Dept Pathol, 13-70 Kitaooji Cho, Akashi, Hyogo 6730021, Japan.						Brylka D, 2009, ABDOM IMAGING, V34, P239, DOI 10.1007/s00261-008-9371-0; Folpe AL, 2001, AM J SURG PATHOL, V25, P1, DOI 10.1097/00000478-200101000-00001; Kamran M, 2016, CARDIOVASC INTER RAD, V39, P940, DOI 10.1007/s00270-015-1280-3; Meis-Kindblom JM, 1998, AM J SURG PATHOL, V22, P683, DOI 10.1097/00000478-199806000-00005; Thalheimer A, 2004, J VASC SURG, V40, P548, DOI 10.1016/j.jvs.2004.06.035	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					574	576		10.1111/pin.12690			3	Pathology	Pathology	GV9EJ	WOS:000446457500006	29920855				2019-10-28	
J	Sakakibara, A; Takahashi, E; Ishikawa, E; Kohno, K; Asano, N; Nakamura, S				Sakakibara, Ayako; Takahashi, Emiko; Ishikawa, Eri; Kohno, Kei; Asano, Naoko; Nakamura, Shigeo			Neoplastic PD-L1 expression on interdigitating dendritic cell sarcoma: A supplementary study of a case report	PATHOLOGY INTERNATIONAL			English	Letter									[Sakakibara, Ayako; Ishikawa, Eri; Kohno, Kei; Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan; [Takahashi, Emiko] Aichi Med Univ Hosp, Dept Surg Pathol, Nagakute, Aichi, Japan; [Asano, Naoko] Nagano Prefectural Shinshu Med Ctr, Dept Mol Diagnost, Suzaka, Japan	Sakakibara, A (reprint author), Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan.		Nakamura, Shigeo/I-1571-2012				Carey CD, 2017, BLOOD, V130, P2420, DOI 10.1182/blood-2017-03-770719; Ilcus C, 2017, ONCOTARGETS THER, V10, P2349, DOI 10.2147/OTT.S133385; NAKAMURA S, 1989, VIRCHOWS ARCH A, V415, P447, DOI 10.1007/BF00747746; NAKAMURA S, 1988, CANCER, V61, P562, DOI 10.1002/1097-0142(19880201)61:3<562::AID-CNCR2820610323>3.0.CO;2-M; Yao ZG, 2016, PATHOLOGY, V48, P744, DOI 10.1016/j.pathol.2016.07.013	5	0	2	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					577	578		10.1111/pin.12711			2	Pathology	Pathology	GV9EJ	WOS:000446457500007	30094900				2019-10-28	
J	Shintaku, M; Yoshida, T; Hirose, T				Shintaku, Masayuki; Yoshida, Toru; Hirose, Takanori			Dedifferentiated liposarcoma of the spermatic cord with features of epithelioid rhabdomyosarcoma and a rapidly fatal outcome	PATHOLOGY INTERNATIONAL			English	Letter							CLINICOPATHOLOGICAL ANALYSIS		[Shintaku, Masayuki] Shiga Gen Hosp, Dept Pathol, Moriyama, Shiga, Japan; [Yoshida, Toru] Shiga Gen Hosp, Dept Urol, Moriyama, Shiga, Japan; [Hirose, Takanori] Kobe Univ, Grad Sch Med, Dept Pathol Reg Commun, Kobe, Hyogo, Japan	Shintaku, M (reprint author), Shiga Gen Hosp, Dept Pathol, Moriyama, Shiga, Japan.						Jo VY, 2011, AM J SURG PATHOL, V35, P1523, DOI 10.1097/PAS.0b013e31822e0907; Makise N, 2017, AM J SURG PATHOL, V41, P1523, DOI 10.1097/PAS.0000000000000910; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; Montgomery E, 2003, AM J SURG PATHOL, V27, P40, DOI 10.1097/00000478-200301000-00005; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	OCT	2018	68	10					579	581		10.1111/pin.12712			3	Pathology	Pathology	GV9EJ	WOS:000446457500008	30094897				2019-10-28	
J	van Pelt, GW; Kjaer-Frifeldt, S; van Krieken, JHJM; Al Dieri, R; Morreau, H; Tollenaar, RAEM; Sorensen, FB; Mesker, WE				van Pelt, G. W.; Kjaer-Frifeldt, S.; van Krieken, J. H. J. M.; Al Dieri, R.; Morreau, H.; Tollenaar, R. A. E. M.; Sorensen, F. B.; Mesker, W. E.			Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations	VIRCHOWS ARCHIV			English	Article						Colon cancer; Protocol; Recommendations; Scoring; Tumor-stroma ratio	SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; INDEPENDENT PREDICTOR; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; SURVIVAL; VALIDATION; CHEMOTHERAPY; PROPORTION; STAGE	The tumor-stroma ratio (TSR) has been reported as a strong, independent prognostic parameter in colon cancer as well as in other epithelial cancer types, and may be implemented to routine pathology diagnostics. The TSR is an easy technique, based on routine hematoxylin and eosin stained histological sections, estimating the amount of stroma present in the primary tumor. It links tumors with high stromal content to poor prognosis. The analysis time is less than 2 min with a low inter-observer variation. Scoring of the TSR has been validated in a number of independent international studies. In this manuscript, we provide a detailed technical description of estimating the TSR in colon cancer, including examples, pitfalls, and recommendations.	[van Pelt, G. W.; Tollenaar, R. A. E. M.; Mesker, W. E.] Leiden Univ, Med Ctr, Dept Surg, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Kjaer-Frifeldt, S.; Sorensen, F. B.] Vejle Hosp, Dept Clin Pathol, Vejle, Denmark; [van Krieken, J. H. J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [Al Dieri, R.] European Soc Pathol, Brussels, Belgium; [Morreau, H.] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; [Sorensen, F. B.] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark; [Sorensen, F. B.] Aarhus Univ Hosp, Univ Inst Pathol, Aarhus, Denmark	Mesker, WE (reprint author), Leiden Univ, Med Ctr, Dept Surg, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	W.E.Mesker@lumc.nl		van Krieken, Joannes/0000-0002-8105-0450; Sorensen, Flemming Brandt/0000-0002-5446-1035			Ahn S, 2012, TUMOR BIOL, V33, P1573, DOI 10.1007/s13277-012-0411-6; Aktepe F, 1996, HISTOPATHOLOGY, V29, P63, DOI 10.1046/j.1365-2559.1996.d01-485.x; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564; Chen Y, 2015, BIOMED RES INT, DOI 10.1155/2015/589301; de Kruijf EM, 2011, BREAST CANCER RES TR, V125, P687, DOI 10.1007/s10549-010-0855-6; Dekker TJA, 2013, BREAST CANCER RES TR, V139, P371, DOI 10.1007/s10549-013-2571-5; Downey CL, 2014, BRIT J CANCER, V110, P1744, DOI 10.1038/bjc.2014.69; Gujam FJA, 2014, BRIT J CANCER, V111, P157, DOI 10.1038/bjc.2014.279; Huijbers A, 2013, ANN ONCOL, V24, P179, DOI 10.1093/annonc/mds246; Li H, 2017, NEOPLASMA, V64, P588, DOI 10.4149/neo_2017_413; Liu J, 2014, GYNECOL ONCOL, V132, P81, DOI 10.1016/j.ygyno.2013.11.003; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Lv Z, 2015, SURGERY, V158, P142, DOI 10.1016/j.surg.2015.02.013; McCluggage WG, 2002, J CLIN PATHOL, V55, P27, DOI 10.1136/jcp.55.1.27; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Moorman AM, 2012, EJSO-EUR J SURG ONC, V38, P307, DOI 10.1016/j.ejso.2012.01.002; Nagtegaal I, 2004, J PATHOL, V204, P183, DOI 10.1002/path.1621; Nagtegaal ID, 2012, NAT REV CLIN ONCOL, V9, P119, DOI 10.1038/nrclinonc.2011.157; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Park JH, 2014, ANN ONCOL, V25, P644, DOI 10.1093/annonc/mdt593; Pongsuvareeyakul Tip, 2015, Asian Pac J Cancer Prev, V16, P4363; Roeke T, 2017, BREAST CANCER RES TR, V166, P435, DOI 10.1007/s10549-017-4445-8; Staal EFWC, 2011, EUR J CANCER, V47, P375, DOI 10.1016/j.ejca.2010.09.043; Staal EFWC, 2010, EUR J CANCER, V46, P720, DOI 10.1016/j.ejca.2009.12.006; Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4; Unlu M, 2013, TURK J PATHOL, V29, P27, DOI 10.5146/tjpath.2013.01144; vansPelt GW, 2016, J MED SURG PATHOL, V1, P116, DOI DOI 10.4172/JMSP.1000116; Wang K, 2012, J THORAC ONCOL, V7, P1457, DOI 10.1097/JTO.0b013e318260dfe8; Wang Zhaofeng, 2013, Zhongguo Fei Ai Za Zhi, V16, P191, DOI 10.3779/j.issn.1009-3419.2013.04.04; West NP, 2010, BRIT J CANCER, V102, P1519, DOI 10.1038/sj.bjc.6605674; Zhang TH, 2015, INT J CLIN EXP PATHO, V8, P11348; Zhang XL, 2014, ONCOL RES TREAT, V37, P480, DOI 10.1159/000365165	33	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					405	412		10.1007/s00428-018-2408-z			8	Pathology	Pathology	GV8HP	WOS:000446380500002	30030621	Green Published			2019-10-28	
J	Park, JS; Yoon, G; Kim, HJ; Park, SY; Choi, GS; Kang, MK; Kim, JG; Jang, JS; Seo, AN				Park, Jun Seok; Yoon, Ghilsuk; Kim, Hye Jin; Park, Soo Yeun; Choi, Gyu Seog; Kang, Min Kyu; Kim, Jong Gwang; Jang, Jung-Sik; Seo, An Na			HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features	VIRCHOWS ARCHIV			English	Article						Rectal cancer; Preoperative chemoradiotherapy; Human epidermal growth factor receptor 2; Prognosis Silver in situ hybridization	COLORECTAL-CANCER; BREAST-CANCER; POSTOPERATIVE CHEMORADIOTHERAPY; AMERICAN-PATHOLOGISTS; MONOCLONAL-ANTIBODY; EXPRESSION; RESECTION; TRIAL; EGFR; RADIOCHEMOTHERAPY	The specific role of human epidermal growth factor receptor-2 (HER2) status in rectal cancers remains unclear. This study therefore aimed to explore clinicopathologic and molecular characteristics, and prognostic value of HER2-positivity in residual mid- and/or low-rectal cancers after preoperative chemoradiotherapy (CRT). Surgical specimens from 145 patients with residual rectal cancer after preoperative CRT between January 2006 and January 2011 were used to evaluate HER2 status. HER2 protein expression and gene amplification were determined using immunohistochemistry (IHC) and silver in situ hybridization (SISH) on whole tissue sections, respectively. Polymerase chain reaction was used to analyze molecular characteristics, including microsatellite instability (MSI) and mutations in KRAS exon 2 (codon 12 and 13) and BRAF V600E mutation. Of 139 eligible patients, 8 (5.8%) had HER2 overexpression (IHC 2+ and 3+) that was not associated with clinicopathologic characteristics and patient survival, except positive circumferential resection margin (CRM) (P = 0.012). SISH was performed on 24 patient samples with IHC 1+ (n = 16), 2+ (n = 6), and 3+ (n = 2). HER2 amplification was identified in 3 patients (2.2%); however, this was also associated with positive CRM (P = 0.009) but not survival (all P > 0.05). Moreover, HER2 overexpression and amplification had no relationship with KRAS or BRAF mutations, and MSI status (all P > 0.05). HER2 positivity was found in a minority of rectal cancer patients and was not significantly associated with clinicopathologic and molecular characteristics. Our findings can be helpful in understanding the clinicopathologic bases of HER2 status in rectal cancers.	[Park, Jun Seok; Kim, Hye Jin; Park, Soo Yeun; Choi, Gyu Seog] Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea; [Park, Jun Seok; Kim, Hye Jin; Park, Soo Yeun; Choi, Gyu Seog] Kyungpook Natl Univ, Colorectal Canc Ctr, Chilgok Hosp, Daegu, South Korea; [Yoon, Ghilsuk; Seo, An Na] Kyungpook Natl Univ, Sch Med, Dept Pathol, 136 Gil 90, Daegu, South Korea; [Yoon, Ghilsuk; Seo, An Na] Kyungpook Natl Univ, Chilgok Hosp, Dept Pathol, 807 Hogukno, Daegu, South Korea; [Kang, Min Kyu] Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea; [Kang, Min Kyu] Kyungpook Natl Univ, Dept Radiat Oncol, Chilgok Hosp, Daegu, South Korea; [Kim, Jong Gwang] Kyungpook Natl Univ, Sch Med, Dept Hematol Oncol, Daegu, South Korea; [Kim, Jong Gwang] Kyungpook Natl Univ, Chilgok Hosp, Dept Hematol Oncol, Daegu, South Korea; [Jang, Jung-Sik] Natl Forens Serv Daegu Inst, Depertment Forens Med Div, Daegu, Gyeongsangbuk D, South Korea	Seo, AN (reprint author), Kyungpook Natl Univ, Sch Med, Dept Pathol, 136 Gil 90, Daegu, South Korea.; Seo, AN (reprint author), Kyungpook Natl Univ, Chilgok Hosp, Dept Pathol, 807 Hogukno, Daegu, South Korea.	san_0729@naver.com			Biomedical Research Institute grant, Kyungpook National University Hospital	This work was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2014).	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bang YJ, 2010, LANCET, V376, P1302; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261; Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Edge SB, 2010, AM JOINT COMMITTEE C; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224; Gutierrez C, 2011, ARCH PATHOL LAB MED, V135, P55, DOI 10.1043/2010-0454-RAR.1; Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1; Lee JH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-576; Lee WS, 2014, CANCER MED-US, V3, P674, DOI 10.1002/cam4.228; Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066; Marx AH, 2010, HUM PATHOL, V41, P1577, DOI 10.1016/j.humpath.2010.02.018; McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252; Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137; Park JS, 2011, ANN SURG, V254, P941, DOI 10.1097/SLA.0b013e318236c448; QUIRKE P, 1986, LANCET, V2, P996; Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rullier A, 2013, EUR J CANCER, V49, P82, DOI 10.1016/j.ejca.2012.06.028; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Schmoll HJ, 2016, LANCET ONCOL, V17, P685, DOI 10.1016/S1470-2045(16)30039-0; Sclafani F, 2013, ANN ONCOL, V24, P3123, DOI 10.1093/annonc/mdt408; Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Spitzner M, 2010, INT J RADIAT ONCOL, V78, P1184, DOI 10.1016/j.ijrobp.2010.06.023; Takegawa N, 2017, CLIN COLORECTAL CANC, V16, P247, DOI 10.1016/j.clcc.2017.03.001; Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yao YF, 2014, DIS COLON RECTUM, V57, P602, DOI 10.1097/DCR.0000000000000107; Yoon G, 2016, TUMOR BIOL, V37, P10209, DOI 10.1007/s13277-016-4899-z; Yoon G, 2016, TUMOR BIOL, V37, P3571, DOI 10.1007/s13277-015-4201-9	40	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					413	423		10.1007/s00428-018-2409-y			11	Pathology	Pathology	GV8HP	WOS:000446380500003	30056472				2019-10-28	
J	Murdaca, G; Calamaro, P; Lantieri, F; Pigozzi, S; Mastracci, L; Grillo, F; Magnani, O; Ceppa, P; Puppo, F; Fiocca, R				Murdaca, Giuseppe; Calamaro, Paola; Lantieri, Francesca; Pigozzi, Simona; Mastracci, Luca; Grillo, Federica; Magnani, Ottavia; Ceppa, Paola; Puppo, Francesco; Fiocca, Roberto			HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact	VIRCHOWS ARCHIV			English	Article						MHC; HLA-G; Gastric cancer; Immunoescape	LEUKOCYTE-ANTIGEN-G; G MOLECULES; T-CELL; PERIPHERAL-BLOOD; CANCER; SUPPRESSES; BIOLOGY	To analyze expression of human leukocyte antigen-G (HLA-G) in gastric adenocarcinoma and correlate its expression with histological and clinical variables. A continuous series of 94 unselected patients with gastric adenocarcinoma (stage I to III) were selected. All histological and clinical variables were collected including the intensity of intra- and peri-tumor lymphocytic infiltration. HLA-G expression was investigated using immunohistochemistry. All histological samples analyzed for HLA-G expression were taken from the primary gastric lesion and included non-neoplastic mucosa. Evaluation of HLA-G expression was performed on the transition zone between tumor and non-neoplastic mucosa, and the invasive front of the tumor and assessment was performed as follows: percentage of positive (strong expression vs weak) cells. A variable amount of HLA-G-positive tumor cells was found in 24 out of 94 cases (25.5%). No significant correlation was found between HLA-G expression and other clinicopathological variables (sex, age, stage, grade, histotype). The overall median survival was worse in patients with HLA-G-positive adenocarcinoma (24.3 months, CI95% 7.7-41.0) compared to those with HLA-G-negative tumors (66.3 months, CI95% 53.0-79.7; p < 0.0001). Two- and 5-year survival rates of HLA-G-negative patients were 88 and 44%, respectively, while were 42 and 11% in those HLA-G-positive. This trend was observed in all stages but was more marked in stage III. HLA-G expression is associated with poor survival in stage III gastric cancer patients and represents a possible immunoescape mechanism of cancer cells.	[Murdaca, Giuseppe; Magnani, Ottavia; Puppo, Francesco] Univ Genoa, Dept Internal Med DIMI, Clin Immunol Unit, Viale Benedetto 15,6, I-16132 Genoa, Italy; [Murdaca, Giuseppe; Calamaro, Paola; Pigozzi, Simona; Mastracci, Luca; Grillo, Federica; Magnani, Ottavia; Ceppa, Paola; Puppo, Francesco; Fiocca, Roberto] Osped Policlin San Martino, Viale Benedetto 15,6, I-16132 Genoa, Italy; [Calamaro, Paola; Pigozzi, Simona; Mastracci, Luca; Grillo, Federica; Ceppa, Paola; Fiocca, Roberto] Univ Genoa, Dept Surg & Diagnost Sci, Anat Pathol Unit, Genoa, Italy; [Lantieri, Francesca] Univ Genoa, Dept Hlth Sci, Biostat Unit, Genoa, Italy	Murdaca, G (reprint author), Univ Genoa, Dept Internal Med DIMI, Clin Immunol Unit, Viale Benedetto 15,6, I-16132 Genoa, Italy.; Murdaca, G (reprint author), Osped Policlin San Martino, Viale Benedetto 15,6, I-16132 Genoa, Italy.	Giuseppe.Murdaca@unige.it	Calamaro, Paola/AAC-3476-2019				Amiot L, 2011, CELL MOL LIFE SCI, V68, P417, DOI 10.1007/s00018-010-0583-4; Bainbridge DRJ, 2000, J REPROD IMMUNOL, V48, P17, DOI 10.1016/S0165-0378(00)00070-X; Barrier BF, 2006, GYNECOL ONCOL, V103, P25, DOI 10.1016/j.ygyno.2006.01.045; Bosman F.T., 2010, WHO CLASSIFICATION T, P45; Carosella ED, 2008, BLOOD, V111, P4862, DOI 10.1182/blood-2007-12-127662; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Cho J, 2017, ONCOTARGET, V8, P13320, DOI 10.18632/oncotarget.14519; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Downs-Kelly E, 2007, SEMIN CANCER BIOL, V17, P451, DOI 10.1016/j.semcancer.2007.07.002; Du LT, 2011, CANCER SCI, V102, P1272, DOI 10.1111/j.1349-7006.2011.01951.x; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Grillo F, 2013, TRANSL ONCOL, V6, P10, DOI 10.1593/tlo.12334; Ishigami S, 2006, ANTICANCER RES, V26, P2467; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039; LeMaoult J, 2003, TISSUE ANTIGENS, V62, P273, DOI 10.1034/j.1399-0039.2003.00143.x; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; Morandi F, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/43; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nuckel H, 2005, BLOOD, V105, P1694, DOI 10.1182/blood-2004-08-3335; O'Callaghan CA, 1998, IMMUNOL REV, V163, P129, DOI 10.1111/j.1600-065X.1998.tb01192.x; Pistoia V, 2007, SEMIN CANCER BIOL, V17, P469, DOI 10.1016/j.semcancer.2007.07.004; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; Rebmann V, 2003, SEMIN CANCER BIOL, V13, P371, DOI 10.1016/S1044-579X(03)00028-2; Riteau B, 2001, INT IMMUNOL, V13, P193, DOI 10.1093/intimm/13.2.193; Rizzo R, 2005, J ALLERGY CLIN IMMUN, V115, P508, DOI 10.1016/j.jaci.2004.11.031; Rouas-Freiss N, 2003, SEMIN CANCER BIOL, V13, P325, DOI 10.1016/S1044-579X(03)00023-3; Rouas-Freiss N, 2014, J IMMUNOL RES, DOI 10.1155/2014/359748; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Sebti Y, 2003, HUM IMMUNOL, V64, P1093, DOI 10.1016/S0198-8559(03)00532-9; Singer G, 2003, CLIN CANCER RES, V9, P4460; Swets M, 2016, HUM IMMUNOL, V77, P773, DOI 10.1016/j.humimm.2016.03.001; Tuncel T, 2013, ASIAN PAC J CANCER P, V14, P7681, DOI 10.7314/APJCP.2013.14.12.7681; Ugurel S, 2001, CANCER, V92, P369, DOI 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U; Urosevic M, 2001, AM J PATHOL, V159, P817, DOI 10.1016/S0002-9440(10)61756-7; Yie SM, 2007, LUNG CANCER, V58, P267, DOI 10.1016/j.lungcan.2007.06.011; Yie SM, 2007, ANN SURG ONCOL, V14, P2721, DOI 10.1245/s10434-007-9464-y	39	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					425	433		10.1007/s00428-018-2379-0			9	Pathology	Pathology	GV8HP	WOS:000446380500004	29845360				2019-10-28	
J	La Rosa, S; Bernasconi, B; Vanoli, A; Sciarra, A; Notohara, K; Albarello, L; Casnedi, S; Billo, P; Zhang, LZ; Tibiletti, MG; Sessa, F				La Rosa, Stefano; Bernasconi, Barbara; Vanoli, Alessandro; Sciarra, Amedeo; Notohara, Kenji; Albarello, Luca; Casnedi, Selenia; Billo, Paola; Zhang, Lizhi; Tibiletti, Maria Grazia; Sessa, Fausto			c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers	VIRCHOWS ARCHIV			English	Article						Acinar cell carcinoma; Pancreas; MANEC; MiNEN; c-myc; Amplification	NEUROENDOCRINE PROSTATE-CANCER; ADENOCARCINOMA	The molecular alterations of pancreatic acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MANECs) are not completely understood, and the possible role of c-MYC amplification in tumor development, progression, and prognosis is not known. We have investigated c-MYC gene amplification in a series of 35 ACCs and 4 MANECs to evaluate its frequency and a possible prognostic role. Gene amplification was investigated using interphasic fluorescence in situ hybridization analysis simultaneously hybridizing c-MYC and the centromere of chromosome 8 probes. Protein expression was immunohistochemically investigated using a specific monoclonal anti-c-myc antibody. Twenty cases had clones with different polysomies of chromosome 8 in absence of c-MYC amplification, and 5 cases had one amplified clone and other clones with chromosome 8 polysomy, while the remaining 14 cases were diploid for chromosome 8 and lacked c-MYC amplification. All MANECs showed c-MYC amplification and/or polysomy which were observed in 54% pure ACCs. Six cases (15.3%) showed nuclear immunoreactivity for c-myc, but only 4/39 cases showed simultaneous c-MYC amplification/polysomy and nuclear protein expression. c-myc immunoreactivity as well as c-MYC amplification and/or chromosome 8 polysomy was not statistically associated with prognosis. Our study demonstrates that a subset of ACCs shows c-MYC alterations including gene amplification and chromosome 8 polysomy. Although they are not associated with a different prognostic signature, the fact that these alterations are present in all MANECs suggests a role in the acinar-neuroendocrine differentiation possibly involved in the pathogenesis of MANECs.	[La Rosa, Stefano; Sciarra, Amedeo] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland; [Bernasconi, Barbara; Sessa, Fausto] Univ Insubria, Dept Med & Surg, Varese, Italy; [Vanoli, Alessandro] Univ Pavia, Dept Mol Med, Pavia, Italy; [Notohara, Kenji] Kurashiki Cent Hosp, Dept Anat Pathol, Kurashiki, Okayama, Japan; [Albarello, Luca] Ist Sci San Raffaele, Pathol Unit, Milan, Italy; [Casnedi, Selenia] Ctr Pathol, Strasbourg, France; [Billo, Paola] Osped Civile, Unit Pathol, Legnano, Italy; [Zhang, Lizhi] Mayo Clin, Dept Pathol, Rochester, MN USA; [Tibiletti, Maria Grazia] ASST Sette Laghi, Dept Pathol, Varese, Italy	La Rosa, S (reprint author), Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland.	stefano.larosa@chuv.ch	Vanoli, Alessandro/J-4469-2016	Vanoli, Alessandro/0000-0002-2976-7032; Sciarra, Amedeo/0000-0002-7550-0312			Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bergmann F, 2014, VIRCHOWS ARCH, V465, P661, DOI 10.1007/s00428-014-1657-8; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Farrell AS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01967-6; Furlan D, 2014, VIRCHOWS ARCH, V464, P553, DOI 10.1007/s00428-014-1562-1; Hastings RJ, 2016, EUR J HUM GENET, V24, P6, DOI 10.1038/ejhg.2015.35; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Jakel C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01118-x; Kloppel G, 2017, WHO CLASSIFICATION T, P211; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa S, 2016, VIRCHOWS ARCH, V468, P289, DOI 10.1007/s00428-015-1882-9; La Rosa S, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00041; La Rosa S, 2012, AM J SURG PATHOL, V36, P1782, DOI 10.1097/PAS.0b013e318263209d; Lee J, 2016, COGENT ARTS HUMANITE, V3, DOI 10.1080/23311983.2016.1201967; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nwanze J, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00209; Lobo VJSA, 2018, GUT, V67, P707, DOI 10.1136/gutjnl-2016-312306; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Shaffer LG, 2013, ISCN INT SYSTEM HUMA; Skoudy Anouchka, 2011, J Gastrointest Cancer, V42, P76, DOI 10.1007/s12029-011-9258-0; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Wisnoski NC, 2008, SURGERY, V144, P141, DOI 10.1016/j.surg.2008.03.006	27	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					435	441		10.1007/s00428-018-2366-5			7	Pathology	Pathology	GV8HP	WOS:000446380500005	29721608				2019-10-28	
J	Gango, A; Batai, B; Varga, M; Kapczar, D; Papp, G; Marschalko, M; Kuroli, E; Schneider, T; Csomor, J; Matolcsy, A; Bodor, C; Szepesi, A				Gango, Ambrus; Batai, Bence; Varga, Martin; Kapczar, Dora; Papp, Gergo; Marschalko, Marta; Kuroli, Eniko; Schneider, Tamas; Csomor, Judit; Matolcsy, Andras; Bodor, Csaba; Szepesi, Agota			Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein	VIRCHOWS ARCHIV			English	Article						Primary cutaneous follicle center lymphoma; del 1p36; TNFRSF14 mutation; BCL2; EZH2	B-CELL LYMPHOMAS; WHO-EORTC CLASSIFICATION; EUROPEAN-ORGANIZATION; PROGNOSIS; GENE; PROLIFERATION; ABNORMALITIES; PROPOSAL; SUBSET; ORIGIN	Primary cutaneous follicle center lymphoma (PCFCL) is an indolent variant of follicular lymphoma (FL) with limited information available on the genetic background of the disease. The genetic hallmark of nodal FL, the t(14;18) translocation, affecting the BCL2 gene, is rare in PCFCL. Loss of 1p36, the most common secondary chromosomal abnormality in nodal FL, has been recently reported in 16.7% of PCFCL cases. In order to further characterize PCFCL, 21 cases were analyzed using interphase fluorescence in situ hybridization with BCL2 break apart and 1p36/1q25 dual color probes. Sanger sequencing was used to investigate TNFRSF14 and EZH2 mutations and immunohistochemistry to assess BCL2, EZH2 protein expressions. 1p36 deletion occurred in 22% (5/21), BCL2 gene break in 10% (2/20) of the PCFCL cases. Mutations of the candidate tumor suppressor gene of the 1p36 region, TNFRSF14 mutations were detected in 4/17 (23.5%) cases with 2 cases presenting with concurrent 1p36 deletion. EZH2 hotspot mutations at Y641, A682, and A692 were not found. High EZH2 protein expression associated with a BCL2 negative phenotype was observed in 43% (9/21) of the cases. BCL2 gene break or 1p36 deletion did not impact the prognosis; however, they showed association with advanced stages at diagnosis (p = 0.016) and a tendency with shorter event free survival (p = 0.052). In conclusion, 1p36 deletion co-occurs with acquired TNFRSF14 mutations, suggesting a role of this tumor suppressor gene in the development of a subgroup of PCFCL. High EZH2 protein expression associated with BCL2 negative phenotype is common and might represent an ideal therapeutic target.	[Gango, Ambrus; Batai, Bence; Matolcsy, Andras; Bodor, Csaba] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, MTA SE Lendulet Mol Oncohematol Res Grp, Budapest, Hungary; [Varga, Martin; Kapczar, Dora; Papp, Gergo; Csomor, Judit; Matolcsy, Andras; Szepesi, Agota] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary; [Marschalko, Marta; Kuroli, Eniko] Semmelweis Univ, Dept Dermatol Dermatooncol & Venerol, Budapest, Hungary; [Schneider, Tamas] Natl Inst Oncol, Budapest, Hungary	Szepesi, A (reprint author), Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Ulloi Ut 26, H-1085 Budapest, Hungary.	szepesi.agota@med.semmelweis-univ.hu	Bodor, Csaba/O-4524-2017	Bodor, Csaba/0000-0002-0729-692X	Momentum grant of the Hungarian Academy of Sciences [LP-95021]; Hungarian National Research, Development and Innovation Office (NKFIH) [NVKP_16-1-2016-0004 KH17-126718]	This work was funded by the Momentum grant (LP-95021) of the Hungarian Academy of Sciences and the NVKP_16-1-2016-0004 KH17-126718 grants of the Hungarian National Research, Development and Innovation Office (NKFIH).	Abdul-Wahab A, 2014, J AM ACAD DERMATOL, V70, P1010, DOI 10.1016/j.jaad.2014.01.862; Bouska A, 2014, BLOOD, V123, P1681, DOI 10.1182/blood-2013-05-500595; Cheung KJJ, 2010, CANCER RES, V70, P9166, DOI 10.1158/0008-5472.CAN-10-2460; Costello RT, 2003, LEUKEMIA, V17, P2500, DOI 10.1038/sj.leu.2403175; Goodlad JR, 2002, AM J SURG PATHOL, V26, P733, DOI 10.1097/00000478-200206000-00006; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Katzenberger T, 2009, BLOOD, V113, P1053, DOI 10.1182/blood-2008-07-168682; Kim BK, 2005, AM J SURG PATHOL, V29, P69, DOI 10.1097/01.pas.0000146015.22624.c7; Kim YH, 2007, BLOOD, V110, P479, DOI 10.1182/blood-2006-10-054601; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Launay E, 2012, LEUKEMIA, V26, P559, DOI 10.1038/leu.2011.266; Lawnicki LC, 2002, AM J CLIN PATHOL, V118, P765; Lee HJ, 2014, LEUKEMIA LYMPHOMA, V55, P2056, DOI 10.3109/10428194.2013.858816; Lucioni M, 2016, CANCER MED-US, V5, P2740, DOI 10.1002/cam4.865; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Papp G, 2017, PATHOL ONCOL RES, V23, P863, DOI 10.1007/s12253-017-0200-z; Pham-Ledard A, 2015, AM J CLIN PATHOL, V143, P362, DOI 10.1309/AJCP4SUBR4NPSPTN; Schmidt J, 2016, BLOOD, V128, P1101, DOI 10.1182/blood-2016-03-703819; Senff NJ, 2007, ARCH DERMATOL, V143, P1520, DOI 10.1001/archderm.143.12.1520; Shi M, 2015, LEUKEMIA LYMPHOMA, V56, P2087, DOI 10.3109/10428194.2014.968780; Streubel B, 2006, AM J SURG PATHOL, V30, P529, DOI 10.1097/00000478-200604000-00015; Swerdlow SH, 2017, WHO CLASSIFICATION T, V2; Szablewski V, 2016, AM J SURG PATHOL, V40, P127, DOI 10.1097/PAS.0000000000000567; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Verdanet E, 2017, HISTOPATHOLOGY, V71, P648, DOI 10.1111/his.13279; Vergier A, 2004, AM J SURG PATHOL, V28, P748, DOI 10.1097/01.pas.0000126775.27698.6e; Willemze R, 1997, BLOOD, V90, P354; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Zhou Z, 2015, LEUKEMIA LYMPHOMA, V56, P2895, DOI 10.3109/10428194.2015.1006220	29	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					453	462		10.1007/s00428-018-2384-3			10	Pathology	Pathology	GV8HP	WOS:000446380500007	29858685				2019-10-28	
J	Onallah, H; Catane, LJ; Trope, CG; Falkenthal, TEH; Reich, R; Davidson, B				Onallah, Hadil; Catane, Liora Jacobs; Trope, Claes G.; Falkenthal, Thea E. Hetland; Reich, Reuven; Davidson, Ben			Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma	VIRCHOWS ARCHIV			English	Article						Lysophosphatidic acid; Autotaxin; High-grade serous carcinoma; Effusion; Survival	OVARIAN-CANCER CELLS; DRUG-RESISTANCE; LPA RECEPTORS; EXPRESSION; LYSOPHOSPHOLIPIDS; BIOMARKERS; EFFUSIONS; MIGRATION; THERAPY; AXIS	The aim of this study was to analyze the expression, biological role and clinical relevance of autotaxin (ATX), the enzyme synthetizing lysophosphatidic acid (LPA), and LPA receptors (LPAR) in high-grade serous carcinoma (HGSC). mRNA expression by qRT-PCR of LPAR1-6 was analyzed in 155 HGSC specimens (88 effusions, 67 solid lesions). ATX mRNA expression was analyzed in 97 specimens. ATX, ERK, and AKT protein expression was studied by Western blotting. LPAR2 mRNA was overexpressed in HGSC cells in effusions compared to solid lesions, with opposite findings for LPAR3 and LPAR6 mRNA and ATX protein. Higher LPAR1 levels were significantly related to longer overall survival (OS) in pre-chemotherapy effusions (p = 0.027). Conversely, higher expression of LPAR1, LPAR2, and LPAR5 in post-chemotherapy effusions was significantly associated with shorter OS (p = 0.037, p = 0.025 and p = 0.021, respectively) and progression-free survival (PFS) (p < 0.001, p = 0.007 and p < 0.001, respectively) in univariate survival analysis. LPAR1 mRNA expression was an independent prognosticator of OS in patients with pre-chemotherapy effusions and PFS in patients with post-chemotherapy effusions (p = 0.013 both). In conclusion, LPAR mRNA and ATX protein levels are anatomic site-dependent in HGSC and the former are informative of disease outcome.	[Onallah, Hadil; Catane, Liora Jacobs; Reich, Reuven] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, IL-91120 Jerusalem, Israel; [Trope, Claes G.; Davidson, Ben] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway; [Falkenthal, Thea E. Hetland] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; [Reich, Reuven] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel; [Reich, Reuven] Hebrew Univ Jerusalem, Adolf & Klara Brettler Ctr Res Mol Pharmacol & Th, Jerusalem, Israel; [Davidson, Ben] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway	Reich, R (reprint author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, IL-91120 Jerusalem, Israel.; Davidson, B (reprint author), Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway.; Reich, R (reprint author), Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel.; Reich, R (reprint author), Hebrew Univ Jerusalem, Adolf & Klara Brettler Ctr Res Mol Pharmacol & Th, Jerusalem, Israel.; Davidson, B (reprint author), Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway.	reuvenr@ekmd.huji.ac.il; bend@medisin.uio.no			The Inger and John Fredriksen Foundation for Ovarian Cancer Research	This work was supported by The Inger and John Fredriksen Foundation for Ovarian Cancer Research.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005; Bai CQ, 2014, J THORAC DIS, V6, P483, DOI 10.3978/j.issn.2072-1439.2014.02.14; Blackburn J, 2012, BONE, V50, P756, DOI 10.1016/j.bone.2011.12.002; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Davidson B, 2018, SEROUS EFFUSIONS; Davidson B, 2016, EXPERT REV MOL DIAGN, V16, P569, DOI 10.1586/14737159.2016.1156532; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Goldsmith Zachariah G, 2011, Genes Cancer, V2, P563, DOI 10.1177/1947601911419362; Gotoh M, 2012, BIOCHEM SOC T, V40, P31, DOI 10.1042/BST20110608; Jeong KJ, 2008, EXP MOL MED, V40, P607, DOI 10.3858/emm.2008.40.6.607; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Lengyel E, 2013, AM J PATHOL, V177, P1053; Liu SY, 2009, CELL CYCLE, V8, P3695, DOI 10.4161/cc.8.22.9937; Murph M, 2007, METHOD ENZYMOL, V433, P1, DOI 10.1016/S0076-6879(07)33001-2; Murph MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005583; Okudaira S, 2010, BIOCHIMIE, V92, P698, DOI 10.1016/j.biochi.2010.04.015; Seo EJ, 2016, STEM CELLS, V34, P551, DOI 10.1002/stem.2279; Tigyi G, 2010, BRIT J PHARMACOL, V161, P241, DOI 10.1111/j.1476-5381.2010.00815.x; Tokumura A, 2007, LIFE SCI, V80, P1641, DOI 10.1016/j.lfs.2006.12.041; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsujiuchi T, 2014, J RECEPT SIG TRANSD, V34, P149, DOI 10.3109/10799893.2013.876042; Venkatraman G, 2015, FASEB J, V29, P772, DOI 10.1096/fj.14-262659; Wang H, 2014, ONCOL LETT, V7, P1581, DOI 10.3892/ol.2014.1926; Wang P, 2007, GYNECOL ONCOL, V104, P714, DOI 10.1016/j.ygyno.2006.10.016; Ward JD, 2015, CANCER LETT, V356, P382, DOI 10.1016/j.canlet.2014.09.030; Ward Jeremy D, 2012, Genes Cancer, V3, P578, DOI 10.1177/1947601913475360; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Willier S, 2013, BIOL CELL, V105, P317, DOI 10.1111/boc.201300011; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Yu XC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2865-1; Yung YC, 2014, J LIPID RES, V55, P1192, DOI 10.1194/jlr.R046458	33	3	3	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					463	470		10.1007/s00428-018-2418-x			8	Pathology	Pathology	GV8HP	WOS:000446380500008	30032361				2019-10-28	
J	Steiner, P; Andreasen, S; Grossmann, P; Hauer, L; Vanecek, T; Miesbauerova, M; Santana, T; Kiss, K; Slouka, D; Skalova, A				Steiner, Petr; Andreasen, Simon; Grossmann, Petr; Hauer, Lukas; Vanecek, Tomas; Miesbauerova, Marketa; Santana, Thalita; Kiss, Katalin; Slouka, David; Skalova, Alena			Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands	VIRCHOWS ARCHIV			English	Article						Salivary gland; Adenoid cystic carcinoma; 1p36 locus deletion; MYB-NFIB; Prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; NFIB GENE FUSION; MYB EXPRESSION; LACRIMAL GLAND; HEAD; REARRANGEMENTS; FEATURES; NUMBER; NECK; TRANSLOCATION	Adenoid cystic carcinoma (AdCC) of the salivary glands is characterized by MYB-NFIB or MYBL1-NFIB fusion, prolonged but relentlessly progressive clinical course with frequent recurrences, and development of distant metastasis resulting in high long-term mortality. Currently, no effective therapy is available for patients with advanced non-resectable and/or metastatic disease. Complicating the clinical management of this patient group is the lack of prognostic markers. The purpose of this study is to investigate the prognostic value of 1p36 loss in patients with AdCC. The presence of 1p36 deletion and gene fusions involving the MYB, NFIB, and MYBL1 genes in a cohort of 93 salivary gland AdCCs was studied using fluorescence in situ hybridization. These results were statistically correlated with clinical data and outcome. Deletion of 1p36 in AdCC was identified in 13 of 85 analyzable cases (15.29%). MYB-NFIB fusion was detected in 57/85 (67.1%), MYBL1-NFIB fusion in 12/85 (14.1%), MYB-X fusion in 4/85 (4.7%), MYBL1-X in 4/85 (4.7%), and NFIB-X in 2/85 (2.4%) of AdCC cases. None of the 1p36-deleted samples showed MYBL1 rearrangement. Statistical analysis demonstrated a significant correlation between 1p36 deletion and advanced tumor stage and solid histology (p = 0.0061 and 0.0007, respectively). Kaplan-Meier survival curves showed statistically significant correlations between 1p36 deletion and decreased overall survival, disease-specific survival, recurrence-free interval, and recurrence-free survival, all of which were maintained in multivariate analysis. We demonstrate that 1p36 deletion can serve as an indicator of unfavorable outcome of patients with salivary gland AdCC.	[Steiner, Petr; Vanecek, Tomas; Miesbauerova, Marketa; Skalova, Alena] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Steiner, Petr; Grossmann, Petr; Vanecek, Tomas] Biopt Lab Ltd, Mol Pathol Lab, Mikulasske Namesti 4, Plzen 32600, Czech Republic; [Andreasen, Simon] Copenhagen Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Rigshosp, Copenhagen, Denmark; [Andreasen, Simon] Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark; [Hauer, Lukas] Charles Univ Prague, Clin Dent, Fac Med Plzen, Dept Maxillofacial Surg, Plzen, Czech Republic; [Santana, Thalita] Univ Sao Paulo, Fac Dent, Dept Oral Pathol, Sao Paulo, Brazil; [Kiss, Katalin] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark; [Slouka, David] Charles Univ Prague, Fac Med Plzen, Dept Otorhinolaryngol, Plzen, Czech Republic	Steiner, P (reprint author), Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic.; Steiner, P (reprint author), Biopt Lab Ltd, Mol Pathol Lab, Mikulasske Namesti 4, Plzen 32600, Czech Republic.	steiner@biopticka.cz	Steiner, Petr/J-4074-2017	Steiner, Petr/0000-0003-0320-8061; Andreasen, Simon/0000-0002-1528-4988	Ministry of Education, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government [SVV-2017-260 391]	This study was supported by the Ministry of Education, Czech Republic (grant SVV-2017-260 391).	Andersson MK, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx017; Andersson MK, 2016, ORAL ONCOL, V57, P63, DOI 10.1016/j.oraloncology.2016.04.002; Andreasen S, 2018, MODERN PATHOL, V31, P1211, DOI 10.1038/s41379-018-0005-y; Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Andreasen S, 2016, ONCOL REP, V35, P2177, DOI 10.3892/or.2016.4621; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bernheim A, 2008, LAB INVEST, V88, P464, DOI 10.1038/labinvest.2008.18; Bjorndal K, 2015, ORAL ONCOL, V51, P1138, DOI 10.1016/j.oraloncology.2015.10.002; Brayer KJ, 2016, CANCER DISCOV, V6, P176, DOI 10.1158/2159-8290.CD-15-0859; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Chen TY, 2017, EYE, V31, P720, DOI 10.1038/eye.2016.307; Coca-Pelaz A, 2015, ORAL ONCOL, V51, P652, DOI 10.1016/j.oraloncology.2015.04.005; Costa AF, 2010, ANAL CELL PATHOL, V33, P217, DOI 10.3233/ACP-CLO-2010-0547; D'Alfonso TM, 2014, HUM PATHOL, V45, P2270, DOI 10.1016/j.humpath.2014.07.013; Ferrarotto R, 2017, J CLIN ONCOL, V35, P352, DOI 10.1200/JCO.2016.67.5264; Freier K, 2005, CANCER GENET CYTOGEN, V159, P89, DOI 10.1016/j.cancergencyto.2004.09.007; Geurts JMW, 1998, ONCOGENE, V16, P865, DOI 10.1038/sj.onc.1201609; Godge P, 2012, CONTEMP CLIN DENT, V3, P223, DOI 10.4103/0976-237X.96838; Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Koshikawa K, 2004, HEPATO-GASTROENTEROL, V51, P186; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P935, DOI 10.14670/HH-18.935; Lefeuvre M, 2009, J ORAL PATHOL MED, V38, P94, DOI 10.1111/j.1600-0714.2008.00666.x; Leonard JH, 2000, CANCER DETECT PREV, V24, P620; Midorikawa Y, 2009, HEPATOLOGY, V49, P513, DOI 10.1002/hep.22698; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2011, CLIN CANCER RES, V17, P7003, DOI 10.1158/1078-0432.CCR-11-1870; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Mohapatra G, 2006, J MOL DIAGN, V8, P268, DOI 10.2353/jmoldx.2006.050109; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Oga A, 2011, ONCOL REP, V26, P1393, DOI 10.3892/or.2011.1446; Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; PERZIN KH, 1978, CANCER, V42, P265, DOI 10.1002/1097-0142(197807)42:1<265::AID-CNCR2820420141>3.0.CO;2-Z; Rao PH, 2008, CLIN CANCER RES, V14, P5181, DOI 10.1158/1078-0432.CCR-08-0158; Rettig EM, 2016, CANCER PREV RES, V9, P265, DOI 10.1158/1940-6207.CAPR-15-0316; Roden AC, 2015, J THORAC ONCOL, V10, P1570, DOI 10.1097/JTO.0000000000000656; Sajed DP, 2017, AM J SURG PATHOL, V41, P1473, DOI 10.1097/PAS.0000000000000945; Seethala RR, 2011, ARCH PATHOL LAB MED, V135, P123, DOI 10.1043/2010-0048-OAR.1; Skalova A, 2018, AM J SURG PATHOL, V42, pE11, DOI 10.1097/PAS.0000000000000980; Stenman G, 2017, WHO CLASSIFICATION H, P164; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; SZANTO PA, 1984, CANCER, V54, P1062, DOI 10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E; Tse DT, 2006, AM J OPHTHALMOL, V141, P54, DOI 10.1016/j.ajo.2005.09.002; van den Bent M J, 2000, Forum (Genova), V10, P108; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Xu B, 2017, AM J SURG PATHOL, V41, P1422, DOI 10.1097/PAS.0000000000000918; Zhang L, 2013, AM J PATHOL, V182, P2048, DOI 10.1016/j.ajpath.2013.02.020	49	5	5	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					471	480		10.1007/s00428-018-2349-6			10	Pathology	Pathology	GV8HP	WOS:000446380500009	29619555				2019-10-28	
J	Williams, HL; Walsh, K; Diamond, A; Oniscu, A; Deans, ZC				Williams, Hannah L.; Walsh, Kathy; Diamond, Austin; Oniscu, Anca; Deans, Zandra C.			Validation of the Oncomine((TM)) focus panel for next-generation sequencing of clinical tumour samples	VIRCHOWS ARCHIV			English	Article						Next-generation sequencing; Molecular pathology; Clinical validation; FFPE	INTEGRATIVE GENOMICS VIEWER	The clinical utility of next-generation sequencing (NGS) for a diverse range of targets is expanding, increasing the need for multiplexed analysis of both DNA and RNA. However, translation into daily use requires a rigorous and comprehensive validation strategy. The aim of this clinical validation was to assess the performance of the Ion Torrent Personal Genome Machine (IonPGM((TM))) and validate the Oncomine((TM)) Focus DNA and RNA Fusion panels for clinical application in solid tumour testing of formalin-fixed, paraffin-embedded (FFPE) tissue. Using a mixture of routine FFPE and reference material across a variety of tissue and specimen types, we sequenced 86 and 31 samples on the Oncomine((TM)) Focus DNA and RNA Fusion assays, respectively. This validation considered a number of parameters including the clinical robustness of the bioinformatics pipeline for variant detection and interpretation. The Oncomine((TM)) Focus DNA assay had a sample and variant-based sensitivity of 99.1 and 97.1%, respectively, and an assay specificity of 100%. The Oncomine((TM)) Focus Fusion panel had a good sensitivity and specificity based upon the samples assessed, however requires further validation to confirm findings due to limited sample numbers. We observed a good sequencing performance based upon amplicon, gene (hotspot variants within gene) and sample specific analysis with 92% of clinical samples obtaining an average amplicon coverage above 500X. Detection of some indels was challenging for the routine IonReporter((TM)) workflow; however, the addition of NextGENeA (R) software improved indel identification demonstrating the importance of both bench and bioinformatic validation. With an increasing number of clinically actionable targets requiring a variety of methodologies, NGS provides a cost-effective and time-saving methodology to assess multiple targets across different modalities. We suggest the use of multiple analysis software to ensure identification of clinically applicable variants.	[Williams, Hannah L.; Deans, Zandra C.] Royal Infirm Edinburgh NHS Trust, UKNEQAS Mol Genet, Edinburgh, Midlothian, Scotland; [Williams, Hannah L.; Walsh, Kathy; Oniscu, Anca] Royal Infirm Edinburgh NHS Trust, NHS Lothian, Dept Mol Pathol, Edinburgh, Midlothian, Scotland; [Williams, Hannah L.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland; [Diamond, Austin] Western Gen Hosp, Mol Genet, NHS Lothian, Edinburgh, Midlothian, Scotland	Williams, HL (reprint author), Royal Infirm Edinburgh NHS Trust, UKNEQAS Mol Genet, Edinburgh, Midlothian, Scotland.; Williams, HL (reprint author), Royal Infirm Edinburgh NHS Trust, NHS Lothian, Dept Mol Pathol, Edinburgh, Midlothian, Scotland.; Williams, HL (reprint author), Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland.	hlw37@st-andrews.ac.uk					[Anonymous], 2012, 15189 ISO; Bragg LM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003031; D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Deans ZC, 2015, PRACTICE GUIDELINES; Do H, 2015, CLIN CHEM, V61; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Hadd AG, 2013, J MOL DIAGN, V15, P234, DOI 10.1016/j.jmoldx.2012.11.006; Hagemann IS, 2015, CLIN NEXT GENERATION, P631; Hall AK, 2014, GAMING OLDER ADULTS, P19, DOI [10.1007/9783-31901904-8_551, DOI 10.1007/9783-31901904-8_55-1]; Hovelson DH, 2015, NEOPLASIA, V17, P385, DOI 10.1016/j.neo.2015.03.004; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Lih CJ, 2017, J MOL DIAGN, V19, P313, DOI 10.1016/j.jmoldx.2016.10.007; Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198; Reiman A, 2017, VALIDATION NGS MUTAT, P1; Robin JD, 2016, SCI REP-UK, V6, DOI 10.1038/srep24067; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Simbolo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062692; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Wilkins B., 2015, RETENTION STORAGE PA; Yeo ZX, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-516	22	4	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					489	503		10.1007/s00428-018-2411-4			15	Pathology	Pathology	GV8HP	WOS:000446380500011	30105577	Green Published, Other Gold			2019-10-28	
J	Letourneau, A; Maerevoet, M; Milowich, D; Dewind, R; Bisig, B; Missiaglia, E; de Leval, L				Letourneau, Audrey; Maerevoet, Marie; Milowich, Dina; Dewind, Roland; Bisig, Bettina; Missiaglia, Edoardo; de Leval, Laurence			Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma	VIRCHOWS ARCHIV			English	Article							LEUKEMIA		[Letourneau, Audrey; Milowich, Dina; Bisig, Bettina; Missiaglia, Edoardo; de Leval, Laurence] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland; [Maerevoet, Marie] Inst Jules Bordet, Dept Haematol, Brussels, Belgium; [Dewind, Roland] Inst Jules Bordet, Dept Pathol, Brussels, Belgium	de Leval, L (reprint author), Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland.	Laurence.deLeval@chuv.ch	de Leval, Laurence/M-4889-2017	de Leval, Laurence/0000-0003-3994-516X; Bisig, Bettina/0000-0002-6840-375X			[Anonymous], 2017, WHO CLASSIFICATION T; Bellanger D, 2014, LEUKEMIA, V28, P417, DOI 10.1038/leu.2013.271; Blombery P, 2016, HAEMATOLOGICA, V101, DOI 10.3324/haematol.2016.146118; Crescenzo R, 2015, CANCER CELL, V27, P516, DOI 10.1016/j.ccell.2015.03.006; Di Napoli A, 2018, BRIT J HAEMATOL, V180, P741, DOI 10.1111/bjh.14431; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Laurent C, 2016, ANN ONCOL, V27, P306, DOI 10.1093/annonc/mdv575; Lechner MG, 2012, CLIN CANCER RES, V18, P4549, DOI 10.1158/1078-0432.CCR-12-0101; Lechner MG, 2011, CANCER-AM CANCER SOC, V117, P1478, DOI 10.1002/cncr.25654; McKinney M, 2017, CANCER DISCOV, V7, P369, DOI 10.1158/2159-8290.CD-16-0330; Miranda RN, 2014, J CLIN ONCOL, V32, P114, DOI 10.1200/JCO.2013.52.7911; Ren Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03042; Roberti A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12602; Waldmann TA, 2017, ANNU REV IMMUNOL, V35, P533, DOI 10.1146/annurev-immunol-110416-120628	15	10	10	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					505	511		10.1007/s00428-018-2352-y			7	Pathology	Pathology	GV8HP	WOS:000446380500012	29637270				2019-10-28	
J	Choschzick, M; Gut, A; Fink, D				Choschzick, M.; Gut, A.; Fink, D.			PD-L1 receptor expression in vulvar carcinomas is HPV-independent	VIRCHOWS ARCHIV			English	Article						PD-L1; Vulvar cancer; HPV; Prognosis	SQUAMOUS-CELL CARCINOMA; RANDOMIZED CONTROLLED-TRIAL; HUMAN-PAPILLOMAVIRUS; OPEN-LABEL; ATEZOLIZUMAB; MULTICENTER; DOCETAXEL; PATHWAY; GENE; HEAD	PD-L1 (programmed cell death 1 ligand) is expressed on many cancer cells and prevents tumor cell death by blocking T cell activity. PD-L1 overexpression has been reported in squamous cell carcinomas of head and neck and lung cancer. To better understand the role of PD-L1 expression in vulvar cancer, we analyzed PD-L1 expression by immunohistochemistry in 55 well-characterized squamous cell carcinomas of vulva. PD-L1 was found in 72.7% of tumors. 27.3% of vulvar carcinomas showed moderate or strong PD-L1 expression. PD-L1 expression was correlated with low tumor stage (p < 0.05). There was no association to other clinicopathological parameters, HPV status, and overall survival of vulvar carcinoma patients. In conclusion, PD-L1 overexpression is detectable in a substantial proportion of vulvar carcinomas in all stages independent of HPV and may be a suitable therapeutic target in these cancers.	[Choschzick, M.; Gut, A.] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Fink, D.] Univ Hosp Zurich, Dept Gynecol, Frauenklin Str 10, CH-8091 Zurich, Switzerland	Choschzick, M (reprint author), Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	Matthias.Choschzick@usz.ch					Berger KN, 2018, GENE, V638, P20, DOI 10.1016/j.gene.2017.09.050; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hecking T, 2017, ONCOTARGET, V8, P92890, DOI 10.18632/oncotarget.21641; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Kerr DA, 2015, AM J SURG PATHOL, V39, P1643, DOI 10.1097/PAS.0000000000000516; Lee LJ, 2016, GYNECOL ONCOL, V142, P293, DOI 10.1016/j.ygyno.2016.05.019; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Smith JS, 2009, OBSTET GYNECOL, V113, P917, DOI 10.1097/AOG.0b013e31819bd6e0; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Udall M, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0689-9	14	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					513	516		10.1007/s00428-018-2364-7			4	Pathology	Pathology	GV8HP	WOS:000446380500013	29736798				2019-10-28	
J	Rupp, NJ; Rechsteiner, M; Freiberger, SN; Lenggenhager, D; Urosevic, M; Burger, IA; Rushing, EJ; Mihic-Probst, D				Rupp, Niels J.; Rechsteiner, Markus; Freiberger, Sandra N.; Lenggenhager, Daniela; Urosevic, Mirjana; Burger, Irene A.; Rushing, Elisabeth J.; Mihic-Probst, Daniela			New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation	VIRCHOWS ARCHIV			English	Article						Melanoma; Sarcoma; Transdifferentiation; Divergent differentiation; Next-generation sequencing	DESMOPLASTIC MELANOMA; DIFFERENTIATION	We describe a highly unusual case of metastatic melanoma in a 61-year-old female that manifested as a single groin lymph node metastasis accompanied by two distinct, subcutaneous sarcomatoid tumors on the same leg, without evidence of a primary tumor. Characterization encompassed extensive immunohistochemical staining as well as next-generation sequencing (NGS). The lymph node metastasis showed obvious features of melanoma. The two subcutaneous lesions, however, were morphologically and immunohistochemically consistent with high-grade myxofibrosarcoma and soft tissue mixed tumor, respectively. All three lesions were BRAF wild-type and found to harbor an identical NRAS p.Q61R mutation. Metachronic intestinal metastases, showing intermingled conventional and sarcomatoid morphology, as well as an identical genetic phenotype, corroborated these findings. The concordant genetic profile provided evidence of biphasic sarcomatoid transdifferentiation of melanoma. Interestingly, the lack of genetic heterogeneity between the three morphologically distinct tumors suggests factors other than genetic mutations to be involved in melanoma transdifferentiation.	[Rupp, Niels J.; Rechsteiner, Markus; Freiberger, Sandra N.; Lenggenhager, Daniela; Mihic-Probst, Daniela] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Urosevic, Mirjana] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland; [Burger, Irene A.] Univ Hosp Zurich, Dept Nucl Med, Zurich, Switzerland; [Rushing, Elisabeth J.] Univ Hosp Zurich, Dept Neuropathol, Zurich, Switzerland	Rupp, NJ (reprint author), Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	niels.rupp@usz.ch					Agaimy A, 2016, AM J SURG PATHOL, V40, P181, DOI 10.1097/PAS.0000000000000527; Banerjee SS, 2008, HISTOPATHOLOGY, V52, P119, DOI 10.1111/j.1365-2559.2007.02823.x; Busam KJ, 2011, CLIN LAB MED, V31, P321, DOI 10.1016/j.cll.2011.03.009; Hocar O, 2012, DERMAT RES PRACT, DOI 10.1155/2012/984096; Jin YH, 2010, ANTICANCER RES, V30, P245; Kiuru M, 2014, AM J SURG PATHOL, V38, P864, DOI 10.1097/PAS.0000000000000201; Movva S, 2015, ONCOTARGET, V6, P12234, DOI 10.18632/oncotarget.3498; Weissinger SE, 2014, MODERN PATHOL, V27, P524, DOI 10.1038/modpathol.2013.162	8	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					517	521		10.1007/s00428-018-2376-3			5	Pathology	Pathology	GV8HP	WOS:000446380500014	29785541				2019-10-28	
J	Losurdo, G; Piscitelli, D; Di Leo, A				Losurdo, Giuseppe; Piscitelli, Domenico; Di Leo, Alfredo			Novel steps forward in the histopathology of non-celiac gluten sensitivity	VIRCHOWS ARCHIV			English	Letter							WHEAT SENSITIVITY		[Losurdo, Giuseppe; Di Leo, Alfredo] Univ Bari, Gastroenterol Sect, Dept Emergency & Organ Transplantat, Bari, Italy; [Piscitelli, Domenico] Univ Bari, Sect Pathol, Dept Emergency & Organ Transplantat, Bari, Italy	Di Leo, A (reprint author), Univ Bari, Gastroenterol Sect, Dept Emergency & Organ Transplantat, Bari, Italy.	alfredo.dileo@uniba.it					Carroccio A, 2013, AM J GASTROENTEROL, V108, P1845, DOI 10.1038/ajg.2013.353; Catassi C, 2015, NUTRIENTS, V7, P4966, DOI 10.3390/nu7064966; Ierardi E, 2018, GASTROENTEROLO HEPAT, V2018; Losurdo G, 2017, GASTROENT RES PRACT, DOI 10.1155/2017/5023680; Losurdo G, 2016, WORLD J GASTROENTERO, V22, P8017, DOI 10.3748/wjg.v22.i35.8017; Villanacci V, 2013, AM J GASTROENTEROL, V108, P619, DOI 10.1038/ajg.2013.22; Zanini B, 2018, VIRCHOWS ARCH, V473, P229, DOI 10.1007/s00428-018-2346-9	7	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					523	523		10.1007/s00428-018-2388-z			1	Pathology	Pathology	GV8HP	WOS:000446380500015	29915943	Bronze			2019-10-28	
J	Zanini, B; Villanacci, V; Marullo, M; Cadei, M; Lanzarotto, F; Bozzola, A; Ricci, C				Zanini, Barbara; Villanacci, Vincenzo; Marullo, Monica; Cadei, Moris; Lanzarotto, Francesco; Bozzola, Anna; Ricci, Chiara			Novel steps forward in the histopathology of non-celiac gluten sensitivity, authors' reply	VIRCHOWS ARCHIV			English	Letter									[Zanini, Barbara; Marullo, Monica; Lanzarotto, Francesco; Ricci, Chiara] Univ Brescia, Dept Clin & Expt Sci, Gastroenterol Unit, Viale Europa 11, I-25123 Brescia, Italy; [Villanacci, Vincenzo; Cadei, Moris; Bozzola, Anna] Spedali Civil Brescia, Inst Pathol, Piazzale Spedali Civili 1, I-25123 Brescia, Italy	Zanini, B (reprint author), Univ Brescia, Dept Clin & Expt Sci, Gastroenterol Unit, Viale Europa 11, I-25123 Brescia, Italy.	barbara.zanini@unibs.it		Zanini, Barbara/0000-0002-1733-9938			Losurdo G, 2017, GASTROENT RES PRACT, DOI 10.1155/2017/5023680; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Zanini B, 2018, VIRCHOWS ARCH, V473, P229, DOI 10.1007/s00428-018-2346-9	3	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	OCT	2018	473	4					525	525		10.1007/s00428-018-2401-6			1	Pathology	Pathology	GV8HP	WOS:000446380500016	29951866	Bronze			2019-10-28	
J	Pillay, TS				Pillay, Tahir S.			Introducing the Journal of Clinical Pathology Grand Rounds: a new multidisciplinary clinical pathology forum	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Pillay, Tahir S.] Univ Cape Town, Div Chem Pathol, Cape Town, South Africa	Pillay, TS (reprint author), Univ Pretoria, Chem Pathol, ZA-0002 Pretoria, South Africa.	jclinpatheic@gmail.com					Kidambi S, 2008, J CLIN PATHOL, V61, P588, DOI 10.1136/jcp.2007.049775; Marais AD, 2018, J CLIN PATHOL, V71; Martin JM, 2018, J CLIN PATHOL, V71, P860, DOI 10.1136/jclinpath-2017-204818; Reynolds TM, 2018, J CLIN PATHOL, V71, P608, DOI 10.1136/jclinpath-2017-204727	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					859	859		10.1136/jclinpath-2018-205372			1	Pathology	Pathology	GV4QG	WOS:000446084700005	30232213				2019-10-28	
J	Martin, JM; Cuesta, A; Velasco, R; Herrero, A; Ramon, D; Monteagudo, C				Martin, Jose M.; Cuesta, Ana; Velasco, Rebeca; Herrero, Ana; Ramon, Dolores; Monteagudo, Carlos			Two-year-old girl with tuberous xanthomas	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							SITOSTEROLEMIA		[Martin, Jose M.; Velasco, Rebeca; Ramon, Dolores] Hosp Clin Univ, Dept Dermatol, Valencia 46010, Spain; [Martin, Jose M.; Ramon, Dolores; Monteagudo, Carlos] Univ Valencia, Sch Med, Valencia, Spain; [Cuesta, Ana] Hosp Clin Univ, Dept Genet, Valencia, Spain; [Herrero, Ana] Hosp Clin Univ, Dept Pediat, Valencia, Spain; [Monteagudo, Carlos] Hosp Clin Univ, Dept Pathol, Valencia, Spain	Martin, JM (reprint author), Hosp Clin Univ, Dept Dermatol, Valencia 46010, Spain.	Martin.josemaria@gmail.com	, Monteagudo/H-6555-2016				Kanaji T, 2013, BLOOD, V122, P2732, DOI 10.1182/blood-2013-06-510461; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; Miettinen TA, 2006, GASTROENTEROLOGY, V130, P542, DOI 10.1053/j.gastro.2005.10.022; Miettinen TA, 2005, AM J CARDIOL, V96, p40D, DOI 10.1016/j.amjcard.2005.03.019; Oosterveer DM, 2009, ATHEROSCLEROSIS, V207, P311, DOI 10.1016/j.atherosclerosis.2009.04.009; Park JH, 2014, J CLIN ENDOCR METAB, V99, P1512, DOI 10.1210/jc.2013-3274; Tremblay AJ, 2011, J LIPID RES, V52, P558, DOI 10.1194/jlr.M011080; Tsubakio-Yamamoto K, 2010, J ATHEROSCLER THROMB, V17, P891, DOI 10.5551/jat.4614; Yoo Eun-Gyong, 2016, Ann Pediatr Endocrinol Metab, V21, P7, DOI 10.6065/apem.2016.21.1.7	10	1	1	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					860	862		10.1136/jclinpath-2017-204818			3	Pathology	Pathology	GV4QG	WOS:000446084700006	30232214				2019-10-28	
J	Marais, AD				Marais, Adrian David			Contrasting effects of sterols on metabolism	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							CHOLESTEROL-SYNTHESIS; SITOSTEROLEMIA; XANTHOMATOSIS		[Marais, Adrian David] Univ Cape Town, Dept Pathol, ZA-7925 Cape Town, South Africa	Marais, AD (reprint author), Univ Cape Town, Dept Pathol, ZA-7925 Cape Town, South Africa.	david.marais@uct.ac.za					Kidambi S, 2008, J CLIN PATHOL, V61, P588, DOI 10.1136/jcp.2007.049775; Park JH, 2014, J CLIN ENDOCR METAB, V99, P1512, DOI 10.1210/jc.2013-3274; Porter FD, 2011, J LIPID RES, V52, P6, DOI 10.1194/jlr.R009548; Rohmer M, 2008, LIPIDS, V43, P1095, DOI 10.1007/s11745-008-3261-7; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1985, J LIPID RES, V26, P1126	6	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					863	864		10.1136/jclinpath-2018-205221			2	Pathology	Pathology	GV4QG	WOS:000446084700008	30232215				2019-10-28	
J	Varma, M; Narahari, K; Mason, M; Oxley, JD; Berney, DM				Varma, Murali; Narahari, Krishna; Mason, Malcolm; Oxley, Jon D.; Berney, Daniel M.			Contemporary prostate biopsy reporting: insights from a survey of clinicians' use of pathology data	JOURNAL OF CLINICAL PATHOLOGY			English	Article							INTERNATIONAL-SOCIETY; UROLOGICAL-PATHOLOGY; EUROPEAN PATHOLOGISTS; ACTIVE SURVEILLANCE; RECOMMENDATIONS; CARCINOMA; AGREEMENT	Aim To determine how clinicians use data in contemporary prostate biopsy reports. Methods A survey was circulated to members of the British Association of Urological Surgeons and the British Uro-oncology Group. Results Responses were received from 114 respondents (88 urologists, 26 oncologists). Ninety-seven (94%) use the number of positive cores from each side and 43 (42%) use the % number of positive cores. When determining the number and percentage of positive cores, 72 (71%) would not differentiate between targeted and non-targeted samples. If multiple Gleason Scores (GS) were included in a report, 77 (78%) would use the worst GS even if present in a core with very little tumour, 12% would use the global GS and 10% the GS in the core most involved by tumour. Fifty-five (55%) either never or rarely used perineural invasion for patient management. Conclusions The number of positive cores is an important parameter for patient management but may be difficult to determine in the laboratory due to core fragmentation so the biopsy taker must indicate the number of biopsies obtained. Multiple biopsies taken from a single site are often interpreted by clinicians as separate cores when determining the number of positive cores so pathologists should also report the number of sites positive. Clinicians have a non-uniform approach to the interpretation of multiple GS in prostate biopsy reports so we recommend that pathologists also include a single 'bottom-line' GS for each case to direct the clinician's treatment decision.	[Varma, Murali] Univ Hosp Wales, Dept Pathol, Cardiff, S Glam, Wales; [Narahari, Krishna] Univ Hosp Wales, Dept Urol, Cardiff, S Glam, Wales; [Mason, Malcolm] Cardiff Univ, Dept Oncol, Cardiff, S Glam, Wales; [Oxley, Jon D.] Southmead Hosp, Dept Pathol, Bristol, Avon, England; [Berney, Daniel M.] Queen Mary Univ London, Dept Mol Oncol, London, England	Varma, M (reprint author), Univ Hosp Wales, Dept Cellular Pathol, Cardiff CF14 4XN, S Glam, Wales.	wptmv@cf.ac.uk	Mason, Malcolm D/H-6979-2013		Orchid Appeal	DMB is supported by The Orchid Appeal.	Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA; Arias-Stella JA, 2015, AM J SURG PATHOL, V39, P1213, DOI 10.1097/PAS.0000000000000499; Athanazio D, 2017, HISTOPATHOLOGY, V70, P1098, DOI 10.1111/his.13179; Berney DM, 2014, VIRCHOWS ARCH, V464, P583, DOI 10.1007/s00428-014-1554-1; Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284; Bjurlin MA, 2016, CENT EUR J UROL, V69, P9, DOI 10.5173/ceju.2016.734; Caras RJ, 2014, CURR UROL REP, V15, DOI 10.1007/s11934-013-0391-0; Egevad L, 2018, PATHOLOGY, V50, P60, DOI 10.1016/j.pathol.2017.09.008; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Kryvenko ON, 2014, UROLOGY, V83, P869, DOI 10.1016/j.urology.2013.12.054; Kweldam CF, 2016, HISTOPATHOLOGY, V69, P441, DOI 10.1111/his.12976; Oxley JD, DATASET HISTOPATHOLO; Rubin MA, 2004, AM J SURG PATHOL, V28, P946, DOI 10.1097/00000478-200407000-00016; Varma M, HISTOPATHOLOGY; Varma M, 2016, J CLIN PATHOL, V69, P852, DOI 10.1136/jclinpath-2016-203658; Varma M, 2013, J CLIN PATHOL, V66, P120, DOI 10.1136/jclinpath-2012-200993; Verhoef EI, 2018, HISTOPATHOLOGY, V72, P760, DOI 10.1111/his.13427	17	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					874	878		10.1136/jclinpath-2018-205093			5	Pathology	Pathology	GV4QG	WOS:000446084700010	29720406				2019-10-28	
J	Barbosa, JR; Cortes, VF; Portilho, MM; Miguel, JC; Marques, VA; Bezerra, CS; de Souza, NV; Lima, DM; Colares, JKB; Lewis-Ximenez, LL; Lampe, E; Villar, LM				Barbosa, Jakeline Ribeiro; Cortes, Vanessa Faria; Portilho, Moyra Machado; Miguel, Juliana Custodio; Marques, Vanessa Alves; Bezerra, Cristianne Sousa; de Souza, Natalia Vasconcelos; Lima, Danielle Malta; Baima Colares, Jeova Keny; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo			Performance of point of care assays for hepatitis B and C viruses in chronic kidney disease patients	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DIAGNOSTIC-TESTS; SURFACE-ANTIGEN; RAPID TESTS; HEMODIALYSIS; INFECTION; HBSAG	Aims Point of care testing (POCT) has been used for hepatitis B and C diagnosis in general population, but little is known about the influence of clinical conditions in the accuracy of these assays. This study aims to evaluate the performance of POCTs for detection of hepatitis B virus surface antigen (HBsAg) and antibodies to Hepatitis C Virus (anti-HCV) in Chronic Kidney Disease (CKD) patients. Methods A total of 286 subjects were included in this study. HBsAg and anti-HCV were detected using commercial EIAs and four POCTs: HBsAg (WAMA ImunoRapido HBsAg and VIKIA HBsAg) and anti-HCV (DOLES HCV teste rapido and WAMA Imuno-Rapido anti-HCV) in serum and whole blood. Results Using EIA, HBsAg and anti-HCV prevalence was 4.5% and 16.1% in CKD patients. HBsAg and anti-HCV POCTs had sensitivities from 92.3% to 100% and 84.8% to 89.1% while specificities were 99.3% to 100% and 99.2% to 99.6%, respectively. POCT using serum samples performed well compared with whole blood samples and true positive samples of POCTs had high optical density to cut-off (OD/CO) values compared with EIA. Conclusions This study demonstrates good performance of HBsAg and anti-HCV POCTs in CKD patients, especially in serum samples indicating low interference of this disease in the performance of these assays. POCTs could be an important tool for HBV and HCV screening in high-risk populations.	[Barbosa, Jakeline Ribeiro; Cortes, Vanessa Faria; Portilho, Moyra Machado; Miguel, Juliana Custodio; Marques, Vanessa Alves; Bezerra, Cristianne Sousa; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Oswaldo Cruz Inst, Viral Hepatitis Lab, Fiocruz, RJ, Brazil; [Barbosa, Jakeline Ribeiro; Lima, Danielle Malta; Baima Colares, Jeova Keny] Univ Fed Ceara, Postgrad Program Pathol, Fortaleza, Ceara, Brazil; [Cortes, Vanessa Faria] Fed Univ Sao Joao Del Rey, Campus Divinopolis, Sao Joao Del Rei, MG, Brazil; [Bezerra, Cristianne Sousa] Fed Inst Sci Educ & Technol Ceara, Fortaleza, Ceara, Brazil; [de Souza, Natalia Vasconcelos] Univ Estadual Ceara, Postgrad Program Northeast Network Biotechnol REN, Fortaleza, Ceara, Brazil; [de Souza, Natalia Vasconcelos] Univ Fortaleza, Fortaleza, Ceara, Brazil; [Lima, Danielle Malta; Baima Colares, Jeova Keny] Univ Fortaleza, Postgrad Program Med Sci, Fortaleza, Ceara, Brazil	Villar, LM (reprint author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Viral Hepatitis Lab, BR-21036004 Rio De Janeiro, Brazil.	liviafiocruz@gmail.com		Sousa Bezerra, Cristianne/0000-0002-9389-5186	Research Support Foundation of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ); Brazilian National Council of Technological and Scientific Development (CNPq)National Council for Scientific and Technological Development (CNPq); Brazilian Ministry of Health, the Coordination of Improvement of Higher Education Personnel (CAPES); Oswaldo Cruz Foundation (FIOCRUZ)	This research was supported by the Research Support Foundation of the State of Rio de Janeiro (FAPERJ), Brazilian National Council of Technological and Scientific Development (CNPq), Brazilian Ministry of Health, the Coordination of Improvement of Higher Education Personnel (CAPES) and Oswaldo Cruz Foundation (FIOCRUZ).	Barbosa JR, 2017, J VIROL METHODS, V248, P244, DOI 10.1016/j.jviromet.2017.08.001; Barbosa JR, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070793; Sette LHBC, 2014, CLINICS, V69, P271, DOI 10.6061/clinics/2014(04)09; Bottero J, 2013, J HEPATOL, V58, P473, DOI 10.1016/j.jhep.2012.11.016; Carvalho-Filho RJ, 2015, WORLD J GASTROENTERO, V21, P408, DOI 10.3748/wjg.v21.i2.408; Chevaliez S, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.01.009; Cohen G, 2012, TOXINS, V4, P962, DOI 10.3390/toxins4110962; Cruz HM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1249-5; Edey M, 2010, NEPHROLOGY, V15, P137, DOI 10.1111/j.1440-1797.2009.01268.x; Fabrizi F, 2000, AM J KIDNEY DIS, V35, P122, DOI 10.1016/S0272-6386(00)70310-6; Firdaus R, 2013, J VIRAL HEPATITIS, V20, P290, DOI 10.1111/jvh.12002; Halle MP, 2016, IRAN J KIDNEY DIS, V10, P304; Honge BL, 2014, HIV MED, V15, P571, DOI 10.1111/hiv.12158; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P290, DOI 10.1053/j.ajkd.2005.06.006; Kalinowski P., 2010, APS; Khuroo MS, 2014, J CLIN EXP HEPATOL, V4, P226, DOI 10.1016/j.jceh.2014.07.008; Khuroo MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121450; Kim MH, 2013, J VIROL METHODS, V193, P379, DOI 10.1016/j.jviromet.2013.07.005; Lee JH, 2015, J GASTROEN HEPATOL, V30, P696, DOI 10.1111/jgh.12788; Marinaki S, 2015, WORLD J HEPATOL, V7, P548, DOI 10.4254/wjh.v7.i3.548; da Silva NMO, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-167; Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60; Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240; Scalioni LD, 2014, J CLIN VIROL, V60, P200, DOI 10.1016/j.jcv.2014.04.001; Sesso Ricardo Cintra, 2016, J. Bras. Nefrol., V38, P54, DOI 10.5935/0101-2800.20160009; Sharma M, 2015, UNITED EUR GASTROENT, V3, P364, DOI 10.1177/2050640615580725	26	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					879	884		10.1136/jclinpath-2018-205024			6	Pathology	Pathology	GV4QG	WOS:000446084700011	29730611				2019-10-28	
J	Kaku, N; Ihara, K; Hirata, Y; Yamada, K; Lee, S; Kanemasa, H; Motomura, Y; Baba, H; Tanaka, T; Sakai, Y; Maehara, Y; Ohga, S				Kaku, Noriyuki; Ihara, Kenji; Hirata, Yuichiro; Yamada, Kenji; Lee, Sooyoung; Kanemasa, Hikaru; Motomura, Yoshitomo; Baba, Haruhisa; Tanaka, Tamami; Sakai, Yasunari; Maehara, Yoshihiko; Ohga, Shouichi			Diagnostic potential of stored dried blood spots for inborn errors of metabolism: a metabolic autopsy of medium-chain acyl-CoA dehydrogenase deficiency	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TANDEM MASS-SPECTROMETRY; SUDDEN-INFANT-DEATH; ACID OXIDATION DISORDERS; UNEXPECTED DEATH; MCAD DEFICIENCY; ACYLCARNITINES; JAPAN; STABILITY; CHILDREN; DISEASE	Aim It is estimated that 1-5% of sudden infant death syndrome (SIDS) cases might be caused by undiagnosed inborn errors of metabolism (IEMs); however, the postmortem identification of IEMs remains difficult. This study aimed to evaluate the usefulness of dried blood spots (DBSs) stored after newborn screening tests as a metabolic autopsy to determine the causes of death in infants and children who died suddenly and unexpectedly. Methods Infants or toddlers who had suddenly died without a definite diagnosis between July 2008 and December 2012 at Kyushu University Hospital in Japan were enrolled in this study. Their Guthrie cards, which had been stored for several years at 4-8 degrees C, were used for an acylcarnitine analysis by tandem mass spectrometry to identify inborn errors of metabolism. Results Fifteen infants and children who died at less than 2 years of age and for whom the cause of death was unknown were enrolled for the study. After correcting the C0 and C8 values assuming the hydrolysation of acylcarnitine in the stored DBSs, the corrected C8 value of one case just exceeded the cut-off level for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency screening. Genetic and biochemical analyses confirmed this patient to have MCAD deficiency. Conclusion DBSs stored after newborn screening tests are a promising tool for metabolic autopsy. The appropriate compensation of acylcarnitine data and subsequent genetic and biochemical analyses are essential for the postmortem diagnosis of inborn errors of metabolism.	[Kaku, Noriyuki; Ihara, Kenji; Hirata, Yuichiro; Lee, Sooyoung; Kanemasa, Hikaru; Motomura, Yoshitomo; Baba, Haruhisa; Tanaka, Tamami; Sakai, Yasunari; Ohga, Shouichi] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Fukuoka, Japan; [Kaku, Noriyuki; Hirata, Yuichiro; Lee, Sooyoung; Motomura, Yoshitomo; Baba, Haruhisa; Maehara, Yoshihiko] Kyushu Univ Hosp, Emergency & Crit Care Ctr, Fukuoka, Fukuoka, Japan; [Ihara, Kenji] Oita Univ, Dept Pediat, Fac Med, Yufu 8795593, Japan; [Yamada, Kenji] Shimane Univ, Fac Med, Dept Pediat, Izumo, Shimane, Japan	Ihara, K (reprint author), Oita Univ, Dept Pediat, Fac Med, Yufu 8795593, Japan.	k-ihara@oita-u.ac.jp	Sakai, Yasunari/S-7965-2018	Sakai, Yasunari/0000-0002-5747-8692; Yamada, Kenji/0000-0002-0738-7960	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP17K12349]	The work was supported in part by JSPS KAKENHI grant number JP17K12349 (N. Kaku).	Boles RG, 1998, J PEDIATR-US, V132, P924, DOI 10.1016/S0022-3476(98)70385-3; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; Chace DH, 2001, CLIN CHEM, V47, P1166; Cote A, 1999, J PEDIATR-US, V135, P437, DOI 10.1016/S0022-3476(99)70165-4; Fingerhut R, 2009, ANAL CHEM, V81, P3571, DOI 10.1021/ac8022235; Hara K, 2016, MOL GENET METAB, V118, P9, DOI 10.1016/j.ymgme.2015.12.011; Homig-Holzel C, 2012, DIAGN MOL PATHOL, V21, P189, DOI 10.1097/PDM.0b013e3182595516; Hori D, 2005, BRAIN DEV-JPN, V27, P39, DOI 10.1016/j.braindev.2004.04.004; Kinney HC, 2009, NEW ENGL J MED, V361, P795, DOI 10.1056/NEJMra0803836; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; Lundemose JB, 1997, J CLIN PATHOL-MOL PA, V50, P212, DOI 10.1136/mp.50.4.212; Moon RY, 2007, LANCET, V370, P1578, DOI 10.1016/S0140-6736(07)61662-6; Olpin SE, 2004, ANN CLIN BIOCHEM, V41, P282, DOI 10.1258/0004563041201473; Opdal SH, 2004, PEDIATRICS, V114, pE506, DOI 10.1542/peds.2004-0683; Pryce JW, 2011, J CLIN PATHOL, V64, P1005, DOI 10.1136/jclinpath-2011-200218; Purevsuren J, 2012, MOL GENET METAB, V107, P237, DOI 10.1016/j.ymgme.2012.06.010; Purevsuren J, 2009, MOL GENET METAB, V96, P77, DOI 10.1016/j.ymgme.2008.10.012; Schulze A, 2003, PEDIATRICS, V111, P1399, DOI 10.1542/peds.111.6.1399; Shigematsu Y, 2002, J CHROMATOGR B, V776, P39, DOI 10.1016/S1570-0232(02)00077-6; Strnadova KA, 2007, CLIN CHEM, V53, P717, DOI 10.1373/clinchem.2006.076679; Tajima G, 2016, MOL GENET METAB, V119, P322, DOI 10.1016/j.ymgme.2016.10.007; Takahashi T, 2015, PEDIATR INT, V57, P348, DOI 10.1111/ped.12660; Taylor BJ, 2015, ARCH DIS CHILD, V100, P1018, DOI 10.1136/archdischild-2015-308239; Vennemann M, 2007, ARCH DIS CHILD, V92, P133, DOI 10.1136/adc.2006.101337; Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225; Wilcken B, 2007, LANCET, V369, P37, DOI 10.1016/S0140-6736(07)60029-4; Wilcox RL, 2002, J PEDIATR-US, V141, P833, DOI 10.1067/mpd.2002.130259; Yamada K, 2016, BRAIN DEV-JPN, V38, P293, DOI 10.1016/j.braindev.2015.08.011; Yamaguchi Seiji, 2008, Ann Acad Med Singapore, V37, P13; Yamamoto T, 2011, MOL GENET METAB, V102, P399, DOI 10.1016/j.ymgme.2010.12.004; Zytkovicz TH, 2001, CLIN CHEM, V47, P1945	31	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					885	889		10.1136/jclinpath-2017-204962			5	Pathology	Pathology	GV4QG	WOS:000446084700012	29720407				2019-10-28	
J	Dias, EP; Picciani, BLS; dos Santos, VDB; Cunha, KS				Dias, Eliane P.; Picciani, Bruna L. S.; dos Santos, Vanessa de C. B.; Cunha, Karin S.			A simple technique to construct tissue macroarrays	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MICROARRAY TECHNOLOGY; HIGH-THROUGHPUT; BREAST-CANCER; IN-SITU; HETEROGENEITY; EXPRESSION; SPECIMENS	Aims In the diagnostic or research field, there is a need that the histopathological evaluation provides as much information as possible, with the shortest time and lowest cost. The development of the tissue microarray (TMA) technology has significantly facilitated and accelerated studies with tissue analyses using in situ technologies. Nevertheless, one of the most recognised limitations of TMA is that the small cores used to construct a TMA may not accurately represent characteristics of the whole tissue specimen. The aim is to present the technical aspects of a simple system to construct tissue macroarrays (TMaAs), its advantages and limitations, and some results of its use in for research purposes. Methods The study presents three possibilities of preparing the specimens with up to 6mm diameter to be included into the TMaA paraffin block using our method. Results With this technique, it was possible to obtain glass slides with multiple whole fragments, which were used in five different studies. Conclusions We presented a method for construction of multi-TMaA paraffin blocks, which is very simple for optimising laboratory techniques requiring paraffin-embedded tissue sections and can be easily implemented in any institution with a histology laboratory.	[Dias, Eliane P.; Picciani, Bruna L. S.; dos Santos, Vanessa de C. B.; Cunha, Karin S.] Fluminense Fed Univ, Sch Med, Dept Pathol, Postgrad Program Pathol, Niteroi, RJ, Brazil	Dias, EP (reprint author), Univ Fed Fluminense, Dept Pathol, BR-24033900 Niteroi, RJ, Brazil.	elianepedra@hotmail.com	Picciani, Bruna/B-8227-2013	Picciani, Bruna/0000-0001-7592-1785			Alkatout I, 2017, EXP MOL PATHOL, V102, P268, DOI 10.1016/j.yexmp.2017.02.013; BATTIFORA H, 1986, LAB INVEST, V55, P244; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Cappellesso R, 2015, HUM PATHOL, V46, P665, DOI 10.1016/j.humpath.2015.02.007; Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14; Eckel-Passow JE, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-48; Fernandez PL, 2001, VIRCHOWS ARCH, V438, P591, DOI 10.1007/s004280100393; Fitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P595, DOI 10.5858/arpa.2013-0566-CP; Fujita H, 2015, CLIN LAB, V61, P569, DOI 10.7754/Clin.Lab.2014.141102; Giltnane JM, 2004, NAT CLIN PRACT ONCOL, V1, P104, DOI 10.1038/ncponc0046; Cunha KSG, 2009, J CLIN PATHOL, V62, P629, DOI 10.1136/jcp.2008.063081; Gulbahce HE, 2012, APPL IMMUNOHISTO M M, V20, P340, DOI 10.1097/PAI.0b013e318241ca14; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Limberger KA, 2017, HISTOCHEM CELL BIOL, V147, P75, DOI 10.1007/s00418-016-1476-x; Mulrane L, 2017, METHODS MOL BIOL, V1501, P311, DOI 10.1007/978-1-4939-6475-8_16; Rehemtulla A, 2012, NEOPLASIA, V14, P1278, DOI 10.1593/neo.122096; Wang L, 2003, APPL IMMUNOHISTO M M, V11, P174, DOI 10.1097/00129039-200306000-00015; Zlobec Inti, 2014, J Vis Exp, P51893, DOI 10.3791/51893	18	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					890	894		10.1136/jclinpath-2018-205076			5	Pathology	Pathology	GV4QG	WOS:000446084700013	29798839				2019-10-28	
J	Ryland, GL; Jones, K; Chin, M; Markham, J; Aydogan, E; Kankanige, Y; Caruso, M; Guinto, J; Dickinson, M; Prince, HM; Yong, K; Blombery, P				Ryland, Georgina L.; Jones, Kate; Chin, Melody; Markham, John; Aydogan, Elle; Kankanige, Yamuna; Caruso, Marisa; Guinto, Jerick; Dickinson, Michael; Prince, H. Miles; Yong, Kwee; Blombery, Piers			Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing	JOURNAL OF CLINICAL PATHOLOGY			English	Article							RAS PATHWAY; CELLS; EXPRESSION; RISK; MUTATIONS; SITE	Aims Multiple myeloma is a genomically complex haematological malignancy with many genomic alterations recognised as important in diagnosis, prognosis and therapeutic decision making. Here, we provide a summary of genomic findings identified through routine diagnostic next-generation sequencing at our centre. Methods A cohort of 86 patients with multiple myeloma underwent diagnostic sequencing using a custom hybridisation-based panel targeting 104 genes. Sequence variants, genome-wide copy number changes and structural rearrangements were detected using an inhouse-developed bioinformatics pipeline. Results At least one mutation was found in 69 (80%) patients. Frequently mutated genes included TP53 (36%), KRAS (22.1%), NRAS (15.1%), FAM46C/DIS3 (8.1%) and TET2/FGFR3 (5.8%), including multiple mutations not previously described in myeloma. Importantly we observed TP53 mutations in the absence of a 17 p deletion in 8% of the cohort, highlighting the need for sequencing-based assessment in addition to cytogenetics to identify these high-risk patients. Multiple novel copy number changes and immunoglobulin heavy chain translocations are also discussed. Conclusions Our results demonstrate that many clinically relevant genomic findings remain in multiple myeloma which have not yet been identified through large-scale sequencing efforts, and provide important mechanistic insights into plasma cell pathobiology.	[Ryland, Georgina L.; Jones, Kate; Aydogan, Elle; Kankanige, Yamuna; Guinto, Jerick; Blombery, Piers] Peter MacCallum Canc Ctr, Dept Pathol, 305 Grattan St, Melbourne, Vic 3000, Australia; [Chin, Melody; Yong, Kwee] UCL, Dept Haematol, Canc Inst, London, England; [Markham, John] Peter MacCallum Canc Ctr, Res Div, Melbourne, Vic, Australia; [Caruso, Marisa; Dickinson, Michael; Prince, H. Miles] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia; [Dickinson, Michael; Prince, H. Miles; Blombery, Piers] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia	Blombery, P (reprint author), Peter MacCallum Canc Ctr, Dept Pathol, 305 Grattan St, Melbourne, Vic 3000, Australia.	piers.blombery@petermac.org			Snowdome Foundation; Vision Super	We gratefully acknowledge funding support from The Snowdome Foundation (http://snowdome.org.au/) and Vision Super (https://www.visionsuper.com.au/).	Amoroso MR, 2012, CELL DEATH DIFFER, V19, P592, DOI 10.1038/cdd.2011.128; Blombery PA, 2018, BRIT J HAEMATOL, V183, P146, DOI 10.1111/bjh.14919; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Bruun J, 2015, CLIN CANCER RES, V21, P3759, DOI 10.1158/1078-0432.CCR-14-3294; Cameron DL, 2017, GENOME RES, V27, P2050, DOI 10.1101/gr.222109.117; Caye A, 2015, NAT GENET, V47, P1334, DOI 10.1038/ng.3420; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chavan SS, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.12; Chin M, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.76; Chubb D, 2013, NAT GENET, V45, P1221, DOI 10.1038/ng.2733; Cleynen A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00638-w; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; French JD, 2002, LEUKEMIA, V16, P1189, DOI 10.1038/sj/leu/2402516; Kamada Y, 2012, INT J HEMATOL, V96, P492, DOI 10.1007/s12185-012-1171-1; Kim SY, 2011, BIOL BLOOD MARROW TR, V17, P810, DOI 10.1016/j.bbmt.2011.01.002; Kortum KM, 2015, BLOOD REV, V29, P329, DOI 10.1016/j.blre.2015.03.003; Kortum KM, 2016, BLOOD, V128, P1226, DOI 10.1182/blood-2016-02-698092; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13656; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Manojlovic Z, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007087; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Miotto B, 2014, CELL REP, V7, P575, DOI 10.1016/j.celrep.2014.03.030; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Ramos-Medina R, 2013, BRIT J HAEMATOL, V160, P106, DOI 10.1111/bjh.12080; Shah V, 2018, LEUKEMIA, V32, P102, DOI 10.1038/leu.2017.179; Sherbenou DW, 2016, J CLIN INVEST, V126, P4640, DOI 10.1172/JCI85856; Walker BA, 2015, J CLIN ONCOL, V33, P3911, DOI 10.1200/JCO.2014.59.1503; Walker BA, 2013, BLOOD, V121, P3413, DOI 10.1182/blood-2012-12-471888	29	5	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					895	899		10.1136/jclinpath-2018-205195			5	Pathology	Pathology	GV4QG	WOS:000446084700014	29760015				2019-10-28	
J	Horan, MP; Chai, SY; Munusamy, N; Tay, KH; Wienholt, L; Tye-Din, JA; Daveson, J; Varney, M; Badrick, T				Horan, Martin Patrick; Chai, Sze Yee; Munusamy, Nalishia; Tay, Kwang Hong; Wienholt, Louise; Tye-Din, Jason A.; Daveson, James; Varney, Michael; Badrick, Tony			High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program	JOURNAL OF CLINICAL PATHOLOGY			English	Article							GUIDELINES; DIAGNOSIS; GASTROENTEROLOGY; MANAGEMENT; SOCIETY	Aim Coeliac disease(CD) is a highly prevalent, gluten-dependent, autoimmune enteropathy.While the diagnosis is based on serological and histological criteria, genotyping of the human leucocyte antigens (HLA) DQ2 and DQ8 has been shown to have substantial clinical utility, especially in excluding the diagnosis in patients who do not carry either antigen. As a result, HLA genotyping is now being performed by more laboratories and has recently become one of the most frequently requested genetic tests in Australia. To date, there has been little scrutiny on the accuracy and reporting of results by laboratories new to HLA typing. In response to clinician feedback that identified potentially clinically significant discrepancies in HLA typing results, the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) undertook a pilot study to assess laboratory performance in the detection of HLA-DQ2/ DQ8 and their associated HLA-DQA1 and HLA-DQB1 alleles. Methods DNA was extracted from 5 patients and sent to 10 laboratories for external quality assurance (EQA) testing. Laboratories were assessed for reporting in genotyping, interpretation and methodology. Results Our findings showed that at least 80% of laboratories underperform with respect to recommended guidelines for HLA typing and reporting for CD, with 40% of laboratories failing to provide any clinical interpretation or full genotyping data. This suboptimal level of reporting may lead to ambiguities for downstream clinical interpretation that may compromise patient management. Conclusions These findings highlight the importance of adherence to standardised guidelines for optimal performance and reporting of HLA results and substantiate the need for EQA and proficiency testing for laboratories providing this service.	[Horan, Martin Patrick; Chai, Sze Yee; Munusamy, Nalishia; Tay, Kwang Hong; Wienholt, Louise; Badrick, Tony] RCPAQAP Mol Genet, Sydney, NSW 2065, Australia; [Tye-Din, Jason A.] Walter & Eliza Hall Inst Med Res, Immunol Div, Parkville, Vic, Australia; [Tye-Din, Jason A.] Royal Melbourne Hosp, Gastroenterol Dept, Parkville, Vic, Australia; [Daveson, James] Univ Queensland, Brisbane, Qld, Australia; [Daveson, James] Wesley Med Res, Brisbane, Qld, Australia; [Daveson, James] St Andrews War Mem Hosp, Brisbane, Qld, Australia; [Varney, Michael] Australian Red Cross Blood Serv, Victorian Transplantat & Immunogenet Serv, Melbourne, Vic, Australia	Horan, MP (reprint author), RCPAQAP Mol Genet, Sydney, NSW 2065, Australia.	martin.horan@rcpaqap.com.au	Tye-Din, Jason A./A-6109-2019; Badrick, Tony/AAC-1610-2019	Tye-Din, Jason A./0000-0001-7687-9654; 			Anderson RP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-188; Daveson AJM, 2017, MED J AUSTRALIA, V207, DOI 10.5694/mja17.00314; Hardy MY, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.58; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Karell K, 2003, HUM IMMUNOL, V64, P469, DOI 10.1016/S0198-8859(03)00027-2; Ludvigsson JF, 2014, GUT, V63, P1210, DOI 10.1136/gutjnl-2013-306578; Patton S, 2014, BRIT J CANCER, V111, P413, DOI 10.1038/bjc.2014.353; Romanos J, 2010, ANN GASTROENTEROLOGY, V2010, P11; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Tye-Din JA, 2015, INTERN MED J, V45, P441, DOI 10.1111/imj.12716	10	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					900	905		10.1136/jclinpath-2018-205209			6	Pathology	Pathology	GV4QG	WOS:000446084700015	29764931				2019-10-28	
J	Alayed, K; Schweitzer, K; Awadallah, A; Shetty, S; Turakhia, S; Meyerson, H				Alayed, Khaled; Schweitzer, Karen; Awadallah, Amad; Shetty, Shashirekha; Turakhia, Samir; Meyerson, Howard			A multicolour flow cytometric assay for c-MYC protein in B-cell lymphoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							RITUXIMAB PLUS CYCLOPHOSPHAMIDE; CHRONIC LYMPHOCYTIC-LEUKEMIA; GERMINAL CENTER; CLINICAL-SIGNIFICANCE; INDUCED MATURATION; ZAP-70 EXPRESSION; TESTICULAR CANCER; BURKITT-LYMPHOMA; POOR-PROGNOSIS; ONCOPROTEIN	Aim Develop an objective assay to detect c-MYC protein expression using multiparametric flow cytometry (FCM) as an alternative to immunohistochemistry (IHC). Methods 57 patient samples and 11 cell line samples were evaluated. Cell suspensions were obtained and c-MYC staining was performed in combination with CD45 and CD19 and, in some samples, CD10. The percentage of c-MYC+ cells by FCM was correlated with the percentage determined by IHC. The relationship between c-MYC protein expression and the presence of a c-MYC gene rearrangement in aggressive and high-grade lymphomas was also assessed. Results c-MYC expression by FCM and IHC demonstrated a high degree of correlation in a training set of 33 patient cases, r=0.92, 11 cell line samples, r=0.81 and in a validation set of 24 aggressive and high-grade B-cell lymphomas, r=0.85. c-MYC gene was rearranged by fluorescence in situ hybridisation in 6/9 samples with high c-MYC expression (>40%) by FCM and 6/14 by IHC. Conclusions We have developed a reliable multicolour FCM assay to detect c-MYC expression suitable for clinical laboratories that should be helpful to accurately quantify c-MYC expression in B-cell lymphomas.	[Alayed, Khaled; Schweitzer, Karen; Awadallah, Amad; Shetty, Shashirekha; Turakhia, Samir; Meyerson, Howard] Univ Hosp Cleveland Med Ctr, Dept Pathol, Cleveland, OH 44106 USA; [Alayed, Khaled; Schweitzer, Karen; Awadallah, Amad; Shetty, Shashirekha; Turakhia, Samir; Meyerson, Howard] Seidman Comprehens Canc Ctr, Cleveland, OH USA; [Alayed, Khaled] King Saud Univ, Dept Pathol, Riyadh, Saudi Arabia	Meyerson, H (reprint author), Univ Hosp Cleveland Med Ctr, Dept Pathol, Cleveland, OH 44106 USA.	hjm2@case.edu			Department of Pathology and University Hospitals Cleveland Medical Center; King Saud UniversityKing Saud University	We thank the Department of Pathology and University Hospitals Cleveland Medical Center and King Saud University for their support.	Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bellas C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098169; Bigras G, 2018, APPL IMMUNOHISTO M M, V26, P1; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; Chana JS, 1999, BRIT J OPHTHALMOL, V83, P110, DOI 10.1136/bjo.83.1.110; Chisholm KM, 2015, AM J SURG PATHOL, V39, P294, DOI 10.1097/PAS.0000000000000365; Chow S, 2005, CYTOM PART A, V67A, P4, DOI 10.1002/cyto.a.20167; Cook JR, 2014, AM J SURG PATHOL, V38, P494, DOI 10.1097/PAS.0000000000000147; Copie-Bergman C, 2009, J CLIN ONCOL, V27, P5573, DOI 10.1200/JCO.2009.22.7058; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENT GA, 1989, CELL TISSUE KINET, V22, P1, DOI 10.1111/j.1365-2184.1989.tb00197.x; DESANTIS L, 1995, ANAL CELL PATHOL, V8, P247; Dominguez-Sola D, 2012, NAT IMMUNOL, V13, P1083, DOI 10.1038/ni.2428; GOPAL V, 1992, LEUKEMIA RES, V16, P1003, DOI 10.1016/0145-2126(92)90080-Q; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Green TM, 2012, AM J SURG PATHOL, V36, P612, DOI 10.1097/PAS.0b013e318244e2ba; Gupta M, 2012, BLOOD, V120, P4400, DOI 10.1182/blood-2012-05-428466; HENDYIBBS P, 1987, BRIT J CANCER, V55, P275, DOI 10.1038/bjc.1987.53; Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kaplan D, 2013, CYTOM PART A, V83A, P127, DOI 10.1002/cyto.a.22059; KASTAN MB, 1989, BLOOD, V74, P1517; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Kluk MJ, 2016, AM J CLIN PATHOL, V145, P166, DOI 10.1093/ajcp/aqv028; Kluk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033813; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Leucci E, 2008, J PATHOL, V216, P440, DOI 10.1002/path.2410; LINCOLN ST, 1989, CYTOMETRY, V10, P456, DOI 10.1002/cyto.990100414; Nguyen L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040116; Lynnhtun K, 2014, PATHOLOGY, V46, P211, DOI 10.1097/PAT.0000000000000076; Mahmoud AZ, 2015, MODERN PATHOL, V28, P545, DOI 10.1038/modpathol.2014.140; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; MASTERS JRW, 1988, UROL RES, V16, P341; Meyerson HJ, 2013, AM J CLIN PATHOL, V140, P658, DOI 10.1309/AJCPDFBEBQZW1OI7; Obermann EC, 2009, J CLIN PATHOL, V62, P754, DOI 10.1136/jcp.2009.065227; Onnis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012960; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; PEDRAZZOLI P, 1989, CANCER RES, V49, P6911; REED JC, 1987, J CLIN INVEST, V80, P101, DOI 10.1172/JCI113034; ROSETTE CD, 1990, CYTOMETRY, V11, P547, DOI 10.1002/cyto.990110414; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; SIKORA K, 1985, BRIT J CANCER, V52, P171, DOI 10.1038/bjc.1985.174; Son SM, 2017, MOD PATHOL, V30; Stasik CJ, 2010, HAEMATOL-HEMATOL J, V95, P597, DOI 10.3324/haematol.2009.012864; SUNDARESAN V, 1991, ANTICANCER RES, V11, P2111; Swerdlow SH, 2008, WHO CLASSIFICATION T; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Valera A, 2013, HAEMATOLOGICA, V98, P1554, DOI 10.3324/haematol.2013.086173; Victora GD, 2012, BLOOD, V120, P2240, DOI 10.1182/blood-2012-03-415380; Wang XJ, 2015, AM J SURG PATHOL, V39, P1250, DOI 10.1097/PAS.0000000000000433; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1987, MOL CELL PROBE, V1, P151, DOI 10.1016/0890-8508(87)90023-5; WATSON JV, 1987, GYNECOL ONCOL, V28, P137, DOI 10.1016/0090-8258(87)90207-1; WATSON JV, 1986, BRIT J CANCER, V53, P331, DOI 10.1038/bjc.1986.56; WHITE MW, 1991, J IMMUNOL, V146, P846; Xu-Monette ZY, 2015, MODERN PATHOL, V28, P1555, DOI 10.1038/modpathol.2015.118; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	60	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					906	915		10.1136/jclinpath-2018-205075			10	Pathology	Pathology	GV4QG	WOS:000446084700016	29769234				2019-10-28	
J	Mauri, G; Valtorta, E; Cerea, G; Amatu, A; Schirru, M; Marrapese, G; Fiorillo, V; Recchimuzzo, P; Cavenago, IS; Bonazzina, EF; Motta, V; Lauricella, C; Veronese, S; Tosi, F; Maiolani, M; Rospo, G; Truini, M; Bonoldi, E; Christiansen, J; Potts, SJ; Siena, S; Sartore-Bianchi, A				Mauri, Gianluca; Valtorta, Emanuele; Cerea, Giulio; Amatu, Alessio; Schirru, Michele; Marrapese, Giovanna; Fiorillo, Vincenzo; Recchimuzzo, Patrizia; Cavenago, Ivana Stella; Bonazzina, Erica Francesca; Motta, Valentina; Lauricella, Calogero; Veronese, Silvio; Tosi, Federica; Maiolani, Martina; Rospo, Giuseppe; Truini, Mauro; Bonoldi, Emanuela; Christiansen, Jason; Potts, Steven J.; Siena, Salvatore; Sartore-Bianchi, Andrea			TRKA expression and NTRK1 gene copy number across solid tumours	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; INHIBITOR ENTRECTINIB; PROTOONCOGENE PRODUCT; TARGETED THERAPY; RECEPTOR; IMMUNOHISTOCHEMISTRY; REARRANGEMENTS; RESISTANCE; MUTATIONS; CARCINOMA	Aims Neurotrophic Tropomyosin Kinase Receptor 1 (NTRK1) gene encodes for the protein Tropomyosin-related kinase A (TRKA). Deregulated activity of TRKA has been shown to have oncogenic potentiaL We present here the results of an immunohistochemical (IHC) observational cohort study of TRKA expression together with gene copy number (GCN) assessment in various solid tumours. Methods Formalin-fixed, paraffin-embedded consecutive samples of different tumour types were tested for TRKA expression. Samples showing TRKA IHC staining in at least 10% of cells were analysed by fluorescence in situ hybridisation to assess NTRK1 gene rearrangements and/or individual GCN gain. All patients underwent this molecular assessment within the phase I ALKA-001 clinical trial. Results 1043 samples were tested and annotation for histology was available in 1023. Most of the samples were colorectal adenocarcinoma (CRC) (n=550, 52.7%) and lung adenocarcinoma (n=312, 29.9%). 24 samples (2.3%) were biliary tract carcinoma (BTC). Overall, 17 (1.6%) samples were characterised by TRKA IHC expression (four weak, eight moderate, five strong): 9/17 lung adenocarcinoma, 3/17 CRC, 3/17 BTC, 1/17 thyroid cancer and 1/17 cancer of unknown primary. Of these, 1/17 with strong TRKA IHC staining displayed NTRK1 gene rearrangement and 15/17 NTRK1 GCN gain by FISH. No correlation was found between intensity of TRKA IHC staining and number of copies of NTRK1. Conclusions TRKA expression can be found in 1.6% of solid tumours and can be paralleled by NTRK1 gene rearrangements or mostly GCN gain. The prognostic and translational therapeutic impact of the latter remains to be established.	[Mauri, Gianluca; Valtorta, Emanuele; Cerea, Giulio; Amatu, Alessio; Schirru, Michele; Marrapese, Giovanna; Fiorillo, Vincenzo; Recchimuzzo, Patrizia; Cavenago, Ivana Stella; Bonazzina, Erica Francesca; Motta, Valentina; Lauricella, Calogero; Veronese, Silvio; Tosi, Federica; Maiolani, Martina; Truini, Mauro; Bonoldi, Emanuela; Siena, Salvatore; Sartore-Bianchi, Andrea] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy; [Mauri, Gianluca; Tosi, Federica; Maiolani, Martina; Siena, Salvatore; Sartore-Bianchi, Andrea] Univ Milan, Dipartimento Ematol & Oncoematol, Milan, Italy; [Valtorta, Emanuele; Fiorillo, Vincenzo; Recchimuzzo, Patrizia; Cavenago, Ivana Stella; Motta, Valentina; Lauricella, Calogero; Veronese, Silvio; Truini, Mauro; Bonoldi, Emanuela] Grande Osped Metropolitano Niguarda, Div Pathol, Dept Lab Med, Milan, Italy; [Rospo, Giuseppe] IRCCS, Candiolo Canc Inst FPO, Turin, Italy; [Christiansen, Jason; Potts, Steven J.] Ignyta Inc, San Diego, CA USA	Sartore-Bianchi, A (reprint author), Univ Milan, Niguarda Canc Ctr, I-20162 Milan, Italy.	andrea.sartorebianchi@ospedaleniguarda.it	Amatu, Alessio/AAB-3878-2019; Sartore-Bianchi, Andrea/AAB-9848-2019; SIENA, SALVATORE/AAC-5806-2019	Amatu, Alessio/0000-0001-5396-3378; Sartore-Bianchi, Andrea/0000-0003-0780-0409; SIENA, SALVATORE/0000-0002-2681-2846; Rospo, Giuseppe/0000-0002-1757-9085; TOSI, FEDERICA MARIA/0000-0001-6146-7411	grant 'Terapia Molecolare dei Tumori' by Fondazione Oncologia Niguarda; Associazione Italiana Ricerca Cancro grant AIRC 5 x mille Project [51000]; AIRC Investigator Grant Project [20685]; AIRC 5 x mille projectAssociazione Italiana per la Ricerca sul Cancro (AIRC) [21091]; CORDIS Community Research and Development Information Service, grant MoTriColor, Horizon 2020 Project [635342]	The molecular screening for NTRK1 was performed within the phase I ALKA-001 clinical trial funded by Ignyta, Inc. The study was partly supported by the grant 'Terapia Molecolare dei Tumori' by Fondazione Oncologia Niguarda; Associazione Italiana Ricerca Cancro grant AIRC 5 x mille Project ID 51000 Special Program Molecular Clinical Oncology; AIRC Investigator Grant Project ID 20685; AIRC 5 x mille project ID Project 21091; CORDIS Community Research and Development Information Service, grant MoTriColor, Horizon 2020 Project ID 635342.	Amatu A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000023; Ardini E, 2014, MOL ONCOL, V8, P1495, DOI 10.1016/j.molonc.2014.06.001; Bahreini F, 2015, BREAST CANCER-TOKYO, V22, P615, DOI 10.1007/s12282-014-0528-0; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Girirajan S, 2011, ANNU REV GENET, V45, P203, DOI 10.1146/annurev-genet-102209-163544; Greco A, 1999, AM J HUM GENET, V64, P1207, DOI 10.1086/302319; Greco A, 2010, MOL CELL ENDOCRINOL, V321, P44, DOI 10.1016/j.mce.2009.10.009; Hanemann CO, 1998, TRENDS NEUROSCI, V21, P282, DOI 10.1016/S0166-2236(97)01222-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kim JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085445; Kingsbury MA, 2006, CELL MOL LIFE SCI, V63, P2626, DOI 10.1007/s00018-006-6169-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lupski JR, 2007, NAT GENET, V39, pS43, DOI 10.1038/ng2084; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Mazieres J, 2016, ANN ONCOL, V27, P281, DOI 10.1093/annonc/mdv573; Pan QL, 2005, J MOL DIAGN, V7, P396, DOI 10.1016/S1525-1578(10)60569-7; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Ross JS, 2014, ONCOLOGIST, V19, P235, DOI 10.1634/theoncologist.2013-0352; Russo M, 2016, CANCER DISCOV, V6, P36, DOI 10.1158/2159-8290.CD-15-0940; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Sartore-Bianchi A, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv306; Schalper KA, 2014, ARCH PATHOL LAB MED, V138, P213, DOI 10.5858/arpa.2012-0617-OA; Schram AM, 2017, NAT REV CLIN ONCOL, V14, P735, DOI 10.1038/nrclinonc.2017.127; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Tang YC, 2013, CELL, V152, P394, DOI 10.1016/j.cell.2012.11.043; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Tsuta K, 2014, BRIT J CANCER, V110, P1571, DOI 10.1038/bjc.2014.36; Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Varga Z, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-615; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116	41	1	1	3	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					926	931		10.1136/jclinpath-2018-205124			6	Pathology	Pathology	GV4QG	WOS:000446084700018	29802225				2019-10-28	
J	Josman, N; Tee, NWS; Maiwald, M; Loo, LH; Ho, CKM				Josman, Nicky; Tee, Nancy W. S.; Maiwald, Matthias; Loo, Liat Hui; Ho, Clement K. M.			Pragmatic and evidence-based approach to paediatric cerebrospinal fluid reference limits for white cell count and concentrations of total protein and glucose	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TRANSCRIPTION-PCR ASSAY; REFERENCE-VALUES; BACTERIAL-MENINGITIS; LUMBAR PUNCTURE; RAPID DETECTION; YOUNG INFANTS; ENTEROVIRUS; CHILDREN; SAMPLES; RNA	Background It is often impractical for each laboratory to establish its own paediatric reference intervals. This is particularly true for specimen types collected using invasive procedures, for example, cerebrospinal fluid (CSF). Methods Published CSF reference intervals for white cell count, and concentrations of total protein and glucose were reviewed by stakeholders in a paediatric hospital. Consensus reference intervals for the three CSF parameters were then subjected to verification using guidelines from the Clinical Laboratory Standards Institute and residual CSF specimens. Results Consensus paediatric reference intervals adapted from published studies with minor modifications were locally verified as follows. White cell count (x10(6) cells/L): 0-20 (<1 month); 0-10 (1-2 months); 0-5 (>2 months). Total protein (g/L): 0.3-1.2 (<1 month); 0.2-0.6 (1-3 months); 0.1-0.4 (>3 months). Glucose (mmol/L): 2.0-5.6 (<6 months); 2.4-4.3 (6 months or older).	[Josman, Nicky; Tee, Nancy W. S.; Maiwald, Matthias; Loo, Liat Hui; Ho, Clement K. M.] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore 229899, Singapore	Ho, CKM (reprint author), KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore 229899, Singapore.	ho@doctors.org.uk	Ho, Clement KM/A-6261-2011	Ho, Clement KM/0000-0003-1469-5467; Maiwald, Matthias/0000-0001-5448-8417			Benschop K, 2008, J CLIN VIROL, V41, P69, DOI 10.1016/j.jcv.2007.10.004; Biou D, 2000, CLIN CHEM, V46, P399; Corless CE, 2002, J MED VIROL, V67, P555, DOI 10.1002/jmv.10138; Deisenhammer F, 2006, EUR J NEUROL, V13, P913, DOI 10.1111/j.1468-1331.2006.01493.x; Horowitz GL, 2008, DEFINING ESTABLISHIN; Hume R, 2005, EARLY HUM DEV, V81, P95, DOI 10.1016/j.earlhumdev.2004.10.005; Kestenbaum LA, 2010, PEDIATRICS, V125, P257, DOI 10.1542/peds.2009-1181; KNIGHT JA, 1981, CLIN CHEM, V27, P1431; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Monpoeho S, 2002, EUR J CLIN MICROBIOL, V21, P532, DOI 10.1007/s10096-002-0766-5; PORTNOY JM, 1985, PEDIATRICS, V75, P484; SARFF LD, 1976, J PEDIATR-US, V88, P473, DOI 10.1016/S0022-3476(76)80271-5; Selvaraju SB, 2013, J CLIN MICROBIOL, V51, P452, DOI 10.1128/JCM.01982-12; Shah SS, 2011, J HOSP MED, V6, P22, DOI 10.1002/jhm.711; Srinivasan L, 2012, SEMIN PERINATOL, V36, P445, DOI 10.1053/j.semperi.2012.06.007; Srinivasan L, 2012, J PEDIATR-US, V161, P729, DOI 10.1016/j.jpeds.2012.03.051; STATZ A, 1983, DEV MED CHILD NEUROL, V25, P152; Straus SE, 2006, JAMA-J AM MED ASSOC, V296, P2012, DOI 10.1001/jama.296.16.2012; Verstrepen WA, 2001, J CLIN MICROBIOL, V39, P4093, DOI 10.1128/JCM.39.11.4093-4096.2001; Widell S, 1958, ACTA PAEDIATR, V47, P711; Wong M, 2000, ARCH PEDIAT ADOL MED, V154, P827, DOI 10.1001/archpedi.154.8.827	21	1	1	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					932	935		10.1136/jclinpath-2018-205090			4	Pathology	Pathology	GV4QG	WOS:000446084700019	29907601				2019-10-28	
J	Sakamoto, H; Yamasaki, T; Sumiyoshi, T; Utsunomiya, N; Takeda, M; Kamba, T; Nakamura, E; Ogawa, O				Sakamoto, Hiromasa; Yamasaki, Toshinari; Sumiyoshi, Takayuki; Utsunomiya, Noriaki; Takeda, Masashi; Kamba, Tomomi; Nakamura, Eijiro; Ogawa, Osamu			A family case with germline TSC1 and mtDNA mutations developing bilateral eosinophilic chromophobe renal cell carcinomas without other typical phenotype of tuberous sclerosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article						renal cancer; genitourinary pathology; cancer genetics	HOGG-DUBE SYNDROME; HAMARTIN; COMPLEX; CLASSIFICATION; ONCOCYTOMA; EXPRESSION; EVEROLIMUS; DIAGNOSIS; CANCER	Aim We examined the genetic alterations in a mother and son with multiple eosinophilic chromophobe renal cell carcinomas (chRCCs) showing no other features. Methods Germline DNA and bilateral renal cell carcinoma DNA were genetically analysed by whole-exome sequencing. Candidate gene alterations in the first patient's germline were investigated in her child's germline and the chRCCs. Results We detected several germline gene alterations in the mother. Among the identified alterations, TSC1 and mitochondrial DNA mutations were also confirmed in her son. Regarding somatic alterations in bilateral chRCCs, no common candidate gene alteration was found. Conclusion To the best of our knowledge, this is the first report of whole-exome sequencing revealing bilateral eosinophilic chRCCs associated with tuberous sclerosis complex in a family case without classical phenotype. These results suggest that germline TSC1 and mitochondrial DNA gene mutations may be involved in the development of chRCCs in some cases.	[Sakamoto, Hiromasa; Yamasaki, Toshinari; Sumiyoshi, Takayuki; Utsunomiya, Noriaki; Takeda, Masashi; Ogawa, Osamu] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan; [Kamba, Tomomi] Kumamoto Univ, Grad Sch Med, Dept Urol, Kumamoto, Japan; [Nakamura, Eijiro] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Dept Lab Malignancy Control Res, Kyoto, Japan	Sakamoto, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan.	ogawao@kuhp.kyoto-u.ac.jp; ogawao@kuhp.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24390367, 26253078, 15H04973]	This work was supported by the Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (no 24390367, no 26253078 and no 15H04973).	Becker AJ, 2001, NEUROPATH APPL NEURO, V27, P105, DOI 10.1046/j.0305-1846.2001.00302.x; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bonsib SM, 2016, PATHOL RES PRACT, V212, P972, DOI 10.1016/j.prp.2016.04.005; Brunelli M, 2005, MODERN PATHOL, V18, P161, DOI 10.1038/modpathol.3800286; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Ebrahimi-Fakhari D, 2016, CELL REP, V17, P1053, DOI 10.1016/j.celrep.2016.09.054; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Houweling AC, 2011, BRIT J CANCER, V105, P1912, DOI 10.1038/bjc.2011.463; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Kanno T, 2012, ONCOGENE, V31, P3098, DOI 10.1038/onc.2011.475; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Li LH, 2016, ONCOTARGET, V7, P31270, DOI 10.18632/oncotarget.8892; Li-Harms X, 2015, BLOOD, V125, P162, DOI 10.1182/blood-2014-07-586396; Ma LJ, 2015, ONCOL REP, V34, P3238, DOI 10.3892/or.2015.4315; Menko FH, 2009, LANCET ONCOL, V10, P1199, DOI 10.1016/S1470-2045(09)70188-3; Mester JL, 2012, UROLOGY, V79, DOI 10.1016/j.urology.2011.12.025; Shuch B, 2013, J UROLOGY, V190, P1990, DOI 10.1016/j.juro.2013.06.012; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; Wobker SE, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.96; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237	26	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					936	943		10.1136/jclinpath-2018-205211			8	Pathology	Pathology	GV4QG	WOS:000446084700001	29960980				2019-10-28	
J	Lippi, G; Tarperi, C; Montagnana, M; Danese, E; Salvagno, GL; Schena, F				Lippi, Giuseppe; Tarperi, Cantor; Montagnana, Martina; Danese, Elisa; Salvagno, Gian Luca; Schena, Federico			Challenges of diagnosing diabetes in endurance athletes	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						haemoglobinopathy; diagnosis; diabetes			[Lippi, Giuseppe; Montagnana, Martina; Danese, Elisa; Salvagno, Gian Luca] Univ Verona, Clin Biochem Sect, I-37100 Verona, Italy; [Tarperi, Cantor; Schena, Federico] Univ Verona, Sch Sport & Exercise Sci, Verona, Italy	Lippi, G (reprint author), Univ Verona, Clin Biochem Sect, I-37100 Verona, Italy.	giuseppe.lippi@univr.it	Lippi, Giuseppe/X-7198-2018	Lippi, Giuseppe/0000-0001-9523-9054			Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002; Cauza E, 2005, INT J SPORTS MED, V26, P774, DOI 10.1055/s-2004-830561; Forga L, 2015, J SPORTS MED PHYS FI, V55, pP357, DOI [10. 1530/endoabs. 32. P357, DOI 10.1530/ENDOABS.32.P357]; Lippi G, 2008, INT J SPORTS MED, V29, P7, DOI 10.1055/s-2007-964898; Lippi G, 2017, J LAB PRECIS MED, V2, P11, DOI DOI 10.21037/JLPM.2017.04.01; Lippi G, 2010, CLIN CHEM LAB MED, V48, P609, DOI 10.1515/CCLM.2010.144; Montagnana M, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.05.19; Telford RD, 2003, J APPL PHYSIOL, V94, P38, DOI 10.1152/japplphysiol.00631.2001; Tuominen JA, 1997, DIABETIC MED, V14, P301, DOI 10.1002/(SICI)1096-9136(199704)14:4<301::AID-DIA346>3.0.CO;2-K	9	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					945	946		10.1136/jclinpath-2018-205043			2	Pathology	Pathology	GV4QG	WOS:000446084700002	29884709				2019-10-28	
J	Timlin, DM; O'Hare, K; Walker, J; Castriciano, G; Connolly, Y; Grant, C; Bacon, CL; Vandenberghe, E; Dunne, B; Jeffers, M; Flavin, R				Timlin, Deirdre Mary; O'Hare, Kevin; Walker, Jan; Castriciano, Giusseppa; Connolly, Yvonne; Grant, Cliona; Bacon, Christopher Larry; Vandenberghe, Elisabeth; Dunne, Barbara; Jeffers, Michael; Flavin, Richard			FISH studies in DLBCL: correlations with cell of origin: the Irish experience	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							LYMPHOMA; SURVIVAL		[Timlin, Deirdre Mary; Walker, Jan; Castriciano, Giusseppa; Dunne, Barbara; Jeffers, Michael; Flavin, Richard] St James Hosp, Histopathol Dept, Dublin 8, Ireland; [O'Hare, Kevin; Jeffers, Michael] Tallaght Hosp, Dept Histopathol, Dublin, Ireland; [Connolly, Yvonne; Grant, Cliona] St James Hosp, Dept Oncol, Dublin, Ireland; [Bacon, Christopher Larry; Vandenberghe, Elisabeth] St James Hosp, Dept Haematol, Dublin, Ireland	Timlin, DM (reprint author), St James Hosp, Histopathol Dept, Dublin 8, Ireland.	dmtoomey@gmail.com		Flavin, Richard/0000-0002-4993-4563			Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Chaganti S, 2016, BRIT J HAEMATOL, V174, P43, DOI 10.1111/bjh.14136; Dojcinov S, 2015, STANDARDS SPECIALIST; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Gutierrez-Garcia G, 2011, BLOOD, V117, P4836, DOI 10.1182/blood-2010-12-322362; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Menter T, 2017, BRIT J HAEMATOL, V179, P681, DOI 10.1111/bjh.14250; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914	8	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10					947	948		10.1136/jclinpath-2018-205247			2	Pathology	Pathology	GV4QG	WOS:000446084700003	29960979				2019-10-28	
J	Reynolds, TM				Reynolds, Tim M.			Sitosterolaemia: a rare cause of accelerated atherosclerosis	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material									[Reynolds, Tim M.] Queens Hosp, Dept Chem Pathol, Burton Upon Trent, England; [Reynolds, Tim M.] Wolverhampton Univ, Div Hlth Sci, Wolverhampton, W Midlands, England	Reynolds, TM (reprint author), Queens Hosp, Clin Chem, Burton Upon Trent DE13 0RB, England.	tim.reynolds@burtonft.nhs.uk					[Anonymous], GEN HOM REF; Fitzgerald ML, 2010, ATHEROSCLEROSIS, V211, P361, DOI 10.1016/j.atherosclerosis.2010.01.011; Kusters DM, 2015, J PEDIAT, V166; Neff AT, 2012, BLOOD, V120, P4283, DOI 10.1182/blood-2012-06-429449	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	OCT	2018	71	10							863	10.1136/jclinpath-2018-205222			1	Pathology	Pathology	GV4QG	WOS:000446084700007	30232216				2019-10-28	
J	Appay, R; Fina, F; Macagno, N; Padovani, L; Colin, C; Barets, D; Ordioni, J; Scavarda, D; Giangaspero, F; Badiali, M; Korshunov, A; Pfister, SM; Jones, DTW; Figarella-Branger, D				Appay, Romain; Fina, Frederic; Macagno, Nicolas; Padovani, Laetitia; Colin, Carole; Barets, Doriane; Ordioni, Joanna; Scavarda, Didier; Giangaspero, Felice; Badiali, Manuela; Korshunov, Andrey; Pfister, Stefan M.; Jones, David T. W.; Figarella-Branger, Dominique			Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas	MODERN PATHOLOGY			English	Article							LOW-GRADE GLIOMAS; GENETIC ALTERATIONS; TRANSCRIPTS; SYSTEM; TUMORS	Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas. They are characterized by alterations in the RAS-MAP kinase pathway, the most frequent being a tandem duplication on chromosome 7q34 involving the BRAF gene, resulting in oncogenic BRAF fusion proteins. BRAF fusion involving the KIAA1549 gene is a hallmark of pilocytic astrocytoma, but it has also been recorded in rare cases of gangliogliomas, 1p/19q co-deleted oligodendroglial tumors, and it is also a common feature of disseminated oligodendroglial-like leptomeningeal neoplasm. In some difficult cases, evidence for KIAA1549-BRAF fusion is of utmost importance for the diagnosis. Moreover, because the KIAA1549-BRAF fusion constitutively activates the MAP kinase pathway, it represents a target for drugs such as MEK inhibitors, and therefore, the detection of this genetic abnormality is highly relevant in the context of clinical trials applying such new approaches. In the present study, we aimed to use the high sensitivity of Droplet Digital PCR (DDPCR (TM)) to predict KIAA1549-BRAF fusion on very small amounts of formalin-fixed paraffin-embedded tissue in routine practice. Therefore, we analyzed a training cohort of 55 pilocytic astrocytomas in which the KIAA1549-BRAF fusion status was known by RNA sequencing used as our gold standard technique. Then, we analyzed a prospective cohort of 40 pilocytic astrocytomas, 27 neuroepithelial tumors remaining difficult to classify (pilocytic astrocytoma versus ganglioglioma or diffuse glioma), 15 dysembryoplastic neuroepithelial tumors, and 18 gangliogliomas. We could demonstrate the usefulness and high accuracy (100% sensitivity and specificity when compared to RNA sequencing) of DDPCR (TM) to assess the KIAA1549-BRAF fusion from very low amounts of DNA isolated from formalin-fixed paraffin-embedded specimens. BRAF duplication is both necessary and sufficient to predict this fusion in most cases and we propose that this single analysis could be used in routine practice to save time, money, and precious tissue.	[Appay, Romain; Fina, Frederic; Macagno, Nicolas; Barets, Doriane; Ordioni, Joanna; Figarella-Branger, Dominique] Hop La Timone, AP HM, Serv Anat Pathol & Neuropathol, Marseille, France; [Appay, Romain; Colin, Carole; Figarella-Branger, Dominique] Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France; [Fina, Frederic] AP HM, Unite Dev Tech, Marseille, France; [Padovani, Laetitia] Hop La Timone, AP HM, Serv Radiotherapie, Marseille, France; [Scavarda, Didier] Hop La Timone, AP HM, Serv Neurochirurg Pediat, Marseille, France; [Giangaspero, Felice] Sapienza Univ, Dept Radiol Oncol & Pathol Sci, Rome, Italy; [Giangaspero, Felice] IRCCS, Neuromed Inst, Isernia, Pozzilli, Italy; [Badiali, Manuela] Microcitem Pediat Hosp, Lab Genet & Genom, Cagliari, Italy; [Korshunov, Andrey] Heidelberg Univ, German Canc Res Ctr, CCU Neuropathol, Heidelberg, Germany; [Korshunov, Andrey] Heidelberg Univ, Dept Neuropathol, Heidelberg, Germany; [Pfister, Stefan M.; Jones, David T. W.] Hopp Childrens Canc Ctr NCT Heidelberg KiTZ, Heidelberg, Germany; [Pfister, Stefan M.] Heidelberg Univ Hosp, Dept Pediat Oncol Hematol Immunol & Pulmonol, Heidelberg, Germany; [Pfister, Stefan M.; Jones, David T. W.] German Canc Res Ctr, German Canc Consortium DKTK, Div Pediat Neurooncol, Heidelberg, Germany	Figarella-Branger, D (reprint author), Hop La Timone, AP HM, Serv Anat Pathol & Neuropathol, Marseille, France.; Figarella-Branger, D (reprint author), Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.	dominique.figarella-branger@univ-amu.fr	Pfister, Stefan M/F-6860-2013; GIANGASPERO, FELICE/Z-4961-2019; Jones, David/Z-1963-2019	Pfister, Stefan M/0000-0002-5447-5322; GIANGASPERO, FELICE/0000-0001-5382-2380; Macagno, Nicolas/0000-0002-9882-2162	Institut National du CancerInstitut National du Cancer (INCA) France [INCa-DGOS-Inserm 6038]; A Kids' Brain Tumor Cure/PLGA (Pediatric Low-Grade Astrocytoma) foundation under the European SIOP-LGG preclinical trial consortium [PLGAO CR3097J7]; Canceropole PACARegion Grand-Est [2017-01]; GEFLUC Marseille Provence (Groupement Entreprises Francaises Lutte contre le Cancer) [CT3097S5GEFL0]	This work was supported by grants from Institut National du Cancer (grant INCa-DGOS-Inserm 6038) and by grants from the A Kids' Brain Tumor Cure/PLGA (Pediatric Low-Grade Astrocytoma) foundation (PLGAO CR3097J7) under the European SIOP-LGG preclinical trial consortium. We thank the Canceropole PACA (2017-01), the GEFLUC Marseille Provence (Groupement Entreprises Francaises Lutte contre le Cancer - CT3097S5GEFL0), the ARTC-Sud patients's association (Association pour le Recherche sur les Tumeurs Cerebrales), and the ACCL association (Association Cassandra contre la leucemie et les cancers pediatriques). We also thank the APHM Tumor Bank (authorization number: AC2013-1786; CRB BB-0033-00097) for retrieving samples.	Badiali M, 2012, BRAIN PATHOL, V22, P841, DOI 10.1111/j.1750-3639.2012.00603.x; Belgrader P, 2013, CLIN CHEM, V59, P991, DOI 10.1373/clinchem.2012.197855; Chappe C, 2013, BRAIN PATHOL, V23, P574, DOI 10.1111/bpa.12048; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Fina F, 2017, ONCOTARGET, V8, P2104, DOI 10.18632/oncotarget.12881; Gupta K, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-18; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Louis DN, 2016, WHO CLASSIFICATION T, P80; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Rodriguez FJ, 2015, ACTA NEUROPATHOL, V129, P609, DOI 10.1007/s00401-015-1400-9; Ryall S, 2017, J NEUROPATH EXP NEUR, V76, P562, DOI 10.1093/jnen/nlx042; Tatevossian RG, 2010, J CELL PHYSIOL, V222, P509, DOI 10.1002/jcp.21978; Tian YJ, 2011, J MOL DIAGN, V13, P669, DOI 10.1016/j.jmoldx.2011.07.002; Tomic TT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175638; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611	17	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1490	1501		10.1038/s41379-018-0050-6			12	Pathology	Pathology	GV3XJ	WOS:000446031300001	29802359				2019-10-28	
J	Dill, EA; Dillon, PM; Bullock, TN; Mills, AM				Dill, Erik A.; Dillon, Patrick M.; Bullock, Timothy N.; Mills, Anne M.			IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1	MODERN PATHOLOGY			English	Article							INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; TUMOR-INFILTRATING LYMPHOCYTES; KYNURENINE PATHWAY; IMMUNE-SYSTEM; PHASE-I; ASSOCIATION; MICROENVIRONMENT; MECHANISM; ESCAPE; SAFETY	The immune inhibitory enzyme indoleamine 2,3-dioxygenase (IDO) has been associated with immune evasion in numerous malignancies and may mark these cancers as susceptible to anti-IDO therapies. We herein address IDO expression in breast cancers, examine the relationship between IDO and PD-L1, and investigate IDO fidelity across breast cancer primaries and metastases. IDO and PD-L1 expression was assessed in tissue microarrays containing 242 invasive primary breast cancers, 20 nodal metastases, and 19 distant metastases. IDO and PD-L1 were scored by extent in the tumor cells and immune infiltrate. Tumor IDO staining was seen in 14% of primaries including 38% of triple-negative cancers. IDO immune cell staining was seen in 14% of primaries and 29% of triple-negative cancers. Tumoral IDO and PD-L1 co-expression was seen in 8% of primaries, including 70% of tumoral PD-L1 -positive cases Immune IDO and PD-L1 co-expression was identified in 14% of primaries, including 48% of immune PD-L1-positive cases. Tumoral and immune cell IDO was conserved in 94% of matched primary/metastasis. In summary, IDO expression is common among high-grade, triple-negative breast cancers and is frequently associated with PD-L1 co-expression, suggesting that IDO might be a mechanism of anti-PD-1/PD-L1 immunotherapy resistance and that dual therapy may be of utility. Tumoral and immune cell IDO expression shows fidelity between primary and metastatic sites in treatment-naive cancers, arguing against IDO as an independent driver for metastatic spread. Clinical trials are needed to assess the efficacy of IDO inhibition relative to IDO expression, as well as its possible role in combination with anti-PD-1/PD-L1 immunotherapy.	[Dill, Erik A.; Bullock, Timothy N.; Mills, Anne M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Dillon, Patrick M.] Univ Virginia, Dept Med, Div Hematol & Oncol, Charlottesville, VA USA	Mills, AM (reprint author), Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.	amm7r@virgnia.edu		Mills, Anne/0000-0002-2686-4857			Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; [Anonymous], 2018, Cancer Discov, V8, pOF3, DOI 10.1158/2159-8290.CD-NB2017-167; Beatty GL, 2017, CLIN CANCER RES, V23, P3269, DOI 10.1158/1078-0432.CCR-16-2272; Becht E, 2016, ADV IMMUNOL, V130, P95, DOI 10.1016/bs.ai.2015.12.002; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chawla A, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28325; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Dill EA, 2017, AM J SURG PATHOL, V41, P334, DOI 10.1097/PAS.0000000000000780; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Engel JB, 2014, ARCH GYNECOL OBSTET, V289, P141, DOI 10.1007/s00404-013-2922-9; Fallarino F, 2009, J IMMUNOL, V183, P6303, DOI 10.4049/jimmunol.0901577; Friedman K, 2016, MODERN PATHOL, V29, P528, DOI 10.1038/modpathol.2016.54; Gurtner GJ, 2003, GASTROENTEROLOGY, V125, P1762, DOI 10.1053/j.gastro.2003.08.031; Heng B, 2016, ONCOTARGET, V7, P6506, DOI 10.18632/oncotarget.6467; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Ino K, 2006, BRIT J CANCER, V95, P1555, DOI 10.1038/sj.bjc.6603477; Ino K, 2008, CLIN CANCER RES, V14, P2310, DOI 10.1158/1078-0432.CCR-07-4144; Larrain MTI, 2014, TUMOR BIOL, V35, P6511, DOI 10.1007/s13277-014-1859-3; Iversen TZ, 2015, BASIC CLIN PHARMACOL, V116, P19, DOI 10.1111/bcpt.12320; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jochems C, 2016, ONCOTARGET, V7, P37762, DOI 10.18632/oncotarget.9326; Joneja U, 2017, J CLIN PATHOL, V70, P255, DOI 10.1136/jclinpath-2016-203874; Kim S, 2017, J CANCER, V8, P124, DOI 10.7150/jca.17437; Liu J, 2015, EXP THER MED, V10, P1947, DOI 10.3892/etm.2015.2714; Mansfield AS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-231; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Mills AM, 2017, AM J SURG PATHOL, V41, P143, DOI 10.1097/PAS.0000000000000747; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nayak A, 2015, EUR J CANCER, V51, pS69, DOI 10.1016/S0959-8049(16)30209-X; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Reiss KA, 2014, IMMUNOTHERAPY-UK, V6, P459, DOI 10.2217/imt.14.9; Schafer K, 2017, CHEM-EUR J, V23, P370, DOI 10.1002/chem.201603807; Soliman H, 2013, CANCER IMMUNOL IMMUN, V62, P829, DOI 10.1007/s00262-013-1393-y; Soliman HH, 2016, ONCOTARGET, V7, P22928, DOI 10.18632/oncotarget.8216; Soliman HH, 2014, ONCOTARGET, V5, P8136, DOI 10.18632/oncotarget.2357; Soliman R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e18310; Sordillo PP, 2017, ANTICANCER RES, V37, P2159, DOI 10.21873/anticanres.11551; Spira AI, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.1103; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Szanto S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2205; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Thompson E, 2016, MODERN PATHOL, V29, P249, DOI 10.1038/modpathol.2015.158; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang MZ, 2017, ONCOTARGETS THER, V10, P1561, DOI 10.2147/OTT.S126424; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	55	11	11	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1513	1522		10.1038/s41379-018-0061-3			10	Pathology	Pathology	GV3XJ	WOS:000446031300003	29802358				2019-10-28	
J	Marchevsky, AM; Hendifar, A; Watts, AE				Marchevsky, Alberto M.; Hendifar, Andrew; Watts, Ann E.			The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence	MODERN PATHOLOGY			English	Article							CELL LUNG-CARCINOMA; HEALTH-ORGANIZATION CLASSIFICATION; EVIDENCE-BASED PATHOLOGY; PROLIFERATIVE INDEX; IMMUNOHISTOCHEMICAL ANALYSIS; CYTOLOGIC DIAGNOSIS; TUMORS; MANAGEMENT; SURVIVAL; EXPRESSION	Although Ki-67 labeling index (Ki-67%) is not a diagnostic or grading criterion in the World Health Organization classification of pulmonary carcinoid tumor, oncologists often request this test. A survey was administered at a North American Society for Neuroendocrine Tumors meeting to understand how Ki-67% is used in oncologic practices. A systematic literature review was performed to gather best evidence regarding the use of Ki-67%. Consecutive pulmonary carcinoids were stratified into pulmonary typical carcinoids with Ki-67% >= 5% (group A, n = 187), typical carcinoids with Ki-67% 5% (group B, n = 38) and atypical carcinoids irrespective of Ki-67% (group C, n = 31). Overall survival, progression-free survival, recurrence proportions and time to recurrence were compared, by group, using the log-rank test, chi-square statistics and ANOVA, respectively. Our survey confirmed that Ki-67% is frequently used by specialists caring for these patients. Ki-67% of 1-7% significantly correlated with overall survival in the literature but we found no information about Ki-67% cut-off values that would accurately distinguish pulmonary typical from atypical carcinoids or estimate the prognosis of patients stratified by World Health Organization diagnosis and Ki-67% cut-off. Overall survival was significantly different in our 3 patient groups (p < 0.001), with survival probabilities decreasing from groups A to C. Progression-free survival was significantly longer in group A than B (p < 0.007). Our results support the concept that by combining World Health Organization diagnosis and Ki-67%, pulmonary carcinoids can be stratified into 3 grades: G1 (typical carcinoids with Ki-67% <5), G2 (typical carcinoids with Ki-67% >= 5%) and G3 (atypical carcinoids) with different prognoses.	[Marchevsky, Alberto M.; Watts, Ann E.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Hendifar, Andrew] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Ctr, Los Angeles, CA 90048 USA	Marchevsky, AM (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.	Alberto.Marchevsky@cshs.org					Al-Khafaji B, 1998, HUM PATHOL, V29, P992, DOI 10.1016/S0046-8177(98)90206-4; Amarapurkara AD, 2003, EUR J GASTROEN HEPAT, V15, P139, DOI 10.1097/01.meg.0000049981.90403.92; Arbiser ZK, 2001, MODERN PATHOL, V14, P1195, DOI 10.1038/modpathol.3880459; Aslan DL, 2005, AM J CLIN PATHOL, V123, P874, DOI 10.1309/QYV05GEGKUL2RTT; Chaabane A, 2016, TUNIS MED, V94, P580; Clay V, 2017, CLIN TRANSL ONCOL, V19, P579, DOI 10.1007/s12094-016-1568-z; COSTES V, 1995, HUM PATHOL, V26, P740, DOI 10.1016/0046-8177(95)90221-X; CREUTZFELDT W, 1994, DIGESTION, V55, P3, DOI 10.1159/000201195; Demirci I, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-19; Drozdov I, 2009, CANCER-AM CANCER SOC, V115, P1638, DOI 10.1002/cncr.24180; Fabbri A, 2017, VIRCHOWS ARCH, V470, P153, DOI 10.1007/s00428-016-2062-2; Gagliano T, 2013, ENDOCR-RELAT CANCER, V20, P463, DOI 10.1530/ERC-13-0042; GOLDMAN A, 1949, J THORAC SURG, V18, P137; Granberg D, 2000, J CLIN ENDOCR METAB, V85, P3425, DOI 10.1210/jc.85.9.3425; Grimaldi Franco, 2011, Front Endocrinol (Lausanne), V2, P20, DOI 10.3389/fendo.2011.00020; Guldhammer B, 2010, J THORAC ONCOL, V5, P453, DOI 10.1097/JTO.0b013e3181ca063b; Helpap B, 2001, VIRCHOWS ARCH, V438, P86, DOI 10.1007/s004280000337; Hendifar AE, 2017, J THORAC ONCOL, V12, P425, DOI 10.1016/j.jtho.2016.11.2222; Igarashi T, 2004, MODERN PATHOL, V17, P1259, DOI 10.1038/modpathol.3800176; Joseph MG, 2015, LUNG CANC INT, V2015; Kim JY, 2016, ARCH PATHOL LAB MED, V140, P437, DOI 10.5858/arpa.2015-0314-RA; Kloppel G, 2017, WHO CLASSIFICATION T, V10, P209; Kouba E, 2016, ENDOCR PATHOL, V27, P188, DOI 10.1007/s12022-016-9444-5; Laitinen KLJ, 2000, CANCER, V88, P1590, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1590::AID-CNCR13>3.0.CO;2-C; Lantuejoul S, 2013, ANN PATHOL, V33, P322, DOI 10.1016/j.annpat.2013.09.010; Liao Hongliang, 2010, Zhongguo Fei Ai Za Zhi, V13, P591, DOI 10.3779/j.issn.1009-3419.2010.06.005; Lin O, 2003, AM J CLIN PATHOL, V120, P209, DOI 10.1309/TGCD66L31DHYX5HK; Liu SZ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0174-z; Marchevsky A M, 1996, Pathology (Phila), V4, P103; Marchevsky AM, 2017, HUM PATHOL, V61, P1, DOI 10.1016/j.humpath.2016.09.002; Marchevsky AM, 2015, SEMIN DIAGN PATHOL, V32, P419, DOI 10.1053/j.semdp.2015.10.011; Marchevsky AM, 2015, ARCH PATHOL LAB MED, V139, P394, DOI 10.5858/arpa.2014-0106-RA; Marchevsky AM, 2010, AM J CLIN PATHOL, V133, P366, DOI [10.1309/AJCPC2O7YSWKCTGS, 10.1309/AJCPC2Q7YSWKCTGS]; Marchio C, 2017, VIRCHOWS ARCH, V471, P713, DOI 10.1007/s00428-017-2177-0; Pelosi G, 2005, AM J SURG PATHOL, V29, P179, DOI 10.1097/01.pas.0000149690.75462.29; Pelosi G, 2003, LUNG CANCER-J IASLC, V42, P203, DOI 10.1016/S0169-5002(03)00294-0; Pelosi G, 2003, CANCER-AM CANCER SOC, V97, P2487, DOI 10.1002/cncr.11376; Pelosi G, 2017, TRANSL LUNG CANCER R, V6, P513, DOI 10.21037/tlcr.2017.09.04; Pelosi G, 2017, HISTOL HISTOPATHOL, V32, P223, DOI 10.14670/HH-11-822; Pelosi G, 2015, SEMIN DIAGN PATHOL, V32, P469, DOI 10.1053/j.semdp.2015.10.009; Pelosi G, 2014, J THORAC ONCOL, V9, P273, DOI 10.1097/JTO.0000000000000092; Priemer DS, 2016, ENDOCR PATHOL, V27, P123, DOI 10.1007/s12022-016-9421-z; Resl M, 2001, PATHOL RES PRACT, V197, P169, DOI 10.1078/0344-0338-00029; Ricci C, 2016, PANCREATOLOGY, V16, P403, DOI 10.1016/j.pan.2016.02.002; Rindi G, 2014, ENDOCR-RELAT CANCER, V21, P1, DOI 10.1530/ERC-13-0246; Rossi G, 2018, HISTOPATHOLOGY, V72, P142, DOI 10.1111/his.13394; Rugge M, 2008, CLIN CANCER RES, V14, P149, DOI 10.1158/1078-0432.CCR-07-1631; Shepherd A, 2017, J THORAC ONCOL, V12, P745, DOI 10.1016/j.jtho.2016.11.2219; Stoll LM, 2010, CANCER CYTOPATHOL, V118, P457, DOI 10.1002/cncy.20105; Swarts DRA, 2017, HISTOPATHOLOGY, V70, P412, DOI 10.1111/his.13096; Tang LH, 2016, AM J SURG PATHOL, V40, P1192, DOI 10.1097/PAS.0000000000000662; Travis WD, 2010, ANN ONCOL, V21, P65, DOI 10.1093/annonc/mdq380; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Travis WD, 1998, AM J SURG PATHOL, V22, P934, DOI 10.1097/00000478-199808000-00003; Travis WD, 1998, HUM PATHOL, V29, P272, DOI 10.1016/S0046-8177(98)90047-8; Travis WD, 2014, THORAC SURG CLIN, V24, P257, DOI 10.1016/j.thorsurg.2014.04.001; Travis William D, 2009, Eur J Cancer, V45 Suppl 1, P251, DOI 10.1016/S0959-8049(09)70040-1; Tsuta K, 2011, AM J CLIN PATHOL, V136, P252, DOI 10.1309/AJCPDXFOPXGEF0RP; Tsuta K, 2011, HUM PATHOL, V42, P578, DOI 10.1016/j.humpath.2009.10.030; Walts AE, 2012, MODERN PATHOL, V25, P1258, DOI 10.1038/modpathol.2012.81; Warth A, 2013, VIRCHOWS ARCH, V462, P507, DOI 10.1007/s00428-013-1408-2; Wolin EM, 2015, ONCOLOGIST, V20, P1123, DOI 10.1634/theoncologist.2015-0198; Yao JC, 2016, LANCET, V387, P968, DOI 10.1016/S0140-6736(15)00817-X; Zahel T, 2012, VIRCHOWS ARCH, V460, P299, DOI 10.1007/s00428-012-1194-2; Zheng G, 2013, ACTA CYTOL, V57, P281, DOI 10.1159/000346394; Zhu Lei, 2013, Zhongguo Fei Ai Za Zhi, V16, P246, DOI 10.3779/j.issn.1009-3419.2013.05.06; Zirbes TK, 1998, HISTOPATHOLOGY, V33, P123, DOI 10.1046/j.1365-2559.1998.00466.x	67	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1523	1531		10.1038/s41379-018-0076-9			9	Pathology	Pathology	GV3XJ	WOS:000446031300004	29802361				2019-10-28	
J	Kaur, HB; Guedes, LB; Lu, JY; Maldonado, L; Reitz, L; Barber, JR; De Marzo, AM; Tosoian, JJ; Tomlins, SA; Schaeffer, EM; Joshu, CE; Sfanos, KS; Lotan, TL				Kaur, Harsimar B.; Guedes, Liana B.; Lu, Jiayun; Maldonado, Laneisha; Reitz, Logan; Barber, John R.; De Marzo, Angelo M.; Tosoian, Jeffrey J.; Tomlins, Scott A.; Schaeffer, Edward M.; Joshu, Corinne E.; Sfanos, Karen S.; Lotan, Tamara L.			Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer	MODERN PATHOLOGY			English	Article							EUROPEAN-AMERICAN MEN; MISMATCH-REPAIR DEFICIENCY; AFRICAN-AMERICAN; PROGNOSTIC-FACTOR; RADICAL PROSTATECTOMY; ANDROGEN RECEPTOR; LUNG-CARCINOMA; PD-1 BLOCKADE; FREE SURVIVAL; LYMPHOCYTES	The inflammatory microenvironment plays an important role in the pathogenesis and progression of tumors and may be associated with somatic genomic alterations. We examined the association of tumor-infiltrating T-cell density with clinical-pathologic variables, tumor molecular subtype, and oncologic outcomes in surgically treated primary prostate cancer occurring in patients of European-American or African-American ancestry. We evaluated 312 primary prostate tumors, enriched for patients with African-American ancestry and high grade disease. Tissue microarrays were immunostained for CD3, CD8, and FOXP3 and were previously immunostained for ERG and PTEN using genetically validated protocols. Image analysis for quantification of T-cell density in tissue microarray tumor spots was performed. Automated quantification of T-cell densities in tumor-containing regions of tissue microarray spots and standard histologic sections were correlated (r = 0.73, p < 0.00001) and there was good agreement between visual and automated T-cell density counts on tissue microarray spots (r = 0.93, p < 0.00001). There was a significant correlation between CD3+, CD8+, and FOXP3+ T-cell densities (p < 0.00001), but these were not associated with most clinical or pathologic variables. Increased T-cell density was significantly associated with ERG positivity (median 309 vs. 188 CD3+ T cells/mm(2); p = 0.0004) and also with PTEN loss (median 317 vs. 192 CD3+ T cells/mm(2) ; p = 0.001) in the combined cohort of matched European-American and African-American ancestry patients. The same association or a similar trend was present in patients of both ancestries when analyzed separately. When the African-American patients from the matched race set were combined with a separate high grade set of African-American cases, there was a weak association of increased FOXP3+ T-cell densities with increased risk of metastasis in multivariable analysis. Though high T-cell density is associated with specific molecular subclasses of prostate cancer, we did not find an association of T-cell density with racial ancestry.	[Kaur, Harsimar B.; Guedes, Liana B.; Maldonado, Laneisha; Reitz, Logan; De Marzo, Angelo M.; Sfanos, Karen S.; Lotan, Tamara L.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Lu, Jiayun; Barber, John R.; Joshu, Corinne E.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [De Marzo, Angelo M.; Sfanos, Karen S.; Lotan, Tamara L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.; Tosoian, Jeffrey J.; Schaeffer, Edward M.; Sfanos, Karen S.] Johns Hopkins Univ, Dept Urol, Sch Med, Baltimore, MD USA; [Tomlins, Scott A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Tomlins, Scott A.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Schaeffer, Edward M.] Northwestern Univ, Dept Urol, Chicago, IL 60611 USA	Lotan, TL (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Lotan, TL (reprint author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21218 USA.	tlotan1@jhmi.edu	Tosoian, Jeffrey/O-1563-2019	Tosoian, Jeffrey/0000-0002-7614-9931	Health Disparity Research Awards from the CDMRP-PCRP [W81XWH-15-1-0661, W81XWH-17-1-0286]; NIH/NCI Prostate SPOREUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50CA58236]; NCI Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5P30CA006973-52]; CUPID (Cancer in the Under-Privileged Indigent or Disadvantaged) Program	Funding for this research was provided in part by two Health Disparity Research Awards from the CDMRP-PCRP (W81XWH-15-1-0661 to SAT, EMS, and TLL and W81XWH-17-1-0286 to KSS, TLL, LBG, and HBK). Additional funding and resources were provided by the NIH/NCI Prostate SPORE P50CA58236 and the NCI Cancer Center Support Grant 5P30CA006973-52. LM was supported by a fellowship from the CUPID (Cancer in the Under-Privileged Indigent or Disadvantaged) Program.	Ahearn TU, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv346; Al-Shibli K, 2010, APMIS, V118, P371, DOI 10.1111/j.1600-0463.2010.02609.x; Benzon B, 2017, PROSTATE CANCER P D, V20, P28, DOI 10.1038/pcan.2016.49; Bezzi M, 2018, NAT MED, V24, P165, DOI 10.1038/nm.4463; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bromwich EJ, 2003, BRIT J CANCER, V89, P1906, DOI 10.1038/sj.bjc.6601400; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Davidsson S, 2013, MODERN PATHOL, V26, P448, DOI 10.1038/modpathol.2012.164; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Eastham JA, 1998, J NATL CANCER I, V90, P756, DOI 10.1093/jnci/90.10.756; Eerola AK, 1999, LUNG CANCER, V26, P73, DOI 10.1016/S0169-5002(99)00072-0; Faisal FA, 2016, EUR UROL, V70, P14, DOI 10.1016/j.eururo.2015.09.031; Flammiger A, 2013, EUR J CANCER, V49, P1273, DOI 10.1016/j.ejca.2012.11.035; Flammiger A, 2012, APMIS, V120, P901, DOI 10.1111/j.1600-0463.2012.02924.x; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Guedes LB, 2017, CLIN CANCER RES, V23, P6863, DOI 10.1158/1078-0432.CCR-17-0955; Haffner MC, 2018, AM J PATHOL, P31179; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Huang FW, 2017, CANCER DISCOV, V7, P973, DOI 10.1158/2159-8290.CD-16-0960; Irani J, 1999, UROLOGY, V54, P467, DOI 10.1016/S0090-4295(99)00152-1; JASS JR, 1987, LANCET, V1, P1303; Kaczmarczyk-Sekula K, 2016, POL J PATHOL, V67, P313, DOI [10.5114/PJP.2016.65861, 10.5114/pjp.2016.65861]; Kalina JL, 2017, CLIN CANCER RES, V23, P7596, DOI 10.1158/1078-0432.CCR-17-0618; Karja V, 2005, ANTICANCER RES, V25, P4435; Khani F, 2014, CLIN CANCER RES, V20, P4925, DOI 10.1158/1078-0432.CCR-13-2265; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee V, 2016, ONCOLOGIST, V21, P1200, DOI 10.1634/theoncologist.2016-0046; Lindquist KJ, 2016, CANCER RES, V76, P1860, DOI 10.1158/0008-5472.CAN-15-1787; Lotan TL, 2016, EUR UROL FOCUS, V2, P180, DOI 10.1016/j.euf.2015.07.005; Magi-Galluzzi C, 2011, PROSTATE, V71, P489, DOI 10.1002/pros.21265; Mani RS, 2016, CELL REP, V17, P2620, DOI 10.1016/j.celrep.2016.11.019; Massoner P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055207; McArdle PA, 2004, BRIT J CANCER, V91, P541, DOI 10.1038/sj.bjc.6601943; Miyahira AK, 2017, PROSTATE, V77, P123, DOI 10.1002/pros.23260; Nakano O, 2001, CANCER RES, V61, P5132; Ness N, 2014, PROSTATE, V74, P1452, DOI 10.1002/pros.22862; Paulo P, 2012, NEOPLASIA, V14, P600, DOI 10.1593/neo.12600; Powell IJ, 2013, CANCER EPIDEM BIOMAR, V22, P891, DOI 10.1158/1055-9965.EPI-12-1238; Reams R Renee, 2009, Infect Agent Cancer, V4 Suppl 1, pS3, DOI 10.1186/1750-9378-4-S1-S3; Richardsen E, 2008, HISTOPATHOLOGY, V53, P30, DOI 10.1111/j.1365-2559.2008.03058.x; Ropponen KM, 1997, J PATHOL, V182, P318, DOI 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6; Roudier MP, 2016, PROSTATE, V76, P810, DOI 10.1002/pros.23171; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Sfanos KS, 2018, NAT REV UROL, V15, P11, DOI 10.1038/nrurol.2017.167; Tosoian JJ, 2017, EUR UROL, V71, P697, DOI 10.1016/j.eururo.2016.07.026; VESALAINEN S, 1994, EUR J CANCER, V30A, P1797, DOI 10.1016/0959-8049(94)E0159-2; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Wright JL, 2016, PROSTATE CANCER P D, V19, P53, DOI 10.1038/pcan.2015.49; Xie WL, 2017, J CLIN ONCOL, V35, P3097, DOI 10.1200/JCO.2017.73.9987; Yoshimoto M, 2008, MODERN PATHOL, V21, P1451, DOI 10.1038/modpathol.2008.96	54	7	7	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1539	1552		10.1038/s41379-018-0083-x			14	Pathology	Pathology	GV3XJ	WOS:000446031300006	29849114	Green Accepted			2019-10-28	
J	Kim, G; Kurnit, KC; Djordjevic, B; Singh, C; Munsell, MF; Wang, WL; Lazar, AJ; Zhang, W; Broaddus, R				Kim, Grace; Kurnit, Katherine C.; Djordjevic, Bojana; Singh, Charanjeet; Munsell, Mark F.; Wang, Wei-Lien; Lazar, Alexander J.; Zhang, Wei; Broaddus, Russell			Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association	MODERN PATHOLOGY			English	Article							ENDOMETRIAL CANCER; DESMOID TUMORS; CARCINOMA; IMMUNOHISTOCHEMISTRY; ACTIVATION; EXPRESSION; GRADE; DEGRADATION; PROGRESSION; RECURRENCE	Although the majority of low-grade, early-stage endometrial cancer patients have good survival with surgery alone, patients who recur tend to do poorly. Identification of patients at high risk of recurrence who would benefit from adjuvant treatment or more extensive surgical staging would help optimize individualized care of endometrial cancer patients. CTNNB1 (encodes beta-catenin) mutations identify a subset of low-grade, early-stage endometrial cancer patients at high risk of recurrence. Mutation of CTNNB1 exon 3 is classically associated with translocation of the beta-catenin protein from the membrane to the nucleus and activation of Wnt/beta-catenin signaling. Given the clinical utility of identifying endometrial carcinomas with CTNNB1 mutation, the purpose of this study was to determine if immunohistochemistry could act as a surrogate for CTNNB1 gene sequencing. Next-generation sequencing was performed on 345 endometrial carcinomas. Immunohistochemical localization of beta-catenin was determined for 53/63 CTNNB1 exon 3 mutant tumors for which tissue was available and a subset of wild-type tumors. Nuclear localization of beta-catenin had 100% specificity in distinguishing CTNNB1 mutant from wild type, but sensitivity was lower (84.9%). Nearly half of CTNNB1 mutant cases had only 5-10% of tumor cells with beta-catenin nuclear localization. The concordance between pathologists blinded to mutation status in assessing nuclear localization was 100%. The extent of beta-catenin nuclear localization was not associated with specific CTNNB1 gene mutation, tumor grade, presence of non-endometrioid component, or specific concurrent gene mutations in the tumor. For comparison, nuclear localization of beta-catenin was more diffuse in desmoid fibromatosis, a tumor also associated with CTNNB1 mutation. Thus, nuclear localization of beta-catenin assessed by immunohistochemistry does not detect all endometrial cancers with CTNNB1 gene mutation. The extent of nuclear localization may be tumor type dependent. For endometrial cancer, immunohistochemistry could be an initial screen, with CTNNB1 sequencing employed when nuclear localization of beta-catenin is absent.	[Kim, Grace] Univ Southern Calif, Keck Sch Med, LAC USC Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA USA; [Kurnit, Katherine C.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Djordjevic, Bojana] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Singh, Charanjeet] Florida Hosp South, Ctr Diagnost Pathol, Orlando, FL USA; [Munsell, Mark F.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Wang, Wei-Lien; Lazar, Alexander J.; Broaddus, Russell] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA; [Zhang, Wei] Wake Forest Univ, Bowmen Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA	Broaddus, R (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA.	rbroaddus@mdanderson.org	Lazar, Alexander JF/A-3416-2008	Lazar, Alexander JF/0000-0002-6395-4499; Kurnit, Katherine/0000-0003-3205-0128	NIH Research Training Grant [T32 CA101642]; NIH SPORE in Uterine Cancer; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P50 CA09825]; Red and Charline McCombs Institute Center for Global Cancer Early Detection	NIH Research Training Grant (KCK) T32 CA101642; NIH SPORE in Uterine Cancer (RB and WZ) NIH 2P50 CA09825; The Red and Charline McCombs Institute Center for Global Cancer Early Detection (RB and WZ).	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Bakkar RM, 2015, INT J GYNECOL PATHOL, V34, P497, DOI 10.1097/PGP.0000000000000205; Bowser JL, 2016, J CLIN INVEST, V126, P220, DOI 10.1172/JCI79380; Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Chen K, 2015, CLIN CHEM, V61, P544, DOI 10.1373/clinchem.2014.231100; Colombo C, 2011, HISTOPATHOLOGY, V59, P336, DOI 10.1111/j.1365-2559.2011.03932.x; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208; Estrella JS, 2015, MOL CANCER THER, V14, P2887, DOI 10.1158/1535-7163.MCT-15-0615; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749; Hale G, 2016, MODERN PATHOL, V29, P1370, DOI 10.1038/modpathol.2016.122; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Jamieson C, 2016, EXP CELL RES, V341, P196, DOI 10.1016/j.yexcr.2016.01.020; Jemal A., 2017, JNCI-J NATL CANCER I, V109, P1975, DOI DOI 10.1093/JNCI/DJX030; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Kafri P, 2016, ELIFE, V5, DOI 10.7554/eLife.16748; Khoury JD, 2018, CLIN CANCER RES, V24, P1; Kovacs G, 2017, HISTOPATHOLOGY, V70, P273, DOI 10.1111/his.13059; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Liu YX, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju245; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Myers A, 2014, GYNECOL ONCOL, V134, P426, DOI 10.1016/j.ygyno.2014.06.010; Palacios J, 1998, CANCER RES, V58, P1344; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shashar M, 2016, ONCOTARGET, V7, P71136, DOI 10.18632/oncotarget.12107; Shukla SA, 2017, GYNECOL ONCOL REP, V19, P42, DOI 10.1016/j.gore.2016.12.009; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003; Stelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878; Tribulo P, 2017, REPRODUCTION, V153, P405, DOI 10.1530/REP-16-0610	37	5	5	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1553	1559		10.1038/s41379-018-0080-0			7	Pathology	Pathology	GV3XJ	WOS:000446031300007	29795437	Green Accepted			2019-10-28	
J	Gonzalez, RS; Cates, JMM; Shi, C				Gonzalez, Raul S.; Cates, Justin M. M.; Shi, Chanjuan			Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors	MODERN PATHOLOGY			English	Article							LYMPH-NODE; COLONIC ADENOCARCINOMA; LIVER METASTASES; SURVIVAL; CANCER; CLASSIFICATION	Mesenteric tumor deposits are an adverse prognostic factor for small intestinal well-differentiated neuroendocrine tumors. Per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (eighth edition), any mesenteric tumor deposit larger than 2 cm signifies pN2 disease. This criterion has not been critically evaluated as a prognostic factor for small intestinal neuroendocrine tumors, nor have multifocality or histologic features of mesenteric tumor deposits. We evaluated 70 small intestinal neuroendocrine tumors with mesenteric tumor deposits for lesional contour, sclerosis, inflammation, calcification, entrapped blood vessels, and perineural invasion. Ki67 proliferative indices of the largest mesenteric tumor deposit from each case were calculated, and number of tumor deposits and size of the largest deposit were recorded. Associations between these factors (along with patient age, primary tumor Ki67 index, and AJCC stage) and development of liver metastases and overall survival were assessed. Median mesenteric tumor deposit size was 1.5 cm (range: 0.2-7.0 cm); median deposit number was 1 (range: 1-13). Primary and tumor deposit Ki67 indices within a given patient were discordant in 40% of cases but showed similar hazard ratios for disease-specific survival. Size of tumor deposits had no significant effect on prognosis, whether analyzed on a continuous scale or dichotomized using the recommended 2 cm cutoff. In contrast, increasing number of deposits was associated with poor prognosis, with multiple deposits conferring an 8.19-fold risk of disease-specific death compared to a single deposit (P = 0.049). Morphologic features of deposits had no prognostic impact. Size of mesenteric tumor deposits does not affect prognosis in small intestinal neuroendocrine tumor patients; instead, deposit multifocality is associated with shorter disease-specific survival and should be incorporated into future staging criteria.	[Gonzalez, Raul S.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; [Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol &Immunology, Nashville, TN USA	Gonzalez, RS (reprint author), Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.	Raul_Gonzalez@URMC.Rochester.edu	Cates, Justin/D-5927-2014	Cates, Justin/0000-0002-7336-5196			Amin MB, 2017, AJCC CANC STAGING MA, P375; Bilimoria KY, 2009, ANN SURG, V249, P63, DOI [10.1097/SLA.0b013e31818c4641, 10.1097/SLA.0b013e31818e4641]; Edge SB FA, 2009, AJCC CANC STAGING MA, P181; Fata CR, 2017, AM J SURG PATHOL, V41, P128, DOI 10.1097/PAS.0000000000000751; Gonzalez RS, 2014, MODERN PATHOL, V27, P1288, DOI 10.1038/modpathol.2013.232; Hellman P, 2002, WORLD J SURG, V26, P991, DOI 10.1007/s00268-002-6630-z; Jin M, 2015, AM J SURG PATHOL, V39, P109, DOI 10.1097/PAS.0000000000000320; Kim MK, 2015, NEUROENDOCRINOLOGY, V101, P58, DOI 10.1159/000371807; Landau M, 2016, ARCH PATHOL LAB MED, V140, P461, DOI 10.5858/arpa.2015-0105-OA; Mocellin S, 2013, ANN ONCOL, V24, P3040, DOI 10.1093/annonc/mdt377; Modlin IM, 2005, GASTROENTEROLOGY, V128, P1717, DOI 10.1053/j.gastro.2005.03.038; Puppa G, 2009, MODERN PATHOL, V22, P410, DOI 10.1038/modpathol.2008.198; Reid MD, 2015, MODERN PATHOL, V28, P686, DOI 10.1038/modpathol.2014.156; Rindi G, 2010, WHO CLASSIFICATION T, V4, P13; Rock JB, 2014, ARCH PATHOL LAB MED, V138, P636, DOI 10.5858/arpa.2013-0166-OA; Shi CJ, 2015, AM J CLIN PATHOL, V143, P398, DOI 10.1309/AJCPQ55SKOCYFZHN; Strosberg JR, 2013, J CLIN ONCOL, V31, P420, DOI 10.1200/JCO.2012.44.5924	17	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1560	1566		10.1038/s41379-018-0075-x			7	Pathology	Pathology	GV3XJ	WOS:000446031300008	29795438				2019-10-28	
J	Wang, BQ; Sun, YM; Zhou, JL; Wu, XN; Chen, SY; Wu, SS; Liu, H; Wang, TL; Ou, XJ; Ha, JD; You, H				Wang, Bingqiong; Sun, Yameng; Zhou, Jialing; Wu, Xiaoning; Chen, Shuyan; Wu, Shanshan; Liu, Hui; Wang, Tailing; Ou, Xiaojuan; Ha, Jidong; You, Hong			Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients	MODERN PATHOLOGY			English	Article							LONG-TERM THERAPY; LIVER FIBROSIS; IMAGE-ANALYSIS; 2ND-HARMONIC GENERATION; CIRRHOSIS; COLLAGEN; MICROSCOPY; REGRESSION; QUANTIFICATION; PROGRESSION	Hepatitis B (HBV)-related fibrosis can be reversed after effective antiviral therapy. However, detailed changes of collagen characteristics during fibrosis regression remain unclear. Paired biopsy samples obtained from chronic hepatitis B patients were imaged with second harmonic generation/two photon excitation fluorescence (SHG/TPEF)-based microscopy to identify and quantify collagen features in portal, septal, and fibrillar areas. According to the changes of Ishak stage and qFibrosis score, a total of 117 patients with paired liver biopsy appeared to have four different outcomes after 78-week antiviral therapy: fast reverse (9%), reverse (63%), stable (15%), or progress (13%) on fibrosis. Among 71 collagen features identified by SHG/TPEF analysis, the most prominent fibrosis reversion occurred in the "septal" area, followed by the "fibrillar" area, but not in the "portal" area (P < 0.001). Further analysis of 1060 individual septa identified four parameters that correlated with fibrosis reversion: average width, maximum width, number of fibers, and number of cross-link fibers (P < 0.001). Average septal width was independently associated with regressive septa (odds ratio (OR) = 5.22, 95% confidence interval (CI): 4.17-6.53; P < 0.001), with an AUROC of 0.96 (95% CI: 0.95-0.97). The threshold used to discriminate reversal of fibrosis was 30 mu m. In conclusion, septal collagen was determined to be the most useful histological feature for evaluation of dynamic changes in liver fibrosis. Septal width was the most predictive indicator of prognosis in liver fibrosis.	[Wang, Bingqiong; Sun, Yameng; Zhou, Jialing; Wu, Xiaoning; Chen, Shuyan; Wu, Shanshan; Ou, Xiaojuan; Ha, Jidong; You, Hong] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing Key Lab Translat Med Liver Cirrhosis,Natl, Beijing, Peoples R China; [Liu, Hui] Capital Med Univ, Beijing Youan Hosp, Dept Pathol, Beijing, Peoples R China; [Wang, Tailing] China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China	You, H (reprint author), Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing Key Lab Translat Med Liver Cirrhosis,Natl, Beijing, Peoples R China.	youhong30@sina.com			National Science and Technology Major Project [2018ZX10302204]; Key Project from Beijing Municipal Science and Technology Commission [D161100002716003, Z171100002217082]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81670539]	This study was funded by National Science and Technology Major Project (2018ZX10302204), Key Project from Beijing Municipal Science and Technology Commission (D161100002716003, Z171100002217082), and National Natural Science Foundation of China (81670539). We thank Yayun Ren, who performed morphometric analyses, and Xiao Teng, who assisted with computer programming.	Arima M, 2004, INTERNAL MED, V43, P902, DOI 10.2169/internalmedicine.43.902; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bedossa P, 2015, LIVER INT, V35, P78, DOI 10.1111/liv.12710; Caballero T, 2001, J HEPATOL, V34, P740, DOI 10.1016/S0168-8278(01)00006-X; Cales Paul, 2015, J Pathol Inform, V6, P20, DOI 10.4103/2153-3539.157782; Chang TT, 2010, HEPATOLOGY, V52, P886, DOI 10.1002/hep.23785; Chen XY, 2012, NAT PROTOC, V7, P654, DOI 10.1038/nprot.2012.009; CHEVALLIER M, 1994, HEPATOLOGY, V20, P349, DOI 10.1016/0270-9139(94)90185-6; Cox G, 2003, J STRUCT BIOL, V141, P53, DOI 10.1016/S1047-8477(02)00576-2; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Duchatelle V, 1998, J HEPATOL, V29, P20, DOI 10.1016/S0168-8278(98)80174-8; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Gailhouste L, 2010, J HEPATOL, V52, P398, DOI 10.1016/j.jhep.2009.12.009; Goodman ZD, 2009, HEPATOLOGY, V50, P1738, DOI 10.1002/hep.23211; Hadziyannis SJ, 2006, GASTROENTEROLOGY, V131, P1743, DOI 10.1053/j.gastro.2006.09.020; Huang Y, 2014, J HEPATOL, V61, P22, DOI 10.1016/j.jhep.2014.02.031; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Kage M, 1997, HEPATOLOGY, V25, P1028, DOI 10.1002/hep.510250439; Lok ASF, 2013, NAT REV GASTRO HEPAT, V10, P199, DOI 10.1038/nrgastro.2013.13; Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1; Sandrini J, 2014, MODERN PATHOL, V27, P1035, DOI 10.1038/modpathol.2013.225; Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028; Sethasine S, 2012, HEPATOLOGY, V55, P1146, DOI 10.1002/hep.24805; Sun WX, 2008, J BIOMED OPT, V13, DOI 10.1117/1.3041159; Sun YM, 2017, HEPATOLOGY, V65, P1438, DOI 10.1002/hep.29009; Tai DCS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3183811; Wanless IR, 2000, ARCH PATHOL LAB MED, V124, P1599; Xu SY, 2014, J HEPATOL, V61, P260, DOI [10.1016/j.jhep.2014.02.015, 10.1016/j.jhep.2014.03.006]; You H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37498; Zhuang ZF, 2013, SCANNING, V35, P12, DOI 10.1002/sca.21029	30	3	3	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1567	1577		10.1038/s41379-018-0059-x			11	Pathology	Pathology	GV3XJ	WOS:000446031300009	29785021				2019-10-28	
J	Wen, KW; Rabinovitch, PS; Huang, DN; Mattis, AN; Lauwers, GY; Choi, WT				Wen, Kwun Wah; Rabinovitch, Peter S.; Huang, Danning; Mattis, Aras N.; Lauwers, Gregory Y.; Choi, Won-Tak			Use of DNA flow cytometry in the diagnosis, risk stratification, and management of gastric epithelial dysplasia	MODERN PATHOLOGY			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; HIGH-GRADE DYSPLASIA; TERM-FOLLOW-UP; INTESTINAL METAPLASIA; PRENEOPLASTIC LESIONS; HELICOBACTER-PYLORI; ATROPHIC GASTRITIS; APC GENE; CANCER; PROGRESSION	The natural history of gastric epithelial dysplasia and the consequential surveillance strategies are not well defined in the West. To date, the diagnosis relies on morphology, and no reliable adjunct methods, either immunohistochemical or molecular, have reproducibly been able to confirm the diagnosis and/or risk stratify gastric epithelial dysplasia. Yet, such a tool would be useful in confirming the diagnosis, and developing objective and rational surveillance guidelines. DNA flow cytometry was performed using formalin-fixed paraffin-embedded gastric tissue from 23 cases of high-grade dysplasia and 38 cases of low-grade dysplasia. Twenty-four benign background mucosal samples from the same cohort (20 biopsies and 4 surgical resections from 16 low- and 8 high-grade dysplasia cases) were utilized as controls. The presence of DNA content abnormality (aneuploidy or elevated 4N fraction) correlated with increasing levels of dysplasia, as DNA content abnormality was detected in 18 (78%) of 23 high-grade dysplasia, 5 (13%) of 38 low-grade dysplasia, and none of 24 non-dysplastic samples. 1 and 4-year detection rates of high-grade dysplasia or gastric adenocarcinoma in low-grade dysplasia patients with DNA content abnormality were 80% (p = 0.003) and 100% (p = 0.005), respectively, whereas patients with low-grade dysplasia but with normal DNA content had 1, 4, and 12-year detection rates of 23, 32, and 54%, respectively. The univariate hazard ratio (HR) for subsequent detection of high-grade dysplasia or gastric adenocarcinoma in low-grade dysplasia patients with DNA content abnormality was 6.9 (p = 0.001). Older patients (HR = 1.1, p = 0.005) and those with familial adenomatous polyposis (HR = 9.7, p = 0.029) also had an increased risk for developing high-grade dysplasia or gastric adenocarcinoma in the univariate analysis, but only DNA content abnormality demonstrated a significantly elevated HR of 5.9 in the multivariate analysis (p = 0.005). While older age showed a minimally elevated risk (HR = 1.1, p = 0.013), no other potential risk factors, including male gender, ethnicity, polypoid endoscopic appearance, Helicobacter pylori infection, and intestinal metaplasia, were significantly associated with subsequent detection of high-grade dysplasia or gastric adenocarcinoma in the multivariate analysis. Among the 18 high-grade dysplasia cases with DNA content abnormality, 13 cases (72%) developed gastric adenocarcinoma within a mean follow-up time of 9 months, conferring a HR of 2.5; however, this did not reach statistical significance. In conclusion, the presence of DNA content abnormality can identify a subset of low-grade dysplasia patients who are at increased risk for subsequent detection of high-grade dysplasia or gastric adenocarcinoma. It can also provide confirmatory evidence to a morphologic impression or suspicion of high-grade dysplasia. The majority of gastric epithelial dysplasia patients with DNA content abnormality developed high-grade dysplasia or gastric adenocarcinoma within a year and thus may benefit from more thorough and rigorous endoscopic surveillance.	[Wen, Kwun Wah; Mattis, Aras N.; Choi, Won-Tak] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Rabinovitch, Peter S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Huang, Danning] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA; [Lauwers, Gregory Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA	Choi, WT (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.	Won-Tak.Choi@ucsf.edu			University California at San Francisco Department of Pathology	University California at San Francisco Department of Pathology	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BEARZI I, 1994, PATHOL RES PRACT, V190, P61, DOI 10.1016/S0344-0338(11)80497-8; Buffart TE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-345; Choi CE, 2015, DIGEST DIS SCI, V60, P2070, DOI 10.1007/s10620-015-3591-2; Choi WT, 2018, GUT, V67, P1229, DOI 10.1136/gutjnl-2017-313815; CORREA P, 1990, CANCER RES, V50, P4737; de Vries AC, 2008, GASTROENTEROLOGY, V134, P945, DOI 10.1053/j.gastro.2008.01.071; DEDOMBAL FT, 1990, GUT, V31, P115, DOI 10.1136/gut.31.1.115; den Hoed CM, 2013, ENDOSCOPY, V45, P249, DOI 10.1055/s-0032-1326379; Dong B, 2005, WORLD J GASTROENTERO, V11, P3595, DOI 10.3748/wjg.v11.i23.3595; Evans JA, 2015, GASTROINTEST ENDOSC, V82, P1, DOI 10.1016/j.gie.2015.03.1967; FARINATI F, 1993, ENDOSCOPY, V25, P261, DOI 10.1055/s-2007-1010310; Fennerty MB, 2003, GASTROENTEROLOGY, V125, P586, DOI 10.1016/S0016-5085(03)00957-0; FERTITTA AM, 1993, ENDOSCOPY, V25, P265, DOI 10.1055/s-2007-1010311; Goddard AF, 2010, GUT, V59, P1270, DOI 10.1136/gut.2009.182089; Goldstein NS, 1997, HUM PATHOL, V28, P127, DOI 10.1016/S0046-8177(97)90095-2; Hamashima C, 2008, JPN J CLIN ONCOL, V38, P259, DOI 10.1093/jjco/hyn017; Kokkola A, 1996, J CLIN PATHOL, V49, P979, DOI 10.1136/jcp.49.12.979; KOLODZIEJCZYK P, 1994, CANCER-AM CANCER SOC, V74, P2896, DOI 10.1002/1097-0142(19941201)74:11<2896::AID-CNCR2820741103>3.0.CO;2-P; LANSDOWN M, 1990, GUT, V31, P977, DOI 10.1136/gut.31.9.977; Lauwers GY, 2007, GASTROENTEROL CLIN N, V36, P813, DOI 10.1016/j.gtc.2007.08.008; Lauwers GY, 1999, GUT, V45, P784, DOI 10.1136/gut.45.5.784; Li D, 2016, AM J GASTROENTEROL, V111, P1104, DOI 10.1038/ajg.2016.188; MACARTNEY JC, 1986, J PATHOL, V150, P113, DOI 10.1002/path.1711500205; Ngamruengphong S, 2014, HERED CANCER CLIN PR, V12, DOI 10.1186/1897-4287-12-4; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; Park SY, 2008, EUR J GASTROEN HEPAT, V20, P966, DOI 10.1097/MEG.0b013e3283013d58; Raftopoulos SC, 2012, EUR J GASTROEN HEPAT, V24, P48, DOI 10.1097/MEG.0b013e32834dc1bb; RUGGE M, 1991, HUM PATHOL, V22, P1002, DOI 10.1016/0046-8177(91)90008-D; RUGGE M, 1994, GASTROENTEROLOGY, V107, P1288, DOI 10.1016/0016-5085(94)90529-0; Sarela AI, 2005, ARCH SURG-CHICAGO, V140, P644, DOI 10.1001/archsurg.140.7.644; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Setia N, 2015, DIAGN HISTOPATHOL, V21, P312; Setia N, 2016, MODERN PATHOL, V29, P772, DOI 10.1038/modpathol.2016.55; Shaib YH, 2013, CLIN GASTROENTEROL H, V11, P1374, DOI 10.1016/j.cgh.2013.03.019; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; Smith GV, 2005, AM J CLIN PATHOL, V123, P415, DOI 10.1309/263A4PQ83R9OCRUF; Srivastava A, 2008, DIGEST LIVER DIS, V40, P641, DOI 10.1016/j.dld.2008.02.039; TAMURA G, 1994, CANCER RES, V54, P1149; Tanaka A, 2008, PATHOL RES PRACT, V204, P1, DOI 10.1016/j.prp.2007.08.014; Teh M, 2002, CANCER-AM CANCER SOC, V95, P499, DOI 10.1002/cncr.10697; Tsai JH, 2017, GASTROENTEROLOGY, V153, P1492, DOI 10.1053/j.gastro.2017.08.031; Vannella L, 2010, ALIMENT PHARM THER, V31, P1042, DOI 10.1111/j.1365-2036.2010.04268.x; Whiting JL, 2002, GUT, V50, P378, DOI 10.1136/gut.50.3.378; Wood LD, 2014, AM J SURG PATHOL, V38, P389, DOI 10.1097/PAS.0000000000000146; Yakirevich E, 2013, GASTROENTEROL CLIN N, V42, P261, DOI 10.1016/j.gtc.2013.01.004; Yasa MH, 2005, INT J CLIN PRACT, V59, P1029, DOI 10.1111/j.1368-5031.2005.00575.x; You WC, 2000, J NATL CANCER I, V92, P1607, DOI 10.1093/jnci/92.19.1607; Zhao GF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132699	49	2	2	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1578	1587		10.1038/s41379-018-0062-2			10	Pathology	Pathology	GV3XJ	WOS:000446031300010	29789650				2019-10-28	
J	Pai, RK; Dudley, B; Karloski, E; Brand, RE; O'Callaghan, N; Rosty, C; Buchanan, DD; Jenkins, MA; Thibodeau, SN; French, AJ; Lindor, NM; Pai, RK				Pai, Rish K.; Dudley, Beth; Karloski, Eve; Brand, Randall E.; O'Callaghan, Neil; Rosty, Christophe; Buchanan, Daniel D.; Jenkins, Mark A.; Thibodeau, Stephen N.; French, Amy J.; Lindor, Noralane M.; Pai, Reetesh K.			DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome	MODERN PATHOLOGY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ENDOMETRIAL CANCER; GERMLINE MUTATION; FREQUENT CAUSE; IMMUNOHISTOCHEMISTRY; RISK; MLH1; METHYLATION; POPULATION; GUIDELINES	Lynch syndrome is the most common form of hereditary colorectal carcinoma. However, establishing the diagnosis of Lynch syndrome is challenging, and ancillary studies that distinguish between sporadic DNA mismatch repair (MMR) protein deficiency and Lynch syndrome are needed, particularly when germline mutation studies are inconclusive. The aim of this study was to determine if MMR protein-deficient non-neoplastic intestinal crypts can help distinguish between patients with and without Lynch syndrome. We evaluated the expression of MMR proteins in non-neoplastic intestinal mucosa obtained from colorectal surgical resection specimens from patients with Lynch syndrome-associated colorectal carcinoma (n = 52) and patients with colorectal carcinoma without evidence of Lynch syndrome (n = 70), including sporadic MMR protein-deficient colorectal carcinoma (n = 30), MMR protein proficient colorectal carcinoma (n = 30), and "Lynch-like" syndrome (n = 10). MMR protein-deficient non-neoplastic colonic crypts were identified in 19 of 122 (16%) patients. MMR protein-deficient colonic crypts were identified in 18 of 52 (35%) patients with Lynch syndrome compared to only 1 of 70 (1%) patients without Lynch syndrome (p < 0.001). This one patient had "Lynch-like" syndrome and harbored two MSH2-deficient non-neoplastic colonic crypts. MMR protein-deficient non-neoplastic colonic crypts were not identified in patients with sporadic MMR protein-deficient or MMR protein proficient colorectal carcinoma. Our findings suggest that MMR protein-deficient colonic crypts are a novel indicator of Lynch syndrome, and evaluation for MMR protein-deficient crypts may be a helpful addition to Lynch syndrome diagnostics.	[Pai, Rish K.] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ USA; [Dudley, Beth; Karloski, Eve; Brand, Randall E.] Univ Pittsburgh, Med Ctr, Dept Internal Med, Div Gastroenterol,Hereditary Tumor Program, Pittsburgh, PA USA; [O'Callaghan, Neil; Rosty, Christophe; Buchanan, Daniel D.] Univ Melbourne, Dept Clin Pathol, Colorectal Oncogen Grp, Parkville, Vic, Australia; [O'Callaghan, Neil; Rosty, Christophe; Buchanan, Daniel D.] Univ Melbourne, Ctr Canc Res, Victorian Comprehens Canc Ctr, Parkville, Vic, Australia; [Rosty, Christophe] Envoi Specialist Pathologists, Herston, Qld, Australia; [Rosty, Christophe] Univ Queensland, Sch Med, Herston, Qld, Australia; [Buchanan, Daniel D.] Royal Melbourne Hosp, Genet Med & Family Canc Clin, Parkville, Vic, Australia; [Jenkins, Mark A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Carlton, Vic 3010, Australia; [Thibodeau, Stephen N.; French, Amy J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Lindor, Noralane M.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA; [Pai, Reetesh K.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15260 USA	Pai, RK (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15260 USA.	pair@upmc.edu	; Jenkins, Mark/P-7803-2015	Buchanan, Daniel/0000-0003-2225-6675; Rosty, Christophe/0000-0001-7671-2651; Jenkins, Mark/0000-0002-8964-6160	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [UM1 CA167551]; Australasian Colorectal Cancer Family Registry [U01 CA074778, U01/U24 CA097735, U01/U24 CA074800]	This work was supported by grant UM1 CA167551 from the National Cancer Institute and through cooperative agreements with Australasian Colorectal Cancer Family Registry (U01 CA074778, U01/U24 CA097735, and U01/U24 CA074800) and was conducted under Colon-CFR approval C-AU-1014-01. CR is the Jass Pathology Fellow. DDB is a University of Melbourne Research at Melbourne Accelerator Program (R@MAP) Senior Research Fellow and National Health and Medical Research Council of Australia (NHMRC) R.D. Wright Career Development Fellow. MAJ is a NHMRC Senior Research Fellow.	Ambry Genetics, LYNCH SYNDR; Balmana J, 2013, ANN ONCOL, V24, P73, DOI 10.1093/annonc/mdt209; Berg AO, 2009, GENET MED, V11, P35, DOI [10.1097/GIM.0b013e31818fa2ff, 10.1097/GIM.0b013e318181fa2ff]; Buchanan DD, 2017, J GASTROEN HEPATOL, V32, P427, DOI 10.1111/jgh.13468; Buchanan DD, 2014, APPL CLIN GENET, V7, P183, DOI 10.2147/TACG.S48625; Buchanan DD, 2014, J CLIN ONCOL, V32, P90, DOI 10.1200/JCO.2013.51.2129; Buchanan DD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011636; Castillejo A, 2014, EUR J CANCER, V50, P2241, DOI 10.1016/j.ejca.2014.05.022; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; Elsayed FA, 2015, EUR J HUM GENET, V23, P1080, DOI 10.1038/ejhg.2014.242; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Giardiello FM, 2014, GASTROENTEROLOGY, V147, P502, DOI 10.1053/j.gastro.2014.04.001; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Jansen AML, 2016, EUR J HUM GENET, V24, P1089, DOI 10.1038/ejhg.2015.252; Kalady MF, 2015, DIS COLON RECTUM, V58, P388, DOI 10.1097/DCR.0000000000000333; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Ligtenberg MJL, 2013, FAM CANCER, V12, P169, DOI 10.1007/s10689-012-9591-x; Mas-Moya J, 2015, HUM PATHOL, V46, P1616, DOI 10.1016/j.humpath.2015.06.022; Mensenkamp AR, 2014, GASTROENTEROLOGY, V146, P643, DOI 10.1053/j.gastro.2013.12.002; Myriad genetics, 2015, LYNCH SYNDR; Overbeek LIH, 2008, AM J SURG PATHOL, V32, P1246, DOI 10.1097/PAS.0b013e31816401bb; Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512; Radu OM, 2011, HUM PATHOL, V42, P1247, DOI 10.1016/j.humpath.2010.11.016; Rhees J, 2014, FAM CANCER, V13, P219, DOI 10.1007/s10689-013-9688-x; Rodriguez-Soler M, 2013, GASTROENTEROLOGY, V144, P926, DOI 10.1053/j.gastro.2013.01.044; Sourrouille I, 2013, FAM CANCER, V12, P27, DOI 10.1007/s10689-012-9568-9; Staffa L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121980; Stoffel EM, 2015, J CLIN ONCOL, V33, P209, DOI 10.1200/JCO.2014.58.1322; Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435; Walsh MD, 2008, CLIN CANCER RES, V14, P1692, DOI 10.1158/1078-0432.CCR-07-1849; Win AK, 2015, GUT, V64, P101, DOI 10.1136/gutjnl-2013-306567; Yousem SA, 2008, AM J SURG PATHOL, V32, P1317, DOI 10.1097/PAS.0b013e31816597ca	33	2	2	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1608	1618		10.1038/s41379-018-0079-6			11	Pathology	Pathology	GV3XJ	WOS:000446031300013	29884888	Green Accepted			2019-10-28	
J	Hartley, CP; Carrillo-Polanco, LF; Rowan, DJ; Hagen, CE				Hartley, Christopher P.; Carrillo-Polanco, Luis F.; Rowan, Daniel J.; Hagen, Catherine E.			Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation	MODERN PATHOLOGY			English	Article							RECIPIENTS; MARROW	Histologic characterization of graft-vs.-host disease in autologous stem cell transplant patients has been limited. The aims of this study were to characterize colonic graft-vs.-host disease in autologous stem cell transplant patients and compare to a control group of allogeneic stem cell transplant patients, to determine whether graft-vs.-host disease can be diagnosed < 21 days post transplantation in autologous stem cell transplant recipients, and to quantify colonic T-cell populations in autologous stem cell transplant patients. Colonic biopsies taken to evaluate for graft-vs.-host disease in both allogenic and autologous stem cell transplant patients were reviewed for the maximum number of apoptotic bodies per 10 contiguous crypts. Immunohistochemical stains for CD4, CD8, and FoxP3 were performed. Clinical information was collected from chart review. The study group consisted of 122 colonic biopsies from 84 patients. Sixteen patients underwent autologous stem cell transplant and 68 allogeneic stem cell transplant. Autologous stem cell transplant patients underwent biopsy significantly earlier compared with allogeneic stem cell transplant patients (median 20 vs. 87 days, p = 0.0002), had significantly higher apoptotic counts compared with matched-related donor patients (7.5 vs. 3.9, p = 0.03), and had higher FoxP3-positive lamina propria lymphocytes counts compared to allogeneic stem cell transplant patients (9.2 vs. 5.3, p = 0.03). In patients undergoing biopsy < 21 days post transplantation, allogeneic stem cell transplant patients showed less CD8-positive lamina propria lymphocytes and a trend of less FoxP3- and CD4-positive lamina propria lymphocytes compared with autologous stem cell transplant patients. Autologous stem cell transplant patients have more prominent crypt apoptosis compared with allogenic stem cell transplant patients and do not have numerically decreased FoxP3-positive lamina propria lymphocytes. Presence of robust T-cell populations in the early period following transplantation suggest that the 21-day cutoff for diagnosis of graft-vs.-host disease is not applicable to autologous stem cell transplant patients.	[Hartley, Christopher P.; Carrillo-Polanco, Luis F.; Rowan, Daniel J.; Hagen, Catherine E.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA	Hagen, CE (reprint author), Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA.	cahagen@mcw.edu					Batra A, 2014, BONE MARROW RES, DOI 10.1155/2014/891427; Cogbill CH, 2011, MODERN PATHOL, V24, P117, DOI 10.1038/modpathol.2010.163; Drobyski WR, 2009, BONE MARROW TRANSPL, V43, P169, DOI 10.1038/bmt.2008.295; EPSTEIN RJ, 1980, GASTROENTEROLOGY, V78, P764; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Holmberg L, 2006, BIOL BLOOD MARROW TR, V12, P226, DOI 10.1016/j.bbmt.2005.10.011; Holtick U, 2014, COCHRANE DB SYST REV, V4; HOOD AF, 1987, ARCH DERMATOL, V123, P745, DOI 10.1001/archderm.123.6.745; LERNER KG, 1974, TRANSPLANT P, V6, P367; Lord JD, 2011, BIOL BLOOD MARROW TR, V17, P486, DOI 10.1016/j.bbmt.2010.09.015; Magenau JM, 2010, BIOL BLOOD MARROW TR, V16, P907, DOI 10.1016/j.bbmt.2010.02.026; Saunders MD, 2000, AM J SURG PATHOL, V24, P1004, DOI 10.1097/00000478-200007000-00012; SNOVER DC, 1990, AM J SURG PATHOL, V14, P101; Tzung S P, 1998, Biol Blood Marrow Transplant, V4, P43	14	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	OCT	2018	31	10					1619	1626		10.1038/s41379-018-0078-7			8	Pathology	Pathology	GV3XJ	WOS:000446031300014	29899549				2019-10-28	
J	Jo, VY; Marino-Enriquez, A; Fletcher, CDM; Hornick, JL				Jo, Vickie Y.; Marino-Enriquez, Adrian; Fletcher, Christopher D. M.; Hornick, Jason L.			Expression of PAX3 Distinguishes Biphenotypic Sinonasal Sarcoma From Histologic Mimics	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						biphenotypic sinonasal sarcoma; PAX3; soft tissue	SOLITARY FIBROUS TUMOR; NERVE SHEATH TUMORS; PAN-TRK IMMUNOHISTOCHEMISTRY; H3K27 TRIMETHYLATION; DIAGNOSTIC MARKER; BETA-CATENIN; ALVEOLAR RHABDOMYOSARCOMA; NEUROENDOCRINE TUMORS; NUCLEAR EXPRESSION; GENE FUSIONS	Biphenotypic sinonasal sarcoma (BSNS) is a distinctive, anatomically restricted, low-grade spindle cell sarcoma that shows considerable histologic overlap with other cellular spindle cell neoplasms. This tumor type shows both myogenic and neural differentiation, which can be demonstrated by immunohistochemistry; however, the available diagnostic markers are relatively nonspecific. BSNS is characterized by PAX3 rearrangements, with MAML3 as the most common fusion partner. Our aim was to determine whether immunohistochemistry using a monoclonal PAX3 antibody could distinguish BSNS from potential histologic mimics, as well as to evaluate a widely available polyclonal PAX8 antibody, which is known to cross-react with other paired box transcription factor family members. Immunohistochemistry for PAX3 and PAX8 was performed on whole sections of 15 BSNS (10 with confirmed PAX3 rearrangement) and 10 cases each of the following histologic mimics: malignant peripheral nerve sheath tumor, monophasic synovial sarcoma, spindle cell rhabdomyosarcoma (RMS), solitary fibrous tumor, sinonasal hemangiopericytoma, and cellular schwannoma, as well as alveolar RMS (which harbors PAX3 or PAX7 gene rearrangements). BSNS showed consistent expression of PAX3 (15/15), all multifocal-to-diffuse and most with moderate-to-strong intensity of staining. One single case of spindle cell RMS showed PAX3 expression (1/10), and all other histologic mimics were completely PAX3-negative. In contrast, nuclear staining for PAX8 was present in all 15 BSNS, 7/10 malignant peripheral nerve sheath tumor, 3/10 cellular schwannomas, 2/10 sinonasal hemangiopericytomas, 1/10 synovial sarcoma, 1 spindle cell RMS, and 1 solitary fibrous tumor. All cases of alveolar RMS were positive for PAX8, and most were also positive for PAX3 (8/10). Immunohistochemical expression of PAX3 is highly sensitive (100%) and specific (98%) for BSNS. A polyclonal PAX8 antibody also stains BSNS (likely due to cross-reactivity with PAX3) but has much lower specificity (75%), with frequent expression in numerous mimics.	[Jo, Vickie Y.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Jo, VY (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	vjo@partners.org					Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Fan R, 2014, FETAL PEDIATR PATHOL, V33, P244, DOI 10.3109/15513815.2014.920441; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; Hechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Hung YP, 2018, MODERN PATHOL, V31, P24; Lai JP, 2015, ENDOCR PATHOL, V26, P54, DOI 10.1007/s12022-014-9346-3; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Le Guellec S, 2017, MODERN PATHOL, V30, P1677, DOI 10.1038/modpathol.2017.91; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Long KB, 2010, AM J SURG PATHOL, V34, P723, DOI 10.1097/PAS.0b013e3181da0a20; Lorenzo PI, 2011, HISTOCHEM CELL BIOL, V136, P595, DOI 10.1007/s00418-011-0866-3; Makise N, 2018, AM J SURG PATHOL, V42, P656, DOI 10.1097/PAS.0000000000001014; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Mito JK, 2017, AM J CLIN PATHOL, V148, P179, DOI [10.1093/AJCP/AQX060, 10.1093/ajcp/aqx060]; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; Poo WC, 2011, AM J CLIN PATHOL, V135, P839, DOI 10.1309/AJCP45SSNAOPXYXU; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Sullivan LM, 2009, AM J SURG PATHOL, V33, P775, DOI 10.1097/PAS.0b013e318191614f; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295	33	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1275	1285		10.1097/PAS.0000000000001092			11	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300001	29863547				2019-10-28	
J	Alharbi, AM; De Marzo, AM; Hicks, JL; Lotan, TL; Epstein, JI				Alharbi, Abdullah M.; De Marzo, Angelo M.; Hicks, Jessica L.; Lotan, Tamara L.; Epstein, Jonathan I.			Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features A Series of 30 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						NKX3.1; PSA; P501S; HOXB13; GATA3; androgen receptor; prostate adenocarcinoma	UROTHELIAL CARCINOMA; CYSTOPROSTATECTOMY SPECIMENS; ANTIANDROGEN RESISTANCE; INTERNATIONAL-SOCIETY; CONSENSUS-CONFERENCE; LINEAGE PLASTICITY; URINARY-BLADDER; USEFUL MARKER; UROPLAKIN II; CANCER	Prostatic adenocarcinoma with focal pleomorphic giant cell features is rare with the only prior series consisting of 6 cases. From 2005 to 2018, we identified 29 cases from our consult service and 1 case from our own institution. Men ranged in age from 39 to 90 years (median = 75.5). Diagnostic specimens consisted of needle biopsies (n = 13); transurethral resections (n = 7), urethral/bladder biopsies (n = 8), radical prostatectomy (n = 1), and orchiectomy (n = 1). In all cases, there was usual acinar prostatic adenocarcinoma, where the highest grade in all cases was Gleason score 9 to 10 (Grade Group 5). On average, 68% of the involved cores had cancer with a maximum percent of cancer averaging 55%; on average, transurethral resections had 85% of the area involved by cancer. Areas of cancer showing pleomorphic giant cell features were focal (< 5%). Two of the needle biopsies showed extraprostatic extension. The radical prostatectomy had seminal vesicle invasion and positive margins with lymphovascular invasion. Prostatic adenocarcinoma with focal pleomorphic giant cell features is always accompanied by extensive usual acinar prostate adenocarcinoma where the highest grade in all cases was Gleason score 9 to 10 (Grade Group 5). Although the pleomorphic component is focal, it can mimic urothelial carcinoma. IHC can be misleading as PSA staining is often negative or focal in both the pleomorphic and usual prostatic adenocarcinoma components. NKX3.1 is the most sensitive prostate marker, but was still focal in 1 usual prostatic adenocarcinoma and negative in 2 pleomorphic components. Prostatic adenocarcinoma with focal pleomorphic giant cell features has a dismal prognosis. In men with no prior diagnosis of prostate adenocarcinoma and > 1-year follow-up, 7/19 (37%) were dead at a median of 8 months after diagnosis. Of the 7 men with a prior history of prostate adenocarcinoma, 4/7 (57%) were dead at a median of 7 months after diagnosis of recurrent prostate adenocarcinoma with pleomorphic giant cell features.	[Alharbi, Abdullah M.; De Marzo, Angelo M.; Hicks, Jessica L.; Lotan, Tamara L.; Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Weinberg Bldg,Rm 2242,401 N Broadway St, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Aparicio AM, 2016, CLIN CANCER RES, V22, P1520, DOI 10.1158/1078-0432.CCR-15-1259; Bruins HM, 2013, J UROLOGY, V190, P1704, DOI 10.1016/j.juro.2013.05.034; Chuang AY, 2007, AM J SURG PATHOL, V31, P1246, DOI 10.1097/PAS.0b013e31802f5d33; ELLIS DW, 1984, AM J CLIN PATHOL, V81, P279, DOI 10.1093/ajcp/81.3.279; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Fine SW, 2010, MODERN PATHOL, V23, P1325, DOI 10.1038/modpathol.2010.120; FORD TF, 1985, BRIT J UROL, V57, P50, DOI 10.1111/j.1464-410X.1985.tb08984.x; Gordetsky J, 2014, AM J SURG PATHOL, V38, P941, DOI 10.1097/PAS.0000000000000178; Guedes LB, 2017, CLIN CANCER RES, V23, P4693, DOI 10.1158/1078-0432.CCR-17-0257; Hoang LL, 2014, ARCH PATHOL LAB MED, V138, P943, DOI 10.5858/arpa.2013-0221-OA; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lane ZL, 2008, AM J SURG PATHOL, V32, P1322, DOI 10.1097/PAS.0b013e3181656ca0; Larnaudie L, 2017, VIRCHOWS ARCH, V471, P133, DOI 10.1007/s00428-017-2134-y; Leapman MS, 2017, EUR UROL, V71, P750, DOI 10.1016/j.eururo.2016.11.032; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Lopez-Beltran A, 2005, ARCH PATHOL LAB MED, V129, P683; MAHADEVIA PS, 1986, CANCER, V58, P2096, DOI 10.1002/1097-0142(19861101)58:9<2096::AID-CNCR2820580922>3.0.CO;2-0; MAI KT, 1996, J UROL PATH, V5, P167; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Moch H, 2016, WHO CLASSIFICATION T; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Parwani AV, 2006, AM J SURG PATHOL, V30, P1254, DOI 10.1097/01.pas.0000209841.77595.4b; Samaratunga H, 2016, HISTOPATHOLOGY, V68, P533, DOI 10.1111/his.12785; SCHELLHAMMER PF, 1977, J UROLOGY, V118, P399, DOI 10.1016/S0022-5347(17)58039-8; SVANHOLM H, 1986, ACTA PATH MICRO IM A, V94, P7; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tsai H, 2015, CLIN CANCER RES, V21, P5619, DOI 10.1158/1078-0432.CCR-15-0744; Varinot J, 2016, VIRCHOWS ARCH, V468, P619, DOI 10.1007/s00428-016-1917-x; WOOD DP, 1989, J UROLOGY, V141, P346, DOI 10.1016/S0022-5347(17)40762-2	31	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1286	1296		10.1097/PAS.0000000000001112			11	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300002	29944471				2019-10-28	
J	Gong, SY; Crane, GM; McCall, CM; Xiao, WB; Ganapathi, KA; Cuka, N; Davies-Hill, T; Xi, LQ; Raffeld, M; Pittaluga, S; Duffield, AS; Jaffe, ES				Gong, Shunyou; Crane, Genevieve M.; McCall, Chad M.; Xiao, Wenbin; Ganapathi, Karthik A.; Cuka, Nathan; Davies-Hill, Theresa; Xi, Liqiang; Raffeld, Mark; Pittaluga, Stefania; Duffield, Amy S.; Jaffe, Elaine S.			Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas A Lesion Associated With Diverse Immunodeficiency Settings	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Epstein-Barr virus; immunodeficiency; posttransplant lymphoproliferative disease; immunosenescence; marginal zone lymphoma; MALT lymphoma; immunosuppression	EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; B-CELL NEOPLASMS; MYOEPITHELIAL SIALADENITIS; MALIGNANT-LYMPHOMA; SJOGRENS-SYNDROME; PAROTID-GLAND; MALT LYMPHOMA; TISSUE MALT; DISEASE	Traditionally low-grade B-cell lymphomas have been excluded from the category of monomorphic posttransplant lymphoproliferative disorders. However, recent reports identified Epstein-Barr virus-positive (EBV+) extranodal marginal zone lymphomas (MZL), almost exclusively seen in the posttransplant setting. Some reported cases responded to reduced immunosuppression, suggesting that they should be considered as a form of posttransplant lymphoproliferative disorders. We identified 10 cases of EBV+ MZL, 9 in extranodal sites and 1 presenting in lymph node. Two cases arose following solid organ transplantation, but other settings included iatrogenic immunosuppression for rheumatoid arthritis (2); prior chemotherapy (2); congenital immune deficiency (1); and increased age (3), as the only potential cause of immune dysfunction. There were 4 males and 6 females; age range 18 to 86. The atypical plasmacytoid and/or monocytoid B cells were positive for EBV in all cases, with either latency I or II in all cases tested. Monotypic light chain expression was shown in all with 6 cases positive for IgG, and 2 for IgM, undetermined in 2. Clonal immunoglobulin gene rearrangement was positive in all cases with successful amplification. MYD88 L265P was wild type in the 6 cases tested. We show that EBV+ MZLs can arise in a variety of clinical settings, and are most often extranodal. Treatment varied, but most patients had clinically indolent disease with response to reduction of immune suppression, or immunochemotherapy.	[Gong, Shunyou; Xiao, Wenbin; Ganapathi, Karthik A.; Davies-Hill, Theresa; Xi, Liqiang; Raffeld, Mark; Pittaluga, Stefania; Jaffe, Elaine S.] NCI, Pathol Lab, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Crane, Genevieve M.; McCall, Chad M.; Cuka, Nathan; Duffield, Amy S.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA	Jaffe, ES (reprint author), NCI, Pathol Lab, Hematopathol Sect, NIH, 10 Ctr Dr,Bldg 10,Room 3S235, Bethesda, MD 20892 USA.	ejaffe@mail.nih.gov		McCall, Chad/0000-0003-3542-9053	Center for Cancer Research, National Cancer Insitute, National Institutes of Health	Supported by the Intramural Research Budget of the Center for Cancer Research, National Cancer Insitute, National Institutes of Health. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abruzzo LV, 2002, AM J SURG PATHOL, V26, P630, DOI 10.1097/00000478-200205000-00009; Armstrong AA, 1998, LEUKEMIA, V12, P1272, DOI 10.1038/sj.leu.2401097; Bates WD, 2003, J CLIN PATHOL, V56, P439, DOI 10.1136/jcp.56.6.439; Bennett JA, 2015, J PEDIAT HEMATOL ONC, V37, pE114, DOI 10.1097/MPH.0b013e31829f3496; Cassidy DP, 2018, AM J CLIN PATHOL, V149, P42, DOI [10.1093/AJCP/AQX134, 10.1093/ajcp/aqx134]; DISS TC, 1995, AM J SURG PATHOL, V19, P531, DOI 10.1097/00000478-199505000-00004; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; FALZON M, 1991, AM J SURG PATHOL, V15, P59, DOI 10.1097/00000478-199101000-00007; Gachard N, 2013, LEUKEMIA, V27, P183, DOI 10.1038/leu.2012.257; Gibson SE, 2011, AM J SURG PATHOL, V35, P807, DOI 10.1097/PAS.0b013e3182190999; Gibson Todd M, 2014, AIDS, V28, P2313, DOI 10.1097/QAD.0000000000000428; Hsi ED, 2000, AM J SURG PATHOL, V24, P100, DOI 10.1097/00000478-200001000-00012; HYJEK E, 1988, HUM PATHOL, V19, P766, DOI 10.1016/S0046-8177(88)80259-4; Kempf W, 2014, AM J DERMATOPATH, V36, P197, DOI 10.1097/DAD.0b013e318289b20e; Kim MJ, 2009, SURG TODAY, V39, P1076, DOI 10.1007/s00595-008-3981-6; Kojima M, 1997, JPN J CLIN ONCOL, V27, P84, DOI 10.1093/jjco/27.2.84; Mucha K, 2010, NEPHROL DIAL TRANSPL, V25, P2089, DOI 10.1093/ndt/gfq231; Nassif S, 2013, PEDIATR TRANSPLANT, V17, pE141, DOI 10.1111/petr.12111; Natkunam Y, 2017, AM J CLIN PATHOL, V147, P129, DOI 10.1093/ajcp/aqw214; Oertel SHK, 2005, AM J TRANSPLANT, V5, P2901, DOI 10.1111/j.1600-6143.2005.01098.x; Oyama T, 2007, CLIN CANCER RES, V13, P5124, DOI 10.1158/1078-0432.CCR-06-2823; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; Royer B, 1997, BLOOD, V90, P766, DOI 10.1182/blood.V90.2.766.766_766_775; Salama S, 2010, J CUTAN PATHOL, V37, P641, DOI 10.1111/j.1600-0560.2009.01449.x; SWERDLOW SH, 1992, HISTOPATHOLOGY, V20, P373, DOI 10.1111/j.1365-2559.1992.tb01007.x; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; TERUYAFELDSTEIN J, 1995, AM J SURG PATHOL, V19, P357, DOI 10.1097/00000478-199503000-00014; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Verma S, 2005, J CUTAN PATHOL, V32, P474, DOI 10.1111/j.0303-6987.2005.00363.x; Wotherspoon AC, 1996, HISTOPATHOLOGY, V28, P129, DOI 10.1046/j.1365-2559.1996.292338.x	32	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1306	1316		10.1097/PAS.0000000000001113			11	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300004	29957733				2019-10-28	
J	Arnold, CA; Frankel, WL; Guo, L; Krishnan, C; Pfeil, S; Schumacher, M; Voltaggio, L; Yearsley, MM; Chen, W				Arnold, Christina A.; Frankel, Wendy L.; Guo, Ling; Krishnan, Chandra; Pfeil, Sheryl; Schumacher, Melinda; Voltaggio, Lysandra; Yearsley, Martha M.; Chen, Wei			Crystal-storing Histiocytosis in the Stomach A Clue to Subtle Hematolymphoid Malignancies	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						crystal-storing histiocytosis (CSH); lymphoma; kappa; lambda; macrophages; immunoglobulin	OF-THE-LITERATURE; RUSSELL BODY GASTRITIS; HELICOBACTER-PYLORI-INFECTION; CHARCOT-LEYDEN CRYSTALS; PLASMA-CELL MYELOMA; KAPPA LIGHT-CHAIN; MULTIPLE-MYELOMA; BONE-MARROW; PATIENT; TONGUE	Crystal-storing histiocytosis (CSH) is an under-recognized entity with a striking association with lymphoproliferative disorders. To study the typical morphologic features of gastric CSH, all lymphomas diagnosed on in-house gastric specimens at The Ohio State University between January 1, 2008 and January 1, 2017 were retrieved. This search yielded 66 specimens from 51 unique patients. All cases were reviewed with CSH identified in 7 stomach biopsies from 4 patients (2 men:2 women; average age, 69 y; range, 56 to 82 y). Endoscopic findings were all abnormal: diffuse nodularity and white discoloration (n = 1), patchy nodularity (n = 1), and malignant-appearing fundic mass with lymphadenopathy (n = 2). We report the typical gastric CSH lesion displays full-thickness expansion of the lamina propria by a lymphohistiocytic infiltrate that distorts the usual gastric glandular architecture. On high power, all cases were defined by the presence of macrophages with abundant eosinophilic cytoplasm containing nonrefractile, nonpolarizable fibrillary cytoplasmic inclusions. Three of the 4 patients had a kappa-restricted lymphoma; the 1 patient with a lambda-restricted lymphoma had the fewest macrophages. Follow-up data were available up to 228 weeks. All 4 patients had persistent/recurrent lymphoma, and 2 patients died of lymphoma-related complications. None of the CSH cases were prospectively recognized as CSH, and 1 case was initially misdiagnosed as a xanthoma. In summary, CSH is an under-recognized lesion historically associated with lymphoproliferative disorders and we found associated with a high mortality in this small series. Since CSH can be so florid as to obscure the concomitant lymphoma, awareness is crucial for accurate diagnosis.	[Arnold, Christina A.; Frankel, Wendy L.; Guo, Ling; Schumacher, Melinda; Yearsley, Martha M.; Chen, Wei] Ohio State Univ, Wexner Med Ctr, Dept Pathol, 410 W 10th Ave, Columbus, OH 43210 USA; [Pfeil, Sheryl] Ohio State Univ, Wexner Med Ctr, Div Gastroenterol Hepatol & Nutr, Columbus, OH 43210 USA; [Krishnan, Chandra] Univ Texas Austin, Dell Med Sch, Dept Pathol, Austin, TX 78712 USA; [Voltaggio, Lysandra] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA	Arnold, CA (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Pathol, 410 W 10th Ave, Columbus, OH 43210 USA.	christina.arnold@OSUMC.edu					Alayed KM, 2010, PATHOLOGY, V42, P85, DOI 10.3109/00313020903434652; Anglesio MS, 2017, NEW ENGL J MED, V376, P1835, DOI 10.1056/NEJMoa1614814; [Anonymous], 2017, BLOOD, V130, P1683, DOI 10.1182/blood-2017-07-794230; Arnold C, 2017, GASTRIC BIOPSY HIST; Bosman C, 1998, ARCH PATHOL LAB MED, V122, P920; Dogan S, 2012, HEAD NECK PATHOL, V6, P111, DOI 10.1007/s12105-011-0326-3; DVORAK AM, 1990, LAB INVEST, V62, P590; Fang H, 2018, AM J CLIN PATHOL, V149, P148, DOI [10.1093/ajcp/aqx150, 10.1093/AJCP/AQX150]; Farooq U, 2009, ANN HEMATOL, V88, P807, DOI 10.1007/s00277-008-0660-z; Galed-Placed I, 2006, ACTA CYTOL, V50, P539, DOI 10.1159/000326010; Jones D, 1999, HUM PATHOL, V30, P1441, DOI 10.1016/S0046-8177(99)90166-1; Joo M, 2017, J PATHOL TRANSL MED, V51, P341, DOI 10.4132/jptm.2017.04.03; Kanagal-Shamanna R, 2016, HISTOPATHOLOGY, V68, P482, DOI 10.1111/his.12768; KAPADIA SB, 1993, AM J SURG PATHOL, V17, P461, DOI 10.1097/00000478-199305000-00004; Kar Rakhee, 2008, Indian J Hematol Blood Transfus, V24, P63, DOI 10.1007/s12288-008-0030-y; Karabagli P, 2012, J GASTROINTEST LIVER, V21, P97; Khurram SA, 2011, ORAL SURG ORAL MED O, V111, P494, DOI 10.1016/j.tripleo.2010.12.019; Krishnan C, 2017, LESS COMMON IS SO CA; Lam-Himlin DAC, 2013, DIAGN HISTOPATHOL, V20, P1; Lam-Himlin D, 2010, AM J SURG PATHOL, V34, P1656, DOI 10.1097/PAS.0b013e3181f2b1f1; Lee JS, 2015, AM J CLIN PATHOL, V143, P300, DOI 10.1309/AJCPC7RWYPYG8UGY; Lewis JT, 2007, AM J SURG PATHOL, V31, P481, DOI 10.1097/01.pas.0000213420.46127.9c; Licci S, 2009, Z GASTROENTEROL, V47, P357, DOI 10.1055/s-2008-1027656; Munday WR, 2015, WORLD J GASTROINTEST, V7, P73, DOI 10.4253/wjge.v7.i1.73; Pock L, 2006, INT J DERMATOL, V45, P1408, DOI 10.1111/j.1365-4632.2006.02919.x; Rossi G, 2013, AM J SURG PATHOL, V37, P906, DOI 10.1097/PAS.0b013e31827b1618; Singh H, 2013, INDIAN J PHARMACOL, V45, P197, DOI 10.4103/0253-7613.108323; Szeto W, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw004; Yang YS, 2010, AM J HEMATOL, V85, P444, DOI 10.1002/ajh.21531; Yorita K, 2017, WORLD J GASTRO ENDOS, V9, P417, DOI 10.4253/wjge.v9.i8.417	30	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	OCT	2018	42	10					1317	1324		10.1097/PAS.0000000000001097			8	Pathology; Surgery	Pathology; Surgery	GV1RN	WOS:000445858300005	29878935				2019-10-28	
